<?xml version='1.0' encoding='ASCII'?>
<!--INTEGIX by Ez-XBRL-->
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2022-02-16" xmlns:country="http://xbrl.sec.gov/country/2024" xmlns:srt="http://fasb.org/srt/2024" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:us-types="http://fasb.org/us-types/2024" xmlns:exch="http://xbrl.sec.gov/exch/2024" xmlns:naics="http://xbrl.sec.gov/naics/2024" xmlns:sic="http://xbrl.sec.gov/sic/2024" xmlns:stpr="http://xbrl.sec.gov/stpr/2024" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:us-gaap-ebp="http://fasb.org/us-gaap-ebp/2024" xmlns:slxn="http://www.silexion.com/20240930" xmlns:ecd="http://xbrl.sec.gov/ecd/2024" xmlns:srt-types="http://fasb.org/srt-types/2024" xmlns:currency="http://xbrl.sec.gov/currency/2024" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0">
<head>
  <meta http-equiv="Content-Type" content="text/html; charset=UTF-8"/>
  <title>Silexion Therapeutics Corp - 2022416 - 2025</title>
</head>
<body style="font-size:10pt;font-family:Times New Roman/Times New Roman, Times, serif;"><div style="font-size: 10pt;">

<div style="display:none">
<ix:header>
  <ix:hidden>
    <ix:nonFraction name="us-gaap:CommonStockValue" contextRef="C_20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_usgaapCommonClassBMember" id="Fxbrl_20241004054608864_hidden-fact-3" unitRef="usd" xsi:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:CommonStockValue" contextRef="C_20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_usgaapCommonClassBMember" id="Fxbrl_20241004054608864_hidden-fact-2" unitRef="usd" xsi:nil="true"></ix:nonFraction>
    <ix:footnote id="FN20241205155356638" xml:lang="en-US">Less than one US dollar</ix:footnote>
    <ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_20221231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" id="F20241205041230498_10" unitRef="usd" xsi:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_20230930_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" id="F20241205041230557_39" unitRef="usd" xsi:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_20231231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" id="F20241205041230590_56" unitRef="usd" xsi:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="C_20240101to20240930_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" id="F20241205041230602_62" unitRef="usd" xsi:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="C_20240101to20240930_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember" id="F20241205041230604_63" unitRef="usd" xsi:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="C_20240101to20240930" id="F20241205041230606_64" unitRef="usd" xsi:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_20230630_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" id="F20241205041230673_98" unitRef="usd" xsi:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_20230930_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" id="F20241205041230720_122" unitRef="usd" xsi:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_20240630_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" id="F20241205041230752_139" unitRef="usd" xsi:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="C_20240101to20240930_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" id="F20241205041230887_172" unitRef="usd" xsi:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="C_20240701to20240930_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" id="F20241205041230912_192" unitRef="usd" xsi:nil="true"></ix:nonFraction>
    <ix:nonFraction name="slxn:StockIssuedDuringPeriodValueIssuanceOfOrdinarySharesUponTransactions" contextRef="C_20240101to20240930_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" id="F20241205041230952_206" unitRef="usd" xsi:nil="true"></ix:nonFraction>
    <ix:nonFraction name="slxn:StockIssuedDuringPeriodValueIssuanceOfOrdinarySharesUponTransactions" contextRef="C_20240101to20240930_usgaapStatementEquityComponentsAxis_usgaapParentMember" id="F20241205041230955_207" unitRef="usd" xsi:nil="true"></ix:nonFraction>
    <ix:nonFraction name="slxn:StockIssuedDuringPeriodValueIssuanceOfOrdinarySharesUponTransactions" contextRef="C_20240101to20240930" id="F20241205041230956_208" unitRef="usd" xsi:nil="true"></ix:nonFraction>
    <ix:nonFraction name="slxn:StockIssuedDuringPeriodValueIssuanceOfOrdinarySharesForElocHolders" contextRef="C_20240101to20240930_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" id="F20241205041230960_211" unitRef="usd" xsi:nil="true"></ix:nonFraction>
    <ix:nonFraction name="slxn:StockIssuedDuringPeriodValueIssuanceOfOrdinarySharesUponTransactions" contextRef="C_20240701to20240930" id="Fxbrl_20241111194750134_20241205041230956_208" unitRef="usd" xsi:nil="true"></ix:nonFraction>
    <ix:nonFraction name="slxn:StockIssuedDuringPeriodValueIssuanceOfOrdinarySharesUponTransactions" contextRef="C_20240701to20240930_usgaapStatementEquityComponentsAxis_usgaapParentMember" id="Fxbrl_20241111194750134_20241205041230955_207" unitRef="usd" xsi:nil="true"></ix:nonFraction>
    <ix:nonFraction name="slxn:StockIssuedDuringPeriodValueIssuanceOfOrdinarySharesUponTransactions" contextRef="C_20240701to20240930_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember" id="F20241205041230967_216" unitRef="usd" xsi:nil="true"></ix:nonFraction>
    <ix:nonFraction name="slxn:StockIssuedDuringPeriodValueIssuanceOfOrdinarySharesUponTransactions" contextRef="C_20240701to20240930_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" id="Fxbrl_20241111194750134_20241205041230952_206" unitRef="usd" xsi:nil="true"></ix:nonFraction>
    <ix:nonFraction name="slxn:StockIssuedDuringPeriodValueIssuanceOfOrdinarySharesForElocHolders" contextRef="C_20240701to20240930_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" id="Fxbrl_20241111194811742_20241205041230960_211" unitRef="usd" xsi:nil="true"></ix:nonFraction>
    <ix:footnote id="FN20241205155632368" xml:lang="en-US">Represents an amount less than $1</ix:footnote>
    <ix:footnote id="FN20241205171327256" xml:lang="en-US">Represents fully vested pre-funded options for the Company&#8217;s ordinary shares at an exercise price of $0.027 or 0.0063 NIS per share</ix:footnote>
    <ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_usgaapCommonClassBMember_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" id="Fhidden-fact-88" unitRef="usd" scale="0" decimals="0">0</ix:nonFraction>
    <ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_20211231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" id="Fixv-39019" unitRef="usd" xsi:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="C_20220101to20221231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" id="Fhidden-fact-104" unitRef="usd" xsi:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_20221231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" id="Fixv-39053" unitRef="usd" xsi:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_20231231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" id="Fixv-39082" unitRef="usd" xsi:nil="true"></ix:nonFraction>
    <ix:footnote id="FN20241004135506058" xml:lang="en-US">Leasehold improvements are amortized by the straight-line method over the expected lease term, which is shorter than the estimated useful life of the improvements.</ix:footnote>
    <ix:nonNumeric name="dei:AmendmentFlag" contextRef="C_20240101to20240930" id="Fixv-39817">false</ix:nonNumeric>
    <ix:nonNumeric name="dei:EntityCentralIndexKey" contextRef="C_20240101to20240930" id="Fixv-39818">0002022416</ix:nonNumeric>
    <ix:nonFraction name="us-gaap:CommonStockValue" contextRef="C_20231231" id="Fixv-38968" unitRef="usd" xsi:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:CommonStockValue" contextRef="C_20221231" id="Fixv-38969" unitRef="usd" xsi:nil="true"></ix:nonFraction>
    <ix:footnote id="FN20241205155658750" xml:lang="en-US">Net of 13,458 treasury shares held by the subsidiary as of December 31, 2023</ix:footnote>
    <ix:nonFraction name="us-gaap:CommonStockValue" contextRef="C_20231231" id="F20241205041230391_62" unitRef="usd" xsi:nil="true"></ix:nonFraction>
    <ix:nonNumeric name="slxn:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTermGranted" contextRef="C_20230101to20231231_usgaapGranteeStatusAxis_slxnShareBasedPaymentArrangementEmployeeAndNonEmployeeMember" id="Fxbrl_20241004180444170">P0Y</ix:nonNumeric>
    <ix:nonNumeric name="slxn:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTermExercised" contextRef="C_20230101to20231231_usgaapGranteeStatusAxis_slxnShareBasedPaymentArrangementEmployeeAndNonEmployeeMember" id="Fxbrl_20241004180513328">P0Y</ix:nonNumeric>
    <ix:nonNumeric name="slxn:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTermForfeited" contextRef="C_20230101to20231231_usgaapGranteeStatusAxis_slxnShareBasedPaymentArrangementEmployeeAndNonEmployeeMember" id="Fxbrl_20241004180602489">P0Y</ix:nonNumeric>
    <ix:nonNumeric name="slxn:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTermExpired" contextRef="C_20230101to20231231_usgaapGranteeStatusAxis_slxnShareBasedPaymentArrangementEmployeeAndNonEmployeeMember" id="Fxbrl_20241004180730561">P0Y</ix:nonNumeric>
    <ix:nonNumeric name="slxn:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTermExpired" contextRef="C_20220101to20221231_usgaapGranteeStatusAxis_slxnShareBasedPaymentArrangementEmployeeAndNonEmployeeMember" id="Fxbrl_20241004180813329">P0Y</ix:nonNumeric>
    <ix:nonFraction name="us-gaap:CommonStockValue" contextRef="C_20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_usgaapCommonClassBMember" id="Fhidden-fact-12" unitRef="usd" xsi:nil="true"></ix:nonFraction>
    <ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" contextRef="C_20220101to20221231_usgaapMeasurementInputTypeAxis_slxnExpectedTimeToIPOMember" id="Fxbrl_20241004181424317">P0Y</ix:nonNumeric>
    <ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_usgaapCommonClassBMember_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" id="Fhidden-fact-70" unitRef="usd" scale="0" decimals="0">0</ix:nonFraction>
    <ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_20240331_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_usgaapCommonClassBMember_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" id="Fhidden-fact-71" unitRef="usd" scale="0" decimals="0">0</ix:nonFraction>
    <ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_usgaapCommonClassBMember_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" id="Fhidden-fact-72" unitRef="usd" scale="0" decimals="0">0</ix:nonFraction>
    </ix:hidden>
  <ix:references> <link:schemaRef xlink:type="simple" xlink:href="slxn-20240930.xsd"/>
    </ix:references>
  <ix:resources>
    <xbrli:context id="C_20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">slxn:MoringaAcquisitionCorpMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">slxn:MoringaAcquisitionCorpMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2024-06-30</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_usgaapCommonClassAMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">slxn:MoringaAcquisitionCorpMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_usgaapCommonClassAMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">slxn:MoringaAcquisitionCorpMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2024-06-30</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_usgaapCommonClassBMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">slxn:MoringaAcquisitionCorpMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_usgaapCommonClassBMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">slxn:MoringaAcquisitionCorpMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2024-06-30</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20240101to20240930">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-09-30</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20230101to20230930">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20240701to20240930">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-07-01</xbrli:startDate>
        <xbrli:endDate>2024-09-30</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20230701to20230930">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-07-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20231231">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20221231">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20240630">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2024-06-30</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20230630">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2023-06-30</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20240930">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2024-09-30</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20230930">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2023-09-30</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20240901to20240908">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-09-01</xbrli:startDate>
        <xbrli:endDate>2024-09-08</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20240901to20240926">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-09-01</xbrli:startDate>
        <xbrli:endDate>2024-09-26</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20240101to20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">slxn:MoringaAcquisitionCorpMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20230101to20230630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">slxn:MoringaAcquisitionCorpMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20240401to20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">slxn:MoringaAcquisitionCorpMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-04-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20230401to20230630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">slxn:MoringaAcquisitionCorpMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-04-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20240101to20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_slxnClassAOrdinaryShareSubjectToPossibleRedemptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">slxn:MoringaAcquisitionCorpMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">slxn:ClassAOrdinaryShareSubjectToPossibleRedemptionMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20230101to20230630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_slxnClassAOrdinaryShareSubjectToPossibleRedemptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">slxn:MoringaAcquisitionCorpMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">slxn:ClassAOrdinaryShareSubjectToPossibleRedemptionMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20240401to20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_slxnClassAOrdinaryShareSubjectToPossibleRedemptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">slxn:MoringaAcquisitionCorpMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">slxn:ClassAOrdinaryShareSubjectToPossibleRedemptionMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-04-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20230401to20230630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_slxnClassAOrdinaryShareSubjectToPossibleRedemptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">slxn:MoringaAcquisitionCorpMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">slxn:ClassAOrdinaryShareSubjectToPossibleRedemptionMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-04-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20240101to20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_slxnNonredeemableClassAandBOrdinaryShareMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">slxn:MoringaAcquisitionCorpMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">slxn:NonredeemableClassAandBOrdinaryShareMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20230101to20230630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_slxnNonredeemableClassAandBOrdinaryShareMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">slxn:MoringaAcquisitionCorpMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">slxn:NonredeemableClassAandBOrdinaryShareMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20240401to20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_slxnNonredeemableClassAandBOrdinaryShareMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">slxn:MoringaAcquisitionCorpMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">slxn:NonredeemableClassAandBOrdinaryShareMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-04-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20230401to20230630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_slxnNonredeemableClassAandBOrdinaryShareMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">slxn:MoringaAcquisitionCorpMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">slxn:NonredeemableClassAandBOrdinaryShareMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-04-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20230101to20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">slxn:MoringaAcquisitionCorpMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20201120_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_usgaapCommonClassAMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">slxn:MoringaAcquisitionCorpMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2020-11-20</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20210219to20210219_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_usgaapCommonClassAMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">slxn:MoringaAcquisitionCorpMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-02-19</xbrli:startDate>
        <xbrli:endDate>2021-02-19</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20210303to20210303_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_usgaapCommonClassAMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">slxn:MoringaAcquisitionCorpMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-03-03</xbrli:startDate>
        <xbrli:endDate>2021-03-03</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20210219_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_usgaapCommonClassAMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">slxn:MoringaAcquisitionCorpMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2021-02-19</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20210303_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_usgaapCommonClassAMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">slxn:MoringaAcquisitionCorpMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2021-03-03</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20210219to20210219_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapSubsidiarySaleOfStockAxis_slxnPublicOfferingMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">slxn:MoringaAcquisitionCorpMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">slxn:PublicOfferingMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-02-19</xbrli:startDate>
        <xbrli:endDate>2021-02-19</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20210303to20210303_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapSubsidiarySaleOfStockAxis_usgaapPrivatePlacementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">slxn:MoringaAcquisitionCorpMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-03-03</xbrli:startDate>
        <xbrli:endDate>2021-03-03</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapRelatedPartyTransactionAxis_slxnFirstExtensionsMember_usgaapStatementClassOfStockAxis_usgaapCommonClassAMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">slxn:MoringaAcquisitionCorpMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">slxn:FirstExtensionsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapRelatedPartyTransactionAxis_slxnSecondExtensionsMember_usgaapStatementClassOfStockAxis_usgaapCommonClassAMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">slxn:MoringaAcquisitionCorpMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">slxn:SecondExtensionsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20201120_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_usgaapCommonClassBMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">slxn:MoringaAcquisitionCorpMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2020-11-20</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20201120to20201120_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_usgaapCommonClassBMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">slxn:MoringaAcquisitionCorpMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-11-20</xbrli:startDate>
        <xbrli:endDate>2020-11-20</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20230101to20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_srtProductOrServiceAxis_slxnLegalExpensesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">slxn:MoringaAcquisitionCorpMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">slxn:LegalExpensesMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20220101to20221231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_srtProductOrServiceAxis_slxnLegalExpensesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">slxn:MoringaAcquisitionCorpMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">slxn:LegalExpensesMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20230101to20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_srtProductOrServiceAxis_slxnAuditBookkeepingAndAccountingMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">slxn:MoringaAcquisitionCorpMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">slxn:AuditBookkeepingAndAccountingMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20220101to20221231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_srtProductOrServiceAxis_slxnAuditBookkeepingAndAccountingMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">slxn:MoringaAcquisitionCorpMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">slxn:AuditBookkeepingAndAccountingMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20230101to20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_srtProductOrServiceAxis_slxnProfessionalServicesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">slxn:MoringaAcquisitionCorpMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">slxn:ProfessionalServicesMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20220101to20221231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_srtProductOrServiceAxis_slxnProfessionalServicesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">slxn:MoringaAcquisitionCorpMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">slxn:ProfessionalServicesMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20230101to20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_srtProductOrServiceAxis_slxnManagementFeesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">slxn:MoringaAcquisitionCorpMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">slxn:ManagementFeesMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20220101to20221231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_srtProductOrServiceAxis_slxnManagementFeesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">slxn:MoringaAcquisitionCorpMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">slxn:ManagementFeesMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20230101to20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_srtProductOrServiceAxis_slxnInsuranceMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">slxn:MoringaAcquisitionCorpMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">slxn:InsuranceMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20220101to20221231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_srtProductOrServiceAxis_slxnInsuranceMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">slxn:MoringaAcquisitionCorpMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">slxn:InsuranceMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20230101to20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_srtProductOrServiceAxis_slxnNasdaqFeesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">slxn:MoringaAcquisitionCorpMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">slxn:NasdaqFeesMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20220101to20221231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_srtProductOrServiceAxis_slxnNasdaqFeesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">slxn:MoringaAcquisitionCorpMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">slxn:NasdaqFeesMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20230101to20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_srtProductOrServiceAxis_slxnOtherExpensesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">slxn:MoringaAcquisitionCorpMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">slxn:OtherExpensesMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20220101to20221231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_srtProductOrServiceAxis_slxnOtherExpensesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">slxn:MoringaAcquisitionCorpMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">slxn:OtherExpensesMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20220101to20221231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">slxn:MoringaAcquisitionCorpMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20230101to20231231">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20221231_usgaapPropertyPlantAndEquipmentByTypeAxis_slxnLaboratoryAndElectronicEquipmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">slxn:LaboratoryAndElectronicEquipmentMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20231231_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapOfficeEquipmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20221231_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapOfficeEquipmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20231231_usgaapPropertyPlantAndEquipmentByTypeAxis_slxnCommunicationEquipmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">slxn:CommunicationEquipmentMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20221231_usgaapPropertyPlantAndEquipmentByTypeAxis_slxnCommunicationEquipmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">slxn:CommunicationEquipmentMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20231231_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapLeaseholdImprovementsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20221231_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapLeaseholdImprovementsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20231231_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapComputerEquipmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20221231_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapComputerEquipmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20220101to20221231">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20231231_usgaapPropertyPlantAndEquipmentByTypeAxis_slxnLaboratoryAndElectronicEquipmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">slxn:LaboratoryAndElectronicEquipmentMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20221231_usgaapPropertyPlantAndEquipmentByTypeAxis_slxnCostMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">slxn:CostMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20231231_usgaapPropertyPlantAndEquipmentByTypeAxis_slxnCostMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">slxn:CostMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20240101to20240930_usgaapRelatedPartyTransactionsByRelatedPartyAxis_usgaapRelatedPartyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-09-30</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20240701to20240930_usgaapRelatedPartyTransactionsByRelatedPartyAxis_usgaapRelatedPartyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-07-01</xbrli:startDate>
        <xbrli:endDate>2024-09-30</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20230101to20230930_usgaapRelatedPartyTransactionsByRelatedPartyAxis_usgaapRelatedPartyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20230701to20230930_usgaapRelatedPartyTransactionsByRelatedPartyAxis_usgaapRelatedPartyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-07-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20210809_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapDebtInstrumentAxis_slxnSecondPromissoryNoteMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">slxn:MoringaAcquisitionCorpMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">slxn:SecondPromissoryNoteMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2021-08-09</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20221231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapDebtInstrumentAxis_slxnThirdAndFourthPromissoryNotesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">slxn:MoringaAcquisitionCorpMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">slxn:ThirdAndFourthPromissoryNotesMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20230208_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapDebtInstrumentAxis_slxnFifthPromissoryNoteMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">slxn:MoringaAcquisitionCorpMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">slxn:FifthPromissoryNoteMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2023-02-08</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapFinancialInstrumentAxis_slxnPrivateWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">slxn:MoringaAcquisitionCorpMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">slxn:PrivateWarrantsMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20230209_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapDebtInstrumentAxis_slxnSixthPromissoryNoteMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">slxn:MoringaAcquisitionCorpMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">slxn:SixthPromissoryNoteMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2023-02-09</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20230219_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapDebtInstrumentAxis_slxnSixthPromissoryNoteMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">slxn:MoringaAcquisitionCorpMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">slxn:SixthPromissoryNoteMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2023-02-19</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20230614_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapDebtInstrumentAxis_slxnSeventhPromissoryNoteMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">slxn:MoringaAcquisitionCorpMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">slxn:SeventhPromissoryNoteMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2023-06-14</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20230614to20230614_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapDebtInstrumentAxis_slxnSeventhPromissoryNoteMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">slxn:MoringaAcquisitionCorpMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">slxn:SeventhPromissoryNoteMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-06-14</xbrli:startDate>
        <xbrli:endDate>2023-06-14</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20230101to20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapDebtInstrumentAxis_slxnSeventhPromissoryNoteMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">slxn:MoringaAcquisitionCorpMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">slxn:SeventhPromissoryNoteMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20230818_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapDebtInstrumentAxis_slxnEighthPromissoryNoteMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">slxn:MoringaAcquisitionCorpMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">slxn:EighthPromissoryNoteMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2023-08-18</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20230819to20230819_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapDebtInstrumentAxis_slxnEighthPromissoryNoteMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">slxn:MoringaAcquisitionCorpMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">slxn:EighthPromissoryNoteMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-08-19</xbrli:startDate>
        <xbrli:endDate>2023-08-19</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20201216_slxnTypeOfAgreementAxis_slxnAdministrativeServicesAgreementMember_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="slxn:TypeOfAgreementAxis">slxn:AdministrativeServicesAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">slxn:MoringaAcquisitionCorpMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2020-12-16</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapRelatedPartyTransactionAxis_slxnPromissoryNotesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">slxn:MoringaAcquisitionCorpMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">slxn:PromissoryNotesMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20221231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapRelatedPartyTransactionAxis_slxnPromissoryNotesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">slxn:MoringaAcquisitionCorpMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">slxn:PromissoryNotesMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapRelatedPartyTransactionAxis_usgaapAssetManagementArrangementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">slxn:MoringaAcquisitionCorpMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:AssetManagementArrangementMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapRelatedPartyTransactionAxis_usgaapRelatedPartyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">slxn:MoringaAcquisitionCorpMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20221231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapRelatedPartyTransactionAxis_usgaapRelatedPartyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">slxn:MoringaAcquisitionCorpMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20221231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapRelatedPartyTransactionAxis_usgaapAssetManagementArrangementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">slxn:MoringaAcquisitionCorpMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:AssetManagementArrangementMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20240101to20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapSubsidiarySaleOfStockAxis_usgaapIPOMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">slxn:MoringaAcquisitionCorpMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20240101to20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapSubsidiarySaleOfStockAxis_usgaapOverAllotmentOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">slxn:MoringaAcquisitionCorpMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapSubsidiarySaleOfStockAxis_usgaapIPOMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">slxn:MoringaAcquisitionCorpMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2024-06-30</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20240101to20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapRelatedPartyTransactionsByRelatedPartyAxis_slxnSponsorMember_usgaapSubsidiarySaleOfStockAxis_usgaapIPOMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">slxn:MoringaAcquisitionCorpMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">slxn:SponsorMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20240101to20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapRelatedPartyTransactionsByRelatedPartyAxis_slxnSponsorMember_usgaapSubsidiarySaleOfStockAxis_usgaapPrivatePlacementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">slxn:MoringaAcquisitionCorpMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">slxn:SponsorMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapRelatedPartyTransactionsByRelatedPartyAxis_slxnSponsorMember_usgaapSubsidiarySaleOfStockAxis_usgaapIPOMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">slxn:MoringaAcquisitionCorpMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">slxn:SponsorMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2024-06-30</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20240101to20240630">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20221231_usgaapStatementClassOfStockAxis_usgaapSeriesAPreferredStockMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20221231_usgaapStatementClassOfStockAxis_slxnSeriesA1PreferredSharesMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">slxn:SeriesA1PreferredSharesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20221231_usgaapStatementClassOfStockAxis_slxnSeriesA2PreferredSharesMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">slxn:SeriesA2PreferredSharesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20221231_usgaapStatementClassOfStockAxis_slxnSeriesA3PreferredSharesMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">slxn:SeriesA3PreferredSharesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20221231_usgaapStatementEquityComponentsAxis_usgaapNoncontrollingInterestMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20221231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20221231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20221231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20221231_usgaapStatementEquityComponentsAxis_usgaapParentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20230101to20230930_usgaapStatementClassOfStockAxis_slxnSeriesA4PreferredSharesMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">slxn:SeriesA4PreferredSharesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20230101to20230930_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20230101to20230930_usgaapStatementEquityComponentsAxis_usgaapParentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20230101to20230930_usgaapStatementEquityComponentsAxis_usgaapNoncontrollingInterestMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20230101to20230930_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20230930_usgaapStatementClassOfStockAxis_usgaapSeriesAPreferredStockMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2023-09-30</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20230930_usgaapStatementClassOfStockAxis_slxnSeriesA1PreferredSharesMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">slxn:SeriesA1PreferredSharesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2023-09-30</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20230930_usgaapStatementClassOfStockAxis_slxnSeriesA2PreferredSharesMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">slxn:SeriesA2PreferredSharesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2023-09-30</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20230930_usgaapStatementClassOfStockAxis_slxnSeriesA3PreferredSharesMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">slxn:SeriesA3PreferredSharesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2023-09-30</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20230930_usgaapStatementClassOfStockAxis_slxnSeriesA4PreferredSharesMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">slxn:SeriesA4PreferredSharesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2023-09-30</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20230930_usgaapStatementEquityComponentsAxis_usgaapNoncontrollingInterestMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2023-09-30</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20230930_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2023-09-30</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20230930_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2023-09-30</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20230930_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2023-09-30</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20230930_usgaapStatementEquityComponentsAxis_usgaapParentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2023-09-30</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20231231_usgaapStatementClassOfStockAxis_usgaapSeriesAPreferredStockMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20231231_usgaapStatementClassOfStockAxis_slxnSeriesA1PreferredSharesMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">slxn:SeriesA1PreferredSharesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20231231_usgaapStatementClassOfStockAxis_slxnSeriesA2PreferredSharesMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">slxn:SeriesA2PreferredSharesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20231231_usgaapStatementClassOfStockAxis_slxnSeriesA3PreferredSharesMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">slxn:SeriesA3PreferredSharesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20231231_usgaapStatementClassOfStockAxis_slxnSeriesA4PreferredSharesMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">slxn:SeriesA4PreferredSharesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20231231_usgaapStatementEquityComponentsAxis_usgaapNoncontrollingInterestMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20231231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20231231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20231231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20231231_usgaapStatementEquityComponentsAxis_usgaapParentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20240101to20240930_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-09-30</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20240101to20240930_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-09-30</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20240101to20240930_usgaapStatementEquityComponentsAxis_usgaapParentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-09-30</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20240101to20240930_usgaapStatementEquityComponentsAxis_usgaapNoncontrollingInterestMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-09-30</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20240101to20240930_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-09-30</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20240101to20240930_usgaapStatementClassOfStockAxis_usgaapSeriesAPreferredStockMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-09-30</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20240101to20240930_usgaapStatementClassOfStockAxis_slxnSeriesA1PreferredSharesMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">slxn:SeriesA1PreferredSharesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-09-30</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20240101to20240930_usgaapStatementClassOfStockAxis_slxnSeriesA2PreferredSharesMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">slxn:SeriesA2PreferredSharesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-09-30</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20240101to20240930_usgaapStatementClassOfStockAxis_slxnSeriesA3PreferredSharesMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">slxn:SeriesA3PreferredSharesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-09-30</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20240101to20240930_usgaapStatementClassOfStockAxis_slxnSeriesA4PreferredSharesMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">slxn:SeriesA4PreferredSharesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-09-30</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20230630_usgaapStatementClassOfStockAxis_usgaapSeriesAPreferredStockMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2023-06-30</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20230630_usgaapStatementClassOfStockAxis_slxnSeriesA1PreferredSharesMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">slxn:SeriesA1PreferredSharesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2023-06-30</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20230630_usgaapStatementClassOfStockAxis_slxnSeriesA2PreferredSharesMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">slxn:SeriesA2PreferredSharesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2023-06-30</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20230630_usgaapStatementClassOfStockAxis_slxnSeriesA3PreferredSharesMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">slxn:SeriesA3PreferredSharesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2023-06-30</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20230630_usgaapStatementEquityComponentsAxis_usgaapNoncontrollingInterestMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2023-06-30</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20230630_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2023-06-30</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20230630_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2023-06-30</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20230630_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2023-06-30</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20230630_usgaapStatementEquityComponentsAxis_usgaapParentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2023-06-30</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20230701to20230930_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-07-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20230701to20230930_usgaapStatementEquityComponentsAxis_usgaapParentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-07-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20230701to20230930_usgaapStatementEquityComponentsAxis_usgaapNoncontrollingInterestMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-07-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20230701to20230930_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-07-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20240630_usgaapStatementClassOfStockAxis_usgaapSeriesAPreferredStockMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2024-06-30</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20240630_usgaapStatementClassOfStockAxis_slxnSeriesA1PreferredSharesMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">slxn:SeriesA1PreferredSharesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2024-06-30</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20240630_usgaapStatementClassOfStockAxis_slxnSeriesA2PreferredSharesMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">slxn:SeriesA2PreferredSharesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2024-06-30</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20240630_usgaapStatementClassOfStockAxis_slxnSeriesA3PreferredSharesMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">slxn:SeriesA3PreferredSharesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2024-06-30</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20240630_usgaapStatementClassOfStockAxis_slxnSeriesA4PreferredSharesMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">slxn:SeriesA4PreferredSharesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2024-06-30</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20240630_usgaapStatementEquityComponentsAxis_usgaapNoncontrollingInterestMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2024-06-30</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20240630_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2024-06-30</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20240630_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2024-06-30</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20240630_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2024-06-30</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20240630_usgaapStatementEquityComponentsAxis_usgaapParentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2024-06-30</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20240701to20240930_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-07-01</xbrli:startDate>
        <xbrli:endDate>2024-09-30</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20240701to20240930_usgaapStatementEquityComponentsAxis_usgaapParentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-07-01</xbrli:startDate>
        <xbrli:endDate>2024-09-30</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20240701to20240930_usgaapStatementEquityComponentsAxis_usgaapNoncontrollingInterestMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-07-01</xbrli:startDate>
        <xbrli:endDate>2024-09-30</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20240701to20240930_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-07-01</xbrli:startDate>
        <xbrli:endDate>2024-09-30</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20240930_usgaapStatementClassOfStockAxis_usgaapSeriesAPreferredStockMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2024-09-30</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20240930_usgaapStatementClassOfStockAxis_slxnSeriesA1PreferredSharesMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">slxn:SeriesA1PreferredSharesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2024-09-30</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20240930_usgaapStatementClassOfStockAxis_slxnSeriesA2PreferredSharesMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">slxn:SeriesA2PreferredSharesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2024-09-30</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20240930_usgaapStatementClassOfStockAxis_slxnSeriesA3PreferredSharesMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">slxn:SeriesA3PreferredSharesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2024-09-30</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20240930_usgaapStatementClassOfStockAxis_slxnSeriesA4PreferredSharesMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">slxn:SeriesA4PreferredSharesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2024-09-30</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20240930_usgaapStatementEquityComponentsAxis_usgaapNoncontrollingInterestMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2024-09-30</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20240930_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2024-09-30</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20240930_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2024-09-30</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20240930_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2024-09-30</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20240930_usgaapStatementEquityComponentsAxis_usgaapParentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2024-09-30</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20221231_usgaapStatementClassOfStockAxis_slxnSeriesA4PreferredSharesMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">slxn:SeriesA4PreferredSharesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20230630_usgaapStatementClassOfStockAxis_slxnSeriesA4PreferredSharesMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">slxn:SeriesA4PreferredSharesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2023-06-30</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20240701to20240930_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-07-01</xbrli:startDate>
        <xbrli:endDate>2024-09-30</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20240701to20240930_usgaapStatementClassOfStockAxis_slxnSeriesA4PreferredSharesMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">slxn:SeriesA4PreferredSharesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-07-01</xbrli:startDate>
        <xbrli:endDate>2024-09-30</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20240701to20240930_usgaapStatementClassOfStockAxis_slxnSeriesA1PreferredSharesMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">slxn:SeriesA1PreferredSharesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-07-01</xbrli:startDate>
        <xbrli:endDate>2024-09-30</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20240701to20240930_usgaapStatementClassOfStockAxis_slxnSeriesA3PreferredSharesMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">slxn:SeriesA3PreferredSharesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-07-01</xbrli:startDate>
        <xbrli:endDate>2024-09-30</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20240701to20240930_usgaapStatementClassOfStockAxis_slxnSeriesA2PreferredSharesMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">slxn:SeriesA2PreferredSharesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-07-01</xbrli:startDate>
        <xbrli:endDate>2024-09-30</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20240701to20240930_usgaapStatementClassOfStockAxis_usgaapSeriesAPreferredStockMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-07-01</xbrli:startDate>
        <xbrli:endDate>2024-09-30</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20230101to20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapSubsidiarySaleOfStockAxis_usgaapOverAllotmentOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">slxn:MoringaAcquisitionCorpMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20230101to20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapSubsidiarySaleOfStockAxis_usgaapIPOMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">slxn:MoringaAcquisitionCorpMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapSubsidiarySaleOfStockAxis_usgaapIPOMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">slxn:MoringaAcquisitionCorpMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20230101to20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapRelatedPartyTransactionsByRelatedPartyAxis_slxnSponsorMember_usgaapSubsidiarySaleOfStockAxis_usgaapIPOMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">slxn:MoringaAcquisitionCorpMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">slxn:SponsorMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20230101to20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapRelatedPartyTransactionsByRelatedPartyAxis_slxnSponsorMember_usgaapSubsidiarySaleOfStockAxis_usgaapPrivatePlacementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">slxn:MoringaAcquisitionCorpMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">slxn:SponsorMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapRelatedPartyTransactionsByRelatedPartyAxis_slxnSponsorMember_usgaapSubsidiarySaleOfStockAxis_usgaapPrivatePlacementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">slxn:MoringaAcquisitionCorpMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">slxn:SponsorMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20211231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_usgaapCommonClassAMember_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">slxn:MoringaAcquisitionCorpMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20211231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_usgaapCommonClassBMember_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">slxn:MoringaAcquisitionCorpMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20211231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">slxn:MoringaAcquisitionCorpMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20211231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">slxn:MoringaAcquisitionCorpMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20211231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">slxn:MoringaAcquisitionCorpMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20220101to20221231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">slxn:MoringaAcquisitionCorpMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20220101to20221231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">slxn:MoringaAcquisitionCorpMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20221231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_usgaapCommonClassAMember_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">slxn:MoringaAcquisitionCorpMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20221231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_usgaapCommonClassBMember_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">slxn:MoringaAcquisitionCorpMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20221231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">slxn:MoringaAcquisitionCorpMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20221231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">slxn:MoringaAcquisitionCorpMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20230101to20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">slxn:MoringaAcquisitionCorpMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20230101to20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_usgaapCommonClassAMember_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">slxn:MoringaAcquisitionCorpMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20230101to20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_usgaapCommonClassBMember_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">slxn:MoringaAcquisitionCorpMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_usgaapCommonClassAMember_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">slxn:MoringaAcquisitionCorpMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_usgaapCommonClassBMember_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">slxn:MoringaAcquisitionCorpMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">slxn:MoringaAcquisitionCorpMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20220101to20221231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_usgaapCommonClassBMember_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">slxn:MoringaAcquisitionCorpMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20220101to20221231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_usgaapCommonClassAMember_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">slxn:MoringaAcquisitionCorpMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20230101to20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">slxn:MoringaAcquisitionCorpMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20221231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">slxn:MoringaAcquisitionCorpMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">slxn:MoringaAcquisitionCorpMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20230101to20231231_srtStatementGeographicalAxis_countryCN">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20230101to20231231_srtStatementGeographicalAxis_countryIL">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:IL</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20220101to20221231_srtStatementGeographicalAxis_countryIL">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:IL</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20230101to20231231_srtStatementGeographicalAxis_slxnSubsidiaryOutsideOfIsraelMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">slxn:SubsidiaryOutsideOfIsraelMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20220101to20221231_srtStatementGeographicalAxis_slxnSubsidiaryOutsideOfIsraelMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">slxn:SubsidiaryOutsideOfIsraelMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20211231">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20241001_usgaapInvestmentTypeAxis_slxnEquityLineOfCreditMember_usgaapSubsequentEventTypeAxis_usgaapSubsequentEventMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">slxn:EquityLineOfCreditMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2024-10-01</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20240901to20241001_usgaapInvestmentTypeAxis_slxnEquityLineOfCreditMember_usgaapSubsequentEventTypeAxis_usgaapSubsequentEventMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">slxn:EquityLineOfCreditMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-09-01</xbrli:startDate>
        <xbrli:endDate>2024-10-01</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20241022_usgaapInvestmentTypeAxis_slxnEquityLineOfCreditMember_usgaapSubsequentEventTypeAxis_usgaapSubsequentEventMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">slxn:EquityLineOfCreditMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2024-10-22</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20241003to20241022_usgaapInvestmentTypeAxis_slxnEquityLineOfCreditMember_usgaapSubsequentEventTypeAxis_usgaapSubsequentEventMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">slxn:EquityLineOfCreditMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-10-03</xbrli:startDate>
        <xbrli:endDate>2024-10-22</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20241003to20241029_usgaapSubsequentEventTypeAxis_usgaapSubsequentEventMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-10-03</xbrli:startDate>
        <xbrli:endDate>2024-10-29</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20220114">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2022-01-14</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20220114_usgaapStatementClassOfStockAxis_slxnSeriesA2PreferredSharesMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">slxn:SeriesA2PreferredSharesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2022-01-14</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20230101to20231231_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20231231_usgaapStatementClassOfStockAxis_slxnSeriesA3PreferredSharesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">slxn:SeriesA3PreferredSharesMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20231231_usgaapClassOfWarrantOrRightAxis_usgaapWarrantMember_usgaapStatementClassOfStockAxis_slxnSeriesA2PreferredSharesMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">slxn:SeriesA2PreferredSharesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20231231_usgaapClassOfWarrantOrRightAxis_usgaapWarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20230530to20230530">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-05-30</xbrli:startDate>
        <xbrli:endDate>2023-05-30</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20230530_usgaapStatementClassOfStockAxis_slxnSeriesA4PreferredSharesMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">slxn:SeriesA4PreferredSharesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2023-05-30</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20230530to20230530_usgaapStatementClassOfStockAxis_slxnSeriesA4PreferredSharesMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">slxn:SeriesA4PreferredSharesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-05-30</xbrli:startDate>
        <xbrli:endDate>2023-05-30</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20230530to20230530_usgaapRelatedPartyTransactionsByRelatedPartyAxis_srtSubsidiariesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:SubsidiariesMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-05-30</xbrli:startDate>
        <xbrli:endDate>2023-05-30</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20230530">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2023-05-30</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20231231_usgaapStatementClassOfStockAxis_slxnSeriesA4PreferredSharesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">slxn:SeriesA4PreferredSharesMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20231231_usgaapStatementClassOfStockAxis_slxnSeriesA2PreferredSharesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">slxn:SeriesA2PreferredSharesMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20230101to20231231_usgaapSubsidiarySaleOfStockAxis_usgaapIPOMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20230101to20231231_usgaapLongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_usgaapResearchAndDevelopmentArrangementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis">us-gaap:ResearchAndDevelopmentArrangementMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20231231_srtRangeAxis_srtMinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20231231_srtRangeAxis_srtMaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20230101to20231231_usgaapRelatedPartyTransactionsByRelatedPartyAxis_slxnSupportGrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">slxn:SupportGrantsMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20240930_srtOwnershipAxis_slxnSilexionEquityFinancingMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:OwnershipAxis">slxn:SilexionEquityFinancingMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2024-09-30</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20240930_usgaapBusinessAcquisitionAxis_slxnNewPubcoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">slxn:NewPubcoMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2024-09-30</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20240815_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_slxnNewPubcoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">slxn:NewPubcoMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2024-08-15</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20240101to20240930_usgaapRelatedPartyTransactionAxis_usgaapRelatedPartyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-09-30</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20230101to20230930_usgaapRelatedPartyTransactionAxis_usgaapRelatedPartyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20240701to20240930_usgaapRelatedPartyTransactionAxis_usgaapRelatedPartyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-07-01</xbrli:startDate>
        <xbrli:endDate>2024-09-30</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20230701to20230930_usgaapRelatedPartyTransactionAxis_usgaapRelatedPartyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-07-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20240930_usgaapRelatedPartyTransactionsByRelatedPartyAxis_usgaapRelatedPartyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2024-09-30</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20231231_usgaapRelatedPartyTransactionsByRelatedPartyAxis_usgaapRelatedPartyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20211231_usgaapStatementClassOfStockAxis_usgaapSeriesAPreferredStockMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20211231_usgaapStatementClassOfStockAxis_slxnSeriesA1PreferredSharesMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">slxn:SeriesA1PreferredSharesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20211231_usgaapStatementClassOfStockAxis_slxnSeriesA2PreferredSharesMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">slxn:SeriesA2PreferredSharesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20211231_usgaapStatementClassOfStockAxis_slxnSeriesA3PreferredSharesMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">slxn:SeriesA3PreferredSharesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20211231_usgaapStatementClassOfStockAxis_slxnSeriesA4PreferredSharesMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">slxn:SeriesA4PreferredSharesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20211231_usgaapStatementEquityComponentsAxis_usgaapNoncontrollingInterestMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20211231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20211231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20211231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20211231_usgaapStatementEquityComponentsAxis_usgaapParentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20220101to20221231_usgaapStatementClassOfStockAxis_slxnSeriesA2PreferredSharesMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">slxn:SeriesA2PreferredSharesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20220101to20221231_usgaapStatementClassOfStockAxis_slxnSeriesA3PreferredSharesMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">slxn:SeriesA3PreferredSharesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20220101to20221231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20220101to20221231_usgaapStatementEquityComponentsAxis_usgaapParentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20220101to20221231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20220101to20221231_usgaapStatementEquityComponentsAxis_usgaapNoncontrollingInterestMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20220101to20221231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20230101to20231231_usgaapStatementClassOfStockAxis_slxnSeriesA4PreferredSharesMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">slxn:SeriesA4PreferredSharesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20230101to20231231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20230101to20231231_usgaapStatementEquityComponentsAxis_usgaapParentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20230101to20231231_usgaapStatementEquityComponentsAxis_usgaapNoncontrollingInterestMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20230101to20231231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20231231_usgaapClassOfWarrantOrRightAxis_usgaapWarrantMember_usgaapStatementClassOfStockAxis_slxnSeriesA4PreferredSharesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">slxn:SeriesA4PreferredSharesMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20231231_srtRangeAxis_srtMaximumMember_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapLeaseholdImprovementsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20220101">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2022-01-01</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20231231_srtRangeAxis_srtMinimumMember_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapLeaseholdImprovementsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20231231_usgaapAwardTypeAxis_slxnOptionPreFundedMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">slxn:OptionPreFundedMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20231231_usgaapAwardTypeAxis_slxnPreFundedOptionsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">slxn:PreFundedOptionsMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20230101to20231231_usgaapAwardTypeAxis_slxnPreFundedOptionsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">slxn:PreFundedOptionsMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20220101to20221231_usgaapAwardTypeAxis_slxnPreFundedOptionsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">slxn:PreFundedOptionsMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20230615_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">slxn:MoringaAcquisitionCorpMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2023-06-15</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20221231_usgaapRelatedPartyTransactionsByRelatedPartyAxis_usgaapRelatedPartyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20231231_usgaapStatementClassOfStockAxis_slxnConvertibleSeriesAPreferredSharesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">slxn:ConvertibleSeriesAPreferredSharesMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20221231_usgaapStatementClassOfStockAxis_slxnConvertibleSeriesAPreferredSharesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">slxn:ConvertibleSeriesAPreferredSharesMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20231231_usgaapStatementClassOfStockAxis_slxnConvertibleSeriesAOnePreferredSharesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">slxn:ConvertibleSeriesAOnePreferredSharesMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20221231_usgaapStatementClassOfStockAxis_slxnConvertibleSeriesAOnePreferredSharesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">slxn:ConvertibleSeriesAOnePreferredSharesMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20231231_usgaapStatementClassOfStockAxis_slxnConvertibleSeriesA2PreferredSharesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">slxn:ConvertibleSeriesA2PreferredSharesMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20221231_usgaapStatementClassOfStockAxis_slxnConvertibleSeriesA2PreferredSharesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">slxn:ConvertibleSeriesA2PreferredSharesMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20231231_usgaapStatementClassOfStockAxis_slxnConvertibleSeriesAThreePreferredSharesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">slxn:ConvertibleSeriesAThreePreferredSharesMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20221231_usgaapStatementClassOfStockAxis_slxnConvertibleSeriesAThreePreferredSharesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">slxn:ConvertibleSeriesAThreePreferredSharesMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20231231_usgaapStatementClassOfStockAxis_slxnConvertibleSeriesAFourPreferredSharesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">slxn:ConvertibleSeriesAFourPreferredSharesMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20221231_usgaapStatementClassOfStockAxis_slxnConvertibleSeriesAFourPreferredSharesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">slxn:ConvertibleSeriesAFourPreferredSharesMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapFairValueByFairValueHierarchyLevelAxis_usgaapFairValueInputsLevel1Member_usgaapFairValueByMeasurementFrequencyAxis_usgaapFairValueMeasurementsRecurringMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">slxn:MoringaAcquisitionCorpMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20221231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapFairValueByFairValueHierarchyLevelAxis_usgaapFairValueInputsLevel1Member_usgaapFairValueByMeasurementFrequencyAxis_usgaapFairValueMeasurementsRecurringMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">slxn:MoringaAcquisitionCorpMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapFairValueByFairValueHierarchyLevelAxis_usgaapFairValueInputsLevel3Member_usgaapFairValueByMeasurementFrequencyAxis_usgaapFairValueMeasurementsRecurringMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">slxn:MoringaAcquisitionCorpMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20221231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapFairValueByFairValueHierarchyLevelAxis_usgaapFairValueInputsLevel3Member_usgaapFairValueByMeasurementFrequencyAxis_usgaapFairValueMeasurementsRecurringMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">slxn:MoringaAcquisitionCorpMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapMeasurementInputTypeAxis_usgaapMeasurementInputSharePriceMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">slxn:MoringaAcquisitionCorpMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20221231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapMeasurementInputTypeAxis_usgaapMeasurementInputSharePriceMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">slxn:MoringaAcquisitionCorpMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapMeasurementInputTypeAxis_slxnMeasurementInputStrikevPriceMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">slxn:MoringaAcquisitionCorpMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">slxn:MeasurementInputStrikevPriceMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20221231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapMeasurementInputTypeAxis_slxnMeasurementInputStrikevPriceMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">slxn:MoringaAcquisitionCorpMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">slxn:MeasurementInputStrikevPriceMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapMeasurementInputTypeAxis_usgaapMeasurementInputPriceVolatilityMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">slxn:MoringaAcquisitionCorpMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20221231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapMeasurementInputTypeAxis_usgaapMeasurementInputPriceVolatilityMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">slxn:MoringaAcquisitionCorpMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapMeasurementInputTypeAxis_usgaapMeasurementInputRiskFreeInterestRateMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">slxn:MoringaAcquisitionCorpMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20221231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapMeasurementInputTypeAxis_usgaapMeasurementInputRiskFreeInterestRateMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">slxn:MoringaAcquisitionCorpMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapMeasurementInputTypeAxis_usgaapMeasurementInputExpectedDividendRateMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">slxn:MoringaAcquisitionCorpMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20221231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapMeasurementInputTypeAxis_usgaapMeasurementInputExpectedDividendRateMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">slxn:MoringaAcquisitionCorpMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20221231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapFairValueByFairValueHierarchyLevelAxis_usgaapFairValueInputsLevel3Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">slxn:MoringaAcquisitionCorpMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20230101to20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapFairValueByFairValueHierarchyLevelAxis_usgaapFairValueInputsLevel3Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">slxn:MoringaAcquisitionCorpMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapFairValueByFairValueHierarchyLevelAxis_usgaapFairValueInputsLevel3Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">slxn:MoringaAcquisitionCorpMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20231231_usgaapRelatedPartyTransactionsByRelatedPartyAxis_slxnSPACMember_usgaapSubsequentEventTypeAxis_usgaapSubsequentEventMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">slxn:SPACMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20231231_usgaapRelatedPartyTransactionsByRelatedPartyAxis_slxnNewPubcoMember_usgaapSubsequentEventTypeAxis_usgaapSubsequentEventMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">slxn:NewPubcoMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20230101to20231231_usgaapRelatedPartyTransactionsByRelatedPartyAxis_slxnNewPubcoMember_usgaapSubsequentEventTypeAxis_usgaapSubsequentEventMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">slxn:NewPubcoMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20240930_usgaapStatementClassOfStockAxis_slxnConvertibleSeriesAOnePreferredSharesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">slxn:ConvertibleSeriesAOnePreferredSharesMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2024-09-30</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20240930_usgaapStatementClassOfStockAxis_slxnConvertibleSeriesA2PreferredSharesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">slxn:ConvertibleSeriesA2PreferredSharesMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2024-09-30</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20240930_usgaapStatementClassOfStockAxis_slxnConvertibleSeriesAThreePreferredSharesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">slxn:ConvertibleSeriesAThreePreferredSharesMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2024-09-30</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20240930_usgaapStatementClassOfStockAxis_slxnConvertibleSeriesAFourPreferredSharesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">slxn:ConvertibleSeriesAFourPreferredSharesMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2024-09-30</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20240930_usgaapStatementClassOfStockAxis_slxnConvertibleSeriesAPreferredSharesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">slxn:ConvertibleSeriesAPreferredSharesMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2024-09-30</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20231231_srtOwnershipAxis_slxnSilexionEquityFinancingMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:OwnershipAxis">slxn:SilexionEquityFinancingMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20241122">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2024-11-22</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20231231_usgaapFairValueByFairValueHierarchyLevelAxis_usgaapFairValueInputsLevel3Member_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20231231_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20231231_usgaapClassOfWarrantOrRightAxis_usgaapWarrantMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20240101to20240930_usgaapClassOfWarrantOrRightAxis_usgaapWarrantMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-09-30</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20240930_usgaapClassOfWarrantOrRightAxis_usgaapWarrantMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2024-09-30</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20240630_usgaapClassOfWarrantOrRightAxis_usgaapWarrantMember_usgaapStatementEquityComponentsAxis_slxnPromissoryNotesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">slxn:PromissoryNotesMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2024-06-30</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20240630_usgaapClassOfWarrantOrRightAxis_usgaapWarrantMember_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2024-06-30</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20240630_usgaapClassOfWarrantOrRightAxis_usgaapWarrantMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2024-06-30</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20231231_usgaapClassOfWarrantOrRightAxis_usgaapWarrantMember_usgaapStatementEquityComponentsAxis_slxnPromissoryNotesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">slxn:PromissoryNotesMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20231231_usgaapClassOfWarrantOrRightAxis_usgaapWarrantMember_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20240701to20240930_usgaapClassOfWarrantOrRightAxis_usgaapWarrantMember_usgaapStatementEquityComponentsAxis_slxnPromissoryNotesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">slxn:PromissoryNotesMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-07-01</xbrli:startDate>
        <xbrli:endDate>2024-09-30</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20240701to20240930_usgaapClassOfWarrantOrRightAxis_usgaapWarrantMember_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-07-01</xbrli:startDate>
        <xbrli:endDate>2024-09-30</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20240701to20240930_usgaapClassOfWarrantOrRightAxis_usgaapWarrantMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-07-01</xbrli:startDate>
        <xbrli:endDate>2024-09-30</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20240101to20240930_usgaapClassOfWarrantOrRightAxis_usgaapWarrantMember_usgaapStatementEquityComponentsAxis_slxnPromissoryNotesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">slxn:PromissoryNotesMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-09-30</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20240101to20240930_usgaapClassOfWarrantOrRightAxis_usgaapWarrantMember_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-09-30</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20240930_usgaapClassOfWarrantOrRightAxis_usgaapWarrantMember_usgaapStatementEquityComponentsAxis_slxnPromissoryNotesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">slxn:PromissoryNotesMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2024-09-30</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20240930_usgaapClassOfWarrantOrRightAxis_usgaapWarrantMember_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2024-09-30</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20240930_usgaapStatementEquityComponentsAxis_slxnPromissoryNotesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">slxn:PromissoryNotesMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2024-09-30</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20240930_usgaapFairValueByFairValueHierarchyLevelAxis_usgaapFairValueInputsLevel3Member_usgaapStatementEquityComponentsAxis_slxnPromissoryNotesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">slxn:PromissoryNotesMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2024-09-30</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20240930_usgaapFairValueByFairValueHierarchyLevelAxis_usgaapFairValueInputsLevel3Member_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2024-09-30</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20230630_usgaapClassOfWarrantOrRightAxis_usgaapWarrantMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2023-06-30</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20221231_usgaapClassOfWarrantOrRightAxis_usgaapWarrantMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20230701to20230930_usgaapClassOfWarrantOrRightAxis_usgaapWarrantMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-07-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20230101to20230930_usgaapClassOfWarrantOrRightAxis_usgaapWarrantMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20230930_usgaapClassOfWarrantOrRightAxis_usgaapWarrantMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2023-09-30</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20240101to20240930_usgaapFairValueByFairValueHierarchyLevelAxis_usgaapFairValueInputsLevel3Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-09-30</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20240801to20240815_usgaapFairValueByFairValueHierarchyLevelAxis_usgaapFairValueInputsLevel3Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-08-01</xbrli:startDate>
        <xbrli:endDate>2024-08-15</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20240101to20240930_srtRangeAxis_srtMinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-09-30</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20240101to20240930_srtRangeAxis_srtMaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-09-30</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20230101to20231231_usgaapRelatedPartyTransactionAxis_usgaapRelatedPartyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20220101to20221231_usgaapRelatedPartyTransactionAxis_usgaapRelatedPartyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20240704_usgaapAwardTypeAxis_usgaapRestrictedStockUnitsRSUMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2024-07-04</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20231231_usgaapGranteeStatusAxis_slxnShareBasedPaymentArrangementEmployeeAndNonEmployeeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">slxn:ShareBasedPaymentArrangementEmployeeAndNonEmployeeMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20230101to20231231_usgaapGranteeStatusAxis_slxnShareBasedPaymentArrangementEmployeeAndNonEmployeeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">slxn:ShareBasedPaymentArrangementEmployeeAndNonEmployeeMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20240101to20240930_usgaapGranteeStatusAxis_slxnShareBasedPaymentArrangementEmployeeAndNonEmployeeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">slxn:ShareBasedPaymentArrangementEmployeeAndNonEmployeeMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-09-30</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20240930_usgaapGranteeStatusAxis_slxnShareBasedPaymentArrangementEmployeeAndNonEmployeeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">slxn:ShareBasedPaymentArrangementEmployeeAndNonEmployeeMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2024-09-30</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20240101to20240930_usgaapIncomeStatementLocationAxis_usgaapResearchAndDevelopmentExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-09-30</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20230101to20230930_usgaapIncomeStatementLocationAxis_usgaapResearchAndDevelopmentExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20240701to20240930_usgaapIncomeStatementLocationAxis_usgaapResearchAndDevelopmentExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-07-01</xbrli:startDate>
        <xbrli:endDate>2024-09-30</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20230701to20230930_usgaapIncomeStatementLocationAxis_usgaapResearchAndDevelopmentExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-07-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20240101to20240930_usgaapIncomeStatementLocationAxis_usgaapGeneralAndAdministrativeExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-09-30</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20230101to20230930_usgaapIncomeStatementLocationAxis_usgaapGeneralAndAdministrativeExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20240701to20240930_usgaapIncomeStatementLocationAxis_usgaapGeneralAndAdministrativeExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-07-01</xbrli:startDate>
        <xbrli:endDate>2024-09-30</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20230701to20230930_usgaapIncomeStatementLocationAxis_usgaapGeneralAndAdministrativeExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-07-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20240806_usgaapStatementClassOfStockAxis_slxnSeriesA1PreferredSharesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">slxn:SeriesA1PreferredSharesMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2024-08-06</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20240101to20240930_usgaapSubsidiarySaleOfStockAxis_usgaapIPOMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-09-30</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20240701to20240704_usgaapAwardTypeAxis_usgaapRestrictedStockUnitsRSUMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-07-01</xbrli:startDate>
        <xbrli:endDate>2024-07-04</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapClassOfWarrantOrRightAxis_slxnPublicWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">slxn:MoringaAcquisitionCorpMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">slxn:PublicWarrantsMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2024-06-30</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapClassOfWarrantOrRightAxis_slxnPrivateWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">slxn:MoringaAcquisitionCorpMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">slxn:PrivateWarrantsMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2024-06-30</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_srtTitleOfIndividualAxis_slxnSecondThirdForthAndFifthPromissoryNotesMember_usgaapDerivativeInstrumentRiskAxis_slxnPrivateWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">slxn:MoringaAcquisitionCorpMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">slxn:SecondThirdForthAndFifthPromissoryNotesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">slxn:PrivateWarrantsMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2024-06-30</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_srtTitleOfIndividualAxis_slxnSecondThirdForthAndFifthPromissoryNotesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">slxn:MoringaAcquisitionCorpMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">slxn:SecondThirdForthAndFifthPromissoryNotesMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2024-06-30</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20230101to20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_slxnClassAOrdinaryShareSubjectToPossibleRedemptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">slxn:MoringaAcquisitionCorpMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">slxn:ClassAOrdinaryShareSubjectToPossibleRedemptionMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20220101to20221231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_slxnClassAOrdinaryShareSubjectToPossibleRedemptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">slxn:MoringaAcquisitionCorpMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">slxn:ClassAOrdinaryShareSubjectToPossibleRedemptionMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20230101to20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_slxnNonredeemableClassAandBOrdinaryShareMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">slxn:MoringaAcquisitionCorpMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">slxn:NonredeemableClassAandBOrdinaryShareMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20220101to20221231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_slxnNonredeemableClassAandBOrdinaryShareMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">slxn:MoringaAcquisitionCorpMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">slxn:NonredeemableClassAandBOrdinaryShareMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20230101to20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapDerivativeInstrumentRiskAxis_slxnPublicWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">slxn:MoringaAcquisitionCorpMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">slxn:PublicWarrantsMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20230101to20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapDerivativeInstrumentRiskAxis_slxnPrivateWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">slxn:MoringaAcquisitionCorpMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">slxn:PrivateWarrantsMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_srtTitleOfIndividualAxis_slxnSecondThirdForthAndFifthPromissoryNotesMember_usgaapDerivativeInstrumentRiskAxis_slxnPrivateWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">slxn:MoringaAcquisitionCorpMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">slxn:SecondThirdForthAndFifthPromissoryNotesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">slxn:PrivateWarrantsMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20210809to20210809_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapDebtInstrumentAxis_slxnSecondPromissoryNoteMember_usgaapRelatedPartyTransactionAxis_slxnSponsorMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">slxn:MoringaAcquisitionCorpMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">slxn:SecondPromissoryNoteMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">slxn:SponsorMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-08-09</xbrli:startDate>
        <xbrli:endDate>2021-08-09</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20221231to20221231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapDebtInstrumentAxis_slxnThirdAndFourthPromissoryNotesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">slxn:MoringaAcquisitionCorpMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">slxn:ThirdAndFourthPromissoryNotesMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-12-31</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20230208to20230208_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapDebtInstrumentAxis_slxnFifthPromissoryNoteMember_usgaapRelatedPartyTransactionAxis_slxnSponsorMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">slxn:MoringaAcquisitionCorpMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">slxn:FifthPromissoryNoteMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">slxn:SponsorMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-02-08</xbrli:startDate>
        <xbrli:endDate>2023-02-08</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20230209to20230209_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapDebtInstrumentAxis_slxnSixthPromissoryNoteMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">slxn:MoringaAcquisitionCorpMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">slxn:SixthPromissoryNoteMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-02-09</xbrli:startDate>
        <xbrli:endDate>2023-02-09</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20230219to20230219_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapDebtInstrumentAxis_slxnSixthPromissoryNoteMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">slxn:MoringaAcquisitionCorpMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">slxn:SixthPromissoryNoteMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-02-19</xbrli:startDate>
        <xbrli:endDate>2023-02-19</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20230818to20230818_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapDebtInstrumentAxis_slxnEighthPromissoryNoteMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">slxn:MoringaAcquisitionCorpMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">slxn:EighthPromissoryNoteMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-08-18</xbrli:startDate>
        <xbrli:endDate>2023-08-18</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20240327to20240327_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">slxn:MoringaAcquisitionCorpMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-03-27</xbrli:startDate>
        <xbrli:endDate>2024-03-27</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20240627to20240627_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">slxn:MoringaAcquisitionCorpMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-06-27</xbrli:startDate>
        <xbrli:endDate>2024-06-27</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20201216to20201216_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapRelatedPartyTransactionAxis_slxnSponsorMember_usgaapTypeOfArrangementAxis_slxnAdministrativeServicesAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">slxn:MoringaAcquisitionCorpMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">slxn:SponsorMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">slxn:AdministrativeServicesAgreementMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-12-16</xbrli:startDate>
        <xbrli:endDate>2020-12-16</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapRelatedPartyTransactionAxis_slxnPromissoryNotesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">slxn:MoringaAcquisitionCorpMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">slxn:PromissoryNotesMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2024-06-30</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapRelatedPartyTransactionAxis_usgaapRelatedPartyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">slxn:MoringaAcquisitionCorpMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2024-06-30</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapRelatedPartyTransactionAxis_usgaapAssetManagementArrangementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">slxn:MoringaAcquisitionCorpMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:AssetManagementArrangementMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2024-06-30</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20240221_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapSubsequentEventTypeAxis_usgaapSubsequentEventMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">slxn:MoringaAcquisitionCorpMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2024-02-21</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20240101to20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapFinancialInstrumentAxis_slxnTenthPromissoryNoteMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">slxn:MoringaAcquisitionCorpMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">slxn:TenthPromissoryNoteMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20240101to20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapFinancialInstrumentAxis_slxnEighthPromissoryNoteMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">slxn:MoringaAcquisitionCorpMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">slxn:EighthPromissoryNoteMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20240806_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_srtStatementScenarioAxis_srtScenarioForecastMember_usgaapStatementClassOfStockAxis_slxnClassAOrdinarySharesSubjectToPossibleRedemptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">slxn:MoringaAcquisitionCorpMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">slxn:ClassAOrdinarySharesSubjectToPossibleRedemptionMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2024-08-06</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20240806_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_srtStatementScenarioAxis_srtScenarioForecastMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">slxn:MoringaAcquisitionCorpMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2024-08-06</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20230630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">slxn:MoringaAcquisitionCorpMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2023-06-30</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20240101to20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_usgaapCommonClassAMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">slxn:MoringaAcquisitionCorpMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20240101to20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapRelatedPartyTransactionAxis_slxnFirstExtensionsMember_usgaapStatementClassOfStockAxis_usgaapCommonClassAMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">slxn:MoringaAcquisitionCorpMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">slxn:FirstExtensionsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20240101to20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapRelatedPartyTransactionAxis_slxnSecondExtensionsMember_usgaapStatementClassOfStockAxis_usgaapCommonClassAMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">slxn:MoringaAcquisitionCorpMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">slxn:SecondExtensionsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20240101to20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_usgaapCommonClassBMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">slxn:MoringaAcquisitionCorpMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20240101to20240930_usgaapInvestmentTypeAxis_slxnUnderwritersPromissoryNoteMember_usgaapTypeOfArrangementAxis_slxnEarlybirdCapitalIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">slxn:UnderwritersPromissoryNoteMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">slxn:EarlybirdCapitalIncMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-09-30</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20240101to20240930_usgaapInvestmentTypeAxis_slxnSponsorPromissoryNoteMember_usgaapTypeOfArrangementAxis_slxnAAndRSponsorPromissoryNoteMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">slxn:SponsorPromissoryNoteMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">slxn:AAndRSponsorPromissoryNoteMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-09-30</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20240930_usgaapInvestmentTypeAxis_slxnSponsorPromissoryNoteMember_usgaapTypeOfArrangementAxis_slxnAAndRSponsorPromissoryNoteMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">slxn:SponsorPromissoryNoteMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">slxn:AAndRSponsorPromissoryNoteMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2024-09-30</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20240101to20240930_usgaapInvestmentTypeAxis_slxnPrivateInvestmentInPublicEntityMember_usgaapTypeOfArrangementAxis_slxnGreenstarLpMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">slxn:PrivateInvestmentInPublicEntityMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">slxn:GreenstarLpMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-09-30</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20240930_usgaapInvestmentTypeAxis_slxnPrivateInvestmentInPublicEntityMember_usgaapTypeOfArrangementAxis_slxnGreenstarLpMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">slxn:PrivateInvestmentInPublicEntityMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">slxn:GreenstarLpMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2024-09-30</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20240101to20240930_usgaapInvestmentTypeAxis_slxnEquityLineOfCreditMember_usgaapTypeOfArrangementAxis_slxnWhiteLionCapitalLlcMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">slxn:EquityLineOfCreditMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">slxn:WhiteLionCapitalLlcMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-09-30</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20240901to20240918_usgaapInvestmentTypeAxis_slxnEquityLineOfCreditMember_usgaapTypeOfArrangementAxis_slxnWhiteLionCapitalLlcMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">slxn:EquityLineOfCreditMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">slxn:WhiteLionCapitalLlcMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-09-01</xbrli:startDate>
        <xbrli:endDate>2024-09-18</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20240701to20240930_usgaapInvestmentTypeAxis_slxnEquityLineOfCreditMember_usgaapTypeOfArrangementAxis_slxnWhiteLionCapitalLlcMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">slxn:EquityLineOfCreditMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">slxn:WhiteLionCapitalLlcMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-07-01</xbrli:startDate>
        <xbrli:endDate>2024-09-30</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20240101to20240930_usgaapInvestmentTypeAxis_slxnSpacWarrantsMember_usgaapTypeOfArrangementAxis_slxnNewWarrantAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">slxn:SpacWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">slxn:NewWarrantAgreementMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-09-30</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20240930_usgaapInvestmentTypeAxis_slxnSpacWarrantsMember_usgaapTypeOfArrangementAxis_slxnNewWarrantAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">slxn:SpacWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">slxn:NewWarrantAgreementMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2024-09-30</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20240930_usgaapInvestmentTypeAxis_slxnEquityLineOfCreditMember_usgaapTypeOfArrangementAxis_slxnWhiteLionCapitalLlcMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">slxn:EquityLineOfCreditMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">slxn:WhiteLionCapitalLlcMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2024-09-30</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20230501to20230530">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-05-01</xbrli:startDate>
        <xbrli:endDate>2023-05-30</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20240806">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2024-08-06</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20231231_usgaapStatementClassOfStockAxis_slxnSeriesA1PreferredSharesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">slxn:SeriesA1PreferredSharesMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20221231_usgaapStatementClassOfStockAxis_slxnSeriesA1PreferredSharesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">slxn:SeriesA1PreferredSharesMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20221231_usgaapStatementClassOfStockAxis_slxnSeriesA3PreferredSharesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">slxn:SeriesA3PreferredSharesMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20221231_usgaapGranteeStatusAxis_slxnShareBasedPaymentArrangementEmployeeAndNonEmployeeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">slxn:ShareBasedPaymentArrangementEmployeeAndNonEmployeeMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20220101to20221231_usgaapGranteeStatusAxis_slxnShareBasedPaymentArrangementEmployeeAndNonEmployeeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">slxn:ShareBasedPaymentArrangementEmployeeAndNonEmployeeMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20211231_usgaapGranteeStatusAxis_slxnShareBasedPaymentArrangementEmployeeAndNonEmployeeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">slxn:ShareBasedPaymentArrangementEmployeeAndNonEmployeeMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20210101to20211231_usgaapGranteeStatusAxis_slxnShareBasedPaymentArrangementEmployeeAndNonEmployeeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">slxn:ShareBasedPaymentArrangementEmployeeAndNonEmployeeMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20220101to20221231_srtRangeAxis_srtMinimumMember_usgaapGranteeStatusAxis_usgaapShareBasedPaymentArrangementEmployeeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20220101to20221231_srtRangeAxis_srtMaximumMember_usgaapGranteeStatusAxis_usgaapShareBasedPaymentArrangementEmployeeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20220101to20221231_usgaapGranteeStatusAxis_usgaapShareBasedPaymentArrangementEmployeeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20221231_usgaapGranteeStatusAxis_usgaapShareBasedPaymentArrangementEmployeeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20220101to20221231_usgaapGranteeStatusAxis_usgaapShareBasedPaymentArrangementNonemployeeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementNonemployeeMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20221231_usgaapGranteeStatusAxis_usgaapShareBasedPaymentArrangementNonemployeeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementNonemployeeMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20230101to20231231_usgaapGranteeStatusAxis_usgaapShareBasedPaymentArrangementEmployeeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20231231_usgaapGranteeStatusAxis_usgaapShareBasedPaymentArrangementEmployeeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20211231_usgaapGranteeStatusAxis_usgaapShareBasedPaymentArrangementEmployeeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20230101to20231231_usgaapGranteeStatusAxis_usgaapShareBasedPaymentArrangementNonemployeeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementNonemployeeMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20211231_usgaapGranteeStatusAxis_usgaapShareBasedPaymentArrangementNonemployeeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementNonemployeeMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20230101to20231231_usgaapIncomeStatementLocationAxis_usgaapResearchAndDevelopmentExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20220101to20221231_usgaapIncomeStatementLocationAxis_usgaapResearchAndDevelopmentExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20230101to20231231_usgaapIncomeStatementLocationAxis_usgaapGeneralAndAdministrativeExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20220101to20221231_usgaapIncomeStatementLocationAxis_usgaapGeneralAndAdministrativeExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20231231_usgaapGranteeStatusAxis_usgaapShareBasedPaymentArrangementNonemployeeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementNonemployeeMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20210219to20210219_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapSubsidiarySaleOfStockAxis_usgaapIPOMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">slxn:MoringaAcquisitionCorpMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-02-19</xbrli:startDate>
        <xbrli:endDate>2021-02-19</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapSubsidiarySaleOfStockAxis_usgaapPrivatePlacementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">slxn:MoringaAcquisitionCorpMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20210303to20210303_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapSubsidiarySaleOfStockAxis_usgaapOverAllotmentOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">slxn:MoringaAcquisitionCorpMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-03-03</xbrli:startDate>
        <xbrli:endDate>2021-03-03</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20210303_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapSubsidiarySaleOfStockAxis_usgaapOverAllotmentOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">slxn:MoringaAcquisitionCorpMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2021-03-03</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapFairValueByFairValueHierarchyLevelAxis_usgaapFairValueInputsLevel1Member_usgaapFairValueByMeasurementFrequencyAxis_usgaapFairValueMeasurementsRecurringMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">slxn:MoringaAcquisitionCorpMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2024-06-30</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapFairValueByFairValueHierarchyLevelAxis_usgaapFairValueInputsLevel3Member_usgaapFairValueByMeasurementFrequencyAxis_usgaapFairValueMeasurementsRecurringMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">slxn:MoringaAcquisitionCorpMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2024-06-30</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapMeasurementInputTypeAxis_usgaapMeasurementInputSharePriceMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">slxn:MoringaAcquisitionCorpMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2024-06-30</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapMeasurementInputTypeAxis_slxnMeasurementInputStrikevPriceMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">slxn:MoringaAcquisitionCorpMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">slxn:MeasurementInputStrikevPriceMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2024-06-30</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapMeasurementInputTypeAxis_usgaapMeasurementInputPriceVolatilityMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">slxn:MoringaAcquisitionCorpMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2024-06-30</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapMeasurementInputTypeAxis_usgaapMeasurementInputRiskFreeInterestRateMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">slxn:MoringaAcquisitionCorpMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2024-06-30</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapMeasurementInputTypeAxis_usgaapMeasurementInputExpectedDividendRateMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">slxn:MoringaAcquisitionCorpMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2024-06-30</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapMeasurementInputTypeAxis_usgaapMeasurementInputCommodityMarketPriceMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">slxn:MoringaAcquisitionCorpMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputCommodityMarketPriceMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2024-06-30</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapMeasurementInputTypeAxis_usgaapMeasurementInputCommodityMarketPriceMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">slxn:MoringaAcquisitionCorpMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputCommodityMarketPriceMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20240101to20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapFairValueByFairValueHierarchyLevelAxis_usgaapFairValueInputsLevel3Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">slxn:MoringaAcquisitionCorpMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapFairValueByFairValueHierarchyLevelAxis_usgaapFairValueInputsLevel3Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">slxn:MoringaAcquisitionCorpMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2024-06-30</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20221231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_usgaapCommonClassAMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">slxn:MoringaAcquisitionCorpMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20221231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_usgaapCommonClassBMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">slxn:MoringaAcquisitionCorpMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20231231_usgaapFairValueByFairValueHierarchyLevelAxis_usgaapFairValueInputsLevel3Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20221231_usgaapFairValueByFairValueHierarchyLevelAxis_usgaapFairValueInputsLevel3Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20221231_usgaapClassOfWarrantOrRightAxis_usgaapWarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20211231_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_slxnSAFEMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">slxn:SAFEMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20230101to20231231_usgaapClassOfWarrantOrRightAxis_usgaapWarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20220101to20221231_usgaapClassOfWarrantOrRightAxis_usgaapWarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20221231_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_slxnSAFEMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">slxn:SAFEMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20230101to20231231_usgaapMeasurementInputTypeAxis_slxnProbabilityOfAnIPOScenarioMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">slxn:ProbabilityOfAnIPOScenarioMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20230101to20231231_usgaapMeasurementInputTypeAxis_slxnExpectedTimeToIPOMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">slxn:ExpectedTimeToIPOMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20230101to20231231_usgaapMeasurementInputTypeAxis_slxnProbabilityOfOtherLiquidationEventsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">slxn:ProbabilityOfOtherLiquidationEventsMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20220101to20221231_usgaapMeasurementInputTypeAxis_slxnProbabilityOfOtherLiquidationEventsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">slxn:ProbabilityOfOtherLiquidationEventsMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20230101to20231231_usgaapMeasurementInputTypeAxis_slxnExpectedTimeToLiquidationMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">slxn:ExpectedTimeToLiquidationMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20220101to20221231_usgaapMeasurementInputTypeAxis_slxnExpectedTimeToLiquidationMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">slxn:ExpectedTimeToLiquidationMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20230101to20231231_usgaapMeasurementInputTypeAxis_slxnExpectedReturnOnEquityMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">slxn:ExpectedReturnOnEquityMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20220101to20221231_usgaapMeasurementInputTypeAxis_slxnExpectedReturnOnEquityMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">slxn:ExpectedReturnOnEquityMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20220101to20221231_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_slxnSAFEMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">slxn:SAFEMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20211231_usgaapClassOfWarrantOrRightAxis_usgaapWarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20220101to20221231_usgaapMeasurementInputTypeAxis_slxnProbabilityOfAnIPOScenarioMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">slxn:ProbabilityOfAnIPOScenarioMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20220101to20221231_usgaapMeasurementInputTypeAxis_slxnExpectedTimeToIPOMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">slxn:ExpectedTimeToIPOMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20210315to20210315_usgaapRelatedPartyTransactionsByRelatedPartyAxis_usgaapInvestorMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:InvestorMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-03-15</xbrli:startDate>
        <xbrli:endDate>2021-03-15</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20231231_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_slxnSAFEMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">slxn:SAFEMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20230101to20231231_srtRangeAxis_srtMaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20230101to20231231_srtRangeAxis_srtMinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20220114to20220114">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-14</xbrli:startDate>
        <xbrli:endDate>2022-01-14</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20220114_usgaapClassOfWarrantOrRightAxis_usgaapWarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2022-01-14</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20230101to20230331_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">slxn:MoringaAcquisitionCorpMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-03-31</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20230101to20230331_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">slxn:MoringaAcquisitionCorpMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-03-31</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20230331_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_usgaapCommonClassAMember_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">slxn:MoringaAcquisitionCorpMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2023-03-31</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20230331_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_usgaapCommonClassBMember_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">slxn:MoringaAcquisitionCorpMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2023-03-31</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20230331_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">slxn:MoringaAcquisitionCorpMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2023-03-31</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20230331_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">slxn:MoringaAcquisitionCorpMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2023-03-31</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20230401to20230630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">slxn:MoringaAcquisitionCorpMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-04-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20230630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_usgaapCommonClassAMember_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">slxn:MoringaAcquisitionCorpMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2023-06-30</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20230630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_usgaapCommonClassBMember_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">slxn:MoringaAcquisitionCorpMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2023-06-30</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20230630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">slxn:MoringaAcquisitionCorpMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2023-06-30</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20240101to20240331_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">slxn:MoringaAcquisitionCorpMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-03-31</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20240101to20240331_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">slxn:MoringaAcquisitionCorpMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-03-31</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20240331_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_usgaapCommonClassAMember_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">slxn:MoringaAcquisitionCorpMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2024-03-31</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20240331_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_usgaapCommonClassBMember_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">slxn:MoringaAcquisitionCorpMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2024-03-31</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20240331_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">slxn:MoringaAcquisitionCorpMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2024-03-31</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20240331_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">slxn:MoringaAcquisitionCorpMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2024-03-31</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20240401to20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">slxn:MoringaAcquisitionCorpMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-04-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_usgaapCommonClassAMember_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">slxn:MoringaAcquisitionCorpMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2024-06-30</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_usgaapCommonClassBMember_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">slxn:MoringaAcquisitionCorpMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2024-06-30</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">slxn:MoringaAcquisitionCorpMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2024-06-30</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20230101to20231231_usgaapRelatedPartyTransactionsByRelatedPartyAxis_usgaapRelatedPartyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20220101to20221231_usgaapRelatedPartyTransactionsByRelatedPartyAxis_usgaapRelatedPartyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002022416</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:unit id="Days">
      <xbrli:measure>slxn:Days</xbrli:measure>
      </xbrli:unit>
    <xbrli:unit id="NIS">
      <xbrli:measure>iso4217:ILS</xbrli:measure>
      </xbrli:unit>
    <xbrli:unit id="Segment">
      <xbrli:measure>slxn:Segment</xbrli:measure>
      </xbrli:unit>
    <xbrli:unit id="ilsPershares"><xbrli:divide>
      <xbrli:unitNumerator>
      <xbrli:measure>iso4217:ILS</xbrli:measure></xbrli:unitNumerator>
      <xbrli:unitDenominator>
      <xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide>
      </xbrli:unit>
    <xbrli:unit id="pure">
      <xbrli:measure>xbrli:pure</xbrli:measure>
      </xbrli:unit>
    <xbrli:unit id="shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
      </xbrli:unit>
    <xbrli:unit id="usd">
      <xbrli:measure>iso4217:USD</xbrli:measure>
      </xbrli:unit>
    <xbrli:unit id="usdPershares"><xbrli:divide>
      <xbrli:unitNumerator>
      <xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator>
      <xbrli:unitDenominator>
      <xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide>
      </xbrli:unit>
    <ix:relationship fromRefs="Fxbrl_20241004054608864_hidden-fact-3" toRefs="FN20241205155356638"/>
    <ix:relationship fromRefs="Fxbrl_20241004054608864_hidden-fact-2" toRefs="FN20241205155356638"/>
    <ix:relationship fromRefs="F20241205041230498_10" toRefs="FN20241205155632368"/>
    <ix:relationship fromRefs="F20241205041230557_39" toRefs="FN20241205155632368"/>
    <ix:relationship fromRefs="F20241205041230590_56" toRefs="FN20241205155632368"/>
    <ix:relationship fromRefs="F20241205041230601_61" toRefs="FN20241205171327256"/>
    <ix:relationship fromRefs="F20241205041230602_62" toRefs="FN20241205155632368"/>
    <ix:relationship fromRefs="F20241205041230604_63" toRefs="FN20241205155632368"/>
    <ix:relationship fromRefs="F20241205041230606_64" toRefs="FN20241205155632368"/>
    <ix:relationship fromRefs="F20241205041230673_98" toRefs="FN20241205155632368"/>
    <ix:relationship fromRefs="F20241205041230720_122" toRefs="FN20241205155632368"/>
    <ix:relationship fromRefs="F20241205041230752_139" toRefs="FN20241205155632368"/>
    <ix:relationship fromRefs="F20241205041230887_172" toRefs="FN20241205155632368"/>
    <ix:relationship fromRefs="F20241205041230912_192" toRefs="FN20241205155632368"/>
    <ix:relationship fromRefs="F20241205041230952_206" toRefs="FN20241205155632368"/>
    <ix:relationship fromRefs="F20241205041230955_207" toRefs="FN20241205155632368"/>
    <ix:relationship fromRefs="F20241205041230956_208" toRefs="FN20241205155632368"/>
    <ix:relationship fromRefs="F20241205041230960_211" toRefs="FN20241205155632368"/>
    <ix:relationship fromRefs="Fxbrl_20241111194750134_20241205041230956_208" toRefs="FN20241205155632368"/>
    <ix:relationship fromRefs="Fxbrl_20241111194750134_20241205041230955_207" toRefs="FN20241205155632368"/>
    <ix:relationship fromRefs="F20241205041230967_216" toRefs="FN20241205155632368"/>
    <ix:relationship fromRefs="Fxbrl_20241111194750134_20241205041230952_206" toRefs="FN20241205155632368"/>
    <ix:relationship fromRefs="Fxbrl_20241111194811742_20241205041230960_211" toRefs="FN20241205155632368"/>
    <ix:relationship fromRefs="Fixv-39019" toRefs="FN20241205155632368"/>
    <ix:relationship fromRefs="Fhidden-fact-104" toRefs="FN20241205155632368"/>
    <ix:relationship fromRefs="Fixv-39053" toRefs="FN20241205155632368"/>
    <ix:relationship fromRefs="Fixv-39082" toRefs="FN20241205155632368"/>
    <ix:relationship fromRefs="Fix_8_fact" toRefs="FN20241004135506058"/>
    <ix:relationship fromRefs="Fxbrl_20241206144615742" toRefs="FN20241004135506058"/>
    <ix:relationship fromRefs="Fixv-38968" toRefs="FN20241205155632368"/>
    <ix:relationship fromRefs="Fixv-38969" toRefs="FN20241205155632368"/>
    <ix:relationship fromRefs="Fxbrl_20241004105335082" toRefs="FN20241205155658750"/>
    <ix:relationship fromRefs="Fxbrl_20241205160916026" toRefs="FN20241205155658750"/>
    <ix:relationship fromRefs="F20241205041230370_13" toRefs="FN20241205155658750"/>
    <ix:relationship fromRefs="Fxbrl_20241205155736145" toRefs="FN20241205155658750"/>
    <ix:relationship fromRefs="F20241205041230391_62" toRefs="FN20241205155632368"/>
    <ix:relationship fromRefs="Fhidden-fact-12" toRefs="FN20241205155356638"/>
    <ix:relationship fromRefs="Fhidden-fact-70" toRefs="FN20241205155356638"/>
    <ix:relationship fromRefs="Fhidden-fact-71" toRefs="FN20241205155356638"/>
    <ix:relationship fromRefs="Fhidden-fact-72" toRefs="FN20241205155356638"/>
    </ix:resources>
  </ix:header></div>

<div>

<div style="font:10pt Times New Roman, Times, Serif">

<div>

<div style="text-align:center;margin-left:0.75pt;line-height:1.25;font-family:'Times New Roman', Times, serif;font-size:10pt;font-weight:bold">

<div style="line-height:1.25;font-weight:bold">

<div style="line-height:1.25;font-weight:bold">As filed with the United States Securities and Exchange Commission on February 12, 2025.</div>
</div> </div>

<div style="text-align:right;line-height:1.25;font-family:'Times New Roman', Times, serif;font-size:10pt">

<div style="margin-left:400.35pt;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold">

<div style="line-height:1.25;font-family:'Times New Roman', Times, serif"><span style="font-weight:bold">Registration No. 333-&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></div>
</div> <hr style="border:none;border-bottom:1px solid black;border-top:4px solid black;height:10px;color:#ffffff;background-color:#ffffff;text-align:center;margin-left:auto;margin-right:auto;text-align:center"/>
</div>

<div style="text-align:left;line-height:1.25;font-family:'Times New Roman',Times,serif;font-size:10pt">&#160;</div>

<div style="text-align:center;line-height:1.25;font-family:'Times New Roman', Times, serif;font-size:10pt;font-weight:bold">UNITED STATES</div>

<div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-size:14pt;font-weight:bold">SECURITIES AND
EXCHANGE COMMISSION</div>

<div style="text-align:center;line-height:1.25;font-family:'Times New Roman', Times, serif;font-size:10pt;font-weight:bold">Washington,
D.C. 20549</div>

<div style="text-align:center;line-height:1.25;font-family:'Times New Roman', Times, serif;font-size:10pt">&#160;</div>

<div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-size:14pt;font-weight:bold">FORM <ix:nonNumeric id="Fixv-37588" name="dei:DocumentType" contextRef="C_20240101to20240930">S-1</ix:nonNumeric></div>

<div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-size:14pt;font-weight:bold">&#160;</div>

<div style="text-align:center;line-height:1.25;font-family:'Times New Roman', Times, serif;font-size:10pt;font-weight:bold"><span style="font-family:'Times New Roman',Times,serif">REGISTRATION
STATEMENT UNDER <span style="font-style:normal"> </span></span></div>

<div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-size:10pt;font-style:normal;font-weight:bold">THE
SECURITIES ACT OF 1933</div>

<div style="text-align:center;line-height:1.25;font-family:'Times New Roman', Times, serif;font-size:10pt">&#160;</div>

<div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-size:16pt;font-weight:bold"><ix:nonNumeric id="Fixv-64" name="dei:EntityRegistrantName" contextRef="C_20240101to20240930">Silexion
Therapeutics Corp</ix:nonNumeric></div>

<div style="text-align:center;line-height:1.25;font-family:'Times New Roman', Times, serif;font-size:10pt">(Exact name of registrant as
specified in its charter)</div>

<div style="text-align:center;line-height:1.25;font-family:'Times New Roman', Times, serif;font-size:10pt">&#160;</div>

<table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">
  <tr>
    <td style="width:32.01%;vertical-align:top;border-bottom:#000000 2px solid">
        <div style="text-align:center;line-height:1.25;font-weight:bold;font-family:'Times New Roman',Times,serif"><ix:nonNumeric id="Fixv-81" name="dei:EntityIncorporationStateCountryCode" contextRef="C_20240101to20240930" format="ixt-sec:edgarprovcountryen">Cayman
        Islands</ix:nonNumeric></div> </td>
    <td style="width:2%;vertical-align:bottom">
        <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div> </td>
    <td style="width:32%;vertical-align:top;border-bottom:#000000 2px solid">
        <div style="text-align:center;line-height:1.25;font-weight:bold;font-family:'Times New Roman',Times,serif">8731</div> </td>
    <td style="width:2%;vertical-align:bottom">
        <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div> </td>
    <td style="width:32%;vertical-align:top;border-bottom:#000000 2px solid">
        <div style="text-align:center;line-height:1.25;font-weight:bold;font-family:'Times New Roman',Times,serif">N/A</div> </td> </tr>
  <tr>
    <td style="width:32.01%;vertical-align:top">
        <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif">(State or other jurisdiction of</div>
        <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif">incorporation or organization)</div> </td>
    <td style="width:2%;vertical-align:top">
        <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div> </td>
    <td style="width:32%;vertical-align:top">
        <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif">(Primary Standard Industrial<br/>Classification
        Code Number)</div> </td>
    <td style="width:2%;vertical-align:top">
        <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div> </td>
    <td style="width:32%;vertical-align:top">
        <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif">(I.R.S. Employer</div>
        <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif">Identification Number)</div> </td> </tr>
  </table>

<div style="text-align:center;line-height:1.25;font-family:'Times New Roman', Times, serif;font-size:10pt;font-weight:bold">&#160;</div>

<div style="text-align:center;line-height:1.25;font-family:'Times New Roman', Times, serif;font-size:10pt;font-weight:bold">12 Abba Hillel
Road</div>

<div style="text-align:center;line-height:1.25;font-family:'Times New Roman', Times, serif;font-size:10pt;font-weight:bold">Ramat Gan,
Israel 5250606</div>

<div style="text-align:center;line-height:1.25;font-family:'Times New Roman', Times, serif;font-size:10pt;font-weight:bold"><span style="text-decoration:underline">+972-8-6286005</span></div>

<div style="text-align:center;line-height:1.25;font-family:'Times New Roman', Times, serif;font-size:10pt">(Address, Including Zip Code,
and Telephone Number, Including Area Code, of Registrant&#8217;s Principal Executive Offices)</div>

<div style="text-align:center;line-height:1.25;font-family:'Times New Roman', Times, serif;font-size:10pt;font-weight:bold">&#160;</div>

<div style="text-align:center;line-height:1.25;font-family:'Times New Roman', Times, serif;font-size:10pt;font-weight:bold"><span style="font-family:'Times New Roman',Times,serif">Puglisi&#160;&amp;
Associates<br/>850 Library Avenue, Suite 204<br/>Newark, DE&#160;19711<span style="text-decoration:underline"></span></span></div>

<div style="text-align:center;line-height:1.25;font-family:'Times New Roman', Times, serif;font-size:10pt;font-weight:bold"><span style="font-family:'Times New Roman',Times,serif"><span style="text-decoration:underline">Telephone:
(302)&#160;738-6680</span></span></div>

<div style="text-align:center;line-height:1.25;font-family:'Times New Roman', Times, serif;font-size:10pt">(Name, Address, Including Zip
Code, and Telephone Number, Including Area Code, of Agent For Service)</div>

<div style="text-align:center;line-height:1.25;font-family:'Times New Roman', Times, serif;font-size:10pt">&#160;</div>

<div style="text-align:center;line-height:1.25;font-family:'Times New Roman', Times, serif;font-size:10pt;font-weight:bold">Copies to:</div>

<div>

<div>&#160;</div>

<table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">
  <tr>
    <td style="width:50%;vertical-align:top">
        <div style="text-align:center;line-height:1.25;font-weight:bold">
        <div style="line-height:1.25">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold">
        <div style="line-height:1.25;font-family:'Times New Roman', Times, serif;font-weight:bold">Jonathan M.&#160;Nathan, Adv.</div> </div>
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold">Meitar Law Offices</div>
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold">16 Abba Hillel Road</div>
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold">Ramat Gan, Israel 5251608</div>
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold">Tel: +972-3-610-3100</div> </div> </div> </td>
    <td style="width:50%;vertical-align:top">
        <div style="text-align:center;text-indent:-0.05pt;margin-right:101.6pt;margin-left:106pt;line-height:1.25;font-weight:bold">
        <div style="line-height:1.25;font-weight:bold">Mark&#160;S.&#160;Selinger,&#160;Esq.</div> </div>
        <div style="text-align:center;text-indent:-0.05pt;margin-right:101.6pt;margin-left:106pt;line-height:1.25;font-weight:bold">Gary Emmanuel,
        Esq.</div>
        <div style="text-align:center;text-indent:-0.05pt;margin-right:101.6pt;margin-left:106pt;line-height:1.25;font-weight:bold">Greenberg
        Traurig, LLP</div>
        <div style="text-align:center;text-indent:-0.05pt;margin-right:101.6pt;margin-left:106pt;line-height:1.25;font-weight:bold">
        <div style="line-height:1.25;font-weight:bold">One&#160;Vanderbilt&#160;Avenue</div> </div>
        <div style="text-align:center;margin-right:89.45pt;margin-left:93.75pt;line-height:1.25;font-weight:bold">
        <div style="line-height:1.25;font-weight:bold">New&#160;York,&#160;New&#160;York&#160;10017-5404</div> </div>
        <div style="text-align:center;margin-right:89.45pt;margin-left:93.75pt;line-height:1.25;font-weight:bold">Tel: (212) 801-9200</div> </td>
        </tr>
  </table> </div>

<div>&#160;</div>

<div>

<div style="text-align:center;line-height:1.25;font-family:'Times New Roman', Times, serif;font-size:10pt">Approximate date of commencement
of proposed sale to the public:</div>

<div style="text-align:center;line-height:1.25;font-family:'Times New Roman', Times, serif;font-size:10pt">&#160;</div>

<div style="text-align:center;line-height:1.25;font-family:'Times New Roman', Times, serif;font-size:10pt;font-weight:bold">

<div style="margin-left:0.8pt;line-height:1.25;font-weight:bold">

<div style="line-height:1.25;font-weight:bold">From time to time on or after this registration statement is declared effective.</div>
</div> </div> </div>

<div style="text-align:justify;text-indent:18pt;line-height:1.25;font-family:'Times New Roman', Times, serif;font-size:10pt">&#160;</div>

<div style="text-align:left;text-indent:25.2pt;margin-right:11.1pt;margin-left:8.15pt;line-height:1.25;font-family:'Times New Roman', Times, serif;font-size:10pt">If
any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the
Securities Act of 1933, check the following box. &#9746;</div>

<div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-size:10pt">&#160;</div>

<div style="text-align:left;text-indent:25.2pt;margin-left:8.15pt;line-height:1.25;font-family:'Times New Roman', Times, serif;font-size:10pt">If
this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, please check the
following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.
&#9744;</div>

<div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-size:10pt">&#160;</div>

<div style="text-align:left;text-indent:25.2pt;margin-right:11.1pt;margin-left:8.15pt;line-height:1.25;font-family:'Times New Roman', Times, serif;font-size:10pt">If
this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities
Act registration statement number of the earlier effective registration statement for the same offering. &#9744;</div>

<div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-size:10pt">&#160;</div>

<div style="text-align:left;text-indent:25.2pt;margin-right:11.1pt;margin-left:8.15pt;line-height:1.25;font-family:'Times New Roman', Times, serif;font-size:10pt">If
this Form is a post-effective amendment filed pursuant to Rule 462(d) under the Securities Act, check the following box and list the Securities
Act registration statement number of the earlier effective registration statement for the same offering. &#9744;</div>

<div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-size:10pt">&#160;</div>

<div style="text-align:left;text-indent:25.2pt;margin-left:8.15pt;line-height:1.25;font-family:'Times New Roman', Times, serif;font-size:10pt">Indicate
by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting
company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221;
&#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</div>

<div style="text-align:justify;text-indent:18pt;line-height:1.25;font-family:'Times New Roman', Times, serif;font-size:10pt">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">
  <tr>
    <td style="width:20%;vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">Large accelerated filer</div> </td>
    <td style="width:30%;vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#9744;</div> </td>
    <td style="width:20%;vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">Accelerated filer</div> </td>
    <td style="width:30%;vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#9744;</div> </td> </tr>
  <tr>
    <td style="width:20%;vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><ix:nonNumeric id="Fixv-208" name="dei:EntityFilerCategory" contextRef="C_20240101to20240930" format="ixt-sec:entityfilercategoryen">Non-accelerated
        filer</ix:nonNumeric></div> </td>
    <td style="width:30%;vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#9746;</div> </td>
    <td style="width:20%;vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">Smaller reporting company</div> </td>
    <td style="width:30%;vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><ix:nonNumeric id="Fixv-215" name="dei:EntitySmallBusiness" contextRef="C_20240101to20240930" format="ixt:fixed-true">&#9746;</ix:nonNumeric></div>
        </td> </tr>
  <tr>
    <td style="width:20%;vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div> </td>
    <td style="width:30%;vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div> </td>
    <td style="width:20%;vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">Emerging growth company</div> </td>
    <td style="width:30%;vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><ix:nonNumeric id="Fixv-223" name="dei:EntityEmergingGrowthCompany" contextRef="C_20240101to20240930" format="ixt:fixed-true">&#9746;</ix:nonNumeric></div>
        </td> </tr>
  </table>

<div style="text-align:justify;text-indent:18pt;line-height:1.25;font-family:'Times New Roman', Times, serif;font-size:10pt">&#160;</div>

<div style="text-align:left;text-indent:25.2pt;margin-left:8.15pt;line-height:1.25;font-family:'Times New Roman', Times, serif;font-size:10pt">If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. <ix:nonNumeric id="Fixv-229" name="dei:EntityExTransitionPeriod" contextRef="C_20240101to20240930" format="ixt:fixed-false">&#9744;</ix:nonNumeric></div>

<div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-size:10pt">&#160;</div>

<div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-size:10pt">

<div style="text-align:justify;line-height:1.25;font-weight:bold;text-indent:27pt">&#160; The Registrant hereby amends this Registration
Statement on such date or dates as may be necessary to delay its effective date until the Registrant shall file a further amendment which
specifically states that this Registration Statement shall thereafter become effective in accordance with Section&#160;8(a)&#160;of the
Securities Act&#160;of&#160;1933, as amended (&#8220;Securities Act&#8221;), or until the Registration Statement shall become effective
on such date as the SEC, acting pursuant to Section&#160;8(a), may determine.</div> </div>

<div style="text-align:left;text-indent:25.2pt;margin-right:11.1pt;margin-left:8.15pt;line-height:1.25;font-family:'Times New Roman', Times, serif;font-size:10pt;font-weight:bold">

<div style="text-indent:36pt;line-height:1.25">

<div style="text-indent:36pt;line-height:1.25">

<div style="text-indent:36pt;line-height:1.25">

<div style="line-height:1.25">&#160;</div> </div> </div> </div> </div>

<div style="clear:both;margin-top:10pt;margin-bottom:10pt">

<div style="page-break-after:always"> <hr style="border-width:0px;clear:both;margin:4px 0px;width:100%;height:2px;color:#000000;background-color:#000000"/>
</div> </div>

<div style="text-align:left;line-height:1.25;font-family:'Times New Roman',Times,serif;font-size:10pt">&#160;<!-- Field: Include-Text; File: pf\body.htm; Date: 2025%2D02%2D12T21:06:06; Size: 0x001F73DD; Options: XMLPreprocess -->
<p style="margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman"> </span></p>

<div><span style="font-family: Times New Roman">&#160; </span>

<div style="line-height: 1.25; font-family: Times New Roman; font-weight: bold; color: rgb(255, 0, 0)">The information in this preliminary
prospectus is not complete and may be changed. The securities described herein may not be sold until the registration statement filed
with the U.S. Securities and Exchange Commission is declared effective. This preliminary prospectus is not an offer to sell these securities
and it is not soliciting an offer to buy these securities in any jurisdiction where the offer or sale is not permitted.</div>

<div style="line-height: 1.25; font-family: Times New Roman; font-weight: bold; color: rgb(255, 0, 0)">&#160;</div>

<div style="text-align: center; line-height: 1.25; font-family: Times New Roman; font-weight: bold; color: rgb(255, 0, 0)">PRELIMINARY
PROSPECTUS</div>

<div style="text-align: center; line-height: 1.25; font-family: Times New Roman,Times,serif; font-weight: bold; color: rgb(255, 0, 0)">

<div style="line-height: 1.25; font-weight: bold">

<div style="line-height: 1.25; font-family: Times New Roman, Times, serif; font-weight: bold">

<div style="margin-left: 0.75pt; line-height: 1.25; font-weight: bold; font-family: Times New Roman">

<div style="line-height: 1.25; font-family: Times New Roman, Times, serif; font-weight: bold">

<div style="line-height: 1.25; font-weight: bold">SUBJECT TO COMPLETION, DATED FEBRUARY 12, 2025</div> </div> </div> </div> </div> </div>

<div style="text-align: center; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: center; line-height: 1.25; font-family: Times New Roman"><img src="image0.jpg" alt="" style="width: 199px; height: 76px"/>&#160;</div>

<div style="text-align: center; line-height: 1.25; font-weight: bold; font-family: Times New Roman">&#160;</div>

<div style="text-align: center; line-height: 1.25; font-weight: bold">Up to 2,377,030 Ordinary Shares</div>

<div style="font: bold 1pt/1.25 Times New Roman, serif">&#160;</div>

<div style="line-height: 1.25"><br/> </div>

<div style="text-indent: 36pt; line-height: 1.25">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">

<div style="text-indent: 36pt; line-height: 1.25">

<div style="text-indent: 36pt; line-height: 1.25">

<div style="text-indent: 36pt; line-height: 1.25">

<div style="text-indent: 36pt; line-height: 1.25">

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">

<div style="text-indent: 36pt; line-height: 1.25">

<div style="text-indent: 36pt; line-height: 1.25">This prospectus relates to the resale, from time to time, by the securityholders named
herein (the &#8220;<span style="font-weight: bold">Selling Securityholders</span>&#8221;)of up to 2,377,030 ordinary shares, par value
$0.0009 per share (&#8220;<span style="font-weight: bold">ordinary shares</span>&#8221; or &#8220;<span style="font-weight: bold">New
Silexion ordinary shares</span>&#8221;) of Silexion Therapeutics Corp, a Cayman Islands exempted company (&#8220;<span style="font-weight: bold">New
Silexion</span>&#8221;, the &#8220;<span style="font-weight: bold">Company</span>&#8221;, &#8220;<span style="font-weight: bold">our company</span>&#8221;,
&#8220;<span style="font-weight: bold">we</span>&#8221; or &#8220;<span style="font-weight: bold">us</span>&#8221;), issuable upon the
exercise of warrants, as further described below under &#8220;Prospectus Summary &#8212; Recent Developments &#8212; Warrant Repricing.&#8221;</div>
</div>

<div style="line-height: 1.25"><br/> </div>

<div style="line-height: 1.25">

<div style="text-indent: 36pt; line-height: 1.25">The Selling Securityholders are identified in the table commencing on page 131. We will
not receive any proceeds from the sale of the ordinary shares by the Selling Securityholders. All net proceeds from the sale of the ordinary
shares covered by this prospectus will go to the Selling Securityholders. However, we may receive the proceeds from any exercise of warrants
if the holders do not exercise the warrants on a cashless basis. See &#8220;Use of Proceeds.&#8221;</div> </div>

<div style="line-height: 1.25"><br/> </div> </div> </div> </div> </div> </div> </div> </div> </div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">&#160;</div>

<div style="line-height: 1.25">

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">The Selling Securityholders may sell all or a portion of the ordinary
shares from time to time in market transactions through any market on which our ordinary shares are then traded, in negotiated transactions
or otherwise, and at prices and on terms that will be determined by the then prevailing market price or at negotiated prices directly
or through a broker or brokers, who may act as agent or as principal or by a combination of such methods of sale. The Selling Securityholders
will pay all brokerage fees and commissions and similar expenses attributable to their sales of securities. We will pay the expenses (except
brokerage fees and commissions and similar expenses) incurred in registering the sale of the securities offered hereby, including legal
and accounting fees. See &#8220;<span style="font-style: italic">Plan of Distribution</span>.&#8221;</div> </div>

<div style="text-indent: 36pt; line-height: 1.25">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25">On November&#160;27, 2024, we effected a 1-for-9 reverse share split of our authorized
ordinary shares, including our issued and outstanding ordinary shares, with a market effectiveness date of November 29, 2024. Unless specifically
provided otherwise herein, all of our (but not that of Moringa Acquisition Corp) share, per share and related option and warrant information
presented in this prospectus has been retroactively adjusted to reflect the reduced number of shares and the increase in the share price
which resulted from the reverse share split.</div>

<div style="line-height: 1.25"><br/> </div>

<div style="line-height: 1.25">

<div style="text-indent: 36pt; line-height: 1.25">Our ordinary shares and warrants are listed on The Nasdaq Stock Market under the symbols
&#8220;SLXN&#8221; and &#8220;SLXNW,&#8221; respectively. On February 11, 2025, the last reported sales price of our ordinary shares was
$1.38 per share and the last reported sales price of our warrants was $0.0684 per warrant.</div> </div>

<div style="line-height: 1.25"><br/> </div>

<div style="text-indent: 36pt; line-height: 1.25; font-weight: bold; font-family: Times New Roman">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif; font-weight: normal">We are an &#8220;emerging
growth company&#8221; as defined under U.S. federal securities laws and, as such, have elected to comply with reduced public company reporting
requirements. This prospectus complies with the requirements that apply to an issuer that is an emerging growth company.</div> </div>

<div style="text-indent: 36pt; line-height: 1.25; font-weight: bold; font-family: Times New Roman"> <br/> </div>

<div style="line-height: 1.25; font-family: Times New Roman"> </div>

<div style="text-indent: 36pt; line-height: 1.25; font-weight: bold">

<div style="line-height: 1.25; font-family: Times New Roman; font-weight: bold">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif; font-weight: bold">Investing in our securities
involves a high degree of risk. You should review carefully the risks and uncertainties described in the section titled &#8220;Risk Factors&#8221;
beginning on page 6 of this prospectus, and under similar headings in any amendments or supplements to this prospectus.</div> </div> </div>

<div style="text-indent: 36pt; line-height: 1.25; font-weight: bold; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-weight: bold; font-family: Times New Roman">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif; font-weight: bold">Neither the Securities
and Exchange Commission nor any state securities commission has approved or disapproved of these securities, or passed upon the accuracy
or adequacy of this prospectus. Any representation to the contrary is a criminal offense.</div> </div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: center; line-height: 1.25; font-family: Times New Roman; font-weight: bold">

<div style="line-height: 1.25; font-family: Times New Roman, Times, serif; font-weight: bold">

<div style="line-height: 1.25; font-weight: bold">

<div style="line-height: 1.25; font-weight: bold">Prospectus dated &#160; &#160; &#160;&#160; , 2025</div> </div> </div> </div>

<div style="text-align: center; line-height: 1.25; font-weight: bold"> <span style="font-family: Times New Roman"><br/> </span></div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: center; line-height: 1.25; font-weight: bold">

<div style="line-height: 1.25; font-weight: bold; font-family: Times New Roman">

<div style="line-height: 1.25; font-family: Times New Roman, Times, serif; font-weight: bold">ABOUT THIS PROSPECTUS</div>

<div style="line-height: 1.25; font-family: Times New Roman, Times, serif">&#160;</div>

<div style="text-align: left; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif"><span style="font-family: Times New Roman,Times,serif; font-weight: normal">This
prospectus is part of a registration statement on Form S-1 that we filed with the Securities and Exchange Commission (the &#8220;SEC&#8221;)
using the &#8220;shelf&#8221; registration process. Under this shelf registration process, the Selling Securityholders may, from time
to time, sell the ordinary shares offered by them described in this prospectus. We will not receive any proceeds from the sale by such
Selling Securityholders of the ordinary shares offered by them described in this prospectus, except with respect to amounts received by
us upon exercise of warrants to the extent such warrants are exercised for cash. Given the current price level of our ordinary shares,
there is no certainty that warrant holders will exercise their warrants and, accordingly, we may not receive any proceeds in relation
to our outstanding warrants.</span></div>

<div style="text-align: left; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">&#160;</div>

<div style="text-align: left; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif; font-weight: normal">Neither
we nor the Selling Securityholders have authorized anyone to provide you with any information or to make any representations other than
those contained in this prospectus or any applicable prospectus supplement or any free writing prospectuses prepared by or on behalf of
us or to which we have referred you. Neither we nor the Selling Securityholders take responsibility for, and can provide no assurance
as to the reliability of, any other information that others may give you. Neither we nor the Selling Securityholders will make an offer
to sell these ordinary shares in any jurisdiction where the offer or sale is not permitted.</div>

<div style="text-align: left; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">&#160;</div>

<div style="text-align: left; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif"><span style="font-family: Times New Roman,Times,serif; font-weight: normal">We
may also provide a prospectus supplement or post-effective amendment to the registration statement to add information to, or update or
change information contained in, this prospectus. You should read both this prospectus and any applicable prospectus supplement or post-effective
amendment to the registration statement together with the additional information to which we refer you in the section of this prospectus
titled </span><span style="font-family: Times New Roman,Times,serif; font-style: italic; font-weight: normal">&#8220;Where You Can Find
More Information.&#8221;</span></div> </div> </div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">Unless the context indicates otherwise, references in
this prospectus to &#8220;<span style="font-weight: bold">New Silexion</span>&#8221;, &#8220;<span style="font-weight: bold">we</span>&#8221;,
&#8220;<span style="font-weight: bold">us,</span>&#8221; &#8220;<span style="font-weight: bold">our</span>,&#8221; &#8220;<span style="font-weight: bold">the
Company</span>&#8221;, &#8220;<span style="font-weight: bold">our company</span>&#8221; and similar terms refer to Silexion Therapeutics
Corp (formerly known as Biomotion Sciences), a Cayman Islands exempted company, and its consolidated subsidiaries. References to &#8220;<span style="font-weight: bold">Silexion</span>&#8221;
refer to Silexion Therapeutics Ltd., an Israeli company and wholly-owned subsidiary of the Company, and references to &#8220;<span style="font-weight: bold">Moringa</span>&#8221;
refer to Moringa Acquisition Corp, a Cayman Islands exempted company and wholly-owned subsidiary of the Company. References to the &#8220;<span style="font-weight: bold">Business
Combination</span>&#8221; refer collectively to the transactions completed on August 15, 2024 pursuant to that certain Amended and Restated
Business Combination Agreement, dated as of April 3, 2024 (as amended, the &#8220;<span style="font-weight: bold">Business Combination
Agreement</span>&#8221;), by and among New Silexion, August M.S.&#160;Ltd., an Israeli company and a wholly-owned&#160;subsidiary of New
Silexion (&#8220;<span style="font-weight: bold">Merger Sub 1</span>&#8221;), Moringa Acquisition Merger Sub Corp, a Cayman Islands exempted
company and a wholly-owned&#160;subsidiary of New Silexion (&#8220;<span style="font-weight: bold">Merger Sub 2</span>&#8221;), Moringa
and Silexion. Pursuant to the Business Combination Agreement, among other things, (i) Merger Sub 2 merged with and into Moringa, with
Moringa continuing as the surviving company and a wholly-owned subsidiary of New Silexion (the &#8220;<span style="font-weight: bold">SPAC
Merger</span>&#8221;) and (ii) Merger Sub 1 merged with and into Silexion, with Silexion continuing as the surviving company and a wholly-owned
subsidiary of New Silexion (the &#8220;<span style="font-weight: bold">Acquisition Merger</span>&#8221;). In connection with the consummation
of the Business Combination (the &#8220;<span style="font-weight: bold">Closing</span>&#8221;), New Silexion changed its name from &#8220;Biomotion
Sciences&#8221; to &#8220;Silexion Therapeutics Corp&#8221;, and the ordinary shares and warrants of New Silexion commenced trading on
the Nasdaq Global Market (&#8220;<span style="font-weight: bold">Nasdaq</span>&#8221;) under the symbols &#8220;SLXN&#8221; and &#8220;SLXNW&#8221;,
respectively, on August 16, 2024.</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">This prospectus contains summaries of certain provisions
contained in some of the documents described herein, but reference is made to the actual documents for complete information. All of the
summaries are qualified in their entirety by the actual documents. Copies of some of the documents referred to herein have been filed,
will be filed or will be incorporated by reference as exhibits to the registration statement of which this prospectus is a part, and you
may obtain copies of those documents as described below under &#8220;<span style="font-style: italic">Where You Can Find More Information</span>&#8221;.</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: center; line-height: 1.25; font-weight: bold; font-family: Times New Roman">SPECIAL NOTE REGARDING FORWARD-LOOKING
STATEMENTS</div>

<div style="text-align: justify; text-indent: 18pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">The statements contained in this prospectus that are not
purely historical are forward-looking statements. Certain statements in this prospectus may constitute &#8220;forward-looking statements&#8221;
for purposes of the federal securities laws. These forward-looking statements include, but are not limited to, statements regarding the
Company&#8217;s and the Company&#8217;s management team&#8217;s expectations, hopes, beliefs, intentions or strategies regarding the future,
including statements regarding our future results of operations or financial condition, business strategy and plans, and objectives of
management for future operations. In addition, any statements that refer to projections, forecasts or other characterizations of future
events or circumstances, including any underlying assumptions, are forward-looking statements. The words &#8220;anticipate,&#8221; &#8220;believe,&#8221;
&#8220;continue,&#8221; &#8220;could,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;intends,&#8221; &#8220;may,&#8221; &#8220;might,&#8221;
&#8220;plan,&#8221; &#8220;possible,&#8221; &#8220;potential,&#8221; &#8220;predict,&#8221; &#8220;project,&#8221; &#8220;should,&#8221;
&#8220;will,&#8221; &#8220;would&#8221; and similar expressions may identify forward-looking statements, but the absence of these words
does not mean that a statement is not forward-looking. Forward-looking statements in this prospectus may include, for example, statements
about:&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif"><span style="font-family: Times New Roman">&#160;
</span>

<table cellspacing="0" cellpadding="0" id="ze0711c706c3e4b46abca09da16db54ba" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">&#160;</div> </td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">the ability to maintain the listing of our ordinary shares and our warrants
        on Nasdaq;</div> </td> </tr>
  <tr>
    <td style="width: 7.69%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">&#160;</div> </td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">&#160;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">&#160;</div> </td> </tr>
  <tr>
    <td style="width: 7.69%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">&#160;</div> </td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">our future performance, including our projected timeline for regulatory approvals
        of its product candidates;</div> </td> </tr>
  </table>

<div style="text-align: left; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<table cellspacing="0" cellpadding="0" id="zdb8994fd65dd4ffb9fde5b4b985d9d3f" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">&#160;</div> </td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">our market opportunity;</div> </td> </tr>
  </table>

<div style="text-align: left; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<table cellspacing="0" cellpadding="0" id="zd58bec60967b4c8c91cb21513bcd15ee" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">&#160;</div> </td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">our strategy, future operations, financial position, projected costs, prospects
        and plans;</div> </td> </tr>
  </table>

<div style="text-align: left; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<table cellspacing="0" cellpadding="0" id="zd3b61659cefd4a65848b820925f8dfca" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">&#160;</div> </td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">expectations regarding the time during which we will be an emerging growth
        company under the JOBS Act;</div> </td> </tr>
  </table>

<div style="text-align: left; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z34770608169e419ca996f602360c6356" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">&#160;</div> </td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">our ability to retain or recruit officers, key employees and directors;</div>
        </td> </tr>
  </table>

<div style="text-align: left; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z1b7a0be74eb1420393a71cf06edbe3ba" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">&#160;</div> </td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">the impact of the regulatory environment and complexities with compliance
        related to such environment;</div> </td> </tr>
  </table>

<div style="text-align: left; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<table cellspacing="0" cellpadding="0" id="zccc4f852b94a4db1ba0913de8fc07e4e" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">&#160;</div> </td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">expectations regarding future partnerships or other relationships with third
        parties; and</div> </td> </tr>
  </table>

<div style="text-align: left; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z146db67359fe4cf1a8c668d8e81015d4" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">&#160;</div> </td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">our future capital requirements and sources and uses of cash, including the
        our ability to obtain additional capital in the future.</div> </td> </tr>
  </table>

<div style="text-align: left; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div> </div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">The forward-looking statements contained in this prospectus
and in any document incorporated by reference are based on current expectations, forecasts and beliefs concerning future developments
and their potential effects on us. There can be no assurance that future developments affecting we will be those that we have anticipated.
These forward-looking statements involve a number of risks, uncertainties, some of which are beyond our control, or other assumptions
that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements.
These risks and uncertainties include, but are not limited to, the following factors:</div> </div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z89c5a3d2b3564ca38f68ab21ed3816d7" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">
        <div style="line-height: 1.25; font-family: Times New Roman, Times, serif">
        <div style="line-height: 1.25">
        <div style="line-height: 1.25; font-family: Times New Roman">we are a development-stage company and have a limited operating history on
        which to assess our business;</div> </div> </div> </div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<table cellspacing="0" cellpadding="0" id="zb3b7309ea37b4113a7460b2429620888" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">
        <div style="line-height: 1.25; font-family: Times New Roman">we have never generated any revenue from product sales and may never be profitable;</div>
        </div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<table cellspacing="0" cellpadding="0" id="zb750f986c1c14b289beeecc857692c7f" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">
        <div style="line-height: 1.25; font-family: Times New Roman, Times, serif">
        <div style="line-height: 1.25; font-family: Times New Roman">we will need to raise substantial additional funding, which may not be available
        on acceptable terms, or at all, and which will cause dilution to our shareholders;</div> </div> </div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<table cellspacing="0" cellpadding="0" id="zd42371efcaa74f23a6f9f9de7a07a722" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">
        <div style="line-height: 1.25; font-family: Times New Roman">the approach we are taking to discover and develop novel RNAi therapeutics
        is unproven for oncology and may never lead to marketable products;</div> </div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="line-height: 1.25">

<div style="line-height: 1.25"><span style="font-family: Times New Roman"><br/> </span> </div> </div>

<table cellspacing="0" cellpadding="0" id="zc876b67e337f4dbf83bab24afccd7c0f" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">we do not have experience producing our product candidates at commercial
        levels, currently have no marketing and sales organization, have an uncertain market receptiveness to our product candidates, and are
        uncertain as to whether there will be insurance coverage and reimbursement for our potential products;</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z41891933d3814a349c2fd7311e2f5dd9" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">we may be unable to attract, develop and/or retain our key personnel or additional
        employees required for our development and future success;</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z13dfd96cbb0449dc82582d1181d17653" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25">we may issue additional ordinary shares or other equity securities without your approval, including: (a)
        up to $15,337,500 of ordinary shares issuable under the Ordinary Share Purchase Agreement, dated August 13, 2024 and effective as of August
        15, 2024, by and between the Company and White Lion Capital, LLC (&#8220;White Lion&#8221;) (the &#8220;White Lion Purchase Agreement&#8221;
        or &#8220;ELOC Agreement&#8221;), which established an equity line of credit for the Company; (b) ordinary shares underlying <span style="font-family: Times New Roman,Times,serif">659,999</span>
        outstanding warrants; and (c) ordinary shares underlying convertible promissory notes that the Company has issued to (i) Moringa&#8217;s
        sponsor, Moringa Sponsor, LP, a Cayman Islands exempted limited partnership (the &#8220;Sponsor&#8221; or &#8220;Moringa Sponsor&#8221;),
        in a principal amount of $3,433,000 (the &#8220;A&amp;R Sponsor Promissory Note&#8221;), in amendment and restatement of all promissory
        notes previously issued by Moringa to the Sponsor for funds borrowed between Moringa&#8217;s initial public offering and the completion
        of the Business Combination, and (ii) EarlyBird Capital, Inc. (&#8220;EarlyBird&#8221;), which served as the representative of the underwriters
        for Moringa&#8217;s initial public offering, in an amount of $1,250,000 (the &#8220;EarlyBird Convertible Note&#8221;), each of which
        would dilute your ownership interest and may depress the market price of our ordinary shares; and </div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z091100cccfb84117a80ae0495e19fb34" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">those additional factors described or incorporated by reference under the
        heading &#8220;<span style="font-style: italic">Risk Factors</span>&#8221; below.</div> </td> </tr>
  </table>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25"> </div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">Should one or more of these risks or uncertainties materialize,
or should any of our assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking
statements. It is not possible to predict or identify all such risks. Accordingly, forward-looking statements in this prospectus and in
any document incorporated herein by reference should not be relied upon as representing our views as of any subsequent date, and we undertake
no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise,
except as may be required under applicable securities laws.</div> </div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">These forward-looking statements are based on information
available as of the date of this prospectus, and current expectations, forecasts and assumptions, and involve a number of judgments, risks
and uncertainties. Accordingly, forward-looking statements should not be relied upon as representing our views as of any subsequent date,
and we do not undertake any obligation to update forward-looking statements to reflect events or circumstances after the date they were
made, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws.</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">You should read this prospectus and the documents that
we reference in this prospectus and have filed as exhibits to the registration statement of which this prospectus is a part, completely
and with the understanding that our actual future results may be materially different from what we expect. We qualify all of our forward-looking
statements by these cautionary statements.</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">In addition, statements that &#8220;we believe&#8221;
and similar statements reflect our beliefs and opinions on the relevant subject. Those statements are based upon information available
to us as of the date of this prospectus and while we believe such information forms a reasonable basis for such statements, such information
may be limited or incomplete, and such statements should not be read to indicate that we have conducted an exhaustive inquiry into, or
review of, all potentially available relevant information. Those statements are inherently uncertain, and investors are cautioned not
to unduly rely upon those statements.</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: center; line-height: 1.25; font-weight: bold; font-family: Times New Roman">TABLE OF CONTENTS</div>

<div style="text-align: center; line-height: 1.25; font-weight: bold; font-family: Times New Roman"> <br/> </div>

<div style="line-height: 1.25; font-weight: 400; font-family: Times New Roman,Times,serif">

<table cellspacing="0" cellpadding="0" id="z5920694690de43f5b107f1e55e7d3c7e" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 94.62%; vertical-align: bottom">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="border-bottom: rgb(0, 0, 0) 2px solid; width: 5.38%; vertical-align: bottom">
        <div style="text-align: center; line-height: 1.25; font-weight: bold">Page</div> </td> </tr>
  <tr>
    <td style="width: 94.62%; vertical-align: bottom; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25"><a href="#SUMMARY">Prospectus Summary</a></div> </td>
    <td style="width: 5.38%; vertical-align: bottom; background-color: rgb(204, 238, 255); text-align: center">1<br/> </td> </tr>
  <tr>
    <td style="width: 94.62%; vertical-align: bottom">
        <div style="line-height: 1.25"><a href="#RISK">Risk Factors</a></div> </td>
    <td style="width: 5.38%; vertical-align: bottom; text-align: center">6<br/> </td> </tr>
  <tr>
    <td style="width: 94.62%; vertical-align: bottom; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25"><a href="#TRANSACTIONS">Transactions Related to Offering Under This Prospectus</a></div> </td>
    <td style="width: 5.38%; vertical-align: bottom; background-color: rgb(204, 238, 255); text-align: center">42<br/> </td> </tr>
  <tr>
    <td style="width: 94.62%; vertical-align: bottom">
        <div style="line-height: 1.25"><a href="#DATA">Market and Industry Data</a></div> </td>
    <td style="width: 5.38%; vertical-align: bottom; text-align: center">42<br/> </td> </tr>
  </table>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 94.62%; vertical-align: bottom; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25"><a href="#PROCEEDS">Use of Proceeds</a></div> </td>
    <td style="width: 5.38%; vertical-align: bottom; background-color: rgb(204, 238, 255); text-align: center">43<br/> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 94.62%; vertical-align: bottom">
        <div style="line-height: 1.25"><a href="#PRICE">Determination of Offering Price</a></div> </td>
    <td rowspan="1" style="width: 5.38%; vertical-align: bottom; text-align: center">44</td> </tr>
  <tr>
    <td style="width: 94.62%; vertical-align: bottom; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25"><a href="#POLICY">Market Information for Securities and Dividend Policy</a></div> </td>
    <td style="width: 5.38%; vertical-align: bottom; background-color: rgb(204, 238, 255); text-align: center">44<br/> </td> </tr>
  <tr>
    <td style="width: 94.62%; vertical-align: bottom">
        <div style="line-height: 1.25"><a href="#INFORMATION">Unaudited Pro Forma Condensed Combined Financial Information</a></div> </td>
    <td style="width: 5.38%; vertical-align: bottom; text-align: center">44<br/> </td> </tr>
  <tr>
    <td style="width: 94.62%; vertical-align: bottom; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25"><a href="#OPERATIONS">Management&#8217;s Discussion and Analysis of Financial Condition and Results of
        Operations</a></div> </td>
    <td style="width: 5.38%; vertical-align: bottom; background-color: rgb(204, 238, 255); text-align: center">57<br/> </td> </tr>
  <tr>
    <td style="width: 94.62%; vertical-align: bottom">
        <div style="line-height: 1.25"><a href="#BUSINESS">Business</a></div> </td>
    <td style="width: 5.38%; vertical-align: bottom; text-align: center">80<br/> </td> </tr>
  <tr>
    <td style="width: 94.62%; vertical-align: bottom; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25"><a href="#MANAGEMENT">Management</a></div> </td>
    <td style="width: 5.38%; vertical-align: bottom; background-color: rgb(204, 238, 255); text-align: center">109<br/> </td> </tr>
  <tr>
    <td style="width: 94.62%; vertical-align: bottom">
        <div style="line-height: 1.25"><a href="#COMPENSATION">Executive Compensation</a></div> </td>
    <td style="width: 5.38%; vertical-align: bottom; text-align: center">115<br/> </td> </tr>
  <tr>
    <td style="width: 94.62%; vertical-align: bottom; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25"><a href="#CERTAIN">Certain Relationships and Related Party Transactions</a></div> </td>
    <td style="width: 5.38%; vertical-align: bottom; background-color: rgb(204, 238, 255); text-align: center">126<br/> </td> </tr>
  <tr>
    <td style="width: 94.62%; vertical-align: bottom">
        <div style="line-height: 1.25"><a href="#BENEFICIAL">Beneficial Ownership of Securities</a></div> </td>
    <td style="width: 5.38%; vertical-align: bottom; text-align: center">129<br/> </td> </tr>
  <tr>
    <td style="width: 94.62%; vertical-align: bottom; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25"><a href="#SECURITYHOLDERS">Selling Securityholders</a></div> </td>
    <td style="width: 5.38%; vertical-align: bottom; background-color: rgb(204, 238, 255); text-align: center">131<br/> </td> </tr>
  <tr>
    <td style="width: 94.62%; vertical-align: bottom">
        <div style="line-height: 1.25"><a href="#CAPITAL">Description of Share Capital</a></div> </td>
    <td style="width: 5.38%; vertical-align: bottom; text-align: center">135<br/> </td> </tr>
  <tr>
    <td style="width: 94.62%; vertical-align: bottom; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25"><a href="#CONSEQUENCES">Material U.S. Federal Income Tax Consequences</a></div> </td>
    <td style="width: 5.38%; vertical-align: bottom; background-color: rgb(204, 238, 255); text-align: center">142<br/> </td> </tr>
  <tr>
    <td style="width: 94.62%; vertical-align: bottom">
        <div style="line-height: 1.25"><a href="#PLAN">Plan of Distribution</a></div> </td>
    <td style="width: 5.38%; vertical-align: bottom; text-align: center">149<br/> </td> </tr>
  <tr>
    <td style="width: 94.62%; vertical-align: bottom; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25"><a href="#LEGAL">Legal Matters</a></div> </td>
    <td style="width: 5.38%; vertical-align: bottom; background-color: rgb(204, 238, 255); text-align: center">151<br/> </td> </tr>
  <tr>
    <td style="width: 94.62%; vertical-align: bottom">
        <div style="line-height: 1.25"><a href="#EXPERTS">Experts</a></div> </td>
    <td style="width: 5.38%; vertical-align: bottom; text-align: center">151<br/> </td> </tr>
  <tr>
    <td style="width: 94.62%; vertical-align: bottom; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25"><a href="#WHERE">Where You Can Find More Information</a></div> </td>
    <td style="width: 5.38%; vertical-align: bottom; background-color: rgb(204, 238, 255); text-align: center">152<br/> </td> </tr>
  <tr>
    <td style="width: 94.62%; vertical-align: bottom">
        <div style="line-height: 1.25"><a href="#a_001">Index to Financial Statements</a></div> </td>
    <td style="width: 5.38%; vertical-align: bottom; text-align: center">
        <div style="line-height: 1.25">F-1</div> </td> </tr>
  </table> </div>

<div style="text-align: center; line-height: 1.25; font-weight: bold; font-family: Times New Roman"> <br/>

<div style="font-family: Times New Roman,Times,serif; font-weight: 400; text-align: left">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">You should rely only on the information
contained in this prospectus, any supplement to this prospectus or in any free writing prospectus, filed with the Securities and Exchange
Commission. Neither we nor the Selling Securityholders have authorized anyone to provide you with additional information or information
different from that contained in this prospectus filed with the Securities and Exchange Commission. We take no responsibility for, and
can provide no assurance as to the reliability of, any other information that others may give you. The Selling Securityholders is offering
to sell, and seeking offers to buy, our securities only in jurisdictions where offers and sales are permitted. The information contained
in this prospectus is accurate only as of the date of this prospectus, regardless of the time of delivery of this prospectus or any sale
of our securities. Our business, financial condition, results of operations and prospects may have changed since that date.</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">For investors outside of the United States:
Neither we nor the Selling Securityholders have done anything that would permit this offering or possession or distribution of this prospectus
in any jurisdiction where action for that purpose is required, other than in the United States. Persons outside the United States who
come into possession of this prospectus must inform themselves about, and observe any restrictions relating to, the offering of our securities
and the distribution of this prospectus outside the United States.</div> </div> <br/> </div> <span style="font-family: Times New Roman">
</span>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>
<!--PROfilePageNumberReset%Num%1%%%-->

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="line-height: 1.25"><span style="font-family: Times New Roman"><br/> </span>

<div>

<div style="border: #000000 2px solid; padding: 5px; width: 99%">

<div style="font-family: Times New Roman">&#160;</div>

<div>

<div style="text-align: center; line-height: 1.25; font-weight: bold; font-family: Times New Roman"><!--Anchor-->PROSPECTUS <span id="SUMMARY"><!--Anchor--></span>SUMMARY</div>

<div style="text-align: center; line-height: 1.25; font-style: italic; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-style: italic; font-family: Times New Roman">This summary highlights information
contained elsewhere in this prospectus and does not contain all of the information that you should consider in making your investment
decision. Before investing in our securities, you should carefully read this entire prospectus, including our consolidated financial statements
and the related notes thereto and the information set forth in the sections titled &#8220;Risk Factors&#8221; and &#8220;Management&#8217;s
Discussion and Analysis of Financial Condition and Results of Operations.&#8221;</div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold; font-family: Times New Roman">Our Business</div>

<div style="text-align: justify; text-indent: 18pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">We are a clinical-stage, oncology-focused biotechnology
company engaged in the discovery and development of proprietary treatments for KRAS-driven cancers. The KRAS gene is an oncogene that
is involved in the regulation of cell division as a result of its ability to relay external signals to the cell nucleus. Based on our
research of refractory solid tumor cancers, we are actively developing a platform focused on the silencing of the KRAS oncogene using
RNA-interference therapeutics. Our lead product candidate, SIL-204B, consists of locally administered small interfering RNAs, or siRNA,
in an extended-release formulation, as a first-line treatment of locally advanced pancreatic cancer patients, or LAPC, in combination
with standard-of-care chemotherapy.</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">The KRAS oncogene is considered to be the most common
oncogenic gene driver in human cancers, and the most notable in pancreatic, lung, and gastrointestinal (GI) (including colorectal, esophagus,
stomach, small bowel, and appendix) cancers. Considered a challenging therapeutic target due to its intrinsic characteristics, recent
advances have been made at directly inhibiting the KRAS proteins produced by the mutated gene. Our platform is designed to silence the
gene, and thus prevent the production of the harmful mutated KRAS proteins driving the growth of cancerous tumors.</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">We are currently focused on treatment for pancreatic cancer
(PC) tumors bearing the KRAS G12D or KRAS G12V mutations where metastases have not been detected and are non-resectable, i.e., they are
not able to be surgically removed. For our first indication, we are targeting the largest and least treatable form of localized pancreatic
tumors referred to as locally advanced pancreatic cancer. LAPC represents approximately 30% of the total pancreatic cancer population.
We are currently developing SIL-204B, a second-generation siRNA product candidate following a Phase 1 and Phase 2 clinical trial with
our first-generation siRNA product candidate, siG12D-LODER, which we also refer to as Loder. Results from the Phase 2 clinical trial showed
a trend for differences between treatment groups in patients with the KRAS G12D/V mutation, with the Loder arm suggesting an overall survival
advantage of 9.3 months.</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">SIL-204B has been designed to optimize Loder with the
aim of improving uptake into tumor cells, enhancing stability, and improving the delivery system. We plan to conduct a Phase 2/3 prospective,
randomized, controlled, multinational, two-arm, open-label trial in LAPC subjects that harbor the KRAS G12D/V mutations to evaluate the
efficacy, safety and tolerability of SIL-204B administered intratumorally in combination with standard of care (SoC) chemotherapy versus
SoC chemotherapy only. In support of our planned Phase 2/3 trial, we held a meeting with the Federal Institute for Drugs and Medical Devices
in Germany (BfArM) to discuss the planned design of the Phase 2/3 trial at which BfArM agreed, in principle, to the design. In preparation
for the study, we plan to initiate toxicology studies of SIL-204B in 2025 followed by the regulatory submission in the second half of
2025 to initiate the Phase 2/3 trial and trial initiation in the first half of 2026 . At this time, we are focused on the further development
of the core siRNA technology underlying the Loder and SIL-204B as well as the clinical development of SIL-204B as the most optimized version
of the technology.</div> </div> </div>

<div style="text-align: justify; text-indent: 18pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold; font-family: Times New Roman">Corporate Information</div>

<div style="text-align: justify; text-indent: 18pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="line-height: 1.25; font-family: Times New Roman">We were originally known as Biomotion Sciences, a Cayman Islands exempted
company. On April 3, 2024, we entered into an amended and restated business combination agreement (the &#8220;Business Combination Agreement&#8221;),
dated April 3, 2024, by and among our company (whose name was subsequently changed to Silexion Therapeutics Corp) (&#8220;New Silexion&#8221;),
August M.S. Ltd., an Israeli company and a wholly owned subsidiary of New Silexion (&#8220;Merger Sub 1&#8221;), Moringa Acquisition Merger
Sub Corp, a Cayman Islands exempted company and a wholly owned subsidiary of Silexion (&#8220;Merger Sub 2&#8221;), Moringa Acquisition
Corp (&#8220;Moringa&#8221;) and Silexion Therapeutics Ltd., an Israeli company (&#8220;Silexion&#8221;). On August 15, 2024 (the &#8220;Closing
Date&#8221;), the transactions contemplated by the Business Combination Agreement (collectively, the &#8220;Business Combination&#8221;)
were completed (the &#8220;Closing&#8221;), following the approval of the Business Combination on August 6, 2024 by the extraordinary
general meeting of Moringa.</div> </div>

<div style="text-indent: 36pt; line-height: 1.25"> <span style="font-family: Times New Roman"><br/> </span> </div> </div> </div> </div>

<div><span style="font-family: Times New Roman"><br/> </span> </div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: rgb(0, 0, 0); font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">1</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div><span style="font-family: Times New Roman"><br/> </span>

<div style="border: #000000 2px solid; padding: 5px; width: 99%">

<div style="font-family: Times New Roman">&#160;</div>

<div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-indent: 35.45pt; line-height: 1.25; font-family: Times New Roman">Our principal executive offices are located at 12 Abba
Hillel Road, Ramat Gan, Israel 5250606, Israel and our phone number is +972-8-6286005. Our corporate website address is www.silexion.com.
Information contained on or accessible through our website is not a part of this prospectus, and the inclusion of our website address
in this prospectus is an inactive textual reference only.</div> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">This prospectus contains trademarks, service marks, trade
names and copyrights of other companies, which are the property of their respective owners. Solely for convenience, trademarks and trade
names referred to in this prospectus may appear without the &#174; or &#8482; symbols, but such references are not intended to indicate,
in any way, that the applicable licensor will not assert, to the fullest extent under applicable law, its rights to these trademarks and
trade names. We do not intend our use or display of other companies&#8217; trade names, trademarks or service marks to imply a relationship
with, or endorsement or sponsorship of us by, any other companies. <span style="font-weight: bold">&#160;</span></div>

<div style="text-indent: 36pt; line-height: 1.25">

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif"><span style="font-family: Times New Roman"><br/> </span> </div>
<span style="font-weight: bold">Reverse Share Split </span>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif"><span style="font-family: Times New Roman"><br/> </span> </div>

<div style="text-indent: 35.45pt; line-height: 1.25">

<div style="line-height: 1.25; font-family: Times New Roman">

<div style="text-indent: 35.45pt; line-height: 1.25; font-family: Times New Roman, Times, serif">On November 27, 2024, we effected a 1-for-9
reverse share split of our authorized ordinary shares, including our issued and outstanding ordinary shares, with a market effectiveness
date of November 29, 2024. Unless specifically provided otherwise herein, all of our (but not that of Moringa Acquisition Corp) share,
per share and related option and warrant information presented in this prospectus, has been retroactively adjusted to reflect the reduced
number of shares and the increase in the share price which resulted from the reverse share split.</div> </div> </div> <span style="font-weight: bold; font-family: Times New Roman">
</span></div>

<div style="text-align: justify; text-indent: 18pt; line-height: 1.25; font-weight: bold"> <span style="font-family: Times New Roman"><br/>
</span></div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold">Nasdaq Market Value-Related Deficiencies</div>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">On November 19, 2024, we received two letters from the Nasdaq Listing
Qualifications Department, each addressing a separate compliance deficiency of the Company under the Nasdaq Listing Rules. The first letter
from the Nasdaq Listing Qualifications Department notified us of our non-compliance with Nasdaq Listing Rule 5450(b)(2)(A), which requires
a company such as ours whose securities are listed on the Nasdaq Global Market under the &#8220;Market Value Standard&#8221; to maintain
a minimum Market Value of Listed Securities (an &#8220;MVLS&#8221;) of $50,000,000. The deficiency was triggered by our MVLS having closed
below the minimum level for a period of 30 consecutive business days. Under Nasdaq Listing Rule 5810(c)(3)(C), we are entitled to a 180-day
period, ending on May 19, 2025, to rectify the deficiency. In order to do so, we must achieve and maintain an MVLS of $50,000,000 or more
for at least 10 consecutive business days. Failure to regain compliance within the 180-day period would result in the delisting of our
securities from Nasdaq, although we would have the right to appeal such a delisting to a Nasdaq hearings panel.</div>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">The second letter informed us of our deficiency in complying with
Nasdaq Listing Rule 5450(b)(2)(C), which requires a minimum Market Value of Publicly Held Shares (an &#8220;MVPHS&#8221;) of $15,000,000
for continued listing on the Nasdaq Global Market under the &#8220;Market Value Standard&#8221;. This deficiency was caused by our MVPHS
having fallen below the minimum threshold for the prior 30 consecutive business days. Under Nasdaq Listing Rule 5810(c)(3)(D), we have
180 calendar days, or until May 19, 2025, to regain compliance, which we can achieve if its MVPHS closes at or above $15,000,000 for at
least 10 consecutive business days. Failure to regain compliance within that 180-day period would result in the delisting of our securities
from Nasdaq, subject to our right to appeal to a Nasdaq hearings panel.</div>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">We intend to actively monitor the market value of our securities
and explore available options to resolve both market value-related deficiencies. As part of our strategy, we may consider applying to
transfer the listing of our securities to the Nasdaq Capital Market, subject to meeting one set of listing requirements for that market.
There can be no assurance, however, that we will successfully regain compliance with either rule within the allotted timeframe or that
any appeal, if necessary, will be successful.</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25"> <br/> </div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold; font-family: Times New Roman">Implications of Being a Smaller Reporting
Company and Emerging Growth Company</div>

<div style="text-align: justify; text-indent: 18pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">We are a &#8220;smaller reporting company&#8221; as defined
in Item 10(f)(1) of Regulation S-K. Smaller reporting companies may take advantage of certain reduced disclosure obligations, including,
among other things, providing only two years of audited financial statements and reduced disclosure obligations regarding executive compensation.
We will remain a smaller reporting company until the last day of any fiscal year for so long as either (1) the market value of our ordinary
shares held by non-affiliates does not equal or exceed $250 million as of the prior June 30th, or (2) our annual revenues did not equal
or exceed $100 million during such completed fiscal year and the market value of our ordinary shares held by non-affiliates did not equal
or exceed $700 million as of the prior June 30th. To the extent we take advantage of any reduced disclosure obligations, it may make the
comparison of our financial statements with other public companies difficult or impossible.</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">We are an &#8220;emerging growth company,&#8221; as defined
in the Jumpstart Our Business Startups Act of 2012 (t<span style="font-weight: normal">he &#8220;JOBS Act&#8221;). A</span>s an emerging
growth company, we are exempt from certain requirements related to executive compensation, including the requirements to hold a nonbinding
advisory vote on executive compensation and to provide information relating to the ratio of total compensation of our Chief Executive
Officer to the median of the annual total compensation of all of our employees, each as required by the Investor Protection and Securities
Reform Act of 2010, which is part of the Dodd-Frank Act.</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif; font-weight: normal">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">Section 102(b)(1) of the JOBS Act exempts
emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that
is, those that have not had a registration statement under the Securities Act of 1933, as amended (the &#8220;<span style="font-weight: bold">Securities
Act</span>&#8221;) declared effective or do not have a class of securities registered under the Exchange Act) are required to comply with
the new or revised financial accounting standards. The JOBS Act provides that a company can elect to opt out of the extended transition
period and comply with the requirements that apply to non-emerging growth companies but any such an election to opt out is irrevocable.
We have elected not to opt out of such extended transition period, which means that when a standard is issued or revised and it has different
application dates for public or private companies, we, as an emerging growth company, can adopt the new or revised standard at the time
private companies adopt the new or revised standard. This may make comparison of New Silexion&#8217;s financial statements with those
of another public company that is neither an emerging growth company nor an emerging growth company that has opted out of using the extended
transition period difficult or impossible because of the potential differences in accounting standards used.</div> </div> </div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">We will remain an emerging growth company
until the earlier of: (1) the last day of the fiscal year (a) following the fifth anniversary of the date on which New Silexion ordinary
shares were offered in exchange for ordinary shares of each of Moringa and Silexion, (b) in which we have total annual gross revenue of
at least $1.235 billion, or (c) in which we are deemed to be a large accelerated filer, which means the market value of our common equity
that is held by non-affiliates exceeds $700 million as of the end of the prior fiscal year&#8217;s second fiscal quarter; and (2) the
date on which we have issued more than $1.00 billion in non-convertible debt securities during the prior three-year period. References
herein to &#8220;emerging growth company&#8221; are to its meaning under the Securities Act, as modified by the JOBS Act.</div> </div>
</div> </div> </div>

<div style="text-indent: 36pt; line-height: 1.25"> <span style="font-family: Times New Roman"><br/> </span> </div> </div> </div> <span style="font-family: Times New Roman"><br/>
</span> </div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: rgb(0, 0, 0); font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">2</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div> <span style="font-family: Times New Roman"><br/> </span> </div>

<div style="line-height: 1.25">

<div style="border: #000000 2px solid; padding: 5px; width: 99%">

<div><span style="font-family: Times New Roman">&#160; </span>

<div style="text-align: justify; line-height: 1.25; font-weight: bold; font-family: Times New Roman,Times,serif">

<div style="line-height: 1.25; font-weight: bold; font-family: Times New Roman">

<div style="line-height: 1.25; font-family: Times New Roman, Times, serif; font-weight: bold">Summary Risk Factors</div> </div> </div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-indent: 36pt; line-height: 1.25">

<div style="line-height: 1.25; font-family: Times New Roman">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">Investing in our securities involves risks.
You should carefully consider the risks described in &#8220;<span style="font-style: italic">Risk Factors</span>&#8221; before making
a decision to invest in our securities. If any of these risks is actualized, our business, financial condition and results of operations
would likely be materially adversely affected. In such case, the trading price of our securities would likely decline, and you may lose
all or part of your investment. In particular, you should consider the risk factors described under &#8220;<span style="font-style: italic">Risk
Factors</span>&#8221; beginning on page 6. Such risks include, but are not limited to:</div> </div> </div> </div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="line-height: 1.25">

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25">
        <div style="line-height: 1.25; font-family: Times New Roman">We are a development-stage company and have a limited operating history on
        which to assess our business. The approach we are taking to discover and develop novel RNAi therapeutics is unproven for oncology and
        may never lead to marketable products.</div> </div> </td> </tr>
  </table>

<div style="text-align: left; line-height: 1.25; font-family: Times New Roman">&#160;</div> </div> </div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">

<table cellspacing="0" cellpadding="0" id="z0d61e00775914ba8b6842c4e39efe34f" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">We have never generated any revenue from product sales and may never be profitable.</div>
        </td> </tr>
  </table>

<div style="text-align: left; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<table cellspacing="0" cellpadding="0" id="ze8da462e9d304bd9852082e362af6784" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25">
        <div style="line-height: 1.25; font-family: Times New Roman">We will need to raise substantial additional funding, which may not be available
        on acceptable terms, or at all, and which will cause dilution to our shareholders.</div> </div> </td> </tr>
  </table>

<div style="text-align: left; line-height: 1.25; font-family: Times New Roman, Times, serif"><span style="font-family: Times New Roman">&#160;<br/>
</span> </div> </div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">

<table cellspacing="0" cellpadding="0" id="ze1b2300bff6e4a61aa54c5046e02fd8d" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25">
        <div style="line-height: 1.25; font-family: Times New Roman">Our independent registered public accounting firm&#8217;s report contains
        an explanatory paragraph that expresses substantial doubt about our ability to continue as a &#8220;going concern.&#8221;.</div> </div>
        </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<table cellspacing="0" cellpadding="0" id="ze26a1c79526a42a4b2cb834a86c4c10b" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25">
        <div style="line-height: 1.25; font-family: Times New Roman">The approach we are taking to discover and develop novel RNAi therapeutics
        is unproven for oncology and may never lead to marketable products.</div> </div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;&#160;</div>

<table cellspacing="0" cellpadding="0" id="zd13bf927e55b49709e8ba1ee33582c25" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25">
        <div style="line-height: 1.25; font-family: Times New Roman">We are heavily dependent on the success of our product candidates, which
        are in the early stages of preclinical or clinical development. We cannot give any assurance that any of our product candidates will receive
        regulatory approval, which is necessary before they can be commercialized.</div> </div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<table cellspacing="0" cellpadding="0" id="zca0315f53cc24058a773a7b2c9e17179" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25">
        <div style="line-height: 1.25; font-family: Times New Roman">The regulatory approval processes of the FDA and comparable foreign authorities
        are lengthy, time consuming, and inherently unpredictable. If we are ultimately unable to obtain regulatory approval for our product candidates,
        our business will be substantially harmed.</div> </div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman, Times, serif"><span style="font-family: Times New Roman">&#160; </span>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25">
        <div style="line-height: 1.25">
        <div style="line-height: 1.25; font-family: Times New Roman">Clinical drug development involves a lengthy and expensive process with an
        uncertain outcome, and results of preclinical activity or earlier studies may not be predictive of future study results.</div> </div>
        </div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div> </div> </div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">

<table cellspacing="0" cellpadding="0" id="zefe169b4fde240579b916f2d9d61748b" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25">
        <div style="line-height: 1.25; font-family: Times New Roman">We may find it difficult to enroll patients in our clinical studies, which
        could delay or prevent clinical studies of our product candidates.</div> </div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z5374cc8bc8fd45c6b401849616c36e4c" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25">
        <div style="line-height: 1.25; font-family: Times New Roman">Our product candidates and the administration of our product candidates may
        cause undesirable side effects or have other properties that could delay or prevent their regulatory approval, limit the commercial profile
        of an approved label, or result in significant negative consequences following marketing approval, if any.</div> </div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z9f6fbf1fc711419a823c2ba01bc2ea55" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25">
        <div style="line-height: 1.25; font-family: Times New Roman">Even if we obtain regulatory approval for a product candidate, our products
        will remain subject to regulatory scrutiny.</div> </div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z87a3fc29dd704c0fae865c4a905d613e" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25">
        <div style="line-height: 1.25; font-family: Times New Roman">We are subject to a multitude of manufacturing risks, any of which could
        substantially increase our costs and limit supply of our product candidates.</div> </div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman, Times, serif"><span style="font-family: Times New Roman">&#160; </span>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25">
        <div style="line-height: 1.25; font-family: Times New Roman">We rely on third parties to conduct our preclinical and clinical studies,
        and to manufacture the raw materials and products that we use to create our product candidates and to supply us with the medical devices
        used to administer such products, which entails regulatory and trade secrets-related risks.</div> </div> </td> </tr>
  </table>

<div> <span style="font-family: Times New Roman"><br/> </span> </div>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25">
        <div style="line-height: 1.25; font-family: Times New Roman">We do not have experience producing our product candidates at commercial
        levels, currently have no marketing and sales organization, have an uncertain market receptiveness to our product candidates, and is uncertain
        as to whether there will be insurance coverage and reimbursement for our potential products.</div> </div> </td> </tr>
  </table>

<div> <span style="font-family: Times New Roman"><br/> </span> </div>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25">
        <div style="line-height: 1.25; font-family: Times New Roman">We face intense competition and rapid technological change and the possibility
        that our competitors may develop therapies that are similar, more advanced, or more effective than ours, which may adversely affect our
        financial condition and our ability to successfully commercialize our product candidates.</div> </div> </td> </tr>
  </table>

<div>

<div style="line-height: 1.25">

<div> <span style="font-family: Times New Roman"><br/> </span> </div> </div>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25">
        <div style="line-height: 1.25; font-family: Times New Roman">If we are unable to obtain and maintain effective patent rights for our product
        candidates or any future product candidates, we may not be able to compete effectively in our markets.</div> </div> </td> </tr>
  </table> </div> </div>

<div style="line-height: 1.25; font-family: Times New Roman, Times, serif">

<div> <span style="font-family: Times New Roman"><br/> </span> </div> </div>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25">
        <div style="line-height: 1.25; font-family: Times New Roman">Third-party claims of intellectual property infringement may prevent or delay
        our development and commercialization efforts.</div> </div> </td> </tr>
  </table>

<div> <span style="font-family: Times New Roman"><br/> </span> </div>

<table cellspacing="0" cellpadding="0" id="z8d8dc9457a9342bd80fde629052cd74f" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25">
        <div style="line-height: 1.25; font-family: Times New Roman">We may be unable to attract, develop and/or retain our key personnel or additional
        employees required for our development and future success.</div> </div> </td> </tr>
  </table>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman">&#160;</div> </div> </div> </div>

<div><span style="font-family: Times New Roman"><br/> </span> </div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: rgb(0, 0, 0); font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">3</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div>

<div style="border: #000000 2px solid; padding: 5px; width: 99%">

<div style="font-family: Times New Roman">&#160;</div>

<div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">

<table cellspacing="0" cellpadding="0" id="z214b15ffbf1f4f319634bb4c6e816653" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="margin-right: 25.05pt; line-height: 1.25">
        <div style="line-height: 1.25; font-family: Times New Roman">Conditions in the Middle East and in Israel may harm our operations.</div>
        </div> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 7.69%; vertical-align: top; font-family: Times New Roman">&#160;</td>
    <td rowspan="1" style="width: 3.85%; vertical-align: top; font-family: Times New Roman">&#160;</td>
    <td rowspan="1" style="width: 88.46%; vertical-align: top; font-family: Times New Roman">&#160;</td> </tr>
  <tr>
    <td rowspan="1" style="width: 7.69%; vertical-align: top; font-family: Times New Roman">&#160;</td>
    <td rowspan="1" style="width: 3.85%; vertical-align: top; font-family: Times New Roman">&#9679;</td>
    <td rowspan="1" style="width: 88.46%; vertical-align: top; font-family: Times New Roman">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">If we fail to maintain compliance with Nasdaq&#8217;s continued
        listing requirements, our securities may be delisted from the Nasdaq Global Market.</div> </td> </tr>
  </table>

<div><br/> </div> </div>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">
        <div style="line-height: 1.25">
        <div style="line-height: 1.25; font-family: Times New Roman">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">A substantial number of our ordinary shares may be issued pursuant
        to the conversion terms of the A&amp;R Sponsor Promissory Note and the EarlyBird Convertible Note, which could cause the price of the
        ordinary shares to decline</div> </div> </div> </div> </td> </tr>
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman">&#160;</td>
    <td style="width: 3.85%; vertical-align: top; font-family: Times New Roman">&#160;</td>
    <td style="width: 88.46%; vertical-align: top; font-family: Times New Roman">&#160;</td> </tr>
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">
        <div style="line-height: 1.25">
        <div style="line-height: 1.25; font-family: Times New Roman">The price of our ordinary shares and our warrants may be volatile.</div>
        </div> </div> </td> </tr>
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman">&#160;</td>
    <td style="width: 3.85%; vertical-align: top; font-family: Times New Roman">&#160;</td>
    <td style="width: 88.46%; vertical-align: top; font-family: Times New Roman">&#160;</td> </tr>
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">
        <div style="line-height: 1.25; font-family: Times New Roman">A substantial number of our ordinary shares may be issued pursuant to the
        White Lion Purchase Agreement and/or the conversion terms of the A&amp;R Sponsor Promissory Note and the EarlyBird Convertible Note, which
        could cause (i) substantial dilution and (ii) the market price of the ordinary shares to decline.</div> </div> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 7.69%; vertical-align: top; font-family: Times New Roman">&#160;</td>
    <td rowspan="1" style="width: 3.85%; vertical-align: top; font-family: Times New Roman">&#160;</td>
    <td rowspan="1" style="width: 88.46%; vertical-align: top; font-family: Times New Roman">&#160;</td> </tr>
  <tr>
    <td rowspan="1" style="width: 7.69%; vertical-align: top; font-family: Times New Roman">&#160;</td>
    <td rowspan="1" style="width: 3.85%; vertical-align: top; font-family: Times New Roman">&#9679;</td>
    <td rowspan="1" style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">We have no current plans to pay cash dividends on our ordinary shares for
        the foreseeable future.</div> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 7.69%; vertical-align: top; font-family: Times New Roman">&#160;</td>
    <td rowspan="1" style="width: 3.85%; vertical-align: top; font-family: Times New Roman">&#160;</td>
    <td rowspan="1" style="width: 88.46%; vertical-align: top; font-family: Times New Roman">&#160;</td> </tr>
  <tr>
    <td rowspan="1" style="width: 7.69%; vertical-align: top; font-family: Times New Roman">&#160;</td>
    <td rowspan="1" style="width: 3.85%; vertical-align: top; font-family: Times New Roman">&#9679;</td>
    <td rowspan="1" style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">Our reverse share split may negatively impact the market for our ordinary
        shares.</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div> </div> </div> </div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: rgb(0, 0, 0); font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">4</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div> <br/>

<div style="border: #000000 2px solid; padding: 5px; width: 99%">

<div><span style="font-family: Times New Roman">&#160; </span>

<div style="text-align: center; line-height: 1.25; font-weight: bold; font-family: Times New Roman">The Offering</div>

<div style="text-align: center; line-height: 1.25; font-weight: bold; font-family: Times New Roman">&#160;</div>

<div>

<table cellspacing="0" cellpadding="0" id="z6e2208d111ee48d5ae1400adc40f1363" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td rowspan="1" style="width: 35%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="line-height: 1.25">
        <div style="line-height: 1.25">Ordinary shares currently outstanding</div> </div> </td>
    <td rowspan="1" style="width: 2%; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td>
    <td rowspan="1" style="width: 63%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">
        <div style="line-height: 1.25; font-family: Times New Roman, Times, serif">8,414,615 ordinary shares.</div> </div> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 35%; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td>
    <td rowspan="1" style="width: 2%; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td>
    <td rowspan="1" style="width: 63%; vertical-align: top">&#160;</td> </tr>
  <tr>
    <td style="width: 35%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="line-height: 1.25; font-family: Times New Roman">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">Securities offered by the selling securityholders</div> </div>
        </td>
    <td style="width: 2%; vertical-align: top; font-family: Times New Roman,Times,serif"><span style="font-family: Times New Roman"><br/> </span>
        </td>
    <td style="width: 63%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">
        <div style="line-height: 1.25">
        <div style="line-height: 1.25">
        <div style="line-height: 1.25">
        <div style="line-height: 1.25">Up to 2,377,030 our ordinary shares, par value $0.0009 per share, consisting of (i) 2,221,523 ordinary
        shares issuable upon the exercise of the New Warrants (as defined below), and (ii) 155,507 ordinary shares issuable upon the exercise
        of the Placement Agent Warrants (as defined below).</div> </div> </div> </div> </div> </div> </td> </tr>
  <tr>
    <td style="width: 35%; vertical-align: top; font-family: Times New Roman,Times,serif"><span style="font-family: Times New Roman"><br/> </span>
        </td>
    <td style="width: 2%; vertical-align: top; font-family: Times New Roman,Times,serif"><span style="font-family: Times New Roman"><br/> </span>
        </td>
    <td style="width: 63%; vertical-align: top; font-family: Times New Roman,Times,serif"><span style="font-family: Times New Roman"><br/> </span>
        </td> </tr>
  <tr>
    <td rowspan="1" style="width: 35%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="line-height: 1.25">Ordinary shares to be outstanding assuming exercise of the warrants</div> </td>
    <td rowspan="1" style="width: 2%; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td>
    <td rowspan="1" style="width: 63%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="line-height: 1.25; font-family: Times New Roman, Times, serif">10,791,645 ordinary shares.</div> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 35%; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td>
    <td rowspan="1" style="width: 2%; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td>
    <td rowspan="1" style="width: 63%; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td> </tr>
  <tr>
    <td style="width: 35%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="line-height: 1.25; font-family: Times New Roman">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">Use of proceeds</div>
        <div style="line-height: 1.25">&#160;</div> </div> </td>
    <td style="width: 2%; vertical-align: top; font-family: Times New Roman,Times,serif"><span style="font-family: Times New Roman"><br/> </span>
        </td>
    <td style="width: 63%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">
        <div style="line-height: 1.25">
        <div style="line-height: 1.25">We will not receive any proceeds from the sale of the ordinary shares issuable upon the exercise of the
        warrants by the selling securityholders. All net proceeds from the sale of the ordinary shares issuable upon the exercise of the warrants
        covered by this prospectus will go to the selling securityholders. However, we may receive the proceeds from any exercise of the warrants
        and placement agent warrants if the holders do not exercise the warrants on a cashless basis. See the section of this prospectus titled
        &#8220;<span style="font-style: italic">Use of Proceeds</span>.&#8221;</div> </div> </div> </div> </td> </tr>
  </table>

<div><br/> </div>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 35%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="line-height: 1.25; font-family: Times New Roman">Risk factors</div> </td>
    <td style="width: 2%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="line-height: 1.25; font-family: Times New Roman">&#160;</div> </td>
    <td style="width: 63%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="line-height: 1.25">
        <div style="line-height: 1.25; font-family: Times New Roman">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">Before investing in our securities, you should carefully read
        and consider the information set forth in &#8220;Risk Factors&#8221; beginning on page 6.</div> </div> </div> </td> </tr>
  <tr>
    <td style="width: 35%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="line-height: 1.25; font-family: Times New Roman">&#160;</div> </td>
    <td style="width: 2%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="line-height: 1.25; font-family: Times New Roman">&#160;</div> </td>
    <td style="width: 63%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="line-height: 1.25; font-family: Times New Roman">&#160;</div> </td> </tr>
  <tr>
    <td style="width: 35%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="line-height: 1.25; font-family: Times New Roman">Nasdaq ticker symbols</div> </td>
    <td style="width: 2%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="line-height: 1.25; font-family: Times New Roman">&#160;</div> </td>
    <td style="width: 63%; vertical-align: top">
        <div style="line-height: 1.25">
        <div style="line-height: 1.25; font-family: Times New Roman">
        <div style="line-height: 1.25; font-family: Times New Roman, Times, serif">
        <div style="line-height: 1.25">New Silexion ordinary shares and New Silexion warrants are listed on Nasdaq under the symbols &#8220;SLXN&#8221;
        and &#8220;SLXNW&#8221;, respectively.</div> </div> </div> </div> </td> </tr>
  </table>

<div> <span style="font-family: Times New Roman"></span><br/>

<div style="line-height: 1.25">For additional information concerning the offering, see &#8220;<span style="font-style: italic">Plan of
Distribution</span>&#8221; beginning on page 149.</div> </div> </div> </div> </div> </div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif; color: rgb(0, 0, 0)">5</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div> <br/>

<div style="text-align: center; line-height: 1.25; font-weight: bold; font-family: Times New Roman"><!--Anchor--><span id="RISK"><!--Anchor--></span>RISK
FACTORS</div>

<div style="text-align: center; line-height: 1.25; font-style: italic; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-style: italic; font-family: Times New Roman">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif; font-style: italic">

<div style="text-indent: 36pt; line-height: 1.25; font-style: italic">Investing in our securities involves a high degree of risk. You
should carefully consider the risks and uncertainties described below together with all of the other information contained in this prospectus,
including our financial statements and related notes appearing at the end of this prospectus and in the section titled &#8220;Management&#8217;s
Discussion and Analysis of Financial Condition and Results of Operations,&#8221; before deciding to invest in our securities. If any of
the events or developments described below were to occur, our business, prospects, operating results and financial condition could suffer
materially, the trading price of our ordinary shares could decline, and you could lose all or part of your investment. The risks and uncertainties
described below are not the only ones we face. Additional risks and uncertainties not presently known to us or that we currently believe
to be immaterial may also adversely affect our business.</div> </div> </div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold; font-family: Times New Roman">&#160;</div>

<div style="line-height: 1.25; font-weight: bold; font-family: Times New Roman">Risks Related to Our Financial Condition and Capital Requirements</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman">&#160;</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman,Times,serif">

<div style="line-height: 1.25; font-family: Times New Roman, Times, serif; font-style: italic; font-weight: bold">

<div style="line-height: 1.25; font-family: Times New Roman; font-style: italic; font-weight: bold">We are a development-stage company
and have a limited operating history on which to assess our business. We have incurred significant losses since our inception and anticipate
that we will continue to incur significant losses for the foreseeable future.</div> </div> </div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">

<div style="line-height: 1.25; font-family: Times New Roman">We are a development stage company with a limited operating history focused
on the discovery and development of treatments based on the emerging therapeutic modality RNA interference (RNAi), a biological process
in which ribonucleic acid (RNA) molecules inhibit gene expression. Our proposed treatment, which we refer to as SIL-204B, consists of
locally administered small interfering RNAs, or siRNA, to KRAS G12D- or KRAS G12V-mutations (G12D/V), which is the gene driver that causes
development of tumors and human cancer (oncogenic). We have incurred net losses since our inception in November 2008, including net losses
of $5.1 million for the year ended December 31, 2023 and $14.8 million for the nine months ended September 30, 2024. As of September 30,
2024, we have an accumulated deficit of $41.6 million.</div> </div> </div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">

<div style="line-height: 1.25; font-family: Times New Roman">We have devoted substantially all of our financial resources to design and
develop our product candidates, including conducting preclinical and clinical studies and providing general and administrative support
for these operations. To date, we have financed our operations primarily through the sale of equity securities and through royalty-bearing
grants that we received from Israel&#8217;s Innovation Authority, or the IIA. The amount of our future net losses will depend, in part,
on the rate of our future expenditures and our ability to obtain funding through equity or debt financings, strategic collaborations,
or grants. Biopharmaceutical product development is a highly speculative undertaking and involves a substantial degree of risk. We are
the early stages of clinical and preclinical development for our product candidates, we have we have not yet commenced pivotal clinical
studies for any product candidate and it may be several years, if ever, before we complete pivotal clinical studies and have a product
candidate approved for commercialization. Even if we obtain regulatory approval to market a product candidate, our future revenue will
depend upon the size of any markets in which our product candidates may receive approval, and our ability to achieve sufficient market
acceptance, pricing, reimbursement from third-party payors, and adequate market share for our product candidates in those markets.</div>
</div> </div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">

<div style="line-height: 1.25; font-family: Times New Roman">We expect to continue to incur significant expenses and increasing operating
losses for the foreseeable future. We anticipate that our expenses will increase substantially if and as we:</div> </div> </div>

<div style="text-indent: -36pt; margin-left: 48pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z374db9074283435c859e52b4036a5e07" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">
        <div style="line-height: 1.25; font-family: Times New Roman">continue and expand our research and preclinical and clinical development
        of our product candidates;</div> </div> </td> </tr>
  </table>

<div style="text-indent: -36pt; margin-left: 48pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z9dfbee1065d84601819f47ad8414432b" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">
        <div style="line-height: 1.25; font-family: Times New Roman">initiate additional preclinical, toxicology, clinical, or other studies for
        our product candidates;</div> </div> </td> </tr>
  </table>

<div style="text-indent: -36pt; margin-left: 48pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z331ea48290d048ab96f8b31010d42ba1" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">
        <div style="line-height: 1.25; font-family: Times New Roman">continue to improve our quality standards and change or add additional manufacturers
        or suppliers;</div> </div> </td> </tr>
  </table>

<div style="text-indent: -36pt; margin-left: 48pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z407e991d09f648b790ceb1649a6f4447" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">
        <div style="line-height: 1.25; font-family: Times New Roman">seek regulatory and marketing approvals for our product candidates that successfully
        complete clinical studies;</div> </div> </td> </tr>
  </table>

<div style="text-indent: -36pt; margin-left: 48pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: rgb(0, 0, 0); font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">6</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<table cellspacing="0" cellpadding="0" id="zaa2c4124583f44ba80526f0c48d77277" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">
        <div style="line-height: 1.25; font-family: Times New Roman">establish a sales, marketing, and distribution infrastructure to commercialize
        any products for which we may obtain marketing approval;</div> </div> </td> </tr>
  </table>

<div style="text-indent: -36pt; margin-left: 48pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">

<table cellspacing="0" cellpadding="0" id="zd574639c2fe549b98f381afb9999fbbc" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">seek to identify, assess, acquire, license, and/or develop other product
        candidates;</div> </td> </tr>
  </table>

<div style="text-indent: -36pt; margin-left: 48pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<table cellspacing="0" cellpadding="0" id="zc6e9eee93f20402ba1d0f60f603f213d" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">enter into license agreements;</div> </td> </tr>
  </table>

<div style="text-indent: -36pt; margin-left: 48pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z37078abb3a0646528db2575cf0313920" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">seek to maintain, protect, and expand our intellectual property portfolio;</div>
        </td> </tr>
  </table>

<div style="text-indent: -36pt; margin-left: 48pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z5dca374fb22e440b9efe0c410eefd7c3" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">seek to attract and retain skilled personnel;</div> </td> </tr>
  </table>

<div style="text-indent: -36pt; margin-left: 48pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z746205026bf84b6e984c93018abc18fa" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25">
        <div style="line-height: 1.25; font-family: Times New Roman">create additional infrastructure to support our operations as a public company
        and our product development and planned future commercialization efforts; and</div> </div> </td> </tr>
  </table>

<div style="text-indent: -36pt; margin-left: 48pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z475580e6a38f4fe19c88ca8db35132a5" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">experience any delays or encounter issues with any of the above, including
        but not limited to failed studies, complex results, safety issues, or other regulatory challenges that require longer follow-up&#160;of
        existing studies, additional major studies, or additional supportive studies in order to pursue marketing approval.</div> </td> </tr>
  </table>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div> </div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman">Further, the net losses we incur may fluctuate significantly
from quarter to quarter and year to year, such that a period-to-period comparison of our results of operations may not be a good indication
of our future performance.</div> </div> </div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman">&#160;</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman,Times,serif">

<div style="line-height: 1.25; font-family: Times New Roman; font-style: italic; font-weight: bold">We have never generated any revenue
from product sales and may never be profitable.</div> </div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="line-height: 1.25; font-family: Times New Roman">We have we have no products approved for commercialization and has never
generated any revenue. Our ability to generate revenue and achieve profitability depends on our ability, alone or with strategic collaboration
partners, to successfully complete the development of, and obtain the regulatory and marketing approvals necessary to commercialize, one
or more of our product candidates. We do not anticipate generating revenue from product sales for the foreseeable future. Our ability
to generate future revenue from product sales depends heavily on our success in many areas, including but not limited to:</div> </div>
</div> </div>

<div style="text-indent: -36pt; margin-left: 48pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">

<table cellspacing="0" cellpadding="0" id="ze96b3296002f439f8d28f29fd7c14f28" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">completing research and preclinical and toxicology and clinical development
        of our product candidates;</div> </td> </tr>
  </table>

<div style="text-indent: -36pt; margin-left: 48pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z6fd355377df64ce8b7ae7dec93b088f0" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25">
        <div style="line-height: 1.25; font-family: Times New Roman">obtaining regulatory and marketing approvals for our product candidates,
        if and when we complete clinical studies;</div> </div> </td> </tr>
  </table>

<div style="text-indent: -36pt; margin-left: 48pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<table cellspacing="0" cellpadding="0" id="zb2ccb82d7ed94c1cbaaf4396183b1240" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">developing a sustainable and scalable in-house&#160;manufacturing process,
        meeting all regulatory standards for approved product candidates, and in some instances, establishing and maintaining supply and manufacturing
        relationships with third parties that can conduct the process and provide adequate (in amount and quality) products to support clinical
        development and the market demand for product candidates, if approved;</div> </td> </tr>
  </table>

<div style="text-indent: -36pt; margin-left: 48pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z85cf760a3d3d4467a595d70db4e7afed" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">launching and commercializing product candidates, if and when we obtain regulatory
        and marketing approval, either directly or with a collaborator or distributor;</div> </td> </tr>
  </table>

<div style="text-indent: -36pt; margin-left: 48pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<table cellspacing="0" cellpadding="0" id="zd2215ee47c874e89b755c309ce7f9dec" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">exposing, educating and training physicians to use our products;</div> </td>
        </tr>
  </table>

<div style="text-indent: -36pt; margin-left: 48pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z5a1d28a450024f7385573536b35632f7" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">obtaining market acceptance of our product candidates as viable treatment
        options;</div> </td> </tr>
  </table>

<div style="text-indent: -36pt; margin-left: 48pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z3d75d43ea54b428f951809543dc0dbe1" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">addressing any competing technological and market developments;</div> </td>
        </tr>
  </table>

<div style="text-indent: -36pt; margin-left: 48pt; line-height: 1.25; font-family: Times New Roman">&#160;</div> </div>

<table cellspacing="0" cellpadding="0" id="z0dc69e9bc1174009ba2e8c6828bf2682" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">identifying, assessing, acquiring and/or developing new product candidates;</div>
        </td> </tr>
  </table>

<div style="text-indent: -36pt; margin-left: 48pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: rgb(0, 0, 0); font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">7</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div> <span style="font-family: Times New Roman"><br/> </span> </div>

<table cellspacing="0" cellpadding="0" id="zcd885c5e0087477f818f70337569cdc4" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">
        <div style="line-height: 1.25; font-family: Times New Roman">negotiating favorable terms in any collaboration, licensing, or other arrangements
        into which we may enter;</div> </div> </td> </tr>
  </table>

<div style="text-indent: -36pt; margin-left: 48pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z8737785af37d4d1a90e4c170c07c49a8" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">
        <div style="line-height: 1.25; font-family: Times New Roman">maintaining, protecting, and expanding our portfolio of intellectual property
        rights, including patents, trade secrets, and know-how; and</div> </div> </td> </tr>
  </table>

<div style="text-indent: -36pt; margin-left: 48pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<table cellspacing="0" cellpadding="0" id="zac78d5c0a16a43cdb5a46704f9f5f811" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">attracting, hiring, and retaining qualified personnel.</div> </td> </tr>
  </table>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">

<div style="line-height: 1.25; font-family: Times New Roman">Even if one or more of the product candidates that we develop is approved
for commercial sale, we anticipate incurring significant costs associated with commercializing any approved product candidate. Our expenses
could increase beyond expectations if we are required by the FDA, the European Medicines Agency (EMA) or other regulatory agencies, domestic
or foreign, or ethical committees in medical centers, to change our manufacturing processes or assays or to perform clinical, nonclinical,
or other types of studies in addition to those that we currently anticipate. In cases where we are successful in obtaining regulatory
approvals to market one or more of our product candidates, our revenue will be dependent, in part, upon the size of the markets in the
territories for which we gain regulatory approval, the accepted price for the product, the ability to get reimbursement at any price,
and whether we own the commercial rights for that territory. If the number of our addressable disease patients is not as significant as
we estimate, the indication approved by regulatory authorities is narrower than we expect, or the reasonably accepted population for treatment
is narrowed by competition, physician choice or treatment guidelines, we may not generate significant revenue from sales of such products,
even if approved. Additionally, there might be changes in supply or other changes in the approved drugs of which our products will be
administrated in combination, where such changes can affect our revenues. Further, if we are not able to generate revenue from the sale
of any approved products, we may be forced to cease operations.</div> </div> </div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman">&#160;</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman,Times,serif">

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman">We will need to raise substantial
additional funding before we can expect to become profitable from product sales. This additional financing may not be available on acceptable
terms, or at all. Failure to obtain this necessary capital when needed may force us to delay, limit, or terminate our product development
efforts or other operations.</div> </div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">

<div style="line-height: 1.25; font-family: Times New Roman">We are currently advancing our SIL-204B platform product through preclinical
and clinical development. Developing our product candidates is expensive, and we expect our research and development expenses to increase
substantially in connection with our ongoing activities, particularly as we advance pour product candidates through clinical studies.</div>
</div> </div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">

<div style="line-height: 1.25; font-family: Times New Roman">If our product candidates enter and advance through preclinical studies and
clinical trials, we will need substantial additional funds to expand our development, regulatory, manufacturing, marketing and sales capabilities
or contract with other organizations to provide those capabilities for it. We have used substantial funds to develop our product candidates
and delivery technologies and will require significant funds to conduct further research and development and preclinical testing and clinical
trials of our product candidates, to seek regulatory approvals for our product candidates and to manufacture and market products, if any,
which are approved for commercial sale.</div> </div> </div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">

<div style="line-height: 1.25"><span style="font-family: Times New Roman"><br/> </span> </div>

<div style="line-height: 1.25; font-family: Times New Roman">As of September 30, 2024, our cash and cash equivalents were $1.97 million.
Based upon our then-expected level of operating expenditures, we have substantial doubt about our ability to continue as a going concern
as of such date. Please see the risk factor below titled &#8220;<span style="font-style: italic">our independent registered public accounting
firm&#8217;s report contains an explanatory paragraph</span>&#8230;&#8221; Beyond our activities for the next 12 months, we furthermore
expect that we will require substantial additional capital to advance manufacturing capabilities for, to obtain regulatory approval for,
and to commercialize, our product candidates. In addition, our operating plans may change as a result of many factors that may currently
be unknown to it, and we may need to seek additional funds sooner than planned. Our future funding requirements will depend on many factors,
including but not limited to:</div> </div> </div>

<div style="text-indent: -36pt; margin-left: 48pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z0cd57490658a4671a15708a9560a3ea6" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">
        <div style="line-height: 1.25; font-family: Times New Roman">the scope, rate of progress, results and cost of our clinical studies, preclinical
        testing, toxicology studies, and other related activities;</div> </div> </td> </tr>
  </table>

<div style="text-indent: -36pt; margin-left: 48pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: rgb(0, 0, 0); font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">8</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="text-indent: -36pt; margin-left: 48pt; line-height: 1.25"> <span style="font-family: Times New Roman"><br/> </span> </div>

<table cellspacing="0" cellpadding="0" id="zf158179c749e4729b0eeb153bce4de5f" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">
        <div style="line-height: 1.25; font-family: Times New Roman">the cost of manufacturing clinical supplies, and establishing commercial
        supplies of our product candidates and any future products;</div> </div> </td> </tr>
  </table>

<div style="text-indent: -36pt; margin-left: 48pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z11798017303346babf879838221a37dd" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">
        <div style="line-height: 1.25; font-family: Times New Roman">the number and characteristics of product candidates that we pursue;</div>
        </div> </td> </tr>
  </table>

<div style="text-indent: -36pt; margin-left: 48pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z29dae668169542319032c65d3f72dc63" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">the cost, timing, and outcomes of regulatory approvals;</div> </td> </tr>
  </table>

<div style="text-indent: -36pt; margin-left: 48pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z4ea2fe1524d041b5878357f78f4b39bd" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">the cost and timing of establishing sales, marketing, and distribution capabilities;
        and</div> </td> </tr>
  </table>

<div style="text-indent: -36pt; margin-left: 48pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<table cellspacing="0" cellpadding="0" id="zd7f878a6d2504c8eac4c500e88b0c901" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">
        <div style="line-height: 1.25; font-family: Times New Roman">the terms and timing of any collaborative, licensing, and other arrangements
        that we may establish.</div> </div> </td> </tr>
  </table>

<div style="line-height: 1.25"><span style="font-family: Times New Roman"><br/> </span> </div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">Any additional fundraising efforts may divert our management
from our&#160;day-to-day&#160;activities, which may adversely affect our abilities to develop and commercialize our product candidates.
In addition, we cannot guarantee that future financing will be available in sufficient amounts or on terms acceptable to us, if at all.
Moreover, the terms of any financing may adversely affect the holdings or the rights of our shareholders, and the issuance of additional
securities, whether equity or debt, by us, or the possibility of such issuance, may cause the market price of our ordinary shares to decline
due to expected or actual dilution. The incurrence of indebtedness could result in increased fixed payment obligations, and we may be
required to agree to certain restrictive covenants, such as limitations on our ability to incur additional debt, limitations on our ability
to acquire, sell, or license intellectual property rights, and other operating restrictions that could adversely impact our ability to
conduct our business. We could also be required to seek funds through arrangements with collaborative partners or otherwise at an earlier
stage than otherwise would be desirable, and we may be required to relinquish rights to some of our technologies or product candidates
or otherwise agree to terms unfavorable to it, any of which may have a material adverse effect on our business, operating results, and
prospects. Even if we believe we have sufficient funds for our current or future operating plans, we may seek additional capital if market
conditions are favorable or if we have specific strategic considerations.</div> </div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">

<div style="line-height: 1.25; font-family: Times New Roman">If we are unable to obtain funding on a timely basis, we may be required
to significantly curtail, delay, or discontinue one or more of our research, development or manufacturing programs or the commercialization
of any product candidates, or be unable to expand our operations or otherwise capitalize on our business opportunities, as desired, which
could materially affect our business, financial condition, and results of operations.</div> </div> </div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman">&#160;</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman,Times,serif">

<div style="line-height: 1.25; font-family: Times New Roman; font-style: italic; font-weight: bold">Our independent registered public
accounting firm&#8217;s report contains an explanatory paragraph that expresses substantial doubt about our ability to continue as a &#8220;going
concern.&#8221;</div> </div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">We have limited cash resources and will need to obtain
additional funds in order to satisfy our liquidity needs. Silexion will require significant funds to conduct further research and development
and preclinical testing and clinical trials of our product candidates, to seek regulatory approvals for our product candidates and to
manufacture and market products, if any, which are approved for commercial sale. In light of our significant working capital needs and
the absence of any committed source of financing to meet those needs, there may be substantial doubt raised about our ability to continue
as a &#8220;going concern.&#8221; Please see the explanatory paragraph under the heading &#8220;Substantial Doubt about the Company&#8217;s
Ability to Continue as a Going Concern&#8221; in our independent auditors&#8217; report on our financial statements that appear in this
prospectus. Those financial statements do not include any adjustments that might result from our inability to continue as a &#8220;going
concern.&#8221;</div> </div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman">&#160;</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman,Times,serif">

<div style="line-height: 1.25; font-family: Times New Roman; font-style: italic; font-weight: bold">The historical financial results of
Silexion and unaudited pro forma financial information included herein may not be indicative of what our actual financial position or
results of operations would have been.</div> </div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">

<div style="line-height: 1.25; font-family: Times New Roman">The historical financial results of Silexion included in this prospectus
do not reflect the financial condition, results of operations or cash flows we would have achieved as a public company during the periods
presented or those the Company will achieve in the future. Our financial condition and future results of operations could be materially
different from amounts reflected in certain of our historical financial statements included elsewhere in this prospectus, and it may be
difficult for investors to compare our future results to historical results or to evaluate our relative performance or trends in our business.</div>
</div> </div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: rgb(0, 0, 0); font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">9</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">Similarly, the unaudited pro forma financial information
included herein is presented for illustrative purposes only and has been prepared based on a number of assumptions. Accordingly, such
pro forma financial information is not necessarily indicative of what our actual financial position or results of operations would have
been had the Business Combination been completed on the dates indicated, and our actual financial condition and results of operations
may vary materially from such pro forma financial information, including as a result of such assumptions not being accurate. See &#8220;Unaudited
Pro Forma Condensed Combined Financial Information.&#8221;</div> </div>

<div style="line-height: 1.25; font-weight: bold; font-family: Times New Roman">&#160;</div>

<div style="line-height: 1.25; font-weight: bold; font-family: Times New Roman,Times,serif">

<div style="line-height: 1.25; font-family: Times New Roman; font-weight: bold">

<div style="line-height: 1.25; font-family: Times New Roman, Times, serif; font-weight: bold">Risks Related to the Research and Development
of Silexion&#8217;s Product Candidates</div> </div> </div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman">&#160;</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman,Times,serif">

<div style="line-height: 1.25; font-family: Times New Roman; font-style: italic; font-weight: bold">The approach we are taking to discover
and develop novel RNAi therapeutics is unproven for oncology and may never lead to marketable products.</div> </div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">We have concentrated our efforts and therapeutic product
research on RNAi technology, and RNAi drug delivery and our future success depends on the successful development of this technology and
products based on it. We have not received regulatory approval to market therapeutics utilizing RNAi based drugs, including siRNAs, the
class of molecule we are trying to develop into products. The scientific discoveries that form the basis for our efforts to discover and
develop new drugs are relatively new. The scientific evidence to support the feasibility of developing drugs and the delivery of such
drugs based on these discoveries is both preliminary and limited. Skepticism as to the feasibility of developing RNAi therapeutics for
oncology has been expressed in scientific literature. For example, there are potential challenges to achieving safe RNAi therapeutics
based on the so-called&#160;off-target&#160;effects and activation of the interferon response, and other potential challenges to achieve
safe and potent levels of RNAi drugs due to complications associated with drug delivery. In addition, decisions by other companies with
respect to their RNAi development efforts may increase skepticism in the marketplace regarding the potential for RNAi therapeutics.</div>
</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">Relatively few product candidates based on these discoveries
have ever been tested in animals or humans. siRNAs may not naturally possess the inherent properties typically required of drugs, such
as the ability to be stable in the body long enough to reach the tissues in which their effects are required, or the ability to enter
cells within these tissues in order to exert their effects. We are currently has only limited data, and no conclusive evidence, to suggest
that it can introduce these drug-like&#160;properties into siRNAs. We may spend large amounts of money trying to introduce these properties,
and may never succeed in doing so. In addition, these compounds may not demonstrate in patients the chemical and pharmacological properties
ascribed to them in laboratory studies, and they may interact with human biological systems in unforeseen, ineffective or harmful ways.
As a result, we may never succeed in developing a marketable product, we may not become profitable and the value of our ordinary shares
may decline.</div> </div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">The FDA has relatively limited experience with RNAi and
siRNA based therapeutics. Limited granted approvals to any person or entity, including us, to market and commercialize therapeutics using
RNAi based drugs including siRNA, which may increase the complexity, uncertainty and length of the regulatory approval process for our
product candidates. Further, siRNA therapies are part of a broader therapeutic category called oligonueciotides, and there are only a
few approved drugs based on this therapeutic category. We may never receive approval to market and commercialize any product candidate.</div>
</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">Further, our focus on RNAi technology for developing drugs,
as opposed to multiple, more proven technologies for drug development, increases the risks associated with the ownership of our ordinary
shares. If we are not successful in developing a product candidate using RNAi technology, we may be required to change the scope and direction
of our product development activities. In that case, we may not be able to identify and implement successfully an alternative product
development strategy.</div> </div>

<div style="text-indent: 36pt; line-height: 1.25"> <span style="font-family: Times New Roman"><br/> </span> </div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="line-height: 1.25; font-style: italic; font-weight: bold">

<div style="line-height: 1.25; font-family: Times New Roman; font-style: italic; font-weight: bold">We are heavily dependent on the success
of our product candidates, which are in the early stages of preclinical or clinical development. We cannot give any assurance that any
of our product candidates will receive regulatory approval, which is necessary before they can be commercialized.</div> </div> </div>

<div style="text-indent: 36pt; line-height: 1.25"> <span style="font-family: Times New Roman"><br/> </span> </div>

<div style="text-indent: 36pt; line-height: 1.25">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">To date, we have invested a substantial amount of our
efforts and financial resources to: (i)&#160;identify and develop our product candidates, including conducting preclinical and clinical
studies and providing general and administrative support for these operations; and (ii)&#160;develop and secure our intellectual property
portfolio for our product candidates. Our future success is dependent on our ability to successfully develop, obtain regulatory approval
for, and then successfully commercialize one or more product candidates. We currently generate no revenue from sales of any drugs or technology
platforms, and we may never be able to develop or commercialize a marketable drug.</div> </div> </div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: rgb(0, 0, 0); font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">10</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">Each of our product candidates is in the early stages
of development and will require additional clinical development (and in some cases additional preclinical development), management of
nonclinical, clinical and manufacturing activities, regulatory approval, obtaining adequate manufacturing supply, building of a commercial
organization, and significant marketing efforts before we generate any revenue from product sales. We have concluded Phase&#160;II study
on first-generation&#160;Loder and moved on to SIL-204B.&#160;Silexion hopes to initiate the next clinical trial with SIL-204B&#160;during
the first half of 2026 for locally advanced pancreatic cancer. We are not permitted to market or promote any of our product candidates
before we receive regulatory approval from the FDA or comparable foreign regulatory authorities, and we may never receive such regulatory
approval for any of our product candidates.</div> </div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">

<div style="line-height: 1.25; font-family: Times New Roman">We have never submitted marketing applications to the FDA or comparable foreign
regulatory authorities. We cannot be certain that any of our product candidates will be successful in clinical studies or receive regulatory
approval. Further, our product candidates may not receive regulatory approval even if they are successful in clinical studies. If we do
not receive regulatory approvals for our product candidates, we may not be able to continue our operations.</div> </div> </div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">

<div style="line-height: 1.25; font-family: Times New Roman">We generally plans to seek regulatory approval to commercialize our product
candidates in the United States, the EU and in additional foreign countries. To obtain regulatory approval in other countries, we must
comply with numerous and varying regulatory requirements of such other countries regarding safety, efficacy, chemistry, manufacturing
and controls, clinical studies, commercial sales, pricing, and distribution of our product candidates. Even if we are successful in obtaining
approval in one jurisdiction, it cannot ensure that we will obtain approval in any other jurisdictions. If we are unable to obtain approval
for our product candidates in multiple jurisdictions, our revenue and results of operations could be negatively affected.</div> </div>
</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman">&#160;</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman,Times,serif">

<div style="line-height: 1.25; font-family: Times New Roman; font-style: italic; font-weight: bold">The regulatory approval processes
of the FDA and comparable foreign authorities are lengthy, time consuming, and inherently unpredictable. If we are ultimately unable to
obtain regulatory approval for our product candidates, our business will be substantially harmed.</div> </div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">

<div style="line-height: 1.25; font-family: Times New Roman">The time required to develop a drug and obtain approval by the FDA and comparable
foreign authorities is unpredictable, typically takes many years following the commencement of clinical studies, and depends upon numerous
factors. In addition, approval policies, regulations, or the type and amount of clinical data necessary to gain approval may change during
the course of a product candidate&#8217;s clinical development and may vary among jurisdictions, which may cause delays in the approval
or the decision not to approve an application. We have we have not obtained regulatory approval for any product candidate, and it is possible
that none of our existing product candidates or any product candidates we may seek to develop in the future will ever obtain regulatory
approval.</div> </div> </div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">Applications for our product candidates could fail to
receive regulatory approval for many reasons, including but not limited to the following:</div>

<div style="text-indent: -36pt; margin-left: 48pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z58ac521c994b420facf8a3e6df0ba7cf" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">
        <div style="line-height: 1.25; font-family: Times New Roman">the FDA or comparable foreign regulatory authorities may disagree with the
        design or implementation of our clinical studies;</div> </div> </td> </tr>
  </table>

<div style="text-indent: -36pt; margin-left: 48pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z36f4834fb66345c0963b81b7273c5f70" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">
        <div style="line-height: 1.25; font-family: Times New Roman, Times, serif">
        <div style="line-height: 1.25; font-family: Times New Roman">We may be unable to demonstrate to the FDA or comparable foreign regulatory
        authorities that a product candidate&#8217;s benefit to risk ratio for our proposed indication is acceptable;</div> </div> </div> </td>
        </tr>
  </table>

<div style="text-indent: -36pt; margin-left: 48pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">

<table cellspacing="0" cellpadding="0" id="z5b66138cffa34392aa73843737b4357e" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">the population studied in the clinical program may not be sufficiently broad
        or representative to assure safety in the full population for which we seek approval;</div> </td> </tr>
  </table>

<div style="text-indent: -36pt; margin-left: 48pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z7c91b4833c2c46899b5fb14c874c9284" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">the FDA or comparable foreign regulatory authorities may disagree with our
        interpretation of data from preclinical studies or clinical studies;</div> </td> </tr>
  </table>

<div style="text-indent: -36pt; margin-left: 48pt; line-height: 1.25; font-family: Times New Roman">&#160;</div> </div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: rgb(0, 0, 0); font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">11</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div>

<div style="line-height: 1.25"><span style="font-family: Times New Roman"><br/> </span> </div>

<table cellspacing="0" cellpadding="0" id="z4766b6a235854b9fa5bd3fd299d1e5af" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">the data collected from clinical studies of our product candidates may not
        be sufficient to support the submission of a new drug application (NDA) or a biologics license application (BLA) or other submission or
        to obtain regulatory approval in the United&#160;States or elsewhere;</div> </td> </tr>
  </table>

<div style="text-indent: -36pt; margin-left: 48pt; line-height: 1.25; font-family: Times New Roman">&#160;&#160;</div>

<table cellspacing="0" cellpadding="0" id="zfe49b4e6da774bbaaa678d14a36dd32c" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">the FDA or comparable foreign regulatory authorities may fail to approve
        the manufacturing processes, test procedures and specifications, or facilities of third-party&#160;manufacturers with which we contract
        for clinical and commercial supplies; and</div> </td> </tr>
  </table>

<div style="text-indent: -36pt; margin-left: 48pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<table cellspacing="0" cellpadding="0" id="zc3c05ac77fe8418a8004d069ec32a709" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">the approval policies or regulations of the FDA or comparable foreign regulatory
        authorities may significantly change in a manner rendering our clinical data insufficient for approval.</div> </td> </tr>
  </table>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div> </div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">

<div style="line-height: 1.25; font-family: Times New Roman">This lengthy development and approval process, as well as the unpredictability
of the results of clinical studies, may result in our failing to obtain regulatory approval to market any of our product candidates, which
would significantly harm our business, and our consolidated results of operations and prospects.</div> </div> </div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman">&#160;</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman">Clinical drug development involves
a lengthy and expensive process with an uncertain outcome, and results of preclinical activity or earlier studies may not be predictive
of future study results.</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">

<div style="line-height: 1.25; font-family: Times New Roman">Before obtaining marketing approval from regulatory authorities for the sale
of our product candidates, we must conduct extensive clinical studies to demonstrate the safety and efficacy of the product candidates
in humans. Clinical testing is expensive and can take many years to complete, and its outcome is inherently uncertain. Failure can occur
at any time during the clinical study process. The results of preclinical studies and early clinical studies of product candidates often
are not predictive of the results of later-stage clinical studies. In general, even product candidates that have shown promising results
in preclinical activities or early-stage clinical studies may still suffer significant setbacks in subsequent registration clinical studies.
For example, the safety or efficacy results generated to date in preclinical and clinical studies for siG12DLoder or preclinical studies
with SIL-204B do not ensure that later clinical studies will demonstrate similar results. There is a high failure rate for drugs and biologics
proceeding through clinical studies, and product candidates in later stages of clinical studies may fail to show the desired safety and
efficacy traits despite having progressed through preclinical studies and initial clinical studies. A number of companies in the biopharmaceutical
industry have suffered significant setbacks in advanced clinical studies due to lack of efficacy or adverse safety profiles, notwithstanding
promising results in earlier studies. Moreover, preclinical and clinical data are often susceptible to varying interpretations and analyses.
We do not know whether any Phase 1, Phase 2, Phase 3 or other clinical studies we may conduct will demonstrate consistent or adequate
efficacy and safety sufficient to obtain regulatory approval to market our drug candidates.</div> </div> </div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">Events that may prevent successful or timely completion
of clinical development include but are not limited to:</div>

<div style="text-indent: -36pt; margin-left: 48pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z901e801e971e4cefa756e624f318d97e" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">inability to generate sufficient preclinical, toxicology, or other&#160;<span style="font-style: italic">in
        vivo</span>&#160;or&#160;<span style="font-style: italic">in vitro</span>&#160;data to support the initiation of human clinical studies;</div>
        </td> </tr>
  </table>

<div style="text-indent: -36pt; margin-left: 48pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z023387806ce844bdaf9217d1486d257b" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">delays in reaching a consensus with regulatory agencies on study design;</div>
        </td> </tr>
  </table>

<div style="text-indent: -36pt; margin-left: 48pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<table cellspacing="0" cellpadding="0" id="zd6ffe274843c4152ab2811f3cb1dfc9a" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">delays in reaching agreement on acceptable terms with prospective contract
        research organizations (CROs) and clinical study sites, the terms of which can be subject to extensive negotiation and may vary significantly
        among different CROs and clinical study sites;</div> </td> </tr>
  </table>

<div style="text-indent: -36pt; margin-left: 48pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<table cellspacing="0" cellpadding="0" id="zfe0d4b12a3ce4494afb2331b9bb24274" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">delays in obtaining required Institutional Review Board (IRB) or Ethics Committee
        approval at each clinical study site;</div> </td> </tr>
  </table>

<div style="text-indent: -36pt; margin-left: 48pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z0190b3f0c39346058298bba3c61d5d50" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">
        <div style="line-height: 1.25; font-family: Times New Roman">imposition of a clinical hold by regulatory agencies, after review of an
        investigational new drug (IND) application, or equivalent application, or an inspection of our clinical study operations or study sites;</div>
        </div> </td> </tr>
  </table>

<div style="text-indent: -36pt; margin-left: 48pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<table cellspacing="0" cellpadding="0" id="zdf333797587944f0a3bb5af1be06e92a" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">difficulty collaborating with patient groups and investigators;</div> </td>
        </tr>
  </table>

<div style="text-indent: -36pt; margin-left: 48pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z928e4090f1a64dfe9aafa93ea56fcc23" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">
        <div style="line-height: 1.25; font-family: Times New Roman">failure by our CROs, other third parties, or us to adhere to clinical study
        requirements;</div> </div> </td> </tr>
  </table>

<div style="text-indent: -36pt; margin-left: 48pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<table cellspacing="0" cellpadding="0" id="ze87ac1c2f67c4cd2b035a399cef248ec" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">failure to perform in accordance with the FDA&#8217;s good clinical practices
        requirements or applicable regulatory guidelines in other countries;</div> </td> </tr>
  </table>

<div style="text-indent: -36pt; margin-left: 48pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: rgb(0, 0, 0); font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">12</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="text-align: center; line-height: 1.25"><span style="font-family: Times New Roman"><br/> </span> </div>

<table cellspacing="0" cellpadding="0" id="z52f3081ca4f5437981126f0c403161a5" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">
        <div style="line-height: 1.25; font-family: Times New Roman">occurrence of serious adverse events associated with the product candidate
        that are viewed to outweigh our potential benefits;</div> </div> </td> </tr>
  </table>

<div style="text-indent: -36pt; margin-left: 48pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z8c5b80b874334edfabd930aff2f23d0f" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">
        <div style="line-height: 1.25; font-family: Times New Roman">the cost of clinical studies of our drug candidates being greater than we
        anticipate;</div> </div> </td> </tr>
  </table>

<div style="text-indent: -36pt; margin-left: 48pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<table cellspacing="0" cellpadding="0" id="zaab9e340f65a45f39505e728c70c10ae" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">
        <div style="line-height: 1.25; font-family: Times New Roman">clinical studies of our drug candidates producing negative or inconclusive
        results, which may result in us deciding, or regulators requiring us, to conduct additional clinical studies or abandon drug development
        programs; and</div> </div> </td> </tr>
  </table>

<div style="text-indent: -36pt; margin-left: 48pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z9e616c8073404f93a6369af482bb1859" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">failures associated with data interpretation, data management and data storage
        of such studies.</div> </td> </tr>
  </table>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">

<div style="line-height: 1.25; font-family: Times New Roman">If we ultimately is unable to successfully complete clinical development
of our product candidates, we would be forced to cease operations. Clinical study delays could also shorten any periods during which our
products have patent protection and may allow our competitors to bring products to market before we do, which could impair our ability
to obtain orphan exclusivity and to successfully commercialize our product candidates.</div> </div> </div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman">&#160;</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman,Times,serif">

<div style="line-height: 1.25; font-family: Times New Roman, Times, serif; font-style: italic; font-weight: bold">

<div style="line-height: 1.25; font-family: Times New Roman; font-style: italic; font-weight: bold">We may find it difficult to enroll
patients in our clinical studies. Difficulty in enrolling patients could delay or prevent clinical studies of our product candidates.</div>
</div> </div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">

<div style="line-height: 1.25; font-family: Times New Roman">Identifying and qualifying patients to participate in clinical studies of
our product candidates is critical to our success. The timing of our clinical studies depends in part on the speed at which we can recruit
patients to participate in testing our product candidates, and we may experience delays in our clinical studies if we encounter difficulties
in enrollment.</div> </div> </div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">

<div style="line-height: 1.25; font-family: Times New Roman">Some of the conditions for which we plan to evaluate our current product
candidates are relatively rare diseases. For example, according to the National Cancer Institute, approximately 61,000 patients were diagnosed
with pancreatic cancer in the U.S. in 2020. Accordingly, there are limited patient pools from which to draw for clinical studies. In addition
to the relative rarity of these diseases, the eligibility criteria of our clinical studies will further limit the pool of available study
participants as we will require that patients have specific characteristics that we can measure or to assure their disease is either severe
enough or not too advanced to include them in a study. We also may not be able to identify, recruit, and enroll a sufficient number of
patients to complete our clinical studies because of the perceived risks and benefits of the product candidate under study, the availability
and efficacy of competing therapies and clinical studies, the proximity and availability of clinical study sites for prospective patients,
and the patient referral practices of physicians.</div> </div> </div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">

<div style="line-height: 1.25; font-family: Times New Roman">In addition, even for the more prevalent diseases which we target, such as
prostate and breast cancer, enrolling patients in our clinical studies may be difficult. There may be several ongoing clinical studies
for these diseases (both RNAi based and otherwise), and we may face competition in enrolling patients. The number of patients in such
clinical studies might be significantly large. In addition, the time period required to achieve indications of safety and efficacy in
such studies may be very long. Some of these competing studies may be conducted by other biopharmaceutical companies with more experience
in clinical testing and with much greater financial, technical and human resources than we have.</div> </div> </div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">

<div style="line-height: 1.25; font-family: Times New Roman">If patients are unwilling to participate in our studies for any reason, the
timeline for recruiting patients, conducting studies, and obtaining regulatory approval of our potential products will be delayed.</div>
</div> </div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman">&#160;</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman,Times,serif">

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman">Our product candidates and the administration
of our product candidates may cause undesirable side effects or have other properties that could delay or prevent their regulatory approval,
limit the commercial profile of an approved label, or result in significant negative consequences following marketing approval, if any.</div>
</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">

<div style="line-height: 1.25; font-family: Times New Roman">Undesirable side effects including toxicology caused by our product candidates
could cause us or regulatory authorities to interrupt, delay, or halt clinical studies and could result in a more restrictive label or
the delay or denial of regulatory approval by the FDA or other comparable foreign authorities. For example, there are known immune stimulation
and other side effects associated with RNAi. The implantation of SIL-204B may entail the use of endoscopic ultrasound (EUS) needles, which
may cause pancreatitis, bleeding or other procedural related safety issues. The Phase 2 clinical study with siG12DLoder indicated that
Loder treatment was well tolerated. Safety events that were observed were primarily related to procedure, mainly reversible abdominal
pain. In addition, the presence of a foreign body such as our SIL-204B) in human tissue may cause inflammation. Results of our studies
could reveal a high and unacceptable severity and prevalence of these or other side effects. In such an event, such studies could be suspended
or terminated, and the FDA or comparable foreign regulatory authorities could order us to cease further development of or deny or withdraw
approval of our product candidates for any or all targeted indications.</div> </div> </div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: rgb(0, 0, 0); font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">13</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="text-align: center; line-height: 1.25"><span style="font-family: Times New Roman"><br/> </span> </div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">The drug-related, drug-product&#160;related, and administration
related side effects could affect patient recruitment, the ability of enrolled patients to complete the study, or result in potential
product liability claims. we do not currently have product liability insurance and does not anticipate obtaining product liability insurance
until such time as we have received FDA or other comparable foreign authority approval for a product and there is a product that is being
provided to patients outside of clinical trials.</div> </div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">

<div style="text-indent: 25.2pt; margin-right: 11.95pt; margin-left: 8.2pt; line-height: 1.25; font-family: Times New Roman">Additionally,
if one or more of our product candidates receives marketing approval, and we or others later identify undesirable side effects caused
by such products, a number of potentially significant negative consequences could result, including but not limited to:</div> </div> </div>

<div style="text-indent: -36pt; margin-left: 48pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<table cellspacing="0" cellpadding="0" id="zc465d99966744a1c978963037edf08ae" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">regulatory authorities may withdraw approvals of such product;</div> </td>
        </tr>
  </table>

<div style="text-indent: -36pt; margin-left: 48pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z5dcfdd6f077948f6bbe98654fa8781ab" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">regulatory authorities may require additional warnings on the label;</div>
        </td> </tr>
  </table>

<div style="text-indent: -36pt; margin-left: 48pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z1285205655294eee9ea3aaa692aa7081" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">
        <div style="line-height: 1.25; font-family: Times New Roman">We may be required to create a Risk Evaluation and Mitigation Strategy (REMS)
        plan or similar plan in other jurisdictions, which could include a medication guide outlining the risks of such side effects for distribution
        to patients, a communication plan for healthcare providers, and/or other elements to assure safe use;</div> </div> </td> </tr>
  </table>

<div style="text-indent: -36pt; margin-left: 48pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z043a62f7dd274e20b1d31a2f80ea41fd" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">
        <div style="line-height: 1.25; font-family: Times New Roman">We could be sued and held liable for harm caused to patients; and</div> </div>
        </td> </tr>
  </table>

<div style="text-indent: -36pt; margin-left: 48pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<table cellspacing="0" cellpadding="0" id="ze83a756bedce4cfbab25c4ec6e00f0f4" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">
        <div style="line-height: 1.25; font-family: Times New Roman">Our reputation may suffer.</div> </div> </td> </tr>
  </table>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">

<div style="text-indent: 25.15pt; margin-right: 11.1pt; margin-left: 8.2pt; line-height: 1.25; font-family: Times New Roman">Any of these
events could prevent us from achieving or maintaining market acceptance of the particular product candidate, if approved, and could significantly
harm our business, results of operations, and prospects.</div> </div> </div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman">&#160;</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman,Times,serif">

<div style="line-height: 1.25; font-family: Times New Roman, Times, serif; font-style: italic; font-weight: bold">

<div style="line-height: 1.25; font-family: Times New Roman; font-style: italic; font-weight: bold">Even if we obtain regulatory approval
for a product candidate, our products will remain subject to regulatory scrutiny.</div> </div> </div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">

<div style="text-indent: 36pt; line-height: 1.25">

<div style="line-height: 1.25; font-family: Times New Roman">If our product candidates are approved, they will be subject to ongoing regulatory
requirements for manufacturing, labeling, packaging, storage, advertising, promotion, sampling, record-keeping, conduct of post-marketing
studies, and submission of safety, efficacy, and other post-market information, including both federal and state requirements in the United
States and other jurisdictions, where the product might be marketed. Accordingly, we and others with whom we work must continue to expend
time, money, and effort in all areas of regulatory compliance, including manufacturing, production, and quality control.</div> </div>
</div> </div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">

<div style="line-height: 1.25; font-family: Times New Roman">Any regulatory approvals that we receive for our product candidates may also
be subject to limitations on the approved indicated uses for which the product may be marketed or to the conditions of approval, or contain
requirements for potentially costly post-marketing testing, including Phase 4 clinical trials, and surveillance to monitor the safety
and efficacy of the product candidate. We will also be required to report certain adverse reactions and production problems, if any, to
the FDA, and to comply with requirements concerning advertising and promotion for our products. Promotional communications with respect
to prescription drugs are subject to a variety of legal and regulatory restrictions and must be consistent with the information in the
product&#8217;s approved label. As such, we may not promote our products for indications or uses for which they do not have FDA approval.
The holder of an approved NDA or BLA must also submit new or supplemental applications and obtain FDA approval for certain changes to
the approved product, product labeling, or manufacturing process. We could also be asked to conduct post-marketing clinical studies to
verify the safety and efficacy of our products in general or in specific patient subsets. If we obtain original marketing approval via
the accelerated approval pathway, we could be required to conduct a successful post-marketing clinical study to confirm clinical benefit
for our products. An unsuccessful post-marketing study or failure to complete such a study could result in the withdrawal of marketing
approval. Furthermore, any new legislation addressing drug safety issues could result in delays in product development or commercialization
or increased costs to assure compliance. Foreign regulatory authorities impose similar requirements.</div> </div> </div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: rgb(0, 0, 0); font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">14</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="text-align: center; line-height: 1.25"><span style="font-family: Times New Roman"><br/> </span> </div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">If a regulatory agency discovers previously unknown problems
with a product, such as adverse events of unanticipated severity or frequency, or disagrees with the promotion, marketing or labeling
of a product, such regulatory agency may impose restrictions on that product or us, including requiring withdrawal of the product from
the market. If we fail to comply with applicable regulatory requirements, a regulatory agency or enforcement authority may, among other
things:</div> </div>

<div style="text-indent: -36pt; margin-left: 48pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z22b5013358a6435fae0f532a6328233f" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman">issue warning letters;</div> </td> </tr>
  </table>

<div style="text-indent: -36pt; margin-left: 48pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z44f74ad5a37c4b19aa255f526131f691" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman">impose civil or criminal penalties;</div> </td> </tr>
  </table>

<div style="text-indent: -36pt; margin-left: 48pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z1ed27b85dbc94a408e87ec93c0841760" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman">suspend or withdraw regulatory approval;</div> </td>
        </tr>
  </table>

<div style="text-indent: -36pt; margin-left: 48pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<table cellspacing="0" cellpadding="0" id="zb895e4f8dccc4f40a4a0fb1a6f3ea9d7" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">
        <div style="text-align: left; line-height: 1.25; font-family: Times New Roman">suspend any of our ongoing clinical studies;</div> </div>
        </td> </tr>
  </table>

<div style="text-indent: -36pt; margin-left: 48pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z34067454981740bd9a3ec073683db622" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman">refuse to approve pending applications or supplements
        to approved applications submitted by Silexion; or</div> </td> </tr>
  </table>

<div style="text-indent: -36pt; margin-left: 48pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z5389eca72c05448bb80477ef151f274f" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman">seize or detain products, or require a product recall.</div>
        </td> </tr>
  </table>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">

<div style="line-height: 1.25; font-family: Times New Roman">Any government investigation of alleged violations of law could require us
to expend significant time and resources in response, and could generate negative publicity. Any failure to comply with ongoing regulatory
requirements may significantly and adversely affect our ability to commercialize and generate revenue from our products. If regulatory
sanctions are applied or if regulatory approval is withdrawn, the value of the Company and our operating results will be adversely affected.</div>
</div> </div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman">&#160;</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman">The FDA and other regulatory agencies
actively enforce the laws and regulations prohibiting the promotion of&#160;off-label&#160;uses.</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">

<div style="line-height: 1.25; font-family: Times New Roman">If any of our product candidates are approved and they are found to have
been improperly promoted for unapproved uses of those products, we may become subject to significant liability. The FDA and other regulatory
agencies or other governmental bodies strictly regulate the promotional claims that may be made about prescription products, such as our
product candidates, if approved. In particular, a product may not be promoted for uses that are not approved by the FDA or such other
regulatory agencies as reflected in the product&#8217;s approved labeling. If we receive marketing approval for a product candidate, physicians
may nevertheless prescribe it to their patients in a manner that is inconsistent with the approved label. If we are found to have promoted
such unapproved, or off-label, uses, they may become subject to significant liability. The U.S. federal government has levied large civil
and criminal fines against companies for alleged improper promotion of off-label use and has enjoined several companies from engaging
in off-label promotion. The FDA has also requested that companies enter into consent decrees or permanent injunctions under which specified
promotional conduct is changed or curtailed. If we cannot successfully manage the promotion of our product candidates, if approved, we
could become subject to significant liability, which would materially adversely affect our business and financial condition.</div> </div>
</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman">&#160;</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman,Times,serif">

<div style="line-height: 1.25; font-style: italic; font-weight: bold">

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman">We and our collaborators are subject
to significant regulation with respect to manufacturing our product candidates. The facilities we subcontract to for manufacturing may
not meet regulatory requirements and may have limited capacity.</div> </div> </div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">

<div style="line-height: 1.25; font-family: Times New Roman">All entities involved in the preparation of therapeutics for clinical studies
or commercial sale are subject to extensive regulation. Components of a finished therapeutic product approved for commercial sale or used
in late-stage clinical studies must be manufactured in accordance with current GMP (cGMP) or, in other countries, GMP. These regulations
govern manufacturing processes and procedures (including record keeping) and the implementation and operation of quality systems to control
and assure the quality of investigational products and products approved for sale. Poor control of production processes can lead to the
introduction of contaminants or to inadvertent changes in the properties or stability of our product candidates that may not be detectable
in final product testing. Us, our collaborators, or any contract manufacturers must supply all necessary documentation in support of an
NDA, BLA, or Marketing Authorization Application (MAA) on a timely basis and must adhere to Good Laboratory Practices (GLP) and cGMP/GMP
regulations enforced by the FDA and other regulatory agencies through their facilities and data and documentation inspection programs.
We have never produced a commercially approved pharmaceutical product and therefore have not obtained the requisite regulatory authority
approvals to do so. Our facilities and quality systems, and those of our collaborators and any third-party contractors, must pass a pre-approval
inspection for compliance with the applicable regulations as a condition of regulatory approval of our product candidates or any of our
other potential products. In addition, the regulatory authorities may, at any time, inspect a manufacturing facility involved with the
preparation of our product candidates or our other potential products or the associated quality systems for compliance with the regulations
applicable to the activities being conducted. If these facilities do not pass a preapproval plant inspection, regulatory approval of the
products may not be granted or may be substantially delayed until any violations are corrected to the satisfaction of the regulatory authority,
if ever.</div> </div> </div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: rgb(0, 0, 0); font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">15</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">

<div style="line-height: 1.25; font-family: Times New Roman">The regulatory authorities also may, at any time following approval of a
product for sale, audit a manufacturing facility. If any such inspection or audit identifies a failure to comply with applicable regulations
or if a violation of our product specifications or applicable regulations occurs independent of such an inspection or audit, we or the
relevant regulatory authority may require remedial measures that may be costly and/or time consuming for us or a third party to implement,
and that may include the temporary or permanent suspension of a clinical study or commercial sales or the temporary or permanent closure
of a facility. Any such remedial measures imposed upon us, or third parties with whom we contract could materially harm our business.</div>
</div> </div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">If we, our collaborators, or any of our third-party&#160;manufacturers
fail to maintain regulatory compliance, the FDA or other applicable regulatory authorities can impose regulatory sanctions including,
among other things, refusal to approve a pending application for a new drug product or biologic product, withdrawal of an approval, or
suspension of production. As a result, our business, financial condition, and results of operations may be materially harmed.</div> </div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">These factors could cause us to incur higher costs and
could cause the delay or termination of clinical studies, regulatory submissions, required approvals, or commercialization of our product
candidates.</div> </div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman">&#160;</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman,Times,serif">

<div style="line-height: 1.25; font-family: Times New Roman, Times, serif; font-style: italic; font-weight: bold">

<div style="line-height: 1.25; font-family: Times New Roman; font-style: italic; font-weight: bold">We are subject to a multitude of manufacturing
risks, any of which could substantially increase our costs and limit supply of our product candidates.</div> </div> </div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">The process of manufacturing our product candidates is
complex, highly regulated, and subject to several risks, including but not limited to:</div> </div>

<div style="text-indent: -36pt; margin-left: 48pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<table cellspacing="0" cellpadding="0" id="zc09517e5f1ed4e1d94f37974829c1930" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">
        <div style="line-height: 1.25; font-family: Times New Roman, Times, serif">
        <div style="line-height: 1.25; font-family: Times New Roman">the process of manufacturing RNAi-drugs, drug substances, and RNAi-delivery
        vehicles, such as our product candidates, is extremely susceptible to product loss due to contamination, equipment failure or improper
        installation or operation of equipment, or vendor or operator error. Even minor deviations from normal manufacturing processes for any
        of our product candidates could result in reduced production yields, product defects, and other supply disruptions. If microbial, viral,
        or other contaminations are discovered in our product candidates or in the manufacturing facilities in which our product candidates are
        made, such manufacturing facilities may need to be closed for an extended period of time to investigate and remedy the contamination;
        and</div> </div> </div> </td> </tr>
  </table>

<div style="text-indent: -36pt; margin-left: 48pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z887190e3e7294474b3f7659dd2015ff9" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">
        <div style="line-height: 1.25; font-family: Times New Roman">the manufacturing facilities in which our product candidates are made could
        be adversely affected by equipment failures, labor shortages, natural disasters, power failures, and numerous other factors.</div> </div>
        </td> </tr>
  </table>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">Any adverse developments affecting manufacturing operations
for our product candidates may result in shipment delays, inventory shortages, lot failures, withdrawals or recalls, or other interruptions
in the supply of our product candidates. We may also have to take inventory write-offs&#160;and incur other charges and expenses for product
candidates that fail to meet specifications, undertake costly remediation efforts, or seek more costly manufacturing alternatives.</div>
</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: rgb(0, 0, 0); font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">16</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="line-height: 1.25; font-weight: bold; font-family: Times New Roman,Times,serif">

<div style="line-height: 1.25; font-family: Times New Roman; font-weight: bold">Risks Related to Our Reliance on Third Parties</div> </div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman">&#160;</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman,Times,serif">

<div style="line-height: 1.25; font-family: Times New Roman, Times, serif; font-style: italic; font-weight: bold">

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman">We rely on third parties to conduct
its preclinical and clinical studies and perform other tasks for us. If these third parties do not successfully carry out their contractual
duties, meet expected deadlines, or comply with regulatory requirements, we may not be able to obtain regulatory approval for or commercialize
its product candidates, and our business could be substantially harmed</div> </div> </div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">

<div style="text-indent: 36pt; line-height: 1.25">

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="line-height: 1.25; font-family: Times New Roman">We have relied upon and plans to continue to rely upon third-party CROs to
monitor and manage data for our ongoing preclinical and clinical programs. We rely on these parties for execution of our preclinical and
clinical studies, and control only certain aspects of their activities. Nevertheless, we are responsible for ensuring that each of our
studies is conducted in accordance with the applicable protocol, legal, regulatory, and scientific standards and our reliance on the CROs
does not relieve us of our regulatory responsibilities. we and our CROs and other vendors are required to comply with cGMP and GLP, which
are regulations and guidelines enforced by the FDA, the Competent Authorities of the Member States of the European Economic Area (EEA)
and comparable foreign regulatory authorities for all of our product candidates in clinical development. Regulatory authorities enforce
these regulations through periodic inspections of study sponsors, principal and other investigators, study sites, and other contractors.
If we or any of our CROs or vendors fail to comply with applicable regulations, the clinical data generated in our clinical studies may
be deemed unreliable and the FDA, EMA, or comparable foreign regulatory authorities may require us to perform additional clinical studies
before approving our marketing applications. We cannot assure you that upon inspection by a given regulatory authority, such regulatory
authority will determine that any of our clinical studies comply with Good Clinical Practices (GCP) regulations. In addition, our clinical
studies must be conducted with product produced under cGMP/GMP regulations. Our failure to comply with these regulations may require us
to repeat clinical studies, which would delay the regulatory approval process.</div> </div> </div> </div> </div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="line-height: 1.25; font-family: Times New Roman">If any of our relationships with these third-party CROs terminate, we may
not be able to enter into arrangements with alternative CROs or do so on commercially reasonable terms. In addition, our CROs are not
our employees, and, except for remedies available to us under our agreements with such CROs, we cannot control whether or not they devote
sufficient time and resources to our on-going clinical, nonclinical, and preclinical programs. If CROs do not successfully carry out their
contractual duties or obligations or meet expected deadlines, if they need to be replaced or if the quality or accuracy of the clinical
data they obtain is compromised due to the failure to adhere to our clinical protocols, regulatory requirements, or for other reasons,
our clinical studies may be extended, delayed, or terminated, and we may not be able to obtain regulatory approval for or successfully
commercialize our product candidates. CROs may also generate higher costs than anticipated. As a result, our results of operations and
the commercial prospects for our product candidates would be harmed, our costs could increase, and our ability to generate revenue could
be delayed.</div> </div> </div> </div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="line-height: 1.25">

<div style="line-height: 1.25; font-family: Times New Roman">Switching or adding additional CROs involves additional cost and requires
management time and focus. In addition, there is a natural transition period when a new CRO commences work. As a result, delays occur,
which can materially impact our ability to meet our desired clinical development timelines. Though we carefully manage our relationships
with our CROs, there can be no assurance that we will not encounter similar challenges or delays in the future or that these delays or
challenges will not have a material adverse impact on our business, financial condition, and prospects.</div> </div> </div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: rgb(0, 0, 0); font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">17</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="text-align: center; line-height: 1.25"><span style="font-family: Times New Roman"><br/> </span> </div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman,Times,serif">

<div style="line-height: 1.25; font-family: Times New Roman, Times, serif; font-style: italic; font-weight: bold">

<div style="line-height: 1.25; font-family: Times New Roman; font-style: italic; font-weight: bold">We currently rely on third parties
to manufacture the raw materials and products that we use to create our product candidates and to supply us with the medical devices used
to administer such product. This reliance requires us to share our trade secrets with these third parties, which increases the possibility
that a competitor will discover them or that our trade secrets will be misappropriated or disclosed.</div> </div> </div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">

<div style="line-height: 1.25; font-family: Times New Roman">Because we rely on third parties to provide us with the materials that we
use to develop and manufacture our product candidates, we may, at times, share trade secrets with such third parties. We seek to protect
our proprietary technology in part by entering into confidentiality agreements and, if applicable, material transfer agreements, collaborative
research agreements, consulting agreements, or other similar agreements with our collaborators, advisors, employees, and consultants prior
to beginning research or disclosing proprietary information. These agreements typically limit the rights of the third parties to use or
disclose our confidential information, such as trade secrets. Despite the contractual provisions employed when working with third parties,
the need to share trade secrets and other confidential information increases the risk that such trade secrets become known by our competitors,
are inadvertently incorporated into the technology of others, or are disclosed or used in violation of these agreements. Given that our
proprietary position is based, in part, on our know- how and trade secrets, a competitor&#8217;s discovery of our trade secrets or other
unauthorized use or disclosure would impair our competitive position and may have a material adverse effect on our business.</div> </div>
</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman">&#160;</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman,Times,serif">

<div style="line-height: 1.25; font-family: Times New Roman, Times, serif; font-style: italic; font-weight: bold">

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif; font-style: italic; font-weight: bold">

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman">Our reliance on third parties to manufacture
the raw materials and products that are used to create our product candidates and to supply us with the medical devices used to administer
such product might cause our business harm if manufacturers fail to provide us with sufficient quantities of these materials and products
or fail to do so at acceptable quality levels or prices.</div> </div> </div> </div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="line-height: 1.25; font-family: Times New Roman">We do not currently have the infrastructure or capability internally to develop
the raw materials and other products that we use to manufacture our product candidates, and we lack the resources and the capability to
manufacture the medical devices which we use to administer our products. There are a limited number of suppliers for these raw materials,
products and devices, and there may be a need to identify alternate suppliers to prevent a possible disruption to our clinical studies,
and, if approved, ultimately for commercial sale. We cannot assure you that we will be able to identify alternate suppliers if the need
arises at acceptable quality levels or prices.</div> </div> </div> </div>

<div style="line-height: 1.25; font-weight: bold; font-family: Times New Roman">&#160;</div>

<div style="line-height: 1.25; font-weight: bold; font-family: Times New Roman,Times,serif">

<div style="line-height: 1.25; font-family: Times New Roman; font-weight: bold">Risks Related to Commercialization of Our Product Candidates</div>
</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman">&#160;</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman,Times,serif">

<div style="line-height: 1.25; font-family: Times New Roman, Times, serif; font-style: italic; font-weight: bold">

<div style="line-height: 1.25; font-family: Times New Roman; font-style: italic; font-weight: bold">If the market opportunities for our
product candidates are smaller than we believe they are, our revenue may be adversely affected, and our business may suffer. Because some
of the target patient populations of our product candidates are small, we must be able to successfully identify patients and achieve a
significant market share to maintain profitability and growth.</div> </div> </div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">

<div style="line-height: 1.25; font-family: Times New Roman">We focus a substantial part of our research and product development on treatments
for locally advanced pancreatic cancer with certain specific mutations. Given the small number of patients who have this disease with
these mutations, it is critical to Silexion&#8217;s ability to grow and become profitable that we continue to successfully identify effected
patients. Our projections of both the number of people who have these diseases, as well as the subset of people with these diseases who
have the potential to benefit from treatment with our product candidates, are based on our beliefs and estimates. These estimates have
been derived from a variety of sources, including the scientific literature, surveys of clinics, patient foundations, or market research,
and may prove to be incorrect. Further, new studies may change the estimated incidence or prevalence of these diseases. The number of
patients may turn out to be lower than expected. The effort to identify patients with diseases we seek to treat is in its early stages,
and we cannot accurately predict the number of patients for whom treatment might be possible. Additionally, the potentially addressable
patient population for each of our product candidates may be limited or may not be amenable to treatment with its product candidates,
and new patients may become increasingly difficult to identify or gain access to, which would adversely affect our results of operations
and business.</div> </div> </div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: rgb(0, 0, 0); font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">18</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman,Times,serif">

<div style="line-height: 1.25; font-family: Times New Roman, Times, serif; font-style: italic; font-weight: bold">

<div style="line-height: 1.25; font-family: Times New Roman; font-style: italic; font-weight: bold">We do not have experience producing
our product candidates at commercial levels and may not achieve the necessary regulatory approvals or produce product candidates at the
quality, quantities, locations, and timing needed to support commercialization. Additionally, we intend to rely on third-party manufacturers
to produce the raw materials and products that we use to manufacture our product candidates, but we have not entered into binding agreements
with any such manufacturers to support commercialization.</div> </div> </div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">We do not currently have the experience or ability to
produce product candidates at commercial levels. We may run into technical or scientific issues related to manufacturing or development
that we may be unable to resolve in a timely manner or with available funds. We also have not completed all of the characterization and
validation activities necessary for commercialization and regulatory approvals. If we do not conduct all such necessary activities, our
commercialization efforts will be harmed.</div> </div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">

<div style="line-height: 1.25; font-family: Times New Roman">Although we intend to rely on third-party manufacturers for the raw materials
and products to support our own manufacturing of our product candidates for commercialization, we have not yet entered into agreements
with such manufacturers. We may be unable to negotiate binding agreements with the manufacturers to support our commercialization activities
at commercially reasonable terms. Additionally, these third party manufacturers may not be able to supply us with the necessary quantities
of these raw materials and products to support our own manufacturing process, or in compliance with cGMP or other pertinent regulatory
requirements, and within our planned timeframe and cost parameters, and the development and sales of our products, if approved, may be
materially harmed.</div> </div> </div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman">&#160;</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman,Times,serif">

<div style="line-height: 1.25; font-family: Times New Roman, Times, serif; font-style: italic; font-weight: bold">

<div style="line-height: 1.25; font-family: Times New Roman; font-style: italic; font-weight: bold">We face intense competition and rapid
technological change and the possibility that our competitors may develop therapies that are similar, more advanced, or more effective
than ours, which may adversely affect our financial condition and our ability to successfully commercialize our product candidates.</div>
</div> </div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">

<div style="line-height: 1.25"><span style="font-family: Times New Roman"><br/> </span> </div>

<div style="line-height: 1.25; font-family: Times New Roman">The biotechnology and pharmaceutical industries are intensely competitive
and subject to rapid and significant technological change. We are currently aware of various existing therapies in the market and in development
that may in the future compete with our product candidates. For example, there is an increasing number of companies commercializing treatments
and/or developing programs specifically targeting KRAS mutations, including KRAS G12D and KRAS G12V, in a variety of manners and for a
variety of indications, including cancer, including Bristol-Myers Squibb Company (through the recently acquired Mirati Therapeutics, Inc.),
Revolution Medicines, Inc., AstraZeneca (in collaboration with Usynova), Boehringer and Gilead. Smaller and other early-stage companies
may also prove to be significant competitors. Treatments for cancer currently include surgery, radiation therapy, chemotherapy, hormone
therapy, immunotherapy and combined treatment modalities such as chemo-radiotherapy. Other approaches may also emerge for the treatment
of any of the disease areas in which we focus.</div> </div> </div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">

<div style="line-height: 1.25; font-family: Times New Roman">We have competitors both in the United States and internationally, including
major multinational pharmaceutical companies, specialty pharmaceutical companies, and biotechnology companies. Our competitors may succeed
in developing, acquiring, or licensing on an exclusive basis, products that are more effective or less costly than any product candidate
that Silexion may develop, or achieve earlier patent protection, regulatory approval, product commercialization, and market penetration
than we do. Additionally, technologies developed by our competitors may render our potential product candidates uneconomical or obsolete,
and we may not be successful in marketing our product candidates against competitors.</div> </div> </div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman">&#160;</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman,Times,serif">

<div style="line-height: 1.25; font-family: Times New Roman; font-style: italic; font-weight: bold">We currently have no marketing and
sales organization. If we are unable to establish sales and marketing capabilities or enter into agreements with third parties to market
and sell our product candidates, we may be unable to generate any revenue.</div> </div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">

<div style="text-indent: 36pt; line-height: 1.25">

<div style="line-height: 1.25; font-family: Times New Roman">We as a company have no experience selling and marketing our product candidates,
and currently have no marketing or sales organization. To successfully commercialize any products that may result from our development
programs, we will need to develop these capabilities, either on our own or with others. If our product candidates receive regulatory approval,
we intend to establish a sales and marketing organization with technical expertise and supporting distribution capabilities to commercialize
our product candidates in major markets, which will be expensive, difficult, and time consuming. Any failure or delay in the development
of our internal sales, marketing, and distribution capabilities would adversely impact the commercialization of our products.</div> </div>
</div> </div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: rgb(0, 0, 0); font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">19</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">

<div style="text-indent: 36pt; line-height: 1.25">

<div style="line-height: 1.25; font-family: Times New Roman">Further, given our lack of prior experience in marketing and selling biopharmaceutical
products, our initial estimate of the size of the required sales force may be materially more or less than the size of the sales force
actually required to effectively commercialize our product candidates. As such, we may be required to hire the commercialization of our
product candidates, or we may incur excess costs as a result of hiring more sales representatives than necessary. With respect to certain
geographical markets, we may enter into collaborations with other entities to utilize their local marketing and distribution capabilities,
but we may be unable to enter into such agreements on favorable terms, if at all. If our future collaborators do not commit sufficient
resources to commercialize our future products, if any, and we are unable to develop the necessary marketing capabilities on our own,
we will be unable to generate sufficient product revenue to sustain our business. We may be competing with companies that currently have
extensive and well-funded marketing and sales operations. Without an internal team or the support of a third party to perform marketing
and sales functions, we may be unable to compete successfully against these more established companies.</div> </div> </div> </div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman">&#160;</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman,Times,serif">

<div style="line-height: 1.25; font-family: Times New Roman; font-style: italic; font-weight: bold">The market may not be receptive to
our product candidates based on a novel therapeutic modality, and we may not generate any future revenue from the sale or licensing of
product candidates.</div> </div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">Even if approval is obtained for a product candidate,
we may not generate or sustain revenue from sales or licensing of the product due to factors such as whether the product can be sold at
a competitive cost and otherwise accepted in the market. The product candidates that we are developing are based on new technologies and
therapeutic approaches. Market participants with significant influence over acceptance of new treatments, such as physicians and third-party&#160;payors,
may not adopt a treatment based on RNAi, including siRNA technology, and we may not be able to convince the medical community and third-party&#160;payors
to accept and use, or to provide favorable reimbursement for, our product candidates. Market acceptance of Silexion&#8217;s product candidates
will depend on, among other factors:</div> </div>

<div style="text-indent: -36pt; margin-left: 48pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z86c6a24581af49268e6bb5ceb2400048" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">
        <div style="line-height: 1.25; font-family: Times New Roman">the timing of our receipt of any marketing and commercialization approvals;</div>
        </div> </td> </tr>
  </table>

<div style="text-indent: -36pt; margin-left: 48pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z4b9c53e6d1fc479fbc58fbbe52014944" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">the terms of any approvals and the countries in which approvals are obtained;</div>
        </td> </tr>
  </table>

<div style="text-indent: -36pt; margin-left: 48pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z291a40e9a6024b62a86327707097e3d2" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">
        <div style="line-height: 1.25; font-family: Times New Roman">the safety and efficacy of our product candidates;</div> </div> </td> </tr>
  </table>

<div style="text-indent: -36pt; margin-left: 48pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z93bd05bf18464a50a48bb43f01b093d3" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">
        <div style="line-height: 1.25; font-family: Times New Roman">the prevalence and severity of any adverse side effects associated with our
        product candidates;</div> </div> </td> </tr>
  </table>

<div style="text-indent: -36pt; margin-left: 48pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z12cb65813d5e443ea1ea56c9cbf31de0" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">limitations or warnings contained in any labeling approved by the FDA or
        other regulatory authorities;</div> </td> </tr>
  </table>

<div style="text-indent: -36pt; margin-left: 48pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<table cellspacing="0" cellpadding="0" id="zde656fd7069a4331a548af36e0d63963" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">
        <div style="line-height: 1.25; font-family: Times New Roman">relative convenience and ease of administration of our product candidates;</div>
        </div> </td> </tr>
  </table>

<div style="text-indent: -36pt; margin-left: 48pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z355d7ffa396744758d68ab3945beb555" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">the willingness of patients to accept any new methods of administration;</div>
        </td> </tr>
  </table>

<div style="text-indent: -36pt; margin-left: 48pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<table cellspacing="0" cellpadding="0" id="za08c8beabff84c0abe75d36e9ce7625a" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">
        <div style="line-height: 1.25; font-family: Times New Roman">the success of our physician education programs;</div> </div> </td> </tr>
  </table>

<div style="text-indent: -36pt; margin-left: 48pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<table cellspacing="0" cellpadding="0" id="zdaef36d738dd40cca34326055ab20d91" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">the availability of adequate government and third-party&#160;payor reimbursement;</div>
        </td> </tr>
  </table>

<div style="text-indent: -36pt; margin-left: 48pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z2f77985e1d2e4997b10e345cd5df8b4c" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">
        <div style="line-height: 1.25; font-family: Times New Roman">the pricing of our products, particularly as compared to alternative treatments;
        and</div> </div> </td> </tr>
  </table>

<div style="text-indent: -36pt; margin-left: 48pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z7e1b27ea77504747b3c3c087d571c53d" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">
        <div style="line-height: 1.25; font-family: Times New Roman">availability of alternative effective treatments for the disease indications
        our product candidates are intended to treat and the relative risks, benefits and costs of those treatments.</div> </div> </td> </tr>
  </table>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">

<div style="line-height: 1.25; font-family: Times New Roman">With Silexion&#8217;s focus on the emerging therapeutic modality RNAi, these
risks may increase to the extent the space becomes more competitive or less favored in the commercial marketplace. Some of Silexion&#8217;s
target diseases, such as pancreatic cancer, are relatively rare. Because of the small patient population for a rare disease, if pricing
is not approved or accepted in the market at an appropriate level for an approved product, such product may not generate enough revenue
to offset costs of development, manufacturing, marketing and commercialization. Market size is also a variable in disease indications
not classified as rare. Our estimates regarding potential market size for any indication may be materially different from what we discover
to exist at the time we commence commercialization, if any, for a product, which could result in significant changes in our business plan
and have a material adverse effect on our business, financial condition, results of operations and prospects.</div> </div> </div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: rgb(0, 0, 0); font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">20</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">

<div style="line-height: 1.25; font-family: Times New Roman">Even if a potential product displays a favorable efficacy and safety profile
in preclinical and clinical studies, market acceptance of the product will not be fully known until after it is launched. Our efforts
to educate the medical community and third-party payors on the benefits of the product candidates may require significant resources and
may never be successful. If our product candidates are approved but fail to achieve an adequate level of acceptance by physicians, patients,
third-party payors, and others in the medical community, we will not be able to generate sufficient revenue for us to become or remain
profitable.</div> </div> </div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman">&#160;</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman,Times,serif">

<div style="line-height: 1.25; font-family: Times New Roman; font-style: italic; font-weight: bold">The insurance coverage and reimbursement
status of&#160;newly-approved&#160;products is uncertain. Failure to obtain or maintain adequate coverage and reimbursement for new or
current products could limit our ability to market those products and decrease our ability to generate revenue.</div> </div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">Some of our target patient populations are small, and,
accordingly, the pricing, coverage, and reimbursement of our respective product candidates, if approved, must be adequate to support our
commercial infrastructure. Our per-patient&#160;prices must be sufficient to recover our development and manufacturing costs and potentially
achieve profitability. Accordingly, the availability and adequacy of coverage and reimbursement by governmental and private payors are
essential for most patients to be able to afford expensive treatments such as our, assuming approval. Sales of our product candidates
will depend substantially, both domestically and abroad, on the extent to which the costs of our product candidates will be paid for by
health maintenance, managed care, pharmacy benefit, and similar healthcare management organizations, or reimbursed by government authorities,
private health insurers, and other third-party&#160;payors. If coverage and reimbursement are not available, or are available only to
limited levels, Silexion may not be able to successfully commercialize our product candidates. Even if coverage is provided, the approved
reimbursement amount may not be high enough to allow us to establish or maintain pricing sufficient to realize a return on our investment.</div>
</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">There is significant uncertainty related to the insurance
coverage and reimbursement of newly approved products. In the United&#160;States, the principal decisions about coverage and reimbursement
for new drugs are typically made by the Centers for Medicare&#160;&amp; Medicaid Services, or CMS, an agency within the U.S.&#160;Department
of Health and Human Services, as CMS decides whether and to what extent a new drug will be covered and reimbursed under Medicare. Private
payors tend to follow the coverage reimbursement policies established by CMS to a substantial degree. It is difficult to predict what
CMS will decide with respect to reimbursement for products such as our&#8217;s.</div> </div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">Outside the United&#160;States, international operations
are generally subject to extensive governmental price controls and other market regulations, and we believe the increasing emphasis on
cost-containment&#160;initiatives in Europe, Canada, and other countries has, and will continue to, put pressure on the pricing and usage
of our product candidates. In many countries, the prices of medical products are subject to varying price control mechanisms as part of
national health systems. In general, the prices of medicines under such systems are substantially lower than in the United&#160;States.
Other countries allow companies to fix their own prices for medicinal products, but monitor and control company profits. Additional foreign
price controls or other changes in pricing regulation could restrict the amount that we are able to charge for our product candidates.
Accordingly, in markets outside the United&#160;States, the reimbursement for our products may be reduced compared with the United&#160;States
and may be insufficient to generate commercially reasonable revenue and profits.</div> </div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">Moreover, increasing efforts by governmental and third-party&#160;payors
in the United&#160;States and abroad to cap or reduce healthcare costs may cause such organizations to limit both coverage and the level
of reimbursement for new products approved, and, as a result, they may not cover or provide adequate payment for our product candidates.
We expect to experience pricing pressures in connection with the sale of any of our product candidates due to the trend toward managed
healthcare, the increasing influence of health maintenance organizations, and additional legislative changes like the Inflation Reduction
Act. The downward pressure on healthcare costs in general, particularly prescription drugs and surgical procedures and other treatments,
has become very intense. As a result, increasingly high barriers are being erected to the entry of new products.</div> </div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: rgb(0, 0, 0); font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">21</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="text-align: center; line-height: 1.25"><span style="font-family: Times New Roman"><br/> </span> </div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman,Times,serif">

<div style="line-height: 1.25; font-family: Times New Roman; font-style: italic; font-weight: bold">Healthcare legislative reform measures
may have a material adverse effect on our business and results of operations.</div> </div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">The business and financial condition of pharmaceutical
and biotechnology companies are affected by the efforts of governmental and third-party&#160;payors to contain or reduce the costs of
health care. The U.S.&#160;Congress has enacted legislation to reform the health care system. While we anticipate that this legislation
may, over time, increase the number of patients who have insurance coverage for pharmaceutical products, it also imposes cost containment
measures that may adversely affect the amount of reimbursement for pharmaceutical products. These measures include increasing the minimum
rebates for products covered by Medicaid programs and extending such rebates to drugs dispensed to Medicaid beneficiaries enrolled in
Medicaid managed care organizations as well as expansion of the 340(B)&#160;Public Health Services drug discount program. In addition,
such legislation contains a number of provisions designed to generate the revenues necessary to fund the coverage expansion. In foreign
jurisdictions there have been, and we expect that there will continue to be, a number of legislative and regulatory proposals aimed at
changing the health care system. For example, in some countries other than the United&#160;States, pricing of prescription drugs is subject
to government control and we expect to see continued efforts to reduce healthcare costs in international markets.</div> </div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">Some U.S.&#160;states are also considering legislation
that would control the prices of drugs, and state Medicaid programs are increasingly requesting manufacturers to pay supplemental rebates
and requiring prior authorization by the state program for use of any drug for which supplemental rebates are not being paid. Managed
care organizations continue to seek price discounts and, in some cases, to impose restrictions on the coverage of particular drugs. Government
efforts to reduce Medicaid expenses may lead to increased use of managed care organizations by Medicaid programs. This may result in managed
care organizations influencing prescription decisions for a larger segment of the population and a corresponding constraint on prices
and reimbursement for drugs. It is likely that federal and state legislatures and health agencies will continue to focus on additional
health care reform in the future although we are unable to predict what additional legislation or regulation, if any, relating to the
health care industry or third-party&#160;coverage and reimbursement may be enacted in the future or what effect such legislation or regulation
would have on our business. Our ability to commercialize any product candidates that Silexion may seek to commercialize, is highly dependent
on the extent to which coverage and reimbursement for these product candidates will be available from government payors, such as Medicare
and Medicaid, private health insurers, including managed care organizations, and other third-party&#160;payors, and any change in reimbursement
levels could materially and adversely affect our business. Further, the pendency or approval of future proposals or reforms could result
in a decrease in our share price or limit our ability to raise capital or to obtain strategic partnerships or licenses.</div> </div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman">&#160;</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman,Times,serif">

<div style="line-height: 1.25; font-family: Times New Roman; font-style: italic; font-weight: bold">Our product candidates may be approved
and/or commercialized only in part, only as neoadjuvant therapy, or as an adjuvant therapy.</div> </div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">Our product candidates may be approved by the FDA or other
regulatory agencies only as a treatment to be provided in association with other treatments, if at all. For example, it may be possible
that our SIL-204B&#160;be used as adjunct therapy with chemotherapy treatments. Limitation in commercialization of such treatments, including
limitations in supply, call-back, clinical holds, changes in medical trends, changes in cost and/or reimbursement policy, may limit our
ability to commercialize our product candidates, either directly or via third parties.</div> </div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: rgb(0, 0, 0); font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">22</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="line-height: 1.25; font-weight: bold; font-family: Times New Roman">&#160;</div>

<div style="line-height: 1.25; font-weight: bold; font-family: Times New Roman">Risks Related to Competition</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman">&#160;</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman,Times,serif">

<div style="line-height: 1.25; font-family: Times New Roman, Times, serif; font-style: italic; font-weight: bold">

<div style="line-height: 1.25; font-family: Times New Roman; font-style: italic; font-weight: bold">The pharmaceutical market is intensely
competitive. If we are unable to compete effectively with existing drugs, new treatment methods and new technologies, we may be unable
to commercialize successfully any drugs that we develop.</div> </div> </div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">The pharmaceutical market is intensely competitive and
rapidly changing. Many large pharmaceutical and biotechnology companies, academic institutions, governmental agencies and other public
and private research organizations are pursuing the development of novel drugs for the same diseases that we are targeting or expect to
target. Many of our competitors have:</div> </div>

<div style="text-indent: -36pt; margin-left: 48pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<table cellspacing="0" cellpadding="0" id="ze538b8485af241c882fc16c138b0b4a6" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">
        <div style="line-height: 1.25; font-family: Times New Roman">much greater financial, technical and human resources than we have at every
        stage of the discovery, development, manufacture and commercialization of products;</div> </div> </td> </tr>
  </table>

<div style="text-indent: -36pt; margin-left: 48pt; line-height: 1.25; font-family: Times New Roman">&#160;&#160;</div>

<table cellspacing="0" cellpadding="0" id="zfcab7d94f4364ce49c107db5d2fa2695" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">more extensive experience in pre-clinical&#160;testing, conducting clinical
        trials, obtaining regulatory approvals, and in manufacturing, marketing and selling pharmaceutical products;</div> </td> </tr>
  </table>

<div style="text-indent: -36pt; margin-left: 48pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<table cellspacing="0" cellpadding="0" id="zecf801beda7740ccba66098bca7ae657" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">product candidates that are based on previously tested or accepted technologies;</div>
        </td> </tr>
  </table>

<div style="text-indent: -36pt; margin-left: 48pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z36d4650b3757454891b48f99615d7779" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">products that have been approved or are in late stages of development; and</div>
        </td> </tr>
  </table>

<div style="text-indent: -36pt; margin-left: 48pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z13631058fdbc4f1ab48f6b504bc86da1" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">
        <div style="line-height: 1.25; font-family: Times New Roman">collaborative arrangements in our target markets with leading companies and
        research institutions.</div> </div> </td> </tr>
  </table>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">We will face intense competition from drugs that have
already been, or may in the future become, approved and accepted by the medical community for the treatment of the conditions for which
we may develop drugs. We also expect to face competition from new drugs that enter the market. We believe a significant number of drugs
are currently under development, and may become commercially available in the future, for the treatment of conditions for which we may
try to develop drugs and therapies. These drugs may be more effective, safer, less expensive, or marketed and sold more effectively, than
any product we develop.</div> </div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">If we successfully develop our product candidates, and
obtains approval for them, we will face competition based on many different factors, including:</div> </div>

<div style="text-indent: -36pt; margin-left: 48pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<table cellspacing="0" cellpadding="0" id="zaf53ac951b3b47b99d2bb69baa9a06f7" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">
        <div style="line-height: 1.25; font-family: Times New Roman">the safety and effectiveness of our product;</div> </div> </td> </tr>
  </table>

<div style="text-indent: -36pt; margin-left: 48pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z0c53bccfdf524b7da13154e650d08adc" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">
        <div style="line-height: 1.25; font-family: Times New Roman">the ease with which our product can be administered and the extent to which
        patients accept relatively new routes of administration;</div> </div> </td> </tr>
  </table>

<div style="text-indent: -36pt; margin-left: 48pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<table cellspacing="0" cellpadding="0" id="zfc08f917b8f8478eb9e5c122e923458c" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">
        <div style="line-height: 1.25; font-family: Times New Roman">the timing and scope of regulatory approvals for our product;</div> </div>
        </td> </tr>
  </table>

<div style="text-indent: -36pt; margin-left: 48pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z4531702db34b4eb98e8d39acb9cc5c46" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">the availability and cost of manufacturing, marketing and sales capabilities;</div>
        </td> </tr>
  </table>

<div style="text-indent: -36pt; margin-left: 48pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z0a50e7f5b9b34be2b23413725a6e0f33" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">price;</div> </td> </tr>
  </table>

<div style="text-indent: -36pt; margin-left: 48pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z0cb0839d37d348c6885563e479ff6aca" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">reimbursement coverage; and</div> </td> </tr>
  </table>

<div style="text-indent: -36pt; margin-left: 48pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<table cellspacing="0" cellpadding="0" id="ze1344c8d0a564dd49d8765c94c69239b" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">patent position.</div> </td> </tr>
  </table>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">Our competitors may develop or commercialize products
with significant advantages over any products we develop based on any of the factors listed above or on other factors. Our competitors
may therefore be more successful in commercializing their products than us, which could adversely affect our competitive position and
business. Competitive products may make any products we develop obsolete or noncompetitive before we can recover the expenses of developing
and commercializing our product candidates. Such competitors could also recruit our employees, which could negatively impact our level
of expertise and the ability to execute on our business plan.</div> </div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman">&#160;</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman,Times,serif">

<div style="line-height: 1.25; font-family: Times New Roman; font-style: italic; font-weight: bold">We face competition from other companies
that are working to develop novel drugs and technology platforms using technology similar or in the same field as our&#8217;s. If these
companies develop drugs more rapidly than us, or their technologies, including delivery technologies, are more effective, our ability
to successfully commercialize drugs may be adversely affected.</div> </div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">In addition to the competition we face from competing
drugs in general, we also face competition from other companies working to develop novel drugs using technology that competes more directly
with our own. We are aware of multiple companies that are working in the field of RNAi therapeutics and or KRAS inhibition, including
major pharmaceutical companies such as Bristol Myers Squibb/Mirati; Amgen; AstraZeneca; E.I.&#160;Lilly; Pfizer, Novartis International
AG, Takeda Pharmaceutical Company Limited and, and biopharmaceutical/pharmaceutical companies such as Alnylam, Revolutions Medicines;
Boehringer Ingelheim; Biomea Fusion Inc; Tekmira Pharmaceuticals Corporation, Arrowhead Research Corporation, Silence Therapeutics plc,
RXi Pharmaceuticals Corporation, Quark Pharmaceuticals, Inc. and Marina Biotech, Inc.</div> </div> </div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: rgb(0, 0, 0); font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">23</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">We also compete with companies working to develop antisense-based&#160;drugs.
Like RNAi therapeutics, antisense drugs target mRNAs in order to suppress the activity of specific genes. Ionis Pharmaceuticals, Inc.
is currently marketing an antisense drug and has several antisense product candidates in clinical trials, albeit none in the oncology
area at this time.</div> </div> </div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">In addition to competition with respect to RNAi and with
respect to specific products, we face substantial competition to discover and develop safe and effective means to deliver RNAi based drugs
to the relevant cell and tissue types. Safe and effective means to deliver RNAi based drugs and to the relevant cell and tissue types
may be developed by our competitors, and our ability to successfully commercialize a competitive product would be adversely affected.
In addition, substantial resources are being expended by third parties in the effort to discover and develop a safe and effective means
of delivering RNAi based drugs and into the relevant cell and tissue types, both in academic laboratories and in the corporate sector.
Some of our competitors have substantially greater resources than we do, and if our competitors are able to negotiate exclusive access
to those delivery solutions developed by third parties, we may be unable to successfully commercialize our product candidates. Also, we
compete with companies working to develop non RNAi based treatments for solid tumor cancers. For example, Novartis is working on a SHP2
inhibitor, and Boehringer Ingelheim and Bayer SOS1 inhibitors; Threshold Pharmaceuticals (Threshold) is working to develop therapies that
target tumor hypoxia, a common characteristic of the tumor microenvironment. Even if we successfully develop our product candidates, and
obtain approval for them, other non RNAi treatments may be preferred, and we may not be successful in commercializing our product candidates</div>
</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">Also, we compete with companies commercializing and/or
working to develop drug delivery systems, including drug delivery systems for local (or regional) release. For example, various companies
are working on nanoparticle technologies, although these products would not give the extended-release&#160;delivery of SIL-204B, and other
companies on PLGA microparticles. In addition other companies such as SurModics, Inc. is a provider of drug delivery and surface modification
technologies to the healthcare industry, including local delivery of drugs from drug eluting stents. We compete with many companies commercializing
and/or working to develop drug delivery systems for specific indications, for example for local ocular (in the eye) release of drugs,
including degradable and non-degradable&#160;products.</div> </div>

<div style="line-height: 1.25; font-weight: bold; font-family: Times New Roman">&#160;</div>

<div style="line-height: 1.25; font-weight: bold; font-family: Times New Roman,Times,serif">

<div style="line-height: 1.25; font-family: Times New Roman; font-weight: bold">Risks Related to Our Intellectual Property</div> </div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman">&#160;</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman,Times,serif">

<div style="line-height: 1.25; font-family: Times New Roman; font-style: italic; font-weight: bold">If we are unable to obtain and maintain
effective patent rights for our product candidates or any future product candidates, we may not be able to compete effectively in our
markets.</div> </div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">

<div style="line-height: 1.25; font-family: Times New Roman">We rely upon a combination of trade secret protection and confidentiality
agreements to protect the intellectual property related to our technologies and product candidates. As further described in detail below,
we have pending PCT application in several international (i.e. non-U.S.) locations relating the SIL-204B, which upon grant will provide
patent protection in the U.S., E.U. and other international jurisdictions. Our success depends in large part on our ability to obtain
and maintain patent and other intellectual property protection in the United States and in other countries with respect to our proprietary
technology and products.</div> </div> </div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">We have sought to protect our proprietary position by
filing patent applications in the United&#160;States and in other countries, with respect to our novel technologies and products, which
are important to our business. This process is expensive and time consuming, and we may not be able to file and prosecute all necessary
or desirable patent applications at a reasonable cost or in a timely manner. It is also possible that we will fail to identify patentable
aspects of our research and development output before it is too late to obtain patent protection.</div> </div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">The patent position of biotechnology and pharmaceutical
companies generally is highly uncertain and involves complex legal and factual questions for which legal principles remain unsolved. The
patent applications that we own may fail to result in issued patents with claims that cover our product candidates in the United&#160;States
or in other foreign countries. There is no assurance that all potentially relevant prior art relating to our patents and patent applications
has been found, which can invalidate a patent or prevent a patent from issuing from a pending patent application. Even if patents do successfully
issue, and even if such patents cover our product candidates, third parties may challenge their validity, enforceability, or scope, which
may result in such patents being narrowed, found unenforceable or invalidated. Furthermore, even if they are unchallenged, our patents
and patent applications may not adequately protect our intellectual property, provide exclusivity for our product candidates, or prevent
others from designing around our claims. Any of these outcomes could impair our ability to prevent competition from third parties, which
may have an adverse impact on our business.</div> </div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: rgb(0, 0, 0); font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">24</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">We cannot offer any assurances about which,
if any, patents will issue, the breadth of any such patent or whether any issued patents will be found invalid and unenforceable or will
be threatened by third parties. Any successful opposition to these patents or any other patents owned by or licensed to us after patent
issuance could deprive us of rights necessary for the successful commercialization of any product candidates that we may develop. Further,
if we encounter delays in regulatory approvals, the period of time during which we could market a product candidate under patent protection
could be reduced.</div> </div> </div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">If we cannot obtain and maintain effective patent rights
for our product candidates, we may not be able to compete effectively, and our business and results of operations would be harmed.</div>
</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman">&#160;</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman,Times,serif">

<div style="line-height: 1.25; font-family: Times New Roman; font-style: italic; font-weight: bold">We may not have sufficient patent
terms to effectively protect our products and business.</div> </div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">In the pharmaceutical and biotechnology industries, the
majority of an innovative product&#8217;s commercial value is realized during our market exclusivity period. In the United&#160;States
and in some other countries, when market exclusivity expires and generic versions are approved and marketed or when biosimilars are introduced
(even if only for a competing product), there are usually very substantial and rapid declines in a product&#8217;s revenues.</div> </div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">Patents have a limited lifespan. In the United&#160;States,
the natural expiration of a patent is generally 20&#160;years after it is filed. Although various extensions may be available, the life
of a patent, and the protection it affords, is limited.</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">While patent term extensions under the Hatch-Waxman&#160;Act
in the United&#160;States and under supplementary protection certificates in Europe may be available to extend the patent exclusivity
term, we cannot provide any assurances that any such patent term extension will be obtained and, if so, for how long. In addition, upon
issuance in the United&#160;States, any patent term can be adjusted based on certain delays caused by the applicant(s)&#160;or the USPTO.&#160;For
example, a patent term can be reduced based on certain delays caused by the patent applicant during patent prosecution. If we do not have
sufficient patent terms or regulatory exclusivity to protect our products, our business and results of operations will be adversely affected.
Furthermore, manufacturers of innovative products as well as generic drug manufacturers may be able to design their products around our
patents and compete with Silexion using the resulting alternative technology. Absent relevant patent protection for a product, once the
exclusivity period expires, generic or alternative versions can be approved and marketed.</div> </div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">Generic and biosimilar product manufacturers as well as
other groups seeking financial gain are also increasingly seeking to challenge patents before they expire, and we could face earlier-than-expected&#160;competition
for any products at any time. Patents covering our key products may be subject to validity, enforceability and infringement challenges
in patent litigations and post-grant&#160;review patent office proceedings. It may be possible for these parties to successfully challenge
our rights and launch their versions of our drugs prior to the expiration of our intellectual property rights.</div> </div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">In addition, both the U.S.&#160;Congress and the U.S.&#160;FDA
have taken steps to promote the development and approval of generic drugs and biosimilar biologics, including by providing generic and
biosimilar developers a private right of action to obtain sufficient quantities of drug samples from the reference product&#8217;s manufacturer
in order to conduct testing necessary to obtain approval for generic or biosimilar products.</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: rgb(0, 0, 0); font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">25</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">Further, in December&#160;2023, the Biden Administration
released a proposed framework that for the first time proposed that a drug&#8217;s price can be a factor in determining that the drug
is not accessible to the public and therefore that the government could exercise &#8220;march-in&#160;rights&#8221; and license it to
a third party to manufacture. A comment period on the proposal ran through February&#160;6, 2024, and we are not able to predict whether
a final rule will be adopted along the lines proposed and, if adopted, whether the government would seek to exercise march-in&#160;rights
for any of our products.</div> </div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman">&#160;</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman,Times,serif">

<div style="line-height: 1.25; font-family: Times New Roman; font-style: italic; font-weight: bold">

<div style="line-height: 1.25; font-family: Times New Roman, Times, serif; font-style: italic; font-weight: bold">Patent law, policy or
rule changes could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or
defense of any issued patent.</div> </div> </div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">

<div style="line-height: 1.25; font-family: Times New Roman">Changes in either the patent laws or interpretation of the patent laws in
the United States and other countries may diminish the value of our patent or narrow the scope of our patent protection. The laws of foreign
countries may not protect our rights to the same extent as the laws of the United States. Publications of discoveries in the scientific
literature often lag behind the actual discoveries, and patent applications in the United States and other jurisdictions are typically
not published until 18 months after filing, or in some cases not at all. We therefore cannot be certain that we or our licensors were
the first to make the invention claimed in our owned and licensed patent or pending applications, or that it or our licensor were the
first to file for patent protection of such inventions. Assuming the other requirements for patentability are met, in the United States
prior to March 15, 2013, the first to make the claimed invention is entitled to the patent, while outside the United States, the first
to file a patent application is entitled to the patent. After March 15, 2013, under the Leahy-Smith America Invents Act, or the Leahy-Smith
Act, enacted on September 16, 2011, the United States has moved to a first to file system. The Leahy-Smith Act also includes a number
of significant changes that affect the way patent applications will be prosecuted and may also affect patent litigation. The USPTO recently
developed new regulations and procedures to govern administration of the Leahy-Smith Act, and accordingly, it is not clear what, if any,
impact the Leahy-Smith Act will have on the operation of our business. The Leahy-Smith Act and our implementation could increase the uncertainties
and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents, all of which could
have a material adverse effect on our business and financial condition.</div> </div> </div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">In addition, patent reform legislation may pass in the
future that could lead to additional uncertainties and increased costs surrounding the prosecution, enforcement and defense of our patents
and pending patent applications. Recent U.S.&#160;Supreme Court rulings have narrowed the scope of patent protection available in certain
circumstances and weakened the rights of patent owners in certain situations. Furthermore, the U.S.&#160;Supreme Court and the U.S.&#160;Court
of Appeals for the Federal Circuit have made, and will likely continue to make, changes in how the patent laws of the United&#160;States
are interpreted. Similarly, foreign countries have made, and will likely continue to make, changes in how the patent laws in their respective
jurisdictions are interpreted. We cannot predict future changes in the interpretation of patent laws or changes to patent laws that might
be enacted into law by United&#160;States and foreign legislative bodies. Those changes may materially affect our patents or patent applications
and our ability to obtain additional patent protection in the future.</div> </div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">The United&#160;States federal government retains certain
rights in inventions produced with our financial assistance under the Patent and Trademark Law Amendments Act, or the Bayh-Dole&#160;Act.
The federal government retains a &#8220;nonexclusive, nontransferable, irrevocable, paid-up&#160;license&#8221; for our own benefit. The
Bayh-Dole&#160;Act also provides federal agencies with &#8220;march-in&#160;rights.&#8221; March-in&#160;rights allow the government,
in specified circumstances, to require the contractor or successors in title to the patent to grant a &#8220;nonexclusive, partially exclusive,
or exclusive license&#8221; to a &#8220;responsible applicant or applicants.&#8221; If the patent owner refuses to do so, the government
may grant the license itself.</div> </div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman">&#160;</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman,Times,serif">

<div style="line-height: 1.25; font-family: Times New Roman; font-style: italic; font-weight: bold">If we are unable to maintain effective
proprietary rights for our product candidates or any future product candidates, Silexion may not be able to compete effectively in our
markets.</div> </div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">In addition to the protection afforded by any patents
that may be granted, we rely on trade secret protection and confidentiality agreements to protect proprietary know-how&#160;that is not
patentable or that we elect not to patent, processes for which patents are difficult to enforce and any other elements of our product
candidate discovery and development processes that involve proprietary know-how, information or technology that is not covered by patents.
However, trade secrets can be difficult to protect. we seek to protect our proprietary technology and processes, in part, by entering
into confidentiality agreements with our employees, consultants, scientific advisors, and contractors. We also seek to preserve the integrity
and confidentiality of our data and trade secrets by maintaining physical security of our premises and physical and electronic security
of our information technology systems. While we have confidence in these individuals, organizations and systems, agreements or security
measures may be breached, and we may not have adequate remedies for any breach. In addition, our trade secrets may otherwise become known
or be independently discovered by competitors.</div> </div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: rgb(0, 0, 0); font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">26</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="text-align: center; line-height: 1.25"><span style="font-family: Times New Roman"><br/> </span> </div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">Although we expect all of our employees and consultants
to assign their inventions to it, and all of our employees, consultants, advisors, and any third parties who have access to our proprietary
know-how, information, or technology to enter into confidentiality agreements, we cannot provide any assurances that all such agreements
have been duly executed or that our trade secrets and other confidential proprietary information will not be disclosed or that competitors
will not otherwise gain access to our trade secrets or independently develop substantially equivalent information and techniques. Misappropriation
or unauthorized disclosure of our trade secrets could impair our competitive position and may have a material adverse effect on our business.
Additionally, if the steps taken to maintain our trade secrets are deemed inadequate, we may have insufficient recourse against third
parties for misappropriating the trade secret.</div> </div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman">&#160;</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman,Times,serif">

<div style="line-height: 1.25; font-family: Times New Roman, Times, serif; font-style: italic; font-weight: bold">

<div style="line-height: 1.25; font-family: Times New Roman; font-style: italic; font-weight: bold">Intellectual property rights of third
parties could adversely affect our ability to commercialize our product candidates, and we might be required to litigate or obtain licenses
from third parties in order to develop or market our product candidate. Such litigation or licenses could be costly or not available on
commercially reasonable terms.</div> </div> </div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">

<div style="text-indent: 36pt; line-height: 1.25">

<div style="line-height: 1.25; font-family: Times New Roman">Because the RNAi intellectual property landscape is still evolving, it is
difficult to conclusively assess our freedom to operate without infringing on third party rights. There are numerous companies that have
pending patent applications and issued patents broadly directed to RNAi generally and to RNAi delivery technologies.&#160;Our competitive
position may suffer if patents issued to third parties or other third party intellectual property rights cover our products or elements
thereof, or our manufacture or uses relevant to our development plans. In such cases, we may not be in a position to develop or commercialize
products or our product candidate unless we successfully pursue litigation to nullify or invalidate the third party intellectual property
right concerned, or enter into a license agreement with the intellectual property right holder, if available on commercially reasonable
terms. we are also aware of pending patent applications, and there may be others of which we are not aware, that if they result in issued
patents, could be alleged to be infringed by our product candidates. If such an infringement claim should be brought and be successful,
we may be required to pay substantial damages, be forced to abandon our product candidates or seek a license from any patent holders.
No assurances can be given that a license will be available on commercially reasonable terms, if at all. It is also possible that we have
failed to identify relevant third party patents or applications. For example, U.S. applications filed before November 29, 2000 and certain
U.S. applications filed after that date that will not be filed outside the U.S. remain confidential until patents issue. Patent applications
in the U.S. and elsewhere are published approximately 18 months after the earliest filing for which priority is claimed, with such earliest
filing date being commonly referred to as the priority date. Therefore, patent applications covering our product candidates or platform
technology could have been filed by others without our knowledge. Additionally, pending patent applications which have been published
can, subject to certain limitations, be later amended in a manner that could cover our platform technologies, our product candidates or
the use of our product candidates. Third party intellectual property right holders may also actively bring infringement claims against
Us. We cannot guarantee that we will be able to successfully settle or otherwise resolve such infringement claims. If we are unable to
successfully settle future claims on terms acceptable to us, we may be required to engage in or continue costly, unpredictable and time-consuming
litigation and may be prevented from or experience substantial delays in pursuing the development of and/or marketing of our product candidates.
If we fail in any such dispute, in addition to being forced to pay damages, we may be temporarily or permanently prohibited from commercializing
our product candidates that are held to be infringing. We might, if possible, also be forced to redesign our product candidates so that
we no longer infringes the third party intellectual property rights. Any of these events, even if we were ultimately to prevail, could
require us to divert substantial financial and management resources that we would otherwise be able to devote to our business.</div> </div>
</div> </div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: rgb(0, 0, 0); font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">27</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="text-align: center; line-height: 1.25"><span style="font-family: Times New Roman"><br/> </span> </div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman,Times,serif">

<div style="line-height: 1.25; font-family: Times New Roman; font-style: italic; font-weight: bold">Third-party&#160;claims of intellectual
property infringement may prevent or delay our development and commercialization efforts.</div> </div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">Our commercial success depends in part on our avoiding
infringement of the patents and proprietary rights of third parties. There have been many lawsuits and other proceedings involving patent
and other intellectual property rights in the biotechnology and pharmaceutical industries, including patent infringement lawsuits, interferences,
oppositions, and reexamination proceedings before the USPTO and corresponding foreign patent offices. Numerous U.S.&#160;and foreign issued
patents and pending patent applications, which are owned by third parties, exist in the fields in which we are developing product candidates.
As the biotechnology and pharmaceutical industries expand and more patents are issued, the risk increases that our product candidates
may be subject to claims of infringement of the patent rights of third parties.</div> </div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">

<div style="line-height: 1.25; font-family: Times New Roman">Third parties may assert that we are employing our proprietary technology
without authorization. There may be third-party patents or patent applications with claims to materials, formulations, methods of manufacture,
or methods for treatment related to the use or manufacture of our product candidates. Because patent applications can take many years
to issue, there may be currently pending patent applications that may later result in issued patents that our product candidates may infringe.
In addition, third parties may obtain patents in the future and claim that use of our technologies infringes upon these patents. If any
third-party patents were held by a court of competent jurisdiction to cover the manufacturing process of any of our product candidates,
any molecules formed during the manufacturing process or any final product itself, the holders of any such patents may be able to block
our ability to commercialize such product candidates unless we obtain a license under the applicable patents, or until such patents expire
or are finally determined to be invalid or unenforceable.</div> </div> </div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">

<div style="line-height: 1.25; font-family: Times New Roman">Similarly, if any third-party patents were held by a court of competent jurisdiction
to cover aspects of our formulations, processes for manufacture, or methods of use, the holders of any such patents may be able to block
our ability to develop and commercialize the applicable product candidate unless we obtain a license or until such patent expires or is
finally determined to be invalid or unenforceable. In either case, such a license may not be available on commercially reasonable terms
or at all.</div> </div> </div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">

<div style="line-height: 1.25; font-family: Times New Roman">Parties making claims against us may obtain injunctive or other equitable
relief, which could effectively block our ability to further develop and commercialize one or more of our product candidates. Defense
of these claims, regardless of their merit, would involve substantial litigation expense and would be a substantial diversion of employee
resources from our business. In the event of a successful claim of infringement against us, we may have to pay substantial damages, including
treble damages and attorneys&#8217; fees for willful infringement, pay royalties, redesign our infringing products or obtain one or more
licenses from third parties, which may be impossible or require substantial time and monetary expenditure.</div> </div> </div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman">&#160;</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman,Times,serif">

<div style="line-height: 1.25; font-family: Times New Roman; font-style: italic; font-weight: bold">We may not be successful in obtaining
or maintaining necessary rights to our product candidates through acquisitions and&#160;in-licenses.</div> </div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">

<div style="line-height: 1.25; font-family: Times New Roman">Because our programs may require the use of proprietary rights held by third
parties, the growth of our business will likely depend in part on our ability to acquire, in-license, or use these proprietary rights.
In addition, our product candidates may require specific formulations to work effectively and efficiently and the rights to these formulations
may be held by others. We may be unable to acquire or in-license any compositions, methods of use, processes, or other third-party intellectual
property rights from third parties that we identify as necessary for our product candidates. The licensing and acquisition of third-party
intellectual property rights is a competitive area, and a number of more established companies are also pursuing strategies to license
or acquire third-party intellectual property rights that we may consider attractive. These established companies may have a competitive
advantage over us due to their size, cash resources, and greater clinical development and commercialization capabilities.</div> </div>
</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: rgb(0, 0, 0); font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">28</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="text-align: center; line-height: 1.25"><span style="font-family: Times New Roman"><br/> </span> </div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">

<div style="line-height: 1.25; font-family: Times New Roman">For example, we sometimes collaborates with U.S. and foreign academic institutions
to accelerate our preclinical research or development under written agreements with these institutions. Typically, these institutions
provide we with an option to negotiate a license to any of the institution&#8217;s rights in technology resulting from the collaboration.
Regardless of such option, we may be unable to negotiate a license within the specified timeframe or under terms that are acceptable to
us. If we are unable to do so, the institution may offer the intellectual property rights to other parties, potentially blocking our ability
to pursue our program.</div> </div> </div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">In addition, companies that perceive us to be a competitor
may be unwilling to assign or license rights to us. We also may be unable to license or acquire third-party&#160;intellectual property
rights on terms that would allow us to make an appropriate return on our investment. If we are unable to successfully obtain rights to
required third-party&#160;intellectual property rights, we may have to abandon development of that program and our business and financial
condition could suffer.</div> </div>

<div style="line-height: 1.25; font-family: Times New Roman; font-style: italic; font-weight: bold"> <br/> </div>

<div style="line-height: 1.25; font-family: Times New Roman; font-style: italic; font-weight: bold">We may be involved in lawsuits to
protect or enforce our current patent applications or future patents, which could be expensive, time consuming, and unsuccessful.</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">Competitors may infringe our current patent
applications, future patents or the patents of our licensors. If we or a future licensing partner were to initiate legal proceedings against
a third party to enforce a patent covering one of our product candidates, the defendant could counterclaim that the patent covering our
product candidate is invalid and/or unenforceable. In patent litigation in the United&#160;States, defendant counterclaims alleging invalidity
and/or unenforceability are commonplace. Grounds for a validity challenge could be an alleged failure to meet any of several statutory
requirements, including lack of novelty, obviousness, or non-enablement. Grounds for an unenforceability assertion could be an allegation
that someone connected with prosecution of the patent withheld relevant information from the USPTO, or made a misleading statement, during
prosecution. The outcome following legal assertions of invalidity and unenforceability is unpredictable.</div> </div> </div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">

<div style="line-height: 1.25; font-family: Times New Roman">Interference proceedings provoked by third parties or brought by us or declared
by the USPTO may be necessary to determine the priority of inventions with respect to our patent or patent applications or those of our
licensors. An unfavorable outcome could require us to cease using the related technology or to attempt to license rights to us from the
prevailing party. Our business could be harmed if the prevailing party does not offer us a license on commercially reasonable terms. Our
defense of litigation or interference proceedings may fail and, even if successful, may result in substantial costs and distract our management
and other employees. In addition, the uncertainties associated with litigation could have a material adverse effect on our ability to
raise the funds necessary to continue our clinical trials, continue our research programs, license necessary technology from third parties,
or enter into development partnerships that would help us bring our product candidates to market.</div> </div> </div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">Furthermore, because of the substantial amount of discovery
required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised
by disclosure during this type of litigation. There could also be public announcements of the results of hearings, motions, or other interim
proceedings or developments. If securities analysts or investors perceive these results to be negative, it could have a material adverse
effect on the price of our ordinary shares.</div> </div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman">&#160;</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman,Times,serif">

<div style="line-height: 1.25; font-family: Times New Roman; font-style: italic; font-weight: bold">We may be subject to claims that our
employees, consultants, or independent contractors have wrongfully used or disclosed confidential information of third parties or that
our employees have wrongfully used or disclosed alleged trade secrets of their former employers.</div> </div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">

<div style="line-height: 1.25; font-family: Times New Roman">We employ or engage as consultants or subcontractors individuals who were
previously employed at universities or other biotechnology or pharmaceutical companies, including our competitors or potential competitors.
Although we try to ensure that our employees, consultants, and independent contractors do not use the proprietary information or know-how
of others in their work for us, we may be subject to claims that we or our employees, consultants, or independent contractors have inadvertently
or otherwise used or disclosed intellectual property, including trade secrets or other proprietary information, of any of our employees&#8217;
former employers or other third parties. Litigation may be necessary to defend against these claims. If we fail in defending any such
claims, in addition to paying monetary damages, we may lose valuable intellectual property rights or personnel, which could adversely
impact our business. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a
distraction to management and other employees.</div> </div> </div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: rgb(0, 0, 0); font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">29</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="text-align: center; line-height: 1.25"><span style="font-family: Times New Roman"><br/> </span> </div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman">

<div style="line-height: 1.25; font-family: Times New Roman, Times, serif; font-style: italic; font-weight: bold">We may be subject to
claims challenging the inventorship of our current patent application or future patents and other intellectual property.</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif; font-style: normal; font-weight: normal">We
may be subject to claims that former employees, collaborators or other third parties have an interest in or right to compensation with
respect to our current patent application, future patents or other intellectual property as an inventor or co-inventor. For example, we
may have inventorship disputes arise from conflicting obligations of consultants or others who are involved in developing our product
candidates. Litigation may be necessary to defend against these and other claims challenging inventorship or claiming the right to compensation.
If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights, such
as exclusive ownership of, or right to use, valuable intellectual property. Such an outcome could have a material adverse effect on our
business. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction
to management and other employees. To the extent that our employees have not effectively waived the right to compensation with respect
to inventions that they helped create, they may be able to assert claims for compensation with respect to our future revenue. As a result,
we may receive less revenue from future products if such claims are successful which in turn could impact our future profitability.</div>
</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman"> <br/> </div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman,Times,serif">

<div style="line-height: 1.25; font-family: Times New Roman; font-style: italic; font-weight: bold">We may not be able to protect our
intellectual property rights throughout the world.</div> </div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">Filing, prosecuting, and defending patents on product
candidates in all countries throughout the world would be prohibitively expensive, and our intellectual property rights in some countries
outside the United&#160;States can be less extensive than those in the United&#160;States. In addition, the laws of some foreign countries
do not protect intellectual property rights to the same extent as federal and state laws in the United&#160;States.</div> </div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">Competitors may use our technologies in
jurisdictions where we have not obtained patent protection to develop their own products and may also export otherwise infringing products
to territories where we have patent protection but where enforcement is not as strong as that in the United&#160;States. These products
may compete with Silexion&#8217;s products and our current patent application, future patents or other intellectual property rights may
not be effective or sufficient to prevent them from competing.</div> </div>

<div style="text-indent: 36pt; line-height: 1.25">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25">Many companies have encountered significant problems in protecting and defending intellectual
property rights in foreign jurisdictions. The legal systems of certain countries, particularly certain developing countries, do not favor
the enforcement of patents, trade secrets, and other intellectual property protection, particularly those relating to biotechnology products,
which could make it difficult for us to stop the infringement of our patents or marketing of competing products in violation of our proprietary
rights generally. Proceedings to enforce our patent rights in foreign jurisdictions, whether or not successful, could result in substantial
costs and divert our efforts and attention from other aspects of our business, could put our current patent applications or future patents
at risk of being invalidated or interpreted narrowly and our patent applications at risk of not issuing and could provoke third parties
to assert claims against us. We may not prevail in any lawsuits that we initiate and the damages or other remedies awarded, if any, may
not be commercially meaningful. Accordingly, our efforts to enforce our intellectual property rights around the world may be inadequate
to obtain a significant commercial advantage from the intellectual property that we develop or license.</div>

<div style="line-height: 1.25; font-weight: bold; font-family: Times New Roman">&#160;</div>

<div style="line-height: 1.25; font-weight: bold; font-family: Times New Roman,Times,serif">

<div style="line-height: 1.25; font-family: Times New Roman; font-weight: bold">Risks Related to our Human Resources</div> </div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman">&#160;</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman,Times,serif">

<div style="line-height: 1.25; font-family: Times New Roman; font-style: italic; font-weight: bold">The loss of the services of our key
personnel would negatively affect our business.</div> </div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">To successfully develop our drug candidates, we must be
able to attract and retain highly skilled personnel, including consultants and employees. The retention of their services cannot be guaranteed.
Our failure to retain or recruit such professionals might impair our performance and materially affect our technological and product development
capabilities and our product marketing ability. Our future success depends to a large extent on the continued services of our senior management
and key personnel, including in particular, Ilan Hadar, Dr.&#160;Mitchell Shirvan, Dr.&#160;Racheli Malka and Michal Yaron. Any loss of
the services of members of our senior management or key employees would adversely affect our business. We do not currently maintain key-person&#160;insurance
on the lives of any of our key personnel.</div> </div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: rgb(0, 0, 0); font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">30</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="text-align: center; line-height: 1.25"><span style="font-family: Times New Roman"><br/> </span> </div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman,Times,serif">

<div style="line-height: 1.25; font-family: Times New Roman; font-style: italic; font-weight: bold">We may be unable to attract, develop
and retain additional employees required for our development and future success.</div> </div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">Our success is largely dependent on the
performance of our management team and certain key employees and our continuing ability to attract, develop, motivate and retain highly
qualified and skilled employees. Qualified individuals are in high demand, and we may incur significant costs to attract and retain them.
The inability to attract suitably qualified persons when needed, could prevent us from executing on our business plan and strategy, and
we may be unable to find adequate replacements on a timely basis, or at all.</div> </div> </div>

<div style="line-height: 1.25; font-weight: bold; font-family: Times New Roman">&#160;</div>

<div style="line-height: 1.25; font-weight: bold; font-family: Times New Roman,Times,serif">

<div style="line-height: 1.25; font-family: Times New Roman; font-weight: bold">Risks Related to Our Operations</div> </div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman">&#160;</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman,Times,serif">

<div style="line-height: 1.25; font-family: Times New Roman; font-style: italic; font-weight: bold">Our business and operations, or those
of our CROs or third parties, may suffer in the event of computer system failures, cyberattacks or deficiencies in our cybersecurity,
which could materially affect our results.</div> </div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">We receive, generate and store significant and increasing
volumes of sensitive information, such as health information, insurance information and other potentially personally identifiable information.
We faces a number of risks relative to protecting the computer systems we rely on and this critical information, including loss of access
risk, inappropriate use or disclosure, inappropriate modification and the risk of being unable to adequately monitor, audit and modify
our controls over our critical information. This risk extends to the computer systems and information of any collaboration partners, medical
institutions, clinical investigators, CROs, contract laboratories, or other third parties involved in our business.</div> </div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">Despite the implementation of security measures, our information
technology systems, as well as those of CROs or other third parties with which we have relationships, are vulnerable to attack and damage
from computer viruses and malware (e.g., ransomware), unauthorized access, natural and manmade disasters, terrorism, war and telecommunication
and electrical failures, malfeasance by external or internal parties, and human error (e.g., social engineering, phishing). Attacks upon
information technology systems are increasing in their frequency, levels of persistence, sophistication and intensity, and are being conducted
by sophisticated and organized groups and individuals with a wide range of motives and expertise. Furthermore, because the technologies
used to obtain unauthorized access to, or to sabotage or disrupt, systems change frequently and often are not recognized until launched
against a target, we may be unable to anticipate these techniques or implement adequate preventative measures. we may also experience
security breaches that may remain undetected for an extended period. We may not be able to anticipate all types of security threats, and
even if identified, we may be unable to adequately investigate or remediate incidents or breaches due to attackers increasingly using
tools and techniques that are designed to circumvent controls, to avoid detection, and to remove or obfuscate forensic evidence. We may
also face increased cybersecurity risks due to our reliance on internet technology and the number of our and our service providers&#8217;
employees who are (and may continue to be) working remotely, which may create additional opportunities for cybercriminals to exploit vulnerabilities.
The White House, SEC and other regulators have also increased their focus on companies&#8217; cybersecurity vulnerabilities and risks.</div>
</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">

<div style="text-indent: 36pt; line-height: 1.25">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">Our CROs and certain of our service providers are from
time to time, subject to cyberattacks and security incidents. While we have not to our knowledge experienced any significant system failure,
accident or security breach to date, if such an event were to occur and cause interruptions in our or our critical third parties&#8217;
operations, it could result in delays and/or material disruptions of our research and development programs, our operations and ultimately,
our financial results. For example, the loss of trial data from completed, ongoing or planned trials could result in delays in our regulatory
approval efforts and significantly increase our costs to recover or reproduce the data. Likewise, we rely on third parties for the manufacture
of our product candidates and to conduct clinical trials, and similar events relating to their computer systems could also adversely impact
our business. Further, due to the current political uncertainty involving Hamas in Gaza, Hezbollah in Lebanon, Russia and Ukraine, there
is an increased likelihood that the tensions could result in cyberattacks or cybersecurity incidents that could either directly or indirectly
impact our or our critical third parties&#8217; operations. To the extent that any disruption or security breach were to result in a loss
of or damage to data or applications, or inappropriate disclosure of personal, confidential or proprietary information, we could incur
liability due to delays in the development and commercialization of our product candidates or other business activities and/or due to
reputational harm, litigation, regulatory investigations and enforcement, fines and penalties, or increased costs of compliance and system
remediation.</div>

<div style="text-indent: 36pt; line-height: 1.25"> <span style="font-family: Times New Roman"><br/> </span> </div> </div> </div> </div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: rgb(0, 0, 0); font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">31</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">Our existing general liability and cyber
liability insurance policies may not cover, or may cover only a portion of, any potential claims related to security breaches to which
we are exposed or may not be adequate to indemnify us for all or any portion of liabilities that may be imposed. We also cannot be certain
that our existing insurance coverage will continue to be available on acceptable terms or in amounts sufficient to cover the potentially
significant losses that may result from a security incident or breach or that the insurer will not deny coverage of any future claim.
If the information technology systems of our CROs or other service providers become subject to disruptions or security breaches, we may
have insufficient recites against such third parties and we may have to expend significant resources to mitigate the impact of such an
event, and to develop and implement protections to prevent future events of this nature from occurring.</div> </div> </div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman">&#160;</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman,Times,serif">

<div style="line-height: 1.25; font-family: Times New Roman, Times, serif; font-style: italic; font-weight: bold">

<div style="line-height: 1.25; font-family: Times New Roman; font-style: italic; font-weight: bold">If product liability lawsuits are
brought against us, we may incur substantial liabilities and may be required to limit commercialization of any approved products.</div>
</div> </div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">

<div style="line-height: 1.25; font-family: Times New Roman">We face an inherent risk of product liability as a result of the clinical
testing of product candidates and will face an even greater risk if we commercialize any products. For example, we may be sued if any
product candidate we develop causes or is perceived to cause injury or is found to be otherwise unsuitable during clinical testing, manufacturing,
marketing or sale. Any such product liability claims may include allegations of defects in manufacturing, defects in design, a failure
to warn of dangers inherent in the product, negligence, strict liability or a breach of warranties. Claims could also be asserted under
state consumer protection acts. If we cannot successfully defend itself against product liability claims, we may incur substantial liabilities
or be required to limit commercialization of any approved products. Even successful defense would require significant financial and management
resources.</div> </div> </div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">Regardless of the merits or eventual outcome, liability
claims may result in:</div>

<div style="text-indent: -36pt; margin-left: 48pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z2989a7a8874744d0817deb503346dd04" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">decreased demand for any approved product;</div> </td> </tr>
  </table>

<div style="text-indent: -36pt; margin-left: 48pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z742b8a88b828425192ff0b1878cb5734" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">
        <div style="line-height: 1.25; font-family: Times New Roman">injury to our reputation;</div> </div> </td> </tr>
  </table>

<div style="text-indent: -36pt; margin-left: 48pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<table cellspacing="0" cellpadding="0" id="zf28fd7be01fc4b73bd24ec10fe0b869e" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">withdrawal of clinical trial participants;</div> </td> </tr>
  </table>

<div style="text-indent: -36pt; margin-left: 48pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<table cellspacing="0" cellpadding="0" id="zecb745dd88004127b899161060ad8aaa" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">initiation of investigations by regulators;</div> </td> </tr>
  </table>

<div style="text-indent: -36pt; margin-left: 48pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<table cellspacing="0" cellpadding="0" id="za6ec254b7881458396b76f90b8b07ad0" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">costs to defend the related litigation;</div> </td> </tr>
  </table>

<div style="text-indent: -36pt; margin-left: 48pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<table cellspacing="0" cellpadding="0" id="zfb9d1f56330348edad629e8b693060fa" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">
        <div style="line-height: 1.25; font-family: Times New Roman">a diversion of management&#8217;s time and our resources;</div> </div> </td>
        </tr>
  </table>

<div style="text-indent: -36pt; margin-left: 48pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z1a6a2c7836fa4b0688b5b267a15a0ae3" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">substantial monetary awards to trial participants or patients;</div> </td>
        </tr>
  </table>

<div style="text-indent: -36pt; margin-left: 48pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<table cellspacing="0" cellpadding="0" id="zdd66c46d647043f088927042d49ae433" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">product recalls, withdrawals or labeling, marketing or promotional restrictions;</div>
        </td> </tr>
  </table>

<div style="text-indent: -36pt; margin-left: 48pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<table cellspacing="0" cellpadding="0" id="zd88575a1d34f403a9f87104491cbe5cf" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">
        <div style="line-height: 1.25; font-family: Times New Roman">exhaustion of any available insurance and our capital resources and potential
        increase in our insurance premiums and/or retention amounts; and</div> </div> </td> </tr>
  </table>

<div style="text-indent: -36pt; margin-left: 48pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<table cellspacing="0" cellpadding="0" id="ze291b82317684e3396c30720fc15cc11" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">the inability to commercialize any product candidate.</div> </td> </tr>
  </table>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">Our inability to obtain sufficient product liability insurance
at an acceptable cost to protect against potential product liability claims could prevent or inhibit the commercialization of products
we develop, alone or with collaboration partners.</div> </div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: rgb(0, 0, 0); font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">32</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="text-align: center; line-height: 1.25"><span style="font-family: Times New Roman"><br/> </span> </div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">Insurance coverage is increasingly expensive.
we may not be able to maintain insurance at a reasonable cost or in an amount adequate to satisfy any liability that may arise, if at
all. Our insurance policy contains various exclusions, and we may be subject to a product liability claim for which we have no coverage.
We may have to pay any amounts awarded by a court or negotiated in a settlement that exceed our coverage limitations or that are not covered
by our insurance, and we may not have, or be able to obtain, sufficient capital to pay such amounts. Even if our agreements with any current
or future collaborator entitle us to indemnification against losses, such indemnification is limited and may not be available or adequate
should any claim arise.</div> </div> </div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman">&#160;</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman,Times,serif">

<div style="line-height: 1.25; font-family: Times New Roman; font-style: italic; font-weight: bold">We may not be able to successfully
identify and execute strategic alliances or other relationships with third parties or to successfully manage the impacts of acquisitions,
dispositions or relationships on our operations.</div> </div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">

<div style="line-height: 1.25; font-family: Times New Roman">We currently have, and may expand the scope of, and may in the future enter
into, strategic alliances with third parties that it believes will complement or augment our existing business. Our ability to complete
further such strategic alliances is dependent upon, and may be limited by, among other things, the availability of suitable candidates
and capital. In addition, strategic alliances could present unforeseen integration obstacles or costs, may not enhance our business and
may involve risks that could adversely affect us, including the investment of significant amounts of management time that may be diverted
from operations in order to pursue and complete such transactions or maintain such strategic alliances. Future strategic alliances could
result in the incurrence of debt, costs and contingent liabilities, and there can be no assurance that future strategic alliances will
achieve, or that our existing strategic alliances will continue to achieve, the expected benefits to our business or that we will be able
to consummate future strategic alliances on satisfactory terms, or at all.</div> </div> </div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">

<div style="text-indent: 25.2pt; margin-right: 11.1pt; margin-left: 8.15pt; line-height: 1.25; font-family: Times New Roman">Although
we do not currently plan to engage in other material strategic transactions, such as acquisitions, we may from time to time consider such
transactions. Material strategic transactions involve a number of risks, including:</div> </div> </div>

<div style="text-indent: -36pt; margin-left: 48pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z4e575f0550e34320b5b69b79a360543e" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">
        <div style="line-height: 1.25; font-family: Times New Roman">the potential disruption of our ongoing business;</div> </div> </td> </tr>
  </table>

<div style="text-indent: -36pt; margin-left: 48pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<table cellspacing="0" cellpadding="0" id="zc896439d38204014825a7e5f8c6ed2ad" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">
        <div style="line-height: 1.25; font-family: Times New Roman">the distraction of management away from the ongoing oversight of our existing
        business activities;</div> </div> </td> </tr>
  </table>

<div style="text-indent: -36pt; margin-left: 48pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z3a4d57204b2f4e7982ad49408fdf4eb9" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">incurring additional indebtedness;</div> </td> </tr>
  </table>

<div style="text-indent: -36pt; margin-left: 48pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<table cellspacing="0" cellpadding="0" id="zfb51b75934174696bbfa6702401e037c" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">the anticipated benefits and cost savings of those transactions not being
        realized fully, or at all, or taking longer to realize than anticipated;</div> </td> </tr>
  </table>

<div style="text-indent: -36pt; margin-left: 48pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z27f6f4da245b4e298ef6c6eb3037a1c4" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">
        <div style="line-height: 1.25; font-family: Times New Roman">an increase in the scope and complexity of our operations; and</div> </div>
        </td> </tr>
  </table>

<div style="text-indent: -36pt; margin-left: 48pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<table cellspacing="0" cellpadding="0" id="zffaf5989462b404eba93518435d1feb5" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">
        <div style="line-height: 1.25; font-family: Times New Roman">the loss or reduction of control over certain of our assets.</div> </div>
        </td> </tr>
  </table>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">A strategic transaction may result in a significant change
in the nature of our business, operations and strategy, and we may encounter unforeseen obstacles or costs in implementing a strategic
transaction or integrating any acquired business into our operations.</div> </div>

<div style="line-height: 1.25; font-weight: bold; font-family: Times New Roman">&#160;</div>

<div style="line-height: 1.25; font-weight: bold; font-family: Times New Roman,Times,serif">

<div style="line-height: 1.25; font-family: Times New Roman; font-weight: bold">

<div style="line-height: 1.25; font-family: Times New Roman, Times, serif; font-weight: bold">Risks Related to our Operations in Israel&#160;and
China</div> </div> </div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman">&#160;</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman">Conditions in the Middle East and
in Israel may harm our operations.</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="line-height: 1.25; font-family: Times New Roman">Our executive offices and research and development facilities are located
in Israel. Most of our officers and directors are residents of Israel. Since the establishment of the State of Israel in 1948, a number
of armed conflicts have taken place between Israel and its neighboring countries, and between Israel and neighboring terrorist organizations,
including Hamas (an Islamist terrorist and political group in the Gaza Strip) and Hezbollah (an Islamist terrorist and political group
in Lebanon).</div> </div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: rgb(0, 0, 0); font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">33</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">In particular, on October&#160;7, 2023, Hamas terrorists
infiltrated Israel&#8217;s southern border from the Gaza Strip and conducted a series of attacks on civilian and military targets. Hamas
also launched extensive rocket attacks on the Israeli population and industrial centers located along Israel&#8217;s border with the Gaza
Strip and in other areas within the State of Israel. These attacks resulted in thousands of deaths and injuries, and Hamas additionally
kidnapped many Israeli civilians and soldiers. Following the attack, Israel&#8217;s security cabinet declared war against Hamas and commenced
a military campaign against Hamas and these terrorist organizations, in parallel to continued rocket and terror attacks against Israel
by Hamas. Upon the start of the war, the Israeli military began to call-up&#160;reservists for active duty.</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25">In parallel with the war against Hamas that began in October 2023, there have been continued
hostilities along Israel&#8217;s northern border, as the Hezbollah terrorist organization based in Lebanon has conducted rocket, drone,
and, more recently, missile attacks against Israel, and there have also been rocket, drone and missile attacks against Israel by the Houthi
movement in Yemen&#160;as well continued hostilities with various rebel militia groups in Syria and Iraq. The hostilities with Hezbollah
have escalated recently, prompting Israel to send its ground forces into southern Lebanon to destroy terrorist positions and infrastructure
used by Hezbollah for attacks on northern and central Israel, which had caused the displacement of residents in northern Israel since
early in the war.&#160;In November 2024, a ceasefire was brokered between Israel and Hezbollah.</div>

<div style="line-height: 1.25"><br/> </div>

<div style="text-indent: 36pt; line-height: 1.25">Iran has furthermore entered the conflict against Israel, shooting ballistic missiles
at Israel twice during the current war (on April&#160;13, 2024 and October 1, 2024). Iran is furthermore widely believed to be developing
nuclear weapons, with which it has threatened Israel&#160;and is also believed to have a strong influence among extremist groups in the
region, such as Hamas in Gaza, Hezbollah in Lebanon, the Houthi movement in Yemen and various rebel militia groups in Syria and Iraq.
There is a risk that other terrorist organizations, including Palestinian military organizations in the West Bank as well as other hostile
countries will join the hostilities against Israel. Such clashes may escalate into a greater regional conflict.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif"><span style="font-family: Times New Roman"><br/> </span> </div>

<div style="text-indent: 36pt; line-height: 1.25">

<div style="text-indent: 36pt; line-height: 1.25">

<div style="line-height: 1.25; font-family: Times New Roman">Armed conflicts, terrorist activities or political instability in Israel
or in the broader Middle East have been, and could continue to, in a more severe way, adversely affect business conditions in Israel,
and could harm our results of operations and make it more difficult for us to raise capital. Parties with whom we do business may decline
to travel to Israel during periods of heightened unrest or tension, forcing Silexion to make alternative arrangements when necessary in
order to meet our business partners face to face. In addition, the political and security situation in Israel may result in parties with
whom we have agreements involving performance in Israel claiming that they are not obligated to perform their commitments under those
agreements pursuant to force majeure provisions in such agreements. Further, in the past, the State of Israel and Israeli companies have
been subjected to economic boycotts. Several countries still restrict business with the State of Israel and with Israeli companies. These
restrictive laws and policies may have an adverse impact on our operating results, financial condition or the expansion of our business.
The interruption or curtailment of trade between Israel and its trading partners could adversely affect our operations and results of
operations.</div> </div> </div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">Our commercial insurance does not cover losses that may
occur as a result of events associated with the security situation in the Middle East. Although the Israeli government currently covers
the reinstatement value of direct damages that are caused by terrorist attacks or acts of war, we cannot assure you that this government
coverage will be maintained. Any losses or damages incurred by us could have a material adverse effect on our business.</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">Finally, political conditions within Israel may also affect
our operations. Israel held five general elections between 2019 and 2022, and prior to October&#160;2023, the Israeli government pursued
extensive changes to Israel&#8217;s judicial system, which sparked extensive political debate and unrest. To date, these initiatives have
been substantially put on hold. Actual or perceived political instability in Israel or any negative changes in the political environment,
may individually or in the aggregate adversely affect the Israeli economy and, in turn, our business, financial condition, results of
operations and growth prospects.</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: rgb(0, 0, 0); font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">34</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="text-align: center; line-height: 1.25"><span style="font-family: Times New Roman"><br/> </span> </div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman,Times,serif">

<div style="line-height: 1.25; font-family: Times New Roman; font-style: italic; font-weight: bold">It may be difficult to enforce a U.S.&#160;judgment
against us, our officers or our directors or to assert U.S.&#160;securities law claims in Israel.</div> </div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">Service of process upon us and upon our directors and
officers, who reside outside the U.S., may be difficult to obtain within the U.S.&#160;In addition, because substantially all of our assets
and most of our directors and officers are located outside the U.S., any judgment obtained in the U.S.&#160;against us or any of our directors
and officers may not be collectible within the U.S.&#160;There is a doubt as to the enforceability of civil liabilities under the Securities
Act or the Exchange&#160;Act pursuant to original actions instituted in Israel. Subject to particular time limitations and provided certain
conditions are met, executory judgments of a U.S.&#160;court for monetary damages in civil matters may be enforced by an Israeli court.</div>
</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman">&#160;</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman,Times,serif">

<div style="line-height: 1.25; font-family: Times New Roman; font-style: italic; font-weight: bold">Under applicable U.S.&#160;and Israeli
law, we may not be able to enforce covenants not to compete and therefore may be unable to prevent our competitors from benefiting from
the expertise of some of our former employees. In addition, employees may be entitled to seek compensation for their inventions irrespective
of their agreements with us, which in turn could impact our future profitability.</div> </div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">We generally enter into non-competition&#160;agreements
with our employees and key consultants. These agreements prohibit our employees and key consultants, if they cease working for us, from
competing directly with it or working for our competitors or clients for a limited period of time. We may be unable to enforce these agreements
under the laws of the jurisdictions in which our employees work and it may be difficult for it to restrict our competitors from benefitting
from the expertise our former employees or consultants developed while working for us. For example, Israeli courts have required employers
seeking to enforce non-compete&#160;undertakings of a former employee to demonstrate that the competitive activities of the former employee
will harm one of a limited number of material interests of the employer which have been recognized by the courts, such as the secrecy
of a company&#8217;s confidential commercial information or the protection of our intellectual property. If it cannot demonstrate that
such interests will be harmed, we may be unable to prevent our competitors from benefiting from the expertise of our former employees
or consultants and our ability to remain competitive may be diminished.</div> </div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">In addition, Chapter&#160;8 of the Israeli Patents Law,&#160;5727-1967,
or the Patents Law, deals with inventions made in the course of an employee&#8217;s service and during his or her term of employment,
whether or not the invention is patentable, or service inventions. Section&#160;134 of the Patents Law, sets forth that if there is no
agreement which explicitly determines whether the employee is entitled to compensation for the service inventions and the extent and terms
of such compensation, such determination will be made by the Compensation and Rewards Committee, a statutory committee of the Israeli
Patents Office. As a result, it is unclear if, and to what extent, our research and development employees may be able to claim compensation
with respect to our future revenue. As a result, Silexion may receive less revenue from future products if such claims are successful,
which in turn could impact our future profitability.</div> </div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman">&#160;</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman,Times,serif">

<div style="line-height: 1.25; font-family: Times New Roman; font-style: italic; font-weight: bold">Governmental control of currency conversion
in China may limit us our ability to utilize our cash balance&#160;effectively and affect the value of our investment.</div> </div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">We may be reliant on dividend payments, equity investments,
or other forms of cash infusion from PRC subsidiaries to fund any cash and financing requirements it may have. The PRC government imposes
controls on the convertibility of the Renminbi into foreign currencies and, in certain cases, the remittance of currency out of China.
Under existing PRC foreign exchange regulations, payments of current account items, including profit distributions, interest payments
and trade and service-related&#160;foreign exchange transactions, can be made in foreign currencies without prior approval of the State
Administration of Foreign Exchange (&#8220;SAFE&#8221;) (the foreign exchange management administrative body of the People&#8217;s Bank
of China) by complying with certain procedural requirements. Specifically, under the existing exchange restrictions, without prior approval
of SAFE, cash generated from the operations of PRC subsidiaries in China may be used to pay dividends to parent companies. However, approval
from or registration with appropriate government authorities is required where Renminbi is to be converted into foreign currency and remitted
out of China to pay capital expenses such as the repayment of loans denominated in foreign currencies. As a result, we would need to obtain
SAFE approval to use cash held at PRC subsidiaries to pay outside China, or to make other capital expenditure payments outside China in
a currency other than Renminbi. The PRC government may at its discretion restrict access to foreign currencies for current account transactions
in the future. If the foreign exchange control system prevents us from obtaining sufficient foreign currencies to satisfy its foreign
currency demands, it may not be able to pay dividends in foreign currencies to our shareholders.</div> </div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: rgb(0, 0, 0); font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">35</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">PRC regulations relating to dividends may restrict the
ability of our PRC subsidiaries to make payments to New Silexion, which may have an adverse effect on our ability to conduct our business.</div>
</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">Under PRC laws and regulations, our PRC subsidiaries (which
are each &#8220;wholly foreign-owned&#160;enterprises&#8221; incorporated in Mainland China) are only permitted to pay dividends out of
their respective accumulated profits, as determined in accordance with PRC accounting standards and regulations. In addition, prior to
distribution of any dividends, our subsidiaries in China are each required to compensate their past losses with after-tax&#160;profits
each year, if any, and then set aside at least 10% of their after-tax&#160;profits each year to fund a statutory reserve until such reserve
reaches 50% of the subsidiary&#8217;s total registered capital. Additionally, if our PRC subsidiaries incur debt on their own behalf in
the future, the instruments governing their debt may restrict their ability to pay dividends or make other distributions to us.</div>
</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">Any limitation on the ability of our PRC subsidiaries
to pay dividends or make other distributions to us could adversely limit our ability to grow, make investments or acquisitions that could
be beneficial to our business, pay dividends, or otherwise fund and conduct our business.</div> </div>

<div style="line-height: 1.25; font-weight: bold; font-family: Times New Roman">&#160;</div>

<div style="line-height: 1.25; font-weight: bold; font-family: Times New Roman">

<div style="line-height: 1.25; font-family: Times New Roman, Times, serif; font-weight: bold">Risks Related to this Offering<br/> <br/>
</div> </div>

<div style="line-height: 1.25">

<table cellspacing="0" cellpadding="0" border="0" id="z70e8924b1e82450689ea92b09b982dc4" style="font: 10pt Times New Roman, Times, serif; color: #000000; width: 100%">
  <tr>
    <td style="width: 100%">
        <div>
        <div style="line-height: 1.25">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif; font-style: italic; font-weight: bold">The
        sale of a substantial amount of our ordinary shares, including resale of the ordinary shares held by the Selling Securityholders in the
        public market could adversely affect the prevailing market price of our ordinary shares.</div> </div> </div> </td> </tr>
  </table> </div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-indent: 36pt; line-height: 1.25">

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold"><br/> </div> </div>

<div>

<div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">We are registering for resale 2,377,030 ordinary shares. Sales
of substantial amounts of shares of our ordinary shares in the public market, or the perception that such sales might occur, could adversely
affect the market price of our ordinary shares, and the market value of our other securities. We cannot predict if and when the Selling
Securityholders may sell such shares in the public markets. Furthermore, in the future, we may issue additional ordinary shares or other
equity or debt securities convertible into ordinary shares. Any such issuance could result in substantial dilution to our existing shareholders
and could cause our share price to decline.</div> </div> </div> </div> </div>

<div style="text-align: justify; text-indent: 18pt; line-height: 1.25"> <br/> </div> <span style="font-family: Times New Roman"></span>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: rgb(0, 0, 0); font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">36</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="line-height: 1.25"><br/>

<div style="line-height: 1.25; font-style: italic; font-weight: bold">Investors who buy shares at different times from the Selling Securityholders
will likely pay different prices.</div>

<div style="line-height: 1.25">

<div style="text-indent: 36pt; line-height: 1.25; font-style: italic; font-weight: bold">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25">The Selling Securityholders will have discretion, subject to market demand, to vary
the timing, prices, and numbers of ordinary shares issuable upon the exercise of the warrants sold by them pursuant to this prospectus.
If and when they do elect to sell ordinary shares issuable upon the exercise of the warrants, the Selling Securityholders may sell all,
some or none of such shares at any time or from time to time at their discretion and at different prices. As a result, investors who purchase
our securities from Selling Securityholders in this offering at different times will likely pay different prices for those securities,
and so may experience different levels of dilution and in some cases substantial dilution and different outcomes in their investment results.
Investors may experience a decline in the value of the securities they purchase from the Selling Securityholders as a result of future
sales made by Selling Securityholders to other investors at prices lower than the prices such earlier investors paid for their securities
from the Selling Securityholders.</div>

<div style="line-height: 1.25"><br/> </div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold">There can be no assurance that the New Warrants will ever be in
the money at the time they become exercisable or otherwise, and they may expire worthless.</div>

<div style="line-height: 1.25"><br/> </div>

<div style="text-indent: 35.45pt; line-height: 1.25">

<div style="text-indent: 35.45pt; line-height: 1.25">The exercise price of the New Warrants is $1.50 per ordinary share. There is no guarantee
that the&#160; warrants will ever be in the money prior to their expiration, and as such, the warrants may expire worthless. We believe
that the likelihood that warrant holders determine to exercise their warrants, and therefore the amount of cash proceeds that we would
receive, is dependent upon the market price of our New Silexion ordinary shares. If the market price for our New Silexion ordinary shares
is less than the exercise price of the warrants (on a per share basis), we believe that warrant holders will be very unlikely to exercise
any of their warrants, and accordingly, we will not receive any such exercise proceeds. There is no assurance that the warrants will be
&#8220;in the money&#8221; prior to their expiration or that the warrant holders will exercise their warrants. As of February 11, 2025,
the closing price of our ordinary shares was $1.38 per share.</div> </div> </div>

<div style="line-height: 1.25"><br/> </div> </div> <span style="font-family: Times New Roman"> </span>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: rgb(0, 0, 0); font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">37</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="line-height: 1.25"><span style="font-family: Times New Roman"><br/> </span> </div>

<div style="line-height: 1.25; font-weight: bold; font-family: Times New Roman,Times,serif">

<div style="line-height: 1.25; font-family: Times New Roman; font-weight: bold">

<div style="line-height: 1.25; font-family: Times New Roman, Times, serif; font-weight: bold">

<div style="line-height: 1.25; font-weight: bold">Risks Related to Owning Our Ordinary Shares</div>

<div style="line-height: 1.25"><br/> </div> </div> </div> </div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman,Times,serif">

<div style="line-height: 1.25; font-family: Times New Roman; font-style: italic; font-weight: bold">The price of our ordinary shares and
our warrants may be volatile, and the value of our ordinary shares and our warrants may decline.</div> </div>

<div style="line-height: 1.25"><span style="font-family: Times New Roman"><br/> </span> </div>

<div style="text-indent: 35.45pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-indent: 35.45pt; line-height: 1.25; font-family: Times New Roman">We cannot predict the prices at which our ordinary
shares or warrants will trade. The price of our ordinary shares and our warrants may not bear any relation to any established criteria
of the value of our business and prospects. In addition, the trading price of our ordinary shares and warrants is likely to be volatile
and could be subject to fluctuations in response to various factors, some of which are beyond our control. These fluctuations could cause
you to lose all or part of your investment in our ordinary shares and our warrants as you might be unable to sell your shares at or above
the price you paid. Factors that could cause fluctuations in the trading price of our ordinary shares and our warrants include the following:</div>
</div>

<div style="line-height: 1.25"><span style="font-family: Times New Roman"><br/> </span> </div>

<div style="line-height: 1.25">

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25">
        <div style="line-height: 1.25; font-family: Times New Roman">actual or anticipated fluctuations in our financial condition or results
        of operations;</div> </div> </td> </tr>
  </table>

<div style="text-indent: 36pt; line-height: 1.25"><span style="font-family: Times New Roman">&#160; </span>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25">
        <div style="line-height: 1.25; font-family: Times New Roman">variance in the projected timeline for regulatory approvals of our product
        candidates from expectations of securities analysts;</div> </div> </td> </tr>
  </table>

<div style="text-indent: 36pt; line-height: 1.25"><span style="font-family: Times New Roman">&#160; </span>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25">
        <div style="line-height: 1.25; font-family: Times New Roman">changes in laws or regulations applicable to our business;</div> </div> </td>
        </tr>
  </table>

<div style="text-indent: 36pt; line-height: 1.25"><span style="font-family: Times New Roman">&#160; </span>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25">
        <div style="line-height: 1.25; font-family: Times New Roman">announcements by us or our competitors of significant business developments;</div>
        </div> </td> </tr>
  </table>

<div style="text-indent: 36pt; line-height: 1.25"><span style="font-family: Times New Roman">&#160; </span>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25">
        <div style="line-height: 1.25; font-family: Times New Roman">significant data breaches, disruptions to or other incidents involving our
        company;</div> </div> </td> </tr>
  </table>

<div style="text-indent: 36pt; line-height: 1.25"><span style="font-family: Times New Roman">&#160; </span>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25">
        <div style="line-height: 1.25; font-family: Times New Roman">conditions or developments affecting the biotechnology industry;</div> </div>
        </td> </tr>
  </table>

<div style="text-indent: 36pt; line-height: 1.25"><span style="font-family: Times New Roman">&#160; </span>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25">
        <div style="line-height: 1.25; font-family: Times New Roman">future sales of New Silexion ordinary shares by us or our shareholders, as
        well as the anticipation of lock-up releases;</div> </div> </td> </tr>
  </table>

<div style="text-indent: 36pt; line-height: 1.25"><span style="font-family: Times New Roman">&#160; </span>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25">
        <div style="line-height: 1.25">
        <div style="line-height: 1.25; font-family: Times New Roman">changes in senior management or key personnel;</div> </div> </div> </td>
        </tr>
  </table>

<div style="text-indent: 36pt; line-height: 1.25"><span style="font-family: Times New Roman">&#160; </span>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25">
        <div style="line-height: 1.25">
        <div style="line-height: 1.25; font-family: Times New Roman">the trading volume of our securities;</div> </div> </div> </td> </tr>
  </table>

<div style="text-indent: 36pt; line-height: 1.25"><span style="font-family: Times New Roman">&#160; </span>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25">
        <div style="line-height: 1.25">
        <div style="line-height: 1.25; font-family: Times New Roman">changes in the anticipated future size and growth rate of our markets;</div>
        </div> </div> </td> </tr>
  </table>

<div style="text-indent: 36pt; line-height: 1.25"><span style="font-family: Times New Roman">&#160; </span>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25">
        <div style="line-height: 1.25">
        <div style="line-height: 1.25; font-family: Times New Roman">publication of research reports or news stories about us, our competitors
        or our industry, or positive or negative recommendations or withdrawal of research coverage by securities analysts;</div> </div> </div>
        </td> </tr>
  </table>

<div style="text-indent: 36pt; line-height: 1.25"><span style="font-family: Times New Roman">&#160; </span>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25">
        <div style="line-height: 1.25">
        <div style="line-height: 1.25; font-family: Times New Roman">general economic and market conditions; and</div> </div> </div> </td> </tr>
  </table>

<div> <span style="font-family: Times New Roman"><br/> </span> </div> </div> </div> </div> </div> </div> </div> </div> </div> </div>
</div> </div>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25">
        <div style="line-height: 1.25">
        <div style="line-height: 1.25; font-family: Times New Roman">other events or factors, including those resulting from war, incidents of
        terrorism, global pandemics or responses to those events.</div> </div> </div> </td> </tr>
  </table>

<div> <span style="font-family: Times New Roman"><br/> </span> </div> </div>

<div style="text-indent: 35.45pt; line-height: 1.25; font-family: Times New Roman">Broad market and industry fluctuations, as well as
general economic, political, regulatory and market conditions, may also negatively impact the market price of our ordinary shares. In
the past, companies that have experienced volatility in the market price of their securities have been subject to securities class action
litigation. We may be the target of this type of litigation in the future, which could result in substantial expenses and divert our management&#8217;s
attention.</div>

<div style="line-height: 1.25"><span style="font-family: Times New Roman"><br/> </span> </div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman">A substantial number of our ordinary
shares may be issued pursuant to the White Lion Purchase Agreement, as well as the conversion terms of our outstanding convertible notes
(consisting of the A&amp;R Sponsor Promissory Note and the EarlyBird Convertible Note), which could cause (i) the price of the ordinary
shares to decline, and (ii) substantial dilution to our existing shareholders.</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">The purchase price per ordinary share to be paid by White
Lion for shares that we may elect to issue and sell to it under the White Lion Purchase Agreement will fluctuate based on the market price
of our ordinary shares at the time we elect to sell such shares. Depending on market liquidity at the time, resales of such ordinary shares
by White Lion may cause the trading price of our ordinary shares to decrease, and any such decrease could be substantial.</div> </div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">If and when we elect to issue and sell ordinary shares
to White Lion, those issuances and sales will result in dilution to the interests of existing holders of our ordinary shares, which dilution
may be substantial. Additionally, the sale of a substantial number of ordinary shares to White Lion, or the anticipation of such sales,
could make it more difficult for us to sell equity or equity-related securities in the future at a time and at a price that we might otherwise
wish to effect sales.</div> </div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">In addition to ordinary shares that may be issued under
the White Lion Purchase Agreement, ordinary shares may also be issued upon conversion of amounts outstanding under two convertible promissory
notes that we issued in connection with the consummation of the Business Combination&#8212; consisting of the A&amp;R Sponsor Promissory
Note, in an amount of $3,433,000, that we issued to the Moringa Sponsor, due February 15, 2027, and the EarlyBird Convertible Note, due
December 31, 2025, in an amount of $1,250,000 that we issued to EarlyBird (together, the &#8220;Convertible Notes&#8221;). The conversion
prices under the Convertible Notes relate to the market price of our ordinary shares and/or the price at which we raise capital from equity
financings. The issuance of additional shares under the Convertible Notes will dilute our other equity holders, which could cause the
price of our ordinary shares to decline.</div> </div> <span style="font-family: Times New Roman"><br/> </span>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: rgb(0, 0, 0); font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">38</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif"><span style="font-family: Times New Roman">&#160; </span>

<div style="line-height: 1.25; font-family: Times New Roman; font-style: italic; font-weight: bold">The ordinary shares (including ordinary
shares underlying warrants) that are being offered by selling securityholders under another registration statement that we currently have
in effect represent a substantial percentage of our outstanding ordinary shares, and the sale of such shares, or the perception that such
sales may occur, could cause the price of our ordinary shares to be more volatile or decrease.</div>

<div style="line-height: 1.25"><span style="font-family: Times New Roman"><br/> </span> </div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">

<div style="text-indent: 36pt; line-height: 1.25">

<div style="line-height: 1.25; font-family: Times New Roman">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">On October 9, 2024, we filed, and on October
16, 2024, the SEC declared effective, a registration statement on Form S-1 (SEC file number 333-282556), in which we registered with the
SEC the sale by selling securityholders named therein of up to 1,705,798 of our ordinary shares and up to 21,112 of our warrants (constituting
our private warrants).<span style="font-weight: bold">&#160;</span>Depending on market liquidity, resales of ordinary shares and warrants
by those selling securityholders may cause the trading price of our ordinary shares and warrants to decrease, and any such decrease could
be substantial. Additionally, the sale of a substantial number of ordinary shares or warrants by those selling securityholders, or the
perception that such sales may take place, could increase the volatility of the market price of the ordinary shares and warrants and depress
the trading price of the ordinary shares and warrants and thereby make it more difficult for us to raise capital by selling equity or
equity-related securities in the future at a time and at a price that we might otherwise wish to effect sales.</div> </div> </div> </div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif"> <span style="font-family: Times New Roman"><br/>
</span> </div> </div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman">The requirement that we repay the
EarlyBird Convertible Note could adversely affect our business plan, liquidity, financial condition, and results of operations.</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">If not converted, we are required to repay, in cash, principal
that is outstanding under the EarlyBird Convertible Note, as well as interest thereon, in connection with equity financings by us, or
upon the maturity of the note on December 31, 2025. That obligation could have important consequences on our business. In particular,
it could:</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z0a95e0605d404bdd8a04fab6f6e1ef73" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">limit our flexibility in planning the payment of expenditures that arise
        in our clinical program and our business and operations generally;</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<table cellspacing="0" cellpadding="0" id="zdc3088c052ee4cb09e181c2f8c4c63f1" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">increase our vulnerability to general adverse economic conditions that hinder
        our ability to obtain equity financings; and</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z08c440c1ab874318a61e8dc357a1c3d2" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">place us at a competitive disadvantage compared to our competitors.</div>
        </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">No assurances can be given that we will be successful
in making the required payments under the EarlyBird Convertible Note. If we are unable to make the required cash payments, there could
be a default under the EarlyBird Convertible Note. In such event, or if a default otherwise occurs under the EarlyBird Convertible Note:</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z3a9adbe702a54ee587ec0a36873cbe79" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">the interest rate payable under the EarlyBird Convertible Note could be increased,
        and EarlyBird, as the holder of the EarlyBird Convertible Note, could declare all outstanding principal and interest to be due and payable;
        and/or</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z56ec2e633c6947dfa6015b31253d1cf1" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">we could be forced into bankruptcy or liquidation.</div> </td> </tr>
  </table>

<div style="line-height: 1.25"><span style="font-family: Times New Roman"><br/> </span> </div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman">Because we have no current plans to
pay cash dividends on our ordinary shares for the foreseeable future, you may not receive any return on investment unless you sell New
Silexion ordinary shares for a price greater than that which you paid for it.</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">We will likely retain future earnings, if any, for future
operations, expansion and debt repayment and have no current plans to pay any cash dividends for the foreseeable future. Any decision
to declare and pay dividends as a public company in the future will be made at the discretion of our board of directors and will depend
on, among other things, our results of operations, financial condition, cash requirements, contractual restrictions, funds lawfully available
therefor and other factors that our board of directors may deem relevant. In addition, our ability to pay dividends may be limited by
covenants of any existing and future outstanding indebtedness we or our subsidiaries incur. As a result, you may not receive any return
on an investment in our ordinary shares unless you sell our ordinary shares for a price greater than that which you paid for it.</div>
</div>

<div style="text-indent: 36pt; line-height: 1.25"> <span style="font-family: Times New Roman"><br/> </span></div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="line-height: 1.25; font-family: Times New Roman, Times, serif; font-style: italic; font-weight: bold">

<div style="line-height: 1.25; font-family: Times New Roman; font-style: italic; font-weight: bold">Our reverse share split may negatively
impact the market for our ordinary shares.</div> </div>

<div style="text-indent: 35.45pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 35.45pt; line-height: 1.25; font-family: Times New Roman, Times, serif">

<div style="line-height: 1.25; font-family: Times New Roman">There can be no assurance that the total market capitalization of our ordinary
shares after our reverse share split will be equal to or greater than the total market capitalization before the reverse share split,
or that the per share market price of our ordinary shares following the reverse share split will increase in proportion to the reduction
in the number of ordinary shares outstanding before the reverse share split. Factors such as the results of our pre-clinical and clinical
trials, progress in seeking regulatory approval for our product candidates, our financial results, developments involving our competitors,
market conditions and the market perception of our product candidates may adversely affect the market price of our ordinary shares. As
a result, a decline in the market price of our ordinary shares after the reverse share split may result in a greater percentage decline
than would occur in the absence of a reverse share split.</div> </div>

<div style="text-indent: 35.45pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal; color: rgb(0, 0, 0)">39</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="text-indent: 35.45pt; line-height: 1.25; font-family: Times New Roman">In addition to market price, the liquidity of our ordinary
shares may also be adversely affected by the reverse share split, given the reduced number of ordinary shares that will be outstanding
following the reverse share split.</div>

<div style="text-indent: 35.45pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 35.45pt; line-height: 1.25; font-family: Times New Roman, Times, serif">

<div style="line-height: 1.25; font-family: Times New Roman">The reverse share split may furthermore increase the number of our shareholders
who own odd lots (less than 100 shares). Any shareholder who owns fewer than 900 ordinary shares, prior to the reverse share split will
own fewer than 100 ordinary shares following the reverse share split. Shareholders who hold odd lots may experience an increase in the
cost of selling their shares and may have greater difficulty in effecting sales.</div> </div>

<div style="text-indent: 35.45pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="line-height: 1.25; font-family: Times New Roman, Times, serif; font-style: italic; font-weight: bold">

<div style="line-height: 1.25; font-family: Times New Roman; font-style: italic; font-weight: bold">Following, and as a partial result
of, our reverse share split, our ordinary shares may experience extreme price volatility unrelated to our actual or expected operating
performance, financial condition or prospects, making it difficult for prospective investors to assess the rapidly changing value of our
ordinary shares.</div> </div>

<div style="line-height: 1.25; font-family: Times New Roman; font-style: italic; font-weight: bold">&#160;</div>

<div style="text-indent: 35.45pt; line-height: 1.25; font-family: Times New Roman, Times, serif">

<div style="line-height: 1.25; font-family: Times New Roman">Recently, there have been instances of extreme share price run-ups followed
by rapid price declines and strong share price volatility with a number of relatively new public companies, especially among companies
with relatively smaller public floats. As a relatively small-capitalization company with relatively small public float, we may experience
greater share price volatility, extreme price run-ups, lower trading volume and less liquidity than large-capitalization companies. The
potential for decrease in liquidity due to our reverse share split may heighten our exposure to those trading trends. In particular, following
the reverse share split, our ordinary shares may be subject to rapid and substantial price volatility, low volume of trades, and large
spreads in bid and ask prices. Such volatility, including any stock run up, may be unrelated to our actual or expected operating performance,
financial condition or prospects, making it difficult for prospective investors to assess the rapidly changing value of our ordinary shares.</div>
</div>

<div style="text-indent: 35.45pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 35.45pt; line-height: 1.25; font-family: Times New Roman">In addition, if the trading volumes of our ordinary
shares are low, persons buying or selling in relatively small quantities may easily influence prices of our ordinary shares. This low
volume of trades could also cause the price of our ordinary shares to fluctuate greatly, with large percentage changes in price occurring
in any trading day session. Holders of our ordinary shares may also not be able to readily liquidate their investment or may be forced
to sell at depressed prices due to low volume trading. If high spreads between the bid and ask prices of our ordinary shares exist at
the time of a purchase, the shares would have to appreciate substantially on a relative percentage basis for an investor to recoup their
investment. Broad market fluctuations and general economic and political conditions (including in Israel, where our operations are centered)
may also adversely affect the market price of our ordinary shares.</div>

<div style="line-height: 1.25; font-family: Times New Roman; font-style: italic; font-weight: bold">&#160;</div>

<div style="text-indent: 35.45pt; line-height: 1.25; font-family: Times New Roman">As a result of this volatility, investors may experience
losses on their investment in our ordinary shares. A volatile market price of our ordinary shares also could adversely affect our ability
to issue additional ordinary shares or other securities and our ability to obtain additional financing in the future, which is a key strategic
goal for us, thereby frustrating our ability to achieve one of the key purposes of our reverse share split.</div>

<div style="line-height: 1.25"><span style="font-family: Times New Roman"><br/> </span> </div>

<div style="line-height: 1.25; font-family: Times New Roman, Times, serif; font-style: italic; font-weight: bold">

<div style="line-height: 1.25; font-family: Times New Roman; font-style: italic; font-weight: bold">Following our reverse share split,
the resulting higher market price of our ordinary shares may not attract new investors, including institutional investors, and may not
satisfy the investing requirements of those investors. Consequently, the trading liquidity of our ordinary shares may not improve.</div>
</div>

<div style="line-height: 1.25"><span style="font-family: Times New Roman"><br/> </span> </div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">

<div style="line-height: 1.25; font-family: Times New Roman">Although we believe that a higher market price of our ordinary shares, which
is expected to result from our reverse share split, may help generate greater or broader investor interest, there can be no assurance
that the reverse share split will result in a share price that will attract new investors, including institutional investors. In addition,
there can be no assurance that the market price of our ordinary shares will satisfy the investing requirements of those investors. As
a result, the trading liquidity of our ordinary shares may not necessarily improve.</div> </div> </div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman">&#160;</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman,Times,serif">

<div style="line-height: 1.25; font-family: Times New Roman, Times, serif; font-style: italic; font-weight: bold">

<div style="line-height: 1.25; font-family: Times New Roman; font-style: italic; font-weight: bold">We qualify as an &#8220;emerging growth
company&#8221; as well as a &#8220;smaller reporting company&#8221; within the meaning of the Securities Act, and if we take advantage
of certain exemptions from disclosure requirements available to emerging growth companies or smaller reporting companies, it could make
our securities less attractive to investors and may make it more difficult to compare our performance to the performance of other public
companies.</div> </div> </div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">

<div style="line-height: 1.25; font-family: Times New Roman">We qualify as an &#8220;emerging growth company&#8221; as defined in Section
2(a)(19) of the Securities Act, as modified by the JOBS Act. As such, we will be eligible for and intend to take advantage of certain
exemptions from various reporting requirements applicable to other public companies that are not emerging growth companies for as long
as we continue to be an emerging growth company, including (a) the exemption from the auditor attestation requirements with respect to
internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act, (b) the exemptions from say-on-pay, say-on-frequency
and say-on-golden parachute voting requirements and (c) reduced disclosure obligations regarding executive compensation in its periodic
reports and proxy statements. We will remain an emerging growth company until the earliest of (i) the last day of the fiscal year in which
the market value of our ordinary shares that are held by non-affiliates is equal to or exceeds $700 million as of the end of that year&#8217;s
second fiscal quarter, (ii) the last day of the fiscal year in which we have total annual gross revenue of $1.235 billion or more during
such fiscal year (as indexed for inflation), (iii) the date on which we have issued more than $1 billion in non-convertible debt in the
prior three-year period or (iv) the last day of the fiscal year following the fifth anniversary of the date of the first issuance of our
ordinary shares in the Business Combination. In addition, Section 107 of the JOBS Act also provides that an emerging growth company can
take advantage of the exemption from complying with new or revised accounting standards provided in Section 7(a)(2)(B) of the Securities
Act as long as the Company is an emerging growth company. An emerging growth company can therefore delay the adoption of certain accounting
standards until those standards would otherwise apply to private companies. We have elected not to opt out of such extended transition
period and, therefore, the Company may not be subject to the same new or revised accounting standards as other public companies that are
not emerging growth companies. Investors may find our ordinary shares less attractive because we rely on these exemptions, which may result
in a less active trading market for our ordinary shares and its price may be more volatile.</div>

<div style="text-indent: 25.2pt; margin-right: 8pt; margin-left: 8.15pt; line-height: 1.25"> <span style="font-family: Times New Roman"><br/>
</span> </div> </div> </div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: rgb(0, 0, 0); font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">40</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">Additionally, we qualify as a &#8220;smaller
reporting company&#8221; as defined in Item&#160;10(f)(1)&#160;of Regulation&#160;S-K&#160;promulgated by the SEC.&#160;Smaller reporting
companies may take advantage of certain reduced disclosure obligations, including, among other things, providing only two&#160;years of
audited financial statements. The Company will remain a smaller reporting company until the last&#160;day of the fiscal year in which
(i)&#160;the market value of our ordinary shares held by non-affiliates&#160;is equal to or exceeds $250&#160;million as of the end of
that year&#8217;s second fiscal quarter, or (ii)&#160;our annual revenues is equal to or exceeds $100&#160;million during such completed
fiscal year and the market value of our ordinary shares held by non-affiliates&#160;is equal to or exceeds $700&#160;million as of the
end of that year&#8217;s second fiscal quarter. To the extent the Company takes advantage of such reduced disclosure obligations, it may
also make comparison of our financial statements with other public companies difficult or impossible.</div> </div>

<div style="line-height: 1.25; font-weight: bold; font-family: Times New Roman">&#160;</div>

<div style="line-height: 1.25; font-weight: bold; font-family: Times New Roman">Risks Related to U.S.&#160;Federal Income Taxation</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman">&#160;</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman">The PFIC status of New Silexion could
result in adverse U.S.&#160;federal income tax consequences to U.S.&#160;Holders.</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">In general, a non-U.S.&#160;corporation is a PFIC for
U.S.&#160;federal income tax purposes for any taxable year in which, after applying certain look-through&#160;rules, either (i)&#160;50%
or more of the average value of its assets (generally determined on the basis of a weighted quarterly average) consists of assets that
produce, or are held for the production of, passive income, or (ii)&#160;75% or more of its gross income consists of passive income. Passive
income generally includes dividends, interest, rents and royalties (other than rents or royalties derived from the active conduct of a
trade or business) and gains from the disposition of passive assets. Cash and cash equivalents generally are passive assets. The value
of goodwill will generally be treated as an active or passive asset based on the nature of the income produced in the activity to which
the goodwill is attributable. For purposes of the PFIC rules, a non-U.S.&#160;corporation that owns, directly or indirectly, at least
25% by value of the stock of another corporation is treated as if it held its proportionate share of the assets of the other corporation
and received directly its proportionate share of the income of the other corporation.</div>

<div style="line-height: 1.25"><span style="font-family: Times New Roman"><br/> </span> </div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">

<div style="line-height: 1.25; font-family: Times New Roman">The annual PFIC income and asset tests in respect of New Silexion will be
applied based on the assets and activities of the combined business. Based on the composition of our income and assets, it cannot be determined
whether we will be classified as a PFIC for our current taxable year or in any future taxable year. Further, changes in the composition
of our income or composition of our assets may cause us to be or become a PFIC for the current or subsequent taxable years. Whether we
are treated as a PFIC for U.S. federal income tax purposes is a factual determination that must be made annually at the close of each
taxable year and, thus, is subject to significant uncertainty.</div> </div> </div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">

<div style="line-height: 1.25; font-family: Times New Roman">If we are treated as a PFIC for any taxable year, or portion thereof, that
is included in the holding period of a U.S. Holder, such U.S. Holder may be subject to certain adverse U.S. federal income tax consequences
and may be subject to additional reporting requirements. For a further discussion, see &#8220;<span style="font-style: italic">Certain
Material U.S. Federal Income Tax Considerations &#8212; PFIC Rules</span>.&#8221; U.S. Holders are strongly encouraged to consult their
own advisors regarding the potential application of these rules to the ownership of our ordinary shares, pre-funded warrants and/or our
ordinary warrants.</div> </div> </div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman">&#160;</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman">If a U.S.&#160;person is treated as
owning at least 10% of the shares of New Silexion, such person may be subject to adverse U.S.&#160;federal income tax consequences.</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">

<div style="text-indent: 36pt; line-height: 1.25">

<div style="line-height: 1.25; font-family: Times New Roman">If a U.S. Holder is treated as owning (directly, indirectly or constructively)
at least 10% of the value or voting power of our shares, such holder may be treated as a &#8220;United States shareholder&#8221; with
respect to each of New Silexion and our direct and indirect subsidiaries (the &#8220;<span style="font-weight: bold">New Silexion Group</span>&#8221;)
that is a &#8220;controlled foreign corporation,&#8221; (a &#8220;CFC&#8221;), for U.S. federal income tax purposes. A non-U.S. corporation
is considered a CFC if more than 50% of (1) the total combined voting power of all classes of stock of such corporation entitled to vote,
or (2) the total value of the stock of such corporation is owned, or is considered as owned by applying certain constructive ownership
rules, by United States shareholders on any day during the taxable year of such non-U.S. corporation. If the New Silexion Group includes
one or more non-U.S. subsidiaries, certain of our non-U.S. subsidiaries could be treated as CFCs regardless of whether we are treated
as a CFC.</div> </div> </div> </div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">

<div style="line-height: 1.25; font-family: Times New Roman">If we or any of our non-U.S. subsidiaries is a CFC, 10% &#8220;United States
shareholders&#8221; will be subject to adverse income inclusion and reporting requirements with respect to such CFC. No assurance can
be provided that we will assist holders in determining whether we or any of our non-U.S. subsidiaries is treated as a CFC or whether any
holder is treated as a United States shareholder with respect to any of such CFCs, or furnish to any holder information that may be necessary
to comply with reporting and tax payment obligations with respect to such CFCs.</div> </div> </div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: rgb(0, 0, 0); font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">41</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="line-height: 1.25; font-weight: bold; font-family: Times New Roman">&#160;</div>

<div style="line-height: 1.25; font-weight: bold; font-family: Times New Roman">General Risks</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman">&#160;</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman">The Company may be subject to securities
litigation, which is expensive and could divert management attention, including securities class action and derivative lawsuits which
could result in substantial costs.</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">Our share price may be volatile and, in the past, companies
that have experienced volatility in the market price of their stock or shares have been subject to securities litigation, including class
action litigation. The Company may be the target of this type of litigation in the future. Litigation of this type could result in substantial
costs and diversion of management&#8217;s attention and resources, which could have a material adverse effect on our business, financial
condition, and results of operations. Any adverse determination in litigation could also subject the Company to significant liabilities.</div>
</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">Securities class action lawsuits and derivative lawsuits
are often brought against public companies that have entered into merger or business combination agreements. Even if the lawsuits are
without merit, defending against these claims can result in substantial costs and divert management time and resources. An adverse judgment
could result in monetary damages, which could have a negative impact on our liquidity and financial condition. We cannot predict whether
any such lawsuits will be filed.</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman"> <br/> </div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">

<table cellspacing="0" cellpadding="0" border="0" id="zb1c1ddb706fc4fe6a0d2857524c52586" style="font: 10pt Times New Roman, Times, serif; color: #000000; width: 100%">
  <tr>
    <td style="width: 100%">
        <div>
        <div style="text-align: center; line-height: 1.25; font-weight: bold"><span id="TRANSACTIONS"><!--Anchor--></span>TRANSACTIONS RELATED
        TO OFFERING UNDER THIS PROSPECTUS</div> </div> </td> </tr>
  </table> </div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman"> <br/> </div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">

<div style="text-indent: 35.45pt; line-height: 1.25; font-family: Times New Roman, Times, serif">The New Silexion securities to be offered
by the Selling Securityholders under this prospectus include, in large part, New Silexion ordinary shares and New Silexion ordinary warrants
that were issued pursuant to a number of transactions completed in connection with the Closing of the Business Combination. We describe
those transactions below:</div>

<div style="line-height: 1.25"><br/> </div>

<div style="line-height: 1.25; font-family: Times New Roman, Times, serif; font-style: italic; font-weight: bold">January 2025 Warrant
Inducement Transaction</div>

<div style="line-height: 1.25"><br/> </div>

<div style="line-height: 1.25">

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">On January 29, 2025,
New Silexion entered into an inducement offer letter agreement (the &#8220;<span style="font-weight: bold">Inducement Letter</span>&#8221;)
with certain holders (each a &#8220;<span style="font-weight: bold">Holder</span>&#8221;) of certain of New Silexion&#8217;s existing
warrants to purchase up to 2,221,523 shares of New Silexion ordinary shares issued on January 17, 2025 with a five year term at an exercise
price of $1.35 per share (the &#8220;<span style="font-weight: bold">Existing Warrants</span>&#8221;).</div> </div>

<div style="line-height: 1.25">

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman, Times, serif">&#160;</div> </div>

<div style="line-height: 1.25">

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">Pursuant to the Inducement
Letter, the Holders agreed to exercise for cash their Existing Warrants to purchase an aggregate of 2,221,523 of New Silexion&#8217;s
ordinary shares at the exercise price of $1.35 per share in consideration of New Silexion&#8217;s agreement to issue new ordinary share
purchase warrants (the &#8220;<span style="font-weight: bold">New Warrants</span>&#8221;) to purchase up to an aggregate of 2,221,523
of New Silexion&#8217;s ordinary shares (the &#8220;<span style="font-weight: bold">New Warrant Shares</span>&#8221;), at an exercise
price of $1.50 per share. The Holders also paid New Silexion an additional $0.125 per New Warrant issued in the offering. New Silexion
received aggregate gross proceeds of approximately $3.3 million from the exercise of the Existing Warrants by the Holders, before deducting
placement agent fees and other offering expenses payable by New Silexion.</div> </div>

<div style="line-height: 1.25">

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman, Times, serif">&#160;</div> </div>

<div style="line-height: 1.25">

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">New Silexion engaged
H.C. Wainwright &amp; Co., LLC (the &#8220;<span style="font-weight: bold">Wainwright</span>&#8221;) to act as its exclusive placement
agent in connection with the transactions contemplated by the Inducement Letter. New Silexion&#160; also issued to Wainwright or its designees
warrants (the &#8220;<span style="font-weight: bold">Placement Agent Warrants</span>&#8221;) to purchase up to 155,507 ordinary shares
(representing 7.0% of the Existing Warrants being exercised), which have the same terms as the New Warrants except the Placement Agent
Warrants have an exercise price equal to $1.8438 per share (125% of the sum of the exercise price of the Existing Warrants and the additional
$0.125 paid per New Warrant). Similar to the New Warrants, the Placement Agent Warrants will be immediately exercisable from the date
of issuance until the twenty-four month anniversary of the effective date of the Resale Registration Statement (as defined below).</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">&#160;</div> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">The closing of the
transactions contemplated pursuant to the Inducement Letter occurred on January 30, 2025 (the &#8220;<span style="font-weight: bold">Closing
Date</span>&#8221;), subject to satisfaction of customary closing conditions. New Silexion also agreed to file this registration statement
(this &#8220;<span style="font-weight: bold">Resale Registration Statement</span>&#8221;) within thirty (30) calendar days of the date
of the Inducement Letter, and to use commercially reasonable efforts to have such Resale Registration Statement declared effective by
the SEC within sixty (60) calendar days following the date of the Inducement Letter (or within ninety (90) calendar days following the
date of the Inducement Letter in case of &#8220;full review&#8221; of the Resale Registration Statement by the SEC) and to keep the Resale
Registration Statement effective at all times until no holder of the New Warrants owns any New Warrants or New Warrant Shares. In the
Inducement Letter, New Silexion agreed not to issue any shares of ordinary shares or ordinary share equivalents or to file any other registration
statement with the SEC (in each case, subject to certain exceptions) until March 18, 2025. New Silexion also agreed not to effect or agree
to effect any Variable Rate Transaction (as defined in the Inducement Letter) until one (1) year after the Closing Date (subject to certain
exceptions).</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif"> <br/> </div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">

<table cellspacing="0" cellpadding="0" border="0" id="z84a8010a6bbe4eeb88a29d396695aa21" style="font: 10pt Times New Roman, Times, serif; color: #000000; width: 100%">
  <tr>
    <td style="width: 100%">
        <div>
        <div style="text-align: center; line-height: 1.25; font-family: Times New Roman,Times,serif; font-weight: bold">MARKET AND INDUSTRY <span id="DATA"><!--Anchor--></span>DATA</div>
        </div> </td> </tr>
  </table> </div>

<div style="text-align: center; line-height: 1.25; font-family: Times New Roman, Times, serif; font-weight: bold">&#160; <br/> </div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">Information contained in this prospectus
concerning the market and the industries in which New Silexion competes, including its market position, general expectations of market
opportunities and market size, is based on information from various third-party sources, publicly available information, various industry
publications, internal data and estimates, and assumptions made by New Silexion based on such sources. Internal data and estimates are
based upon information obtained from trade and business organizations and other contacts in the markets in which New Silexion operates
and New Silexion management&#8217;s understanding of industry conditions. This information and any estimates provided herein involve numerous
assumptions and limitations, and you are cautioned not to give undue weight to such information. Third-party sources generally state that
the information contained in such sources has been obtained from sources believed to be reliable. Although we believe that such information
is reliable, there can be no assurance as to the accuracy or completeness of such information. Industry and market data could be wrong
because of the method by which sources obtained their data and because information cannot always be verified with complete certainty due
to the limits on the availability and reliability of raw data, the voluntary nature of the data gathering process and other limitations
and uncertainties. Although we are responsible for all of the disclosure contained in this prospectus and we believe the third-party market
position, general expectations of market opportunity and market size data included in this prospectus are reliable, we have not independently
verified any third-party information and each publication speaks as of its original publication date (and not as of the date of this prospectus).
In addition, we do not know all of the assumptions regarding general economic conditions or growth that were used in preparing the forecasts
from the sources relied upon or cited herein.</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-family: Times New Roman,Times,serif; font-weight: normal; font-style: normal">42</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="text-align: justify; text-indent: 18pt; line-height: 1.25; font-family: Times New Roman, Times, serif">&#160; <br/> </div>
</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-align: center; line-height: 1.25; font-family: Times New Roman; font-weight: bold"><!--Anchor-->USE OF <span id="PROCEEDS"><!--Anchor--></span>PROCEEDS</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="line-height: 1.25; font-family: Times New Roman">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">All of the ordinary shares issuable upon
the exercise of the warrants offered by the Selling Securityholders pursuant to this prospectus will be sold by the Selling Securityholders
for their respective own accounts. We will not receive any of the proceeds from the resale of the ordinary shares issuable upon the exercise
of the warrants by the Selling Securityholders. However, we may receive up to up to an aggregate of approximately $3.6 million from the
exercise of the outstanding warrants, assuming the exercise in full of all such warrants for cash. There is no assurance that the holders
of the warrants will elect to exercise any or all of the warrants. Given the relative lack of liquidity in our ordinary shares, there
is no certainty that warrant holders will exercise their warrants and, accordingly, we may not receive any proceeds in relation to our
outstanding warrants. We believe that the likelihood that warrant holders determine to exercise their warrants, and therefore the amount
of cash proceeds that we would receive, is dependent upon the market price of our New Silexion ordinary shares. If the market price for
our ordinary shares is less than the exercise price of the warrants (on a per share basis), we believe that warrant holders will be very
unlikely to exercise any of their warrants, and accordingly, we will not receive any such proceeds. There is no assurance that the warrants
will be &#8220;in the money&#8221; prior to their expiration or that the warrant holders will exercise their warrants. As of February
11, 2025, the closing price of our ordinary shares was $1.38 per share.</div> </div>

<div style="line-height: 1.25; font-family: Times New Roman"> <br/> </div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">We expect to use the net proceeds received
from the exercise of the warrants, if any, for general corporate purposes, including working capital. Accordingly, we retain broad discretion
over the use of the proceeds from the exercise of the warrants. The precise amount and timing of the application of such proceeds will
depend upon our liquidity needs and the availability and cost of other capital over which we have little or no control. As of the date
hereof, we cannot specify with certainty the particular uses for the proceeds, if any, from the exercise of the warrants See &#8220;<span style="font-style: italic">Plan
of Distribution</span>&#8221; elsewhere in this prospectus for more information.</div>

<div style="margin-left: 69.65pt; line-height: 1.25; font-family: Times New Roman">&#8203;</div> </div>

<div style="text-align: center; line-height: 1.25; font-weight: bold; font-family: Times New Roman"><!--Anchor--></div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: rgb(0, 0, 0); font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">43</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div>

<div style="text-align: center; line-height: 1.25; font-weight: bold; font-family: Times New Roman"><br/> </div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-align: center; line-height: 1.25; font-family: Times New Roman, Times, serif; font-weight: bold">DETERMINATION OF OFFERING
<span id="PRICE"><!--Anchor--></span>PRICE</div>

<div style="text-align: center; line-height: 1.25; font-family: Times New Roman, Times, serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">We cannot currently determine the price
or prices at which ordinary shares issuable upon the exercise of the warrants may be sold by the Selling Securityholders under this prospectus.</div>
</div> <br/> </div>

<div style="text-align: center; line-height: 1.25; font-weight: bold; font-family: Times New Roman"><!--Anchor--></div>

<div style="text-align: center; line-height: 1.25; font-weight: bold; font-family: Times New Roman"><!--Anchor-->MARKET INFORMATION FOR
SECURITIES AND DIVIDEND <span id="POLICY"><!--Anchor--></span>POLICY</div>

<div style="text-align: center; line-height: 1.25; font-weight: bold; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold; font-family: Times New Roman">Market Information</div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="line-height: 1.25">

<div style="text-indent: 25.2pt; margin-right: 17.4pt; margin-left: 8.15pt; line-height: 1.25; font-family: Times New Roman">

<div style="text-indent: 25.2pt; line-height: 1.25; font-family: Times New Roman, Times, serif">Our ordinary shares and warrants are currently
listed on Nasdaq under the symbols &#8220;SLXN&#8221; and &#8220;SLXNW,&#8221; respectively. On December 31, 2024, there were 26 holders
of record of the ordinary shares and three holders of record of our warrants.</div> </div> </div> </div> </div>

<div style="text-align: justify; text-indent: 18pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold; font-family: Times New Roman">Dividend Policy</div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">We have never declared or paid any dividends on ordinary
shares. We anticipate that we will retain all of our future earnings, if any, for use in the operation and expansion of our business and
do not anticipate paying cash dividends in the foreseeable future. Any decision to declare and pay dividends in the future will depend
on, among other things, the consent of our lender(s), our results of operations, cash requirements, financial condition, contractual restrictions,
funds lawfully available therefor and other factors that our board of directors may deem relevant.</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: center; line-height: 1.25; font-weight: bold; font-family: Times New Roman"><!--Anchor-->UNAUDITED PRO FORMA CONDENSED
COMBINED FINANCIAL <span id="INFORMATION"><!--Anchor--></span>INFORMATION</div>

<div style="line-height: 1.25; font-weight: bold; font-family: Times New Roman">&#160;</div>

<div style="line-height: 1.25; font-weight: bold; font-family: Times New Roman">Introduction</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">The registrant, Silexion Therapeutics Corp (formerly known
as Biomotion Sciences), a Cayman Islands exempted company (&#8220;<span style="font-weight: bold">New Silexion</span>&#8221;) is providing
the following unaudited pro forma condensed combined financial information to aid you in your analysis of the financial aspects of the
business combination and related transactions (collectively, the &#8220;<span style="font-weight: bold">Transactions</span>&#8221;) involving
Moringa Acquisition Corp (&#8220;<span style="font-weight: bold">Moringa</span>&#8221;) and Silexion Therapeutics Ltd. (&#8220;<span style="font-weight: bold">Silexion</span>&#8221;).
The following unaudited pro forma condensed combined financial information presents the combination of the financial information of Moringa
and Silexion, as adjusted to give effect to the Transactions. Capitalized terms included in this section containing unaudited pro forma
condensed combined financial information and not otherwise defined in this section have the same meaning as is provided elsewhere in this
prospectus.</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="line-height: 1.25; font-weight: bold; font-family: Times New Roman">Parties to the Transaction</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">Moringa is a Cayman Islands exempted company that was
originally a blank check company that was formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase,
recapitalization, reorganization or similar business combination with one or more businesses. As of June 30, 2024 and December 31, 2023,
there was approximately $5.924 million and $5.698 million, respectively, held in Moringa&#8217;s trust account, which was held for the
benefit of Moringa&#8217;s public shareholders (the &#8220;<span style="font-weight: bold">Trust Account</span>&#8221;). The Trust Account
was liquidated upon the completion of the Transactions, as described below.</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">Silexion, an Israeli company that was known previously
as Silenseed Ltd., is a pioneering biopharma developmental-stage company dedicated to the development of innovative treatments for pancreatic
cancer.</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">New Silexion is a newly formed entity that was formed
for the purpose of effecting the Transactions, and now serves as a publicly-traded holding company of its subsidiaries &#8212; including
Moringa and Silexion &#8212; after the Closing of the Transactions.</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: rgb(0, 0, 0); font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">44</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="line-height: 1.25; font-weight: bold; font-family: Times New Roman">&#160;</div>

<div style="line-height: 1.25; font-weight: bold; font-family: Times New Roman">Description of the Transactions</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">On August 15, 2024, the parties completed the previously-reported
Transactions pursuant to that certain amended and restated business combination agreement, dated April 3, 3024 (the &#8220;<span style="font-weight: bold">Business
Combination Agreement</span>&#8221;) by and among New Silexion (then known as Biomotion Sciences), August M.S. Ltd., an Israeli company
and a wholly owned subsidiary of New Silexion (&#8220;<span style="font-weight: bold">Merger Sub 1</span>&#8221;), Moringa Acquisition
Merger Sub Corp, a Cayman Islands exempted company and a wholly owned subsidiary of New Silexion (&#8220;<span style="font-weight: bold">Merger
Sub 2</span>&#8221;), Moringa and Silexion.</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="line-height: 1.25; font-family: Times New Roman">Pursuant to the Transactions, Merger Sub 2 merged with and into Moringa,
with Moringa continuing as the surviving company of such merger and a wholly-owned subsidiary of New Silexion (the &#8220;<span style="font-weight: bold">SPAC
Merger</span>&#8221;), and Merger Sub 1 merged with and into Silexion, with Silexion continuing as the surviving company of such merger
and a wholly-owned subsidiary of New Silexion (the &#8220;<span style="font-weight: bold">Acquisition Merger</span>&#8221;). Upon the
effectiveness of the SPAC Merger, each outstanding Moringa Class A ordinary share and the sole outstanding Moringa Class B ordinary share
converted into an ordinary share of New Silexion on a one-for-one basis. Each outstanding warrant to purchase one Moringa Class A ordinary
share converted into a warrant to purchase one New Silexion ordinary share, at the same exercise price. Upon the effectiveness of the
Acquisition Merger, each outstanding ordinary share and preferred share of Silexion converted into such number of ordinary shares of New
Silexion as is equal to the quotient obtained by dividing (x) the quotient obtained by dividing (1) $62,500,000 by (2) the number of fully
diluted Silexion equity securities, by (y) $90.00 (the &#8220;<span style="font-weight: bold">Silexion Equity Exchange Ratio</span>&#8221;).
Each outstanding Silexion warrant and Silexion option to purchase one Silexion share, and Silexion restricted share unit (RSU) that may
be potentially settled for one Silexion share, became exercisable for, or became subject to settlement for (as applicable), such number
of New Silexion ordinary shares as are equal to the Silexion Equity Exchange Ratio. The exercise price per New Silexion ordinary share
of each such converted Silexion option and Silexion warrant were adjusted based on dividing the existing per share exercise price by the
Silexion Equity Exchange Ratio. The terms of vesting, exercise and/or settlement, as applicable, of such converted options, warrants and
RSUs remain the same following such conversion, except that the vesting of each Silexion option accelerated immediately prior to the Acquisition
Merger, such that the New Silexion option into which it has been converted was fully vested, and all Silexion warrants were exercised
(on a cashless basis) immediately prior to the Acquisition Merger.</div> </div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">Immediately prior to the Closing, seven directors were
appointed to New Silexion&#8217;s board of directors, of whom five were designated by Silexion and two were designated by Moringa&#8217;s
sponsor (Moringa Sponsor, LP, a Cayman Islands exempted limited partnership and/or its wholly-owned subsidiary, Moringa Sponsor US L.P.,
a Delaware limited partnership) (collectively, the &#8220;<span style="font-weight: bold">Moringa Sponsor</span>&#8221;).</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">In connection with the Closing, the ordinary shares and
warrants of New Silexion were approved for listing on the Nasdaq Global Market and began trading under the symbols &#8220;SLXN&#8221;
and &#8220;SLXNW&#8221;, respectively.</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">The Business Combination was accounted for as a reverse
recapitalization in accordance with US GAAP. Under this method of accounting, Silexion was treated as the accounting acquirer and Moringa
was treated as the &#8220;acquired&#8221; company for financial reporting purposes. Silexion was determined to be the accounting acquirer
based on evaluation of the following facts and circumstances:</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z3a6b7979fa224072bb1d168cfd83610a" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">Silexion&#8217;s shareholders holding approximately 61.55% of the outstanding
        voting interests in New Silexion upon the Closing of the Transactions;</div> </td> </tr>
  </table>

<div style="margin-left: 18pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z55f0ce87b9a04ea0a677c30fc17ce10e" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">Silexion&#8217;s senior management comprise the senior management of New
        Silexion;</div> </td> </tr>
  </table>

<div style="margin-left: 18pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z9956ef0cd16a4b3fba29e158340b135d" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">the directors nominated by Silexion constitute the majority of the board
        of directors of New Silexion (five out of seven of the initial directors); and</div> </td> </tr>
  </table>

<div style="margin-left: 18pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: rgb(0, 0, 0); font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">45</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<table cellspacing="0" cellpadding="0" id="z67c4a48f0a7d468d8cf1bee18d508a16" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">Silexion&#8217;s operations comprise the ongoing operations of New Silexion.</div>
        </td> </tr>
  </table>

<div style="margin-left: 18pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">Under the reverse recapitalization accounting method,
the Business Combination is deemed to be the equivalent of a capital transaction in which Silexion has issued shares for the net assets
of Moringa. The net assets of Moringa are stated at fair value, with no goodwill or other intangible assets recorded. Operations prior
to the Business Combination are of Silexion.</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="line-height: 1.25; font-family: Times New Roman; text-indent: 36pt">The unaudited pro forma condensed combined financial statements
were prepared in accordance with Article 11 of SEC Regulation S-X, as amended by the final rule, SEC Release No. 33-10786 &#8220;Amendments
to Financial Disclosures About Acquired and Disposed Businesses&#8221;. The adjustments presented in the unaudited pro forma condensed
combined financial statements (collectively, the &#8220;<span style="font-weight: bold">Pro Forma Adjustments</span>&#8221;) have been
identified and presented to provide relevant information necessary for an understanding of New Silexion upon consummation of the Business
Combination and related transactions.</div>

<div style="line-height: 1.25"><span style="font-family: Times New Roman"><br/> </span> </div>

<div style="line-height: 1.25; font-family: Times New Roman; text-indent: 36pt">

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">The unaudited pro forma combined statements of operations for
the nine-months period ended September 30, 2024 and for the year ended December 31, 2023 combine the historical statements of operations
of Moringa for the year ended December 31, 2023 (audited), and for the period from January&#160;1 to August 14, 2024 (unaudited), and
the updated financial statements of New Silexion (formerly: Silexion) that show the effects of the reverse share split and reverse recapitalization
for the year ended December 31, 2023 (audited), and for the nine-months period ended September 30, 2024 (unaudited), subject to the Pro
Forma Adjustments, giving effect to the Business Combination as if it had been consummated on January 1, 2023.</div> </div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="line-height: 1.25; font-weight: bold; font-family: Times New Roman">Unaudited Condensed Combined Pro Forma Financial Statements</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="line-height: 1.25; font-family: Times New Roman">The unaudited pro forma condensed combined financial statements have been
derived from, are qualified in their entirety by, and should be read in conjunction with:</div> </div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z220f6b1956664f48835c740372ea7b3d" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">the accompanying notes to the unaudited pro forma condensed combined financial
        statements;</div> </td> </tr>
  </table>

<div style="margin-left: 18pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<table cellspacing="0" cellpadding="0" id="zf7787c8647b548a2937d0b60d5c7c162" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">the historical unaudited financial statements of Moringa as of and for the
        six-months period ended June 30, 2024 and the related notes included elsewhere in this prospectus;</div> </td> </tr>
  </table>

<div style="margin-left: 18pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z330aaa74b86a45aebf95de09dcc33a03" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">
        <div style="line-height: 1.25; font-family: Times New Roman">the historical unaudited financial statements of New Silexion as of and for
        the nine-months period ended September 30, 2024 and the related notes included elsewhere in this prospectus;</div> </div> </td> </tr>
  </table>

<div style="margin-left: 18pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z2fb9e50e6feb4e999804608db9bd4f93" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">the historical audited financial statements of Moringa as of and for the
        year ended December 31, 2023 and the related notes included elsewhere in this prospectus;</div> </td> </tr>
  </table>

<div style="margin-left: 18pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<table cellspacing="0" cellpadding="0" id="zfb24564a26b24d2db6cc9757ff87f0be" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">
        <div style="line-height: 1.25; font-family: Times New Roman">the historical audited financial statements of New Silexion as of and for
        the year ended December 31, 2023 and the related notes included elsewhere in this prospectus;</div> </div> </td> </tr>
  </table>

<div style="margin-left: 18pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="margin-left: 18pt; line-height: 1.25; font-family: Times New Roman"> </div>

<table cellspacing="0" cellpadding="0" id="z9d40d1803fcb4fd4af0d164dbdae8ca9" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">
        <div style="line-height: 1.25; font-family: Times New Roman">
        <div style="line-height: 1.25; font-family: Times New Roman, Times, serif">the sections entitled &#8220;Management&#8217;s Discussion
        and Analysis of Financial Condition and Results of Operations&#8221; included in Moringa&#8217;s annual report on Form 10-K for the year
        ended December 31, 2023 and quarterly report on Form 10-Q for the quarter ended June 30, 2024, filed with the SEC on April 1, 2024 and
        August 13, 2024, respectively (the &#8220;<span style="font-weight: bold">Moringa 2023 Form 10-K</span>&#8221; and &#8220;<span style="font-weight: bold">Moringa
        Q2 Form 10-Q</span>,&#8221; respectively), and &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of
        Operations&#8221; included in this prospectus;</div> </div> </div> </td> </tr>
  </table>

<div style="margin-left: 18pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z44ae154d5bb1496ea51ab5c563f8ca0f" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">
        <div style="line-height: 1.25; font-family: Times New Roman">the other financial information relating to Moringa and New Silexion included
        in this prospectus; and</div> </div> </td> </tr>
  </table>

<div style="margin-left: 18pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<table cellspacing="0" cellpadding="0" id="zfc3711ad22b54eb8b3e28c64d88f2564" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">factors detailed under the section entitled &#8220;<span style="font-style: italic">Risk
        Factors</span>&#8221; in this prospectus.</div> </td> </tr>
  </table>

<div style="margin-left: 18pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">The unaudited pro forma condensed combined financial information
is for illustrative purposes only and is not necessarily indicative of what the actual results of operations and financial position would
have been had the Transactions included in the Pro Forma Adjustments taken place on the dates indicated, nor are they indicative of the
future results of operations or financial position of New Silexion. The Pro Forma Adjustments are based on currently available information
and certain assumptions and estimates that New Silexion believes are reasonable under the circumstances. Management performed a comprehensive
review of the accounting policies between the two entities. Management is not aware of any significant accounting policy differences and
has therefore not made any adjustments to the pro forma condensed combined financial information related to any potential differences.</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: rgb(0, 0, 0); font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">46</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>
<!--PROfilePageNumberReset%Num%49%%%-->

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: center; line-height: 1.25; font-weight: bold; font-family: Times New Roman,Times,serif"><span style="font-family: Times New Roman">SILEXION
THERAPEUTICS CORP <br/> </span>

<div style="margin-right: 126.35pt; margin-left: 127.2pt; line-height: 1.25; font-family: Times New Roman; font-weight: bold">UNAUDITED
PRO FORMA CONDENSED COMBINED STATEMENT OF OPERATIONS </div>

<div style="margin-right: 126.35pt; margin-left: 127.2pt; line-height: 1.25; font-family: Times New Roman; font-weight: bold">FOR NINE-MONTHS
PRIOD ENDED SEPTEMBER 30, 2024</div> <span style="font-family: Times New Roman"> (in thousands, except share and per share amounts)</span></div>

<div style="line-height: 1.25; font-weight: bold; font-family: Times New Roman,Times,serif"><span style="font-family: Times New Roman">
<br/> </span></div>

<div style="line-height: 1.25; font-weight: bold; font-family: Times New Roman,Times,serif"><br/>

<table cellspacing="0" cellpadding="0" id="z2663ce1c8bba4fcb8eefd53d5a959bba" class="cfttable" style="font: 10pt Times New Roman, Times, serif; text-align: left; color: #000000; width: 100%">
  <tr>
    <td style="vertical-align: bottom; vertical-align: top; padding-bottom: 2px; width: 39%">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px; width: 1%">&#160;</td>
    <td colspan="2" style="border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; text-align: center">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif; font-weight: bold">Historical</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px; width: 1%">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px; width: 1%">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom">
        <div style="text-align: center; line-height: 1.25; font-weight: bold">Historical</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px; width: 1%">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px; width: 1%">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px; width: 4%">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px; width: 1%">&#160;</td>
    <td colspan="7" style="border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; text-align: center">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif; font-weight: bold">Actual Redemption</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px; width: 1%">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: top; padding-bottom: 2px; width: 39%">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px; width: 1%">&#160;</td>
    <td colspan="2" style="border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; text-align: center">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif; font-weight: bold">Moringa Acquisition</div>
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif; font-weight: bold">Corp (Period between January 1 and August
        14, 2024)</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px; width: 1%">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px; width: 1%">&#160;</td>
    <td colspan="2" style="border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; text-align: center">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif; font-weight: bold">New Silexion</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px; width: 1%">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px; width: 1%">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px; width: 4%">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px; width: 1%">&#160;</td>
    <td colspan="2" style="border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; text-align: center">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif; font-weight: bold">Business Combination</div>
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif; font-weight: bold">Adjustments</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px; width: 1%">&#160;</td>
    <td style="vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px; width: 4%">
        <div style="text-align: center; line-height: 1.25">&#160;</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px; width: 1%">&#160;</td>
    <td colspan="2" style="border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; text-align: center">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif; font-weight: bold">Pro Forma Statement of Operations</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px; width: 1%">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: top; background-color: rgb(204, 238, 255); width: 39%">
        <div style="line-height: 1.25">Research and development expenses, net</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25">$</div> </td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9.99%">
        <div style="line-height: 1.25">&#8212;</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25">$</div> </td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9.99%">
        <div style="line-height: 1.25">4,944</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 4%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif; text-align: center">A</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25">$</div> </td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9.99%">
        <div style="line-height: 1.25">(2,424</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25">)</div> </td>
    <td style="vertical-align: bottom; vertical-align: top; background-color: rgb(204, 238, 255); width: 4%">
        <div style="line-height: 1.25">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25">$</div> </td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9.99%">
        <div style="line-height: 1.25">2,520</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: top; width: 39%">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9.99%">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9.99%">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; text-align: center; vertical-align: bottom; width: 4%">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9.99%">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">&#160;</td>
    <td style="vertical-align: bottom; vertical-align: top; width: 4%">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9.99%">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">&#160;</td> </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: top; background-color: rgb(204, 238, 255); width: 39%">
        <div style="line-height: 1.25">General and administrative expenses</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9.99%">
        <div style="line-height: 1.25">551</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9.99%">
        <div style="line-height: 1.25">5,727</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 4%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif; text-align: center">A</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9.99%">
        <div style="line-height: 1.25">(3,438</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25">)</div> </td>
    <td style="vertical-align: bottom; vertical-align: top; background-color: rgb(204, 238, 255); width: 4%">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9.99%">
        <div style="line-height: 1.25">2,449</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: top; width: 39%">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9.99%">
        <div style="line-height: 1.25">&#8212;</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9.99%">
        <div style="line-height: 1.25">&#8212;</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 4%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif; text-align: center">B</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9.99%">
        <div style="line-height: 1.25">75</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">&#160;</td>
    <td style="vertical-align: bottom; vertical-align: top; width: 4%">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9.99%">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">&#160;</td> </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: top; background-color: rgb(204, 238, 255); width: 39%; padding-bottom: 2px">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9.99%">
        <div style="line-height: 1.25">&#8212;</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; padding-bottom: 2px">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9.99%">
        <div style="line-height: 1.25">&#8212;</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; padding-bottom: 2px">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 4%; padding-bottom: 2px">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif; text-align: center">C</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9.99%">
        <div style="line-height: 1.25">(466</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; padding-bottom: 2px">
        <div style="line-height: 1.25">)</div> </td>
    <td style="vertical-align: bottom; vertical-align: top; background-color: rgb(204, 238, 255); width: 4%; padding-bottom: 2px">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; padding-bottom: 2px">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9.99%; padding-bottom: 2px">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; padding-bottom: 2px">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: top; width: 39%">
        <div style="line-height: 1.25">OPERATING LOSS</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9.99%">
        <div style="line-height: 1.25">551</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9.99%">
        <div style="line-height: 1.25">10,671</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; text-align: center; vertical-align: bottom; width: 4%">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9.99%">
        <div style="line-height: 1.25">(6,253</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25">)</div> </td>
    <td style="vertical-align: bottom; vertical-align: top; width: 4%">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9.99%">
        <div style="line-height: 1.25">4,969</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">&#160;</td> </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: top; background-color: rgb(204, 238, 255); width: 39%">
        <div style="line-height: 1.25">Financial expenses (income), net</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9.99%">
        <div style="line-height: 1.25">(155</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25">)</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9.99%">
        <div style="line-height: 1.25">4,092</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 4%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif; text-align: center">D</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9.99%">
        <div style="line-height: 1.25">(134</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25">)</div> </td>
    <td style="vertical-align: bottom; vertical-align: top; background-color: rgb(204, 238, 255); width: 4%">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9.99%">
        <div style="line-height: 1.25">(740</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25">)</div> </td> </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: top; width: 39%">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9.99%">
        <div style="line-height: 1.25">&#8212;</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9.99%">
        <div style="line-height: 1.25">&#8212;</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 4%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif; text-align: center">E</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9.99%">
        <div style="line-height: 1.25">(4,783</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25">)</div> </td>
    <td style="vertical-align: bottom; vertical-align: top; width: 4%">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9.99%">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">&#160;</td> </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: top; background-color: rgb(204, 238, 255); width: 39%">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9.99%">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9.99%">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 4%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif; text-align: center">F</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9.99%">
        <div style="line-height: 1.25">123</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%">&#160;</td>
    <td style="vertical-align: bottom; vertical-align: top; background-color: rgb(204, 238, 255); width: 4%">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9.99%">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: top; width: 39%">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9.99%">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9.99%">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 4%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif; text-align: center">G</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9.99%">
        <div style="line-height: 1.25">(337</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25">)</div> </td>
    <td style="vertical-align: bottom; vertical-align: top; width: 4%">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9.99%">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">&#160;</td> </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: top; width: 39%; padding-bottom: 2px; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9.99%; padding-bottom: 2px; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9.99%; padding-bottom: 2px; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 4%; padding-bottom: 2px; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif; text-align: center">H</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; text-align: right; width: 9.99%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25">454</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align: bottom; vertical-align: top; width: 4%; padding-bottom: 2px; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9.99%; padding-bottom: 2px; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255)">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: top; width: 39%">
        <div style="line-height: 1.25">Loss before income tax</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9.99%">
        <div style="line-height: 1.25">396</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9.99%">
        <div style="line-height: 1.25">14,763</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; text-align: center; vertical-align: bottom; width: 4%">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9.99%">
        <div style="line-height: 1.25">(10,930</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25">)</div> </td>
    <td style="vertical-align: bottom; vertical-align: top; width: 4%">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9.99%">
        <div style="line-height: 1.25">4,229</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">&#160;</td> </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: top; width: 39%; padding-bottom: 2px; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25">Tax on Income</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; text-align: right; width: 9.99%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25">&#8212;</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; text-align: right; width: 9.99%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25">9</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; text-align: center; vertical-align: bottom; width: 4%; padding-bottom: 2px; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; text-align: right; width: 9.99%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25">&#8212;</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align: bottom; vertical-align: top; width: 4%; padding-bottom: 2px; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9.99%; padding-bottom: 2px; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25">9</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255)">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: top; width: 39%; padding-bottom: 4px">
        <div style="line-height: 1.25; font-weight: bold">LOSS FOR THE PERIOD</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 4px">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 4px double; vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25">$</div> </td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 4px double; vertical-align: bottom; text-align: right; width: 9.99%">
        <div style="line-height: 1.25">396</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 4px">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 4px">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 4px double; vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25">$</div> </td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 4px double; vertical-align: bottom; text-align: right; width: 9.99%">
        <div style="line-height: 1.25">14,772</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 4px">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 4px">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; text-align: center; vertical-align: bottom; width: 4%; padding-bottom: 4px">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 4px">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 4px double; vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25">$</div> </td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 4px double; vertical-align: bottom; text-align: right; width: 9.99%">
        <div style="line-height: 1.25">(10,930</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 4px">
        <div style="line-height: 1.25">)</div> </td>
    <td style="vertical-align: bottom; vertical-align: top; width: 4%; padding-bottom: 4px">
        <div style="line-height: 1.25">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 4px">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 4px">
        <div style="line-height: 1.25">$</div> </td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9.99%; padding-bottom: 4px">
        <div style="line-height: 1.25">4,238</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 4px">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: top; width: 39%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9.99%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9.99%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; text-align: center; vertical-align: bottom; width: 4%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9.99%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align: bottom; vertical-align: top; width: 4%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9.99%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: top; width: 39%">
        <div style="line-height: 1.25">Attributable to:</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9.99%">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9.99%">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; text-align: center; vertical-align: bottom; width: 4%">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9.99%">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">&#160;</td>
    <td style="vertical-align: bottom; vertical-align: top; width: 4%">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9.99%">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">&#160;</td> </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: top; width: 39%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25">Equity holders of the Company</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9.99%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25">&#8212;</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9.99%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25">14,696</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 4%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif; text-align: center">I</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9.99%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25">76</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align: bottom; vertical-align: top; width: 4%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9.99%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25">4,238</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: top; width: 39%">
        <div style="line-height: 1.25">Non-controlling interests</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9.99%">
        <div style="line-height: 1.25">&#8212;</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9.99%">
        <div style="line-height: 1.25">76</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 4%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif; text-align: center">I</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9.99%">
        <div style="line-height: 1.25">(76</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25">)</div> </td>
    <td style="vertical-align: bottom; vertical-align: top; width: 4%">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9.99%">
        <div style="line-height: 1.25">&#8212;</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">&#160;</td> </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: top; width: 39%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9.99%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9.99%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; text-align: center; vertical-align: bottom; width: 4%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9.99%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align: bottom; vertical-align: top; width: 4%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9.99%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: top; width: 39%">
        <div style="line-height: 1.25">PROFIT (LOSS) PER SHARE, BASIC AND DILUTED</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9.99%">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9.99%">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; text-align: center; vertical-align: bottom; width: 4%">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9.99%">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">&#160;</td>
    <td style="vertical-align: bottom; vertical-align: top; width: 4%">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9.99%">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">&#160;</td> </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: top; width: 39%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25">Ordinary share subject to possible redemption</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25">$</div> </td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9.99%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25">0.39</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25">$</div> </td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9.99%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25">&#8212;</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; text-align: center; vertical-align: bottom; width: 4%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25">$</div> </td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9.99%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25">(0.39</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25">)</div> </td>
    <td style="vertical-align: bottom; vertical-align: top; width: 4%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25">$</div> </td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9.99%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25">&#8212;</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: top; width: 39%">
        <div style="line-height: 1.25">Non-redeemable ordinary shares</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25">$</div> </td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9.99%">
        <div style="line-height: 1.25">(0.18</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25">)</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25">$</div> </td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9.99%">
        <div style="line-height: 1.25">(50.43</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25">)</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; text-align: center; vertical-align: bottom; width: 4%">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25">$</div> </td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9.99%">
        <div style="line-height: 1.25">46.85</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">&#160;</td>
    <td style="vertical-align: bottom; vertical-align: top; width: 4%">
        <div style="line-height: 1.25">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25">$</div> </td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9.99%">
        <div style="line-height: 1.25">(3.76</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25">)</div> </td> </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: top; width: 39%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25">WEIGHTED AVERAGE NUMBER OF SHARES OUTSTANDING USED IN</div>
        <div style="line-height: 1.25">COMPUTATION OF BASIC AND DILUTED LOSS PER SHARE</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9.99%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9.99%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; text-align: center; vertical-align: bottom; width: 4%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9.99%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align: bottom; vertical-align: top; width: 4%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9.99%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: top; width: 39%">
        <div style="line-height: 1.25">Ordinary shares subject to possible redemption</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9.99%">
        <div style="line-height: 1.25">87,722</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9.99%">
        <div style="line-height: 1.25">&#8212;</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; text-align: center; vertical-align: bottom; width: 4%">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9.99%">
        <div style="line-height: 1.25">(87,722</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25">)</div> </td>
    <td style="vertical-align: bottom; vertical-align: top; width: 4%">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9.99%">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">&#160;</td> </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: top; width: 39%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25">Non-redeemable ordinary shares</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9.99%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25">3,355,000</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9.99%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25">291,407</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; text-align: center; vertical-align: bottom; width: 4%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9.99%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25">(2,519,042</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25">)</div> </td>
    <td style="vertical-align: bottom; vertical-align: top; width: 4%; background-color: rgb(204, 238, 255)">
        <div style="text-align: center; line-height: 1.25">J</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9.99%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25">1,127,365</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
        </tr>
  </table> </div>

<div style="text-align: center; line-height: 1.25; font-weight: bold; font-family: Times New Roman">&#160;</div>

<div style="line-height: 1.25; font-weight: 400; font-family: Times New Roman,Times,serif"> </div>

<div style="text-align: center; line-height: 1.25; font-family: Times New Roman">See accompanying notes to the unaudited pro forma condensed
combined financial information.</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: rgb(0, 0, 0); font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">47</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="text-align: center; line-height: 1.25"><span style="font-family: Times New Roman"><br/> </span> </div>

<div style="text-align: center; line-height: 1.25; font-weight: bold; font-family: Times New Roman">SILEXION THERAPEUTICS CORP<br/> UNAUDITED
PRO FORMA CONDENSED COMBINED STATEMENT OF OPERATIONS<br/> FOR THE YEAR ENDED DECEMBER 31, 2023<br/> (in thousands, except share and
per share amounts)</div>

<div style="line-height: 1.25; font-weight: bold; font-family: Times New Roman"> </div>

<div style="line-height: 1.25; font-weight: 400; font-family: Times New Roman,Times,serif">

<div> <br/>

<table cellspacing="0" cellpadding="0" border="0" id="z7fa5b0e9e4bc49f5a41a44c3e9a6ebad" class="cfttable" style="font: 10pt Times New Roman, Times, serif; text-align: left; color: #000000; width: 100%">
  <tr>
    <td style="vertical-align: bottom; vertical-align: top; padding-bottom: 2px; width: 36%">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px; width: 1%">&#160;</td>
    <td colspan="2" style="border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; text-align: center">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif; font-weight: bold">Moringa Acquisition</div>
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif; font-weight: bold">Corp</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px; width: 1%">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px; width: 1%">&#160;</td>
    <td colspan="2" style="border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; text-align: center">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif; font-weight: bold">New Silexion</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px; width: 1%">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px; width: 1%">&#160;</td>
    <td style="vertical-align: bottom; vertical-align: bottom; width: 4%">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px; width: 1%">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px; width: 1%">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px; width: 1%">&#160;</td>
    <td colspan="2" style="border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; text-align: center">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif; font-weight: bold">Business Combination</div>
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif; font-weight: bold">Adjustments</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px; width: 1%">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px; width: 4%">&#160;</td>
    <td style="vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px; width: 1%">
        <div style="text-align: center; line-height: 1.25">&#160;</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px; width: 1%">&#160;</td>
    <td colspan="2" style="border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; text-align: center">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif; font-weight: bold">Pro Forma Statement</div>
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif; font-weight: bold">of Operations</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px; width: 1%">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: top; background-color: rgb(204, 238, 255); width: 36%">
        <div style="line-height: 1.25">Research and development expenses, net</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25">$</div> </td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 10%">
        <div style="line-height: 1.25">&#8212;</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25">$</div> </td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 10%">
        <div style="line-height: 1.25">3,708</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); text-align: center; vertical-align: bottom; width: 4%">A</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%"><br/>
        </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 10%">
        <div style="line-height: 1.25">$</div> </td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 1%">
        <div style="line-height: 1.25">2,424</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 4%">&#160;</td>
    <td style="vertical-align: bottom; vertical-align: bottom; background-color: rgb(204, 238, 255); width: 1%">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25">$</div> </td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 10%">
        <div style="line-height: 1.25">6,132</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: top; width: 36%">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 10%">
        <div style="line-height: 1.25">&#8212;</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 10%">
        <div style="line-height: 1.25">&#8212;</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; white-space: nowrap; text-align: center; vertical-align: bottom; width: 4%">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%"><br/> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 10%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 1%">
        <div style="line-height: 1.25">-</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 4%">&#160;</td>
    <td style="vertical-align: bottom; vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 10%">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">&#160;</td> </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: top; background-color: rgb(204, 238, 255); width: 36%">
        <div style="line-height: 1.25">General and administrative expenses</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 10%">
        <div style="line-height: 1.25">1,122</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 10%">
        <div style="line-height: 1.25">973</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); text-align: center; vertical-align: bottom; width: 4%">A</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%"><br/>
        </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 10%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 1%">
        <div style="line-height: 1.25">3,438</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 4%">&#160;</td>
    <td style="vertical-align: bottom; vertical-align: bottom; background-color: rgb(204, 238, 255); width: 1%">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 10%">
        <div style="line-height: 1.25">6,119</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: top; width: 36%">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 10%">
        <div style="line-height: 1.25">&#8212;</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 10%">
        <div style="line-height: 1.25">&#8212;</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; white-space: nowrap; text-align: center; vertical-align: bottom; width: 4%">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%"><br/> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 10%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 1%">
        <div style="line-height: 1.25">-</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 4%">&#160;</td>
    <td style="vertical-align: bottom; vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 10%">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">&#160;</td> </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: top; background-color: rgb(204, 238, 255); width: 36%">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 10%">
        <div style="line-height: 1.25">&#8212;</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 10%">
        <div style="line-height: 1.25">&#8212;</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); text-align: center; vertical-align: bottom; width: 4%">B</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%"><br/>
        </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 10%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 1%">
        <div style="line-height: 1.25">120</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 4%">&#160;</td>
    <td style="vertical-align: bottom; vertical-align: bottom; background-color: rgb(204, 238, 255); width: 1%">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 10%">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: top; width: 36%">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 10%">
        <div style="line-height: 1.25">&#8212;</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 10%">
        <div style="line-height: 1.25">&#8212;</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; white-space: nowrap; text-align: center; vertical-align: bottom; width: 4%">C</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%"><br/> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 10%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 1%">
        <div style="line-height: 1.25">466</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 4%">&#160;</td>
    <td style="vertical-align: bottom; vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 10%">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">&#160;</td> </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: top; background-color: rgb(204, 238, 255); width: 36%; padding-bottom: 2px">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 10%">
        <div style="line-height: 1.25">&#8212;</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; padding-bottom: 2px">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 10%">
        <div style="line-height: 1.25; font-style: italic">&#8212;</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; padding-bottom: 2px">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); text-align: center; vertical-align: bottom; width: 4%; padding-bottom: 2px">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; padding-bottom: 2px"><br/>
        </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; padding-bottom: 2px">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 10%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 1%">
        <div style="line-height: 1.25">-</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; padding-bottom: 2px">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; padding-bottom: 2px; width: 4%">&#160;</td>
    <td style="vertical-align: bottom; vertical-align: bottom; background-color: rgb(204, 238, 255); width: 1%; padding-bottom: 2px">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 10%">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; padding-bottom: 2px">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: top; width: 36%">
        <div style="line-height: 1.25">OPERATING LOSS</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 10%">
        <div style="line-height: 1.25">1,122</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 10%">
        <div style="line-height: 1.25">4,681</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; white-space: nowrap; text-align: center; vertical-align: bottom; width: 4%">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%"><br/> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 10%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 1%">
        <div style="line-height: 1.25">6,448</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 4%">&#160;</td>
    <td style="vertical-align: bottom; vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 10%">
        <div style="line-height: 1.25">12,251</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">&#160;</td> </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: top; background-color: rgb(204, 238, 255); width: 36%">
        <div style="line-height: 1.25">Financial expenses (income), net</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 10%">
        <div style="line-height: 1.25">(1,385</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25">)</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 10%">
        <div style="line-height: 1.25">395</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); text-align: center; vertical-align: bottom; width: 4%">D
        <br/> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%"><br/>
        </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 10%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 1%">
        <div style="line-height: 1.25">(86</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25">)</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 4%">&#160;</td>
    <td style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255); width: 1%">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 10%">
        <div style="line-height: 1.25">6,047</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: top; width: 36%">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 10%">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 10%">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; white-space: nowrap; text-align: center; vertical-align: bottom; width: 4%">E
        <br/> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%"><br/> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 10%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 1%">
        <div style="line-height: 1.25">4,783</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 4%">&#160;</td>
    <td style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 10%">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">&#160;</td> </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: top; background-color: rgb(204, 238, 255); width: 36%">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 10%">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 10%">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); text-align: center; vertical-align: bottom; width: 4%">F
        <br/> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%"><br/>
        </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 10%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 1%">
        <div style="line-height: 1.25">1,364</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 4%">&#160;</td>
    <td style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255); width: 1%">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 10%">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: top; width: 36%">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 10%">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 10%">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; white-space: nowrap; text-align: center; vertical-align: bottom; width: 4%">G
        <br/> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%"><br/> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 10%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 1%">
        <div style="line-height: 1.25">337</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 4%">&#160;</td>
    <td style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 10%">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">&#160;</td> </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: top; width: 36%; padding-bottom: 2px; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 10%; padding-bottom: 2px; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 10%; padding-bottom: 2px; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; white-space: nowrap; text-align: center; vertical-align: bottom; width: 4%; padding-bottom: 2px; background-color: rgb(204, 238, 255)">H
        <br/> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255)"><br/>
        </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; width: 10%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; text-align: right; width: 1%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25">639</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px; background-color: rgb(204, 238, 255); width: 4%">&#160;</td>
    <td style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 10%; padding-bottom: 2px; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255)">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: top; width: 36%">
        <div style="line-height: 1.25">Loss before income tax</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 10%">
        <div style="line-height: 1.25">(263</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25">)</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 10%">
        <div style="line-height: 1.25">5,076</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; white-space: nowrap; text-align: center; vertical-align: bottom; width: 4%">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%"><br/> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 10%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 1%">
        <div style="line-height: 1.25">13,485</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 4%">&#160;</td>
    <td style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 10%">
        <div style="line-height: 1.25">18,298</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">&#160;</td> </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: top; width: 36%; padding-bottom: 2px; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25">Tax on Income</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; text-align: right; width: 10%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25">&#8212;</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; text-align: right; width: 10%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25">32</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; white-space: nowrap; text-align: center; vertical-align: bottom; width: 4%; padding-bottom: 2px; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255)"><br/>
        </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; width: 10%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; text-align: right; width: 1%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25">&#8212;</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px; background-color: rgb(204, 238, 255); width: 4%">&#160;</td>
    <td style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; text-align: right; width: 10%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25">32</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255)">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: top; width: 36%">
        <div style="line-height: 1.25; font-weight: bold">LOSS FOR THE PERIOD</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25">$</div> </td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 10%">
        <div style="line-height: 1.25">(263</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25">)</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25">$</div> </td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 10%">
        <div style="line-height: 1.25">5,108</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; white-space: nowrap; text-align: center; vertical-align: bottom; width: 4%">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%"><br/> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 10%">
        <div style="line-height: 1.25">$</div> </td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 1%">
        <div style="line-height: 1.25">13,485</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 4%">&#160;</td>
    <td style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25">$</div> </td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 10%">
        <div style="line-height: 1.25">18,330</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">&#160;</td> </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: top; width: 36%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 10%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 10%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; white-space: nowrap; text-align: center; vertical-align: bottom; width: 4%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)"><br/>
        </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 10%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255); width: 4%">&#160;</td>
    <td style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 10%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: top; width: 36%">
        <div style="line-height: 1.25">Attributable to:</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 10%">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 10%">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; white-space: nowrap; text-align: center; vertical-align: bottom; width: 4%">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%"><br/> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 10%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 1%">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 4%">&#160;</td>
    <td style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 10%">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">&#160;</td> </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: top; width: 36%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25">Equity holders of the Company</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 10%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25">&#8212;</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 10%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25">4,942</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; white-space: nowrap; text-align: center; vertical-align: bottom; width: 4%; background-color: rgb(204, 238, 255)">I
        <br/> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)"><br/>
        </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 10%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 1%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25">166</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255); width: 4%">&#160;</td>
    <td style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 10%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25">18,330</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: top; width: 36%">
        <div style="line-height: 1.25">Non-controlling interests</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 10%">
        <div style="line-height: 1.25">&#8212;</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 10%">
        <div style="line-height: 1.25">166</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; white-space: nowrap; text-align: center; vertical-align: bottom; width: 4%">I
        <br/> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%"><br/> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 10%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 1%">
        <div style="line-height: 1.25">(166</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25">)</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 4%">&#160;</td>
    <td style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">
        <div style="text-align: center; line-height: 1.25">&#160;</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 10%">
        <div style="line-height: 1.25">&#8212;</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">&#160;</td> </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: top; width: 36%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 10%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 10%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 4%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 10%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255); width: 4%">&#160;</td>
    <td style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">
        <div style="text-align: center; line-height: 1.25">&#160;</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 10%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: top; width: 36%">
        <div style="line-height: 1.25">PROFIT (LOSS) PER SHARE, BASIC AND DILUTED</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 10%">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 10%">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 4%">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 10%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 1%">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 4%">&#160;</td>
    <td style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">
        <div style="text-align: center; line-height: 1.25">&#160;</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 10%">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">&#160;</td> </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: top; width: 36%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25">Ordinary share subject to possible redemption</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25">$</div> </td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 10%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25">0.51</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25">$</div> </td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 10%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25">&#8212;</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 4%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 10%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25">$</div> </td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 1%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25">(0.51</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25">)</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255); width: 4%">&#160;</td>
    <td style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">
        <div style="text-align: center; line-height: 1.25">&#160;</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25">$</div> </td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 10%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25">&#8212;</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: top; width: 36%">
        <div style="line-height: 1.25">Non-redeemable ordinary shares</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25">$</div> </td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 10%">
        <div style="line-height: 1.25">(0.34</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25">)</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25">$</div> </td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 10%">
        <div style="line-height: 1.25">(44.23</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25">)</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 4%">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 10%">
        <div style="line-height: 1.25">$</div> </td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 1%">
        <div style="line-height: 1.25">28.30</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 4%">&#160;</td>
    <td style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">
        <div style="text-align: center; line-height: 1.25">&#160;</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25">$</div> </td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 10%">
        <div style="line-height: 1.25">(16.27</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25">)</div> </td> </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: top; width: 36%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25">WEIGHTED AVERAGE NUMBER OF SHARES OUTSTANDING USED IN COMPUTATION OF BASIC AND DILUTED LOSS PER SHARE</div>
        </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 10%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 10%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 4%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 10%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255); width: 4%">&#160;</td>
    <td style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">
        <div style="text-align: center; line-height: 1.25">&#160;</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 10%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: top; width: 36%">
        <div style="line-height: 1.25">Ordinary shares subject to possible redemption</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 10%">
        <div style="line-height: 1.25">2,774,850</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 10%">
        <div style="line-height: 1.25">&#8212;</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 4%">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 10%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; text-align: right; width: 1%">
        <div style="line-height: 1.25">(2,774,850</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25">)</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 4%">&#160;</td>
    <td style="vertical-align: bottom; vertical-align: bottom; width: 1%">
        <div style="text-align: center; line-height: 1.25">&#160;</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; text-align: right; width: 10%">
        <div style="line-height: 1.25">&#8212;</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">&#160;</td> </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: top; width: 36%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25">Non-redeemable ordinary shares</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 10%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25">3,355,000</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 10%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25">111,726</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 4%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 10%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; text-align: right; width: 1%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25">(2,340,293</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25">)</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; text-align: center; vertical-align: bottom; background-color: rgb(204, 238, 255); width: 4%">&#160;J</td>
    <td style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)"><br/> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; text-align: right; width: 10%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25">1,126,433</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
        </tr>
  </table> <br/> </div>

<div> </div>

<div> </div> </div>

<div style="text-align: center; line-height: 1.25; font-family: Times New Roman">See accompanying notes to the unaudited pro forma condensed
combined financial information.</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: rgb(0, 0, 0); font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">48</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="text-align: center; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="line-height: 1.25; font-weight: bold; font-family: Times New Roman">NOTES TO UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL
INFORMATION</div>

<div style="line-height: 1.25; font-weight: bold; font-family: Times New Roman">&#160;</div>

<div style="line-height: 1.25; font-weight: bold; font-family: Times New Roman">1. Description of the Business Combination</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">On August 15, 2024, the parties completed the previously-reported
transactions (the &#8220;<span style="font-weight: bold">Transactions</span>&#8221; or &#8220;<span style="font-weight: bold">Business
Combination</span>&#8221;) pursuant to that certain amended and restated business combination agreement, dated April 3, 3024 (the &#8220;Business
Combination Agreement&#8221;) by and among the registrant (&#8220;<span style="font-weight: bold">New Silexion</span>&#8221;, which was
then known as Biomotion Sciences), August M.S. Ltd., an Israeli company and a wholly owned subsidiary of New Silexion (&#8220;<span style="font-weight: bold">Merger
Sub 1</span>&#8221;), Moringa Acquisition Merger Sub Corp, a Cayman Islands exempted company and a wholly owned subsidiary of New Silexion
(&#8220;<span style="font-weight: bold">Merger Sub 2</span>&#8221;), Moringa and Silexion.</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="line-height: 1.25; font-family: Times New Roman">

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">Pursuant to the Transactions, Merger Sub 2 merged with and into
Moringa, with Moringa continuing as the surviving company of such merger and a wholly-owned subsidiary of New Silexion (the &#8220;<span style="font-weight: bold">SPAC
Merger</span>&#8221;), and Merger Sub 1 merged with and into Silexion, with Silexion continuing as the surviving company of such merger
and a wholly-owned subsidiary of New Silexion (the &#8220;<span style="font-weight: bold">Acquisition Merger</span>&#8221;). Upon the
effectiveness of the SPAC Merger, each outstanding Moringa Class A ordinary share and the sole outstanding Moringa Class B ordinary share
converted into an ordinary share of New Silexion on a nine-to-one basis (after adjustments for the reverse share split described below).
Each outstanding warrant to purchase nine Moringa Class A ordinary share converted into a warrant to purchase one New Silexion ordinary
share, at the same exercise price. Upon the effectiveness of the Acquisition Merger, each outstanding ordinary share and preferred share
of Silexion converted into such number of ordinary shares of New Silexion as is equal to the quotient obtained by dividing (x) the quotient
obtained by dividing (1) $62,500,000 by (2) the number of fully diluted Silexion equity securities, by (y) $90.00 (after adjustment for
the subsequent New Silexion 1-for-9 reverse share split, as described below) (the &#8220;<span style="font-weight: bold">Silexion Equity
Exchange Ratio</span>&#8221;). Each outstanding Silexion warrant and Silexion option to purchase one Silexion share, and Silexion restricted
share unit (RSU) that may be potentially settled for one Silexion share, became exercisable for, or will be subject to settlement for
(as applicable), such number of New Silexion ordinary shares as are equal to the Silexion Equity Exchange Ratio. The exercise price per
New Silexion ordinary share of each such converted Silexion option and Silexion warrant was adjusted based on dividing the existing per
share exercise price by the Silexion Equity Exchange Ratio. The terms of vesting, exercise and/or settlement, as applicable, of such converted
options, warrants and RSUs remains the same following that conversion, except that the vesting of each Silexion option accelerated immediately
prior to the Acquisition Merger, such that the New Silexion option into which it has been converted is fully vested, and all Silexion
warrants were exercised (on a cashless basis) immediately prior to the Acquisition Merger.</div> </div> </div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="line-height: 1.25; font-family: Times New Roman">

<div style="text-indent: 35.45pt; line-height: 1.25; font-family: Times New Roman,Times,serif; font-style: italic">Unless indicated otherwise
in these notes to the Pro Forma Condensed Combined Financial Information, all share and per share numbers of New Silexion have been adjusted
retroactively to reflect the one-for-nine reverse share split effected by New Silexion with respect to its ordinary shares on November
27, 2024 (which reverse share split was reflected in trading prices at the start of trading on November 29, 2024). All share and per share
numbers of Moringa and Silexion have not been so adjusted.</div> </div>

<div style="line-height: 1.25; font-family: Times New Roman"> <br/> </div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">Immediately prior to the closing of the Business Combination
(the &#8220;<span style="font-weight: bold">Closing</span>&#8221;), seven directors were appointed to New Silexion&#8217;s board of directors,
of whom five were designated by Silexion and two were designated by Moringa&#8217;s sponsor (Moringa Sponsor, LP, a Cayman Islands exempted
limited partnership and/or its wholly-owned subsidiary, Moringa Sponsor US L.P., a Delaware limited partnership) (collectively, the &#8220;<span style="font-weight: bold">Moringa
Sponsor</span>&#8221;). Also upon Closing, New Silexion&#8217;s articles of association were amended and restated as appears in Exhibit
3.1 to the registration statement of which this prospectus forms a part. In connection with the Closing, the ordinary shares and warrants
of New Silexion were approved for listing on the Nasdaq Global Market and began trading under the symbols &#8220;SLXN&#8221; and &#8220;SLXNW&#8221;,
respectively.</div>

<div style="text-indent: 28.35pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">In addition, at the Closing, each of the following additional
actions was taken, in accordance with the terms of the Business Combination Agreement (in certain cases, as modified by subsequent agreements):</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="line-height: 1.25"> </div>

<table cellspacing="0" cellpadding="0" id="zae5c92928d6246e4b864ddfae5cf90e5" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">
        <div style="line-height: 1.25; font-family: Times New Roman">Moringa Sponsor forfeited for retirement 1,308,000 of the Moringa founders
        shares held by it, while 1,567,000 of the Moringa founders shares were transferred to non-affiliated third-party investors (including
        316,750 founders shares to certain security holders) as Backstop Shares (as defined in the Business Combination Agreement);</div> </div>
        </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: rgb(0, 0, 0); font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">49</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="text-align: center; line-height: 1.25"><span style="font-family: Times New Roman"><br/> </span> </div>

<table cellspacing="0" cellpadding="0" id="z129fcac9cbfb43828a9c84108e2d9d1a" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">New Silexion issued to the Moringa Sponsor the A&amp;R Sponsor Promissory
        Note in an amount of $3,433,000, in replacement of all promissory notes that Moringa had issued to the Moringa Sponsor for amounts owed
        by Moringa to the Moringa Sponsor prior to the Closing;</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="line-height: 1.25; font-family: Times New Roman"> </div>

<table cellspacing="0" cellpadding="0" id="z6d5eda5f8a844389920ef5458f87fdbd" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">
        <div style="line-height: 1.25; font-family: Times New Roman, Times, serif">New Silexion, Moringa Sponsor, the investor in the PIPE financing
        (described below) and certain additional shareholders of New Silexion entered into an Amended and Restated Registration Rights and Lock-Up
        Agreement granting them registration rights with respect to the ordinary shares of New Silexion issued to them; and</div> </div> </td>
        </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z95bda054dfcf4df581739c4a0e1e17e9" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">
        <div style="line-height: 1.25; font-family: Times New Roman">Guangzhou Sino-Israel Bio-Industry Investment Fund I (&#8220;<span style="font-weight: bold">GIBF</span>&#8221;),
        a shareholder of Silexion, transferred its noncontrolling interest in Silexion&#8217;s Chinese subsidiary, Silenseed (China) Ltd., directly
        to New Silexion, such that the subsidiary became a wholly-owned subsidiary of New Silexion, and was issued 203,971 ordinary shares of
        New Silexion as consideration for that transfer (the &#8220;<span style="font-weight: bold">Chinese Subsidiary Transfer</span>&#8221;)
        (in addition to the 16,817 New Silexion ordinary shares that GIBF received upon the accelerated vesting of RSUs granted to it).</div>
        </div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">In connection with the Moringa extraordinary general meeting
at which the three proposals related to the Business Combination&#8212;the Business Combination Proposal, the Merger Proposal and the
Articles Amendment Proposal&#8212; were approved by the requisite majorities of Moringa&#8217;s shareholders, holders of an aggregate
of 427,297 Moringa public shares properly exercised their right to have their shares redeemed for a full pro rata portion of the Trust
Account holding the proceeds from Moringa&#8217;s IPO, which was approximately $11.575 per share, or $4,946,046 in the aggregate. Also
prior to the Closing, Moringa reached agreement with EarlyBird on a reduction, from $4.025 million to $1.6 million, in the aggregate,
of the fee payable to EarlyBird under the Business Combination Marketing Agreement, dated February 19, 2021 (the &#8220;<span style="font-weight: bold">Marketing
Agreement</span>&#8221;), entered into by Moringa with EarlyBird at the time of Moringa&#8217;s initial public offering. Pursuant to the
final invoice provided by EarlyBird under the Marketing Agreement at the Closing, Moringa paid $350,000 of cash to EarlyBird at the Closing,
and New Silexion issued to EarlyBird a convertible promissory note, due December 31, 2025, in an amount of $1.25 million to be paid by
New Silexion to EarlyBird in cash and/or via conversion of outstanding amounts into ordinary shares of New Silexion. After the redemption
payments, the payment to EarlyBird, and the satisfaction of amounts due to parties that arranged financing and/or capital markets advisory
services in connection with the Closing, the remaining balance of the Trust Account immediately prior to the Closing of $333,936 was used
to partially fund the Business Combination.</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">In connection with, and immediately prior
to the Closing of, the Business Combination, Moringa raised $2.0 million via a private investment in public entity (PIPE) financing, whereby
Moringa sold to Greenstar, L.P. 200,000 Moringa ordinary shares (which does not reflect the reverse share split) at a price of $10.00
per share. Those funds, together with remaining funds in Moringa&#8217;s Trust Account after payments to redeeming public shareholders,
were used for financing support for Moringa and New Silexion, as well as for payment to service providers to whom outstanding amounts
were owed by Moringa, including parties that had provided financial advisory services and capital markets advisory services to Moringa
during the period leading up to the Closing.</div> </div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">Also in connection with the Closing, New Silexion entered
into an ordinary share purchase agreement for an equity line of credit with White Lion, whereby New Silexion will be able to request to
sell to White Lion, and White Lion will be required to purchase, via private placement transactions, up to $15.0 million of New Silexion
ordinary shares from time to time after the Closing, up until December 31, 2025 (unless the agreement is terminated sooner), subject to
certain limitations and conditions as described therein. The number of New Silexion ordinary shares that New Silexion may require White
Lion to purchase in any single sales notice will depend on a number of factors, including the type of purchase notice that New Silexion
delivers. Similarly, the purchase price to be paid by White Lion for any shares that New Silexion requires them to purchase will depend
on the type of sales notice that New Silexion delivers. New Silexion has also granted registration rights to White Lion pursuant to an
accompanying registration rights agreement.</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: rgb(0, 0, 0); font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">50</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="text-align: center; line-height: 1.25"><span style="font-family: Times New Roman"><br/> </span> </div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman">

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">In consideration for the commitments of White Lion, New Silexion
agreed to issue to White Lion an aggregate of $337,500 of New Silexion ordinary shares based on the closing price of the New Silexion
ordinary shares on September 16, 2024. Based on the closing price of the ordinary shares on September 16, 2024, New Silexion issued to
White Lion, on September 18, 2024, 40,602 ordinary shares in respect of White Lion&#8217;s commitments under the White Lion Purchase Agreement.</div>
</div> </div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="line-height: 1.25; font-family: Times New Roman">Separately, the Moringa Sponsor transferred to third-party investors (in
lieu of forfeiting) all 1,567,000 Moringa founders shares that had been designated to serve as Backstop Shares under the Business Combination
Agreement, including 316,750 founders shares to certain security holders.</div> </div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">Various issuances and other actions impacted the final
number of New Silexion ordinary shares that were issued upon the Closing of the Business Combination, including the following:</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z4b7cc12a7eaf4e398a85755f4f7d3e70" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">the redemption of the 427,297 Moringa public shares described above;</div>
        </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z79869c82df874d1fa7d208c10ced102c" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">the separation of each former Moringa unit into one Moringa Class A ordinary
        share and one-half of a Moringa warrant;</div> </td> </tr>
  </table> <br/>

<table cellspacing="0" cellpadding="0" id="z0a07f6957f944bc19f3735526a9505df" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">
        <div style="line-height: 1.25; font-family: Times New Roman">
        <div style="line-height: 1.25; font-family: Times New Roman, Times, serif">
        <div style="line-height: 1.25">t1he Sponsor Founder Shares Forfeiture (as defined in the Business Combination Agreement) of 1,308,000
        Moringa founders shares, and the transfer of the remaining 1,567,000 Moringa founders shares to third parties (including 316,750 Moringa
        founders shares to certain securityholders) as Backstop Shares, which resulted in the issuance of 174,112 ordinary shares of New Silexion;</div>
        </div> </div> </div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z2e910853dc304691ac76664812968288" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">
        <div style="line-height: 1.25; font-family: Times New Roman">the issuance of 9,747 New Silexion ordinary shares in exchange for 87,722
        Moringa public shares that remained outstanding immediately prior to the Closing (following the redemptions described above);</div> </div>
        </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="line-height: 1.25; font-family: Times New Roman"> </div>

<table cellspacing="0" cellpadding="0" id="z84226729164347d68c4507c375937029" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">
        <div style="line-height: 1.25; font-family: Times New Roman">
        <div style="line-height: 1.25; font-family: Times New Roman, Times, serif">the issuance of 42,223 New Silexion ordinary shares in exchange
        for 380,000 Moringa private shares;</div> </div> </div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="line-height: 1.25; font-family: Times New Roman"> </div>

<table cellspacing="0" cellpadding="0" id="zcbf8aaf50132412ea082083665a504d2" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">
        <div style="line-height: 1.25; font-family: Times New Roman">
        <div style="line-height: 1.25; font-family: Times New Roman, Times, serif">the issuance of 11,112 New Silexion ordinary shares to EarlyBird
        in exchange for 100,000 Moringa representative shares;</div> </div> </div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z466b2f26c3714de69adb8a01b7d76cb8" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">
        <div style="line-height: 1.25; font-family: Times New Roman">
        <div style="line-height: 1.25; font-family: Times New Roman, Times, serif">the issuance by New Silexion to the Sponsor and/or its limited
        partners to whom the Sponsor distributed such shares of the 153,592 Sponsor Investment Shares (as defined in the Business Combination
        Agreement);</div> </div> </div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z37ddacb7045b4ad1bc1a5d5757b6a0c9" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">
        <div style="line-height: 1.25; font-family: Times New Roman">the issuance of 22,223 New Silexion ordinary shares to Greenstar, L.P. in
        exchange for 200,000 Moringa shares that were purchased in the $2.0 million PIPE financing, as described above;</div> </div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z2edd974f1c99416bb20e7995836cd585" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">
        <div style="line-height: 1.25; font-family: Times New Roman">
        <div style="line-height: 1.25; font-family: Times New Roman, Times, serif">the issuance of 446,835 New Silexion ordinary shares as the
        Silexion Merger Consideration (as defined in the Business Combination Agreement) to security holders of Silexion;</div> </div> </div>
        </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z97d79b348a7a442dbc5ae6467b089bd7" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">
        <div style="line-height: 1.25; font-family: Times New Roman">the issuance of 203,971 New Silexion ordinary shares to GIBF in respect of
        the Chinese Subsidiary Transfer (in addition to 16,817 New Silexion ordinary shares issued to GIBF upon the accelerated vesting of RSUs
        granted to it), as described above; and</div> </div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z75a9ade9a7b3496c8c3ca39426e2512d" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">
        <div style="line-height: 1.25; font-family: Times New Roman">the issuance of 4,370 New Silexion ordinary shares to a non-employee director
        of New Silexion upon acceleration of vesting, and settlement, of an equivalent number of New Silexion RSUs granted to the director.</div>
        </div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="line-height: 1.25; font-family: Times New Roman">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">As a result of each of the foregoing, upon
the Closing, there were 1,084,998 New Silexion ordinary shares issued and outstanding.</div> </div> </div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: rgb(0, 0, 0); font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">51</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="text-indent: 36pt; line-height: 1.25"> <span style="font-family: Times New Roman"><br/> </span> </div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="line-height: 1.25; font-family: Times New Roman">

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">Upon the Closing, the ownership structure
for New Silexion was as set forth in the table below, based on actual number of redemptions of Moringa public shares (with the numbers
of New Silexion shares in the table retroactively reflecting the one-for-nine reverse share split of New Silexion):</div> </div> </div>
</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif"><span style="font-family: Times New Roman">&#160; </span>

<table cellspacing="0" cellpadding="0" class="cfttable" id="z21d64e3de7754326b11c5abfbebf000f" style="font: 10pt Times New Roman, Times, serif; text-align: left; color: #000000; width: 100%">
  <tr>
    <td style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman"><span style="line-height: 1.25">&#160;</span></div>
        <div style="line-height: 1.25; font-family: Times New Roman"><span style="line-height: 1.25">&#160;</span></div>
        <div style="line-height: 1.25; font-weight: bold; font-family: Times New Roman">Equity Holders</div> </td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px; font-family: Times New Roman">&#160;</td>
    <td colspan="2" style="border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; text-align: center">
        <div style="line-height: 1.25; font-family: Times New Roman"><span style="line-height: 1.25"> </span></div>
        <div style="line-height: 1.25; font-family: Times New Roman"><span style="line-height: 1.25"> </span></div>
        <div style="line-height: 1.25; font-family: Times New Roman; font-weight: bold">Shares</div> </td>
    <td class="cftfncell" colspan="1" style="white-space: nowrap; text-align: center; vertical-align: bottom; padding-bottom: 2px; font-family: Times New Roman">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; text-align: center; font-family: Times New Roman">&#160;</td>
    <td colspan="2" style="border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; text-align: center">
        <div style="line-height: 1.25; font-family: Times New Roman; font-weight: bold; text-indent: 8pt">Percentage of</div>
        <div style="line-height: 1.25; font-family: Times New Roman; font-weight: bold; text-indent: 10pt">Outstanding </div>
        <div style="line-height: 1.25; font-family: Times New Roman; font-weight: bold; text-indent: 10pt">Shares</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px; font-family: Times New Roman">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: top; background-color: #CCEEFF; width: 76%">
        <div style="line-height: 1.25; font-family: Times New Roman">Moringa Public Shareholders(1)</div> </td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman">9,747</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman">0.88</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; background-color: #CCEEFF; vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25; font-family: Times New Roman">%</div> </td> </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: top; width: 76%">
        <div style="line-height: 1.25; font-family: Times New Roman">Silexion Shareholders(2)</div> </td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman">694,491</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; font-family: Times New Roman">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman">62.46</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25; font-family: Times New Roman">%</div> </td> </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: top; background-color: #CCEEFF; width: 76%">
        <div style="line-height: 1.25; font-family: Times New Roman">Moringa Sponsor Shares(3)</div> </td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman">187,798</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman">16.89</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; background-color: #CCEEFF; vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25; font-family: Times New Roman">%</div> </td> </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: top; width: 76%">
        <div style="line-height: 1.25; font-family: Times New Roman">Distributees of Sponsor Investment Shares</div> </td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman">5,000</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; font-family: Times New Roman">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman">0.45</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25; font-family: Times New Roman">%</div> </td> </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: top; background-color: #CCEEFF; width: 76%">
        <div style="line-height: 1.25; font-family: Times New Roman">PIPE investor</div> </td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman">22,223</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman">2.00</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; background-color: #CCEEFF; vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25; font-family: Times New Roman">%</div> </td> </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: top; width: 76%">
        <div style="line-height: 1.25; font-family: Times New Roman">Founders Shares/ Backstop Shares</div> </td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman">174,112</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; font-family: Times New Roman">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman">15.66</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25; font-family: Times New Roman">%</div> </td> </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: top; background-color: #CCEEFF; width: 76%">
        <div style="line-height: 1.25; font-family: Times New Roman">EarlyBird(3)</div> </td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman">14,127</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman">1.27</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; background-color: #CCEEFF; vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25; font-family: Times New Roman">%</div> </td> </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: top; width: 76%; padding-bottom: 2px">
        <div style="line-height: 1.25; font-family: Times New Roman">Director receiving RSU grant upon Closing</div> </td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: Times New Roman">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: Times New Roman">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px">
        <div style="line-height: 1.25; font-family: Times New Roman">4,370</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: Times New Roman">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: Times New Roman">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; width: 1%; font-family: Times New Roman">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman">0.39</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 2px">
        <div style="line-height: 1.25; font-family: Times New Roman">%</div> </td> </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: top; background-color: #CCEEFF; width: 76%; padding-bottom: 2px">
        <div style="line-height: 1.25; font-weight: bold; font-family: Times New Roman">Total</div> </td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); font-family: Times New Roman">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: Times New Roman">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px">
        <div style="line-height: 1.25; font-family: Times New Roman">1,111,868</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: Times New Roman">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); font-family: Times New Roman">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; border-bottom: #000000 2px solid; background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-weight: bold; font-family: Times New Roman">100</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; background-color: #CCEEFF; vertical-align: bottom; width: 1%; padding-bottom: 2px">
        <div style="line-height: 1.25; font-weight: bold; font-family: Times New Roman">%</div> </td> </tr>
  </table> </div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<table cellspacing="0" cellpadding="0" id="zdc2a93f8cc9c4f0b91506c0f3a2e6620" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">(1)</div> </td>
    <td style="width: 96.15%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">
        <div style="line-height: 1.25; font-family: Times New Roman">
        <div style="line-height: 1.25; font-family: Times New Roman, Times, serif">Excludes 638,889 public warrants held by Moringa&#8217;s public
        shareholders, which will be exercisable for New Silexion ordinary shares at an exercise price of $103.50 per share beginning 30 days after
        the Closing of the Business Combination.</div> </div> </div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<table cellspacing="0" cellpadding="0" id="zf25fe6e8bfee4827b9dff336d138e890" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">(2)</div> </td>
    <td style="width: 96.15%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">
        <div style="line-height: 1.25; font-family: Times New Roman">Includes all securities issuable to security holders of Silexion on a fully-diluted
        basis, including New Silexion ordinary shares, New Silexion warrants, New Silexion options and New Silexion RSUs, and also includes 203,971
        New Silexion ordinary shares issued directly to GIBF in respect of the Chinese Subsidiary Transfer, as well as 16,817 New Silexion ordinary
        shares issued to GIBF upon the accelerated vesting of RSUs granted to it.</div> </div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<table cellspacing="0" cellpadding="0" id="zcbba5441ff784984b05fe1bb7778a3a3" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">(3)</div> </td>
    <td style="width: 96.15%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">
        <div style="line-height: 1.25; font-family: Times New Roman">
        <div style="line-height: 1.25; font-family: Times New Roman, Times, serif">Excludes 21,112 private warrants held, in the aggregate, by
        the Moringa Sponsor and EarlyBird, which will be exercisable for New Silexion ordinary shares at an exercise price of $103.50 per share
        beginning 30 days after the Closing of the Business Combination.</div> </div> </div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-weight: bold; font-family: Times New Roman">&#160;&#160;</div>

<div style="line-height: 1.25; font-weight: bold; font-family: Times New Roman">2. Basis of Pro Forma Presentation</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">The unaudited pro forma condensed combined financial statements
were prepared in accordance with Article 11 of SEC Regulation S-X, as amended by the final rule, SEC Release No. 33-10786 &#8220;Amendments
to Financial Disclosures About Acquired and Disposed Businesses&#8221;. The adjustments presented in the unaudited pro forma condensed
combined financial statements (collectively, the &#8220;<span style="font-weight: bold">Pro Forma Adjustments</span>&#8221;) have been
identified and presented to provide relevant information necessary for an understanding of New Silexion upon consummation of the Business
Combination and related transactions.</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="line-height: 1.25; font-family: Times New Roman">

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">The unaudited pro forma combined statements of operations for
the nine-months period ended September 30, 2024 and for the year ended December 31, 2023 combine the historical statements of operations
of Moringa for the year ended December 31, 2023 (audited), and for the period from January&#160;1 to August 14, 2024 (unaudited), and
the updated financial statements of New Silexion (formerly: Silexion) that show the effects of the reverse share split and reverse recapitalization
for the year ended December 31, 2023 (audited), and for the nine-months period ended September 30, 2024 (unaudited), subject to the Pro
Forma Adjustments, giving effect to the Business Combination as if it had been consummated on January 1, 2023.</div> </div> </div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">The historical financial information has been adjusted
to reflect the Pro Forma Adjustments giving effect to the Business Combination and related transactions as described in more detail below.</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: rgb(0, 0, 0); font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">52</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>
<!--PROfilePageNumberReset%Num%55%%%-->

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="line-height: 1.25"><span style="font-family: Times New Roman">The unaudited pro forma condensed combined financial information
is for illustrative purposes only. The financial results may have been different had New Silexion and Moringa been always combined. You
should not rely on the unaudited pro forma condensed combined financial information as being indicative of the historical results that
would have been achieved had Moringa always been combined or the future results that the Company will experience.</span> </div> </div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">The unaudited pro forma condensed combined financial information
does not give effect to any anticipated synergies, operating efficiencies, tax savings, or cost savings that may be associated with the
Business Combination and related transactions as described in more detail below. Moringa and Silexion have not had any historical relationship
prior to the Business Combination. Accordingly, no pro forma adjustments were required to eliminate activities between the companies.
However, the unaudited pro forma condensed combined financial information includes certain share-based compensation that was granted upon
the consummation of the Business Combination, as well as net exercise of all Silexion warrants outstanding for New Silexion ordinary shares,
which occurred upon the consummation of the Business Combination.</div>

<div style="line-height: 1.25; font-weight: bold; font-family: Times New Roman">&#160;</div>

<div style="line-height: 1.25">

<div style="line-height: 1.25; font-family: Times New Roman; font-style: italic; font-weight: bold">Pro forma adjustments giving effect
to the Business Combination and related transactions:</div> </div>

<div style="line-height: 1.25"><span style="font-family: Times New Roman">&#160;<br/> </span>

<div style="line-height: 1.25">

<div style="line-height: 1.25; font-family: Times New Roman; text-indent: 36pt">A) Immediately prior to the Effective Time of the Acquisition
Merger, the vesting of all outstanding Silexion share-based incentive awards was accelerated and those awards became fully vested. At
the Effective Time of the Acquisition Merger, all of Silexion&#8217;s share-based incentive awards were assumed by New Silexion and converted
into options to purchase New Silexion ordinary shares, based on the Equity Exchange Ratio. These pro forma financial statements reflect
the acceleration of the awards as a 2023 adjustment and subsequent elimination of remaining expenses in 2024.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif; text-indent: 36pt"> <span style="font-family: Times New Roman"><br/>
</span> </div> </div>

<div style="line-height: 1.25; font-family: Times New Roman; text-indent: 36pt">

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">In addition, the adjustment reflects the
issuance of 177,736 new RSUs of Silexion (before adjustment for reverse share split), which converted into 78,650 new RSUs of New Silexion
and issuance of 4,370 new RSU&#8217;s of New Silexion, in the aggregate, at the Closing, to directors of New Silexion and employees of
New Silexion and its subsidiaries (of which 22,070 RSUs were granted to New Silexion directors) with a grant date fair value of $70.908
per RSU (each such number of RSUs of New Silexion retroactively reflects the reverse share split). All of the foregoing new RSUs were
vested&#160;upon the Closing, and the RSUs were settled for equivalent numbers of underlying New Silexion ordinary shares. In these pro
forma statements of operations, this expense was eliminated from the period ended September 30, 2024 and was moved back to 2023 as a pro
forma adjustment.</div> </div> </div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif; text-indent: 36pt"> <span style="font-family: Times New Roman"><br/>
</span> </div>

<div style="line-height: 1.25; font-family: Times New Roman; text-indent: 36pt"> B) To reflect additional cash compensation to be paid
to Ilan Levin, a director of New Silexion, in an amount of $10 thousand per month, commencing on Closing and for a period of 36 months.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif; text-indent: 36pt"> <span style="font-family: Times New Roman"><br/>
</span>

<div style="line-height: 1.25; font-family: Times New Roman">C) To reflect Transactions-related costs in an amount of $466. In the pro
forma statement of operations, it was assumed that the expenses were incurred in 2023 rather than 2024. </div> </div> </div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: rgb(0, 0, 0); font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">53</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="text-align: center; line-height: 1.25"><span style="font-family: Times New Roman"><br/> </span> </div>

<div style="line-height: 1.25; font-family: Times New Roman; text-indent: 36pt"> Therefore, Transactions-related expenses recorded in
New Silexion&#8217;s statements of operations for the period ended September 30, 2024 were moved back to 2023 as a pro forma adjustment.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif; text-indent: 36pt"> <span style="font-family: Times New Roman"><br/>
D) These unaudited pro forma financial statements reflect net exercise of all Silexion warrants over Preferred Shares outstanding and
their conversion to New Silexion ordinary shares, which occurred upon the consummation of the Business Combination. Related fair value
measurement gains or losses of those warrants were eliminated from the pro forma combined statements of operations.</span></div>

<div style="line-height: 1.25"><span style="font-family: Times New Roman"><br/> </span> </div>

<div style="line-height: 1.25; text-indent: 36pt; font-family: Times New Roman">E) To reflect financing loss recorded by New Silexion
upon Closing, equal to the difference between Moringa&#8217;s net assets and liability-classified instruments measured at fair value issued
by New Silexion as part of the Business Combination. This loss was recorded in New Silexion&#8217;s statements of operations for the period
ended September 30, 2024 and was moved back to 2023 as a pro forma adjustment.</div>

<div style="line-height: 1.25; text-indent: 36pt; font-family: Times New Roman">&#160;</div>

<div style="line-height: 1.25; text-indent: 36pt; font-family: Times New Roman">F) To reflect the elimination of unrealized interest income
on investments held in the Trust Account.</div> <span style="font-family: Times New Roman"><br/> </span>

<div style="line-height: 1.25; text-indent: 36pt; font-family: Times New Roman">G) Represents an obligation to issue ordinary shares of
New Silexion with a value of $337,500 (the &#8220;<span style="font-weight: bold">ELOC Commitment Shares</span>&#8221;) to White Lion
as a fee in consideration of White Lion&#8217;s commitment to purchase New Silexion ordinary shares from New Silexion under the ordinary
share purchase agreement for New Silexion's equity line of credit.</div>

<div style="line-height: 1.25"><span style="font-family: Times New Roman"><br/> </span> </div>

<div style="text-indent: 36pt; line-height: 1.25">H) To reflect fair value changes of New Silexion&#8217;s A&amp;R Sponsor Promissory
Note and EarlyBird Convertible Note (the &#8220;Notes&#8221;). See also Note 3(a) and (b) of New Silexion&#8217;s interim financial statements
for the period ended September 30, 2024. It was assumed that fair value changes of the Notes until August 15, 2024 are equal to the unwinding
of the Notes&#8217; discount, using the discount rates in the Notes&#8217; valuation work.</div>

<div style="line-height: 1.25"><br/> </div>

<div style="text-indent: 36pt; line-height: 1.25">I) To reflect the transfer by GIBF of its noncontrolling interest in Silexion&#8217;s
Chinese subsidiary, Silenseed (China) Ltd., to New Silexion in exchange for 203,971 New Silexion ordinary shares upon the completion of
the Business Combination.</div>

<div style="line-height: 1.25"><br/> </div>

<div style="line-height: 1.25; font-style: italic"><span style="font-weight: bold">Pro forma weighted average shares outstanding</span>:</div>

<div style="line-height: 1.25"><br/> </div>

<div style="text-indent: 36pt; line-height: 1.25">J) As the Business Combination is being reflected as if it had occurred at the beginning
of the earliest period presented, the calculation of weighted average shares outstanding for basic and diluted net loss per share assumes
that the shares issuable in connection with the Pro Forma Adjustments have been outstanding for the entirety of the periods presented.
Weighted average shares outstanding - basic and diluted (excluding a combined 660,001 ordinary shares underlying outstanding public warrants
and private placement warrants because including them would have had an anti-dilutive effect on net loss per share) for the nine-months
period ended September 30, 2024, and for the year ended December 31, 2023 are calculated based on the actual pro forma number of New Silexion
ordinary shares that were issued and outstanding upon the Closing, after taking into account actual redemptions of Moringa public shares.</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: rgb(0, 0, 0); font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">54</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="text-align: center; line-height: 1.25"><span style="font-family: Times New Roman"><br/> </span> </div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman">Comparative Share Information</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25">The following table sets forth selected historical comparative share information for
each of Moringa and New Silexion and unaudited pro forma condensed combined per share information for New Silexion after giving effect
to the Business Combination.</div>

<div style="text-indent: 36pt; line-height: 1.25">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25">The weighted average shares outstanding and net earnings per share information reflect
the Business Combination as if it had occurred on January 1, 2023.</div>

<div style="text-indent: 36pt; line-height: 1.25">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25">This information is only a summary and should be read together with the historical financial
statements of Moringa and New Silexion and related notes. The unaudited pro forma condensed combined per share information of Moringa
and New Silexion is derived from, and should be read in conjunction with, the unaudited pro forma combined financial statements and related
notes included above.</div>

<div style="text-indent: 36pt; line-height: 1.25">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25">

<div style="text-indent: 36pt; line-height: 1.25">The unaudited pro forma combined earnings per share information below does not purport
to represent the earnings per share which would have occurred had Moringa and New Silexion been combined during the periods presented,
nor the earnings per share for any future date or period. Historically, Moringa&#8217;s statement of operations included a presentation
of profit (loss) per share in a manner similar to the two-class method of income (loss) per ordinary shares. The two-class method is not
required in the pro forma income (loss) per ordinary shares as the Moringa Class A ordinary shares are no longer subject to redemption.
Moringa has included the effect of the warrants to purchase an aggregate of 660,001 Class A ordinary shares, in the aggregate, sold in
the IPO and the concurrent private placement in the calculation of diluted earnings per share, as they became exercisable commencing 30
days following the Closing. As a result, diluted earnings per ordinary share differs from basic earnings per ordinary share for the periods
presented. The share and per share information appearing in the table below does not reflect the reverse share split with respect to Moringa
historical data, but does reflect the reverse share split for the New Silexion historical data and for the pro forma combined data of
New Silexion.</div> </div>

<div style="text-indent: 36pt; line-height: 1.25"> <br/> </div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: rgb(0, 0, 0); font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">55</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="line-height: 1.25; font-family: Times New Roman">

<table cellspacing="0" cellpadding="0" id="zcefc3fcea2274a84b6f61d3cd3ae5112" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 52%; vertical-align: bottom">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 1%; vertical-align: bottom">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td colspan="6" style="border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom">
        <div style="text-align: center; line-height: 1.25; font-weight: bold">Moringa Acquisition Corp (Period between January 1 and August 14,
        2024)<br/> (Historical)</div> </td>
    <td style="white-space: nowrap; width: 1%; vertical-align: bottom">
        <div style="text-align: center; line-height: 1.25">&#160;</div> </td>
    <td style="width: 1%; vertical-align: bottom">
        <div style="text-align: center; line-height: 1.25">&#160;</div> </td>
    <td colspan="2" style="vertical-align: bottom">
        <div style="text-align: center; line-height: 1.25">&#160;</div> </td>
    <td style="white-space: nowrap; width: 1%; vertical-align: bottom">
        <div style="text-align: center; line-height: 1.25">&#160;</div> </td>
    <td style="width: 1%; vertical-align: bottom">
        <div style="text-align: center; line-height: 1.25">&#160;</div> </td>
    <td colspan="2" style="vertical-align: bottom">
        <div style="text-align: center; line-height: 1.25">&#160;</div> </td>
    <td style="white-space: nowrap; width: 1%; vertical-align: bottom">
        <div style="line-height: 1.25">&#160;</div> </td> </tr>
  <tr>
    <td style="border-bottom: rgb(0, 0, 0) 2px solid; width: 52%; vertical-align: bottom">
        <div style="line-height: 1.25; font-weight: bold">For the nine-months period ended September 30, 2024</div> </td>
    <td style="width: 1%; vertical-align: bottom">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td colspan="2" style="border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom">
        <div style="text-align: center; line-height: 1.25; font-weight: bold">Class A<br/> subject to<br/> Possible<br/> Redemption</div> </td>
    <td style="white-space: nowrap; width: 1%; vertical-align: bottom">
        <div style="text-align: center; line-height: 1.25">&#160;</div> </td>
    <td style="width: 1%; vertical-align: bottom">
        <div style="text-align: center; line-height: 1.25">&#160;</div> </td>
    <td colspan="2" style="border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom">
        <div style="text-align: center; line-height: 1.25; font-weight: bold">Non-<br/> redeemable<br/> Class A and<br/> Class B</div> </td>
    <td style="white-space: nowrap; width: 1%; vertical-align: bottom">
        <div style="text-align: center; line-height: 1.25">&#160;</div> </td>
    <td style="width: 1%; vertical-align: bottom">
        <div style="text-align: center; line-height: 1.25">&#160;</div> </td>
    <td colspan="2" style="border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom">
        <div style="text-align: center; line-height: 1.25; font-weight: bold">New Silexion<br/> (Historical)</div> </td>
    <td style="white-space: nowrap; width: 1%; vertical-align: bottom">
        <div style="text-align: center; line-height: 1.25">&#160;</div> </td>
    <td style="width: 1%; vertical-align: bottom">
        <div style="text-align: center; line-height: 1.25">&#160;</div> </td>
    <td colspan="2" style="border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom">
        <div style="text-align: center; line-height: 1.25; font-weight: bold">Pro Forma<br/> Combined<br/> (Actual<br/> Redemption)</div> </td>
    <td style="white-space: nowrap; width: 1%; vertical-align: bottom">
        <div style="line-height: 1.25">&#160;</div> </td> </tr>
  <tr>
    <td style="width: 52%; vertical-align: bottom">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 1%; vertical-align: bottom">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td colspan="2" style="vertical-align: bottom">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="white-space: nowrap; width: 1%; vertical-align: bottom">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 1%; vertical-align: bottom">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td colspan="2" style="vertical-align: bottom">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="white-space: nowrap; width: 1%; vertical-align: bottom">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 1%; vertical-align: bottom">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td colspan="2" style="vertical-align: bottom">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="white-space: nowrap; width: 1%; vertical-align: bottom">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 1%; vertical-align: bottom">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td colspan="2" style="vertical-align: bottom">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="white-space: nowrap; width: 1%; vertical-align: bottom">
        <div style="line-height: 1.25">&#160;</div> </td> </tr>
  <tr>
    <td style="width: 52%; vertical-align: bottom; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25">Weighted average shares outstanding &#8211; basic and diluted</div> </td>
    <td style="width: 1%; vertical-align: bottom; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 1%; vertical-align: bottom; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 9%; vertical-align: bottom; background-color: rgb(204, 238, 255)">
        <div style="text-align: right; line-height: 1.25">87,722</div> </td>
    <td style="white-space: nowrap; width: 1%; vertical-align: bottom; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 1%; vertical-align: bottom; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 1%; vertical-align: bottom; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 9%; vertical-align: bottom; background-color: rgb(204, 238, 255)">
        <div style="text-align: right; line-height: 1.25">3,355,000</div> </td>
    <td style="white-space: nowrap; width: 1%; vertical-align: bottom; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 1%; vertical-align: bottom; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 1%; vertical-align: bottom; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 9%; vertical-align: bottom; background-color: rgb(204, 238, 255)">
        <div style="text-align: right; line-height: 1.25">291,407</div> </td>
    <td style="white-space: nowrap; width: 1%; vertical-align: bottom; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 1%; vertical-align: bottom; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 1%; vertical-align: bottom; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 9%; vertical-align: bottom; background-color: rgb(204, 238, 255)">
        <div style="text-align: right; line-height: 1.25">1,127,365</div> </td>
    <td style="white-space: nowrap; width: 1%; vertical-align: bottom; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25">&#160;</div> </td> </tr>
  <tr>
    <td style="width: 52%; vertical-align: bottom">
        <div style="line-height: 1.25">Net profit (loss) per share &#8211; basic</div> </td>
    <td style="width: 1%; vertical-align: bottom">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 1%; vertical-align: bottom">
        <div style="line-height: 1.25">$</div> </td>
    <td style="width: 9%; vertical-align: bottom">
        <div style="text-align: right; line-height: 1.25">0.39</div> </td>
    <td style="white-space: nowrap; width: 1%; vertical-align: bottom">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 1%; vertical-align: bottom">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 1%; vertical-align: bottom">
        <div style="line-height: 1.25">$</div> </td>
    <td style="width: 9%; vertical-align: bottom">
        <div style="text-align: right; line-height: 1.25">(0.18</div> </td>
    <td style="white-space: nowrap; width: 1%; vertical-align: bottom">
        <div style="line-height: 1.25">)</div> </td>
    <td style="width: 1%; vertical-align: bottom">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 1%; vertical-align: bottom">
        <div style="line-height: 1.25">$</div> </td>
    <td style="width: 9%; vertical-align: bottom">
        <div style="text-align: right; line-height: 1.25">(50.43</div> </td>
    <td style="white-space: nowrap; width: 1%; vertical-align: bottom">
        <div style="line-height: 1.25">)</div> </td>
    <td style="width: 1%; vertical-align: bottom">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 1%; vertical-align: bottom">
        <div style="line-height: 1.25">$</div> </td>
    <td style="width: 9%; vertical-align: bottom">
        <div style="text-align: right; line-height: 1.25">
        <div style="line-height: 1.25">(3.76</div> </div> </td>
    <td style="white-space: nowrap; width: 1%; vertical-align: bottom">
        <div style="line-height: 1.25">)</div> </td> </tr>
  </table> </div> <br/>

<div style="line-height: 1.25; font-family: Times New Roman">

<table cellspacing="0" cellpadding="0" id="z2c84810ffc884198bb0022938d3917fc" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 52%; vertical-align: bottom">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 1%; vertical-align: bottom">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td colspan="6" style="border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom">
        <div style="text-align: center; line-height: 1.25; font-weight: bold">Moringa Acquisition Corp<br/> (Historical)</div> </td>
    <td style="white-space: nowrap; width: 1%; vertical-align: bottom">
        <div style="text-align: center; line-height: 1.25">&#160;</div> </td>
    <td style="width: 1%; vertical-align: bottom">
        <div style="text-align: center; line-height: 1.25">&#160;</div> </td>
    <td colspan="2" style="vertical-align: bottom">
        <div style="text-align: center; line-height: 1.25">&#160;</div> </td>
    <td style="white-space: nowrap; width: 1%; vertical-align: bottom">
        <div style="text-align: center; line-height: 1.25">&#160;</div> </td>
    <td style="width: 1%; vertical-align: bottom">
        <div style="text-align: center; line-height: 1.25">&#160;</div> </td>
    <td colspan="2" style="vertical-align: bottom">&#160;</td>
    <td style="white-space: nowrap; width: 1%; vertical-align: bottom">
        <div style="line-height: 1.25">&#160;</div> </td> </tr>
  <tr>
    <td style="border-bottom: rgb(0, 0, 0) 2px solid; width: 52%; vertical-align: bottom">
        <div style="line-height: 1.25; font-weight: bold">For the year ended December 31, 2023</div> </td>
    <td style="width: 1%; vertical-align: bottom">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td colspan="2" style="border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom">
        <div style="text-align: center; line-height: 1.25; font-weight: bold">Class A<br/> subject to<br/> Possible<br/> Redemption</div> </td>
    <td style="white-space: nowrap; width: 1%; vertical-align: bottom">
        <div style="text-align: center; line-height: 1.25">&#160;</div> </td>
    <td style="width: 1%; vertical-align: bottom">
        <div style="text-align: center; line-height: 1.25">&#160;</div> </td>
    <td colspan="2" style="border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom">
        <div style="text-align: center; line-height: 1.25; font-weight: bold">Non-<br/> redeemable<br/> Class A and<br/> Class B</div> </td>
    <td style="white-space: nowrap; width: 1%; vertical-align: bottom">
        <div style="text-align: center; line-height: 1.25">&#160;</div> </td>
    <td style="width: 1%; vertical-align: bottom">
        <div style="text-align: center; line-height: 1.25">&#160;</div> </td>
    <td colspan="2" style="border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom">
        <div style="text-align: center; line-height: 1.25; font-weight: bold">New Silexion<br/> (Historical)</div> </td>
    <td style="white-space: nowrap; width: 1%; vertical-align: bottom">
        <div style="text-align: center; line-height: 1.25">&#160;</div> </td>
    <td style="width: 1%; vertical-align: bottom">
        <div style="text-align: center; line-height: 1.25">&#160;</div> </td>
    <td colspan="2" style="border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom">
        <div style="text-align: center; line-height: 1.25; font-weight: bold">Pro Forma</div>
        <div style="text-align: center; line-height: 1.25; font-weight: bold">Combined<br/> (Actual<br/> Redemption)</div> </td>
    <td style="white-space: nowrap; width: 1%; vertical-align: bottom">
        <div style="line-height: 1.25">&#160;</div> </td> </tr>
  <tr>
    <td style="width: 52%; vertical-align: bottom">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 1%; vertical-align: bottom">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td colspan="2" style="vertical-align: bottom">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="white-space: nowrap; width: 1%; vertical-align: bottom">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 1%; vertical-align: bottom">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td colspan="2" style="vertical-align: bottom">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="white-space: nowrap; width: 1%; vertical-align: bottom">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 1%; vertical-align: bottom">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td colspan="2" style="vertical-align: bottom">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="white-space: nowrap; width: 1%; vertical-align: bottom">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 1%; vertical-align: bottom">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td colspan="2" style="vertical-align: bottom">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="white-space: nowrap; width: 1%; vertical-align: bottom">
        <div style="line-height: 1.25">&#160;</div> </td> </tr>
  <tr>
    <td style="width: 52%; vertical-align: bottom; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25">Weighted average shares outstanding &#8211; basic and diluted</div> </td>
    <td style="width: 1%; vertical-align: bottom; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 1%; vertical-align: bottom; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 9%; vertical-align: bottom; background-color: rgb(204, 238, 255)">
        <div style="text-align: right; line-height: 1.25">2,774,850</div> </td>
    <td style="white-space: nowrap; width: 1%; vertical-align: bottom; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 1%; vertical-align: bottom; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 1%; vertical-align: bottom; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 9%; vertical-align: bottom; background-color: rgb(204, 238, 255)">
        <div style="text-align: right; line-height: 1.25">3,355,000</div> </td>
    <td style="white-space: nowrap; width: 1%; vertical-align: bottom; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 1%; vertical-align: bottom; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 1%; vertical-align: bottom; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 9%; vertical-align: bottom; background-color: rgb(204, 238, 255)">
        <div style="text-align: right; line-height: 1.25">111,726</div> </td>
    <td style="white-space: nowrap; width: 1%; vertical-align: bottom; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 1%; vertical-align: bottom; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 1%; vertical-align: bottom; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 9%; vertical-align: bottom; background-color: rgb(204, 238, 255)">
        <div style="text-align: right; line-height: 1.25">1,126,433</div> </td>
    <td style="white-space: nowrap; width: 1%; vertical-align: bottom; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25">&#160;</div> </td> </tr>
  <tr>
    <td style="width: 52%; vertical-align: bottom">
        <div style="line-height: 1.25">Net profit (loss) per share &#8211; basic</div> </td>
    <td style="width: 1%; vertical-align: bottom">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 1%; vertical-align: bottom">
        <div style="line-height: 1.25">$</div> </td>
    <td style="width: 9%; vertical-align: bottom">
        <div style="text-align: right; line-height: 1.25">0.51</div> </td>
    <td style="white-space: nowrap; width: 1%; vertical-align: bottom">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 1%; vertical-align: bottom">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 1%; vertical-align: bottom">
        <div style="line-height: 1.25">$</div> </td>
    <td style="width: 9%; vertical-align: bottom">
        <div style="text-align: right; line-height: 1.25">(0.34</div> </td>
    <td style="white-space: nowrap; width: 1%; vertical-align: bottom">
        <div style="line-height: 1.25">)</div> </td>
    <td style="width: 1%; vertical-align: bottom">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 1%; vertical-align: bottom">
        <div style="line-height: 1.25">$</div> </td>
    <td style="width: 9%; vertical-align: bottom">
        <div style="text-align: right; line-height: 1.25">(44.23</div> </td>
    <td style="white-space: nowrap; width: 1%; vertical-align: bottom">
        <div style="line-height: 1.25">)</div> </td>
    <td style="width: 1%; vertical-align: bottom">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 1%; vertical-align: bottom">
        <div style="line-height: 1.25">$</div> </td>
    <td style="width: 9%; vertical-align: bottom">
        <div style="text-align: right; line-height: 1.25">
        <div style="line-height: 1.25">(16.27</div> </div> </td>
    <td style="white-space: nowrap; width: 1%; vertical-align: bottom">
        <div style="line-height: 1.25">)</div> </td> </tr>
  </table> </div>

<div style="line-height: 1.25; font-family: Times New Roman"> &#160; </div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: rgb(0, 0, 0); font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">56</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>
<!--PROfilePageNumberReset%Num%59%%%-->

<div style="text-align: center; line-height: 1.25"><span style="font-family: Times New Roman"><br/> </span> </div>

<div style="text-align: center; line-height: 1.25; font-weight: bold; font-family: Times New Roman"><!--Anchor-->MANAGEMENT&#8217;S DISCUSSION
AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF </div>

<div style="text-align: center; line-height: 1.25; font-weight: bold; font-family: Times New Roman"><span id="OPERATIONS"><!--Anchor--></span>OPERATIONS</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="line-height: 1.25; font-weight: bold; font-family: Times New Roman">Introductory Note</div>

<div style="text-indent: 18pt; line-height: 1.25; font-style: italic; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-style: italic; font-family: Times New Roman">The following discussion and analysis
of our financial condition and results of operations (this &#8220;<span style="font-weight: bold">MD&amp;A</span>&#8221;) should be read
in conjunction with the financial statements and the related notes included elsewhere in this prospectus. Some of the information contained
in this discussion and analysis or set forth in this prospectus, including information with respect to our plans, objectives, expectations,
projections, and strategy for our business and related financing, includes forward-looking statements that involve risks and uncertainties.
As a result of many factors, including those factors set out in the &#8220;Risk Factors&#8221; sections of this prospectus, our actual
results could differ materially from the results described in or implied by these forward-looking statements. See also the section entitled
&#8220;Special Note Regarding Forward-Looking Statements&#8221; in this prospectus.</div>

<div style="text-indent: 36pt; line-height: 1.25; font-style: italic; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-style: italic; font-family: Times New Roman">Unless the context otherwise requires,
references to the &#8220;Company,&#8221; &#8220;we,&#8221; &#8220;us&#8221; and &#8220;our&#8221; in this MD&amp;A generally refer to
Silexion Therapeutics Ltd., an Israeli company (&#8220;Silexion&#8221;), or, from and after the Business Combination, Silexion Therapeutics
Corp (formerly known as Biomotion Sciences), a Cayman Islands exempted company (also referred to herein as &#8220;New Silexion&#8221;).</div>

<div style="text-indent: 36pt; line-height: 1.25; font-style: italic; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-style: italic; font-family: Times New Roman">On August 15, 2024, New Silexion,
Silexion and Moringa completed the Business Combination pursuant to the Business Combination Agreement.</div>

<div style="line-height: 1.25; font-weight: bold; font-family: Times New Roman">&#160;</div>

<div style="line-height: 1.25; font-weight: bold; font-family: Times New Roman">Overview</div>

<div style="text-indent: 18pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="line-height: 1.25">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">We are a Cayman Islands exempted company that was originally
formed for the purpose of effectuating the Business Combination and that now serves as a publicly-traded holding company for each of Silexion
(through which our operations are carried out) and Moringa (which has no operations). Our ordinary shares and warrants are listed on the
Nasdaq Global Market under the trading symbols &#8220;SLXN&#8221; and &#8220;SLXNW&#8221;, respectively.</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif"> <span style="font-family: Times New Roman"><br/>
</span> </div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">

<div style="line-height: 1.25; font-family: Times New Roman">We conduct operations primarily through our principal subsidiary&#8212; Silexion&#8212;
which is a clinical-stage, oncology-focused biotechnology company engaged in the discovery and development of proprietary treatments for
KRAS-driven cancers. The KRAS gene is an oncogene that is involved in the regulation of cell division as a result of its ability to relay
external signals to the cell nucleus. Based on its research of refractory solid tumor cancers, Silexion is actively developing a platform
focused on the silencing of the KRAS oncogene using RNA-interference therapeutics. Silexion&#8217;s lead product candidate, SIL-204B,
consists of locally administered small interfering RNAs, or siRNA, in an extended-release formulation, as a first-line treatment of locally
advanced pancreatic cancer patients, in combination with standard-of-care chemotherapy.</div> </div> </div> </div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="line-height: 1.25">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">To date, Silexion has financed its operations primarily
with the net proceeds from private offerings of its ordinary shares and convertible preferred shares, grants from the Israeli Innovation
Authority (the &#8220;IIA&#8221;), convertible financing agreements and Simple Agreement for Future Equity (SAFE) financings, and royalty-bearing
grants from the IIA (which totaled $5.8 million through September 30, 2024). Since its inception, Silexion has incurred significant operating
losses. Silexion&#8217;s net losses were $5.1 million and $3.5 million for the years ended December 31, 2023 and December 31, 2022, respectively.
The combined company&#8217;s net losses (consisting of Silexion&#8217;s net losses for all periods through the Business Combination, and
the combined company's net losses for all periods after) were $14.8 million and $3.4 million for the nine-month periods ended September
30, 2024, and 2023, respectively. As of September 30, 2024, we had an accumulated deficit of $41.6 million (reflecting Silexion's accumulated
deficit for all periods through August 15, 2024 and the combined company's accumulated deficit from August 16, 2024 through September
30, 2024). Silexion has not recognized any revenue to date.</div> </div> </div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">

<div style="line-height: 1.25; font-family: Times New Roman">We expect to continue to incur significant expenses and operating losses
for the foreseeable future. The net losses it incurs may fluctuate significantly from quarter to quarter. Our expenses will depend on
many factors, including the timing and extent of spending to further develop SIL-204 and initiate pre-clinical and clinical trials, support
research and development efforts, investments in potential additional pipe-line products, and increased overall compensation as we continue
to hire additional personnel. We anticipate that our expenses will increase if and as we:</div> </div> </div>

<div style="text-indent: -36pt; margin-left: 48pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<table cellspacing="0" cellpadding="0" id="za79210aca577483c8c90bd7bacad6de0" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">
        <div style="line-height: 1.25; font-family: Times New Roman">apply for Orphan Drug Designation in both the U.S. and EU for its SIL-204B
        product;</div> </div> </td> </tr>
  </table>

<div style="text-indent: -36pt; margin-left: 48pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z5bb79032f2704e0eae0d76c2529698a7" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">
        <div style="line-height: 1.25; font-family: Times New Roman">initiate a clinical trial powered for statistical significance with respect
        to SIL-204B;</div> </div> </td> </tr>
  </table>

<div>

<div style="text-align: center; line-height: 1.25"><span style="font-family: Times New Roman"><br/> </span> </div> <span style="font-family: Times New Roman">
</span>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman,Times,serif"><span style="font-family: Times New Roman"><br/>
        </span> </td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">
        <div style="line-height: 1.25; font-family: Times New Roman">initiate toxicological studies with respect to SIL-204B;</div> </div> </td>
        </tr>
  </table>

<div style="text-indent: -36pt; margin-left: 48pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">
        <div style="line-height: 1.25; font-family: Times New Roman">seek marketing approvals for SIL-204B in various territories;</div> </div>
        </td> </tr>
  </table>

<div style="text-indent: -36pt; margin-left: 48pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">
        <div style="line-height: 1.25; font-family: Times New Roman">maintain, expand and protect our intellectual property portfolio;</div> </div>
        </td> </tr>
  </table>

<div style="text-indent: -36pt; margin-left: 48pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">
        <div style="line-height: 1.25; font-family: Times New Roman">hire additional operational, clinical, quality control and scientific personnel;</div>
        </div> </td> </tr>
  </table>

<div style="text-indent: -36pt; margin-left: 48pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">
        <div style="line-height: 1.25; font-family: Times New Roman">add operational, financial and management information systems and personnel,
        including personnel to support our product development, any future commercialization efforts and our prospective transition to a public
        company; and</div> </div> </td> </tr>
  </table>

<div style="text-indent: -36pt; margin-left: 48pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">
        <div style="line-height: 1.25; font-family: Times New Roman">invest in research and development and regulatory approval efforts in order
        to utilize our technology as a platform focused on the silencing of the KRAS oncogene using RNA-interference therapeutics.</div> </div>
        </td> </tr>
  </table>

<div style="line-height: 1.25; font-weight: bold; font-family: Times New Roman">&#160;</div> </div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: rgb(0, 0, 0); font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">57</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div> </div>

<div><br/>

<div style="line-height: 1.25; font-weight: bold">

<div style="line-height: 1.25; font-family: Times New Roman; font-weight: bold">Reverse Share Split</div> </div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif"><span style="font-family: Times New Roman"><br/> </span> </div>

<div style="text-indent: 35.45pt; line-height: 1.25">

<div style="line-height: 1.25; font-family: Times New Roman">

<div style="text-indent: 35.45pt; line-height: 1.25; font-family: Times New Roman, Times, serif">On November 27, 2024, we effected a 1-for-9
reverse share split of our authorized ordinary shares, including our issued and outstanding ordinary shares, with a market effective date
of November 29, 2024. Unless specifically provided otherwise herein, all share, per share and related option and warrant information for
New Silexion (but not Moringa) presented in this prospectus has been retroactively adjusted to reflect the reduced number of shares and
the increase in the share price which resulted from the reverse share split.</div>

<div style="text-indent: 35.45pt; line-height: 1.25; font-family: Times New Roman, Times, serif">&#160;</div> </div> </div>

<div style="line-height: 1.25">

<div style="line-height: 1.25; font-family: Times New Roman">

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif; font-weight: 400">

<div style="line-height: 1.25; font-family: Times New Roman, Times, serif; font-weight: bold">Recent Developments</div>

<div style="line-height: 1.25; font-family: Times New Roman, Times, serif; font-weight: bold">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">Our prospective financial condition and
results of operations in the period following the Closing of the Business Combination will be impacted by the following transactions,
all of which were entered into at or around the time of the Closing:</div>

<div style="line-height: 1.25; font-family: Times New Roman, Times, serif; font-weight: bold">&#160;</div>

<div style="line-height: 1.25; font-family: Times New Roman, Times, serif; font-style: italic; font-weight: bold">January 2025 Warrant
Inducement Transaction</div>

<div style="line-height: 1.25"><br/> </div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">For a description of the Warrant Inducement
Transaction, please see &#8220;<span style="font-style: italic">January 2025</span>&#160;<span style="font-style: italic">Transactions
Related to Offering Under This Prospectus&#8212;January 2025 Warrant Inducement Transaction</span>&#8221; above in this prospectus, which
description is incorporated by reference herein.</div>

<div style="line-height: 1.25"><br/> </div>

<div style="line-height: 1.25; font-family: Times New Roman, Times, serif; font-style: italic; font-weight: bold">January 2025 Financing</div>

<div style="line-height: 1.25"><br/> </div>

<div style="line-height: 1.25">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">On January 15, 2025, New Silexion offered
and sold in a public offering on a best efforts basis (the &#8220;<span style="font-weight: bold">January 2025</span>&#160;<span style="font-weight: bold">Offering</span>&#8221;)
(i) 2,145,998 of New Silexion ordinary shares, (ii) 1,557,705 pre-funded warrants to purchase up to 1,557,705 New Silexion ordinary shares
(the &#8220;<span style="font-weight: bold">January 2025 Pre-Funded Warrants</span>&#8221;), and (iii) 3,703,703 warrants to purchase
up to 3,703,703 New Silexion ordinary shares (the &#8220;<span style="font-weight: bold">January 2025</span>&#160;<span style="font-weight: bold">Investor
Warrants</span>&#8221; and together with the Pre-Funded Warrants, the &#8220;<span style="font-weight: bold">January 2025</span>&#160;<span style="font-weight: bold">Warrants</span>&#8221;),
at a purchase price of $1.35 per share and accompanying January 2025 Investor Warrant, and $1.3499 per January 2025 Pre-Funded Warrant
and accompanying January 2025 Investor Warrant. Aggregate gross proceeds from the January 2025 Offering (without taking into account any
proceeds from any future exercises of January 2025 Warrants) were approximately $5 million. The January Offering closed on January 17,
2025, subject to the satisfaction of customary closing conditions.</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">The January 2025 Pre-Funded Warrants are
immediately exercisable at an exercise price of $0.0001 per share and will not expire until exercised in full. The January 2025 Investor
Warrants have an exercise price of $1.35 per share, are immediately exercisable, and may be exercised for five years from issuance.</div>
</div>

<div style="line-height: 1.25">

<div style="line-height: 1.25"><br/> </div> </div>

<div style="line-height: 1.25">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">A holder of the January 2025 Warrants will
not have the right to exercise any portion of its Pre-Funded Warrants and Investor Warrants if the holder (together with such holder&#8217;s
affiliates, and any persons acting as a group together with such holder or any of such holder&#8217;s affiliates or any other persons
whose beneficial ownership of ordinary shares would be aggregated with the holder&#8217;s or any of the holder&#8217;s affiliates), would
beneficially own ordinary shares in excess of 4.99% (or, at the election of the holder, 9.99%) of the number of the ordinary shares outstanding
immediately after giving effect to such exercise.</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal">58</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">&#160;&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">Certain investors in the January 2025 Offering
entered into a definitive securities purchase agreement with the Company (the &#8220;<span style="font-weight: bold">January 2025 Purchase
Agreement</span>&#8221;). The Purchase Agreement contains representations, warranties, indemnification and other provisions customary
for transactions of this nature. Pursuant to the January 2025 Purchase Agreement, New Silexion agreed to abide by certain customary standstill
restrictions for a period of sixty (60) days following the closing of the January 2025 Offering. In addition, subject to limited exceptions,
the January 2025 Purchase Agreement provides that for a period of one year following the closing of the January 2025 Offering, the Company
will not effect or enter into an agreement to effect a &#8220;variable rate transaction&#8221; as defined in the January 2025 Purchase
Agreement.</div>

<div style="line-height: 1.25"><br/> </div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">Wainwright acted as the sole placement agent
(the &#8220;<span style="font-weight: bold">Placement Agent</span>&#8221;), on a &#8220;best efforts&#8221; basis, in connection with
the January 2025 Offering. Pursuant to an engagement agreement that New Silexion entered into with Wainwright, New Silexion issued to
Wainwright or its designees 259,259 warrants to purchase up to 259,259 New Silexion ordinary shares, representing 7.0% of the sum of the
shares and January 2025 Pre-Funded Warrants sold in the January 2025 Offering (the &#8220;<span style="font-weight: bold">January 2025</span>&#160;<span style="font-weight: bold">Placement
Agent Warrants</span>&#8221;). The January 2025 Placement Agent Warrants have an exercise price of $1.6875 per share (representing 125%
of the public offering price per share and accompanying January 2025 Investor Warrant), are exercisable for five&#160;years from the date
of the commencement of sales in this offering, and otherwise reflect substantially the same terms as the January 2025 Investor Warrants.</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">&#160;</div> </div>

<div style="line-height: 1.25">

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">The net proceeds to
New Silexion from the January 2025 Offering were approximately $4.26 million before deducting estimated offering expenses payable by New
Silexion.&#160;</div>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">

<div style="text-indent: 36pt; line-height: 1.25">Prior to the January 2025 Warrant Inducement Transaction, a total of 640,257 January
2025 Investor Warrants were exercised into 640,257 New Silexion ordinary shares and 1,557,705 January 2025 Pre-Funded Warrants were exercised
into 1,557,705 New Silexion ordinary shares, for a total net proceeds of $0.86 million. As of February 11, 2025, the January 2025 Pre-Funded
Warrants have been exercised in full and 841,923 January 2025 Investor Warrants remain unexercised at an exercise price of $1.35 per share.</div>
</div> </div>

<div style="line-height: 1.25"><br/> </div>

<div style="line-height: 1.25; font-family: Times New Roman, Times, serif; font-style: italic; font-weight: bold">Completion of Business
Combination Transaction</div>

<div style="line-height: 1.25; font-family: Times New Roman, Times, serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">On August 15, 2024, New Silexion, Silexion
and Moringa completed the previously-announced Business Combination pursuant to the Amended and Restated Business Combination Agreement,
dated April 3, 2024, by and among New Silexion, Merger Sub 1, Merger Sub 2, Moringa and Silexion. In connection with the Closing of the
Business Combination, New Silexion changed its name from &#8220;Biomotion Sciences&#8221; to &#8220;Silexion Therapeutics Corp&#8221;.</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">&#160;&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">Pursuant to the Business Combination Agreement,
among other things, (i) Merger Sub 2 merged with and into Moringa, with Moringa continuing as the surviving company and a wholly-owned
subsidiary of New Silexion and (ii) Merger Sub 1 merged with and into Silexion, with Silexion continuing as the surviving company and
a wholly-owned subsidiary of New Silexion.</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">Upon the effectiveness of the SPAC Merger,
each outstanding Moringa Class&#160;A ordinary share, that had not been redeemed and the sole outstanding Moringa Class&#160;B ordinary
share converted into a New Silexion ordinary share on a one-for-one&#160;basis. Each outstanding Moringa warrant converted into a New
Silexion warrant, exercisable at the same exercise price. Upon the effectiveness of the Acquisition Merger, each outstanding ordinary
share and preferred share of Silexion converted into such number of New Silexion ordinary shares as is equal to the quotient obtained
by dividing (x)&#160;the quotient obtained by dividing (1)&#160;$62,500,000 by (2)&#160;the number of fully diluted Silexion equity securities,
by (y)&#160;$10.00 (the &#8220;<span style="font-weight: bold">Silexion Equity Exchange Ratio</span>&#8221;). Each outstanding Silexion
warrant and Silexion option to purchase one Silexion share, and Silexion restricted share unit (RSU) that may be potentially settled for
one Silexion share, became exercisable for, or became subject to settlement for (as applicable), such number of New Silexion ordinary
shares as are equal to the Silexion Equity Exchange Ratio. The exercise price per New Silexion ordinary share of each such converted Silexion
option and Silexion warrant were adjusted based on dividing the existing per share exercise price by the Silexion Equity Exchange Ratio.
The terms of vesting, exercise and/or settlement, as applicable, of such converted options, warrants and RSUs remain the same following
such conversion, except that the vesting of each Silexion option accelerated immediately prior to the Acquisition Merger, such that the
New Silexion option into which it has been converted was fully vested, and all Silexion warrants were exercised (on a cashless basis)
immediately prior to the Acquisition Merger.</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal">59</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">&#160;&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">In connection with the Moringa shareholder
vote to approve the Business Combination Agreement and the Business Combination, holders of an aggregate of 427,297 Moringa ordinary shares
properly exercised their right to have their shares redeemed for a full pro rata portion of the Trust Account holding the proceeds from
Moringa&#8217;s IPO, which was approximately $11.575 per share, or $4,946,046 in the aggregate.</div>

<div style="line-height: 1.25"><br/> </div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">As a result of the redemptions of Moringa
ordinary shares, a total of 87,722 Moringa public shares remained outstanding at the Closing. After giving effect to the Business Combination
and additional changes to share capital, immediately following the Closing, there were 9,768,396 New Silexion ordinary shares issued and
outstanding.</div>

<div style="line-height: 1.25; font-family: Times New Roman, Times, serif">&#160;</div>

<div style="line-height: 1.25; font-family: Times New Roman, Times, serif; font-style: italic; font-weight: bold">PIPE Financing</div>

<div style="line-height: 1.25; font-family: Times New Roman, Times, serif; font-style: italic; font-weight: bold">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">In connection with, and immediately prior
to the Closing of, the Business Combination, Moringa raised $2.0 million via a private investment in public entity financing (the &#8220;<span style="font-weight: bold">PIPE
Financing</span>&#8221;), whereby Moringa sold to Greenstar, LP, an affiliate of the Moringa Sponsor (the &#8220;<span style="font-weight: bold">PIPE
Investor</span>&#8221;), 200,000 newly issued Moringa ordinary shares at a price of $10.00 per share, pursuant to a subscription agreement,
dated as of August 15, 2024, by and among Moringa, New Silexion and the PIPE Investor (the &#8220;<span style="font-weight: bold">PIPE
Agreement</span>&#8221;). Those 200,000 shares automatically converted upon the Closing of the Business Combination into an equivalent
number of New Silexion ordinary shares (the &#8220;<span style="font-weight: bold">PIPE Shares</span>&#8221;). The PIPE Investor is entitled
to customary registration rights in respect of the PIPE Shares under the PIPE Agreement, pursuant to which New Silexion has agreed that,
within 60 days after the date of the Closing, it will file with the SEC a registration statement registering the resale of the PIPE Shares
by the PIPE Investor, and use its commercially reasonable efforts to have that registration statement declared effective by 180 days after
the Closing (or 90 days after the Closing if the SEC does not review that filing).</div>

<div style="line-height: 1.25; font-family: Times New Roman, Times, serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">The funds raised from the PIPE Financing,
together with remaining funds in Moringa&#8217;s Trust Account after payments to redeeming public shareholders, were used for financing
support for Moringa and New Silexion, as well as for payment to service providers to whom outstanding amounts were owed by Moringa, including
parties that had provided financial advisory services and capital markets advisory services to Moringa during the period leading up to
the Closing.</div>

<div style="line-height: 1.25; font-family: Times New Roman, Times, serif">&#160;</div>

<div style="text-indent: 35.45pt; line-height: 1.25; font-family: Times New Roman, Times, serif">The foregoing summary provides only a
brief description of the PIPE Agreement and does not purport to be complete. The summary is qualified in its entirety by the full text
of the PIPE Agreement, which serves as Exhibit 10.2 to the registration statement of which this prospectus forms a part, and which is
incorporated herein by reference.</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">&#160;&#160;</div>

<div style="line-height: 1.25; font-family: Times New Roman, Times, serif; font-style: italic; font-weight: bold">Settlement of Amounts
Due Under Marketing Agreement with EarlyBird</div>

<div style="line-height: 1.25; font-family: Times New Roman, Times, serif">&#160;&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">Prior to the Closing, Moringa reached agreement
with EarlyBird on the reduction, to $1.6 million, in the aggregate, of the fee payable to EarlyBird under the Business Combination Marketing
Agreement entered into by Moringa with EarlyBird at the time of Moringa&#8217;s initial public offering (the &#8220;<span style="font-weight: bold">Marketing
Agreement</span>&#8221;). Pursuant to the final invoice provided by EarlyBird under the Marketing Agreement at the Closing, Moringa paid
$350,000 of cash to EarlyBird from Moringa&#8217;s trust account holding the proceeds from Moringa&#8217;s IPO and its concurrent private
placement (the &#8220;<span style="font-weight: bold">Trust Account</span>&#8221;) at the Closing, and New Silexion issued to EarlyBird
the EarlyBird Convertible Note, which is due on December 31, 2025, in an amount of $1,250,000 to be paid by New Silexion to EarlyBird
in cash and/or via conversion of outstanding amounts into New Silexion ordinary shares.</div>

<div style="line-height: 1.25"><br/> </div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">The EarlyBird Convertible Note bears interest
at a rate of 6% per annum and matures on December 31, 2025 (the &#8220;<span style="font-weight: bold">Maturity Date</span>&#8221;). If
not repaid on or prior to the Maturity Date or such earlier date as to which the repayment obligation may be accelerated under the note,
or not converted in accordance with the terms thereof, the rate of interest applicable to the unpaid principal amount would be adjusted
to (15%) per annum. New Silexion is required to make mandatory prepayments on the note (which shall first be applied to accrued interest
and then to principal) from time to time in amounts equal to ten percent (10%) of the gross proceeds received by New Silexion from any
equity financings consummated by it prior to the Maturity Date. New Silexion is entitled to voluntarily prepay any additional part of,
or all of, the principal and accrued interest, in one or more installments without penalty, prior to the Maturity Date.</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal">60</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="line-height: 1.25; font-family: Times New Roman, Times, serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">EarlyBird, in turn, may elect, at its sole
discretion, at any time on or prior to the Maturity Date, to elect to convert all or part of the then outstanding principal and/or accrued
interest under the EarlyBird Convertible Note into New Silexion ordinary shares, at a per share conversion price equal to 95% of the volume
weighted average price of a New Silexion ordinary share for the five trading days immediately prior to the date of New Silexion&#8217;s
receipt of a conversion notice, provided, however, New Silexion is not required to issue, and EarlyBird may not elect to convert the principal
and/or accrued interest into an aggregate number of New Silexion ordinary shares that would exceed the maximum number of ordinary shares
permitted by Section 5635 of the Nasdaq Listing Rules to be issued without the approval of New Silexion&#8217;s shareholders, unless such
approval is obtained.</div>

<div style="line-height: 1.25; font-family: Times New Roman, Times, serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">Under the EarlyBird Convertible Note, New
Silexion agreed to promptly file a registration statement with the SEC covering the resale of the ordinary shares that may be issued upon
conversion of the note and use its best efforts to have such registration statement declared effective as soon thereafter as possible.
In the event such registration statement is not declared effective by the SEC within 180 days from the date hereof, then an event of default
shall have occurred under the note, triggering all amounts under the note to become due and payable immediately and automatically. The
registration statement of which this prospectus forms a part is being filed, in part, to comply with that registration requirement.</div>

<div style="line-height: 1.25; font-family: Times New Roman, Times, serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">The foregoing summary provides only a brief
description and does not purport to be complete. The summary is qualified in its entirety by the full text of the final invoice provided
by EarlyBird under the Marketing Agreement at the Closing, and the EarlyBird Convertible Note, which serve as Exhibits 10.1.1 and 10.1.2
to the registration statement of which this prospectus forms a part, and which are incorporated herein by reference.</div>

<div style="line-height: 1.25; font-family: Times New Roman, Times, serif">&#160;</div>

<div style="line-height: 1.25; font-family: Times New Roman, Times, serif; font-style: italic; font-weight: bold">Amended and Restated
Sponsor Promissory Note</div>

<div style="line-height: 1.25; font-family: Times New Roman, Times, serif"><span style="font-weight: bold; font-style: italic">&#160;</span>&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">Effective as of the Closing, New Silexion
issued to the Sponsor, and Sponsor accepted, in amendment and restatement, and replacement, in their entirety, of all existing promissory
notes issued by Moringa to the Sponsor from the IPO until the Closing (and as to which the obligations of Moringa were assigned to New
Silexion upon the Closing), the A&amp;R Sponsor Promissory Note, in an amount of $3,433,000, which reflected the total amount owed by
Moringa to the Sponsor through the Closing. The maturity date of the A&amp;R Sponsor Promissory Note is the 30-month anniversary of the
Closing (i.e., February 15, 2027). Amounts outstanding under the A&amp;R Sponsor Promissory Note may be repaid (unless otherwise decided
by New Silexion) only by way of conversion into New Silexion ordinary shares (&#8220;<span style="font-weight: bold">Note Shares</span>&#8221;)
in accordance with the terms set forth in the form of A&amp;R Sponsor Promissory Note. New Silexion and the Sponsor may also convert amounts
outstanding under the A&amp;R Sponsor Promissory Note at the price per share at which New Silexion conducts an equity financing following
the Closing, subject to a minimum conversion amount of $100,000, in an amount of Note Shares constituting up to thirty percent (30%) of
the number of New Silexion ordinary shares issued and sold by New Silexion in such equity financing. The Sponsor may also elect to convert
amounts of principal outstanding under the note into New Silexion ordinary shares at any time following the 24-month anniversary of the
Closing, subject to a minimum conversion of $10,000, at a price per share equal to the volume weighted average price of the New Silexion
ordinary shares on the principal market on which they are traded during the 20 consecutive trading days prior to the conversion date.</div>

<div style="line-height: 1.25; font-family: Times New Roman, Times, serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">The foregoing summary provides only a brief
description of the A&amp;R Sponsor Promissory Note and does not purport to be complete. The summary is qualified in its entirety by the
full text of the A&amp;R Sponsor Promissory Note, which serves as Exhibit 10.5 to the registration statement of which this prospectus
forms a part, and which is incorporated herein by reference.</div>

<div style="line-height: 1.25; font-family: Times New Roman, Times, serif">&#160;</div>

<div style="line-height: 1.25; font-family: Times New Roman, Times, serif; font-style: italic; font-weight: bold">ELOC Financing</div>

<div style="line-height: 1.25; font-family: Times New Roman, Times, serif; font-weight: bold">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">Also in connection with the Closing, New
Silexion entered into the White Lion Purchase Agreement with White Lion, for an equity line of credit, whereby New Silexion will be able
to request to sell to White Lion, and White Lion, which agreement was amended as of January 14, 2025, will be required to purchase, via
private placement transactions, up to $15.0 million of New Silexion ordinary shares from time to time after the Closing, up until December
31, 2025 (unless the agreement is terminated sooner), subject to certain limitations and conditions as described therein. The number of
New Silexion ordinary shares that New Silexion may require White Lion to purchase in any single sales notice will depend on a number of
factors, including the type of purchase notice that New Silexion delivers. Similarly, the purchase price to be paid by White Lion for
any shares that New Silexion requires it to purchase will depend on the type of sales notice that New Silexion delivers. New Silexion
has also granted registration rights to White Lion pursuant to an accompanying registration rights agreement.</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal">61</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">In consideration for the commitments of
White Lion, New Silexion agreed to issue to White Lion an aggregate of $337,500 of New Silexion ordinary shares based on the closing price
of the New Silexion ordinary shares on the day that is the earlier of (i) the business day prior to effectiveness of the registration
statement registering the resale of the shares issuable under the White Lion Purchase Agreement and (ii) the business day prior to the
180<sup style="vertical-align: text-top; line-height: 1; font-size: smaller">th</sup> day following the Closing Date of the Business Combination.
Based on the closing price of the ordinary shares on September 16, 2024, we have issued to White Lion, on September 18, 2024, 365,418
ordinary shares in respect of White Lion&#8217;s commitments under the White Lion Purchase Agreement.</div>

<div style="line-height: 1.25"><br/> </div>

<div style="line-height: 1.25; font-family: Times New Roman, Times, serif; font-style: italic; font-weight: bold">Amended and Restated
Registration Rights and Lock-Up Agreement</div>

<div style="line-height: 1.25; font-family: Times New Roman, Times, serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">Prior to the Closing under the Business
Combination Agreement, on August 14, 2024, New Silexion, Moringa, Moringa Sponsor, the distributees of Sponsor Investment Shares, certain
of Silexion&#8217;s pre-Business Combination shareholders and the PIPE Investor entered into (and EarlyBird will be bound by) the A&amp;R
Registration Rights and Lock-Up Agreement, which became effective as of the Closing. Under the agreement, New Silexion has assumed Moringa&#8217;s
existing obligations under Moringa&#8217;s prior registration rights agreement (entered into in connection with its IPO) and has granted
registration rights to the Moringa Sponsor, the distributees of Sponsor Investment Shares, certain of Silexion&#8217;s pre-Business Combination
shareholders, the PIPE Investor and EarlyBird with respect to certain securities of New Silexion.</div>

<div style="line-height: 1.25; font-family: Times New Roman, Times, serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">Under the A&amp;R Registration Rights and
Lock-Up Agreement, New Silexion has agreed to provide the holders party thereto customary demand and shelf registration rights (subject
to certain minimum size offerings) and piggy-back rights on primary and secondary offerings, subject to customary cut-back provisions.</div>

<div style="line-height: 1.25; font-family: Times New Roman, Times, serif">&#160;</div>

<div style="text-indent: 35.45pt; line-height: 1.25; font-family: Times New Roman, Times, serif">Under the lock-up provisions of the agreement,
lock-up periods will apply following the Closing to securities of New Silexion that are held by the holders who are party to the agreement,
subject to permitted transfers to certain categories of &#8220;Permitted Transferees&#8221;. Specifically, those lock-up periods will
apply to the following categories of securities for the following periods of time post-Closing:</div>

<div style="line-height: 1.25; font-family: Times New Roman, Times, serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="zf505a8d1de09424281fb3dd4cbd73e82" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.68%; vertical-align: top">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 3.84%; vertical-align: top">
        <div style="line-height: 1.25">&#9679;</div> </td>
    <td style="width: 88.48%; vertical-align: top">
        <div style="line-height: 1.25"><span style="font-style: italic">Sponsor/Silexion Lock-Up Period</span>: (A) 50% of the Sponsor Investment
        Shares held by the Sponsor and its distributees and 50% of the New Silexion securities held by the former Silexion shareholders who are
        party to the agreement, in each case, upon the Closing, are subject to a lock-up period ending on the earlier of (i) six (6) months after
        the completion of the Business Combination, and (ii) the date on which New Silexion will consummate a liquidation, merger, amalgamation,
        share exchange, reorganization, or other similar transaction after the Business Combination that results in all of New Silexion&#8217;s
        shareholders having the right to exchange their ordinary shares for cash, securities or other property, and (B) the other 50% of the Sponsor
        Investment Shares held by the Sponsor and its distributees and 50% of the New Silexion securities held by the former Silexion shareholders
        party to the agreement, in each case, upon the Closing, will be subject to a lock-up period that will end on the earliest of (x) six (6)
        months after the date of the consummation of the Business Combination, (y) the date on which New Silexion consummates a liquidation, merger,
        amalgamation, share exchange, reorganization, or other similar transaction after the Business Combination that results in all of New Silexion&#8217;s
        shareholders having the right to exchange their ordinary shares for cash, securities or other property, or (z) the date on which the last
        reported sale price of New Silexion&#8217;s ordinary shares equals or exceeds $12.00 per share (as adjusted for share splits, share dividends,
        rights issuances, subdivisions, reorganizations, recapitalizations and the like) for any 20 trading days within any 30-trading day period.</div>
        </td> </tr>
  </table>

<div style="line-height: 1.25"><br/> </div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal">62</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<table cellspacing="0" cellpadding="0" id="z55accd3219c6499b96514432731a0c84" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.68%; vertical-align: top">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 3.84%; vertical-align: top">
        <div style="line-height: 1.25">&#9679;</div> </td>
    <td style="width: 88.48%; vertical-align: top">
        <div style="line-height: 1.25"><span style="font-style: italic">Private Shares and Private Warrants Lock-Up Period:</span> The lock-up
        period on all New Silexion ordinary shares issued pursuant to the Business Combination in exchange for private placement shares and private
        placement warrants purchased by or issued to the Sponsor and EarlyBird concurrently with Moringa&#8217;s initial public offering will
        remain (as provided in the documentation for Moringa&#8217;s initial public offering) 30 days after the Closing.</div> </td> </tr>
  </table>

<div style="line-height: 1.25"><br/> </div>

<table cellspacing="0" cellpadding="0" id="zc524021ecc694e74bc53b6848ec13a67" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.68%; vertical-align: top">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 3.84%; vertical-align: top">
        <div style="line-height: 1.25">&#9679;</div> </td>
    <td style="width: 88.48%; vertical-align: top">
        <div style="line-height: 1.25"><span style="font-style: italic">Representative Shares</span>&#160;<span style="font-style: italic">Lock-Up
        Period</span>. The lock-up period on all representative shares that are held by EarlyBird will remain (as provided in the documentation
        for Moringa&#8217;s initial public offering) three months after the Closing.</div> </td> </tr>
  </table>

<div style="line-height: 1.25"><br/> </div>

<table cellspacing="0" cellpadding="0" id="z078f307bf06347c1a2fea323f28fdb52" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.68%; vertical-align: top">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 3.84%; vertical-align: top">
        <div style="line-height: 1.25">&#9679;</div> </td>
    <td style="width: 88.48%; vertical-align: top">
        <div style="line-height: 1.25"><span style="font-style: italic">Note Shares and PIPE Shares</span>&#160;<span style="font-style: italic">Lock-Up
        Period</span>. Note Shares (as defined under &#8220;<span style="font-style: italic">Amended and Restated Sponsor Promissory Note</span>&#8221;
        below) issued to the Sponsor upon conversion of amounts due under the A&amp;R Sponsor Promissory Note and PIPE Shares issued to the PIPE
        Investor are not subject to any lock-up periods following the Closing.</div> </td> </tr>
  </table>

<div style="line-height: 1.25"><br/> </div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">The foregoing summary provides only a brief
description of the A&amp;R Registration Rights and Lock-Up Agreement and does not purport to be complete. The summary is qualified in
its entirety by the full text of the A&amp;R Registration Rights and Lock-Up Agreement, which serves as Exhibit 10.4 to the registration
statement of which this prospectus forms a part, and which is incorporated herein by reference.</div> <br/> </div> </div>

<div style="text-indent: 35.45pt; line-height: 1.25"> </div>

<div style="line-height: 1.25; font-weight: bold; font-family: Times New Roman">Components of our Results of Operations</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman">&#160;</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman">Operating Expenses</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman">&#160;</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman">Research and Development Expenses</div>

<div style="text-indent: 18pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">Research and development expenses include costs directly
attributable to the conduct of research and development programs, including the cost of payroll and related expenses, payroll taxes and
other employee benefits including share-based compensation related to employees, subcontractors, lab expenses, preclinical and clinical
trials cost, material costs and consulting fees.</div> </div>

<div style="text-indent: 36pt; line-height: 1.25"> <span style="font-family: Times New Roman"><br/> </span> </div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">We expect to continue to invest in research and development
to develop SIL-204, including hiring additional employees and continuing the research and development of that product candidate. As a
result, we expect that our research and development expenses will continue to increase in the future.</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman">&#160;</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman">General and Administrative Expenses</div>

<div style="text-indent: 18pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">General and administrative expenses consist primarily
of personnel costs, including share-based compensation related to directors and employees, patent application fees, office space rental
costs, and maintenance expenses, external professional service costs, including legal, accounting, audit, finance, human resource services,
travel expenses and other consulting fees.</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">We expect that our general and administrative expenses
will increase in the future to fund our continued research and development activities, primarily due to increased headcount to support
anticipated growth in the business and due to incremental costs associated with operating as a public company, including costs to comply
with the rules and regulations applicable to public companies such as costs related to compliance and reporting obligations pursuant to
the rules and regulations of the SEC and stock exchange listing standards, public relations, insurance and professional services.</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman">&#160;</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman">Financial expenses (income), net</div>

<div style="text-indent: 18pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">The finance expenses consisted primarily of change in
fair value of warrants and financial liabilities measured at fair value, interest income and exchange rate differences expenses.</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: rgb(0, 0, 0); font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">63</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>
<!--PROfilePageNumberReset%Num%61%%%-->

<div style="text-align: center; line-height: 1.25"><span style="font-family: Times New Roman"><br/> </span> </div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman">Results of Operations</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman">&#160;</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman,Times,serif">

<div style="margin-left: 8.2pt; line-height: 1.25; font-family: Times New Roman, Times, serif; font-weight: bold">

<div style="line-height: 1.25; font-family: Times New Roman; font-style: italic; font-weight: bold">Comparison of nine-month period ended
September 30, 2024 and 2023</div> </div> </div>

<div style="text-indent: 18pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="line-height: 1.25">

<div style="text-indent: 35.45pt; line-height: 1.25; font-family: Times New Roman">The following table summarizes our results of operations
for the nine-month periods ended September 30, 2024 and 2023:</div> </div> </div>

<div style="text-indent: 18pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 18pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<table cellspacing="0" cellpadding="0" class="cfttable" id="zf4f25337ed564ce7ba43b10fe0bc38a7" style="font: 10pt Times New Roman, Times, serif; text-align: left; color: #000000; width: 100%">
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px"><span style="font-family: Times New Roman"><br/> </span>
        </td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px; font-family: Times New Roman">&#160;</td>
    <td colspan="6" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom">
        <div style="text-align: center; line-height: 1.25; font-weight: bold; font-family: Times New Roman">Nine-month period ended<br/> September
        30,</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px; font-family: Times New Roman">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px"><span style="font-family: Times New Roman"><br/> </span>
        </td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px; font-family: Times New Roman">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; font-weight: bold; text-align: center; font-family: Times New Roman">2024</td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px; font-family: Times New Roman">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px; font-family: Times New Roman">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom">
        <div style="text-align: center; line-height: 1.25; font-weight: bold; font-family: Times New Roman"> 2023</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px; font-family: Times New Roman">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom"><span style="font-family: Times New Roman"><br/> </span> </td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; font-family: Times New Roman">&#160;</td>
    <td colspan="6" style="vertical-align: bottom; vertical-align: bottom">
        <div style="text-align: center; line-height: 1.25; font-family: Times New Roman">(U.S. dollars, in thousands)</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; font-family: Times New Roman">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25; font-weight: bold; font-family: Times New Roman">Operating expenses:</div> </td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: Times New Roman">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: Times New Roman">&#160;</td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: Times New Roman">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: Times New Roman">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: Times New Roman">&#160;</td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: Times New Roman">&#160;</td>
        </tr>
  <tr>
    <td rowspan="1" style="vertical-align: bottom; vertical-align: bottom; font-family: Times New Roman">&#160;</td>
    <td class="cftguttercell" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; vertical-align: bottom; font-family: Times New Roman">&#160;</td>
    <td colspan="2" rowspan="1" style="vertical-align: bottom; vertical-align: bottom; text-align: right; font-family: Times New Roman">&#160;</td>
    <td class="cftfncell" colspan="1" rowspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; font-family: Times New Roman">&#160;</td>
    <td class="cftguttercell" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; vertical-align: bottom; font-family: Times New Roman">&#160;</td>
    <td colspan="2" rowspan="1" style="vertical-align: bottom; vertical-align: bottom; text-align: right; font-family: Times New Roman">&#160;</td>
    <td class="cftfncell" colspan="1" rowspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; font-family: Times New Roman">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; background-color: rgb(204, 238, 255); width: 76%">
        <div style="line-height: 1.25; font-family: Times New Roman">Research and development, net</div> </td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25; font-family: Times New Roman">$</div> </td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman">4,944</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25; font-family: Times New Roman">$</div> </td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman">2,451</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; width: 76%">
        <div style="line-height: 1.25; font-family: Times New Roman">General and administrative</div> </td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; text-align: right; vertical-align: bottom; width: 1%; font-family: Times New Roman">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman">5,727</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; font-family: Times New Roman">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; text-align: right; vertical-align: bottom; width: 1%; font-family: Times New Roman">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman">502</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; font-family: Times New Roman">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; background-color: rgb(204, 238, 255); width: 76%">
        <div style="line-height: 1.25; font-family: Times New Roman">Total operating expenses</div> </td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman">10,671</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman">2,953</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; width: 76%">
        <div style="line-height: 1.25; font-weight: bold; font-family: Times New Roman">Operating loss</div> </td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; text-align: right; vertical-align: bottom; width: 1%; font-family: Times New Roman">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman">10,671</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; font-family: Times New Roman">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; text-align: right; vertical-align: bottom; width: 1%; font-family: Times New Roman">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman">2,953</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; font-family: Times New Roman">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; background-color: rgb(204, 238, 255); width: 76%">
        <div style="line-height: 1.25; font-family: Times New Roman">Financial expenses, net</div> </td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman">4,092</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman">449</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; width: 76%">
        <div style="line-height: 1.25; font-weight: bold; font-family: Times New Roman">Loss before income tax</div> </td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; text-align: right; vertical-align: bottom; width: 1%; font-family: Times New Roman">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-weight: bold; font-family: Times New Roman">14,763</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; font-family: Times New Roman">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; text-align: right; vertical-align: bottom; width: 1%; font-family: Times New Roman">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-weight: bold; font-family: Times New Roman">3,402</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; font-family: Times New Roman">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; background-color: rgb(204, 238, 255); width: 76%">
        <div style="line-height: 1.25; font-family: Times New Roman">Income tax</div> </td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman">9</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman">26</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; width: 76%">
        <div style="line-height: 1.25; font-weight: bold; font-family: Times New Roman">Net loss for the nine-month period</div> </td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; text-align: right; vertical-align: bottom; width: 1%; font-family: Times New Roman">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25; font-family: Times New Roman"><span style="font-weight: bold">$</span></div> </td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman"><span style="font-weight: bold">14,772</span></div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; font-family: Times New Roman">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; text-align: right; vertical-align: bottom; width: 1%; font-family: Times New Roman">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25; font-weight: bold; font-family: Times New Roman">$</div> </td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-weight: bold; font-family: Times New Roman">3,428</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; font-family: Times New Roman">&#160;</td>
        </tr>
  </table> </div>

<div style="text-indent: 18pt; line-height: 1.25; font-family: Times New Roman,Times,serif"> <span style="font-family: Times New Roman"><br/>
</span> </div>

<div style="line-height: 1.25; font-style: italic; font-family: Times New Roman">Research and Development Expenses</div>

<div style="text-indent: 18pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="line-height: 1.25">

<div style="text-indent: 35.45pt; line-height: 1.25; font-family: Times New Roman">The following table summarizes our research and development
expenses for the nine-month periods ended September 30, 2024 and 2023:</div> </div> </div>

<div style="text-indent: 18pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 18pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<table cellspacing="0" cellpadding="0" class="cfttable" id="z062ce2c2f9504300ac3a20cbbf8ac45e" style="font: 10pt Times New Roman, Times, serif; text-align: left; color: #000000; width: 100%">
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px">
        <div style="line-height: 1.25; font-family: Times New Roman">&#160;</div> </td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px; font-family: Times New Roman">&#160;</td>
    <td colspan="6" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom">
        <div style="text-align: center; line-height: 1.25; font-weight: bold; font-family: Times New Roman">Nine-month period ended<br/> September
        30,</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px; font-family: Times New Roman">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px">
        <div style="line-height: 1.25; font-family: Times New Roman">&#160;</div> </td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px; font-family: Times New Roman">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom">
        <div style="text-align: center; line-height: 1.25; font-weight: bold; font-family: Times New Roman"> 2024</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px; font-family: Times New Roman">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px; font-family: Times New Roman">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom">
        <div style="text-align: center; line-height: 1.25; font-weight: bold; font-family: Times New Roman">2023</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px; font-family: Times New Roman">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom">
        <div style="line-height: 1.25; font-family: Times New Roman">&#160;</div> </td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; font-family: Times New Roman">&#160;</td>
    <td colspan="6" style="vertical-align: bottom; vertical-align: bottom">
        <div style="text-align: center; line-height: 1.25; font-family: Times New Roman">(U.S. dollars, in thousands)</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; font-family: Times New Roman">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; background-color: rgb(204, 238, 255); width: 76%">
        <div style="line-height: 1.25; font-family: Times New Roman">Payroll and related expenses</div> </td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25; font-family: Times New Roman">$</div> </td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman">928</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25; font-family: Times New Roman">$</div> </td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman">729</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; width: 76%">
        <div style="line-height: 1.25; font-family: Times New Roman">Share-based compensation expenses</div> </td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman">2,424</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; font-family: Times New Roman">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman">57</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; font-family: Times New Roman">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; background-color: rgb(204, 238, 255); width: 76%">
        <div style="line-height: 1.25; font-family: Times New Roman">Subcontractors and consultants</div> </td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman">1,425</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman">1,444</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; width: 76%">
        <div style="line-height: 1.25; font-family: Times New Roman">Materials</div> </td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman">3</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; font-family: Times New Roman">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman">16</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; font-family: Times New Roman">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; background-color: rgb(204, 238, 255); width: 76%">
        <div style="line-height: 1.25; font-family: Times New Roman">Rent and maintenance</div> </td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman">106</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman">124</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; width: 76%">
        <div style="line-height: 1.25; font-family: Times New Roman">Travel expenses</div> </td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman">13</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; font-family: Times New Roman">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman">27</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; font-family: Times New Roman">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; background-color: rgb(204, 238, 255); width: 76%">
        <div style="line-height: 1.25; font-family: Times New Roman">Other</div> </td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman">45</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman">54</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; width: 76%">
        <div style="line-height: 1.25; font-family: Times New Roman">Total research and development expenses</div> </td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25; font-family: Times New Roman">$</div> </td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman">4,944</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; font-family: Times New Roman">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25; font-family: Times New Roman">$</div> </td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman">2,451</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; font-family: Times New Roman">&#160;</td>
        </tr>
  </table> </div>

<div style="text-indent: 18pt; line-height: 1.25; font-family: Times New Roman,Times,serif"> <span style="font-family: Times New Roman"><br/>
</span> </div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="line-height: 1.25">

<div style="text-indent: 35.45pt; line-height: 1.25; font-family: Times New Roman">Research and development expenses increased by approximately
$2.4 million, or 96%, to $4.9 million for the nine-month period ended September 30, 2024, compared to $2.5 million for the nine-month
period ended September 30, 2023. The increase resulted mainly from an increase in non-cash share-based compensation expenses in an amount
of $2.4 million and from an increase in payroll and related expenses in an amount of $0.2 million.</div> </div> </div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="line-height: 1.25">

<div style="text-indent: 35.45pt; line-height: 1.25; font-family: Times New Roman">Research and development expenses for the nine-month
periods ended September 30, 2024 and September 30, 2023 included approximately $0.2 million and $0.9 million, respectively, related to
the development of Loder, and $4.7 million and $1.6 million, respectively, related to the development of SIL-204B. Aggregate research
and development expenses since inception for our Loder program, as of September 30, 2024 and as of September 30, 2023, were approximately
$18.4 million and $18.3 million, respectively. Aggregate research and development expenses since inception for the SIL-204B program, as
of September 30, 2024 and as of September 30, 2023, were approximately $8.3 million and $2.2 million, respectively.</div> </div> </div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: rgb(0, 0, 0); font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">64</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="text-align: center; line-height: 1.25"><span style="font-family: Times New Roman"><br/> </span> </div>

<div style="line-height: 1.25; font-style: italic; font-family: Times New Roman">General and Administrative Expenses</div>

<div style="text-indent: 18pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="line-height: 1.25">

<div style="text-indent: 35.45pt; line-height: 1.25; font-family: Times New Roman">The following table summarizes our general and administrative
expenses for the nine-month periods ended September 30, 2024 and 2023:</div>

<div style="text-indent: 35.45pt; line-height: 1.25; font-family: Times New Roman, Times, serif"> <span style="font-family: Times New Roman"><br/>
</span> </div> </div> </div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">

<table cellspacing="0" cellpadding="0" id="za4662af4a133429fbc82bd43ac81eeed" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 75.99%; vertical-align: bottom; padding-bottom: 2px">
        <div style="line-height: 1.25; font-family: Times New Roman">&#160;</div> </td>
    <td style="width: 1%; vertical-align: bottom; padding-bottom: 2px">
        <div style="line-height: 1.25; font-family: Times New Roman">&#160;</div> </td>
    <td colspan="6" style="border-bottom: rgb(0, 0, 0) 2px solid; width: 22.01%; vertical-align: bottom">
        <div style="text-align: center; line-height: 1.25; font-weight: bold; font-family: Times New Roman">Nine-month periods ended<br/> September
        30,</div> </td>
    <td style="white-space: nowrap; width: 1%; vertical-align: bottom; padding-bottom: 2px">
        <div style="line-height: 1.25; font-family: Times New Roman">&#160;</div> </td> </tr>
  <tr>
    <td style="width: 75.99%; vertical-align: bottom; padding-bottom: 2px">
        <div style="line-height: 1.25; font-family: Times New Roman">&#160;</div> </td>
    <td style="width: 1%; vertical-align: bottom; padding-bottom: 2px">
        <div style="line-height: 1.25; font-family: Times New Roman">&#160;</div> </td>
    <td colspan="2" style="border-bottom: rgb(0, 0, 0) 2px solid; width: 10%; vertical-align: bottom">
        <div style="text-align: center; line-height: 1.25; font-weight: bold; font-family: Times New Roman">2024</div> </td>
    <td style="white-space: nowrap; width: 1%; vertical-align: bottom; padding-bottom: 2px">
        <div style="line-height: 1.25; font-family: Times New Roman">&#160;</div> </td>
    <td style="width: 1%; vertical-align: bottom; padding-bottom: 2px">
        <div style="line-height: 1.25; font-family: Times New Roman">&#160;</div> </td>
    <td colspan="2" style="border-bottom: rgb(0, 0, 0) 2px solid; width: 10%; vertical-align: bottom">
        <div style="text-align: center; line-height: 1.25; font-weight: bold; font-family: Times New Roman">2023</div> </td>
    <td style="white-space: nowrap; width: 1%; vertical-align: bottom; padding-bottom: 2px">
        <div style="line-height: 1.25; font-family: Times New Roman">&#160;</div> </td> </tr>
  <tr>
    <td style="width: 75.99%; vertical-align: bottom">
        <div style="line-height: 1.25; font-family: Times New Roman">&#160;</div> </td>
    <td style="width: 1%; vertical-align: bottom">
        <div style="line-height: 1.25; font-family: Times New Roman">&#160;</div> </td>
    <td colspan="6" style="width: 22.01%; vertical-align: bottom">
        <div style="text-align: center; line-height: 1.25; font-family: Times New Roman">(U.S. dollars, in thousands)</div> </td>
    <td style="white-space: nowrap; width: 1%; vertical-align: bottom">
        <div style="line-height: 1.25; font-family: Times New Roman">&#160;</div> </td> </tr>
  <tr>
    <td style="width: 75.99%; vertical-align: bottom; background-color: #CCEEFF">
        <div style="line-height: 1.25; font-family: Times New Roman">Payroll and related expenses</div> </td>
    <td style="width: 1%; vertical-align: bottom; background-color: #CCEEFF">
        <div style="line-height: 1.25; font-family: Times New Roman">&#160;</div> </td>
    <td style="width: 1%; vertical-align: bottom; background-color: #CCEEFF">
        <div style="line-height: 1.25; font-family: Times New Roman">$</div> </td>
    <td style="width: 9%; vertical-align: bottom; background-color: #CCEEFF">
        <div style="text-align: right; line-height: 1.25; font-family: Times New Roman">856</div> </td>
    <td style="white-space: nowrap; width: 1%; vertical-align: bottom; background-color: #CCEEFF">
        <div style="line-height: 1.25; font-family: Times New Roman">&#160;</div> </td>
    <td style="width: 1%; vertical-align: bottom; background-color: #CCEEFF">
        <div style="line-height: 1.25; font-family: Times New Roman">&#160;</div> </td>
    <td style="width: 1%; vertical-align: bottom; background-color: #CCEEFF">
        <div style="line-height: 1.25; font-family: Times New Roman">$</div> </td>
    <td style="width: 9%; vertical-align: bottom; background-color: #CCEEFF">
        <div style="text-align: right; line-height: 1.25; font-family: Times New Roman">190</div> </td>
    <td style="white-space: nowrap; width: 1%; vertical-align: bottom; background-color: #CCEEFF">
        <div style="line-height: 1.25; font-family: Times New Roman">&#160;</div> </td> </tr>
  <tr>
    <td style="width: 75.99%; vertical-align: bottom">
        <div style="line-height: 1.25; font-family: Times New Roman">Share-based compensation expenses</div> </td>
    <td style="width: 1%; vertical-align: bottom">
        <div style="line-height: 1.25; font-family: Times New Roman">&#160;</div> </td>
    <td style="width: 1%; vertical-align: bottom">
        <div style="line-height: 1.25; font-family: Times New Roman">&#160;</div> </td>
    <td style="width: 9%; vertical-align: bottom">
        <div style="text-align: right; line-height: 1.25; font-family: Times New Roman">3,438</div> </td>
    <td style="white-space: nowrap; width: 1%; vertical-align: bottom">
        <div style="line-height: 1.25; font-family: Times New Roman">&#160;</div> </td>
    <td style="width: 1%; vertical-align: bottom">
        <div style="line-height: 1.25; font-family: Times New Roman">&#160;</div> </td>
    <td style="width: 1%; vertical-align: bottom">
        <div style="line-height: 1.25; font-family: Times New Roman">&#160;</div> </td>
    <td style="width: 9%; vertical-align: bottom">
        <div style="text-align: right; line-height: 1.25; font-family: Times New Roman">39</div> </td>
    <td style="white-space: nowrap; width: 1%; vertical-align: bottom">
        <div style="line-height: 1.25; font-family: Times New Roman">&#160;</div> </td> </tr>
  <tr>
    <td style="width: 75.99%; vertical-align: bottom; background-color: #CCEEFF">
        <div style="line-height: 1.25; font-family: Times New Roman">Professional services</div> </td>
    <td style="width: 1%; vertical-align: bottom; background-color: #CCEEFF">
        <div style="line-height: 1.25; font-family: Times New Roman">&#160;</div> </td>
    <td style="width: 1%; vertical-align: bottom; background-color: #CCEEFF">
        <div style="line-height: 1.25; font-family: Times New Roman">&#160;</div> </td>
    <td style="width: 9%; vertical-align: bottom; background-color: #CCEEFF">
        <div style="text-align: right; line-height: 1.25; font-family: Times New Roman">1,053</div> </td>
    <td style="white-space: nowrap; width: 1%; vertical-align: bottom; background-color: #CCEEFF">
        <div style="line-height: 1.25; font-family: Times New Roman">&#160;</div> </td>
    <td style="width: 1%; vertical-align: bottom; background-color: #CCEEFF">
        <div style="line-height: 1.25; font-family: Times New Roman">&#160;</div> </td>
    <td style="width: 1%; vertical-align: bottom; background-color: #CCEEFF">
        <div style="line-height: 1.25; font-family: Times New Roman">&#160;</div> </td>
    <td style="width: 9%; vertical-align: bottom; background-color: #CCEEFF">
        <div style="text-align: right; line-height: 1.25; font-family: Times New Roman">79</div> </td>
    <td style="white-space: nowrap; width: 1%; vertical-align: bottom; background-color: #CCEEFF">
        <div style="line-height: 1.25; font-family: Times New Roman">&#160;</div> </td> </tr>
  <tr>
    <td style="width: 75.99%; vertical-align: bottom">
        <div style="line-height: 1.25; font-family: Times New Roman">Depreciation</div> </td>
    <td style="width: 1%; vertical-align: bottom">
        <div style="line-height: 1.25; font-family: Times New Roman">&#160;</div> </td>
    <td style="width: 1%; vertical-align: bottom">
        <div style="line-height: 1.25; font-family: Times New Roman">&#160;</div> </td>
    <td style="width: 9%; vertical-align: bottom">
        <div style="text-align: right; line-height: 1.25; font-family: Times New Roman">37</div> </td>
    <td style="white-space: nowrap; width: 1%; vertical-align: bottom">
        <div style="line-height: 1.25; font-family: Times New Roman">&#160;</div> </td>
    <td style="width: 1%; vertical-align: bottom">
        <div style="line-height: 1.25; font-family: Times New Roman">&#160;</div> </td>
    <td style="width: 1%; vertical-align: bottom">
        <div style="line-height: 1.25; font-family: Times New Roman">&#160;</div> </td>
    <td style="width: 9%; vertical-align: bottom">
        <div style="text-align: right; line-height: 1.25; font-family: Times New Roman">39</div> </td>
    <td style="white-space: nowrap; width: 1%; vertical-align: bottom">
        <div style="line-height: 1.25; font-family: Times New Roman">&#160;</div> </td> </tr>
  <tr>
    <td style="width: 75.99%; vertical-align: bottom; background-color: #CCEEFF">
        <div style="line-height: 1.25; font-family: Times New Roman">Rent and maintenance</div> </td>
    <td style="width: 1%; vertical-align: bottom; background-color: #CCEEFF">
        <div style="line-height: 1.25; font-family: Times New Roman">&#160;</div> </td>
    <td style="width: 1%; vertical-align: bottom; background-color: #CCEEFF">
        <div style="line-height: 1.25; font-family: Times New Roman">&#160;</div> </td>
    <td style="width: 9%; vertical-align: bottom; background-color: #CCEEFF">
        <div style="text-align: right; line-height: 1.25; font-family: Times New Roman">90</div> </td>
    <td style="white-space: nowrap; width: 1%; vertical-align: bottom; background-color: #CCEEFF">
        <div style="line-height: 1.25; font-family: Times New Roman">&#160;</div> </td>
    <td style="width: 1%; vertical-align: bottom; background-color: #CCEEFF">
        <div style="line-height: 1.25; font-family: Times New Roman">&#160;</div> </td>
    <td style="width: 1%; vertical-align: bottom; background-color: #CCEEFF">
        <div style="line-height: 1.25; font-family: Times New Roman">&#160;</div> </td>
    <td style="width: 9%; vertical-align: bottom; background-color: #CCEEFF">
        <div style="text-align: right; line-height: 1.25; font-family: Times New Roman">67</div> </td>
    <td style="white-space: nowrap; width: 1%; vertical-align: bottom; background-color: #CCEEFF">
        <div style="line-height: 1.25; font-family: Times New Roman">&#160;</div> </td> </tr>
  <tr>
    <td style="width: 75.99%; vertical-align: bottom">
        <div style="line-height: 1.25; font-family: Times New Roman">Patent registration</div> </td>
    <td style="width: 1%; vertical-align: bottom">
        <div style="line-height: 1.25; font-family: Times New Roman">&#160;</div> </td>
    <td style="width: 1%; vertical-align: bottom">
        <div style="line-height: 1.25; font-family: Times New Roman">&#160;</div> </td>
    <td style="width: 9%; vertical-align: bottom">
        <div style="text-align: right; line-height: 1.25; font-family: Times New Roman">25</div> </td>
    <td style="white-space: nowrap; width: 1%; vertical-align: bottom">
        <div style="line-height: 1.25; font-family: Times New Roman">&#160;</div> </td>
    <td style="width: 1%; vertical-align: bottom">
        <div style="line-height: 1.25; font-family: Times New Roman">&#160;</div> </td>
    <td style="width: 1%; vertical-align: bottom">
        <div style="line-height: 1.25; font-family: Times New Roman">&#160;</div> </td>
    <td style="width: 9%; vertical-align: bottom">
        <div style="text-align: right; line-height: 1.25; font-family: Times New Roman">18</div> </td>
    <td style="white-space: nowrap; width: 1%; vertical-align: bottom">
        <div style="line-height: 1.25; font-family: Times New Roman">&#160;</div> </td> </tr>
  <tr>
    <td style="width: 75.99%; vertical-align: bottom; background-color: #CCEEFF">
        <div style="line-height: 1.25; font-family: Times New Roman">Travel expenses</div> </td>
    <td style="width: 1%; vertical-align: bottom; background-color: #CCEEFF">
        <div style="line-height: 1.25; font-family: Times New Roman">&#160;</div> </td>
    <td style="width: 1%; vertical-align: bottom; background-color: #CCEEFF">
        <div style="line-height: 1.25; font-family: Times New Roman">&#160;</div> </td>
    <td style="width: 9%; vertical-align: bottom; background-color: #CCEEFF">
        <div style="text-align: right; line-height: 1.25; font-family: Times New Roman">72</div> </td>
    <td style="white-space: nowrap; width: 1%; vertical-align: bottom; background-color: #CCEEFF">
        <div style="line-height: 1.25; font-family: Times New Roman">&#160;</div> </td>
    <td style="width: 1%; vertical-align: bottom; background-color: #CCEEFF">
        <div style="line-height: 1.25; font-family: Times New Roman">&#160;</div> </td>
    <td style="width: 1%; vertical-align: bottom; background-color: #CCEEFF">
        <div style="line-height: 1.25; font-family: Times New Roman">&#160;</div> </td>
    <td style="width: 9%; vertical-align: bottom; background-color: #CCEEFF">
        <div style="text-align: right; line-height: 1.25; font-family: Times New Roman">31</div> </td>
    <td style="white-space: nowrap; width: 1%; vertical-align: bottom; background-color: #CCEEFF">
        <div style="line-height: 1.25; font-family: Times New Roman">&#160;</div> </td> </tr>
  <tr>
    <td style="width: 75.99%; vertical-align: bottom">
        <div style="line-height: 1.25; font-family: Times New Roman">Other</div> </td>
    <td style="width: 1%; vertical-align: bottom">
        <div style="line-height: 1.25; font-family: Times New Roman">&#160;</div> </td>
    <td style="width: 1%; vertical-align: bottom">
        <div style="line-height: 1.25; font-family: Times New Roman">&#160;</div> </td>
    <td style="width: 9%; vertical-align: bottom">
        <div style="text-align: right; line-height: 1.25; font-family: Times New Roman">156</div> </td>
    <td style="white-space: nowrap; width: 1%; vertical-align: bottom">
        <div style="line-height: 1.25; font-family: Times New Roman">&#160;</div> </td>
    <td style="width: 1%; vertical-align: bottom">
        <div style="line-height: 1.25; font-family: Times New Roman">&#160;</div> </td>
    <td style="width: 1%; vertical-align: bottom">
        <div style="line-height: 1.25; font-family: Times New Roman">&#160;</div> </td>
    <td style="width: 9%; vertical-align: bottom">
        <div style="text-align: right; line-height: 1.25; font-family: Times New Roman">39</div> </td>
    <td style="white-space: nowrap; width: 1%; vertical-align: bottom">
        <div style="line-height: 1.25; font-family: Times New Roman">&#160;</div> </td> </tr>
  <tr>
    <td style="width: 75.99%; vertical-align: bottom; background-color: #CCEEFF">
        <div style="line-height: 1.25; font-family: Times New Roman">&#160; &#160;Total general and administrative expenses</div> </td>
    <td style="width: 1%; vertical-align: bottom; background-color: #CCEEFF">
        <div style="line-height: 1.25; font-family: Times New Roman">&#160;</div> </td>
    <td style="width: 1%; vertical-align: bottom; background-color: #CCEEFF">
        <div style="line-height: 1.25; font-family: Times New Roman">$</div> </td>
    <td style="width: 9%; vertical-align: bottom; background-color: #CCEEFF">
        <div style="text-align: right; line-height: 1.25; font-family: Times New Roman">5,727</div> </td>
    <td style="white-space: nowrap; width: 1%; vertical-align: bottom; background-color: #CCEEFF">
        <div style="line-height: 1.25; font-family: Times New Roman">&#160;</div> </td>
    <td style="width: 1%; vertical-align: bottom; background-color: #CCEEFF">
        <div style="line-height: 1.25; font-family: Times New Roman">&#160;</div> </td>
    <td style="width: 1%; vertical-align: bottom; background-color: #CCEEFF">
        <div style="line-height: 1.25; font-family: Times New Roman">$</div> </td>
    <td style="width: 9%; vertical-align: bottom; background-color: #CCEEFF">
        <div style="text-align: right; line-height: 1.25; font-family: Times New Roman">502</div> </td>
    <td style="white-space: nowrap; width: 1%; vertical-align: bottom; background-color: #CCEEFF">
        <div style="line-height: 1.25; font-family: Times New Roman">&#160;</div> </td> </tr>
  </table> <span style="font-family: Times New Roman"> &#160;</span></div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="line-height: 1.25">

<div style="text-indent: 35.45pt; line-height: 1.25; font-family: Times New Roman">General and administrative expenses increased by approximately
$5.2 million, or 1,040%, to $5.7 million for the nine-month period ended September 30, 2024, compared to $0.5 million for the nine-month
period ended September 30, 2023. The increase resulted mainly from an increase in non-cash share-based compensation expenses in an amount
of $3.4 million, an increase in professional services costs primarily related to one-time legal, accounting, and other expenses associated
with the costs of becoming a public company and the SPAC merger in an amount of $1.0 million, and an increase in payroll and related expenses
in an amount of $0.7 million.</div> </div> </div>

<div style="line-height: 1.25; font-style: italic; font-family: Times New Roman">&#160;</div>

<div style="line-height: 1.25; font-style: italic; font-family: Times New Roman,Times,serif">

<div style="line-height: 1.25">

<div style="line-height: 1.25; font-family: Times New Roman; font-style: italic">Financial expenses, net</div> </div> </div>

<div style="text-indent: 18pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="line-height: 1.25">

<div style="text-indent: 35.45pt; line-height: 1.25; font-family: Times New Roman">Financial expenses, net increased by approximately
$3.7 million, or 925%, to an expense of $4.1 million for the nine-months ended September 30, 2024 compared to an expense of $0.4 million
for the nine months ended September 30, 2023. This increase was mainly due to an increase in an amount of $4.8 million in one-time loss
upon entering Transactions expenses, offset in part by (i) an increase in revaluation income of financial instruments (warrants and promissory
notes) in an amount of $0.9 million, and (ii) a decrease in foreign exchange loss in an amount of $0.3 million for the nine-month period
ended September 30, 2024.</div> </div> </div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: rgb(0, 0, 0); font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">65</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>
<!--PROfilePageNumberReset%Num%63%%%-->

<div style="text-indent: 18pt; line-height: 1.25; font-style: italic; font-family: Times New Roman">&#160;</div>

<div style="line-height: 1.25; font-style: italic; font-family: Times New Roman">Net loss</div>

<div style="text-indent: 18pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="line-height: 1.25">

<div style="text-indent: 35.45pt; line-height: 1.25; font-family: Times New Roman">Net loss increased by approximately $11.4 million,
or 335.3%, to $14.8 million for the nine-month period ended September 30, 2024, compared to $3.4 million for the nine-month period ended
September 30, 2023. The increase was mainly due to an increase in our research and development expenses, general and administrative expenses,
and financial expenses including significant non-cash items related to share-based compensation, transaction costs and costs related to
becoming a public company.</div> </div> </div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman,Times,serif">

<div style="line-height: 1.25">

<div style="line-height: 1.25; font-family: Times New Roman; font-style: italic; font-weight: bold">Comparison of three-month periods
ended September 30, 2024 and 2023</div> </div> </div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="line-height: 1.25">

<div style="text-indent: 35.45pt; line-height: 1.25; font-family: Times New Roman">The following table summarizes our results of operations
for the three-month periods ended September 30, 2024 and 2023:</div> </div> </div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">

<table cellspacing="0" cellpadding="0" class="cfttable" id="z73116b1a000946dab2ce6135cb2609bd" style="font: 10pt Times New Roman, Times, serif; text-align: left; color: #000000; width: 100%">
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px">
        <div style="line-height: 1.25; font-family: Times New Roman">&#160;</div> </td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px; font-family: Times New Roman">&#160;</td>
    <td colspan="6" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom">
        <div style="text-align: center; line-height: 1.25; font-weight: bold; font-family: Times New Roman">Three-month period ended<br/> September
        30,</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px; font-family: Times New Roman">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px">
        <div style="line-height: 1.25; font-family: Times New Roman">&#160;</div> </td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px; font-family: Times New Roman">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom">
        <div style="text-align: center; line-height: 1.25; font-weight: bold; font-family: Times New Roman"> 2024</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px; font-family: Times New Roman">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px; font-family: Times New Roman">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom">
        <div style="text-align: center; line-height: 1.25; font-weight: bold; font-family: Times New Roman">2023</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px; font-family: Times New Roman">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25; font-weight: bold; font-family: Times New Roman">Operating expenses:</div> </td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: Times New Roman">&#160;</td>
    <td colspan="6" style="vertical-align: bottom; vertical-align: bottom; background-color: rgb(204, 238, 255)">
        <div style="text-align: center; line-height: 1.25; font-family: Times New Roman">(U.S. dollars, in thousands)</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: Times New Roman">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; width: 76%">
        <div style="line-height: 1.25; font-family: Times New Roman">Research and development, net</div> </td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25; font-family: Times New Roman">$</div> </td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman">3,217</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; font-family: Times New Roman">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25; font-family: Times New Roman">$</div> </td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman">535</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; font-family: Times New Roman">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; width: 76%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25; font-family: Times New Roman">General and administrative</div> </td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25; font-family: Times New Roman">4,819</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25; font-family: Times New Roman">196</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; width: 76%">
        <div style="line-height: 1.25; font-family: Times New Roman">Total operating expenses</div> </td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman">8,036</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; font-family: Times New Roman">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman">731</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; font-family: Times New Roman">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; width: 76%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25; font-weight: bold; font-family: Times New Roman">Operating loss</div> </td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25; font-family: Times New Roman">8,036</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25; font-family: Times New Roman">731</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; width: 76%">
        <div style="line-height: 1.25; font-family: Times New Roman">Financial expenses, net</div> </td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman">3,822</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; font-family: Times New Roman">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman">72</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; font-family: Times New Roman">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; width: 76%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25; font-weight: bold; font-family: Times New Roman">Loss before income tax</div> </td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25; font-weight: bold; font-family: Times New Roman">11,858</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25; font-weight: bold; font-family: Times New Roman">803</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; width: 76%">
        <div style="line-height: 1.25; font-family: Times New Roman">Income tax</div> </td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman">2</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; font-family: Times New Roman">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman">6</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; font-family: Times New Roman">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; width: 76%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25; font-weight: bold; font-family: Times New Roman">Net loss for the three-month period</div> </td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25; font-weight: bold; font-family: Times New Roman">$</div> </td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25; font-weight: bold; font-family: Times New Roman">11,860</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25; font-weight: bold; font-family: Times New Roman">$</div> </td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25; font-weight: bold; font-family: Times New Roman">809</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman">&#160;</td>
        </tr>
  </table> </div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif"> <span style="font-family: Times New Roman"><br/>
</span> </div>

<div style="line-height: 1.25; font-style: italic; font-family: Times New Roman">Research and Development Expenses</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="line-height: 1.25">

<div style="text-indent: 35.45pt; line-height: 1.25; font-family: Times New Roman">The following table summarizes our research and development
expenses for the three-month periods ended September 30, 2024 and 2023:</div> </div> </div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">

<table cellspacing="0" cellpadding="0" class="cfttable" id="z739781daaea043ec99b8e858b644f2f0" style="font: 10pt Times New Roman, Times, serif; text-align: left; color: #000000; width: 100%">
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px">
        <div style="line-height: 1.25; font-family: Times New Roman">&#160;</div> </td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px; font-family: Times New Roman">&#160;</td>
    <td colspan="6" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom">
        <div style="text-align: center; line-height: 1.25; font-weight: bold; font-family: Times New Roman">Three-month period ended<br/> September
        30,</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px; font-family: Times New Roman">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px">
        <div style="line-height: 1.25; font-family: Times New Roman">&#160;</div> </td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px; font-family: Times New Roman">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom">
        <div style="text-align: center; line-height: 1.25; font-weight: bold; font-family: Times New Roman"> 2024</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px; font-family: Times New Roman">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px; font-family: Times New Roman">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom">
        <div style="text-align: center; line-height: 1.25; font-weight: bold; font-family: Times New Roman">2023</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px; font-family: Times New Roman">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom">
        <div style="line-height: 1.25; font-family: Times New Roman">&#160;</div> </td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; font-family: Times New Roman">&#160;</td>
    <td colspan="6" style="vertical-align: bottom; vertical-align: bottom">
        <div style="text-align: center; line-height: 1.25; font-family: Times New Roman">(U.S. dollars, in thousands)</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; font-family: Times New Roman">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; background-color: #CCEEFF; width: 76%">
        <div style="line-height: 1.25; font-family: Times New Roman">Payroll and related expenses</div> </td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25; font-family: Times New Roman">$</div> </td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman">453</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25; font-family: Times New Roman">$</div> </td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman">198</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; width: 76%">
        <div style="line-height: 1.25; font-family: Times New Roman">Share-based compensation expenses</div> </td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman">2,385</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; font-family: Times New Roman">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman">19</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; font-family: Times New Roman">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; background-color: #CCEEFF; width: 76%">
        <div style="line-height: 1.25; font-family: Times New Roman">Subcontractors and consultants</div> </td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman">297</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman">236</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; width: 76%">
        <div style="line-height: 1.25; font-family: Times New Roman">Materials</div> </td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman">-</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; font-family: Times New Roman">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman">-</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; font-family: Times New Roman">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; background-color: #CCEEFF; width: 76%">
        <div style="line-height: 1.25; font-family: Times New Roman">Rent and maintenance</div> </td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman">57</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman">46</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; width: 76%">
        <div style="line-height: 1.25; font-family: Times New Roman">Travel expenses</div> </td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman">-</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; font-family: Times New Roman">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman">-</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; font-family: Times New Roman">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; background-color: #CCEEFF; width: 76%">
        <div style="line-height: 1.25; font-family: Times New Roman">Other</div> </td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman">25</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman">36</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; width: 76%">
        <div style="line-height: 1.25; font-family: Times New Roman">Total research and development expenses</div> </td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25; font-family: Times New Roman">$</div> </td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman">3,217</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; font-family: Times New Roman">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25; font-family: Times New Roman">$</div> </td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman">535</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; font-family: Times New Roman">&#160;</td>
        </tr>
  </table> </div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif"> <span style="font-family: Times New Roman"><br/>
</span> </div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="margin-left: 1pt; line-height: 1.25; font-family: Times New Roman; font-style: italic">Research and Development Expenses</div>
</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif"> <span style="font-family: Times New Roman"><br/>
</span> </div>

<div style="line-height: 1.25">

<div style="text-indent: 35.45pt; line-height: 1.25; font-family: Times New Roman">Research and development expenses increased by approximately
$2.7 million, or 540%, to $3.2 million for the three-month period ended September 30, 2024, compared to $0.5 million for the three-month
period ended September 30, 2023. The increase resulted mainly from an increase in non-cash share-based compensation expenses in an amount
of $2.4 million and from an increase in payroll and related expenses in an amount of $0.3 million.</div>

<div style="text-indent: 35.45pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 35.45pt; line-height: 1.25; font-family: Times New Roman">Research and development expenses for the three-month
periods ended September 30, 2024 and September 30, 2023 included approximately $0.01 million and $0.4 million, respectively, related to
the development of Loder, and $3.2 million and $0.2 million, respectively, related to the development of SIL-204B.</div> </div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: rgb(0, 0, 0); font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">66</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="line-height: 1.25; font-style: italic; font-family: Times New Roman,Times,serif">

<div style="line-height: 1.25">

<div style="line-height: 1.25; font-family: Times New Roman; font-style: italic">General and Administrative Expenses</div> </div> </div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="line-height: 1.25">

<div style="text-indent: 35.45pt; line-height: 1.25; font-family: Times New Roman">The following table summarizes our general and administrative
expenses for the three-month periods ended September 30, 2024 and 2023:</div> </div> </div>

<div> <span style="font-family: Times New Roman"><br/> </span>

<table cellspacing="0" cellpadding="0" class="cfttable" id="z16533337eac5418daf59f47be8cef1fc" style="font: 10pt Times New Roman, Times, serif; text-align: left; color: #000000; width: 100%">
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px"><span style="font-family: Times New Roman"><br/> </span>
        </td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px; font-family: Times New Roman">&#160;</td>
    <td colspan="6" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom">
        <div style="text-align: center; line-height: 1.25; font-weight: bold; font-family: Times New Roman">Three-month period ended<br/> September
        30,</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px; font-family: Times New Roman">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px"><span style="font-family: Times New Roman"><br/> </span>
        </td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px; font-family: Times New Roman">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; text-align: center"> <span style="font-weight: bold; font-family: Times New Roman">2024</span></td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px; font-family: Times New Roman">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px; font-family: Times New Roman">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom">
        <div style="text-align: center; line-height: 1.25; font-weight: bold; font-family: Times New Roman"> 2023</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px; font-family: Times New Roman">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom">
        <div style="line-height: 1.25; font-family: Times New Roman">&#160;</div> </td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; font-family: Times New Roman">&#160;</td>
    <td colspan="6" style="vertical-align: bottom; vertical-align: bottom">
        <div style="text-align: center; line-height: 1.25; font-family: Times New Roman">(U.S. dollars, in thousands)</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; font-family: Times New Roman">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; background-color: #CCEEFF; width: 76%">
        <div style="line-height: 1.25; font-family: Times New Roman">Payroll and related expenses</div> </td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25; font-family: Times New Roman">$</div> </td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman">575</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25; font-family: Times New Roman">$</div> </td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman">71</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; width: 76%">
        <div style="line-height: 1.25; font-family: Times New Roman">Share-based compensation expenses</div> </td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; text-align: right; vertical-align: bottom; width: 1%; font-family: Times New Roman">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman">3,413</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; font-family: Times New Roman">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; text-align: right; vertical-align: bottom; width: 1%; font-family: Times New Roman">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman">13</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; font-family: Times New Roman">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; background-color: #CCEEFF; width: 76%">
        <div style="line-height: 1.25; font-family: Times New Roman">Professional services</div> </td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman">605</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman">51</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; width: 76%">
        <div style="line-height: 1.25; font-family: Times New Roman">Depreciation</div> </td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; text-align: right; vertical-align: bottom; width: 1%; font-family: Times New Roman">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman">22</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; font-family: Times New Roman">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; text-align: right; vertical-align: bottom; width: 1%; font-family: Times New Roman">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman">10</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; font-family: Times New Roman">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; background-color: #CCEEFF; width: 76%">
        <div style="line-height: 1.25; font-family: Times New Roman">Rent and maintenance</div> </td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman">18</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman">25</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; width: 76%">
        <div style="line-height: 1.25; font-family: Times New Roman">Patent registration</div> </td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; text-align: right; vertical-align: bottom; width: 1%; font-family: Times New Roman">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman">-</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; font-family: Times New Roman">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; text-align: right; vertical-align: bottom; width: 1%; font-family: Times New Roman">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman">2</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; font-family: Times New Roman">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; background-color: #CCEEFF; width: 76%">
        <div style="line-height: 1.25; font-family: Times New Roman">Travel expenses</div> </td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman">56</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman">15</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; width: 76%">
        <div style="line-height: 1.25; font-family: Times New Roman">Other</div> </td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; text-align: right; vertical-align: bottom; width: 1%; font-family: Times New Roman">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman">130</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; font-family: Times New Roman">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; text-align: right; vertical-align: bottom; width: 1%; font-family: Times New Roman">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman">9</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; font-family: Times New Roman">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; background-color: #CCEEFF; width: 76%">
        <div style="line-height: 1.25; font-family: Times New Roman">Total general and administrative expenses</div> </td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25; font-family: Times New Roman">$</div> </td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman">4,819</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25; font-family: Times New Roman">$</div> </td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman">196</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman">&#160;</td>
        </tr>
  </table> <span style="font-family: Times New Roman"><br/> </span>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="line-height: 1.25">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">General and administrative expenses increased by approximately
$4.6 million, or 2,300%, to $4.8 million for the three-month period ended September 30, 2024, compared to $0.2 million for the three-month
period ended September 30, 2023. The increase resulted mainly from an increase in non-cash share-based compensation expenses in an amount
of $3.4 million, an increase in professional services costs primarily related to one-time legal, accounting, and other expenses associated
with the costs of becoming a public company and the SPAC merger in an amount of $0.6 million, and an increase in payroll and related expenses
in an amount of $0.5 million.</div> </div> </div>

<div style="line-height: 1.25; font-style: italic; font-family: Times New Roman">&#160;</div>

<div style="line-height: 1.25; font-style: italic; font-family: Times New Roman">Financial expenses, net</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-indent: 35.45pt; line-height: 1.25; font-family: Times New Roman, Times, serif"><span style="font-family: Times New Roman">Financial
expenses, net increased by approximately $3.7 million, or 3,700% to expense of $3.8 million for the three-month period ended September
30, 2024 compared to financial expenses, net of $0.1 million for the three-month period ended September 30, 2023. This increase was mainly
due to an increase in an amount of $4.8 million in one-time loss upon entering Transactions, offset, in part, by an increase in revaluation
income of financial instruments (warrants and promissory notes) in the amount of $1.1 million.</span></div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: rgb(0, 0, 0); font-weight: normal; font-style: normal">67</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>
<!--PROfilePageNumberReset%Num%65%%%--></div>

<div style="line-height: 1.25; font-style: italic; font-family: Times New Roman">&#160;</div>

<div style="line-height: 1.25; font-style: italic; font-family: Times New Roman">Net loss</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="line-height: 1.25">

<div style="text-indent: 35.45pt; line-height: 1.25; font-family: Times New Roman">Net loss increased by approximately $11.1 million,
or 1,387.5%, to $11.9 million for the three-month period ended September 30, 2024, compared to $0.8 million for the three-month period
ended September 30, 2023. The increase was mainly due to an increase in our research and development expenses, general and administrative
expenses, and financial expenses including significant non-cash items related to share-based compensation, transaction costs and costs
related to becoming a public company.</div>

<div style="text-indent: 35.45pt; line-height: 1.25; font-family: Times New Roman, Times, serif"> <span style="font-family: Times New Roman"><br/>
</span> </div>

<div style="line-height: 1.25">

<table cellspacing="0" cellpadding="0" border="0" id="zcd0668fc1aec42efaf968bff3553adbe" style="font: 10pt Times New Roman, Times, serif; color: #000000; width: 100%">
  <tr>
    <td style="width: 100%">
        <div>
        <div style="text-align: left; line-height: 1.25; font-family: Times New Roman; font-style: italic; font-weight: bold">Comparison of Years
        ended December 31, 2023 and 2022</div> </div> </td> </tr>
  </table> </div>

<div style="line-height: 1.25; font-weight: 400"> <span style="font-family: Times New Roman"><br/> </span>

<div style="line-height: 1.25; font-family: Times New Roman">The following table summarizes our results of operations for the years ended
December 31, 2023 and 2022:</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<table cellspacing="0" cellpadding="0" class="cfttable" id="z35a81afd4c0c44fb908defe426dfe2b1" style="font: 10pt Times New Roman, Times, serif; text-align: left; color: #000000; width: 100%">
  <tr>
    <td rowspan="1" style="vertical-align: bottom; vertical-align: top; padding-bottom: 2px; font-family: Times New Roman">&#160;</td>
    <td class="cftguttercell" colspan="1" rowspan="1" style="vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px; font-family: Times New Roman">&#160;</td>
    <td colspan="6" rowspan="1" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: top">
        <div style="text-align: center; line-height: 1.25; font-family: Times New Roman; font-weight: bold">Years ended December 31,</div> </td>
    <td class="cftfncell" colspan="1" rowspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px; font-family: Times New Roman">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: top; padding-bottom: 2px; font-family: Times New Roman">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px; font-family: Times New Roman">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: top">
        <div style="text-align: center; line-height: 1.25; font-family: Times New Roman; font-weight: bold"> 2023</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; text-align: center; vertical-align: bottom; padding-bottom: 2px; font-family: Times New Roman">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px; text-align: center; font-family: Times New Roman">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: top">
        <div style="text-align: center; line-height: 1.25; font-family: Times New Roman; font-weight: bold">2022</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px; font-family: Times New Roman">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: top; background-color: #CCEEFF">
        <div style="line-height: 1.25; font-weight: bold; font-family: Times New Roman">Operating expenses:</div> </td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: Times New Roman">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; vertical-align: top; background-color: rgb(204, 238, 255); font-family: Times New Roman">&#160;</td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; font-family: Times New Roman">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: Times New Roman">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; vertical-align: top; background-color: rgb(204, 238, 255); font-family: Times New Roman">&#160;</td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; font-family: Times New Roman">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: top; width: 76%">
        <div style="margin-left: 6.25pt; line-height: 1.25; font-family: Times New Roman">Research and development, net</div> </td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25; font-family: Times New Roman">$</div> </td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman">3,708</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; font-family: Times New Roman">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25; font-family: Times New Roman">$</div> </td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman">3,226</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; font-family: Times New Roman">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: top; background-color: #CCEEFF; width: 76%; padding-bottom: 2px">
        <div style="margin-left: 6.25pt; line-height: 1.25; font-family: Times New Roman">General and administrative</div> </td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); font-family: Times New Roman">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; border-bottom: #000000 2px solid; background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman">973</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: Times New Roman">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); font-family: Times New Roman">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; border-bottom: #000000 2px solid; background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman">634</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: Times New Roman">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: top; width: 76%; padding-bottom: 2px">
        <div style="line-height: 1.25; font-family: Times New Roman">Total operating expenses</div> </td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: Times New Roman">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; width: 1%; font-family: Times New Roman">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman">4,681</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: Times New Roman">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: Times New Roman">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; width: 1%; font-family: Times New Roman">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman">3,860</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: Times New Roman">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: top; background-color: #CCEEFF; width: 76%; padding-bottom: 2px">
        <div style="line-height: 1.25; font-weight: bold; font-family: Times New Roman">Operating loss</div> </td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); font-family: Times New Roman">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; border-bottom: #000000 2px solid; background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman">4,681</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: Times New Roman">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); font-family: Times New Roman">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; border-bottom: #000000 2px solid; background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman">3,860</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: Times New Roman">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: top; width: 76%; padding-bottom: 2px">
        <div style="margin-left: 6.25pt; line-height: 1.25; font-family: Times New Roman">Financial expenses (income), net</div> </td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: Times New Roman">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; width: 1%; font-family: Times New Roman">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman">395</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: Times New Roman">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: Times New Roman">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; width: 1%; font-family: Times New Roman">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman">(396</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 2px">
        <div style="line-height: 1.25; font-family: Times New Roman">)</div> </td> </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: top; background-color: #CCEEFF; width: 76%; padding-bottom: 2px">
        <div style="line-height: 1.25; font-weight: bold; font-family: Times New Roman">Loss before income tax</div> </td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); font-family: Times New Roman">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; border-bottom: #000000 2px solid; background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-weight: bold; font-family: Times New Roman">5,076</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: Times New Roman">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); font-family: Times New Roman">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; border-bottom: #000000 2px solid; background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-weight: bold; font-family: Times New Roman">3,464</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: Times New Roman">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: top; width: 76%; padding-bottom: 2px">
        <div style="margin-left: 6.25pt; line-height: 1.25; font-family: Times New Roman">Income tax</div> </td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: Times New Roman">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; width: 1%; font-family: Times New Roman">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman">32</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: Times New Roman">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: Times New Roman">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; width: 1%; font-family: Times New Roman">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman">24</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: Times New Roman">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: top; background-color: #CCEEFF; width: 76%; padding-bottom: 2px">
        <div style="line-height: 1.25; font-weight: bold; font-family: Times New Roman">Net loss for the year</div> </td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); font-family: Times New Roman">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; border-bottom: #000000 2px solid; background-color: #CCEEFF; vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25; font-family: Times New Roman"><span style="font-weight: bold">$</span></div> </td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; border-bottom: #000000 2px solid; background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman"><span style="font-weight: bold">5,108</span></div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: Times New Roman">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); font-family: Times New Roman">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; border-bottom: #000000 2px solid; background-color: #CCEEFF; vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25; font-family: Times New Roman"><span style="font-weight: bold">$</span></div> </td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; border-bottom: #000000 2px solid; background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman"><span style="font-weight: bold">3,488</span></div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: Times New Roman">&#160;</td>
        </tr>
  </table>

<div> <span style="font-family: Times New Roman"><br/> </span> </div>

<div>

<table cellspacing="0" cellpadding="0" border="0" id="z1216f701a4fe4946a9d03f56e07d9616" style="font: 10pt Times New Roman, Times, serif; color: #000000; width: 100%">
  <tr>
    <td style="width: 100%">
        <div>
        <div style="text-align: left; line-height: 1.25; font-style: italic; font-family: Times New Roman">Research and Development Expenses</div>
        </div> </td> </tr>
  </table> </div>

<div> <span style="font-family: Times New Roman"><br/> </span> </div>

<div style="line-height: 1.25; font-family: Times New Roman">The following table summarizes our research and development expenses for
the years ended December 31, 2023 and 2022:</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<table cellspacing="0" cellpadding="0" class="cfttable" id="z27818604f36b4c848eb72aa8f0a85e1b" style="font: 10pt Times New Roman, Times, serif; text-align: left; color: #000000; width: 100%">
  <tr>
    <td rowspan="1" style="vertical-align: bottom; vertical-align: top; padding-bottom: 2px; font-family: Times New Roman">&#160;</td>
    <td class="cftguttercell" colspan="1" rowspan="1" style="vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px; font-family: Times New Roman">&#160;</td>
    <td colspan="6" rowspan="1" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: top">
        <div style="text-align: center; line-height: 1.25; font-family: Times New Roman; font-weight: bold">Years ended December 31,</div> </td>
    <td class="cftfncell" colspan="1" rowspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px; font-family: Times New Roman">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: top; padding-bottom: 2px; font-family: Times New Roman">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px; font-family: Times New Roman">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: top; font-weight: bold; text-align: center; font-family: Times New Roman">
        2023</td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; text-align: center; vertical-align: bottom; padding-bottom: 2px; font-weight: bold; font-family: Times New Roman">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px; font-weight: bold; text-align: center; font-family: Times New Roman">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: top; font-weight: bold; text-align: center; font-family: Times New Roman">
        2022</td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px; font-family: Times New Roman">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: top; background-color: rgb(204, 238, 255); width: 76%">
        <div style="line-height: 1.25; font-family: Times New Roman">Payroll and related expenses</div> </td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25; font-family: Times New Roman">$</div> </td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman">973</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25; font-family: Times New Roman">$</div> </td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman">1,192</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: top; width: 76%">
        <div style="line-height: 1.25; font-family: Times New Roman">Subcontractors and consultants</div> </td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman">2,467</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; font-family: Times New Roman">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman">1,595</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; font-family: Times New Roman">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: top; background-color: rgb(204, 238, 255); width: 76%">
        <div style="line-height: 1.25; font-family: Times New Roman">Materials</div> </td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman">13</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman">191</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: top; width: 76%">
        <div style="line-height: 1.25; font-family: Times New Roman">Rent and maintenance</div> </td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman">160</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; font-family: Times New Roman">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman">175</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; font-family: Times New Roman">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: top; background-color: rgb(204, 238, 255); width: 76%">
        <div style="line-height: 1.25; font-family: Times New Roman">Travel expenses</div> </td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman">37</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman">42</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: top; width: 76%; padding-bottom: 2px">
        <div style="line-height: 1.25; font-family: Times New Roman">Other</div> </td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: Times New Roman">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; width: 1%; font-family: Times New Roman">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman">58</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: Times New Roman">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: Times New Roman">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; width: 1%; font-family: Times New Roman">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman">31</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: Times New Roman">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: top; background-color: rgb(204, 238, 255); width: 76%; padding-bottom: 4px">
        <div style="margin-left: 6.25pt; line-height: 1.25; font-family: Times New Roman">Total research and development expenses</div> </td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: Times New Roman">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 4px double; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25; font-family: Times New Roman">$</div> </td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 4px double; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman">3,708</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: Times New Roman">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: Times New Roman">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 4px double; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25; font-family: Times New Roman">$</div> </td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 4px double; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman">3,226</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: Times New Roman">&#160;</td>
        </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman">Research and development expenses increased by approximately
$0.5 million, or 15.6% to $3.7 million for the year ended December 31, 2023, compared to $3.2 million for the year ended December 31,
2022. The increase resulted mainly from an increase in subcontractors in the amount of $0.9 million partially offset by a decrease in
payroll and related expenses in the amount of $0.2 million and a decrease in materials costs in the amount of $0.2 million.</div>

<div style="line-height: 1.25"><span style="font-family: Times New Roman"><br/> </span> </div>

<div style="line-height: 1.25; font-family: Times New Roman">Research and development expenses for the year ended December 31, 2023 and
December 31, 2022 included approximately $0.8 million and $2.6 million related to the development of Loder, respectively, and $2.9 million
and $0.6 million related to the development of SIL-204B, respectively. Aggregate research and development expenses since inception for
Loder program, as of December 31, 2023 and as of December 31, 2022, were approximately $18.2 million and $17.4 million, respectively.
Aggregate research and development expenses since inception for SIL-204B program, as of December 31, 2023 and as of December 31, 2022,
were approximately $3.6 million and $0.6 million, respectively.</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: rgb(0, 0, 0); font-weight: normal; font-style: normal">68</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>
<!--PROfilePageNumberReset%Num%66%%%-->

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="line-height: 1.25; font-family: Times New Roman">The following table summarizes our general and administrative expenses for
the years ended December 31, 2023 and 2022:</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<table cellspacing="0" cellpadding="0" class="cfttable" id="zd48e496357034412ae4cb42c1d93df05" style="font: 10pt Times New Roman, Times, serif; text-align: left; color: #000000; width: 100%">
  <tr>
    <td rowspan="1" style="vertical-align: bottom; vertical-align: top; padding-bottom: 2px; font-family: Times New Roman">&#160;</td>
    <td class="cftguttercell" colspan="1" rowspan="1" style="vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px; font-family: Times New Roman">&#160;</td>
    <td colspan="6" rowspan="1" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: top">
        <div style="text-align: center; line-height: 1.25; font-family: Times New Roman; font-weight: bold">Years ended December 31,</div> </td>
    <td class="cftfncell" colspan="1" rowspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px; font-family: Times New Roman">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: top; padding-bottom: 2px; font-family: Times New Roman">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px; font-family: Times New Roman">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: top">
        <div style="text-align: center; line-height: 1.25; font-family: Times New Roman; font-weight: bold">2023</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; text-align: center; vertical-align: bottom; padding-bottom: 2px; font-family: Times New Roman">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px; text-align: center; font-family: Times New Roman">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: top">
        <div style="text-align: center; line-height: 1.25; font-family: Times New Roman; font-weight: bold">2022</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px; font-family: Times New Roman">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: top; background-color: rgb(204, 238, 255); width: 76%">
        <div style="line-height: 1.25; font-family: Times New Roman">Payroll and related expenses</div> </td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25; font-family: Times New Roman">$</div> </td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman">356</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25; font-family: Times New Roman">$</div> </td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman">219</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: top; width: 76%">
        <div style="line-height: 1.25; font-family: Times New Roman">Professional Services</div> </td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman">386</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; font-family: Times New Roman">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman">197</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; font-family: Times New Roman">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: top; background-color: rgb(204, 238, 255); width: 76%">
        <div style="line-height: 1.25; font-family: Times New Roman">Depreciation</div> </td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman">45</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman">57</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: top; width: 76%">
        <div style="line-height: 1.25; font-family: Times New Roman">Rent and maintenance</div> </td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman">86</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; font-family: Times New Roman">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman">71</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; font-family: Times New Roman">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: top; background-color: rgb(204, 238, 255); width: 76%">
        <div style="line-height: 1.25; font-family: Times New Roman">Patent registration</div> </td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman">22</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman">32</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: top; width: 76%">
        <div style="line-height: 1.25; font-family: Times New Roman">Travel expenses</div> </td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman">31</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; font-family: Times New Roman">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman">&#8212;</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; font-family: Times New Roman">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: top; background-color: rgb(204, 238, 255); width: 76%; padding-bottom: 2px">
        <div style="line-height: 1.25; font-family: Times New Roman">Other</div> </td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); font-family: Times New Roman">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman">47</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: Times New Roman">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); font-family: Times New Roman">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman">58</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: Times New Roman">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: top; width: 76%; padding-bottom: 4px">
        <div style="margin-left: 6.3pt; line-height: 1.25; font-family: Times New Roman">Total general and administrative expenses</div> </td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: Times New Roman">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 4px double; vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25; font-family: Times New Roman">$</div> </td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 4px double; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman">973</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: Times New Roman">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: Times New Roman">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 4px double; vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25; font-family: Times New Roman">$</div> </td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 4px double; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman">634</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: Times New Roman">&#160;</td>
        </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="line-height: 1.25; font-family: Times New Roman">General and administrative expenses increased by approximately $0.4 million,
or 66.7% to approximately $1.0 million for year ended December 31, 2023, compared to approximately $0.6 million for the year ended December
31, 2022. The increase resulted mainly from an increase in payroll and related expenses in the amount of $0.1 million and from an increase
of professional services costs in the amount of $0.2 million.</div>

<div style="line-height: 1.25"> <span style="font-family: Times New Roman"><br/> </span> </div>

<div style="line-height: 1.25">

<table cellspacing="0" cellpadding="0" border="0" id="ze4c706659cca48479f8756902533eacc" style="font: 10pt Times New Roman, Times, serif; color: #000000; width: 100%">
  <tr>
    <td style="width: 100%">
        <div>
        <div style="text-align: left; line-height: 1.25; font-family: Times New Roman; font-style: italic">Financial expenses, net</div> </div>
        </td> </tr>
  </table> </div>

<div style="line-height: 1.25"> <span style="font-family: Times New Roman"><br/> </span> </div>

<div style="line-height: 1.25; font-family: Times New Roman">Financial expenses (income), net increased by approximately $0.8 million,
or 200.0% to expense of $0.4 million for the year ended December 31, 2023 compared to income of $0.4 million for the year ended December
31, 2022. This increase was mainly due to revaluation of warrants in the amount of $1.0 million for the year ended December 31, 2022 offset
by a decrease of $0.2 million in foreign exchange loss.</div>

<div style="line-height: 1.25"> <span style="font-family: Times New Roman"><br/> </span> </div>

<div style="line-height: 1.25">

<table cellspacing="0" cellpadding="0" border="0" id="z43cf9311711b4de68ccd28157390814c" style="font: 10pt Times New Roman, Times, serif; color: #000000; width: 100%">
  <tr>
    <td style="width: 100%">
        <div>
        <div style="text-align: left; line-height: 1.25; font-family: Times New Roman; font-style: italic">Net loss</div> </div> </td> </tr>
  </table> </div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="line-height: 1.25; font-family: Times New Roman">Net loss increased by approximately $1.6 million, or 45.7% to $5.1 million
for the year ended December 31, 2023, compared to $3.5 million for the year ended December 31, 2022. The increase was mainly due to increase
in our research and development expenses, general and administrative expenses and financial expenses.</div> </div> </div> </div>

<div style="line-height: 1.25; font-weight: bold; font-family: Times New Roman,Times,serif"> <span style="font-family: Times New Roman"><br/>
</span> </div>

<div style="line-height: 1.25; font-weight: bold; font-family: Times New Roman">Liquidity and Capital Resources</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman">&#160;</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman">Overview</div>

<div style="text-indent: 18pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="line-height: 1.25; font-family: Times New Roman">Our capital requirements will depend on many factors, including the timing
and extent of spending to further develop SIL-204 and initiate pre-clinical and clinical trials, support research and development efforts,
investments in potential additional pipe-line products, and increased overall compensation as we continue to hire additional personnel.
For the nine-month periods ended September 30, 2024 and 2023, and for the years ended December 31, 2023 and 2022, we had net losses of
$14.8 million and $3.4 million, and $5.1 million and $3.5 million, respectively. As of September 30, 2024, our cash and cash equivalents
totaled $2.0 million.</div> </div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: rgb(0, 0, 0); font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">69</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="text-align: center; line-height: 1.25"><span style="font-family: Times New Roman"><br/> </span> </div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">To date, our principal sources of liquidity have been
proceeds from private offerings of our ordinary shares and convertible preferred shares, grants from the Israeli Innovation Authority,
and issuance of convertible financing agreements (CFA) and Simple Agreement for Future Equity (SAFE).</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="line-height: 1.25; font-family: Times New Roman">Based on our current business plan, we believe our current cash and cash
equivalents, and anticipated cash flow from operations, will not be sufficient to meet our anticipated cash requirements for the next
12 months from the date of this prospectus. We will need to raise additional capital to finance our operations, expand our business and
pipeline, or for other reasons.</div> </div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">

<div style="line-height: 1.25; font-family: Times New Roman">Our audited consolidated financial statements for the year ended December
31, 2023 and our unaudited condensed financial statements for the nine-month period ended September 30, 2024 included in this prospectus
note that there is substantial doubt about our ability to continue as a going concern as of such date; and in its report accompanying
our audited consolidated financial statements included herein, our independent registered public accounting firm included an explanatory
paragraph stating that our recurring losses from operations and our cash outflows from operating activities raise substantial doubt as
to our ability to continue as a going concern. This means that our management and our independent registered public accounting firm have
expressed substantial doubt about our ability to continue our operations without an additional infusion of capital from external sources.
Our audited consolidated financial statements have been prepared on a going concern basis and do not include any adjustments that may
be necessary should we be unable to continue as a going concern. If we are unable to finance our operations, our business would be in
jeopardy and we might not be able to continue operations and might have to liquidate our assets. In that case, investors might receive
less than the value at which those assets are carried on our unaudited condensed financial statements for the nine-month period ended
September 30, 2024 and year ended December 31, 2023, and it is likely that investors would lose all or a part of their investment.</div>
</div> </div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">We have lease obligations and other contractual obligations
and commitments as part of our ordinary course of business. See &#8220;<span style="font-style: italic">Note 4: Operating Leases</span>&#8221;
and &#8220;<span style="font-style: italic">Note 6: Commitments and Contingent Liabilities&#8221;</span> to our consolidated financial
statements for the year ended December 31, 2023 for information about our lease obligations.</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">We did not have during the periods presented, and we do
not currently have, any off-balance sheet arrangements involving commitments or obligations, including contingent obligations, arising
from arrangements with unconsolidated entities or persons that have or are reasonably likely to have a material current or future effect
on our financial condition, results of operations, liquidity, cash requirements or capital resources.</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman"> <br/> </div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="line-height: 1.25; font-style: normal; font-weight: 400">

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman, Times, serif; font-style: italic; font-weight: bold">January
2025 Warrant Inducement Transaction</div>

<div style="line-height: 1.25"><br/> </div>

<div style="line-height: 1.25">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">On January 29, 2025, New Silexion entered
into the Inducement Letter with certain Holders of certain of New Silexion&#8217;s existing warrants to purchase up to 2,221,523 shares
of New Silexion ordinary shares issued on January 17, 2025 with a five year term at an exercise price of $1.35 per share (the &#8220;<span style="font-weight: bold">Existing
Warrants</span>&#8221;).</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal">70</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div> </div>

<div style="line-height: 1.25">

<div style="line-height: 1.25; font-family: Times New Roman, Times, serif">&#160;</div> </div>

<div style="line-height: 1.25">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">Pursuant to the Inducement Letter, the Holders
agreed to exercise for cash their Existing Warrants to purchase an aggregate of 2,221,523 of New Silexion&#8217;s ordinary shares at the
exercise price of $1.35 per share in consideration of New Silexion&#8217;s agreement to issue new ordinary share purchase warrants (the
&#8220;<span style="font-weight: bold">New Warrants</span>&#8221;) to purchase up to an aggregate of 2,221,523 of New Silexion&#8217;s
ordinary shares (the &#8220;<span style="font-weight: bold">New Warrant Shares</span>&#8221;), at an exercise price of $1.50 per share.
The Holders also paid New Silexion an additional $0.125 per New Warrant issued in the offering. New Silexion received aggregate gross
proceeds of approximately $3.3 million from the exercise of the Existing Warrants by the Holders, before deducting placement agent fees
and other offering expenses payable by New Silexion.</div> </div>

<div style="line-height: 1.25">

<div style="line-height: 1.25; font-family: Times New Roman, Times, serif">&#160;</div> </div>

<div style="line-height: 1.25">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">New Silexion engaged Wainwright to act as
its exclusive placement agent in connection with the transactions contemplated by the Inducement Letter. New Silexion&#160; also issued
to Wainwright or its designees warrants (the &#8220;<span style="font-weight: bold">Placement Agent Warrants</span>&#8221;) to purchase
up to 155,507 ordinary shares (representing 7.0% of the Existing Warrants being exercised), which have the same terms as the New Warrants
except the Placement Agent Warrants have an exercise price equal to $1.8438 per share (125% of the sum of the exercise price of the Existing
Warrants and the additional $0.125 paid per New Warrant). Similar to the New Warrants, the Placement Agent Warrants will be immediately
exercisable from the date of issuance until the twenty-four month anniversary of the effective date of the Resale Registration Statement
(as defined below).</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">&#160;</div> </div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">The closing of the transactions contemplated
pursuant to the Inducement Letter occurred on January 30, 2025 (the &#8220;<span style="font-weight: bold">Closing Date</span>&#8221;),
subject to satisfaction of customary closing conditions. New Silexion also agreed to file this registration statement (this &#8220;<span style="font-weight: bold">Resale
Registration Statement</span>&#8221;) within thirty (30) calendar days of the date of the Inducement Letter, and to use commercially reasonable
efforts to have such Resale Registration Statement declared effective by the SEC within sixty (60) calendar days following the date of
the Inducement Letter (or within ninety (90) calendar days following the date of the Inducement Letter in case of &#8220;full review&#8221;
of the Resale Registration Statement by the SEC) and to keep the Resale Registration Statement effective at all times until no holder
of the New Warrants owns any New Warrants or New Warrant Shares. In the Inducement Letter, New Silexion agreed not to issue any shares
of ordinary shares or ordinary share equivalents or to file any other registration statement with the SEC (in each case, subject to certain
exceptions) until March 18, 2025. New Silexion also agreed not to effect or agree to effect any Variable Rate Transaction (as defined
in the Inducement Letter) until one (1) year after the Closing Date (subject to certain exceptions).</div>

<div style="line-height: 1.25"><br/> </div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman, Times, serif; font-style: italic; font-weight: bold">January
2025 Financing</div>

<div style="line-height: 1.25"><br/> </div>

<div style="line-height: 1.25">

<div style="text-indent: 36pt; line-height: 1.25">On January 15, 2025, New Silexion offered and sold in a public offering on a best efforts
basis (the &#8220;<span style="font-weight: bold">January 2025</span>&#160;<span style="font-weight: bold">Offering</span>&#8221;) (i)
2,145,998 of New Silexion ordinary shares, (ii) 1,557,705 pre-funded warrants to purchase up to 1,557,705 New Silexion ordinary shares
(the &#8220;<span style="font-weight: bold">January 2025 Pre-Funded Warrants</span>&#8221;), and (iii) 3,703,703 warrants to purchase
up to 3,703,703 New Silexion ordinary shares (the &#8220;<span style="font-weight: bold">January 2025</span>&#160;<span style="font-weight: bold">Investor
Warrants</span>&#8221; and together with the Pre-Funded Warrants, the &#8220;<span style="font-weight: bold">January 2025</span>&#160;<span style="font-weight: bold">Warrants</span>&#8221;),
at a purchase price of $1.35 per share and accompanying January 2025 Investor Warrant, and $1.3499 per January 2025 Pre-Funded Warrant
and accompanying January 2025 Investor Warrant. Aggregate gross proceeds from the January 2025 Offering (without taking into account any
proceeds from any future exercises of January 2025 Warrants) were approximately $5 million. The January Offering closed on January 17,
2025, subject to the satisfaction of customary closing conditions.</div>

<div style="text-indent: 36pt; line-height: 1.25">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25">The January 2025 Pre-Funded Warrants are immediately exercisable at an exercise price
of $0.0001 per share and will not expire until exercised in full. The January 2025 Investor Warrants have an exercise price of $1.35 per
share, are immediately exercisable, and may be exercised for five years from issuance.</div> </div>

<div style="line-height: 1.25">

<div style="line-height: 1.25"><br/> </div> </div>

<div style="line-height: 1.25">

<div style="text-indent: 36pt; line-height: 1.25">A holder of the January 2025 Warrants will not have the right to exercise any portion
of its Pre-Funded Warrants and Investor Warrants if the holder (together with such holder&#8217;s affiliates, and any persons acting as
a group together with such holder or any of such holder&#8217;s affiliates or any other persons whose beneficial ownership of ordinary
shares would be aggregated with the holder&#8217;s or any of the holder&#8217;s affiliates), would beneficially own ordinary shares in
excess of 4.99% (or, at the election of the holder, 9.99%) of the number of the ordinary shares outstanding immediately after giving effect
to such exercise.</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal">71</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">&#160;&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25">Certain investors in the January 2025 Offering entered into a definitive securities
purchase agreement with the Company (the &#8220;<span style="font-weight: bold">January 2025 Purchase Agreement</span>&#8221;). The Purchase
Agreement contains representations, warranties, indemnification and other provisions customary for transactions of this nature. Pursuant
to the January 2025 Purchase Agreement, New Silexion agreed to abide by certain customary standstill restrictions for a period of sixty
(60) days following the closing of the January 2025 Offering. In addition, subject to limited exceptions, the January 2025 Purchase Agreement
provides that for a period of one year following the closing of the January 2025 Offering, the Company will not effect or enter into an
agreement to effect a &#8220;variable rate transaction&#8221; as defined in the January 2025 Purchase Agreement.</div>

<div style="line-height: 1.25"><br/> </div>

<div style="text-indent: 36pt; line-height: 1.25">Wainwright acted as the sole placement agent (the &#8220;<span style="font-weight: bold">Placement
Agent</span>&#8221;), on a &#8220;best efforts&#8221; basis, in connection with the January 2025 Offering. Pursuant to an engagement agreement
that New Silexion entered into with Wainwright, New Silexion issued to Wainwright or its designees 259,259 warrants to purchase up to
259,259 New Silexion ordinary shares, representing 7.0% of the sum of the shares and January 2025 Pre-Funded Warrants sold in the January
2025 Offering (the &#8220;<span style="font-weight: bold">January 2025</span>&#160;<span style="font-weight: bold">Placement Agent Warrants</span>&#8221;).
The January 2025 Placement Agent Warrants have an exercise price of $1.6875 per share (representing 125% of the public offering price
per share and accompanying January 2025 Investor Warrant), are exercisable for five&#160;years from the date of the commencement of sales
in this offering, and otherwise reflect substantially the same terms as the January 2025 Investor Warrants.</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25">The net proceeds to New Silexion from the January 2025 Offering were approximately $4.26
million before deducting estimated offering expenses payable by New Silexion.&#160;</div>

<div style="line-height: 1.25"><br/> </div>

<div style="text-indent: 36pt; line-height: 1.25">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">Prior to the January 2025 Warrant Inducement
Transaction, a total of 640,257 January 2025 Investor Warrants were exercised into 640,257 New Silexion ordinary shares and 1,557,705
January 2025 Pre-Funded Warrants were exercised into 1,557,705 New Silexion ordinary shares, for a total net proceeds of $0.86 million.
As of February 11, 2025, the January 2025 Pre-Funded Warrants have been exercised in full and 841,923 January 2025 Investor Warrants remain
unexercised at an exercise price of $1.35 per share.</div> </div> </div> </div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman"> <br/> </div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman">ELOC Financing</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="line-height: 1.25; text-indent: 36pt; font-family: Times New Roman">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">In connection with the Closing of the Business
Combination, we entered into an ordinary share purchase agreement, dated August 13, 2024, but effective as of the Closing (the &#8220;ELOC
Agreement&#8221;), for an equity line of credit (the &#8220;ELOC&#8221;) with White Lion Capital, LLC (the &#8220;ELOC Investor&#8221;).
The agreement was amended as of January 14, 2025. Under the ELOC, we have the right to request to sell to the ELOC Investor, and the ELOC
Investor is required to purchase, via private placement transactions, up to $15.0 million of our ordinary shares from time to time after
the Closing, up until December 31, 2025 (unless the agreement is terminated sooner), subject to certain limitations and conditions as
described therein. The number of ordinary shares that we may require the ELOC Investor to purchase in any single sales notice depends
on a number of factors, including the type of purchase notice that we deliver. Similarly, the purchase price to be paid by the ELOC Investor
for any shares that we require it to purchase depends on the type of sales notice that we deliver, and is derived from the market price
of our ordinary shares for a certain period of time following our purchase request or as of the date of our purchase request. We also
granted registration rights to the ELOC Investor pursuant to an accompanying registration rights agreement, also dated August 15, 2024,
by and between New Silexion and the ELOC Investor (the &#8220;ELOC Registration Rights Agreement&#8221;), for which we filed a registration
statement on Form S-1 (SEC file number 333-282017), which was declared effective by the SEC on September 17, 2024.</div> </div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="line-height: 1.25; text-indent: 36pt; font-family: Times New Roman">Pursuant to the ELOC Agreement, New Silexion agreed, among
other things, that if our sales to the ELOC Investor under the ELOC exceed 19.99% of our total number of ordinary shares outstanding,
we will seek the approval of our shareholders for the issuance of any ordinary shares under the ELOC in excess of that amount, in accordance
with the Nasdaq Listing Rules, subject to certain exceptions based on the price of our ordinary shares to be sold in excess of that limit.</div>

<div style="line-height: 1.25; text-indent: 36pt; font-family: Times New Roman">&#160;</div>

<div style="line-height: 1.25; text-indent: 36pt; font-family: Times New Roman">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">In consideration for the commitments of
the ELOC Investor, we agreed to issue to the ELOC Investor an aggregate of $337,500 of our ordinary shares (the &#8220;ELOC Commitment
Shares&#8221;) based on the closing price of the ordinary shares on the day that is the earlier of (i) the business day prior to effectiveness
of the registration statement registering the resale of the shares issuable under the ELOC ordinary share purchase agreement and (ii)
the business day prior to the 180th day following the date of Closing of the Business Combination. In fulfillment of that commitment fee,
we issued to the ELOC Investor 40,602 ordinary shares as the ELOC Commitment Shares on September 18, 2024.</div> </div>

<div style="line-height: 1.25"><span style="font-family: Times New Roman"><br/> </span> </div>

<div style="text-align: justify; line-height: 1.25; text-indent: 36pt; font-family: Times New Roman">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">

<div style="text-indent: 36pt; line-height: 1.25">

<div style="text-indent: 36pt; line-height: 1.25">Through February 11, 2025, we have issued and sold an aggregate of 763,713 ordinary
shares (which includes the foregoing 40,602 ordinary shares issued as a commitment fee) to White Lion under the White Lion Purchase Agreement
for aggregate proceeds to us of approximately $3.1 million.</div> </div> </div> </div>

<div style="line-height: 1.25"><span style="font-family: Times New Roman"><br/> </span> </div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman">Settlement of Amounts Due Under Marketing
Agreement with EarlyBirdCapital</div>

<div style="text-indent: 25.2pt; margin-right: 10.65pt; margin-left: 8.15pt; line-height: 1.25"><span style="font-family: Times New Roman"><br/>
</span> </div>

<div style="line-height: 1.25; text-indent: 36pt; font-family: Times New Roman">Prior to the Closing of the Business Combination, Moringa
reached agreement with EarlyBirdCapital on the reduction, to $1.6 million, in the aggregate, of the fee payable to EarlyBirdCapital under
the Marketing Agreement. Pursuant to the final invoice provided by EarlyBirdCapital under the Marketing Agreement at the Closing, Moringa
paid $350,000 of cash to EarlyBirdCapital from the trust account at the Closing, and we issued to EarlyBirdCapital a convertible promissory
note, due December 31, 2025, in an amount of $1.25 million to be paid by us to EarlyBirdCapital in cash and/or via conversion of outstanding
amounts into ordinary shares (the &#8220;EarlyBird Convertible Note&#8221;).</div>

<div style="text-indent: 25.2pt; margin-right: 10.65pt; margin-left: 8.15pt; line-height: 1.25"><span style="font-family: Times New Roman"><br/>
</span> </div>

<div style="line-height: 1.25; text-indent: 36pt; font-family: Times New Roman">The EarlyBird Convertible Note bears interest at a rate
of 6% per annum and matures on December 31, 2025. If not repaid on or prior to that maturity date or such earlier date as to which the
repayment obligation may be accelerated under the note, or not converted in accordance with the terms thereof, the rate of interest applicable
to the unpaid principal amount would be adjusted to (15%) per annum. We are required to make mandatory prepayments on the note (which
shall first be applied to accrued interest and then to principal) from time to time in amounts equal to ten percent (10%) of the gross
proceeds received by us from any equity financings consummated by us prior to the maturity date. We are entitled to voluntarily prepay
any additional part of, or all of, the principal and accrued interest, in one or more installments without penalty, prior to the maturity
date.</div>

<div style="text-indent: 25.2pt; margin-right: 10.65pt; margin-left: 8.15pt; line-height: 1.25"><span style="font-family: Times New Roman"><br/>
</span> </div>

<div style="line-height: 1.25; text-indent: 36pt; font-family: Times New Roman">EarlyBirdCapital, in turn, may elect, at its sole discretion,
at any time on or prior to the maturity date, to elect to convert all or part of the then outstanding principal and/or accrued interest
under the EarlyBird Convertible Note into ordinary shares, at a per share conversion price equal to 95% of the volume weighted average
price of an ordinary share for the five trading days immediately prior to the date of our receipt of a conversion notice, provided, however,
we are not required to issue, and EarlyBirdCapital may not elect to convert the principal and/or accrued interest into an aggregate number
of ordinary shares that would exceed the maximum number of ordinary shares permitted by Section 5635 of the Nasdaq Listing Rules to be
issued without the approval of our shareholders, unless such approval is obtained.</div>

<div style="text-indent: 25.2pt; margin-right: 10.65pt; margin-left: 8.15pt; line-height: 1.25"><span style="font-family: Times New Roman"><br/>
</span> </div>

<div style="text-align: justify; line-height: 1.25; text-indent: 36pt; font-family: Times New Roman">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">&#160;Through the date hereof, we have made
one payment of $407,556 to EarlyBirdCapital due to amounts raised by us.</div> </div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: rgb(0, 0, 0); font-weight: normal; font-style: normal">72</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="line-height: 1.25"><span style="font-family: Times New Roman"><br/> </span> </div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman">PIPE Financing</div>

<div style="text-indent: 25.2pt; margin-right: 10.65pt; margin-left: 8.15pt; line-height: 1.25"><span style="font-family: Times New Roman"><br/>
</span> </div>

<div style="line-height: 1.25; text-indent: 36pt; font-family: Times New Roman">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">In connection with, and immediately prior
to the Closing of, the Business Combination, Moringa raised $2.0 million via a private investment in public entity financing (the &#8220;PIPE
Financing&#8221;), whereby Moringa sold to Greenstar, LP, an affiliate of the Moringa sponsor (the &#8220;PIPE Investor&#8221;), 200,000
newly issued Moringa ordinary shares (which does not reflect the reverse share split) at a price of $10.00 per share, pursuant to a subscription
agreement, dated as of August 15, 2024, by and among Moringa, New Silexion and the PIPE Investor (the &#8220;PIPE Agreement&#8221;). Those
200,000 shares automatically converted upon the Closing of the Business Combination 22,223 New Silexion ordinary shares (the &#8220;PIPE
Shares&#8221;).</div> </div>

<div style="text-indent: 25.2pt; margin-right: 10.65pt; margin-left: 8.15pt; line-height: 1.25"><span style="font-family: Times New Roman"><br/>
</span> </div>

<div style="line-height: 1.25; text-indent: 36pt; font-family: Times New Roman">The funds raised from the PIPE Financing, together with
remaining funds in the trust account after payments to redeeming public shareholders, were used for financing support for Moringa and
New Silexion, as well as for payment to service providers to whom outstanding amounts were owed by Moringa, including parties that had
provided financial advisory services and capital markets advisory services to Moringa during the period leading up to the Closing.</div>

<div style="text-indent: 25.2pt; margin-right: 10.65pt; margin-left: 8.15pt; line-height: 1.25"><span style="font-family: Times New Roman"><br/>
</span> </div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman">Issuance of Amended and Restated Sponsor
Promissory Note</div>

<div style="text-indent: 25.2pt; margin-right: 10.65pt; margin-left: 8.15pt; line-height: 1.25"><span style="font-family: Times New Roman"><br/>
</span> </div>

<div style="line-height: 1.25; text-indent: 36pt; font-family: Times New Roman">Effective as of the Closing, we issued to the sponsor,
and the sponsor accepted, in amendment and restatement, and replacement, in their entirety, of all existing promissory notes issued by
Moringa to the sponsor from the IPO until the Closing (and as to which the obligations of Moringa were assigned to New Silexion upon the
Closing), an amended and restated promissory note (the &#8220;A&amp;R Sponsor Promissory Note&#8221;) in an amount of $3,433,000, which
reflected the total amount owed by Moringa to the sponsor through the Closing Date. The maturity date of the A&amp;R Sponsor Promissory
Note is the 30-month anniversary of the Closing Date (i.e., February 15, 2027). Amounts outstanding under the A&amp;R Sponsor Promissory
Note may be repaid (unless otherwise decided by us) only by way of conversion into ordinary shares (&#8220;Note Shares&#8221;) in accordance
with the terms set forth in the form of A&amp;R Sponsor Promissory Note. New Silexion and the Sponsor may also convert amounts outstanding
under the A&amp;R Sponsor Promissory Note at the price per share at which we conduct an equity financing following the Closing, subject
to a minimum conversion amount of $100,000, in an amount of Note Shares constituting up to thirty percent (30%) of the number of ordinary
shares issued and sold by us in such equity financing. The sponsor may also elect to convert amounts of principal outstanding under the
note into ordinary shares at any time following the 24-month anniversary of the date of the Closing, subject to a minimum conversion of
$10,000, at a price per share equal to the volume weighted average price of the ordinary shares on the principal market on which they
are traded during the 20 consecutive trading days prior to the conversion date.</div> </div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman">&#160;</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman">Government Grants</div>

<div style="text-indent: 18pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-indent: 25.2pt; margin-right: 16.2pt; margin-left: 8.15pt; line-height: 1.25; font-family: Times New Roman">Our research
and development efforts were financed, in part, through royalty-bearing grants from the Israeli Innovation Authority, or the IIA. As of
September 30, 2024, we received IIA royalty-bearing grants totaling approximately $5.8 million.</div> </div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">We are committed to pay royalties to the IIA at a rate
of approximately 3.0% to 5.0% of the sales of all of our product candidates and other related revenues generated from such projects, that
were developed, in whole or in part, using the IIA royalty-bearing grants we received under IIA programs up to the total amount of royalty-bearing
grants received, linked to the U.S. dollar and bearing annual interest at rates prescribed by the IIA&#8217;s rules and guidelines.</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">We may in the future apply to receive additional grants
from the IIA. However, we cannot predict whether we will be entitled to any future grants, or the amounts of any such grants.</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">Under the Israeli Innovation Law, research and development
programs that meet specified criteria and are approved by a committee of the IIA are eligible for grants. A company that receives a royalty-bearing
grant from the IIA is typically required to pay royalties to the IIA on income generated from products incorporating IIA-funded know-how
(including income derived from services associated with such products and from IIA-funded know-how), up to 100% of the U.S. dollar-linked
royalty-bearing grant amount plus interest.</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: rgb(0, 0, 0); font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">73</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="text-indent: 36pt; line-height: 1.25"> <span style="font-family: Times New Roman"><br/> </span> </div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">The obligation to pay royalties is contingent on actual
income generated from such products and services. In the absence of such income, no payment of royalties is required.</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="line-height: 1.25; font-family: Times New Roman">As of September 30, 2024, the total royalty amount that may be payable by
the Company is approximately $5.8 million ($6.5 million including interest).</div> </div>

<div style="text-indent: 18pt; line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman">&#160;</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman">Cash Flows</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman">&#160;</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman,Times,serif">

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman">Cash flows for the nine-month period
ended September 30, 2024 and 2023</div> </div>

<div style="text-indent: 18pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="line-height: 1.25; font-family: Times New Roman">The following table summarizes our cash flows for the periods indicated:</div>
</div>

<div style="text-indent: 18pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif"> </div>

<table cellspacing="0" cellpadding="0" class="cfttable" id="zd62abe5223464d9da396ec9efafe536b" style="font: 10pt Times New Roman, Times, serif; text-align: left; color: #000000; width: 100%">
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px">
        <div style="line-height: 1.25; font-family: Times New Roman">&#160;</div> </td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px; font-family: Times New Roman">&#160;</td>
    <td colspan="6" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom">
        <div style="text-align: center; line-height: 1.25; font-weight: bold; font-family: Times New Roman,Times,serif">
        <div style="line-height: 1.25; font-weight: bold; font-family: Times New Roman">Nine-month period ended<br/> September 30,</div> </div>
        </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px; font-family: Times New Roman">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px">
        <div style="line-height: 1.25; font-family: Times New Roman">&#160;</div> </td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px; font-family: Times New Roman">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid; vertical-align: bottom">
        <div style="text-align: center; line-height: 1.25; font-weight: bold; font-family: Times New Roman"> 2024</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px; font-family: Times New Roman">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px; font-family: Times New Roman">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid; vertical-align: bottom">
        <div style="text-align: center; line-height: 1.25; font-weight: bold; font-family: Times New Roman">2023</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px; font-family: Times New Roman">&#160;</td>
        </tr>
  <tr>
    <td rowspan="1" style="vertical-align: bottom; vertical-align: bottom; font-family: Times New Roman">&#160;</td>
    <td rowspan="1" class="cftguttercell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; font-family: Times New Roman">&#160;</td>
    <td rowspan="1" colspan="6" style="vertical-align: bottom; vertical-align: bottom">
        <div style="text-align: center; line-height: 1.25; font-family: Times New Roman">(U.S. dollars, in thousands)</div> </td>
    <td rowspan="1" class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; font-family: Times New Roman">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; background-color: rgb(204, 238, 255); width: 76%">
        <div style="line-height: 1.25; font-weight: bold; font-family: Times New Roman,Times,serif">
        <div style="line-height: 1.25; font-weight: bold; font-family: Times New Roman">Cash and cash equivalents and restricted cash at beginning
        of the period</div> </div> </td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25; font-family: Times New Roman">$</div> </td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman">4,645</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">
        <div style="line-height: 1.25; font-family: Times New Roman">$</div> </div> </td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">
        <div style="line-height: 1.25; font-family: Times New Roman">8,309</div> </div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; width: 76%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">
        <div style="line-height: 1.25; margin-left: 9pt; font-family: Times New Roman">Net cash used in operating activities</div> </div> </td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; text-align: right; vertical-align: bottom; width: 1%; font-family: Times New Roman">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">
        <div style="line-height: 1.25; font-family: Times New Roman">(5,470</div> </div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">
        <div style="line-height: 1.25; font-family: Times New Roman">)</div> </div> </td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; text-align: right; vertical-align: bottom; width: 1%; font-family: Times New Roman">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">
        <div style="line-height: 1.25; font-family: Times New Roman">(3,272</div> </div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">
        <div style="line-height: 1.25; font-family: Times New Roman">)</div> </div> </td> </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; background-color: rgb(204, 238, 255); width: 76%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">
        <div style="line-height: 1.25; margin-left: 9pt; font-family: Times New Roman">Net cash provided by (used in) investing activities</div>
        </div> </td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman">(22</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25; font-family: Times New Roman">)</div> </td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">
        <div style="line-height: 1.25; font-family: Times New Roman">577</div> </div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; width: 76%; padding-bottom: 2px">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">
        <div style="line-height: 1.25; margin-left: 9pt; font-family: Times New Roman">Net cash provided by financing activities</div> </div>
        </td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: Times New Roman">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; width: 1%; font-family: Times New Roman">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman">2,920</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: Times New Roman">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: Times New Roman">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; width: 1%; font-family: Times New Roman">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">
        <div style="line-height: 1.25; font-family: Times New Roman">522</div> </div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: Times New Roman">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; background-color: rgb(204, 238, 255); width: 76%">
        <div style="line-height: 1.25; font-weight: bold; font-family: Times New Roman,Times,serif">
        <div style="line-height: 1.25; font-weight: bold; font-family: Times New Roman">Net decrease in cash and cash equivalents and restricted
        cash</div> </div> </td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">
        <div style="line-height: 1.25; font-family: Times New Roman">$</div> </div> </td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">
        <div style="line-height: 1.25; font-family: Times New Roman">(2,572</div> </div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">
        <div style="line-height: 1.25; font-family: Times New Roman">)</div> </div> </td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">
        <div style="line-height: 1.25; font-family: Times New Roman">$</div> </div> </td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">
        <div style="line-height: 1.25; font-family: Times New Roman">(2,173</div> </div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">
        <div style="line-height: 1.25; font-family: Times New Roman">)</div> </div> </td> </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; width: 76%; padding-bottom: 4px">
        <div style="line-height: 1.25; font-weight: bold; font-family: Times New Roman,Times,serif">
        <div style="line-height: 1.25; font-weight: bold; font-family: Times New Roman">Translation adjustments on cash and cash equivalents and
        restricted cash</div> </div> </td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: Times New Roman">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 4px double; vertical-align: bottom; width: 1%; font-family: Times New Roman">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 4px double; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman">(50</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 4px">
        <div style="line-height: 1.25; font-family: Times New Roman">)</div> </td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: Times New Roman">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 4px double; vertical-align: bottom; width: 1%; font-family: Times New Roman">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 4px double; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">
        <div style="line-height: 1.25; font-family: Times New Roman">(324</div> </div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 4px">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">
        <div style="line-height: 1.25; font-family: Times New Roman">)</div> </div> </td> </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; background-color: rgb(204, 238, 255); width: 76%; padding-bottom: 4px">
        <div style="line-height: 1.25; font-weight: bold; font-family: Times New Roman,Times,serif">
        <div style="line-height: 1.25; font-weight: bold; font-family: Times New Roman">Cash and cash equivalents and restricted cash at end of
        the period</div> </div> </td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: Times New Roman">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 4px double; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">
        <div style="line-height: 1.25; font-family: Times New Roman">$</div> </div> </td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 4px double; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">
        <div style="line-height: 1.25; font-family: Times New Roman">2,023</div> </div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: Times New Roman">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: Times New Roman">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 4px double; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">
        <div style="line-height: 1.25; font-family: Times New Roman">$</div> </div> </td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 4px double; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">
        <div style="line-height: 1.25; font-family: Times New Roman">5,812</div> </div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: Times New Roman">&#160;</td>
        </tr>
  </table>

<div style="text-indent: -36pt; margin-left: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="line-height: 1.25; font-style: italic; font-family: Times New Roman,Times,serif">

<div style="line-height: 1.25; font-style: italic; font-family: Times New Roman">Cash Flows from Operating Activities</div> </div>

<div style="text-indent: 18pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="line-height: 1.25; font-family: Times New Roman">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">Net cash used in operating activities increased
by approximately $2.2 million, or 66.7%, to $5.5 million for the nine-month period ended September 30, 2024, compared to $3.3 million
for the nine-month period ended September 30, 2023. This increase was mainly due to an increase of $11.3 million in the net loss for the
nine-month period ended September 30, 2024, and from an increase in net working capital in an amount of $0.3 million, subject to reduction,
in part, to account for non-cash items included in net loss, including an increase of $5.8 million in share-based compensation expenses
and an increase of $3.6 million in non-cash financial expenses.</div> </div> </div>

<div style="line-height: 1.25; font-style: italic; font-family: Times New Roman">&#160;</div>

<div style="line-height: 1.25; font-style: italic; font-family: Times New Roman">Cash Flows from Investing Activities</div>

<div style="text-indent: 18pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="line-height: 1.25; font-family: Times New Roman">Net cash provided by (used in) investing activities decreased by $0.6 million,
or 100%, to $0 million for the nine-month period ended September 30, 2024, compared to $0.6 million of cash provided by investing activities
in the nine-month period ended September 30, 2023. This decrease was mainly due to a reduction in short-term deposits in an amount of
$0.5 million, which cash was used for operating activities.</div> </div>

<div style="line-height: 1.25; font-style: italic; font-family: Times New Roman">&#160;</div>

<div style="line-height: 1.25; font-style: italic; font-family: Times New Roman">Cash Flows from Financing Activities</div>

<div style="text-indent: 18pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="line-height: 1.25; font-family: Times New Roman">Net cash provided by financing activities increased by $2.4 million, or 480%,
to approximately $2.9 million for the nine-month period ended September 30, 2024, compared to $0.5 million the nine-month period ended
September 30, 2023. This increase was mainly due to an increase in cash received from transactions upon the closing of the Business Combination
in an amount of $2.3 million and from an increase in proceeds from issuance of ordinary shares under the ELOC in an amount of $0.6 million,
offset by a decrease of $0.5 million in proceeds from issuance of preferred shares, occurred in the nine-month period ended September
30, 2023.</div> </div>

<div style="text-indent: 36pt; line-height: 1.25"> <span style="font-family: Times New Roman"><br/> </span> </div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: rgb(0, 0, 0); font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">74</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="text-indent: 18pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman,Times,serif">

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman">Cash flows for the three-month periods
ended September 30, 2024 and 2023</div> </div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="line-height: 1.25; font-family: Times New Roman">The following table summarizes our cash flows for the periods indicated:</div>
</div>

<div style="text-indent: 18pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif"> </div>

<table cellspacing="0" cellpadding="0" class="cfttable" id="zf466c68c99294805ae15cbf2c4e6861c" style="font: 10pt Times New Roman, Times, serif; text-align: left; color: #000000; width: 100%">
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px">
        <div style="line-height: 1.25; font-family: Times New Roman">&#160;</div> </td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px; font-family: Times New Roman">&#160;</td>
    <td colspan="6" style="vertical-align: bottom; border-bottom: #000000 2px solid; vertical-align: bottom">
        <div style="text-align: center; line-height: 1.25; font-weight: bold; font-family: Times New Roman">Three-month period ended<br/> September
        30,</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px; font-family: Times New Roman">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px">
        <div style="line-height: 1.25; font-family: Times New Roman">&#160;</div> </td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px; font-family: Times New Roman">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid; vertical-align: bottom">
        <div style="text-align: center; line-height: 1.25; font-weight: bold; font-family: Times New Roman"> 2024</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px; font-family: Times New Roman">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px; font-family: Times New Roman">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid; vertical-align: bottom">
        <div style="text-align: center; line-height: 1.25; font-weight: bold; font-family: Times New Roman">2023</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px; font-family: Times New Roman">&#160;</td>
        </tr>
  <tr>
    <td rowspan="1" style="vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px; font-family: Times New Roman">&#160;</td>
    <td class="cftguttercell" colspan="1" rowspan="1" style="vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px; font-family: Times New Roman">&#160;</td>
    <td colspan="6" rowspan="1" style="vertical-align: bottom; border-bottom: #000000 2px solid; vertical-align: bottom">
        <div style="text-align: center; line-height: 1.25; font-family: Times New Roman">(U.S. dollars, in thousands)</div> </td>
    <td class="cftfncell" colspan="1" rowspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px; font-family: Times New Roman">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; background-color: rgb(204, 238, 255); width: 76%">
        <div style="line-height: 1.25; font-weight: bold; font-family: Times New Roman,Times,serif">
        <div style="line-height: 1.25; font-weight: bold; font-family: Times New Roman">Cash and cash equivalents and restricted cash at the beginning
        of the period</div> </div> </td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">
        <div style="line-height: 1.25; font-family: Times New Roman">$</div> </div> </td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">
        <div style="line-height: 1.25; font-family: Times New Roman">1,747</div> </div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25; font-family: Times New Roman">$</div> </td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman">6,491</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; width: 76%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">
        <div style="line-height: 1.25; margin-left: 9pt; font-family: Times New Roman">Net cash used in operating activities</div> </div> </td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; text-align: right; vertical-align: bottom; width: 1%; font-family: Times New Roman">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">
        <div style="line-height: 1.25; font-family: Times New Roman">(2,653</div> </div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">
        <div style="line-height: 1.25; font-family: Times New Roman">)</div> </div> </td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; text-align: right; vertical-align: bottom; width: 1%; font-family: Times New Roman">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman">(685</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25; font-family: Times New Roman">)</div> </td> </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; background-color: rgb(204, 238, 255); width: 76%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">
        <div style="line-height: 1.25; margin-left: 9pt; font-family: Times New Roman">Net cash provided by (used in) investing activities</div>
        </div> </td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman">(16</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; background-color: #CCEEFF; vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25; font-family: Times New Roman">)</div> </td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman">72</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; width: 76%; padding-bottom: 2px">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">
        <div style="line-height: 1.25; margin-left: 9pt; font-family: Times New Roman">Net cash provided by financing activities</div> </div>
        </td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: Times New Roman">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; width: 1%; font-family: Times New Roman">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman">2,920</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: Times New Roman">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: Times New Roman">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; width: 1%; font-family: Times New Roman">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman">-</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: Times New Roman">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; background-color: rgb(204, 238, 255); width: 76%">
        <div style="line-height: 1.25; font-weight: bold; font-family: Times New Roman,Times,serif">
        <div style="line-height: 1.25; font-weight: bold; font-family: Times New Roman">Net decrease in cash and cash equivalents and restricted
        cash</div> </div> </td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25; font-family: Times New Roman">$</div> </td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman">251</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25; font-family: Times New Roman">$</div> </td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman">(613</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; background-color: #CCEEFF; vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25; font-family: Times New Roman">)</div> </td> </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; width: 76%; padding-bottom: 4px">
        <div style="line-height: 1.25; font-weight: bold; font-family: Times New Roman,Times,serif">
        <div style="line-height: 1.25; font-weight: bold; font-family: Times New Roman">Translation adjustments on cash and cash equivalents and
        restricted cash</div> </div> </td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: Times New Roman">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 4px double; vertical-align: bottom; width: 1%; font-family: Times New Roman">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 4px double; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman">25</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: Times New Roman">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: Times New Roman">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 4px double; vertical-align: bottom; width: 1%; font-family: Times New Roman">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 4px double; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman">(66</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 4px">
        <div style="line-height: 1.25; font-family: Times New Roman">)</div> </td> </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; background-color: rgb(204, 238, 255); width: 76%; padding-bottom: 4px">
        <div style="line-height: 1.25; font-weight: bold; font-family: Times New Roman,Times,serif">
        <div style="line-height: 1.25; font-weight: bold; font-family: Times New Roman">Cash and cash equivalents and restricted cash at the end
        of the period</div> </div> </td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: Times New Roman">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; border-bottom: #000000 4px double; background-color: #CCEEFF; vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">
        <div style="line-height: 1.25; font-family: Times New Roman">$</div> </div> </td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; border-bottom: #000000 4px double; background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">
        <div style="line-height: 1.25; font-family: Times New Roman">2,023</div> </div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: Times New Roman">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: Times New Roman">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; border-bottom: #000000 4px double; background-color: #CCEEFF; vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25; font-family: Times New Roman">$</div> </td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; border-bottom: #000000 4px double; background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman">5,812</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: Times New Roman">&#160;</td>
        </tr>
  </table>

<div style="line-height: 1.25; font-style: italic; font-family: Times New Roman">&#160;</div>

<div style="line-height: 1.25; font-style: italic; font-family: Times New Roman">Cash Flows from Operating Activities</div>

<div style="text-indent: 18pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="line-height: 1.25; font-family: Times New Roman">Net cash used in operating activities increased by approximately $2 million,
or 285.7%, to $2.7 million for the three-month period ended September 30, 2024, compared to $0.7 million for the three-month period ended
September 30, 2023. This increase was mainly from an increase of $11.1 million in the net loss for the three-month period ended September
30, 2024, and from an increase of $0.4 million in change of net working capital, offset by (i) an increase of $5.8 million in share-based
compensation and (ii) an increase of $3.6 million in non-cash financial expenses included in the net loss.</div> </div>

<div style="line-height: 1.25; font-style: italic; font-family: Times New Roman">&#160;</div>

<div style="line-height: 1.25; font-style: italic; font-family: Times New Roman">Cash Flows from Financing Activities</div>

<div style="text-indent: 18pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="line-height: 1.25">

<div style="line-height: 1.25; font-family: Times New Roman">Net cash provided by financing activities increased by $2.9 million, to approximately
$2.9 million for the three-month period ended September 30, 2024, compared to $0 for the three-month period ended September 30, 2023.
This increase was mainly due to an increase in cash received from transactions in connection with the closing of the Business Combination
in an amount of $2.3 million and from an increase in proceeds from issuance of ordinary shares under the ELOC in an amount of $0.6 million.</div>
</div> </div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman">&#160;</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman">Cash flows for the&#160;Years ended
December&#160;31, 2023 and 2022</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">The following table summarizes our cash flows for the
years ended December 31, 2023 and 2022:</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<table cellspacing="0" cellpadding="0" class="cfttable" id="z993ae18fe96d41c88c1f51903d2ed91c" style="font: 10pt Times New Roman, Times, serif; text-align: left; color: #000000; width: 100%">
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px">
        <div style="line-height: 1.25; font-family: Times New Roman">&#160;</div> </td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px; font-family: Times New Roman">&#160;</td>
    <td colspan="6" style="vertical-align: bottom; border-bottom: #000000 2px solid; vertical-align: bottom">
        <div style="text-align: center; line-height: 1.25; font-weight: bold; font-family: Times New Roman">Year ended December 31,</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px; font-family: Times New Roman">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px">
        <div style="line-height: 1.25; font-family: Times New Roman">&#160;</div> </td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px; font-family: Times New Roman">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid; vertical-align: bottom">
        <div style="text-align: center; line-height: 1.25; font-weight: bold; font-family: Times New Roman"> 2023</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px; font-family: Times New Roman">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px; font-family: Times New Roman">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid; vertical-align: bottom">
        <div style="text-align: center; line-height: 1.25; font-weight: bold; font-family: Times New Roman">2022</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px; font-family: Times New Roman">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; background-color: #CCEEFF; width: 76%">
        <div style="line-height: 1.25; font-weight: bold; font-family: Times New Roman">Cash and cash equivalents and restricted cash at beginning
        of the period</div> </td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25; font-family: Times New Roman">$</div> </td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman">8,309</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25; font-family: Times New Roman">$</div> </td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman">10,083</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; width: 76%">
        <div style="line-height: 1.25; margin-left: 9pt; font-family: Times New Roman">Net cash used in operating activities</div> </td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman">(4,529</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25; font-family: Times New Roman">)</div> </td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%; font-family: Times New Roman">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman">(3,335</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25; font-family: Times New Roman">)</div> </td> </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; background-color: #CCEEFF; width: 76%">
        <div style="line-height: 1.25; margin-left: 9pt; font-family: Times New Roman">Net cash provided by (used in) investing activities</div>
        </td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman">573</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; font-family: Times New Roman">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman">(524</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; background-color: #CCEEFF; vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25; font-family: Times New Roman">)</div> </td> </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; width: 76%; padding-bottom: 2px">
        <div style="line-height: 1.25; margin-left: 9pt; font-family: Times New Roman">Net cash provided by financing activities</div> </td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: Times New Roman">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; width: 1%; font-family: Times New Roman">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman">522</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: Times New Roman">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: Times New Roman">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; width: 1%; font-family: Times New Roman">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman">2,752</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: Times New Roman">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; background-color: #CCEEFF; width: 76%">
        <div style="line-height: 1.25; font-weight: bold; font-family: Times New Roman">Net decrease in cash and cash equivalents and restricted
        cash</div> </td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25; font-family: Times New Roman">$</div> </td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman">(3,434</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; background-color: #CCEEFF; vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25; font-family: Times New Roman">)</div> </td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: Times New Roman">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25; font-family: Times New Roman">$</div> </td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman">(1,107</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; background-color: #CCEEFF; vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25; font-family: Times New Roman">)</div> </td> </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; width: 76%; padding-bottom: 4px">
        <div style="line-height: 1.25; font-weight: bold; font-family: Times New Roman">Translation adjustments on cash and cash equivalents and
        restricted cash</div> </td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: Times New Roman">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 4px double; vertical-align: bottom; width: 1%; font-family: Times New Roman">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 4px double; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman">(230</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 4px">
        <div style="line-height: 1.25; font-family: Times New Roman">)</div> </td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: Times New Roman">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 4px double; vertical-align: bottom; width: 1%; font-family: Times New Roman">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 4px double; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman">(667</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 4px">
        <div style="line-height: 1.25; font-family: Times New Roman">)</div> </td> </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; background-color: #CCEEFF; width: 76%; padding-bottom: 4px">
        <div style="line-height: 1.25; font-weight: bold; font-family: Times New Roman">Cash and cash equivalents and restricted cash at the end
        of the period</div> </td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: Times New Roman">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; border-bottom: #000000 4px double; background-color: #CCEEFF; vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25; font-family: Times New Roman">$</div> </td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; border-bottom: #000000 4px double; background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman">4,645</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: Times New Roman">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: Times New Roman">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; border-bottom: #000000 4px double; background-color: #CCEEFF; vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25; font-family: Times New Roman">$</div> </td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; border-bottom: #000000 4px double; background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman">8,309</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: Times New Roman">&#160;</td>
        </tr>
  </table>

<div style="line-height: 1.25; font-style: italic; font-family: Times New Roman">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: rgb(0, 0, 0); font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">75</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="line-height: 1.25; font-style: italic; font-family: Times New Roman">Cash Flows from Operating Activities</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">Net cash used in operating activities increased by approximately
$1.2&#160;million, or 36.4%, to $4.5&#160;million for the year ended December&#160;31, 2023, compared to $3.3&#160;million for the year
ended December&#160;31, 2022. This increase was mainly from an increase of $1.6&#160;million in the loss for the year, offset by a decrease
of $0.6&#160;million in non-cash financial expenses.</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;<span style="font-style: italic">&#160;</span></div>

<div style="line-height: 1.25; font-style: italic; font-family: Times New Roman">Cash Flows from Investing Activities</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">Net cash provided by (used in) investing activities increased
by $1.1&#160;million, or 220.0%, to $0.6&#160;million for the year ended December&#160;31, 2023, compared to investment of $0.5&#160;million
for the year ended December&#160;31, 2022. This increase was mainly due to change short-term deposit in the amount of $1.0&#160;million.</div>

<div style="line-height: 1.25; font-style: italic; font-family: Times New Roman">&#160;</div>

<div style="line-height: 1.25; font-style: italic; font-family: Times New Roman">Cash Flows from Financing Activities</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">Net cash provided by financing activities decreased by
$2.3&#160;million, or 82.1%, to approximately $0.5&#160;million for the year ended December&#160;31, 2023, compared to $2.8&#160;million
for the year ended December&#160;31, 2022. This decrease was mainly due to a decrease in proceeds from issuance of preferred shares which
was higher in the amount of $2.2&#160;million in 2022.</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman">Funding Requirements</div>

<div style="text-indent: 18pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">We expect to devote substantial financial resources to
our ongoing and planned activities, particularly further development of SIL-204 and as we conduct our planned pre-clinical and clinical
trials.</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">Identifying potential product candidates and conducting
pre-clinical testing and clinical trials is a time-consuming, expensive, and uncertain process that takes years to complete, and we may
never generate the necessary data or results required to obtain marketing approval and achieve product sales. In addition, our product
candidates, if approved, may not achieve commercial success. For additional information please refer to the &#8220;<span style="font-style: italic">Risk
Factors</span>&#8221; section of this prospectus, including &#8220;<span style="font-style: italic">Risks Related to Our Financial Condition
and Capital Requirements</span> &#8212; <span style="font-style: italic">we have never generated any revenue from product sales and may
never be profitable&#8221; and &#8220;Risks Related to the Research and Development of our Product Candidates &#8212; Silexion is heavily
dependent on the success of its product candidates</span>&#8230;&#8221;.</div> </div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">We expect our expenses to increase substantially in connection
with our ongoing activities, particularly as we advance our pre-clinical studies and clinical trials. In addition, if we obtain marketing
approval for SIL-204 in any indication or for any other product candidate we are developing or may develop in the future, we expect to
incur significant commercialization expenses related to product manufacturing, sales, marketing, and distribution. Furthermore, upon the
closing of the Business Combination, we expect to incur additional costs associated with operating as a public company. Accordingly, we
will need to obtain substantial additional funding.</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">Our future capital requirements will depend on many factors,
including:</div>

<div style="text-indent: -36pt; margin-left: 48pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z7bc972d6a136451d98b0e92e9180014e" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman">Material cost.</div> </td> </tr>
  </table>

<div style="text-indent: -36pt; margin-left: 48pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<table cellspacing="0" cellpadding="0" id="za47831a686e44512a67f31fd9ec39fb7" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman">Regulatory pathway; and</div> </td> </tr>
  </table>

<div style="text-indent: -36pt; margin-left: 48pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z0f5c9191cb7448c492ee647641d35137" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">
        <div style="text-align: left; line-height: 1.25; font-family: Times New Roman">Human clinical trial costs.</div> </div> </td> </tr>
  </table>

<div style="text-indent: 18pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">

<div style="line-height: 1.25; font-family: Times New Roman">As of September 30, 2024, we had cash and cash equivalents of $2.0 million.
Based on our current cash balance, as well as its history of operating losses and negative cash flows from operation, combined with its
anticipated use of cash to, among other things, (i) fund the preclinical and clinical development of our products, (ii) identify and develop
new product candidates, and (iii) seek approval for SIL-204 and any other product candidates we may develop, our management has concluded
that we do not have sufficient cash to fund our operations for 12 months from the date of its unaudited condensed financial statements
for the nine-month period ended September 30, 2024 included in this prospectus without additional financing, and as a result, there is
substantial doubt about our ability to continue as a going concern.</div> </div> </div>

<div style="text-indent: 18pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: rgb(0, 0, 0); font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">76</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="text-align: center; line-height: 1.25"><span style="font-family: Times New Roman"><br/> </span> </div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="line-height: 1.25; font-family: Times New Roman">In making this determination, applicable accounting standards prohibited
us from considering the potential mitigating effect of plans that have not been fully implemented as of the date of our unaudited condensed
financial statements for the nine-month period ended September 30, 2024, including, without limitation, plans to consummate the Business
Combination discussed below and to raise additional capital. Our financial information throughout this prospectus, and our unaudited condensed
financial statements for the nine -month period ended September 30, 2024 contained herein have been prepared on a basis that assumes that
we will continue as a going concern, which contemplates the realization of assets and the satisfaction of liabilities and commitments
in the normal course of business. This financial information and our unaudited condensed financial statements for the nine -month period
ended September 30, 2024 do not include any adjustments that may result from an unfavorable outcome of this uncertainty.</div> </div>

<div style="text-indent: 18pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">

<div style="line-height: 1.25; font-family: Times New Roman">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">

<div style="text-indent: 36pt; line-height: 1.25">Without giving effect to the receipt of any proceeds from this offering, we currently
estimate that our existing cash and cash equivalents are sufficient to fund business operations through the end of first quarter of 2025.</div>
</div> </div> </div> </div>

<div style="text-indent: 18pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="line-height: 1.25; font-family: Times New Roman">We have based these estimates and expectations on assumptions that may prove
to be wrong, and our operating plan may change as a result of many factors currently unknown to us. We could not, as of the September
30, 2024 balance sheet date of the unaudited condensed financial statements for the three and nine-month periods ended September 30, 2024,
determine the exact level of funds that will be available to us upon potential equity financings. Our expected use of funds represents
our intentions based upon our current plans and business condition, which could change in the future as our plans and business condition
evolve and the level of funding available to us becomes clear. In addition, changing circumstances could cause us to consume capital significantly
faster than we currently anticipate, and we may need to spend more than currently expected because of circumstances beyond our control.
As a result, we could deplete our capital resources sooner than we currently expect. In addition, because the successful development of
SIL-204 and any studies or other product candidates that we pursue is highly uncertain, at this time we cannot reasonably estimate or
know the nature, timing and costs of the efforts that will be necessary to complete the development of any product candidate.</div> </div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">Until such time, if ever, as we can generate substantial
revenues from product sales, we expect to finance our cash needs through a combination of public and private equity offerings and debt
financings, including the private placement of ordinary shares pursuant to the White Lion Purchase Agreement, strategic alliances, collaborations,
and marketing, distribution, or licensing arrangements. However, adequate additional financing may not be available to us on acceptable
terms, or at all, and may be impacted by the economic climate and market conditions.</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif"> <span style="font-family: Times New Roman"><br/>
</span> </div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-indent: 25.2pt; margin-right: 8pt; margin-left: 8.15pt; line-height: 1.25; font-family: Times New Roman">Reliance on
the ELOC or other similar types of equity financings as a source of ongoing funding for our operations following the Business Combination
could involve significant issuances of ordinary shares by us that could cause the following impacts (among others):</div>

<div style="line-height: 1.25"><span style="font-family: Times New Roman"><br/> </span> </div>

<div style="line-height: 1.25">

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 33.35pt"><span style="font-family: Times New Roman"><br/> </span> </td>
    <td style="width: 20.65pt; vertical-align: top; font-family: Times New Roman">&#9679;</td>
    <td style="width: auto; vertical-align: top">
        <div style="font-family: Times New Roman">significant dilution to the equity interests of our current shareholders;</div> </td> </tr>
  </table>

<div style="line-height: 1.25"><span style="font-family: Times New Roman"><br/> </span> </div> </div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z823a73d6ad734bd9bca4489d764d309d" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 33.35pt"><span style="font-family: Times New Roman"><br/> </span> </td>
    <td style="width: 20.65pt; vertical-align: top; font-family: Times New Roman">&#9679;</td>
    <td style="width: auto; vertical-align: top">
        <div style="font-family: Times New Roman">a deemed change of control of our company due to the issuance of a substantial number of ordinary
        shares, which may affect, among other things, our ability to use our net operating loss carry forwards, if any, and could result in a
        change in the officers and directors of our company relative to our current officers and directors, to the extent any shareholders build
        up significant beneficial ownership from ordinary shares issued pursuant to the ELOC;</div> </td> </tr>
  </table>

<div style="line-height: 1.25"><span style="font-family: Times New Roman"><br/> </span> </div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="za0a2fdf5a2bf49cb86568f2eff981630" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 33.35pt"><span style="font-family: Times New Roman"><br/> </span> </td>
    <td style="width: 20.65pt; vertical-align: top; font-family: Times New Roman">&#9679;</td>
    <td style="width: auto; vertical-align: top">
        <div style="font-family: Times New Roman">may have the effect of delaying or preventing a change of control of our company by diluting
        the share ownership or voting rights of a person seeking to obtain control; and</div> </td> </tr>
  </table>

<div style="line-height: 1.25">

<div style="line-height: 1.25"><span style="font-family: Times New Roman"><br/> </span> </div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 33.35pt"><span style="font-family: Times New Roman"><br/> </span> </td>
    <td style="width: 20.65pt; vertical-align: top; font-family: Times New Roman">&#9679;</td>
    <td style="width: auto; vertical-align: top">
        <div style="font-family: Times New Roman,Times,serif">
        <div style="line-height: 1.25; font-family: Times New Roman">may adversely affect prevailing market prices for our ordinary shares or
        warrants.</div> </div> </td> </tr>
  </table> </div>

<div style="text-indent: 25.2pt; margin-right: 8pt; margin-left: 8.15pt; line-height: 1.25"><span style="font-family: Times New Roman"><br/>
</span> </div> </div>

<div style="line-height: 1.25; font-weight: bold; font-family: Times New Roman">Critical Accounting Policies and Estimates</div>

<div style="text-indent: 18pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">

<div style="line-height: 1.25; font-family: Times New Roman">For a description of our significant accounting policies, see Note 2 to our
consolidated financial statements for the year ended December 31, 2023 and unaudited condensed consolidated financial statements for the
nine-month period ended September 30, 2024 included in this prospectus.</div> </div> </div>

<div style="text-indent: 18pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="line-height: 1.25; font-family: Times New Roman">The preparation of our consolidated financial statements for the year ended
December 31, 2023 and unaudited condensed consolidated financial statements for the nine-month period ended September 30, 2024 in conformity
with U.S. GAAP requires management to make estimates and assumptions in certain circumstances that affect the amounts reported in the
accompanying consolidated financial statements for the year ended December 31, 2023 and unaudited condensed consolidated financial statements
for the nine-month period ended September 30, 2024 and related footnotes. Actual results may differ from these estimates. We base our
judgments on our experience and on various assumptions that we believe to be reasonable under the circumstances.</div> </div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: rgb(0, 0, 0); font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">77</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="line-height: 1.25; font-family: Times New Roman">Of our policies, the following are considered critical to an understanding
of our consolidated financial statements for the year ended December 31, 2023 and unaudited condensed consolidated financial statements
for the nine-month period ended September 30, 2024 as they require the application of subjective and complex judgment, involving critical
accounting estimates and assumptions impacting our consolidated financial statements for the year ended December 31, 2023 and unaudited
condensed consolidated financial statements for the nine-month period ended September 30, 2024.</div> </div>

<div style="text-indent: 18pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">The critical accounting estimates relate to the following:</div>

<div style="margin-left: 36pt; line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 17.45pt; margin-left: 18pt; line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman">Share-Based
Compensation</div>

<div style="text-indent: 17.45pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">Share-based compensation expense related to share awards
is recognized based on the fair value of the awards granted. The fair value of each option award is estimated on the grant date using
the Black-Scholes option pricing model. The Black-Scholes option pricing model requires the input of highly subjective assumptions, including
the fair value of the underlying ordinary shares (see below), the expected term of the option, and the expected volatility of the price
of our ordinary shares. These estimates involve inherent uncertainties and the application of management&#8217;s judgment. The related
share-based compensation expense is recognized on a straight-line basis over the requisite service period of the awards, including awards
with graded vesting and no additional conditions for vesting other than service conditions. Forfeitures are accounted for as they occur
instead of estimating the number of awards expected to be forfeited.</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">Our use of the Black-Scholes option-pricing model requires
the input of highly subjective assumptions. If factors change and different assumptions are used, our share-based compensation expense
could be materially different in the future.</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">We will continue to use judgment in evaluating the assumptions
related to our share-based compensation on a prospective basis. As we continue to accumulate additional data related to our ordinary shares,
we may refine our estimation process, which could materially impact our future share-based compensation expense.</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman">&#160;</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman">Valuations of instruments convertible
to our Ordinary and Preferred Shares</div>

<div style="text-indent: 18pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">Our preferred shares are classified as temporary equity,
as they include clauses that could constitute as in-substance redemption clauses that are outside our control. Warrants and other instruments
over our Preferred Shares are classified as liabilities under ASC 480 and measured at fair value, with subsequent changes in fair value
recognized in the statements of operations in each period.</div> </div>

<div style="text-indent: 18pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">The fair value of our preferred shares underlying our
convertible instruments was determined by our board of directors, after considering contemporaneous third-party valuations and input from
management. In the absence of a public trading market, our board of directors, with input from management, exercised significant judgment
and considered various objective and subjective factors to determine the fair value of our equity including the following factors:</div>
</div>

<div style="text-indent: -36pt; margin-left: 48pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<table cellspacing="0" cellpadding="0" id="zbca26175a81d4f60ab89ee305f3d89a2" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman">History of transactions in our preferred shares;</div>
        </td> </tr>
  </table>

<div style="text-indent: -36pt; margin-left: 48pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z922f3073fa8e43a4932cb0bc8ae0fd03" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman">Probability of an IPO scenario (including de SPAC transaction);</div>
        </td> </tr>
  </table>

<div style="text-indent: -36pt; margin-left: 48pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<table cellspacing="0" cellpadding="0" id="zfe63197659f04a21b0454b34268aa860" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman">Probability of other liquidation events;</div> </td>
        </tr>
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">&#160;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman">&#160;</div> </td> </tr>
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman">Expected time to liquidation; and</div> </td> </tr>
  </table>

<div style="text-indent: -36pt; margin-left: 48pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<table cellspacing="0" cellpadding="0" id="zd52cc5b3c25b4ab295ea7cc904e417f8" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman">Expected return on equity.</div> </td> </tr>
  </table>

<div style="text-indent: 18pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">The resulting equity value was then allocated to each
share class based on differences in liquidation preferences of the various share classes using an Option Pricing Model (&#8220;OPM&#8221;)
through the use of a series of call options and by implementing a Monte Carlo simulation. The OPM allocates the overall company value
to the various share classes based on differences in liquidation preferences, using a series of call options. The OPM is appropriate to
use when the range of possible future outcomes is difficult to predict. Starting from 2023, for the IPO scenario (including de SPAC transaction)
we utilized a probability-weighted expected return method (&#8220;PWERM&#8221;) to allocate value among the various share classes. The
PWERM involves the estimation of the value of our company under multiple future potential outcomes and estimates the probability of each
potential outcome. After the value of each applicable class of shares was determined, a discount for lack of marketability (&#8220;DLOM&#8221;)
was applied to arrive at the fair value of the ordinary shares on a non-marketable basis. A DLOM is applied in order to reflect the lack
of a recognized market for a closely held interest and the fact that a non-controlling equity interest may not be readily transferable.
A market participant purchasing this share would recognize this illiquidity associated with the shares, which would reduce the overall
fair market value.</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: rgb(0, 0, 0); font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">78</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="text-indent: 18pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">In some cases, we considered the amount of time between
rounds of financing to determine whether to use a mid price calculation between two dates.</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">Upon completion of the Business Combination, our ordinary
shares are publicly traded, and we rely on the closing price of our ordinary shares as reported on the date of the applicable valuations.</div>
</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">The fair value of the warrants for the purchase of preferred
shares was calculated using the OPM as part of the allocation of the equity value to the various share classes (as described above). The
critical accounting estimates for the valuation of those warrants include (a) the fair value of the underlying preferred shares, as mentioned
above, and (b) volatility &#8212; based on peer companies&#8217; volatility.</div>

<div style="line-height: 1.25; font-weight: bold; font-family: Times New Roman">&#160;</div>

<div style="line-height: 1.25; font-weight: bold; font-family: Times New Roman">Recent Accounting Pronouncements</div>

<div style="text-indent: 18pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">See Note 2 on page F-75 to our financial statements for
the year ended December 31, 2023 included in this prospectus for a description of recent accounting pronouncements applicable to our financial
statements for the year ended December 31, 2023.</div> </div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold; font-family: Times New Roman">Smaller Reporting Company Status</div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">We are a &#8220;smaller reporting company,&#8221; meaning
that the market value of our ordinary shares held by non-affiliates is less than $700 million and our (via its Silexion subsidiary) annual
revenue was less than $100 million during the most recently completed fiscal year. We will continue to be a smaller reporting company
if either (i) the market value of our shares held by non-affiliates is less than $250 million or (ii) our annual revenue was less than
$100 million during the most recently completed fiscal year and the market value of our shares held by non-affiliates is less than $700
million. As a smaller reporting company, we may choose to present only the two most recent fiscal years of audited financial statements
and we have reduced disclosure obligations regarding executive compensation.</div> </div> </div>

<div style="text-align: justify; text-indent: 18pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold; font-family: Times New Roman">Emerging Growth Company Status</div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">Section 102(b)(1) of the Jumpstart Our Business Startups
Act of 2012, or the JOBS Act, exempts emerging growth companies from being required to comply with new or revised financial accounting
standards until private companies are required to comply with the new or revised financial accounting standards. The JOBS Act provides
that a company can choose not to take advantage of the extended transition period and comply with the requirements that apply to non-emerging
growth companies, and any such election to not take advantage of the extended transition period is irrevocable.</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">We are an &#8220;emerging growth company&#8221; as defined
in Section 2(a) of the Securities Act, and has elected to take advantage of the benefits of the extended transition period for new or
revised financial accounting standards. We will remain an emerging growth company until the earliest of (i) the last day of the fiscal
year in which the market value of ordinary shares that is held by non-affiliates exceeds $700 million as of the end of that year&#8217;s
second fiscal quarter, (ii) the last day of the fiscal year in which we have total annual gross revenue of $1.235 billion or more during
such fiscal year (as indexed for inflation), (iii) the date on which we have issued more than $1.0 billion in non-convertible debt in
the prior three-year period, or (iv) December 31, 2025. We expect to continue to take advantage of the benefits of the extended transition
period, although it may decide to early adopt such new or revised accounting standards to the extent permitted by such standards. This
may make it difficult or impossible to compare our financial results with the financial results of another public company that is either
not an emerging growth company or is an emerging growth company that has chosen not to take advantage of the extended transition period
exemptions because of the potential differences in accounting standards used.</div> </div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: rgb(0, 0, 0); font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">79</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="text-align: justify; text-indent: 18pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: center; line-height: 1.25; font-weight: bold; font-family: Times New Roman"><!--Anchor--><span id="BUSINESS"><!--Anchor--></span>BUSINESS</div>

<div style="text-align: center; line-height: 1.25; font-weight: bold; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-style: italic; font-family: Times New Roman">Unless the context otherwise requires,
in this &#8220;Business&#8221; section, the terms &#8220;we,&#8221; &#8220;us&#8221; and &#8220;our&#8221; generally refer to Silexion
Therapeutics Ltd., an Israeli company (&#8220;Silexion&#8221;), or, from and after the Business Combination, to Silexion Therapeutics
Corp (formerly known as Biomotion Sciences), a Cayman Islands exempted company (&#8220;New Silexion&#8221;).</div>

<div style="line-height: 1.25; font-weight: bold; font-family: Times New Roman">&#160;</div>

<div style="line-height: 1.25; font-weight: bold; font-family: Times New Roman">Business Overview</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">We are a clinical-stage, oncology-focused&#160;biotechnology
company engaged in the discovery and development of proprietary treatments for KRAS-driven&#160;cancers. The KRAS gene is an oncogene
that is&#160;involved in the regulation of cell division as a result of its ability to relay external signals to the cell nucleus. Based
on our research of refractory solid tumor cancers, we are actively developing a platform focused on the silencing of the KRAS oncogene
using RNA-interference&#160;therapeutics. Our lead product candidate, SIL-204B, consists of locally administered small interfering RNAs,
or siRNA, in an extended-release&#160;formulation, as a first-line&#160;treatment of locally advanced pancreatic cancer patients, or LAPC,
in combination with standard-of-care&#160;chemotherapy.</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">The KRAS oncogene is considered to be the most common
oncogenic gene driver in human cancers, and the most notable in pancreatic, lung, and gastrointestinal (GI) (including colorectal, esophagus,
stomach, small bowel, and appendix) cancers. Considered a challenging therapeutic target due to its intrinsic characteristics, recent
advances have been made at directly inhibiting the KRAS proteins produced by the mutated gene. Our platform is designed to silence the
gene, and thus prevent the production of the harmful mutated KRAS proteins driving the growth of cancerous tumors.</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">We are currently focused on treatment for pancreatic cancer
(PC) tumors bearing the KRAS G12D or KRAS G12V mutations where metastases have not been detected and are non-resectable, i.e. they are
not able to be surgically removed. For our first indication, we are targeting the largest and least treatable form of localized pancreatic
tumors referred to as locally advanced pancreatic cancer.&#160;LAPC represents approximately 30% of the total pancreatic cancer population.
We are currently developing SIL-204B, a second-generation&#160;siRNA product candidate following a Phase 1 and Phase 2 clinical trial
with our first-generation&#160;siRNA product candidate, siG12D-LODER, which we also refer to as Loder. Results from the Phase 2 clinical
trial showed a trend for differences between treatment groups in patients with the KRAS G12D/V mutation, with the Loder arm suggesting
an overall survival advantage of 9.3&#160;months.</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">SIL-204B has been designed to optimize Loder with the
aim of improving uptake into tumor cells, enhancing stability, and improving the delivery system. We plan to conduct a Phase 2/3 prospective,
randomized, controlled, multinational, two-arm, open-label trial in LAPC subjects that harbor the KRAS G12D/V mutations to evaluate the
efficacy, safety and tolerability of SIL-204B administered intratumorally in combination with standard of care (SoC) chemotherapy versus
SoC chemotherapy only. In support of our planned Phase 2/3 trial, we held a meeting with the Federal Institute for Drugs and Medical Devices
in Germany (BfArM) to discuss the planned design of the Phase 2/3 trial at which BfArM agreed, in principle, to the design. In preparation
for the study, we plan to initiate toxicology studies of SIL-204B in 2025 followed by the regulatory submission in the second half of
2025&#160; to initiate the Phase 2/3 trial and trial initiation in the first half of 2026. At this time, we are focused on the further
development of the core siRNA technology underlying the Loder and SIL-204B as well as the clinical development of SIL-204B as the most
optimized version of the technology.</div> <span style="font-family: Times New Roman"><br/> </span> </div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: rgb(0, 0, 0); font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">80</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="line-height: 1.25; font-weight: bold; font-family: Times New Roman">Our Market Opportunity</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">Activating mutations in&#160;KRAS&#160;are among the most
prevalent oncogenic driver mutations in human cancers. In a recent study of over 400,000 patients with various cancer type malignancies,
23% of adult pan-cancer&#160;samples had KRAS alterations, 88% of which were mutations, most commonly G12D, G12V, G12C, G13D and G12R,
making the KRAS target a sought-out&#160;target in for many cancers (&#8220;Comprehensive pan-cancer&#160;genomic landscape of KRAS altered
cancers and real-world&#160;outcomes in solid tumors&#8221;, by Jessica K.&#160;Lee, etc., NPJ Precision Oncology 2022; 6:&#160;91). In
addition, the study found that various cancers have an amplification of the non-mutated&#160;KRAS protein. Tumor types with a high prevalence
of KRAS mutations included pancreatic ductal adenocarcinoma (PDAC) (92%), colorectal cancer (CRC) (49%), and non-squamous&#160;non-small&#160;cell
lung cancer (NSCLC) (35%). These three cancers represent 71% of the KRAS mutant pan-tumor&#160;population studied.</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">The following chart shows the distribution of various
alternations of the KRAS oncogene in various type of cancers:</div>

<div style="text-align: center; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: center; line-height: 1.25; font-family: Times New Roman"><img src="image1.jpg" alt="" style="width: 620px; height: 401px"/>&#160;</div>

<div style="text-align: center; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: rgb(0, 0, 0); font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">81</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman">Pancreatic Cancer</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">By the next decade, pancreatic cancer is expected to become
the second most deadly cancer. Every year in the U.S.&#160;approximately 50,000 people die from pancreatic cancer, while approximately
61,000 new patients are diagnosed with pancreatic cancer annually (American Cancer Society Statistics 2023).</div>

<div style="text-align: center; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: center; line-height: 1.25; font-family: Times New Roman"><img src="image2.jpg" alt="" style="width: 142px; height: 191px"/>&#160;</div>

<div style="text-align: center; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: center; line-height: 1.25; font-family: Times New Roman"><img src="image3.jpg" alt="" style="width: 611px; height: 333px"/>&#160;</div>

<div style="text-align: center; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">Studies have shown that pancreatic cancer patients have
short survival rates compared to other cancer types (see, for example, &#8220;Prognosis and survival analysis of patients with pancreatic
cancer: retrospective experience of a single institution&#8221;, by Qi Li and others, World Journal of Surgical Oncology, 2022; 20:11).
There are four basic forms of pancreatic cancer: Resectable, those where a surgeon can remove a tumor; Borderline Resectable (BRPC) where
the tumor is not currently permissible for surgery but prior treatment with chemotherapy or radiation could in some cases allow for surgical
removal; LAPC where the tumor has surrounded more than half of a major artery or vein and is not surgically removable; and Metastatic
where the cancerous tumor has spread to other organs. Of the forms of pancreatic cancer that are localized (those which have not yet spread),
the largest and most life threatening is LAPC, which constitutes approximately 30% of pancreatic cancers (&#8220;Locally Advanced Pancreatic
Cancer: A Review of Local Ablative Therapies&#8221;, by Alette Ruarus and others, Cancers BaseI, January&#160;2018; 10(1):16).</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: rgb(0, 0, 0); font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">82</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">Below is a curve of overall survival in LAPC patients:</div>

<div style="text-align: center; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: center; line-height: 1.25; font-family: Times New Roman"><img src="image4.jpg" alt="" style="width: 622px; height: 430px"/>&#160;</div>

<div style="text-align: center; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">Fig. Comparison of overall survival between different
chemotherapy regimens in non-resected&#160;locally advanced pancreatic cancer patients. CHT indicates chemotherapy; FFX, FOLFIRINOX; Gem,
gemcitabine. Reference Gemenetzis, G et al. 2019. Annals of Surgery. 270 (2):340</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">KRAS mutations across their various forms are responsible
for approximately 92% of all pancreatic cancers, of which the KRAS G12D and KRAS12V mutations account for over 70% of the cases traced
to KRAS mutations (Bailey, P.&#160;<span style="font-style: italic">et al.</span>&#160;Genomic analyses identify molecular subtypes of
pancreatic cancer.&#160;<span style="font-style: italic">Nature</span>&#160;531(7592), 47&#160;&#8211;&#160;52.&#160;<span style="font-style: italic">https://doi.org/10.1038/nature16965</span>&#160;(2016)&#160;(Art.
No. 7592)). Unfortunately, those with LAPC have a short survival time, about 17&#160;months, and constitute about 30% of the total pancreatic
cancer population (&#8220;Survival in Locally Advanced Pancreatic Cancer After Neoadjuvant Therapy and Surgical Resection&#8221;, by Georgio
Gemenetzis, MD, and others, Annals of Surgery. 270 (2):1, March&#160;2018). Among those patients with KRAS mutations, those with the mutation
type G12D and G12V show the shortest OS among the G12x mutation type.</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: rgb(0, 0, 0); font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">83</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="text-align: center; line-height: 1.25"><span style="font-family: Times New Roman"><br/> </span> </div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">Distribution of KRAS Mutations in Pancreatic Cancer</div>

<div style="text-align: center; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: center; line-height: 1.25; font-family: Times New Roman"><img src="image5.jpg" alt="" style="width: 532px; height: 326px"/>&#160;</div>

<div style="text-align: center; line-height: 1.25; font-weight: bold; font-family: Times New Roman">&#160;</div>

<div style="line-height: 1.25; font-weight: bold; font-family: Times New Roman">Our Technology</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">Our research is focused on the development of a platform
of therapeutics that is designed to silence the KRAS oncogene using small interfering RNA, or siRNA. This function is called interference
RNA (RNAi). When the RNAi is double stranded of 19-25&#160;nucleotides (NTs), in length, it is referred to as siRNA. This class of siRNA
therapeutics exert their effect by inducing the enzymatic breakdown of the messenger (mRNA) of a targeted gene inhibiting the process
called translation, which turns the message (mRNA) into a protein. The general mechanism for the silencing the oncogene is actually an
evolutionary process developed by cells to protect against viruses.</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">We believe our approach also builds upon the validation
of our target KRAS mutations as a target for cancers, as seen with the two small molecule KRAS inhibitors currently on the market for
non-small&#160;cell lung cancer, and the validation of siRNA technology, as it is currently on the market for five non-oncological&#160;indications.
None of these agents is appropriate for our intended primary indication, but we believe they do support our premises regarding target
(KRAS) and basic technology (siRNA) for use in the oncological area. A key distinction between our technology and the existing inhibitors
of KRAS is that our siRNA technology prevents the production of the protein, as indicated by a decrease in the mRNA and physiological
decrease in human tumor cell line growth shown in our preclinical studies. By contrast, the existing inhibitors and to our knowledge,
those in development inhibit its activity, and clinical use of the existing inhibitors has shown that they potentially leave large unmet
needs.</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">The specific mechanism of this silencing activity is depicted
in the figure below. siRNAs, usually&#160;19-25&#160;NTs, enter the cell as a double-standard&#160;complex. Once in the inner cell matrix,
they bind to an RNA-induced&#160;silencing complex of enzymes (RISC), which splits the siRNA into two single RNA strands referred to as
the passenger (sense) strand and the guide (antisense) strand. It is the antisense which is the active part. The single guide strand has
complementary binding&#160;to the target mRNA and thereby acts as an inducing guide for other enzymes in the RISC complex to bind&#160;and
induce specific cleavage of the now double stranded target mRNA. As the siRNA guide strand is designed to be complementary to the RNA
message around the site of the mutation of the gene to be silenced, in our case the mutated KRAS oncogene, once the message (mRNA) is
destroyed, the oncogene is silenced. As the sense-strand&#160;of the siRNA is designed to be specific for the KRAS, there is a specificity
to the silencing of this driver of cancer.</div>

<div style="text-align: center; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: rgb(0, 0, 0); font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">84</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="text-align: center; line-height: 1.25"><span style="font-family: Times New Roman"><br/> </span> </div>

<div style="text-align: center; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: center; line-height: 1.25; font-family: Times New Roman"><img src="image6.jpg" alt="" style="width: 595px; height: 417px"/>&#160;</div>

<div style="text-align: center; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">Our first-generation&#160;siRNA product candidate, siG12D,
is an extended-release&#160;formulation of siRNA. While originally designed to combat the KRAS G12D mutation in patients with LAPC, siG12D
was shown to have silencing activity in other KRAS mutations including G12V as well as to a lesser degree in G12C and G12R. The product
candidate is comprised of the anti-KRAS(G12D) siRNA drug substance (siG12D), formulated in a biodegradable polymeric matrix (PLGA) as
solid rods in order to obtain an extended-release&#160;profile. To overcome the difficulties of a systemic drug to enter the pancreatic
tumor environment and to obtain a sufficiently high level of siRNA in the pancreatic cell without inducing unnecessary side effects, the
siRNA is directly delivered intratumorally using a standard ultrasound guided endoscopy (EUS). Since patients should undergo anesthesia
prior to the endoscopy, the same as that required for a biopsy, the siRNA has been formulated as an extended-release&#160;formulation
to increase the time between administrations. We refer to this product formulation as siG12D-LODER&#160;or Loder. Loder has undergone
extensive pre-clinical&#160;testing as well as two open-label&#160;clinical trials.</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">Our second-generation&#160;siRNA product candidate, SIL-204B,
is an optimized form of the first-generation&#160;Loder comprised of an anti-KRAS&#160;siRNA drug substance (SIL-204) encapsulated into
a biodegradable polymeric matrix (PLGA). While pre-clinical&#160;testing of SIL-204B&#160;has shown silencing activity of KRAS mutations
including G12D, G12V, G12C and G12R in varying degrees, it is designed to mainly combat the KRAS G12D and KRAS G12V mutations in patients
with LAPC where silencing activity is more enhanced. The second-generation&#160;siRNA drug substance aims to provide improved uptake into
tumor cells by introduction of a hydrophobic tail that enhances movement across the cell membrane. Additionally, second-generation&#160;siRNA
drug substance includes modified nucleotides in the siRNA that enhance stability and corresponding half life. Most significantly, the
delivery system has been improved in which PLGA-rods&#160;used in Loder have been replaced by PLGA-microparticles, allowing the drug substance
to be injected as a suspension, facilitating administration through smaller needles. As with Loder, the administration is by ultrasound
guided endoscopy (EUS), of the type typically used for pancreatic biopsies to diagnose pancreatic cancer and can be done by a typical
gastrointestinal endoscopist.</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: rgb(0, 0, 0); font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">85</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="text-align: center; line-height: 1.25"><span style="font-family: Times New Roman"><br/> </span> </div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">As discussed further below, Silexion plans to conduct
a Phase 2/3 clinical trial of SIL-204B&#160;targeting KRAS G12D and G12V mutations. The targeting of additional mutations is expected
to require additional clinical trials.</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">We believe the optimization of Loder allows for more of
a personalized medicine approach to the dosing, allowing the siRNA dose to be adjusted to the tumor size. The small volume of suspension
is expected to allow for treatment of smaller tumors than those treated with Loder, and to continue treatment for a longer period of time
with tumors shrinking in size. Furthermore, delivery of the extended-release&#160;PLGA formulated siRNA, SIL-204B, to be administered
using a much smaller needle is expected to allow more flexibility and decrease the risk associated with administration.</div>

<div style="line-height: 1.25; font-weight: bold; font-family: Times New Roman">&#160;</div>

<div style="line-height: 1.25; font-weight: bold; font-family: Times New Roman">Pre-Clinical Studies</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">We have conducted the evaluation of our first-generation&#160;siRNA
product candidate, Loder, in pharmacology, pharmacokinetics (PK), and toxicology studies with both the siG12D and siG12D-LODER. The results
of the extensive in vitro and in vivo nonclinical studies conducted with Loder have demonstrated its effects on the KRAS oncogene, tumor
development, and the development of new metastases. In these studies, the mechanism of action (MOA) was elucidated and the effect of Loder
on a variety of downstream processes, ultimately leading to cell apoptosis, tumor necrosis, and halting of new metastases, was investigated.</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">Pre-clinical&#160;data show that the siG12D silencing
is very specific and effective (peak mRNA degradation effect in vivo was found to be 98%), can down-regulate&#160;signaling pathways,
reduce pancreatic cancer cell viability, decelerate cancer cell migration, and suppress expression of genes involved in Epithelial-to-Mesenchymal&#160;Transition
(EMT). It was demonstrated in vivo that Loder protects siG12D against degradation. The product candidate induces apoptosis and necrosis
throughout the entire tumor, hinders the appearance of metastases, decelerates the development and growth of pancreatic tumors, induces
an innate immune response locally within the tumor and extends survival.</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">siG12D was also found to be additive with FOLFIRINOX,
Gemcitabine, and Gemcitabine+nab-Paclitaxel. When administered into the tumor, siG12D molecules are in part spontaneously taken up into
tumor cells; the siG12D drug is distributed from the siG12D-LODER&#160;throughout the entire tumor, by diffusion and convection, and covers
the entire tumor after about a week, increasing the &#8220;void volume&#8221; in the tumor microenvironment.</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">PK studies yielded validated methods for detecting siG12D
in rat and human plasma, and confirmed distribution and absorption at the local tissue level.</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">The toxicological study confirmed siG12D tolerability,
with minimal, not drug related, focal effect at the implantation site and No Observed Adverse Effect Level (NOAEL) 24.2 times higher than
the dose in the Loder Phase 2 trial.</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">Taken together, these converging effects on multiple genetic,
cellular, tumor tissue, tumor microenvironment, systemic levels and survival aspects act to produce a durable and prolonged anti-tumor&#160;effect
both in in vitro and in vivo pancreatic cancer models.</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">We have also conducted pre-clinical&#160;studies of our
second-generation&#160;siRNA product candidate, SIL-204B. There are three key preclinical studies which support our advancing SIL-204B&#160;into
a planned Phase 2/3 clinical trial.</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">The first key clinical study was a dose response analysis
of SIL-204&#160;in mouse Hepa1-6&#160;cells together with a relevant Dual Glo reporter plasmid. SIL-204&#160;in this study showed inhibition
of the drug substance across KRAS mutations G12D, G12V, G12C and G12R and the wild type to cover the KRAS amplifications. Similar to the
results found with the siRNA in the Loder (siG12D) three of the mutations (G12D, G12V, and G12R) were highly inhibited. However, whereas
G12C was mildly silenced (inhibited) with siG12D, it was significantly more inhibited with SIL-204&#160;which has implications for potentially
broadening the indications for SIL-204B&#160;to include all four of the major KRAS mutations and the wild-type. Additionally in this model,
when a prototype of SIL-204&#160;was tested for its silencing activity with and without the lipid lead we are conjugating to the siRNA
with SIL-204, the results showed that the lipid-conjugated&#160;siRNA enhanced the silencing activity of the siRNA by two-fold. The siG12D
(siRNA in the Loder) does not have the lipid conjugate.</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: rgb(0, 0, 0); font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">86</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">The second key pre-clinical&#160;study examined the stability
of the guide strand of SIL-204&#160;in human serum. Whereas siG12D was completely broken down (enzymatically cleaved) in &lt; 1 hour,
SIL-204&#160;showed complete stability at 48 hours. Consistently, when SIL-204&#160;was administered to rats via subcutaneous injection,
the plasma half-life&#160;was 5 hours. In contrast when siG12D was administered systemically to mice the half life was 1 minute.</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">In a third key pre-clinical&#160;study, the human pancreatic
cell line CAPAN-1&#160;harboring the KRAS G12V mutation was xenografted (transplanted) to mice and the tumor growth and necrosis (death
of body tissue) in the tumor was observed following daily treatments of SIL-204&#160;compared to the controls (untreated and vehicle treated
mice). Results showed a significant growth of the tumor in the control mice while in the SIL-204-treated&#160;mice, the tumor growth was
significantly curtailed, as indicated by a significant reduction in the tumor volume and weight. In addition, when analyzing tumor slices
from the center of the tumor, the results showed a statistically significant increase in tumor necrosis in SIL-204&#160;treated mice compared
to untreated- and vehicle-treated&#160;mice.</div>

<div style="line-height: 1.25; font-weight: bold; font-family: Times New Roman">&#160;</div>

<div style="line-height: 1.25; font-weight: bold; font-family: Times New Roman">Clinical Studies</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman">&#160;</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman">Phase 1 Clinical Study</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">An escalating dose, multicenter Phase 1 clinical study
of Loder was conducted in Israel from 2011 to 2015 at three sites enrolling a total of 15 patients with unresectable LAPC. The study was
designed as an open-label, single-arm, single-administration&#160;of siG12D-LODER&#160;(concomitantly with standard of care chemotherapy),
dose-escalating&#160;Phase 1 study, enrolling LAPC patients with a target tumor accessible for intra-tumor&#160;administration, with a
Karnofsky performance status equal or greater than 70% and with a life expectancy of at least three months. Single escalating doses of
LODER (0.025, 0.75, 1.5 or 3 mg) by insertion into the tumor were administered by standard EUS procedures. Following insertion, patients
received standard of care chemotherapy as first line treatment in accordance with treating physician recommendation, Gemcitabine (nine
patients) or modified FOLFIRINOX (four patients), while one patient refused to receive any chemotherapy. After study drug administration,
the patients were to be monitored for signs of systemic or local treatment- related toxicity. Active follow-up&#160;comprised scheduled
physical and clinical examinations, vital sign measurements, laboratory tests, abdominal CT and disease assessments.</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">The primary endpoint of the study was to assess the safety
and tolerability of siG12D-LODER, and to define the dose-limiting&#160;toxicities (DLT) of siG12D-LODER. Secondary endpoints included
the recommended Phase&#160;2 dose and defining the maximum tolerated dose (MTD). In the event of surgery, assessment of siG12D-LODER&#160;local
distribution and efficacy were to be based on histopathology measurements and RNA analysis. Progression free survival (PFS) and overall
survival (OS) were to be assessed only by long term follow-up. Due to the small size of the trial, it was not powered for statistical
significance. The study met its primary endpoints. The 15 patients reported a total of 125 adverse events (AEs). 111 of the reported AEs
(89%) were grade 1 and&#160;2, which were transient and resolved. The most common AE (grade 1-2) was diarrhea which was reported by seven
(46.7%) patients, abdominal pain and nausea were both reported by six (40%) patients, whereas fatigue was reported by five (33.3%) patients.
Thirteen severe AEs of grade 3 and one grade 4 severe were reported by 10 (66.7%) patients. The most common grade 3-4&#160;AEs were neutropenia
and cholangitis reported by three patients and two patients, respectively. Pancreatitis was reported by the investigator as possibly related
to the procedure. One adverse event (cholangitis) in one patient was considered as definitely related to the EUS intervention. At the
doses tested, no DLTs were observed and therefore if there was a DLT it was defined as being greater than 3mg, the highest dose administered.
The study also met the secondary endpoint of establishing the Phase 2 dose of up to 3mg however the MTD was not determined.</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">Evidence of tumor response was observed, noting that none
of the patients presented progressive disease (PD) and tumor response durability was demonstrated. The tumor marker CA19-9&#160;decreased
in 70% of relevant cases soon after siG12D-LODER&#160;administration and time to metastasis (TTM) and overall survival were comparable
to (or better than) the historical data of the disease in a similar population. However, no clear dose response was observed between the
dose of siG12D-LODER&#160;and OS or TTM probably due to several factors, including the small size of the study, the single dosing administration,
without repeat dosing, and the level of dose at the low-dose&#160;cohort, which was selected to be ~5 times higher than then the minimal
effective dose level as predicted in pre-clinical&#160;studies.</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: rgb(0, 0, 0); font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">87</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="text-align: center; line-height: 1.25"><span style="font-family: Times New Roman"><br/> </span> </div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman">Phase 2 Clinical Study</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">From 2018 to 2023, we conducted a prospective, multi-center,
Phase II, open label study to evaluate the efficacy, safety and tolerability of siG12D-LODER&#160;in two separate cohorts across five
sites in Israel and four in the U.S.</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">Cohort 1 was a randomized and controlled two-arm&#160;study
of 37 subjects with unresectable LAPC to assess the efficacy, safety, tolerability and pharmacokinetics of siG12D-LODER&#160;when used
in combination with standard chemotherapy treatment (gemcitabine + nab-Paclitaxel) compared to gemcitabine + nab-Paclitaxel&#160;alone
in subjects. Cohort 2 was a single arm study of 22 subjects with unresectable and borderline resectable LAPC to assess the efficacy, safety,
and tolerability of siG12D-LODER&#160;in combination with standard of care chemotherapy treatment (gemcitabine + nab-paclitaxel&#160;or
FOLFIRINOX or modified FOLFIRINOX).</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">For comparative purposes, we evaluated the randomized
section of the trial for efficacy (Cohort 1) and both cohorts (Cohort 1 and Cohort 2) for safety. All patients who met the inclusion criteria
were accepted to the trial, regardless of whether they had a KRAS mutation or which specific mutation they had.</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">The KRAS mutation status was however determined post-hoc&#160;in
a sample of 31 patients (21 of whom were Loder treated) in the table below:</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z55885ad377654c669df621187739cd2c" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="border-bottom: #000000 2px solid; width: 14.99%; vertical-align: bottom">
        <div style="text-align: center; line-height: 1.25; font-weight: bold; font-family: Times New Roman">KRAS<br/> G12x<br/> Mutation</div>
        </td>
    <td style="white-space: nowrap; width: 1%; vertical-align: bottom">
        <div style="line-height: 1.25; font-family: Times New Roman">&#160;</div> </td>
    <td style="border-bottom: #000000 2px solid; width: 15%; vertical-align: bottom">
        <div style="text-align: center; line-height: 1.25; font-weight: bold; font-family: Times New Roman">Cohort 1<br/> Arm 2<br/> (Control)</div>
        </td>
    <td style="white-space: nowrap; width: 1%; vertical-align: bottom">
        <div style="line-height: 1.25; font-family: Times New Roman">&#160;</div> </td>
    <td style="border-bottom: #000000 2px solid; width: 15%; vertical-align: bottom">
        <div style="text-align: center; line-height: 1.25; font-weight: bold; font-family: Times New Roman">Cohort 1<br/> Arm 1<br/> (Treatment)</div>
        </td>
    <td style="white-space: nowrap; width: 1%; vertical-align: bottom">
        <div style="line-height: 1.25; font-family: Times New Roman">&#160;</div> </td>
    <td style="border-bottom: #000000 2px solid; width: 15%; vertical-align: bottom">
        <div style="text-align: center; line-height: 1.25; font-weight: bold; font-family: Times New Roman">Cohort 1<br/> % Arm 1<br/> Tx</div>
        </td>
    <td style="white-space: nowrap; width: 1%; vertical-align: bottom">
        <div style="line-height: 1.25; font-family: Times New Roman">&#160;</div> </td>
    <td style="border-bottom: #000000 2px solid; width: 15%; vertical-align: bottom">
        <div style="text-align: center; line-height: 1.25; font-weight: bold; font-family: Times New Roman">Cohort 2<br/> (Treatment)</div> </td>
    <td style="white-space: nowrap; width: 1%; vertical-align: bottom">
        <div style="line-height: 1.25; font-family: Times New Roman">&#160;</div> </td>
    <td style="border-bottom: #000000 2px solid; width: 20%; vertical-align: bottom">
        <div style="text-align: center; line-height: 1.25; font-weight: bold; font-family: Times New Roman">All<br/> Treated<br/> %</div> </td>
        </tr>
  <tr>
    <td style="width: 14.99%; vertical-align: bottom; background-color: #CCEEFF">
        <div style="text-align: center; line-height: 1.25; font-family: Times New Roman">R</div> </td>
    <td style="white-space: nowrap; width: 1%; vertical-align: bottom; background-color: #CCEEFF">
        <div style="line-height: 1.25; font-family: Times New Roman">&#160;</div> </td>
    <td style="width: 15%; vertical-align: bottom; background-color: #CCEEFF">
        <div style="text-align: center; line-height: 1.25; font-family: Times New Roman">5/10</div> </td>
    <td style="white-space: nowrap; width: 1%; vertical-align: bottom; background-color: #CCEEFF">
        <div style="line-height: 1.25; font-family: Times New Roman">&#160;</div> </td>
    <td style="width: 15%; vertical-align: bottom; background-color: #CCEEFF">
        <div style="text-align: center; line-height: 1.25; font-family: Times New Roman">1/12</div> </td>
    <td style="white-space: nowrap; width: 1%; vertical-align: bottom; background-color: #CCEEFF">
        <div style="line-height: 1.25; font-family: Times New Roman">&#160;</div> </td>
    <td style="width: 15%; vertical-align: bottom; background-color: #CCEEFF">
        <div style="text-align: center; line-height: 1.25; font-family: Times New Roman">8</div> </td>
    <td style="white-space: nowrap; width: 1%; vertical-align: bottom; background-color: #CCEEFF">
        <div style="line-height: 1.25; font-family: Times New Roman">&#160;</div> </td>
    <td style="width: 15%; vertical-align: bottom; background-color: #CCEEFF">
        <div style="text-align: center; line-height: 1.25; font-family: Times New Roman">2/9</div> </td>
    <td style="white-space: nowrap; width: 1%; vertical-align: bottom; background-color: #CCEEFF">
        <div style="line-height: 1.25; font-family: Times New Roman">&#160;</div> </td>
    <td style="width: 20%; vertical-align: bottom; background-color: #CCEEFF">
        <div style="text-align: center; line-height: 1.25; font-family: Times New Roman">26 (8/31)</div> </td> </tr>
  <tr>
    <td style="width: 14.99%; vertical-align: bottom">
        <div style="text-align: center; line-height: 1.25; font-family: Times New Roman">D</div> </td>
    <td style="white-space: nowrap; width: 1%; vertical-align: bottom">
        <div style="line-height: 1.25; font-family: Times New Roman">&#160;</div> </td>
    <td style="width: 15%; vertical-align: bottom">
        <div style="text-align: center; line-height: 1.25; font-family: Times New Roman">2/10</div> </td>
    <td style="white-space: nowrap; width: 1%; vertical-align: bottom">
        <div style="line-height: 1.25; font-family: Times New Roman">&#160;</div> </td>
    <td style="width: 15%; vertical-align: bottom">
        <div style="text-align: center; line-height: 1.25; font-family: Times New Roman">3/12</div> </td>
    <td style="white-space: nowrap; width: 1%; vertical-align: bottom">
        <div style="line-height: 1.25; font-family: Times New Roman">&#160;</div> </td>
    <td style="width: 15%; vertical-align: bottom">
        <div style="text-align: center; line-height: 1.25; font-family: Times New Roman">25</div> </td>
    <td style="white-space: nowrap; width: 1%; vertical-align: bottom">
        <div style="line-height: 1.25; font-family: Times New Roman">&#160;</div> </td>
    <td style="width: 15%; vertical-align: bottom">
        <div style="text-align: center; line-height: 1.25; font-family: Times New Roman">2/9</div> </td>
    <td style="white-space: nowrap; width: 1%; vertical-align: bottom">
        <div style="line-height: 1.25; font-family: Times New Roman">&#160;</div> </td>
    <td style="width: 20%; vertical-align: bottom">
        <div style="text-align: center; line-height: 1.25; font-family: Times New Roman">23 (7/31)</div> </td> </tr>
  <tr>
    <td style="width: 14.99%; vertical-align: bottom; background-color: #CCEEFF">
        <div style="text-align: center; line-height: 1.25; font-family: Times New Roman">V</div> </td>
    <td style="white-space: nowrap; width: 1%; vertical-align: bottom; background-color: #CCEEFF">
        <div style="line-height: 1.25; font-family: Times New Roman">&#160;</div> </td>
    <td style="width: 15%; vertical-align: bottom; background-color: #CCEEFF">
        <div style="text-align: center; line-height: 1.25; font-family: Times New Roman">3/10</div> </td>
    <td style="white-space: nowrap; width: 1%; vertical-align: bottom; background-color: #CCEEFF">
        <div style="line-height: 1.25; font-family: Times New Roman">&#160;</div> </td>
    <td style="width: 15%; vertical-align: bottom; background-color: #CCEEFF">
        <div style="text-align: center; line-height: 1.25; font-family: Times New Roman">8/12</div> </td>
    <td style="white-space: nowrap; width: 1%; vertical-align: bottom; background-color: #CCEEFF">
        <div style="line-height: 1.25; font-family: Times New Roman">&#160;</div> </td>
    <td style="width: 15%; vertical-align: bottom; background-color: #CCEEFF">
        <div style="text-align: center; line-height: 1.25; font-family: Times New Roman">67</div> </td>
    <td style="white-space: nowrap; width: 1%; vertical-align: bottom; background-color: #CCEEFF">
        <div style="line-height: 1.25; font-family: Times New Roman">&#160;</div> </td>
    <td style="width: 15%; vertical-align: bottom; background-color: #CCEEFF">
        <div style="text-align: center; line-height: 1.25; font-family: Times New Roman">5/9</div> </td>
    <td style="white-space: nowrap; width: 1%; vertical-align: bottom; background-color: #CCEEFF">
        <div style="line-height: 1.25; font-family: Times New Roman">&#160;</div> </td>
    <td style="width: 20%; vertical-align: bottom; background-color: #CCEEFF">
        <div style="text-align: center; line-height: 1.25; font-family: Times New Roman">52 (16/31)</div> </td> </tr>
  </table>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">A total of up to eight Loders (2.8 mg) were inserted into
the pancreatic tumor per single administration. Insertion was done using EUS. The trial consisted of a screening period (28 days), a treatment
phase (12-week&#160;Loder treatment cycles at investigator&#8217;s discretion with concomitant chemotherapy treatment cycles) and a follow-up&#160;phase
(up to six months until end of study which is defined as death, withdrawn consent or lost to follow-up). For efficacy, the primary endpoint
in the randomized section of the trial (Cohort 1) was overall survival (OS), defined as the time that passed from study entry (screening
visit) until death from any cause. For Cohort&#160;2, the primary endpoint was the overall response rate (ORR) by end of treatment; ORR
was defined as the proportion of subjects with best overall confirmed response (BOCR) of either a complete response (CR) or partial response
(PR). Concerning the secondary endpoint of safety, the endpoints were incidence of adverse events (AEs), and serious adverse events (SAEs)
overall, by severity, by relationship to each study intervention, and those that led to discontinuation of study interventions. Other
secondary endpoints included ORR for Cohort&#160;1, progression free survival, time to metastatis, time to response, duration of response
and rate of disease control.</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">Overall, a total of 59 subjects with LAPC were enrolled
in the study, 38 were treated with Loder and 48 subjects overall (81.3%) completed the study. In Cohort&#160;1, 15/19 (78.9%) completed
the Loder arm and 11/18 (61.1%) completed the standard of care arm. In Cohort&#160;2, 21/22 (95.5%) completed the study.</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">In Cohort&#160;1, OS was comparable between the two treatment
arms. Median time to death was 691 days in the Loder-treated&#160;group, compared with 666 days in the standard of care group. The Hazard
Ratio (Loder/SoC) was 1.47 (95% CI; 0.643, 3.365) with a non-significant&#160;p-value&#160;of 0.361 for the treatment difference. In the
sub-group&#160;of subjects with D or V KRAS mutation (n=16), the median OS was 691 days for the 11 Loder treated subjects, compared to
409 days for the five SoC subjects. The Hazard Ratio was 0.59 (95% CI; 0.179, 1.963) with a non-significant&#160;p-value&#160;of 0.393.
In the subjects who were not found to have D or V KRAS mutation (n=13), the median OS in the seven Loder treated subjects was 637 days
compared to 937 days in the six SoC treated subjects. The hazard ratio was 2.87 (95% CI; 0.705, 11.650) with a p-value&#160;of 0.141.
The ORR was 44.4% (8/18) in the Loder group compared to 27.3% in the SoC group (3/11). No subject had a CR in either group. The ORR in
subjects with D or V KRAS mutation was 63.6% (7/11) in the Loder group compared to 20% in the SoC group (1/5).</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: rgb(0, 0, 0); font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">88</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">In Cohort&#160;2, the ORR was 31.6% reflecting 6/19 subjects
with partial responses. No subject had CR. In subjects with D or V KRAS mutation, the ORR was 57.1% (4/7), however, these subjects also
had a shorter median OS compared to subjects without these mutations (414 days vs. 671 days).</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">As depicted below, the survival probability in subjects
of Cohort 1 bearing a KRAS G12D/V mutation compared to the control group, showed a median survival in the Loder group (n=11) of 22.8&#160;months
compared to 13.8&#160;months in the control group (n=5).</div>

<div style="text-align: center; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: center; line-height: 1.25; font-family: Times New Roman"><img src="image7.jpg" alt="" style="width: 560px; height: 285px"/>&#160;</div>

<div style="text-align: center; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">Based on the above, although the primary endpoints of
all patients were not met, the results showed a trend for differences between treatment groups in patients with the KRAS G12D/V mutation,
with the Loder arm suggesting an overall survival advantage of 9.3&#160;months. With respect to the secondary efficacy endpoints, no statistically
significant differences were observed or there was insufficient data to evaluate although with respect to ORR in Cohort&#160;1, a positive
trend in the KRAS G12D/V mutation subgroup was observed. Due to the small size of the trial, it was not powered for statistical significance.</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">The secondary safety endpoints were met. In Cohort&#160;1,
all subjects in the Loder treatment group reported at least one moderate or severe treatment emergent adverse event (TEAE) (18 subjects).
One subject was reported with a TEAE leading to death (sepsis). This event was deemed as not related to the Loder or the EUS procedure.
Of the remaining 17 subjects, one subject was reported with a life-threatening&#160;TEAE, gastrointestinal disorders (colitis). The majority
of moderate and severe TEAEs reported in the Loder treatment group were attributed to gastrointestinal disorders (10), blood/lymphatic
disorders (14), general disorders and administration site conditions (11), metabolism and nutrition disorders (11), and investigations
(10). In the SoC treatment group, all subjects reported at least one moderate or severe TEAE (11 subjects). No subjects were reported
with a TEAE leading to death. Two subjects were reported with a life- threatening TEAE. The majority of moderate and severe TEAEs reported
in the SoC treatment group were attributed to gastrointestinal disorders (10), blood/lymphatic disorders (9), general disorders and administration
site conditions (9), metabolism and nutrition disorders (8), and investigations (9).</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">In Cohort&#160;2, all subjects in the Loder treatment
group reported at least one moderate or severe TEAE (20 subjects). One subject was reported with a TEAE leading to death (gastrointestinal
disorder). This event was deemed as not related to the Loder or the EUS procedure. Three subjects were reported with a life-threatening&#160;TEAE.
Of the three subjects, one subject was investigation (neutrophil count decreased) and two subjects were metabolism/nutrition (hyperglycaemia,
hyperkalaemia). The majority of moderate and severe TEAEs reported in the Loder treatment group were attributed to gastrointestinal disorders
(13), nervous system disorder (10) and investigations (11).</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: rgb(0, 0, 0); font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">89</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="line-height: 1.25; font-weight: bold; font-family: Times New Roman">Manufacturing</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">We rely on and intend to continue to rely on third-party&#160;contract
manufacturing organizations for drug substance and drug products for our clinical trials. We have agreements with contract manufacturers
for the manufacturing of SIL-204B&#160;for clinical development.</div>

<div style="line-height: 1.25; font-weight: bold; font-family: Times New Roman">&#160;</div>

<div style="line-height: 1.25; font-weight: bold; font-family: Times New Roman">Future Development Plans</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">We plan to conduct a Phase 2/3 prospective, randomized,
controlled, multinational, two-arm, open-label&#160;trial in LAPC subjects that harbor the KRAS G12D/V mutations to evaluate the efficacy,
safety and tolerability of SIL-204B&#160;administered intratumorally in combination with SoC chemotherapy versus SoC chemotherapy only.
The study design, including the dose and dosing frequency, the combination with SoC chemotherapy, the proposed target population and safety
monitoring is based on the experience with the preceding Phase 1 and 2 clinical studies with the first-generation&#160;siRNA product candidate,
Loder.</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">The study is initially planned to enroll approximately
350 subjects and has an adaptive design with several segments; a screening period which includes a biopsy eligibility test for G12D/V
mutations, a CT scan and physiologic profiling to ensure subjects are qualified for treatment; concurrent with this, all subjects will
receive run-in&#160;SoC chemotherapy; a Phase 2 safety run-in&#160;and treatment period where initially 30 subjects will be randomized
2:1 to receive SIL-204B&#160;and SoC Chemotherapy or SoC Chemotherapy at which point a Data and Safety Monitoring Board (DSMB) will perform
a safety review and recommend whether the study is safe to proceed; a Phase 2 expansion period to continue enrollment; and when approximately
60 events have occurred, an unblinded interim analysis for sample size re-estimation&#160;and futility will be conducted, to expand the
trial from Phase 2 to Phase&#160;3, which is expected to happen approximately one year from start of enrollment. Following the interim
analysis, the study will continue into a Phase 3 treatment period to complete the enrollment of the remaining subjects for a total treatment
period of 24&#160;months. The study design is powered for statistical significance.</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">In support of our planned Phase 2/3 trial of SIL-204B,
we held a meeting with the Federal Institute for Drugs and Medical Devices in Germany (BfArM) to discuss the planned design of the Phase
2/3 trial, at which BfArM agreed, in principle, to the design. In preparation for the study, we plan to initiate toxicology studies of
SIL-204B&#160;in 2025 followed by the regulatory submission in late 2025 to initiate the Phase 2/3 trial. Currently, we are upscaling
SIL-204&#160;and planning for GMP production. At this time, Silexion is focused on the further development of the core siRNA technology
underlying the Loder and SIL-204B&#160;as well as the clinical development of SIL-204B&#160;as the most optimized version of the technology.</div>
</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">We expect to apply in 2024 for Orphan Drug Designation
in both the U.S. and EU.&#160;In the U.S., Orphan Drug designation by the FDA gives a company exclusive marketing rights for a seven-year&#160;period,
along with other benefits to recoup the costs of researching and developing drugs to treat rare diseases. In the EU, a company receives
data exclusivity for 10&#160;years which provides protection from similar drugs being approved. We believe the size of the localized pancreatic
cancer market fits the requirements for this designation however there can be no assurance that we will be granted such designation and
such designation neither shortens the development time or regulatory review time of a drug nor does it increase the likelihood for any
approval in the regulatory review process. Our continued development plans for SIL-204B&#160;are not dependent on whether we are granted
Orphan Drug Designation.</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: rgb(0, 0, 0); font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">90</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="text-align: center; line-height: 1.25"><span style="font-family: Times New Roman"><br/> </span> </div>

<div style="line-height: 1.25; font-weight: bold; font-family: Times New Roman">Our Strategy</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">Our goal is to have a positive impact on the health and
treatment of KRAS driven cancer patients, in general and initially with pancreatic cancer through the continued development and commercialization
of our pipeline. Key elements of our strategy to advance toward this goal include the following:</div>

<div style="text-indent: -36pt; margin-left: 48pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z3f4ebc1c561c4f2b833aa0ab0cb15634" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25"><span style="font-weight: bold; font-style: italic; font-family: Times New Roman">Advancing the clinical
        development of SIL-204B&#160;for the treatment of LAPC</span><span style="font-family: Times New Roman">.&#160;&#160;&#160;&#160;Our Phase&#160;2
        trial with our first-generation&#160;siRNA product, Loder in LAPC patients acts as a validation of approach and foundation for our continued
        development efforts. As further described in &#8220;Future Development Plans&#8221;, Silexion plans to initiate toxicology studies of
        SIL-204B&#160;in 2025 followed by the regulatory submission in late 2025 to initiate a Phase 2/3 trial of SIL-204B&#160;powered for statistical
        significance. At this time, Silexion is focused on the further development of the core siRNA technology underlying the Loder and SIL-204B&#160;as
        well as the clinical development of SIL-204B&#160;as the most optimized version of the technology.</span></div> </td> </tr>
  </table>

<div style="text-indent: -36pt; margin-left: 48pt; line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z7e7e46d0e37849bcb6f0706aad4919e4" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25"><span style="font-weight: bold; font-style: italic; font-family: Times New Roman">Leveraging our platform
        to other oncological indications&#160;</span><span style="font-family: Times New Roman">harboring the KRASG12D/V mutation.</span></div>
        </td> </tr>
  </table>

<div style="text-indent: -36pt; margin-left: 48pt; line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z4cfdce62b53f4a62a2bf92caf131a30a" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25"><span style="font-weight: bold; font-style: italic; font-family: Times New Roman">Advancing SIL-204B&#160;to
        commercialization.</span><span style="font-family: Times New Roman">&#160;&#160;&#160;&#160;We have assembled a world class clinical advisory
        board for better understanding the market in the U.S.&#160;and EU.</span></div> </td> </tr>
  </table>

<div style="text-indent: -36pt; margin-left: 48pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z918502e287e4422291dae40fe4606272" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25"><span style="font-weight: bold; font-style: italic; font-family: Times New Roman">Forming strategic alliances
        and collaborating with partners to augment our capabilities</span><span style="font-family: Times New Roman">.&#160;&#160;&#160;&#160;We
        may pursue strategic alliances with other biopharmaceutical companies with well-established&#160;presences in the specialties we aim to
        target for our indications. This may include co-marketing, co-promotion, and co-development&#160;relationships, or a partnership with
        a diagnostics company to help improve availability of rapid testing. We also intend to explore options to work with partners to augment
        the study and treatment of patients and the impact of our product candidates, including medical professionals, healthcare professional
        networks, pharmacy benefit managers, insurance companies, and artificial intelligence companies.</span></div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-weight: bold; font-family: Times New Roman">&#160;</div>

<div style="line-height: 1.25; font-weight: bold; font-family: Times New Roman,Times,serif">

<div style="line-height: 1.25; font-family: Times New Roman; font-weight: bold">Our History</div> </div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">

<div style="line-height: 1.25; font-family: Times New Roman">Silexion was established as Silenseed Ltd in 2008 as an Israeli company which
underwent a name change to Silexion Therapeutics Ltd. in May 2023. On June 13, 2014, Silexion filed a registration statement on Form F-1
with the SEC, in contemplation of an initial public offering, and the listing of its shares on Nasdaq. Subsequently, the public offering
process was abandoned because our board of directors was not satisfied with our valuation in the offering, and no securities were sold
under the registration statement. During April 2022, our management was replaced following a health condition of the then-founder and
CEO of Silexion, and the new management, after evaluating the viability of commercializing the Loder, has decided to pivot from the first-generation
siRNA product candidate to the second-generation siRNA product candidate and develop SIL-204.</div> </div> </div>

<div style="line-height: 1.25; font-weight: bold; font-family: Times New Roman">&#160;</div>

<div style="line-height: 1.25; font-weight: bold; font-family: Times New Roman">Competition</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">The biotechnology and pharmaceutical industries, and the
oncology sector, are characterized by a rapid evolution of technologies, fierce competition and strong defense of intellectual property
rights. While we believe that our discovery programs and technology provide us with competitive advantages, we face competition from major
biotechnology and pharmaceutical companies, academic institutions, governmental agencies and public and private research institutions,
among others.</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">Any product candidates that we successfully develop and
commercialize will compete with currently approved therapies and new therapeutics that may become available in the future. Key product
features that would affect our ability to effectively compete with other therapeutics include efficacy, safety and convenience of our
products as compared to other available therapeutics.</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">There are a large number of companies developing or marketing
treatments for cancer, including major biotechnology and pharmaceutical companies. These treatments consist of novel treatments based
on small molecule drug products, cell-based&#160;therapies, as well as traditional chemotherapy treatments. There are also an increasing
number of companies commercializing treatments and/or developing programs specifically targeting KRAS mutations, including KRAS G12D and
KRAS G12V, in a variety of manners and for a variety of indications, including cancer, including Amgen Inc., Bristol-Myers&#160;Squibb
Company (through the recently acquired Mirati Therapeutics, Inc.), Revolution Medicines, Inc., AstraZeneca (in collaboration with Usynova),
BioNTech, Roche, Merck/Moderna, Boehringer and Gilead. Smaller and other early-stage&#160;companies may also prove to be significant competitors.
In addition, academic research departments and public and private research institutions may be conducting research on compounds that could
prove to be competitive.</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: rgb(0, 0, 0); font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">91</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="text-align: center; line-height: 1.25"><span style="font-family: Times New Roman"><br/> </span> </div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">Many of the companies against which we may compete have
significantly greater financial resources and expertise in the research and development, manufacturing, preclinical testing, conducting
clinical trials, obtaining regulatory approvals and marketing approved products than we do. Similar or early-stage&#160;companies may
also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. These
competitors also compete with us in recruiting and retaining qualified scientific and management personnel, and establishing clinical
trial sites and patient registration for clinical trials, as well as acquiring technologies complementary to, or necessary for, our programs.</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">Our competitors have already and/or may obtain more rapidly
than we may obtain approval FDA, or other regulatory approval for commercialization of product. As a result, our competitors could establish
a strong market position before we are able to enter the market with our products. The availability of coverage and reimbursement from
government and other third-party&#160;payors for competing products at the time of commercialization of our products will also significantly
affect the pricing and competitiveness of our products.</div>

<div style="line-height: 1.25; font-weight: bold; font-family: Times New Roman">&#160;</div>

<div style="line-height: 1.25; font-weight: bold; font-family: Times New Roman">Intellectual Property</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25">Our business depends, in part, on our ability to develop and maintain the proprietary
aspects of our products.</div>

<div style="line-height: 1.25"><br/> </div>

<div style="text-indent: 36pt; line-height: 1.25">We are seeking patent protection for our product (SIL-204) in International Patent Application
No. PCT/IL2023/051276 filed on December 14, 2023 (the &#8220;276 Application&#8221;)</div>

<div style="text-indent: 36pt; line-height: 1.25"><br/> </div>

<div style="text-indent: 36pt; line-height: 1.25">The minimum expiration date of any patent that is issued from the 276 Application is
December 14, 2043. However, given typical practice with respect to regulatory-related patent term extensions, this date may be extended
up to an additional five years in many countries, depending on the length of the regulatory process, to a maximum final expiration date
of December 14, 2048.</div>

<div style="text-indent: 36pt; line-height: 1.25"><br/> </div>

<div style="text-indent: 36pt; line-height: 1.25">The 276 Application was published on June 20, 2024 as International Patent Publication
No. WO 2024/127405.</div>

<div style="text-indent: 36pt; line-height: 1.25">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25">In addition to patent laws, we rely on copyright and trade secret laws to protect our
proprietary rights. We also attempt to protect our trade secrets and other proprietary information through agreements with vendors, employees,
and consultants.</div>

<div style="line-height: 1.25">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: rgb(0, 0, 0); font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">92</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="text-align: center; line-height: 1.25"><span style="font-family: Times New Roman"><br/> </span> </div>

<div style="line-height: 1.25; font-weight: bold; font-family: Times New Roman">Property and Facilities</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">Our principal executive officers are currently
located in Ramat-Gan, Israel, where we lease a space of 464 square meters consisting of offices, under a lease agreement that will expire
on October&#160;31, 2026.</div> </div>

<div style="line-height: 1.25; font-weight: bold; font-family: Times New Roman">&#160;</div>

<div style="line-height: 1.25; font-weight: bold; font-family: Times New Roman">Employees</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">As of the date of this prospectus, we have
eleven full time and three part time employees. All of our employees are based in Israel. None of our employees are represented by labor
unions or covered by collective bargaining agreements. We believe that we maintain good relations with all of our employees.</div> </div>
</div>

<div style="line-height: 1.25; font-weight: bold; font-family: Times New Roman">&#160;</div>

<div style="line-height: 1.25; font-weight: bold; font-family: Times New Roman">Grants from the Israeli Innovation Authority</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">During 2009 to 2020, we received several approvals from
the IIA for participation in research and development activities performed by us in a total amount of $5.8&#160;million.</div> </div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">The Company is obligated to pay royalties to the IIA amounting
to 3%-5% of the sales of all of its product candidates and other related revenues generated from such projects, up to 100% of the grants
received, linked to the U.S.&#160;dollar and bearing interest at the rate of LIBOR.&#160;The obligation to pay these royalties is contingent
upon actual sales of the products and, in the absence of such sales, no payment is required. In October&#160;2023, it was published that
the interest rate of the grants will be replaced with the 12-month&#160;term SOFR published on the first&#160;trading day of each calendar
year.</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">As of December&#160;31, 2023, the total royalty amount
that may be payable by the Company is approximately $5.8&#160;million ($6.4&#160;million including interest).</div>

<div style="line-height: 1.25; font-weight: bold; font-family: Times New Roman">&#160;</div>

<div style="line-height: 1.25; font-weight: bold; font-family: Times New Roman">Legal Proceedings</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">From time to time, we may become involved in actions,
claims, suits, and other legal proceedings arising in the ordinary course of our business, including assertions by third parties relating
to intellectual property infringement, breaches of contract or warranties, or employment-related&#160;matters. We are not currently subject
to any material legal proceedings.</div>

<div style="line-height: 1.25; font-weight: bold; font-family: Times New Roman">&#160;</div>

<div style="line-height: 1.25; font-weight: bold; font-family: Times New Roman">Regulatory Environment</div>

<div style="line-height: 1.25; font-weight: bold; font-family: Times New Roman">&#160;</div>

<div style="line-height: 1.25; font-weight: bold; font-family: Times New Roman">Government Regulation</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">Clinical trials, the drug approval process, and the marketing
of drugs are intensively regulated in the United&#160;States and in all major foreign countries. Government authorities in the United&#160;States
(including federal, state, and local authorities) and in other countries (including federal, state, and local authorities) extensively
regulate, among other things, the manufacturing, research and clinical development, marketing, labeling and packaging, storage, distribution,
post-approval&#160;monitoring and reporting, advertising and promotion, pricing, and export and import of pharmaceutical products, such
as those we are developing. The process of obtaining regulatory approvals and the subsequent compliance with appropriate federal, state,
local, and foreign statutes and regulations require the expenditure of substantial time and financial resources.</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman">&#160;</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman">U.S.&#160;Government Regulation</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">In the United&#160;States, the Food and Drug Administration,
or FDA, regulates drugs under the Federal Food, Drug, and Cosmetic Act (FDCA) and related regulations and biologics under the FDCA and
the Public Health Service Act (PHSA) and its implementing regulations. FDA approval is required before any new unapproved drug or dosage
form, including a new use of a previously approved drug, can be marketed in the United&#160;States. Drugs and biologics are also subject
to other federal, state and local statutes and regulations. Failure to comply with the applicable United&#160;States&#160;regulatory requirements
at any time during the product development process, approval process or after approval may subject an applicant to administrative or judicial
sanctions. These sanctions could include the imposition by the FDA or an Institutional Review Board, or IRB, of a clinical hold on trials,
the FDA&#8217;s refusal to approve pending applications or supplements, license suspension or revocation, withdrawal of an approval, warning
letters, product recalls, product seizures, total or partial suspension of production or distribution, injunctions, fines, civil penalties
or criminal prosecution. Any agency or judicial enforcement action could have a material adverse effect on us.</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: rgb(0, 0, 0); font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">93</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="text-align: center; line-height: 1.25"><span style="font-family: Times New Roman"><br/> </span> </div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">The FDA and comparable regulatory agencies in state and
local jurisdictions and in foreign countries impose substantial requirements upon the clinical development, manufacture and marketing
of pharmaceutical products. These agencies and other federal, state and local entities regulate research and development activities and
the testing, manufacture, quality control, safety, effectiveness, labeling, storage, distribution, record keeping, approval, advertising
and promotion of our products.</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">The FDA&#8217;s policies may change and additional government
regulations may be enacted that could prevent or delay regulatory approval of our platforms and candidate products or any future product
candidates or approval of new disease indications or label changes. We cannot predict the likelihood, nature or extent of adverse governmental
regulation that might arise from future legislative or administrative action, either in the United&#160;States or abroad.</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman">&#160;</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman">Marketing Approval</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">The process required by the FDA before product candidates
may be marketed in the United&#160;States, the European Medicines Agency, or EMA, before a product can be marketed in Europe, and Medicines&#160;&amp;
Healthcare products Regulatory Agency (MHRA) for the United Kingdom. Generally involves the following:</div>

<div style="text-indent: -36pt; margin-left: 48pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z5121d58fa6db4d72aa183b2834bccc74" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">completion of extensive preclinical laboratory tests and preclinical animal
        studies, all performed in accordance with the GLP regulations;</div> </td> </tr>
  </table>

<div style="text-indent: -36pt; margin-left: 48pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<table cellspacing="0" cellpadding="0" id="zedcfcf96870e411ba89ec49829908e6a" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">submission to the FDA of an investigational new drug application, or IND,
        Clinical Trial Application (CTA) for Europe which must become effective or approved before human clinical studies may begin and must be
        updated on a regular basis;</div> </td> </tr>
  </table>

<div style="text-indent: -36pt; margin-left: 48pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<table cellspacing="0" cellpadding="0" id="zcc4be9d0935a4334b83e4630da906169" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">approval by an independent institutional review board, or IRB, or ethics
        committee representing each clinical site before each clinical study may be initiated;</div> </td> </tr>
  </table>

<div style="text-indent: -36pt; margin-left: 48pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<table cellspacing="0" cellpadding="0" id="zba8f8c8d969f4c3488c3a3a6638b166a" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">performance of adequate and well-controlled&#160;human clinical studies to
        establish the safety and efficacy of the product candidate for each proposed indication;</div> </td> </tr>
  </table>

<div style="text-indent: -36pt; margin-left: 48pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z25924eac06ce459a865bea5f65816338" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">preparation of and submission to the FDA of a new drug application, or NDA,
        or biologics license application, or BLA, or for Europe a Marketing Authorization Application (MAA) after completion of all pivotal clinical
        studies;</div> </td> </tr>
  </table>

<div style="text-indent: -36pt; margin-left: 48pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z8d3dfcd36179464ab37f508f93ba46be" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">potential review of the product application by an FDA advisory committee,
        where appropriate and if applicable. In the EU, the Committee for Medicinal Products for Human Use (CHMP) issues a scientific opinion
        to the European Commission which issues the marketing authorization;</div> </td> </tr>
  </table>

<div style="text-indent: -36pt; margin-left: 48pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z8459538af75a4c04b7eff0137c2b6a02" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">a determination by the FDA within 60&#160;days of its receipt of an NDA or
        BLA to file the application for review;</div> </td> </tr>
  </table>

<div style="text-indent: -36pt; margin-left: 48pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z5a0ca5324b484f0d85a6192039a4f812" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">satisfactory completion of an FDA pre-approval&#160;inspection of the manufacturing
        facilities where the proposed product drug substance is produced to assess compliance with cGMP;&#160;and</div> </td> </tr>
  </table>

<div style="text-indent: -36pt; margin-left: 48pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z53f643c59e934f7c9113f73ef2f86bd3" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">FDA review and approval of an NDA or BLA or marketing authorization in the
        European Union (EU) in all European Union Member States plus Norway, Iceland and Liechtenstein, prior to any commercial marketing or sale
        of the drug in the United&#160;States. Note that if the centralized procedure is used, which is mandatory for all new anticancer products,
        a marketing authorization is issued centrally by the EU commission, which is valid immediately in all member states of the EEA (EU plus
        Iceland, Norway, and Liechtenstein).</div> </td> </tr>
  </table>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">The testing and approval process requires substantial
time and financial resources, and we cannot be certain that any approvals for our candidate products will be granted on a timely basis,
if at all.</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: rgb(0, 0, 0); font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">94</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="text-align: center; line-height: 1.25"><span style="font-family: Times New Roman"><br/> </span> </div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">An IND/CTA is a request for authorization from the FDA/national
regulatory authorities in Europe to administer an investigational new drug product to humans. The central focus of an IND/CTA submission
is on the general investigational plan and the protocol(s)&#160;for human studies. The IND and CTA also include results of animal and&#160;<span style="font-style: italic">in
vitro</span>&#160;studies assessing the toxicology, pharmacokinetics, pharmacology, and pharmacodynamic characteristics of the product;
chemistry, manufacturing, and controls information; and any available human data or literature to support the use of the investigational
new drug. An IND or a CTA must become effective before human clinical trials may begin. An IND will automatically become effective 30&#160;days
after receipt by the FDA, unless before that time the FDA raises concerns or questions related to the proposed clinical studies. In such
a case, the IND may be placed on clinical hold and the IND sponsor and the FDA must resolve any outstanding concerns or questions before
clinical studies can begin. Accordingly, submission of an IND may or may not result in the FDA allowing clinical studies to commence.
In Europe, a CTA is required to be approved by regulators, which may take several months. Accordingly, submission of a CTA to European
regulators may or may not result in permission to commence clinical studies in Europe.</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">We will need to successfully complete an extensive additional
clinical trial or some clinical trials in order to be in a position to submit a new drug application to the FDA.&#160;Our planned future
clinical trials for our candidate products may not begin or be completed on schedule, if at all. Clinical trials can be delayed for a
variety of reasons, including delays in:</div>

<div style="text-indent: -36pt; margin-left: 48pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<table cellspacing="0" cellpadding="0" id="zb13a38d9f88c484c96ce46fac039305c" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">obtaining regulatory approval to commence a study;</div> </td> </tr>
  </table>

<div style="text-indent: -36pt; margin-left: 48pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z11eec5df6ca5491fbfa96315d05e83f5" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">reaching agreement with third-party&#160;clinical trial sites and their subsequent
        performance in conducting accurate and reliable studies on a timely basis;</div> </td> </tr>
  </table>

<div style="text-indent: -36pt; margin-left: 48pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z2a2acf1d05c8492183bbf25bca92a7a4" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">obtaining institutional review board approval or an Ethics Committee approval
        to conduct a study at a prospective site;</div> </td> </tr>
  </table>

<div style="text-indent: -36pt; margin-left: 48pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<table cellspacing="0" cellpadding="0" id="zfe456f69d0bc4f91addebb6f6084f2d8" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">recruiting patients to participate in a study; and</div> </td> </tr>
  </table>

<div style="text-indent: -36pt; margin-left: 48pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z95ebd73c3fc44deeb814a7b8ebce48c3" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">supply of the drug.</div> </td> </tr>
  </table>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">We must reach agreement with the FDA/European national
authorities on the proposed protocols for our future clinical trials in the United&#160;States and EU.&#160;A separate submission apart
from any IND or initial CTA application we submit must be made for each successive clinical trial to be conducted during product development.
Further, an independent IRB or EC for each site proposing to conduct the clinical trial must review and approve the plan for any clinical
trial before it commences at that site. Informed consent must also be obtained from each study subject. Regulatory authorities, an IRB
or EC, a data safety monitoring board or the Sponsor may suspend or terminate a clinical trial at any time on various grounds, including
a finding that the participants are being exposed to an unacceptable health risk.</div>

<div style="line-height: 1.25; font-style: italic; font-family: Times New Roman">&#160;</div>

<div style="line-height: 1.25; font-style: italic; font-family: Times New Roman">Clinical Studies</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">Clinical studies involve the administration of the investigational
new drug to human subjects under the supervision of qualified investigators in accordance with current cGCP/GCP, which include the requirement
that all research subjects provide their informed consent for their participation in any clinical study. Clinical studies are conducted
under protocols detailing, among other things, the objectives of the study, the parameters to be used in monitoring safety, and the efficacy
criteria to be evaluated. A protocol for each clinical study and any subsequent protocol amendments must be submitted to the FDA and/or
European national authorities as part of the IND or CTA.&#160;Additionally, approval must also be obtained from each clinical study site&#8217;s
IRB or EC before the studies may be initiated, and the IRB/EC must monitor the study until completed. There are also requirements governing
the reporting of ongoing clinical studies and clinical study results to public registries.</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">Our objective is to conduct additional clinical trials
for our candidate products and, if those trials are successful, seek marketing approval from the FDA and other worldwide regulatory bodies.</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: rgb(0, 0, 0); font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">95</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="text-align: center; line-height: 1.25"><span style="font-family: Times New Roman"><br/> </span> </div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">For purposes of NDA approval, human clinical trials are
typically conducted in phases that may overlap.</div>

<div style="text-indent: -36pt; margin-left: 48pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<table cellspacing="0" cellpadding="0" id="zf17d0fabd1fd4aebb731e6261bee163e" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25"><span style="font-style: italic; font-family: Times New Roman">Phase&#160;1.&#160;&#160;&#160;&#160;</span><span style="font-family: Times New Roman">The
        drug is initially introduced into healthy human subjects and tested for safety, dosage tolerance, absorption, metabolism, distribution
        and excretion. In the case of some products for severe or life-threatening&#160;diseases, especially when the product may be too inherently
        toxic to ethically administer to healthy volunteers, the initial human testing is often conducted in patients.</span></div> </td> </tr>
  </table>

<div style="text-indent: -36pt; margin-left: 48pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z50c6683df50a468180dde6afb5d7bfce" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25"><span style="font-style: italic; font-family: Times New Roman">Phase&#160;2.&#160;&#160;&#160;&#160;</span><span style="font-family: Times New Roman">This
        phase involves trials in a limited patient population to identify possible adverse effects and safety risks, to preliminarily evaluate
        the efficacy of the product for specific targeted diseases and to determine dosage tolerance and optimal dosage.</span></div> </td> </tr>
  </table>

<div style="text-indent: -36pt; margin-left: 48pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<table cellspacing="0" cellpadding="0" id="zbf894391e546432e8fe7be4cb5774b8b" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25"><span style="font-style: italic; font-family: Times New Roman">Phase&#160;3.&#160;&#160;&#160;&#160;</span><span style="font-family: Times New Roman">This
        phase involves trials undertaken to further evaluate dosage, clinical efficacy and safety in an expanded patient population, often at
        geographically dispersed clinical trial sites. These trials are intended to establish the overall risk/benefit ratio of the product and
        provide an adequate basis for product labeling.</span></div> </td> </tr>
  </table>

<div style="text-indent: -36pt; margin-left: 48pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<table cellspacing="0" cellpadding="0" id="za01ce26abd774788a3280734b813ea5f" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25"><span style="font-style: italic; font-family: Times New Roman">Phase&#160;4.&#160;&#160;&#160;&#160;</span><span style="font-family: Times New Roman">In
        some cases, the FDA or the EMA may condition approval of an NDA or BLA or MAA for a product candidate on the Sponsor&#8217;s agreement
        to conduct additional clinical studies after approval. In other cases, a sponsor may voluntarily conduct additional clinical studies after
        approval to gain more information about the drug. Such post-approval&#160;studies are typically referred to as Phase&#160;4 clinical studies.</span></div>
        </td> </tr>
  </table>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">A pivotal study is a clinical study that adequately meets
regulatory agency requirements for the evaluation of a drug candidate&#8217;s efficacy and safety such that it can be used to justify
the approval of the product. Generally, pivotal studies are Phase&#160;3 studies, but the FDA or EMA may accept results from a Phase&#160;2
study if such study&#8217;s design provides a well-controlled&#160;and reliable assessment of clinical benefit, particularly in situations
where there is an unmet medical need and the results are sufficiently robust.</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">The FDA/EMA, the IRB/EC, or the clinical study sponsor
may suspend or terminate a clinical study at any time on various grounds, including a finding that the research subjects are being exposed
to an unacceptable health risk.</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">Additionally, some clinical studies are overseen by an
independent group of qualified experts organized by the clinical study sponsor, known as a data safety monitoring board or committee.
This group provides authorization or recommendation for whether or not a study may move forward at designated check points based on access
to certain data from the study. We may also suspend or terminate a clinical study based on evolving business objectives and/or competitive
climate. All of these trials must be conducted in accordance with cGCP requirements in order for the data to be considered reliable for
regulatory purposes.</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">The clinical study process can take several (2- 12 or
more) years to complete, and there can be no assurance that the data collected will support FDA or EU Commission approval or licensure
of the product. Government regulation may delay or prevent marketing of product candidates or new drugs for a considerable period of time
and impose costly procedures upon our activities. We cannot be certain that the FDA or any other regulatory agency will grant approvals
for our candidate products or any future product candidates on a timely basis, if at all. Success in early stage clinical trials does
not ensure success in later stage clinical trials. Data obtained from clinical activities is not always conclusive and may be susceptible
to varying interpretations, which could delay, limit or prevent regulatory approval.</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman">&#160;</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman">The NDA Approval Process</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">Assuming successful completion of all required testing
in accordance with all applicable regulatory requirements, detailed investigational new drug product information is submitted to the FDA
in the form of an NDA or BLA requesting approval to market the product for one or more indications. Under federal law, the submission
of most NDAs and BLAs is subject to an application user fee. For fiscal year 2014, the application user fee exceeds $2.1&#160;million,
and the Sponsor of an approved NDA or BLA is also subject to annual product and establishment user fees, set at $104,060 per product and
$554,600 per establishment. These fees are typically increased annually. Applications for orphan drug products are exempted from the NDA
and BLA user fees and may be exempted from product and establishment user fees, unless the application includes an indication for other
than a rare disease or condition.</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: rgb(0, 0, 0); font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">96</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="text-align: center; line-height: 1.25"><span style="font-family: Times New Roman"><br/> </span> </div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">An NDA or BLA must include all relevant data available
from pertinent preclinical and clinical studies, including negative or ambiguous results as well as positive findings, together with detailed
information relating to the product&#8217;s chemistry, manufacturing, controls, and proposed labeling, among other things. Data can come
from company-sponsored&#160;clinical studies intended to test the safety and effectiveness of a use of a product, or from a number of
alternative sources, including studies initiated by investigators. To support marketing approval, the data submitted must be sufficient
in quality and quantity to establish the safety and effectiveness of the investigational new drug product to the satisfaction of the FDA.</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">The FDA will initially review the NDA for completeness
before it accepts it for filing. The FDA has 60&#160;days from its receipt of an NDA to determine whether the application will be accepted
for filing based on the agency&#8217;s threshold determination that the application is sufficiently complete to permit substantive review.
After the NDA submission is accepted for filing, the FDA reviews the NDA to determine, among other things, whether the proposed product
is safe and effective for its intended use, and whether the product is being manufactured in accordance with cGMP to assure and preserve
the product&#8217;s identity, strength, quality and purity. The FDA may refer applications for novel drug products or drug products that
present difficult questions of safety or efficacy to an advisory committee, typically a panel that includes clinicians and other experts,
for review, evaluation and a recommendation as to whether the application should be approved and, if so, under what conditions. The FDA
is not bound by the recommendations of an advisory committee, but it considers such recommendations carefully when making decisions.</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">Based on pivotal Phase&#160;3 trial results submitted
in an NDA, upon the request of an applicant, the FDA may grant a priority review designation to a product, which sets the target date
for FDA action on the application at six&#160;months, rather than the standard ten&#160;months. Priority review is given where preliminary
estimates indicate that a product, if approved, has the potential to provide a significant improvement compared to marketed products or
offers a therapy where no satisfactory alternative therapy exists. Priority review designation does not change the scientific/medical
standard for approval or the quality of evidence necessary to support approval.</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">After the FDA completes its initial review of an NDA,
it will communicate to the sponsor that the drug will either be approved, or it will issue a complete response letter to communicate that
the NDA will not be approved in its current form and inform the sponsor of changes that must be made or additional clinical, nonclinical
or manufacturing data that must be received before the application can be approved, with no implication regarding the ultimate approvability
of the application.</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">Before approving an NDA or BLA, the FDA will typically
inspect the facilities at which the product is manufactured. The FDA will not approve the product unless it determines that the manufacturing
processes and facilities are in compliance with cGMP requirements and adequate to assure consistent production of the product within required
specifications.</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">Additionally, before approving an NDA, the FDA may inspect
one or more clinical sites to assure compliance with GCPs. If the FDA determines the application, manufacturing process or manufacturing
facilities are not acceptable, it typically will outline the deficiencies and often will request additional testing or information. This
may significantly delay further review of the application. If the FDA finds that a clinical site did not conduct the clinical trial in
accordance with GCP, the FDA may determine the data generated by the clinical site should be excluded from the primary efficacy analyses
provided in the NDA.&#160;Additionally, notwithstanding the submission of any requested additional information, the FDA ultimately may
decide that the application does not satisfy the regulatory criteria for approval.</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">The testing and approval process for a drug requires substantial
time, effort and financial resources, and this process may take several&#160;years to complete. Data obtained from clinical activities
are not always conclusive and may be susceptible to varying interpretations, which could delay, limit or prevent regulatory approval.
The FDA may not grant approval on a timely basis, or at all. We may encounter difficulties or unanticipated costs in our efforts to secure
necessary governmental approvals, which could delay or preclude us from marketing our products.</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: rgb(0, 0, 0); font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">97</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="text-align: center; line-height: 1.25"><span style="font-family: Times New Roman"><br/> </span> </div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">The FDA may require, or companies may pursue, additional
clinical trials after a product is approved. These so-called&#160;Phase&#160;4 studies may be made a condition to be satisfied for continuing
drug approval. The results of Phase&#160;4 studies can confirm the effectiveness of a product candidate and can provide important safety
information. In addition, the FDA now has express statutory authority to require sponsors to conduct post-market&#160;studies to specifically
address safety issues identified by the agency.</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">Any approvals that we may ultimately receive could be
withdrawn if required post-marketing&#160;trials or analyses do not meet the FDA requirements, which could materially harm the commercial
prospects for our candidate products.</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">The FDA also has authority to require a Risk Evaluation
and Mitigation Strategy, or REMS, from manufacturers to ensure that the benefits of a drug or biological product outweigh its risks. A
sponsor may also voluntarily propose a REMS as part of the NDA submission. The need for a REMS is determined as part of the review of
the NDA.&#160;Based on statutory standards, elements of a REMS may include &#8220;dear doctor letters,&#8221; a medication guide, more
elaborate targeted educational programs, and in some cases restrictions on distribution. These elements are negotiated as part of the
NDA approval, and in some cases if consensus is not obtained until after the PDUFA review cycle, the approval date may be delayed. Once
adopted, REMS are subject to periodic assessment and modification.</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">Even if a product candidate receives regulatory approval,
the approval may be limited to specific disease states, patient populations and dosages, or might contain significant limitations on use
in the form of warnings, precautions or contraindications, or in the form of onerous risk management plans, restrictions on distribution,
or post-marketing&#160;study requirements. Further, even after regulatory approval is obtained, later discovery of previously unknown
problems with a product may result in restrictions on the product or even complete withdrawal of the product from the market. Delay in
obtaining, or failure to obtain, regulatory approval for our candidate products, or obtaining approval but for significantly limited use,
would harm our business. In addition, we cannot predict what adverse governmental regulations may arise from future U.S.&#160;or foreign
governmental action.</div>

<div style="line-height: 1.25; font-style: italic; font-family: Times New Roman">&#160;</div>

<div style="line-height: 1.25; font-style: italic; font-family: Times New Roman">Expedited Review and Accelerated Approval Programs</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">A sponsor may seek approval of its product candidate under
programs designed to accelerate FDA&#8217;s review and approval of NDAs and BLAs. For example, Fast Track Designation may be granted to
a drug intended for treatment of a serious or life-threatening&#160;disease or condition that has potential to address unmet medical needs
for the disease or condition. The key benefits of fast track designation are the eligibility for priority review, rolling review (submission
of portions of an application before the complete marketing application is submitted), and accelerated approval, if relevant criteria
are met. Based on results of the Phase&#160;3 clinical study(ies) submitted in an NDA or BLA, upon the request of an applicant, the FDA
may grant the NDA or BLA a priority review designation, which sets the target date for FDA action on the application at six&#160;months
after the FDA accepts the application for filing. Priority review is granted where there is evidence that the proposed product would be
a significant improvement in the safety or effectiveness of the treatment, diagnosis, or prevention of a serious condition. If criteria
are not met for priority review, the application is subject to the standard FDA review period of ten&#160;months after FDA accepts the
application for filing. Priority review designation does not change the scientific/medical standard for approval or the quality of evidence
necessary to support approval.</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">Under the accelerated approval program, the FDA may approve
an NDA or a BLA on the basis of either a surrogate endpoint that is reasonably likely to predict clinical benefit, or on a clinical endpoint
that can be measured earlier than irreversible morbidity or mortality, that is reasonably likely to predict an effect on irreversible
morbidity or mortality or other clinical benefit, taking into account the severity, rarity, or prevalence of the condition and the availability
or lack of alternative treatments. Post-marketing&#160;studies or completion of ongoing studies after marketing approval are generally
required to verify the drug&#8217;s clinical benefit in relationship to the surrogate endpoint or ultimate outcome in relationship to
the clinical benefit. In addition, the Food and Drug Administration Safety and Innovation Act (FDASIA), which was enacted and signed into
law in 2012, established the new &#8220;breakthrough therapy&#8221; designation. A sponsor may seek FDA designation of its product candidate
as a breakthrough therapy if the drug is intended, alone or in combination with one or more other drugs, to treat a serious or life-threatening&#160;disease
or condition and preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over existing therapies
on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development.</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: rgb(0, 0, 0); font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">98</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="text-align: center; line-height: 1.25"><span style="font-family: Times New Roman"><br/> </span> </div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman">FDA Post-Approval Requirements</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">Drugs manufactured or distributed pursuant to FDA approvals
are subject to pervasive and continuing regulation by the FDA, including, among other things, requirements relating to recordkeeping,
periodic reporting, product sampling and distribution, advertising and promotion and reporting of adverse experiences with the product.
After approval, most changes to the approved product, such as adding new indications or other labeling claims are subject to prior FDA
review and approval. There also are continuing, annual user fee requirements for any marketed products and the establishments at which
such products are manufactured, as well as new application fees for supplemental applications with clinical data.</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">Drug manufacturers are subject to periodic unannounced
inspections by the FDA and state agencies for compliance with cGMP requirements. Changes to the manufacturing process are strictly regulated,
and, depending on the significance of the change, may require prior FDA approval before being implemented. FDA regulations also require
investigation and correction of any deviations from cGMP and impose reporting and documentation requirements upon us and any third-party&#160;manufacturers
that we may decide to use. Accordingly, manufacturers must continue to expend time, money and effort in the area of production and quality
control to maintain compliance with cGMP and other aspects of regulatory compliance.</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">We rely, and expect to continue to rely, on third parties
for the production of clinical quantities of our product candidates, and expect to rely in the future on third parties for the production
of commercial quantities. Future FDA and state inspections may identify compliance issues at our facilities or at the facilities of our
contract manufacturers that may disrupt production or distribution, or require substantial resources to correct. In addition, discovery
of previously unknown problems with a product or the failure to comply with applicable requirements may result in restrictions on a product,
manufacturer or holder of an approved NDA or BLA, including withdrawal or recall of the product from the market or other voluntary, FDA-initiated&#160;or
judicial action that could delay or prohibit further marketing. Also, new government requirements, including those resulting from new
legislation, may be established, or the FDA&#8217;s policies may change, which could delay or prevent regulatory approval of our products
under development.</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">The FDA may withdraw approval if compliance with regulatory
requirements and standards is not maintained or if problems occur after the product reaches the market. Later discovery of previously
unknown problems with a product, including adverse events of unanticipated severity or frequency, or with manufacturing processes, or
failure to comply with regulatory requirements, may result in revisions to the approved labeling to add new safety information, imposition
of post-market&#160;studies or clinical studies to assess new safety risks, or imposition of distribution restrictions or other restrictions
under a REMS program. Other potential consequences include, among other things:</div>

<div style="text-indent: -36pt; margin-left: 48pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z3983cdfedf824f858cd12b1b97fedba5" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">restrictions on the marketing or manufacturing of the product, complete withdrawal
        of the product from the market or product recalls;</div> </td> </tr>
  </table>

<div style="text-indent: -36pt; margin-left: 48pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<table cellspacing="0" cellpadding="0" id="zae31718e0af54197a010f6b9eb951abb" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">fines, warning letters or holds on post-approval&#160;clinical studies;</div>
        </td> </tr>
  </table>

<div style="text-indent: -36pt; margin-left: 48pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<table cellspacing="0" cellpadding="0" id="zd178b9290dd84c9eb48222df14e662ea" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">refusal of the FDA to approve pending NDAs or supplements to approved NDAs,
        or suspension or revocation of product license approvals;</div> </td> </tr>
  </table>

<div style="text-indent: -36pt; margin-left: 48pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z5be3e2c180714d439f2f10a5dd179152" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">injunctions or the imposition of civil or criminal penalties; or</div> </td>
        </tr>
  </table>

<div style="text-indent: -36pt; margin-left: 48pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z70b8f62de30d4a6ea4cef99e8888ef52" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">product seizure or detention, or refusal to permit the import or export of
        products.</div> </td> </tr>
  </table>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">The FDA strictly regulates marketing, labeling, advertising,
and promotion of products that are placed on the market. Drugs may be promoted only for the approved indications and in accordance with
the provisions of the approved label. The FDA and other agencies actively enforce the laws and regulations prohibiting the promotion of
off-label&#160;uses, and a company that is found to have improperly promoted off-label&#160;uses may be subject to significant liability.</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: rgb(0, 0, 0); font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">99</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="text-align: center; line-height: 1.25"><span style="font-family: Times New Roman"><br/> </span> </div>

<div style="line-height: 1.25; font-style: italic; font-family: Times New Roman">Orphan Designation and Exclusivity</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">The FDA may grant orphan drug designation to drugs intended
to treat a rare disease or condition that affects fewer than 200,000 individuals in the United&#160;States, or, if it affects more than
200,000 individuals in the United&#160;States, when there is no reasonable expectation that the cost of developing and making the drug
for this type of disease or condition will be recovered from sales in the United&#160;States.</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">Orphan drug designation entitles a party to financial
incentives such as opportunities for grant funding of clinical study costs, tax advantages, and user-fee&#160;waivers. In addition, if
a product receives FDA approval for the indication for which it has orphan designation, the product is entitled to orphan drug exclusivity,
which means the FDA may not approve any other application to market the same drug for the same indication for a period of seven&#160;years,
except in limited circumstances, such as a showing of clinical superiority over the product with orphan exclusivity.</div>

<div style="line-height: 1.25; font-style: italic; font-family: Times New Roman">&#160;</div>

<div style="line-height: 1.25; font-style: italic; font-family: Times New Roman">Patent Term Restoration</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">Depending upon the timing, duration, and specifics of
the FDA approval of the use of our product candidates, U.S.&#160;patents that may be granted to us in the future may be eligible for limited
patent term extension under the Drug Price Competition and Patent Term Restoration Act&#160;of&#160;1984, commonly referred to as the
Hatch-Waxman&#160;Amendments. The Hatch-Waxman&#160;Amendments permit a patent restoration term of up to five&#160;years as compensation
for patent term lost during product development and the FDA regulatory review process. However, patent term restoration cannot extend
the remaining term of a patent beyond a total of 14&#160;years from the product&#8217;s approval date. The patent term restoration period
is generally one-half&#160;the time between the effective date of an IND and the submission date of an NDA or BLA, plus the time between
the submission date and the approval of that application. Only one patent applicable to an approved product is eligible for the extension
and the application for the extension must be submitted prior to the expiration of the patent. The USPTO, in consultation with the FDA,
reviews and approves the application for any patent term extension or restoration. In the future, we may apply for restoration of patent
term for one of our currently owned or licensed patents to add patent life beyond its current expiration date, depending on the expected
length of the clinical studies and other factors involved in the filing of the relevant NDA or BLA.</div>

<div style="line-height: 1.25; font-style: italic; font-family: Times New Roman">&#160;</div>

<div style="line-height: 1.25; font-style: italic; font-family: Times New Roman">Biosimilars and Exclusivity</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">The Patient Protection and Affordable Care Act, or Affordable
Care Act, signed into law on March&#160;23, 2010, includes a subtitle called the Biologics Price Competition and Innovation Act&#160;of&#160;2009
(BPCI Act), which created an abbreviated approval pathway for biological products shown to be similar to, or interchangeable with, an
FDA-licensed&#160;reference biological product. This amendment to the PHSA attempts to minimize duplicative testing. Biosimilarity, which
requires that there be no clinically meaningful differences between the biological product and the reference product in terms of safety,
purity, and potency, can be shown through analytical studies, animal studies, and a clinical study or studies. Interchangeability requires
that a product is biosimilar to the reference product and the product must demonstrate that it can be expected to produce the same clinical
results as the reference product and, for products administered multiple times, the biologic and the reference biologic may be switched
after one has been previously administered without increasing safety risks or risks of diminished efficacy relative to exclusive use of
the reference biologic. However, complexities associated with the larger, and often more complex, structure of biological products, as
well as the process by which such products are manufactured, pose significant hurdles to implementation that are still being worked out
by the FDA.</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">A reference biologic is granted twelve&#160;years of exclusivity
from the time of first licensure of the reference product. The first biologic product submitted under the abbreviated approval pathway
that is determined to be interchangeable with the reference product has exclusivity against other biologics submitting under the abbreviated
approval pathway for the lesser of (i)&#160;one year after the first commercial marketing, (ii)&#160;eighteen&#160;months after approval
if there is no legal challenge, (iii)&#160;eighteen&#160;months after the resolution in the applicant&#8217;s favor of a lawsuit challenging
the biologics&#8217; patents if an application has been submitted, or (iv)&#160;42&#160;months after the application has been approved
if a lawsuit is ongoing within the 42-month&#160;period.</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: rgb(0, 0, 0); font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">100</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="text-align: center; line-height: 1.25"><span style="font-family: Times New Roman"><br/> </span> </div>

<div style="line-height: 1.25; font-style: italic; font-family: Times New Roman">Abbreviated New Drug Applications for Generic Drugs</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">In 1984, with passage of the Hatch-Waxman&#160;Act, Congress
authorized the FDA to approve generic drugs that are the same as drugs previously approved by the FDA under the NDA provisions of the
statute. To obtain approval of a generic drug, an applicant must submit an abbreviated new drug application (ANDA) to the agency. In support
of such applications, a generic manufacturer may rely on the preclinical and clinical testing previously conducted for a drug product
previously approved under an NDA, known as the reference listed drug (RLD).</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">Specifically, in order for an ANDA to be approved, the
FDA must find that the generic version is identical to the RLD with respect to the active ingredients, the route of administration, the
dosage form, and the strength of the drug. At the same time, the FDA must also determine that the generic drug is &#8220;bioequivalent&#8221;
to the innovator drug. Under the statute, a generic drug is bioequivalent to an RLD if &#8220;the rate and extent of absorption of the
[generic] drug do not show a significant difference from the rate and extent of absorption of the listed drug. . . .&#8221;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">Upon approval of an ANDA, the FDA indicates that the generic
product is &#8220;therapeutically equivalent&#8221; to the RLD and it assigns a therapeutic equivalence rating to the approved generic
drug in its publication &#8220;Approved Drug Products with Therapeutic Equivalence Evaluations,&#8221; also referred to as the &#8220;Orange
Book.&#8221; Physicians and pharmacists consider an &#8220;AB&#8221; therapeutic equivalence rating to mean that a generic drug is fully
substitutable for the RLD.&#160;In addition, by operation of certain state laws and numerous health insurance programs, the FDA&#8217;s
designation of an &#8220;AB&#8221; rating often results in substitution of the generic drug without the knowledge or consent of either
the prescribing physician or patient.</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">The FDCA provides a period of five&#160;years of non-patent&#160;exclusivity
for a new drug containing a new chemical entity. In cases where such exclusivity has been granted, an ANDA may not be filed with the FDA
until the expiration of five&#160;years unless the submission is accompanied by a Paragraph&#160;IV certification, in which case the applicant
may submit its application four&#160;years following the original product approval. The FDCA also provides for a period of three&#160;years
of exclusivity if the NDA includes reports of one or more new clinical investigations, other than bioavailability or bioequivalence studies,
that were conducted by or for the applicant and are essential to the approval of the application. This three-year&#160;exclusivity period
often protects changes to a previously approved drug product, such as a new dosage form, route of administration, combination or indication.</div>

<div style="line-height: 1.25; font-style: italic; font-family: Times New Roman">&#160;</div>

<div style="line-height: 1.25; font-style: italic; font-family: Times New Roman">Hatch-Waxman Patent Certification and the 30-Month Stay</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">Upon approval of an NDA or a supplement thereto, NDA sponsors
are required to list with the FDA each patent with claims that cover the applicant&#8217;s product or a method of using the product. Each
of the patents listed by the NDA sponsor is published in the Orange Book. When an ANDA applicant files its application with the FDA, the
applicant is required to certify to the FDA concerning any patents listed for the reference product in the Orange Book, except for patents
covering methods of use for which the ANDA applicant is not seeking approval.</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">Specifically, the applicant must certify with respect
to each patent that:</div>

<div style="text-indent: -36pt; margin-left: 48pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z2c51fb7f344d4e6a947dd4d4aad86471" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">the required patent information has not been filed;</div> </td> </tr>
  </table>

<div style="text-indent: -36pt; margin-left: 48pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<table cellspacing="0" cellpadding="0" id="zd15a6f0694b044d1954e4de07bf3a8e8" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">the listed patent has expired;</div> </td> </tr>
  </table>

<div style="text-indent: -36pt; margin-left: 48pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<table cellspacing="0" cellpadding="0" id="za2fc222730244435bda6b8d23fc9f38c" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">the listed patent has not expired, but will expire on a particular date and
        approval is sought after patent expiration; or</div> </td> </tr>
  </table>

<div style="text-indent: -36pt; margin-left: 48pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<table cellspacing="0" cellpadding="0" id="zb9859f28670343a49fb8c230445259bc" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">the listed patent is invalid, unenforceable or will not be infringed by the
        new product.</div> </td> </tr>
  </table>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">A certification that the new product will not infringe
the already approved product&#8217;s listed patents or that such patents are invalid or unenforceable is called a Paragraph&#160;IV certification.
If the applicant does not challenge the listed patents or indicates that it is not seeking approval of a patented method of use, the ANDA
application will not be approved until all the listed patents claiming the referenced product have expired.</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: rgb(0, 0, 0); font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">101</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="text-align: center; line-height: 1.25"><span style="font-family: Times New Roman"><br/> </span> </div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">If the ANDA applicant has provided a Paragraph&#160;IV
certification to the FDA, the applicant must also send notice of the Paragraph&#160;IV certification to the NDA and patent holders once
the ANDA has been accepted for filing by the FDA.&#160;The NDA and patent holders may then initiate a patent infringement lawsuit in response
to the notice of the Paragraph&#160;IV certification. The filing of a patent infringement lawsuit within 45&#160;days after the receipt
of a Paragraph&#160;IV certification automatically prevents the FDA from approving the ANDA until the earlier of 30&#160;months after
the receipt of the Paragraph&#160;IV notice, expiration of the patent, or a decision in the infringement case that is favorable to the
ANDA applicant.</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman">&#160;</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman">European Union/Rest of World Government
Regulation</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">In addition to regulations in the United&#160;States,
we will be subject to a variety of regulations in other jurisdictions governing, among other things, clinical studies and any commercial
sales and distribution of our products.</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">Whether or not we obtain FDA approval for a product, we
must obtain the requisite approvals from regulatory authorities in foreign countries prior to the commencement of clinical studies or
marketing of the product in those countries. Certain countries outside of the United&#160;States have a similar process that requires
the submission of a clinical study application much like the IND prior to the commencement of human clinical studies. In the European
Union, for example, a clinical study application, or CTA, must be submitted for each clinical protocol to each country&#8217;s national
health authority and an independent ethics committee, much like the FDA and IRB, respectively. Once the CTA is accepted in accordance
with a country&#8217;s requirements, the clinical study may proceed.</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">The requirements and process governing the conduct of
clinical studies vary from country to country. In all cases, the clinical studies are conducted in accordance with cGCP, the applicable
regulatory requirements, and the ethical principles that have their origin in the Declaration of Helsinki.</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">To obtain regulatory approval of an investigational medicinal
product under European Union regulatory systems, we must submit a marketing authorization application. The content of the NDA or BLA filed
in the United&#160;States is similar to that required in the European Union, with the exception of, among other things, country-specific&#160;document
requirements.</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">For other countries outside of the European Union, such
as countries in Eastern Europe, Latin America or Asia, the requirements governing product licensing, pricing, and reimbursement vary from
country to country.</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">Countries that are part of the European Union, as well
as countries outside of the European Union, have their own governing bodies, requirements, and processes with respect to the approval
of pharmaceutical products. If we fail to comply with applicable foreign regulatory requirements, we may be subject to, among other things,
fines, suspension or withdrawal of regulatory approvals, product recalls, seizure of products, operating restrictions and criminal prosecution.</div>

<div style="line-height: 1.25; font-style: italic; font-family: Times New Roman">&#160;</div>

<div style="line-height: 1.25; font-style: italic; font-family: Times New Roman">Authorization Procedures in the European Union</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">Medicines can be authorized in the European Union by using
either the centralized authorization procedure or national authorization procedures.</div>

<div style="line-height: 1.25; font-style: italic; font-family: Times New Roman">&#160;</div>

<div style="line-height: 1.25; font-style: italic; font-family: Times New Roman">Centralized procedure</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">The EMA implemented the centralized procedure for the
approval of human medicines to facilitate marketing authorizations that are valid throughout the European Economic Area, or EEA, which
is comprised of the 27 member states of the European Union plus Norway, Iceland, and Lichtenstein. This procedure results in a single
marketing authorization issued by the EMA that is valid across the EEA.&#160;The centralized procedure is compulsory for human medicines
that are: derived from biotechnology processes, such as genetic engineering, contain a new active substance indicated for the treatment
of certain diseases, such as HIV/AIDS, cancer, diabetes, neurodegenerative disorders or autoimmune diseases and other immune dysfunctions,
and officially designated orphan medicines.</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: rgb(0, 0, 0); font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">102</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="text-align: center; line-height: 1.25"><span style="font-family: Times New Roman"><br/> </span> </div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">For medicines that do not fall within these categories,
an applicant has the option of submitting an application for a centralized marketing authorization to the European Commission following
a favorable opinion by the EMA, as long as the medicine concerned is a significant therapeutic, scientific or technical innovation, or
if its authorization would be in the interest of public health.</div>

<div style="line-height: 1.25; font-style: italic; font-family: Times New Roman">&#160;</div>

<div style="line-height: 1.25; font-style: italic; font-family: Times New Roman">National authorization procedures</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">There are also two other possible routes to authorize
medicinal products in several European Union countries, which are available for investigational medicinal products that fall outside the
scope of the centralized procedure:</div>

<div style="text-indent: -36pt; margin-left: 48pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<table cellspacing="0" cellpadding="0" id="ze3ea29ac7fb8496d9b3f699d5917434d" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25"><span style="font-style: italic; font-family: Times New Roman">Decentralized procedure</span><span style="font-family: Times New Roman">.&#160;&#160;&#160;&#160;Using
        the decentralized procedure, an applicant may apply for simultaneous authorization in more than one European Union country of medicinal
        products that have not yet been authorized in any European Union country and that do not fall within the mandatory scope of the centralized
        procedure.</span></div> </td> </tr>
  </table>

<div style="text-indent: -36pt; margin-left: 48pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z7f198634ab2646f1b0497ab6a3966f44" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25"><span style="font-style: italic; font-family: Times New Roman">Mutual recognition procedure.</span><span style="font-family: Times New Roman">&#160;&#160;&#160;&#160;In
        the mutual recognition procedure, a medicine is first authorized in one European Union Member State, in accordance with the national procedures
        of that country. Following this, further marketing authorizations can be sought from other European Union countries in a procedure whereby
        the countries concerned agree to recognize the validity of the original, national marketing authorization.</span></div> </td> </tr>
  </table>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">In most cases, a Pediatric Investigation Plan, and/or
a request for waiver or deferral, is required for submission prior to submitting a marketing authorization application. A PIP describes,
among other things, proposed pediatric studies and their timing relative to clinical studies in adults.</div>

<div style="line-height: 1.25; font-style: italic; font-family: Times New Roman">&#160;</div>

<div style="line-height: 1.25; font-style: italic; font-family: Times New Roman">New Chemical Entity Exclusivity</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">In the European Union, new chemical entities, sometimes
referred to as new active substances, qualify for eight&#160;years of data exclusivity upon marketing authorization and an additional
two&#160;years of market exclusivity. This data exclusivity, if granted, prevents regulatory authorities in the European Union from referencing
the innovator&#8217;s data to assess a generic (abbreviated) application for eight&#160;years, after which generic marketing authorization
can be submitted, and the innovator&#8217;s data may be referenced, but not approved for two&#160;years. The overall ten-year&#160;period
will be extended to a maximum of eleven&#160;years if, during the first eight&#160;years of those ten&#160;years, the marketing authorization
holder obtains an authorization for one or more new therapeutic indications which, during the scientific evaluation prior to their authorization,
are held to bring a significant clinical benefit in comparison with existing therapies.</div>

<div style="line-height: 1.25; font-style: italic; font-family: Times New Roman">&#160;</div>

<div style="line-height: 1.25; font-style: italic; font-family: Times New Roman">Orphan Designation and Exclusivity</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">In the European Union, the EMA&#8217;s Committee for Orphan
Medicinal Products, or COMP, grants orphan drug designation to promote the development of products that are intended for the diagnosis,
prevention or treatment of life-threatening&#160;or chronically debilitating conditions affecting not more than 5 in 10,000&#160;persons
in the European Union Community and for which no satisfactory method of diagnosis, prevention, or treatment has been authorized (or the
product would be a significant benefit to those affected). Additionally, designation is granted for products intended for the diagnosis,
prevention, or treatment of a life-threatening, seriously debilitating or serious and chronic condition and when, without incentives,
it is unlikely that sales of the drug in the European Union would be sufficient to justify the necessary investment in developing the
medicinal product.</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">In the European Union, orphan drug designation entitles
a party to financial incentives such as reduction of fees or fee waivers and 10&#160;years of market exclusivity is granted following
medicinal product approval. This period may be reduced to six&#160;years if the orphan drug designation criteria are no longer met, including
where it is shown that the product is sufficiently profitable not to justify maintenance of market exclusivity, and may be prolonged to
a total of 12 years, if pediatric studies in accordance with a PIP are being performed.</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: rgb(0, 0, 0); font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">103</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">Orphan drug designation must be requested before submitting
an application for marketing approval. Orphan drug designation does not convey any advantage in, or shorten the duration of, the regulatory
review and approval process.</div>

<div style="line-height: 1.25; font-style: italic; font-family: Times New Roman">&#160;</div>

<div style="line-height: 1.25; font-style: italic; font-family: Times New Roman">Exceptional Circumstances/Conditional Approval</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">Orphan drugs or drugs with unmet medical needs may be
eligible for EU approval under exceptional circumstances or with conditional approval. Approval under exceptional circumstances is applicable
to orphan and non-orphan&#160;products and is used when an applicant is unable to provide comprehensive data on the efficacy and safety
under normal conditions of use because the indication for which the product is intended is encountered so rarely that the applicant cannot
reasonably be expected to provide comprehensive evidence, when the present state of scientific knowledge does not allow comprehensive
information to be provided, or when it is medically unethical to collect such information. Conditional marketing authorization is applicable
to orphan medicinal products, medicinal products for seriously debilitating or life-threatening&#160;diseases, or medicinal products to
be used in emergency situations in response to recognized public threats. Conditional marketing authorization can be granted on the basis
of less complete data than is normally required in order to meet unmet medical needs and in the interest of public health, provided the
risk-benefit&#160;balance is positive, it is likely that the applicant will be able to provide the comprehensive clinical data, and unmet
medical needs will be fulfilled. Conditional marketing authorization is subject to certain specific obligations to be reviewed annually.</div>

<div style="line-height: 1.25; font-style: italic; font-family: Times New Roman">&#160;</div>

<div style="line-height: 1.25; font-style: italic; font-family: Times New Roman">Accelerated Review</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">Under the Centralized Procedure in the European Union,
the maximum timeframe for the evaluation of a marketing authorization application is 210&#160;days (excluding clock stops, when additional
written or oral information is to be provided by the applicant in response to questions asked by the EMA&#8217;s Committee for Medicinal
Products for Human Use (CHMP)). Accelerated evaluation might be granted by the CHMP in exceptional cases, when a medicinal product is
expected to be of a major public health interest, particularly from the point of view of therapeutic innovation. In this circumstance,
EMA ensures that the opinion of the CHMP is given within 150&#160;days, excluding clock stops.</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman">&#160;</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman">Pharmaceutical Coverage, Pricing and
Reimbursement</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">Significant uncertainty exists as to the coverage and
reimbursement status of any drug products for which we obtain regulatory approval. In the United&#160;States and markets in other countries,
sales of any products for which we receive regulatory approval for commercial sale will depend in part on the availability of coverage
and reimbursement from third-party&#160;payors. Third-party&#160;payors include government authorities, managed care providers, private
health insurers and other organizations. The process for determining whether a payor will provide coverage for a drug product may be separate
from the process for setting the reimbursement rate that the payor will pay for the drug product. Third-party&#160;payors may limit coverage
to specific drug products on an approved list, or formulary, which might not include all of the FDA-approved&#160;drugs for a particular
indication. Moreover, a payor&#8217;s decision to provide coverage for a drug product does not imply that an adequate reimbursement rate
will be approved. Adequate third-party&#160;reimbursement may not be available to enable us to maintain price levels sufficient to realize
an appropriate return on our investment in product development.</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">Third-party&#160;payors are increasingly challenging the
price and examining the medical necessity and cost-effectiveness&#160;of medical products and services, in addition to their safety and
efficacy. In order to obtain coverage and reimbursement for any product that might be approved for sale, we may need to conduct expensive
pharmacoeconomic studies in order to demonstrate the medical necessity and cost-effectiveness&#160;of our products, in addition to the
costs required to obtain regulatory approvals. Our product candidates may not be considered medically necessary or cost-effective. If
third-party&#160;payors do not consider a product to be cost-effective&#160;compared to other available therapies, they may not cover
the product after approval as a benefit under their plans or, if they do, the level of payment may not be sufficient to allow a company
to sell its products at a profit.</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: rgb(0, 0, 0); font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">104</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="text-align: center; line-height: 1.25"><span style="font-family: Times New Roman"><br/> </span> </div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">The U.S.&#160;government, state legislatures and foreign
governments have shown significant interest in implementing cost containment programs to limit the growth of government-paid&#160;health
care costs, including price controls, restrictions on reimbursement and requirements for substitution of generic products for branded
prescription drugs. By way of example, the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation
Act, collectively, the Healthcare Reform Law, contains provisions that may reduce the profitability of drug products, including, for example,
increased rebates for drugs sold to Medicaid programs, extension of Medicaid rebates to Medicaid managed care plans, mandatory discounts
for certain Medicare Part&#160;D beneficiaries and annual fees based on pharmaceutical companies&#8217; share of sales to federal health
care programs. Adoption of government controls and measures, and tightening of restrictive policies in jurisdictions with existing controls
and measures, could limit payments for pharmaceuticals.</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">In the European Community, governments influence the price
of pharmaceutical products through their pricing and reimbursement rules and control of national health care systems that fund a large
part of the cost of those products to consumers. Some jurisdictions operate positive and negative list systems under which products may
only be marketed once a reimbursement price has been agreed to by the government. To obtain reimbursement or pricing approval, some of
these countries may require the completion of clinical studies that compare the cost-effectiveness&#160;of a particular product candidate
to currently available therapies. Other member states allow companies to fix their own prices for medicines, but monitor and control company
profits. The downward pressure on health care costs in general, particularly prescription drugs, has become very intense. As a result,
increasingly high barriers are being erected to the entry of new products. In addition, in some countries, cross-border&#160;imports from
low-priced&#160;markets exert a commercial pressure on pricing within a country.</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">The marketability of any products for which we receive
regulatory approval for commercial sale may suffer if the government and third-party&#160;payors fail to provide adequate coverage and
reimbursement. In addition, an increasing emphasis on cost containment measures in the United&#160;States and other countries has increased
and we expect will continue to increase the pressure on pharmaceutical pricing. Coverage policies and third-party&#160;reimbursement rates
may change at any time. Even if favorable coverage and reimbursement status is attained for one or more products for which we receive
regulatory approval, less favorable coverage policies and reimbursement rates may be implemented in the future.</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman">&#160;</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman">Other Healthcare Laws and Compliance
Requirements</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">If we obtain regulatory approval for any of our product
candidates, we may be subject to various federal and state laws targeting fraud and abuse in the healthcare industry. These laws may impact,
among other things, our proposed sales, marketing and education programs. In addition, we may be subject to patient privacy regulation
by both the federal government and the states in which we conduct our business. The laws that may affect our ability to operate include:</div>

<div style="text-indent: -36pt; margin-left: 48pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z8633eab223104e809b98d32c44a0a8dc" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">the federal Anti-Kickback&#160;Statute, which prohibits, among other things,
        persons from knowingly and willfully soliciting, receiving, offering or paying remuneration, directly or indirectly, to induce, or in
        return for, the purchase or recommendation of an item or service reimbursable under a federal healthcare program, such as the Medicare
        and Medicaid programs;</div> </td> </tr>
  </table>

<div style="text-indent: -36pt; margin-left: 48pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<table cellspacing="0" cellpadding="0" id="zcd5d1814eed64b23895994c80beaf7c5" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">federal civil and criminal false claims laws and civil monetary penalty laws,
        which prohibit, among other things, individuals or entities from knowingly presenting, or causing to be presented, claims for payment
        from Medicare, Medicaid, or other third-party&#160;payers that are false or fraudulent;</div> </td> </tr>
  </table>

<div style="text-indent: -36pt; margin-left: 48pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<table cellspacing="0" cellpadding="0" id="zc76f16ad513c4a39b658aed0eff7e6b8" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">the federal Health Insurance Portability and Accountability Act&#160;of&#160;1996,
        or HIPAA, which created new federal criminal statutes that prohibit executing a scheme to defraud any healthcare benefit program and making
        false statements relating to healthcare matters;</div> </td> </tr>
  </table>

<div style="text-indent: -36pt; margin-left: 48pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: rgb(0, 0, 0); font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">105</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="text-align: center; line-height: 1.25"><span style="font-family: Times New Roman"><br/> </span> </div>

<table cellspacing="0" cellpadding="0" id="zc2930a90ce2c4869b3013a7eb9b4114a" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">the federal transparency laws, including the federal Physician Payment Sunshine
        Act, that requires drug manufacturers to disclose payments and other transfers of value provided to physicians and teaching hospitals;</div>
        </td> </tr>
  </table>

<div style="text-indent: -36pt; margin-left: 48pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z6ea890036f464c9d81ffc114ebddac30" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">HIPAA, as amended by HITECH and its implementing regulations, which imposes
        certain requirements relating to the privacy, security and transmission of individually identifiable health information; and</div> </td>
        </tr>
  </table>

<div style="text-indent: -36pt; margin-left: 48pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<table cellspacing="0" cellpadding="0" id="za70b7f9691504469972c68d712a6e659" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">state law equivalents of each of the above federal laws, such as anti-kickback&#160;and
        false claims laws which may apply to items or services reimbursed by any third-party&#160;payer, including commercial insurers, and state
        laws governing the privacy and security of health information in certain circumstances, many of which differ from each other in significant
        ways and may not have the same effect, thus complicating compliance efforts.</div> </td> </tr>
  </table>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">The Healthcare Reform Law broadened the reach of the fraud
and abuse laws by, among other things, amending the intent requirement of the federal Anti-Kickback&#160;Statute and the applicable criminal
healthcare fraud statutes contained within 42&#160;U.S.C. &#167;&#160;1320a-7b, effective March&#160;23, 2010. Pursuant to the statutory
amendment, a person or entity no longer needs to have actual knowledge of this statute or specific intent to violate it in order to have
committed a violation. In addition, the Healthcare Reform Law provides that the government may assert that a claim including items or
services resulting from a violation of the federal Anti-Kickback&#160;Statute constitutes a false or fraudulent claim for purposes of
the civil False Claims Act (discussed below) or the civil monetary penalties statute. Many states have adopted laws similar to the federal
Anti-Kickback&#160;Statute, some of which apply to the referral of patients for healthcare items or services reimbursed by any source,
not only the Medicare and Medicaid programs.</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">We are also subject to the Foreign Corrupt Practices Act,
or FCPA, which prohibits improper payments or offers of payments to foreign governments and their officials for the purpose of obtaining
or retaining business.</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">Safeguards we implement to discourage improper payments
or offers of payments by our employees, consultants, and others may be ineffective, and violations of the FCPA and similar laws may result
in severe criminal or civil sanctions, or other liabilities or proceedings against us, any of which would likely harm our reputation,
business, financial condition and result of operations.</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">If our operations are found to be in violation of any
of the laws described above or any other governmental regulations that apply to us, we may be subject to penalties, including civil and
criminal penalties, exclusion from participation in government healthcare programs, such as Medicare and Medicaid and imprisonment, damages,
fines and the curtailment or restructuring of our operations, any of which could adversely affect our ability to operate our business
and our results of operations.</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman">&#160;</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman">Labeling, Marketing and Promotion</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">The FDA closely regulates the labeling, marketing and
promotion of drugs. While doctors are free to prescribe any drug approved by the FDA for any use, a company can only make claims relating
to safety and efficacy of a drug that are consistent with FDA approval, and the Company is allowed to actively market a drug only for
the particular use and treatment approved by the FDA.&#160;In addition, any claims we make for our products in advertising or promotion
must be appropriately balanced with important safety information and otherwise be adequately substantiated. Failure to comply with these
requirements can result in adverse publicity, warning letters, corrective advertising, injunctions and potential civil and criminal penalties.
Government regulators recently have increased their scrutiny of the promotion and marketing of drugs.</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman">&#160;</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman">Pediatric Research Equity Act</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">The Pediatric Research Equity Act (PREA) amended the FDCA
to authorize the FDA to require certain research into drugs used in pediatric patients. The intent of PREA is to compel sponsors whose
drugs have pediatric applicability to study those drugs in pediatric populations, rather than ignoring pediatric indications for adult
indications that could be more economically desirable. The Secretary of Health and Human Services may defer or waive these requirements
under specified circumstances.</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: rgb(0, 0, 0); font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">106</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="text-align: center; line-height: 1.25"><span style="font-family: Times New Roman"><br/> </span> </div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman">Anti-Kickback and False Claims Laws</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">In the United&#160;States, the research, manufacturing,
distribution, sale and promotion of drug products and medical devices are potentially subject to regulation by various federal, state
and local authorities in addition to the FDA, including the Centers for Medicare&#160;&amp; Medicaid Services, other divisions of the
U.S.&#160;Department of Health and Human Services (e.g., the Office of Inspector General), the U.S.&#160;Department of Justice, state
Attorneys General, and other state and local government agencies. For example, sales, marketing and scientific/educational grant programs
must comply with the Medicare-Medicaid&#160;Anti-Fraud&#160;and Abuse Act, as amended (the &#8220;Anti-Kickback&#160;Statute&#8221;),
the False Claims Act, as amended, the privacy regulations promulgated under the Health Insurance Portability and Accountability Act, or
HIPAA, and similar state laws. Pricing and rebate programs must comply with the Medicaid Drug Rebate Program requirements of the Omnibus
Budget Reconciliation Act&#160;of&#160;1990, as amended, and the Veterans Health Care Act&#160;of&#160;1992, as amended. If products are
made available to authorized users of the Federal Supply Schedule of the General Services Administration, additional laws and requirements
apply. All of these activities are also potentially subject to federal and state consumer protection and unfair competition laws.</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">In the United&#160;States, we are subject to complex laws
and regulations pertaining to healthcare &#8220;fraud and abuse,&#8221; including, but not limited to, the Anti-Kickback&#160;Statute,
the federal False Claims Act, and other state and federal laws and regulations. The Anti-Kickback&#160;Statute makes it illegal for any
person, including a prescription drug manufacturer (or a party acting on its behalf) to knowingly and willfully solicit, receive, offer,
or pay any remuneration that is intended to induce the referral of business, including the purchase, order, or prescription of a particular
drug, for which payment may be made under a federal healthcare program, such as Medicare or Medicaid.</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">The federal False Claims Act prohibits anyone from knowingly
presenting, or causing to be presented, for payment to federal programs (including Medicare and Medicaid) claims for items or services,
including drugs, that are false or fraudulent, claims for items or services not provided as claimed, or claims for medically unnecessary
items or services.</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">There are also an increasing number of state laws that
require manufacturers to make reports to states on pricing and marketing information. Many of these laws contain ambiguities as to what
is required to comply with the laws. In addition, as discussed below, beginning in 2013, a similar federal requirement will require manufacturers
to track and report to the federal government certain payments made to physicians and teaching hospitals made in the previous calendar
year. These laws may affect our sales, marketing, and other promotional activities by imposing administrative and compliance burdens on
us. In addition, given the lack of clarity with respect to these laws and their implementation, our reporting actions could be subject
to the penalty provisions of the pertinent state, and soon federal, authorities.</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman">&#160;</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman">Patient Protection and Affordable
Health Care Act</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">In March&#160;2010, the Patient Protection and Affordable
Health Care Act, as amended by the Health Care and Education Reconciliation Act&#160;of&#160;2010 (collectively, PPACA) was enacted, which
includes measures that have or will significantly change the way health care is financed by both governmental and private insurers. The
fees, discounts and other provisions of this law are expected to have a significant negative effect on the profitability of pharmaceuticals.</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">Many of the details regarding the implementation of PPACA
are yet to be determined, and at this time, it remains unclear the full effect that PPACA would have on our business.</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman">&#160;</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman">Other Regulations</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">We are also subject to numerous federal, state and local
laws relating to such matters as safe working conditions, manufacturing practices, environmental protection, fire hazard control, and
disposal of hazardous or potentially hazardous substances. We may incur significant costs to comply with such laws and regulations now
or in the future.</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: rgb(0, 0, 0); font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">107</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="text-align: center; line-height: 1.25"><span style="font-family: Times New Roman"><br/> </span> </div>

<div style="line-height: 1.25; font-weight: bold; font-family: Times New Roman">Israel</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman">&#160;</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman">Clinical Testing in Israel</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">In order to conduct clinical testing on humans in the
State of Israel, special authorization must first be obtained from the ethics committee and general manager of the institution in which
the clinical studies are scheduled to be conducted, as required under the Guidelines for Clinical Trials in Human Subjects implemented
pursuant to the Israeli Public Health Regulations (Clinical Trials in Human Subjects)&#160;5741-1980, as amended from time to time, and
other applicable legislation. These regulations require authorization by the institutional ethics committee and general manager as well
as from the Israeli Ministry of Health, except in certain circumstances, and in the case of genetic trials, special fertility trials and
complex clinical trials, an additional authorization of the Ministry of Health&#8217;s overseeing ethics committee. The institutional
ethics committee must, among other things, evaluate the anticipated benefits that are likely to be derived from the project to determine
if it justifies the risks and inconvenience to be inflicted on the human subjects, and the committee must ensure that adequate protection
exists for the rights and safety of the participants as well as the accuracy of the information gathered in the course of the clinical
testing. Since we perform a portion of the clinical studies on certain of our therapeutic candidates in Israel, we are required to obtain
authorization from the ethics committee and general manager of each institution in which we intend to conduct our clinical trials, and
in most cases, from the Israeli Ministry of Health.</div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold; font-family: Times New Roman">New Silexion Corporate Information</div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">New Silexion was formed on April 2, 2024 under the name
Biomotion Sciences as a Cayman Islands exempted limited company for the purpose of effecting a business combination with Moringa and Silexion.
On April 3, 2024, New Silexion entered into the Business Combination Agreement by and among New Silexion, Moringa, Silexion, and New Silexion&#8217;s
two wholly-owned subsidiaries&#8212; Merger Sub 1 and Merger Sub 2. On the Closing Date of August 15, 2024, following the approval of
the Business Combination (among other matters) at Moringa&#8217;s extraordinary general meeting that was held on August 6, 2024, the transactions
contemplated by the Business Combination Agreement were completed. As a result, Moringa and Silexion merged with Merger Sub 2 and Merger
Sub 1 pursuant to the SPAC Merger and Acquisition Merger, respectively, and became New Silexion&#8217;s wholly-owned subsidiaries, and
their securityholders became securityholders of New Silexion at previously agreed-upon exchange ratios. In addition, New Silexion&#8217;s
ordinary shares and warrants were listed, and began trading, on the Nasdaq Global Market on August 16, 2024, and its name was changed
to Silexion Therapeutics Corp.</div>

<div style="text-align: justify; text-indent: 18pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="line-height: 1.25; font-family: Times New Roman">New Silexion&#8217;s principal executive offices are located at 12 Abba Hillel
Road, Ramat Gan, Israel 5250606, and its phone number is +972-8-6286005. New Silexion&#8217;s corporate website address is www.silexion.com.
Information contained on or accessible through that website is not a part of this prospectus, and the inclusion of that website address
in this prospectus is an inactive textual reference only.</div> </div>

<div style="text-align: justify; text-indent: 18pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman, Times, serif; font-weight: bold">Properties</div>

<div style="line-height: 1.25"><br/> </div>

<div style="line-height: 1.25">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">We currently lease 464 square meters of
office space at <span style="font-style: italic">12 Abba Hillel Silver St</span>, Ramat Gan, Israel. The lease term is for 24 months beginning
on November 1, 2024 and ending on 31 October 2026, with an option to extend for an additional 24 months. Monthly rent payments, including
utilities, amount to approximately $12,839 per month</div> </div> </div>

<div style="text-align: justify; text-indent: 18pt; line-height: 1.25; font-family: Times New Roman"> <br/> </div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold; font-family: Times New Roman">Access to Company Information</div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">The Company files or furnishes periodic reports and amendments
thereto, including its Annual Reports on Form 10-K, its Quarterly Reports on Form 10-Q and Current Reports on Form 8-K, proxy statements
and other information with the SEC. In addition, the SEC maintains a website (www.sec.gov) that contains reports, proxy and information
statements, and other information regarding issuers that file electronically. New Silexion&#8217;s internet address is https://www.silexion.com.
The Company makes available, free of charge, its Annual Report on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K,
and all amendments to those reports as soon as reasonably practicable after such reports have been filed with or furnished to the SEC
through its internet website.</div>

<div style="text-align: justify; text-indent: 18pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: rgb(0, 0, 0); font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">108</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="text-align: center; line-height: 1.25"><span style="font-family: Times New Roman"><br/> </span> </div>

<div style="text-align: center; line-height: 1.25; font-weight: bold; font-family: Times New Roman"><!--Anchor--><span id="MANAGEMENT"><!--Anchor--></span>MANAGEMENT</div>

<div style="line-height: 1.25; font-weight: bold; font-family: Times New Roman">&#160;</div>

<div style="line-height: 1.25; font-weight: bold; font-family: Times New Roman">Management and Board of Directors</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif; font-weight: normal">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">Our board of directors (sometimes referred to as the &#8220;New
Silexion Board&#8221;) is comprised of the six directors listed below.</div> </div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif; font-weight: normal">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">Each director will hold office until his or her successor
is duly elected or appointed and qualified in accordance with applicable law or until his or her death, resignation or removal in accordance
with law and our governing documents, including our Amended and Restated Memorandum and Articles of Association (the &#8220;Articles&#8221;),
which went into effect upon the Closing of the Business Combination.</div> </div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">The following sets forth certain information known as
of the date hereof concerning the persons who currently serve as directors and executive officers of New Silexion (who have served as
such since the consummation of the Business Combination):</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z38579b82743b4bf19195dc9e7a65619a" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="border-bottom: #000000 2px solid; width: 43.99%; vertical-align: bottom">
        <div style="line-height: 1.25; font-weight: bold; font-family: Times New Roman">Name</div> </td>
    <td style="white-space: nowrap; width: 1%; vertical-align: bottom">
        <div style="line-height: 1.25; font-family: Times New Roman">&#160;</div> </td>
    <td style="border-bottom: #000000 2px solid; width: 8%; vertical-align: bottom">
        <div style="text-align: center; line-height: 1.25; font-weight: bold; font-family: Times New Roman">Age</div> </td>
    <td style="white-space: nowrap; width: 1%; vertical-align: bottom">
        <div style="line-height: 1.25; font-family: Times New Roman">&#160;</div> </td>
    <td style="border-bottom: #000000 2px solid; width: 46%; vertical-align: bottom">
        <div style="text-align: center; line-height: 1.25; font-weight: bold; font-family: Times New Roman">Position(s)</div> </td> </tr>
  <tr>
    <td style="width: 43.99%; vertical-align: top">
        <div style="line-height: 1.25; font-weight: bold; font-family: Times New Roman">Directors</div> </td>
    <td style="white-space: nowrap; width: 1%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">&#160;</div> </td>
    <td style="width: 8%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">&#160;</div> </td>
    <td style="white-space: nowrap; width: 1%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">&#160;</div> </td>
    <td style="width: 46%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">&#160;</div> </td> </tr>
  <tr>
    <td style="width: 43.99%; vertical-align: top; background-color: #CCEEFF">
        <div style="line-height: 1.25; font-family: Times New Roman">Ilan Hadar</div> </td>
    <td style="white-space: nowrap; width: 1%; vertical-align: top; background-color: #CCEEFF">
        <div style="line-height: 1.25; font-family: Times New Roman">&#160;</div> </td>
    <td style="width: 8%; vertical-align: top; background-color: #CCEEFF">
        <div style="text-align: center; line-height: 1.25; font-family: Times New Roman">55</div> </td>
    <td style="white-space: nowrap; width: 1%; vertical-align: top; background-color: #CCEEFF">
        <div style="line-height: 1.25; font-family: Times New Roman">&#160;</div> </td>
    <td style="width: 46%; vertical-align: top; background-color: #CCEEFF">
        <div style="line-height: 1.25; font-family: Times New Roman">Chairman and Chief Executive Officer</div> </td> </tr>
  <tr>
    <td style="width: 43.99%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">Dror J.&#160;Abramov</div> </td>
    <td style="white-space: nowrap; width: 1%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">&#160;</div> </td>
    <td style="width: 8%; vertical-align: top">
        <div style="text-align: center; line-height: 1.25; font-family: Times New Roman">63</div> </td>
    <td style="white-space: nowrap; width: 1%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">&#160;</div> </td>
    <td style="width: 46%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">Director</div> </td> </tr>
  <tr>
    <td style="width: 43.99%; vertical-align: top; background-color: #CCEEFF">
        <div style="line-height: 1.25; font-family: Times New Roman">Ruth Alon</div> </td>
    <td style="white-space: nowrap; width: 1%; vertical-align: top; background-color: #CCEEFF">
        <div style="line-height: 1.25; font-family: Times New Roman">&#160;</div> </td>
    <td style="width: 8%; vertical-align: top; background-color: #CCEEFF">
        <div style="text-align: center; line-height: 1.25; font-family: Times New Roman">72</div> </td>
    <td style="white-space: nowrap; width: 1%; vertical-align: top; background-color: #CCEEFF">
        <div style="line-height: 1.25; font-family: Times New Roman">&#160;</div> </td>
    <td style="width: 46%; vertical-align: top; background-color: #CCEEFF">
        <div style="line-height: 1.25; font-family: Times New Roman">Director</div> </td> </tr>
  <tr>
    <td style="width: 43.99%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">Ilan Levin</div> </td>
    <td style="white-space: nowrap; width: 1%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">&#160;</div> </td>
    <td style="width: 8%; vertical-align: top">
        <div style="text-align: center; line-height: 1.25; font-family: Times New Roman">58</div> </td>
    <td style="white-space: nowrap; width: 1%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">&#160;</div> </td>
    <td style="width: 46%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">Director</div> </td> </tr>
  <tr>
    <td style="width: 43.99%; vertical-align: top; background-color: #CCEEFF">
        <div style="line-height: 1.25; font-family: Times New Roman">Avner Lushi</div> </td>
    <td style="white-space: nowrap; width: 1%; vertical-align: top; background-color: #CCEEFF">
        <div style="line-height: 1.25; font-family: Times New Roman">&#160;</div> </td>
    <td style="width: 8%; vertical-align: top; background-color: #CCEEFF">
        <div style="text-align: center; line-height: 1.25; font-family: Times New Roman">57</div> </td>
    <td style="white-space: nowrap; width: 1%; vertical-align: top; background-color: #CCEEFF">
        <div style="line-height: 1.25; font-family: Times New Roman">&#160;</div> </td>
    <td style="width: 46%; vertical-align: top; background-color: #CCEEFF">
        <div style="line-height: 1.25; font-family: Times New Roman">Director</div> </td> </tr>
  <tr>
    <td style="width: 43.99%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">Shlomo Noy</div> </td>
    <td style="white-space: nowrap; width: 1%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">&#160;</div> </td>
    <td style="width: 8%; vertical-align: top">
        <div style="text-align: center; line-height: 1.25; font-family: Times New Roman">71</div> </td>
    <td style="white-space: nowrap; width: 1%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">&#160;</div> </td>
    <td style="width: 46%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">Director</div> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 43.99%; vertical-align: top; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25">Amnon Peled</div> </td>
    <td rowspan="1" style="white-space: nowrap; width: 1%; vertical-align: top; background-color: rgb(204, 238, 255)">&#160;</td>
    <td rowspan="1" style="width: 8%; vertical-align: top; text-align: center; background-color: rgb(204, 238, 255)">65<br/> </td>
    <td rowspan="1" style="white-space: nowrap; width: 1%; vertical-align: top; background-color: rgb(204, 238, 255)">&#160;</td>
    <td rowspan="1" style="width: 46%; vertical-align: top; background-color: rgb(204, 238, 255)">Director</td> </tr>
  <tr>
    <td style="width: 43.99%; vertical-align: top">
        <div style="line-height: 1.25; font-weight: bold; font-family: Times New Roman">Executive&#160;Officers&#160;(who&#160;are&#160;not&#160;also&#160;directors)</div>
        </td>
    <td style="white-space: nowrap; width: 1%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">&#160;</div> </td>
    <td style="width: 8%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">&#160;</div> </td>
    <td style="white-space: nowrap; width: 1%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">&#160;</div> </td>
    <td style="width: 46%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">&#160;</div> </td> </tr>
  <tr>
    <td style="width: 43.99%; vertical-align: top; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25; font-family: Times New Roman">Dr.&#160;Mitchell Shirvan</div> </td>
    <td style="white-space: nowrap; width: 1%; vertical-align: top; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25; font-family: Times New Roman">&#160;</div> </td>
    <td style="width: 8%; vertical-align: top; background-color: rgb(204, 238, 255)">
        <div style="text-align: center; line-height: 1.25; font-family: Times New Roman">70</div> </td>
    <td style="white-space: nowrap; width: 1%; vertical-align: top; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25; font-family: Times New Roman">&#160;</div> </td>
    <td style="width: 46%; vertical-align: top; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25; font-family: Times New Roman">Chief Scientific and Development Officer</div> </td> </tr>
  <tr>
    <td style="width: 43.99%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">Mirit Horenshtein Hadar, CPA</div> </td>
    <td style="white-space: nowrap; width: 1%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">&#160;</div> </td>
    <td style="width: 8%; vertical-align: top">
        <div style="text-align: center; line-height: 1.25; font-family: Times New Roman">40</div> </td>
    <td style="white-space: nowrap; width: 1%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">&#160;</div> </td>
    <td style="width: 46%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">EVP of Finance Affairs, Chief Financial Officer and Secretary</div> </td>
        </tr>
  </table>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman">&#160;</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman">Directors</div>

<div style="text-indent: 36pt; line-height: 1.25; font-weight: bold; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25"><span style="font-weight: bold; font-family: Times New Roman">Ilan Hadar</span><span style="font-family: Times New Roman">,&#160;55,<span style="font-weight: bold">&#160;</span>was
appointed as Chief Executive Officer of New Silexion, serving on a full-time&#160;basis, effective upon the Business Combination, and
has served as our (previously, Silexion&#8217;s) Chairman of the Board since May 2024. Previously, he served as Managing Director of Silexion
from April 2022 until the Business Combination. Mr. Hadar has over 20&#160;years of multinational managerial and corporate experience
with pharmaceutical and high-tech&#160;companies, as described below, over which time period he has acquired the experience and skills
to serve as a valuable member of the board of directors of a company such as Biomotion Sciences. In addition to his current role at Silexion,
Mr.&#160;Hadar has served as the Chief Executive Officer of Painreform Ltd (Nasdaq: PRFX) since November&#160;2020, a position he will
relinquish following the consummation of the Business Combination. Prior to joining Painreform and Silexion, Mr.&#160;Hadar served as
Country Manager Israel and Chief Financial Officer at Foamix Pharmaceuticals Ltd. (currently, Nasdaq: VYNE) from 2014 until August&#160;2020,
where he was instrumental in building the organization and launching new innovative topical drugs in the U.S., and also focused on capital
markets and mergers and acquisitions. Prior to his role at Foamix, Mr.&#160;Hadar was Finance Director at Pfizer PFR Pharmaceuticals Israel
Ltd., where he oversaw all commercial, financial and operational activities of the local entity of the large pharmaceutical company. Before
his tenure at Pfizer, Mr.&#160;Hadar served as Finance Manager at HP Indigo Ltd., a world-leading&#160;company in digital printing and,
prior to that, served as Finance Director at BAE Systems, the third-largest&#160;defense company in the world, where he was responsible
for all financial activities of BAE Systems Israel. From 1998 to 2006, Mr.&#160;Hadar was Chief Financial Officer at Mango DSP, a global
leader of Intelligent Video Solutions. Mr.&#160;Hadar served on the board of directors of Kadimastem, a public Israeli biopharmaceutical
company from 2019 to 2022. He received his MBA in Finance and Business Entrepreneurship and BA from The Hebrew University in Jerusalem,
Israel. We believe Mr.&#160;Hadar is qualified to serve on our board of directors due to his extensive knowledge as Silexion&#8217;s Managing
Director, and his extensive commercial, financial and managerial experience with high-tech&#160;and pharmaceutical companies, both private
and public.</span></div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: rgb(0, 0, 0); font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">109</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="text-indent: 36pt; line-height: 1.25; font-weight: bold; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25"><span style="font-weight: bold; font-family: Times New Roman">Dror J.&#160;Abramov,&#160;</span><span style="font-family: Times New Roman">63,
was appointed as a director of New Silexion effective upon the consummation of the Business Combination. Mr.&#160;Abramov&#8217;s experience
of over 15 years in multiple roles in changing and growing companies and markets within dynamic environments, and in particular his multi-disciplinary&#160;experience
in R&amp;D, consulting, taxes, sales, business development, finance and government, lend to his being an appropriate board member of Biomotion
Sciences. Mr.&#160;Abramov has served as Managing Director of Hewlett Packard Inc. Israel since 2015. Mr.&#160;Abramov held several other
management positions in Hewlett Packard Inc. Israel from 2006 to 2015, including finance director, general manager of imaging and printing
divisions and general manager of printing and personal systems division. From 2002 through 2006, Mr.&#160;Abramov served as Chief Financial
Officer of Applied Materials UK and Applied Materials Israel, both part of Applied Materials, Inc. (Nasdaq: AMAT), a nanomanufacturing
company that supplies equipment, services and software for the manufacture of semiconductor chips for electronics. From 2000 through 2002,
Mr.&#160;Abramov served as Vice President of business management at Avaya Communication, a cloud communications and workstream collaboration
technology company. From 1997 until 2000, Mr.&#160;Abramov held positions in Mainsoft Corporation, first as director of finance and operations
and later as general manager. From 1991 through 1997, Mr.&#160;Abramov served as consultant and manager at Maron, Sobel, Shor &amp; Co.,
an Israeli CPA firm. Mr.&#160;Abramov is a licensed CPA and holds a Bachelor of Accounting, Master of Business Administration and Bachelor
of Science in physics and computer sciences, all three degrees from Tel Aviv University. We believe Mr.&#160;Abramov is qualified to serve
on our board of directors due to his extensive financial and business management experience.</span></div>

<div style="text-indent: 36pt; line-height: 1.25; font-weight: bold; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25">

<div style="text-indent: 36pt; line-height: 1.25"><span style="font-weight: bold; font-family: Times New Roman">Ruth Alon</span><span style="font-family: Times New Roman">,&#160;72,<span style="font-weight: bold">&#160;</span>became
a director of New Silexion effective upon the consummation of the Business Combination. Ms. Alon&#8217;s international experience of over
30 years in the high-tech&#160;medical industry and with Israeli life sciences companies, in particular, make her a prospective valuable
member of the board of directors of Biomotion Sciences. Ms. Alon is the Founder and Chief Executive Officer of Medstrada, which was started
in 2016. From 1997 until 2016, Ms. Alon served as a General Partner in Pitango Venture Capital, where she headed the life sciences activities
and helped to facilitate the acquisition of several of the company&#8217;sportfolio companies. Currently, Ms. Alon also serves on the
board of directors of a number of private and public companies as a member or chairperson, including Vascular Biogenics Ltd. (Nasdaq:
VBLT), Brainsgate and KadimaStem. Ms. Alon previously worked on Wall Street where she held senior positions as a senior medical device
analyst with Montgomery Securities (from 1981 to 1987) and Kidder Peabody&#160;&amp; Co. (from 1987 to 1993). She also managed her own
independent consulting business in San Francisco from 1995 to 1996, providing broad-based&#160;services to early-stage&#160;companies
and venture capitalists in the medical devices industry. Ms. Alon was also instrumental in the establishment, in 2005, of Israel Life
Science Industry (ILSI), a not-for-profit&#160;organization which represented, as of 2005, the mutual goals of approximately 700 Israeli
life science companies. She is the Co-Founder&#160;of IATI, an umbrella organization established in 2012, representing Israel&#8217;s
High Tech and Life Sciences industries. Ms. Alon holds a B.A. in Economics from the Hebrew University of Jerusalem, an M.B.A. from Boston
University, and an M.Sc. from the Columbia University School of Physicians and Surgeons. We believe Ms. Alon is qualified to serve on
our board of directors given her above-described&#160;extensive experience in the high-tech&#160;medical industry and with Israeli life
sciences companies, in particular.</span></div> </div>

<div style="text-indent: 36pt; line-height: 1.25; font-weight: bold; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25"><span style="font-weight: bold; font-family: Times New Roman">Ilan Levin</span><span style="font-family: Times New Roman">,&#160;58,<span style="font-weight: bold; font-style: italic">&#160;</span>who
was the co-founder, Chairman and Chief Executive Officer of Moringa, was appointed as a director of New Silexion after its formation in
April 2024 and has continued as a director following the consummation of the Business Combination. Mr.&#160;Levin has been involved, for
approximately 25&#160;years, as an executive and venture capital/private equity investor in high-tech, Israel-related&#160;ventures. His
experience as an executive and board member in managing growth companies that develop technology, and his knowledge of that industry in
Israel in particular, suit him well to serve as a director of Biomotion Sciences. From 2000 to 2018, Mr.&#160;Levin was a member of the
Board and Executive Committee of Objet Ltd., which as a result of a merger with Stratasys, Inc. in 2012, formed Stratasys Ltd. (Nasdaq:
SSYS), the pioneer and global leader in 3D printing. During his tenure at Objet/Stratasys, Mr.&#160;Levin held various positions including
President, Vice Chairman and from 2016 to 2018, Chief Executive Officer. From 2004 to 2009, Mr.&#160;Levin was the Chief Executive Officer
of CellGuide, a developer of software-based&#160;GPS for mobile devices. Since 1997, Mr.&#160;Levin has also served as a member of the
board of directors and as an advisor for a wide variety of Israel-based&#160;technology-related&#160;companies, including currently serving
as Chairman of Vision Sigma (TLV:&#160;VISN: IT), an Israel-based&#160;real estate and investment company. Early in his career, Mr.&#160;Levin
was a practicing attorney focusing on corporate and securities related matters. In addition to his role as our Chairman and Chief Executive
Officer, Mr.&#160;Levin also serves as the sole director and sole equity owner of an Israeli company that serves as the sole general partner
of the Sponsor. Mr.&#160;Levin earned an LL.B. from Tel Aviv University and a B.A.Sc. in Industrial Engineering from the University of
Toronto. We believe Mr.&#160;Levin is qualified to serve on our board of directors given his above-described&#160;experience in managing
growth companies that develop technology, and his knowledge of that industry in Israel in particular.</span></div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: rgb(0, 0, 0); font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">110</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="text-indent: 36pt; line-height: 1.25; font-weight: bold; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25"><span style="font-weight: bold; font-family: Times New Roman">Avner Lushi</span><span style="font-family: Times New Roman">,&#160;57,<span style="font-weight: bold">&#160;</span>was
appointed as a director of New Silexion effective upon the consummation of the Business Combination. His experience of over 20 years and
skills acquired in his managing roles at an Israeli life sciences venture capital fund and in life sciences investment banking make him
suitable to provide similar support as a member of the board of directors of Biomotion Sciences. Mr.&#160;Lushi co-founded&#160;Guangzhou
Sino-Israel&#160;Bio-industry Investment Fund (GIBF), which currently includes two approximately $100&#160;million funds focused on introducing
Israeli and other foreign companies in the field of life sciences to the Chinese market, in which he also serves as a Managing Partner&#160;&amp;
CEO of the GP since 2016. From 2004 to 2015, Mr.&#160;Lushi served as a Partner and Managing Director of Israel Healthcare Ventures (IHCV),
a prominent Israeli life sciences venture capital fund. Before joining IHCV, Mr.&#160;Lushi was the Co-Founder&#160;&amp; CEO of Life
Sciences Transaction Support Ltd. (LTS), a PwC subsidiary dealing with life sciences investment banking. Since 2005, Mr.&#160;Lushi has
served as an independent director on the boards of nine public companies, including, currently, Brainsway Ltd. (Nasdaq: BWAY) and Ginegar
Plastic Products Ltd. In addition, he serves as a board member of several private companies as part of his role at GIBF.&#160;From 1997
to 2001, prior to turning to the private sector, he held increasingly senior roles within the Israeli Prime Minister&#8217;s Chamber and
the Israeli Supreme Court. Mr.&#160;Lushi holds an LLM in Law from the Hebrew University of Jerusalem, LLB in Law and a BA in Economics
from the Haifa University. We believe Mr.&#160;Lushi is qualified to serve on our board of directors due to his extensive executive and
board experience with life sciences companies.</span></div>

<div style="text-indent: 36pt; line-height: 1.25; font-weight: bold; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25"><span style="font-weight: bold; font-family: Times New Roman">Shlomo Noy</span><span style="font-family: Times New Roman">,
MD PhD,&#160;71,<span style="font-weight: bold">&#160;</span>was appointed as a director of New Silexion effective upon the consummation
of the Business Combination. Professor Noy&#8217;s international-level&#160;expertise in healthcare management, tech transfer, building
ecosystems and focusing hospitals on research and clinical trials will provide important knowledge to the Biomotion Sciences board of
directors in the realm of Israeli research and clinical trial activities. Professor Noy has served as Chief Medical Officer of GIBF since
January&#160;2017. Professor&#160;Noy served as the Director of&#160;the Rehabilitation Hospital at Sheba Medical Center from 1993 to
2017 and Vice President of Research and Development and Academic Affairs at Sheba Medical Center from 2000 to 2017. Prof. Noy was a Professor
at Sackler School of Medicine at Tel-Aviv&#160;University from 1993 to 2016. Prof.&#160;Noy serves as a board member of several private
companies as part of his role at GIBF. Prof. Noy&#160;possesses 25&#160;years&#8217; experience in health care management and is active
in promoting research and education at an Israeli national level as well as at an international level. Prof. Noy received his MD from
the Hebrew University, Hadassah Medical School, Jerusalem, Israel, and completed his MBA at the European School of Business Administration
(INSEAD) Fontainebleau, France, and holds a PhD degree from Tel-Aviv&#160;University, Faculty of Medicine and Management. We believe Mr.&#160;Noy
is qualified to serve on our board of directors due to his extensive medical and health care management experience.</span></div>

<div style="text-indent: 36pt; line-height: 1.25; font-weight: bold; font-family: Times New Roman">&#160;<span style="font-style: italic">&#160;</span></div>

<div style="line-height: 1.25; font-weight: 400; font-family: Times New Roman,Times,serif">

<div style="line-height: 1.25">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif"><span style="font-weight: bold">Amnon Peled</span>,
PhD, 65, was appointed as a director in December 2024. Professor Peled has served as an associate professor at Hadassah Medical Center,
Jerusalem since August 2000. Professor Peled also served as Director of the Gene Therapy Institute at Hadassah Medical Center from October
2021 to February 2024. He specializes in cytokine research, hematopoietic stem cell biology, inflammation, and cancer, leading the development
of therapies now in Phase II/III trials. Professor Peled served as Founder and CEO of Biokine Therapeutics, and as its Chief Scientific
Officer, from July 2000 to February 2024, where he advanced the CXCR4 antagonist BKT140/BL8040. Prof. Peled is an author of over 100 publications
and holder of 200+ patents and patent applications, and holds a Bachelor&#8217;s degree in agriculture from the Hebrew University of Jerusalem,
a Master&#8217;s degree in cell biology and histology from Tel Aviv University, and a Ph.D. from the Weizmann Institute. He completed
postdoctoral training at Harvard Medical School and the Weizmann Institute.</div> </div> </div>

<div style="text-indent: 36pt; line-height: 1.25; font-weight: bold; font-family: Times New Roman"><span style="font-style: italic"> <br/>
</span></div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman">Executive Officers</div>

<div style="text-indent: 36pt; line-height: 1.25; font-weight: bold; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25"><span style="font-weight: bold; font-family: Times New Roman">Mitchell Shirvan</span><span style="font-family: Times New Roman">,&#160;70,
has served as the Chief Scientific and Development Officer of New Silexion since the Business Combination, and, before the Business Combination,
of Silexion, since April&#160;2022. Prior to joining Silexion, Dr.&#160;Shirvan served as the Senior Vice President of R&amp;D and&#160;V.P.&#160;Innovation
and Discovery at Foamix Pharmaceuticals Ltd. from 2014 to 2019. Dr.&#160;Shirvan has over 25&#160;years of industry experience, previously
holding positions as Chief Executive Officer at Macrocure Ltd. from 2008 to 2012. From 1992 until 2008, Dr.&#160;Shirvan held various
positions of increasing responsibility at Teva Pharmaceutical Industries, including Senior Director, Strategic Business Planning and Senior
Manager, Research&#160;&amp; Development. Prior to his tenure at Teva, he was a research fellow at the U.S.&#160;National Institutes of
Health. Dr.&#160;Shirvan holds a Ph.D. in microbiology from The Hebrew University of Jerusalem and an MBA from the University of Bradford.</span></div>

<div style="text-indent: 36pt; line-height: 1.25; font-weight: bold; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25"><span style="font-weight: bold; font-family: Times New Roman">Mirit Horenshtein Hadar</span><span style="font-family: Times New Roman">,&#160;40,
has served as the Chief Financial Officer and Secretary of New Silexion since the Business Combination, and served as the Executive Vice
President of Finance Affairs at Silexion before the Business Combination, beginning in January&#160;2024. From August 2023 to January
2024, Ms. Horenshtein Hadar served as a part-time&#160;consultant in a Strategy &amp; Corporate Finance Advisory capacity. Ms. Horenshtein
Hadar has over 15&#160;years of corporate finance experience in senior financial positions of public companies and privately held companies,
in the pharmaceutical and high-tech&#160;industries, where she has been instrumental in building financial infrastructures for growth,
U.S. GAAP financial reporting and FP&amp;A functions, and has led the accounting and reporting of complex M&amp;A transactions, integration
processes and public offerings. Prior to joining Silexion, from January&#160;2021 to December&#160;2022, Ms. Horenshtein Hadar served
as VP of Finance and then CFO Israel of Gauzy Ltd. (currently, Nasdaq: GAUZ), a nanotechnology company that develops and markets smart
glass and vision control technologies. Since December&#160;2022, Ms. Horenshtein Hadar continues to serve as an external advisor to the
finance department at Gauzy. Prior to Gauzy, Ms. Horenshtein Hadar served as Senior Director of Finance and Head of FP&amp;A, Accounting
and Financial Reporting at Foamix Pharmaceuticals Ltd. (currently, Nasdaq: VYNE) from July&#160;2016 until December&#160;2020. Prior to
Foamix, Ms. Horenshtein Hadar was a Senior Manager at PwC Israel, as an external auditor, from 2008 to 2016. Ms. Horenshtein Hadar became
a Qualified CPA in 2011 and received a BA in Accounting, Economics and Business Management from Tel Aviv University.</span></div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: rgb(0, 0, 0); font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">111</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="line-height: 1.25; font-weight: bold; font-family: Times New Roman">&#160;</div>

<div style="line-height: 1.25; font-weight: bold; font-family: Times New Roman">Family Relationships</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">Mirit Horenshtein Hadar and Ilan Hadar are married to
one another. There are no other family relationships between the individuals who serve as directors and executive officers of the Company.</div>

<div style="line-height: 1.25; font-weight: bold; font-family: Times New Roman">&#160;</div>

<div style="line-height: 1.25; font-weight: bold; font-family: Times New Roman">Corporate Governance Practices</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman">&#160;</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman">Overall</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">The Company does not qualify as a &#8220;foreign private
issuer&#8221; under U.S.&#160;securities laws and is therefore not currently eligible to exempt itself from any of the Nasdaq listing
rule requirements in a manner that other non-U.S.&#160;issuers often do.</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman">&#160;</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman">Composition of the New Silexion Board
After the Business Combination</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">New Silexion&#8217;s business and affairs are managed
under the direction of the New Silexion Board. Under the terms of the Articles, the New Silexion Board may be composed of between three
and nine directors, as may be amended from time to time exclusively by ordinary resolution under Cayman Islands law, being a resolution
passed by a simple majority of the shareholders of New Silexion as, being entitled to do so, vote in person or by proxy at a general meeting
(an &#8220;<span style="font-weight: bold">Ordinary Resolution</span>&#8221;). The size of the New Silexion Board was set by our shareholders
as seven members effective upon the Closing. Ilan Hadar serves as Chairman of the New Silexion Board. Subsequent to the Closing, Ilan
Shiloah stepped down from the Board, citing competing demands on his time, thereby leaving the current size of the Board as six members.</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="line-height: 1.25; font-family: Times New Roman">Pursuant to the Articles, New Silexion&#8217;s directors are appointed by
an Ordinary Resolution at an annual general meeting. Unless the Board resolves that the election of nominees of the Board (referred to
as &#8220;<span style="font-weight: bold">Nominees</span>&#8221;) or of nominees of any shareholders entitled to present such nomination
(referred to as &#8220;<span style="font-weight: bold">Alternate Nominees</span>&#8221;) will be determined by plurality vote, the Nominees
or Alternate Nominees shall be appointed by Ordinary Resolution at the annual general meeting at which they are proposed for election.</div>
</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman">Officers</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">New Silexion&#8217;s Chief Executive Officer is responsible
for the company&#8217;s&#160;day-to-day&#160;management. The Chief Executive Officer is appointed by, and serves at the discretion of,
the New Silexion Board, subject to his employment agreement. All other executive officers are proposed for appointment by the Chief Executive
Officer, subject to approval by the New Silexion Board, and will be subject to the terms of any applicable employment or consulting agreements
that Silexion may enter into with them.</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman">&#160;</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman">Director Independence</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">Nasdaq listing standards require that a majority of the
New Silexion Board be independent. An &#8220;independent director&#8221; is defined generally as a person who has no material relationship
with the listed company (either directly or as a partner, shareholder or officer of an organization that has a relationship with the listed
company) that would interfere with the exercise of independent judgment in carrying out the responsibilities of a director. In making
these determinations, the New Silexion Board considers the current and prior relationships that each non-employee director has with the
Company and all other facts and circumstances the New Silexion Board deems relevant in determining their independence, including the beneficial
ownership of our securities by each non-employee&#160;director and the transactions described in the section titled &#8220;<span style="font-style: italic">Certain
Relationships and Related Party Transactions</span>.&#8221;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">The New Silexion Board has determined that
each of Messrs. Dror J. Abramov, Ilan Levin, Avner Lushi, Amon Peled and Shlomo Noy, and Ms. Ruth Alon, meets the definition of &#8220;independent
director&#8221; as defined in Nasdaq listing standards. For purposes of SEC rules applicable to members of the audit committee and compensation
committee, each of Messrs Abramov and Peled and Ms. Alon are deemed independent.</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif"> <br/> </div> </div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: rgb(0, 0, 0); font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">112</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman">&#160;</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman">Board Committees</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">The New Silexion Board has established an audit committee,
a compensation committee and a nominating and corporate governance committee, each of which has the composition and the responsibilities
described below. Each of these committees operates under a written charter, approved by the New Silexion Board and effective upon the
Closing, that satisfies the applicable Nasdaq rules, copies of which are available on the investor relations portion of our website. Members
will serve on these committees until their resignation or until otherwise determined by the New Silexion Board. The New Silexion Board
may establish other committees as it deems necessary or appropriate from time to time.</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman">&#160;</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman">Audit Committee</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">Our audit committee consists of Dror&#160;J.
Abramov, Amnon Peled and Ruth Alon, with Mr.&#160;Abramov serving as chair. Ilan Shiloah had served as the third member of the audit committee
from the Closing until his resignation from the New Silexion Board on September 16, 2024. Rule&#160;10A-3&#160;of the Exchange&#160;Act
and the Nasdaq listing standards require that our audit committee be composed entirely of independent members. The Nasdaq listing standards
require that the audit committee be composed of at least three members. With the resignation of Mr. Siloah from the New Silexion Board
and its audit committee, we will have until the earlier of our 2025 annual general meeting or one year after Mr. Shiloah&#8217;s resignation
to restore the size of the audit committee to three members. The New Silexion Board has determined that each of Messrs Abramov and Peled
and Ms. Alon meets the definition of &#8220;independent director&#8221; for purposes of serving on the audit committee under Rule&#160;10A-3&#160;of
the Exchange&#160;Act and the Nasdaq listing standards and also meets the financial literacy requirements of the Nasdaq listing standards.
In addition, the New Silexion Board has determined that Mr.&#160;Abramov qualifies as an &#8220;audit committee financial expert&#8221;
within the meaning of the SEC regulations.</div> </div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">The primary purpose of the audit committee is to discharge
the responsibilities of the New Silexion Board with respect to our corporate accounting and financial reporting processes, systems of
internal control and financial statement audits and to oversee our independent registered public accounting firm. The principal functions
of the audit committee include, among other things:</div>

<div style="text-indent: -36pt; margin-left: 48pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z9097d7be7db3435785b2ce03eaa9992a" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">helping the New Silexion Board oversee our corporate accounting and financial
        reporting processes;</div> </td> </tr>
  </table>

<div style="text-indent: -36pt; margin-left: 48pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: rgb(0, 0, 0); font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">113</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="text-align: center; line-height: 1.25"><span style="font-family: Times New Roman"><br/> </span> </div>

<table cellspacing="0" cellpadding="0" id="z861746bb0b4d4472890438d4b872976c" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">managing the selection, engagement, qualifications, independence, and performance
        of a qualified firm to serve as the independent registered public accounting firm to audit our financial statements;</div> </td> </tr>
  </table>

<div style="text-indent: -36pt; margin-left: 48pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<table cellspacing="0" cellpadding="0" id="zeb78c03ae18b44708f6987ab3efed940" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">reviewing and discussing the scope and results of the audit with the independent
        registered public accounting firm, and reviewing, with management and the independent accountants, our interim and year-end&#160;operating
        results;</div> </td> </tr>
  </table>

<div style="text-indent: -36pt; margin-left: 48pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<table cellspacing="0" cellpadding="0" id="ze7f4b14b20ff4606aa0e37052cc6022c" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">obtaining and reviewing a report by the independent registered public accounting
        firm at least annually that describes our internal quality control procedures, any material issues with such procedures and any steps
        taken to deal with such issues when required by applicable law;</div> </td> </tr>
  </table>

<div style="text-indent: -36pt; margin-left: 48pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<table cellspacing="0" cellpadding="0" id="zbacafa00026547878185f98d86ab4c19" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">establishing procedures for employees to submit concerns anonymously about
        questionable accounting or audit matters;</div> </td> </tr>
  </table>

<div style="text-indent: -36pt; margin-left: 48pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z58f04559fc3a43b9bda663ed05c9bd4d" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">overseeing our policies on risk assessment and risk management;</div> </td>
        </tr>
  </table>

<div style="text-indent: -36pt; margin-left: 48pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z1ed43727d6174fe99a74f86f68088aa2" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">overseeing compliance with our code of business conduct and ethics;</div>
        </td> </tr>
  </table>

<div style="text-indent: -36pt; margin-left: 48pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<table cellspacing="0" cellpadding="0" id="zc60acbed6fce473487013bef822296e0" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">reviewing related person transactions; and</div> </td> </tr>
  </table>

<div style="text-indent: -36pt; margin-left: 48pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z0b850dd1d4d3484b9572c78b9553a0a5" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">approving or, as required, pre-approving&#160;audit and permissible non-audit&#160;services
        to be performed by the independent registered public accounting firm.</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman">&#160;</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman">Compensation Committee</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">Our compensation committee consists of Dror
J. Abramov, Amon Peled and Ruth Alon. The chair of the compensation committee will be chosen from among the committee&#8217;s members.
The New Silexion Board has determined that each of Messrs.&#160;Abramov and Peled and Ms. Alon meets the definition of &#8220;independent
director&#8221; for purposes of serving on the compensation committee under the Nasdaq listing standards, including the heightened independence
standards for members of a compensation committee.</div> </div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">The primary purpose of our compensation committee is to
discharge the responsibilities of the New Silexion Board in overseeing our compensation policies, plans and programs and to review and
determine the compensation to be paid to our executive officers, directors and other senior management, as appropriate. The principal
functions of the compensation committee include, among other things:</div>

<div style="text-indent: -36pt; margin-left: 48pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<table cellspacing="0" cellpadding="0" id="zf1b59ab9a6e1453ca90625606a3be881" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">reviewing, approving and determining, or making recommendations to the New
        Silexion Board regarding the compensation of our chief executive officer, other executive officers and senior management;</div> </td>
        </tr>
  </table>

<div style="text-indent: -36pt; margin-left: 48pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z54ebd187c94c4941b9fb81d2c7d0ecd5" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">reviewing, evaluating and recommending to the New Silexion Board succession
        plans for our executive officers;</div> </td> </tr>
  </table>

<div style="text-indent: -36pt; margin-left: 48pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<table cellspacing="0" cellpadding="0" id="zb1f63e5f8fad4c54b0c375494d7f4bc5" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">reviewing and recommending to the New Silexion Board the compensation paid
        to our non-employee&#160;directors;</div> </td> </tr>
  </table>

<div style="text-indent: -36pt; margin-left: 48pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z17b20258efc748909326f44044ea699d" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">administering our equity incentive plans and other benefit programs;</div>
        </td> </tr>
  </table>

<div style="text-indent: -36pt; margin-left: 48pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<table cellspacing="0" cellpadding="0" id="zec03f6075b44422fa4dc3de384ab88eb" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">reviewing, adopting, amending and terminating incentive compensation and
        equity plans, severance agreements, profit sharing plans, bonus plans, change-of-control&#160;protections and any other compensatory arrangements
        for our executive officers and other senior management; and</div> </td> </tr>
  </table>

<div style="text-indent: -36pt; margin-left: 48pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<table cellspacing="0" cellpadding="0" id="zaf6370aaef4a42d4a7bfd3fd1cd78396" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">reviewing and establishing general policies relating to compensation and
        benefits of our employees, including our overall compensation philosophy.</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: rgb(0, 0, 0); font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">114</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold"> <span style="font-family: Times New Roman"><br/> </span> </div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman">Corporate Governance and Nominating
Committee</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">We have appointed a corporate governance
and nominating committee that currently consists of Dror J. Abramov, Ilan Levin, Amnon Peled and Ruth Alon. The chair of the committee
will be chosen from among the committee&#8217;s members. The New Silexion Board has determined that each of Messrs. Abramov, Peled and
Levin, and Ms. Alon, meets the definition of &#8220;independent director&#8221; under the Nasdaq listing standards.</div> </div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">Our corporate governance and nominating committee is responsible
for, among other things:</div>

<div style="text-indent: -36pt; margin-left: 48pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<table cellspacing="0" cellpadding="0" id="zf8302c0e876a440f80d7e0012d679246" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">identifying and evaluating candidates, including the nomination of incumbent
        directors for reelection and nominees recommended by shareholders, to serve on the New Silexion Board;</div> </td> </tr>
  </table>

<div style="text-indent: -36pt; margin-left: 48pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z7b4496a5d1d5446cb9645f601d319454" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">considering and making recommendations to the New Silexion Board regarding
        the composition and chairmanship of the committees of the New Silexion Board;</div> </td> </tr>
  </table>

<div style="text-indent: -36pt; margin-left: 48pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z26fabef288724e8ca0ee376c67630eba" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">instituting plans or programs for the continuing education of the New Silexion
        Board and the orientation of new directors;</div> </td> </tr>
  </table>

<div style="text-indent: -36pt; margin-left: 48pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z90ae751f13554c7c824da7e7d5644f06" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">developing and making recommendations to the New Silexion Board regarding
        corporate governance guidelines and matters;</div> </td> </tr>
  </table>

<div style="text-indent: -36pt; margin-left: 48pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<table cellspacing="0" cellpadding="0" id="zb1ed06d8d80545b28a94eee4837814bf" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">overseeing our corporate governance practices;</div> </td> </tr>
  </table>

<div style="text-indent: -36pt; margin-left: 48pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z65062a11e51c43bbb48bdd3558309060" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">overseeing periodic evaluations of the New Silexion Board&#8217;s performance,
        including committees of the New Silexion Board; and</div> </td> </tr>
  </table>

<div style="text-indent: -36pt; margin-left: 48pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z6112659489ea42579537598450d98f39" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">contributing to succession planning.</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman">&#160;</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman">Compensation Committee Interlocks
and Insider Participation</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">None of the members of Silexion&#8217;s compensation committee
is currently, or has been at any time, one of Silexion&#8217;s, Moringa&#8217;s or Silexion&#8217;s executive officers or employees. None
of our executive officers serves as a member of the board of directors or compensation committee (or other committee performing equivalent
functions) of any entity that had one or more executive officers serving on our board of directors or compensation committee during 2023.</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman">&#160;</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman">Code of Business Conduct and Ethics</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">Prior to the completion of the Business Combination, we
adopted a written code of business conduct and ethics that applies to our directors, officers and employees, including our principal executive
officer, principal financial officer, principal accounting officer or controller, or persons performing similar functions. A copy of the
code is posted on the investor relations portion of our website. In addition, we intend to post on our website all disclosures that are
required by law or Nasdaq listing standards concerning any amendments to, or waivers from, any provision of the code.</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: center; line-height: 1.25; font-weight: bold; font-family: Times New Roman"><!--Anchor-->EXECUTIVE <span id="COMPENSATION"><!--Anchor--></span>COMPENSATION</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;<span style="font-weight: bold">Silexion</span></div>

<div style="text-indent: 36pt; line-height: 1.25; font-style: italic; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-style: italic; font-family: Times New Roman">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif; font-style: italic">Unless the context requires
otherwise, references in this &#8220;Executive Compensation&#8221; section to &#8220;we,&#8221; &#8220;our,&#8221; &#8220;us&#8221; and
the &#8220;Company&#8221; generally refer to our company on a consolidated basis, for all periods following the completion of the Business
Combination (on August 15, 2024), and to our wholly-owned subsidiary, Silexion Therapeutics Ltd., an Israeli company (&#8220;Silexion&#8221;),
and its subsidiaries, for all periods prior to the completion of the Business Combination.</div> </div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: rgb(0, 0, 0); font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">115</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="line-height: 1.25; font-weight: bold; font-family: Times New Roman">&#160;</div>

<div style="line-height: 1.25; font-weight: bold; font-family: Times New Roman">Overview</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">The following tables and accompanying narrative
set forth information about the compensation, for 2024, provided to our chief executive officer (or person serving in an equivalent position)
and the two most highly compensated executive officers (other than our chief executive officer) who were serving as executive officers
as of December&#160;31, 2024, each of whom served as an executive officer of Silexion prior to the completion of the Business Combination.
These executive officers consist of: Ilan Hadar, who was Silexion&#8217;s Managing Director and now serves as New Silexion&#8217;s Chairman
and Chief Executive Officer; Mirit Horenshtein Hadar, who was Silexion&#8217;s EVP Finance and now serves as New Silexion&#8217;s Chief
Financial Officer; and Dr.&#160;Mitchell Shirvan, who was Silexion&#8217;s&#8212; and is now New Silexion&#8217;s&#8212; Chief Scientific
and Development Officer. These executive officers are referred to in this section as our &#8220;named executive officers&#8221; or &#8220;NEOs.&#8221;</div>
</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">This discussion may contain forward-looking&#160;statements
that are based on our current plans, considerations, expectations and determinations regarding future compensation programs, in the period
immediately following the Business Combination. Actual compensation programs that we adopt in the future may differ materially from the
plans summarized in this discussion.</div>

<div style="line-height: 1.25; font-weight: bold; font-family: Times New Roman">&#160;</div>

<div style="line-height: 1.25; font-weight: bold; font-family: Times New Roman">Summary Compensation Table</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">The following table presents summary information
regarding the total compensation for services rendered in all capacities that was awarded to, earned by, or paid to our named executive
officers for 2024.</div> </div>

<div style="text-indent: -36pt; margin-left: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif"> </div>

<div> <br/> </div>

<div>

<table cellspacing="0" cellpadding="0" border="0" class="cfttable" id="z866542dec24f4163bbde81cbf6b3b707" style="font: 10pt Times New Roman, Times, serif; text-align: left; color: #000000; width: 100%">
  <tr>
    <td style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; width: 42%">
        <div style="line-height: 1.25; font-weight: bold">Name and Principal Position</div> </td>
    <td colspan="1" style="vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px; width: 1%">&#160;</td>
    <td style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; width: 9%">
        <div style="text-align: center; line-height: 1.25; font-weight: bold">Year</div> </td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px; width: 1%">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom">
        <div style="text-align: center; line-height: 1.25; font-weight: bold">Base Gross<br/> Salary<br/> ($)<sup style="vertical-align: text-top; line-height: 1; font-size: smaller">(1)</sup></div>
        </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px; width: 1%">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px; width: 1%">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom">
        <div style="text-align: center; line-height: 1.25; font-weight: bold">Stock<br/> Awards<br/> ($)</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px; width: 1%">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px; width: 1%">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom">
        <div style="text-align: center; line-height: 1.25; font-weight: bold">All Other<br/> Compensation<br/> ($)<sup style="vertical-align: text-top; line-height: 1; font-size: smaller">(1)(2)</sup></div>
        </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px; width: 1%">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px; width: 1%">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom">
        <div style="text-align: center; line-height: 1.25; font-weight: bold">Total<br/> ($)<sup style="vertical-align: text-top; line-height: 1; font-size: smaller">(1)</sup></div>
        </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px; width: 1%">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; background-color: rgb(204, 238, 255); width: 42%">
        <div style="line-height: 1.25">Ilan Hadar<br/> <span style="font-style: italic">Chief Executive Officer (formerly Managing Director of
        Silexion)</span><sup style="vertical-align: text-top; line-height: 1; font-size: smaller">(3)</sup></div> </td>
    <td colspan="1" style="vertical-align: bottom; vertical-align: bottom; background-color: rgb(204, 238, 255); width: 1%">&#160;</td>
    <td style="vertical-align: bottom; vertical-align: bottom; background-color: rgb(204, 238, 255); width: 9%">
        <div style="text-align: center; line-height: 1.25">2024</div> </td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">240,560</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">1,192,785</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">107,283</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">1,540,628</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; width: 42%"><br/> </td>
    <td colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td style="vertical-align: bottom; vertical-align: bottom; width: 9%">
        <div style="text-align: center; line-height: 1.25">2023</div> </td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">182,976</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">-</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">70,638</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">253,614</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">&#160;</td> </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; width: 42%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25">Mirit Horenshtein Hadar<br/> <span style="font-style: italic">Chief Financial Officer (formerly EVP Finance
        of Silexion)</span><sup style="vertical-align: text-top; line-height: 1; font-size: smaller">(4)</sup></div> </td>
    <td colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align: bottom; vertical-align: bottom; width: 9%; background-color: rgb(204, 238, 255)">
        <div style="text-align: center; line-height: 1.25">2024</div> </td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25">233,532</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25">447,291</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25">89,267</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25">770,090</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; width: 42%">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td style="vertical-align: bottom; vertical-align: bottom; width: 9%">
        <div style="text-align: center; line-height: 1.25">2023</div> </td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">26,238</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">-</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">-</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">26,238</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">&#160;</td> </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; background-color: rgb(204, 238, 255); width: 42%">
        <div style="line-height: 1.25">Dr.&#160;Mitchell Shirvan<br/> <span style="font-style: italic">Chief Scientific and Development Officer</span><sup style="vertical-align: text-top; line-height: 1; font-size: smaller">(5)</sup></div>
        </td>
    <td colspan="1" style="vertical-align: bottom; vertical-align: bottom; background-color: rgb(204, 238, 255); width: 1%">&#160;</td>
    <td style="vertical-align: bottom; vertical-align: bottom; background-color: rgb(204, 238, 255); width: 9%">
        <div style="text-align: center; line-height: 1.25">2024</div> </td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">190,286</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">1,043,699</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">67,505</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">1,301,490</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; width: 42%">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td style="vertical-align: bottom; vertical-align: bottom; width: 9%">
        <div style="text-align: center; line-height: 1.25">2023</div> </td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">156,140</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">-</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">50,660</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">206,800</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">&#160;</td> </tr>
  </table> </div>

<div> <br/> </div>

<div>

<table cellspacing="0" cellpadding="0" id="zbe1743eacbae449389d57a786d13148d" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 3.81%; vertical-align: top">
        <div style="line-height: 1.25">(1)</div> </td>
    <td style="width: 96.19%; vertical-align: top">
        <div style="line-height: 1.25">Amounts reported for the named executive officer and paid in New Israeli Shekels are converted from New
        Israeli Shekels to U.S.&#160;dollars using the 2024 and 2023 (as applicable) average exchange rates as published by Bank of Israel of
        3.699 and 3.689 New Israeli Shekels, respectively, to 1 U.S.&#160;Dollar.</div> </td> </tr>
  <tr>
    <td style="width: 3.81%; vertical-align: top">
        <div style="line-height: 1.25">(2)</div> </td>
    <td style="width: 96.19%; vertical-align: top">
        <div style="line-height: 1.25">The amounts in this column include payments for a leased car or car maintenance, contributions to a pension
        fund, compensation fund, and continuing education fund, or payments in lieu of a continuing education fund.</div> </td> </tr>
  <tr>
    <td style="width: 3.81%; vertical-align: top">
        <div style="line-height: 1.25">(3)</div> </td>
    <td style="width: 96.19%; vertical-align: top">
        <div style="line-height: 1.25">This was for a part-time&#160;(75%) position prior to, and a full-time position following, completion of
        the Business Combination.</div> </td> </tr>
  <tr>
    <td style="width: 3.81%; vertical-align: top">
        <div style="line-height: 1.25">(4)</div> </td>
    <td style="width: 96.19%; vertical-align: top">
        <div style="line-height: 1.25">For 2023, Ms. Horenshtein Hadar&#8217;s compensation was for a period of 4.5&#160;months during which she
        served as a part-time&#160;consultant in a Strategy &amp; Corporate Finance Advisory capacity.</div> </td> </tr>
  <tr>
    <td style="width: 3.81%; vertical-align: top">
        <div style="line-height: 1.25">(5)</div> </td>
    <td style="width: 96.19%; vertical-align: top">
        <div style="line-height: 1.25">This was for a part-time&#160;(80%) position prior to, and a full-time position following, completion of
        the Business Combination.</div> </td> </tr>
  </table> </div>

<div> <br/> </div>

<div style="line-height: 1.25; font-weight: bold; font-family: Times New Roman">Narrative Disclosure to Summary Compensation Table</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman">&#160;</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman">Base Salary</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">The named executive officers receive base salaries to compensate
them for services rendered to us. The base gross salary payable to each named executive officer is intended to provide a fixed component
of compensation reflecting the executive&#8217;s skill set, experience, role, and responsibilities. The annual base salaries for Ilan
Hadar, Mirit Horenshtein Hadar and Dr.&#160;Mitchell Shirvan, for 2024 and 2023 were $1,540,628 and $253,614 for Mr. Hadar, $770,090 and
$26,238 for Ms. Horenshtein Hadar, and $1,301,490 and $206,800 for Dr. Shirvan, respectively.</div> </div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: rgb(0, 0, 0); font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">116</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman">&#160;</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold">Equity Compensation</div>

<div style="text-indent: 36pt; line-height: 1.25">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25">From time to time, we have granted equity awards under the Silexion Therapeutics Ltd.
2013 Equity Incentive Plan, which was replaced by the Silexion Therapeutics Ltd. 2023 Equity Incentive Plan (the &#8220;2013 Plan&#8221;
and &#8220;2023 Plan&#8221;, respectively, collectively referred to as the &#8220;Silexion Plans&#8221;), as incentives to attract, retain
and motivate our named executive officers. During 2024, we granted restricted share units (RSUs) that could be settled for 16,821, 6,308&#160;
and 14,718 ordinary shares of Silexion, to Ilan Hadar, Mirit Horenshtein Hadar, and Dr. Mitchell Shirvan, respectively (each such number
of Silexion ordinary shares does not reflect the exchange ratio in the Business Combination or the subsequent reverse share split of New
Silexion). The vesting of those RSUs accelerated upon the Closing of the Business Combination, entitling each such officer to receive
New Silexion ordinary shares in accordance with the exchange ratio upon the Closing.</div>

<div style="text-indent: 36pt; line-height: 1.25">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25">During 2022, Silexion granted 32,400 and 16,200 options to purchase Silexion ordinary
shares to Ilan Hadar and Dr.&#160;Mitchell Shirvan, respectively (each such number of options does not reflect the equity exchange ratio
in the Business Combination or the subsequent reverse share split of New Silexion). Vesting of those options was to occur over a period
of 48&#160;months, provided that Ilan Hadar or Dr.&#160;Mitchell Shirvan, as applicable, remains engaged by Silexion (or a Silexion affiliate),
and is subject to the Silexion<span style="font-weight: bold">&#160;</span>Plans. Upon consummation of an initial public offering of Silexion&#8217;s
securities or an M&amp;A Transaction (as defined in Silexion&#8217;s articles of association), which included the Business Combination,
the vesting of those options was to accelerate, such that all unvested options were to immediately vest, provided that such IPO or M&amp;A
Transaction was to be consummated after January&#160;1, 2023.</div>

<div style="line-height: 1.25"><br/> </div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold">Employment Agreements</div>

<div style="text-indent: 36pt; line-height: 1.25">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25">Following the Closing, Silexion has entered or will enter into employment agreements
with each of its NEOs.</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold">&#160;</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold">Silexion 2013 Equity Incentive Plan and Silexion 2023 Equity Incentive
Plan</div>

<div style="text-indent: 36pt; line-height: 1.25">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25">Silexion (and, following the Business Combination, New Silexion) has maintained the
Silexion Plans in order to provide additional incentives for employees, directors and consultants, and to provide incentives to attract,
retain and motivate eligible persons whose present and potential contributions are important to Silexion&#8217;s (and New Silexion&#8217;s)
success. The 2013 Plan was adopted on July&#160;25, 2013 and was replaced by the 2023 Plan, which was adopted on April&#160;4, 2023. For
a complete description of the 2013 Plan and the 2023 Plan, please see &#8220;<span style="font-style: italic">Silexion Share Incentive
Plans</span>&#8221; below.</div>

<div style="text-indent: 36pt; line-height: 1.25">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25">The Silexion Plans provide for grants of options to purchase ordinary shares of Silexion
(following the Business Combination, New Silexion), shares, restricted shares and RSUs. As described above, during 2022, Silexion granted
option awards under the Silexion Plans to Ilan Hadar and Dr.&#160;Mitchell Shirvan and during 2024, Silexion granted RSUs to Ilan Hadar,
Mirit Horenshtein Hadar, and Dr. Mitchell Shirvan, respectively.</div>

<div style="text-indent: 36pt; line-height: 1.25">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25">Immediately prior to the effective time of the Acquisition Merger, all outstanding Silexion
options and Silexion RSUs accelerated and became fully vested (and, in the case of RSUs, settled for underlying shares). At the effective
time of the Acquisition Merger, all Silexion options outstanding immediately prior to the Acquisition Merger automatically and without
any action on the part of any Silexion option holder or beneficiary thereof, were assumed by New Silexion, and each such Silexion option
was converted into an option to purchase New Silexion ordinary shares (based on the equity exchange ratio for Silexion under the Business
Combination Agreement).</div>

<div style="text-indent: 36pt; line-height: 1.25">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25">In addition, immediately prior to the completion of the Business Combination, New Silexion
adopted the 2024 Equity Incentive Plan (described below), which provides for the grant of equity-based&#160;incentive awards to its employees,
directors, office holders, service providers and consultants in order to incentivize them to increase their efforts on behalf of New Silexion
and to promote the success of New Silexion&#8217;s business.</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: rgb(0, 0, 0); font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">117</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="line-height: 1.25; font-weight: bold; font-family: Times New Roman">&#160;</div>

<div style="line-height: 1.25; font-weight: bold; font-family: Times New Roman">Outstanding Equity Awards at Fiscal Year-End</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">The following table provides information
regarding equity awards held by Silexion&#8217;s named executive officers that were outstanding as of December&#160;31, 2024. The awards
listed in this table were granted under the Silexion Plans, which are summarized above under &#8220;<span style="font-style: italic">&#8212;&#160;Narrative
Disclosure to Summary Compensation Table&#160;&#8212;&#160;Silexion 2013 Equity Incentive Plan and Silexion 2023 Equity Incentive Plan</span>.&#8221;</div>
</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="line-height: 1.25; font-family: Times New Roman">

<table cellspacing="0" cellpadding="0" id="zc293059ef4a34a139e11f74d52cc3b96" class="cfttable" style="font: 10pt Times New Roman, Times, serif; text-align: left; color: #000000; width: 100%">
  <tr>
    <td style="vertical-align: bottom; vertical-align: top; background-color: rgb(255, 255, 255); padding-bottom: 2px">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
    <td colspan="18" rowspan="1" style="vertical-align: bottom; border-bottom: #000000 2px solid; vertical-align: middle; background-color: rgb(255, 255, 255)">
        <div style="text-align: center; line-height: 1.25; font-family: Times New Roman,Times,serif; font-weight: bold">Option awards</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255); vertical-align: bottom; padding-bottom: 2px">&#160;</td>
        </tr>
  <tr>
    <td style="border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; background-color: rgb(255, 255, 255)">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">Name</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
    <td colspan="2" style="border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; background-color: rgb(255, 255, 255); text-align: center">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">Number of securities underlying unexercised options<br/> (#)
        exercisable</div> </td>
    <td colspan="1" class="cftfncell" style="white-space: nowrap; background-color: rgb(255, 255, 255); text-align: center; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; padding-bottom: 2px; text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; background-color: rgb(255, 255, 255); text-align: center">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">Number of securities<br/> underlying<br/> unexercised<br/>
        options<br/> (#) unexercisable</div> </td>
    <td colspan="1" class="cftfncell" style="white-space: nowrap; background-color: rgb(255, 255, 255); text-align: center; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; padding-bottom: 2px; text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; background-color: rgb(255, 255, 255); text-align: center">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">Equity<br/> incentive<br/> plan awards: Number of<br/> securities<br/>
        underlying<br/> unexercised<br/> unearned<br/> options<br/> (#)</div> </td>
    <td colspan="1" class="cftfncell" style="white-space: nowrap; background-color: rgb(255, 255, 255); text-align: center; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; padding-bottom: 2px; text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; background-color: rgb(255, 255, 255); text-align: center">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">Option<br/> exercise price<br/> ($)</div> </td>
    <td colspan="1" class="cftfncell" style="white-space: nowrap; background-color: rgb(255, 255, 255); text-align: center; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; padding-bottom: 2px; text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; background-color: rgb(255, 255, 255); text-align: center">
        <div style="line-height: 1.25"><span style="line-height: 1.25"> </span></div>
        <div style="line-height: 1.25"><span style="line-height: 1.25"> </span></div>
        <div style="line-height: 1.25"><span style="line-height: 1.25"> </span></div>
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">Option expiration date</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255); vertical-align: bottom; padding-bottom: 2px">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: middle; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25">Ilan Hadar<br/> <span style="font-style: italic">Chief Executive Officer (formerly Managing Director of
        Silexion</span></div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right">
        <div style="line-height: 1.25">14,339</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right">-</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; vertical-align: middle; background-color: rgb(204, 238, 255); text-align: right">-<br/> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right">
        <div style="line-height: 1.25">60.51</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; background-color: rgb(204, 238, 255); text-align: right">
        <div style="line-height: 1.25"><span style="line-height: 1.25"> </span></div>
        <div style="line-height: 1.25"><span style="line-height: 1.25"> </span></div>
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif; text-align: center">24/03/2032</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: middle; width: 40%">
        <div style="line-height: 1.25">Mirit Horenshtein Hadar<br/> <span style="font-style: italic">Chief Financial Officer (formerly EVP Finance
        of Silexion</span></div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">--</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">-</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">-</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">-</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25"><span style="line-height: 1.25"></span></div>
        <div style="line-height: 1.25"><span style="line-height: 1.25"></span></div>
        <div style="line-height: 1.25">-</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">&#160;</td> </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: middle; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25">Dr.&#160;Mitchell Shirvan<br/> <span style="font-style: italic">Chief Scientific and Development Officer</span><sup style="vertical-align: text-top; line-height: 1; font-size: smaller">(</sup></div>
        </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right">
        <div style="line-height: 1.25">7,170</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right">-</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; vertical-align: middle; background-color: rgb(204, 238, 255); text-align: right">-</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right">
        <div style="line-height: 1.25">60.51</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; background-color: rgb(204, 238, 255); text-align: right">
        <div style="line-height: 1.25"><span style="line-height: 1.25"> </span></div>
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif; text-align: center">07/06/2032</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom">&#160;</td>
        </tr>
  </table> </div>

<div style="line-height: 1.25; font-family: Times New Roman"> <br/> </div>

<div style="line-height: 1.25; font-weight: bold">Director Compensation</div>

<div style="line-height: 1.25"><br/> </div>

<table cellspacing="0" cellpadding="0" border="0" id="zadbe50c432dd402380bcc2ed3443392f" class="cfttable" style="font: 10pt Times New Roman,Times,serif; text-align: left; color: rgb(0, 0, 0); width: 100%">
  <tr>
    <td style="border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; background-color: rgb(255, 255, 255)">
        <div style="line-height: 1.25">Name</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
    <td colspan="2" style="border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; background-color: rgb(255, 255, 255); text-align: center">
        <div style="line-height: 1.25">Fees earned or paid in cash<br/> ($)</div> </td>
    <td colspan="1" class="cftfncell" style="white-space: nowrap; background-color: rgb(255, 255, 255); text-align: center; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; padding-bottom: 2px; text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; background-color: rgb(255, 255, 255); text-align: center">
        <div style="line-height: 1.25">Stock awards<br/> ($)</div> </td>
    <td colspan="1" class="cftfncell" style="white-space: nowrap; background-color: rgb(255, 255, 255); text-align: center; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; padding-bottom: 2px; text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; background-color: rgb(255, 255, 255); text-align: center">
        <div style="line-height: 1.25">Option awards<br/> ($)</div> </td>
    <td colspan="1" class="cftfncell" style="white-space: nowrap; background-color: rgb(255, 255, 255); text-align: center; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; padding-bottom: 2px; text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; background-color: rgb(255, 255, 255); text-align: center">
        <div style="line-height: 1.25">All other compensation<br/> ($)</div> </td>
    <td colspan="1" class="cftfncell" style="white-space: nowrap; background-color: rgb(255, 255, 255); text-align: center; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; padding-bottom: 2px; text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; background-color: rgb(255, 255, 255); text-align: center">
        <div style="line-height: 1.25">Total<br/> ($)</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255); vertical-align: bottom; padding-bottom: 2px">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; background-color: rgb(204, 238, 255); padding-bottom: 2px">
        <div style="line-height: 1.25">Ilan Hadar</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; background-color: rgb(204, 238, 255); text-align: center">
        <div style="line-height: 1.25"><span style="text-decoration: underline">See Summary Compensation Table above <br/> </span></div> </td>
    <td colspan="1" class="cftfncell" style="white-space: nowrap; background-color: rgb(204, 238, 255); text-align: center; vertical-align: bottom; padding-bottom: 2px"><br/>
        </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; padding-bottom: 2px; background-color: rgb(204, 238, 255); text-align: center"><br/>
        </td>
    <td colspan="2" style="vertical-align: bottom; background-color: rgb(204, 238, 255); text-align: center">
        <div style="line-height: 1.25"><span style="text-decoration: underline">See Summary Compensation Table above</span></div> </td>
    <td colspan="1" class="cftfncell" style="white-space: nowrap; background-color: rgb(204, 238, 255); text-align: center; vertical-align: bottom; padding-bottom: 2px"><br/>
        </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; padding-bottom: 2px; background-color: rgb(204, 238, 255); text-align: center"><br/>
        </td>
    <td colspan="2" style="vertical-align: bottom; background-color: rgb(204, 238, 255); text-align: center">
        <div style="line-height: 1.25"><span style="text-decoration: underline">See Summary Compensation Table above</span></div> </td>
    <td colspan="1" class="cftfncell" style="white-space: nowrap; background-color: rgb(204, 238, 255); text-align: center; vertical-align: bottom; padding-bottom: 2px"><br/>
        </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; padding-bottom: 2px; background-color: rgb(204, 238, 255); text-align: center"><br/>
        </td>
    <td colspan="2" style="vertical-align: bottom; background-color: rgb(204, 238, 255); text-align: center">
        <div style="line-height: 1.25"><span style="text-decoration: underline">See Summary Compensation Table above</span></div> </td>
    <td colspan="1" class="cftfncell" style="white-space: nowrap; background-color: rgb(204, 238, 255); text-align: center; vertical-align: bottom; padding-bottom: 2px"><br/>
        </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; padding-bottom: 2px; background-color: rgb(204, 238, 255); text-align: center"><br/>
        </td>
    <td colspan="2" style="vertical-align: bottom; background-color: rgb(204, 238, 255); text-align: center">
        <div style="line-height: 1.25"><span style="text-decoration: underline">See Summary Compensation Table above</span></div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; padding-bottom: 2px">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: middle; width: 40%; padding-bottom: 2px">
        <div style="line-height: 1.25; font-family: Times New Roman, Times, serif">Dror Abramov</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman, Times, serif">-</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 2px">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman, Times, serif">313,800</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 2px">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman, Times, serif">-</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 2px">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman, Times, serif">-</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 2px">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman, Times, serif">313,800</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 2px">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: middle; background-color: rgb(204, 238, 255); width: 40%; padding-bottom: 2px">
        <div style="line-height: 1.25; font-family: Times New Roman, Times, serif">Ruth Alon</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman, Times, serif">-</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; padding-bottom: 2px">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman, Times, serif">-</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; padding-bottom: 2px">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman, Times, serif">-</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; padding-bottom: 2px">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman, Times, serif">-</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; padding-bottom: 2px">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman, Times, serif">-</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; padding-bottom: 2px">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: middle; width: 40%; padding-bottom: 2px">
        <div style="line-height: 1.25; font-family: Times New Roman, Times, serif">Ilan Levin</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman, Times, serif">-</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 2px">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman, Times, serif">-</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 2px">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman, Times, serif">-</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 2px">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman, Times, serif">45,000</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 2px">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman, Times, serif">45,000</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 2px">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: middle; background-color: rgb(204, 238, 255); width: 40%; padding-bottom: 2px">
        <div style="line-height: 1.25; font-family: Times New Roman, Times, serif">Avner Lushi</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman, Times, serif">-</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; padding-bottom: 2px">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman, Times, serif">313,800</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; padding-bottom: 2px">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman, Times, serif">-</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; padding-bottom: 2px">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman, Times, serif">-</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; padding-bottom: 2px">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman, Times, serif">313,800</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; padding-bottom: 2px">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: middle; width: 40%; padding-bottom: 2px">
        <div style="line-height: 1.25; font-family: Times New Roman, Times, serif">Shlomo Noy</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman, Times, serif">-</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 2px">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman, Times, serif">313,800</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 2px">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman, Times, serif">-</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 2px">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman, Times, serif">-</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 2px">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman, Times, serif">313,800</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 2px">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: middle; background-color: rgb(204, 238, 255); width: 40%; padding-bottom: 2px">
        <div style="line-height: 1.25; font-family: Times New Roman, Times, serif">Amnon Peled</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman, Times, serif">-</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; padding-bottom: 2px">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman, Times, serif">-</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; padding-bottom: 2px">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman, Times, serif">-</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; padding-bottom: 2px">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman, Times, serif">-</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; padding-bottom: 2px">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman, Times, serif">-</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; padding-bottom: 2px">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: middle; width: 40%; padding-bottom: 2px">
        <div style="line-height: 1.25; font-family: Times New Roman, Times, serif">Ilan Shiloah (<span style="font-style: italic">former director</span>)</div>
        </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman, Times, serif">-</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 2px">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman, Times, serif">313,800</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 2px">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman, Times, serif">-</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 2px">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman, Times, serif">-</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 2px">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; font-family: Times New Roman, Times, serif">313,800</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 2px">&#160;</td>
        </tr>
  </table>

<div style="line-height: 1.25"><br/> </div>

<div style="text-indent: 36pt; line-height: 1.25">In the year ended December&#160;31, 2024, we did not pay any cash fees to, but we did
grant equity&#160;awards, consisting of 22,070 RSUs that could be settled for New Silexion ordinary shares (such number of RSUs reflects
the one-for-nine reverse share split of New Silexion), all of which became fully vested at the Closing, to&#160; each non-employee&#160;member
of our board of directors for his or her service as a director.</div>

<div style="line-height: 1.25; font-weight: bold">&#160;</div>

<div style="line-height: 1.25; font-weight: bold">New Silexion Executive Compensation</div>

<div style="text-indent: 36pt; line-height: 1.25">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25">Following the Closing, we are developing an executive compensation program that is designed
to align compensation with our business objectives and the creation of shareholder value, while enabling us to attract, retain, incentivize
and reward individuals who contribute to the long-term&#160;success of New Silexion. Decisions regarding the executive compensation program
will be made by our compensation committee.</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman"> <br/> </div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman">New Silexion Equity Compensation</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="line-height: 1.25; font-family: Times New Roman">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">It is anticipated that equity-based compensation
will continue to be an important element of executive compensation following the consummation of the Business Combination in order to
maintain a strong link between executive incentives and the creation of shareholder value. Upon the consummation of the Business Combination,
we granted 78,650 RSUs, in the aggregate, to directors of New Silexion and employees of New Silexion and its subsidiaries (of which 22,070
RSUs were granted to New Silexion directors) as a means of incentivizing them and aligning their interests with those of the shareholders
of the Company. We furthermore expect that the additional 63,953 New Silexion ordinary shares that will be available under the 2024 Equity
Incentive Plan (as referenced below) following the consummation of the Business Combination will be an important element of the new compensation
arrangements for New Silexion.</div> </div> </div>

<div style="line-height: 1.25; font-weight: bold; font-family: Times New Roman">&#160;</div>

<div style="line-height: 1.25; font-weight: bold; font-family: Times New Roman">Silexion Share Incentive Plans</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman">&#160;</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman">2013 Share Option Plan</div>

<div style="text-indent: 36pt; line-height: 1.25; font-style: italic; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25">

<div style="text-indent: 36pt; line-height: 1.25"><span style="font-style: italic">Shares Reserved under the 2013 Share Option Plan. </span>The
total number of authorized but unissued Silexion ordinary shares available for issuance under Silexion&#8217;s 2013 Share Option Plan
(the &#8220;<span style="font-weight: bold">2013 Plan</span>&#8221;) is 33,828 (which number does not reflect the exchange ratio in the
Business Combination or New Silexion&#8217;s one-for-nine reverse share split). Any option which has expired or has been cancelled, without
having been exercised in full, is available again for issuance under the 2013 Plan. Upon the termination of the 2013 Plan, any unissued
New Silexion ordinary shares available under the 2013 Plan shall cease to be reserved for the purpose of the 2013 Plan, other than New
Silexion ordinary shares underlying then-outstanding&#160;options under the 2013 Plan.</div> </div>

<div style="text-indent: 36pt; line-height: 1.25; font-style: italic; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25"><span style="font-style: italic; font-family: Times New Roman">Administration.&#160;&#160;&#160;&#160;</span><span style="font-family: Times New Roman">Our
board of directors, or a duly authorized compensation committee of the board of directors, has the power to administer the 2013 Plan.
Subject to applicable laws and the relevant provisions of the 2013 Plan, any member of the designated committee is eligible to receive
options under the 2013 Plan. The committee has the authority, subject to applicable law and our articles of association, to interpret
the terms of the 2013 Plan and any option agreements granted thereunder, designate participants in the 2013 Plan, determine and amend
the terms of respective option agreements, including the exercise price of an option, the fair market value of the New Silexion ordinary
shares, the time and vesting schedule applicable to the option, accelerate or amend the vesting schedule applicable to an option, prescribe
the forms of option agreement for use under the 2013 Plan and take all other actions and make all other determinations necessary for the
administration of the 2013 Plan.</span></div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: rgb(0, 0, 0); font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">118</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="text-indent: 36pt; line-height: 1.25; font-style: italic; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25"><span style="font-style: italic; font-family: Times New Roman">Eligibility.&#160;&#160;&#160;&#160;</span><span style="font-family: Times New Roman">The
2013 Plan provides for granting options under various tax regimes, including, without limitation, in compliance with Section&#160;102
or Section&#160;3(i)&#160;of the Israeli Tax Ordinance (the &#8220;<span style="font-weight: bold">Ordinance</span>&#8221;), and for awards
granted to Silexion&#8217;s United&#160;States employees or service providers, including those who are deemed to be residents of the United&#160;States
for tax purposes, Section&#160;422 of the U.S. Internal Revenue Code of 1986, as amended (the &#8220;<span style="font-weight: bold">Code</span>&#8221;)
and Section&#160;409A of the Code.</span></div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;<span style="font-style: italic">&#160;</span></div>

<div style="text-indent: 36pt; line-height: 1.25"><span style="font-style: italic; font-family: Times New Roman">Options.&#160;&#160;&#160;&#160;</span><span style="font-family: Times New Roman">All
options granted pursuant to the 2013 Plan are evidenced by an option agreement, in a form approved, from time to time, by the committee
in its sole discretion. The option agreement sets forth the terms and conditions of the number of shares to which the option relates and
the type of option granted thereunder, the purchase price per share and the vesting schedule to which such option shall become exercisable.</span></div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">Unless otherwise determined by the committee or the board
of directors and as stated in the option agreement, and subject to the conditions of the 2013 Plan, options become exercisable under the
following schedule: 25% of the shares covered by the option on the first anniversary of the date on which such option was granted and
12.5% of the shares covered by the option at the end of each subsequent six-month&#160;period during the second, third and fourth&#160;years
from the date of grant, with the committee and/or board of directors reserving the exclusive authority to accelerate the periods for exercising
an option.</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">Each option shall expire after ten&#160;years from the
date of the grant thereof, or five&#160;years with respect to incentive stock options unless a shorter term of expiration is otherwise
designated by the committee.</div>

<div style="text-indent: 36pt; line-height: 1.25; font-style: italic; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25"><span style="font-style: italic; font-family: Times New Roman">Grants.&#160;&#160;&#160;&#160;</span><span style="font-family: Times New Roman">The
2013 Plan provides for the grant of options (including incentive stock options and nonqualified stock options).</span></div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">Options granted under the 2013 Plan to Silexion employees
who are U.S.&#160;residents may qualify as &#8220;incentive stock options&#8221; within the meaning of Section&#160;422 of the Code, or
may be non-qualified&#160;stock options. The exercise price of an option may not be less than the par value of the shares (if the shares
bear a par value) for which such option is exercisable. The exercise price of an Incentive Stock Option may not be less than 100% of the
fair market value of the underlying share on the date of grant or such other amount as may be required pursuant to the Code, and in the
case of Incentive Stock Options granted to ten percent (10%) shareholders, not less than 110%.</div>

<div style="text-indent: 36pt; line-height: 1.25; font-style: italic; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25"><span style="font-style: italic; font-family: Times New Roman">Exercise.&#160;&#160;&#160;&#160;</span><span style="font-family: Times New Roman">An
option under the 2013 Plan may be exercised by providing us with a written notice of exercise and full payment of the exercise price for
such shares underlying the award, if applicable, in such form and method as may be determined by the committee and the trustee and permitted
by applicable law.</span></div>

<div style="text-indent: 36pt; line-height: 1.25; font-style: italic; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25"><span style="font-style: italic; font-family: Times New Roman">Transferability.&#160;&#160;&#160;&#160;</span><span style="font-family: Times New Roman">No
option shall be assignable, transferable or given as collateral or any right with respect to them given to any third party whatsoever,
and during the lifetime of the option-holder&#160;each and all of such option-holder&#8217;s rights to purchase New Silexion ordinary
shares thereunder shall be exercisable only by the option-holder.</span></div>

<div style="text-indent: 36pt; line-height: 1.25; font-style: italic; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25"><span style="font-style: italic; font-family: Times New Roman">Termination of Employment.&#160;&#160;&#160;&#160;</span><span style="font-family: Times New Roman">An
option may be exercised after the date of termination of option-holder&#8217;s service or employment with Silexion or any of its affiliates
or termination of an affiliate&#8217;s status as such only with respect to the number of options already vested and unexpired at the time
of such termination according to the vesting and expiration periods of the options set forth in the 2013 Plan, or under a different period
prescribed by the committee or by the board of directors and specified in relevant option agreement, provided however, that (i)&#160;such
termination is without cause, in which case the options shall be exercisable within not more than 90&#160;days from the effective date
of such termination, or (ii)&#160;such termination is the result of death or disability of the option-holder, in which case the options
shall be exercisable within 12&#160;months, and in the event of death, the option shall be exercisable by the option-holder&#8217;s estate,
all in accordance the 2013 Plan. If termination of employment or service is for cause, any outstanding unexercised option (whether vested
or non-vested), will immediately expire and terminate, and the option-holder&#160;shall not have any right in connection to such outstanding
options.</span></div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: rgb(0, 0, 0); font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">119</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="text-indent: 36pt; line-height: 1.25; font-style: italic; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25"><span style="font-style: italic; font-family: Times New Roman">Voting Rights.&#160;&#160;&#160;&#160;</span><span style="font-family: Times New Roman">Option-holders&#160;shall
not have any of the rights or privileges of shareholders of New Silexion in respect of any New Silexion ordinary shares purchasable upon
the exercise of any part of an option unless and until, following exercise in accordance with the terms of the 2013 Plan and the option,
registration of the option-holder&#160;as holder of such New Silexion ordinary shares in New Silexion&#8217;s register of members, but
in case of options and New Silexion ordinary shares held by the trustee, subject to the provisions of the 2013 Plan.</span></div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;<span style="font-style: italic">&#160;</span></div>

<div style="text-indent: 36pt; line-height: 1.25"><span style="font-style: italic; font-family: Times New Roman">Dividends.&#160;&#160;&#160;&#160;</span><span style="font-family: Times New Roman">With
respect to all New Silexion ordinary shares (in contrast to options not exercised for New Silexion ordinary shares) issued upon the exercise
of options purchased by an option holder, the option holder, as a shareholder of New Silexion shall be entitled to receive dividends in
accordance with the quantity of such New Silexion ordinary shares and the amended and restated memorandum and articles of association
of New Silexion, and subject to any applicable taxation on distribution of dividends.</span></div>

<div style="text-indent: 36pt; line-height: 1.25; font-style: italic; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25"><span style="font-style: italic; font-family: Times New Roman">Transactions.&#160;&#160;&#160;&#160;</span><span style="font-family: Times New Roman">If
the outstanding shares of New Silexion shall at any time be changed or exchanged by declaration of a dividend, split, share subdivision,
combination or exchange of shares, recapitalization, or any other like event of New Silexion, then in such event only and as often as
the same shall occur, the number, class and kind of New Silexion ordinary shares (including New Silexion ordinary shares issuable pursuant
to the 2013 Plan, in respect of which options have not yet been exercised) subject to the 2013 Plan or subject to any options granted
thereunder, and the purchase prices of the options, shall be appropriately and equitably adjusted so as to maintain the proportionate
number of New Silexion ordinary shares without changing the aggregate purchase price of the options.</span></div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">In the event of a merger or consolidation of New Silexion
or a sale of all, or substantially all, of our shares or assets or other transaction having a similar effect on New Silexion, or change
in the composition of the board of directors, or such other transaction or circumstances that the New Silexion Board determines to be
a relevant transaction, the merger agreement will provide for one or more of the following, without the consent of the option-holder:
(i)&#160;any outstanding option will be assumed or substituted by the successor corporation; (ii)&#160;the cancellation of such options
and a payment to the option-holder, as provided in the 2013 Plan; and (iii)&#160;the full exercisability of the option and full vesting
of the New Silexion ordinary shares subject to the option, followed by the cancellation of the option.</div> </div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman">&#160;</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman">2023 Equity Incentive Plan</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">The 2023 Equity Incentive (the&#160;<span style="font-weight: bold">&#8220;2023
Plan&#8221;</span>) was adopted by our board of directors in 2023. The purpose of the 2023 Plan is to provide equity-based&#160;incentive
awards in order to link the compensation and benefits of the individuals and entities providing services to Silexion or its affiliates
with the success of Silexion and long-term&#160;shareholder value. The 2023 Plan enabled Silexion to grant options to purchase ordinary
shares of Silexion (currently, following the Business Combination, New Silexion ordinary shares), restricted shares and restricted share
units, all of which are referred to as &#8220;awards&#8221;.</div> </div>

<div style="text-indent: 36pt; line-height: 1.25; font-style: italic; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25">

<div style="text-indent: 36pt; line-height: 1.25"><span style="font-style: italic; font-family: Times New Roman">Shares Available for
Grants.&#160;&#160;&#160;&#160;</span><span style="font-family: Times New Roman">The total number of shares available for issuance under
the 2023 Plan was determined from time to time by our board of directors, subject to certain adjustments as described in the 2023 Plan.
If any shares subject to awards under the 2023 Plan expires or otherwise terminates in accordance with the terms thereunder, such shares
shall become available for future grants thereunder.</span></div> </div>

<div style="text-indent: 36pt; line-height: 1.25; font-style: italic; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25">

<div style="text-indent: 36pt; line-height: 1.25"><span style="font-style: italic; font-family: Times New Roman">Administration.&#160;&#160;&#160;&#160;</span><span style="font-family: Times New Roman">our
board of directors (currently, following the Business Combination, the board of directors of New Silexion), or a duly authorized committee
of its board of directors (the&#160;<span style="font-weight: bold">&#8220;Administrator&#8221;</span>), is authorized to administer the
2023 Plan. Under the 2023 Plan, the Administrator has the authority, subject to applicable law, to interpret the terms of the 2023 Plan
and any award agreements or awards granted thereunder, designate recipients of awards, determine and amend the terms of awards, including
the number of awards granted, the exercise price of an award, the time and vesting schedule applicable to an award or the method of payment
for an award, accelerate or amend the vesting schedule applicable to an award, prescribe the forms of agreement for use under the 2023
Plan and take all other actions and make all other determinations necessary for the administration of the 2023 Plan.</span></div> </div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">The Administrator also has the authority to determine
the circumstances under which awards may be settled, cancelled, forfeited, exchanged, or surrendered under and in accordance with the
2023 Plan of any or all awards or shares, and the authority to prescribe, amend and rescind rules and regulations relating to the 2023
Plan, including the form of award agreements and rules governing the grant of awards in jurisdictions in which Silexion or any affiliate
operate, or to terminate the 2023 Plan at any time before the date of expiration of its ten-year&#160;term, provided that such termination
shall not materially affect the rights of grantees, to whom awards have already been granted.</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: rgb(0, 0, 0); font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">120</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="text-indent: 36pt; line-height: 1.25; font-style: italic; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25"><span style="font-style: italic; font-family: Times New Roman">Eligibility.&#160;&#160;&#160;&#160;</span><span style="font-family: Times New Roman">The
2023 Plan provides for granting awards under the Israeli tax regime, including compliance with Section&#160;102 or Section&#160;3(i)&#160;of
the Ordinance.</span></div>

<div style="text-indent: 36pt; line-height: 1.25; font-style: italic; font-family: Times New Roman">&#160;&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25"><span style="font-style: italic; font-family: Times New Roman">Grants.&#160;&#160;&#160;&#160;</span><span style="font-family: Times New Roman">All
awards granted pursuant to the 2023 Plan are evidenced by an award letter, in a form approved, from time to time, by the administrator
in its sole discretion. The award letter sets forth the terms and conditions of the award, including the type of award, number of shares
subject to such award, vesting schedule and conditions (including performance goals or measures) and the exercise price, if applicable.</span></div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">Unless otherwise determined by the Administrator and stated
in the award letter, and subject to the conditions of the 2023 Plan, awards vest and become exercisable under the following schedule:
25% of the shares covered by the award on the first anniversary of the vesting commencement date determined by the Administrator (and
in the absence of such determination, the date on which such award was granted) and the remaining 75% of the award shall vest (equally)
on a quarterly basis, over 12 quarters as of the commencement date&#8217;s first annual anniversary; provided that the grantee remains
continuously as an employee or provides services to Silexion throughout such vesting dates.</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">Each award will expire ten&#160;years from the date of
the grant thereof, unless a shorter term of expiration is otherwise designated by the Administrator.</div>

<div style="text-indent: 36pt; line-height: 1.25; font-style: italic; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25"><span style="font-style: italic; font-family: Times New Roman">Awards.&#160;&#160;&#160;&#160;</span><span style="font-family: Times New Roman">The
2023 Plan provides for the grant of options, shares, restricted shares, RSUs, and other share-based&#160;awards.</span></div>

<div style="text-indent: 36pt; line-height: 1.25; font-style: italic; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25"><span style="font-style: italic; font-family: Times New Roman">Exercise.&#160;&#160;&#160;&#160;</span><span style="font-family: Times New Roman">An
award under the 2023 Plan may be exercised by providing Silexion (currently, New Silexion) a written notice of exercise and full payment
of the exercise price for such shares underlying the award, if applicable, in such form and method as may be determined by the Administrator
and permitted by applicable law. The 2023 Plan allows for a net exercise of awards (as may be included in the award letter or otherwise
approved by the Administrator). An award may not be exercised for a fraction of a share.</span></div>

<div style="text-indent: 36pt; line-height: 1.25; font-style: italic; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25"><span style="font-style: italic; font-family: Times New Roman">Transferability.&#160;&#160;&#160;&#160;</span><span style="font-family: Times New Roman">No
person other than the grantee shall have any right with respect to any award granted under the 2023 Plan. No transfer of any right to
any award or its underlying shares, by will or by the laws of descent, shall effectively bind Silexion (currently, New Silexion) unless
and until furnished with the certain signed and notarized documents, as described in the 2023 Plan.</span></div>

<div style="text-indent: 36pt; line-height: 1.25; font-style: italic; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25"><span style="font-style: italic; font-family: Times New Roman">Termination of Engagement.&#160;&#160;&#160;&#160;</span><span style="font-family: Times New Roman">In
the event of termination of a grantee&#8217;s employment or service with Silexion or any of its affiliates, for any reason other than
death, retirement, disability or cause, any vested and unexercised awards held by such grantee as of the date of termination may be exercised
within 90-days&#160;after such date of termination, unless otherwise determined by the Administrator, but in no event later than the date
of expiration of the award as set forth in the award letter. After such 90-days&#160;period, all such unexercised awards will terminate
and the shares covered by such awards become available for issuance under the 2023 Plan.</span></div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">In the event of termination of a grantee&#8217;s employment
or service with Silexion or any of its affiliates due to such grantee&#8217;s death, retirement or permanent disability, any vested but
unexercised awards shall be exercisable (a)&#160;in the case of death, by such grantee&#8217;s estate, personal representative or beneficiary,
or (b)&#160;in the case of retirement or Disability, by such grantee or his/her personal representative (as the case may be), until the
earlier of (i)&#160;180&#160;days following the date of termination for any such reason; or (ii)&#160;the date of expiration of each such
as set forth in the award letter. All such grantee&#8217;s other awards shall expire upon the date of such termination.</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">Notwithstanding any of the foregoing, if a grantee&#8217;s
employment or services with Silexion or any of its affiliates is terminated for &#8220;cause&#8221; (as defined in the 2023 Plan), all
outstanding awards held by such grantee (whether vested or unvested) shall expire. With respect to any and all shares owned by such grantee
pursuant to the exercise of any and all awards granted under the 2023 Plan, the board of directors of Silexion may convert such shares
into deferred shares of Silexion.</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: rgb(0, 0, 0); font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">121</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="text-indent: 36pt; line-height: 1.25; font-style: italic; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25">

<div style="text-indent: 36pt; line-height: 1.25"><span style="font-style: italic; font-family: Times New Roman">Voting Rights.&#160;&#160;&#160;&#160;</span><span style="font-family: Times New Roman">Until
consummation of our initial public offering (or equivalent transaction, such as the Business Combination), shares underlying awards held
by grantees or the trustee, as applicable, were to be voted by an irrevocable proxy assigned to a person appointed by the board of directors.</span></div>
</div>

<div style="text-indent: 36pt; line-height: 1.25; font-style: italic; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25"><span style="font-style: italic; font-family: Times New Roman">Dividends.&#160;&#160;&#160;&#160;</span><span style="font-family: Times New Roman">Grantees
holding shares issuable or issued upon exercise of awards granted under the 2023 Plan will, as a shareholder of New Silexion, be entitled
to receive dividends and other distributions with respect to the underlying shares.</span></div>

<div style="text-indent: 36pt; line-height: 1.25; font-style: italic; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25"><span style="font-style: italic; font-family: Times New Roman">Transactions.&#160;&#160;&#160;&#160;</span><span style="font-family: Times New Roman">In
the event of any division or subdivision of Silexion&#8217;s (currently, New Silexion&#8217;s) issued and outstanding share capital, any
distribution of bonus shares (share split or subdivision), consolidation or combination of the share capital (reverse share split), reclassification
of the shares or any similar recapitalization event, as well as any reorganization, merger, consolidation, split-up, spin-off, combination,
repurchase, or exchange of the shares or other securities of Silexion (currently, New Silexion), or any other change in Silexion&#8217;s
(currently, New Silexion&#8217;s) corporate structure affecting the shares, the administrator may, in order to prevent diminution or enlargement
of the benefits or potential benefits intended to be made available under the 2023 Plan, adjust (A)&#160;the number and class of shares
that may be issued under the 2023 Plan; (B)&#160;the number, class, and exercise price of underlying shares for each outstanding award;
(C)&#160;any other term of the awards that in the administrator&#8217;s opinion should be adjusted (including those concerning the vesting,
exercisability and term of outstanding awards); provided, that no adjustment shall be made by reason of the distribution of subscription
rights (rights offering) on outstanding shares.</span></div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">Upon any such adjustment, references herein to shares
and underlying shares shall be construed to mean those shares of Silexion (currently, New Silexion) subject to the 2023 Plan as determined
by the Administrator following such adjustment. Any fractional shares resulting from such adjustment shall be rounded down to the nearest
whole number of share and Silexion (currently, New Silexion) shall have no obligation to make any cash or other payment with respect to
such fractional shares. The adjustments shall be made by the Administrator. If the applicable awards or underlying shares are deposited
with a trustee, all of the shares formed by such adjustments shall also be deposited with the trustee on the same terms as such awards
or underlying shares.</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">In the event of a merger, reorganization or consolidation
of Silexion (currently, New Silexion) with or into another incorporated entity, or its acquisition by another incorporated entity by means
of any transaction or series of related transactions, except any such merger, reorganization or consolidation in which the issued shares
of Silexion (currently, New Silexion) as of immediately prior to such transaction continue to represent, or are converted into or exchanged
for shares that represent, immediately following such merger, reorganization, or consolidation, at least a majority, by voting power,
of the outstanding shares of the surviving or acquiring incorporated entity; or a sale of all, or substantially all, of our shares or
assets or other transaction having a similar effect on our company, or change in the composition of the board of directors, or liquidation
or dissolution, or such other transaction or circumstances that our board of directors determines to be a relevant transaction, then without
the consent of the grantee, (i)&#160;unless otherwise determined by the Administrator, any outstanding award will be assumed or substituted
by such successor corporation or substituted by our company or by any affiliate of the successor corporation, as determined by the Administrator,
and (ii)&#160;regardless of whether or not the award is assumed or substituted, the Administrator may:</div>

<div style="text-indent: -36pt; margin-left: 48pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z7545a129dda14c6da0959f652a9d7dc8" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">(a)</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">entitle a grantee to exercise an award, or to otherwise provide for the acceleration
        of such award&#8217;s vesting schedule, as to all or part of its underlying shares, including with respect to awards that would not otherwise
        be exercisable or vested, under such terms and conditions as the Administrator shall determine, including the cancellation of all unexercised
        awards upon or immediately prior to the closing of a transaction or as of such other date (the&#160;<span style="font-weight: bold">&#8220;Cut-Off&#160;Date&#8221;</span>),
        and/or the termination of all awards (whether vested but un-exercised&#160;or un-vested) as of the relevant Cut-Off&#160;Date, as of which
        they shall no longer be exercisable by the applicable grantees; and/or</div> </td> </tr>
  </table>

<div style="text-indent: -36pt; margin-left: 48pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<table cellspacing="0" cellpadding="0" id="za395e52441ed4da6a979e449547526da" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">(b)</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">provide for the cancellation of outstanding awards at or immediately prior
        to the closing of a transaction, and payment to the applicable grantee of a consideration determined by the Administrator to be fair in
        the circumstances (whether in shares, cash, other securities, property, or any combination thereof), taking into account the value of
        each underlying share of any such award&#8217;s vested portion as reflected by the terms of such transaction, and the exercise price of
        each such underlying share, and subject to such terms and conditions as determined by the Administrator.</div> </td> </tr>
  </table>

<div style="text-indent: 24.1pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 24.1pt; line-height: 1.25; font-family: Times New Roman">The Administrator shall have full authority to select
the method for determining the payment to the grantees, as well as to set such payment to zero, with respect to underlying shares valued
at less than their exercise price or to those of awards that would not otherwise be exercisable or vested, or to determine that such payment
be made only in excess of the exercise price.</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: rgb(0, 0, 0); font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">122</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="line-height: 1.25">

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div> </div>

<div style="line-height: 1.25">

<div style="line-height: 1.25; font-weight: bold; font-family: Times New Roman">New Silexion Share Incentive Plans</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman">&#160;</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman">2024 Equity Incentive Plan</div> </div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">Pursuant to written resolutions adopted by our board of
directors and shareholders prior to the Closing, we have approved and adopted the 2024 Equity Incentive Plan (the &#8220;<span style="font-weight: bold">2024
Plan</span>&#8221;), which became effective immediately upon the Closing.</div> </div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="line-height: 1.25; font-family: Times New Roman">Upon the Closing, a total of 63,953 New Silexion ordinary shares were reserved
for issuance under the terms of the 2024 Plan, which, together with New Silexion ordinary shares allocated for issuance under the existing
2013 Plan and 2023 Plan, equaled 10% of the total number of New Silexion ordinary shares on a fully diluted basis immediately following
the Closing. A summary of the other material terms of the 2024 Incentive Plan is provided below:</div> </div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-style: italic; font-family: Times New Roman">Administration</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">The compensation committee of our board of directors is
the administrator of the 2024 Plan. Except as provided otherwise under the 2024 Plan, the administrator has plenary authority to grant
awards pursuant to the terms of the 2024 Plan to eligible individuals, determine the types of awards and the number of shares covered
by the awards, establish the terms and conditions for awards and take all other actions necessary or desirable to carry out the purpose
and intent of the 2024 Plan.</div>

<div style="text-indent: 36pt; line-height: 1.25; font-style: italic; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-style: italic; font-family: Times New Roman">Eligibility and Participation</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">The administrator selects the individuals who participate
in the 2024 Plan. Eligibility to participate is open to officers, directors and employees of, and other individuals who provide bona fide
services to or for, us or any of our subsidiaries. Our board of directors may also select as participants prospective officers, employees
and individual service providers who have accepted an offer of employment or another service relationship from us or one of our subsidiaries.
Any awards granted to such a prospect before the individual&#8217;s start date may not become vested or exercisable, and no shares may
be issued to such individual, before the date the individual first commences performance of services with us.</div>

<div style="text-indent: 36pt; line-height: 1.25; font-style: italic; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-style: italic; font-family: Times New Roman">Share Pool Under the 2024 Plan</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="line-height: 1.25; font-family: Times New Roman">The initial number of New Silexion ordinary shares allocated to the 2024
Plan is 63,953. The number of New Silexion ordinary shares available under the 2024 Plan (the &#8220;<span style="font-weight: bold">Share
Pool</span>&#8221;) will be subject to the following annual allocations and adjustments:</div> </div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">The Share Pool will be increased automatically on January
1 of each calendar year, beginning on January 1, 2025 and for each of the subsequent nine calendar years, through (and including) January
1, 2034, in an amount equal to the lesser of (i) 5% of the number of New Silexion ordinary shares issued and outstanding as of that January
1 date, or (ii) an amount determined by our board of directors prior to such date.</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">The following additional rules apply to the number of
New Silexion ordinary shares available under the Share Pool on an ongoing basis:</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z4e6255e6eb584a64a85fbddac5aea7a6" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">&#160;</div> </td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">The Share Pool will be reduced by one share for each share made subject to
        an award granted under the 2024 Plan;</div> </td> </tr>
  <tr>
    <td style="width: 7.69%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">&#160;</div> </td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">&#160;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">&#160;</div> </td> </tr>
  <tr>
    <td style="width: 7.69%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">&#160;</div> </td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">The Share Pool will be increased by the number of unissued shares underlying
        or used as a reference measure for any award or portion of an award granted under the 2024 Plan that is cancelled, forfeited, expired,
        terminated unearned or settled in cash, in any such case without the issuance of shares;</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z91808c1c92b84b0d9c5e0375ba939007" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">The Share Pool will be increased by the number of shares that are forfeited
        back or surrendered for no consideration to us after issuance due to a failure to meet an award contingency or condition with respect
        to any award or portion of an award granted under the 2024 Plan;</div> </td> </tr>
  </table>

<div style="text-align: center; line-height: 1.25"><span style="font-family: Times New Roman"><br/> </span> </div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: rgb(0, 0, 0); font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">123</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z026645a89cca43b4a9c855557185fa5e" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">The Share Pool shall be increased, on the exercise date, by the number of
        shares withheld by or surrendered (either actually or through attestation) to the Company in payment of the exercise price of any award
        granted under the 2024 Plan; and</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z514abefe64364b72a07fe43449788ea0" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">The Share Pool shall be increased, on the relevant date, by the number of
        shares withheld by or surrendered (either actually or through attestation) to the Company in payment of any tax withholding obligation
        that arises in connection with any award granted under the 2024 Plan.</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">In the event of a merger, consolidation, share rights
offering, statutory share exchange or similar event affecting the Company or a share dividend, share split, reverse share split, separation,
spinoff, reorganization, extraordinary dividend of cash or other property, share combination or subdivision, or recapitalization or similar
event affecting the capital structure of the Company, our board of directors will make equitable and appropriate substitutions or proportionate
adjustments to the Share Pool to reflect the transaction or event. Similar adjustments will be made to the award limitations described
below and to the terms of outstanding awards.</div>

<div style="line-height: 1.25; font-style: italic; font-family: Times New Roman">&#160;</div>

<div style="line-height: 1.25; font-style: italic; font-family: Times New Roman">ISO Award Limit</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="line-height: 1.25; font-family: Times New Roman">The maximum number of New Silexion ordinary shares that may be issued in
connection with awards granted under the 2024 Plan that are intended to qualify as incentive stock options under Section 422 of the Code
is 63,953.</div> </div>

<div style="line-height: 1.25; font-style: italic; font-family: Times New Roman">&#160;</div>

<div style="line-height: 1.25; font-style: italic; font-family: Times New Roman">Types of Awards</div>

<div style="line-height: 1.25; font-style: italic; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25"><span style="font-style: italic; font-family: Times New Roman">General</span><span style="font-family: Times New Roman">.
The 2024 Plan enables the grant of share awards, performance shares, restricted share units, cash-based performance units, other share-based
awards, share options, share appreciation rights, and share unit awards, each of which may be granted separately or in tandem with other
awards. The administrator may establish sub-plans under the 2024 Plan under which awards that qualify for preferred tax treatment for
recipients in jurisdictions outside the U.S. may be granted.</span></div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">We have adopted a sub-plan for Israeli participants, which
provides for granting awards in compliance with Section 102 (&#8220;<span style="font-weight: bold">Section 102</span>&#8221;) and Section
3(i) of the Israeli Income Tax Ordinance (New Version), 5721-1961, as amended (the &#8220;<span style="font-weight: bold">ITO</span>&#8221;).
Section 102 allows employees, directors and officers who are not controlling shareholders and who are considered Israeli residents for
tax purposes to receive favorable tax treatment for compensation in the form of shares, options or certain other types of equity awards,
subject to certain terms and conditions. Our non-employee service providers and controlling shareholders who are considered Israeli residents
for tax purposes may be granted awards under Section 3(i) of the ITO, which do not provide for similar tax benefits as Section 102.</div>
</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">Out of the three tax tracks that are available under Section
102 ((i) the &#8220;ordinary income track&#8221; with a trustee, (ii) the &#8220;capital gains track&#8221; with a trustee and (iii) grants
without a trustee and without a trust period), we have elected the &#8220;capital gain track&#8221; for grants to eligible Israeli grantees
as provided above, which may allow favorable tax treatment for such grantees.</div> </div>

<div style="text-indent: 36pt; line-height: 1.25"> <span style="font-family: Times New Roman"><br/> </span> </div>

<div style="line-height: 1.25; font-style: italic; font-family: Times New Roman">Adjustments to Awards for Corporate Transactions and
Other Events</div>

<div style="line-height: 1.25; font-style: italic; font-family: Times New Roman">&#160;</div>

<div style="line-height: 1.25"><span style="font-style: italic; font-family: Times New Roman">Mandatory Adjustments</span><span style="font-family: Times New Roman">.</span></div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">In the event of a merger, amalgamation, consolidation,
share rights offering, share exchange or similar event affecting the Company (a &#8220;<span style="font-weight: bold">Corporate Event</span>&#8221;)
or a share dividend, share split, reverse share split, separation, spinoff, reorganization, extraordinary dividend of cash or other property,
share combination or subdivision, or recapitalization, capital reduction distribution or similar event affecting the capital structure
of the Company, the administrator will make equitable and appropriate substitutions or proportionate adjustments to:</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z8154cb3c657c4612bd1abfdb34dded0a" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">&#160;</div> </td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">the aggregate number and kind of shares or other securities that may be granted
        to eligible individuals under the 2024 Plan;</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: rgb(0, 0, 0); font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">124</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="text-align: center; line-height: 1.25"><span style="font-family: Times New Roman"><br/> </span> </div>

<table cellspacing="0" cellpadding="0" id="z7fd55846ee9c4d5ea42cd4b6db162ff8" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">&#160;</div> </td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">the maximum number of shares or other securities that may be issued with
        respect to incentive share options granted under the 2024 Plan;</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<table cellspacing="0" cellpadding="0" id="ze89f4849277647cf809ce9a3dce8251c" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">&#160;</div> </td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">the number of shares or other securities covered by each outstanding award
        and the exercise price, base price or other price per share, if any, and other relevant terms of each outstanding award; and</div> </td>
        </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<table cellspacing="0" cellpadding="0" id="zf3f721a959b142e686b64e7e54d99e95" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">&#160;</div> </td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">all other numerical limitations relating to awards, whether contained in
        the 2024 Plan or in award agreements.</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">Notwithstanding the foregoing, any fractional shares resulting
from the above mandatory adjustments will be eliminated.</div>

<div style="line-height: 1.25; font-style: italic; font-family: Times New Roman">&#160;</div>

<div style="line-height: 1.25"><span style="font-style: italic; font-family: Times New Roman">Discretionary Adjustments</span><span style="font-family: Times New Roman">.</span></div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">In addition to the adjustments specified above, in the
case of Corporate Events, the administrator may make such other adjustments to outstanding awards as it determines to be appropriate and
desirable, which adjustments may include, without limitation, (i) the cancellation of outstanding awards in exchange for payments of cash,
securities or other property or a combination thereof having an aggregate value equal to the value of such awards, (ii) the substitution
of securities or other property (including, without limitation, cash or other securities of the Company and securities of entities other
than the Company) for the shares subject to outstanding awards, and (iii) the substitution of equivalent awards, as determined in the
sole discretion of the administrator, of the surviving or successor entity or a parent thereof. The administrator may, in its discretion,
adjust the performance goals applicable to any awards to reflect any unusual or non-recurring events and other extraordinary items, impact
of charges for restructurings, discontinued operations and the cumulative effects of accounting or tax changes.</div>

<div style="line-height: 1.25; font-style: italic; font-family: Times New Roman">&#160;</div>

<div style="line-height: 1.25"><span style="font-style: italic; font-family: Times New Roman">Repricing</span><span style="font-family: Times New Roman">.</span></div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">The administrator may reprice any share options or share
appreciation rights without the approval of the shareholders of the Company. For this purpose, &#8220;reprice&#8221; means (i) any of
the following or any other action that has the same effect: (A) lowering the exercise price or base price of an option or share appreciation
right after it is granted other than an adjustment made pursuant to the provisions of the 2024 Plan, (B) any other action that is treated
as a repricing under applicable accounting principles; (C) cancelling a share option or share appreciation right at a time when its exercise
price or base price exceeds the fair market value of the underlying share, in exchange for another share option, share appreciation right,
restricted share or other equity, unless the cancellation and exchange occurs in connection with a merger, acquisition, spin-off or other
similar corporate transaction; and (ii) any other action that is considered to be a repricing under formal or informal guidance issued
by the primary securities market or exchange on which the shares are listed or admitted for trading.</div>

<div style="line-height: 1.25; font-style: italic; font-family: Times New Roman">&#160;</div>

<div style="line-height: 1.25; font-style: italic; font-family: Times New Roman">Treatment of Awards upon Dissolution or Liquidation or
a Change in Control</div>

<div style="line-height: 1.25; font-style: italic; font-family: Times New Roman">&#160;</div>

<div style="line-height: 1.25"><span style="font-style: italic; font-family: Times New Roman">Dissolution or Liquidation</span><span style="font-family: Times New Roman">.</span></div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">Unless the administrator determines otherwise, all awards
outstanding under the 2024 Plan will terminate upon the winding up, liquidation or dissolution of the Company.</div>

<div style="line-height: 1.25; font-style: italic; font-family: Times New Roman">&#160;</div>

<div style="line-height: 1.25; font-style: italic; font-family: Times New Roman">Amendment and Termination</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">Our board of directors or the compensation committee may
terminate, amend or modify the 2024 Plan or any portion of it at any time; provided, that, (i) if required to comply with Cayman Islands
law and any other applicable laws or marketplace or listing rules of a securities market or securities exchange (other than any requirement
from which the Company may opt out based on any available home country exemption), the Company shall obtain shareholder approval of any
2024 Plan amendment in such a manner and to such a degree as required, and (ii) no such termination or amendment may materially impair
the rights of a participant with respect to a previously granted award (other than as required to comply with applicable law or the rules
of any securities exchange or market on which the shares are listed or to prevent adverse tax or accounting consequences to the Company
or the participant) without such participant&#8217;s consent.</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: rgb(0, 0, 0); font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">125</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">The 2024 Plan is scheduled to expire on August 14, 2034,
which is ten years after the effective date of its adoption by our board of directors. After that time, no further grants may be made
under the 2024 Plan, but any then-outstanding grants will remain subject to the terms of the plan.</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">The foregoing description of the 2024 Incentive Plan is
qualified in its entirety by the full text of the 2024 Incentive Plan, which is attached to the registration statement of which this prospectus
forms a part as Exhibit 10.12 and incorporated herein by reference.</div>

<div style="text-align: justify; text-indent: 18pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold; font-family: Times New Roman">Rule 10b5-1 Sales Plans</div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">Our directors and executive officers may adopt written
plans, known as Rule 10b5-1 plans, in which they will contract with a broker to buy or sell ordinary shares on a periodic basis. Under
a Rule 10b5-1 plan, a broker executes trades pursuant to parameters established by the director or executive officer when entering into
the plan, without further direction from them. The director or executive officer may amend a Rule 10b5-1 plan in some circumstances and
may terminate a plan at any time. Our directors and executive officers also may buy or sell additional shares outside of a Rule 10b5-1
plan when they are not in possession of material nonpublic information, subject to compliance with the terms of our insider trading policy.</div>
</div>

<div style="text-align: justify; text-indent: 18pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold; font-family: Times New Roman">Emerging Growth Company Status</div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">We are an &#8220;emerging growth company,&#8221; as defined
in the JOBS Act. As an emerging growth company, it is exempt from certain requirements related to executive compensation, including the
requirements to hold a nonbinding advisory vote on executive compensation and to provide information relating to the ratio of total compensation
of its chief executive officer to the median of the annual total compensation of all of its employees, each as required by the Investor
Protection and Securities Reform Act of 2010, which is part of the Dodd-Frank Wall Street Reform and Consumer Protection Act.</div> </div>

<div style="text-align: justify; text-indent: 18pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: center; line-height: 1.25; font-weight: bold; font-family: Times New Roman"><!--Anchor--><span id="CERTAIN"><!--Anchor--></span>CERTAIN
RELATIONSHIPS AND RELATED PARTY TRANSACTIONS</div>

<div style="text-align: center; line-height: 1.25; font-weight: bold; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">Other than the compensation arrangements for our directors
and executive officers, which are described in the section titled &#8220;Executive Compensation&#8221;, below is a description of transactions
since our formation on April 2, 2024 to which we have been a party, in which:</div>

<div style="text-indent: 18pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<table cellspacing="0" cellpadding="0" id="zb402104a5eb8482ea5295015db74bbbe" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">the amounts involved exceeded or will exceed $120,000; and</div> </td> </tr>
  </table>

<div style="text-indent: -18pt; margin-left: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z9bea474bcac542ad8ec1d804e7fccf80" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">any of our directors, executive officers or holders of more than 5% of our
        share capital, or any member of the immediate family of, or person sharing the household with, the foregoing persons, had or will have
        a direct or indirect material interest.</div> </td> </tr>
  </table>

<div style="text-indent: -18pt; margin-left: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="line-height: 1.25; font-weight: bold; font-family: Times New Roman">Related Party Transactions</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman">&#160;</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman">Arrangements with Executive Officers</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="line-height: 1.25">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">

<div style="line-height: 1.25; font-family: Times New Roman">Ilan Hadar serves as our Chief Executive Officer and Chairman of the our
Board. Mr. Hadar&#8217;s employment agreement with us, as to be amended in the period following the Closing of the Business Combination,
subject to corporate approvals, will provide for him to receive an annual base salary of $357,820 (based on the average exchange rate
for 2023, as published by the Bank of Israel), customary disbursements toward his providence fund, further education fund and severance
pay fund, and other fringe benefits commensurate with such position. During 2022, Silexion granted Mr. Hadar 14,339 options to purchase
New Silexion ordinary shares, vesting over a period of 48 months, provided that Mr. Hadar remains engaged by us (or a Silexion affiliate)
at the end of each vesting period and subject to the Silexion Plan. Upon completion of the Business Combination, the vesting of all such
options is expected to accelerate, such that all unvested options shall become fully vested at that time.</div> </div> </div> </div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25">

<div style="text-indent: 36pt; line-height: 1.25">

<div style="text-indent: 36pt; line-height: 1.25">

<div style="line-height: 1.25; font-family: Times New Roman">Mirit Horenshtein Hadar, our Executive VP of Finance, Chief Financial Officer
and Secretary, is Mr. Hadar&#8217;s spouse. Ms. Horenshtein Hadar&#8217;s employment agreement with us provides for her to receive an
annual base salary of $234,210 (based on the average exchange rate for 2023, as published by the Bank of Israel), as well as customary
disbursements toward her providence fund, further education fund and severance pay fund, and other fringe benefits commensurate with such
position.</div> </div> </div>

<div style="text-indent: 36pt; line-height: 1.25"> <span style="font-family: Times New Roman"><br/> </span></div> </div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: rgb(0, 0, 0); font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">126</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman">&#160;</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman">Indemnification Agreements</div>

<div style="text-indent: 36pt; line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="line-height: 1.25">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">On the date of, and in connection with, the Closing of
the Business Combination, the Company entered into indemnification agreements with each of its directors and executive officers, which
provide for indemnification and advancements by the Company of certain expenses and costs under certain circumstances. The indemnification
agreements provide that we will indemnify each of its directors and executive officers against any and all expenses incurred by that director
or executive officer because of his or her status as a director or officer of New Silexion, to the fullest extent permitted under Cayman
law and the Articles.</div> </div> </div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="line-height: 1.25; font-family: Times New Roman">The foregoing description of the indemnification agreements does not purport
to be complete and is qualified in its entirety by reference to the text of the form of indemnification agreement that is filed as Exhibit
10.6 to the registration statement of which this prospectus forms a part, which is incorporated herein by reference.</div> </div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman">&#160;</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman">Conversion Transaction with GIBF</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25">

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">

<div style="line-height: 1.25; font-family: Times New Roman">Immediately following the Closing of the Business Combination, Guangzhou
Sino-Israel Bio-Industry Investment Fund I (&#8220;GIBF&#8221;) beneficially owned 20.3% of our issued and outstanding share capital.
GIBF had held the remaining 49% of the issued and outstanding share capital of our 51%-held Chinese subsidiary, Silenseed (China) Ltd.
(which 49% interest had been received by it in return for its equity investments in the Chinese subsidiary, rather than equity investments
directly in us). In connection with the consummation of the Business Combination, GIBF was to exchange its entire holdings in the Chinese
subsidiary for preferred shares of Silexion according to the terms set out in the contract for the establishment of the Chinese subsidiary,
dated August 30, 2021, as amended, which preferred shares were to be automatically converted into 203,971 New Silexion ordinary shares
in accordance with the equity exchange ratio for our shareholders&#8217; exchange of shares of Silexion for our shares under the Business
Combination Agreement.</div> </div> </div> </div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">

<div style="line-height: 1.25; font-family: Times New Roman">However, in order to simplify the transfer of GIBF&#8217;s 49% interest in
our Chinese subsidiary to our company, in lieu of transferring that interest to Silexion, GIBF instead transferred the interest directly
to New Silexion pursuant to an Agreement on Arrangements Related to Equity Interest Conversion, dated as of August 5, 2024 (the &#8220;GIBF
Conversion Agreement&#8221;). As consideration for its transfer of that 49% interest to us, GIBF received 203,971 New Silexion ordinary
shares at the Closing. GIBF furthermore received an additional 16,817 of our ordinary shares upon consummation of the Business Combination
due to the conversion of our shares that were issued to it upon settlement of RSUs of Silexion that were subject to accelerated vesting
at the Closing. Those RSUs were granted to GIBF subject to GIBF&#8217;s providing certain services to us in connection with the transfer
of funds from our Chinese subsidiary to us. Avner Lushi and Shlomo Noy, both of whom serve as our directors since the Closing, share voting
and investment power over the 220,788 of our ordinary shares beneficially owned by GIBF after the Closing.</div> </div> </div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="line-height: 1.25; font-style: italic; font-weight: normal; font-family: Times New Roman">PIPE Financing</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25">

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">

<div style="line-height: 1.25; font-family: Times New Roman">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">In connection with, and immediately prior
to the Closing of, the Business Combination, Moringa raised $2.0 million via a private investment in public entity financing (the &#8220;PIPE
Financing&#8221;), whereby Moringa sold to Greenstar, LP (the &#8220;PIPE Investor&#8221;), a Cayman Islands exempted limited partnership
and affiliate of the Moringa Sponsor, 200,000 newly issued Moringa ordinary shares (the &#8220;PIPE Shares&#8221;) (which does not reflect
the reverse share split) at a price of $10.00 per share, pursuant to the PIPE Agreement, dated as of August 15, 2024, by and among Moringa,
us and the PIPE Investor. Those 200,000 shares automatically converted upon the Closing of the Business Combination into an equivalent
number of our ordinary shares (at a number prior to the effectiveness of the reverse share split), or the PIPE Shares. The PIPE Investor
is entitled to customary registration rights in respect of the PIPE Shares under the PIPE Agreement, pursuant to which we have agreed
that, within 60 days after the Closing Date, it will file with the SEC a registration statement registering the resale of the PIPE Shares
by the PIPE Investor, and use its commercially reasonable efforts to have that registration statement be declared effective by 180 days
after the Closing Date (or 90 days after the Closing Date if the SEC does not review that filing).</div> </div> </div> </div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif"> <span style="font-family: Times New Roman"><br/> </span> </div>
</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: rgb(0, 0, 0); font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">127</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">The funds raised from the PIPE Financing, together with
remaining funds in Moringa&#8217;s trust account after payments to redeeming public shareholders of Moringa, were used for financing support
for Moringa and New Silexion, as well as for payment to service providers to whom outstanding amounts were owed by Moringa, including
parties that had provided financial advisory services and capital markets advisory services to Moringa during the period leading up to
the Closing.</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">The foregoing summary provides only a brief description
of the PIPE Agreement and does not purport to be complete. The summary is qualified in its entirety by the full text of the PIPE Agreement,
a copy of which serves as Exhibit 10.2 to the registration statement of which this prospectus forms a part, and which is incorporated
herein by reference.</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman">Amended and Restated Sponsor Promissory
Note</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="line-height: 1.25">

<div style="line-height: 1.25">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">Effective as of the Closing, we issued to the Sponsor,
and Sponsor accepted, in amendment and restatement, and replacement, in their entirety, of all existing promissory notes issued by Moringa
to the Sponsor from the IPO until the Closing (and as to which the obligations of Moringa were assigned to us upon the Closing), the A&amp;R
Sponsor Promissory Note in an amount of $3,433,000, which reflected the total amount owed by Moringa to the Sponsor through the Closing
Date. The maturity date of the A&amp;R Sponsor Promissory Note is the 30-month anniversary of the Closing Date (i.e., February 15, 2027).
Amounts outstanding under the A&amp;R Sponsor Promissory Note may be repaid (unless otherwise decided by us) only by way of conversion
into our ordinary shares (&#8220;<span style="font-weight: bold">Note Shares</span>&#8221;) in accordance with the terms set forth in
the form of A&amp;R Sponsor Promissory Note. Us and the Sponsor may also convert amounts outstanding under the A&amp;R Sponsor Promissory
Note at the price per share at which we conduct an equity financing following the Closing, subject to a minimum conversion amount of $100,000,
in an amount of Note Shares constituting up to thirty percent (30%) of the number of our ordinary shares issued and sold by us in such
equity financing. The Sponsor may also elect to convert amounts of principal outstanding under the note into our ordinary shares at any
time following the 24-month anniversary of the Closing Date, subject to a minimum conversion of $10,000, at a price per share equal to
the volume weighted average price of the our ordinary shares on the principal market on which they are traded during the 20 consecutive
trading days prior to the conversion date.</div> </div> </div> </div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">The foregoing summary provides only a brief description
of the A&amp;R Sponsor Promissory Note and does not purport to be complete. The summary is qualified in its entirety by the full text
of the A&amp;R Sponsor Promissory Note, a copy of which serves as Exhibit 10.5 to the registration statement of which this prospectus
forms a part, and which is incorporated herein by reference.</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman">&#160;</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman">Amended and Restated Registration
Rights and Lock-Up Agreement</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="line-height: 1.25">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">Prior to the Closing under the Business Combination Agreement,
on August 14, 2024, us, Moringa, Moringa Sponsor, the distributees of the Sponsor Investment Shares (as defined under the Business Combination
Agreement), certain of our pre-Business Combination shareholders and the PIPE Investor entered into (and EarlyBird will be bound by) an
amended and restated registration rights and lock-up&#160;agreement which became effective as of the Closing of the Business Combination
(the &#8220;A&amp;R Registration Rights and Lock-Up Agreement&#8221;). Under the agreement, we have assumed Moringa&#8217;s existing obligations
under Moringa&#8217;s prior registration rights agreement (entered into in connection with Moringa&#8217;s initial public offering, or
IPO) and has granted registration rights to the Moringa Sponsor, the distributees of Sponsor Investment Shares, certain of our pre-Business
Combination shareholders, the PIPE Investor and EarlyBird with respect to certain securities of ours.</div> </div> </div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">Under the A&amp;R Registration Rights and Lock-Up Agreement,
we have agreed to provide the holders party thereto customary demand and shelf registration rights (subject to certain minimum size offerings)
and piggy-back rights on primary and secondary offerings, subject to customary cut-back provisions.</div> </div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: rgb(0, 0, 0); font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">128</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">Under the lock-up provisions of the agreement, lock-up
periods apply following the Closing to of our securities that are held by the holders who are party to the agreement, subject to permitted
transfers to certain categories of &#8220;Permitted Transferees&#8221;. Specifically, those lock-up periods apply to the following categories
of securities for the following periods of time post-Closing:</div> </div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman"> </div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman"> <br/> </div>

<table cellspacing="0" cellpadding="0" id="z3be9287273a14029aaf88ec260b14f72" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25">
        <div style="line-height: 1.25">
        <div style="line-height: 1.25">
        <div style="line-height: 1.25"><span style="font-style: italic">Sponsor Investment Shares and securities held by former Silexion shareholders</span>:
        (A) 50% of the Sponsor Investment Shares held by the Sponsor and its distributees and 50% of the New Silexion securities held by the former
        Silexion shareholders who are party to the agreement, in each case, upon the Closing, are subject to a lock-up period ending on the earlier
        of (i) six (6) months after the completion of the Business Combination, and (ii) the date on which New Silexion will consummate a liquidation,
        merger, amalgamation, share exchange, reorganization, or other similar transaction after the Business Combination that results in all
        of our shareholders having the right to exchange their ordinary shares for cash, securities or other property, and (B) the other 50% of
        the Sponsor Investment Shares held by the Sponsor and its distributees and 50% of the our securities held by the former Silexion shareholders
        party to the agreement, in each case, upon the Closing, will be subject to a lock-up period that will end on the earliest of (x) six (6)
        months after the date of the consummation of the Business Combination, (y) the date on which we consummate a liquidation, merger, amalgamation,
        share exchange, reorganization, or other similar transaction after the Business Combination that results in all of our shareholders having
        the right to exchange their ordinary shares for cash, securities or other property, or (z) the date on which the closing price of our
        ordinary shares equals or exceeds $12.00 per share (as adjusted for share splits, share dividends, rights issuances, subdivisions, reorganizations,
        recapitalizations and the like) for any 20 trading days within any 30-trading day period.</div> </div> </div> </div> </td> </tr>
  </table>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z64eeb5a6f5604a4a87ab776311fecf70" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25"><span style="font-style: italic; font-family: Times New Roman">Private Shares and Private Warrants:</span><span style="font-family: Times New Roman">
        The lock-up period on all New Silexion ordinary shares issued pursuant to the SPAC Merger in exchange for private placement shares and
        private placement warrants purchased by or issued to the Sponsor and EarlyBird concurrently with Moringa&#8217;s initial public offering
        will remain (as provided in the documentation for Moringa&#8217;s initial public offering) 30 days after the Closing.</span></div> </td>
        </tr>
  </table>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z7110f4afe2584a048dc707ec9ce30701" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25"><span style="font-style: italic; font-family: Times New Roman">Representative Shares</span><span style="font-family: Times New Roman">.
        The lock-up period on all Representative Shares (as defined in the Amended and Restated Registration Rights and Lock-Up Agreement) that
        are held by EarlyBird will remain (as provided in the documentation for Moringa&#8217;s initial public offering) three months after the
        Closing.</span></div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z4e84242ac4de40618ee9c6f8189a8579" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25"><span style="font-style: italic; font-family: Times New Roman">Note Shares and PIPE Shares</span><span style="font-family: Times New Roman">.
        Note Shares issued to the Sponsor upon conversion of amounts due under the A&amp;R Sponsor Promissory Note and PIPE Shares issued to the
        PIPE Investor will not be subject to any lock-up periods following the Closing.</span></div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">The foregoing summary provides only a brief description
of the A&amp;R Registration Rights and Lock-Up Agreement and does not purport to be complete. The summary is qualified in its entirety
by the full text of the A&amp;R Registration Rights and Lock-Up Agreement, which serves as Exhibit 10.4 to the registration statement
of which this prospectus forms a part, and which is incorporated herein by reference.</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman">&#160;</div>

<div style="text-align: center; line-height: 1.25; font-weight: bold; font-family: Times New Roman"><!--Anchor--><span id="BENEFICIAL"><!--Anchor--></span>BENEFICIAL
OWNERSHIP OF SECURITIES</div>

<div style="text-align: justify; text-indent: 18pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-indent: 36pt; line-height: 1.25">

<div style="line-height: 1.25; font-family: Times New Roman">

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">

<div style="text-indent: 36pt; line-height: 1.25">The following table sets forth information known to the Company regarding the beneficial
ownership of New Silexion ordinary shares as of February 11, 2025 by:</div> </div> </div> </div> </div> </div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z2a52c29de6ad45a095f4746665700f2e" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman">each person who is the beneficial owner of more than
        5% of the outstanding New Silexion ordinary shares;</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z97995235e7c0446aaf9edeff96591a8b" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">
        <div style="text-align: left; line-height: 1.25; font-family: Times New Roman">our named executive officer and directors; and</div> </div>
        </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z116fc5073e5c4be28023e82f3d01148e" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">
        <div style="text-align: left; line-height: 1.25; font-family: Times New Roman">all of our executive officers and directors as a group.</div>
        </div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: rgb(0, 0, 0); font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">129</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="text-indent: 36pt; line-height: 1.25"> <br/> </div>

<div style="text-indent: 36pt; line-height: 1.25">

<div style="text-indent: 36pt; line-height: 1.25">

<div style="text-indent: 36pt; line-height: 1.25">Beneficial ownership is determined according to the rules of the SEC, which generally
provide that a person has beneficial ownership of a security if he, she or it possesses sole or shared voting or investment power over
that security, including options and warrants that are currently exercisable or exercisable within 60 days. In computing the number of
ordinary shares beneficially owned by a person and the percentage ownership, we include, as outstanding, those ordinary shares that are
subject to warrants held by that person that are currently exercisable or exercisable within 60 days of February 11, 2025. We do not deem
those shares to be outstanding, however, for the purpose of computing the percentage ownership of any other person.</div> </div> </div>

<div style="text-indent: 36pt; line-height: 1.25">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25">Unless otherwise indicated, we believe that all persons named in the table have sole
voting and investment power with respect to all New Silexion ordinary shares beneficially owned by them.</div>

<div style="text-indent: 36pt; line-height: 1.25">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25">

<div style="text-indent: 36pt; line-height: 1.25">

<div style="text-indent: 36pt; line-height: 1.25">

<div style="text-indent: 36pt; line-height: 1.25">The percentage ownership of New Silexion ordinary shares is based on&#160;8,414,615
New Silexion ordinary shares outstanding as of February 11, 2025.</div> </div> </div> </div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman">&#160;

<table cellspacing="0" cellpadding="0" id="zb532e7a7e299464c98694890d2ddcdd9" class="cfttable" style="font: 10pt Times New Roman, Times, serif; text-align: left; color: #000000; width: 100%">
  <tr>
    <td style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom">
        <div style="line-height: 1.25">&#160;</div>
        <div style="line-height: 1.25; font-weight: bold">Name and Address of Beneficial Owner(1)</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom">
        <div style="text-align: center; text-indent: 10pt; line-height: 1.25; font-weight: bold">Number of Shares</div>
        <div style="text-align: center; text-indent: 11pt; line-height: 1.25; font-weight: bold">Beneficially Owned</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom">
        <div style="text-align: center; text-indent: 8pt; line-height: 1.25; font-weight: bold">Approximate<br/> Percentage of</div>
        <div style="text-align: center; line-height: 1.25; font-weight: bold; text-indent: 9.4pt">Outstanding</div>
        <div style="text-align: center; line-height: 1.25; font-weight: bold; text-indent: 9.4pt">Ordinary Shares</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: top">
        <div style="line-height: 1.25; font-style: italic; font-weight: bold">Directors and Executive Officers of New Silexion:</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; vertical-align: top">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; vertical-align: top">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom">&#160;</td> </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: top; background-color: rgb(204, 238, 255); width: 72.7%">
        <div style="line-height: 1.25">Ilan Hadar</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1.1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1.1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 10.25%">
        <div style="line-height: 1.25">31,160</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1.23%">
        <div style="line-height: 1.25"><sup style="vertical-align: text-top; line-height: 1; font-size: smaller">(2)</sup>&#160;</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1.1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1.1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 10.25%">
        <div style="line-height: 1.25">*</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1.1%">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: top; width: 72.7%">
        <div style="line-height: 1.25">Dror Abramov</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1.1%">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1.1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 10.25%">
        <div style="line-height: 1.25">4,425</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1.23%">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1.1%">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1.1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 10.25%">
        <div style="line-height: 1.25">*</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1.1%">&#160;</td> </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: top; background-color: rgb(204, 238, 255); width: 72.7%">
        <div style="line-height: 1.25">Ruth Alon</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1.1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1.1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 10.25%">
        <div style="line-height: 1.25">6,037</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1.23%">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1.1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1.1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 10.25%">
        <div style="line-height: 1.25">*</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1.1%">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: top; width: 72.7%">
        <div style="line-height: 1.25">Ilan Levin(3)</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1.1%">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1.1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 10.25%">
        <div style="line-height: 1.25">229,624</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1.23%">
        <div style="line-height: 1.25"><sup style="vertical-align: text-top; line-height: 1; font-size: smaller">(4)</sup>&#160;</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1.1%">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1.1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 10.25%">
        <div style="line-height: 1.25">2.7</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1.1%">
        <div style="line-height: 1.25">%</div> </td> </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: top; background-color: rgb(204, 238, 255); width: 72.7%">
        <div style="line-height: 1.25">Avner Lushi(5)</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1.1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1.1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 10.25%">
        <div style="line-height: 1.25">220,788</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1.23%">
        <div style="line-height: 1.25"><sup style="vertical-align: text-top; line-height: 1; font-size: smaller">(6)</sup>&#160;</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1.1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1.1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 10.25%">
        <div style="line-height: 1.25">2.6</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1.1%">
        <div style="line-height: 1.25">%</div> </td> </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: top; width: 72.7%">
        <div style="line-height: 1.25">Shlomo Noy(7)</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1.1%">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1.1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 10.25%">
        <div style="line-height: 1.25">220,788</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1.23%">
        <div style="line-height: 1.25"><sup style="vertical-align: text-top; line-height: 1; font-size: smaller">(6)</sup>&#160;</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1.1%">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1.1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 10.25%">
        <div style="line-height: 1.25">2.6</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1.1%">
        <div style="line-height: 1.25">%</div> </td> </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: top; background-color: rgb(204, 238, 255); width: 72.7%">
        <div style="line-height: 1.25">Amnon Peled</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1.1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1.1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 10.25%">
        <div style="line-height: 1.25">-</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1.23%">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1.1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1.1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 10.25%">
        <div style="line-height: 1.25">-</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1.1%">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: top; width: 72.7%">
        <div style="line-height: 1.25">Dr. Mitchell Shirvan</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1.1%">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1.1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 10.25%">
        <div style="line-height: 1.25">21,888</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1.23%">
        <div style="line-height: 1.25"><sup style="vertical-align: text-top; line-height: 1; font-size: smaller">(8)</sup>&#160;</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1.1%">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1.1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 10.25%">
        <div style="line-height: 1.25">*</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1.1%">
        <div style="line-height: 1.25">%</div> </td> </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: top; background-color: rgb(204, 238, 255); width: 72.7%">
        <div style="line-height: 1.25">Mirit Horenshtein Hadar, CPA</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1.1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1.1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 10.25%">
        <div style="line-height: 1.25">6,308</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1.23%">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1.1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1.1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 10.25%">
        <div style="line-height: 1.25">*</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1.1%">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: top; width: 72.7%">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1.1%">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1.1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 10.25%">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1.23%">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1.1%">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1.1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 10.25%">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1.1%">&#160;</td> </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: top; background-color: rgb(204, 238, 255); width: 72.7%">
        <div style="line-height: 1.25; font-style: italic; font-weight: bold">All executive officers and directors as a group (8 individuals)</div>
        </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1.1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1.1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 10.25%">
        <div style="line-height: 1.25">520,230</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1.23%">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1.1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1.1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 10.25%">
        <div style="line-height: 1.25">6.2</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1.1%">
        <div style="line-height: 1.25">%</div> </td> </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: top; width: 72.7%">
        <div style="line-height: 1.25; font-style: italic; font-weight: bold">Five Percent Holders:</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1.1%">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1.1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 10.25%">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1.23%">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1.1%">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1.1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 10.25%">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1.1%">&#160;</td> </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: top; background-color: rgb(204, 238, 255); width: 72.7%">
        <div style="line-height: 1.25">Hudson Bay Master Fund (9)</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1.1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1.1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 10.25%">
        <div style="line-height: 1.25">740,741</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1.23%">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1.1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1.1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 10.25%">
        <div style="line-height: 1.25">8.1</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1.1%">
        <div style="line-height: 1.25">%</div> </td> </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: top; width: 72.7%">
        <div style="line-height: 1.25">Entities affiliated with Anson Advisors Inc and Anson Funds Management LP (10)</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1.1%">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1.1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 10.25%">
        <div style="line-height: 1.25">740,741</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1.23%">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1.1%">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1.1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 10.25%">
        <div style="line-height: 1.25">6.4</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1.1%">
        <div style="line-height: 1.25">%</div> </td> </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: top; background-color: rgb(204, 238, 255); width: 72.7%">
        <div style="line-height: 1.25">CVI Investments, Inc. (11)</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1.1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1.1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 10.25%">
        <div style="line-height: 1.25">740,766</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1.23%">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1.1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1.1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 10.25%">
        <div style="line-height: 1.25">8.1</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1.1%">
        <div style="line-height: 1.25">%</div> </td> </tr>
  </table> </div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div> </div>

<div> </div> </div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif"> <span style="font-family: Times New Roman"><br/>
</span> </div>

<table cellspacing="0" cellpadding="0" id="z47aac06a0c7740ea81571da2de94107b" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 4.62%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">*</div> </td>
    <td style="width: 95.38%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman">Less than 1%.</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="line-height: 1.25"> </div>

<table cellspacing="0" cellpadding="0" id="zeb9fb806fdca4194abe3c049f6254892" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 4.62%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">(1)</div> </td>
    <td style="width: 95.38%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">
        <div style="line-height: 1.25; font-family: Times New Roman">Unless otherwise noted, the business address of each beneficial owner listed
        in the above table is c/o Silexion Therapeutics Corp, 12 Abba Hillel Road, Ramat Gan, Israel 5250606.</div> </div> </td> </tr>
  </table>

<div style="line-height: 1.25"><span style="font-family: Times New Roman"><br/> </span> </div>

<table cellspacing="0" cellpadding="0" id="z37468714bf2f4c64aefefac462bbb032" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 4.62%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">(2)</div> </td>
    <td style="width: 95.38%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">
        <div style="line-height: 1.25; font-family: Times New Roman">Includes 14,339 New Silexion ordinary shares issuable upon exercise of options,
        at an exercise price of $60.48 per share, all of which are vested and currently exercisable.</div> </div> </td> </tr>
  <tr>
    <td style="width: 4.62%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">&#160;</div> </td>
    <td style="width: 95.38%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">&#160;</div> </td> </tr>
  <tr>
    <td style="width: 4.62%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">(3)</div> </td>
    <td style="width: 95.38%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">The shares reported in this row are held of record by the Sponsor, Moringa
        Sponsor, LP, and/or by the PIPE Investor, Greenstar, L.P., each a Cayman Islands exempted limited partnership, as described in footnote
        (4) below. Moringa Partners Ltd., an Israeli company that is wholly-owned by Mr. Ilan Levin, serves as the sole general partner of each
        of the Sponsor and the PIPE Investor. Mr. Levin, a director of New Silexion, is the sole director of that general partner. As a result
        of his ownership of that general partner, Mr. Levin possesses sole voting and investment authority with respect to the shares indirectly
        held by the Sponsor and the PIPE Investor. The limited partnership interests of the Sponsor and the PIPE Investor are held by various
        individuals and entities, including Mr. Levin. Mr. Levin disclaims beneficial ownership of the securities held by the Sponsor and the
        PIPE Investor other than to the extent of his direct or indirect pecuniary interest in such securities. The address of each of the entities
        beneficially owning the shares that are reported in this row is c/o Moringa Acquisition Corp, 250 Park Avenue, 7<sup style="vertical-align: text-top; line-height: 1; font-size: smaller">th</sup>
        floor, New York, NY 10177.</div> </td> </tr>
  </table>

<div><span style="font-family: Times New Roman"><br/> </span> </div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: rgb(0, 0, 0); font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">130</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 4.62%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">(4)</div> </td>
    <td style="width: 95.38%; vertical-align: top">
        <div style="line-height: 1.25">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">
        <div style="line-height: 1.25; font-family: Times New Roman">Consists of the total of: (i) 148,592 New Silexion ordinary shares issued
        to the Sponsor as Sponsor Investment Shares (as defined under the Business Combination Agreement); (ii) 39,206 New Silexion ordinary shares
        issued to the Sponsor upon the Closing of the Business Combination due to the conversion, on a one-for-one basis, of the 352,857 Moringa
        private shares held by it; (iii) 19,603 New Silexion ordinary shares underlying New Silexion warrants issued to the Sponsor upon the Closing
        of the Business Combination due to the conversion, on a one-for-one basis, of the 176,429 Moringa private warrants held by the Sponsor
        (which New Silexion warrants will be exercisable beginning 30 days after the Closing Date); and (iv) 22,223 New Silexion ordinary shares
        issued to Greenstar, L.P., the PIPE Investor, as PIPE Shares in respect of the PIPE Financing. The foregoing beneficial ownership of New
        Silexion ordinary shares by the Sponsor does not include any Note Shares that may be issued to the Sponsor following the Closing upon
        conversion of amounts owed by New Silexion to the Sponsor under the A&amp;R Sponsor Promissory Note, as the potential number of Note Shares,
        and the timing of issuance of Note Shares, cannot be determined in advance.</div> </div> </div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<table cellspacing="0" cellpadding="0" id="zcca75589be0b48c08f65a070a5e8d568" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 4.62%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">(5)</div> </td>
    <td style="width: 95.38%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">The shares reported in this row consist entirely of New Silexion ordinary
        shares held of record by Guangzhou Sino-Israel Biotech Fund (&#8220;<span style="font-weight: bold">GIBF</span>&#8221;), with respect
        to which Mr. Lushi possesses shared voting and investment authority as a result of his serving as a Managing Partner and CEO of GIBF.</div>
        </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z1bf3cd0ce986458ab26b363b1fa2874a" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 4.62%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">(6)</div> </td>
    <td style="width: 95.38%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">
        <div style="line-height: 1.25; font-family: Times New Roman, Times, serif">
        <div style="line-height: 1.25; font-family: Times New Roman">Includes 203,971 New Silexion ordinary shares issued to GIBF at the Closing
        in respect of its transfer of its noncontrolling interest in our Chinese subsidiary, Silenseed (China) Ltd., to New Silexion pursuant
        to the Chinese Subsidiary Transfer.</div> </div> </div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z5867bebbb63f4fb2b48febab262ed6ab" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 4.62%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">(7)</div> </td>
    <td style="width: 95.38%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">The shares reported in this row consist entirely of New Silexion ordinary
        shares held of record by GIBF, with respect to which Mr. Noy possesses shared voting and investment authority as a result of his serving
        as Chief Medical Officer of GIBF.</div> </td> </tr>
  <tr>
    <td style="width: 4.62%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">&#160;</div> </td>
    <td style="width: 95.38%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">&#160;</div> </td> </tr>
  <tr>
    <td style="width: 4.62%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">(8)</div> </td>
    <td style="width: 95.38%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">
        <div style="line-height: 1.25; font-family: Times New Roman">Includes 7,170 New Silexion ordinary shares issuable upon exercise of options,
        at an exercise price of $60.48 per share, all of which are vested and currently exercisable.</div> </div> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 4.62%; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 95.38%; vertical-align: top">&#160;</td> </tr>
  <tr>
    <td style="width: 4.62%; vertical-align: top"> (9)<br/> </td>
    <td style="width: 95.38%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">Represents 740,741 ordinary shares issuable upon exercise of
        warrants issued in connection with the Warrant Repricing. Hudson Bay Capital Management LP, the investment manager of Hudson Bay Master
        Fund Ltd., has voting and investment power over these securities. Sander Gerber is the managing member of Hudson Bay Capital GP LLC, which
        is the general partner of Hudson Bay Capital Management LP. Each of Hudson Bay Master Fund Ltd. and Sander Gerber disclaims beneficial
        ownership over these securities.</div> </div> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 4.62%; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 95.38%; vertical-align: top">&#160;</td> </tr>
  <tr>
    <td style="width: 4.62%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">(10)</div> </td>
    <td style="width: 95.38%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">Represents (i) 577,778 ordinary shares issuable upon exercise
        of warrants issued in connection with the Warrant Repricing held by Anson Investments Master Fund LP (&#8220;AIMF&#8221;) and (ii) 162,963
        ordinary shares issuable upon exercise of warrants issued in connection with the Warrant Repricing held by Anson East Master Fund LP (&#8220;AEMF&#8221;).
        Anson Advisors Inc and Anson Funds Management LP, the Co-Investment Advisers of AIMF and AEMF, hold voting and dispositive power over
        the ordinary shares held by each of AIMF and AEMF. Tony Moore is the managing member of Anson Management GP LLC, which is the general
        partner of Anson Funds Management LP. Moez Kassam and Amin Nathoo are directors of Anson Advisors Inc. Mr. Moore, Mr. Kassam and Mr. Nathoo
        each disclaim beneficial ownership of these ordinary shares except to the extent of their pecuniary interest therein. The principal business
        address of each of AIMF and AEMF is Maples Corporate Services Limited, PO Box 309, Ugland House, Grand Cayman, KY1-1104, Cayman Islands.</div>
        </div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z7e6d77105f034ca591e9096f55832bdd" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 4.62%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">(11)</div> </td>
    <td style="width: 95.38%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">Represents (i) 463,741 ordinary shares issuable upon exercise
        of warrant issued in our January 2025 financing, (ii) 277,000 ordinary shares issuable upon exercise of warrants issued in connection
        with the Warrant Repricing and (iii) 25 ordinary shares issuable upon the exercise of warrants issued by Moringa that the Company assumed
        in connection with the Business Combination. Heights Capital Management, Inc., the authorized agent of CVI Investments, Inc. (&#8220;CVI&#8221;),
        has discretionary authority to vote and dispose of the shares held by CVI and may be deemed to be the beneficial owner of these shares.
        Martin Kobinger, in his capacity as President of Heights Capital Management, Inc., may also be deemed to have investment discretion and
        voting power over the shares held by CVI. Mr. Kobinger disclaims any such beneficial ownership of the shares. CVI Investments, Inc.is
        affiliated with one or more FINRA member, none of whom are currently expected to participate in the sale pursuant to the prospectus contained
        in the Registration Statement of shares purchased by the investor in this offering.</div> </div> </td> </tr>
  </table>

<div style="font-family: Times New Roman,Times,serif">

<div style="text-align: center; line-height: 1.25; font-family: Times New Roman, Times, serif; font-weight: bold"> <br/> </div>

<div style="text-align: center; line-height: 1.25; font-family: Times New Roman, Times, serif; font-weight: bold">SELLING <span id="SECURITYHOLDERS"><!--Anchor--></span>SECURITYHOLDERS</div>

<div style="text-align: center; line-height: 1.25; font-family: Times New Roman, Times, serif; font-weight: bold">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">The ordinary shares
being offered by the Selling Securityholders are ordinary shares issuable upon exercise of the New Warrants and Placement Agent Warrants
previously issued in connection with the January 2025 Warrant Inducement Transaction. For additional information regarding the issuance
of those shares of common stock and warrants, see &#8220;<span style="font-style: italic">January 2025</span>&#160;<span style="font-style: italic">Transactions
Related to Offering Under This Prospectus&#8212;January 2025 Warrant Inducement Transaction</span>&#8221; above. We are registering the
ordinary shares in order to permit the selling stockholders to offer the shares of common stock for resale from time to time. Other than
with respect to Wainwright, which acted as our placement agent in the January 2025 Warrant Inducement Transaction and January 2025 financing
and the other Selling Securityholders (excluding Wainwright), which was an investor in our January 2025 financing, except for the ownership
of the warrants and Placement Agent Warrants issued, and the ordinary shares issued and issuable pursuant to prior financings, the Selling
Securityholders have not had any material relationship with us within the past three years.</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">

<div style="text-indent: 36pt; line-height: 1.25">The table below lists the Selling Securityholders and other information regarding the
beneficial ownership of the ordinary shares by each of the Selling Securityholders. The second column lists the number the ordinary shares
beneficially owned by each selling stockholder, based on its ownership of the ordinary shares, including shares underlying the New Warrants
or Placement Agent Warrants, as of February 11, 2025, assuming exercise of the New Warrants or Placement Agent Warrants held by the Selling
Securityholders on that date, without regard to any limitations on conversions or exercises. The third column lists the maximum number
of ordinary shares being offered in this prospectus by the Selling Securityholders. The fourth and fifth columns list the amount of ordinary
shares owned after the offering, by number of ordinary shares and percentage of outstanding the shares of common stock (assuming for the
purpose of such percentage, 8,414,615 shares outstanding as of February 11, 2025) assuming in both cases the sale of all of the ordinary
shares offered by the Selling Securityholders pursuant to this prospectus, and without regard to any limitations on conversions or exercises.</div>
</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">Under the terms of
the New Warrants and Placement Agent Warrants issued in the January 2025 Warrant Inducement Transaction, a Selling Securityholder may
not exercise the warrants to the extent such exercise would cause such Selling Securityholder, together with its affiliates, to beneficially
own a number of ordinary shares which would exceed 4.99% or 9.99%, as applicable, of our then outstanding ordinary shares following such
exercise, excluding for purposes of such determination ordinary shares not yet issuable upon exercise of the warrants which have not been
exercised. The number of shares does not reflect this limitation. The Selling Securityholder may sell all, some or none of their ordinary
shares or New Warrants or Placement Agent Warrants in this offering. See &#8220;<span style="font-style: italic">Plan of Distribution</span>.&#8221;&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal">131</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="line-height: 1.25"><br/> </div>

<table cellspacing="0" cellpadding="0" id="z7045eaa1618f4bffabc582a977b0104a" class="cfttable" style="font: 10pt Times New Roman, Times, serif; text-align: left; color: #000000; width: 100%">
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px">
        <div style="text-align: center; line-height: 1.25"><br/> <span style="font-weight: bold">&#160;</span></div> </td>
    <td rowspan="1" colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
    <td rowspan="1" colspan="2" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom">
        <div style="text-align: center; line-height: 1.25; font-weight: bold">Number of Shares of Ordinary Owned Prior to Offering</div> </td>
    <td rowspan="1" colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
    <td rowspan="1" colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
    <td rowspan="1" colspan="2" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom">
        <div style="text-align: center; line-height: 1.25; font-weight: bold">Maximum Number of Ordinary Shares to be Sold Pursuant to this Prospectus</div>
        </td>
    <td rowspan="1" colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
    <td rowspan="1" colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
    <td rowspan="1" colspan="2" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom">
        <div style="text-align: center; line-height: 1.25; font-weight: bold">Number of Ordinary Shares Owned After the Offering</div> </td>
    <td rowspan="1" colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom">
        <div style="text-align: center; line-height: 1.25; font-weight: bold">Percentage of Ordinary Shares Owned After the Offering</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; background-color: rgb(204, 238, 255); width: 52%">
        <div style="line-height: 1.25">CVI Investments, Inc. <sup style="vertical-align: text-top; line-height: 1; font-size: smaller">(1)</sup></div>
        </td>
    <td rowspan="1" colspan="1" class="cftguttercell" style="vertical-align: bottom; text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td rowspan="1" colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%">&#160;</td>
    <td rowspan="1" colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">740,766</div> </td>
    <td rowspan="1" colspan="1" class="cftfncell" style="white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: top; width: 1%"><sup style="vertical-align: text-top; line-height: 1; font-size: smaller">(2)</sup></td>
    <td rowspan="1" colspan="1" class="cftguttercell" style="vertical-align: bottom; text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td rowspan="1" colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%">&#160;</td>
    <td rowspan="1" colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">277,000</div> </td>
    <td rowspan="1" colspan="1" class="cftfncell" style="white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: top; width: 1%"><sup style="vertical-align: text-top; line-height: 1; font-size: smaller">(3)</sup></td>
    <td rowspan="1" colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td rowspan="1" colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%">&#160;</td>
    <td rowspan="1" colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">463,766</div> </td>
    <td rowspan="1" colspan="1" class="cftfncell" style="white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: top; width: 1%"><sup style="vertical-align: text-top; line-height: 1; font-size: smaller">(4)</sup></td>
    <td colspan="1" class="cftguttercell" style="vertical-align: top; width: 1%; background-color: rgb(204, 238, 255)"><sup style="vertical-align: text-top; line-height: 1; font-size: smaller">&#160;</sup></td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">
        <div style="line-height: 1.25">5.5</div> </div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25">
        <div style="line-height: 1.25">%</div> </div> </td> </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; width: 52%">
        <div style="line-height: 1.25">Anson Investments Master Fund LP <sup style="vertical-align: text-top; line-height: 1; font-size: smaller">(5)</sup></div>
        </td>
    <td rowspan="1" colspan="1" class="cftguttercell" style="vertical-align: bottom; text-align: right; vertical-align: bottom; width: 1%">&#160;</td>
    <td rowspan="1" colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td rowspan="1" colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">577,778</div> </td>
    <td rowspan="1" colspan="1" class="cftfncell" style="white-space: nowrap; vertical-align: top; width: 1%"><sup style="vertical-align: text-top; line-height: 1; font-size: smaller">(6)</sup></td>
    <td rowspan="1" colspan="1" class="cftguttercell" style="vertical-align: bottom; text-align: right; vertical-align: bottom; width: 1%">&#160;</td>
    <td rowspan="1" colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td rowspan="1" colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">577,778</div> </td>
    <td rowspan="1" colspan="1" class="cftfncell" style="white-space: nowrap; vertical-align: top; width: 1%"><sup style="vertical-align: text-top; line-height: 1; font-size: smaller">(6)</sup></td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">-</div> </td>
    <td colspan="1" class="cftfncell" style="white-space: nowrap; vertical-align: top; width: 1%"><sup style="vertical-align: text-top; line-height: 1; font-size: smaller">&#160;</sup></td>
    <td colspan="1" class="cftguttercell" style="vertical-align: top; width: 1%"><sup style="vertical-align: text-top; line-height: 1; font-size: smaller">&#160;</sup></td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">-</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">&#160;</td> </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; background-color: rgb(204, 238, 255); width: 52%">
        <div style="line-height: 1.25">Anson East Master Fund LP <sup style="vertical-align: text-top; line-height: 1; font-size: smaller">(7)</sup></div>
        </td>
    <td rowspan="1" colspan="1" class="cftguttercell" style="vertical-align: bottom; text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td rowspan="1" colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%">&#160;</td>
    <td rowspan="1" colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">162,963</div> </td>
    <td rowspan="1" colspan="1" class="cftfncell" style="white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: top; width: 1%"><sup style="vertical-align: text-top; line-height: 1; font-size: smaller">(8)</sup></td>
    <td rowspan="1" colspan="1" class="cftguttercell" style="vertical-align: bottom; text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td rowspan="1" colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%">&#160;</td>
    <td rowspan="1" colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">162,963</div> </td>
    <td rowspan="1" colspan="1" class="cftfncell" style="white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: top; width: 1%"><sup style="vertical-align: text-top; line-height: 1; font-size: smaller">(8)</sup></td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">-</div> </td>
    <td colspan="1" class="cftfncell" style="white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: top; width: 1%"><sup style="vertical-align: text-top; line-height: 1; font-size: smaller">&#160;</sup></td>
    <td colspan="1" class="cftguttercell" style="vertical-align: top; width: 1%; background-color: rgb(204, 238, 255)"><sup style="vertical-align: text-top; line-height: 1; font-size: smaller">&#160;</sup></td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">-</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; width: 52%">
        <div style="line-height: 1.25">Hudson Bay Master Fund Ltd. <sup style="vertical-align: text-top; line-height: 1; font-size: smaller">(9)</sup></div>
        </td>
    <td rowspan="1" colspan="1" class="cftguttercell" style="vertical-align: bottom; text-align: right; vertical-align: bottom; width: 1%">&#160;</td>
    <td rowspan="1" colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td rowspan="1" colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">740,741</div> </td>
    <td rowspan="1" colspan="1" class="cftfncell" style="white-space: nowrap; vertical-align: top; width: 1%"><sup style="vertical-align: text-top; line-height: 1; font-size: smaller">(10)</sup></td>
    <td rowspan="1" colspan="1" class="cftguttercell" style="vertical-align: bottom; text-align: right; vertical-align: bottom; width: 1%">&#160;</td>
    <td rowspan="1" colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td rowspan="1" colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">740,741</div> </td>
    <td rowspan="1" colspan="1" class="cftfncell" style="white-space: nowrap; vertical-align: top; width: 1%"><sup style="vertical-align: text-top; line-height: 1; font-size: smaller">(10)</sup></td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">-</div> </td>
    <td colspan="1" class="cftfncell" style="white-space: nowrap; vertical-align: top; width: 1%"><sup style="vertical-align: text-top; line-height: 1; font-size: smaller">&#160;</sup></td>
    <td colspan="1" class="cftguttercell" style="vertical-align: top; width: 1%"><sup style="vertical-align: text-top; line-height: 1; font-size: smaller">&#160;</sup></td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">-</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">&#160;</td> </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; background-color: rgb(204, 238, 255); width: 52%">
        <div style="line-height: 1.25">3i, LP <sup style="vertical-align: text-top; line-height: 1; font-size: smaller">(11)</sup></div> </td>
    <td rowspan="1" colspan="1" class="cftguttercell" style="vertical-align: bottom; text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td rowspan="1" colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%">&#160;</td>
    <td rowspan="1" colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">150,000</div> </td>
    <td rowspan="1" colspan="1" class="cftfncell" style="white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: top; width: 1%"><sup style="vertical-align: text-top; line-height: 1; font-size: smaller">(12)</sup></td>
    <td rowspan="1" colspan="1" class="cftguttercell" style="vertical-align: bottom; text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td rowspan="1" colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%">&#160;</td>
    <td rowspan="1" colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">150,000</div> </td>
    <td rowspan="1" colspan="1" class="cftfncell" style="white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: top; width: 1%"><sup style="vertical-align: text-top; line-height: 1; font-size: smaller">(12)</sup></td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">-</div> </td>
    <td colspan="1" class="cftfncell" style="white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: top; width: 1%"><sup style="vertical-align: text-top; line-height: 1; font-size: smaller">&#160;</sup></td>
    <td colspan="1" class="cftguttercell" style="vertical-align: top; width: 1%; background-color: rgb(204, 238, 255)"><sup style="vertical-align: text-top; line-height: 1; font-size: smaller">&#160;</sup></td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">-</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; width: 52%">
        <div style="line-height: 1.25">Intracoastal Capital LLC <sup style="vertical-align: text-top; line-height: 1; font-size: smaller">(13)</sup></div>
        </td>
    <td rowspan="1" colspan="1" class="cftguttercell" style="vertical-align: bottom; text-align: right; vertical-align: bottom; width: 1%">&#160;</td>
    <td rowspan="1" colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td rowspan="1" colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">240,741</div> </td>
    <td rowspan="1" colspan="1" class="cftfncell" style="white-space: nowrap; vertical-align: top; width: 1%"><sup style="vertical-align: text-top; line-height: 1; font-size: smaller">(14)</sup></td>
    <td rowspan="1" colspan="1" class="cftguttercell" style="vertical-align: bottom; text-align: right; vertical-align: bottom; width: 1%">&#160;</td>
    <td rowspan="1" colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td rowspan="1" colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">240,741</div> </td>
    <td rowspan="1" colspan="1" class="cftfncell" style="white-space: nowrap; vertical-align: top; width: 1%"><sup style="vertical-align: text-top; line-height: 1; font-size: smaller">(14)</sup></td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">-</div> </td>
    <td colspan="1" class="cftfncell" style="white-space: nowrap; vertical-align: top; width: 1%"><sup style="vertical-align: text-top; line-height: 1; font-size: smaller">&#160;</sup></td>
    <td colspan="1" class="cftguttercell" style="vertical-align: top; width: 1%"><sup style="vertical-align: text-top; line-height: 1; font-size: smaller">&#160;</sup></td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">-</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">&#160;</td> </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; background-color: rgb(204, 238, 255); width: 52%">
        <div style="line-height: 1.25">Boothbay Absolute Return Strategies, LP <sup style="vertical-align: text-top; line-height: 1; font-size: smaller">(15)</sup></div>
        </td>
    <td rowspan="1" colspan="1" class="cftguttercell" style="vertical-align: bottom; text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td rowspan="1" colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%">&#160;</td>
    <td rowspan="1" colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">15,300</div> </td>
    <td rowspan="1" colspan="1" class="cftfncell" style="white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: top; width: 1%"><sup style="vertical-align: text-top; line-height: 1; font-size: smaller">(16)</sup></td>
    <td rowspan="1" colspan="1" class="cftguttercell" style="vertical-align: bottom; text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td rowspan="1" colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%">&#160;</td>
    <td rowspan="1" colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">15,300</div> </td>
    <td rowspan="1" colspan="1" class="cftfncell" style="white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: top; width: 1%"><sup style="vertical-align: text-top; line-height: 1; font-size: smaller">(16)</sup></td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">-</div> </td>
    <td colspan="1" class="cftfncell" style="white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: top; width: 1%"><sup style="vertical-align: text-top; line-height: 1; font-size: smaller">&#160;</sup></td>
    <td colspan="1" class="cftguttercell" style="vertical-align: top; width: 1%; background-color: rgb(204, 238, 255)"><sup style="vertical-align: text-top; line-height: 1; font-size: smaller">&#160;</sup></td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">
        <div style="line-height: 1.25">-</div> </div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25">%</div> </td> </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; width: 52%">
        <div style="line-height: 1.25">Orca Capital AG <sup style="vertical-align: text-top; line-height: 1; font-size: smaller">(17)</sup></div>
        </td>
    <td rowspan="1" colspan="1" class="cftguttercell" style="vertical-align: bottom; text-align: right; vertical-align: bottom; width: 1%">&#160;</td>
    <td rowspan="1" colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td rowspan="1" colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">37,000</div> </td>
    <td rowspan="1" colspan="1" class="cftfncell" style="white-space: nowrap; vertical-align: top; width: 1%"><sup style="vertical-align: text-top; line-height: 1; font-size: smaller">(18)</sup></td>
    <td rowspan="1" colspan="1" class="cftguttercell" style="vertical-align: bottom; text-align: right; vertical-align: bottom; width: 1%">&#160;</td>
    <td rowspan="1" colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td rowspan="1" colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">37,000</div> </td>
    <td rowspan="1" colspan="1" class="cftfncell" style="white-space: nowrap; vertical-align: top; width: 1%"><sup style="vertical-align: text-top; line-height: 1; font-size: smaller">(18)</sup></td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">-</div> </td>
    <td colspan="1" class="cftfncell" style="white-space: nowrap; vertical-align: top; width: 1%"><sup style="vertical-align: text-top; line-height: 1; font-size: smaller">&#160;</sup></td>
    <td colspan="1" class="cftguttercell" style="vertical-align: top; width: 1%"><sup style="vertical-align: text-top; line-height: 1; font-size: smaller">&#160;</sup></td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">
        <div style="line-height: 1.25">-</div> </div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25">%</div> </td> </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; background-color: rgb(204, 238, 255); width: 52%">
        <div style="line-height: 1.25">KBB Asset Management, LLC <sup style="vertical-align: text-top; line-height: 1; font-size: smaller">(19)</sup></div>
        </td>
    <td rowspan="1" colspan="1" class="cftguttercell" style="vertical-align: bottom; text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td rowspan="1" colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%">&#160;</td>
    <td rowspan="1" colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">20,000</div> </td>
    <td rowspan="1" colspan="1" class="cftfncell" style="white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: top; width: 1%"><sup style="vertical-align: text-top; line-height: 1; font-size: smaller">(20)</sup></td>
    <td rowspan="1" colspan="1" class="cftguttercell" style="vertical-align: bottom; text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td rowspan="1" colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%">&#160;</td>
    <td rowspan="1" colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">20,000</div> </td>
    <td rowspan="1" colspan="1" class="cftfncell" style="white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: top; width: 1%"><sup style="vertical-align: text-top; line-height: 1; font-size: smaller">(20)</sup></td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">-</div> </td>
    <td colspan="1" class="cftfncell" style="white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: top; width: 1%"><sup style="vertical-align: text-top; line-height: 1; font-size: smaller">&#160;</sup></td>
    <td colspan="1" class="cftguttercell" style="vertical-align: top; width: 1%; background-color: rgb(204, 238, 255)"><sup style="vertical-align: text-top; line-height: 1; font-size: smaller">&#160;</sup></td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">
        <div style="line-height: 1.25">-</div> </div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25">%</div> </td> </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; width: 52%">
        <div style="line-height: 1.25">Michael Vasinkevich <sup style="vertical-align: text-top; line-height: 1; font-size: smaller">(21)</sup></div>
        </td>
    <td rowspan="1" colspan="1" class="cftguttercell" style="vertical-align: bottom; text-align: right; vertical-align: bottom; width: 1%">&#160;</td>
    <td rowspan="1" colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td rowspan="1" colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">265,969</div> </td>
    <td rowspan="1" colspan="1" class="cftfncell" style="white-space: nowrap; vertical-align: top; width: 1%"><sup style="vertical-align: text-top; line-height: 1; font-size: smaller">(22)</sup></td>
    <td rowspan="1" colspan="1" class="cftguttercell" style="vertical-align: bottom; text-align: right; vertical-align: bottom; width: 1%">&#160;</td>
    <td rowspan="1" colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td rowspan="1" colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">99,719</div> </td>
    <td rowspan="1" colspan="1" class="cftfncell" style="white-space: nowrap; vertical-align: top; width: 1%"><sup style="vertical-align: text-top; line-height: 1; font-size: smaller">(23)</sup></td>
    <td rowspan="1" colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td rowspan="1" colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td rowspan="1" colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">166,250</div> </td>
    <td rowspan="1" colspan="1" class="cftfncell" style="white-space: nowrap; vertical-align: top; width: 1%"><sup style="vertical-align: text-top; line-height: 1; font-size: smaller">(24)</sup></td>
    <td colspan="1" class="cftguttercell" style="vertical-align: top; width: 1%"><sup style="vertical-align: text-top; line-height: 1; font-size: smaller">&#160;</sup></td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">1.2</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25">%</div> </td> </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; background-color: rgb(204, 238, 255); width: 52%">
        <div style="line-height: 1.25">Noam Rubinstein <sup style="vertical-align: text-top; line-height: 1; font-size: smaller">(21)</sup></div>
        </td>
    <td rowspan="1" colspan="1" class="cftguttercell" style="vertical-align: bottom; text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td rowspan="1" colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%">&#160;</td>
    <td rowspan="1" colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">130,651</div> </td>
    <td rowspan="1" colspan="1" class="cftfncell" style="white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: top; width: 1%"><sup style="vertical-align: text-top; line-height: 1; font-size: smaller">(25)</sup></td>
    <td rowspan="1" colspan="1" class="cftguttercell" style="vertical-align: bottom; text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td rowspan="1" colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%">&#160;</td>
    <td rowspan="1" colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">48,985</div> </td>
    <td rowspan="1" colspan="1" class="cftfncell" style="white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: top; width: 1%"><sup style="vertical-align: text-top; line-height: 1; font-size: smaller">(26)</sup></td>
    <td rowspan="1" colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td rowspan="1" colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%">&#160;</td>
    <td rowspan="1" colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">81,666</div> </td>
    <td rowspan="1" colspan="1" class="cftfncell" style="white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: top; width: 1%"><sup style="vertical-align: text-top; line-height: 1; font-size: smaller">(27)</sup></td>
    <td colspan="1" class="cftguttercell" style="vertical-align: top; width: 1%; background-color: rgb(204, 238, 255)"><sup style="vertical-align: text-top; line-height: 1; font-size: smaller">&#160;</sup></td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">*</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25">%</div> </td> </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; width: 52%">
        <div style="line-height: 1.25">Craig Schwabe <sup style="vertical-align: text-top; line-height: 1; font-size: smaller">(21)</sup></div>
        </td>
    <td rowspan="1" colspan="1" class="cftguttercell" style="vertical-align: bottom; text-align: right; vertical-align: bottom; width: 1%">&#160;</td>
    <td rowspan="1" colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td rowspan="1" colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">13,998</div> </td>
    <td rowspan="1" colspan="1" class="cftfncell" style="white-space: nowrap; vertical-align: top; width: 1%"><sup style="vertical-align: text-top; line-height: 1; font-size: smaller">(28)</sup></td>
    <td rowspan="1" colspan="1" class="cftguttercell" style="vertical-align: bottom; text-align: right; vertical-align: bottom; width: 1%">&#160;</td>
    <td rowspan="1" colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td rowspan="1" colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">5,248</div> </td>
    <td rowspan="1" colspan="1" class="cftfncell" style="white-space: nowrap; vertical-align: top; width: 1%"><sup style="vertical-align: text-top; line-height: 1; font-size: smaller">(29)</sup></td>
    <td rowspan="1" colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td rowspan="1" colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td rowspan="1" colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">8,750</div> </td>
    <td rowspan="1" colspan="1" class="cftfncell" style="white-space: nowrap; vertical-align: top; width: 1%"><sup style="vertical-align: text-top; line-height: 1; font-size: smaller">(30)</sup></td>
    <td colspan="1" class="cftguttercell" style="vertical-align: top; width: 1%"><sup style="vertical-align: text-top; line-height: 1; font-size: smaller">&#160;</sup></td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">*</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25">%</div> </td> </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; background-color: rgb(204, 238, 255); width: 52%">
        <div style="line-height: 1.25">Charles Worthman <sup style="vertical-align: text-top; line-height: 1; font-size: smaller">(21)</sup></div>
        </td>
    <td rowspan="1" colspan="1" class="cftguttercell" style="vertical-align: bottom; text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td rowspan="1" colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%">&#160;</td>
    <td rowspan="1" colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">4,148</div> </td>
    <td rowspan="1" colspan="1" class="cftfncell" style="white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: top; width: 1%"><sup style="vertical-align: text-top; line-height: 1; font-size: smaller">(31)</sup></td>
    <td rowspan="1" colspan="1" class="cftguttercell" style="vertical-align: bottom; text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td rowspan="1" colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%">&#160;</td>
    <td rowspan="1" colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">1,555</div> </td>
    <td rowspan="1" colspan="1" class="cftfncell" style="white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: top; width: 1%"><sup style="vertical-align: text-top; line-height: 1; font-size: smaller">(32)</sup></td>
    <td rowspan="1" colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td rowspan="1" colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%">&#160;</td>
    <td rowspan="1" colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">2,593</div> </td>
    <td rowspan="1" colspan="1" class="cftfncell" style="white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: top; width: 1%"><sup style="vertical-align: text-top; line-height: 1; font-size: smaller">(33)</sup></td>
    <td colspan="1" class="cftguttercell" style="vertical-align: top; width: 1%; background-color: rgb(204, 238, 255)"><sup style="vertical-align: text-top; line-height: 1; font-size: smaller">&#160;</sup></td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">*</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25">%</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<div style="line-height: 1.25"><img src="image00008.jpg" alt="" style="width: 576px; height: 2px"/></div>

<div style="line-height: 1.25">&#160;</div>

<table cellspacing="0" cellpadding="0" id="zd10ed077af4947d3888f64d8ac525c24" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="white-space: nowrap; width: 8.66%; vertical-align: top">
        <div style="line-height: 1.25">*</div> </td>
    <td style="width: 91.34%; vertical-align: middle">
        <div style="line-height: 1.25">Less than 1%</div> </td> </tr>
  <tr>
    <td style="white-space: nowrap; width: 8.66%; vertical-align: top">&#160;</td>
    <td style="width: 91.34%; vertical-align: middle">&#160;</td> </tr>
  <tr>
    <td style="white-space: nowrap; width: 8.66%; vertical-align: top">
        <div style="line-height: 1.25">(1)</div> </td>
    <td style="width: 91.34%; vertical-align: middle">
        <div style="text-align: justify; line-height: 1.25">Heights Capital Management, Inc., the authorized agent of CVI Investments, Inc. (&#8220;CVI&#8221;),
        has discretionary authority to vote and dispose of the shares held by CVI and may be deemed to be the beneficial owner of these shares.
        Martin Kobinger, in his capacity as President of Heights Capital Management, Inc., may also be deemed to have investment discretion and
        voting power over the shares held by CVI. Mr. Kobinger disclaims any such beneficial ownership of the shares. CVI Investments, Inc.is
        affiliated with one or more FINRA member, none of whom are currently expected to participate in the sale pursuant to the prospectus contained
        in the Registration Statement of shares purchased by the investor in this offering.</div> </td> </tr>
  <tr>
    <td style="white-space: nowrap; width: 8.66%; vertical-align: top">
        <div style="line-height: 1.25">(2)</div> </td>
    <td style="width: 91.34%; vertical-align: middle">
        <div style="text-align: justify; line-height: 1.25">Represents (i) 463,741 ordinary shares issuable upon exercise of warrant issued in
        our January 2025 financing, (ii) 277,000 ordinary shares issuable upon exercise of warrants issued in connection with the Warrant Repricing
        and (iii) 25 ordinary shares issuable upon the exercise of warrants issued by Moringa that the Company assumed in connection with the
        Business Combination.</div> </td> </tr>
  <tr>
    <td style="white-space: nowrap; width: 8.66%; vertical-align: top">
        <div style="line-height: 1.25">(3)</div> </td>
    <td style="width: 91.34%; vertical-align: middle">
        <div style="text-align: justify; line-height: 1.25">Represents 277,000 ordinary shares issuable upon exercise of warrants issued in connection
        with the Warrant Repricing.</div> </td> </tr>
  <tr>
    <td style="white-space: nowrap; width: 8.66%; vertical-align: top">
        <div style="line-height: 1.25">(4)</div> </td>
    <td style="width: 91.34%; vertical-align: middle">
        <div style="text-align: justify; line-height: 1.25">Represents (i) 463,741 ordinary shares issuable upon exercise of warrant issued in
        our January 2025 financing and (ii) 25 ordinary shares issuable upon the exercise of warrants issued by Moringa that the Company assumed
        in connection with the Business Combination.</div> </td> </tr>
  <tr>
    <td style="white-space: nowrap; width: 8.66%; vertical-align: top">
        <div style="line-height: 1.25">(5)</div> </td>
    <td style="width: 91.34%; vertical-align: middle">
        <div style="text-align: justify; line-height: 1.25">Anson Advisors Inc and Anson Funds Management LP, the Co-Investment Advisers of Anson
        Investments Master Fund LP (&#8220;Anson&#8221;), hold voting and dispositive power over the ordinary shares held by Anson. Tony Moore
        is the managing member of Anson Management GP LLC, which is the general partner of Anson Funds Management LP. Moez Kassam and Amin Nathoo
        are directors of Anson Advisors Inc. Mr. Moore, Mr. Kassam and Mr. Nathoo each disclaim beneficial ownership of these ordinary shares
        except to the extent of their pecuniary interest therein. The principal business address of Anson is Maples Corporate Services Limited,
        PO Box 309, Ugland House, Grand Cayman, KY1-1104, Cayman Islands.</div> </td> </tr>
  </table>

<div><br/> </div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal">132</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div><br/> </div>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="white-space: nowrap; width: 8.66%; vertical-align: top">
        <div style="line-height: 1.25">(6)</div> </td>
    <td style="width: 91.34%; vertical-align: middle">
        <div style="text-align: justify; line-height: 1.25">Represents 577,778 ordinary shares issuable upon exercise of warrants issued in connection
        with the Warrant Repricing.</div> </td> </tr>
  <tr>
    <td style="white-space: nowrap; width: 8.66%; vertical-align: top">
        <div style="line-height: 1.25">(7)</div> </td>
    <td style="width: 91.34%; vertical-align: middle">
        <div style="text-align: justify; line-height: 1.25">Anson Advisors Inc and Anson Funds Management LP, the Co-Investment Advisers of Anson
        East Master Fund LP (&#8220;Anson&#8221;), hold voting and dispositive power over the ordinary shares held by Anson. Tony Moore is the
        managing member of Anson Management GP LLC, which is the general partner of Anson Funds Management LP. Moez Kassam and Amin Nathoo are
        directors of Anson Advisors Inc. Mr. Moore, Mr. Kassam and Mr. Nathoo each disclaim beneficial ownership of these ordinary shares except
        to the extent of their pecuniary interest therein. The principal business address of Anson is Maples Corporate Services Limited, PO Box
        309, Ugland House, Grand Cayman, KY1-1104, Cayman Islands.</div> </td> </tr>
  <tr>
    <td style="white-space: nowrap; width: 8.66%; vertical-align: top">
        <div style="line-height: 1.25">(8)</div> </td>
    <td style="width: 91.34%; vertical-align: middle">
        <div style="text-align: justify; line-height: 1.25">Represents 162,963 ordinary shares issuable upon exercise of warrants issued in connection
        with the Warrant Repricing.</div> </td> </tr>
  <tr>
    <td style="white-space: nowrap; width: 8.66%; vertical-align: top">
        <div style="line-height: 1.25">(9)</div> </td>
    <td style="width: 91.34%; vertical-align: middle">
        <div style="text-align: justify; line-height: 1.25">Hudson Bay Capital Management LP, the investment manager of Hudson Bay Master Fund
        Ltd., has voting and investment power over these securities. Sander Gerber is the managing member of Hudson Bay Capital GP LLC, which
        is the general partner of Hudson Bay Capital Management LP. Each of Hudson Bay Master Fund Ltd. and Sander Gerber disclaims beneficial
        ownership over these securities.</div> </td> </tr>
  <tr>
    <td style="white-space: nowrap; width: 8.66%; vertical-align: top">
        <div style="line-height: 1.25">(10)</div> </td>
    <td style="width: 91.34%; vertical-align: middle">
        <div style="text-align: justify; line-height: 1.25">Represents 740,741 ordinary shares issuable upon exercise of warrants issued in connection
        with the Warrant Repricing.</div> </td> </tr>
  <tr>
    <td style="white-space: nowrap; width: 8.66%; vertical-align: top">
        <div style="line-height: 1.25">(11)</div> </td>
    <td style="width: 91.34%; vertical-align: middle">
        <div style="text-align: justify; line-height: 1.25">3i Management LLC is the general partner of 3i, LP, and Maier Joshua Tarlow is the
        manager of 3i Management LLC. As such, Mr. Tarlow exercises sole voting and investment discretion over securities beneficially owned directly
        or indirectly by 3i, LP and 3i Management LLC. Mr. Tarlow disclaims beneficial ownership of the securities beneficially owned directly
        by 3i, LP and indirectly by 3i Management LLC. The business address of each of the aforementioned parties is 2 Wooster Street, 2nd Floor,
        New York, NY 10013. We have been advised that none of Mr. Tarlow, 3i Management LLC, or 3i, LP is a member of the Financial Industry Regulatory
        Authority, or FINRA, or an independent broker-dealer, or an affiliate or associated person of a FINRA member or independent broker-dealer.</div>
        </td> </tr>
  <tr>
    <td style="white-space: nowrap; width: 8.66%; vertical-align: top">
        <div style="line-height: 1.25">(12)</div> </td>
    <td style="width: 91.34%; vertical-align: middle">
        <div style="text-align: justify; line-height: 1.25">Represents 150,000 ordinary shares issuable upon exercise of warrants issued in connection
        with the Warrant Repricing.</div> </td> </tr>
  <tr>
    <td style="white-space: nowrap; width: 8.66%; vertical-align: top">
        <div style="line-height: 1.25">(13)</div> </td>
    <td style="width: 91.34%; vertical-align: middle">
        <div style="text-align: justify; line-height: 1.25">Mitchell P. Kopin (&#8220;Mr. Kopin&#8221;) and Daniel B. Asher (&#8220;Mr. Asher&#8221;),
        each of whom are managers of Intracoastal Capital LLC (&#8220;Intracoastal&#8221;), have shared voting control and investment discretion
        over the securities reported herein that are held by Intracoastal. Asa result, each of Mr. Kopin and Mr. Asher may be deemed to have beneficial
        ownership (as determined under Section 13(d) of the Securities Exchange Act of 1934, as amended(the &#8220;Exchange Act&#8221;)) of the
        securities reported herein that are held by Intracoastal.</div> </td> </tr>
  <tr>
    <td style="white-space: nowrap; width: 8.66%; vertical-align: top">
        <div style="line-height: 1.25">(14)</div> </td>
    <td style="width: 91.34%; vertical-align: middle">
        <div style="text-align: justify; line-height: 1.25">Represents 240,741 ordinary shares issuable upon exercise of warrants issued in connection
        with the Warrant Repricing.</div> </td> </tr>
  <tr>
    <td style="white-space: nowrap; width: 8.66%; vertical-align: top">
        <div style="line-height: 1.25">(15)</div> </td>
    <td style="width: 91.34%; vertical-align: middle">
        <div style="text-align: justify; line-height: 1.25">Boothbay Absolute Return Strategies LP, a Delaware limited partnership (the &#8220;Fund&#8221;),
        is managed by Boothbay Fund Management, LLC, a Delaware limited liability company (the &#8220;Adviser&#8221;). The Adviser, in its capacity
        as the investment manager of the Fund, has the power to vote and the power to direct the disposition of all securities held by the Fund.&#160;
        Ari Glass is the Managing Member of the Adviser.&#160;&#160; Each of the Fund, the Adviser and Mr. Glass disclaim beneficial ownership
        of these securities, except to the extent of any pecuniary interest therein.</div> </td> </tr>
  <tr>
    <td style="white-space: nowrap; width: 8.66%; vertical-align: top">
        <div style="line-height: 1.25">(16)</div> </td>
    <td style="width: 91.34%; vertical-align: middle">
        <div style="text-align: justify; line-height: 1.25">Represents 15,300 ordinary shares issuable upon exercise of warrants issued in connection
        with the Warrant Repricing.</div> </td> </tr>
  <tr>
    <td style="white-space: nowrap; width: 8.66%; vertical-align: top">
        <div style="line-height: 1.25">(17)</div> </td>
    <td style="width: 91.34%; vertical-align: middle">
        <div style="text-align: justify; line-height: 1.25">Roman Grodon, Thomas Koenig, and Beate Ruhle-Burkhardt have shared voting control
        and investment discretion over the securities reported herein that are held by Orca Capital AG (&#8220;Orca Capital&#8221;). As a result,
        each of Roman Grodon, Thomas Koenig, and Beate Ruhle-Burkhardt may be deemed to have beneficial ownership (as determined under Section
        13(d) of the Securities and Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;)) of the securities reported herein that
        are held by Orca Capital. The principal business address of Orca Capital is Sperl-Ring 2, 85276 Hettenshausen, Germany.</div> </td> </tr>
  <tr>
    <td style="white-space: nowrap; width: 8.66%; vertical-align: top">
        <div style="line-height: 1.25">(18)</div> </td>
    <td style="width: 91.34%; vertical-align: middle">
        <div style="text-align: justify; line-height: 1.25">Represents 37,000 ordinary shares issuable upon exercise of warrants issued in connection
        with the Warrant Repricing.</div> </td> </tr>
  <tr>
    <td style="white-space: nowrap; width: 8.66%; vertical-align: top">
        <div style="line-height: 1.25">(19)</div> </td>
    <td style="width: 91.34%; vertical-align: middle">
        <div style="text-align: justify; line-height: 1.25">Steven Segal is the natural person voting control and investment discretion over the
        securities reported herein. The address of the selling shareholder is 47 Calle Del Sur Palm Coast Fl 32137.</div> </td> </tr>
  <tr>
    <td style="white-space: nowrap; width: 8.66%; vertical-align: top">
        <div style="line-height: 1.25">(20)</div> </td>
    <td style="width: 91.34%; vertical-align: middle">
        <div style="text-align: justify; line-height: 1.25">Represents 20,000 ordinary shares issuable upon exercise of warrants issued in connection
        with the Warrant Repricing.</div> </td> </tr>
  </table>

<div><br/> </div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal">133</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div><br/> </div>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="white-space: nowrap; width: 8.66%; vertical-align: top">
        <div style="line-height: 1.25">(21)</div> </td>
    <td style="width: 91.34%; vertical-align: middle">
        <div style="text-align: justify; line-height: 1.25">Referenced person is affiliated with Wainwright, a registered broker-dealer with a
        registered address of H.C. Wainwright &amp; Co., LLC, 430 Park Ave, 3rd Floor, New York, NY 10022. Wainwright acted as our placement agent
        in our January 2025 financing. Referenced person has sole voting and dispositive power over the securities held, acquired the securities
        in the ordinary course of business and, at the time the securities were acquired, the selling stockholder had no agreement or understanding,
        directly or indirectly, with any person to distribute such securities.</div> </td> </tr>
  <tr>
    <td style="white-space: nowrap; width: 8.66%; vertical-align: top">
        <div style="line-height: 1.25">(22)</div> </td>
    <td style="width: 91.34%; vertical-align: middle">
        <div style="text-align: justify; line-height: 1.25">Represents (i) 166,250 ordinary shares issuable upon exercise of placement agent warrants
        issued in connection with our January 2025 financing and (ii) 99,719 ordinary shares issuable upon exercise of placement agent warrants
        issued in connection with the Warrant Repricing.</div> </td> </tr>
  <tr>
    <td style="white-space: nowrap; width: 8.66%; vertical-align: top">
        <div style="line-height: 1.25">(23)</div> </td>
    <td style="width: 91.34%; vertical-align: middle">
        <div style="text-align: justify; line-height: 1.25">Represents 99,719 ordinary shares issuable upon exercise of placement agent warrants
        issued in connection with the Warrant Repricing.</div> </td> </tr>
  <tr>
    <td style="white-space: nowrap; width: 8.66%; vertical-align: top">
        <div style="line-height: 1.25">(24)</div> </td>
    <td style="width: 91.34%; vertical-align: middle">
        <div style="text-align: justify; line-height: 1.25">Represents 166,250 ordinary shares issuable upon exercise of placement agent warrants
        issued in connection with our January 2025 financing.</div> </td> </tr>
  <tr>
    <td style="white-space: nowrap; width: 8.66%; vertical-align: top">
        <div style="line-height: 1.25">(25)</div> </td>
    <td style="width: 91.34%; vertical-align: middle">
        <div style="text-align: justify; line-height: 1.25">Represents (i) 81,666 ordinary shares issuable upon exercise of placement agent warrants
        issued in connection with our January 2025 financing and (ii) 48,985 ordinary shares issuable upon exercise of placement agent warrants
        issued in connection with the Warrant Repricing.</div> </td> </tr>
  <tr>
    <td style="white-space: nowrap; width: 8.66%; vertical-align: top">
        <div style="line-height: 1.25">(26)</div> </td>
    <td style="width: 91.34%; vertical-align: middle">
        <div style="text-align: justify; line-height: 1.25">Represents 48,985 ordinary shares issuable upon exercise of placement agent warrants
        issued in connection with the Warrant Repricing.</div> </td> </tr>
  <tr>
    <td style="white-space: nowrap; width: 8.66%; vertical-align: top">
        <div style="line-height: 1.25">(27)</div> </td>
    <td style="width: 91.34%; vertical-align: middle">
        <div style="text-align: justify; line-height: 1.25">Represents 81,666 ordinary shares issuable upon exercise of placement agent warrants
        issued in connection with our January 2025 financing.</div> </td> </tr>
  <tr>
    <td style="white-space: nowrap; width: 8.66%; vertical-align: top">
        <div style="line-height: 1.25">(28)</div> </td>
    <td style="width: 91.34%; vertical-align: middle">
        <div style="text-align: justify; line-height: 1.25">Represents (i) 8,750 ordinary shares issuable upon exercise of placement agent warrants
        issued in connection with our January 2025 financing and (ii) 5,248 ordinary shares issuable upon exercise of placement agent warrants
        issued in connection with the Warrant Repricing.</div> </td> </tr>
  <tr>
    <td style="white-space: nowrap; width: 8.66%; vertical-align: top">
        <div style="line-height: 1.25">(29)</div> </td>
    <td style="width: 91.34%; vertical-align: middle">
        <div style="text-align: justify; line-height: 1.25">Represents 5,248 ordinary shares issuable upon exercise of placement agent warrants
        issued in connection with the Warrant Repricing.</div> </td> </tr>
  <tr>
    <td style="white-space: nowrap; width: 8.66%; vertical-align: top">
        <div style="line-height: 1.25">(30)</div> </td>
    <td style="width: 91.34%; vertical-align: middle">
        <div style="text-align: justify; line-height: 1.25">Represents 8,750 ordinary shares issuable upon exercise of placement agent warrants
        issued in connection with our January 2025 financing.</div> </td> </tr>
  <tr>
    <td style="white-space: nowrap; width: 8.66%; vertical-align: top">
        <div style="line-height: 1.25">(31)</div> </td>
    <td style="width: 91.34%; vertical-align: middle">
        <div style="text-align: justify; line-height: 1.25">Represents (i) 2,593 ordinary shares issuable upon exercise of placement agent warrants
        issued in connection with our January 2025 financing and (ii) 1,555 ordinary shares issuable upon exercise of placement agent warrants
        issued in connection with the Warrant Repricing.</div> </td> </tr>
  <tr>
    <td style="white-space: nowrap; width: 8.66%; vertical-align: top">
        <div style="line-height: 1.25">(32)</div> </td>
    <td style="width: 91.34%; vertical-align: middle">
        <div style="text-align: justify; line-height: 1.25">Represent 1,555 ordinary shares issuable upon exercise of placement agent warrants
        issued in connection with the Warrant Repricing.</div> </td> </tr>
  <tr>
    <td style="white-space: nowrap; width: 8.66%; vertical-align: top">
        <div style="line-height: 1.25">(33)</div> </td>
    <td style="width: 91.34%; vertical-align: middle">
        <div style="text-align: justify; line-height: 1.25">Represents 2,593 ordinary shares issuable upon exercise of placement agent warrants
        issued in connection with our January 2025 financing.</div> </td> </tr>
  </table>

<div style="line-height: 1.25"><br/> </div> </div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: rgb(0, 0, 0); font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">134</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="text-align: justify; text-indent: -18pt; margin-left: 18pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: center; line-height: 1.25; font-weight: bold; font-family: Times New Roman"><!--Anchor--></div>

<div style="text-align: center; line-height: 1.25; font-weight: bold; font-family: Times New Roman,Times,serif">

<div style="line-height: 1.25; font-weight: bold; font-family: Times New Roman">DESCRIPTION OF SHARE <span id="CAPITAL"><!--Anchor--></span>

<!--Anchor-->CAPITAL</div> </div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">In connection with the consummation of the Business Combination,
New Silexion adopted the Articles. The following summary of the material terms of New Silexion&#8217;s securities is not intended to be
a complete summary of the rights and preferences of such securities. You are encouraged to read the Articles and the agreements governing
New Silexion&#8217;s warrants in their entirety, which serve as Exhibit 3.1 and Exhibits 4.1 and 4.2, respectively, to the registration
statement of which this prospectus forms a part, along with the applicable provisions of Cayman Islands law, for a complete description
of the rights and preferences of New Silexion&#8217;s securities.</div>

<div style="line-height: 1.25; font-weight: bold; font-family: Times New Roman">&#160;</div>

<div style="line-height: 1.25; font-weight: bold; font-family: Times New Roman">Authorized and Outstanding Share Capital</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-indent: 36pt; line-height: 1.25">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">

<div style="text-indent: 25.2pt; margin-right: 11.1pt; margin-left: 8.2pt; line-height: 1.25; font-family: Times New Roman">

<div style="text-indent: 25.2pt; line-height: 1.25; font-family: Times New Roman, Times, serif">

<div style="text-indent: 25.2pt; line-height: 1.25">

<div style="text-indent: 25.2pt; line-height: 1.25">

<div style="text-indent: 25.2pt; line-height: 1.25">The Articles of New Silexion authorize the issuance of 22,222,222 shares, consisting
of 22,222,222 ordinary shares, $0.0009 par value per share. As of February 11, 2025, there were 8,414,615 New Silexion ordinary shares
outstanding. All of such outstanding New Silexion ordinary shares were validly issued, fully paid and non-assessable.</div> </div> </div>
</div> </div> </div> </div> </div> </div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: rgb(0, 0, 0); font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">135</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="line-height: 1.25; font-weight: bold; font-family: Times New Roman">Ordinary Shares</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman">&#160;</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman">Voting Power</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">Holders of New Silexion ordinary shares are entitled to
one vote in respect of each share held of record by such holder on all matters to be voted on by shareholders.</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman">&#160;</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman">Dividends</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">Subject to applicable law, holders of New Silexion ordinary
shares are entitled to receive dividends when, as and if declared by the New Silexion Board, payable in cash, property or shares.</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman">&#160;</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman">Winding Up, Liquidation and Dissolution</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="line-height: 1.25; font-family: Times New Roman">Upon New Silexion&#8217;s winding up and liquidation and after payment in
full of all amounts required to be paid to creditors, the holders of New Silexion ordinary shares are entitled to receive a pro rata share
of New Silexion&#8217;s remaining assets available for distribution.</div> </div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman">&#160;</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman">Preemptive or Other Rights</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">Holders of New Silexion ordinary shares will not be entitled
to preemptive rights, and New Silexion ordinary shares will not be subject to conversion, redemption or sinking fund provisions.</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman">&#160;</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman">Appointment of Directors</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="line-height: 1.25; font-family: Times New Roman">The New Silexion Board will consist of up to nine (9) directors and not less
than three (3) directors, unless increased or decreased from time to time by Ordinary Resolution in a general meeting.</div> </div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">Directors will generally be appointed by an Ordinary Resolution
passed at each annual general meeting.</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">Prior to each annual general meeting, the New Silexion
Board (or a nominating committee established by the New Silexion Board for such purpose) may select, via a resolution adopted by a majority
of the New Silexion Board or such committee, a number of persons to be proposed to the shareholders for appointment as directors at such
annual general meeting, for service until the next annual general meeting (the &#8220;Nominees&#8221;). Any shareholder entitled under
applicable law to propose one or more persons as nominees for appointment as directors at an annual general meeting (each such nominee,
an &#8220;Alternate Nominee&#8221;) may make such proposal only if a written notice of such shareholder&#8217;s intent to that effect
has been given to the Secretary of the Company (or, if there is no such Secretary, the chief executive officer) within the periods set
out in the Articles.</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">Unless the New Silexion Board resolves that the appointment
of Nominees or Alternate Nominees will be determined based on those Nominees or Alternate Nominees receiving the highest number of votes
of Members in favor of their appointment&#8212; even if less than a majority of all Members&#8217; votes that are cast, the Nominees or
Alternate Nominees shall be appointed by Ordinary Resolution at the annual general meeting at which they are proposed for appointment.
If the appointment of the Nominees or Alternate Nominees proposed to be appointed would cause the total number of directors (including
those then in office) to exceed the maximum number, then any directors then in office who are not named as Nominees or Alternate Nominees
will cease to hold office following the conclusion of such annual general, if any such Nominees or Alternate Nominees are appointed in
such meeting, and upon such Nominees or Alternate Nominees taking office. If (a) the appointment of the Nominees or Alternate Nominees
proposed to be appointed would not cause the total number of directors to exceed the maximum, or (b) no Nominees or Alternate Nominees
are proposed to be appointed at an annual general meeting by either the Board or Members, or (c) no Nominees or Alternate Nominees are
eventually appointed in such annual general meeting &#8212; all directors then in office shall continue to hold office until the convening
of a general meeting at which Nominees or Alternate Nominees shall be proposed and appointed, and where such appointment would cause the
total number of directors to exceed the maximum.</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: rgb(0, 0, 0); font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">136</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">Each director will hold office until the next succeeding
annual general meeting and until his or her successor is appointed and qualified, or until such director&#8217;s earlier death, resignation,
disqualification or removal. The Articles will not provide for cumulative voting for the appointment of directors.</div>

<div style="line-height: 1.25; font-weight: bold; font-family: Times New Roman">&#160;</div>

<div style="line-height: 1.25; font-weight: bold; font-family: Times New Roman">New Silexion Warrants</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="line-height: 1.25; font-family: Times New Roman">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">Following the Closing of the Business Combination
and as of October 1, 2024, there were 660,001 New Silexion warrants to purchase New Silexion ordinary shares outstanding, consisting of
638,889 New Silexion public warrants issued upon conversion of an equivalent number of Moringa public warrants and 21,112 New Silexion
private warrants issued upon conversion of an equivalent number of Moringa private warrants (of which 19,603 and 1,508 private warrants
are held by the Sponsor and EarlyBird, respectively). In connection with the Closing, each Moringa warrant was exchanged for a New Silexion
warrant on substantially similar terms, including exercise price.</div> </div> </div> </div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="line-height: 1.25">

<div style="line-height: 1.25; font-family: Times New Roman">Each New Silexion public warrant entitles the registered holder to purchase
one New Silexion ordinary share at a price of $103.50 per share, subject to adjustment as discussed below, at any time commencing one
month after the Closing. However, no New Silexion public warrants will be exercisable for cash unless there is an effective and current
registration statement covering the New Silexion ordinary shares issuable upon exercise of the New Silexion public warrants and a current
prospectus relating to such New Silexion ordinary shares. Notwithstanding the foregoing, if a registration statement covering the New
Silexion ordinary shares issuable upon exercise of the New Silexion public warrants is not effective within 60 business days from the
closing of the Business Combination, warrant holders may, until such time as there is an effective registration statement and during any
period when the Company shall have failed to maintain an effective registration statement, exercise New Silexion public warrants on a
cashless basis pursuant to the exemption provided by Section 3(a)(9) of the Securities Act, provided that such exemption is available.
If that exemption, or another exemption, is not available, holders will not be able to exercise their warrants on a cashless basis. In
the case of a cashless exercise, each holder would pay the exercise price by surrendering the warrants for that number of New Silexion
ordinary shares equal to the quotient obtained by dividing (x) the product of the number of New Silexion ordinary shares underlying the
warrants, multiplied by the difference between the exercise price of the warrants and the &#8220;fair market value&#8221; (defined below)
by (y) the fair market value. The &#8220;fair market value&#8221; for this purpose will mean the average reported last sale price of the
ordinary shares for the five trading days ending on the trading day prior to the date of exercise. The New Silexion public warrants will
expire five years from the Closing of the Business Combination (i.e., on August 15, 2029) at 5:00 p.m., New York City time.</div> </div>
</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">The New Silexion private warrants are identical to the
New Silexion public warrants, except that each New Silexion private warrant will be exercisable for cash (even if a registration statement
covering the New Silexion ordinary shares issuable upon exercise of such warrants is not effective) or on a cashless basis, at the holder&#8217;s
option, and will not be redeemable by the Company, in each case so long as they are still held by the Sponsor, EarlyBird or their respective
affiliates.</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">From and after the time the New Silexion warrants become
exercisable, we may call them for redemption (excluding the New Silexion private warrants), in whole and not in part, at a price of $0.01
per warrant, upon not less than 30 days&#8217; prior written notice of redemption to each warrant holder, if and only if</div>

<div style="text-indent: -36pt; margin-left: 48pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z70dd68a70a924132ae0fb17dd7f9967d" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">
        <div style="line-height: 1.25; font-family: Times New Roman">the reported last sale price of the ordinary shares equals or exceeds $162.00
        per share (as adjusted for share sub-divisions, share capitalizations, reorganizations and recapitalizations), for any 20 trading days
        within a 30 trading day period commencing after the warrants become exercisable and ending on the third business day prior to the notice
        of redemption to warrant holders; and</div> </div> </td> </tr>
  </table>

<div style="text-indent: -36pt; margin-left: 48pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<table cellspacing="0" cellpadding="0" id="zd2ffc8fab902467b8f0afbc343184a4f" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman">a registration statement is then in effect with respect to the New Silexion
        ordinary shares underlying such warrants.</div> </td> </tr>
  </table>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">The right to exercise will be forfeited unless the New
Silexion warrants are exercised prior to the date specified in the notice of redemption. On and after the redemption date, a record holder
of a New Silexion warrant will have no further rights except to receive the redemption price for such holder&#8217;s warrant upon surrender
of such warrant.</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: rgb(0, 0, 0); font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">137</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">The redemption criteria for New Silexion warrants have
been established at a price which is intended to provide warrant holders a reasonable premium to the initial exercise price and provide
a sufficient differential between the then-prevailing&#160;share price and the warrant exercise price so that if the share price declines
as a result of our redemption call, the redemption will not cause the share price to drop below the exercise price of the warrants.</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">If New Silexion calls the New Silexion warrants for redemption
as described above, its management will have the option to require all holders that wish to exercise warrants prior to redemption to do
so on a &#8220;cashless basis.&#8221; In such event, each holder would pay the exercise price by surrendering the warrants for that number
of New Silexion ordinary shares equal to the quotient obtained by dividing (x)&#160;the product of the number of New Silexion ordinary
shares underlying the warrants, multiplied by the difference between the exercise price of the warrants and the &#8220;fair market value&#8221;
(defined below) by (y)&#160;the fair market value. The &#8220;fair market value&#8221; shall mean the average reported last sale price
of the New Silexion ordinary shares for the 5&#160;trading days ending on the third&#160;trading day prior to the date on which the notice
of redemption is sent to the holders of warrants.</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">The New Silexion warrants will be issued in registered
form under a warrant agreement between Continental Stock Transfer&#160;&amp; Trust Company, as warrant agent, and New Silexion (as assignee
of Moringa). The warrant agreement provides that the terms of the warrants may be amended without the consent of any holder to cure any
ambiguity or correct any defective provision, but requires the approval, by written consent or vote, of the holders of at least 50% of
the then outstanding public warrants in order to make any change that adversely affects the interests of the registered holders.</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">The exercise price and number of New Silexion ordinary
shares issuable on exercise of the warrants may be adjusted in certain circumstances including in the event of a share capitalization
or our recapitalization, reorganization, merger or consolidation. However, the warrants will not be adjusted for issuances of New Silexion
ordinary shares at a price below their respective exercise prices.</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">The New Silexion warrants may be exercised upon surrender
of the warrant certificate on or prior to the expiration date at the offices of the warrant agent, with the exercise form on the reverse
side of the warrant certificate completed and executed as indicated, accompanied by full payment of the exercise price, by certified or
official bank check payable to us, for the number of warrants being exercised. The warrant holders do not have the rights or privileges
of holders of New Silexion ordinary shares and any voting rights until they exercise their warrants and receive New Silexion ordinary
shares. After the issuance of New Silexion ordinary shares upon exercise of the warrants, each holder will be entitled to one vote for
each share held of record on all matters to be voted on by shareholders.</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">Under the terms of the warrant agreement, New Silexion
(as assignee of Moringa) has agreed to use its best efforts to have declared effective a registration statement relating to the New Silexion
ordinary shares issuable upon exercise of the warrants and keep such registration statement and its included prospectus current until
the expiration of the warrants. However, we cannot assure you that we will be able to do so and, if we do not maintain a current prospectus
relating to the New Silexion ordinary shares issuable upon exercise of the warrants, holders will be unable to exercise their warrants
for cash and we will not be required to net cash settle or cash settle the warrant exercise.</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">Warrant holders may elect to be subject to a restriction
on the exercise of their warrants such that an electing warrant holder would not be able to exercise their warrants to the extent that,
after giving effect to such exercise, such holder would beneficially own in excess of 9.9% of the New Silexion ordinary shares outstanding.</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">No fractional shares will be issued upon exercise of the
New Silexion warrants. If, upon exercise of the warrants, a holder would be entitled to receive a fractional interest in a share, we will,
upon exercise, round up to the nearest whole number the number of New Silexion ordinary shares to be issued to the warrant holder.</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman">Contractual Arrangements with respect
to the New Silexion private warrants</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">So long as the New Silexion private warrants are still
held by the Sponsor, EarlyBird or their affiliates, the Company will not redeem such warrants, and the Company will allow the holders
to exercise such warrants on a cashless basis (even if a registration statement covering the New Silexion ordinary shares issuable upon
exercise of such warrants is not effective). However, once any of the New Silexion private warrants are transferred from the Sponsor,
EarlyBird or their affiliates, these arrangements will no longer apply. Furthermore, because the New Silexion private warrants were issued
in a private transaction, the holders and their transferees will be allowed to exercise the New Silexion private warrants for cash even
if a registration statement covering the New Silexion ordinary shares issuable upon exercise of such warrants is not effective and receive
unregistered New Silexion ordinary shares.</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: rgb(0, 0, 0); font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">138</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="line-height: 1.25; font-weight: bold; font-family: Times New Roman">&#160;</div>

<div style="line-height: 1.25; font-weight: bold; font-family: Times New Roman">Listing of Securities</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">Our ordinary shares and New Silexion warrants are listed
on the Nasdaq under the symbols &#8220;SLXN&#8221; and &#8220;SLXNW&#8221;, respectively.</div> </div>

<div style="line-height: 1.25; font-weight: bold; font-family: Times New Roman">&#160;</div>

<div style="line-height: 1.25; font-weight: bold; font-family: Times New Roman">Transfer Agent and Registrar</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">The transfer agent and registrar for the New Silexion
ordinary shares and warrant agent for the New Silexion warrants is Continental Stock Transfer&#160;&amp; Trust Company.</div>

<div style="line-height: 1.25; font-weight: bold; font-family: Times New Roman">&#160;</div>

<div style="line-height: 1.25; font-weight: bold; font-family: Times New Roman">Anti-Takeover&#160;Provisions in Our Articles.</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">Some provisions of our Articles may discourage, delay
or prevent a change in control of our company or management that shareholders may consider favorable.</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">However, under Cayman Islands law, our directors may only
exercise the rights and powers granted to them under our Articles, as amended and restated from time to time, for a proper purpose and
for what they believe in good faith to be in the best interests of our company.</div>

<div style="line-height: 1.25; font-style: italic; font-family: Times New Roman">&#160;</div>

<div style="line-height: 1.25; font-style: italic; font-family: Times New Roman,Times,serif">

<div style="line-height: 1.25; font-style: italic; font-family: Times New Roman">Authorized but Unissued Shares</div> </div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">The authorized but unissued New Silexion ordinary shares
are available for future issuance without shareholder approval, subject to any limitations imposed by the listing standards of the Nasdaq
and the Articles. These additional shares may be used for a variety of corporate finance transactions, acquisitions and employee benefit
plans. The existence of authorized but unissued and unreserved New Silexion ordinary shares could make more difficult or discourage an
attempt to obtain control of New Silexion by means of a proxy contest, tender offer, merger or otherwise.</div>

<div style="line-height: 1.25; font-style: italic; font-family: Times New Roman">&#160;</div>

<div style="line-height: 1.25; font-style: italic; font-family: Times New Roman">Shareholder Action; Extraordinary General Meetings</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">Our Articles provide that shareholders may take action
by unanimous written resolutions or at annual or extraordinary general meetings. As a result, a holder controlling a majority of New Silexion
ordinary shares would not be able to amend the Articles or remove directors without holding a meeting of shareholders called in accordance
with the Articles or the shareholders of New Silexion passing unanimous written resolutions to approve the same. Further, the Articles
provide that only the chairperson of the Board, or the New Silexion Board pursuant to a resolution adopted by a majority of the directors
then in office&#160;&#8212;&#160;and not shareholders&#160;&#8212;&#160;may call extraordinary general meetings of shareholders, thus
prohibiting a holder of New Silexion ordinary shares from calling an extraordinary general meeting. These provisions might delay the ability
of shareholders to force consideration of a proposal or for shareholders controlling a majority of New Silexion to take any action, including
the removal of directors.</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;<span style="font-style: italic">&#160;</span></div>

<div style="line-height: 1.25; font-style: italic; font-family: Times New Roman">Advance Notice Requirements for Shareholder Proposals
and Director Nominations</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">The Articles provide that shareholders seeking to bring
business before our annual general meeting, or to nominate candidates for appointment as directors at its annual general meeting, must
provide timely notice. To be timely, a shareholder&#8217;s notice will need to be delivered to the Secretary of New Silexion at its principal
executive offices not less than 90&#160;days nor more than 120&#160;calendar days prior to the one-year&#160;anniversary of the preceding
year&#8217;s annual general meeting. In the event that no annual general meeting was held during the preceding year or the date of the
annual general meeting is more than 30&#160;days before or more than 60&#160;days after such anniversary date, to be timely, a shareholder&#8217;s
notice must be so delivered no earlier than the close of business on the 120<sup style="vertical-align: text-top; line-height: 1; font-size: smaller">th</sup>&#160;day
prior to such annual general meeting and not later than the 90<sup style="vertical-align: text-top; line-height: 1; font-size: smaller">th</sup>&#160;day
prior to such annual general meeting or, if later, the 10<sup style="vertical-align: text-top; line-height: 1; font-size: smaller">th</sup>&#160;day
following the&#160;day on which public disclosure of the date of such annual general meeting is first made by New Silexion. The Articles
also specify certain requirements as to the form and content of a shareholders&#8217; notice. These provisions may preclude New Silexion
shareholders from bringing matters before our annual general meeting or from making nominations for directors at our annual general meeting.</div>
</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: rgb(0, 0, 0); font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">139</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="line-height: 1.25; font-style: italic; font-family: Times New Roman">&#160;</div>

<div style="line-height: 1.25; font-style: italic; font-family: Times New Roman">Supermajority Requirements for the Amendment of the Articles</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">Under the Companies Act (As Revised) of the Cayman Islands,
the Articles may be amended by a special resolution of shareholders, being a resolution passed by not less than two-thirds&#160;(2/3)
of our shareholders as being entitled to do so, vote in person or by proxy at a general meeting.</div> </div>

<div style="line-height: 1.25; font-style: italic; font-family: Times New Roman">&#160;</div>

<div style="line-height: 1.25; font-style: italic; font-family: Times New Roman">Board Vacancies</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">The Articles provide that any vacancy on the New Silexion
Board may be filled by the affirmative vote of a majority of the directors then in office, even if less than a quorum, or by a sole remaining
director, and not by our shareholders. Any director chosen to fill a vacancy will hold office until the next annual general meeting and
until his or her successor is duly appointed and qualified, or until his or her earlier death, resignation, disqualification or removal.
In addition, the number of directors constituting the then-authorized&#160;size of the New Silexion Board is permitted to be set only
by a resolution adopted by the Board.</div> </div>

<div style="line-height: 1.25; font-style: italic; font-family: Times New Roman">&#160;</div>

<div style="line-height: 1.25; font-style: italic; font-family: Times New Roman">Exclusive Forum Selection</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">The Articles provide that, unless New Silexion consents
in writing to the selection of an alternative forum and to the fullest extent permitted by law, the courts of the Cayman Islands have
exclusive jurisdiction over any claim or dispute arising out of or in connection with the Articles or otherwise related in any way to
each shareholder&#8217;s shareholding in the Company, including but not limited to (i)&#160;any derivative action or proceeding brought
on behalf of the Company, (ii)&#160;any action asserting a claim of breach of a fiduciary duty owed by any director, officer or other
employee of the Company to the Company or our shareholders, or (iii)&#160;any action asserting a claim arising pursuant to any provision
of the Companies Act (As Revised) of the Cayman Islands or the Articles, and each shareholder shall be deemed to have irrevocably submitted
to the exclusive jurisdiction of the courts of the Cayman Islands over all such claims or disputes.</div> </div> </div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">However, such forum selection provisions will not apply
to suits brought to enforce any liability or duty created by the Securities Act or the Exchange&#160;Act. The Articles also provide that,
unless New Silexion consents in writing to the selection of an alternative forum, the federal district courts of the United&#160;States
of America will be the exclusive forum for the resolution of any complaint asserting a cause of action arising under the Securities Act
or the Exchange Act. There is uncertainty as to whether a court would enforce that exclusivity provision. Furthermore, investors cannot
waive compliance with the U.S. federal securities laws and the rules and regulations thereunder.</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">Any person or entity purchasing or otherwise acquiring
any interest in New Silexion shares shall be deemed to have notice of and consented to the forum selection provisions in the Articles.</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">The choice of forum provisions may limit a shareholder&#8217;s
ability to bring a claim in a judicial forum that it finds favorable for disputes with New Silexion or its directors, officers, or other
employees, which may discourage such lawsuits against New Silexion and its directors, officers, and other employees. Alternatively, if
a court were to find the choice of forum provisions contained in the Articles to be inapplicable or unenforceable in an action, New Silexion
may incur additional costs associated with resolving such action in other jurisdictions, which could harm its business, results of operations,
and financial condition.</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: rgb(0, 0, 0); font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">140</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="line-height: 1.25; font-style: italic; font-family: Times New Roman">&#160;</div>

<div style="line-height: 1.25; font-style: italic; font-family: Times New Roman">Transactions with Interested Shareholders.</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">Cayman Islands law does not have a business combination
statute (like in Delaware) applicable to public companies prohibiting them from engaging in certain business combinations with an &#8220;interested
shareholder&#8221;. As a result, we cannot avail ourselves of the types of protections afforded by a business combination statute. However,
although Cayman Islands law does not regulate transactions between a company and its significant shareholders, it does provide that such
transactions must be entered into bona fide in the best interests of the company and for a proper corporate purpose and not with the effect
of constituting a fraud on the minority shareholders.</div>

<div style="line-height: 1.25; font-style: italic; font-family: Times New Roman">&#160;</div>

<div style="line-height: 1.25; font-style: italic; font-family: Times New Roman">Limitation on Liability and Indemnification of Directors
and Officers</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="line-height: 1.25; font-family: Times New Roman">Cayman Islands law does not limit the extent to which a company&#8217;s memorandum
and articles of association may provide for indemnification of officers and directors, except to the extent any such provision may be
held by the Cayman Islands courts to be contrary to public policy, such as to provide indemnification against willful default, willful
neglect, actual fraud or the consequences of committing a crime. Our Articles provide that our directors and officers shall be indemnified
out of the assets of New Silexion against any liability, action, proceeding, claim, demand, costs, damages or expenses, including legal
expenses, whatsoever which they or any of them may incur as a result of any act or failure to act in carrying out their functions other
than such liability (if any) that they may incur by reason of their own actual fraud, willful neglect or willful default. No such indemnified
person shall be liable to New Silexion for any loss or damage incurred by New Silexion as a result (whether direct or indirect) of the
carrying out of their functions unless that liability arises through the actual fraud, willful neglect or willful default of such indemnified
person. No person shall be found to have committed actual fraud, willful neglect or willful default under the foregoing unless or until
a court of competent jurisdiction shall have made a finding to that effect.. In addition, the Articles provide for the advancing of certain
fees and costs to such indemnified persons and the purchase by New Silexion for insurance for the benefit of its directors and officers
as further described in the Articles.</div> </div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">Insofar as indemnification for liabilities arising under
the Securities Act may be permitted to New Silexion directors, officers and controlling persons pursuant to the foregoing provisions,
or otherwise, in the opinion of the SEC, such indemnification is against public policy as expressed in the Securities Act and is, therefore,
unenforceable.</div>

<div style="line-height: 1.25"><span style="font-family: Times New Roman"><br/> </span> </div> </div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-family: Times New Roman,Times,serif; font-weight: normal; font-style: normal">141</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div>&#160;

<div style="text-align: center; line-height: 1.25; font-weight: bold; font-family: Times New Roman,Times,serif">

<div style="margin-left: 0.7pt; line-height: 1.25; font-weight: bold; font-family: Times New Roman">

<div style="line-height: 1.25; font-family: Times New Roman, Times, serif; font-weight: bold">MATERIAL U.S. FEDERAL INCOME TAX <span id="CONSEQUENCES"><!--Anchor--></span>CONSEQUENCES</div>
</div> </div>

<div style="text-align: center; line-height: 1.25; font-weight: bold; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">

<div style="text-align: left; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">The following discussion
is a summary of certain material U.S. federal income tax considerations generally applicable to the ownership and disposition of our ordinary
shares and the exercise, disposition and lapse of our warrants. The ordinary shares and the warrants are referred to collectively herein
as our securities. All prospective holders of our securities should consult their tax advisors with respect to the U.S. federal, state,
local and non-U.S. tax consequences of the ownership and disposition of our securities.</div> </div> </div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">

<div style="text-align: left; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">This discussion is not
a complete analysis of all potential U.S. federal income tax consequences relating to the ownership and disposition of our securities.
This summary is based upon current provisions of the Code, existing U.S. Treasury Regulations promulgated thereunder, published administrative
pronouncements and rulings of the U.S. Internal Revenue Service (the &#8220;<span style="font-weight: bold">IRS</span>&#8221;), and judicial
decisions, all as in effect as of the date of this prospectus. These authorities are subject to change and differing interpretation, possibly
with retroactive effect. Any change or differing interpretation could alter the tax consequences to holders described in this discussion.
There can be no assurance that a court or the IRS will not challenge one or more of the tax consequences described herein, and we have
not obtained, nor do we intend to obtain, a ruling with respect to the U.S. federal income tax consequences to a holder of the ownership
or disposition of our securities.</div> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif"> <span style="font-family: Times New Roman"><br/>
</span> </div> </div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman,Times,serif">

<div style="line-height: 1.25; font-family: Times New Roman, Times, serif; font-style: italic; font-weight: bold">Tax Consequences of
Ownership and Disposition of New Silexion Securities</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif"> </div> </div>

<div style="line-height: 1.25; font-style: italic; font-family: Times New Roman">&#160;</div>

<div style="line-height: 1.25; font-style: italic; font-family: Times New Roman,Times,serif">

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman; font-style: italic">

<div style="text-align: left; line-height: 1.25; font-family: Times New Roman, Times, serif; font-style: italic">Distributions on New
Silexion ordinary shares</div> </div> </div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">

<div style="text-indent: 36pt; line-height: 1.25">

<div style="text-indent: 36pt; line-height: 1.25">

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">

<div style="text-align: left; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">Subject to the PFIC rules
discussed below, the gross amount of any distribution on New Silexion ordinary shares that is made out of New Silexion&#8217;s current
or accumulated earnings and profits (as determined for U.S.&#160;federal income tax purposes) generally will be taxable to a U.S.&#160;Holder
as ordinary dividend income on the date such distribution is actually or constructively received. Any such dividends generally will not
be eligible for the dividends received deduction allowed to corporations in respect of dividends received from U.S.&#160;corporations.
To the extent that the amount of the distribution exceeds New Silexion&#8217;s current and accumulated earnings and profits (as determined
under U.S.&#160;federal income tax principles), such excess amount will be treated first as a non-taxable&#160;return of capital to the
extent of the U.S.&#160;Holder&#8217;s tax basis in its New Silexion ordinary shares, and thereafter as capital gain recognized on a sale
or exchange. However, it is not expected that New Silexion will maintain calculations of its earnings and profits principles. U.S.&#160;Holders
should therefore assume that any distribution by New Silexion with respect to New Silexion ordinary shares will be reported as dividend
income.<sup style="vertical-align: text-top; line-height: 1; font-size: smaller">&#160;</sup>U.S.&#160;Holders should consult their own
tax advisors with respect to the appropriate U.S.&#160;federal income tax treatment of any distribution received from New Silexion.</div>
</div> </div>

<div style="text-indent: 36pt; line-height: 1.25"> <span style="font-family: Times New Roman"><br/> </span> </div> </div> </div> </div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: rgb(0, 0, 0); font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">142</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">

<div style="text-align: left; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">Subject to the PFIC rules
discussed below, dividends received by non-corporate&#160;U.S.&#160;Holders (including individuals) from a &#8220;qualified foreign corporation&#8221;
may be eligible for reduced rates of taxation, provided that certain holding period requirements and other conditions are satisfied. For
these purposes, a non-U.S.&#160;corporation will be treated as a qualified foreign corporation if it is eligible for the benefits of a
comprehensive income tax treaty with the United&#160;States that meets certain requirements. A non-U.S.&#160;corporation is also treated
as a qualified foreign corporation with respect to dividends it pays on shares that are readily tradable on an established securities
market in the United&#160;States. U.S.&#160;Treasury guidance indicates that shares listed on Nasdaq (such as the New Silexion ordinary
shares) will be considered readily tradable on an established securities market in the United&#160;States. There can be no assurance that
New Silexion ordinary shares will be considered readily tradable on an established securities market in future&#160;years. Further, New
Silexion will not constitute a qualified foreign corporation for purposes of these rules if it is a PFIC for the taxable year in which
it pays a dividend or for the preceding taxable year.</div> </div> </div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">

<div style="line-height: 1.25; font-family: Times New Roman">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">Subject to certain conditions and limitations,
non-refundable&#160;withholding taxes (at a rate not in excess of any applicable income tax treaty rate), if any, on dividends paid by
New Silexion may be treated as foreign taxes eligible for credit against a U.S.&#160;Holder&#8217;s U.S.&#160;federal income tax liability
under the U.S.&#160;foreign tax credit rules. However, as a result of recent changes to the U.S.&#160;foreign tax credit rules, a withholding
tax generally may need to satisfy certain additional requirements in order to be considered a creditable tax for a U.S.&#160;Holder. New
Silexion has not determined whether these requirements have been met with respect to any withholding tax that may apply to dividends paid
by New Silexion and, accordingly, no assurance can be given that any such withholding tax will be creditable. For purposes of calculating
the U.S.&#160;foreign tax credit, dividends paid on New Silexion ordinary shares will generally be treated as income from sources outside
the United&#160;States and will generally constitute passive category income. The rules governing the U.S.&#160;foreign tax credit are
complex. U.S.&#160;Holders should consult their tax advisors regarding the availability of the U.S.&#160;foreign tax credit under their
particular circumstances.</div> </div> </div> </div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="line-height: 1.25; font-style: italic; font-family: Times New Roman,Times,serif">

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman; font-style: italic">

<div style="text-align: left; line-height: 1.25; font-family: Times New Roman, Times, serif; font-style: italic">Sale, Taxable Exchange
or Other Taxable Disposition of New Silexion Securities</div> </div> </div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">

<div style="text-align: left; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">Subject to the PFIC rules
discussed below, upon any sale, exchange or other taxable disposition of any New Silexion security, a U.S.&#160;Holder generally will
recognize gain or loss in an amount equal to the difference between (i)&#160;the sum of (x)&#160;the amount cash and (y)&#160;the fair
market value of any other property, received in such sale, taxable exchange or other taxable disposition and (ii)&#160;the U.S.&#160;Holder&#8217;s
adjusted tax basis in such New Silexion security. Any such gain or loss generally will be capital gain or loss and will be long-term&#160;capital
gain or loss if the U.S.&#160;Holder&#8217;s holding period for such New Silexion security exceeds one year. Long-term&#160;capital gain
realized by a non-corporate&#160;U.S.&#160;Holder generally will be taxable at a reduced rate. The deductibility of capital losses is
subject to limitations.</div> </div> </div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">This gain or loss generally will
be treated as U.S.&#160;source gain or loss. Accordingly, in the event that any non-U.S.&#160;tax (including withholding tax) is imposed
upon such sale, exchange or other taxable disposition, a U.S.&#160;Holder may not be able to utilize foreign tax credits in respect of
such non-U.S.&#160;tax. In addition, there may be other limitations on utilizing foreign tax credits even if a U.S.&#160;Holder has foreign
source income or gain in the same category from other sources. The rules governing foreign tax credits are complex and U.S.&#160;Holders
are urged to consult their tax advisers regarding the creditability of foreign taxes in their particular circumstances.</div> </div>

<div style="line-height: 1.25; font-style: italic; font-family: Times New Roman">&#160;</div>

<div style="line-height: 1.25; font-style: italic; font-family: Times New Roman,Times,serif">

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman; font-style: italic">

<div style="text-align: left; line-height: 1.25; font-family: Times New Roman, Times, serif; font-style: italic">Exercise, Lapse or Redemption
of a New Silexion Public Warrant</div> </div> </div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">

<div style="text-align: left; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">Subject to the PFIC rules
discussed below, a U.S.&#160;Holder generally will not recognize gain or loss upon the acquisition of a New Silexion ordinary share on
the exercise of a New Silexion public warrant for cash. A U.S.&#160;Holder&#8217;s tax basis in a New Silexion ordinary share received
upon exercise of the New Silexion public warrant generally will equal the sum of the U.S.&#160;Holder&#8217;s tax basis in such New Silexion
public warrant and the exercise price. It is unclear whether a U.S.&#160;Holder&#8217;s holding period for the New Silexion ordinary share
received will commence on the date of exercise of the New Silexion public warrant or the&#160;day following the date of exercise of the
New Silexion public warrant; in either case, the holding period will not include the period during which the U.S.&#160;Holder held the
New Silexion public warrant. If a New Silexion public warrant is allowed to lapse unexercised, a U.S.&#160;Holder generally will recognize
a capital loss equal to such holder&#8217;s tax basis in the New Silexion public warrant.</div> </div> </div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif"> <span style="font-family: Times New Roman"><br/>
</span> </div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: rgb(0, 0, 0); font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">143</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">

<div style="text-align: left; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">The tax consequences of
a cashless exercise of a warrant are not clear under current law. Subject to the PFIC rules discussed below, a cashless exercise may not
be taxable, either because the exercise is not a realization event or because the exercise is treated as a recapitalization for U.S.&#160;federal
income tax purposes. In either situation, a U.S.&#160;Holder&#8217;s tax basis in New Silexion ordinary shares received generally should
equal the U.S.&#160;Holder&#8217;s tax basis in the New Silexion public warrants exercised therefor. If the cashless exercise was not
a realization event, it is unclear whether a U.S.&#160;Holder&#8217;s holding period for the New Silexion ordinary shares received would
be treated as commencing on the date of exercise of the New Silexion public warrants or the&#160;day following the date of exercise of
the New Silexion public warrants; in either case, the holding period will not include the period during which the U.S.&#160;Holder held
the New Silexion public warrants. If the cashless exercise were treated as a recapitalization, the holding period of the New Silexion
ordinary shares received would include the holding period of the New Silexion public warrants.</div> </div> </div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">

<div style="text-align: left; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">It is also possible that
a cashless exercise could be treated in part as a taxable exchange in which gain or loss would be recognized. In such event, a U.S.&#160;Holder
could be deemed to have surrendered a number of New Silexion public warrants equal to the number of New Silexion ordinary shares having
a value equal to the exercise price for the total number of New Silexion public warrants to be exercised. In such case, subject to the
PFIC rules discussed below, the U.S.&#160;Holder would recognize capital gain or loss with respect to the New Silexion public warrants
deemed surrendered in an amount equal to the difference between the fair market value of the New Silexion ordinary shares that would have
been received in a regular exercise of the New Silexion public warrants deemed surrendered and the U.S.&#160;Holder&#8217;s tax basis
in the New Silexion public warrants deemed surrendered. In this case, a U.S.&#160;Holder&#8217;s aggregate tax basis in the New Silexion
ordinary shares received would equal the sum of the U.S.&#160;Holder&#8217;s tax basis in the New Silexion public warrants deemed exercised
and the aggregate exercise price of such New Silexion public warrants. It is unclear whether a U.S.&#160;Holder&#8217;s holding period
for the New Silexion ordinary shares would commence on the date of exercise of the New Silexion public warrants or the&#160;day following
the date of exercise of the New Silexion public warrants; in either case, the holding period will not include the period during which
the U.S.&#160;Holder held the New Silexion public warrants.</div> </div> </div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">

<div style="text-align: left; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">Due to the absence of
authority on the U.S.&#160;federal income tax treatment of a cashless exercise, including when a U.S.&#160;Holder&#8217;s holding period
would commence with respect to New Silexion ordinary shares received, there can be no assurance regarding which, if any, of the alternative
tax consequences and holding periods described above would be adopted by the IRS or a court of law. Accordingly, U.S.&#160;Holders should
consult their tax advisors regarding the tax consequences of a cashless exercise.</div> </div> </div>

<div style="line-height: 1.25; font-style: italic; font-family: Times New Roman">&#160;</div>

<div style="line-height: 1.25; font-style: italic; font-family: Times New Roman">Possible Constructive Distributions</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">

<div style="text-indent: 36pt; line-height: 1.25">

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">

<div style="text-align: left; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">The terms of each New
Silexion public warrant provide for an adjustment to the number of New Silexion ordinary shares for which the New Silexion public warrant
may be exercised or to the exercise price of the New Silexion public warrant in certain events, as discussed in the section of this prospectus
entitled &#8220;<span style="font-style: italic">Description of New Silexion Securities&#160;&#8212;&#160;Warrants.</span>&#8221; An adjustment
which has the effect of preventing dilution generally is not taxable. U.S.&#160;Holders of New Silexion public warrants would, however,
be treated as receiving a constructive distribution from New Silexion if, for example, the adjustment increases such U.S.&#160;Holders&#8217;
proportionate interest in New Silexion&#8217;s assets or earnings and profits (e.g., through an increase in the number of New Silexion
ordinary shares that would be obtained upon exercise or through a decrease in the exercise price of the New Silexion public warrants),
which adjustment may be made as a result of a distribution of cash or other property to the holders of New Silexion ordinary shares. Such
constructive distribution to a U.S.&#160;Holder of New Silexion public warrants would be treated as if such U.S.&#160;Holder had received
a cash distribution from New Silexion generally equal to the fair market value of such increased interest (taxed as described above under
&#8220;&#8212;<span style="font-style: italic">&#160;Distributions on New Silexion ordinary shares</span>&#8221;).</div> </div> </div>

<div style="text-indent: 36pt; line-height: 1.25"> <span style="font-family: Times New Roman"><br/> </span> </div> </div> </div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: rgb(0, 0, 0); font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">144</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman">&#160;</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman">PFIC Rules</div>

<div style="line-height: 1.25; font-style: italic; font-family: Times New Roman">&#160;</div>

<div style="line-height: 1.25; font-style: italic; font-family: Times New Roman">In General</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">

<div style="text-align: left; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">The treatment of U.S.&#160;Holders
of New Silexion securities could be materially different from that described above if New Silexion is treated as a PFIC for U.S.&#160;federal
income tax purposes.</div> </div> </div> </div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman; text-align: left">In general, a non-U.S.&#160;corporation
is a PFIC for U.S.&#160;federal income tax purposes for any taxable year in which, after applying certain look-through&#160;rules, (i)&#160;50%
or more of the value of its assets (generally determined on the basis of a weighted quarterly average) consists of assets that produce,
or are held for the production of, passive income, or (ii)&#160;75% or more of its gross income consists of passive income. Passive income
generally includes dividends, interest, rents and royalties (other than rents or royalties derived from the active conduct of a trade
or business) and gains from the disposition of passive assets. Cash and cash equivalents generally are passive assets. The value of goodwill
will generally be treated as an active or passive asset based on the nature of the income produced in the activity to which the goodwill
is attributable. For purposes of the PFIC rules, a non-U.S.&#160;corporation that owns, directly or indirectly, at least 25% by value
of the stock of another corporation is treated as if it held its proportionate share of the assets of the other corporation and directly
received its proportionate share of the income of the other corporation.</div> </div> </div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">

<div style="text-align: left; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">The application of the
PFIC rules to warrants is uncertain. The Code provides that, to the extent provided in Treasury Regulations, if any person has an option
to acquire shares of a PFIC, the shares will be considered as owned by that person for purposes of the PFIC rules. Under proposed Treasury
Regulations that have a retroactive effective date, an option to acquire shares of a PFIC is generally treated as ownership of those PFIC
shares. The remainder of this discussion assumes that the PFIC rules will apply to New Silexion public warrants if New Silexion was a
PFIC.&#160;However, U.S.&#160;Holders should consult their tax advisers regarding the application of the PFIC rules to New Silexion public
warrants prior to the finalization of the proposed Treasury Regulations.</div> </div> </div> </div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">If non-U.S.&#160;corporation is treated as a PFIC during
a U.S.&#160;Holder&#8217;s holding period, it will, with respect to such U.S.&#160;Holder, always be treated as a PFIC, regardless of
whether it satisfied either of the qualification tests in subsequent&#160;years, subject to certain exceptions (such as upon making a
&#8220;deemed sale&#8221; election).</div> </div> </div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">

<div style="text-align: left; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">The adverse impact of
the PFIC rules on a U.S.&#160;Holder that holds shares in a PFIC may generally be mitigated if the U.S.&#160;Holder makes a timely qualified
electing fund (&#8220;<span style="font-weight: bold">QEF</span>&#8221;) election or mark-to-market&#160;election for the PFIC&#8217;s
first taxable year as a PFIC in which the U.S.&#160;Holder held (or was deemed to hold) shares, or a QEF election along with an applicable
purging election (collectively, &#8220;<span style="font-weight: bold">PFIC Elections</span>&#8221;). Further detail about the PFIC Elections
is provided below under &#8220;&#8212;<span style="font-style: italic">&#160;New Silexion Securities</span>&#8221;.</div> </div> </div>
</div>

<div style="line-height: 1.25; font-style: italic; font-family: Times New Roman">&#160;</div>

<div style="line-height: 1.25; font-style: italic; font-family: Times New Roman,Times,serif">

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman; font-style: italic">

<div style="text-align: left; line-height: 1.25; font-family: Times New Roman, Times, serif; font-style: italic">New Silexion Securities</div>
</div> </div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">

<div style="text-align: left; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">The annual PFIC income
and asset tests in respect of New Silexion will be applied based on the assets and activities of the combined business. Based on the projected
composition of New Silexion&#8217;s income and assets, it cannot be determined whether New Silexion will be classified as a PFIC for its
taxable year that includes the date of the Business Combination or in any future taxable year. Further, changes in the composition of
New Silexion&#8217;s income or composition of New Silexion&#8217;s assets may cause New Silexion to be or become a PFIC for the current
or subsequent taxable&#160;years. Whether New Silexion is treated as a PFIC for U.S.&#160;federal income tax purposes is a factual determination
that must be made annually at the close of each taxable year and, thus, is subject to significant uncertainty.</div> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: rgb(0, 0, 0); font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">145</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">If Moringa is determined to be a PFIC with
respect to any U.S.&#160;Holder who exchanges Moringa securities for New Silexion securities in connection with the SPAC Merger, the U.S.&#160;Holder
did not make any of the PFIC Elections, and the U.S.&#160;Holder is not subject to tax on the receipt of the New Silexion securities under
Section&#160;1291(f)&#160;of the Code or otherwise, then, although not free from doubt, New Silexion may also be treated as a PFIC as
to the New Silexion ordinary shares received by such U.S.&#160;Holder in the SPAC Merger, even if New Silexion is not a PFIC in its own
right. In addition, it is possible that proposed Treasury Regulations could be finalized in a manner that would treat any New Silexion
public warrants that are received in the SPAC Merger as subject to the PFIC rules.</div> </div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman"> <br/> </div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">If New Silexion is or becomes a PFIC during any year in
which a U.S.&#160;Holder holds New Silexion securities, there are three separate taxation regimes that could apply to such U.S.&#160;Holder
under the PFIC rules: (i)&#160;the excess distribution regime (which is the default regime), (ii)&#160;the QEF regime, or (iii)&#160;the
mark-to-market&#160;regime. A U.S.&#160;Holder who holds (actually or constructively) stock in a non-U.S.&#160;corporation during any
year in which such corporation qualifies as a PFIC is subject to U.S.&#160;federal income taxation under one of these three regimes. The
effect of the PFIC rules on a U.S.&#160;Holder will depend upon which of these regimes applies to such U.S.&#160;Holder. However, dividends
paid by a PFIC are not eligible for the lower rates of taxation applicable to qualified dividend income under any of the foregoing regimes.</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">

<div style="text-align: left; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif"><span style="text-decoration: underline">Excess
Distribution Regime</span>.&#160;&#160;&#160;&#160;If a U.S.&#160;Holder does not make or is not eligible to make a QEF election or a
mark-to-market&#160;election, as described below, the U.S.&#160;Holder will be subject to the default &#8220;excess distribution regime&#8221;
under the PFIC rules with respect to (i)&#160;any gain realized on a sale or other disposition (including a pledge) of New Silexion securities,
and (ii)&#160;any &#8220;excess distribution&#8221; on New Silexion securities (generally, any distributions in excess of 125% of the
average of the annual distributions on New Silexion securities during the preceding three taxable&#160;years or the U.S.&#160;Holder&#8217;s
Holding period, for the New Silexion securities that preceded the taxable year of the distribution whichever is shorter). Generally, under
this excess distribution regime</div> </div> </div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif"><span style="font-family: Times New Roman">&#160;
</span>

<table cellspacing="0" cellpadding="0" id="zd426ed8b8e324835a5b03189011ed912" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman">
        <div style="text-align: left; line-height: 1.25; font-family: Times New Roman,Times,serif">the U.S.&#160;Holder&#8217;s gain or excess
        distribution will be allocated ratably over the U.S.&#160;Holder&#8217;s holding period for the New Silexion securities;</div> </div>
        </td> </tr>
  </table>

<div style="text-align: justify; text-indent: -36pt; margin-left: 48pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z3fc2c36058ad4aeb8531aed57898349a" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman">
        <div style="text-align: left; line-height: 1.25; font-family: Times New Roman,Times,serif">the amount allocated to the U.S.&#160;Holder&#8217;s
        taxable year in which the U.S.&#160;Holder recognized the gain or received the excess distribution, or to the period in the U.S.&#160;Holder&#8217;s
        holding period before the first&#160;day of New Silexion&#8217;s first taxable year in which New Silexion is a PFIC, will be taxed as
        ordinary income;</div> </div> </td> </tr>
  </table>

<div style="text-align: justify; text-indent: -36pt; margin-left: 48pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z6ac643e6d22e47abbc140b44d46045e1" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman">the amount allocated to other taxable&#160;years (or
        portions thereof) of the U.S.&#160;Holder and included in its holding period will be taxed at the highest tax rate in effect for that
        year and applicable to the U.S.&#160;Holder without regard to the U.S.&#160;Holder&#8217;s other items of income and loss for such year;
        and</div> </td> </tr>
  </table>

<div style="text-align: justify; text-indent: -36pt; margin-left: 48pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z4561133b31ef4d0b97f50032b460cd33" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 7.69%; vertical-align: top; font-family: Times New Roman">&#160;</td>
    <td style="width: 3.85%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman">&#9679;</div> </td>
    <td style="width: 88.46%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman">an additional amount equal to the interest charge generally
        applicable to underpayments of tax will be imposed on the U.S.&#160;Holder with respect to the tax attributable to each such other taxable
        year of the U.S.&#160;Holder.</div> </td> </tr>
  </table>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div> </div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">

<div style="text-align: left; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">The tax liability for
amounts allocated to&#160;years prior to the year of disposition or excess distribution will be payable generally without regard to offsets
from deductions, losses and expenses. In addition, gains (but not losses) realized on the sale of a U.S.&#160;Holder&#8217;s New Silexion
securities cannot be treated as capital gains, even if such securities are held as capital assets. Further, no portion of any distribution
will be treated as qualified dividend income.</div> </div> </div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">

<div style="text-align: left; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">If New Silexion is, or
is treated as, a PFIC for any taxable year during which a U.S.&#160;Holder owns New Silexion securities and any entity in which New Silexion
owns equity interests is also a PFIC (a &#8220;lower-tier&#160;PFIC&#8221;), the U.S.&#160;Holder will be deemed to own their proportionate
amount (by value) of the shares of each lower-tier&#160;PFIC and will be subject to U.S.&#160;federal income tax according to the rules
described above on (i)&#160;certain distributions by a lower-tier&#160;PFIC and (ii)&#160;dispositions of shares of lower-tier&#160;PFICs,
in each case, as if the U.S.&#160;Holder held such shares directly, even though the U.S.&#160;Holder will not receive any proceeds of
those distributions or dispositions.</div> </div> </div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="line-height: 1.25; font-family: Times New Roman">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif"><span style="text-decoration: underline">QEF
Regime</span>. A valid QEF election is effective for the taxable year for which the election is made and all subsequent taxable&#160;years
and may not be revoked without the consent of the IRS.&#160;If a U.S.&#160;Holder makes a timely QEF election with respect to its direct
or indirect interest in a PFIC, the U.S.&#160;Holder will be required to include in income each year its allocable portion of the ordinary
earnings and net capital gains of the PFIC as QEF income inclusions, even if such portion is not distributed to the U.S.&#160;Holder.
Thus, the U.S.&#160;Holder may be required to report taxable income as a result of QEF income inclusions without corresponding receipts
of cash. U.S.&#160;Holders of New Silexion securities should not expect that they will receive cash distributions from New Silexion sufficient
to cover their respective U.S.&#160;tax liability with respect to such QEF income inclusions. In addition, U.S.&#160;Holders of New Silexion
public warrants will not be able to make a QEF election with respect to their New Silexion public warrants.</div> </div> </div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: rgb(0, 0, 0); font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">146</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">The timely QEF election also allows
the electing U.S.&#160;Holder to: (i)&#160;generally treat any gain recognized on the disposition of its shares of the PFIC as capital
gain; (ii)&#160;treat its share of the PFIC&#8217;s net capital gain, if any, as long-term&#160;capital gain instead of ordinary income;
and (iii)&#160;either avoid interest charges resulting from PFIC status, or make an annual election, subject to certain limitations, to
defer payment of current taxes on its undistributed QEF income inclusions, subject to an interest charge on the deferred tax computed
by using the statutory rate of interest applicable to an extension of time for payment of tax. In addition, net losses (if any) of a PFIC
will not pass through to its shareholders and may not be carried back or forward in computing such PFIC&#8217;s ordinary earnings and
net capital gain in other taxable&#160;years.</div> </div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">

<div style="text-align: left; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">A U.S.&#160;Holder&#8217;s
tax basis in New Silexion ordinary shares will be increased to reflect QEF income inclusions and will be decreased to reflect distributions
of amounts previously included in income as QEF income inclusions. No portion of the QEF income inclusions attributable to ordinary income
will be treated as qualified dividend income. Amounts included as QEF income inclusions with respect to direct and indirect PFICs generally
will not be taxed again when distributed by such PFICs.</div> </div> </div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">A U.S.&#160;Holder may make a QEF election with respect to its
New Silexion ordinary shares only if New Silexion provides U.S.&#160;Holders on an annual basis with certain information, including a
&#8220;PFIC annual information statement&#8221; as described in the Treasury Regulations. If New Silexion determines that it is a PFIC
for any taxable year, it will endeavor to provide to a U.S.&#160;Holder such information as the IRS may require, including a PFIC annual
information statement, in order to enable a U.S.&#160;Holder to make and maintain a QEF election. However, there can be no assurance that
New Silexion will have timely knowledge of its status as a PFIC in the future or that New Silexion will timely provide U.S.&#160;Holders
with the required information on an annual basis to allow U.S.&#160;Holders to make and maintain a QEF election with respect to the New
Silexion ordinary shares in the event New Silexion is treated as a PFIC for any taxable year. The failure to provide such information
on an annual basis could prevent a U.S.&#160;Holder from making a QEF election or result in the invalidation or termination of a U.S.&#160;Holder&#8217;s
prior QEF election. In addition, as mentioned above, U.S.&#160;Holders of New Silexion public warrants will not be able to make a QEF
election with respect to their warrants.</div> </div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman"> <br/> </div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="line-height: 1.25; font-family: Times New Roman">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">

<div style="text-indent: 36pt; line-height: 1.25">If a U.S.&#160;Holder makes a QEF election with respect to its New Silexion ordinary
shares in a year after New Silexion&#8217;s first taxable year as a PFIC in which the U.S.&#160;Holder held (or was deemed to hold) New
Silexion ordinary shares, then notwithstanding such QEF election, the excess distribution regime discussed above, adjusted to take into
account the QEF income inclusions resulting from the QEF election, will continue to apply with respect to such U.S.&#160;Holder&#8217;s
New Silexion ordinary shares, unless the U.S.&#160;Holder makes a purging election under the PFIC rules. Under one type of purging election,
the U.S.&#160;Holder will be deemed to have sold such New Silexion ordinary shares at their fair market value and any gain recognized
on such deemed sale will be treated as an excess distribution, as described above. As a result of such purging election, the U.S.&#160;Holder
will have additional basis (to the extent of any gain recognized on the deemed sale) and, solely for purposes of the PFIC rules, a new
holding period in the New Silexion ordinary shares.</div> </div> </div> <span style="font-family: Times New Roman"> </span> </div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">

<div style="text-align: left; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">In addition, as mentioned
above, U.S.&#160;Holders of New Silexion public warrants will not be able to make a QEF election with respect to their warrants. As a
result, if a U.S.&#160;Holder sells or otherwise disposes of such New Silexion public warrants (other than upon exercise of such New Silexion
public warrants) and New Silexion were a PFIC at any time during the U.S.&#160;Holder&#8217;s holding period of such New Silexion public
warrants, any gain recognized generally will be treated as an excess distribution, taxed as described above. If a U.S.&#160;Holder that
exercises such New Silexion public warrants properly makes and maintains a QEF election with respect to the newly acquired New Silexion
ordinary shares (or has previously made a QEF election with respect to New Silexion ordinary shares), the QEF election will apply to the
newly acquired New Silexion ordinary shares. Notwithstanding such QEF election, the excess distribution rules discussed above, adjusted
to take into account the current income inclusions resulting from the QEF election, will continue to apply with respect to such newly
acquired New Silexion ordinary shares (which, while not entirely clear, generally will be deemed to have a holding period for purposes
of the PFIC rules that includes the period the U.S.&#160;Holder held the New Silexion public warrants), unless the U.S.&#160;Holder makes
a purging election under the PFIC rules. U.S.&#160;Holders are urged to consult their tax advisors as to the application of the rules
governing purging elections to their particular circumstances.</div> </div> </div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: rgb(0, 0, 0); font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">147</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="line-height: 1.25; font-family: Times New Roman">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif"><span style="text-decoration: underline">Mark-to-Market&#160;Regime</span>.&#160;
Alternatively, a U.S.&#160;Holder may make an election to mark marketable shares in a PFIC to market on an annual basis. PFIC shares generally
are marketable if they are &#8220;regularly traded&#8221; on a national securities exchange that is registered with the SEC, such as Nasdaq.
New Silexion ordinary shares are listed on Nasdaq but there can be no assurance that New Silexion ordinary shares will continue to be
so listed or will be &#8220;regularly traded&#8221; for purposes of these rules. Pursuant to such an election, a U.S.&#160;Holder of New
Silexion ordinary shares would include in each year as ordinary income the excess, if any, of the fair market value of such stock or shares
over its adjusted basis at the end of the taxable year. A U.S.&#160;Holder may treat as ordinary loss any excess of the adjusted basis
of the New Silexion ordinary shares over its fair market value at the end of the year, but only to the extent of the net amount previously
included in income as a result of the election in prior&#160;years. A U.S.&#160;Holder&#8217;s adjusted tax basis in the New Silexion
ordinary shares will be increased to reflect any amounts included in income, and decreased to reflect any amounts deducted, as a result
of a mark-to-market&#160;election. Any gain recognized on a disposition of New Silexion ordinary shares in a taxable year in which New
Silexion is a PFIC will be treated as ordinary income and any loss will be treated as ordinary loss (but only to the extent of the net
amount of income previously included as a result of a mark-to-market&#160;election, and any loss in excess of such prior inclusions generally
would be treated as a capital loss). A mark-to-market&#160;election applies for the taxable year in which the election was made, and for
each subsequent taxable year, unless the PFIC shares cease to be marketable or the IRS consents to the revocation of the election. U.S.&#160;Holders
should also be aware that the Code and the Treasury Regulations do not allow a mark-to-market&#160;election with respect to stock of lower-tier&#160;PFICs
that is non-marketable. There is also no provision in the Code, Treasury Regulations or other published authority that specifically provides
that a mark-to-market&#160;election with respect to the stock of a publicly traded holding company (such as New Silexion) effectively
exempts stock of any lower-tier&#160;PFICs from the negative tax consequences arising from the general PFIC rules. U.S.&#160;Holders are
advised to consult their own tax advisor to determine whether the mark-to-market&#160;tax election is available to them and the consequences
resulting from such election. In addition, U.S.&#160;Holders of New Silexion public warrants will not be able to make a mark-to-market&#160;election
with respect to their New Silexion public warrants.</div> </div> </div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;<span style="font-style: italic">&#160;</span></div>

<div style="line-height: 1.25; font-style: italic; font-family: Times New Roman">PFIC Reporting Requirements</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">A U.S.&#160;Holder that owns (or
is deemed to own) shares in a PFIC during any taxable year of the U.S.&#160;Holder generally is required to file an IRS Form&#160;8621
with such U.S.&#160;Holder&#8217;s U.S.&#160;federal income tax return and provide such other information as the IRS may require. Failure
to file IRS Form&#160;8621 for each applicable taxable year may result in substantial penalties and result in the U.S.&#160;Holder&#8217;s
taxable&#160;years being open to audit by the IRS until such forms are properly filed.</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">

<div style="text-align: left; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">THE RULES DEALING WITH
PFICS AND PFIC ELECTIONS ARE VERY COMPLEX AND ARE AFFECTED BY VARIOUS FACTORS IN ADDITION TO THOSE DESCRIBED ABOVE. ACCORDINGLY, U.S.&#160;HOLDERS
OF NEW SILEXION SECURITIES ARE URGED TO CONSULT THEIR OWN TAX ADVISORS CONCERNING THE APPLICATION OF THE PFIC RULES TO NEW SILEXION SECURITIES
UNDER THEIR PARTICULAR CIRCUMSTANCES.</div> </div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman">&#160;</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman">Additional Reporting Requirements</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">

<div style="text-align: left; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">Certain U.S.&#160;Holders
may be required to file an IRS Form&#160;926 (Return by a U.S.&#160;Transferor of Property to a Foreign Corporation) to report a transfer
of property (including cash) to New Silexion. Substantial penalties may be imposed on a U.S.&#160;Holder that fails to comply with this
reporting requirement, and the period of limitations on assessment and collection of U.S.&#160;federal income taxes will be extended in
the event of a failure to comply. Furthermore, certain U.S.&#160;Holders who are individuals and certain entities will be required to
report information with respect to such U.S.&#160;Holder&#8217;s investment in &#8220;specified foreign financial assets&#8221; on IRS
Form&#160;8938 (Statement of Specified Foreign Financial Assets), subject to certain exceptions. Specified foreign financial assets generally
include any financial account maintained with a non-U.S.&#160;financial institution and should also include New Silexion ordinary shares
and New Silexion public warrants if they are not held in an account maintained with a U.S.&#160;financial institution. Persons who are
required to report specified foreign financial assets and fail to do so may be subject to substantial penalties, and the period of limitations
on assessment and collection of U.S.&#160;federal income taxes may be extended in the event of a failure to comply. U.S.&#160;Holders
are urged to consult their tax advisors regarding the foreign financial asset and other reporting obligations and their application to
an investment in New Silexion ordinary shares and New Silexion public warrants.</div> </div> </div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: rgb(0, 0, 0); font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">148</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman,Times,serif"><span style="font-family: Times New Roman">&#160;
</span> </div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold; font-family: Times New Roman">Information Reporting and Backup Withholding</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">

<div style="text-align: left; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">Dividend payments with
respect to New Silexion ordinary shares and proceeds from the sale, exchange or redemption of New Silexion securities may be subject to
information reporting to the IRS and possible backup withholding. Backup withholding will not apply, however, to a U.S.&#160;Holder who
furnishes a correct taxpayer identification number and makes other required certifications, or who is otherwise exempt from backup withholding
and establishes such exempt status.</div> </div> </div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">Backup withholding is not an additional
tax. Amounts withheld as backup withholding may be credited against a U.S.&#160;Holder&#8217;s U.S.&#160;federal income tax liability,
and a U.S.&#160;Holder generally may obtain a refund of any excess amounts withheld under the backup withholding rules by timely filing
the appropriate claim for refund with the IRS and furnishing any required information.</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif"> <span style="font-family: Times New Roman"><br/>
</span> </div> </div>

<div style="text-align: center; line-height: 1.25; font-weight: bold; font-family: Times New Roman"><!--Anchor--><span id="PLAN"><!--Anchor--></span>PLAN
OF DISTRIBUTION</div>

<div style="text-align: center; line-height: 1.25; font-weight: bold; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 35.45pt; line-height: 1.25">

<div style="text-indent: 35.45pt; line-height: 1.25">We are registering the issuance by us of up to 2,377,030 New Silexion ordinary shares,
consisting of (i) 2,221,523 New Silexion ordinary shares issuable upon the exercise of the New Warrants, and (ii) 155,507 New Silexion
ordinary shares issuable upon the exercise of the Placement Agent Warrants.</div> </div>

<div style="text-indent: 35.45pt; line-height: 1.25"> <br/> </div>

<div style="text-indent: 35.45pt; line-height: 1.25">The Selling Securityholders, which as used herein includes donees, pledgees, transferees
or other successors-in-interest selling New Silexion ordinary shares or New Silexion warrants received after the date of this prospectus
from a Selling Securityholder as a gift, pledge, partnership distribution or other transfer, may, from time to time, sell, transfer or
otherwise dispose of any or all of their New Silexion ordinary shares and New Silexion warrants (including New Silexion ordinary shares
underlying such New Silexion warrants once issued upon the exercise of such warrants) on any stock exchange, market or trading facility
on which the New Silexion ordinary shares or New Silexion warrants are traded or in private transactions. These dispositions may be at
fixed prices, at prevailing market prices at the time of sale, at prices related to the prevailing market price, at varying prices determined
at the time of sale, or at negotiated prices.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-indent: 35.45pt; line-height: 1.25">The Selling Securityholders may use any one or more of the following methods when
disposing of New Silexion ordinary shares or New Silexion warrants:</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="line-height: 1.25; font-family: Times New Roman">

<table cellspacing="0" cellpadding="0" border="0" id="zf53291b6a56e4e53a84d40f9cc2ce552" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 5%; vertical-align: middle">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="white-space: nowrap; width: 2%; vertical-align: middle">
        <div style="line-height: 1.25">&#9679;</div> </td>
    <td style="width: 93%; vertical-align: middle">
        <div style="line-height: 1.25">ordinary brokerage transactions and transactions in which the broker-dealer solicits purchasers;</div>
        </td> </tr>
  <tr>
    <td style="width: 5%; vertical-align: middle">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="white-space: nowrap; width: 2%; vertical-align: middle">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 93%; vertical-align: middle">
        <div style="line-height: 1.25">&#160;</div> </td> </tr>
  <tr>
    <td style="width: 5%; vertical-align: middle">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="white-space: nowrap; width: 2%; vertical-align: middle">
        <div style="line-height: 1.25">&#9679;</div> </td>
    <td style="width: 93%; vertical-align: middle">
        <div style="line-height: 1.25">block trades in which the broker-dealer will attempt to sell the shares as agent, but may position and
        resell a portion of the block as principal to facilitate the transaction;</div> </td> </tr>
  <tr>
    <td style="width: 5%; vertical-align: middle">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="white-space: nowrap; width: 2%; vertical-align: middle">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 93%; vertical-align: middle">
        <div style="line-height: 1.25">&#160;</div> </td> </tr>
  <tr>
    <td style="width: 5%; vertical-align: middle">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="white-space: nowrap; width: 2%; vertical-align: middle">
        <div style="line-height: 1.25">&#9679;</div> </td>
    <td style="width: 93%; vertical-align: middle">
        <div style="line-height: 1.25">purchases by a broker-dealer as principal and resale by the broker-dealer for their account;</div> </td>
        </tr>
  <tr>
    <td style="width: 5%; vertical-align: middle">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="white-space: nowrap; width: 2%; vertical-align: middle">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 93%; vertical-align: middle">
        <div style="line-height: 1.25">&#160;</div> </td> </tr>
  <tr>
    <td style="width: 5%; vertical-align: middle">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="white-space: nowrap; width: 2%; vertical-align: middle">
        <div style="line-height: 1.25">&#9679;</div> </td>
    <td style="width: 93%; vertical-align: middle">
        <div style="line-height: 1.25">an exchange distribution in accordance with the rules of the applicable exchange;</div> </td> </tr>
  <tr>
    <td style="width: 5%; vertical-align: middle">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="white-space: nowrap; width: 2%; vertical-align: middle">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 93%; vertical-align: middle">
        <div style="line-height: 1.25">&#160;</div> </td> </tr>
  <tr>
    <td style="width: 5%; vertical-align: middle">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="white-space: nowrap; width: 2%; vertical-align: middle">
        <div style="line-height: 1.25">&#9679;</div> </td>
    <td style="width: 93%; vertical-align: middle">
        <div style="line-height: 1.25">privately negotiated transactions;</div> </td> </tr>
  <tr>
    <td style="width: 5%; vertical-align: middle">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="white-space: nowrap; width: 2%; vertical-align: middle">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 93%; vertical-align: middle">
        <div style="line-height: 1.25">&#160;</div> </td> </tr>
  <tr>
    <td style="width: 5%; vertical-align: middle">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="white-space: nowrap; width: 2%; vertical-align: middle">
        <div style="line-height: 1.25">&#9679;</div> </td>
    <td style="width: 93%; vertical-align: middle">
        <div style="line-height: 1.25">short sales effected after the date the registration statement of which this prospectus is a part is declared
        effective by the SEC;</div> </td> </tr>
  <tr>
    <td style="width: 5%; vertical-align: middle">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="white-space: nowrap; width: 2%; vertical-align: middle">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 93%; vertical-align: middle">
        <div style="line-height: 1.25">&#160;</div> </td> </tr>
  <tr>
    <td style="width: 5%; vertical-align: middle">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="white-space: nowrap; width: 2%; vertical-align: middle">
        <div style="line-height: 1.25">&#9679;</div> </td>
    <td style="width: 93%; vertical-align: middle">
        <div style="line-height: 1.25">through the writing or settlement of options or other hedging transactions, whether through an options
        exchange or otherwise;</div> </td> </tr>
  </table>

<div> <br/> </div> </div>

<div style="line-height: 1.25; font-family: Times New Roman">

<table cellspacing="0" cellpadding="0" id="zb9484690aaa242dea2a57497cfed4370" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 5%; vertical-align: middle">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="white-space: nowrap; width: 2%; vertical-align: middle">
        <div style="line-height: 1.25">&#9679;</div> </td>
    <td style="width: 93%; vertical-align: middle">
        <div style="line-height: 1.25">broker-dealers may agree with the Selling Securityholders&#160; to sell a specified number of such shares
        at a stipulated price per share;</div> </td> </tr>
  <tr>
    <td style="width: 5%; vertical-align: middle">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="white-space: nowrap; width: 2%; vertical-align: middle">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 93%; vertical-align: middle">
        <div style="line-height: 1.25">&#160;</div> </td> </tr>
  <tr>
    <td style="width: 5%; vertical-align: middle">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="white-space: nowrap; width: 2%; vertical-align: middle">
        <div style="line-height: 1.25">&#9679;</div> </td>
    <td style="width: 93%; vertical-align: middle">
        <div style="line-height: 1.25">a combination of any such methods of sale; and</div> </td> </tr>
  <tr>
    <td style="width: 5%; vertical-align: middle">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="white-space: nowrap; width: 2%; vertical-align: middle">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 93%; vertical-align: middle">
        <div style="line-height: 1.25">&#160;</div> </td> </tr>
  <tr>
    <td style="width: 5%; vertical-align: middle">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="white-space: nowrap; width: 2%; vertical-align: middle">
        <div style="line-height: 1.25">&#9679;</div> </td>
    <td style="width: 93%; vertical-align: middle">
        <div style="line-height: 1.25">any other method permitted by applicable law.</div> </td> </tr>
  </table> </div>

<div style="line-height: 1.25; font-family: Times New Roman"> <br/> </div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif; color: rgb(0, 0, 0)">149</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div> <br/>

<div style="line-height: 1.25; font-weight: bold; font-family: Times New Roman"></div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">

<div style="text-indent: 35.45pt; line-height: 1.25; font-family: Times New Roman, Times, serif">The Selling Securityholders may, from
time to time, pledge or grant a security interest in some or all of the New Silexion ordinary shares or New Silexion warrants owned by
them and, if they default in the performance of their secured obligations, the pledgees or secured parties may offer and sell the New
Silexion ordinary shares or New Silexion warrants, from time to time, under this prospectus, or under an amendment to this prospectus
under Rule 424(b)(3) or other applicable provision of the Securities Act amending the list of Selling Securityholders to include the pledgee,
transferee or other successors in interest as Selling Securityholders under this prospectus. The Selling Securityholders also may transfer
the New Silexion ordinary shares or New Silexion warrants in other circumstances, in which case the transferees, pledgees or other successors
in interest will be the selling beneficial owners for purposes of this prospectus.</div>

<div style="text-indent: 35.45pt; line-height: 1.25; font-family: Times New Roman, Times, serif"> <br/> </div>

<div style="text-indent: 35.45pt; line-height: 1.25; font-family: Times New Roman, Times, serif">

<div style="text-indent: 35.45pt; line-height: 1.25">In connection with the sale of New Silexion ordinary shares or New Silexion warrants,
the Selling Securityholders may enter into hedging transactions with broker-dealers or other financial institutions, which may in turn
engage in short sales of New Silexion ordinary shares or New Silexion warrants in the course of hedging the positions they assume. The
Selling Securityholders may also sell New Silexion ordinary shares or New Silexion warrants short and deliver these securities to close
out their short positions, or loan or pledge New Silexion ordinary shares or New Silexion warrants to broker-dealers that in turn may
sell these securities. The Selling Securityholders may also enter into option or other transactions with broker-dealers or other financial
institutions or the creation of one or more derivative securities which require the delivery to such broker-dealer or other financial
institution of New Silexion ordinary shares or New Silexion warrants offered by this prospectus, which New Silexion ordinary shares or
New Silexion warrants such broker-dealer or other financial institution may resell pursuant to this prospectus (as supplemented or amended
to reflect such transaction).</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-indent: 35.45pt; line-height: 1.25">Each of the Selling Securityholders reserves the right to accept and, together with
their agents from time to time, to reject, in whole or in part, any proposed purchase of New Silexion ordinary shares or New Silexion
warrants to be made directly or through agents. We will not receive any of the proceeds from this offering. Upon any exercise of New Silexion
warrants by payment of cash, however, we will receive the exercise price of the warrants.</div>

<div style="text-indent: 35.45pt; line-height: 1.25"> <br/> </div>

<div style="text-indent: 35.45pt; line-height: 1.25">

<div style="text-indent: 35.45pt; line-height: 1.25">The Selling Securityholders and any underwriters, broker-dealers or agents that participate
in the sale of the ordinary shares or interests therein may be &#8220;underwriters&#8221; within the meaning of Section 2(11) of the Securities
Act. Any discounts, commissions, concessions or profit they earn on any resale of the shares may be underwriting discounts and commissions
under the Securities Act. Selling Securityholders who are &#8220;underwriters&#8221; within the meaning of Section 2(11) of the Securities
Act will be subject to the prospectus delivery requirements of the Securities Act.</div>

<div style="text-indent: 35.45pt; line-height: 1.25"> <br/> </div>

<div style="text-indent: 35.45pt; line-height: 1.25">

<div style="text-indent: 35.45pt; line-height: 1.25">In addition, a Selling Securityholder that is an entity may elect to make a pro rata
in-kind distribution of securities to its members, partners or shareholders pursuant to the registration statement of which this prospectus
is a part by delivering a prospectus with a plan of distribution. Such members, partners or shareholders would thereby receive freely
tradeable securities pursuant to the distribution through a registration statement.</div> </div> </div> </div> </div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 35.45pt; line-height: 1.25">To the extent required, the New Silexion ordinary shares or New Silexion warrants
to be sold, the names of the Selling Securityholders, the respective purchase prices and public offering prices, the names of any agents,
dealer or underwriter, any applicable commissions or discounts with respect to a particular offer will be set forth in an accompanying
prospectus supplement or, if appropriate, a post-effective amendment to the registration statement that includes this prospectus.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-indent: 35.45pt; line-height: 1.25">In order to comply with the securities laws of some states, if applicable, the New
Silexion ordinary shares or New Silexion warrants may be sold in these jurisdictions only through registered or licensed brokers or dealers.
In addition, in some states the New Silexion ordinary shares or New Silexion warrants may not be sold unless they have been registered
or qualified for sale or an exemption from registration or qualification requirements is available and is complied with.</div>

<div style="line-height: 1.25"><br/> </div>

<div style="text-indent: 35.45pt; line-height: 1.25">We have advised the Selling Securityholders that the anti-manipulation rules of Regulation
M under the Exchange Act may apply to sales of New Silexion ordinary shares or New Silexion warrants in the market and to the activities
of the Selling Securityholders and their affiliates. In addition, to the extent applicable we will make copies of this prospectus (as
it may be supplemented or amended from time to time) available to the Selling Securityholders for the purpose of satisfying the prospectus
delivery requirements of the Securities Act. The Selling Securityholders may indemnify any broker-dealer that participates in transactions
involving the sale of the shares against certain liabilities, including liabilities arising under the Securities Act.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-indent: 35.45pt; line-height: 1.25">A holder of New Silexion warrants may exercise its New Silexion warrants in accordance
with the applicable governing warrant agreement on or before the expiration date set forth therein by surrendering, at the office of the
warrant agent, Continental Stock Transfer &amp; Trust Company, the certificate evidencing such Freightos Warrant, with the form of election
to purchase set forth thereon, properly completed and duly executed, accompanied by full payment of the exercise price and any and all
applicable taxes due in connection with the exercise of the Freightos Warrant, subject to any applicable provisions relating to cashless
exercises in accordance with the applicable warrant agreement.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-indent: 35.45pt; line-height: 1.25">We have agreed to indemnify the Selling Securityholders against liabilities, including
liabilities under the Securities Act and state securities laws, relating to the registration of the New Silexion ordinary shares or New
Silexion warrants offered by this prospectus.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-indent: 35.45pt; line-height: 1.25">We have agreed with the Selling Securityholders to keep the registration statement
of which this prospectus constitutes a part effective until all of the New Silexion ordinary shares or New Silexion warrants covered by
this prospectus have been disposed of pursuant to and in accordance with the registration statement or the securities have been withdrawn.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif"><span style="font-family: Times New Roman"><br/> </span> </div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">Our ordinary shares and warrants are currently listed
on the Nasdaq Global Market under the symbols &#8220;SLXN&#8221; and &#8220;SLXNW&#8221;, respectively.</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif; color: rgb(0, 0, 0)">150</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="text-align: center; line-height: 1.25; font-weight: bold; font-family: Times New Roman"><!--Anchor--><span id="LEGAL"><!--Anchor--></span>LEGAL
MATTERS</div>

<div style="text-align: center; line-height: 1.25; font-weight: bold; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">

<div style="text-indent: 36pt; line-height: 1.25">

<div style="text-indent: 36pt; line-height: 1.25">

<div style="text-indent: 36pt; line-height: 1.25">Conyers Dill &amp; Pearman LLP will pass upon the validity of the ordinary shares of
the Company to be offered pursuant to the offering under this prospectus and matters of Cayman Islands law.</div> </div> </div> </div>
</div> </div>

<div style="text-align: justify; text-indent: 18pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: center; line-height: 1.25; font-weight: bold; font-family: Times New Roman"><!--Anchor--><span id="EXPERTS"><!--Anchor--></span>EXPERTS</div>

<div style="text-align: center; line-height: 1.25; font-weight: bold; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">

<div style="text-indent: 36pt; line-height: 1.25">

<div style="line-height: 1.25; font-family: Times New Roman">The financial statements of Moringa Acquisition Corp as of December 31, 2023
and 2022, and for the two years ended December 31, 2023, included in this prospectus, have been so included in reliance on the report
(which contains an explanatory paragraph relating to the Company&#8217;s ability to continue as a going concern as described in Note 1E
to the financial statements) of Kesselman &amp; Kesselman, a member firm of PricewaterhouseCoopers International Limited, an independent
registered public accounting firm, given on the authority of said firm as experts in auditing and accounting.</div> </div> </div> </div>
</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">

<div style="text-indent: 36pt; line-height: 1.25">

<div style="line-height: 1.25; font-family: Times New Roman">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">The financial statements of Silexion Therapeutics
Corp (formerly known as Silexion Therapeutics Ltd.) as of December 31, 2023 and 2022, and for the two years ended December 31, 2023, included
in this prospectus have been so included in reliance on the report (which contains an explanatory paragraph relating to the Company&#8217;s
ability to continue as a going concern as described in Note 1e to the financial statements) of Kesselman &amp; Kesselman, a member firm
of PricewaterhouseCoopers International Limited, an independent registered public accounting firm, given on the authority of said firm
as experts in auditing and accounting.</div> </div> </div> </div> </div> </div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: rgb(0, 0, 0); font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">151</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-align: center; line-height: 1.25; font-weight: bold; font-family: Times New Roman"><!--Anchor--><span id="WHERE"><!--Anchor--></span>WHERE
YOU CAN FIND MORE INFORMATION</div>

<div style="text-align: center; line-height: 1.25; font-weight: bold; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">We have filed with the SEC a registration statement on
Form S-1 under the Securities Act, with respect to the securities being offered by this prospectus. This prospectus, which constitutes
part of the registration statement, does not contain all of the information in the registration statement and its exhibits. For further
information with respect to New Silexion and the securities offered by this prospectus, we refer you to the registration statement and
its exhibits. Statements contained in this prospectus as to the contents of any contract or any other document referred to are not necessarily
complete, and in each instance, we refer you to the copy of the contract or other document filed as an exhibit to the registration statement.
Each of these statements is qualified in all respects by this reference. You can read our SEC filings, including the registration statement,
over the internet at the SEC&#8217;s website at <span style="font-style: italic">www.sec.gov</span>.</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman">We are subject to the information reporting requirements
of the Exchange Act, and we file reports, proxy statements and other information with the SEC. These reports, proxy statements and other
information will be available for review at the SEC&#8217;s website at www.sec.gov. We also maintain a website at https://www.completesolaria.com/,
at which you may access these materials free of charge as soon as reasonably practicable after they are electronically filed with, or
furnished to, the SEC. The information contained in, or that can be accessed through, our website is not part of this prospectus.</div>

<div style="line-height: 1.25; font-family: Times New Roman">&#160;</div> </div> </div>

<p style="margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman"> </span></p>

<div class="BRPFPageNumberArea" style="text-align: center; font-family: Times New Roman"><span class="BRPFPageNumber" style="color: rgb(0, 0, 0); font-weight: normal; font-style: normal; font-family: Times New Roman,Times,serif">152</span></div>


<p style="margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman"> </span></p>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000"/></div>
</div>

<p style="margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman"> </span></p>
<!-- Field: /Include-Text -->

</div> </div>

<div style="font-family:'Times New Roman',Times,serif;font-size:10pt"><span id="a_022"></span></div> </div>

<div><a id="a_001"></a>

<p style="font:10pt 'Times New Roman',Times,serif;margin:0pt 0px;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>INDEX
TO FINANCIAL STATEMENTS</strong></span></span></p>

<p style="font:10pt 'Times New Roman',Times,serif;margin:0pt 0px;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>TABLE
OF CONTENTS</strong></span></span></p>

<p style="font:10pt 'Times New Roman',Times,serif;margin:0pt 0px;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>MORINGA
ACQUISITION CORP</strong></span></span></p>

<div>&#160;</div>

<table cellpadding="0" cellspacing="0" style="font:10pt Times New Roman, Times, Serif;width:100%;border-collapse:collapse">
  <tr style="vertical-align:bottom">
    <td style="padding-bottom:1.5pt;width:89%;font-family:'Times New Roman',Times,serif;font-size:10pt">&#160;</td>
    <td style="padding-bottom:1.5pt;white-space:nowrap;width:1%;text-align:center;font-family:'Times New Roman',Times,serif;font-size:10pt">&#160;</td>
    <td style="border-bottom:1.5pt solid Black;width:10%;text-align:center;font-family:'Times New Roman',Times,serif;font-size:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>Page</strong></span></span></td></tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="font-family:'Times New Roman',Times,serif;font-size:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>Moringa
        Acquisition Corp Condensed Consolidated Financial Statements</strong></span></span></td>
    <td style="white-space:nowrap;text-align:center;font-family:'Times New Roman',Times,serif;font-size:10pt">&#160;</td>
    <td style="text-align:center;font-family:'Times New Roman',Times,serif;font-size:10pt">&#160;</td></tr>
  <tr style="vertical-align:bottom">
    <td style="font-family:'Times New Roman',Times,serif;font-size:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="#f_001">Condensed
        Consolidated Balance Sheets</a></span></span></td>
    <td style="white-space:nowrap;text-align:center;font-family:'Times New Roman',Times,serif;font-size:10pt">&#160;</td>
    <td style="text-align:center;font-family:'Times New Roman',Times,serif;font-size:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">F-2</span></span></td></tr>
  <tr style="vertical-align:bottom;background-color:rgb(204, 238, 255)">
    <td style="font-family:'Times New Roman',Times,serif;font-size:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="#f_002">Condensed
        Consolidated Statements of Operations</a></span></span></td>
    <td style="white-space:nowrap;text-align:center;font-family:'Times New Roman',Times,serif;font-size:10pt">&#160;</td>
    <td style="text-align:center;font-family:'Times New Roman',Times,serif;font-size:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">F-3</span></span></td></tr>
  <tr style="vertical-align:bottom">
    <td style="font-family:'Times New Roman',Times,serif;font-size:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="#f_003">Condensed
        Consolidated Statements of Changes in Capital Deficiency</a></span></span></td>
    <td style="white-space:nowrap;text-align:center;font-family:'Times New Roman',Times,serif;font-size:10pt">&#160;</td>
    <td style="text-align:center;font-family:'Times New Roman',Times,serif;font-size:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">F-4</span></span></td></tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="font-family:'Times New Roman',Times,serif;font-size:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="#f_004">Condensed
        Consolidated Statements of Cash Flows</a></span></span></td>
    <td style="white-space:nowrap;text-align:center;font-family:'Times New Roman',Times,serif;font-size:10pt">&#160;</td>
    <td style="text-align:center;font-family:'Times New Roman',Times,serif;font-size:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">F-5</span></span></td></tr>
  <tr style="vertical-align:bottom">
    <td style="font-family:'Times New Roman',Times,serif;font-size:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="#f_005">Notes
        to the Condensed Consolidated Financial Statements</a></span></span></td>
    <td style="white-space:nowrap;text-align:center;font-family:'Times New Roman',Times,serif;font-size:10pt">&#160;</td>
    <td style="text-align:center;font-family:'Times New Roman',Times,serif;font-size:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">F-6
        - F-21</span></span></td></tr>
  <tr style="vertical-align:bottom;background-color:rgb(204, 238, 255)">
    <td style="text-align:center;font-family:'Times New Roman',Times,serif;font-size:10pt">&#160;</td>
    <td style="white-space:nowrap;text-align:center;font-family:'Times New Roman',Times,serif;font-size:10pt">&#160;</td>
    <td style="text-align:center;font-family:'Times New Roman',Times,serif;font-size:10pt">&#160;</td></tr>
  <tr style="vertical-align:bottom">
    <td style="font-family:'Times New Roman',Times,serif;font-size:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>Moringa
        Acquisition Corp Audited Financial Statements</strong></span></span></td>
    <td style="white-space:nowrap;text-align:center;font-family:'Times New Roman',Times,serif;font-size:10pt">&#160;</td>
    <td style="text-align:center;font-family:'Times New Roman',Times,serif;font-size:10pt">&#160;</td></tr>
  <tr style="vertical-align:bottom;background-color:rgb(204, 238, 255)">
    <td style="font-family:'Times New Roman',Times,serif;font-size:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="#f_006">Report
        of Independent Registered Public Accounting Firm (PCAOB ID #&#160;1309)</a></span></span></td>
    <td style="white-space:nowrap;text-align:center;font-family:'Times New Roman',Times,serif;font-size:10pt">&#160;</td>
    <td style="text-align:center;font-family:'Times New Roman',Times,serif;font-size:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">F-22</span></span></td></tr>
  <tr style="vertical-align:bottom">
    <td style="font-family:'Times New Roman',Times,serif;font-size:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="#f_007">Balance
        Sheets</a></span></span></td>
    <td style="white-space:nowrap;text-align:center;font-family:'Times New Roman',Times,serif;font-size:10pt">&#160;</td>
    <td style="text-align:center;font-family:'Times New Roman',Times,serif;font-size:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">F-23</span></span></td></tr>
  <tr style="vertical-align:bottom;background-color:rgb(204, 238, 255)">
    <td style="font-family:'Times New Roman',Times,serif;font-size:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="#f_008">Statements
        of Operations</a></span></span></td>
    <td style="white-space:nowrap;text-align:center;font-family:'Times New Roman',Times,serif;font-size:10pt">&#160;</td>
    <td style="text-align:center;font-family:'Times New Roman',Times,serif;font-size:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">F-24</span></span></td></tr>
  <tr style="vertical-align:bottom">
    <td style="font-family:'Times New Roman',Times,serif;font-size:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="#f_009">Statements
        of Changes in Capital Deficiency</a></span></span></td>
    <td style="white-space:nowrap;text-align:center;font-family:'Times New Roman',Times,serif;font-size:10pt">&#160;</td>
    <td style="text-align:center;font-family:'Times New Roman',Times,serif;font-size:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">F-25</span></span></td></tr>
  <tr style="vertical-align:bottom;background-color:rgb(204, 238, 255)">
    <td style="font-family:'Times New Roman',Times,serif;font-size:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="#f_010">Statements
        of Cash Flows</a></span></span></td>
    <td style="white-space:nowrap;text-align:center;font-family:'Times New Roman',Times,serif;font-size:10pt">&#160;</td>
    <td style="text-align:center;font-family:'Times New Roman',Times,serif;font-size:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">F-26</span></span></td></tr>
  <tr style="vertical-align:bottom">
    <td style="font-family:'Times New Roman',Times,serif;font-size:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="#f_011">Notes
        to Financial Statements</a></span></span></td>
    <td style="white-space:nowrap;text-align:center;font-family:'Times New Roman',Times,serif;font-size:10pt">&#160;</td>
    <td style="text-align:center;font-family:'Times New Roman',Times,serif;font-size:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">F-27
        - F-39</span></span></td></tr>
  </table>

<div>&#160;</div>

<p style="font:10pt 'Times New Roman',Times,serif;margin:0pt 0px;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>SILEXION
THERAPEUTICS CORP</strong></span></span></p>

<p style="font:10pt 'Times New Roman',Times,serif;margin:0pt 0px;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>CONSOLIDATED
FINANCIAL STATEMENTS</strong></span></span></p>

<div>&#160;</div>

<table cellpadding="0" cellspacing="0" style="font:10pt Times New Roman, Times, Serif;width:100%;border-collapse:collapse">
  <tr style="vertical-align:bottom">
    <td style="padding-bottom:1.5pt;width:89%;font-family:'Times New Roman',Times,serif;font-size:10pt">&#160;</td>
    <td style="padding-bottom:1.5pt;white-space:nowrap;width:1%;text-align:center;font-family:'Times New Roman',Times,serif;font-size:10pt">&#160;</td>
    <td style="border-bottom:1.5pt solid Black;width:10%;text-align:center;font-family:'Times New Roman',Times,serif;font-size:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>Page</strong></span></span></td></tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="font-family:'Times New Roman',Times,serif;font-size:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>S</strong></span></span><strong style="font-size:10pt">ilexion
        Therapeutics Corp Condensed Consolidated Financial Statements</strong></td>
    <td style="white-space:nowrap;text-align:center;font-family:'Times New Roman',Times,serif;font-size:10pt">&#160;</td>
    <td style="text-align:center;font-size:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>&#160;</span></span></span></td></tr>
  <tr style="vertical-align:bottom">
    <td style="font-family:'Times New Roman',Times,serif;font-size:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="#BALANCESHEETS">Condensed
        Consolidated Balance Sheets (unaudited)</a></span></span></td>
    <td style="white-space:nowrap;text-align:center;font-family:'Times New Roman',Times,serif;font-size:10pt">&#160;</td>
    <td style="text-align:center;font-family:'Times New Roman',Times,serif;font-size:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">F-42
        - F-44</span></span></td></tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="font-family:'Times New Roman',Times,serif;font-size:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="#STATEMENTSOFOPERATIONS">Condensed
        Consolidated Statements of Operations (unaudited)</a></span></span></td>
    <td style="white-space:nowrap;text-align:center;font-family:'Times New Roman',Times,serif;font-size:10pt">&#160;</td>
    <td style="text-align:center;font-family:'Times New Roman',Times,serif;font-size:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">F-45</span></span></td></tr>
  <tr style="vertical-align:bottom">
    <td style="font-family:'Times New Roman',Times,serif;font-size:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="#CAPITALDEFICIENCY">Condensed
        Consolidated Statements of Changes in Redeemable Convertible Preferred Shares and Capital Deficiency (unaudited)</a></span></span></td>
    <td style="white-space:nowrap;text-align:center;font-family:'Times New Roman',Times,serif;font-size:10pt">&#160;</td>
    <td style="text-align:center;font-family:'Times New Roman',Times,serif;font-size:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">F-46
        - F-47</span></span></td></tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="font-family:'Times New Roman',Times,serif;font-size:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="#CASHFLOWS">Condensed
        Consolidated Statements of Cash Flows (unaudited)</a></span></span></td>
    <td style="white-space:nowrap;text-align:center;font-family:'Times New Roman',Times,serif;font-size:10pt">&#160;</td>
    <td style="text-align:center;font-family:'Times New Roman',Times,serif;font-size:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">F-48
        -F-49</span></span></td></tr>
  <tr style="vertical-align:bottom">
    <td style="font-family:'Times New Roman',Times,serif;font-size:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="#FINANCIALSTATEMENTS">Notes
        to Condensed Consolidated Financial Statements (unaudited)</a></span></span></td>
    <td style="white-space:nowrap;text-align:center;font-family:'Times New Roman',Times,serif;font-size:10pt">&#160;</td>
    <td style="text-align:center;font-family:'Times New Roman',Times,serif;font-size:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">F-50
        - F64</span></span></td></tr>
  </table>

<div>&#160;</div>

<table cellpadding="0" cellspacing="0" style="font:10pt Times New Roman, Times, Serif;width:100%;border-collapse:collapse">
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="width:89%;font-family:'Times New Roman',Times,serif;font-size:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>S</strong></span></span><strong style="font-size:10pt"><strong>ilexion
        Therapeutics&#160;</strong><strong><strong>Corp</strong></strong>&#160;Audited Financial Statements</strong></td>
    <td style="white-space:nowrap;width:1%;text-align:center;font-family:'Times New Roman',Times,serif;font-size:10pt">&#160;</td>
    <td style="width:10%;text-align:center;font-family:'Times New Roman',Times,serif;font-size:10pt">&#160;</td></tr>
  <tr style="vertical-align:bottom">
    <td style="font-family:'Times New Roman',Times,serif;font-size:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="#ACCOUNTINGFIRM">Report
        of Independent Registered Public Accounting Firm</a></span></span></td>
    <td style="white-space:nowrap;text-align:center;font-family:'Times New Roman',Times,serif;font-size:10pt">&#160;</td>
    <td style="text-align:center;font-family:'Times New Roman',Times,serif;font-size:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">F-67</span></span></td></tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="font-family:'Times New Roman',Times,serif;font-size:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>CONSOLIDATED
        FINANCIAL STATEMENTS:</strong></span></span></td>
    <td style="white-space:nowrap;text-align:center;font-family:'Times New Roman',Times,serif;font-size:10pt">&#160;</td>
    <td style="text-align:center;font-family:'Times New Roman',Times,serif;font-size:10pt">&#160;</td></tr>
  <tr style="vertical-align:bottom">
    <td style="font-family:'Times New Roman',Times,serif;font-size:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="#DBALANCESHEETS">Consolidated
        Balance Sheets</a></span></span></td>
    <td style="white-space:nowrap;text-align:center;font-family:'Times New Roman',Times,serif;font-size:10pt">&#160;</td>
    <td style="text-align:center;font-family:'Times New Roman',Times,serif;font-size:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">F-68
        -F-69</span></span></td></tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="font-family:'Times New Roman',Times,serif;font-size:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="#DSTATEMENTSOFOPERATIONS">Consolidated
        Statements of Operations</a></span></span></td>
    <td style="white-space:nowrap;text-align:center;font-family:'Times New Roman',Times,serif;font-size:10pt">&#160;</td>
    <td style="text-align:center;font-family:'Times New Roman',Times,serif;font-size:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">F-70</span></span></td></tr>
  <tr style="vertical-align:bottom">
    <td style="font-family:'Times New Roman',Times,serif;font-size:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="#DCAPITALDEFICIENCY">Consolidated
        Statements of Changes in Redeemable Convertible Preferred Shares and Capital Deficiency</a></span></span></td>
    <td style="white-space:nowrap;text-align:center;font-family:'Times New Roman',Times,serif;font-size:10pt">&#160;</td>
    <td style="text-align:center;font-family:'Times New Roman',Times,serif;font-size:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">F-71</span></span></td></tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="font-family:'Times New Roman',Times,serif;font-size:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="#FCASHFLOWS">Consolidated
        Statements of Cash Flows</a></span></span></td>
    <td style="white-space:nowrap;text-align:center;font-family:'Times New Roman',Times,serif;font-size:10pt">&#160;</td>
    <td style="text-align:center;font-family:'Times New Roman',Times,serif;font-size:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">F-72
        - F-73</span></span></td></tr>
  <tr style="vertical-align:bottom">
    <td style="font-family:'Times New Roman',Times,serif;font-size:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="#DFINANCIALSTATEMENTS">Notes
        to Consolidated Financial Statements</a></span></span></td>
    <td style="white-space:nowrap;text-align:center;font-family:'Times New Roman',Times,serif;font-size:10pt">&#160;</td>
    <td style="text-align:center;font-family:'Times New Roman',Times,serif;font-size:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">F-74</span></span></td></tr>
  </table>

<div>&#160;</div>

<div style="border-bottom:Black 1.5pt solid;margin-top:12pt;margin-bottom:6pt">

<p style="font:10pt 'Times New Roman',Times,serif;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>F-1</span></span></span></p></div>

<div style="break-before:page;margin-top:6pt;margin-bottom:12pt">

<p style="margin:0pt;font-family:'Times New Roman',Times,serif;font-size:10pt">&#160;</p>

<p style="margin:0pt;font-family:'Times New Roman',Times,serif;font-size:10pt">&#160;</p>

<p style="margin:0pt;font-family:'Times New Roman',Times,serif;font-size:10pt">&#160;</p></div></div>

<div style="font:10pt Times New Roman, Times, Serif">

<div>

<div>

<div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span id="f_001"></span></span></span></div>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong>MORINGA
ACQUISITION CORP</strong></span></span></span></span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>UNAUDITED
CONDENSED CONSOLIDATED BALANCE SHEETS</span></span></span></span></p>

<div>&#160;</div>

<table cellpadding="0" cellspacing="0" style="width:100%">
  <tr style="vertical-align:bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align:center">&#160;</td>
    <td style="font-weight:bold">&#160;</td>
    <td colspan="2" style="font-weight:bold;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>June&#160;30,</span></span></span></span></td>
    <td style="font-weight:bold">&#160;</td>
    <td style="font-weight:bold">&#160;</td>
    <td colspan="2" style="font-weight:bold;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>December&#160;31,</span></span></span></span></td>
    <td style="font-weight:bold">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td>&#160;</td>
    <td style="font-weight:bold;padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;font-weight:bold;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Note</span></span></span></span></td>
    <td style="font-weight:bold;padding-bottom:1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom:Black 1.5pt solid;font-weight:bold;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>2024</span></span></span></span></td>
    <td style="padding-bottom:1.5pt;font-weight:bold">&#160;</td>
    <td style="font-weight:bold;padding-bottom:1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom:Black 1.5pt solid;font-weight:bold;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>2023</span></span></span></span></td>
    <td style="padding-bottom:1.5pt;font-weight:bold">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="padding-bottom:1.5pt;font-weight:bold;text-align:center">&#160;</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="text-align:center">&#160;</td>
    <td style="font-weight:bold;padding-bottom:1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom:Black 1.5pt solid;font-weight:bold;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>U.S.
        Dollars</span></span></span></span></td>
    <td style="padding-bottom:1.5pt;font-weight:bold">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align:center">&#160;</td>
    <td>&#160;</td>
    <td colspan="6" style="text-align:center">&#160;</td>
    <td>&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong>Assets</strong></span></span></span></span></td>
    <td>&#160;</td>
    <td style="text-align:center">&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align:right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align:right">&#160;</td>
    <td>&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>ASSETS:</span></span></span></span></td>
    <td>&#160;</td>
    <td style="text-align:center">&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align:right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align:right">&#160;</td>
    <td>&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="text-align:left;padding-left:9pt;width:64%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Cash
        and cash equivalents</span></span></span></span></td>
    <td style="width:1%">&#160;</td>
    <td style="text-align:center;width:11%">&#160;</td>
    <td style="width:1%">&#160;</td>
    <td style="text-align:left;width:1%">&#160;</td>
    <td style="text-align:right;width:9%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20241004054608827_ixv-37589" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="C_20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">17,880</ix:nonFraction></span></span></span></span></td>
    <td style="text-align:left;width:1%">&#160;</td>
    <td style="width:1%">&#160;</td>
    <td style="text-align:left;width:1%">&#160;</td>
    <td style="text-align:right;width:9%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20241004054608827_ixv-37590" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="C_20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">108,278</ix:nonFraction></span></span></span></span></td>
    <td style="text-align:left;width:1%">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="text-align:left;padding-left:9pt;width:64%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Investments
        held in Trust Account</span></span></span></span></td>
    <td style="width:1%">&#160;</td>
    <td style="text-align:center;width:11%">&#160;</td>
    <td style="width:1%">&#160;</td>
    <td style="text-align:left;width:1%">&#160;</td>
    <td style="text-align:right;width:9%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20241004054608831_ixv-37591" name="us-gaap:AssetsHeldInTrust" contextRef="C_20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,924,118</ix:nonFraction></span></span></span></span></td>
    <td style="text-align:left;width:1%">&#160;</td>
    <td style="width:1%">&#160;</td>
    <td style="text-align:left;width:1%">&#160;</td>
    <td style="text-align:right;width:9%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20241004054608831_ixv-37592" name="us-gaap:AssetsHeldInTrust" contextRef="C_20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,697,632</ix:nonFraction></span></span></span></span></td>
    <td style="text-align:left;width:1%">&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="text-align:left;padding-bottom:1.5pt;padding-left:9pt;width:64%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Prepaid
        expenses</span></span></span></span></td>
    <td style="padding-bottom:1.5pt;width:1%">&#160;</td>
    <td style="text-align:center;padding-bottom:1.5pt;width:11%">&#160;</td>
    <td style="padding-bottom:1.5pt;width:1%">&#160;</td>
    <td style="border-bottom:1.5pt solid black;text-align:left;width:1%">&#160;</td>
    <td style="border-bottom:1.5pt solid black;text-align:right;width:9%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20241004054608836_ixv-37593" name="us-gaap:PrepaidExpenseCurrent" contextRef="C_20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">24,808</ix:nonFraction></span></span></span></span></td>
    <td style="padding-bottom:1.5pt;text-align:left;width:1%">&#160;</td>
    <td style="padding-bottom:1.5pt;width:1%">&#160;</td>
    <td style="border-bottom:1.5pt solid black;text-align:left;width:1%">&#160;</td>
    <td style="border-bottom:1.5pt solid black;text-align:right;width:9%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20241004054608836_ixv-37594" name="us-gaap:PrepaidExpenseCurrent" contextRef="C_20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">28,305</ix:nonFraction></span></span></span></span></td>
    <td style="padding-bottom:1.5pt;text-align:left;width:1%">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="font-weight:bold;text-align:left;padding-left:9pt;width:64%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>TOTAL
        ASSETS</span></span></span></span></td>
    <td style="width:1%">&#160;</td>
    <td style="text-align:center;width:11%">&#160;</td>
    <td style="width:1%">&#160;</td>
    <td style="text-align:left;width:1%">&#160;</td>
    <td style="text-align:right;width:9%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20241004054608838_ixv-37595" name="us-gaap:Assets" contextRef="C_20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,966,806</ix:nonFraction></span></span></span></span></td>
    <td style="text-align:left;width:1%">&#160;</td>
    <td style="width:1%">&#160;</td>
    <td style="text-align:left;width:1%">&#160;</td>
    <td style="text-align:right;width:9%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20241004054608838_ixv-37596" name="us-gaap:Assets" contextRef="C_20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,834,215</ix:nonFraction></span></span></span></span></td>
    <td style="text-align:left;width:1%">&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="text-align:center;width:64%">&#160;</td>
    <td style="width:1%">&#160;</td>
    <td style="text-align:center;width:11%">&#160;</td>
    <td style="width:1%">&#160;</td>
    <td style="text-align:left;width:1%">&#160;</td>
    <td style="text-align:right;width:9%">&#160;</td>
    <td style="text-align:left;width:1%">&#160;</td>
    <td style="width:1%">&#160;</td>
    <td style="text-align:left;width:1%">&#160;</td>
    <td style="text-align:right;width:9%">&#160;</td>
    <td style="text-align:left;width:1%">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="font-weight:bold;text-align:left;width:64%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Liabilities
        and shares subject to possible redemption net of capital deficiency</span></span></span></span></td>
    <td style="width:1%">&#160;</td>
    <td style="text-align:center;width:11%">&#160;</td>
    <td style="width:1%">&#160;</td>
    <td style="text-align:left;width:1%">&#160;</td>
    <td style="text-align:right;width:9%">&#160;</td>
    <td style="text-align:left;width:1%">&#160;</td>
    <td style="width:1%">&#160;</td>
    <td style="text-align:left;width:1%">&#160;</td>
    <td style="text-align:right;width:9%">&#160;</td>
    <td style="text-align:left;width:1%">&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="font-weight:bold;width:64%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>LIABILITIES:</span></span></span></span></td>
    <td style="width:1%">&#160;</td>
    <td style="text-align:center;width:11%">&#160;</td>
    <td style="width:1%">&#160;</td>
    <td style="text-align:left;width:1%">&#160;</td>
    <td style="text-align:right;width:9%">&#160;</td>
    <td style="text-align:left;width:1%">&#160;</td>
    <td style="width:1%">&#160;</td>
    <td style="text-align:left;width:1%">&#160;</td>
    <td style="text-align:right;width:9%">&#160;</td>
    <td style="text-align:left;width:1%">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="text-align:left;padding-left:9pt;width:64%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Accrued
        expenses</span></span></span></span></td>
    <td style="width:1%">&#160;</td>
    <td style="text-align:center;width:11%">&#160;</td>
    <td style="width:1%">&#160;</td>
    <td style="text-align:left;width:1%">&#160;</td>
    <td style="text-align:right;width:9%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20241004054608841_ixv-37597" name="us-gaap:OtherAccountsPayableAndAccruedLiabilities" contextRef="C_20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">55,191</ix:nonFraction></span></span></span></span></td>
    <td style="text-align:left;width:1%">&#160;</td>
    <td style="width:1%">&#160;</td>
    <td style="text-align:left;width:1%">&#160;</td>
    <td style="text-align:right;width:9%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20241004054608841_ixv-37598" name="us-gaap:OtherAccountsPayableAndAccruedLiabilities" contextRef="C_20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">115,560</ix:nonFraction></span></span></span></span></td>
    <td style="text-align:left;width:1%">&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="text-align:left;padding-left:9pt;width:64%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Related
        party</span></span></span></span></td>
    <td style="width:1%">&#160;</td>
    <td style="text-align:center;width:11%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>4</span></span></span></span></td>
    <td style="width:1%">&#160;</td>
    <td style="text-align:left;width:1%">&#160;</td>
    <td style="text-align:right;width:9%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20241004054608843_ixv-37599" name="us-gaap:NotesPayableCurrent" contextRef="C_20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,346,000</ix:nonFraction></span></span></span></span></td>
    <td style="text-align:left;width:1%">&#160;</td>
    <td style="width:1%">&#160;</td>
    <td style="text-align:left;width:1%">&#160;</td>
    <td style="text-align:right;width:9%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20241004054608843_ixv-37600" name="us-gaap:NotesPayableCurrent" contextRef="C_20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,861,000</ix:nonFraction></span></span></span></span></td>
    <td style="text-align:left;width:1%">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="text-align:left;padding-bottom:1.5pt;padding-left:9pt;width:64%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Private
        warrant liability</span></span></span></span></td>
    <td style="padding-bottom:1.5pt;width:1%">&#160;</td>
    <td style="text-align:center;padding-bottom:1.5pt;width:11%">&#160;</td>
    <td style="padding-bottom:1.5pt;width:1%">&#160;</td>
    <td style="border-bottom:1.5pt solid black;text-align:left;width:1%">&#160;</td>
    <td style="border-bottom:1.5pt solid black;text-align:right;width:9%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20241004054608846_ixv-37601" name="us-gaap:WarrantsAndRightsOutstanding" contextRef="C_20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">27,284</ix:nonFraction></span></span></span></span></td>
    <td style="padding-bottom:1.5pt;text-align:left;width:1%">&#160;</td>
    <td style="padding-bottom:1.5pt;width:1%">&#160;</td>
    <td style="border-bottom:1.5pt solid black;text-align:left;width:1%">&#160;</td>
    <td style="border-bottom:1.5pt solid black;text-align:right;width:9%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20241004054608846_ixv-37602" name="us-gaap:WarrantsAndRightsOutstanding" contextRef="C_20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,531</ix:nonFraction></span></span></span></span></td>
    <td style="padding-bottom:1.5pt;text-align:left;width:1%">&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="font-weight:bold;text-align:left;padding-bottom:1.5pt;padding-left:9pt;width:64%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>TOTAL
        LIABILITIES</span></span></span></span></td>
    <td style="padding-bottom:1.5pt;width:1%">&#160;</td>
    <td style="text-align:center;padding-bottom:1.5pt;width:11%">&#160;</td>
    <td style="padding-bottom:1.5pt;width:1%">&#160;</td>
    <td style="border-bottom:1.5pt solid black;text-align:left;width:1%">&#160;</td>
    <td style="border-bottom:1.5pt solid black;text-align:right;width:9%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20241004054608849_ixv-37603" name="us-gaap:Liabilities" contextRef="C_20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,428,475</ix:nonFraction></span></span></span></span></td>
    <td style="padding-bottom:1.5pt;text-align:left;width:1%">&#160;</td>
    <td style="padding-bottom:1.5pt;width:1%">&#160;</td>
    <td style="border-bottom:1.5pt solid black;text-align:left;width:1%">&#160;</td>
    <td style="border-bottom:1.5pt solid black;text-align:right;width:9%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20241004054608849_ixv-37604" name="us-gaap:Liabilities" contextRef="C_20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,985,091</ix:nonFraction></span></span></span></span></td>
    <td style="padding-bottom:1.5pt;text-align:left;width:1%">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="width:64%">&#160;</td>
    <td style="width:1%">&#160;</td>
    <td style="text-align:center;width:11%">&#160;</td>
    <td style="width:1%">&#160;</td>
    <td style="text-align:left;width:1%">&#160;</td>
    <td style="text-align:right;width:9%">&#160;</td>
    <td style="text-align:left;width:1%">&#160;</td>
    <td style="width:1%">&#160;</td>
    <td style="text-align:left;width:1%">&#160;</td>
    <td style="text-align:right;width:9%">&#160;</td>
    <td style="text-align:left;width:1%">&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="font-weight:bold;text-align:left;padding-bottom:1.5pt;width:64%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>COMMITMENTS
        AND CONTINGENCIES</span></span></span></span></td>
    <td style="padding-bottom:1.5pt;width:1%">&#160;</td>
    <td style="text-align:center;padding-bottom:1.5pt;width:11%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>5</span></span></span></span></td>
    <td style="padding-bottom:1.5pt;width:1%">&#160;</td>
    <td style="border-bottom:1.5pt solid black;text-align:left;width:1%">&#160;</td>
    <td style="border-bottom:1.5pt solid black;text-align:right;width:9%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20241004054608854_xbrl_20241004044359123" name="us-gaap:CommitmentsAndContingencies" contextRef="C_20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></span></span></td>
    <td style="padding-bottom:1.5pt;text-align:left;width:1%">&#160;</td>
    <td style="padding-bottom:1.5pt;width:1%">&#160;</td>
    <td style="border-bottom:1.5pt solid black;text-align:left;width:1%">&#160;</td>
    <td style="border-bottom:1.5pt solid black;text-align:right;width:9%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20241004054608854_xbrl_20241004044433500" name="us-gaap:CommitmentsAndContingencies" contextRef="C_20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></span></span></td>
    <td style="padding-bottom:1.5pt;text-align:left;width:1%">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="width:64%">&#160;</td>
    <td style="width:1%">&#160;</td>
    <td style="text-align:center;width:11%">&#160;</td>
    <td style="width:1%">&#160;</td>
    <td style="text-align:left;width:1%">&#160;</td>
    <td style="text-align:right;width:9%">&#160;</td>
    <td style="text-align:left;width:1%">&#160;</td>
    <td style="width:1%">&#160;</td>
    <td style="text-align:left;width:1%">&#160;</td>
    <td style="text-align:right;width:9%">&#160;</td>
    <td style="text-align:left;width:1%">&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="font-weight:bold;text-align:left;padding-bottom:1.5pt;text-indent:-9pt;padding-left:9pt;width:64%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>CLASS
        A ORDINARY SHARES SUBJECT TO POSSIBLE REDEMPTION: <span style="font-style:normal;font-weight:normal"><ix:nonFraction id="Fxbrl_20241004120741524" name="us-gaap:TemporaryEquitySharesOutstanding" contextRef="C_20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_usgaapCommonClassAMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">515,019</ix:nonFraction>
        shares at redemption value of $<ix:nonFraction id="Fxbrl_20241004120754778" name="us-gaap:TemporaryEquityParOrStatedValuePerShare" contextRef="C_20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_usgaapCommonClassAMember" unitRef="usdPershares" scale="0" decimals="3" format="ixt:num-dot-decimal">11.50
        </ix:nonFraction>and $<ix:nonFraction id="Fxbrl_20241004120811522" name="us-gaap:TemporaryEquityParOrStatedValuePerShare" contextRef="C_20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_usgaapCommonClassAMember" unitRef="usdPershares" scale="0" decimals="2" format="ixt:num-dot-decimal">11.06</ix:nonFraction>
        as of June 30, 2024 and December 31, 2023, respectively</span></span></span></span></span></td>
    <td style="padding-bottom:1.5pt;width:1%">&#160;</td>
    <td style="text-align:center;padding-bottom:1.5pt;width:11%">&#160;</td>
    <td style="padding-bottom:1.5pt;width:1%">&#160;</td>
    <td style="border-bottom:1.5pt solid black;text-align:left;width:1%">&#160;</td>
    <td style="border-bottom:1.5pt solid black;text-align:right;width:9%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20241004054608859_ixv-37609" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" contextRef="C_20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_usgaapCommonClassAMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,924,118</ix:nonFraction></span></span></span></span></td>
    <td style="padding-bottom:1.5pt;text-align:left;width:1%">&#160;</td>
    <td style="padding-bottom:1.5pt;width:1%">&#160;</td>
    <td style="border-bottom:1.5pt solid black;text-align:left;width:1%">&#160;</td>
    <td style="border-bottom:1.5pt solid black;text-align:right;width:9%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20241004054608859_ixv-37610" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" contextRef="C_20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_usgaapCommonClassAMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,697,632</ix:nonFraction></span></span></span></span></td>
    <td style="padding-bottom:1.5pt;text-align:left;width:1%">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="padding-left:10pt;width:64%">&#160;</td>
    <td style="width:1%">&#160;</td>
    <td style="text-align:center;width:11%">&#160;</td>
    <td style="width:1%">&#160;</td>
    <td style="text-align:left;width:1%">&#160;</td>
    <td style="text-align:right;width:9%">&#160;</td>
    <td style="text-align:left;width:1%">&#160;</td>
    <td style="width:1%">&#160;</td>
    <td style="text-align:left;width:1%">&#160;</td>
    <td style="text-align:right;width:9%">&#160;</td>
    <td style="text-align:left;width:1%">&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="font-weight:bold;text-align:left;width:64%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>CAPITAL
        DEFICIENCY:</span></span></span></span></td>
    <td style="width:1%">&#160;</td>
    <td style="text-align:center;width:11%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>7</span></span></span></span></td>
    <td style="width:1%">&#160;</td>
    <td style="text-align:left;width:1%">&#160;</td>
    <td style="text-align:right;width:9%">&#160;</td>
    <td style="text-align:left;width:1%">&#160;</td>
    <td style="width:1%">&#160;</td>
    <td style="text-align:left;width:1%">&#160;</td>
    <td style="text-align:right;width:9%">&#160;</td>
    <td style="text-align:left;width:1%">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="text-align:left;text-indent:-9pt;padding-left:9pt;width:64%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Class
        A Ordinary Shares, $<ix:nonFraction id="Fxbrl_20241004124428632" name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="C_20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_usgaapCommonClassAMember" unitRef="usdPershares" scale="0" decimals="4" format="ixt:num-dot-decimal"><ix:nonFraction id="Fxbrl_20241004124423872" name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="C_20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_usgaapCommonClassAMember" unitRef="usdPershares" scale="0" decimals="4" format="ixt:num-dot-decimal">0.0001</ix:nonFraction></ix:nonFraction>
        par value; <ix:nonFraction id="Fxbrl_20241004124103663" name="us-gaap:CommonStockSharesAuthorized" contextRef="C_20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_usgaapCommonClassAMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="Fxbrl_20241004124056483" name="us-gaap:CommonStockSharesAuthorized" contextRef="C_20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_usgaapCommonClassAMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">500,000,000</ix:nonFraction></ix:nonFraction>
        shares authorized, <ix:nonFraction id="Fxbrl_20241004124205179" name="us-gaap:CommonStockSharesOutstanding" contextRef="C_20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_usgaapCommonClassAMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="Fxbrl_20241004124158838" name="us-gaap:CommonStockSharesIssued" contextRef="C_20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_usgaapCommonClassAMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="Fxbrl_20241004124147886" name="us-gaap:CommonStockSharesOutstanding" contextRef="C_20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_usgaapCommonClassAMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="Fxbrl_20241004124142984" name="us-gaap:CommonStockSharesIssued" contextRef="C_20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_usgaapCommonClassAMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">3,354,999</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction>
        issued and outstanding (excluding 515,019 shares subject to possible redemption) as of June 30, 2024 and December 31, 2023;</span></span></span></span></td>
    <td style="width:1%">&#160;</td>
    <td style="text-align:center;width:11%">&#160;</td>
    <td style="width:1%">&#160;</td>
    <td style="text-align:left;width:1%">&#160;</td>
    <td style="text-align:right;width:9%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20241004054608862_ixv-37619" name="us-gaap:CommonStockValue" contextRef="C_20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_usgaapCommonClassAMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">336</ix:nonFraction></span></span></span></span></td>
    <td style="text-align:left;width:1%">&#160;</td>
    <td style="width:1%">&#160;</td>
    <td style="text-align:left;width:1%">&#160;</td>
    <td style="text-align:right;width:9%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20241004054608862_ixv-37620" name="us-gaap:CommonStockValue" contextRef="C_20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_usgaapCommonClassAMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">336</ix:nonFraction></span></span></span></span></td>
    <td style="text-align:left;width:1%">&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="text-align:left;text-indent:-10pt;padding-left:0.25in;width:64%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Class
        B Ordinary Shares, $<ix:nonFraction id="Fxbrl_20241004124445560" name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="C_20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_usgaapCommonClassBMember" unitRef="usdPershares" scale="0" decimals="4" format="ixt:num-dot-decimal"><ix:nonFraction id="Fxbrl_20241004124342863" name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="C_20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_usgaapCommonClassBMember" unitRef="usdPershares" scale="0" decimals="4" format="ixt:num-dot-decimal">0.0001</ix:nonFraction></ix:nonFraction>
        par value; <ix:nonFraction id="Fxbrl_20241004124607686" name="us-gaap:CommonStockSharesAuthorized" contextRef="C_20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_usgaapCommonClassBMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="Fxbrl_20241004124602293" name="us-gaap:CommonStockSharesAuthorized" contextRef="C_20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_usgaapCommonClassBMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">50,000,000</ix:nonFraction></ix:nonFraction>
        shares authorized, <ix:nonFraction id="Fxbrl_20241004124709401" name="us-gaap:CommonStockSharesOutstanding" contextRef="C_20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_usgaapCommonClassBMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="Fxbrl_20241004124701422" name="us-gaap:CommonStockSharesIssued" contextRef="C_20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_usgaapCommonClassBMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="Fxbrl_20241004124648879" name="us-gaap:CommonStockSharesOutstanding" contextRef="C_20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_usgaapCommonClassBMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="Fxbrl_20241004124643246" name="us-gaap:CommonStockSharesIssued" contextRef="C_20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_usgaapCommonClassBMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">1</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction>
        issued and outstanding as of June 30, 2024 and December 31, 2023;</span></span></span></span></td>
    <td style="width:1%">&#160;</td>
    <td style="text-align:center;width:11%">&#160;</td>
    <td style="width:1%">&#160;</td>
    <td style="text-align:left;width:1%">&#160;</td>
    <td style="text-align:right;width:9%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span style="-sec-ix-hidden:Fxbrl_20241004054608864_hidden-fact-2">*</span></span></span></span></span></td>
    <td style="text-align:left;width:1%">&#160;</td>
    <td style="width:1%">&#160;</td>
    <td style="text-align:left;width:1%">&#160;</td>
    <td style="text-align:right;width:9%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span style="-sec-ix-hidden:Fxbrl_20241004054608864_hidden-fact-3">*</span></span></span></span></span></td>
    <td style="text-align:left;width:1%">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="text-align:left;text-indent:-10pt;padding-left:0.25in;width:64%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Preferred
        Shares, $<ix:nonFraction id="Fxbrl_20241004124849683" name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="C_20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="usdPershares" scale="0" decimals="4" format="ixt:num-dot-decimal"><ix:nonFraction id="Fxbrl_20241004124816713" name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="C_20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="usdPershares" scale="0" decimals="4" format="ixt:num-dot-decimal">0.0001</ix:nonFraction></ix:nonFraction>
        par value; <ix:nonFraction id="Fxbrl_20241004124924968" name="us-gaap:PreferredStockSharesAuthorized" contextRef="C_20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="Fxbrl_20241004124921281" name="us-gaap:PreferredStockSharesAuthorized" contextRef="C_20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">5,000,000</ix:nonFraction></ix:nonFraction>
        shares authorized, <ix:nonFraction id="Fxbrl_20241004132221375" name="us-gaap:PreferredStockSharesOutstanding" contextRef="C_20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="shares" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="Fxbrl_20241004132214715" name="us-gaap:PreferredStockSharesIssued" contextRef="C_20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="shares" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="Fxbrl_20241004132204312" name="us-gaap:PreferredStockSharesOutstanding" contextRef="C_20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="shares" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="Fxbrl_20241004132133690" name="us-gaap:PreferredStockSharesIssued" contextRef="C_20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="shares" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction>
        shares issued and outstanding as of June 30, 2024 and December 31, 2023.</span></span></span></span></td>
    <td style="width:1%">&#160;</td>
    <td style="text-align:center;width:11%">&#160;</td>
    <td style="width:1%">&#160;</td>
    <td style="text-align:left;width:1%">&#160;</td>
    <td style="text-align:right;width:9%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20241004054608869_xbrl_20241003053051232_ixv-37619" name="us-gaap:PreferredStockValue" contextRef="C_20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></span></span></td>
    <td style="text-align:left;width:1%">&#160;</td>
    <td style="width:1%">&#160;</td>
    <td style="text-align:left;width:1%">&#160;</td>
    <td style="text-align:right;width:9%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20241004054608869_xbrl_20241003053051232_ixv-37620" name="us-gaap:PreferredStockValue" contextRef="C_20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></span></span></td>
    <td style="text-align:left;width:1%">&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="text-align:left;padding-bottom:1.5pt;text-indent:-10pt;padding-left:0.25in;width:64%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Accumulated
        deficit</span></span></span></span></td>
    <td style="padding-bottom:1.5pt;width:1%">&#160;</td>
    <td style="text-align:center;padding-bottom:1.5pt;width:11%">&#160;</td>
    <td style="padding-bottom:1.5pt;width:1%">&#160;</td>
    <td style="border-bottom:1.5pt solid black;text-align:left;width:1%">&#160;</td>
    <td style="border-bottom:1.5pt solid black;text-align:right;width:9%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>(<ix:nonFraction id="Fxbrl_20241004054608872_ixv-37633" name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="C_20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">3,386,123</ix:nonFraction></span></span></span></span></td>
    <td style="padding-bottom:1.5pt;text-align:left;width:1%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>)</span></span></span></span></td>
    <td style="padding-bottom:1.5pt;width:1%">&#160;</td>
    <td style="border-bottom:1.5pt solid black;text-align:left;width:1%">&#160;</td>
    <td style="border-bottom:1.5pt solid black;text-align:right;width:9%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>(<ix:nonFraction id="Fxbrl_20241004054608872_ixv-37634" name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="C_20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">2,848,844</ix:nonFraction></span></span></span></span></td>
    <td style="padding-bottom:1.5pt;text-align:left;width:1%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>)</span></span></span></span></td>
        </tr>
  <tr style="vertical-align:bottom">
    <td style="font-weight:bold;text-align:left;padding-bottom:1.5pt;text-indent:-10pt;padding-left:0.25in;width:64%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>TOTAL
        CAPITAL DEFICIENCY</span></span></span></span></td>
    <td style="padding-bottom:1.5pt;width:1%">&#160;</td>
    <td style="text-align:center;padding-bottom:1.5pt;width:11%">&#160;</td>
    <td style="padding-bottom:1.5pt;width:1%">&#160;</td>
    <td style="border-bottom:1.5pt solid black;text-align:left;width:1%">&#160;</td>
    <td style="border-bottom:1.5pt solid black;text-align:right;width:9%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>(<ix:nonFraction id="Fxbrl_20241004054608875_ixv-37635" name="us-gaap:StockholdersEquity" contextRef="C_20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">3,385,787</ix:nonFraction></span></span></span></span></td>
    <td style="padding-bottom:1.5pt;text-align:left;width:1%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>)</span></span></span></span></td>
    <td style="padding-bottom:1.5pt;width:1%">&#160;</td>
    <td style="border-bottom:1.5pt solid black;text-align:left;width:1%">&#160;</td>
    <td style="border-bottom:1.5pt solid black;text-align:right;width:9%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>(<ix:nonFraction id="Fxbrl_20241004054608875_ixv-37636" name="us-gaap:StockholdersEquity" contextRef="C_20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">2,848,508</ix:nonFraction></span></span></span></span></td>
    <td style="padding-bottom:1.5pt;text-align:left;width:1%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>)</span></span></span></span></td>
        </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="font-weight:bold;text-align:left;padding-bottom:4pt;width:64%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>TOTAL
        LIABILITIES AND SHARES SUBJECT TO POSSIBLE REDEMPTION NET OF CAPITAL DEFICIENCY</span></span></span></span></td>
    <td style="padding-bottom:4pt;width:1%">&#160;</td>
    <td style="text-align:center;padding-bottom:4pt;width:11%">&#160;</td>
    <td style="padding-bottom:4pt;width:1%">&#160;</td>
    <td style="border-bottom:4pt double black;text-align:left;width:1%">&#160;</td>
    <td style="border-bottom:4pt double black;text-align:right;width:9%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20241004054608877_ixv-37637" name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="C_20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,966,806</ix:nonFraction></span></span></span></span></td>
    <td style="padding-bottom:4pt;text-align:left;width:1%">&#160;</td>
    <td style="padding-bottom:4pt;width:1%">&#160;</td>
    <td style="border-bottom:4pt double black;text-align:left;width:1%">&#160;</td>
    <td style="border-bottom:4pt double black;text-align:right;width:9%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20241004054608877_ixv-37638" name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="C_20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,834,215</ix:nonFraction></span></span></span></span></td>
    <td style="padding-bottom:4pt;text-align:left;width:1%">&#160;</td> </tr>
  </table>

<div>&#160;</div>

<table cellpadding="0" cellspacing="0" style="font:10pt Times New Roman, Times, Serif;margin-top:0pt;margin-bottom:0pt;width:100%">
  <tr style="vertical-align:top;text-align:justify">
    <td style="width:0.25in;text-align:left"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong>*</strong></span></span></span></span></td>
    <td><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Less than one US dollar</span></span></span></span></td>
        </tr>
  </table>

<div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong>&#160;</strong></span></span></span></span></div>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong>The
accompanying notes are an integral part of these unaudited condensed consolidated financial statements</strong>.</span></span></span></span></p>
</div> </div>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center">&#160;</p>

<div style="margin-top:12pt;margin-bottom:6pt;border-bottom:Black 1.5pt solid">

<p style="font:10pt Times New Roman, Times, Serif;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>F-2</span></span></span></p>
</div>

<div style="break-before:page;margin-top:6pt;margin-bottom:12pt">

<p style="margin:0pt">&#160;</p> </div>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center">&#160;</p>

<div><span id="f_002"></span></div> </div>

<div style="font:10pt Times New Roman, Times, Serif">

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>MORINGA
ACQUISITION CORP</strong></span></span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">UNAUDITED
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</span></span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width:100%">
  <tr style="vertical-align:bottom">
    <td>&#160;</td>
    <td style="font-weight:bold;padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;font-weight:bold;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Note</span></span></td>
    <td style="font-weight:bold;padding-bottom:1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom:Black 1.5pt solid;font-weight:bold;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Six&#160;months&#160;ended<br/>June
        30,</span></span></td>
    <td style="padding-bottom:1.5pt;font-weight:bold">&#160;</td>
    <td style="font-weight:bold;padding-bottom:1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom:Black 1.5pt solid;font-weight:bold;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Three
        months ended<br/>June 30,</span></span></td>
    <td style="padding-bottom:1.5pt;font-weight:bold">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td>&#160;</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td>&#160;</td>
    <td style="font-weight:bold;padding-bottom:1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom:Black 1.5pt solid;font-weight:bold;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2024</span></span></td>
    <td style="padding-bottom:1.5pt;font-weight:bold">&#160;</td>
    <td style="font-weight:bold;padding-bottom:1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom:Black 1.5pt solid;font-weight:bold;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2023</span></span></td>
    <td style="padding-bottom:1.5pt;font-weight:bold">&#160;</td>
    <td style="font-weight:bold;padding-bottom:1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom:Black 1.5pt solid;font-weight:bold;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2024</span></span></td>
    <td style="padding-bottom:1.5pt;font-weight:bold">&#160;</td>
    <td style="font-weight:bold;padding-bottom:1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom:Black 1.5pt solid;font-weight:bold;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2023</span></span></td>
    <td style="padding-bottom:1.5pt;font-weight:bold">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td>&#160;</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td>&#160;</td>
    <td style="font-weight:bold;padding-bottom:1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom:Black 1.5pt solid;font-weight:bold;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">U.S.
        Dollars</span></span></td>
    <td style="padding-bottom:1.5pt;font-weight:bold">&#160;</td>
    <td style="font-weight:bold;padding-bottom:1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom:Black 1.5pt solid;font-weight:bold;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">U.S.
        Dollars</span></span></td>
    <td style="padding-bottom:1.5pt;font-weight:bold">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td>&#160;</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td>&#160;</td>
    <td style="font-weight:bold;padding-bottom:1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom:Black 1.5pt solid;font-weight:bold;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Except
        share data</span></span></td>
    <td style="padding-bottom:1.5pt;font-weight:bold">&#160;</td>
    <td style="font-weight:bold;padding-bottom:1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom:Black 1.5pt solid;font-weight:bold;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Except
        share data</span></span></td>
    <td style="padding-bottom:1.5pt;font-weight:bold">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="text-align:left;text-indent:-9pt;padding-left:9pt;width:42%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">INTEREST
        EARNED ON INVESTMENTS HELD IN TRUST ACCOUNT</span></span></td>
    <td style="width:1%">&#160;</td>
    <td style="width:9%">&#160;</td>
    <td style="width:1%">&#160;</td>
    <td style="text-align:left;width:1%">&#160;</td>
    <td style="text-align:right;width:9%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fixv-37639" name="us-gaap:InvestmentIncomeInterest" contextRef="C_20240101to20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">149,236</ix:nonFraction></span></span></td>
    <td style="text-align:left;width:1%">&#160;</td>
    <td style="width:1%">&#160;</td>
    <td style="text-align:left;width:1%">&#160;</td>
    <td style="text-align:right;width:9%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fixv-37640" name="us-gaap:InvestmentIncomeInterest" contextRef="C_20230101to20230630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">1,063,043</ix:nonFraction></span></span></td>
    <td style="text-align:left;width:1%">&#160;</td>
    <td style="width:1%">&#160;</td>
    <td style="text-align:left;width:1%">&#160;</td>
    <td style="text-align:right;width:9%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fixv-37641" name="us-gaap:InvestmentIncomeInterest" contextRef="C_20240401to20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">75,305</ix:nonFraction></span></span></td>
    <td style="text-align:left;width:1%">&#160;</td>
    <td style="width:1%">&#160;</td>
    <td style="text-align:left;width:1%">&#160;</td>
    <td style="text-align:right;width:9%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fixv-37642" name="us-gaap:InvestmentIncomeInterest" contextRef="C_20230401to20230630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">318,002</ix:nonFraction></span></span></td>
    <td style="text-align:left;width:1%">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="text-align:left;text-indent:-9pt;padding-left:9pt;width:42%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">GENERAL
        AND ADMINISTRATIVE</span></span></td>
    <td style="width:1%">&#160;</td>
    <td style="width:9%">&#160;</td>
    <td style="width:1%">&#160;</td>
    <td style="text-align:left;width:1%">&#160;</td>
    <td style="text-align:right;width:9%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fixv-37643" name="us-gaap:GeneralAndAdministrativeExpense" contextRef="C_20240101to20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">441,276</ix:nonFraction></span></span></td>
    <td style="text-align:left;width:1%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></td>
    <td style="width:1%">&#160;</td>
    <td style="text-align:left;width:1%">&#160;</td>
    <td style="text-align:right;width:9%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fixv-37644" name="us-gaap:GeneralAndAdministrativeExpense" contextRef="C_20230101to20230630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">592,201</ix:nonFraction></span></span></td>
    <td style="text-align:left;width:1%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></td>
    <td style="width:1%">&#160;</td>
    <td style="text-align:left;width:1%">&#160;</td>
    <td style="text-align:right;width:9%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fixv-37645" name="us-gaap:GeneralAndAdministrativeExpense" contextRef="C_20240401to20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">179,135</ix:nonFraction></span></span></td>
    <td style="text-align:left;width:1%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></td>
    <td style="width:1%">&#160;</td>
    <td style="text-align:left;width:1%">&#160;</td>
    <td style="text-align:right;width:9%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fixv-37646" name="us-gaap:GeneralAndAdministrativeExpense" contextRef="C_20230401to20230630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">155,472</ix:nonFraction></span></span></td>
    <td style="text-align:left;width:1%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></td>
        </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="text-indent:-9pt;padding-left:9pt;width:42%">&#160;</td>
    <td style="width:1%">&#160;</td>
    <td style="text-align:center;width:9%">&#160;</td>
    <td style="width:1%">&#160;</td>
    <td style="text-align:left;width:1%">&#160;</td>
    <td style="text-align:right;width:9%">&#160;</td>
    <td style="text-align:left;width:1%">&#160;</td>
    <td style="width:1%">&#160;</td>
    <td style="text-align:left;width:1%">&#160;</td>
    <td style="text-align:right;width:9%">&#160;</td>
    <td style="text-align:left;width:1%">&#160;</td>
    <td style="width:1%">&#160;</td>
    <td style="text-align:left;width:1%">&#160;</td>
    <td style="text-align:right;width:9%">&#160;</td>
    <td style="text-align:left;width:1%">&#160;</td>
    <td style="width:1%">&#160;</td>
    <td style="text-align:left;width:1%">&#160;</td>
    <td style="text-align:right;width:9%">&#160;</td>
    <td style="text-align:left;width:1%">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="text-align:left;padding-bottom:1.5pt;text-indent:-9pt;padding-left:9pt;width:42%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">CHANGE
        IN FAIR VALUE OF WARRANT LIABILITY</span></span></td>
    <td style="padding-bottom:1.5pt;width:1%">&#160;</td>
    <td style="text-align:center;padding-bottom:1.5pt;width:9%">&#160;</td>
    <td style="padding-bottom:1.5pt;width:1%">&#160;</td>
    <td style="border-bottom:1.5pt solid black;text-align:left;width:1%">&#160;</td>
    <td style="border-bottom:1.5pt solid black;text-align:right;width:9%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fixv-37647" name="us-gaap:FairValueAdjustmentOfWarrants" contextRef="C_20240101to20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">18,753</ix:nonFraction></span></span></td>
    <td style="padding-bottom:1.5pt;text-align:left;width:1%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></td>
    <td style="padding-bottom:1.5pt;width:1%">&#160;</td>
    <td style="border-bottom:1.5pt solid black;text-align:left;width:1%">&#160;</td>
    <td style="border-bottom:1.5pt solid black;text-align:right;width:9%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fixv-37648" name="us-gaap:FairValueAdjustmentOfWarrants" contextRef="C_20230101to20230630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">5,301</ix:nonFraction></span></span></td>
    <td style="padding-bottom:1.5pt;text-align:left;width:1%">&#160;</td>
    <td style="padding-bottom:1.5pt;width:1%">&#160;</td>
    <td style="border-bottom:1.5pt solid black;text-align:left;width:1%">&#160;</td>
    <td style="border-bottom:1.5pt solid black;text-align:right;width:9%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fixv-37649" name="us-gaap:FairValueAdjustmentOfWarrants" contextRef="C_20240401to20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,745</ix:nonFraction></span></span></td>
    <td style="padding-bottom:1.5pt;text-align:left;width:1%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></td>
    <td style="padding-bottom:1.5pt;width:1%">&#160;</td>
    <td style="border-bottom:1.5pt solid black;text-align:left;width:1%">&#160;</td>
    <td style="border-bottom:1.5pt solid black;text-align:right;width:9%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fixv-37650" name="us-gaap:FairValueAdjustmentOfWarrants" contextRef="C_20230401to20230630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">418</ix:nonFraction></span></span></td>
    <td style="padding-bottom:1.5pt;text-align:left;width:1%">&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="font-weight:bold;text-align:left;padding-bottom:4pt;text-indent:-9pt;padding-left:9pt;width:42%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">NET
        PROFIT (LOSS) FOR THE PERIOD</span></span></td>
    <td style="padding-bottom:4pt;width:1%">&#160;</td>
    <td style="text-align:center;padding-bottom:4pt;width:9%">&#160;</td>
    <td style="padding-bottom:4pt;width:1%">&#160;</td>
    <td style="border-bottom:4pt double black;text-align:left;width:1%">&#160;</td>
    <td style="border-bottom:4pt double black;text-align:right;width:9%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fixv-37651" name="us-gaap:ProfitLoss" contextRef="C_20240101to20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">310,793</ix:nonFraction></span></span></td>
    <td style="padding-bottom:3pt;text-align:left;width:1%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></td>
    <td style="padding-bottom:4pt;width:1%">&#160;</td>
    <td style="border-bottom:4pt double black;text-align:left;width:1%">&#160;</td>
    <td style="border-bottom:4pt double black;text-align:right;width:9%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fixv-37652" name="us-gaap:ProfitLoss" contextRef="C_20230101to20230630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">476,143</ix:nonFraction></span></span></td>
    <td style="padding-bottom:2.5pt;text-align:left;width:1%">&#160;</td>
    <td style="padding-bottom:4pt;width:1%">&#160;</td>
    <td style="border-bottom:4pt double black;text-align:left;width:1%">&#160;</td>
    <td style="border-bottom:4pt double black;text-align:right;width:9%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fixv-37653" name="us-gaap:ProfitLoss" contextRef="C_20240401to20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">110,575</ix:nonFraction></span></span></td>
    <td style="padding-bottom:3pt;text-align:left;width:1%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></td>
    <td style="padding-bottom:4pt;width:1%">&#160;</td>
    <td style="border-bottom:4pt double black;text-align:left;width:1%">&#160;</td>
    <td style="border-bottom:4pt double black;text-align:right;width:9%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fixv-37654" name="us-gaap:ProfitLoss" contextRef="C_20230401to20230630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">162,948</ix:nonFraction></span></span></td>
    <td style="padding-bottom:4pt;text-align:left;width:1%">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="text-indent:-9pt;padding-left:9pt;width:42%">&#160;</td>
    <td style="width:1%">&#160;</td>
    <td style="text-align:center;width:9%">&#160;</td>
    <td style="width:1%">&#160;</td>
    <td style="text-align:left;width:1%">&#160;</td>
    <td style="text-align:right;width:9%">&#160;</td>
    <td style="text-align:left;width:1%">&#160;</td>
    <td style="width:1%">&#160;</td>
    <td style="text-align:left;width:1%">&#160;</td>
    <td style="text-align:right;width:9%">&#160;</td>
    <td style="text-align:left;width:1%">&#160;</td>
    <td style="width:1%">&#160;</td>
    <td style="text-align:left;width:1%">&#160;</td>
    <td style="text-align:right;width:9%">&#160;</td>
    <td style="text-align:left;width:1%">&#160;</td>
    <td style="width:1%">&#160;</td>
    <td style="text-align:left;width:1%">&#160;</td>
    <td style="text-align:right;width:9%">&#160;</td>
    <td style="text-align:left;width:1%">&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="padding-bottom:1.5pt;font-weight:bold;text-align:left;text-indent:-9pt;padding-left:9pt;width:42%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">WEIGHTED
        AVERAGE NUMBER OF CLASS A ORDINARY SHARES SUBJECT TO POSSIBLE REDEMPTION</span></span></td>
    <td style="padding-bottom:1.5pt;width:1%">&#160;</td>
    <td style="padding-bottom:1.5pt;text-align:center;width:9%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">8</span></span></td>
    <td style="padding-bottom:1.5pt;width:1%">&#160;</td>
    <td style="border-bottom:1.5pt solid black;text-align:left;width:1%">&#160;</td>
    <td style="border-bottom:1.5pt solid black;text-align:right;width:9%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fixv-37655" name="us-gaap:WeightedAverageNumberOfSharesIssuedBasic" contextRef="C_20240101to20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_slxnClassAOrdinaryShareSubjectToPossibleRedemptionMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">515,019</ix:nonFraction></span></span></td>
    <td style="padding-bottom:1.5pt;text-align:left;width:1%">&#160;</td>
    <td style="padding-bottom:1.5pt;width:1%">&#160;</td>
    <td style="border-bottom:1.5pt solid black;text-align:left;width:1%">&#160;</td>
    <td style="border-bottom:1.5pt solid black;text-align:right;width:9%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fixv-37656" name="us-gaap:WeightedAverageNumberOfSharesIssuedBasic" contextRef="C_20230101to20230630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_slxnClassAOrdinaryShareSubjectToPossibleRedemptionMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">5,015,185</ix:nonFraction></span></span></td>
    <td style="padding-bottom:1.5pt;text-align:left;width:1%">&#160;</td>
    <td style="padding-bottom:1.5pt;width:1%">&#160;</td>
    <td style="border-bottom:1.5pt solid black;text-align:left;width:1%">&#160;</td>
    <td style="border-bottom:1.5pt solid black;text-align:right;width:9%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fixv-37657" name="us-gaap:WeightedAverageNumberOfSharesIssuedBasic" contextRef="C_20240401to20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_slxnClassAOrdinaryShareSubjectToPossibleRedemptionMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">515,019</ix:nonFraction></span></span></td>
    <td style="padding-bottom:1.5pt;text-align:left;width:1%">&#160;</td>
    <td style="padding-bottom:1.5pt;width:1%">&#160;</td>
    <td style="border-bottom:1.5pt solid black;text-align:left;width:1%">&#160;</td>
    <td style="border-bottom:1.5pt solid black;text-align:right;width:9%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fixv-37658" name="us-gaap:WeightedAverageNumberOfSharesIssuedBasic" contextRef="C_20230401to20230630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_slxnClassAOrdinaryShareSubjectToPossibleRedemptionMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">2,589,567</ix:nonFraction></span></span></td>
    <td style="padding-bottom:1.5pt;text-align:left;width:1%">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="font-weight:bold;text-align:left;padding-bottom:4pt;text-indent:-9pt;padding-left:9pt;width:42%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">NET
        PROFIT PER CLASS A ORDINARY SHARE SUBJECT TO POSSIBLE REDEMPTION &#8211; BASIC AND DILUTED</span></span></td>
    <td style="padding-bottom:4pt;width:1%">&#160;</td>
    <td style="padding-bottom:4pt;width:9%">&#160;</td>
    <td style="padding-bottom:4pt;width:1%">&#160;</td>
    <td style="border-bottom:4pt double black;text-align:left;width:1%">&#160;</td>
    <td style="border-bottom:4pt double black;text-align:right;width:9%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20241003011922954" name="us-gaap:EarningsPerShareDiluted" contextRef="C_20240101to20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_slxnClassAOrdinaryShareSubjectToPossibleRedemptionMember" unitRef="usdPershares" scale="0" decimals="2" format="ixt:num-dot-decimal"><ix:nonFraction id="Fixv-37659" name="us-gaap:EarningsPerShareBasic" contextRef="C_20240101to20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_slxnClassAOrdinaryShareSubjectToPossibleRedemptionMember" unitRef="usdPershares" scale="0" decimals="2" format="ixt:num-dot-decimal">0.32</ix:nonFraction></ix:nonFraction></span></span></td>
    <td style="padding-bottom:4pt;text-align:left;width:1%">&#160;</td>
    <td style="padding-bottom:4pt;width:1%">&#160;</td>
    <td style="border-bottom:4pt double black;text-align:left;width:1%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></td>
    <td style="border-bottom:4pt double black;text-align:right;width:9%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20241003011941050" name="us-gaap:EarningsPerShareDiluted" contextRef="C_20230101to20230630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_slxnClassAOrdinaryShareSubjectToPossibleRedemptionMember" unitRef="usdPershares" scale="0" decimals="2" format="ixt:num-dot-decimal"><ix:nonFraction id="Fixv-37660" name="us-gaap:EarningsPerShareBasic" contextRef="C_20230101to20230630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_slxnClassAOrdinaryShareSubjectToPossibleRedemptionMember" unitRef="usdPershares" scale="0" decimals="2" format="ixt:num-dot-decimal">0.22</ix:nonFraction></ix:nonFraction></span></span></td>
    <td style="padding-bottom:4pt;text-align:left;width:1%">&#160;</td>
    <td style="padding-bottom:4pt;width:1%">&#160;</td>
    <td style="border-bottom:4pt double black;text-align:left;width:1%">&#160;</td>
    <td style="border-bottom:4pt double black;text-align:right;width:9%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20241003011957530" name="us-gaap:EarningsPerShareDiluted" contextRef="C_20240401to20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_slxnClassAOrdinaryShareSubjectToPossibleRedemptionMember" unitRef="usdPershares" scale="0" decimals="2" format="ixt:num-dot-decimal"><ix:nonFraction id="Fixv-37661" name="us-gaap:EarningsPerShareBasic" contextRef="C_20240401to20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_slxnClassAOrdinaryShareSubjectToPossibleRedemptionMember" unitRef="usdPershares" scale="0" decimals="2" format="ixt:num-dot-decimal">0.17</ix:nonFraction></ix:nonFraction></span></span></td>
    <td style="padding-bottom:4pt;text-align:left;width:1%">&#160;</td>
    <td style="padding-bottom:4pt;width:1%">&#160;</td>
    <td style="border-bottom:4pt double black;text-align:left;width:1%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></td>
    <td style="border-bottom:4pt double black;text-align:right;width:9%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20241003012015225" name="us-gaap:EarningsPerShareDiluted" contextRef="C_20230401to20230630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_slxnClassAOrdinaryShareSubjectToPossibleRedemptionMember" unitRef="usdPershares" scale="0" decimals="2" format="ixt:num-dot-decimal"><ix:nonFraction id="Fixv-37662" name="us-gaap:EarningsPerShareBasic" contextRef="C_20230401to20230630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_slxnClassAOrdinaryShareSubjectToPossibleRedemptionMember" unitRef="usdPershares" scale="0" decimals="2" format="ixt:num-dot-decimal">0.19</ix:nonFraction></ix:nonFraction></span></span></td>
    <td style="padding-bottom:4pt;text-align:left;width:1%">&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="text-indent:-9pt;padding-left:9pt;width:42%">&#160;</td>
    <td style="width:1%">&#160;</td>
    <td style="width:9%">&#160;</td>
    <td style="width:1%">&#160;</td>
    <td style="text-align:left;width:1%">&#160;</td>
    <td style="text-align:right;width:9%">&#160;</td>
    <td style="text-align:left;width:1%">&#160;</td>
    <td style="width:1%">&#160;</td>
    <td style="text-align:left;width:1%">&#160;</td>
    <td style="text-align:right;width:9%">&#160;</td>
    <td style="text-align:left;width:1%">&#160;</td>
    <td style="width:1%">&#160;</td>
    <td style="text-align:left;width:1%">&#160;</td>
    <td style="text-align:right;width:9%">&#160;</td>
    <td style="text-align:left;width:1%">&#160;</td>
    <td style="width:1%">&#160;</td>
    <td style="text-align:left;width:1%">&#160;</td>
    <td style="text-align:right;width:9%">&#160;</td>
    <td style="text-align:left;width:1%">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="padding-bottom:1.5pt;font-weight:bold;text-align:left;text-indent:-9pt;padding-left:9pt;width:42%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">WEIGHTED
        AVERAGE NUMBER OF NON-REDEEMABLE CLASS A AND CLASS B ORDINARY SHARES</span></span></td>
    <td style="padding-bottom:1.5pt;width:1%">&#160;</td>
    <td style="padding-bottom:1.5pt;text-align:center;width:9%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">8</span></span></td>
    <td style="padding-bottom:1.5pt;width:1%">&#160;</td>
    <td style="border-bottom:1.5pt solid black;text-align:left;width:1%">&#160;</td>
    <td style="border-bottom:1.5pt solid black;text-align:right;width:9%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fixv-37663" name="us-gaap:WeightedAverageNumberOfSharesIssuedBasic" contextRef="C_20240101to20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_slxnNonredeemableClassAandBOrdinaryShareMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">3,355,000</ix:nonFraction></span></span></td>
    <td style="padding-bottom:1.5pt;text-align:left;width:1%">&#160;</td>
    <td style="padding-bottom:1.5pt;width:1%">&#160;</td>
    <td style="border-bottom:1.5pt solid black;text-align:left;width:1%">&#160;</td>
    <td style="border-bottom:1.5pt solid black;text-align:right;width:9%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fixv-37664" name="us-gaap:WeightedAverageNumberOfSharesIssuedBasic" contextRef="C_20230101to20230630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_slxnNonredeemableClassAandBOrdinaryShareMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">3,355,000</ix:nonFraction></span></span></td>
    <td style="padding-bottom:1.5pt;text-align:left;width:1%">&#160;</td>
    <td style="padding-bottom:1.5pt;width:1%">&#160;</td>
    <td style="border-bottom:1.5pt solid black;text-align:left;width:1%">&#160;</td>
    <td style="border-bottom:1.5pt solid black;text-align:right;width:9%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fixv-37665" name="us-gaap:WeightedAverageNumberOfSharesIssuedBasic" contextRef="C_20240401to20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_slxnNonredeemableClassAandBOrdinaryShareMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">3,355,000</ix:nonFraction></span></span></td>
    <td style="padding-bottom:1.5pt;text-align:left;width:1%">&#160;</td>
    <td style="padding-bottom:1.5pt;width:1%">&#160;</td>
    <td style="border-bottom:1.5pt solid black;text-align:left;width:1%">&#160;</td>
    <td style="border-bottom:1.5pt solid black;text-align:right;width:9%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fixv-37666" name="us-gaap:WeightedAverageNumberOfSharesIssuedBasic" contextRef="C_20230401to20230630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_slxnNonredeemableClassAandBOrdinaryShareMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">3,355,000</ix:nonFraction></span></span></td>
    <td style="padding-bottom:1.5pt;text-align:left;width:1%">&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="font-weight:bold;text-align:left;padding-bottom:4pt;text-indent:-9pt;padding-left:9pt;width:42%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">NET
        LOSS PER NON-REDEEMABLE CLASS A AND CLASS B ORDINARY SHARES &#8211; BASIC AND DILUTED</span></span></td>
    <td style="padding-bottom:4pt;width:1%">&#160;</td>
    <td style="text-align:right;padding-bottom:4pt;width:9%">&#160;</td>
    <td style="padding-bottom:4pt;width:1%">&#160;</td>
    <td style="border-bottom:4pt double black;text-align:left;width:1%">&#160;</td>
    <td style="border-bottom:4pt double black;text-align:right;width:9%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fxbrl_20241003012046420" name="us-gaap:EarningsPerShareDiluted" contextRef="C_20240101to20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_slxnNonredeemableClassAandBOrdinaryShareMember" unitRef="usdPershares" scale="0" decimals="2" format="ixt:num-dot-decimal" sign="-"><ix:nonFraction id="Fixv-37667" name="us-gaap:EarningsPerShareBasic" contextRef="C_20240101to20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_slxnNonredeemableClassAandBOrdinaryShareMember" unitRef="usdPershares" scale="0" decimals="2" format="ixt:num-dot-decimal" sign="-">0.14</ix:nonFraction></ix:nonFraction></span></span></td>
    <td style="padding-bottom:4pt;text-align:left;width:1%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></td>
    <td style="padding-bottom:4pt;width:1%">&#160;</td>
    <td style="border-bottom:4pt double black;text-align:left;width:1%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></td>
    <td style="border-bottom:4pt double black;text-align:right;width:9%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fxbrl_20241003012101706" name="us-gaap:EarningsPerShareDiluted" contextRef="C_20230101to20230630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_slxnNonredeemableClassAandBOrdinaryShareMember" unitRef="usdPershares" scale="0" decimals="2" format="ixt:num-dot-decimal" sign="-"><ix:nonFraction id="Fixv-37668" name="us-gaap:EarningsPerShareBasic" contextRef="C_20230101to20230630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_slxnNonredeemableClassAandBOrdinaryShareMember" unitRef="usdPershares" scale="0" decimals="2" format="ixt:num-dot-decimal" sign="-">0.19</ix:nonFraction></ix:nonFraction></span></span></td>
    <td style="padding-bottom:4pt;text-align:left;width:1%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></td>
    <td style="padding-bottom:4pt;width:1%">&#160;</td>
    <td style="border-bottom:4pt double black;text-align:left;width:1%">&#160;</td>
    <td style="border-bottom:4pt double black;text-align:right;width:9%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fxbrl_20241003012114195" name="us-gaap:EarningsPerShareDiluted" contextRef="C_20240401to20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_slxnNonredeemableClassAandBOrdinaryShareMember" unitRef="usdPershares" scale="0" decimals="2" format="ixt:num-dot-decimal" sign="-"><ix:nonFraction id="Fixv-37669" name="us-gaap:EarningsPerShareBasic" contextRef="C_20240401to20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_slxnNonredeemableClassAandBOrdinaryShareMember" unitRef="usdPershares" scale="0" decimals="2" format="ixt:num-dot-decimal" sign="-">0.06</ix:nonFraction></ix:nonFraction></span></span></td>
    <td style="padding-bottom:4pt;text-align:left;width:1%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></td>
    <td style="padding-bottom:4pt;width:1%">&#160;</td>
    <td style="border-bottom:4pt double black;text-align:left;width:1%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></td>
    <td style="border-bottom:4pt double black;text-align:right;width:9%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fxbrl_20241003012125221" name="us-gaap:EarningsPerShareDiluted" contextRef="C_20230401to20230630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_slxnNonredeemableClassAandBOrdinaryShareMember" unitRef="usdPershares" scale="0" decimals="2" format="ixt:num-dot-decimal" sign="-"><ix:nonFraction id="Fixv-37670" name="us-gaap:EarningsPerShareBasic" contextRef="C_20230401to20230630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_slxnNonredeemableClassAandBOrdinaryShareMember" unitRef="usdPershares" scale="0" decimals="2" format="ixt:num-dot-decimal" sign="-">0.10</ix:nonFraction></ix:nonFraction></span></span></td>
    <td style="padding-bottom:4pt;text-align:left;width:1%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></td>
        </tr>
  </table>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="text-indent:0.25in;font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>The
accompanying notes are an integral part of these unaudited condensed consolidated financial statements.</strong></span></span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center">&#160;</p>

<div style="margin-top:12pt;margin-bottom:6pt;border-bottom:Black 1.5pt solid">

<p style="font:10pt Times New Roman, Times, Serif;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>F-3</span></span></span></p>
</div>

<div style="break-before:page;margin-top:6pt;margin-bottom:12pt">

<p style="margin:0pt">&#160;</p> </div>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>&#160;</strong></span></span></p>

<div><span id="f_003"></span></div> </div>

<div style="font:10pt Times New Roman, Times, Serif">

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center"><strong>MORINGA ACQUISITION CORP</strong></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center">UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CHANGES
IN CAPITAL DEFICIENCY</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font:10pt Times New Roman, Times, Serif;border-collapse:collapse;width:100%">
  <tr style="vertical-align:bottom">
    <td style="text-align:center">&#160;</td>
    <td style="font-weight:bold;padding-bottom:1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom:Black 1.5pt solid;font-weight:bold;text-align:center">Class A<br/>ordinary shares</td>
    <td style="padding-bottom:1.5pt;font-weight:bold">&#160;</td>
    <td style="font-weight:bold;padding-bottom:1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom:Black 1.5pt solid;font-weight:bold;text-align:center">Class B<br/>ordinary shares</td>
    <td style="padding-bottom:1.5pt;font-weight:bold">&#160;</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td colspan="2" style="text-align:center">&#160;</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td colspan="2" style="text-align:center;margin-top:0pt;margin-bottom:0pt"><strong style="margin-top:0pt;margin-bottom:0pt">Total</strong></td>
    <td style="padding-bottom:1.5pt">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="text-align:center">&#160;</td>
    <td style="font-weight:bold;padding-bottom:1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom:1.5pt solid black;font-weight:bold;text-align:center;margin-top:0pt;margin-bottom:0pt">
        <p style="margin-top:0pt;margin-bottom:0pt">Number&#160;of</p>
        <p style="margin-top:0pt;margin-bottom:0pt">shares</p> </td>
    <td style="padding-bottom:1.5pt;font-weight:bold">&#160;</td>
    <td style="font-weight:bold;padding-bottom:1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom:1.5pt solid black;font-weight:bold;text-align:center;margin-top:0pt;margin-bottom:0pt">Par value</td>
    <td style="padding-bottom:1.5pt;font-weight:bold">&#160;</td>
    <td style="font-weight:bold;padding-bottom:1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom:1.5pt solid black;font-weight:bold;text-align:center;margin-top:0pt;margin-bottom:0pt">
        <p style="margin-top:0pt;margin-bottom:0pt">Number&#160;of</p>
        <p style="margin-top:0pt;margin-bottom:0pt">shares</p> </td>
    <td style="padding-bottom:1.5pt;font-weight:bold">&#160;</td>
    <td style="font-weight:bold;padding-bottom:1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom:1.5pt solid black;font-weight:bold;text-align:center;margin-top:0pt;margin-bottom:0pt">Par value</td>
    <td style="padding-bottom:1.5pt;font-weight:bold">&#160;</td>
    <td style="font-weight:bold;padding-bottom:1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom:1.5pt solid black;font-weight:bold;text-align:center;margin-top:0pt;margin-bottom:0pt">
        <p style="margin-top:0pt;margin-bottom:0pt">Accumulated</p>
        <p style="margin-top:0pt;margin-bottom:0pt">deficit</p> </td>
    <td style="padding-bottom:1.5pt;font-weight:bold">&#160;</td>
    <td style="font-weight:bold;padding-bottom:1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom:1.5pt solid black;font-weight:bold;text-align:center;margin-top:0pt;margin-bottom:0pt">
        <p style="margin-top:0pt;margin-bottom:0pt">capital</p>
        <p style="margin-top:0pt;margin-bottom:0pt">deficiency</p> </td>
    <td style="padding-bottom:1.5pt;font-weight:bold">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="22">&#160;</td>
    <td>&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="width:37%;font-weight:bold;text-indent:-9pt;padding-left:9pt">BALANCE AT December 31, 2022</td>
    <td style="width:0.5%">&#160;</td>
    <td style="width:0.5%;text-align:left">&#160;</td>
    <td style="width:9%;text-align:right"><ix:nonFraction id="Fixv-37671" name="us-gaap:SharesOutstanding" contextRef="C_20221231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_usgaapCommonClassAMember_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">480,000</ix:nonFraction></td>
    <td style="width:0.5%;text-align:left">&#160;</td>
    <td style="width:0.5%">&#160;</td>
    <td style="width:0.5%;text-align:left">&#160;</td>
    <td style="width:9%;text-align:right"><ix:nonFraction id="Fixv-37672" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_20221231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_usgaapCommonClassAMember_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">48</ix:nonFraction></td>
    <td style="width:0.5%;text-align:left">&#160;</td>
    <td style="width:0.5%">&#160;</td>
    <td style="width:0.5%;text-align:left">&#160;</td>
    <td style="width:9%;text-align:right"><ix:nonFraction id="Fixv-37673" name="us-gaap:SharesOutstanding" contextRef="C_20221231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_usgaapCommonClassBMember_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">2,875,000</ix:nonFraction></td>
    <td style="width:0.5%;text-align:left">&#160;</td>
    <td style="width:0.5%">&#160;</td>
    <td style="width:0.5%;text-align:left">&#160;</td>
    <td style="width:9%;text-align:right"><ix:nonFraction id="Fixv-37674" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_20221231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_usgaapCommonClassBMember_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">288</ix:nonFraction></td>
    <td style="width:0.5%;text-align:left">&#160;</td>
    <td style="width:0.5%">&#160;</td>
    <td style="width:0.5%;text-align:left">&#160;</td>
    <td style="width:9%;text-align:right">(<ix:nonFraction id="Fixv-37675" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_20221231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">1,203,097</ix:nonFraction></td>
    <td style="width:0.5%;text-align:left">)</td>
    <td style="width:0.5%">&#160;</td>
    <td style="width:0.5%;text-align:left">&#160;</td>
    <td style="width:9%;text-align:right">(<ix:nonFraction id="Fixv-37676" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_20221231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">1,202,761</ix:nonFraction></td>
    <td style="width:0.5%;text-align:left">)</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="text-align:left;text-indent:-9pt;padding-left:9pt">&#160;Subsequent accretion of Class A Ordinary Shares subject to possible redemption
        to amount as of March 31, 2023</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">(<ix:nonFraction id="Fixv-37677" name="us-gaap:TemporaryEquityAccretionToRedemptionValueAdjustment" contextRef="C_20230101to20230331_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">905,040</ix:nonFraction></td>
    <td style="text-align:left">)</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">(<ix:nonFraction id="Fixv-37678" name="us-gaap:TemporaryEquityAccretionToRedemptionValueAdjustment" contextRef="C_20230101to20230331_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">905,040</ix:nonFraction></td>
    <td style="text-align:left">)</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="text-align:left;padding-bottom:1.5pt;text-indent:-9pt;padding-left:9pt">Net profit for the period</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right">&#160;</td>
    <td style="padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right">&#160;</td>
    <td style="padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right">&#160;</td>
    <td style="padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right">&#160;</td>
    <td style="padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right"><ix:nonFraction id="Fixv-37679" name="us-gaap:ProfitLoss" contextRef="C_20230101to20230331_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">313,195</ix:nonFraction></td>
    <td style="padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right"><ix:nonFraction id="Fixv-37680" name="us-gaap:ProfitLoss" contextRef="C_20230101to20230331_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">313,195</ix:nonFraction></td>
    <td style="padding-bottom:1.5pt;text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="font-weight:bold;padding-bottom:4pt;text-indent:-9pt;padding-left:9pt">BALANCE AT March 31, 2023</td>
    <td style="padding-bottom:4pt">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:left">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:right"><ix:nonFraction id="Fixv-37681" name="us-gaap:SharesOutstanding" contextRef="C_20230331_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_usgaapCommonClassAMember_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">480,000</ix:nonFraction></td>
    <td style="padding-bottom:4pt;text-align:left">&#160;</td>
    <td style="padding-bottom:4pt">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:left">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:right"><ix:nonFraction id="Fixv-37682" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_20230331_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_usgaapCommonClassAMember_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">48</ix:nonFraction></td>
    <td style="padding-bottom:4pt;text-align:left">&#160;</td>
    <td style="padding-bottom:4pt">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:left">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:right"><ix:nonFraction id="Fixv-37683" name="us-gaap:SharesOutstanding" contextRef="C_20230331_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_usgaapCommonClassBMember_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">2,875,000</ix:nonFraction></td>
    <td style="padding-bottom:4pt;text-align:left">&#160;</td>
    <td style="padding-bottom:4pt">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:left">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:right"><ix:nonFraction id="Fixv-37684" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_20230331_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_usgaapCommonClassBMember_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">288</ix:nonFraction></td>
    <td style="padding-bottom:4pt;text-align:left">&#160;</td>
    <td style="padding-bottom:4pt">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:left">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:right">(<ix:nonFraction id="Fixv-37685" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_20230331_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">1,794,942</ix:nonFraction></td>
    <td style="padding-bottom:2.5pt;text-align:left">)</td>
    <td style="padding-bottom:4pt">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:left">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:right">(<ix:nonFraction id="Fixv-37686" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_20230331_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">1,794,606</ix:nonFraction></td>
    <td style="padding-bottom:2.5pt;text-align:left">)</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="text-indent:-9pt;padding-left:9pt">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="text-align:left;text-indent:-9pt;padding-left:9pt">Subsequent accretion of Class A Ordinary Shares subject to possible redemption
        to amount as of June 30, 2023</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">(<ix:nonFraction id="Fixv-37687" name="us-gaap:TemporaryEquityAccretionToRedemptionValueAdjustment" contextRef="C_20230401to20230630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">558,002</ix:nonFraction></td>
    <td style="text-align:left">)</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">(<ix:nonFraction id="Fixv-37688" name="us-gaap:TemporaryEquityAccretionToRedemptionValueAdjustment" contextRef="C_20230401to20230630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">558,002</ix:nonFraction></td>
    <td style="text-align:left">)</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="text-align:left;padding-bottom:1.5pt;text-indent:-9pt;padding-left:9pt">Net profit for the period</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right">&#160;</td>
    <td style="padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right">&#160;</td>
    <td style="padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right">&#160;</td>
    <td style="padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right">&#160;</td>
    <td style="padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right"><ix:nonFraction id="Fixv-37689" name="us-gaap:ProfitLoss" contextRef="C_20230401to20230630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">162,948</ix:nonFraction></td>
    <td style="padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right"><ix:nonFraction id="Fixv-37690" name="us-gaap:ProfitLoss" contextRef="C_20230401to20230630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">162,948</ix:nonFraction></td>
    <td style="padding-bottom:1.5pt;text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="font-weight:bold;padding-bottom:4pt;text-indent:-9pt;padding-left:9pt">BALANCE AT June 30, 2023</td>
    <td style="padding-bottom:4pt">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:left">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:right"><ix:nonFraction id="Fixv-37691" name="us-gaap:SharesOutstanding" contextRef="C_20230630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_usgaapCommonClassAMember_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">480,000</ix:nonFraction></td>
    <td style="padding-bottom:4pt;text-align:left">&#160;</td>
    <td style="padding-bottom:4pt">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:left">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:right"><ix:nonFraction id="Fixv-37692" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_20230630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_usgaapCommonClassAMember_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">48</ix:nonFraction></td>
    <td style="padding-bottom:4pt;text-align:left">&#160;</td>
    <td style="padding-bottom:4pt">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:left">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:right"><ix:nonFraction id="Fixv-37693" name="us-gaap:SharesOutstanding" contextRef="C_20230630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_usgaapCommonClassBMember_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">2,875,000</ix:nonFraction></td>
    <td style="padding-bottom:4pt;text-align:left">&#160;</td>
    <td style="padding-bottom:4pt">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:left">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:right"><ix:nonFraction id="Fixv-37694" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_20230630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_usgaapCommonClassBMember_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">288</ix:nonFraction></td>
    <td style="padding-bottom:4pt;text-align:left">&#160;</td>
    <td style="padding-bottom:4pt">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:left">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:right">(<ix:nonFraction id="Fixv-37695" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_20230630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">2,189,996</ix:nonFraction></td>
    <td style="padding-bottom:2.5pt;text-align:left">)</td>
    <td style="padding-bottom:4pt">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:left">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:right">(<ix:nonFraction id="Fixv-37696" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_20230630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">2,189,660</ix:nonFraction></td>
    <td style="padding-bottom:2.5pt;text-align:left">)</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="text-indent:-9pt;padding-left:9pt">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="font-weight:bold;text-indent:-9pt;padding-left:9pt">BALANCE AT December 31, 2023</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right"><ix:nonFraction id="Fixv-37697" name="us-gaap:SharesOutstanding" contextRef="C_20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_usgaapCommonClassAMember_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">3,354,999</ix:nonFraction></td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right"><ix:nonFraction id="Fixv-37698" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_usgaapCommonClassAMember_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">336</ix:nonFraction></td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right"><ix:nonFraction id="Fixv-37699" name="us-gaap:SharesOutstanding" contextRef="C_20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_usgaapCommonClassBMember_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">1</ix:nonFraction></td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right"><span style="-sec-ix-hidden:Fhidden-fact-70">*</span></td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">(<ix:nonFraction id="Fixv-37700" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">2,848,844</ix:nonFraction></td>
    <td style="text-align:left">)</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">(<ix:nonFraction id="Fixv-37701" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">2,848,508</ix:nonFraction></td>
    <td style="text-align:left">)</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="text-align:left;text-indent:-9pt;padding-left:9pt">Subsequent accretion of Class A Ordinary Shares subject to possible redemption
        to amount as of March 31, 2024</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">(<ix:nonFraction id="Fixv-37702" name="us-gaap:TemporaryEquityAccretionToRedemptionValueAdjustment" contextRef="C_20240101to20240331_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">112,558</ix:nonFraction></td>
    <td style="text-align:left">)</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">(<ix:nonFraction id="Fixv-37703" name="us-gaap:TemporaryEquityAccretionToRedemptionValueAdjustment" contextRef="C_20240101to20240331_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">112,558</ix:nonFraction></td>
    <td style="text-align:left">)</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="text-align:left;padding-bottom:1.5pt;text-indent:-9pt;padding-left:9pt">Net loss for the period</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right">&#160;</td>
    <td style="padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right">&#160;</td>
    <td style="padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right">&#160;</td>
    <td style="padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right">&#160;</td>
    <td style="padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right">(<ix:nonFraction id="Fixv-37704" name="us-gaap:ProfitLoss" contextRef="C_20240101to20240331_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">200,218</ix:nonFraction></td>
    <td style="padding-bottom:1.5pt;text-align:left">)</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right">(<ix:nonFraction id="Fixv-37705" name="us-gaap:ProfitLoss" contextRef="C_20240101to20240331_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">200,218</ix:nonFraction></td>
    <td style="padding-bottom:1.5pt;text-align:left">)</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="font-weight:bold;padding-bottom:4pt;text-indent:-9pt;padding-left:9pt">BALANCE AT March 31, 2024</td>
    <td style="padding-bottom:4pt">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:left">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:right"><ix:nonFraction id="Fixv-37706" name="us-gaap:SharesOutstanding" contextRef="C_20240331_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_usgaapCommonClassAMember_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">3,354,999</ix:nonFraction></td>
    <td style="padding-bottom:4pt;text-align:left">&#160;</td>
    <td style="padding-bottom:4pt">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:left">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:right"><ix:nonFraction id="Fixv-37707" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_20240331_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_usgaapCommonClassAMember_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">336</ix:nonFraction></td>
    <td style="padding-bottom:4pt;text-align:left">&#160;</td>
    <td style="padding-bottom:4pt">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:left">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:right"><ix:nonFraction id="Fixv-37708" name="us-gaap:SharesOutstanding" contextRef="C_20240331_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_usgaapCommonClassBMember_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">1</ix:nonFraction></td>
    <td style="padding-bottom:4pt;text-align:left">&#160;</td>
    <td style="padding-bottom:4pt">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:left">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:right"><span style="-sec-ix-hidden:Fhidden-fact-71">*</span></td>
    <td style="padding-bottom:4pt;text-align:left">&#160;</td>
    <td style="padding-bottom:4pt">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:left">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:right">(<ix:nonFraction id="Fixv-37709" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_20240331_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">3,161,620</ix:nonFraction></td>
    <td style="padding-bottom:2.5pt;text-align:left">)</td>
    <td style="padding-bottom:4pt">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:left">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:right">(<ix:nonFraction id="Fixv-37710" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_20240331_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">3,161,284</ix:nonFraction></td>
    <td style="padding-bottom:2.5pt;text-align:left">)</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="text-indent:-9pt;padding-left:9pt">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="text-align:left;text-indent:-9pt;padding-left:9pt">Subsequent accretion of Class A Ordinary Shares subject to possible redemption
        to amount as of June 30, 2024</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">(<ix:nonFraction id="Fixv-37711" name="us-gaap:TemporaryEquityAccretionToRedemptionValueAdjustment" contextRef="C_20240401to20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">113,928</ix:nonFraction></td>
    <td style="text-align:left">)</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">(<ix:nonFraction id="Fixv-37712" name="us-gaap:TemporaryEquityAccretionToRedemptionValueAdjustment" contextRef="C_20240401to20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">113,928</ix:nonFraction></td>
    <td style="text-align:left">)</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="text-align:left;padding-bottom:1.5pt;text-indent:-9pt;padding-left:9pt">Net loss for the period</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right">&#160;</td>
    <td style="padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right">&#160;</td>
    <td style="padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right">&#160;</td>
    <td style="padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right">&#160;</td>
    <td style="padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right">(<ix:nonFraction id="Fixv-37713" name="us-gaap:ProfitLoss" contextRef="C_20240401to20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">110,575</ix:nonFraction></td>
    <td style="padding-bottom:1.5pt;text-align:left">)</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right">(<ix:nonFraction id="Fixv-37714" name="us-gaap:ProfitLoss" contextRef="C_20240401to20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">110,575</ix:nonFraction></td>
    <td style="padding-bottom:1.5pt;text-align:left">)</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="font-weight:bold;padding-bottom:4pt;text-indent:-9pt;padding-left:9pt">BALANCE AT June 30, 2024</td>
    <td style="padding-bottom:4pt">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:left">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:right"><ix:nonFraction id="Fixv-37715" name="us-gaap:SharesOutstanding" contextRef="C_20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_usgaapCommonClassAMember_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">3,354,999</ix:nonFraction></td>
    <td style="padding-bottom:4pt;text-align:left">&#160;</td>
    <td style="padding-bottom:4pt">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:left">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:right"><ix:nonFraction id="Fixv-37716" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_usgaapCommonClassAMember_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">336</ix:nonFraction></td>
    <td style="padding-bottom:4pt;text-align:left">&#160;</td>
    <td style="padding-bottom:4pt">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:left">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:right"><ix:nonFraction id="Fixv-37717" name="us-gaap:SharesOutstanding" contextRef="C_20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_usgaapCommonClassBMember_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">1</ix:nonFraction></td>
    <td style="padding-bottom:4pt;text-align:left">&#160;</td>
    <td style="padding-bottom:4pt">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:left">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:right"><span style="-sec-ix-hidden:Fhidden-fact-72">*</span></td>
    <td style="padding-bottom:4pt;text-align:left">&#160;</td>
    <td style="padding-bottom:4pt">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:left">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:right">(<ix:nonFraction id="Fixv-37718" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">3,386,123</ix:nonFraction></td>
    <td style="padding-bottom:2.5pt;text-align:left">)</td>
    <td style="padding-bottom:4pt">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:left">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:right">(<ix:nonFraction id="Fixv-37719" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">3,385,787</ix:nonFraction></td>
    <td style="padding-bottom:2.5pt;text-align:left">)</td> </tr>
  </table>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font:10pt Times New Roman, Times, Serif;margin-top:0pt;margin-bottom:0pt;width:100%">
  <tr style="vertical-align:top;text-align:justify">
    <td style="width:0.25in;text-align:left"><strong>*</strong></td>
    <td style="text-align:justify">Less than one US dollar</td> </tr>
  </table>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center"><strong>The accompanying notes are an integral part
of these unaudited condensed consolidated financial statements.</strong></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center">&#160;</p>

<div style="margin-top:12pt;margin-bottom:6pt;border-bottom:Black 1.5pt solid">

<p style="font:10pt Times New Roman, Times, Serif;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">F-4</span></p>
</div>

<div style="break-before:page;margin-top:6pt;margin-bottom:12pt">

<p style="margin:0pt">&#160;</p> </div>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center"><strong>&#160;</strong></p>

<div><span id="f_004"></span></div> </div>

<div style="font:10pt Times New Roman, Times, Serif">

<div>

<div>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center"><strong style="font-size:10pt">MORINGA ACQUISITION CORP</strong></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">UNAUDITED
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</span></span></p>

<div>&#160;</div>

<table cellpadding="0" cellspacing="0" style="width:100%">
  <tr style="vertical-align:bottom">
    <td style="text-align:center">&#160;</td>
    <td style="font-weight:bold;padding-bottom:1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom:Black 1.5pt solid;font-weight:bold;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Six
        months ended<br/>June 30,</span></span></td>
    <td style="padding-bottom:1.5pt;font-weight:bold">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="text-align:center">&#160;</td>
    <td style="font-weight:bold;padding-bottom:1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom:Black 1.5pt solid;font-weight:bold;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2024</span></span></td>
    <td style="padding-bottom:1.5pt;font-weight:bold">&#160;</td>
    <td style="font-weight:bold;padding-bottom:1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom:Black 1.5pt solid;font-weight:bold;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2023</span></span></td>
    <td style="padding-bottom:1.5pt;font-weight:bold">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="font-weight:bold;text-align:left"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">CASH FLOWS
        FROM OPERATING ACTIVITIES:</span></span></td>
    <td>&#160;</td>
    <td colspan="2" style="text-align:right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align:right">&#160;</td>
    <td>&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="text-align:left;padding-left:9pt;width:76%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Net
        profit (loss) for the period</span></span></td>
    <td style="width:1%">&#160;</td>
    <td style="text-align:left;width:1%">&#160;</td>
    <td style="text-align:right;width:9%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fxbrl_20241004055526668_ixv-37721" name="us-gaap:ProfitLoss" contextRef="C_20240101to20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">310,793</ix:nonFraction></span></span></td>
    <td style="text-align:left;width:1%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></td>
    <td style="width:1%">&#160;</td>
    <td style="text-align:left;width:1%">&#160;</td>
    <td style="text-align:right;width:9%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20241004055526668_ixv-37722" name="us-gaap:ProfitLoss" contextRef="C_20230101to20230630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">476,143</ix:nonFraction></span></span></td>
    <td style="text-align:left;width:1%">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="text-align:left;padding-left:9pt;width:76%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Adjustments
        to reconcile net profit (loss) to net cash provided by (used in) operating activities:</span></span></td>
    <td style="width:1%">&#160;</td>
    <td style="text-align:left;width:1%">&#160;</td>
    <td style="text-align:right;width:9%">&#160;</td>
    <td style="text-align:left;width:1%">&#160;</td>
    <td style="width:1%">&#160;</td>
    <td style="text-align:left;width:1%">&#160;</td>
    <td style="text-align:right;width:9%">&#160;</td>
    <td style="text-align:left;width:1%">&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="text-align:left;padding-left:0.25in;width:76%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Change
        in the fair value of the private warrant liability</span></span></td>
    <td style="width:1%">&#160;</td>
    <td style="text-align:left;width:1%">&#160;</td>
    <td style="text-align:right;width:9%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20241004055526672_ixv-37723" name="us-gaap:FairValueAdjustmentOfWarrants" contextRef="C_20240101to20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">18,753</ix:nonFraction></span></span></td>
    <td style="text-align:left;width:1%">&#160;</td>
    <td style="width:1%">&#160;</td>
    <td style="text-align:left;width:1%">&#160;</td>
    <td style="text-align:right;width:9%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fxbrl_20241004055526672_ixv-37724" name="us-gaap:FairValueAdjustmentOfWarrants" contextRef="C_20230101to20230630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">5,301</ix:nonFraction></span></span></td>
    <td style="text-align:left;width:1%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></td>
        </tr>
  <tr style="vertical-align:bottom">
    <td style="text-align:left;padding-left:9pt;width:76%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Changes
        in operating assets and liabilities:</span></span></td>
    <td style="width:1%">&#160;</td>
    <td style="text-align:left;width:1%">&#160;</td>
    <td style="text-align:right;width:9%">&#160;</td>
    <td style="text-align:left;width:1%">&#160;</td>
    <td style="width:1%">&#160;</td>
    <td style="text-align:left;width:1%">&#160;</td>
    <td style="text-align:right;width:9%">&#160;</td>
    <td style="text-align:left;width:1%">&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="text-align:left;padding-left:0.25in;width:76%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Decrease
        in prepaid expenses</span></span></td>
    <td style="width:1%">&#160;</td>
    <td style="text-align:left;width:1%">&#160;</td>
    <td style="text-align:right;width:9%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20241004055526675_ixv-37725" name="us-gaap:IncreaseDecreaseInPrepaidExpense" contextRef="C_20240101to20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">3,497</ix:nonFraction></span></span></td>
    <td style="text-align:left;width:1%">&#160;</td>
    <td style="width:1%">&#160;</td>
    <td style="text-align:left;width:1%">&#160;</td>
    <td style="text-align:right;width:9%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20241004055526675_ixv-37726" name="us-gaap:IncreaseDecreaseInPrepaidExpense" contextRef="C_20230101to20230630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">2,023</ix:nonFraction></span></span></td>
    <td style="text-align:left;width:1%">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="text-align:left;padding-left:0.25in;width:76%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Increase
        (decrease) in related party</span></span></td>
    <td style="width:1%">&#160;</td>
    <td style="text-align:left;width:1%">&#160;</td>
    <td style="text-align:right;width:9%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fxbrl_20241004055526678_ixv-37727" name="us-gaap:IncreaseDecreaseInDueFromRelatedParties" contextRef="C_20240101to20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">20,000</ix:nonFraction></span></span></td>
    <td style="text-align:left;width:1%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></td>
    <td style="width:1%">&#160;</td>
    <td style="text-align:left;width:1%">&#160;</td>
    <td style="text-align:right;width:9%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20241004055526678_ixv-37728" name="us-gaap:IncreaseDecreaseInDueFromRelatedParties" contextRef="C_20230101to20230630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">30,000</ix:nonFraction></span></span></td>
    <td style="text-align:left;width:1%">&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="text-align:left;padding-bottom:1.5pt;padding-left:0.25in;width:76%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Increase
        (decrease) in accrued expenses</span></span></td>
    <td style="padding-bottom:1.5pt;width:1%">&#160;</td>
    <td style="border-bottom:1.5pt solid black;text-align:left;width:1%">&#160;</td>
    <td style="border-bottom:1.5pt solid black;text-align:right;width:9%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fxbrl_20241004055526680_ixv-37729" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" contextRef="C_20240101to20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">60,369</ix:nonFraction></span></span></td>
    <td style="padding-bottom:1.5pt;text-align:left;width:1%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></td>
    <td style="padding-bottom:1.5pt;width:1%">&#160;</td>
    <td style="border-bottom:1.5pt solid black;text-align:left;width:1%">&#160;</td>
    <td style="border-bottom:1.5pt solid black;text-align:right;width:9%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20241004055526680_ixv-37730" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" contextRef="C_20230101to20230630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">14,993</ix:nonFraction></span></span></td>
    <td style="padding-bottom:1.5pt;text-align:left;width:1%">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="text-align:left;padding-bottom:1.5pt;padding-left:9pt;width:76%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Net
        cash provided by (used in) operating activities</span></span></td>
    <td style="padding-bottom:1.5pt;width:1%">&#160;</td>
    <td style="border-bottom:1.5pt solid black;text-align:left;width:1%">&#160;</td>
    <td style="border-bottom:1.5pt solid black;text-align:right;width:9%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fxbrl_20241004055526685_ixv-37731" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="C_20240101to20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">368,912</ix:nonFraction></span></span></td>
    <td style="padding-bottom:1.5pt;text-align:left;width:1%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></td>
    <td style="padding-bottom:1.5pt;width:1%">&#160;</td>
    <td style="border-bottom:1.5pt solid black;text-align:left;width:1%">&#160;</td>
    <td style="border-bottom:1.5pt solid black;text-align:right;width:9%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20241004055526685_ixv-37732" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="C_20230101to20230630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">517,858</ix:nonFraction></span></span></td>
    <td style="padding-bottom:1.5pt;text-align:left;width:1%">&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="padding-left:9pt;width:76%">&#160;</td>
    <td style="width:1%">&#160;</td>
    <td style="text-align:left;width:1%">&#160;</td>
    <td style="text-align:right;width:9%">&#160;</td>
    <td style="text-align:left;width:1%">&#160;</td>
    <td style="width:1%">&#160;</td>
    <td style="text-align:left;width:1%">&#160;</td>
    <td style="text-align:right;width:9%">&#160;</td>
    <td style="text-align:left;width:1%">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="font-weight:bold;text-align:left;width:76%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">CASH
        FLOWS FROM FINANCING ACTIVITIES:</span></span></td>
    <td style="width:1%">&#160;</td>
    <td style="text-align:left;width:1%">&#160;</td>
    <td style="text-align:right;width:9%">&#160;</td>
    <td style="text-align:left;width:1%">&#160;</td>
    <td style="width:1%">&#160;</td>
    <td style="text-align:left;width:1%">&#160;</td>
    <td style="text-align:right;width:9%">&#160;</td>
    <td style="text-align:left;width:1%">&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="text-align:left;padding-left:0.125in;width:76%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Partial
        redemption of Class A ordinary shares subject to possible redemption</span></span></td>
    <td style="width:1%">&#160;</td>
    <td style="text-align:left;width:1%">&#160;</td>
    <td style="text-align:right;width:9%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></td>
    <td style="text-align:left;width:1%">&#160;</td>
    <td style="width:1%">&#160;</td>
    <td style="text-align:left;width:1%">&#160;</td>
    <td style="text-align:right;width:9%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fxbrl_20241004055526688_ixv-37733" name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="C_20230101to20230630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">90,750,217</ix:nonFraction></span></span></td>
    <td style="text-align:left;width:1%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></td>
        </tr>
  <tr style="vertical-align:bottom">
    <td style="text-align:left;padding-bottom:1.5pt;padding-left:0.125in;width:76%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Proceeds
        from promissory notes &#8211; related party</span></span></td>
    <td style="padding-bottom:1.5pt;width:1%">&#160;</td>
    <td style="border-bottom:1.5pt solid black;text-align:left;width:1%">&#160;</td>
    <td style="border-bottom:1.5pt solid black;text-align:right;width:9%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20241004055526690_ixv-37734" name="us-gaap:ProceedsFromRelatedPartyDebt" contextRef="C_20240101to20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">505,000</ix:nonFraction></span></span></td>
    <td style="padding-bottom:1.5pt;text-align:left;width:1%">&#160;</td>
    <td style="padding-bottom:1.5pt;width:1%">&#160;</td>
    <td style="border-bottom:1.5pt solid black;text-align:left;width:1%">&#160;</td>
    <td style="border-bottom:1.5pt solid black;text-align:right;width:9%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20241004055526690_ixv-37735" name="us-gaap:ProceedsFromRelatedPartyDebt" contextRef="C_20230101to20230630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">920,000</ix:nonFraction></span></span></td>
    <td style="padding-bottom:1.5pt;text-align:left;width:1%">&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="text-align:left;padding-bottom:1.5pt;padding-left:0.125in;width:76%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Net
        cash provided by (used in) financing activities</span></span></td>
    <td style="padding-bottom:1.5pt;width:1%">&#160;</td>
    <td style="border-bottom:1.5pt solid black;text-align:left;width:1%">&#160;</td>
    <td style="border-bottom:1.5pt solid black;text-align:right;width:9%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20241004055526692_ixv-37736" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="C_20240101to20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">505,000</ix:nonFraction></span></span></td>
    <td style="padding-bottom:1.5pt;text-align:left;width:1%">&#160;</td>
    <td style="padding-bottom:1.5pt;width:1%">&#160;</td>
    <td style="border-bottom:1.5pt solid black;text-align:left;width:1%">&#160;</td>
    <td style="border-bottom:1.5pt solid black;text-align:right;width:9%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fxbrl_20241004055526692_ixv-37737" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="C_20230101to20230630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">89,830,217</ix:nonFraction></span></span></td>
    <td style="padding-bottom:1.5pt;text-align:left;width:1%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></td>
        </tr>
  <tr style="vertical-align:bottom">
    <td style="padding-left:9pt;width:76%">&#160;</td>
    <td style="width:1%">&#160;</td>
    <td style="text-align:left;width:1%">&#160;</td>
    <td style="text-align:right;width:9%">&#160;</td>
    <td style="text-align:left;width:1%">&#160;</td>
    <td style="width:1%">&#160;</td>
    <td style="text-align:left;width:1%">&#160;</td>
    <td style="text-align:right;width:9%">&#160;</td>
    <td style="text-align:left;width:1%">&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="text-indent:-0.125in;font-weight:bold;text-align:left;padding-left:0.125in;width:76%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">INCREASE
        (DECREASE) IN CASH, CASH EQUIVALENTS AND INVESTMENTS HELD IN A TRUST ACCOUNT</span></span></td>
    <td style="width:1%">&#160;</td>
    <td style="text-align:left;width:1%">&#160;</td>
    <td style="text-align:right;width:9%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20241004055526695_ixv-37738" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" contextRef="C_20240101to20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">136,088</ix:nonFraction></span></span></td>
    <td style="text-align:left;width:1%">&#160;</td>
    <td style="width:1%">&#160;</td>
    <td style="text-align:left;width:1%">&#160;</td>
    <td style="text-align:right;width:9%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fxbrl_20241004055526695_ixv-37739" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" contextRef="C_20230101to20230630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">89,312,359</ix:nonFraction></span></span></td>
    <td style="text-align:left;width:1%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></td>
        </tr>
  <tr style="vertical-align:bottom">
    <td style="font-weight:bold;text-align:left;padding-bottom:1.5pt;text-indent:-9pt;padding-left:9pt;width:76%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">CASH,
        CASH EQUIVALENTS AND INVESTMENTS HELD IN A TRUST ACCOUNT AT BEGINNING OF PERIOD</span></span></td>
    <td style="padding-bottom:1.5pt;width:1%">&#160;</td>
    <td style="border-bottom:1.5pt solid black;text-align:left;width:1%">&#160;</td>
    <td style="border-bottom:1.5pt solid black;text-align:right;width:9%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20241004055526697_ixv-37740" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="C_20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,805,910</ix:nonFraction></span></span></td>
    <td style="padding-bottom:1.5pt;text-align:left;width:1%">&#160;</td>
    <td style="padding-bottom:1.5pt;width:1%">&#160;</td>
    <td style="border-bottom:1.5pt solid black;text-align:left;width:1%">&#160;</td>
    <td style="border-bottom:1.5pt solid black;text-align:right;width:9%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20241004055526697_ixv-37741" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="C_20221231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">116,751,752</ix:nonFraction></span></span></td>
    <td style="padding-bottom:1.5pt;text-align:left;width:1%">&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="font-weight:bold;text-align:left;padding-bottom:4pt;text-indent:-10pt;padding-left:10pt;width:76%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">CASH,
        CASH EQUIVALENTS AND INVESTMENTS HELD IN A TRUST ACCOUNT AT END OF PERIOD</span></span></td>
    <td style="padding-bottom:4pt;width:1%">&#160;</td>
    <td style="border-bottom:4pt double black;text-align:left;width:1%">&#160;</td>
    <td style="border-bottom:4pt double black;text-align:right;width:9%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20241004055526701_ixv-37742" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="C_20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,941,998</ix:nonFraction></span></span></td>
    <td style="padding-bottom:4pt;text-align:left;width:1%">&#160;</td>
    <td style="padding-bottom:4pt;width:1%">&#160;</td>
    <td style="border-bottom:4pt double black;text-align:left;width:1%">&#160;</td>
    <td style="border-bottom:4pt double black;text-align:right;width:9%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20241004055526701_ixv-37743" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="C_20230630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">27,439,393</ix:nonFraction></span></span></td>
    <td style="padding-bottom:4pt;text-align:left;width:1%">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="text-indent:-10pt;padding-left:10pt;width:76%">&#160;</td>
    <td style="width:1%">&#160;</td>
    <td style="text-align:left;width:1%">&#160;</td>
    <td style="text-align:right;width:9%">&#160;</td>
    <td style="text-align:left;width:1%">&#160;</td>
    <td style="width:1%">&#160;</td>
    <td style="text-align:left;width:1%">&#160;</td>
    <td style="text-align:right;width:9%">&#160;</td>
    <td style="text-align:left;width:1%">&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="text-indent:-0.125in;padding-left:0.125in;font-weight:bold;text-align:left;width:76%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">RECONCILIATION
        OF CASH, CASH EQUIVALENTS AND INVESTMENTS HELD IN A TRUST ACCOUNT:</span></span></td>
    <td style="width:1%">&#160;</td>
    <td style="text-align:left;width:1%">&#160;</td>
    <td style="text-align:right;width:9%">&#160;</td>
    <td style="text-align:left;width:1%">&#160;</td>
    <td style="width:1%">&#160;</td>
    <td style="text-align:left;width:1%">&#160;</td>
    <td style="text-align:right;width:9%">&#160;</td>
    <td style="text-align:left;width:1%">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="text-align:left;padding-left:0.125in;width:76%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Cash
        and cash equivalents</span></span></td>
    <td style="width:1%">&#160;</td>
    <td style="text-align:left;width:1%">&#160;</td>
    <td style="text-align:right;width:9%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20241004055526703_ixv-37744" name="us-gaap:CashEquivalentsAtCarryingValue" contextRef="C_20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">17,880</ix:nonFraction></span></span></td>
    <td style="text-align:left;width:1%">&#160;</td>
    <td style="width:1%">&#160;</td>
    <td style="text-align:left;width:1%">&#160;</td>
    <td style="text-align:right;width:9%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20241004055526703_ixv-37745" name="us-gaap:CashEquivalentsAtCarryingValue" contextRef="C_20230630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">34,530</ix:nonFraction></span></span></td>
    <td style="text-align:left;width:1%">&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="text-align:left;padding-bottom:1.5pt;padding-left:0.125in;width:76%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Investments
        held in trust account</span></span></td>
    <td style="padding-bottom:1.5pt;width:1%">&#160;</td>
    <td style="border-bottom:1.5pt solid black;text-align:left;width:1%">&#160;</td>
    <td style="border-bottom:1.5pt solid black;text-align:right;width:9%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20241004055526706_ixv-37746" name="us-gaap:AssetsHeldInTrust" contextRef="C_20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,924,118</ix:nonFraction></span></span></td>
    <td style="padding-bottom:1.5pt;text-align:left;width:1%">&#160;</td>
    <td style="padding-bottom:1.5pt;width:1%">&#160;</td>
    <td style="border-bottom:1.5pt solid black;text-align:left;width:1%">&#160;</td>
    <td style="border-bottom:1.5pt solid black;text-align:right;width:9%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20241004055526706_ixv-37747" name="us-gaap:AssetsHeldInTrust" contextRef="C_20230630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">27,404,863</ix:nonFraction></span></span></td>
    <td style="padding-bottom:1.5pt;text-align:left;width:1%">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="text-align:left;padding-bottom:4pt;padding-left:0.125in;width:76%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Total
        cash, cash equivalents and investments held in a trust account</span></span></td>
    <td style="padding-bottom:4pt;width:1%">&#160;</td>
    <td style="border-bottom:4pt double black;text-align:left;width:1%">&#160;</td>
    <td style="border-bottom:4pt double black;text-align:right;width:9%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20241004055526708_ixv-37748" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="C_20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,941,998</ix:nonFraction></span></span></td>
    <td style="padding-bottom:4pt;text-align:left;width:1%">&#160;</td>
    <td style="padding-bottom:4pt;width:1%">&#160;</td>
    <td style="border-bottom:4pt double black;text-align:left;width:1%">&#160;</td>
    <td style="border-bottom:4pt double black;text-align:right;width:9%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20241004055526708_ixv-37749" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="C_20230630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">27,439,393</ix:nonFraction></span></span></td>
    <td style="padding-bottom:4pt;text-align:left;width:1%">&#160;</td> </tr>
  </table>

<div>&#160;</div>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>The
accompanying notes are an integral part of these unaudited condensed consolidated financial statements.</strong></span></span></p> </div>
</div>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center">&#160;</p>

<div style="margin-top:12pt;margin-bottom:6pt;border-bottom:Black 1.5pt solid">

<p style="font:10pt Times New Roman, Times, Serif;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">F-5</span></p>
</div>

<div style="break-before:page;margin-top:6pt;margin-bottom:12pt">

<p style="margin:0pt">&#160;</p> </div>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center">&#160;</p>

<div><span id="f_005"></span></div> </div>

<div style="font:10pt Times New Roman, Times, Serif">

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center"><strong>MORINGA ACQUISITION CORP</strong></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0"><strong>&#160;</strong></p> </div> <ix:nonNumeric id="Fxbrl_20241003000117614" name="us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock" contextRef="C_20240101to20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" escape="true">

<div>

<div style="font:10pt Times New Roman, Times, Serif">

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0"><strong>NOTE 1 - DESCRIPTION OF ORGANIZATION AND BUSINESS OPERATIONS:</strong></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0"><strong>&#160;</strong></p>

<table cellpadding="0" cellspacing="0" style="font:10pt Times New Roman, Times, Serif;width:100%;border-collapse:collapse">
  <tr style="vertical-align:top">
    <td style="width:72px">&#160;</td>
    <td style="width:24px"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt"><strong>a.</strong></span></td>
    <td><span style="font-family:Times New Roman, Times, Serif;font-size:10pt"><strong>Organization and General</strong></span></td> </tr>
  </table>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in;text-align:left">Moringa Acquisition Corp (hereafter &#8211; the
Company) is a blank check company, incorporated on September 24, 2020 as a Cayman Islands exempted company, formed for the purpose of
effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination (hereafter &#8211;
the Business Combination). The Company is an emerging growth company, as defined in Section&#160;2(a) of the Securities Act of 1933, as
amended (the &#8220;Securities Act&#8221;), as modified by the Jumpstart Our Business Startups Act of 2012 (the &#8220;JOBS Act&#8221;).</p>

<p style="font:10pt Times New Roman, Times, Serif;text-align:left;margin:0pt 0 0pt 1in">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in;text-align:left">The Company has selected December 31 as its fiscal
year end.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font:10pt Times New Roman, Times, Serif;width:100%;border-collapse:collapse">
  <tr style="vertical-align:top">
    <td style="width:72px">&#160;</td>
    <td style="width:24px"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt"><strong>b.</strong></span></td>
    <td><span style="font-family:Times New Roman, Times, Serif;font-size:10pt"><strong>Sponsor and Financing</strong></span></td> </tr>
  </table>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in;text-align:left">The Company&#8217;s sponsor is Moringa Sponsor,
L.P., a Cayman exempted limited partnership (which is referred to herein, together with its wholly-owned subsidiary, Moringa Sponsor (US)
LP, a Delaware limited partnership, as the &#8220;Sponsor&#8221;).</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in;text-align:justify">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in;text-align:left">Refer to Note 7(a) for information regarding the
aggregate withdrawals of approximately $<ix:nonFraction id="Fixv-37750" name="slxn:PartialRedemptionsAmount" contextRef="C_20240101to20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="usd" scale="6" decimals="-6" format="ixt:num-dot-decimal">113</ix:nonFraction>
million, due to partial redemptions.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font:10pt Times New Roman, Times, Serif;width:100%;border-collapse:collapse">
  <tr style="vertical-align:top">
    <td style="width:72px">&#160;</td>
    <td style="width:24px"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt"><strong>c.</strong></span></td>
    <td><span style="font-family:Times New Roman, Times, Serif;font-size:10pt"><strong>The Trust Account</strong></span></td> </tr>
  </table>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in;text-align:left">The proceeds held in the Trust Account are invested
in money market funds registered under the Investment Company Act and compliant with Rule 2a-7 thereof that maintain a stable net asset
value of $<ix:nonFraction id="Fixv-37751" name="us-gaap:NetAssetValuePerShare" contextRef="C_20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="usdPershares" scale="0" decimals="2" format="ixt:num-dot-decimal">1.00</ix:nonFraction>.</p>

<p style="font:10pt Times New Roman, Times, Serif;text-align:left;margin:0pt 0 0pt 1in">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in;text-align:left">The Company complies with the provisions of ASU
2016-18, under which changes in Investments held in the Trust Account are accounted for as Changes in Cash, Cash Equivalents and Investments
Held in a Trust Account in the Company&#8217;s Statements of Cash Flows.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in;text-align:justify">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in;text-align:left">Refer to Note 4(a) for information regarding proceeds
received from the Sponsor under the Sixth and Eighth Promissory Notes, deposited into the Trust Account.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in;text-align:left">&#160;</p>

<div><ix:exclude>

<div style="margin-top:12pt;margin-bottom:6pt;border-bottom:Black 1.5pt solid">

<p style="font:10pt Times New Roman, Times, Serif;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">F-6</span></p>
</div>

<div style="break-before:page;margin-top:6pt;margin-bottom:12pt">

<p style="margin:0pt">&#160;</p> </div>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center">&#160;</p>

<p style="font:10pt Times New Roman, Times, serif;margin:10pt 0px 0pt;text-align:center"><strong>MORINGA ACQUISITION CORP</strong></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center">(CONTINUED)</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0"><strong>&#160;</strong></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0"><strong>NOTE 1 - DESCRIPTION OF ORGANIZATION AND BUSINESS OPERATIONS </strong>(continued)<strong>:</strong></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p> </ix:exclude></div>

<table cellpadding="0" cellspacing="0" style="font:10pt Times New Roman, Times, Serif;width:100%;border-collapse:collapse">
  <tr style="vertical-align:top">
    <td style="width:72px">&#160;</td>
    <td style="width:24px"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt"><strong>d.</strong></span></td>
    <td><span style="font-family:Times New Roman, Times, Serif;font-size:10pt"><strong>Initial Business Combination</strong></span></td> </tr>
  </table>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in;text-align:left">The Company&#8217;s management has broad discretion
with respect to the specific application of the net proceeds of the Public Offering, although substantially all of the net proceeds of
the Public Offering and the Private Placement are intended to be generally applied toward consummating an initial Business Combination.
The initial Business Combination must occur with one or more operating businesses or assets with a fair market value equal to at least
<ix:nonFraction id="Fixv-37752" name="slxn:BusinessCombinationOfNetAssetsHeldInTrustAccount" contextRef="C_20240101to20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">80</ix:nonFraction>%
of the net assets held in the Trust Account (excluding taxes payable on the income accrued in the Trust Account). There is no assurance
that the Company will be able to successfully consummate an initial Business Combination.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in;text-align:justify">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in;text-align:left">The Company, after signing a definitive agreement
for an Initial Business Combination, will provide its public shareholders the opportunity to redeem all or a portion of their shares upon
the completion of the initial Business Combination, either (i) in connection with a shareholder meeting called to approve the business
combination or (ii) by means of a tender offer.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in;text-align:justify">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in;text-align:left">If the Company holds a shareholder vote or there
is a tender offer for shares in connection with an initial Business Combination, a public shareholder will have the right to redeem its
shares for an amount in cash equal to its pro rata share of the aggregate amount then on deposit in the Trust Account, calculated as of
two days prior to the general meeting or commencement of the Company&#8217;s tender offer, including interest but less taxes payable.
As a result, the Company&#8217;s Public Class A ordinary shares are classified as temporary equity upon the completion of the Public Offering,
in accordance with the Financial Accounting Standards Board (&#8220;FASB&#8221;) Accounting Standards Codification (&#8220;ASC&#8221;)
480, &#8220;Distinguishing Liabilities from Equity.&#8221;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in;text-align:justify">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in;text-align:left">Pursuant to the Company&#8217;s amended and restated
memorandum and articles of association, as amended, if the Company is unable to complete the initial Business Combination within 42 months
from the Closing of the Public Offering, the Company will (i) cease all operations except for the purpose of winding up, (ii) as promptly
as reasonably possible but not more than ten business days thereafter, redeem the public shares, at a per-share price, payable in cash,
equal to the aggregate amount then on deposit in the Trust Account, including interest (which interest shall be net of taxes payable,
and less up to $<ix:nonFraction id="Fixv-37753" name="slxn:InterestToPayDissolutionExpenses" contextRef="C_20240101to20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="usd" scale="0" decimals="0" format="ixt:num-dot-decimal">100,000</ix:nonFraction>
of interest to pay dissolution expenses), divided by the number of then outstanding public shares, which redemption will completely extinguish
public shareholders&#8217; rights as shareholders (including the right to receive further liquidating distributions, if any), and (iii)
as promptly as reasonably possible following such redemption, subject to the approval of the Company&#8217;s remaining shareholders and
the Company&#8217;s board of directors, liquidate and dissolve, subject in each case to the Company&#8217;s obligations under Cayman Islands
law to provide for claims of creditors and the requirements of other applicable law.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in;text-align:justify">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in;text-align:left">The Sponsor and the Company&#8217;s officers and
directors have entered into a letter agreement with the Company, pursuant to which they have waived their rights to liquidating distributions
from the Trust Account with respect to any Class B ordinary share (as described in Note 7) held by them if the Company fails to complete
the initial Business Combination within 24 months of the Closing of the Public Offering or during any extended time that the Company has
to consummate an initial Business Combination beyond 24 months as a result of a shareholder vote to amend its amended and restated memorandum
and articles of association. However, if the Sponsor or any of the Company&#8217;s directors or officers acquire any Class A ordinary
shares, they will be entitled to liquidating distributions from the Trust Account with respect to such shares if the Company fails to
complete the Initial Business Combination within the prescribed time period.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in;text-align:center">&#160;</p> </div>

<div><ix:exclude>

<div style="margin-top:12pt;margin-bottom:6pt;border-bottom:Black 1.5pt solid">

<p style="font:10pt Times New Roman, Times, Serif;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">F-7</span></p>
</div>

<div style="break-before:page;margin-top:6pt;margin-bottom:12pt">

<p style="margin:0pt">&#160;</p> </div>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in;text-align:center">&#160;</p>

<p style="font:10pt Times New Roman, Times, serif;margin:10pt 0px 0pt;text-align:center"><strong>MORINGA ACQUISITION CORP</strong></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center">(CONTINUED)</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0"><strong>&#160;</strong></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0"><strong>NOTE 1 - DESCRIPTION OF ORGANIZATION AND BUSINESS OPERATIONS </strong>(continued)<strong>:</strong></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p> </ix:exclude></div>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in;text-align:left">In the event of a liquidation, dissolution or
winding up of the Company after an initial Business Combination, the Company&#8217;s shareholders are entitled to share ratably in all
assets remaining available for distribution to them after payment of liabilities and after provision is made for each class of stock,
if any, having preference over the ordinary shares. The Company&#8217;s shareholders have no preemptive or other subscription rights.
There are no sinking fund provisions applicable to the ordinary shares, except that the Company will provide its shareholders with the
opportunity to redeem their public shares for cash equal to their pro rata share of the aggregate amount then on deposit in the Trust
Account, under the circumstances, and, subject to the limitations, described herein.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in;text-align:justify">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in;text-align:left">On February 9, 2023 the Company held an extraordinary
general meeting in lieu of the 2022 annual general meeting of the Company (hereafter &#8211; the First Extension Meeting). At the First
Extension Meeting, the Company&#8217;s shareholders approved the proposal to adopt, by way of special resolution, an amendment to the
Amended and Restated Articles to extend the date by which the Company has to consummate a business combination from the 24 month anniversary
of the Closing of the Public Offering &#8211; i.e., February 19, 2023 to August 19, 2023 (hereafter &#8211; the Extended Mandatory Liquidation
Date) or such earlier date as may be determined by the Board in its sole discretion.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in;text-align:justify">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in;text-align:left">On August 18, 2023 the Company held an extraordinary
general meeting in lieu of the 2023 annual general meeting of the Company (hereafter &#8211; the Second Extension Meeting). At the Second
Extension Meeting, the Company&#8217;s shareholders approved, among other proposals, an amendment to the Amended and Restated Memorandum
and Articles of Association to further extend the date by which the Company has to consummate a business combination from the Extended
Mandatory Liquidation Date to August 19, 2024 (hereafter &#8211; the Second Extended Mandatory Liquidation Date) or such earlier date
as may be determined by the Board in its sole discretion.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in;text-align:justify">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in;text-align:left">Refer to Note 7(a) for information regarding the
partial redemptions of Class A ordinary shares subject to possible redemption, following the First and Second Extensions, and for information
regarding the conversion of Class B ordinary shares into Class A ordinary shares, following the Second Extension Meeting.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font:10pt Times New Roman, Times, Serif;width:100%;border-collapse:collapse">
  <tr style="vertical-align:top">
    <td style="width:72px">&#160;</td>
    <td style="width:24px"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt"><strong>e.</strong></span></td>
    <td><span style="font-family:Times New Roman, Times, Serif;font-size:10pt"><strong>Substantial Doubt about the Company&#8217;s Ability to
        Continue as a Going Concern</strong></span></td> </tr>
  </table>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in;text-align:left">As of June 30, 2024, the Company had approximately
$<ix:nonFraction id="Fixv-37754" name="us-gaap:Cash" contextRef="C_20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">18</ix:nonFraction>
thousand of cash and an accumulated deficit of $<ix:nonFraction id="Fixv-37755" name="us-gaap:RetainedEarningsAppropriated" contextRef="C_20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,386</ix:nonFraction>
thousand. In connection with the Company&#8217;s assessment of going concern considerations in accordance with Financial Accounting Standard
Board&#8217;s Accounting Standard Codification 205-40, &#8220;Going Concern&#8221;, the Company will need to obtain additional funds in
order to satisfy its liquidity needs in its current endeavors to consummate the Proposed Silexion Merger, as detailed in Note 1(f), or
a different Initial Business Combination, if the former does not occur.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in;text-align:left">&#160;</p>

<div><ix:exclude>

<div style="margin-top:12pt;margin-bottom:6pt;border-bottom:Black 1.5pt solid">

<p style="font:10pt Times New Roman, Times, Serif;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">F-8</span></p>
</div>

<div style="break-before:page;margin-top:6pt;margin-bottom:12pt">

<p style="margin:0pt">&#160;</p> </div>

<p style="font:10pt Times New Roman, Times, Serif;margin-top:0pt;margin-bottom:0pt;text-align:center">&#160;</p>

<p style="font:10pt Times New Roman, Times, serif;margin:10pt 0px 0pt;text-align:center"><strong>MORINGA ACQUISITION CORP</strong></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center">(CONTINUED)</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0"><strong>&#160;</strong></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0"><strong>NOTE 1 - DESCRIPTION OF ORGANIZATION AND BUSINESS OPERATIONS </strong>(continued)<strong>:</strong></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p> </ix:exclude></div>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in;text-align:left">Since its inception date and through the issuance
date of these unaudited condensed consolidated financial statements, the Company&#8217;s liquidity needs were satisfied through an initial
capital injection from the Sponsor, followed by net Private Placement proceeds, as well as several withdrawals of the Sponsor promissory
notes. Management has determined that it will need to continue to rely and is significantly dependent on both outstanding and future promissory
notes, or other forms of financial support (all of which the Sponsor is not obligated to provide). Moreover, following the Second Extension
Meeting, the Company has until August 19, 2024 to consummate an Initial Business Combination. If a business combination is not consummated
by this date, there will be a mandatory liquidation and subsequent dissolution of the Company. There can be no assurance that the Company
will be able to consummate any business combination ahead of the Second Extended Mandatory Liquidation Date, nor will it be able to raise
sufficient funds to complete an Initial Business Combination. These matters raise substantial doubt about the Company&#8217;s ability
to continue as a going concern, for the subsequent twelve months following the issuance date of these unaudited condensed consolidated
financial statements.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in;text-align:justify">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in;text-align:left">In February 2024, the Company entered into a Business
Combination Agreement with Silexion Therapeutics Ltd. (hereafter &#8211; Silexion), an Israeli company which is in its developmental stage,
dedicated to the development of innovative treatments for pancreatic cancer. Refer to Note 1(f) for further information regarding the
Proposed Silexion Merger.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in;text-align:justify">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in;text-align:left">No adjustments have been made to the carrying
amounts of assets or liabilities should the company fail to obtain financial support in its pursuit to consummate an Initial Business
Combination, nor if it is required to liquidate after the Second Extended Mandatory Liquidation Date.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in;text-align:justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font:10pt Times New Roman, Times, Serif;width:100%;border-collapse:collapse">
  <tr style="vertical-align:top">
    <td style="width:72px">&#160;</td>
    <td style="width:24px"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt"><strong>f.</strong></span></td>
    <td><span style="font-family:Times New Roman, Times, Serif;font-size:10pt"><strong>Proposed Business Combination</strong></span></td> </tr>
  </table>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in;text-align:left">On February 21, 2024, the Company, together with
its wholly-owned Israeli subsidiary <span>April M.G. Ltd</span>. &#8211; which was incorporated due to the original business combination
structure, entered into a business combination agreement with Silexion (hereafter &#8211; the Proposed Silexion Merger).</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in;text-align:justify">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in;text-align:left">The&#160;Proposed Silexion Merger is expected
to close in the third quarter of 2024, subject to the satisfaction of customary closing conditions under the Business Combination Agreement,
including the approval of the business combination by Silexion&#8217;s and the Company&#8217;s shareholders, as well as Nasdaq&#8217;s
approval of the initial listing of the combined company&#8217;s securities.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in;text-align:justify">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in;text-align:left">The Proposed Silexion Merger have been unanimously
approved by the boards of directors of the Company and&#160;Silexion.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in;text-align:justify">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 70.9pt;text-align:left">On April 3, 2024, the Proposed Silexion Merger
contemplated under the original Proposed Silexion Merger agreement was restructured pursuant to the Business Combination Agreement, by
and among New Pubco (a newly formed Cayman Islands exempted company), its two newly-formed subsidiaries &#8211; Merger Sub 1 and Merger
Sub 2 &#8211; the Company and Silexion.&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 70.9pt;text-align:justify">&#160;</p>

<div><ix:exclude>

<div style="margin-top:12pt;margin-bottom:6pt;border-bottom:Black 1.5pt solid">

<p style="font:10pt Times New Roman, Times, Serif;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">F-9</span></p>
</div>

<div style="break-before:page;margin-top:6pt;margin-bottom:12pt">

<p style="margin:0pt">&#160;</p> </div>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 70.9pt;text-align:justify">&#160;</p>

<p style="font:10pt Times New Roman, Times, serif;margin:10pt 0px 0pt;text-align:center"><strong>MORINGA ACQUISITION CORP</strong></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center">(CONTINUED)</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 70.9pt;text-align:justify">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0"><strong>NOTE 1 - DESCRIPTION OF ORGANIZATION AND BUSINESS OPERATIONS </strong>(continued)<strong>:</strong></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p> </ix:exclude></div>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 70.9pt;text-align:left">As contemplated under the Business Combination
Agreement, Merger Sub 2 will merge with and into the Company, with the Company continuing as the surviving company and a wholly-owned
subsidiary of New Pubco, and Merger Sub 1 will merge with and into Silexion, with Silexion continuing as the surviving company and a wholly-owned
subsidiary of New Pubco. The shareholders and other equity holders of each of the Company and Silexion will receive corresponding securities
of New Pubco as consideration in the Prospective Business Combination at set ratios in exchange for their securities of Company and Silexion,
respectively.&#160;New Pubco will serve as the public company upon completion of the Proposed Business Combination, with its ordinary
shares and warrants listed for trading on Nasdaq.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 70.9pt;text-align:justify">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 70.9pt;text-align:left">The foregoing description of the Proposed Business
Combination, as amended, does not purport to be complete. For further information and access to the full agreement and all other related
agreements, refer to the Company&#8217;s Current Report on Form 8-K filed with the SEC on April 3, 2024.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 70.9pt;text-align:justify">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 70.9pt">In connection with the Proposed Silexion Merger, on May 9,
2024, New Pubco filed with the SEC a Registration Statement on Form S-4, and has subsequently filed amendments on June 24, 2024, July
7, 2024 and July 12, 2024, that include a document that will serve as both a prospectus for the securities to be issued by New Pubco in
the Prospective Business Combination to security holders of the Company and Silexion, as well as a proxy statement of the Company for
the Company&#8217;s extraordinary general meeting at which the Prospective Business Combination and the Business Combination Agreement
(among other matters) was presented for approval (see note 9). The SEC staff declared the New Pubco Registration Statement effective on
July 16, 2024.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 70.9pt;text-align:justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font:10pt Times New Roman, Times, Serif;width:100%;border-collapse:collapse">
  <tr style="vertical-align:top">
    <td style="width:72px">&#160;</td>
    <td style="width:24px"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt"><strong>g.</strong></span></td>
    <td><span style="font-family:Times New Roman, Times, Serif;font-size:10pt"><strong>Impact of War in Israel</strong></span></td> </tr>
  </table>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in;text-align:justify">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in;text-align:left">Israel&#8217;s current war against the terrorist
organization Hamas continued to rage during the second quarter of 2024. The intensity and duration of the war has varied since it began
on October 7, 2023. Up to the balance sheet date and subsequently, the war has not had a material effect on the Company. However, the
war may cause wider macroeconomic deterioration in Israel, which may have a material adverse effect on the Company&#8217;s ability to
effectively complete the Proposed Business Combination.</p> </div> </ix:nonNumeric>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in;text-align:justify">&#160;</p>

<div style="margin-top:12pt;margin-bottom:6pt;border-bottom:Black 1.5pt solid">

<p style="font:10pt Times New Roman, Times, Serif;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">F-10</span></p>
</div>

<div style="break-before:page;margin-top:6pt;margin-bottom:12pt">

<p style="margin:0pt">&#160;</p> </div>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in;text-align:justify">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in;text-align:justify">&#160;</p>

<div style="font:10pt Times New Roman, Times, Serif">

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center"><strong>MORINGA ACQUISITION CORP</strong></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center">(CONTINUED)</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0"><strong>&#160;</strong></p> <ix:nonNumeric id="Fxbrl_20241003102832557" name="us-gaap:SignificantAccountingPoliciesTextBlock" contextRef="C_20240101to20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" escape="true">

<div>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0"><strong>NOTE 2 - SIGNIFICANT ACCOUNTING POLICIES:</strong></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-indent:-0.5in">&#160;</p> <ix:nonNumeric id="Fxbrl_20241003102923627" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" contextRef="C_20240101to20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" escape="true">

<div>

<table cellpadding="0" cellspacing="0" style="font:10pt Times New Roman, Times, serif;width:100%;border-collapse:collapse;border:0px">
  <tr style="vertical-align:top">
    <td style="width:72px">&#160;</td>
    <td style="width:24px"><span style="font-size:10pt;font-family:Times New Roman, Times, serif"><strong>a.</strong></span></td>
    <td><strong style="font-size:10pt">Basis of Presentation</strong></td> </tr>
  </table>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in;text-align:left">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in;text-align:left">The condensed consolidated financial statements
herein are unaudited; however, such information reflects all adjustments (consisting of normal, recurring adjustments), which are, in
the opinion of the management, necessary for a fair statement of results for the interim period. The results of the operation for the
six and three-month periods ended June 30, 2024, are not necessarily indicative of the results to be expected for the full year. The year-end
condensed consolidated balance sheet data was derived from audited financial statements for the year ended December 31, 2023 as filed
on April 1, 2024, but does not include all disclosures required by accounting principles generally accepted in the United States of America
(&#8220;U.S. GAAP&#8221;). These unaudited condensed consolidated financial statements should be read in conjunction with the audited
financial statements and related notes thereto of Moringa Acquisition Corp.</p> </div> </ix:nonNumeric>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0"><strong>&#160;</strong></p> <ix:nonNumeric id="Fxbrl_20241003102956859" name="slxn:EmergingGrowthCompanyPolicyTextBlock" contextRef="C_20240101to20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" escape="true">

<div>

<table cellpadding="0" cellspacing="0" style="font:10pt Times New Roman, Times, Serif;width:100%;border-collapse:collapse">
  <tr style="vertical-align:top">
    <td style="width:72px">&#160;</td>
    <td style="width:24px"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt"><strong>b.</strong></span></td>
    <td><span style="font-family:Times New Roman, Times, Serif;font-size:10pt"><strong>Emerging Growth Company</strong></span></td> </tr>
  </table>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in;text-align:left">Section 102(b)(1) of the JOBS Act exempts emerging
growth companies from being required to comply with new or revised financial accounting standards until private companies (that is, those
that have not had a Securities Act registration statement declared effective or do not have a class of securities registered under the
Exchange Act) are required to comply with the new or revised financial accounting standards.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in;text-align:justify">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in;text-align:left">The JOBS Act provides that a company can elect
to opt out of the extended transition period and comply with the requirements that apply to non-emerging growth companies but any such
election to opt out is irrevocable. The Company has elected not to opt out of such extended transition period which means that when a
standard is issued or revised and it has different application dates for public or private companies, the Company, as an emerging growth
company, can adopt the new or revised standard at the time private companies adopt the new or revised standard.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in;text-align:justify">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in;text-align:left">This may make comparison of the Company&#8217;s
unaudited condensed consolidated financial statements with another public company which is neither an emerging growth company nor an emerging
growth company which has opted out of using the extended transition period difficult or impossible, because of the potential differences
in accounting standards used.</p> </div> </ix:nonNumeric>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in;text-align:center">&#160;</p>

<div><ix:exclude>

<div style="margin-top:12pt;margin-bottom:6pt;border-bottom:Black 1.5pt solid">

<p style="font:10pt Times New Roman, Times, Serif;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">F-11</span></p>
</div>

<div style="break-before:page;margin-top:6pt;margin-bottom:12pt">

<p style="margin:0pt">&#160;</p> </div>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in;text-align:center">&#160;</p>

<p style="font:10pt Times New Roman, Times, serif;margin-top:10pt;margin-bottom:0pt;text-align:center"><strong>MORINGA ACQUISITION CORP</strong></p>

<p style="font:10pt Times New Roman, Times, Serif;margin-top:0pt;margin-bottom:0pt;text-align:center">NOTES TO CONDENSED CONSOLIDATED
FINANCIAL STATEMENTS (UNAUDITED)</p>

<p style="font:10pt Times New Roman, Times, Serif;margin-top:0pt;margin-bottom:0pt;text-align:center">(CONTINUED)</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0"><strong>NOTE 2 - SIGNIFICANT ACCOUNTING POLICIES </strong>(continued)<strong>:</strong></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p> </ix:exclude></div>

<div> <ix:nonNumeric id="Fxbrl_20241003103038419" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" contextRef="C_20240101to20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" escape="true">

<div>

<table cellpadding="0" cellspacing="0" style="font:10pt Times New Roman, Times, serif;width:100%;border-collapse:collapse;border:0px">
  <tr style="vertical-align:top">
    <td style="width:72px">&#160;</td>
    <td style="width:24px"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong><span>c.</span></strong></span></span></td>
    <td><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong><strong style="font-size:10pt">Cash and cash
        equivalents</strong></strong></span></span></td> </tr>
  </table>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in;text-align:left">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in;text-align:left">The Company considers as cash equivalents all
short-term, highly liquid investments, which include short-term bank deposits with original maturities of three months or less from the
date of purchase that are not restricted as to withdrawal or use by nature of the account and are readily convertible to known amounts
of cash.</p> </div> </ix:nonNumeric>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in">&#160;</p> <ix:nonNumeric id="Fxbrl_20241003103058000" name="us-gaap:SharesSubjectToMandatoryRedemptionChangesInRedemptionValuePolicyTextBlock" contextRef="C_20240101to20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" escape="true">

<div>

<table cellpadding="0" cellspacing="0" style="font:10pt Times New Roman, Times, serif;width:100%;border-collapse:collapse;border:0px">
  <tr style="vertical-align:top">
    <td style="width:72px">&#160;</td>
    <td style="width:24px"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><strong>d.</strong></span></span></span></td>
    <td><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong style="font-size:10pt">Class A Ordinary Shares
        subject to possible redemption</strong></span></span></td> </tr>
  </table>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in;text-align:left">As discussed in Note 1, all of the <ix:nonFraction id="Fixv-37756" name="slxn:NumberOfUnitSale" contextRef="C_20240101to20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_usgaapCommonClassAMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">11,500,000</ix:nonFraction>
shares of Class&#160;A ordinary shares sold as parts of the Units in the Public Offering contain a redemption feature. In accordance with
the Accounting Standards Codification 480-10-S99-3A &#8220;Classification and Measurement of Redeemable Securities&#8221;, redemption
provisions not solely within the control of the Company require the security to be classified outside of permanent equity. The Company
has classified all of the shares sold under the Public Units as subject to possible redemption.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in;text-align:justify">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in;text-align:left">Refer to Note 7(a) for information regarding the
partial redemptions of Class A ordinary shares subject to possible redemption, following the First and Second Extensions. Also, refer
to Note 9(c) regarding an additional redemption after the balance sheet date.</p> </div> </ix:nonNumeric>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in;text-align:justify">&#160;</p> <ix:nonNumeric id="Fxbrl_20241003103118401" name="us-gaap:EarningsPerSharePolicyTextBlock" contextRef="C_20240101to20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" escape="true">

<div>

<table cellpadding="0" cellspacing="0" style="font:10pt Times New Roman, Times, Serif;width:100%;border-collapse:collapse">
  <tr style="vertical-align:top">
    <td style="width:72px">&#160;</td>
    <td style="width:24px"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt"><strong>e.</strong></span></td>
    <td><span style="font-family:Times New Roman, Times, Serif;font-size:10pt"><strong>Net profit (loss) per share</strong></span></td> </tr>
  </table>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in;text-align:left">The Company complies with accounting and disclosure
requirements of FASB ASC Topic 260, Earnings Per Share. Net profit (loss) per share is computed by dividing net profit (loss) by the weighted
average number of shares outstanding during the period. The Company applies the two-class method in calculating net profit (loss) per
each class of shares: the non-redeemable shares, which include the Private Class A Ordinary Shares, as defined in Note 7, and the Class
B ordinary shares (hereafter and collectively &#8211; Non-Redeemable class A and B ordinary shares); and the Class A ordinary shares subject
to possible redemption.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in;text-align:justify">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in;text-align:left">In order to determine the net profit (loss) attributable
to each class, the Company first considered the total profit (loss) allocable to both sets of shares. This is calculated using the total
net profit (loss) less any interest earned on investments held in trust account. Then, the accretion is fully allocated to the Class A
ordinary shares subject to redemption.</p> </div> </ix:nonNumeric>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in;text-align:justify">&#160;</p> <ix:nonNumeric id="Fxbrl_20241003103135474" name="us-gaap:ConcentrationRiskDisclosureTextBlock" contextRef="C_20240101to20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" escape="true">

<div>

<table cellpadding="0" cellspacing="0" style="font:10pt Times New Roman, Times, Serif;width:100%;border-collapse:collapse">
  <tr style="vertical-align:top">
    <td style="width:72px;text-align:justify">&#160;</td>
    <td style="width:24px;text-align:justify"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt"><strong>f.</strong></span></td>
    <td style="text-align:justify"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt"><strong>Concentration of credit risk</strong></span></td>
        </tr>
  </table>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in;text-align:justify;text-indent:1.1pt">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in;text-align:left;text-indent:1.1pt">Financial instruments that potentially
subject the Company to concentrations of credit risk consist of cash accounts in a financial institution, which, at times, may exceed
the Federal Depository Insurance Coverage of $<ix:nonFraction id="Fixv-37757" name="us-gaap:FederalDepositInsuranceCorporationPremiumExpense" contextRef="C_20240101to20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="usd" scale="0" decimals="0" format="ixt:num-dot-decimal">250,000</ix:nonFraction>.
From the Company&#8217;s incorporation and through June 30, 2024, the Company has not experienced any losses on these accounts.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in;text-align:justify;text-indent:1.1pt">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in;text-align:left">As of June 30, 2024, the Company held its cash
and cash equivalents in an SVB bank account, and its investments Held in Trust Account in Goldman Sachs money market funds. Money market
funds are characterized as Level 1 investments within the fair value hierarchy under ASC 820.</p> </div> </ix:nonNumeric>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in;text-align:justify;text-indent:1.1pt">&#160;</p> </div>

<div><ix:exclude>

<div style="margin-top:12pt;margin-bottom:6pt;border-bottom:Black 1.5pt solid">

<p style="font:10pt Times New Roman, Times, Serif;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">F-12</span></p>
</div>

<div style="break-before:page;margin-top:6pt;margin-bottom:12pt">

<p style="margin:0pt">&#160;</p> </div>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in;text-align:center">&#160;</p>

<p style="font:10pt Times New Roman, Times, serif;margin:10pt 0px 0pt;text-align:center"><strong>MORINGA ACQUISITION CORP</strong></p>

<p style="font:10pt Times New Roman, Times, Serif;margin-top:0pt;margin-bottom:0pt;text-align:center">NOTES TO CONDENSED CONSOLIDATED
FINANCIAL STATEMENTS (UNAUDITED)</p>

<p style="font:10pt Times New Roman, Times, Serif;margin-top:0pt;margin-bottom:0pt;text-align:center">(CONTINUED)</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0"><strong>&#160;</strong></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0"><strong>NOTE 2 - SIGNIFICANT ACCOUNTING POLICIES </strong>(continued)<strong>:</strong></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p> </ix:exclude></div>

<div> <ix:nonNumeric id="Fxbrl_20241003103255403" name="slxn:PublicWarrantsPolicyTextBlock" contextRef="C_20240101to20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" escape="true">

<div>

<table cellpadding="0" cellspacing="0" style="font:10pt Times New Roman, Times, Serif;width:100%;border-collapse:collapse">
  <tr style="vertical-align:top">
    <td style="width:72px;text-align:justify">&#160;</td>
    <td style="width:24px;text-align:justify"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt"><strong>g.</strong></span></td>
    <td style="text-align:justify"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt"><strong>Public Warrants</strong></span></td>
        </tr>
  </table>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in;text-align:justify">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in;text-align:left">The Company applied the provisions of ASC 815-40
and classified its public warrants, issued as part of the Public Units as detailed in Note 3, as equity securities.</p> </div> </ix:nonNumeric>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in;text-align:justify">&#160;</p> <ix:nonNumeric id="Fxbrl_20241003103316342" name="slxn:PrivateWarrantLiabilityPolicyTextBlock" contextRef="C_20240101to20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" escape="true">

<div>

<table cellpadding="0" cellspacing="0" style="font:10pt Times New Roman, Times, Serif;width:100%;border-collapse:collapse">
  <tr style="vertical-align:top">
    <td style="width:72px;text-align:justify">&#160;</td>
    <td style="width:24px;text-align:justify"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt"><strong>h.</strong></span></td>
    <td style="text-align:justify"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt"><strong>Private Warrant liability </strong></span></td>
        </tr>
  </table>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify"><strong>&#160;</strong></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in;text-align:left">The Company accounts for the warrants in accordance
with the guidance contained in Accounting Standards Codification 815 (&#8220;ASC 815&#8221;), &#8220;Derivatives and Hedging&#8221;, under
which the warrants do not meet the criteria for equity treatment and must be recorded as derivative liabilities. Accordingly, the Company
classifies the private warrants as liabilities at their fair value and adjusts the private warrants to fair value at each reporting period.
This liability is subject to re-measurement at each balance sheet date until the private warrants are exercised or expire, and any change
in fair value is recognized in the Company&#8217;s statements of operations. Refer to Note 6 for information regarding the model used
to estimate the fair value of the Private Warrants (as defined in Note 3).</p> </div> </ix:nonNumeric>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p> <ix:nonNumeric id="Fxbrl_20241003103331776" name="us-gaap:FairValueOfFinancialInstrumentsPolicy" contextRef="C_20240101to20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" escape="true">

<div>

<table cellpadding="0" cellspacing="0" style="font:10pt Times New Roman, Times, Serif;width:100%;border-collapse:collapse">
  <tr style="vertical-align:top">
    <td style="width:72px">&#160;</td>
    <td style="width:24px"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt"><strong>i.</strong></span></td>
    <td><span style="font-family:Times New Roman, Times, Serif;font-size:10pt"><strong>Financial instruments</strong></span></td> </tr>
  </table>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in;text-align:left">The fair value of the Company&#8217;s assets and
liabilities, which qualify as financial instruments under the FASB ASC 820, &#8220;Fair Value Measurements and Disclosures&#8221;, approximates
the carrying amounts represented in the balance sheet, primarily due to their short-term nature.</p> </div> </ix:nonNumeric>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in;text-align:justify">&#160;</p> <ix:nonNumeric id="Fxbrl_20241003103546537" name="us-gaap:UseOfEstimates" contextRef="C_20240101to20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" escape="true">

<div>

<table cellpadding="0" cellspacing="0" style="font:10pt Times New Roman, Times, Serif;width:100%;border-collapse:collapse">
  <tr style="vertical-align:top">
    <td style="width:72px">&#160;</td>
    <td style="width:24px"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt"><strong>j.</strong></span></td>
    <td><span style="font-family:Times New Roman, Times, Serif;font-size:10pt"><strong>Use of estimates in the preparation of financial statements</strong></span></td>
        </tr>
  </table>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 45.05pt;text-indent:-0.5in"><strong>&#160;</strong></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in;text-align:left">The preparation of the financial statements in
conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities,
the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during
the reporting period. Actual results may differ from those estimates and such differences may have a material impact on the Company&#8217;s
financial statements.</p> </div> </ix:nonNumeric>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in;text-align:justify">&#160;</p> </div> <ix:nonNumeric id="Fxbrl_20241003103614387" name="us-gaap:IncomeTaxPolicyTextBlock" contextRef="C_20240101to20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" escape="true">

<div>

<div>

<table cellpadding="0" cellspacing="0" style="font:10pt Times New Roman, Times, Serif;width:100%;border-collapse:collapse">
  <tr style="vertical-align:top">
    <td style="width:72px;text-align:justify">&#160;</td>
    <td style="width:24px;text-align:justify"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt"><strong>m.</strong></span></td>
    <td style="text-align:justify"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt"><strong>Income tax</strong></span></td>
        </tr>
  </table>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in;text-align:justify">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in;text-align:left">The Company accounts for income taxes in accordance
with ASC 740, &#8220;Income Taxes (hereafter &#8211; ASC&#160;740). ASC 740 prescribes the use of the liability method whereby deferred
tax asset and liability account balances are determined based on differences between the financial reporting and tax bases of assets and
liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse.
The Company provides a valuation allowance, if necessary, to reduce deferred tax assets to their estimated realizable value if it is more
likely than not that a portion or all of the deferred tax assets will not be realized, based on the weight of available positive and negative
evidence. Deferred tax liabilities and assets are classified as non-current in accordance with ASU&#160;2015-17.</p> </div> </div> </ix:nonNumeric>

<p style="margin:0pt">&#160;</p>

<div><ix:exclude>

<div style="margin-top:12pt;margin-bottom:6pt;border-bottom:Black 1.5pt solid">

<p style="font:10pt Times New Roman, Times, Serif;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">F-13</span></p>
</div>

<div style="break-before:page;margin-top:6pt;margin-bottom:12pt">

<p style="margin:0pt">&#160;</p> </div>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in;text-align:center">&#160;</p>

<p style="font:10pt Times New Roman, Times, serif;margin-top:10pt;margin-bottom:0pt;text-align:center"><strong>MORINGA ACQUISITION CORP</strong></p>

<p style="font:10pt Times New Roman, Times, Serif;margin-top:0pt;margin-bottom:0pt;text-align:center">NOTES TO CONDENSED CONSOLIDATED
FINANCIAL STATEMENTS (UNAUDITED)</p>

<p style="font:10pt Times New Roman, Times, Serif;margin-top:0pt;margin-bottom:0pt;text-align:center">(CONTINUED)</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0"><strong>&#160;</strong></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0"><strong>NOTE 2 - SIGNIFICANT ACCOUNTING POLICIES </strong>(continued)<strong>:</strong></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p> </ix:exclude></div>

<div> <ix:nonNumeric id="Fxbrl_20241003103637026" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" contextRef="C_20240101to20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" escape="true">

<div>

<table cellpadding="0" cellspacing="0" style="font:10pt Times New Roman, Times, Serif;width:100%;border-collapse:collapse">
  <tr style="vertical-align:top">
    <td style="width:72px;text-align:justify">&#160;</td>
    <td style="width:24px;text-align:justify"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt"><strong>n.</strong></span></td>
    <td><span style="font-family:Times New Roman, Times, Serif;font-size:10pt"><strong>Recent accounting pronouncements</strong></span></td> </tr>
  </table>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 49.65pt;text-align:justify"><strong>&#160;</strong></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in;text-align:left">Management does not believe that any recently
issued, but not yet effective, accounting pronouncements, if currently adopted would have a material effect on the Company&#8217;s financial
statements.</p> </div> </ix:nonNumeric> </div> </div> </ix:nonNumeric>

<p style="font:10pt Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><strong>&#160;</strong></p> </div>

<div style="font:10pt Times New Roman, Times, Serif"> <ix:nonNumeric id="Fxbrl_20241004103824622" name="slxn:PublicOfferingAndPrivatePlacementsTextBlock" contextRef="C_20240101to20240630" escape="true">

<div>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0"><strong>NOTE 3 - PUBLIC OFFERING AND PRIVATE PLACEMENTS:</strong></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0"><strong>&#160;</strong></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in;text-align:left">In the Initial Public Offering, the Company issued
and sold <ix:nonFraction id="Fixv-37758" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" contextRef="C_20240101to20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapSubsidiarySaleOfStockAxis_usgaapIPOMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">11,500,000</ix:nonFraction>
units (including <ix:nonFraction id="Fixv-37759" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" contextRef="C_20240101to20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapSubsidiarySaleOfStockAxis_usgaapOverAllotmentOptionMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">1,500,000</ix:nonFraction>
units sold at a second closing pursuant to the underwriters&#8217; exercise of their over-allotment option in full) at an offering price
of $<ix:nonFraction id="Fixv-37760" name="us-gaap:SaleOfStockPricePerShare" contextRef="C_20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapSubsidiarySaleOfStockAxis_usgaapIPOMember" unitRef="usdPershares" scale="0" decimals="2" format="ixt:num-dot-decimal">10.00</ix:nonFraction>
per unit (hereafter &#8211; the Units). The Sponsor and EarlyBirdCapital, Inc. (the representative of the underwriters) purchased, in
a private placement that occurred simultaneously with the two closings of the initial Public Offering (hereafter &#8211; the Private Placement),
an aggregate of <ix:nonFraction id="Fixv-37761" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" contextRef="C_20240101to20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapRelatedPartyTransactionsByRelatedPartyAxis_slxnSponsorMember_usgaapSubsidiarySaleOfStockAxis_usgaapIPOMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">352,857</ix:nonFraction>
and <ix:nonFraction id="Fixv-37762" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" contextRef="C_20240101to20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapRelatedPartyTransactionsByRelatedPartyAxis_slxnSponsorMember_usgaapSubsidiarySaleOfStockAxis_usgaapPrivatePlacementMember" unitRef="shares" scale="0" decimals="0" format="ixt:num-dot-decimal">27,143</ix:nonFraction>
Units, respectively, at a price of $<ix:nonFraction id="Fixv-37763" name="us-gaap:SaleOfStockPricePerShare" contextRef="C_20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapRelatedPartyTransactionsByRelatedPartyAxis_slxnSponsorMember_usgaapSubsidiarySaleOfStockAxis_usgaapIPOMember" unitRef="usdPershares" scale="0" decimals="2" format="ixt:num-dot-decimal">10.00</ix:nonFraction>
per Unit.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in;text-align:justify">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in;text-align:left">Once the Public Warrants become exercisable, the
Company may redeem them in whole and not in part at a price of $<ix:nonFraction id="Fixv-37764" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="C_20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="usdPershares" scale="0" decimals="2" format="ixt:num-dot-decimal">0.01</ix:nonFraction>
per Warrant upon a minimum of 30 days&#8217; prior written notice of redemption, if and only if the last reported sale price of the Company&#8217;s
Class A ordinary shares equals or exceeds $<ix:nonFraction id="Fixv-37765" name="slxn:WarrantPricePerSharesExceeds" contextRef="C_20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_usgaapCommonClassAMember" unitRef="usdPershares" scale="0" decimals="2" format="ixt:num-dot-decimal">18.00</ix:nonFraction>
per share (as adjusted) for any 20 trading days within a 30-trading day period ending on the third trading day prior to the date on which
the Company sends the notice of redemption to the Public Warrant holders.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in;text-align:left">The Private Warrants are identical to the Public
Warrants except that, for so long as they are held by the Sponsor, EarlyBirdCapital, Inc. or their respective affiliates: (1) will not
be redeemable by the Company; (2) may not (including the Class A ordinary shares issuable upon exercise thereof), subject to certain limited
exceptions, be transferred, assigned or sold by the holders thereof until 30 days after the completion of the Company&#8217;s Initial
Business Combination; (3) may be exercised by the holders thereof on a cashless basis; and (4) they (including the Class A ordinary shares
issuable upon exercise thereof) are entitled to registration rights.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in;text-align:justify">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in;text-align:left">The Company paid an underwriting commission of
<ix:nonFraction id="Fixv-37766" name="slxn:UnderwritingCommissionPercentage" contextRef="C_20240101to20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">2.0</ix:nonFraction>%
of the gross proceeds of the Public Offering and the full exercise of the underwriters&#8217; over-allotment, or $<ix:nonFraction id="Fixv-37767" name="slxn:AggregateUnderwritersAmount" contextRef="C_20240101to20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapSubsidiarySaleOfStockAxis_usgaapOverAllotmentOptionMember" unitRef="usd" scale="0" decimals="0" format="ixt:num-dot-decimal">2,300,000</ix:nonFraction>,
in the aggregate, to the underwriters at the two closings of the Public Offering. Refer to Notes 5(a) and 9(a) for more information regarding
an additional fee payable to the underwriters upon the consummation of an Initial Business Combination, and an amendment to the agreement.</p>
</div> </ix:nonNumeric>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in;text-align:justify">&#160;</p>

<div style="margin-top:12pt;margin-bottom:6pt;border-bottom:Black 1.5pt solid">

<p style="font:10pt Times New Roman, Times, Serif;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">F-14</span></p>
</div>

<div style="break-before:page;margin-top:6pt;margin-bottom:12pt">

<p style="margin:0pt">&#160;</p> </div>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in;text-align:justify">&#160;</p>

<p style="font:10pt Times New Roman, Times, serif;margin-top:10pt;margin-bottom:0pt;text-align:center"><strong>MORINGA ACQUISITION CORP</strong></p>

<p style="font:10pt Times New Roman, Times, Serif;margin-top:0pt;margin-bottom:0pt;text-align:center">NOTES TO CONDENSED CONSOLIDATED
FINANCIAL STATEMENTS (UNAUDITED)</p>

<p style="font:10pt Times New Roman, Times, Serif;margin-top:0pt;margin-bottom:0pt;text-align:center">(CONTINUED)</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0"><strong>&#160;</strong></p> </div>

<div style="font:10pt Times New Roman, Times, Serif">

<div> <ix:nonNumeric id="Fxbrl_20241003115700638" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock" contextRef="C_20240101to20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" escape="true">

<div>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0"><strong>NOTE 4 - RELATED PARTY TRANSACTIONS:</strong></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font:10pt Times New Roman, Times, Serif;width:100%;border-collapse:collapse">
  <tr style="vertical-align:top">
    <td style="width:72px">&#160;</td>
    <td style="width:24px"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt"><strong>a.</strong></span></td>
    <td><span style="font-family:Times New Roman, Times, Serif;font-size:10pt"><strong>Promissory Notes</strong></span></td> </tr>
  </table>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in;text-align:left">The Company has issued several promissory note
agreements to its Sponsor throughout its life term, in order to fulfil its ongoing operational needs or preparations towards an Initial
Business Combination. All outstanding promissory notes bear no interest and are repayable in full upon the earlier of (a) the date of
the consummation of the Company&#8217;s Initial Business Combination, or (b) Second Extended Mandatory Liquidation Date (hereafter and
collectively &#8211; the Maturity Date).</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in;text-align:justify">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in;text-align:justify"><i>Second to Fifth Promissory Notes</i></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in;text-align:justify"><i>&#160;</i></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in;text-align:left">On August 9, 2021 the Company issued its Second
Promissory Note to the Sponsor, according to which the former may withdraw up to $<ix:nonFraction id="Fixv-37768" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="C_20210809to20210809_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapDebtInstrumentAxis_slxnSecondPromissoryNoteMember_usgaapRelatedPartyTransactionAxis_slxnSponsorMember" unitRef="usd" scale="6" decimals="-6" format="ixt:num-dot-decimal">1</ix:nonFraction>
million &#8211; which has been withdrawn in full in several installments up until June 2022.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in;text-align:justify">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in;text-align:left">In December 2022 the Company issued its Third
and Fourth Promissory Notes, according to which the Company may withdraw up to an aggregate amount of $<ix:nonFraction id="Fixv-37769" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="C_20221231to20221231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapDebtInstrumentAxis_slxnThirdAndFourthPromissoryNotesMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">190</ix:nonFraction>
thousand &#8211; which were withdrawn in full on the same month.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in;text-align:justify">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in;text-align:left">On February 8, 2023 the Company issued its Fifth
Promissory Note to the Sponsor, in an amount of up to $<ix:nonFraction id="Fixv-37770" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="C_20230208to20230208_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapDebtInstrumentAxis_slxnFifthPromissoryNoteMember_usgaapRelatedPartyTransactionAxis_slxnSponsorMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">310</ix:nonFraction>
thousand, which were withdrawn in full in several installments between February and June 2023.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in;text-align:justify">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in;text-align:left">According to the terms of the outstanding Second,
Third, Fourth and Fifth Promissory Notes, which comprise an aggregate principal of $<ix:nonFraction id="Fixv-37771" name="us-gaap:DebtInstrumentFaceAmount" contextRef="C_20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="usd" scale="6" decimals="-5" format="ixt:num-dot-decimal">1.5</ix:nonFraction>
million, the Sponsor may elect to convert any portion of the amounts outstanding into private warrants to purchase Class A ordinary shares
at a conversion price of $<ix:nonFraction id="Fixv-37772" name="us-gaap:DebtInstrumentConvertibleConversionPrice1" contextRef="C_20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapClassOfWarrantOrRightAxis_slxnPrivateWarrantsMember" unitRef="usdPershares" scale="0" decimals="0" format="ixt:num-dot-decimal">1</ix:nonFraction>
per private warrant on the Maturity Date. Such private warrants will have an exercise price of $<ix:nonFraction id="Fixv-37773" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="C_20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapClassOfWarrantOrRightAxis_slxnPrivateWarrantsMember" unitRef="usdPershares" scale="0" decimals="1" format="ixt:num-dot-decimal">11.5</ix:nonFraction>
and shall be identical to the private warrants included in the private units.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in"><i>Sixth Promissory Note</i></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in;text-align:left">On February 9, 2023 the Company issued its Sixth
Promissory Note to the Sponsor, in an amount of $<ix:nonFraction id="Fixv-37774" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="C_20230209to20230209_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapDebtInstrumentAxis_slxnSixthPromissoryNoteMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">480</ix:nonFraction>
thousand &#8211; under which the funds that were loaned by the Sponsor were deposited into the Company&#8217;s Trust Account, in connection
with the First Extension. The Sponsor provided six monthly injections of $<ix:nonFraction id="Fixv-37775" name="slxn:SponsorPay" contextRef="C_20230219to20230219_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapDebtInstrumentAxis_slxnSixthPromissoryNoteMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">80</ix:nonFraction>
thousand into the Company&#8217;s Trust Account under the Sixth Promissory Note, starting February 19, 2023.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in"><i>Seventh Promissory Note</i></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in;text-align:left">On June 14, 2023 the Company issued its Seventh
Promissory Note to the Sponsor in an amount of up to $<ix:nonFraction id="Fixv-37776" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="C_20230614to20230614_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapDebtInstrumentAxis_slxnSeventhPromissoryNoteMember" unitRef="usd" scale="6" decimals="-6" format="ixt:num-dot-decimal">1</ix:nonFraction>
million, which were withdrawn in full in several installments between June 2023 and March 2024.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in;text-align:left">&#160;</p>

<div><ix:exclude>

<div style="margin-top:12pt;margin-bottom:6pt;border-bottom:1.5pt solid black">

<p style="margin-top:0pt;margin-bottom:0pt;text-align:center;line-height:normal;font-size:10pt;font-style:normal;font-weight:normal;font-family:Times New Roman, Times, serif"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">F-15</span></p>
</div>

<div style="break-before:page;margin-top:6pt;margin-bottom:12pt">

<p style="margin:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p> </div>

<p style="margin:0pt 0px 0pt 1in;text-align:justify;line-height:normal;font-size:10pt;font-style:normal;font-weight:normal;font-family:Times New Roman, Times, serif">&#160;</p>

<p style="margin-top:10pt;margin-bottom:0pt;text-align:center;line-height:normal;font-size:10pt;font-style:normal;font-weight:normal;font-family:Times New Roman, Times, serif"><strong>MORINGA
ACQUISITION CORP</strong></p>

<p style="margin-top:0pt;margin-bottom:0pt;text-align:center;line-height:normal;font-size:10pt;font-style:normal;font-weight:normal;font-family:Times New Roman, Times, serif">NOTES
TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)</p>

<p style="margin-top:0pt;margin-bottom:0pt;text-align:center;line-height:normal;font-size:10pt;font-style:normal;font-weight:normal;font-family:Times New Roman, Times, serif">(CONTINUED)</p>

<p style="margin:0pt 0px;line-height:normal;font-size:10pt;font-style:normal;font-weight:normal;font-family:Times New Roman, Times, serif"><strong>&#160;</strong></p>

<p style="font:10pt Times New Roman, Times, serif;margin:0pt 0px"><strong>NOTE 4 - RELATED PARTY TRANSACTIONS </strong>(continued)<strong>:</strong></p>

<p style="font:10pt Times New Roman, Times, serif;margin:0pt 0px">&#160;</p> </ix:exclude></div>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in"><i>Eighth Promissory Note</i></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in;text-align:left">On August 18, 2023 the Company issued its Eighth
Promissory Note to the Sponsor, in an amount of approximately $<ix:nonFraction id="Fixv-37777" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="C_20230818to20230818_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapDebtInstrumentAxis_slxnEighthPromissoryNoteMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">154</ix:nonFraction>
thousand &#8211; under which the funds that were loaned by the Sponsor were deposited into the Company&#8217;s Trust Account, in connection
with the Second Extension. The Sponsor shall make monthly injections of approximately $<ix:nonFraction id="Fixv-37778" name="slxn:SponsorPay" contextRef="C_20230819to20230819_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapDebtInstrumentAxis_slxnEighthPromissoryNoteMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">13</ix:nonFraction>
thousand into the Company&#8217;s Trust Account, starting August 19, 2023 and up until the earlier of the Second Extended Mandatory Liquidation
Date (or such earlier date that the Board determines to liquidate the Company) or the date on which an Initial Business Combination is
completed. During the six months ended June 30, 2024, approximately $<ix:nonFraction id="Fixv-37779" name="slxn:InstallmentsAmount" contextRef="C_20240101to20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">77</ix:nonFraction>
thousand have been injected into the trust account in six monthly installments.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in;text-align:justify">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in"><i>Ninth Promissory Note</i></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in;text-align:justify">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in;text-align:left">On March 27, 2024, the Company issued its Ninth
Promissory Note, according to which the Company may withdraw up to an aggregate amount of $<ix:nonFraction id="Fixv-37780" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="C_20240327to20240327_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">180</ix:nonFraction>
thousand. As of June 30, 2024 the Ninth Promissory Note has been fully withdrawn.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in"><i>Tenth Promissory Note</i></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in;text-align:justify">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in;text-align:left">On June 27, 2024, the Company issued its Tenth
Promissory Note, according to which the Company may withdraw up to an aggregate amount of $<ix:nonFraction id="Fixv-37781" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="C_20240627to20240627_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">250</ix:nonFraction>
thousand. The Company has made partial withdrawals in June and July 2024.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in;text-align:justify">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in;text-align:justify"><i>A&amp;R Promissory Note </i></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in;text-align:justify">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in;text-align:left">Upon the closing of the proposed business combination,
and according to the terms of the amended Silexion Business Combination agreement, all promissory notes shall be converted into one sponsor
promissory note &#8211; the A&amp;R Sponsor Promissory Note, which will be subject to a cap of (i) $<ix:nonFraction id="Fixv-37782" name="slxn:SponsorPay" contextRef="C_20240101to20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="usd" scale="6" decimals="-5" format="ixt:num-dot-decimal">5.5</ix:nonFraction>
million, minus (ii) any fee that may be paid or owed under the amended Business Marketing Agreement (See Notes 5(a) and 9(a)). Any outstanding
amount loaned by the sponsor to the Company in excess of the cap, will be attributed to the conversion shares issuable under the A&amp;R
Sponsor Promissory Note as additional paid-in capital.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in;text-align:justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font:10pt Times New Roman, Times, Serif;width:100%;border-collapse:collapse">
  <tr style="vertical-align:top">
    <td style="width:72px;text-align:justify">&#160;</td>
    <td style="width:24px;text-align:justify"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt"><strong>b.</strong></span></td>
    <td style="text-align:justify"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt"><strong>Administrative Services Agreement
        </strong></span></td> </tr>
  </table>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 53.2pt;text-align:justify">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in;text-align:left">On December 16, 2020, the Company signed an agreement
with the Sponsor, under which the Company shall pay the Sponsor a fixed $<ix:nonFraction id="Fixv-37783" name="us-gaap:OtherGeneralAndAdministrativeExpense" contextRef="C_20201216to20201216_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapRelatedPartyTransactionAxis_slxnSponsorMember_usgaapTypeOfArrangementAxis_slxnAdministrativeServicesAgreementMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">10</ix:nonFraction>
thousand per month for office space, utilities and other administrative expenses. The monthly payments under this administrative services
agreement commenced on the effective date of the registration statement for the initial Public Offering and will continue until the earlier
of (i) the consummation of the Company&#8217;s initial Business Combination, or (ii) the Company&#8217;s liquidation.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in;text-align:justify">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in;text-align:left">The composition of the Related Party balance as
of June 30, 2024 and December 31, 2023 is as follows:&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in">&#160;</p> <ix:nonNumeric id="Fxbrl_20241003120028982" name="us-gaap:ScheduleOfCompensatingBalancesTextBlock" contextRef="C_20240101to20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" escape="true">

<table cellpadding="0" cellspacing="0" style="font:10pt Times New Roman, Times, Serif;border-collapse:collapse;width:100%">
  <tr style="vertical-align:bottom">
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="padding-bottom:1.5pt;font-weight:bold">&#160;</td>
    <td colspan="2" style="border-bottom:Black 1.5pt solid;font-weight:bold;text-align:center">June&#160;30,<br/>2024</td>
    <td style="padding-bottom:1.5pt;font-weight:bold">&#160;</td>
    <td style="padding-bottom:1.5pt;font-weight:bold">&#160;</td>
    <td colspan="2" style="border-bottom:Black 1.5pt solid;font-weight:bold;text-align:center">December&#160;31,<br/>2023</td>
    <td style="padding-bottom:1.5pt;font-weight:bold">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td>&#160;</td>
    <td style="font-weight:bold;padding-bottom:1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom:Black 1.5pt solid;font-weight:bold;text-align:center">In U.S. dollars</td>
    <td style="padding-bottom:1.5pt;font-weight:bold">&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="width:76%;text-align:left">Promissory notes</td>
    <td style="width:1%">&#160;</td>
    <td style="width:1%;text-align:left">&#160;</td>
    <td style="width:9%;text-align:right"><ix:nonFraction id="Fixv-37785" name="us-gaap:NotesPayableCurrent" contextRef="C_20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapRelatedPartyTransactionAxis_slxnPromissoryNotesMember" unitRef="usd" scale="0" decimals="0" format="ixt:num-dot-decimal">3,346,000</ix:nonFraction></td>
    <td style="width:1%;text-align:left">&#160;</td>
    <td style="width:1%">&#160;</td>
    <td style="width:1%;text-align:left">&#160;</td>
    <td style="width:9%;text-align:right"><ix:nonFraction id="Fixv-37786" name="us-gaap:NotesPayableCurrent" contextRef="C_20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapRelatedPartyTransactionAxis_slxnPromissoryNotesMember" unitRef="usd" scale="0" decimals="0" format="ixt:num-dot-decimal">2,841,000</ix:nonFraction></td>
    <td style="width:1%;text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="text-align:left;padding-bottom:1.5pt">Accrual for Administrative Services Agreement</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right"><ix:nonFraction id="Fxbrl_20241004161900128" name="us-gaap:NotesPayableCurrent" contextRef="C_20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapRelatedPartyTransactionAxis_usgaapAssetManagementArrangementMember" unitRef="usd" scale="0" decimals="0" format="ixt:fixed-zero">-</ix:nonFraction></td>
    <td style="padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right"><ix:nonFraction id="Fixv-37787" name="us-gaap:NotesPayableCurrent" contextRef="C_20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapRelatedPartyTransactionAxis_usgaapAssetManagementArrangementMember" unitRef="usd" scale="0" decimals="0" format="ixt:num-dot-decimal">20,000</ix:nonFraction></td>
    <td style="padding-bottom:1.5pt;text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="padding-bottom:4pt">&#160;</td>
    <td style="padding-bottom:4pt">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:left">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:right"><ix:nonFraction id="Fixv-37788" name="us-gaap:NotesPayableCurrent" contextRef="C_20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapRelatedPartyTransactionAxis_usgaapRelatedPartyMember" unitRef="usd" scale="0" decimals="0" format="ixt:num-dot-decimal">3,346,000</ix:nonFraction></td>
    <td style="padding-bottom:4pt;text-align:left">&#160;</td>
    <td style="padding-bottom:4pt">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:left">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:right"><ix:nonFraction id="Fixv-37789" name="us-gaap:NotesPayableCurrent" contextRef="C_20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapRelatedPartyTransactionAxis_usgaapRelatedPartyMember" unitRef="usd" scale="0" decimals="0" format="ixt:num-dot-decimal">2,861,000</ix:nonFraction></td>
    <td style="padding-bottom:4pt;text-align:left">&#160;</td> </tr>
  </table> </ix:nonNumeric> </div> </ix:nonNumeric>

<p style="margin:0pt">&#160;</p>

<div style="margin-top:12pt;margin-bottom:6pt;border-bottom:1.5pt solid black">

<p style="margin-top:0pt;margin-bottom:0pt;text-align:center;line-height:normal;font-size:10pt;font-style:normal;font-weight:normal;font-family:Times New Roman, Times, serif"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">F-16</span></p>
</div>

<div style="break-before:page;margin-top:6pt;margin-bottom:12pt">

<p style="margin:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p> </div>

<p style="margin:0pt 0px 0pt 1in;text-align:justify;line-height:normal;font-size:10pt;font-style:normal;font-weight:normal;font-family:Times New Roman, Times, serif">&#160;</p>

<p style="margin-top:10pt;margin-bottom:0pt;text-align:center;line-height:normal;font-size:10pt;font-style:normal;font-weight:normal;font-family:Times New Roman, Times, serif"><strong>MORINGA
ACQUISITION CORP</strong></p>

<p style="margin-top:0pt;margin-bottom:0pt;text-align:center;line-height:normal;font-size:10pt;font-style:normal;font-weight:normal;font-family:Times New Roman, Times, serif">NOTES
TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)</p>

<p style="margin-top:0pt;margin-bottom:0pt;text-align:center;line-height:normal;font-size:10pt;font-style:normal;font-weight:normal;font-family:Times New Roman, Times, serif">(CONTINUED)</p>

<p style="margin-top:0pt;margin-bottom:0pt;text-align:center;line-height:normal;font-size:10pt;font-style:normal;font-weight:normal;font-family:Times New Roman, Times, serif">&#160;</p>
</div> </div>

<div style="font:10pt Times New Roman, Times, Serif"> <ix:nonNumeric id="Fixv-18432" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" contextRef="C_20240101to20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" escape="true">

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0"><strong>NOTE 5 - COMMITMENTS AND CONTINGENCIES:</strong></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font:10pt Times New Roman, Times, Serif;width:100%;border-collapse:collapse">
  <tr style="vertical-align:top">
    <td style="width:72px">&#160;</td>
    <td style="width:24px"><strong>a.</strong></td>
    <td style="text-align:justify"><strong>Underwriters&#8217; deferred discount</strong></td> </tr>
  </table>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in;text-align:justify;text-indent:1.1pt">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in;text-align:left;text-indent:1.1pt">Under the Business Combination
Marketing Agreement, the Company shall pay an additional fee (hereafter &#8211; the Deferred Commission) of <ix:nonFraction id="Fixv-37790" name="slxn:DeferredCommissionPercentage" contextRef="C_20240101to20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">3.5</ix:nonFraction>%
of the gross proceeds of the Public Offering (or $<ix:nonFraction id="Fixv-37791" name="slxn:DeferredCommission" contextRef="C_20240101to20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="usd" scale="0" decimals="0" format="ixt:num-dot-decimal">4,025,000</ix:nonFraction>)
payable upon the Company&#8217;s completion of the Initial Business Combination. The Deferred Commission will become payable to the underwriters
from the amounts held in the Trust Account solely in the event the Company completes an Initial Business Combination.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in;text-align:justify;text-indent:1.1pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font:10pt Times New Roman, Times, Serif;margin-top:0pt;margin-bottom:0pt" width="100%">
  <tr style="vertical-align:top">
    <td style="width:0.75in">&#160;</td>
    <td style="width:18pt"><strong>b.</strong></td>
    <td style="text-align:justify"><strong>Advisory and Placement Agent Agreement with Cohen &amp; Company</strong></td> </tr>
  </table>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify"><strong>&#160;</strong></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in;text-align:left;text-indent:1.1pt">Refer to Note 9(d) for information
regarding the agreement entered into after the balance sheet date.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in;text-indent:1.1pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font:10pt Times New Roman, Times, Serif;width:100%;border-collapse:collapse">
  <tr style="vertical-align:top">
    <td style="width:72px">&#160;</td>
    <td style="width:24px"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt"><strong>c.</strong></span></td>
    <td><span style="font-family:Times New Roman, Times, Serif;font-size:10pt"><strong>Nasdaq Deficiency Notice </strong></span></td>
    <td>&#160;</td> </tr>
  </table>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in;text-align:justify">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in"><i>Third Deficiency Notice</i></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in;text-align:left">On February 20, 2024, the Company received a notice
from the staff of the Listing Qualifications Department of The Nasdaq Stock Market LLC indicating that unless the Company timely requests
a hearing before the Nasdaq Hearings Panel (hereafter - the Panel), trading of the Company&#8217;s securities on The Nasdaq Capital Market
would be suspended at the opening of business on February 29, 2024, due to the Company&#8217;s non-compliance with Nasdaq IM-5101-2, which
requires that a special purpose acquisition company complete one or more business combinations within 36 months of the effectiveness of
its IPO registration statement.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in;text-align:justify">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in;text-align:left">The Company timely requested a hearing before
the Panel to request sufficient time to complete its previously disclosed proposed business combination with Silexion. The hearing request
has resulted in a stay of any suspension or delisting action pending the hearing, which was held on April 23, 2024.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in;text-align:justify">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in;text-align:left">On April 23, 2024, the Company participated in
a hearing with Nasdaq in which the Company presented its request that Nasdaq provide the Company an additional six months to remedy the
Company&#8217;s non-compliance with Nasdaq IM-5101-2, which requires that a special purpose acquisition company complete one or more business
combinations within 36 months of the effectiveness of its IPO registration statement. The Company&#8217;s plan for regaining compliance
focused on the Company&#8217;s efforts to complete its previously disclosed Proposed Business Combination with Silexion. On May 10, 2024,
the Company received the results of the hearing, under which Nasdaq approved the Company&#8217;s request for a six-month extension&#8212;
until the Second Extension Date&#8212; to remain listed on Nasdaq and complete its proposed business combination.</p> </ix:nonNumeric>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in;text-align:justify">&#160;</p>

<div style="margin-top:12pt;margin-bottom:6pt;border-bottom:Black 1.5pt solid">

<p style="font:10pt Times New Roman, Times, Serif;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">F-17</span></p>
</div>

<div style="break-before:page;margin-top:6pt;margin-bottom:12pt">

<p style="margin:0pt">&#160;</p> </div>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in;text-align:justify">&#160;</p>

<p style="font:10pt Times New Roman, Times, serif;margin-top:10pt;margin-bottom:0pt;text-align:center"><strong>MORINGA ACQUISITION CORP</strong></p>

<p style="font:10pt Times New Roman, Times, Serif;margin-top:0pt;margin-bottom:0pt;text-align:center">NOTES TO CONDENSED CONSOLIDATED
FINANCIAL STATEMENTS (UNAUDITED)</p>

<p style="font:10pt Times New Roman, Times, Serif;margin-top:0pt;margin-bottom:0pt;text-align:center">(CONTINUED)</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in;text-align:justify">&#160;</p> </div>

<div style="font:10pt Times New Roman, Times, Serif"> <ix:nonNumeric id="Fixv-18501" name="us-gaap:FairValueDisclosuresTextBlock" contextRef="C_20240101to20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" escape="true">

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0"><strong>NOTE 6 - FAIR VALUE MEASUREMENTS:</strong></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in;text-align:left">The fair value of a financial instrument is the
amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at
the measurement date (i.e., the exit price).</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in;text-align:justify">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in;text-align:left">The fair value hierarchy under ASC 820 prioritizes
the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in
active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements).
The three levels of the fair value hierarchy are as follows:</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in;text-align:justify">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in"><strong>Basis for Fair Value Measurement</strong></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in;text-align:left">Level 1: Unadjusted quoted prices in active markets
that are accessible at the measurement date for identical, unrestricted assets or liabilities;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in;text-align:justify">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in;text-align:left">Level 2: Quoted prices in markets that are not
active or financial instruments for which significant inputs to models are observable (including but not limited to quoted prices for
similar securities, interest rates, foreign exchange rates, volatility and credit risk), either directly or indirectly;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in;text-align:justify">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in;text-align:left">Level 3: Prices or valuations that require significant
unobservable inputs (including the Management&#8217;s assumptions in determining fair value measurement).</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in;text-align:center">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in;text-align:left">The following table presents information about
the Company&#8217;s assets and liabilities that are measured at fair value on a recurring basis at June 30, 2024 and December 31, 2023
by level within the fair value hierarchy:</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in;text-align:left">&#160;</p> <ix:nonNumeric id="Fxbrl_20241003131657032" name="us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" contextRef="C_20240101to20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" escape="true">

<div>

<table cellpadding="0" cellspacing="0" style="font:10pt Times New Roman, Times, Serif;border-collapse:collapse;width:100%">
  <tr style="vertical-align:bottom">
    <td>&#160;</td>
    <td style="font-weight:bold;padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;font-weight:bold;text-align:center">Level</td>
    <td style="font-weight:bold;padding-bottom:1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom:Black 1.5pt solid;font-weight:bold;text-align:center">June&#160;30,<br/>2024</td>
    <td style="padding-bottom:1.5pt;font-weight:bold">&#160;</td>
    <td style="font-weight:bold;padding-bottom:1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom:Black 1.5pt solid;font-weight:bold;text-align:center">December&#160;31,<br/>2023</td>
    <td style="padding-bottom:1.5pt;font-weight:bold">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="font-weight:bold">Assets:</td>
    <td>&#160;</td>
    <td style="text-align:center">&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align:right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align:right">&#160;</td>
    <td>&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="width:64%;text-align:left">Money market funds held in Trust Account</td>
    <td style="width:1%">&#160;</td>
    <td style="width:11%;text-align:center">1</td>
    <td style="width:1%">&#160;</td>
    <td style="width:1%;text-align:left">&#160;</td>
    <td style="width:9%;text-align:right"><ix:nonFraction id="Fixv-37793" name="us-gaap:AssetsHeldInTrustCurrent" contextRef="C_20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapFairValueByFairValueHierarchyLevelAxis_usgaapFairValueInputsLevel1Member_usgaapFairValueByMeasurementFrequencyAxis_usgaapFairValueMeasurementsRecurringMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,924,118</ix:nonFraction></td>
    <td style="width:1%;text-align:left">&#160;</td>
    <td style="width:1%">&#160;</td>
    <td style="width:1%;text-align:left">&#160;</td>
    <td style="width:9%;text-align:right"><ix:nonFraction id="Fixv-37794" name="us-gaap:AssetsHeldInTrustCurrent" contextRef="C_20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapFairValueByFairValueHierarchyLevelAxis_usgaapFairValueInputsLevel1Member_usgaapFairValueByMeasurementFrequencyAxis_usgaapFairValueMeasurementsRecurringMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,697,632</ix:nonFraction></td>
    <td style="width:1%;text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="font-weight:bold">Liabilities:</td>
    <td>&#160;</td>
    <td style="text-align:center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="text-align:left;padding-bottom:4pt">Private Warrant Liability</td>
    <td style="padding-bottom:4pt">&#160;</td>
    <td style="text-align:center;padding-bottom:4pt">3</td>
    <td style="padding-bottom:4pt">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:left">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:right"><ix:nonFraction id="Fixv-37795" name="us-gaap:WarrantsAndRightsOutstanding" contextRef="C_20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapFairValueByFairValueHierarchyLevelAxis_usgaapFairValueInputsLevel3Member_usgaapFairValueByMeasurementFrequencyAxis_usgaapFairValueMeasurementsRecurringMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">27,284</ix:nonFraction></td>
    <td style="padding-bottom:4pt;text-align:left">&#160;</td>
    <td style="padding-bottom:4pt">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:left">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:right"><ix:nonFraction id="Fixv-37796" name="us-gaap:WarrantsAndRightsOutstanding" contextRef="C_20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapFairValueByFairValueHierarchyLevelAxis_usgaapFairValueInputsLevel3Member_usgaapFairValueByMeasurementFrequencyAxis_usgaapFairValueMeasurementsRecurringMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,531</ix:nonFraction></td>
    <td style="padding-bottom:4pt;text-align:left">&#160;</td> </tr>
  </table> </div> </ix:nonNumeric>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in;text-align:left">The estimated fair value of the Private Placement
Warrants was determined using a binomial model to extract the market&#8217;s implied probability for an Initial Business Combination,
using the Public Warrant&#8217;s market price. Once probability was extracted, a Black-Scholes-Merton model with Level 3 inputs was used
to calculate the Private Warrants&#8217; fair value. Inherent in a Black-Scholes-Merton model are assumptions related to expected life
(term), expected stock price, volatility, risk-free interest rate and dividend yield. The Company estimates the volatility of its warrants
based on implied volatility from the Company&#8217;s traded warrants and from historical volatility of selected peer companies&#8217;
Class A ordinary shares that matches the expected remaining life of the warrants. The risk-free interest rate is based on the U.S. Treasury
zero-coupon yield curve on the grant date for a maturity similar to the expected remaining life of the warrants. The expected life of
the warrants is assumed to be equivalent to their remaining contractual term. The dividend rate is based on the historical rate, which
the Company anticipates remaining at zero.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in;text-align:left">The following table provides quantitative information
regarding Level 3 fair value measurements inputs:</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in;text-align:left">&#160;</p> <ix:nonNumeric id="Fxbrl_20241003131709811" name="us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" contextRef="C_20240101to20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" escape="true">

<div>

<table cellpadding="0" cellspacing="0" style="font:10pt Times New Roman, Times, Serif;border-collapse:collapse;width:100%">
  <tr style="vertical-align:bottom">
    <td>&#160;</td>
    <td style="font-weight:bold;padding-bottom:1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom:Black 1.5pt solid;font-weight:bold;text-align:center">As of<br/>June&#160;30,<br/>2024</td>
    <td style="padding-bottom:1.5pt;font-weight:bold">&#160;</td>
    <td style="font-weight:bold;padding-bottom:1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom:Black 1.5pt solid;font-weight:bold;text-align:center">As of<br/>December&#160;31,<br/>2023</td>
    <td style="padding-bottom:1.5pt;font-weight:bold">&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="width:76%">Share price</td>
    <td style="width:1%">&#160;</td>
    <td style="width:1%;text-align:left">$</td>
    <td style="width:9%;text-align:right"><ix:nonFraction id="Fixv-37798" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="C_20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapMeasurementInputTypeAxis_usgaapMeasurementInputSharePriceMember" unitRef="pure" scale="0" decimals="1" format="ixt:num-dot-decimal">10.0</ix:nonFraction></td>
    <td style="width:1%;text-align:left">&#160;</td>
    <td style="width:1%">&#160;</td>
    <td style="width:1%;text-align:left">$</td>
    <td style="width:9%;text-align:right"><ix:nonFraction id="Fixv-37799" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="C_20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapMeasurementInputTypeAxis_usgaapMeasurementInputSharePriceMember" unitRef="pure" scale="0" decimals="1" format="ixt:num-dot-decimal">10.0</ix:nonFraction></td>
    <td style="width:1%;text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td>Strike price</td>
    <td>&#160;</td>
    <td style="text-align:left">$</td>
    <td style="text-align:right"><ix:nonFraction id="Fixv-37800" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="C_20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapMeasurementInputTypeAxis_slxnMeasurementInputStrikevPriceMember" unitRef="pure" scale="0" decimals="1" format="ixt:num-dot-decimal">11.5</ix:nonFraction></td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">$</td>
    <td style="text-align:right"><ix:nonFraction id="Fixv-37801" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="C_20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapMeasurementInputTypeAxis_slxnMeasurementInputStrikevPriceMember" unitRef="pure" scale="0" decimals="1" format="ixt:num-dot-decimal">11.5</ix:nonFraction></td>
    <td style="text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td>Volatility</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right"><ix:nonFraction id="Fixv-37802" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="C_20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapMeasurementInputTypeAxis_usgaapMeasurementInputPriceVolatilityMember" unitRef="pure" scale="0" decimals="0" format="ixt:num-dot-decimal">60</ix:nonFraction></td>
    <td style="text-align:left">%</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right"><ix:nonFraction id="Fixv-37803" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="C_20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapMeasurementInputTypeAxis_usgaapMeasurementInputPriceVolatilityMember" unitRef="pure" scale="0" decimals="0" format="ixt:num-dot-decimal">60</ix:nonFraction></td>
    <td style="text-align:left">%</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="text-align:left">Risk-free interest rate</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right"><ix:nonFraction id="Fixv-37804" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="C_20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapMeasurementInputTypeAxis_usgaapMeasurementInputRiskFreeInterestRateMember" unitRef="pure" scale="0" decimals="2" format="ixt:num-dot-decimal">4.34</ix:nonFraction></td>
    <td style="text-align:left">%</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right"><ix:nonFraction id="Fixv-37805" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="C_20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapMeasurementInputTypeAxis_usgaapMeasurementInputRiskFreeInterestRateMember" unitRef="pure" scale="0" decimals="2" format="ixt:num-dot-decimal">4.78</ix:nonFraction></td>
    <td style="text-align:left">%</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="text-align:left">Dividend yield</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right"><ix:nonFraction id="Fixv-37806" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="C_20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapMeasurementInputTypeAxis_usgaapMeasurementInputExpectedDividendRateMember" unitRef="pure" scale="0" decimals="2" format="ixt:num-dot-decimal">0.00</ix:nonFraction></td>
    <td style="text-align:left">%</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right"><ix:nonFraction id="Fixv-37807" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="C_20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapMeasurementInputTypeAxis_usgaapMeasurementInputExpectedDividendRateMember" unitRef="pure" scale="0" decimals="2" format="ixt:num-dot-decimal">0.00</ix:nonFraction></td>
    <td style="text-align:left">%</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="text-align:left">Public warrant market price</td>
    <td>&#160;</td>
    <td style="text-align:left">$</td>
    <td style="text-align:right"><ix:nonFraction id="Fixv-37808" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="C_20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapMeasurementInputTypeAxis_usgaapMeasurementInputCommodityMarketPriceMember" unitRef="pure" scale="0" decimals="2" format="ixt:num-dot-decimal">0.08</ix:nonFraction></td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">$</td>
    <td style="text-align:right"><ix:nonFraction id="Fixv-37809" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="C_20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapMeasurementInputTypeAxis_usgaapMeasurementInputCommodityMarketPriceMember" unitRef="pure" scale="0" decimals="2" format="ixt:num-dot-decimal">0.03</ix:nonFraction></td>
    <td style="text-align:left">&#160;</td> </tr>
  </table> </div> </ix:nonNumeric>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in">&#160;</p> <ix:nonNumeric id="Fixv-18660" name="us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" contextRef="C_20240101to20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" escape="true">

<table cellpadding="0" cellspacing="0" style="font:10pt Times New Roman, Times, Serif;border-collapse:collapse;width:100%">
  <tr style="vertical-align:bottom">
    <td>&#160;</td>
    <td style="font-weight:bold;padding-bottom:1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom:Black 1.5pt solid;font-weight:bold;text-align:center">In&#160;U.S&#160;dollars</td>
    <td style="padding-bottom:1.5pt;font-weight:bold">&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="width:88%;text-align:left;text-indent:-9pt;padding-left:9pt">Value of warrant liability measured with Level 3 inputs at December
        31, 2023</td>
    <td style="width:1%">&#160;</td>
    <td style="width:1%;text-align:left">&#160;</td>
    <td style="width:9%;text-align:right"><ix:nonFraction id="Fixv-37810" name="us-gaap:WarrantsAndRightsOutstanding" contextRef="C_20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapFairValueByFairValueHierarchyLevelAxis_usgaapFairValueInputsLevel3Member" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,531</ix:nonFraction></td>
    <td style="width:1%;text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="text-align:left;padding-bottom:1.5pt;text-indent:-9pt;padding-left:9pt">Change in fair value of private warrant liability measured
        with Level 3 inputs</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right"><ix:nonFraction id="Fixv-37811" name="us-gaap:LiabilitiesFairValueAdjustment" contextRef="C_20240101to20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapFairValueByFairValueHierarchyLevelAxis_usgaapFairValueInputsLevel3Member" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">18,753</ix:nonFraction></td>
    <td style="padding-bottom:1.5pt;text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="text-align:left;padding-bottom:4pt;text-indent:-9pt;padding-left:9pt">Value of warrant liability measured with Level 3 inputs at
        June 30, 2024</td>
    <td style="padding-bottom:4pt">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:left">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:right"><ix:nonFraction id="Fixv-37812" name="us-gaap:WarrantsAndRightsOutstanding" contextRef="C_20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapFairValueByFairValueHierarchyLevelAxis_usgaapFairValueInputsLevel3Member" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">27,284</ix:nonFraction></td>
    <td style="padding-bottom:4pt;text-align:left">&#160;</td> </tr>
  </table> </ix:nonNumeric> </ix:nonNumeric>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center">&#160;</p>

<div style="margin-top:12pt;margin-bottom:6pt;border-bottom:Black 1.5pt solid">

<p style="font:10pt Times New Roman, Times, Serif;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">F-18</span></p>
</div>

<div style="break-before:page;margin-top:6pt;margin-bottom:12pt">

<p style="margin:0pt">&#160;</p> </div>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, serif;margin-top:10pt;margin-bottom:0pt;text-align:center"><strong>MORINGA ACQUISITION CORP</strong></p>

<p style="font:10pt Times New Roman, Times, Serif;margin-top:0pt;margin-bottom:0pt;text-align:center">NOTES TO CONDENSED CONSOLIDATED
FINANCIAL STATEMENTS (UNAUDITED)</p>

<p style="font:10pt Times New Roman, Times, Serif;margin-top:0pt;margin-bottom:0pt;text-align:center">(CONTINUED)</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0"><strong>&#160;</strong></p> </div>

<div style="font:10pt Times New Roman, Times, Serif"> <ix:nonNumeric id="Fixv-18711" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" contextRef="C_20240101to20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" escape="true">

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0"><strong>NOTE 7 - CAPITAL DEFICIENCY:</strong></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0"><strong>&#160;</strong></p>

<table cellpadding="0" cellspacing="0" style="font:10pt Times New Roman, Times, Serif;width:100%;border-collapse:collapse">
  <tr style="vertical-align:top">
    <td style="width:72px">&#160;</td>
    <td style="width:24px"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt"><strong>a.</strong></span></td>
    <td><span style="font-family:Times New Roman, Times, Serif;font-size:10pt"><strong>Ordinary Shares</strong></span></td> </tr>
  </table>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in"><strong>&#160;</strong></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in"><i>Class A Ordinary Shares</i></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in;text-indent:-0.5in"><strong>&#160;</strong></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in;text-align:left">On November 20, 2020 the Company issued <ix:nonFraction id="Fixv-37813" name="us-gaap:CommonStockSharesIssued" contextRef="C_20201120_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_usgaapCommonClassAMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">100,000</ix:nonFraction>
Class A ordinary shares of $<ix:nonFraction id="Fixv-37814" name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="C_20201120_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_usgaapCommonClassAMember" unitRef="usdPershares" scale="0" decimals="4" format="ixt:num-dot-decimal">0.0001</ix:nonFraction>
par value each to designees of the Representative (hereafter &#8211; the Representative Shares) for a consideration equal to the par value
of the shares. The Representative Shares are deemed to be underwriters&#8217; compensation by FINRA pursuant to Rule 5110 of the FINRA
Manual.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in;text-align:justify">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in;text-align:left">The Company accounted for the issuance of the
Representative Shares as compensation expenses amounting to $<ix:nonFraction id="Fixv-37815" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_20240101to20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="usd" scale="0" decimals="0" format="ixt:num-dot-decimal">860</ix:nonFraction>,
with a corresponding credit to Additional Paid-In Capital, for the excess value over the consideration paid. The Company estimated the
fair value of the issuance based upon the price of Class B Ordinary Shares that were issued to the Sponsor.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in;text-align:justify">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in;text-align:left">Pursuant to the initial Public Offering and the
concurrent Private Placement that were each effected in two closings &#8211; on February 19, 2021 and March 3, 2021 &#8211; the Company
issued and sold an aggregate of <ix:nonFraction id="Fixv-37816" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" contextRef="C_20210219to20210219_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_usgaapCommonClassAMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">11,500,000</ix:nonFraction>
and <ix:nonFraction id="Fixv-37817" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" contextRef="C_20210303to20210303_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_usgaapCommonClassAMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">380,000</ix:nonFraction>
Class A ordinary shares as part of the Units sold in those respective transactions. The Units (which also included Warrants) were sold
at a price of $<ix:nonFraction id="Fxbrl_20241003172049435" name="us-gaap:SaleOfStockPricePerShare" contextRef="C_20210303_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_usgaapCommonClassAMember" unitRef="usdPershares" scale="0" decimals="0" format="ixt:num-dot-decimal"><ix:nonFraction id="Fixv-37818" name="us-gaap:SaleOfStockPricePerShare" contextRef="C_20210219_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_usgaapCommonClassAMember" unitRef="usdPershares" scale="0" decimals="0" format="ixt:num-dot-decimal">10</ix:nonFraction></ix:nonFraction>
per Unit, and for an aggregate consideration of $<ix:nonFraction id="Fixv-37820" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" contextRef="C_20210219to20210219_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapSubsidiarySaleOfStockAxis_slxnPublicOfferingMember" unitRef="usd" scale="6" decimals="-6" format="ixt:num-dot-decimal">115</ix:nonFraction>
million and $<ix:nonFraction id="Fixv-37821" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" contextRef="C_20210303to20210303_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapSubsidiarySaleOfStockAxis_usgaapPrivatePlacementMember" unitRef="usd" scale="6" decimals="-5" format="ixt:num-dot-decimal">3.8</ix:nonFraction>
million in the Public Offering and Private Placement, respectively. See Note 3 above for further information regarding those share issuances.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in;text-align:justify">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in;text-align:left">The Company classified its <ix:nonFraction id="Fixv-37822" name="us-gaap:TemporaryEquitySharesIssued" contextRef="C_20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_usgaapCommonClassAMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">11,500,000</ix:nonFraction>
Public Class A ordinary shares as temporary equity. The remaining <ix:nonFraction id="Fixv-37823" name="us-gaap:ReclassificationsOfTemporaryToPermanentEquity" contextRef="C_20240101to20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_usgaapCommonClassAMember" unitRef="usd" scale="0" decimals="0" format="ixt:num-dot-decimal">480,000</ix:nonFraction>
Private Class A ordinary shares were classified as permanent equity.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in;text-align:left"><span>In conjunction with the First and Second
Extensions, <ix:nonFraction id="Fixv-37824" name="us-gaap:StockRedeemedOrCalledDuringPeriodShares" contextRef="C_20240101to20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapRelatedPartyTransactionAxis_slxnFirstExtensionsMember_usgaapStatementClassOfStockAxis_usgaapCommonClassAMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">8,910,433</ix:nonFraction>
and <ix:nonFraction id="Fixv-37825" name="us-gaap:StockRedeemedOrCalledDuringPeriodShares" contextRef="C_20240101to20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapRelatedPartyTransactionAxis_slxnSecondExtensionsMember_usgaapStatementClassOfStockAxis_usgaapCommonClassAMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">2,074,548</ix:nonFraction>
Class A Ordinary Shares subject to possible redemption were redeemed, respectively, for their redemption value, including accrued interest.
As part of the partial redemptions approximately $<ix:nonFraction id="Fixv-37826" name="us-gaap:StockRedeemedOrCalledDuringPeriodValue" contextRef="C_20240101to20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_usgaapCommonClassAMember" unitRef="usd" scale="6" decimals="-6" format="ixt:num-dot-decimal">113</ix:nonFraction>
million has been withdrawn from the Investments held in Trust Account.</span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in;text-align:justify">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in;text-align:justify"><i>Class B Ordinary Shares</i></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in;text-align:justify">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in;text-align:left">On November 20, 2020, the Company issued <ix:nonFraction id="Fixv-37827" name="us-gaap:CommonStockSharesIssued" contextRef="C_20201120_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_usgaapCommonClassBMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">2,875,000</ix:nonFraction>
Class B ordinary shares of $<ix:nonFraction id="Fixv-37828" name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="C_20201120_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_usgaapCommonClassBMember" unitRef="usdPershares" scale="0" decimals="4" format="ixt:num-dot-decimal">0.0001</ix:nonFraction>
par value each for a total consideration of $<ix:nonFraction id="Fixv-37829" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" contextRef="C_20201120to20201120_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_usgaapCommonClassBMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">25</ix:nonFraction>
thousand to the Sponsor&#8217;s wholly-owned Delaware subsidiary.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in;text-align:justify">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in;text-align:left">Class B ordinary shares are convertible into non-redeemable
Class A ordinary shares, on a one-for-one basis, automatically on the day of the Business Combination or at the election of the holder
thereof at any time prior to the Business Combination. Class B ordinary shares also possess the sole right to vote for the election or
removal of directors, until the consummation of an Initial Business Combination.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in;text-align:left">Following the Second Extension Meeting, the Sponsor
converted <ix:nonFraction id="Fixv-37830" name="us-gaap:ConversionOfStockSharesConverted1" contextRef="C_20240101to20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_usgaapCommonClassBMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">2,874,999</ix:nonFraction>
of its <ix:nonNumeric id="Fixv-37831" name="us-gaap:ConversionOfStockTypeOfStockConverted" contextRef="C_20240101to20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember">Class
B ordinary shares into Class A ordinary shares on a one to one basis</ix:nonNumeric>.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in;text-align:justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font:10pt Times New Roman, Times, Serif;width:100%;border-collapse:collapse">
  <tr style="vertical-align:top">
    <td style="width:72px;text-align:justify">&#160;</td>
    <td style="width:24px;text-align:justify"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt"><strong>b.</strong></span></td>
    <td style="text-align:justify"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt"><strong>Preferred shares</strong></span></td>
        </tr>
  </table>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in;text-align:justify"><strong>&#160;</strong></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in;text-align:left">The Company is authorized to issue up to <ix:nonFraction id="Fixv-37832" name="us-gaap:PreferredStockSharesAuthorized" contextRef="C_20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">5,000,000</ix:nonFraction>
Preferred Shares of $<ix:nonFraction id="Fixv-37833" name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="C_20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="usdPershares" scale="0" decimals="4" format="ixt:num-dot-decimal">0.0001</ix:nonFraction>
par value each. As of June 30, 2024, the Company has no preferred shares issued and outstanding.</p> </ix:nonNumeric>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center">&#160;</p>

<div style="margin-top:12pt;margin-bottom:6pt;border-bottom:Black 1.5pt solid">

<p style="font:10pt Times New Roman, Times, Serif;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">F-19</span></p>
</div>

<div style="break-before:page;margin-top:6pt;margin-bottom:12pt">

<p style="margin:0pt">&#160;</p> </div>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0"><strong>&#160;</strong></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center"><strong>MORINGA ACQUISITION CORP</strong></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center">(CONTINUED)</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.25in;text-indent:-10pt"><strong>&#160;</strong></p> </div>

<div style="font:10pt Times New Roman, Times, Serif"> <ix:nonNumeric id="Fixv-18792" name="us-gaap:EarningsPerShareTextBlock" contextRef="C_20240101to20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" escape="true">

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0"><strong>NOTE 8 - NET PROFIT (LOSS) PER SHARE:</strong></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0"><strong>&#160;</strong></p> <ix:nonNumeric id="Fxbrl_20241004104311685" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" contextRef="C_20240101to20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" escape="true">

<div>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.75in;text-align:left">The following table reflects the calculation
of basic and diluted net profit (loss) per share (in dollars, except share amounts):</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.75in;text-align:left">&#160;</p>

<div>

<table cellpadding="0" cellspacing="0" style="font:10pt Times New Roman, Times, Serif;border-collapse:collapse;width:100%">
  <tr style="vertical-align:bottom">
    <td>&#160;</td>
    <td style="font-weight:bold;padding-bottom:1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom:Black 1.5pt solid;font-weight:bold;text-align:center">Six months ended<br/>June 30,</td>
    <td style="padding-bottom:1.5pt;font-weight:bold">&#160;</td>
    <td style="font-weight:bold;padding-bottom:1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom:Black 1.5pt solid;font-weight:bold;text-align:center">Three months ended<br/>June 30,</td>
    <td style="padding-bottom:1.5pt;font-weight:bold">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td>&#160;</td>
    <td style="font-weight:bold;padding-bottom:1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom:Black 1.5pt solid;font-weight:bold;text-align:center">2024</td>
    <td style="padding-bottom:1.5pt;font-weight:bold">&#160;</td>
    <td style="font-weight:bold;padding-bottom:1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom:Black 1.5pt solid;font-weight:bold;text-align:center">2023</td>
    <td style="padding-bottom:1.5pt;font-weight:bold">&#160;</td>
    <td style="font-weight:bold;padding-bottom:1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom:Black 1.5pt solid;font-weight:bold;text-align:center">2024</td>
    <td style="padding-bottom:1.5pt;font-weight:bold">&#160;</td>
    <td style="font-weight:bold;padding-bottom:1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom:Black 1.5pt solid;font-weight:bold;text-align:center">2023</td>
    <td style="padding-bottom:1.5pt;font-weight:bold">&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="width:52%;text-align:left;text-indent:-9pt;padding-left:9pt">Net profit (loss) for the period</td>
    <td style="width:1%">&#160;</td>
    <td style="width:1%;text-align:left">$</td>
    <td style="width:9%;text-align:right">(<ix:nonFraction id="Fixv-37835" name="us-gaap:NetIncomeLoss" contextRef="C_20240101to20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">310,793</ix:nonFraction></td>
    <td style="width:1%;text-align:left">)</td>
    <td style="width:1%">&#160;</td>
    <td style="width:1%;text-align:left">$</td>
    <td style="width:9%;text-align:right"><ix:nonFraction id="Fixv-37836" name="us-gaap:NetIncomeLoss" contextRef="C_20230101to20230630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">476,143</ix:nonFraction></td>
    <td style="width:1%;text-align:left">&#160;</td>
    <td style="width:1%">&#160;</td>
    <td style="width:1%;text-align:left">$</td>
    <td style="width:9%;text-align:right">(<ix:nonFraction id="Fixv-37837" name="us-gaap:NetIncomeLoss" contextRef="C_20240401to20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">110,575</ix:nonFraction></td>
    <td style="width:1%;text-align:left">)</td>
    <td style="width:1%">&#160;</td>
    <td style="width:1%;text-align:left">$</td>
    <td style="width:9%;text-align:right"><ix:nonFraction id="Fixv-37838" name="us-gaap:NetIncomeLoss" contextRef="C_20230401to20230630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">162,948</ix:nonFraction></td>
    <td style="width:1%;text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="text-align:left;padding-bottom:1.5pt;text-indent:-9pt;padding-left:9pt">Less &#8211; interest earned on Investment held in Trust
        Account</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right">(<ix:nonFraction id="Fixv-37839" name="us-gaap:InvestmentIncomeInterest" contextRef="C_20240101to20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">149,236</ix:nonFraction></td>
    <td style="padding-bottom:1.5pt;text-align:left">)</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right">(<ix:nonFraction id="Fixv-37840" name="us-gaap:InvestmentIncomeInterest" contextRef="C_20230101to20230630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">1,063,043</ix:nonFraction></td>
    <td style="padding-bottom:1.5pt;text-align:left">)</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right">(<ix:nonFraction id="Fixv-37841" name="us-gaap:InvestmentIncomeInterest" contextRef="C_20240401to20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">75,305</ix:nonFraction></td>
    <td style="padding-bottom:1.5pt;text-align:left">)</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right">(<ix:nonFraction id="Fixv-37842" name="us-gaap:InvestmentIncomeInterest" contextRef="C_20230401to20230630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">318,002</ix:nonFraction></td>
    <td style="padding-bottom:1.5pt;text-align:left">)</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="text-align:left;padding-bottom:1.5pt;text-indent:-9pt;padding-left:9pt">Net loss excluding interest</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">$</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right">(<ix:nonFraction id="Fixv-37843" name="us-gaap:GrossProfit" contextRef="C_20240101to20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">460,029</ix:nonFraction></td>
    <td style="padding-bottom:1.5pt;text-align:left">)</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">$</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right">(<ix:nonFraction id="Fixv-37844" name="us-gaap:GrossProfit" contextRef="C_20230101to20230630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">586,900</ix:nonFraction></td>
    <td style="padding-bottom:1.5pt;text-align:left">)</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">$</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right">(<ix:nonFraction id="Fixv-37845" name="us-gaap:GrossProfit" contextRef="C_20240401to20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">185,880</ix:nonFraction></td>
    <td style="padding-bottom:1.5pt;text-align:left">)</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">$</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right">(<ix:nonFraction id="Fixv-37846" name="us-gaap:GrossProfit" contextRef="C_20230401to20230630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">155,054</ix:nonFraction></td>
    <td style="padding-bottom:1.5pt;text-align:left">)</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="text-indent:-9pt;padding-left:9pt">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="font-weight:bold;text-align:left;text-indent:-9pt;padding-left:9pt">Class A ordinary shares subject to possible redemption:</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="text-indent:-9pt;padding-left:9pt">Numerator:</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="text-align:left;text-indent:-9pt;padding-left:0.25in">Net loss excluding interest</td>
    <td>&#160;</td>
    <td style="text-align:left">$</td>
    <td style="text-align:right">(<ix:nonFraction id="Fixv-37847" name="us-gaap:TemporaryEquityAccretionOfInterest" contextRef="C_20240101to20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_slxnClassAOrdinaryShareSubjectToPossibleRedemptionMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">61,220</ix:nonFraction></td>
    <td style="text-align:left">)</td>
    <td>&#160;</td>
    <td style="text-align:left">$</td>
    <td style="text-align:right">(<ix:nonFraction id="Fixv-37848" name="us-gaap:TemporaryEquityAccretionOfInterest" contextRef="C_20230101to20230630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_slxnClassAOrdinaryShareSubjectToPossibleRedemptionMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">351,654</ix:nonFraction></td>
    <td style="text-align:left">)</td>
    <td>&#160;</td>
    <td style="text-align:left">$</td>
    <td style="text-align:right">(<ix:nonFraction id="Fixv-37849" name="us-gaap:TemporaryEquityAccretionOfInterest" contextRef="C_20240401to20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_slxnClassAOrdinaryShareSubjectToPossibleRedemptionMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">24,737</ix:nonFraction></td>
    <td style="text-align:left">)</td>
    <td>&#160;</td>
    <td style="text-align:left">$</td>
    <td style="text-align:right">(<ix:nonFraction id="Fixv-37850" name="us-gaap:TemporaryEquityAccretionOfInterest" contextRef="C_20230401to20230630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_slxnClassAOrdinaryShareSubjectToPossibleRedemptionMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">67,544</ix:nonFraction></td>
    <td style="text-align:left">)</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="text-align:left;padding-bottom:1.5pt;text-indent:-9pt;padding-left:0.25in">Accretion to Class A ordinary shares subject to possible
        redemption to redemption amount (&#8220;Accretion&#8221;)</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right"><ix:nonFraction id="Fixv-37851" name="us-gaap:TemporaryEquityAccretionToRedemptionValue" contextRef="C_20240101to20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_slxnClassAOrdinaryShareSubjectToPossibleRedemptionMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">226,486</ix:nonFraction></td>
    <td style="padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right"><ix:nonFraction id="Fixv-37852" name="us-gaap:TemporaryEquityAccretionToRedemptionValue" contextRef="C_20230101to20230630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_slxnClassAOrdinaryShareSubjectToPossibleRedemptionMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,463,043</ix:nonFraction></td>
    <td style="padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right"><ix:nonFraction id="Fixv-37853" name="us-gaap:TemporaryEquityAccretionToRedemptionValue" contextRef="C_20240401to20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_slxnClassAOrdinaryShareSubjectToPossibleRedemptionMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">113,930</ix:nonFraction></td>
    <td style="padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right"><ix:nonFraction id="Fixv-37854" name="us-gaap:TemporaryEquityAccretionToRedemptionValue" contextRef="C_20230401to20230630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_slxnClassAOrdinaryShareSubjectToPossibleRedemptionMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">558,002</ix:nonFraction></td>
    <td style="padding-bottom:1.5pt;text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="text-indent:-9pt;padding-left:9pt">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">$</td>
    <td style="text-align:right"><ix:nonFraction id="Fixv-37855" name="us-gaap:TemporaryEquityNetIncome" contextRef="C_20240101to20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_slxnClassAOrdinaryShareSubjectToPossibleRedemptionMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">165,266</ix:nonFraction></td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">$</td>
    <td style="text-align:right"><ix:nonFraction id="Fixv-37856" name="us-gaap:TemporaryEquityNetIncome" contextRef="C_20230101to20230630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_slxnClassAOrdinaryShareSubjectToPossibleRedemptionMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">1,111,389</ix:nonFraction></td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">$</td>
    <td style="text-align:right"><ix:nonFraction id="Fixv-37857" name="us-gaap:TemporaryEquityNetIncome" contextRef="C_20240401to20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_slxnClassAOrdinaryShareSubjectToPossibleRedemptionMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">89,193</ix:nonFraction></td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">$</td>
    <td style="text-align:right"><ix:nonFraction id="Fixv-37858" name="us-gaap:TemporaryEquityNetIncome" contextRef="C_20230401to20230630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_slxnClassAOrdinaryShareSubjectToPossibleRedemptionMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">490,458</ix:nonFraction></td>
    <td style="text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="text-indent:-9pt;padding-left:9pt">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="text-indent:-9pt;padding-left:9pt">Denominator:</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="padding-bottom:1.5pt;text-indent:-9pt;padding-left:0.25in">weighted average number of shares</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right"><ix:nonFraction id="Fixv-37859" name="us-gaap:WeightedAverageNumberOfSharesIssuedBasic" contextRef="C_20240101to20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_slxnClassAOrdinaryShareSubjectToPossibleRedemptionMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">515,019</ix:nonFraction></td>
    <td style="padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right"><ix:nonFraction id="Fixv-37860" name="us-gaap:WeightedAverageNumberOfSharesIssuedBasic" contextRef="C_20230101to20230630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_slxnClassAOrdinaryShareSubjectToPossibleRedemptionMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">5,015,185</ix:nonFraction></td>
    <td style="padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right"><ix:nonFraction id="Fixv-37861" name="us-gaap:WeightedAverageNumberOfSharesIssuedBasic" contextRef="C_20240401to20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_slxnClassAOrdinaryShareSubjectToPossibleRedemptionMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">515,019</ix:nonFraction></td>
    <td style="padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right"><ix:nonFraction id="Fixv-37862" name="us-gaap:WeightedAverageNumberOfSharesIssuedBasic" contextRef="C_20230401to20230630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_slxnClassAOrdinaryShareSubjectToPossibleRedemptionMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">2,589,567</ix:nonFraction></td>
    <td style="padding-bottom:1.5pt;text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="text-indent:-9pt;padding-left:9pt">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="font-weight:bold;text-align:left;padding-bottom:4pt;text-indent:-9pt;padding-left:9pt">Net profit per Class A ordinary share subject
        to possible redemption &#8211; basic and diluted</td>
    <td style="padding-bottom:4pt">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:left">$</td>
    <td style="border-bottom:Black 4pt double;text-align:right"><ix:nonFraction id="Fixv-37863" name="us-gaap:EarningsPerShareBasic" contextRef="C_20240101to20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_slxnClassAOrdinaryShareSubjectToPossibleRedemptionMember" unitRef="usdPershares" scale="0" decimals="2" format="ixt:num-dot-decimal">0.32</ix:nonFraction></td>
    <td style="padding-bottom:4pt;text-align:left">&#160;</td>
    <td style="padding-bottom:4pt">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:left">$</td>
    <td style="border-bottom:Black 4pt double;text-align:right"><ix:nonFraction id="Fixv-37864" name="us-gaap:EarningsPerShareBasic" contextRef="C_20230101to20230630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_slxnClassAOrdinaryShareSubjectToPossibleRedemptionMember" unitRef="usdPershares" scale="0" decimals="2" format="ixt:num-dot-decimal">0.22</ix:nonFraction></td>
    <td style="padding-bottom:4pt;text-align:left">&#160;</td>
    <td style="padding-bottom:4pt">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:left">$</td>
    <td style="border-bottom:Black 4pt double;text-align:right"><ix:nonFraction id="Fixv-37865" name="us-gaap:EarningsPerShareBasic" contextRef="C_20240401to20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_slxnClassAOrdinaryShareSubjectToPossibleRedemptionMember" unitRef="usdPershares" scale="0" decimals="2" format="ixt:num-dot-decimal">0.17</ix:nonFraction></td>
    <td style="padding-bottom:4pt;text-align:left">&#160;</td>
    <td style="padding-bottom:4pt">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:left">$</td>
    <td style="border-bottom:Black 4pt double;text-align:right"><ix:nonFraction id="Fixv-37866" name="us-gaap:EarningsPerShareBasic" contextRef="C_20230401to20230630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_slxnClassAOrdinaryShareSubjectToPossibleRedemptionMember" unitRef="usdPershares" scale="0" decimals="2" format="ixt:num-dot-decimal">0.19</ix:nonFraction></td>
    <td style="padding-bottom:4pt;text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="text-indent:-9pt;padding-left:9pt">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="font-weight:bold;text-align:left;text-indent:-9pt;padding-left:9pt">Non-redeemable Class A and B ordinary shares:</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="text-indent:-9pt;padding-left:9pt">Numerator:</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="text-align:left;text-indent:-9pt;padding-left:0.25in">Net loss excluding interest</td>
    <td>&#160;</td>
    <td style="text-align:left">$</td>
    <td style="text-align:right">(<ix:nonFraction id="Fixv-37867" name="us-gaap:TemporaryEquityAccretionOfInterest" contextRef="C_20240101to20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_slxnNonredeemableClassAandBOrdinaryShareMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">398,809</ix:nonFraction></td>
    <td style="text-align:left">)</td>
    <td>&#160;</td>
    <td style="text-align:left">$</td>
    <td style="text-align:right">(<ix:nonFraction id="Fixv-37868" name="us-gaap:TemporaryEquityAccretionOfInterest" contextRef="C_20230101to20230630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_slxnNonredeemableClassAandBOrdinaryShareMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">235,246</ix:nonFraction></td>
    <td style="text-align:left">)</td>
    <td>&#160;</td>
    <td style="text-align:left">$</td>
    <td style="text-align:right">(<ix:nonFraction id="Fixv-37869" name="us-gaap:TemporaryEquityAccretionOfInterest" contextRef="C_20240401to20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_slxnNonredeemableClassAandBOrdinaryShareMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">161,143</ix:nonFraction></td>
    <td style="text-align:left">)</td>
    <td>&#160;</td>
    <td style="text-align:left">$</td>
    <td style="text-align:right">(<ix:nonFraction id="Fixv-37870" name="us-gaap:TemporaryEquityAccretionOfInterest" contextRef="C_20230401to20230630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_slxnNonredeemableClassAandBOrdinaryShareMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">87,510</ix:nonFraction></td>
    <td style="text-align:left">)</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="padding-bottom:1.5pt;text-indent:-9pt;padding-left:0.25in">Accretion</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right">(<ix:nonFraction id="Fixv-37871" name="slxn:Accretion" contextRef="C_20240101to20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_slxnNonredeemableClassAandBOrdinaryShareMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">77,250</ix:nonFraction></td>
    <td style="padding-bottom:1.5pt;text-align:left">)</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right">(<ix:nonFraction id="Fixv-37872" name="slxn:Accretion" contextRef="C_20230101to20230630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_slxnNonredeemableClassAandBOrdinaryShareMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">400,000</ix:nonFraction></td>
    <td style="padding-bottom:1.5pt;text-align:left">)</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right">(<ix:nonFraction id="Fixv-37873" name="slxn:Accretion" contextRef="C_20240401to20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_slxnNonredeemableClassAandBOrdinaryShareMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">38,625</ix:nonFraction></td>
    <td style="padding-bottom:1.5pt;text-align:left">)</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right">(<ix:nonFraction id="Fixv-37874" name="slxn:Accretion" contextRef="C_20230401to20230630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_slxnNonredeemableClassAandBOrdinaryShareMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">240,000</ix:nonFraction></td>
    <td style="padding-bottom:1.5pt;text-align:left">)</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="text-indent:-9pt;padding-left:9pt">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">(<ix:nonFraction id="Fixv-37875" name="us-gaap:TemporaryEquityNetIncome" contextRef="C_20240101to20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_slxnNonredeemableClassAandBOrdinaryShareMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">476,059</ix:nonFraction></td>
    <td style="text-align:left">)</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">(<ix:nonFraction id="Fixv-37876" name="us-gaap:TemporaryEquityNetIncome" contextRef="C_20230101to20230630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_slxnNonredeemableClassAandBOrdinaryShareMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">635,246</ix:nonFraction></td>
    <td style="text-align:left">)</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">(<ix:nonFraction id="Fixv-37877" name="us-gaap:TemporaryEquityNetIncome" contextRef="C_20240401to20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_slxnNonredeemableClassAandBOrdinaryShareMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">199,768</ix:nonFraction></td>
    <td style="text-align:left">)</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">(<ix:nonFraction id="Fixv-37878" name="us-gaap:TemporaryEquityNetIncome" contextRef="C_20230401to20230630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_slxnNonredeemableClassAandBOrdinaryShareMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">327,510</ix:nonFraction></td>
    <td style="text-align:left">)</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="text-indent:-9pt;padding-left:9pt">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="text-indent:-9pt;padding-left:9pt">Denominator:</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="padding-bottom:1.5pt;text-indent:-9pt;padding-left:0.25in">weighted average number of shares</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right"><ix:nonFraction id="Fixv-37879" name="us-gaap:WeightedAverageNumberOfSharesIssuedBasic" contextRef="C_20240101to20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_slxnNonredeemableClassAandBOrdinaryShareMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">3,355,000</ix:nonFraction></td>
    <td style="padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right"><ix:nonFraction id="Fixv-37880" name="us-gaap:WeightedAverageNumberOfSharesIssuedBasic" contextRef="C_20230101to20230630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_slxnNonredeemableClassAandBOrdinaryShareMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">3,355,000</ix:nonFraction></td>
    <td style="padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right"><ix:nonFraction id="Fixv-37881" name="us-gaap:WeightedAverageNumberOfSharesIssuedBasic" contextRef="C_20240401to20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_slxnNonredeemableClassAandBOrdinaryShareMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">3,355,000</ix:nonFraction></td>
    <td style="padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right"><ix:nonFraction id="Fixv-37882" name="us-gaap:WeightedAverageNumberOfSharesIssuedBasic" contextRef="C_20230401to20230630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_slxnNonredeemableClassAandBOrdinaryShareMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">3,355,000</ix:nonFraction></td>
    <td style="padding-bottom:1.5pt;text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="text-indent:-9pt;padding-left:9pt">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="font-weight:bold;text-align:left;padding-bottom:4pt;text-indent:-9pt;padding-left:9pt">Net loss per non-redeemable Class A and
        B ordinary share &#8211; basic and diluted</td>
    <td style="padding-bottom:4pt">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:left">$</td>
    <td style="border-bottom:Black 4pt double;text-align:right">(<ix:nonFraction id="Fixv-37883" name="us-gaap:EarningsPerShareBasic" contextRef="C_20240101to20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_slxnNonredeemableClassAandBOrdinaryShareMember" unitRef="usdPershares" scale="0" decimals="2" format="ixt:num-dot-decimal" sign="-">0.14</ix:nonFraction></td>
    <td style="padding-bottom:2.5pt;text-align:left">)</td>
    <td style="padding-bottom:4pt">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:left">$</td>
    <td style="border-bottom:Black 4pt double;text-align:right">(<ix:nonFraction id="Fixv-37884" name="us-gaap:EarningsPerShareBasic" contextRef="C_20230101to20230630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_slxnNonredeemableClassAandBOrdinaryShareMember" unitRef="usdPershares" scale="0" decimals="2" format="ixt:num-dot-decimal" sign="-">0.19</ix:nonFraction></td>
    <td style="padding-bottom:2.5pt;text-align:left">)</td>
    <td style="padding-bottom:4pt">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:left">$</td>
    <td style="border-bottom:Black 4pt double;text-align:right">(<ix:nonFraction id="Fixv-37885" name="us-gaap:EarningsPerShareBasic" contextRef="C_20240401to20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_slxnNonredeemableClassAandBOrdinaryShareMember" unitRef="usdPershares" scale="0" decimals="2" format="ixt:num-dot-decimal" sign="-">0.06</ix:nonFraction></td>
    <td style="padding-bottom:2.5pt;text-align:left">)</td>
    <td style="padding-bottom:4pt">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:left">$</td>
    <td style="border-bottom:Black 4pt double;text-align:right">(<ix:nonFraction id="Fixv-37886" name="us-gaap:EarningsPerShareBasic" contextRef="C_20230401to20230630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_slxnNonredeemableClassAandBOrdinaryShareMember" unitRef="usdPershares" scale="0" decimals="2" format="ixt:num-dot-decimal" sign="-">0.10</ix:nonFraction></td>
    <td style="padding-bottom:2.5pt;text-align:left">)</td> </tr>
  </table> </div> </div> </ix:nonNumeric>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 42.55pt;text-align:justify">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.75in;text-align:left">The potential exercise of <ix:nonFraction id="Fixv-37887" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="C_20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapClassOfWarrantOrRightAxis_slxnPublicWarrantsMember" unitRef="shares" scale="0" decimals="0" format="ixt:num-dot-decimal">5,750,000</ix:nonFraction>
Public Warrants and <ix:nonFraction id="Fixv-37888" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="C_20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapClassOfWarrantOrRightAxis_slxnPrivateWarrantsMember" unitRef="shares" scale="0" decimals="0" format="ixt:num-dot-decimal">190,000</ix:nonFraction>
Private Warrants sold in the Public Offering and Private Placements as detailed in Note 3 into <ix:nonFraction id="Fixv-37889" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="C_20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="shares" scale="0" decimals="0" format="ixt:num-dot-decimal">5,940,000</ix:nonFraction>
shares has not been included in the calculation of diluted net profit (loss) per share, since the exercise of the warrants is contingent
upon the occurrence of a future event.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 42.55pt;text-align:justify">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.75in;text-align:left">Additionally, the effect of the conversion
of the Second, Third, Fourth and Fifth Promissory Notes into an aggregate amount of <ix:nonFraction id="Fixv-37890" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="C_20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_srtTitleOfIndividualAxis_slxnSecondThirdForthAndFifthPromissoryNotesMember_usgaapDerivativeInstrumentRiskAxis_slxnPrivateWarrantsMember" unitRef="shares" scale="0" decimals="0" format="ixt:num-dot-decimal">1,500,000</ix:nonFraction>
private warrants (exercisable into <ix:nonFraction id="Fixv-37891" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="C_20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_srtTitleOfIndividualAxis_slxnSecondThirdForthAndFifthPromissoryNotesMember" unitRef="shares" scale="0" decimals="0" format="ixt:num-dot-decimal">1,500,000</ix:nonFraction>
shares) as detailed in Note 4, has not been included in the calculation of diluted net profit (loss) per share, since the conversion of
the abovementioned promissory notes is contingent upon the occurrence of a future event.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 42.55pt;text-align:justify">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.75in;text-align:left">As a result, diluted net profit (loss) per
share is the same as basic net profit (loss) per share for each of the periods presented, and for each class.</p> </ix:nonNumeric>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center">&#160;</p>

<div style="margin-top:12pt;margin-bottom:6pt;border-bottom:Black 1.5pt solid">

<p style="font:10pt Times New Roman, Times, Serif;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">F-20</span></p>
</div>

<div style="break-before:page;margin-top:6pt;margin-bottom:12pt">

<p style="margin:0pt">&#160;</p> </div>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, serif;margin:10pt 0px 0pt;text-align:center"><strong>MORINGA ACQUISITION CORP</strong></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center">(CONTINUED)</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p> </div>

<div style="font:10pt Times New Roman, Times, Serif"> <ix:nonNumeric id="Fixv-19308" name="us-gaap:SubsequentEventsTextBlock" contextRef="C_20240101to20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" escape="true">

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0"><span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"><strong style="margin-top:0pt;margin-bottom:0pt">NOTE
9 - SUBSEQUENT EVENTS:</strong></span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font:10pt Times New Roman, Times, Serif;margin-top:0pt;margin-bottom:0pt" width="100%">
  <tr style="vertical-align:top">
    <td style="width:0.75in">&#160;</td>
    <td style="width:18pt"><strong>a.</strong></td>
    <td><strong>Additional withdrawals under the Promissory Notes</strong></td> </tr>
  </table>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 42.55pt;text-align:justify">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in;text-align:left">Since the balance sheet date and up until the
filing date of these financial statements, an aggregate amount of $<ix:nonFraction id="Fixv-37892" name="slxn:AggregateWithdrawnAmount" contextRef="C_20240101to20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapFinancialInstrumentAxis_slxnTenthPromissoryNoteMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">62</ix:nonFraction>
thousand has been withdrawn under the Tenth Promissory Note, and a final injection into the trust account of approximately $<ix:nonFraction id="Fixv-37893" name="slxn:AggregateWithdrawnAmount" contextRef="C_20240101to20240630_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapFinancialInstrumentAxis_slxnEighthPromissoryNoteMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">13</ix:nonFraction>
thousand has been withdrawn under the Eighth Promissory Note &#8211; rendering the latter fully withdrawn.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 60.55pt;text-align:justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font:10pt Times New Roman, Times, Serif;margin-top:0pt;margin-bottom:0pt" width="100%">
  <tr style="vertical-align:top">
    <td style="width:0.75in">&#160;</td>
    <td style="width:18pt"><strong>b.</strong></td>
    <td style="text-align:left"><strong>Extraordinary General Meeting and redemption of Class A ordinary shares subject to possible redemption</strong></td>
        </tr>
  </table>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.75in;text-align:justify">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in;text-align:left">On August 6, 2024 the Extraordinary General Meeting
has approved the proposed business combination with Silexion. In connection with the meeting, an additional <ix:nonFraction id="Fixv-37894" name="us-gaap:TemporaryEquitySharesOutstanding" contextRef="C_20240806_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_srtStatementScenarioAxis_srtScenarioForecastMember_usgaapStatementClassOfStockAxis_slxnClassAOrdinarySharesSubjectToPossibleRedemptionMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">427,297</ix:nonFraction>
Class A ordinary shares subject to possible redemption have been redeemed. Consequently, $<ix:nonFraction id="Fixv-37895" name="slxn:AmountWithdrawnFromTrustAccount" contextRef="C_20240806_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_srtStatementScenarioAxis_srtScenarioForecastMember" unitRef="usd" scale="6" decimals="-5" format="ixt:num-dot-decimal">4.8</ix:nonFraction>
million has been withdrawn from the trust account.</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 60.55pt;text-align:justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font:10pt Times New Roman, Times, Serif;margin-top:0pt;margin-bottom:0pt" width="100%">
  <tr style="vertical-align:top">
    <td style="width:0.75in">&#160;</td>
    <td style="width:18pt"><strong>c.</strong></td>
    <td><strong>Advisory and Placement Agent Agreement with Cohen &amp; Company</strong></td> </tr>
  </table>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify"><strong>&#160;</strong></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in;text-align:left">On July 29, 2024 the Company has entered into
agreement with Cohen &amp; Company, for providing capital markets advisory and placement agent services, in connection with both (i) the
completion of the proposed business combination with Silexion, and (ii) a private placement of equity, equity-linked, convertible and
/ or debt securities to be consummated with the business combination.</p> </ix:nonNumeric>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify"><strong>&#160;</strong></p>

<div style="margin-top:12pt;margin-bottom:6pt;border-bottom:Black 1.5pt solid">

<p style="font:10pt Times New Roman, Times, Serif;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">F-21</span></p>
</div>

<div style="break-before:page;margin-top:6pt;margin-bottom:12pt">

<p style="margin:0pt">&#160;</p> </div>

<p style="font:10pt Times New Roman, Times, Serif;margin-top:0pt;margin-right:0;margin-bottom:0pt;text-align:left"><strong>&#160;</strong></p>

<p style="font:10pt Times New Roman, Times, Serif;margin-top:0pt;margin-right:0;margin-bottom:0pt;text-align:left">&#160;</p>

<div><span id="f_006"></span></div> </div>

<div style="font:10pt Times New Roman, Times, Serif">

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt"><strong>Report
of Independent Registered Public Accounting Firm</strong></span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">&#160;</span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">To
the Board of Directors and Shareholders of Moringa Acquisition Corp</span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt"><strong><i>&#160;</i></strong></span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt"><strong><i>Opinion
on the Financial Statements</i></strong></span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-indent:0.25in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">We
have audited the accompanying balance sheets of Moringa Acquisition Corp (the &#8220;Company&#8221;) as of December&#160;31, 2023 and
2022, and the related statements of operations, changes in capital deficiency and cash flows for each of the two&#160;years in the period
ended December&#160;31, 2023, including the related notes (collectively referred to as the &#8220;financial statements&#8221;). In our
opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December&#160;31,
2023 and 2022, and the results of its operations and its cash flows for each of the two&#160;years in the period ended December&#160;31,
2023 in conformity with accounting principles generally accepted in the United&#160;States of America.</span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-indent:0.25in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt"><i>&#160;</i></span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt"><i>Substantial
Doubt about the Company&#8217;s Ability to Continue as a Going Concern</i></span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-indent:0.25in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">The
accompanying financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note&#160;1(e)&#160;to
the financial statements, the Company has limited cash and has incurred losses since inception. Moreover, if the Company is unable to
complete a business combination by August&#160;19, 2024 then the Company will cease all operations except for the purpose of liquidating.
These matters raise substantial doubt about the Company&#8217;s ability to continue as a going concern. Management&#8217;s plans in regard
to these matters are also described in Note&#160;1(e). The financial statements do not include any adjustments that might result from
the outcome of this uncertainty.</span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt"><strong><i>&#160;</i></strong></span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt"><strong><i>Basis
for Opinion</i></strong></span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-indent:0.25in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">These
financial statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on the Company&#8217;s
financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board
(United&#160;States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S.&#160;federal securities
laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-indent:24pt">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-indent:0.25in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">We
conducted our audits of these financial statements in accordance with the standards of the PCAOB.&#160;Those standards require that we
plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether
due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial
reporting. As part of our audits we are required to obtain an understanding of internal control over financial reporting but not for the
purpose of expressing an opinion on the effectiveness of the Company&#8217;s internal control over financial reporting. Accordingly, we
express no such opinion.</span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-indent:24pt"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">&#160;</span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-indent:0.25in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">Our
audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or
fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding
the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant
estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide
a reasonable basis for our opinion.</span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-indent:24pt">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">/s/&#160;Kesselman&#160;&amp;
Kesselman &#160;</span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin-top:0pt;margin-bottom:0pt">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">Certified
Public Accountants (Isr.)<br/>A member firm of PricewaterhouseCoopers International Limited</span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">&#160;</span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">Tel-Aviv,
Israel<br/>April&#160;1, 2024</span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">&#160;</span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">We
have served as the Company&#8217;s auditor since 2020.</span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">&#160;</span></p>

<div style="margin-top:12pt;margin-bottom:6pt;border-bottom:Black 1.5pt solid">

<p style="font:10pt Times New Roman, Times, Serif;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">F-22</span></p></div>

<div style="break-before:page;margin-top:6pt;margin-bottom:12pt">

<p style="margin:0pt">&#160;</p></div>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt"><strong>&#160;</strong></span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center">&#160;</p></div>

<div style="font:10pt Times New Roman, Times, Serif">

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center"><span id="f_007"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><strong>MORINGA
ACQUISITION CORP</strong></span></span></span></span><br/><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><strong>BALANCE
SHEETS</strong></span></span></span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><strong>&#160;</strong></span></span></span></p>

<table cellpadding="0" cellspacing="0" style="width:100%">
  <tr style="vertical-align:bottom">
    <td>&#160;</td>
    <td style="font-weight:bold;padding-bottom:1.5pt">&#160;</td>
    <td style="font-weight:bold;text-align:center;border-bottom:Black 1.5pt solid"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Note</span></span></td>
    <td style="font-weight:bold;padding-bottom:1.5pt">&#160;</td>
    <td colspan="2" style="font-weight:bold;text-align:center;border-bottom:Black 1.5pt solid"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">December&#160;31,<br/>2023</span></span></td>
    <td style="padding-bottom:1.5pt;font-weight:bold">&#160;</td>
    <td style="font-weight:bold;padding-bottom:1.5pt">&#160;</td>
    <td colspan="2" style="font-weight:bold;text-align:center;border-bottom:Black 1.5pt solid"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">December&#160;31,<br/>2022</span></span></td>
    <td style="padding-bottom:1.5pt;font-weight:bold">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td>&#160;</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td>&#160;</td>
    <td style="font-weight:bold;padding-bottom:1.5pt">&#160;</td>
    <td colspan="6" style="font-weight:bold;text-align:center;border-bottom:Black 1.5pt solid"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">U.S.&#160;Dollars</span></span></td>
    <td style="padding-bottom:1.5pt;font-weight:bold">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="font-weight:bold;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Assets</span></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">ASSETS:</span></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="text-align:left;text-indent:-0.125in;padding-left:0.25in;width:64%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Cash
        and cash equivalents</span></span></td>
    <td style="width:1%">&#160;</td>
    <td style="text-align:center;width:11%">&#160;</td>
    <td style="width:1%">&#160;</td>
    <td style="text-align:left;width:1%">&#160;</td>
    <td style="text-align:right;width:9%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fixv-37896" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="C_20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">108,278</ix:nonFraction></span></span></td>
    <td style="text-align:left;width:1%">&#160;</td>
    <td style="width:1%">&#160;</td>
    <td style="text-align:left;width:1%">&#160;</td>
    <td style="text-align:right;width:9%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fixv-37897" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="C_20221231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">59,714</ix:nonFraction></span></span></td>
    <td style="text-align:left;width:1%">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="text-align:left;text-indent:-0.125in;padding-left:0.25in;width:64%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Investments
        held in Trust Account</span></span></td>
    <td style="width:1%">&#160;</td>
    <td style="text-align:center;width:11%">&#160;</td>
    <td style="width:1%">&#160;</td>
    <td style="text-align:left;width:1%">&#160;</td>
    <td style="text-align:right;width:9%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fixv-37898" name="us-gaap:AssetsHeldInTrust" contextRef="C_20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,697,632</ix:nonFraction></span></span></td>
    <td style="text-align:left;width:1%">&#160;</td>
    <td style="width:1%">&#160;</td>
    <td style="text-align:left;width:1%">&#160;</td>
    <td style="text-align:right;width:9%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fixv-37899" name="us-gaap:AssetsHeldInTrust" contextRef="C_20221231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">116,692,038</ix:nonFraction></span></span></td>
    <td style="text-align:left;width:1%">&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="text-align:left;padding-bottom:1.5pt;text-indent:-0.125in;padding-left:0.25in;width:64%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Prepaid
        expenses</span></span></td>
    <td style="padding-bottom:1.5pt;width:1%">&#160;</td>
    <td style="text-align:center;padding-bottom:1.5pt;width:11%">&#160;</td>
    <td style="padding-bottom:1.5pt;width:1%">&#160;</td>
    <td style="border-bottom:1.5pt solid black;text-align:left;width:1%">&#160;</td>
    <td style="border-bottom:1.5pt solid black;text-align:right;width:9%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fixv-37900" name="us-gaap:PrepaidExpenseCurrent" contextRef="C_20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">28,305</ix:nonFraction></span></span></td>
    <td style="padding-bottom:1.5pt;text-align:left;width:1%">&#160;</td>
    <td style="padding-bottom:1.5pt;width:1%">&#160;</td>
    <td style="border-bottom:1.5pt solid black;text-align:left;width:1%">&#160;</td>
    <td style="border-bottom:1.5pt solid black;text-align:right;width:9%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fixv-37901" name="us-gaap:PrepaidExpenseCurrent" contextRef="C_20221231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">43,853</ix:nonFraction></span></span></td>
    <td style="padding-bottom:1.5pt;text-align:left;width:1%">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="font-weight:bold;text-align:left;text-indent:-0.125in;padding-left:0.25in;width:64%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">TOTAL
        ASSETS</span></span></td>
    <td style="width:1%">&#160;</td>
    <td style="text-align:center;width:11%">&#160;</td>
    <td style="width:1%">&#160;</td>
    <td style="text-align:left;width:1%">&#160;</td>
    <td style="text-align:right;width:9%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fixv-37902" name="us-gaap:Assets" contextRef="C_20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,834,215</ix:nonFraction></span></span></td>
    <td style="text-align:left;width:1%">&#160;</td>
    <td style="width:1%">&#160;</td>
    <td style="text-align:left;width:1%">&#160;</td>
    <td style="text-align:right;width:9%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fixv-37903" name="us-gaap:Assets" contextRef="C_20221231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">116,795,605</ix:nonFraction></span></span></td>
    <td style="text-align:left;width:1%">&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="text-indent:-0.125in;padding-left:0.125in;width:64%">&#160;</td>
    <td style="width:1%">&#160;</td>
    <td style="text-align:center;width:11%">&#160;</td>
    <td style="width:1%">&#160;</td>
    <td style="text-align:left;width:1%">&#160;</td>
    <td style="text-align:right;width:9%">&#160;</td>
    <td style="text-align:left;width:1%">&#160;</td>
    <td style="width:1%">&#160;</td>
    <td style="text-align:left;width:1%">&#160;</td>
    <td style="text-align:right;width:9%">&#160;</td>
    <td style="text-align:left;width:1%">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="font-weight:bold;text-align:center;text-indent:-0.125in;padding-left:0.125in;width:64%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Liabilities
        and shares subject to possible redemption<br/>net of capital deficiency</span></span></td>
    <td style="width:1%">&#160;</td>
    <td style="text-align:center;width:11%">&#160;</td>
    <td style="width:1%">&#160;</td>
    <td style="text-align:left;width:1%">&#160;</td>
    <td style="text-align:right;width:9%">&#160;</td>
    <td style="text-align:left;width:1%">&#160;</td>
    <td style="width:1%">&#160;</td>
    <td style="text-align:left;width:1%">&#160;</td>
    <td style="text-align:right;width:9%">&#160;</td>
    <td style="text-align:left;width:1%">&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="font-weight:bold;text-indent:-0.125in;padding-left:0.125in;width:64%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">LIABILITIES:</span></span></td>
    <td style="width:1%">&#160;</td>
    <td style="text-align:center;width:11%">&#160;</td>
    <td style="width:1%">&#160;</td>
    <td style="text-align:left;width:1%">&#160;</td>
    <td style="text-align:right;width:9%">&#160;</td>
    <td style="text-align:left;width:1%">&#160;</td>
    <td style="width:1%">&#160;</td>
    <td style="text-align:left;width:1%">&#160;</td>
    <td style="text-align:right;width:9%">&#160;</td>
    <td style="text-align:left;width:1%">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="text-align:left;text-indent:-0.125in;padding-left:0.25in;width:64%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Accrued
        expenses</span></span></td>
    <td style="width:1%">&#160;</td>
    <td style="text-align:center;width:11%">&#160;</td>
    <td style="width:1%">&#160;</td>
    <td style="text-align:left;width:1%">&#160;</td>
    <td style="text-align:right;width:9%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fixv-37904" name="us-gaap:OtherAccountsPayableAndAccruedLiabilities" contextRef="C_20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">115,560</ix:nonFraction></span></span></td>
    <td style="text-align:left;width:1%">&#160;</td>
    <td style="width:1%">&#160;</td>
    <td style="text-align:left;width:1%">&#160;</td>
    <td style="text-align:right;width:9%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fixv-37905" name="us-gaap:OtherAccountsPayableAndAccruedLiabilities" contextRef="C_20221231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">86,688</ix:nonFraction></span></span></td>
    <td style="text-align:left;width:1%">&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="text-align:left;text-indent:-0.125in;padding-left:0.25in;width:64%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Related
        party</span></span></td>
    <td style="width:1%">&#160;</td>
    <td style="text-align:center;width:11%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">4</span></span></td>
    <td style="width:1%">&#160;</td>
    <td style="text-align:left;width:1%">&#160;</td>
    <td style="text-align:right;width:9%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fixv-37906" name="us-gaap:NotesPayableCurrent" contextRef="C_20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,861,000</ix:nonFraction></span></span></td>
    <td style="text-align:left;width:1%">&#160;</td>
    <td style="width:1%">&#160;</td>
    <td style="text-align:left;width:1%">&#160;</td>
    <td style="text-align:right;width:9%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fixv-37907" name="us-gaap:NotesPayableCurrent" contextRef="C_20221231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,190,000</ix:nonFraction></span></span></td>
    <td style="text-align:left;width:1%">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="text-align:left;padding-bottom:1.5pt;text-indent:-0.125in;padding-left:0.25in;width:64%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Private
        warrant liability</span></span></td>
    <td style="padding-bottom:1.5pt;width:1%">&#160;</td>
    <td style="text-align:center;padding-bottom:1.5pt;width:11%">&#160;</td>
    <td style="padding-bottom:1.5pt;width:1%">&#160;</td>
    <td style="border-bottom:1.5pt solid black;text-align:left;width:1%">&#160;</td>
    <td style="border-bottom:1.5pt solid black;text-align:right;width:9%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fixv-37908" name="us-gaap:WarrantsAndRightsOutstanding" contextRef="C_20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,531</ix:nonFraction></span></span></td>
    <td style="padding-bottom:1.5pt;text-align:left;width:1%">&#160;</td>
    <td style="padding-bottom:1.5pt;width:1%">&#160;</td>
    <td style="border-bottom:1.5pt solid black;text-align:left;width:1%">&#160;</td>
    <td style="border-bottom:1.5pt solid black;text-align:right;width:9%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fixv-37909" name="us-gaap:WarrantsAndRightsOutstanding" contextRef="C_20221231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">29,640</ix:nonFraction></span></span></td>
    <td style="padding-bottom:1.5pt;text-align:left;width:1%">&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="font-weight:bold;text-align:left;padding-bottom:1.5pt;text-indent:-0.125in;padding-left:0.25in;width:64%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">TOTAL
        LIABILITIES</span></span></td>
    <td style="padding-bottom:1.5pt;width:1%">&#160;</td>
    <td style="text-align:center;padding-bottom:1.5pt;width:11%">&#160;</td>
    <td style="padding-bottom:1.5pt;width:1%">&#160;</td>
    <td style="border-bottom:1.5pt solid black;text-align:left;width:1%">&#160;</td>
    <td style="border-bottom:1.5pt solid black;text-align:right;width:9%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fixv-37910" name="us-gaap:Liabilities" contextRef="C_20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,985,091</ix:nonFraction></span></span></td>
    <td style="padding-bottom:1.5pt;text-align:left;width:1%">&#160;</td>
    <td style="padding-bottom:1.5pt;width:1%">&#160;</td>
    <td style="border-bottom:1.5pt solid black;text-align:left;width:1%">&#160;</td>
    <td style="border-bottom:1.5pt solid black;text-align:right;width:9%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fixv-37911" name="us-gaap:Liabilities" contextRef="C_20221231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,306,328</ix:nonFraction></span></span></td>
    <td style="padding-bottom:1.5pt;text-align:left;width:1%">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="text-indent:-0.125in;padding-left:0.125in;width:64%">&#160;</td>
    <td style="width:1%">&#160;</td>
    <td style="text-align:center;width:11%">&#160;</td>
    <td style="width:1%">&#160;</td>
    <td style="text-align:left;width:1%">&#160;</td>
    <td style="text-align:right;width:9%">&#160;</td>
    <td style="text-align:left;width:1%">&#160;</td>
    <td style="width:1%">&#160;</td>
    <td style="text-align:left;width:1%">&#160;</td>
    <td style="text-align:right;width:9%">&#160;</td>
    <td style="text-align:left;width:1%">&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="font-weight:bold;text-align:left;padding-bottom:1.5pt;text-indent:-0.125in;padding-left:0.125in;width:64%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">COMMITMENTS
        AND CONTINGENCIES</span></span></td>
    <td style="padding-bottom:1.5pt;width:1%">&#160;</td>
    <td style="text-align:center;padding-bottom:1.5pt;width:11%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">5</span></span></td>
    <td style="padding-bottom:1.5pt;width:1%">&#160;</td>
    <td style="border-bottom:1.5pt solid black;text-align:left;width:1%">&#160;</td>
    <td style="border-bottom:1.5pt solid black;text-align:right;width:9%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20241003060205872_ixv-37910" name="us-gaap:CommitmentsAndContingencies" contextRef="C_20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></td>
    <td style="padding-bottom:1.5pt;text-align:left;width:1%">&#160;</td>
    <td style="padding-bottom:1.5pt;width:1%">&#160;</td>
    <td style="border-bottom:1.5pt solid black;text-align:left;width:1%">&#160;</td>
    <td style="border-bottom:1.5pt solid black;text-align:right;width:9%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20241003060205872_ixv-37911" name="us-gaap:CommitmentsAndContingencies" contextRef="C_20221231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></td>
    <td style="padding-bottom:1.5pt;text-align:left;width:1%">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="text-indent:-0.125in;padding-left:0.125in;width:64%">&#160;</td>
    <td style="width:1%">&#160;</td>
    <td style="text-align:center;width:11%">&#160;</td>
    <td style="width:1%">&#160;</td>
    <td style="text-align:left;width:1%">&#160;</td>
    <td style="text-align:right;width:9%">&#160;</td>
    <td style="text-align:left;width:1%">&#160;</td>
    <td style="width:1%">&#160;</td>
    <td style="text-align:left;width:1%">&#160;</td>
    <td style="text-align:right;width:9%">&#160;</td>
    <td style="text-align:left;width:1%">&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="font-weight:bold;text-align:left;padding-bottom:1.5pt;text-indent:-0.125in;padding-left:0.125in;width:64%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">CLASS
        A ORDINARY SHARES SUBJECT TO POSSIBLE&#160;REDEMPTION:&#160;<ix:nonFraction id="Fixv-37912" name="us-gaap:TemporaryEquitySharesOutstanding" contextRef="C_20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_usgaapCommonClassAMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">515,019</ix:nonFraction>&#160;and&#160;<ix:nonFraction id="Fxbrl_20241004141149130" name="us-gaap:TemporaryEquitySharesOutstanding" contextRef="C_20221231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_usgaapCommonClassAMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">11,500,000</ix:nonFraction>&#160;shares
        at redemption value $<ix:nonFraction id="Fixv-37914" name="us-gaap:TemporaryEquityParOrStatedValuePerShare" contextRef="C_20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_usgaapCommonClassAMember" unitRef="usdPershares" scale="0" decimals="2" format="ixt:num-dot-decimal">11.06</ix:nonFraction>&#160;and
        $<ix:nonFraction id="Fixv-37915" name="us-gaap:TemporaryEquityParOrStatedValuePerShare" contextRef="C_20221231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_usgaapCommonClassAMember" unitRef="usdPershares" scale="0" decimals="2" format="ixt:num-dot-decimal">10.15</ix:nonFraction>&#160;as
        of December&#160;31, 2023 and 2022, respectively</span></span></td>
    <td style="padding-bottom:1.5pt;width:1%">&#160;</td>
    <td style="text-align:center;padding-bottom:1.5pt;width:11%">&#160;</td>
    <td style="padding-bottom:1.5pt;width:1%">&#160;</td>
    <td style="border-bottom:1.5pt solid black;text-align:left;width:1%">&#160;</td>
    <td style="border-bottom:1.5pt solid black;text-align:right;width:9%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fixv-37916" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" contextRef="C_20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_usgaapCommonClassAMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,697,632</ix:nonFraction></span></span></td>
    <td style="padding-bottom:1.5pt;text-align:left;width:1%">&#160;</td>
    <td style="padding-bottom:1.5pt;width:1%">&#160;</td>
    <td style="border-bottom:1.5pt solid black;text-align:left;width:1%">&#160;</td>
    <td style="border-bottom:1.5pt solid black;text-align:right;width:9%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fixv-37917" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" contextRef="C_20221231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_usgaapCommonClassAMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">116,692,038</ix:nonFraction></span></span></td>
    <td style="padding-bottom:1.5pt;text-align:left;width:1%">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="text-indent:-0.125in;padding-left:0.125in;width:64%">&#160;</td>
    <td style="width:1%">&#160;</td>
    <td style="text-align:center;width:11%">&#160;</td>
    <td style="width:1%">&#160;</td>
    <td style="text-align:left;width:1%">&#160;</td>
    <td style="text-align:right;width:9%">&#160;</td>
    <td style="text-align:left;width:1%">&#160;</td>
    <td style="width:1%">&#160;</td>
    <td style="text-align:left;width:1%">&#160;</td>
    <td style="text-align:right;width:9%">&#160;</td>
    <td style="text-align:left;width:1%">&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="font-weight:bold;text-align:left;text-indent:-0.125in;padding-left:0.125in;width:64%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">CAPITAL
        DEFICIENCY:</span></span></td>
    <td style="width:1%">&#160;</td>
    <td style="text-align:center;width:11%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">7</span></span></td>
    <td style="width:1%">&#160;</td>
    <td style="text-align:left;width:1%">&#160;</td>
    <td style="text-align:right;width:9%">&#160;</td>
    <td style="text-align:left;width:1%">&#160;</td>
    <td style="width:1%">&#160;</td>
    <td style="text-align:left;width:1%">&#160;</td>
    <td style="text-align:right;width:9%">&#160;</td>
    <td style="text-align:left;width:1%">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="text-align:left;text-indent:-0.125in;padding-left:0.25in;width:64%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Class&#160;A
        Ordinary Shares, $<ix:nonFraction id="Fxbrl_20241003170218970" name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="C_20221231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_usgaapCommonClassAMember" unitRef="usdPershares" scale="0" decimals="4" format="ixt:num-dot-decimal"><ix:nonFraction id="Fixv-37918" name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="C_20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_usgaapCommonClassAMember" unitRef="usdPershares" scale="0" decimals="4" format="ixt:num-dot-decimal">0.0001</ix:nonFraction></ix:nonFraction>&#160;par
        value;&#160;<ix:nonFraction id="Fxbrl_20241003170238212" name="us-gaap:CommonStockSharesAuthorized" contextRef="C_20221231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_usgaapCommonClassAMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="Fixv-37920" name="us-gaap:CommonStockSharesAuthorized" contextRef="C_20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_usgaapCommonClassAMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">500,000,000</ix:nonFraction></ix:nonFraction>&#160;shares
        authorized,&#160;<ix:nonFraction id="Fxbrl_20241003170417394" name="us-gaap:CommonStockSharesOutstanding" contextRef="C_20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_usgaapCommonClassAMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="Fixv-37922" name="us-gaap:CommonStockSharesIssued" contextRef="C_20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_usgaapCommonClassAMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">3,354,999</ix:nonFraction></ix:nonFraction>&#160;and&#160;<ix:nonFraction id="Fxbrl_20241003170453400" name="us-gaap:CommonStockSharesOutstanding" contextRef="C_20221231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_usgaapCommonClassAMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="Fixv-37924" name="us-gaap:CommonStockSharesIssued" contextRef="C_20221231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_usgaapCommonClassAMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">480,000</ix:nonFraction></ix:nonFraction>&#160;issued
        and outstanding (excluding 515,019 and 11,500,000 shares subject to possible redemption) as of December&#160;31, 2023 and 2022, respectively;</span></span></td>
    <td style="width:1%">&#160;</td>
    <td style="text-align:center;width:11%">&#160;</td>
    <td style="width:1%">&#160;</td>
    <td style="text-align:left;width:1%">&#160;</td>
    <td style="text-align:right;width:9%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fixv-37926" name="us-gaap:CommonStockValue" contextRef="C_20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_usgaapCommonClassAMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">336</ix:nonFraction></span></span></td>
    <td style="text-align:left;width:1%">&#160;</td>
    <td style="width:1%">&#160;</td>
    <td style="text-align:left;width:1%">&#160;</td>
    <td style="text-align:right;width:9%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fixv-37927" name="us-gaap:CommonStockValue" contextRef="C_20221231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_usgaapCommonClassAMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">48</ix:nonFraction></span></span></td>
    <td style="text-align:left;width:1%">&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="text-align:left;text-indent:-0.125in;padding-left:0.25in;width:64%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Class&#160;B
        Ordinary Shares, $<ix:nonFraction id="Fxbrl_20241003170513312" name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="C_20221231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_usgaapCommonClassBMember" unitRef="usdPershares" scale="0" decimals="4" format="ixt:num-dot-decimal"><ix:nonFraction id="Fixv-37928" name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="C_20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_usgaapCommonClassBMember" unitRef="usdPershares" scale="0" decimals="4" format="ixt:num-dot-decimal">0.0001</ix:nonFraction></ix:nonFraction>&#160;par
        value;&#160;<ix:nonFraction id="Fxbrl_20241003170529994" name="us-gaap:CommonStockSharesAuthorized" contextRef="C_20221231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_usgaapCommonClassBMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="Fixv-37930" name="us-gaap:CommonStockSharesAuthorized" contextRef="C_20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_usgaapCommonClassBMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">50,000,000</ix:nonFraction></ix:nonFraction>&#160;shares
        authorized,&#160;<ix:nonFraction id="Fxbrl_20241003170549074" name="us-gaap:CommonStockSharesOutstanding" contextRef="C_20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_usgaapCommonClassBMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="Fixv-37932" name="us-gaap:CommonStockSharesIssued" contextRef="C_20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_usgaapCommonClassBMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">1</ix:nonFraction></ix:nonFraction>&#160;and&#160;<ix:nonFraction id="Fxbrl_20241003170625385" name="us-gaap:CommonStockSharesOutstanding" contextRef="C_20221231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_usgaapCommonClassBMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="Fixv-37934" name="us-gaap:CommonStockSharesIssued" contextRef="C_20221231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_usgaapCommonClassBMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">2,875,000</ix:nonFraction></ix:nonFraction>&#160;issued
        and outstanding as of December&#160;31, 2023 and 2022, respectively;</span></span></td>
    <td style="width:1%">&#160;</td>
    <td style="text-align:center;width:11%">&#160;</td>
    <td style="width:1%">&#160;</td>
    <td style="text-align:left;width:1%">&#160;</td>
    <td style="text-align:right;width:9%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="-sec-ix-hidden:Fhidden-fact-12">*</span></span></span></td>
    <td style="text-align:left;width:1%">&#160;</td>
    <td style="width:1%">&#160;</td>
    <td style="text-align:left;width:1%">&#160;</td>
    <td style="text-align:right;width:9%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fixv-37936" name="us-gaap:CommonStockValue" contextRef="C_20221231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_usgaapCommonClassBMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">288</ix:nonFraction></span></span></td>
    <td style="text-align:left;width:1%">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="text-indent:-0.125in;padding-left:0.25in;width:64%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Preferred
        Shares, $<ix:nonFraction id="Fxbrl_20241004130455363" name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="C_20221231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="usdPershares" scale="0" decimals="4" format="ixt:num-dot-decimal"><ix:nonFraction id="Fxbrl_20241004130450733" name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="C_20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="usdPershares" scale="0" decimals="4" format="ixt:num-dot-decimal">0.0001</ix:nonFraction></ix:nonFraction>&#160;par
        value;&#160;<ix:nonFraction id="Fxbrl_20241004130534018" name="us-gaap:PreferredStockSharesAuthorized" contextRef="C_20221231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="Fxbrl_20241004130530146" name="us-gaap:PreferredStockSharesAuthorized" contextRef="C_20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">5,000,000</ix:nonFraction></ix:nonFraction>&#160;shares
        authorized, <ix:nonFraction id="Fxbrl_20241004133205153" name="us-gaap:PreferredStockSharesOutstanding" contextRef="C_20221231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="shares" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="Fxbrl_20241004133156405" name="us-gaap:PreferredStockSharesIssued" contextRef="C_20221231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="shares" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="Fxbrl_20241004133140765" name="us-gaap:PreferredStockSharesOutstanding" contextRef="C_20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="shares" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="Fxbrl_20241004133131102" name="us-gaap:PreferredStockSharesIssued" contextRef="C_20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="shares" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction>&#160;shares
        issued and outstanding as of December&#160;31, 2023 and 2022.</span></span></td>
    <td style="width:1%">&#160;</td>
    <td style="text-align:center;width:11%">&#160;</td>
    <td style="width:1%">&#160;</td>
    <td style="text-align:left;width:1%">&#160;</td>
    <td style="text-align:right;width:9%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20241003060107337_ixv-37926" name="us-gaap:PreferredStockValue" contextRef="C_20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></td>
    <td style="text-align:left;width:1%">&#160;</td>
    <td style="width:1%">&#160;</td>
    <td style="text-align:left;width:1%">&#160;</td>
    <td style="text-align:right;width:9%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20241003060107337_ixv-37927" name="us-gaap:PreferredStockValue" contextRef="C_20221231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></td>
    <td style="text-align:left;width:1%">&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="text-align:left;text-indent:-0.125in;padding-left:0.25in;width:64%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Additional
        paid-in capital</span></span></td>
    <td style="width:1%">&#160;</td>
    <td style="text-align:center;width:11%">&#160;</td>
    <td style="width:1%">&#160;</td>
    <td style="text-align:left;width:1%">&#160;</td>
    <td style="text-align:right;width:9%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20241003060110144_ixv-37926" name="us-gaap:AdditionalPaidInCapital" contextRef="C_20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></td>
    <td style="text-align:left;width:1%">&#160;</td>
    <td style="width:1%">&#160;</td>
    <td style="text-align:left;width:1%">&#160;</td>
    <td style="text-align:right;width:9%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20241003060110144_ixv-37927" name="us-gaap:AdditionalPaidInCapital" contextRef="C_20221231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></td>
    <td style="text-align:left;width:1%">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="text-align:left;padding-bottom:1.5pt;text-indent:-0.125in;padding-left:0.25in;width:64%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Accumulated
        deficit</span></span></td>
    <td style="padding-bottom:1.5pt;width:1%">&#160;</td>
    <td style="text-align:center;padding-bottom:1.5pt;width:11%">&#160;</td>
    <td style="padding-bottom:1.5pt;width:1%">&#160;</td>
    <td style="border-bottom:1.5pt solid black;text-align:left;width:1%">&#160;</td>
    <td style="border-bottom:1.5pt solid black;text-align:right;width:9%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fixv-37941" name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="C_20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">2,848,844</ix:nonFraction></span></span></td>
    <td style="padding-bottom:1.5pt;text-align:left;width:1%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></td>
    <td style="padding-bottom:1.5pt;width:1%">&#160;</td>
    <td style="border-bottom:1.5pt solid black;text-align:left;width:1%">&#160;</td>
    <td style="border-bottom:1.5pt solid black;text-align:right;width:9%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fixv-37942" name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="C_20221231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">1,203,097</ix:nonFraction></span></span></td>
    <td style="padding-bottom:1.5pt;text-align:left;width:1%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></td>
        </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="font-weight:bold;text-align:left;padding-bottom:1.5pt;text-indent:-0.125in;padding-left:0.25in;width:64%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">TOTAL
        CAPITAL DEFICIENCY</span></span></td>
    <td style="padding-bottom:1.5pt;width:1%">&#160;</td>
    <td style="text-align:center;padding-bottom:1.5pt;width:11%">&#160;</td>
    <td style="padding-bottom:1.5pt;width:1%">&#160;</td>
    <td style="border-bottom:1.5pt solid black;text-align:left;width:1%">&#160;</td>
    <td style="border-bottom:1.5pt solid black;text-align:right;width:9%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fixv-37943" name="us-gaap:StockholdersEquity" contextRef="C_20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">2,848,508</ix:nonFraction></span></span></td>
    <td style="padding-bottom:1.5pt;text-align:left;width:1%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></td>
    <td style="padding-bottom:1.5pt;width:1%">&#160;</td>
    <td style="border-bottom:1.5pt solid black;text-align:left;width:1%">&#160;</td>
    <td style="border-bottom:1.5pt solid black;text-align:right;width:9%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fixv-37944" name="us-gaap:StockholdersEquity" contextRef="C_20221231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">1,202,761</ix:nonFraction></span></span></td>
    <td style="padding-bottom:1.5pt;text-align:left;width:1%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></td>
        </tr>
  <tr style="vertical-align:bottom">
    <td style="font-weight:bold;text-align:left;padding-bottom:1.5pt;text-indent:-0.125in;padding-left:0.125in;width:64%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">TOTAL
        LIABILITIES AND SHARES SUBJECT TO POSSIBLE REDEMPTION NET OF CAPITAL DEFICIENCY</span></span></td>
    <td style="padding-bottom:1.5pt;width:1%">&#160;</td>
    <td style="text-align:center;padding-bottom:1.5pt;width:11%">&#160;</td>
    <td style="padding-bottom:1.5pt;width:1%">&#160;</td>
    <td style="border-bottom:1.5pt solid black;text-align:left;width:1%">&#160;</td>
    <td style="border-bottom:1.5pt solid black;text-align:right;width:9%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fixv-37945" name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="C_20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,834,215</ix:nonFraction></span></span></td>
    <td style="padding-bottom:1.5pt;text-align:left;width:1%">&#160;</td>
    <td style="padding-bottom:1.5pt;width:1%">&#160;</td>
    <td style="border-bottom:1.5pt solid black;text-align:left;width:1%">&#160;</td>
    <td style="border-bottom:1.5pt solid black;text-align:right;width:9%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fixv-37946" name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="C_20221231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">116,795,605</ix:nonFraction></span></span></td>
    <td style="padding-bottom:1.5pt;text-align:left;width:1%">&#160;</td> </tr>
  </table>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 24pt;text-indent:-24pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>&#160;</span></span></span></p>

<div style="margin-top:0pt;margin-bottom:0pt;width:25%">

<div style="font-size:1pt;border-top:Black 1.5pt solid">&#160;</div> </div>

<table cellpadding="0" cellspacing="0" style="font:10pt Times New Roman, Times, Serif;margin-top:0pt;margin-bottom:0pt;width:100%">
  <tr>
    <td style="width:0.25in;text-align:left">&#160;</td>
    <td style="text-align:justify">&#160;</td> </tr>
  <tr style="vertical-align:top;text-align:justify">
    <td style="width:0.25in;text-align:left"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>*</span></span></span></td>
    <td style="text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Less than&#160;one US dollar.</span></span></td>
        </tr>
  </table>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><strong>&#160;</strong></span></span></span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><strong>The
accompanying notes are an integral part of these financial statements</strong>.</span></span></span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>&#160;</span></span></span></p>

<div style="margin-top:12pt;margin-bottom:6pt;border-bottom:Black 1.5pt solid">

<p style="font:10pt Times New Roman, Times, Serif;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>F-23</span></span></span></p>
</div>

<div style="break-before:page;margin-top:6pt;margin-bottom:12pt">

<p style="margin:0pt">&#160;</p> </div>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><strong>&#160;</strong></span></span></span></p>

<div><span id="f_008"></span></div> </div>

<div style="font:10pt Times New Roman, Times, Serif">

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><strong>MORINGA
ACQUISITION CORP<br/>STATEMENTS OF OPERATIONS</strong></span></span></span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><strong>&#160;</strong></span></span></span></p>

<table cellpadding="0" cellspacing="0" style="width:100%">
  <tr style="vertical-align:bottom">
    <td style="padding-left:0.125in;text-indent:-0.125in">&#160;</td>
    <td style="font-weight:bold;padding-bottom:1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom:Black 1.5pt solid;font-weight:bold;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Note</span></span></td>
    <td style="padding-bottom:1.5pt;font-weight:bold">&#160;</td>
    <td style="font-weight:bold;padding-bottom:1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom:Black 1.5pt solid;font-weight:bold;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Year
        ended<br/>December&#160;31,<br/>2023</span></span></td>
    <td style="padding-bottom:1.5pt;font-weight:bold">&#160;</td>
    <td style="font-weight:bold;padding-bottom:1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom:Black 1.5pt solid;font-weight:bold;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Year
        ended<br/>December&#160;31,<br/>2022</span></span></td>
    <td style="padding-bottom:1.5pt;font-weight:bold">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="padding-left:0.125in;text-indent:-0.125in">&#160;</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td colspan="2">&#160;</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="font-weight:bold;padding-bottom:1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom:Black 1.5pt solid;font-weight:bold;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">U.S.&#160;Dollars</span></span></td>
    <td style="padding-bottom:1.5pt;font-weight:bold">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="padding-left:0.125in;text-indent:-0.125in">&#160;</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td colspan="2">&#160;</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="font-weight:bold;padding-bottom:1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom:Black 1.5pt solid;font-weight:bold;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Except
        share data</span></span></td>
    <td style="padding-bottom:1.5pt;font-weight:bold">&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="padding-left:0.125in;text-indent:-0.125in;text-align:left;width:64%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Interest
        earned on investments held in trust account</span></span></td>
    <td style="width:1%">&#160;</td>
    <td style="text-align:left;width:1%">&#160;</td>
    <td style="text-align:center;width:9%">&#160;</td>
    <td style="text-align:left;width:1%">&#160;</td>
    <td style="width:1%">&#160;</td>
    <td style="text-align:left;width:1%">&#160;</td>
    <td style="text-align:right;width:9%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fixv-37947" name="us-gaap:InvestmentIncomeInterest" contextRef="C_20230101to20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,364,444</ix:nonFraction></span></span></td>
    <td style="text-align:left;width:1%">&#160;</td>
    <td style="width:1%">&#160;</td>
    <td style="text-align:left;width:1%">&#160;</td>
    <td style="text-align:right;width:9%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fixv-37948" name="us-gaap:InvestmentIncomeInterest" contextRef="C_20220101to20221231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,685,666</ix:nonFraction></span></span></td>
    <td style="text-align:left;width:1%">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="padding-left:0.125in;text-indent:-0.125in;text-align:left;width:64%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">General
        and administrative</span></span></td>
    <td style="width:1%">&#160;</td>
    <td style="text-align:left;width:1%">&#160;</td>
    <td style="text-align:center;width:9%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">9</span></span></td>
    <td style="text-align:left;width:1%">&#160;</td>
    <td style="width:1%">&#160;</td>
    <td style="text-align:left;width:1%">&#160;</td>
    <td style="text-align:right;width:9%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fixv-37949" name="us-gaap:GeneralAndAdministrativeExpense" contextRef="C_20230101to20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">1,122,480</ix:nonFraction></span></span></td>
    <td style="text-align:left;width:1%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></td>
    <td style="width:1%">&#160;</td>
    <td style="text-align:left;width:1%">&#160;</td>
    <td style="text-align:right;width:9%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fixv-37950" name="us-gaap:GeneralAndAdministrativeExpense" contextRef="C_20220101to20221231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">1,232,342</ix:nonFraction></span></span></td>
    <td style="text-align:left;width:1%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></td>
        </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="padding-left:0.125in;text-indent:-0.125in;text-align:left;padding-bottom:1.5pt;width:64%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Change
        in fair value of Private Warrant liability</span></span></td>
    <td style="padding-bottom:1.5pt;width:1%">&#160;</td>
    <td style="padding-bottom:1.5pt;text-align:left;width:1%">&#160;</td>
    <td style="padding-bottom:1.5pt;text-align:center;width:9%">&#160;</td>
    <td style="padding-bottom:1.5pt;text-align:left;width:1%">&#160;</td>
    <td style="padding-bottom:1.5pt;width:1%">&#160;</td>
    <td style="border-bottom:1.5pt solid black;text-align:left;width:1%">&#160;</td>
    <td style="border-bottom:1.5pt solid black;text-align:right;width:9%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fixv-37951" name="us-gaap:FairValueAdjustmentOfWarrants" contextRef="C_20230101to20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">21,109</ix:nonFraction></span></span></td>
    <td style="padding-bottom:1.5pt;text-align:left;width:1%">&#160;</td>
    <td style="padding-bottom:1.5pt;width:1%">&#160;</td>
    <td style="border-bottom:1.5pt solid black;text-align:left;width:1%">&#160;</td>
    <td style="border-bottom:1.5pt solid black;text-align:right;width:9%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fixv-37952" name="us-gaap:FairValueAdjustmentOfWarrants" contextRef="C_20220101to20221231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">130,701</ix:nonFraction></span></span></td>
    <td style="padding-bottom:1.5pt;text-align:left;width:1%">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="padding-left:0.125in;text-indent:-0.125in;font-weight:bold;text-align:left;width:64%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Net
        profit for the year</span></span></td>
    <td style="width:1%">&#160;</td>
    <td style="text-align:left;width:1%">&#160;</td>
    <td style="text-align:center;width:9%">&#160;</td>
    <td style="text-align:left;width:1%">&#160;</td>
    <td style="width:1%">&#160;</td>
    <td style="text-align:left;width:1%">&#160;</td>
    <td style="text-align:right;width:9%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fixv-37953" name="us-gaap:ProfitLoss" contextRef="C_20230101to20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">263,073</ix:nonFraction></span></span></td>
    <td style="text-align:left;width:1%">&#160;</td>
    <td style="width:1%">&#160;</td>
    <td style="text-align:left;width:1%">&#160;</td>
    <td style="text-align:right;width:9%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fixv-37954" name="us-gaap:ProfitLoss" contextRef="C_20220101to20221231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">584,025</ix:nonFraction></span></span></td>
    <td style="text-align:left;width:1%">&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="padding-left:0.125in;text-indent:-0.125in;width:64%">&#160;</td>
    <td style="width:1%">&#160;</td>
    <td style="text-align:left;width:1%">&#160;</td>
    <td style="text-align:center;width:9%">&#160;</td>
    <td style="text-align:left;width:1%">&#160;</td>
    <td style="width:1%">&#160;</td>
    <td style="text-align:left;width:1%">&#160;</td>
    <td style="text-align:right;width:9%">&#160;</td>
    <td style="text-align:left;width:1%">&#160;</td>
    <td style="width:1%">&#160;</td>
    <td style="text-align:left;width:1%">&#160;</td>
    <td style="text-align:right;width:9%">&#160;</td>
    <td style="text-align:left;width:1%">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="padding-left:0.125in;text-indent:-0.125in;font-weight:bold;text-align:left;width:64%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Weighted
        average number of Class&#160;A Ordinary Shares subject to Possible Redemption</span></span></td>
    <td style="width:1%">&#160;</td>
    <td style="text-align:left;width:1%">&#160;</td>
    <td style="text-align:center;width:9%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">8</span></span></td>
    <td style="text-align:left;width:1%">&#160;</td>
    <td style="width:1%">&#160;</td>
    <td style="text-align:left;width:1%">&#160;</td>
    <td style="text-align:right;width:9%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fixv-37955" name="us-gaap:WeightedAverageNumberOfSharesIssuedBasic" contextRef="C_20230101to20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_slxnClassAOrdinaryShareSubjectToPossibleRedemptionMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">2,774,850</ix:nonFraction></span></span></td>
    <td style="text-align:left;width:1%">&#160;</td>
    <td style="width:1%">&#160;</td>
    <td style="text-align:left;width:1%">&#160;</td>
    <td style="text-align:right;width:9%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fixv-37956" name="us-gaap:WeightedAverageNumberOfSharesIssuedBasic" contextRef="C_20220101to20221231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_slxnClassAOrdinaryShareSubjectToPossibleRedemptionMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">11,500,000</ix:nonFraction></span></span></td>
    <td style="text-align:left;width:1%">&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="padding-left:0.125in;text-indent:-0.125in;font-weight:bold;text-align:left;padding-bottom:4pt;width:64%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Basic
        and diluted net profit per Class&#160;A Ordinary Shares subject to Possible Redemption</span></span></td>
    <td style="padding-bottom:4pt;width:1%">&#160;</td>
    <td style="padding-bottom:4pt;text-align:left;width:1%">&#160;</td>
    <td style="padding-bottom:4pt;text-align:center;width:9%">&#160;</td>
    <td style="padding-bottom:4pt;text-align:left;width:1%">&#160;</td>
    <td style="padding-bottom:4pt;width:1%">&#160;</td>
    <td style="border-bottom:4pt double black;text-align:left;width:1%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></td>
    <td style="border-bottom:4pt double black;text-align:right;width:9%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20241003013900186" name="us-gaap:EarningsPerShareDiluted" contextRef="C_20230101to20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_slxnClassAOrdinaryShareSubjectToPossibleRedemptionMember" unitRef="usdPershares" scale="0" decimals="2" format="ixt:num-dot-decimal"><ix:nonFraction id="Fixv-37957" name="us-gaap:EarningsPerShareBasic" contextRef="C_20230101to20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_slxnClassAOrdinaryShareSubjectToPossibleRedemptionMember" unitRef="usdPershares" scale="0" decimals="2" format="ixt:num-dot-decimal">0.51</ix:nonFraction></ix:nonFraction></span></span></td>
    <td style="padding-bottom:4pt;text-align:left;width:1%">&#160;</td>
    <td style="padding-bottom:4pt;width:1%">&#160;</td>
    <td style="border-bottom:4pt double black;text-align:left;width:1%">&#160;</td>
    <td style="border-bottom:4pt double black;text-align:right;width:9%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20241003013918307" name="us-gaap:EarningsPerShareDiluted" contextRef="C_20220101to20221231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_slxnClassAOrdinaryShareSubjectToPossibleRedemptionMember" unitRef="usdPershares" scale="0" decimals="2" format="ixt:num-dot-decimal"><ix:nonFraction id="Fixv-37958" name="us-gaap:EarningsPerShareBasic" contextRef="C_20220101to20221231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_slxnClassAOrdinaryShareSubjectToPossibleRedemptionMember" unitRef="usdPershares" scale="0" decimals="2" format="ixt:num-dot-decimal">0.07</ix:nonFraction></ix:nonFraction></span></span></td>
    <td style="padding-bottom:4pt;text-align:left;width:1%">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="padding-left:0.125in;text-indent:-0.125in;width:64%">&#160;</td>
    <td style="width:1%">&#160;</td>
    <td style="text-align:left;width:1%">&#160;</td>
    <td style="text-align:center;width:9%">&#160;</td>
    <td style="text-align:left;width:1%">&#160;</td>
    <td style="width:1%">&#160;</td>
    <td style="text-align:left;width:1%">&#160;</td>
    <td style="text-align:right;width:9%">&#160;</td>
    <td style="text-align:left;width:1%">&#160;</td>
    <td style="width:1%">&#160;</td>
    <td style="text-align:left;width:1%">&#160;</td>
    <td style="text-align:right;width:9%">&#160;</td>
    <td style="text-align:left;width:1%">&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="padding-left:0.125in;text-indent:-0.125in;font-weight:bold;text-align:left;width:64%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Weighted
        average number of non-redeemable Class&#160;A and Class&#160;B Ordinary shares</span></span></td>
    <td style="width:1%">&#160;</td>
    <td style="text-align:left;width:1%">&#160;</td>
    <td style="text-align:center;width:9%">&#160;</td>
    <td style="text-align:left;width:1%">&#160;</td>
    <td style="width:1%">&#160;</td>
    <td style="text-align:left;width:1%">&#160;</td>
    <td style="text-align:right;width:9%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fixv-37959" name="us-gaap:WeightedAverageNumberOfSharesIssuedBasic" contextRef="C_20230101to20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_slxnNonredeemableClassAandBOrdinaryShareMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">3,355,000</ix:nonFraction></span></span></td>
    <td style="text-align:left;width:1%">&#160;</td>
    <td style="width:1%">&#160;</td>
    <td style="text-align:left;width:1%">&#160;</td>
    <td style="text-align:right;width:9%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fixv-37960" name="us-gaap:WeightedAverageNumberOfSharesIssuedBasic" contextRef="C_20220101to20221231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_slxnNonredeemableClassAandBOrdinaryShareMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">3,355,000</ix:nonFraction></span></span></td>
    <td style="text-align:left;width:1%">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="padding-left:0.125in;text-indent:-0.125in;font-weight:bold;text-align:left;padding-bottom:4pt;vertical-align:middle;width:64%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Basic
        and diluted net loss per non-redeemable Class&#160;A and Class&#160;B Ordinary shares</span></span></td>
    <td style="padding-bottom:4pt;vertical-align:middle;width:1%">&#160;</td>
    <td style="padding-bottom:4pt;text-align:left;vertical-align:middle;width:1%">&#160;</td>
    <td style="padding-bottom:4pt;text-align:center;vertical-align:middle;width:9%">&#160;</td>
    <td style="padding-bottom:4pt;text-align:left;vertical-align:middle;width:1%">&#160;</td>
    <td style="padding-bottom:4pt;vertical-align:middle;width:1%">&#160;</td>
    <td style="border-bottom:4pt double black;text-align:left;vertical-align:middle;width:1%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></td>
    <td style="border-bottom:4pt double black;text-align:right;vertical-align:middle;width:9%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fxbrl_20241003014030827" name="us-gaap:EarningsPerShareDiluted" contextRef="C_20230101to20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_slxnNonredeemableClassAandBOrdinaryShareMember" unitRef="usdPershares" scale="0" decimals="2" format="ixt:num-dot-decimal" sign="-"><ix:nonFraction id="Fixv-37961" name="us-gaap:EarningsPerShareBasic" contextRef="C_20230101to20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_slxnNonredeemableClassAandBOrdinaryShareMember" unitRef="usdPershares" scale="0" decimals="2" format="ixt:num-dot-decimal" sign="-">0.34</ix:nonFraction></ix:nonFraction></span></span></td>
    <td style="padding-bottom:4px;text-align:left;vertical-align:middle;width:1%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></td>
    <td style="padding-bottom:4pt;vertical-align:middle;width:1%">&#160;</td>
    <td style="border-bottom:4pt double black;text-align:left;vertical-align:middle;width:1%">&#160;</td>
    <td style="border-bottom:4pt double black;text-align:right;vertical-align:middle;width:9%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fxbrl_20241003014051827" name="us-gaap:EarningsPerShareDiluted" contextRef="C_20220101to20221231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_slxnNonredeemableClassAandBOrdinaryShareMember" unitRef="usdPershares" scale="0" decimals="2" format="ixt:num-dot-decimal" sign="-"><ix:nonFraction id="Fixv-37962" name="us-gaap:EarningsPerShareBasic" contextRef="C_20220101to20221231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_slxnNonredeemableClassAandBOrdinaryShareMember" unitRef="usdPershares" scale="0" decimals="2" format="ixt:num-dot-decimal" sign="-">0.07</ix:nonFraction></ix:nonFraction></span></span></td>
    <td style="padding-bottom:4pt;text-align:left;vertical-align:middle;width:1%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></td>
        </tr>
  </table>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><strong>&#160;</strong></span></span></span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><strong>The
accompanying notes are an integral part of these financial statements.</strong></span></span></span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center">&#160;</p>

<div style="margin-top:12pt;margin-bottom:6pt;border-bottom:Black 1.5pt solid">

<p style="font:10pt Times New Roman, Times, Serif;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>F-24</span></span></span></p>
</div>

<div style="break-before:page;margin-top:6pt;margin-bottom:12pt">

<p style="margin:0pt">&#160;</p> </div>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><strong>&#160;</strong></span></span></span></p>

<div><span id="f_009"></span></div> </div>

<div style="font:10pt Times New Roman, Times, Serif">

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><strong>MORINGA
ACQUISITION CORP<br/>STATEMENTS OF CHANGES IN CAPITAL DEFICIENCY</strong></span></span></span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width:100%">
  <tr style="vertical-align:bottom">
    <td style="padding-bottom:1.5pt;font-weight:bold">&#160;</td>
    <td style="padding-bottom:1.5pt;font-weight:bold">&#160;</td>
    <td colspan="6" style="border-bottom:Black 1.5pt solid;font-weight:bold;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Class&#160;A<br/>ordinary
        shares</span></span></td>
    <td style="padding-bottom:1.5pt;font-weight:bold">&#160;</td>
    <td style="padding-bottom:1.5pt;font-weight:bold">&#160;</td>
    <td colspan="6" style="border-bottom:Black 1.5pt solid;font-weight:bold;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Class&#160;B<br/>ordinary
        shares</span></span></td>
    <td style="padding-bottom:1.5pt;font-weight:bold">&#160;</td>
    <td style="padding-bottom:1.5pt;font-weight:bold">&#160;</td>
    <td colspan="2" style="font-weight:bold;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Additional</span></span></td>
    <td style="padding-bottom:1.5pt;font-weight:bold">&#160;</td>
    <td style="padding-bottom:1.5pt;font-weight:bold">&#160;</td>
    <td colspan="2" style="padding-bottom:1.5pt;font-weight:bold;text-align:right">&#160;</td>
    <td style="padding-bottom:1.5pt;font-weight:bold">&#160;</td>
    <td style="padding-bottom:1.5pt;font-weight:bold">&#160;</td>
    <td colspan="2" style="padding-bottom:1.5pt;font-weight:bold;text-align:right">&#160;</td>
    <td style="padding-bottom:1.5pt;font-weight:bold">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="padding-bottom:1.5pt;font-weight:bold">&#160;</td>
    <td style="padding-bottom:1.5pt;font-weight:bold">&#160;</td>
    <td colspan="2" style="border-bottom:Black 1.5pt solid;font-weight:bold;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Number&#160;of<br/>shares</span></span></td>
    <td style="padding-bottom:1.5pt;font-weight:bold">&#160;</td>
    <td style="padding-bottom:1.5pt;font-weight:bold">&#160;</td>
    <td colspan="2" style="border-bottom:Black 1.5pt solid;font-weight:bold;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Par<br/>value</span></span></td>
    <td style="padding-bottom:1.5pt;font-weight:bold">&#160;</td>
    <td style="padding-bottom:1.5pt;font-weight:bold">&#160;</td>
    <td colspan="2" style="border-bottom:Black 1.5pt solid;font-weight:bold;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Number&#160;of<br/>shares</span></span></td>
    <td style="padding-bottom:1.5pt;font-weight:bold">&#160;</td>
    <td style="padding-bottom:1.5pt;font-weight:bold">&#160;</td>
    <td colspan="2" style="border-bottom:Black 1.5pt solid;font-weight:bold;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Par<br/>value</span></span></td>
    <td style="padding-bottom:1.5pt;font-weight:bold">&#160;</td>
    <td style="padding-bottom:1.5pt;font-weight:bold">&#160;</td>
    <td colspan="2" style="border-bottom:Black 1.5pt solid;font-weight:bold;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">paid-in<br/>capital</span></span></td>
    <td style="padding-bottom:1.5pt;font-weight:bold">&#160;</td>
    <td style="padding-bottom:1.5pt;font-weight:bold">&#160;</td>
    <td colspan="2" style="border-bottom:Black 1.5pt solid;font-weight:bold;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Accumulated<br/>deficit</span></span></td>
    <td style="padding-bottom:1.5pt;font-weight:bold">&#160;</td>
    <td style="padding-bottom:1.5pt;font-weight:bold">&#160;</td>
    <td colspan="2" style="border-bottom:Black 1.5pt solid;font-weight:bold;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Total</span></span></td>
    <td style="padding-bottom:1.5pt;font-weight:bold">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="font-weight:bold">&#160;</td>
    <td style="font-weight:bold">&#160;</td>
    <td colspan="26" style="border-bottom:Black 1.5pt solid;font-weight:bold;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">U.S.&#160;Dollars
        (except share data)</span></span></td>
    <td style="font-weight:bold">&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="font-weight:bold;text-indent:-0.125in;padding-left:0.125in;width:34%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">BALANCE
        AT December&#160;31, 2021</span></span></td>
    <td style="width:1%">&#160;</td>
    <td style="text-align:left;width:1%">&#160;</td>
    <td style="text-align:right;width:6%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fixv-37963" name="us-gaap:SharesOutstanding" contextRef="C_20211231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_usgaapCommonClassAMember_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">480,000</ix:nonFraction></span></span></td>
    <td style="text-align:left;width:1%">&#160;</td>
    <td style="width:1%">&#160;</td>
    <td style="text-align:left;width:1%">&#160;</td>
    <td style="text-align:right;width:6%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fixv-37964" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_20211231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_usgaapCommonClassAMember_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">48</ix:nonFraction></span></span></td>
    <td style="text-align:left;width:1%">&#160;</td>
    <td style="width:1%">&#160;</td>
    <td style="text-align:left;width:1%">&#160;</td>
    <td style="text-align:right;width:7%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fixv-37965" name="us-gaap:SharesOutstanding" contextRef="C_20211231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_usgaapCommonClassBMember_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">2,875,000</ix:nonFraction></span></span></td>
    <td style="text-align:left;width:1%">&#160;</td>
    <td style="width:1%">&#160;</td>
    <td style="text-align:left;width:1%">&#160;</td>
    <td style="text-align:right;width:6%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fixv-37966" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_20211231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_usgaapCommonClassBMember_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">288</ix:nonFraction></span></span></td>
    <td style="text-align:left;width:1%">&#160;</td>
    <td style="width:1%">&#160;</td>
    <td style="text-align:left;width:1%">&#160;</td>
    <td style="text-align:right;width:6%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fixv-37967" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_20211231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">855,994</ix:nonFraction></span></span></td>
    <td style="text-align:left;width:1%">&#160;</td>
    <td style="width:1%">&#160;</td>
    <td style="text-align:left;width:1%">&#160;</td>
    <td style="text-align:right;width:8%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fixv-37968" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_20211231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">951,078</ix:nonFraction></span></span></td>
    <td style="text-align:left;width:1%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></td>
    <td style="width:1%">&#160;</td>
    <td style="text-align:left;width:1%">&#160;</td>
    <td style="text-align:right;width:6%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fixv-37969" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_20211231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">94,748</ix:nonFraction></span></span></td>
    <td style="text-align:left;width:1%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></td>
        </tr>
  <tr style="vertical-align:bottom">
    <td style="text-align:left;text-indent:-0.125in;padding-left:0.125in;width:34%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Subsequent
        accretion of Class&#160;A Ordinary Shares subject to possible redemption to amount as of December&#160;31, 2022</span></span></td>
    <td style="width:1%">&#160;</td>
    <td style="text-align:left;width:1%">&#160;</td>
    <td style="text-align:right;width:6%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></td>
    <td style="text-align:left;width:1%">&#160;</td>
    <td style="width:1%">&#160;</td>
    <td style="text-align:left;width:1%">&#160;</td>
    <td style="text-align:right;width:6%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20241004163808943" name="us-gaap:TemporaryEquityAccretionToRedemptionValueAdjustment" contextRef="C_20220101to20221231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_usgaapCommonClassAMember_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></td>
    <td style="text-align:left;width:1%">&#160;</td>
    <td style="width:1%">&#160;</td>
    <td style="text-align:left;width:1%">&#160;</td>
    <td style="text-align:right;width:7%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></td>
    <td style="text-align:left;width:1%">&#160;</td>
    <td style="width:1%">&#160;</td>
    <td style="text-align:left;width:1%">&#160;</td>
    <td style="text-align:right;width:6%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20241004163749617" name="us-gaap:TemporaryEquityAccretionToRedemptionValueAdjustment" contextRef="C_20220101to20221231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_usgaapCommonClassBMember_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></td>
    <td style="text-align:left;width:1%">&#160;</td>
    <td style="width:1%">&#160;</td>
    <td style="text-align:left;width:1%">&#160;</td>
    <td style="text-align:right;width:6%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fixv-37970" name="us-gaap:TemporaryEquityAccretionToRedemptionValueAdjustment" contextRef="C_20220101to20221231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">855,994</ix:nonFraction></span></span></td>
    <td style="text-align:left;width:1%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></td>
    <td style="width:1%">&#160;</td>
    <td style="text-align:left;width:1%">&#160;</td>
    <td style="text-align:right;width:8%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fixv-37971" name="us-gaap:TemporaryEquityAccretionToRedemptionValueAdjustment" contextRef="C_20220101to20221231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">836,044</ix:nonFraction></span></span></td>
    <td style="text-align:left;width:1%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></td>
    <td style="width:1%">&#160;</td>
    <td style="text-align:left;width:1%">&#160;</td>
    <td style="text-align:right;width:6%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fixv-37972" name="us-gaap:TemporaryEquityAccretionToRedemptionValueAdjustment" contextRef="C_20220101to20221231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">1,692,038</ix:nonFraction></span></span></td>
    <td style="text-align:left;width:1%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></td>
        </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="text-align:left;padding-bottom:1.5pt;text-indent:-0.125in;padding-left:0.125in;width:34%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Net
        profit for the year</span></span></td>
    <td style="padding-bottom:1.5pt;width:1%">&#160;</td>
    <td style="border-bottom:1.5pt solid black;text-align:left;width:1%">&#160;</td>
    <td style="border-bottom:1.5pt solid black;text-align:right;width:6%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></td>
    <td style="padding-bottom:1.5pt;text-align:left;width:1%">&#160;</td>
    <td style="padding-bottom:1.5pt;width:1%">&#160;</td>
    <td style="border-bottom:1.5pt solid black;text-align:left;width:1%">&#160;</td>
    <td style="border-bottom:1.5pt solid black;text-align:right;width:6%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20241004163904281" name="us-gaap:ProfitLoss" contextRef="C_20220101to20221231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_usgaapCommonClassAMember_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></td>
    <td style="padding-bottom:1.5pt;text-align:left;width:1%">&#160;</td>
    <td style="padding-bottom:1.5pt;width:1%">&#160;</td>
    <td style="border-bottom:1.5pt solid black;text-align:left;width:1%">&#160;</td>
    <td style="border-bottom:1.5pt solid black;text-align:right;width:7%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></td>
    <td style="padding-bottom:1.5pt;text-align:left;width:1%">&#160;</td>
    <td style="padding-bottom:1.5pt;width:1%">&#160;</td>
    <td style="border-bottom:1.5pt solid black;text-align:left;width:1%">&#160;</td>
    <td style="border-bottom:1.5pt solid black;text-align:right;width:6%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20241004163859376" name="us-gaap:ProfitLoss" contextRef="C_20220101to20221231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_usgaapCommonClassBMember_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></td>
    <td style="padding-bottom:1.5pt;text-align:left;width:1%">&#160;</td>
    <td style="padding-bottom:1.5pt;width:1%">&#160;</td>
    <td style="border-bottom:1.5pt solid black;text-align:left;width:1%">&#160;</td>
    <td style="border-bottom:1.5pt solid black;text-align:right;width:6%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20241004163853673" name="us-gaap:ProfitLoss" contextRef="C_20220101to20221231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></td>
    <td style="padding-bottom:1.5pt;text-align:left;width:1%">&#160;</td>
    <td style="padding-bottom:1.5pt;width:1%">&#160;</td>
    <td style="border-bottom:1.5pt solid black;text-align:left;width:1%">&#160;</td>
    <td style="border-bottom:1.5pt solid black;text-align:right;width:8%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fixv-37973" name="us-gaap:ProfitLoss" contextRef="C_20220101to20221231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">584,025</ix:nonFraction></span></span></td>
    <td style="padding-bottom:1.5pt;text-align:left;width:1%">&#160;</td>
    <td style="padding-bottom:1.5pt;width:1%">&#160;</td>
    <td style="border-bottom:1.5pt solid black;text-align:left;width:1%">&#160;</td>
    <td style="border-bottom:1.5pt solid black;text-align:right;width:6%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fixv-37974" name="us-gaap:ProfitLoss" contextRef="C_20220101to20221231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">584,025</ix:nonFraction></span></span></td>
    <td style="padding-bottom:1.5pt;text-align:left;width:1%">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="font-weight:bold;padding-bottom:4pt;text-indent:-0.125in;padding-left:0.125in;width:34%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">BALANCE
        AT December&#160;31, 2022</span></span></td>
    <td style="padding-bottom:4pt;width:1%">&#160;</td>
    <td style="border-bottom:4pt double black;text-align:left;width:1%">&#160;</td>
    <td style="border-bottom:4pt double black;text-align:right;width:6%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fixv-37975" name="us-gaap:SharesOutstanding" contextRef="C_20221231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_usgaapCommonClassAMember_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">480,000</ix:nonFraction></span></span></td>
    <td style="padding-bottom:4pt;text-align:left;width:1%">&#160;</td>
    <td style="padding-bottom:4pt;width:1%">&#160;</td>
    <td style="border-bottom:4pt double black;text-align:left;width:1%">&#160;</td>
    <td style="border-bottom:4pt double black;text-align:right;width:6%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fixv-37976" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_20221231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_usgaapCommonClassAMember_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">48</ix:nonFraction></span></span></td>
    <td style="padding-bottom:4pt;text-align:left;width:1%">&#160;</td>
    <td style="padding-bottom:4pt;width:1%">&#160;</td>
    <td style="border-bottom:4pt double black;text-align:left;width:1%">&#160;</td>
    <td style="border-bottom:4pt double black;text-align:right;width:7%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fixv-37977" name="us-gaap:SharesOutstanding" contextRef="C_20221231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_usgaapCommonClassBMember_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">2,875,000</ix:nonFraction></span></span></td>
    <td style="padding-bottom:4pt;text-align:left;width:1%">&#160;</td>
    <td style="padding-bottom:4pt;width:1%">&#160;</td>
    <td style="border-bottom:4pt double black;text-align:left;width:1%">&#160;</td>
    <td style="border-bottom:4pt double black;text-align:right;width:6%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fixv-37978" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_20221231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_usgaapCommonClassBMember_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">288</ix:nonFraction></span></span></td>
    <td style="padding-bottom:4pt;text-align:left;width:1%">&#160;</td>
    <td style="padding-bottom:4pt;width:1%">&#160;</td>
    <td style="border-bottom:4pt double black;text-align:left;width:1%">&#160;</td>
    <td style="border-bottom:4pt double black;text-align:right;width:6%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20241004164156746" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_20221231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></td>
    <td style="padding-bottom:4pt;text-align:left;width:1%">&#160;</td>
    <td style="padding-bottom:4pt;width:1%">&#160;</td>
    <td style="border-bottom:4pt double black;text-align:left;width:1%">&#160;</td>
    <td style="border-bottom:4pt double black;text-align:right;width:8%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fixv-37979" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_20221231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">1,203,097</ix:nonFraction></span></span></td>
    <td style="padding-bottom:4pt;text-align:left;width:1%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></td>
    <td style="padding-bottom:4pt;width:1%">&#160;</td>
    <td style="border-bottom:4pt double black;text-align:left;width:1%">&#160;</td>
    <td style="border-bottom:4pt double black;text-align:right;width:6%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fixv-37980" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_20221231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">1,202,761</ix:nonFraction></span></span></td>
    <td style="padding-bottom:4pt;text-align:left;width:1%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></td>
        </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="text-indent:-0.125in;padding-left:0.125in;width:34%">&#160;</td>
    <td style="width:1%">&#160;</td>
    <td style="text-align:left;width:1%">&#160;</td>
    <td style="text-align:right;width:6%">&#160;</td>
    <td style="text-align:left;width:1%">&#160;</td>
    <td style="width:1%">&#160;</td>
    <td style="text-align:left;width:1%">&#160;</td>
    <td style="text-align:right;width:6%">&#160;</td>
    <td style="text-align:left;width:1%">&#160;</td>
    <td style="width:1%">&#160;</td>
    <td style="text-align:left;width:1%">&#160;</td>
    <td style="text-align:right;width:7%">&#160;</td>
    <td style="text-align:left;width:1%">&#160;</td>
    <td style="width:1%">&#160;</td>
    <td style="text-align:left;width:1%">&#160;</td>
    <td style="text-align:right;width:6%">&#160;</td>
    <td style="text-align:left;width:1%">&#160;</td>
    <td style="width:1%">&#160;</td>
    <td style="text-align:left;width:1%">&#160;</td>
    <td style="text-align:right;width:6%">&#160;</td>
    <td style="text-align:left;width:1%">&#160;</td>
    <td style="width:1%">&#160;</td>
    <td style="text-align:left;width:1%">&#160;</td>
    <td style="text-align:right;width:8%">&#160;</td>
    <td style="text-align:left;width:1%">&#160;</td>
    <td style="width:1%">&#160;</td>
    <td style="text-align:left;width:1%">&#160;</td>
    <td style="text-align:right;width:6%">&#160;</td>
    <td style="text-align:left;width:1%">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="text-align:left;text-indent:-0.125in;padding-left:0.125in;width:34%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Subsequent
        accretion of Class&#160;A Ordinary Shares subject to possible redemption to amount as of December&#160;31, 2023</span></span></td>
    <td style="width:1%">&#160;</td>
    <td style="text-align:left;width:1%">&#160;</td>
    <td style="text-align:right;width:6%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></td>
    <td style="text-align:left;width:1%">&#160;</td>
    <td style="width:1%">&#160;</td>
    <td style="text-align:left;width:1%">&#160;</td>
    <td style="text-align:right;width:6%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20241004164115912" name="us-gaap:TemporaryEquityAccretionToRedemptionValueAdjustment" contextRef="C_20230101to20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_usgaapCommonClassAMember_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></td>
    <td style="text-align:left;width:1%">&#160;</td>
    <td style="width:1%">&#160;</td>
    <td style="text-align:left;width:1%">&#160;</td>
    <td style="text-align:right;width:7%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></td>
    <td style="text-align:left;width:1%">&#160;</td>
    <td style="width:1%">&#160;</td>
    <td style="text-align:left;width:1%">&#160;</td>
    <td style="text-align:right;width:6%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20241004164048712" name="us-gaap:TemporaryEquityAccretionToRedemptionValueAdjustment" contextRef="C_20230101to20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_usgaapCommonClassBMember_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></td>
    <td style="text-align:left;width:1%">&#160;</td>
    <td style="width:1%">&#160;</td>
    <td style="text-align:left;width:1%">&#160;</td>
    <td style="text-align:right;width:6%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20241004164037935" name="us-gaap:TemporaryEquityAccretionToRedemptionValueAdjustment" contextRef="C_20230101to20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></td>
    <td style="text-align:left;width:1%">&#160;</td>
    <td style="width:1%">&#160;</td>
    <td style="text-align:left;width:1%">&#160;</td>
    <td style="text-align:right;width:8%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fixv-37981" name="us-gaap:TemporaryEquityAccretionToRedemptionValueAdjustment" contextRef="C_20230101to20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">1,908,820</ix:nonFraction></span></span></td>
    <td style="text-align:left;width:1%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></td>
    <td style="width:1%">&#160;</td>
    <td style="text-align:left;width:1%">&#160;</td>
    <td style="text-align:right;width:6%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fixv-37982" name="us-gaap:TemporaryEquityAccretionToRedemptionValueAdjustment" contextRef="C_20230101to20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">1,908,820</ix:nonFraction></span></span></td>
    <td style="text-align:left;width:1%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></td>
        </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="text-align:left;text-indent:-0.125in;padding-left:0.125in;width:34%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Conversion
        of Class&#160;B ordinary shares into Class&#160;A ordinary shares</span></span></td>
    <td style="width:1%">&#160;</td>
    <td style="text-align:left;width:1%">&#160;</td>
    <td style="text-align:right;width:6%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fixv-37983" name="us-gaap:ConversionOfStockSharesConverted1" contextRef="C_20230101to20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_usgaapCommonClassAMember_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">2,874,999</ix:nonFraction></span></span></td>
    <td style="text-align:left;width:1%">&#160;</td>
    <td style="width:1%">&#160;</td>
    <td style="text-align:left;width:1%">&#160;</td>
    <td style="text-align:right;width:6%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fixv-37984" name="us-gaap:ConversionOfStockAmountConverted1" contextRef="C_20230101to20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_usgaapCommonClassAMember_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">288</ix:nonFraction></span></span></td>
    <td style="text-align:left;width:1%">&#160;</td>
    <td style="width:1%">&#160;</td>
    <td style="text-align:left;width:1%">&#160;</td>
    <td style="text-align:right;width:7%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fixv-37985" name="us-gaap:ConversionOfStockSharesConverted1" contextRef="C_20230101to20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_usgaapCommonClassBMember_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal" sign="-">2,874,999</ix:nonFraction></span></span></td>
    <td style="text-align:left;width:1%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></td>
    <td style="width:1%">&#160;</td>
    <td style="text-align:left;width:1%">&#160;</td>
    <td style="text-align:right;width:6%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fixv-37986" name="us-gaap:ConversionOfStockAmountConverted1" contextRef="C_20230101to20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_usgaapCommonClassBMember_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">288</ix:nonFraction></span></span></td>
    <td style="text-align:left;width:1%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></td>
    <td style="width:1%">&#160;</td>
    <td style="text-align:left;width:1%">&#160;</td>
    <td style="text-align:right;width:6%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20241004164445979" name="us-gaap:ConversionOfStockAmountConverted1" contextRef="C_20230101to20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></td>
    <td style="text-align:left;width:1%">&#160;</td>
    <td style="width:1%">&#160;</td>
    <td style="text-align:left;width:1%">&#160;</td>
    <td style="text-align:right;width:8%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20241004164503938" name="us-gaap:ConversionOfStockAmountConverted1" contextRef="C_20230101to20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></td>
    <td style="text-align:left;width:1%">&#160;</td>
    <td style="width:1%">&#160;</td>
    <td style="text-align:left;width:1%">&#160;</td>
    <td style="text-align:right;width:6%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20241004164507507" name="us-gaap:ConversionOfStockAmountConverted1" contextRef="C_20230101to20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></td>
    <td style="text-align:left;width:1%">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="text-align:left;padding-bottom:1.5pt;text-indent:-0.125in;padding-left:0.125in;width:34%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Net
        profit for the year</span></span></td>
    <td style="padding-bottom:1.5pt;width:1%">&#160;</td>
    <td style="border-bottom:1.5pt solid black;text-align:left;width:1%">&#160;</td>
    <td style="border-bottom:1.5pt solid black;text-align:right;width:6%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></td>
    <td style="padding-bottom:1.5pt;text-align:left;width:1%">&#160;</td>
    <td style="padding-bottom:1.5pt;width:1%">&#160;</td>
    <td style="border-bottom:1.5pt solid black;text-align:left;width:1%">&#160;</td>
    <td style="border-bottom:1.5pt solid black;text-align:right;width:6%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20241004164611020" name="us-gaap:ProfitLoss" contextRef="C_20230101to20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_usgaapCommonClassAMember_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></td>
    <td style="padding-bottom:1.5pt;text-align:left;width:1%">&#160;</td>
    <td style="padding-bottom:1.5pt;width:1%">&#160;</td>
    <td style="border-bottom:1.5pt solid black;text-align:left;width:1%">&#160;</td>
    <td style="border-bottom:1.5pt solid black;text-align:right;width:7%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></td>
    <td style="padding-bottom:1.5pt;text-align:left;width:1%">&#160;</td>
    <td style="padding-bottom:1.5pt;width:1%">&#160;</td>
    <td style="border-bottom:1.5pt solid black;text-align:left;width:1%">&#160;</td>
    <td style="border-bottom:1.5pt solid black;text-align:right;width:6%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20241004164605083" name="us-gaap:ProfitLoss" contextRef="C_20230101to20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_usgaapCommonClassBMember_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></td>
    <td style="padding-bottom:1.5pt;text-align:left;width:1%">&#160;</td>
    <td style="padding-bottom:1.5pt;width:1%">&#160;</td>
    <td style="border-bottom:1.5pt solid black;text-align:left;width:1%">&#160;</td>
    <td style="border-bottom:1.5pt solid black;text-align:right;width:6%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20241004164555833" name="us-gaap:ProfitLoss" contextRef="C_20230101to20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></td>
    <td style="padding-bottom:1.5pt;text-align:left;width:1%">&#160;</td>
    <td style="padding-bottom:1.5pt;width:1%">&#160;</td>
    <td style="border-bottom:1.5pt solid black;text-align:left;width:1%">&#160;</td>
    <td style="border-bottom:1.5pt solid black;text-align:right;width:8%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fixv-37987" name="us-gaap:ProfitLoss" contextRef="C_20230101to20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">263,073</ix:nonFraction></span></span></td>
    <td style="padding-bottom:1.5pt;text-align:left;width:1%">&#160;</td>
    <td style="padding-bottom:1.5pt;width:1%">&#160;</td>
    <td style="border-bottom:1.5pt solid black;text-align:left;width:1%">&#160;</td>
    <td style="border-bottom:1.5pt solid black;text-align:right;width:6%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fixv-37988" name="us-gaap:ProfitLoss" contextRef="C_20230101to20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">263,073</ix:nonFraction></span></span></td>
    <td style="padding-bottom:1.5pt;text-align:left;width:1%">&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="font-weight:bold;padding-bottom:4pt;text-indent:-0.125in;padding-left:0.125in;width:34%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">BALANCE
        AT December&#160;31, 2023</span></span></td>
    <td style="padding-bottom:4pt;width:1%">&#160;</td>
    <td style="border-bottom:4pt double black;text-align:left;width:1%">&#160;</td>
    <td style="border-bottom:4pt double black;text-align:right;width:6%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fixv-37989" name="us-gaap:SharesOutstanding" contextRef="C_20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_usgaapCommonClassAMember_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">3,354,999</ix:nonFraction></span></span></td>
    <td style="padding-bottom:4pt;text-align:left;width:1%">&#160;</td>
    <td style="padding-bottom:4pt;width:1%">&#160;</td>
    <td style="border-bottom:4pt double black;text-align:left;width:1%">&#160;</td>
    <td style="border-bottom:4pt double black;text-align:right;width:6%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fixv-37990" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_usgaapCommonClassAMember_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">336</ix:nonFraction></span></span></td>
    <td style="padding-bottom:4pt;text-align:left;width:1%">&#160;</td>
    <td style="padding-bottom:4pt;width:1%">&#160;</td>
    <td style="border-bottom:4pt double black;text-align:left;width:1%">&#160;</td>
    <td style="border-bottom:4pt double black;text-align:right;width:7%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fixv-37991" name="us-gaap:SharesOutstanding" contextRef="C_20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_usgaapCommonClassBMember_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">1</ix:nonFraction></span></span></td>
    <td style="padding-bottom:4pt;text-align:left;width:1%">&#160;</td>
    <td style="padding-bottom:4pt;width:1%">&#160;</td>
    <td style="border-bottom:4pt double black;text-align:left;width:1%">&#160;</td>
    <td style="border-bottom:4pt double black;text-align:right;width:6%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="-sec-ix-hidden:Fhidden-fact-88">*</span></span></span></td>
    <td style="padding-bottom:4pt;text-align:left;width:1%">&#160;</td>
    <td style="padding-bottom:4pt;width:1%">&#160;</td>
    <td style="border-bottom:4pt double black;text-align:left;width:1%">&#160;</td>
    <td style="border-bottom:4pt double black;text-align:right;width:6%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20241004164626074" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></td>
    <td style="padding-bottom:4pt;text-align:left;width:1%">&#160;</td>
    <td style="padding-bottom:4pt;width:1%">&#160;</td>
    <td style="border-bottom:4pt double black;text-align:left;width:1%">&#160;</td>
    <td style="border-bottom:4pt double black;text-align:right;width:8%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fixv-37992" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">2,848,844</ix:nonFraction></span></span></td>
    <td style="padding-bottom:4pt;text-align:left;width:1%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></td>
    <td style="padding-bottom:4pt;width:1%">&#160;</td>
    <td style="border-bottom:4pt double black;text-align:left;width:1%">&#160;</td>
    <td style="border-bottom:4pt double black;text-align:right;width:6%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fixv-37993" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">2,848,508</ix:nonFraction></span></span></td>
    <td style="padding-bottom:4pt;text-align:left;width:1%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></td>
        </tr>
  </table>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>&#160;</span></span></span></p>

<div style="margin-top:0pt;margin-bottom:0pt;width:25%">

<div style="font-size:1pt;border-top:Black 1.5pt solid">&#160;</div> </div>

<table cellpadding="0" cellspacing="0" style="font:10pt Times New Roman, Times, Serif;margin-top:0pt;margin-bottom:0pt;width:100%">
  <tr>
    <td style="width:0.25in;text-align:left">&#160;</td>
    <td style="text-align:justify">&#160;</td> </tr>
  <tr style="vertical-align:top;text-align:justify">
    <td style="width:0.25in;text-align:left"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>*</span></span></span></td>
    <td style="text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Less than&#160;one US dollar.</span></span></td>
        </tr>
  </table>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><strong>&#160;</strong></span></span></span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><strong>The
accompanying notes are an integral part of these financial statements.</strong></span></span></span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>&#160;</span></span></span></p>

<div style="margin-top:12pt;margin-bottom:6pt;border-bottom:Black 1.5pt solid">

<p style="font:10pt Times New Roman, Times, Serif;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>F-25</span></span></span></p>
</div>

<div style="break-before:page;margin-top:6pt;margin-bottom:12pt">

<p style="margin:0pt">&#160;</p> </div>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><strong>&#160;</strong></span></span></span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p>

<div><span id="f_010"></span></div> </div>

<div style="font:10pt Times New Roman, Times, Serif">

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><strong>MORINGA
ACQUISITION CORP<br/>STATEMENTS OF CASH FLOWS</strong></span></span></span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><strong>&#160;</strong></span></span></span></p>

<table cellpadding="0" cellspacing="0" style="width:100%">
  <tr style="vertical-align:bottom">
    <td>&#160;</td>
    <td style="font-weight:bold;padding-bottom:1.5pt">&#160;</td>
    <td colspan="2" style="font-weight:bold;text-align:center;border-bottom:Black 1.5pt solid"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Year
        ended<br/>December&#160;31,<br/>2023</span></span></td>
    <td style="padding-bottom:1.5pt;font-weight:bold">&#160;</td>
    <td style="font-weight:bold;padding-bottom:1.5pt">&#160;</td>
    <td colspan="2" style="font-weight:bold;text-align:center;border-bottom:Black 1.5pt solid"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Year
        ended<br/>December&#160;31,<br/>2022</span></span></td>
    <td style="padding-bottom:1.5pt;font-weight:bold">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td>&#160;</td>
    <td style="font-weight:bold;padding-bottom:1.5pt">&#160;</td>
    <td colspan="6" style="font-weight:bold;text-align:center;border-bottom:Black 1.5pt solid"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">U.S.&#160;Dollars</span></span></td>
    <td style="padding-bottom:1.5pt;font-weight:bold">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="font-weight:bold;text-align:left"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">CASH FLOWS
        FROM OPERATING ACTIVITIES:</span></span></td>
    <td>&#160;</td>
    <td colspan="2" style="text-align:right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align:right">&#160;</td>
    <td>&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="text-align:left;text-indent:-0.125in;padding-left:0.25in;width:76%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Net
        profit for the year</span></span></td>
    <td style="width:1%">&#160;</td>
    <td style="text-align:left;width:1%">&#160;</td>
    <td style="text-align:right;width:9%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fixv-37994" name="us-gaap:ProfitLoss" contextRef="C_20230101to20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">263,073</ix:nonFraction></span></span></td>
    <td style="text-align:left;width:1%">&#160;</td>
    <td style="width:1%">&#160;</td>
    <td style="text-align:left;width:1%">&#160;</td>
    <td style="text-align:right;width:9%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fixv-37995" name="us-gaap:ProfitLoss" contextRef="C_20220101to20221231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">584,025</ix:nonFraction></span></span></td>
    <td style="text-align:left;width:1%">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="text-align:left;text-indent:-0.125in;padding-left:0.25in;width:76%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Adjustments
        to reconcile net profit to net cash provided by operating activities:</span></span></td>
    <td style="width:1%">&#160;</td>
    <td style="text-align:left;width:1%">&#160;</td>
    <td style="text-align:right;width:9%">&#160;</td>
    <td style="text-align:left;width:1%">&#160;</td>
    <td style="width:1%">&#160;</td>
    <td style="text-align:left;width:1%">&#160;</td>
    <td style="text-align:right;width:9%">&#160;</td>
    <td style="text-align:left;width:1%">&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="text-align:left;text-indent:-0.125in;padding-left:0.375in;width:76%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Changes
        in the fair value of the private warrant liability</span></span></td>
    <td style="width:1%">&#160;</td>
    <td style="text-align:left;width:1%">&#160;</td>
    <td style="text-align:right;width:9%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fixv-37996" name="us-gaap:FairValueAdjustmentOfWarrants" contextRef="C_20230101to20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">21,109</ix:nonFraction></span></span></td>
    <td style="text-align:left;width:1%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></td>
    <td style="width:1%">&#160;</td>
    <td style="text-align:left;width:1%">&#160;</td>
    <td style="text-align:right;width:9%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fixv-37997" name="us-gaap:FairValueAdjustmentOfWarrants" contextRef="C_20220101to20221231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">130,701</ix:nonFraction></span></span></td>
    <td style="text-align:left;width:1%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></td>
        </tr>
  <tr style="vertical-align:bottom">
    <td style="text-align:left;text-indent:-0.125in;padding-left:0.25in;width:76%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Changes
        in operating assets and liabilities:</span></span></td>
    <td style="width:1%">&#160;</td>
    <td style="text-align:left;width:1%">&#160;</td>
    <td style="text-align:right;width:9%">&#160;</td>
    <td style="text-align:left;width:1%">&#160;</td>
    <td style="width:1%">&#160;</td>
    <td style="text-align:left;width:1%">&#160;</td>
    <td style="text-align:right;width:9%">&#160;</td>
    <td style="text-align:left;width:1%">&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="text-align:left;text-indent:-0.125in;padding-left:0.375in;width:76%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Decrease
        in prepaid expenses</span></span></td>
    <td style="width:1%">&#160;</td>
    <td style="text-align:left;width:1%">&#160;</td>
    <td style="text-align:right;width:9%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fixv-37998" name="us-gaap:IncreaseDecreaseInPrepaidExpense" contextRef="C_20230101to20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">15,548</ix:nonFraction></span></span></td>
    <td style="text-align:left;width:1%">&#160;</td>
    <td style="width:1%">&#160;</td>
    <td style="text-align:left;width:1%">&#160;</td>
    <td style="text-align:right;width:9%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fixv-37999" name="us-gaap:IncreaseDecreaseInPrepaidExpense" contextRef="C_20220101to20221231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">325,000</ix:nonFraction></span></span></td>
    <td style="text-align:left;width:1%">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="text-align:left;text-indent:-0.125in;padding-left:0.375in;width:76%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Increase
        (decrease) in related party</span></span></td>
    <td style="width:1%">&#160;</td>
    <td style="text-align:left;width:1%">&#160;</td>
    <td style="text-align:right;width:9%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fixv-38000" name="us-gaap:IncreaseDecreaseInDueFromRelatedParties" contextRef="C_20230101to20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">20,000</ix:nonFraction></span></span></td>
    <td style="text-align:left;width:1%">&#160;</td>
    <td style="width:1%">&#160;</td>
    <td style="text-align:left;width:1%">&#160;</td>
    <td style="text-align:right;width:9%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fixv-38001" name="us-gaap:IncreaseDecreaseInDueFromRelatedParties" contextRef="C_20220101to20221231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">10,000</ix:nonFraction></span></span></td>
    <td style="text-align:left;width:1%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></td>
        </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="text-align:left;padding-bottom:1.5pt;text-indent:-0.125in;padding-left:0.375in;width:76%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Increase
        in accrued expenses</span></span></td>
    <td style="padding-bottom:1.5pt;width:1%">&#160;</td>
    <td style="border-bottom:1.5pt solid black;text-align:left;width:1%">&#160;</td>
    <td style="border-bottom:1.5pt solid black;text-align:right;width:9%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fixv-38002" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" contextRef="C_20230101to20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">28,872</ix:nonFraction></span></span></td>
    <td style="padding-bottom:1.5pt;text-align:left;width:1%">&#160;</td>
    <td style="padding-bottom:1.5pt;width:1%">&#160;</td>
    <td style="border-bottom:1.5pt solid black;text-align:left;width:1%">&#160;</td>
    <td style="border-bottom:1.5pt solid black;text-align:right;width:9%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fixv-38003" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" contextRef="C_20220101to20221231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">48,112</ix:nonFraction></span></span></td>
    <td style="padding-bottom:1.5pt;text-align:left;width:1%">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="text-align:left;padding-bottom:1.5pt;text-indent:-0.125in;padding-left:0.25in;width:76%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Net
        cash provided by operating activities</span></span></td>
    <td style="padding-bottom:1.5pt;width:1%">&#160;</td>
    <td style="border-bottom:1.5pt solid black;text-align:left;width:1%">&#160;</td>
    <td style="border-bottom:1.5pt solid black;text-align:right;width:9%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fixv-38004" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="C_20230101to20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">306,384</ix:nonFraction></span></span></td>
    <td style="padding-bottom:1.5pt;text-align:left;width:1%">&#160;</td>
    <td style="padding-bottom:1.5pt;width:1%">&#160;</td>
    <td style="border-bottom:1.5pt solid black;text-align:left;width:1%">&#160;</td>
    <td style="border-bottom:1.5pt solid black;text-align:right;width:9%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fixv-38005" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="C_20220101to20221231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">816,436</ix:nonFraction></span></span></td>
    <td style="padding-bottom:1.5pt;text-align:left;width:1%">&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="text-indent:-0.125in;padding-left:0.125in;width:76%">&#160;</td>
    <td style="width:1%">&#160;</td>
    <td style="text-align:left;width:1%">&#160;</td>
    <td style="text-align:right;width:9%">&#160;</td>
    <td style="text-align:left;width:1%">&#160;</td>
    <td style="width:1%">&#160;</td>
    <td style="text-align:left;width:1%">&#160;</td>
    <td style="text-align:right;width:9%">&#160;</td>
    <td style="text-align:left;width:1%">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="font-weight:bold;text-align:left;text-indent:-0.125in;padding-left:0.125in;width:76%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">CASH
        FLOWS FROM FINANCING ACTIVITIES:</span></span></td>
    <td style="width:1%">&#160;</td>
    <td style="text-align:left;width:1%">&#160;</td>
    <td style="text-align:right;width:9%">&#160;</td>
    <td style="text-align:left;width:1%">&#160;</td>
    <td style="width:1%">&#160;</td>
    <td style="text-align:left;width:1%">&#160;</td>
    <td style="text-align:right;width:9%">&#160;</td>
    <td style="text-align:left;width:1%">&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="text-align:left;text-indent:-0.125in;padding-left:0.375in;width:76%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Partial
        redemption of Class&#160;A ordinary shares subject to possible redemption</span></span></td>
    <td style="width:1%">&#160;</td>
    <td style="text-align:left;width:1%">&#160;</td>
    <td style="text-align:right;width:9%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fixv-38006" name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="C_20230101to20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">112,903,226</ix:nonFraction></span></span></td>
    <td style="text-align:left;width:1%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></td>
    <td style="width:1%">&#160;</td>
    <td style="text-align:left;width:1%">&#160;</td>
    <td style="text-align:right;width:9%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></td>
    <td style="text-align:left;width:1%">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="text-align:left;padding-bottom:1.5pt;text-indent:-0.125in;padding-left:0.375in;width:76%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Proceeds
        from a promissory note&#160;&#8211;&#160;related party</span></span></td>
    <td style="padding-bottom:1.5pt;width:1%">&#160;</td>
    <td style="border-bottom:1.5pt solid black;text-align:left;width:1%">&#160;</td>
    <td style="border-bottom:1.5pt solid black;text-align:right;width:9%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fixv-38007" name="us-gaap:ProceedsFromRelatedPartyDebt" contextRef="C_20230101to20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,651,000</ix:nonFraction></span></span></td>
    <td style="padding-bottom:1.5pt;text-align:left;width:1%">&#160;</td>
    <td style="padding-bottom:1.5pt;width:1%">&#160;</td>
    <td style="border-bottom:1.5pt solid black;text-align:left;width:1%">&#160;</td>
    <td style="border-bottom:1.5pt solid black;text-align:right;width:9%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fixv-38008" name="us-gaap:ProceedsFromRelatedPartyDebt" contextRef="C_20220101to20221231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">890,000</ix:nonFraction></span></span></td>
    <td style="padding-bottom:1.5pt;text-align:left;width:1%">&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="text-align:left;padding-bottom:1.5pt;text-indent:-0.125in;padding-left:0.25in;width:76%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Net
        cash provided by (used in) financing activities</span></span></td>
    <td style="padding-bottom:1.5pt;width:1%">&#160;</td>
    <td style="border-bottom:1.5pt solid black;text-align:left;width:1%">&#160;</td>
    <td style="border-bottom:1.5pt solid black;text-align:right;width:9%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fixv-38009" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="C_20230101to20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">111,252,226</ix:nonFraction></span></span></td>
    <td style="padding-bottom:1.5pt;text-align:left;width:1%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></td>
    <td style="padding-bottom:1.5pt;width:1%">&#160;</td>
    <td style="border-bottom:1.5pt solid black;text-align:left;width:1%">&#160;</td>
    <td style="border-bottom:1.5pt solid black;text-align:right;width:9%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fixv-38010" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="C_20220101to20221231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">890,000</ix:nonFraction></span></span></td>
    <td style="padding-bottom:1.5pt;text-align:left;width:1%">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="text-indent:-0.125in;padding-left:0.125in;width:76%">&#160;</td>
    <td style="width:1%">&#160;</td>
    <td style="text-align:left;width:1%">&#160;</td>
    <td style="text-align:right;width:9%">&#160;</td>
    <td style="text-align:left;width:1%">&#160;</td>
    <td style="width:1%">&#160;</td>
    <td style="text-align:left;width:1%">&#160;</td>
    <td style="text-align:right;width:9%">&#160;</td>
    <td style="text-align:left;width:1%">&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="font-weight:bold;text-align:left;text-indent:-0.125in;padding-left:0.125in;width:76%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">INCREASE
        (DECREASE) IN CASH, CASH EQUIVALENTS AND INVESTMENTS HELD IN A TRUST ACCOUNT</span></span></td>
    <td style="width:1%">&#160;</td>
    <td style="text-align:left;width:1%">&#160;</td>
    <td style="text-align:right;width:9%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fixv-38011" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" contextRef="C_20230101to20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">110,945,842</ix:nonFraction></span></span></td>
    <td style="text-align:left;width:1%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></td>
    <td style="width:1%">&#160;</td>
    <td style="text-align:left;width:1%">&#160;</td>
    <td style="text-align:right;width:9%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fixv-38012" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" contextRef="C_20220101to20221231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,706,436</ix:nonFraction></span></span></td>
    <td style="text-align:left;width:1%">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="font-weight:bold;text-align:left;padding-bottom:1.5pt;text-indent:-0.125in;padding-left:0.125in;width:76%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">CASH,
        CASH EQUIVALENTS AND INVESTMENTS HELD IN A TRUST&#160;ACCOUNT AT BEGINNING OF YEAR</span></span></td>
    <td style="padding-bottom:1.5pt;width:1%">&#160;</td>
    <td style="border-bottom:1.5pt solid black;text-align:left;width:1%">&#160;</td>
    <td style="border-bottom:1.5pt solid black;text-align:right;width:9%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fixv-38013" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="C_20221231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">116,751,752</ix:nonFraction></span></span></td>
    <td style="padding-bottom:1.5pt;text-align:left;width:1%">&#160;</td>
    <td style="padding-bottom:1.5pt;width:1%">&#160;</td>
    <td style="border-bottom:1.5pt solid black;text-align:left;width:1%">&#160;</td>
    <td style="border-bottom:1.5pt solid black;text-align:right;width:9%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fixv-38014" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="C_20211231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">115,045,316</ix:nonFraction></span></span></td>
    <td style="padding-bottom:1.5pt;text-align:left;width:1%">&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="font-weight:bold;text-align:left;padding-bottom:4pt;text-indent:-0.125in;padding-left:0.125in;width:76%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">CASH,
        CASH EQUIVALENTS AND INVESTMENTS HELD IN A TRUST&#160;ACCOUNT AT END OF YEAR</span></span></td>
    <td style="padding-bottom:4pt;width:1%">&#160;</td>
    <td style="border-bottom:4pt double black;text-align:left;width:1%">&#160;</td>
    <td style="border-bottom:4pt double black;text-align:right;width:9%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fixv-38015" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="C_20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,805,910</ix:nonFraction></span></span></td>
    <td style="padding-bottom:4pt;text-align:left;width:1%">&#160;</td>
    <td style="padding-bottom:4pt;width:1%">&#160;</td>
    <td style="border-bottom:4pt double black;text-align:left;width:1%">&#160;</td>
    <td style="border-bottom:4pt double black;text-align:right;width:9%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fixv-38016" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="C_20221231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">116,751,752</ix:nonFraction></span></span></td>
    <td style="padding-bottom:4pt;text-align:left;width:1%">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="text-indent:-0.125in;padding-left:0.125in;width:76%">&#160;</td>
    <td style="width:1%">&#160;</td>
    <td style="text-align:left;width:1%">&#160;</td>
    <td style="text-align:right;width:9%">&#160;</td>
    <td style="text-align:left;width:1%">&#160;</td>
    <td style="width:1%">&#160;</td>
    <td style="text-align:left;width:1%">&#160;</td>
    <td style="text-align:right;width:9%">&#160;</td>
    <td style="text-align:left;width:1%">&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="font-weight:bold;text-align:left;text-indent:-0.125in;padding-left:0.125in;width:76%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">RECONCILIATION
        OF CASH, CASH EQUIVALENTS AND INVESTMENTS HELD IN A TRUST ACCOUNT:</span></span></td>
    <td style="width:1%">&#160;</td>
    <td style="text-align:left;width:1%">&#160;</td>
    <td style="text-align:right;width:9%">&#160;</td>
    <td style="text-align:left;width:1%">&#160;</td>
    <td style="width:1%">&#160;</td>
    <td style="text-align:left;width:1%">&#160;</td>
    <td style="text-align:right;width:9%">&#160;</td>
    <td style="text-align:left;width:1%">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="text-align:left;text-indent:-0.125in;padding-left:0.375in;width:76%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Cash
        and cash equivalents</span></span></td>
    <td style="width:1%">&#160;</td>
    <td style="text-align:left;width:1%">&#160;</td>
    <td style="text-align:right;width:9%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fixv-38017" name="us-gaap:CashEquivalentsAtCarryingValue" contextRef="C_20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">108,278</ix:nonFraction></span></span></td>
    <td style="text-align:left;width:1%">&#160;</td>
    <td style="width:1%">&#160;</td>
    <td style="text-align:left;width:1%">&#160;</td>
    <td style="text-align:right;width:9%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fixv-38018" name="us-gaap:CashEquivalentsAtCarryingValue" contextRef="C_20221231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">59,714</ix:nonFraction></span></span></td>
    <td style="text-align:left;width:1%">&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="text-align:left;padding-bottom:1.5pt;text-indent:-0.125in;padding-left:0.375in;width:76%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Investments
        held in trust account</span></span></td>
    <td style="padding-bottom:1.5pt;width:1%">&#160;</td>
    <td style="border-bottom:1.5pt solid black;text-align:left;width:1%">&#160;</td>
    <td style="border-bottom:1.5pt solid black;text-align:right;width:9%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fixv-38019" name="us-gaap:AssetsHeldInTrust" contextRef="C_20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,697,632</ix:nonFraction></span></span></td>
    <td style="padding-bottom:1.5pt;text-align:left;width:1%">&#160;</td>
    <td style="padding-bottom:1.5pt;width:1%">&#160;</td>
    <td style="border-bottom:1.5pt solid black;text-align:left;width:1%">&#160;</td>
    <td style="border-bottom:1.5pt solid black;text-align:right;width:9%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fixv-38020" name="us-gaap:AssetsHeldInTrust" contextRef="C_20221231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">116,692,038</ix:nonFraction></span></span></td>
    <td style="padding-bottom:1.5pt;text-align:left;width:1%">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="text-align:left;padding-bottom:4pt;text-indent:-0.125in;padding-left:0.25in;width:76%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Total
        cash, cash equivalents and investments held in a trust account</span></span></td>
    <td style="padding-bottom:4pt;width:1%">&#160;</td>
    <td style="border-bottom:4pt double black;text-align:left;width:1%">&#160;</td>
    <td style="border-bottom:4pt double black;text-align:right;width:9%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fixv-38021" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="C_20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,805,910</ix:nonFraction></span></span></td>
    <td style="padding-bottom:4pt;text-align:left;width:1%">&#160;</td>
    <td style="padding-bottom:4pt;width:1%">&#160;</td>
    <td style="border-bottom:4pt double black;text-align:left;width:1%">&#160;</td>
    <td style="border-bottom:4pt double black;text-align:right;width:9%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fixv-38022" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="C_20221231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">116,751,752</ix:nonFraction></span></span></td>
    <td style="padding-bottom:4pt;text-align:left;width:1%">&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="text-indent:-0.125in;padding-left:0.125in;width:76%">&#160;</td>
    <td style="width:1%">&#160;</td>
    <td style="text-align:left;width:1%">&#160;</td>
    <td style="text-align:right;width:9%">&#160;</td>
    <td style="text-align:left;width:1%">&#160;</td>
    <td style="width:1%">&#160;</td>
    <td style="text-align:left;width:1%">&#160;</td>
    <td style="text-align:right;width:9%">&#160;</td>
    <td style="text-align:left;width:1%">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="font-weight:bold;text-align:left;text-indent:-0.125in;padding-left:0.125in;width:76%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">SUPPLEMENTARY
        INFORMATION REGARDING NON-CASH ACTIVITIES:</span></span></td>
    <td style="width:1%">&#160;</td>
    <td style="text-align:left;width:1%">&#160;</td>
    <td style="text-align:right;width:9%">&#160;</td>
    <td style="text-align:left;width:1%">&#160;</td>
    <td style="width:1%">&#160;</td>
    <td style="text-align:left;width:1%">&#160;</td>
    <td style="text-align:right;width:9%">&#160;</td>
    <td style="text-align:left;width:1%">&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="text-align:left;padding-bottom:4pt;text-indent:-0.125in;padding-left:0.375in;width:76%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Conversion
        of Class&#160;B ordinary shares into Class&#160;A ordinary shares</span></span></td>
    <td style="padding-bottom:4pt;width:1%">&#160;</td>
    <td style="border-bottom:4pt double black;text-align:left;width:1%">&#160;</td>
    <td style="border-bottom:4pt double black;text-align:right;width:9%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fixv-38023" name="us-gaap:StockIssued1" contextRef="C_20230101to20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">288</ix:nonFraction></span></span></td>
    <td style="padding-bottom:4pt;text-align:left;width:1%">&#160;</td>
    <td style="padding-bottom:4pt;width:1%">&#160;</td>
    <td style="border-bottom:4pt double black;text-align:left;width:1%">&#160;</td>
    <td style="border-bottom:4pt double black;text-align:right;width:9%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20241004165034887" name="us-gaap:StockIssued1" contextRef="C_20220101to20221231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></td>
    <td style="padding-bottom:4pt;text-align:left;width:1%">&#160;</td> </tr>
  </table>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><strong>&#160;</strong></span></span></span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><strong>The
accompanying notes are an integral part of these financial statements.</strong></span></span></span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><strong>&#160;</strong></span></span></span></p>

<div style="margin-top:12pt;margin-bottom:6pt;border-bottom:Black 1.5pt solid">

<p style="font:10pt Times New Roman, Times, Serif;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>F-26</span></span></span></p>
</div>

<div style="break-before:page;margin-top:6pt;margin-bottom:12pt">

<p style="margin:0pt">&#160;</p> </div>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><strong>&#160;</strong></span></span></span></p>

<div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span id="f_011"></span></span></span></div>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><strong>MORINGA
ACQUISITION CORP<br/>NOTES TO FINANCIAL STATEMENTS</strong></span></span></span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><strong>&#160;</strong></span></span></span></p>
</div>

<div style="font:10pt Times New Roman, Times, Serif"> <ix:nonNumeric id="Fxbrl_20241003001008037" name="us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock" contextRef="C_20230101to20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" escape="true">

<div>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt"><strong>NOTE
1&#160;&#8212;&#160;DESCRIPTION OF ORGANIZATION AND BUSINESS OPERATIONS:</strong></span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in;text-indent:-24pt"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt"><strong>&#160;</strong></span></p>

<table cellpadding="0" cellspacing="0" style="font:10pt Times New Roman, Times, Serif;margin-top:0pt;margin-bottom:0pt;width:100%">
  <tr style="vertical-align:top;text-align:justify">
    <td style="width:0.25in">&#160;</td>
    <td style="width:0.25in;text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt"><strong>a.</strong></span></td>
    <td style="text-align:justify"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt"><strong>Organization and General</strong></span></td>
        </tr>
  </table>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">&#160;</span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">Moringa
Acquisition Corp (hereafter&#160;&#8212;&#160;the Company) is a blank check company, incorporated on September&#160;24, 2020 as a Cayman
Islands exempted company, formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization
or similar business combination (hereafter&#160;&#8212;&#160;the Business Combination). The Company is an emerging growth company, as
defined in Section&#160;2(a)&#160;of the Securities Act&#160;of&#160;1933, as amended (the &#8220;Securities Act&#8221;), as modified
by the Jumpstart Our Business Startups Act&#160;of&#160;2012 (the &#8220;JOBS Act&#8221;).</span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">&#160;</span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">All
activity for the year ended December&#160;31, 2023 relates to the Company&#8217;s search for a target company, as well as attempts to
consummate the Proposed Holisto Merger which was terminated on August&#160;8, 2023 as detailed in Note&#160;1(f).</span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">&#160;</span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">In
February&#160;2024, the Company entered into a Business Combination Agreement with Silexion. Refer to Note&#160;10(b)&#160;for further
information regarding the Proposed Business Combination.</span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">&#160;</span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">The
Company has selected December&#160;31 as its fiscal year end.</span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in;text-indent:-24pt"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt"><strong>&#160;</strong></span></p>

<table cellpadding="0" cellspacing="0" style="font:10pt Times New Roman, Times, Serif;margin-top:0pt;margin-bottom:0pt;width:100%">
  <tr style="vertical-align:top;text-align:justify">
    <td style="width:0.25in">&#160;</td>
    <td style="width:0.25in;text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt"><strong>b.</strong></span></td>
    <td style="text-align:justify"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt"><strong>Sponsor and Financing</strong></span></td>
        </tr>
  </table>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">&#160;</span></p>

<p style="text-align:left;font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">The
Company&#8217;s sponsor is Moringa Sponsor, L.P., a Cayman exempted limited partnership (which is referred to herein, together with its
wholly-owned subsidiary, Moringa Sponsor (US) LP, a Delaware limited partnership, as the &#8220;Sponsor&#8221;).</span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">&#160;</span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">The
registration statement relating to the Company&#8217;s Public Offering was declared effective by the United&#160;States Securities and
Exchange Commission (the &#8220;SEC&#8221;) on February&#160;16, 2021. The initial stage of the Company&#8217;s Public Offering&#160;&#8212;&#160;the
sale of&#160;<ix:nonFraction id="Fixv-38024" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" contextRef="C_20210219to20210219_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapSubsidiarySaleOfStockAxis_usgaapIPOMember" unitRef="shares" scale="0" decimals="0" format="ixt:num-dot-decimal">10,000,000</ix:nonFraction>&#160;Units&#160;&#8212;&#160;closed
on February&#160;19, 2021 (hereafter&#160;&#8212;&#160;the Closing of the Public Offering). Upon that closing and the concurrent closing
of the initial stage of the Private Placement (as defined below in Note&#160;3). $<ix:nonFraction id="Fixv-38025" name="us-gaap:AssetsHeldInTrust" contextRef="C_20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapSubsidiarySaleOfStockAxis_usgaapPrivatePlacementMember" unitRef="usd" scale="0" decimals="0" format="ixt:num-dot-decimal">100,000,000</ix:nonFraction>&#160;was
placed in a trust account (the &#8220;Trust Account&#8221;) (discussed in Note&#160;1(c)&#160;below). On March&#160;3, 2021 upon the full
exercise by the underwriters of their over-allotment option for the Public Offering, the second stage of the Public Offering&#160;&#8212;&#160;the
sale of&#160;<ix:nonFraction id="Fixv-38026" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" contextRef="C_20210303to20210303_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapSubsidiarySaleOfStockAxis_usgaapOverAllotmentOptionMember" unitRef="shares" scale="0" decimals="0" format="ixt:num-dot-decimal">1,500,000</ix:nonFraction>&#160;Units&#160;&#8212;&#160;closed.
Upon that closing and the concurrent closing of the second stage of the Private Placement, an additional $<ix:nonFraction id="Fixv-38027" name="us-gaap:AssetsHeldInTrust" contextRef="C_20210303_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapSubsidiarySaleOfStockAxis_usgaapOverAllotmentOptionMember" unitRef="usd" scale="0" decimals="0" format="ixt:num-dot-decimal">15,000,000</ix:nonFraction>&#160;was
placed in the Trust Account. As part of the partial redemptions in conjunction with the First and Second Extensions, approximately $<ix:nonFraction id="Fixv-38028" name="slxn:AmountFromTheInvestmentsHeldInTrustAccount" contextRef="C_20230101to20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="usd" scale="6" decimals="-6" format="ixt:num-dot-decimal">113</ix:nonFraction>&#160;million
have been withdrawn from the Investments held in Trust Account. The Company intends to finance its Initial Business Combination with the
net proceeds from the Public Offering and the Private Placement.</span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in;text-indent:-24pt"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt"><strong>&#160;</strong></span></p>

<table cellpadding="0" cellspacing="0" style="font:10pt Times New Roman, Times, Serif;margin-top:0pt;margin-bottom:0pt;width:100%">
  <tr style="vertical-align:top;text-align:justify">
    <td style="width:0.25in">&#160;</td>
    <td style="width:0.25in;text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt"><strong>c.</strong></span></td>
    <td style="text-align:justify"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt"><strong>The Trust Account</strong></span></td>
        </tr>
  </table>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">&#160;</span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">The
proceeds held in the Trust Account are invested in money market funds registered under the Investment Company Act and compliant with Rule&#160;2a-7
thereof that maintain a stable net asset value of&#160;$<ix:nonFraction id="Fixv-38029" name="us-gaap:NetAssetValuePerShare" contextRef="C_20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="usdPershares" scale="0" decimals="2" format="ixt:num-dot-decimal">1.00</ix:nonFraction>.</span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">&#160;</span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">The
Company&#8217;s complies with the provisions of ASU&#160;2016-18, under which changes in proceeds held in the Trust Account are accounted
for as Changes in Cash, Cash Equivalents and Investments Held in a&#160;Trust Account in the Company&#8217;s Statements of Cash Flows.</span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">&#160;</span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">Refer
to Note&#160;4(a)&#160;for information regarding proceeds loaned by the Sponsor under the Sixth and Eighth Promissory Notes, deposited
into the Trust Account.</span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in;text-indent:-24pt"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt"><strong>&#160;</strong></span></p>

<table cellpadding="0" cellspacing="0" style="font:10pt Times New Roman, Times, Serif;margin-top:0pt;margin-bottom:0pt;width:100%">
  <tr style="vertical-align:top;text-align:justify">
    <td style="width:0.25in">&#160;</td>
    <td style="width:0.25in;text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt"><strong>d.</strong></span></td>
    <td style="text-align:justify"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt"><strong>Initial Business Combination</strong></span></td>
        </tr>
  </table>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">&#160;</span></p>

<p style="text-align:left;font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">The
Company&#8217;s management has broad discretion with respect to the specific application of the net proceeds of the Public Offering, although
substantially all of the net proceeds of the Public Offering and the Private Placement are intended to be generally applied toward consummating
an Initial Business Combination. The Initial Business Combination must occur with one or more operating businesses or assets with a fair
market value equal to at least&#160;<ix:nonFraction id="Fixv-38030" name="slxn:BusinessCombinationOfNetAssetsHeldInTrustAccount" contextRef="C_20230101to20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">80</ix:nonFraction>%
of the net assets held in the Trust Account (excluding taxes payable on the income accrued in the Trust Account) as of the time of entry
into the related definitive agreement for the Initial Business Combination. There is no assurance that the Company will be able to successfully
consummate an Initial Business Combination.</span></p>

<p style="text-align:left;font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in">&#160;</p>

<div><ix:exclude>

<div style="margin-top:12pt;margin-bottom:6pt;border-bottom:Black 1.5pt solid">

<p style="font:10pt Times New Roman, Times, Serif;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">F-27</span></p>
</div>

<div style="break-before:page;margin-top:6pt;margin-bottom:12pt">

<p style="margin:0pt">&#160;</p> </div>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">&#160;</span></p>

<p style="font:10pt Times New Roman, Times, serif;margin:10pt 0px 0pt;text-align:center"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt"><strong>MORINGA
ACQUISITION CORP<br/>NOTES TO FINANCIAL STATEMENTS</strong></span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt"><strong>&#160;</strong></span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt"><strong>NOTE
1&#160;&#8212;&#160;DESCRIPTION OF ORGANIZATION AND BUSINESS OPERATIONS:</strong> (cont.)</span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">&#160;</p> </ix:exclude></div>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">The
Company, after signing a definitive agreement for an Initial Business Combination, will provide its public shareholders the opportunity
to redeem all or a portion of their shares upon the completion of the Initial Business Combination, either (i)&#160;in connection with
a shareholder meeting called to approve the business combination or (ii)&#160;by means of a tender offer.</span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">&#160;</span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">If
the Company holds a shareholder vote or there is a tender offer for shares in connection with an Initial Business Combination, a public
shareholder will have the right to redeem its shares for an amount in cash equal to its pro rata share of the aggregate amount then on
deposit in the Trust Account, calculated as of two&#160;days prior to the general meeting or commencement of the Company&#8217;s tender
offer, including interest but less taxes payable. As a result, the Company&#8217;s Class&#160;A ordinary shares subject to possible redemption
are classified as temporary equity upon the completion of the Public Offering, in accordance with the Financial Accounting Standards Board
(&#8220;FASB&#8221;) Accounting Standards Codification (&#8220;ASC&#8221;) 480, &#8220;Distinguishing Liabilities from Equity&#8221;.</span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">&#160;</span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">Pursuant
to the Company&#8217;s amended and restated memorandum and articles of association, if the Company is unable to complete the Initial Business
Combination within 24&#160;months (as was subsequently extended, as described below) from the Closing of the Public Offering, the Company
will (i)&#160;cease all operations except for the purpose of winding up, (ii)&#160;as promptly as reasonably possible but not more than
ten&#160;business days thereafter, redeem the public shares, at a per-share price, payable in cash, equal to the aggregate amount then
on deposit in the Trust Account, including interest (which interest shall be net of taxes payable, and less up to $<ix:nonFraction id="Fixv-38031" name="slxn:InterestToPayDissolutionExpenses" contextRef="C_20230101to20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="usd" scale="0" decimals="0" format="ixt:num-dot-decimal">100,000</ix:nonFraction>&#160;of
interest to pay dissolution expenses), divided by the number of then outstanding public shares, which redemption will completely extinguish
public shareholders&#8217; rights as shareholders (including the right to receive further liquidating distributions, if any), and (iii)&#160;as
promptly as reasonably possible following such redemption, subject to the approval of the Company&#8217;s remaining shareholders and the
Company&#8217;s board of directors, liquidate and dissolve, subject in each case to the Company&#8217;s obligations under Cayman Islands
law to provide for claims of creditors and the requirements of other applicable law.</span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">&#160;</span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">The
Sponsor and the Company&#8217;s officers and directors have entered into a letter agreement with the Company, pursuant to which they have
waived their rights to liquidating distributions from the Trust Account with respect to any Class&#160;B ordinary share, including any
Class&#160;A ordinary share issuable upon conversion of such Class&#160;B ordinary shares, and Class&#160;A ordinary share (as described
in Note&#160;7) held by them if the Company fails to complete the Initial Business Combination within 24&#160;months (as was subsequently
extended) of the Closing of the Public Offering or during any extended time that the Company has to consummate an Initial Business Combination
beyond 24&#160;months as a result of a shareholder vote to amend its amended and restated memorandum and articles of association. However,
if the Sponsor or any of the Company&#8217;s directors or officers acquire any Class&#160;A ordinary shares subject to possible redemption,
they will be entitled to liquidating distributions from the Trust Account with respect to such shares if the Company fails to complete
the Initial Business Combination within the prescribed time period.</span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">&#160;</span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">In
the event of a liquidation, dissolution or winding up of the Company after an Initial Business Combination, the Company&#8217;s shareholders
are entitled to share ratably in all assets remaining available for distribution to them after payment of liabilities and after provision
is made for each class of stock, if any, having preference over the ordinary shares. The Company&#8217;s shareholders have no preemptive
or other subscription rights. There are no sinking fund provisions applicable to the ordinary shares, except that the Company will provide
its shareholders with the opportunity to redeem their public shares for cash equal to their pro rata share of the aggregate amount then
on deposit in the Trust Account, under the circumstances, and, subject to the limitations, described herein.</span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in">&#160;</p>

<div><ix:exclude>

<div style="margin-top:12pt;margin-bottom:6pt;border-bottom:Black 1.5pt solid">

<p style="font:10pt Times New Roman, Times, Serif;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">F-28</span></p>
</div>

<div style="break-before:page;margin-top:6pt;margin-bottom:12pt">

<p style="margin:0pt">&#160;</p> </div>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt"><strong>&#160;</strong></span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt"><strong>MORINGA
ACQUISITION CORP<br/>NOTES TO FINANCIAL STATEMENTS</strong></span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt"><strong>&#160;</strong></span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt"><strong>NOTE
1&#160;&#8212;&#160;DESCRIPTION OF ORGANIZATION AND BUSINESS OPERATIONS:</strong> (cont.)</span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">&#160;</p> </ix:exclude></div>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">On
February&#160;9, 2023 the Company held an extraordinary general meeting in lieu of the 2022 annual general meeting of the Company (hereafter&#160;&#8212;&#160;the
First Extension Meeting). At the First Extension Meeting, the Company&#8217;s shareholders approved the proposal to adopt, by way of special
resolution, an amendment to the Amended and Restated Articles to extend the date by which the Company has to consummate a business combination
from the 24 month anniversary of the Closing of the Public Offering&#160;&#8212;&#160;i.e., February&#160;19, 2023 to August&#160;19,
2023 (hereafter&#160;&#8212;&#160;the Extended Mandatory Liquidation Date) or such earlier date as may be determined by the Board in its
sole discretion.</span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">&#160;</span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">On
August&#160;18, 2023 the Company held an extraordinary general meeting in lieu of the 2023 annual general meeting of the Company (hereafter&#160;&#8212;&#160;the
Second Extension Meeting). At the Second Extension Meeting, the Company&#8217;s shareholders approved, among other proposals, an amendment
to the Amended and Restated Memorandum and Articles of Association to further extend the date by which the Company has to consummate a
business combination from the Extended Mandatory Liquidation Date to August&#160;19, 2024 (hereafter&#160;&#8212;&#160;the Second Extended
Mandatory Liquidation Date) or such earlier date as may be determined by the Board in its sole discretion.</span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">&#160;</span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">Refer
to Note&#160;4(a)&#160;for information regarding proceeds received by the Company from the Sponsor under the Sixth and Eighth Promissory
Notes, which were deposited into the Trust Account.</span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">&#160;</span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">Refer
to Note&#160;7(a)&#160;for information regarding the partial redemptions of Class&#160;A ordinary shares subject to possible redemption,
following the First and Second Extension Meetings.</span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">&#160;</span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">Refer
to Note&#160;5(b)&#160;for information regarding the conversion of Class&#160;B ordinary shares into Class&#160;A ordinary shares, following
the Second Extension Meeting.</span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in;text-indent:-24pt"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt"><strong>&#160;</strong></span></p>

<table cellpadding="0" cellspacing="0" style="font:10pt Times New Roman, Times, Serif;margin-top:0pt;margin-bottom:0pt;width:100%">
  <tr style="vertical-align:top;text-align:justify">
    <td style="width:0.25in">&#160;</td>
    <td style="width:0.25in;text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt"><strong>e.</strong></span></td>
    <td style="text-align:justify"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt"><strong>Substantial Doubt about the
        Company&#8217;s Ability to Continue as a Going Concern</strong></span></td> </tr>
  </table>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">&#160;</span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">As
of December&#160;31, 2023 the Company had approximately $<ix:nonFraction id="Fixv-38032" name="us-gaap:Cash" contextRef="C_20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">108</ix:nonFraction>&#160;thousand
of cash and an accumulated deficit of approximately $<ix:nonFraction id="Fixv-38033" name="us-gaap:RetainedEarningsAppropriated" contextRef="C_20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,848</ix:nonFraction>&#160;thousand.
In connection with the Company&#8217;s assessment of going concern considerations in accordance with Financial Accounting Standard Board&#8217;s
Accounting Standard Codification&#160;205-40, &#8220;Going Concern&#8221;, the Company will need to obtain additional funds in order to
satisfy its liquidity needs in its endeavors to consummate a business combination.</span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">&#160;</span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">Since
its inception date and through the issuance date of these financial statements, the Company&#8217;s liquidity needs were satisfied through
an initial capital injection from the Sponsor, followed by net Private Placement proceeds, as well as several withdrawals of the Sponsor
promissory notes. Management has determined that it will need to continue to rely and is significantly dependent on both outstanding and
future promissory notes, or other forms of financial support (all of which the Sponsor is not obligated to provide). Moreover, following
the Second Extension Meeting, the Company has until August&#160;19, 2024 to consummate an Initial Business Combination. If a business
combination is not consummated by this date, there will be a mandatory liquidation and subsequent dissolution of the Company. There can
be no assurance that the Company will be able to consummate any business combination ahead of the Second Extended Mandatory Liquidation
Date, nor will it be able to raise sufficient funds to complete an Initial Business Combination. These matters raise substantial doubt
about the Company&#8217;s ability to continue as a going concern, for the subsequent twelve&#160;months following the issuance date of
these financial statements. In February&#160;2024, the Company entered into a Business Combination Agreement with Silexion Therapeutics
Ltd. (hereafter&#160;&#8212;&#160;Silexion). Refer to Note&#160;10(b)&#160;for further information regarding the Proposed Business Combination.</span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">&#160;</span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">No
adjustments have been made to the carrying amounts of assets or liabilities should the company fail to obtain financial support in its
pursuit to consummate an Initial Business Combination, nor if it is required to liquidate after the Second Extended Mandatory Liquidation
Date.</span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in">&#160;</p>

<div><ix:exclude>

<div style="margin-top:12pt;margin-bottom:6pt;border-bottom:Black 1.5pt solid">

<p style="font:10pt Times New Roman, Times, Serif;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">F-29</span></p>
</div>

<div style="break-before:page;margin-top:6pt;margin-bottom:12pt">

<p style="margin:0pt">&#160;</p> </div>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt"><strong>&#160;</strong></span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt"><strong>MORINGA
ACQUISITION CORP<br/>NOTES TO FINANCIAL STATEMENTS</strong></span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt"><strong>&#160;</strong></span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt"><strong>NOTE
1&#160;&#8212;&#160;DESCRIPTION OF ORGANIZATION AND BUSINESS OPERATIONS:</strong> (cont.)</span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">&#160;</p> </ix:exclude></div>

<table cellpadding="0" cellspacing="0" style="font:10pt Times New Roman, Times, Serif;margin-top:0pt;margin-bottom:0pt;width:100%">
  <tr style="vertical-align:top;text-align:justify">
    <td style="width:0.25in">&#160;</td>
    <td style="width:0.25in;text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt"><strong>f.</strong></span></td>
    <td style="text-align:justify"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt"><strong>Proposed Business Combination</strong></span></td>
        </tr>
  </table>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">&#160;</span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">On
June&#160;9, 2022 the Company entered into a Business Combination Agreement for a proposed business combination (hereafter&#160;&#8212;&#160;the
Proposed Holisto Merger) with Holisto Ltd., a company organized under the laws of the State of Israel (hereafter&#160;&#8212;&#160;Holisto)
and Holisto MergerSub, Inc., a Cayman Islands exempted company and wholly-owned subsidiary of Holisto.</span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">&#160;</span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">On
August&#160;7, 2023 Holisto notified the Company that it was terminating the Proposed Holisto Merger agreement. The termination became
effective as of August&#160;8, 2023. Upon termination of the Proposed Holisto Merger, all rights and obligations of each party to the
agreement ceased, except for those obligations of the parties that are intended to survive such termination and which remain in effect
in accordance with their respective terms. Neither the Company nor Holisto has any remaining substantive obligation to one another following
the above-mentioned termination, as of date of these financial statements.</span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">&#160;</span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">In
February&#160;2024, the Company entered into a Business Combination Agreement with Silexion. Refer to Note&#160;10(b)&#160;for further
information regarding the Proposed Business Combination.</span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in;text-indent:-24pt"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt"><strong>&#160;</strong></span></p>

<table cellpadding="0" cellspacing="0" style="font:10pt Times New Roman, Times, Serif;margin-top:0pt;margin-bottom:0pt;width:100%">
  <tr style="vertical-align:top;text-align:justify">
    <td style="width:0.25in">&#160;</td>
    <td style="width:0.25in;text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt"><strong>g.</strong></span></td>
    <td style="text-align:justify"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt"><strong>Impact of War in Israel</strong></span></td>
        </tr>
  </table>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">&#160;</span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">On
October&#160;7, 2023 Hamas terrorists infiltrated Israel&#8217;s southern border from the Gaza Strip and conducted a series of attacks
on civilian and military targets. Hamas also launched extensive rocket attacks on Israeli population and industrial centers located along
Israel&#8217;s border with the Gaza Strip and in other areas within the State of Israel. These attacks resulted in extensive deaths, injuries
and kidnapping of civilians and soldiers. Following the attack, Israel&#8217;s security cabinet declared war against Hamas and a military
campaign against these terrorist organizations commenced in parallel to their continued rocket and terror attacks.</span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">&#160;</span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">The
intensity and duration of Israel&#8217;s current war against Hamas is difficult to predict, as are such war&#8217;s economic implications
on the business and operations on any target company with which the Company may combine, and on Israel&#8217;s economy in general. These
events may cause wider macroeconomic deterioration in Israel, which may have a material adverse effect on the Company&#8217;s ability
to effectively complete an Initial Business Combination, or on the operations of an Israel-centered target company with which the Company
may combine.</span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">&#160;</span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">Refer
to Note&#160;10(b)&#160;for further information regarding the Proposed Business Combination.</span></p> </div> </ix:nonNumeric>

<p style="margin:0pt">&#160;</p> </div>

<div style="font:10pt Times New Roman, Times, Serif"> <ix:nonNumeric id="Fxbrl_20241003104814981" name="us-gaap:SignificantAccountingPoliciesTextBlock" contextRef="C_20230101to20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" escape="true">

<div>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt"><strong>NOTE
2 &#8212;&#160;SIGNIFICANT ACCOUNTING POLICIES:</strong></span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in;text-indent:-24pt"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt"><strong>&#160;</strong></span></p>
<ix:nonNumeric id="Fxbrl_20241003105429224" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" contextRef="C_20230101to20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" escape="true">

<div>

<table cellpadding="0" cellspacing="0" style="font:10pt Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;width:100%;border:0px">
  <tr style="vertical-align:top;text-align:justify">
    <td style="width:0.25in">&#160;</td>
    <td style="width:0.25in;text-align:left"><span style="font-size:10pt;font-family:Times New Roman, Times, serif"><strong>a.</strong></span></td>
    <td style="text-align:justify"><strong style="font-size:10pt">Basis of Presentation</strong></td> </tr>
  </table>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">The
Company&#8217;s financial statements have been prepared in accordance with accounting principles generally accepted in the United&#160;States
of America (&#8220;U.S.&#160;GAAP&#8221;) and the rules and regulations of the SEC.</span></p> </div> </ix:nonNumeric>

<p style="margin:0pt">&#160;</p> <ix:nonNumeric id="Fxbrl_20241003105542454" name="slxn:EmergingGrowthCompanyPolicyTextBlock" contextRef="C_20230101to20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" escape="true">

<div>

<div>

<table cellpadding="0" cellspacing="0" style="font:10pt Times New Roman, Times, Serif;margin-top:0pt;margin-bottom:0pt;width:100%">
  <tr style="vertical-align:top;text-align:justify">
    <td style="width:0.25in">&#160;</td>
    <td style="width:0.25in;text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt"><strong>b.</strong></span></td>
    <td style="text-align:justify"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt"><strong>Emerging Growth Company</strong></span></td>
        </tr>
  </table>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">&#160;</span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">Section&#160;102(b)(1)&#160;of
the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until
private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a class
of securities registered under the Exchange&#160;Act) are required to comply with the new or revised financial accounting standards.</span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">&#160;</span></p>

<p style="font:10pt Times New Roman, Times, Serif;text-align:left;margin:0pt 0 0pt 0.5in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">The
JOBS Act provides that a company can elect to opt out of the extended transition period and comply with the&#160;requirements that apply
to non-emerging growth companies but any such election to opt out is irrevocable. The Company has elected not to opt out of such extended
transition period which means that&#160;</span>when a standard is issued or revised and it has different application dates for public
or private companies, the Company, as an emerging growth company, can adopt the new or revised standard at the time private companies
adopt the new or revised standard.</p> </div>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">&#160;</span></p>

<div><ix:exclude>

<div style="margin-top:12pt;margin-bottom:6pt;border-bottom:Black 1.5pt solid">

<p style="font:10pt Times New Roman, Times, Serif;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">F-30</span></p>
</div>

<div style="break-before:page;margin-top:6pt;margin-bottom:12pt">

<p style="margin:0pt">&#160;</p> </div>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt"><strong>MORINGA
ACQUISITION CORP<br/>NOTES TO FINANCIAL STATEMENTS</strong></span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt"><strong>&#160;</strong></span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt"><strong>NOTE
2 &#8212;&#160;SIGNIFICANT ACCOUNTING POLICIES:</strong> (cont.)</span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">&#160;</p> </ix:exclude></div>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">This
may make comparison of the Company&#8217;s financial statements with another public company which is neither an emerging growth company
nor an emerging growth company which has opted out of using the extended transition period difficult or impossible, because of the potential
differences in accounting standards used.</span></p> </div> </ix:nonNumeric>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in;text-indent:-24pt"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt"><strong>&#160;</strong></span></p>
<ix:nonNumeric id="Fxbrl_20241003105605485" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" contextRef="C_20230101to20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" escape="true">

<div>

<table cellpadding="0" cellspacing="0" style="font:10pt Times New Roman, Times, Serif;margin-top:0pt;margin-bottom:0pt;width:100%">
  <tr style="vertical-align:top;text-align:justify">
    <td style="width:0.25in">&#160;</td>
    <td style="width:0.25in;text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt"><strong>c.</strong></span></td>
    <td style="text-align:justify"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt"><strong>Cash and cash equivalents</strong></span></td>
        </tr>
  </table>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">&#160;</span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">The
Company considers as cash equivalents all short-term, highly liquid investments, which include short-term bank deposits with original
maturities of three&#160;months or less from the date of purchase that are not restricted as to withdrawal or use by nature of the account
and are readily convertible to known amounts of cash.</span></p> </div> </ix:nonNumeric>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in;text-indent:-24pt"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt"><strong>&#160;</strong></span></p>
<ix:nonNumeric id="Fxbrl_20241003105639003" name="us-gaap:SharesSubjectToMandatoryRedemptionChangesInRedemptionValuePolicyTextBlock" contextRef="C_20230101to20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" escape="true">

<div>

<table cellpadding="0" cellspacing="0" style="font:10pt Times New Roman, Times, Serif;margin-top:0pt;margin-bottom:0pt;width:100%">
  <tr style="vertical-align:top;text-align:justify">
    <td style="width:0.25in">&#160;</td>
    <td style="width:0.25in;text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt"><strong>d.</strong></span></td>
    <td style="text-align:justify"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt"><strong>Class&#160;A Ordinary Shares
        subject to possible redemption</strong></span></td> </tr>
  </table>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">&#160;</span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">As
discussed in Note&#160;1(b), all of the&#160;<ix:nonFraction id="Fxbrl_20241004144253613" name="us-gaap:TemporaryEquitySharesIssued" contextRef="C_20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_usgaapCommonClassAMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">11,500,000</ix:nonFraction>&#160;Class&#160;A
ordinary shares sold as part of the Units&#160;in the Public Offering contained a redemption feature. In accordance with the Accounting
Standards Codification&#160;480-10-S99-3A &#8220;Classification and Measurement of Redeemable Securities&#8221;, redemption provisions
not solely within the control of the Company require the security to be classified outside of permanent equity. The Company has classified
all of the shares sold under the Public Units&#160;as subject to possible redemption.</span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">&#160;</span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">Refer
to Note&#160;7(a)&#160;for information regarding the partial redemptions of Class&#160;A ordinary shares subject to possible redemption,
following the First Extension Meeting and the Second Extension Meeting.</span></p> </div> </ix:nonNumeric>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in;text-indent:-24pt"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt"><strong>&#160;</strong></span></p>
<ix:nonNumeric id="Fxbrl_20241003105657056" name="us-gaap:EarningsPerSharePolicyTextBlock" contextRef="C_20230101to20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" escape="true">

<div>

<table cellpadding="0" cellspacing="0" style="font:10pt Times New Roman, Times, Serif;margin-top:0pt;margin-bottom:0pt;width:100%">
  <tr style="vertical-align:top;text-align:justify">
    <td style="width:0.25in">&#160;</td>
    <td style="width:0.25in;text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt"><strong>e.</strong></span></td>
    <td style="text-align:justify"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt"><strong>Net profit (loss) per share</strong></span></td>
        </tr>
  </table>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">&#160;</span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">The
Company complies with accounting and disclosure requirements of FASB ASC Topic&#160;260, Earnings Per Share. Net profit (loss) per share
is computed by dividing net profit (loss) by the weighted average number of shares outstanding during the period. The Company applies
the two-class method in calculating net profit (loss) per each class of shares: the non-redeemable shares, which include the Private Class&#160;A
Ordinary Shares, as defined in Note&#160;7(a), and the Class&#160;B ordinary shares (hereafter and collectively&#160;&#8212;&#160;Non-Redeemable
class A and B ordinary shares); and the Class&#160;A ordinary shares subject to possible redemption.</span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">&#160;</span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">In
order to determine the net profit (loss) attributable to each class, the Company first considered the total profit (loss) allocable to
both sets of shares. This is calculated using the total net profit (loss) less any interest earned on investments held in the Trust Account.
Then, any accretion is fully allocated to the Class&#160;A ordinary shares subject to redemption.</span></p> </div> </ix:nonNumeric>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in;text-indent:-24pt">&#160;</p> <ix:nonNumeric id="Fxbrl_20241003105714772" name="us-gaap:ConcentrationRiskDisclosureTextBlock" contextRef="C_20230101to20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" escape="true">

<div>

<table cellpadding="0" cellspacing="0" style="font:10pt Times New Roman, Times, Serif;margin-top:0pt;margin-bottom:0pt;width:100%">
  <tr style="vertical-align:top;text-align:justify">
    <td style="width:0.25in">&#160;</td>
    <td style="width:0.25in;text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt"><strong>f.</strong></span></td>
    <td style="text-align:justify"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt"><strong>Concentration of credit risk</strong></span></td>
        </tr>
  </table>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">&#160;</span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">Financial
instruments that potentially subject the Company to concentrations of credit risk consist of cash accounts in a financial institution,
which, at times, may exceed the Federal Depository Insurance Coverage of $<ix:nonFraction id="Fixv-38035" name="us-gaap:FederalDepositInsuranceCorporationPremiumExpense" contextRef="C_20230101to20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="usd" scale="0" decimals="0" format="ixt:num-dot-decimal">250,000</ix:nonFraction>.
From the Company&#8217;s incorporation and through December&#160;31, 2023 the Company has not experienced any losses on these accounts.</span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">&#160;</span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">As
of December&#160;31, 2023 the Company held its cash and cash equivalents in an SVB bank account, and its investments Held in Trust Account
in Goldman Sachs money market funds. Money market funds are characterized as Level 1 investments within the fair value hierarchy under
ASC&#160;820.</span></p> </div> </ix:nonNumeric>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in">&#160;</p>

<div><ix:exclude>

<div style="margin-top:12pt;margin-bottom:6pt;border-bottom:Black 1.5pt solid">

<p style="font:10pt Times New Roman, Times, Serif;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">F-31</span></p>
</div>

<div style="break-before:page;margin-top:6pt;margin-bottom:12pt">

<p style="margin:0pt">&#160;</p> </div>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt"><strong>&#160;</strong></span></p>

<p style="font:10pt Times New Roman, Times, serif;margin:10pt 0px 0pt;text-align:center"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt"><strong>MORINGA
ACQUISITION CORP<br/>NOTES TO FINANCIAL STATEMENTS</strong></span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt"><strong>&#160;</strong></span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt"><strong>NOTE
2 &#8212;&#160;SIGNIFICANT ACCOUNTING POLICIES:</strong> (cont.)</span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">&#160;</p> </ix:exclude></div> <ix:nonNumeric id="Fxbrl_20241003105739676" name="slxn:PublicWarrantsPolicyTextBlock" contextRef="C_20230101to20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" escape="true">

<div>

<table cellpadding="0" cellspacing="0" style="font:10pt Times New Roman, Times, Serif;margin-top:0pt;margin-bottom:0pt;width:100%">
  <tr style="vertical-align:top;text-align:justify">
    <td style="width:0.25in">&#160;</td>
    <td style="width:0.25in;text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt"><strong>g.</strong></span></td>
    <td style="text-align:justify"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt"><strong>Public Warrants</strong></span></td>
        </tr>
  </table>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">&#160;</span></p>

<p style="text-align:left;font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">The
Company applied the provisions of ASC&#160;815-40 and classified its public warrants, issued as part of the Public Units&#160;as detailed
in Note&#160;3, as equity securities.</span></p> </div> </ix:nonNumeric>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in;text-indent:-24pt"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt"><strong>&#160;</strong></span></p>
<ix:nonNumeric id="Fxbrl_20241003105757356" name="slxn:PrivateWarrantLiabilityPolicyTextBlock" contextRef="C_20230101to20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" escape="true">

<div>

<table cellpadding="0" cellspacing="0" style="font:10pt Times New Roman, Times, Serif;margin-top:0pt;margin-bottom:0pt;width:100%">
  <tr style="vertical-align:top;text-align:justify">
    <td style="width:0.25in">&#160;</td>
    <td style="width:0.25in;text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt"><strong>h.</strong></span></td>
    <td style="text-align:justify"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt"><strong>Private Warrant liability</strong></span></td>
        </tr>
  </table>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">&#160;</span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">The
Company accounts for the warrants in accordance with the guidance contained in Accounting Standards Codification 815 (&#8220;ASC&#160;815&#8221;),
&#8220;Derivatives and Hedging&#8221;, under which the warrants do not meet the criteria for equity treatment and must be recorded as
derivative liabilities. Accordingly, the Company classifies the warrants as liabilities at their fair value and adjusts the warrants to
fair value at each reporting period. This liability is subject to re-measurement at each balance sheet date until the warrants are exercised
or expire, and any change in fair value is recognized in the Company&#8217;s statement of operations. Refer to Note&#160;6 for information
regarding the model used to estimate the fair value of the Private Warrants (as defined in Note&#160;3).</span></p> </div> </ix:nonNumeric>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in;text-indent:-24pt"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt"><strong>&#160;</strong></span></p>
<ix:nonNumeric id="Fxbrl_20241003105809886" name="us-gaap:FairValueOfFinancialInstrumentsPolicy" contextRef="C_20230101to20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" escape="true">

<div>

<table cellpadding="0" cellspacing="0" style="font:10pt Times New Roman, Times, Serif;margin-top:0pt;margin-bottom:0pt;width:100%">
  <tr style="vertical-align:top;text-align:justify">
    <td style="width:0.25in">&#160;</td>
    <td style="width:0.25in;text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt"><strong>i.</strong></span></td>
    <td style="text-align:justify"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt"><strong>Financial instruments</strong></span></td>
        </tr>
  </table>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">&#160;</span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">The
fair value of the Company&#8217;s assets and liabilities, which qualify as financial instruments under the FASB ASC&#160;820, &#8220;Fair
Value Measurements and Disclosures&#8221;, approximates the carrying amounts represented in the balance sheet, primarily due to their
short-term nature.</span></p> </div> </ix:nonNumeric>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in;text-indent:-24pt"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt"><strong>&#160;</strong></span></p>
<ix:nonNumeric id="Fxbrl_20241003105838625" name="us-gaap:UseOfEstimates" contextRef="C_20230101to20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" escape="true">

<div>

<table cellpadding="0" cellspacing="0" style="font:10pt Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;width:100%;border:0px">
  <tr style="vertical-align:top;text-align:justify">
    <td style="width:0.25in">&#160;</td>
    <td style="width:0.25in;text-align:left"><span style="font-size:10pt;font-family:Times New Roman, Times, serif"><strong>j.</strong></span></td>
    <td style="text-align:justify">
        <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt;font-family:Times New Roman, Times, serif"><strong>Use
        of estimates in the preparation of financial statements</strong></span></p> </td> </tr>
  </table>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">The
preparation of the financial statements in conformity with U.S.&#160;GAAP requires management to make estimates and assumptions that affect
the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements
and the reported amounts of expenses during the reporting period. Actual results may differ from those estimates and such differences
may have a material impact on the Company&#8217;s financial statements.</span></p> </div> </ix:nonNumeric>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in;text-indent:-24pt"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt"><strong>&#160;</strong></span></p>
<ix:nonNumeric id="Fxbrl_20241003105853286" name="us-gaap:IncomeTaxPolicyTextBlock" contextRef="C_20230101to20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" escape="true">

<div>

<table cellpadding="0" cellspacing="0" style="font:10pt Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;width:100%;border:0px">
  <tr style="vertical-align:top;text-align:justify">
    <td style="width:0.25in">&#160;</td>
    <td style="width:0.25in;text-align:left"><span style="font-size:10pt;font-family:Times New Roman, Times, serif"><strong>k.</strong></span></td>
    <td style="text-align:justify">
        <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-size:10pt;font-family:Times New Roman, Times, serif"><strong>Income
        tax</strong></span></p> </td> </tr>
  </table>

<p style="font:10pt Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">&#160;</span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">The
Company accounts for income taxes in accordance with ASC&#160;740, &#8220;Income Taxes (hereafter&#160;&#8212;&#160;ASC&#160;740). ASC&#160;740
prescribes the use of the liability method whereby deferred tax asset and liability account balances are determined based on differences
between the financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws that will
be in effect when the differences are expected to reverse. The Company provides a valuation allowance, if necessary, to reduce deferred
tax assets to their estimated realizable value if it is more likely than not that a portion or all of the deferred tax assets will not
be realized, based on the weight of available positive and negative evidence. Deferred tax liabilities and assets are classified as non-current
in accordance with ASU&#160;2015-17.</span></p> </div> </ix:nonNumeric>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in;text-indent:-24pt"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt"><strong>&#160;</strong></span></p>
<ix:nonNumeric id="Fxbrl_20241003105910323" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" contextRef="C_20230101to20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" escape="true">

<div>

<table cellpadding="0" cellspacing="0" style="font:10pt Times New Roman, Times, Serif;margin-top:0pt;margin-bottom:0pt;width:100%">
  <tr style="vertical-align:top;text-align:justify">
    <td style="width:0.25in">&#160;</td>
    <td style="width:0.25in;text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt"><strong>l.</strong></span></td>
    <td style="text-align:justify"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt"><strong>Recent accounting pronouncements</strong></span></td>
        </tr>
  </table>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">&#160;</span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">Management
does not believe that any recently issued, but not yet effective, accounting pronouncements, if currently adopted would have a material
effect on the Company&#8217;s financial statements.</span></p> </div> </ix:nonNumeric> </div> </ix:nonNumeric>

<p style="margin:0pt">&#160;</p> </div>

<div style="font:10pt Times New Roman, Times, Serif">

<div>

<div> <ix:nonNumeric id="Fxbrl_20241004103903070" name="slxn:PublicOfferingAndPrivatePlacementsTextBlock" contextRef="C_20230101to20231231" escape="true">

<div>

<p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"><strong><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">NOTE
3 &#8212;&#160;PUBLIC OFFERING AND PRIVATE PLACEMENTS:</span></span></strong></p>

<p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>

<p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;margin-left:37pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">In
the initial Public Offering, the Company issued and sold&#160;<ix:nonFraction id="Fixv-38034" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" contextRef="C_20230101to20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapSubsidiarySaleOfStockAxis_usgaapIPOMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">11,500,000</ix:nonFraction>&#160;units
(including&#160;<ix:nonFraction id="Fixv-38037" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" contextRef="C_20230101to20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapSubsidiarySaleOfStockAxis_usgaapOverAllotmentOptionMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">1,500,000</ix:nonFraction>&#160;units
sold at a second closing pursuant to the underwriters&#8217; exercise of their over-allotment option in full) at an offering price of
$<ix:nonFraction id="Fixv-38038" name="us-gaap:SaleOfStockPricePerShare" contextRef="C_20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapSubsidiarySaleOfStockAxis_usgaapIPOMember" unitRef="usdPershares" scale="0" decimals="2" format="ixt:num-dot-decimal">10.00</ix:nonFraction>&#160;per
unit (hereafter&#160;&#8212;&#160;the Units). The Sponsor and EarlyBirdCapital, Inc. (the representative of the underwriters) purchased,
in a private placement that occurred simultaneously with the two closings of the initial Public Offering (hereafter&#160;&#8212;&#160;the
Private Placement), an aggregate of&#160;<ix:nonFraction id="Fixv-38039" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" contextRef="C_20230101to20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapRelatedPartyTransactionsByRelatedPartyAxis_slxnSponsorMember_usgaapSubsidiarySaleOfStockAxis_usgaapIPOMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">352,857</ix:nonFraction>&#160;and&#160;<ix:nonFraction id="Fixv-38040" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" contextRef="C_20230101to20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapRelatedPartyTransactionsByRelatedPartyAxis_slxnSponsorMember_usgaapSubsidiarySaleOfStockAxis_usgaapPrivatePlacementMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">27,143</ix:nonFraction>&#160;Units,
respectively, at a price of $<ix:nonFraction id="Fixv-38042" name="us-gaap:SaleOfStockPricePerShare" contextRef="C_20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapRelatedPartyTransactionsByRelatedPartyAxis_slxnSponsorMember_usgaapSubsidiarySaleOfStockAxis_usgaapPrivatePlacementMember" unitRef="usdPershares" scale="0" decimals="2" format="ixt:num-dot-decimal">10.00</ix:nonFraction>&#160;per
Unit.</span></span></p>

<p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;margin-left:30pt">&#160;</p>

<div>

<div>

<div><ix:exclude>

<div style="border-bottom:Black 1.5pt solid;margin-top:12pt;margin-bottom:6pt">

<p style="font:10pt Times New Roman, Times, Serif;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">F-32</span></p>
</div>

<div style="break-before:page;margin-top:6pt;margin-bottom:12pt"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">&#160;</span></div>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt"><strong>MORINGA
ACQUISITION CORP<br/>NOTES TO FINANCIAL STATEMENTS</strong></span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center">&#160;</p>

<p style="font:10pt Times New Roman, Times, serif;margin:0pt 0px"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong><span>NOTE
3 &#8212;&#160;PUBLIC OFFERING AND PRIVATE PLACEMENTS:&#160;</span></strong><span>(cont.)</span></span></span></p>

<p style="font:10pt Times New Roman, Times, serif;margin:0pt 0px">&#160;</p> </ix:exclude></div> </div> </div>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">Each
Unit (both those sold in the initial Public Offering and in the Private Placement) consists of one Class&#160;A ordinary share, $<ix:nonFraction id="Fixv-38043" name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="C_20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_usgaapCommonClassAMember" unitRef="usdPershares" scale="0" decimals="4" format="ixt:num-dot-decimal">0.0001</ix:nonFraction>&#160;par
value, and one-half of one warrant, with each whole warrant exercisable for one Class&#160;A ordinary share (hereafter&#160;&#8212;&#160;each,
a Public Warrant and a Private Warrant, and collectively, the Warrants). Each Warrant entitles the holder thereof to purchase one whole
Class&#160;A ordinary share at a price of $<ix:nonFraction id="Fixv-38044" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="C_20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_usgaapCommonClassAMember" unitRef="usdPershares" scale="0" decimals="2" format="ixt:num-dot-decimal">11.50</ix:nonFraction>&#160;per
share, subject to adjustment. No fractional shares will be issued upon exercise of the Warrants and only whole Warrants trade. Each Warrant
will become exercisable 30&#160;days after the completion of the Company&#8217;s Initial Business Combination and will expire at 5:00&#160;p.m.,
New&#160;York City time, five years&#160;after the completion of the Initial Business Combination or earlier upon redemption (only in
the case of the Public Warrants) or liquidation.</span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">&#160;</span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">Once
the Public Warrants become exercisable, the Company may redeem them in whole and not in part at a price of $<ix:nonFraction id="Fixv-38045" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="C_20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="usdPershares" scale="0" decimals="2" format="ixt:num-dot-decimal">0.01</ix:nonFraction>&#160;per
Warrant upon a minimum of 30&#160;days&#8217; prior written notice of redemption, if and only if the last reported sale price of the Company&#8217;s
Class&#160;A ordinary shares equals or exceeds $<ix:nonFraction id="Fixv-38046" name="slxn:WarrantPricePerSharesExceeds" contextRef="C_20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_usgaapCommonClassAMember" unitRef="usdPershares" scale="0" decimals="2" format="ixt:num-dot-decimal">18.00</ix:nonFraction>&#160;per
share (as adjusted) for any 20&#160;trading days within a 30-trading&#160;day period ending on the third&#160;trading day prior to the
date on which the Company sends the notice of redemption to the Public Warrant holders.</span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">&#160;</span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">The
Private Warrants are identical to the Public Warrants except that, for so long as they are held by the Sponsor, EarlyBirdCapital, Inc.
or their respective affiliates: (1)&#160;will not be redeemable by the Company; (2)&#160;may not (including the Class&#160;A ordinary
shares issuable upon exercise thereof), subject to certain limited exceptions, be transferred, assigned or sold by the holders thereof
until 30&#160;days after the completion of the Company&#8217;s Initial Business Combination; (3)&#160;may be exercised by the holders
thereof on a cashless basis; and (4)&#160;they (including the Class&#160;A ordinary shares issuable upon exercise thereof) are entitled
to registration rights.</span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">&#160;</span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">The
Company paid an underwriting commission of&#160;<ix:nonFraction id="Fixv-38047" name="slxn:UnderwritingCommissionPercentage" contextRef="C_20230101to20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">2.0</ix:nonFraction>%
of the gross proceeds of the Public Offering and the full exercise of the underwriters&#8217; over-allotment, or $<ix:nonFraction id="Fixv-38048" name="slxn:AggregateUnderwritersAmount" contextRef="C_20230101to20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapSubsidiarySaleOfStockAxis_usgaapOverAllotmentOptionMember" unitRef="usd" scale="0" decimals="0" format="ixt:num-dot-decimal">2,300,000</ix:nonFraction>,
in the aggregate, to the underwriters at the two closings of the Public Offering. Refer to Note&#160;5(a)&#160;for more information regarding
an additional fee payable to the underwriters upon the consummation of an Initial Business Combination.</span></p> </div> </ix:nonNumeric>
</div> </div>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p> </div>

<div style="font:10pt Times New Roman, Times, Serif"> <ix:nonNumeric id="Fxbrl_20241003122251232" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock" contextRef="C_20230101to20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" escape="true">

<div>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt"><strong>NOTE
4 &#8212;&#160;RELATED PARTY TRANSACTIONS:</strong></span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in;text-indent:-24pt"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt"><strong>&#160;</strong></span></p>

<table cellpadding="0" cellspacing="0" style="font:10pt Times New Roman, Times, Serif;margin-top:0pt;margin-bottom:0pt;width:100%">
  <tr style="vertical-align:top;text-align:justify">
    <td style="width:0.25in">&#160;</td>
    <td style="width:0.25in;text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt"><strong>a.</strong></span></td>
    <td style="text-align:justify"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt"><strong>Promissory Notes</strong></span></td>
        </tr>
  </table>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">&#160;</span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">The
Company has issued several promissory note agreements to its Sponsor throughout its life term, in order to fulfil its ongoing operational
needs or preparations towards an Initial Business Combination. All outstanding promissory notes bear no interest and are repayable in
full upon the earlier of (a)&#160;the date of the consummation of the Company&#8217;s Initial Business Combination, or (b)&#160;Second
Extended Mandatory Liquidation Date (hereafter and collectively&#160;&#8212;&#160;the Maturity Date).</span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt"><i>&#160;</i></span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt"><i>First
Promissory Note</i></span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">&#160;</span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">The
First Promissory Note withdrawn was borrowed and repaid in full in early 2021 and has subsequently expired.</span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt"><i>&#160;</i></span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt"><i>Second
to Fifth Promissory Notes</i></span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">&#160;</span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">On
August&#160;9, 2021 the Company issued its Second Promissory Note to the Sponsor, according to which the former may withdraw up to $<ix:nonFraction id="Fixv-38049" name="us-gaap:ConvertibleNotesPayable" contextRef="C_20210809_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapDebtInstrumentAxis_slxnSecondPromissoryNoteMember" unitRef="usd" scale="6" decimals="-6" format="ixt:num-dot-decimal">1</ix:nonFraction>&#160;million&#160;&#8212;&#160;which
has been withdrawn in full in several installments up until June&#160;2022.</span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">&#160;</span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">In
December&#160;2022 the Company issued its Third and Fourth Promissory Notes (hereafter&#160;&#8212;&#160;the Third and Fourth Promissory
Notes), according to which the Company may withdraw up to an aggregate amount of $<ix:nonFraction id="Fixv-38050" name="us-gaap:ConvertibleNotesPayable" contextRef="C_20221231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapDebtInstrumentAxis_slxnThirdAndFourthPromissoryNotesMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">190</ix:nonFraction>&#160;thousand&#160;&#8212;&#160;which
were withdrawn in full on the same month.</span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in">&#160;</p>

<div><ix:exclude>

<div style="margin-top:12pt;margin-bottom:6pt;border-bottom:1.5pt solid black">

<p style="margin-top:0pt;margin-bottom:0pt;text-align:center;line-height:normal;font-size:10pt;font-style:normal;font-weight:normal;font-family:Times New Roman, Times, serif"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">F-33</span></p>
</div>

<div style="break-before:page;margin-top:6pt;margin-bottom:12pt"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</span></div>

<p style="margin:0pt 0px;text-align:center;line-height:normal;font-size:10pt;font-style:normal;font-weight:normal;font-family:Times New Roman, Times, serif">&#160;</p>

<p style="margin:0pt 0px;text-align:center;line-height:normal;font-size:10pt;font-style:normal;font-weight:normal;font-family:Times New Roman, Times, serif">&#160;</p>

<p style="margin:0pt 0px;text-align:center;line-height:normal;font-size:10pt;font-style:normal;font-weight:normal;font-family:Times New Roman, Times, serif"><span style="font-size:10pt;font-family:Times New Roman, Times, serif"><strong>MORINGA
ACQUISITION CORP<br/>NOTES TO FINANCIAL STATEMENTS</strong></span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt"><strong>NOTE
4 &#8212;&#160;RELATED PARTY TRANSACTIONS:</strong> (cont.)</span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">&#160;</p> </ix:exclude></div>

<p style="text-align:left;font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">On
February&#160;8, 2023 the Company issued its Fifth Promissory Note to the Sponsor, in an amount of up to $<ix:nonFraction id="Fixv-38051" name="us-gaap:ConvertibleNotesPayable" contextRef="C_20230208_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapDebtInstrumentAxis_slxnFifthPromissoryNoteMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">310</ix:nonFraction>&#160;thousand,
which were withdrawn in full in several installments between February and June&#160;2023.</span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">&#160;</span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">According
to the terms of the outstanding Second, Third, Fourth and Fifth Promissory Notes, which comprise an aggregate principal of $<ix:nonFraction id="Fixv-38052" name="us-gaap:DebtInstrumentFaceAmount" contextRef="C_20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="usd" scale="6" decimals="-5" format="ixt:num-dot-decimal">1.5</ix:nonFraction>&#160;million,
the Sponsor may elect to convert any portion of the amounts outstanding into private warrants to purchase Class&#160;A ordinary shares
at a conversion price of $<ix:nonFraction id="Fixv-38053" name="us-gaap:DebtInstrumentConvertibleConversionPrice1" contextRef="C_20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_usgaapCommonClassAMember" unitRef="usdPershares" scale="0" decimals="0" format="ixt:num-dot-decimal">1</ix:nonFraction>&#160;per
private warrant on the Maturity Date. Such private warrants will have an exercise price of $<ix:nonFraction id="Fixv-38054" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="C_20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapFinancialInstrumentAxis_slxnPrivateWarrantsMember" unitRef="usdPershares" scale="0" decimals="1" format="ixt:num-dot-decimal">11.5</ix:nonFraction>&#160;and
shall be identical to the private warrants included in the private units.</span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt"><i>&#160;</i></span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt"><i>Sixth
Promissory Note</i></span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">&#160;</span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">On
February&#160;9, 2023 the Company issued its Sixth Promissory Note to the Sponsor, in an amount of $<ix:nonFraction id="Fixv-38055" name="us-gaap:ConvertibleNotesPayable" contextRef="C_20230209_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapDebtInstrumentAxis_slxnSixthPromissoryNoteMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">480</ix:nonFraction>&#160;thousand&#160;&#8212;&#160;under
which the funds that were loaned by the Sponsor were deposited into the Company&#8217;s Trust Account, in connection with the First Extension.
The Sponsor provided six monthly injections of $<ix:nonFraction id="Fixv-38056" name="us-gaap:ConvertibleNotesPayable" contextRef="C_20230219_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapDebtInstrumentAxis_slxnSixthPromissoryNoteMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">80</ix:nonFraction>&#160;thousand
into the Company&#8217;s Trust Account under the Sixth Promissory Note, starting February&#160;19, 2023.</span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt"><i>&#160;</i></span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt"><i>Seventh
Promissory Note</i></span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">&#160;</span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">On
June&#160;14, 2023 the Company issued its Seventh Promissory Note to the Sponsor in an amount of up to $<ix:nonFraction id="Fixv-38057" name="us-gaap:ConvertibleNotesPayable" contextRef="C_20230614_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapDebtInstrumentAxis_slxnSeventhPromissoryNoteMember" unitRef="usd" scale="6" decimals="-6" format="ixt:num-dot-decimal">1</ix:nonFraction>&#160;million,
of which $<ix:nonFraction id="Fixv-38058" name="slxn:WithdrawnAmount" contextRef="C_20230614to20230614_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapDebtInstrumentAxis_slxnSeventhPromissoryNoteMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">210</ix:nonFraction>&#160;thousand
were withdrawn at the same date; and approximately $<ix:nonFraction id="Fixv-38059" name="slxn:WithdrawnAmount" contextRef="C_20230101to20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapDebtInstrumentAxis_slxnSeventhPromissoryNoteMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">586</ix:nonFraction>&#160;thousand
were withdrawn up until December&#160;31, 2023.</span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt"><i>&#160;</i></span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt"><i>Eighth
Promissory Note</i></span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">&#160;</span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">On
August&#160;18, 2023 the Company issued its Eighth Promissory Note to the Sponsor, in an amount of approximately $<ix:nonFraction id="Fixv-38060" name="us-gaap:ConvertibleNotesPayable" contextRef="C_20230818_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapDebtInstrumentAxis_slxnEighthPromissoryNoteMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">154</ix:nonFraction>&#160;thousand&#160;&#8212;&#160;under
which the funds that were loaned by the Sponsor were deposited into the Company&#8217;s Trust Account, in connection with the Second Extension.
The Sponsor shall make monthly injections of approximately $<ix:nonFraction id="Fixv-38061" name="slxn:SponsorPay" contextRef="C_20230819to20230819_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapDebtInstrumentAxis_slxnEighthPromissoryNoteMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">13</ix:nonFraction>&#160;thousand
into the Company&#8217;s Trust Account, starting August&#160;19, 2023 and up until the earlier of the Second Extended Mandatory Liquidation
Date (or such earlier date that the Board determines to liquidate the Company) or the date on which an Initial Business Combination is
completed.</span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in;text-indent:-24pt"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt"><strong>&#160;</strong></span></p>

<table cellpadding="0" cellspacing="0" style="font:10pt Times New Roman, Times, Serif;margin-top:0pt;margin-bottom:0pt;width:100%">
  <tr style="vertical-align:top;text-align:justify">
    <td style="width:0.25in">&#160;</td>
    <td style="width:0.25in;text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt"><strong>b.</strong></span></td>
    <td style="text-align:justify"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt"><strong>Administrative Services Agreement</strong></span></td>
        </tr>
  </table>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">&#160;</span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">On
December&#160;16, 2020 the Company signed an agreement with the Sponsor, under which the Company shall pay the Sponsor a fixed $<ix:nonFraction id="Fixv-38062" name="slxn:MonthlyOfficeSpaceExpenses" contextRef="C_20201216_slxnTypeOfAgreementAxis_slxnAdministrativeServicesAgreementMember_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">10</ix:nonFraction>&#160;thousand
per month for office space, utilities and other administrative expenses. The monthly payments under this administrative services agreement
commenced on the effective date of the registration statement for the initial Public Offering and will continue until the earlier of (i)&#160;the
consummation of the Company&#8217;s Initial Business Combination, or (ii)&#160;the Company&#8217;s liquidation.</span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">&#160;</span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">The
composition of the Related Party balance as of December 31, 2023 and 2022 is as follows:</span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">&#160;</span></p>
<ix:nonNumeric id="Fxbrl_20241003122446878" name="us-gaap:ScheduleOfCompensatingBalancesTextBlock" contextRef="C_20230101to20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" escape="true">

<table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width:100%;font:10pt Times New Roman, Times, Serif">
  <tr style="vertical-align:bottom">
    <td>&#160;</td>
    <td style="font-weight:bold;padding-bottom:1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom:Black 1.5pt solid;font-weight:bold;text-align:center">December&#160;31,<br/>2023</td>
    <td style="padding-bottom:1.5pt;font-weight:bold">&#160;</td>
    <td style="font-weight:bold;padding-bottom:1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom:Black 1.5pt solid;font-weight:bold;text-align:center">December&#160;31,<br/>2022</td>
    <td style="padding-bottom:1.5pt;font-weight:bold">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td>&#160;</td>
    <td style="font-weight:bold;padding-bottom:1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom:Black 1.5pt solid;font-weight:bold;text-align:center">U.S.&#160;dollars</td>
    <td style="padding-bottom:1.5pt">&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="width:76%;text-align:left">Promissory notes</td>
    <td style="width:1%">&#160;</td>
    <td style="width:1%;text-align:left">&#160;</td>
    <td style="width:9%;text-align:right"><ix:nonFraction id="Fixv-38063" name="us-gaap:NotesPayableCurrent" contextRef="C_20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapRelatedPartyTransactionAxis_slxnPromissoryNotesMember" unitRef="usd" scale="0" decimals="0" format="ixt:num-dot-decimal">2,841,000</ix:nonFraction></td>
    <td style="width:1%;text-align:left">&#160;</td>
    <td style="width:1%">&#160;</td>
    <td style="width:1%;text-align:left">&#160;</td>
    <td style="width:9%;text-align:right"><ix:nonFraction id="Fixv-38064" name="us-gaap:NotesPayableCurrent" contextRef="C_20221231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapRelatedPartyTransactionAxis_slxnPromissoryNotesMember" unitRef="usd" scale="0" decimals="0" format="ixt:num-dot-decimal">1,190,000</ix:nonFraction></td>
    <td style="width:1%;text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="text-align:left;padding-bottom:1.5pt">Accrual for Administrative Services Agreement</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right"><ix:nonFraction id="Fixv-38065" name="us-gaap:NotesPayableCurrent" contextRef="C_20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapRelatedPartyTransactionAxis_usgaapAssetManagementArrangementMember" unitRef="usd" scale="0" decimals="0" format="ixt:num-dot-decimal">20,000</ix:nonFraction></td>
    <td style="padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right"><ix:nonFraction id="Fxbrl_20241003122518486" name="us-gaap:NotesPayableCurrent" contextRef="C_20221231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapRelatedPartyTransactionAxis_usgaapAssetManagementArrangementMember" unitRef="usd" scale="0" decimals="0" format="ixt:fixed-zero">-</ix:nonFraction></td>
    <td style="padding-bottom:1.5pt;text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="padding-bottom:4pt">&#160;</td>
    <td style="padding-bottom:4pt">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:left">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:right"><ix:nonFraction id="Fixv-38066" name="us-gaap:NotesPayableCurrent" contextRef="C_20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapRelatedPartyTransactionAxis_usgaapRelatedPartyMember" unitRef="usd" scale="0" decimals="0" format="ixt:num-dot-decimal">2,861,000</ix:nonFraction></td>
    <td style="padding-bottom:4pt;text-align:left">&#160;</td>
    <td style="padding-bottom:4pt">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:left">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:right"><ix:nonFraction id="Fixv-38067" name="us-gaap:NotesPayableCurrent" contextRef="C_20221231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapRelatedPartyTransactionAxis_usgaapRelatedPartyMember" unitRef="usd" scale="0" decimals="0" format="ixt:num-dot-decimal">1,190,000</ix:nonFraction></td>
    <td style="padding-bottom:4pt;text-align:left">&#160;</td> </tr>
  </table> </ix:nonNumeric> </div> </ix:nonNumeric>

<div style="margin-top:12pt;margin-bottom:6pt;border-bottom:1.5pt solid black">

<p style="margin-top:0pt;margin-bottom:0pt;text-align:center;line-height:normal;font-size:10pt;font-style:normal;font-weight:normal;font-family:Times New Roman, Times, serif">&#160;</p>

<p style="margin-top:0pt;margin-bottom:0pt;text-align:center;line-height:normal;font-size:10pt;font-style:normal;font-weight:normal;font-family:Times New Roman, Times, serif"><span style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt">F-34</span></p>
</div>

<div style="break-before:page;margin-top:6pt;margin-bottom:12pt"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</span></div>

<p style="margin:0pt 0px;text-align:center;line-height:normal;font-size:10pt;font-style:normal;font-weight:normal;font-family:Times New Roman, Times, serif">&#160;</p>

<p style="margin:0pt 0px;text-align:center;line-height:normal;font-size:10pt;font-style:normal;font-weight:normal;font-family:Times New Roman, Times, serif">&#160;</p>

<p style="margin:0pt 0px;text-align:center;line-height:normal;font-size:10pt;font-style:normal;font-weight:normal;font-family:Times New Roman, Times, serif"><span style="font-size:10pt;font-family:Times New Roman, Times, serif"><strong>MORINGA
ACQUISITION CORP<br/>NOTES TO FINANCIAL STATEMENTS</strong></span></p>

<p style="margin:0pt 0px;text-align:center;line-height:normal;font-size:10pt;font-style:normal;font-weight:normal;font-family:Times New Roman, Times, serif">&#160;</p>
</div>

<div style="font:10pt Times New Roman, Times, Serif"> <ix:nonNumeric id="Fixv-21706" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" contextRef="C_20230101to20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" escape="true">

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt"><strong>NOTE
5 &#8212;&#160;COMMITMENTS AND CONTINGENCIES:</strong></span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in;text-indent:-24pt"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt"><strong>&#160;</strong></span></p>

<table cellpadding="0" cellspacing="0" style="font:10pt Times New Roman, Times, Serif;margin-top:0pt;margin-bottom:0pt;width:100%">
  <tr style="vertical-align:top;text-align:justify">
    <td style="width:0.25in">&#160;</td>
    <td style="width:0.25in;text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt"><strong>a.</strong></span></td>
    <td style="text-align:justify"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt"><strong>Underwriters&#8217; Deferred
        Discount</strong></span></td> </tr>
  </table>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">&#160;</span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">Under
the Business Combination Marketing Agreement, the Company shall pay an additional fee (hereafter&#160;&#8212;&#160;the Deferred Commission)
of&#160;<ix:nonFraction id="Fixv-38068" name="slxn:DeferredCommissionPercentage" contextRef="C_20230101to20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapSubsidiarySaleOfStockAxis_usgaapIPOMember" unitRef="pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">3.5</ix:nonFraction>%
of the gross proceeds of the Public Offering (or $<ix:nonFraction id="Fixv-38069" name="slxn:AdditionalFeePayable" contextRef="C_20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapSubsidiarySaleOfStockAxis_usgaapIPOMember" unitRef="usd" scale="0" decimals="0" format="ixt:num-dot-decimal">4,025,000</ix:nonFraction>)
payable upon the Company&#8217;s completion of the Initial Business Combination. The Deferred Commission will become payable to the underwriters
from the amounts held in the Trust Account solely in the event the Company completes an Initial Business Combination.</span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in;text-indent:-24pt"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt"><strong>&#160;</strong></span></p>

<table cellpadding="0" cellspacing="0" style="font:10pt Times New Roman, Times, Serif;margin-top:0pt;margin-bottom:0pt;width:100%">
  <tr style="vertical-align:top;text-align:justify">
    <td style="width:0.25in">&#160;</td>
    <td style="width:0.25in;text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt"><strong>b.</strong></span></td>
    <td style="text-align:justify"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt"><strong>Nasdaq Deficiency Notices</strong></span></td>
        </tr>
  </table>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt"><i>&#160;</i></span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt"><i>First
Deficiency Notice</i></span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">&#160;</span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">On
March&#160;28, 2023 the Company received a notice from the Nasdaq Listing Qualifications Department indicating that it is not in compliance
with Nasdaq Listing Rule&#160;5550(a)(3)&#160;(hereafter&#160;&#8212;&#160;the First Deficiency), according to which the Company must
satisfy the Minimum Public Holders Rule which requires listed companies to have at least 300 public holders. The Company has submitted
its compliance plan on May&#160;11, 2023 which was accepted by Nasdaq, which has then granted an extension of up to 180 calendar&#160;days
from the date of the notice&#160;&#8212;&#160;until September&#160;24, 2023 &#8212;&#160;to evidence compliance with the rule.</span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">&#160;</span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">On
September&#160;27, 2023 the Company received a notice from the Nasdaq Listing Qualifications Department indicating that it has regained
compliance with the First Deficiency.</span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt"><i>&#160;</i></span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt"><i>Second
Deficiency Notice</i></span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">&#160;</span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">On
June&#160;15, 2023 the Company received another notice from Nasdaq Listing Qualifications Department indicating that it is not in compliance
with Nasdaq Listing Rule&#160;5550(b)(2)&#160;(hereafter&#160;&#8212;&#160;the Second Deficiency), according to which the Company must
sustain a market value of listed securities of at least $<ix:nonFraction id="Fixv-38070" name="us-gaap:MarketableSecurities" contextRef="C_20230615_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="usd" scale="6" decimals="-6" format="ixt:num-dot-decimal">35</ix:nonFraction>&#160;million,
for continued listing on the Nasdaq Capital Market. The notice was only a notification of deficiency, not of imminent delisting, and has
no current effect on the listing or trading of the Company&#8217;s securities on the Nasdaq Capital Market.</span></p> </ix:nonNumeric>

<p style="margin:0pt">&#160;</p> </div>

<div style="font:10pt Times New Roman, Times, Serif"> <ix:nonNumeric id="Fxbrl_20241003132408563" name="us-gaap:FairValueDisclosuresTextBlock" contextRef="C_20230101to20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" escape="true">

<div>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt"><strong>NOTE
6 &#8212;&#160;FAIR VALUE MEASUREMENTS:</strong></span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">&#160;</span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">Following
the Second Extension Meeting, the Sponsor converted&#160;<ix:nonFraction id="Fixv-38071" name="us-gaap:ConversionOfStockSharesConverted1" contextRef="C_20230101to20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_usgaapCommonClassBMember_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="shares" scale="0" decimals="0" format="ixt:num-dot-decimal" sign="-">2,874,999</ix:nonFraction>&#160;of
its Class&#160;B ordinary shares on a one to one basis into Class&#160;A ordinary shares, in an effort to regain compliance with the Second
Deficiency.</span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">&#160;</span></p>

<p style="text-align:left;font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">On
November&#160;24, 2023 the Company received a notice from the Nasdaq Listing Qualifications Department indicating that it has regained
compliance with the Second Deficiency.</span></p>

<p style="text-align:left;font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">&#160;</span></p>

<p style="text-align:left;font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">The
fair value of a financial instrument is the amount that would be received to sell an asset or paid to transfer a liability in an orderly
transaction between market participants at the measurement date (i.e., the exit price).</span></p>

<p style="text-align:left;font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">&#160;</span></p>

<p style="text-align:left;font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">The
fair value hierarchy under ASC&#160;820 prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy gives
the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the
lowest priority to unobservable inputs (Level 3 measurements). The three levels of the fair value hierarchy are as follows:</span></p>

<p style="text-align:left;font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">&#160;</span></p>

<p style="text-align:left;font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">Level
1: Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities;</span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">&#160;</span></p>

<div><ix:exclude>

<div style="margin-top:12pt;margin-bottom:6pt;border-bottom:Black 1.5pt solid">

<p style="font:10pt Times New Roman, Times, Serif;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">F-35</span></p>
</div>

<div style="break-before:page;margin-top:6pt;margin-bottom:12pt">

<p style="margin:0pt">&#160;</p> </div>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt"><strong>&#160;</strong></span></p>

<p style="font:10pt Times New Roman, Times, serif;margin:10pt 0px 0pt;text-align:center"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt"><strong>MORINGA
ACQUISITION CORP<br/>NOTES TO FINANCIAL STATEMENTS</strong></span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt"><strong>&#160;</strong></span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt"><strong>NOTE
6 &#8212;&#160;FAIR VALUE MEASUREMENTS:</strong> (cont.)</span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">&#160;</p> </ix:exclude></div>

<p style="font:10pt Times New Roman, Times, Serif;text-align:left;margin:0pt 0 0pt 0.5in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">Level
2: Quoted prices in markets that are not active or financial instruments for which significant inputs to models are observable (including
but not limited to quoted prices for similar securities, interest rates, foreign exchange rates, volatility and credit risk), either directly
or indirectly;</span></p>

<p style="font:10pt Times New Roman, Times, Serif;text-align:left;margin:0pt 0 0pt 0.5in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">&#160;</span></p>

<p style="font:10pt Times New Roman, Times, Serif;text-align:left;margin:0pt 0 0pt 0.5in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">Level
3: Prices or valuations that require significant unobservable inputs (including the Management&#8217;s assumptions in determining fair
value measurement).</span></p>

<p style="font:10pt Times New Roman, Times, Serif;text-align:left;margin:0pt 0 0pt 0.5in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt"><strong>&#160;</strong></span></p>

<p style="font:10pt Times New Roman, Times, Serif;text-align:left;margin:0pt 0 0pt 0.5in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt"><strong>Basis
for Fair Value Measurement</strong></span></p>

<p style="font:10pt Times New Roman, Times, Serif;text-align:left;margin:0pt 0 0pt 0.5in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">&#160;</span></p>

<p style="font:10pt Times New Roman, Times, Serif;text-align:left;margin:0pt 0 0pt 0.5in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">The
following table presents information about the Company&#8217;s assets and liabilities that are measured at fair value on a recurring basis
at December&#160;31, 2023 by level within the fair value hierarchy:</span></p>

<p style="font:10pt Times New Roman, Times, Serif;text-align:left;margin:0pt 0 0pt 0.5in">&#160;</p> <ix:nonNumeric id="Fxbrl_20241003132225298" name="us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" contextRef="C_20230101to20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" escape="true">

<div>

<table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width:100%;font:10pt Times New Roman, Times, Serif">
  <tr style="vertical-align:bottom">
    <td>&#160;</td>
    <td style="font-weight:bold;padding-bottom:1.5pt">&#160;</td>
    <td colspan="2" style="font-weight:bold;text-align:center;border-bottom:Black 1.5pt solid">Level</td>
    <td style="padding-bottom:1.5pt;font-weight:bold">&#160;</td>
    <td style="font-weight:bold;padding-bottom:1.5pt">&#160;</td>
    <td colspan="2" style="font-weight:bold;text-align:center;border-bottom:Black 1.5pt solid">December&#160;31,<br/>2023</td>
    <td style="padding-bottom:1.5pt;font-weight:bold">&#160;</td>
    <td style="font-weight:bold;padding-bottom:1.5pt">&#160;</td>
    <td colspan="2" style="font-weight:bold;text-align:center;border-bottom:Black 1.5pt solid">December&#160;31,<br/>2022</td>
    <td style="padding-bottom:1.5pt;font-weight:bold">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="font-weight:bold;text-indent:-10pt;padding-left:10pt">Assets:</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="width:64%;text-align:left;text-indent:-10pt;padding-left:10pt">Money market funds held in Trust Account</td>
    <td style="width:1%">&#160;</td>
    <td style="width:1%;text-align:left">&#160;</td>
    <td style="width:9%;text-align:right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;1</td>
    <td style="width:1%;text-align:left">&#160;</td>
    <td style="width:1%">&#160;</td>
    <td style="width:1%;text-align:left">&#160;</td>
    <td style="width:9%;text-align:right"><ix:nonFraction id="Fixv-38072" name="us-gaap:AssetsHeldInTrustCurrent" contextRef="C_20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapFairValueByFairValueHierarchyLevelAxis_usgaapFairValueInputsLevel1Member_usgaapFairValueByMeasurementFrequencyAxis_usgaapFairValueMeasurementsRecurringMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,697,632</ix:nonFraction></td>
    <td style="width:1%;text-align:left">&#160;</td>
    <td style="width:1%">&#160;</td>
    <td style="width:1%;text-align:left">&#160;</td>
    <td style="width:9%;text-align:right"><ix:nonFraction id="Fixv-38073" name="us-gaap:AssetsHeldInTrustCurrent" contextRef="C_20221231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapFairValueByFairValueHierarchyLevelAxis_usgaapFairValueInputsLevel1Member_usgaapFairValueByMeasurementFrequencyAxis_usgaapFairValueMeasurementsRecurringMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">116,692,038</ix:nonFraction></td>
    <td style="width:1%;text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="font-weight:bold;text-indent:-10pt;padding-left:10pt">Liabilities:</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="text-align:left;padding-bottom:4pt;text-indent:-10pt;padding-left:10pt">Private warrant liability</td>
    <td style="padding-bottom:4pt">&#160;</td>
    <td style="padding-bottom:4pt;text-align:left">&#160;</td>
    <td style="padding-bottom:4pt;text-align:right">3</td>
    <td style="padding-bottom:4pt;text-align:left">&#160;</td>
    <td style="padding-bottom:4pt">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:left">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:right"><ix:nonFraction id="Fixv-38074" name="us-gaap:WarrantsAndRightsOutstanding" contextRef="C_20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapFairValueByFairValueHierarchyLevelAxis_usgaapFairValueInputsLevel3Member_usgaapFairValueByMeasurementFrequencyAxis_usgaapFairValueMeasurementsRecurringMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,531</ix:nonFraction></td>
    <td style="padding-bottom:4pt;text-align:left">&#160;</td>
    <td style="padding-bottom:4pt">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:left">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:right"><ix:nonFraction id="Fixv-38075" name="us-gaap:WarrantsAndRightsOutstanding" contextRef="C_20221231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapFairValueByFairValueHierarchyLevelAxis_usgaapFairValueInputsLevel3Member_usgaapFairValueByMeasurementFrequencyAxis_usgaapFairValueMeasurementsRecurringMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">29,640</ix:nonFraction></td>
    <td style="padding-bottom:4pt;text-align:left">&#160;</td> </tr>
  </table> </div> </ix:nonNumeric>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">&#160;</span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">The
estimated fair value of the Private Placement Warrants was determined using a binomial model to extract the market&#8217;s implied probability
for an Initial Business Combination, using the Public Warrant&#8217;s market price. Once probability was extracted, a Black-Scholes-Merton
model with Level 3 inputs was used to calculate the Private Warrants&#8217; fair value. Inherent in a Black-Scholes-Merton model are assumptions
related to expected life (term), expected stock price, volatility, risk-free interest rate and dividend yield. The Company estimates the
volatility of its warrants based on implied volatility from the Company&#8217;s traded warrants and from historical volatility of selected
peer companies&#8217; Class&#160;A ordinary shares that matches the expected remaining life of the warrants. The risk-free interest rate
is based on the U.S.&#160;Treasury zero-coupon yield curve on the grant date for a maturity similar to the expected remaining life of
the warrants. The expected life of the warrants is assumed to be equivalent to their remaining contractual term. The dividend rate is
based on the historical rate, which the Company anticipates remaining at zero.</span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">&#160;</span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">The
following table provides quantitative information regarding Level&#160;3 fair value measurements inputs:</span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in">&#160;</p> <ix:nonNumeric id="Fxbrl_20241003132237883" name="us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" contextRef="C_20230101to20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" escape="true">

<div>

<table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width:100%;font:10pt Times New Roman, Times, Serif">
  <tr style="vertical-align:bottom">
    <td>&#160;</td>
    <td style="font-weight:bold;padding-bottom:1.5pt">&#160;</td>
    <td colspan="2" style="font-weight:bold;text-align:center;border-bottom:Black 1.5pt solid">As of<br/>December&#160;31,<br/>2023</td>
    <td style="padding-bottom:1.5pt;font-weight:bold">&#160;</td>
    <td style="font-weight:bold;padding-bottom:1.5pt">&#160;</td>
    <td colspan="2" style="font-weight:bold;text-align:center;border-bottom:Black 1.5pt solid">As of<br/>December&#160;31,<br/>2022</td>
    <td style="padding-bottom:1.5pt;font-weight:bold">&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="width:76%;text-indent:-10pt;padding-left:10pt">Share price</td>
    <td style="width:1%">&#160;</td>
    <td style="width:1%;text-align:left">$</td>
    <td style="width:9%;text-align:right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonFraction id="Fixv-38076" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="C_20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapMeasurementInputTypeAxis_usgaapMeasurementInputSharePriceMember" unitRef="pure" scale="0" decimals="1" format="ixt:num-dot-decimal">10.0</ix:nonFraction></td>
    <td style="width:1%;text-align:left">&#160;</td>
    <td style="width:1%">&#160;</td>
    <td style="width:1%;text-align:left">$</td>
    <td style="width:9%;text-align:right">&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonFraction id="Fixv-38077" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="C_20221231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapMeasurementInputTypeAxis_usgaapMeasurementInputSharePriceMember" unitRef="pure" scale="0" decimals="1" format="ixt:num-dot-decimal">10.0</ix:nonFraction></td>
    <td style="width:1%;text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="text-indent:-10pt;padding-left:10pt">Strike price</td>
    <td>&#160;</td>
    <td style="text-align:left">$</td>
    <td style="text-align:right"><ix:nonFraction id="Fixv-38078" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="C_20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapMeasurementInputTypeAxis_slxnMeasurementInputStrikevPriceMember" unitRef="pure" scale="0" decimals="1" format="ixt:num-dot-decimal">11.5</ix:nonFraction></td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">$</td>
    <td style="text-align:right"><ix:nonFraction id="Fixv-38079" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="C_20221231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapMeasurementInputTypeAxis_slxnMeasurementInputStrikevPriceMember" unitRef="pure" scale="0" decimals="1" format="ixt:num-dot-decimal">11.5</ix:nonFraction></td>
    <td style="text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="text-indent:-10pt;padding-left:10pt">Volatility</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right"><ix:nonFraction id="Fixv-38080" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="C_20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapMeasurementInputTypeAxis_usgaapMeasurementInputPriceVolatilityMember" unitRef="pure" scale="0" decimals="0" format="ixt:num-dot-decimal">60</ix:nonFraction></td>
    <td style="text-align:left">%</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right"><ix:nonFraction id="Fixv-38081" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="C_20221231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapMeasurementInputTypeAxis_usgaapMeasurementInputPriceVolatilityMember" unitRef="pure" scale="0" decimals="0" format="ixt:num-dot-decimal">50</ix:nonFraction></td>
    <td style="text-align:left">%</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="text-align:left;text-indent:-10pt;padding-left:10pt">Risk-free interest rate</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right"><ix:nonFraction id="Fixv-38082" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="C_20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapMeasurementInputTypeAxis_usgaapMeasurementInputRiskFreeInterestRateMember" unitRef="pure" scale="0" decimals="2" format="ixt:num-dot-decimal">4.78</ix:nonFraction></td>
    <td style="text-align:left">%</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right"><ix:nonFraction id="Fixv-38083" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="C_20221231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapMeasurementInputTypeAxis_usgaapMeasurementInputRiskFreeInterestRateMember" unitRef="pure" scale="0" decimals="2" format="ixt:num-dot-decimal">4.00</ix:nonFraction></td>
    <td style="text-align:left">%</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="text-align:left;text-indent:-10pt;padding-left:10pt">Dividend yield</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right"><ix:nonFraction id="Fixv-38084" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="C_20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapMeasurementInputTypeAxis_usgaapMeasurementInputExpectedDividendRateMember" unitRef="pure" scale="0" decimals="2" format="ixt:num-dot-decimal">0.00</ix:nonFraction></td>
    <td style="text-align:left">%</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right"><ix:nonFraction id="Fixv-38085" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="C_20221231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapMeasurementInputTypeAxis_usgaapMeasurementInputExpectedDividendRateMember" unitRef="pure" scale="0" decimals="2" format="ixt:num-dot-decimal">0.00</ix:nonFraction></td>
    <td style="text-align:left">%</td> </tr>
  </table> </div> </ix:nonNumeric>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">&#160;</span></p>
<ix:nonNumeric id="Fixv-21995" name="us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" contextRef="C_20230101to20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" escape="true">

<table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width:100%;font:10pt Times New Roman, Times, Serif">
  <tr style="vertical-align:bottom">
    <td>&#160;</td>
    <td style="font-weight:bold;padding-bottom:1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom:Black 1.5pt solid;font-weight:bold;text-align:center">U.S.&#160;dollars</td>
    <td style="padding-bottom:1.5pt;font-weight:bold">&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="width:88%;text-align:left">Value of warrant liability measured with Level 3 inputs at December&#160;31, 2022</td>
    <td style="width:1%">&#160;</td>
    <td style="width:1%;text-align:left">&#160;</td>
    <td style="width:9%;text-align:right"><ix:nonFraction id="Fixv-38086" name="us-gaap:WarrantsAndRightsOutstanding" contextRef="C_20221231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapFairValueByFairValueHierarchyLevelAxis_usgaapFairValueInputsLevel3Member" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">29,640</ix:nonFraction></td>
    <td style="width:1%;text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="text-align:left;padding-bottom:1.5pt">Change in fair value of private warrant liability measured with Level 3 inputs</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right">(<ix:nonFraction id="Fixv-38087" name="us-gaap:LiabilitiesFairValueAdjustment" contextRef="C_20230101to20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapFairValueByFairValueHierarchyLevelAxis_usgaapFairValueInputsLevel3Member" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">21,109</ix:nonFraction></td>
    <td style="padding-bottom:1.5pt;text-align:left">)</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="text-align:left;padding-bottom:4pt">Value of warrant liability measured with Level 3 inputs at December&#160;31, 2023</td>
    <td style="padding-bottom:4pt">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:left">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:right"><ix:nonFraction id="Fixv-38088" name="us-gaap:WarrantsAndRightsOutstanding" contextRef="C_20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapFairValueByFairValueHierarchyLevelAxis_usgaapFairValueInputsLevel3Member" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,531</ix:nonFraction></td>
    <td style="padding-bottom:4pt;text-align:left">&#160;</td> </tr>
  </table> </ix:nonNumeric> </div> </ix:nonNumeric>

<p style="margin-top:0;margin-bottom:0">&#160;</p>

<div style="margin-top:12pt;margin-bottom:6pt;border-bottom:Black 1.5pt solid">

<p style="font:10pt Times New Roman, Times, Serif;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">F-36</span></p>
</div>

<div style="break-before:page;margin-top:6pt;margin-bottom:12pt">

<p style="margin:0pt">&#160;</p> </div>

<p style="margin-top:0;margin-bottom:0"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt"><strong>&#160;</strong></span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt"><strong>MORINGA
ACQUISITION CORP<br/>NOTES TO FINANCIAL STATEMENTS</strong></span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center"><span style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt"><strong style="margin-top:0pt;margin-bottom:0pt">&#160;</strong></span></p>
</div>

<div style="font:10pt Times New Roman, Times, Serif"> <ix:nonNumeric id="Fixv-22047" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" contextRef="C_20230101to20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" escape="true">

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt"><strong>NOTE
7 &#8212;&#160;CAPITAL DEFICIENCY:</strong></span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in;text-indent:-24pt"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt"><strong>&#160;</strong></span></p>

<table cellpadding="0" cellspacing="0" style="font:10pt Times New Roman, Times, Serif;margin-top:0pt;margin-bottom:0pt;width:100%">
  <tr style="vertical-align:top;text-align:justify">
    <td style="width:0.25in">&#160;</td>
    <td style="width:0.25in;text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt"><strong>a.</strong></span></td>
    <td style="text-align:justify"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt"><strong>Ordinary Shares</strong></span></td>
        </tr>
  </table>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt"><i>&#160;</i></span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt"><i>Class&#160;A
Ordinary Shares</i></span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">&#160;</span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">On
November&#160;20, 2020 the Company issued&#160;<ix:nonFraction id="Fixv-38089" name="us-gaap:CommonStockSharesIssued" contextRef="C_20201120_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_usgaapCommonClassAMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">100,000</ix:nonFraction>&#160;Class&#160;A
ordinary shares of $<ix:nonFraction id="Fixv-38090" name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="C_20201120_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_usgaapCommonClassAMember" unitRef="usdPershares" scale="0" decimals="4" format="ixt:num-dot-decimal">0.0001</ix:nonFraction>&#160;par
value each to designees of the Representative (hereafter&#160;&#8212;&#160;the Representative Shares) for a consideration equal to the
par value of the shares. The Representative Shares are deemed to be underwriters&#8217; compensation by FINRA pursuant to Rule&#160;5110
of the FINRA Manual.</span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">&#160;</span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">The
Company accounted for the issuance of the Representative Shares as compensation expenses amounting to $<ix:nonFraction id="Fixv-38091" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_20230101to20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="usd" scale="0" decimals="0" format="ixt:num-dot-decimal">860</ix:nonFraction>,
with a corresponding credit to Additional Paid-In Capital, for the excess value over the consideration paid. The Company estimated the
fair value of the issuance based upon the price of Class&#160;B Ordinary Shares that were issued to the Sponsor.</span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">&#160;</span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">Pursuant
to the initial Public Offering and the concurrent Private Placement that were each effected in two closings&#160;&#8212;&#160;on February&#160;19,
2021 and March&#160;3, 2021 &#8212;&#160;the Company issued and sold an aggregate of&#160;<ix:nonFraction id="Fixv-38092" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" contextRef="C_20210219to20210219_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_usgaapCommonClassAMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">11,500,000</ix:nonFraction>&#160;and&#160;<ix:nonFraction id="Fixv-38093" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" contextRef="C_20210303to20210303_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_usgaapCommonClassAMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">380,000</ix:nonFraction>&#160;Class&#160;A
ordinary shares as part of the Units&#160;sold in those respective transactions. The Units&#160;(which also included Warrants) were sold
at a price of $<ix:nonFraction id="Fxbrl_20241003171011236" name="us-gaap:SaleOfStockPricePerShare" contextRef="C_20210303_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_usgaapCommonClassAMember" unitRef="usdPershares" scale="0" decimals="0" format="ixt:num-dot-decimal"><ix:nonFraction id="Fixv-38094" name="us-gaap:SaleOfStockPricePerShare" contextRef="C_20210219_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_usgaapCommonClassAMember" unitRef="usdPershares" scale="0" decimals="0" format="ixt:num-dot-decimal">10</ix:nonFraction></ix:nonFraction>&#160;per
Unit, and for an aggregate consideration of $<ix:nonFraction id="Fixv-38096" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" contextRef="C_20210219to20210219_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapSubsidiarySaleOfStockAxis_slxnPublicOfferingMember" unitRef="usd" scale="6" decimals="-6" format="ixt:num-dot-decimal">115</ix:nonFraction>&#160;million
and $<ix:nonFraction id="Fixv-38097" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" contextRef="C_20210303to20210303_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapSubsidiarySaleOfStockAxis_usgaapPrivatePlacementMember" unitRef="usd" scale="6" decimals="-5" format="ixt:num-dot-decimal">3.8</ix:nonFraction>&#160;million
in the Public Offering and Private Placement, respectively. See Note&#160;3 above for further information regarding those share issuances.</span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">&#160;</span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">The
Company classified its&#160;<ix:nonFraction id="Fixv-38098" name="us-gaap:TemporaryEquitySharesIssued" contextRef="C_20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_usgaapCommonClassAMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">11,500,000</ix:nonFraction>&#160;Class&#160;A
ordinary shares subject to possible redemption as temporary equity. The remaining&#160;<ix:nonFraction id="Fixv-38099" name="slxn:RemainingTemporaryEquityShares" contextRef="C_20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_usgaapCommonClassAMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">480,000</ix:nonFraction>&#160;Private
Class&#160;A ordinary shares were classified as permanent equity.</span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">&#160;</span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">In
conjunction with the First and Second Extensions,&#160;<ix:nonFraction id="Fixv-38100" name="us-gaap:TemporaryEquitySharesIssued" contextRef="C_20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapRelatedPartyTransactionAxis_slxnFirstExtensionsMember_usgaapStatementClassOfStockAxis_usgaapCommonClassAMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">8,910,433</ix:nonFraction>&#160;and&#160;<ix:nonFraction id="Fixv-38101" name="us-gaap:TemporaryEquitySharesIssued" contextRef="C_20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapRelatedPartyTransactionAxis_slxnSecondExtensionsMember_usgaapStatementClassOfStockAxis_usgaapCommonClassAMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">2,074,548</ix:nonFraction>&#160;Class&#160;A
Ordinary Shares subject to possible redemption were redeemed, respectively, for their redemption value, including accrued interest. As
part of the partial redemptions approximately $<ix:nonFraction id="Fixv-38102" name="slxn:PartialRedemptionWithdrawnFromInvestmentHeldInTrustAccount" contextRef="C_20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="usd" scale="6" decimals="-6" format="ixt:num-dot-decimal">113</ix:nonFraction>&#160;million
has been withdrawn from the Investments held in Trust Account.</span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt"><i>&#160;</i></span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt"><i>Class&#160;B
Ordinary Shares</i></span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">&#160;</span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">On
November&#160;20, 2020 the Company issued&#160;<ix:nonFraction id="Fixv-38103" name="us-gaap:CommonStockSharesIssued" contextRef="C_20201120_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_usgaapCommonClassBMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">2,875,000</ix:nonFraction>&#160;Class&#160;B
ordinary shares of $<ix:nonFraction id="Fixv-38104" name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="C_20201120_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_usgaapCommonClassBMember" unitRef="usdPershares" scale="0" decimals="4" format="ixt:num-dot-decimal">0.0001</ix:nonFraction>&#160;par
value each for a total consideration of $<ix:nonFraction id="Fixv-38105" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" contextRef="C_20201120to20201120_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_usgaapCommonClassBMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">25</ix:nonFraction>&#160;thousand
to the Sponsor&#8217;s wholly-owned Delaware subsidiary. Out of the&#160;</span><span style="font-size:10pt;font-family:Times New Roman, Times, serif"><ix:nonFraction id="Fxbrl_20241004165829305" name="us-gaap:CommonStockSharesIssued" contextRef="C_20201120_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_usgaapCommonClassBMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">2,875,000</ix:nonFraction>&#160;</span><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">Class&#160;B
ordinary shares, up to&#160;<ix:nonFraction id="Fixv-38106" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationForfeited" contextRef="C_20201120to20201120_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_usgaapCommonClassBMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">375,000</ix:nonFraction>&#160;were
subject to forfeiture if the underwriters were to not exercise their over-allotment in full or in part. Because the underwriters exercised
their over-allotment option in full on March&#160;3, 2021 that potential forfeiture did not occur.</span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">&#160;</span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">Class&#160;B
ordinary shares are convertible into non-redeemable Class&#160;A ordinary shares, on a one-for-one basis, automatically on the&#160;day
of the Business Combination or at the election of the holder thereof at any time prior to the Business Combination. Class&#160;B ordinary
shares also possess the sole right to vote for the election or removal of directors, until the consummation of an Initial Business Combination.</span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">&#160;</span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">Refer
to Note&#160;5(b)&#160;for information regarding the conversion of Class&#160;B ordinary shares into Class&#160;A ordinary shares following
the Second Extension Meeting.</span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in;text-indent:-24pt"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt"><strong>&#160;</strong></span></p>

<table cellpadding="0" cellspacing="0" style="font:10pt Times New Roman, Times, Serif;margin-top:0pt;margin-bottom:0pt;width:100%">
  <tr style="vertical-align:top;text-align:justify">
    <td style="width:0.25in">&#160;</td>
    <td style="width:0.25in;text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt"><strong>b.</strong></span></td>
    <td style="text-align:justify"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt"><strong>Preferred shares</strong></span></td>
        </tr>
  </table>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">&#160;</span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">The
Company is authorized to issue up to&#160;<ix:nonFraction id="Fixv-38107" name="us-gaap:PreferredStockSharesAuthorized" contextRef="C_20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">5,000,000</ix:nonFraction>&#160;Preferred
Shares of $<ix:nonFraction id="Fixv-38108" name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="C_20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="usdPershares" scale="0" decimals="4" format="ixt:num-dot-decimal">0.0001</ix:nonFraction>&#160;par
value each. As of December&#160;31, 2023 the Company has <ix:nonFraction id="Fxbrl_20241004133939813" name="us-gaap:PreferredStockSharesOutstanding" contextRef="C_20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="shares" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="Fxbrl_20241004133925479" name="us-gaap:PreferredStockSharesIssued" contextRef="C_20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="shares" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction>
preferred shares issued and outstanding.</span></p> </ix:nonNumeric>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">&#160;</span></p>

<div style="margin-top:12pt;margin-bottom:6pt;border-bottom:Black 1.5pt solid">

<p style="font:10pt Times New Roman, Times, Serif;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">F-37</span></p>
</div>

<div style="break-before:page;margin-top:6pt;margin-bottom:12pt">

<p style="margin:0pt">&#160;</p> </div>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt"><strong>&#160;</strong></span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt"><strong>MORINGA
ACQUISITION CORP<br/>NOTES TO FINANCIAL STATEMENTS</strong></span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center">&#160;</p> </div>

<div style="font:10pt Times New Roman, Times, Serif"> <ix:nonNumeric id="Fixv-22152" name="us-gaap:EarningsPerShareTextBlock" contextRef="C_20230101to20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" escape="true">

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt"><strong>NOTE
8 &#8212;&#160;NET PROFIT (LOSS) PER SHARE:</strong></span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">&#160;</span></p>
<ix:nonNumeric id="Fxbrl_20241004104439701" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" contextRef="C_20230101to20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" escape="true">

<div>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">The
following table reflects the calculation of basic and diluted net profit (loss) per share (in dollars, except share amounts):</span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in">&#160;</p>

<div>

<table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width:100%;font:10pt Times New Roman, Times, Serif">
  <tr style="vertical-align:bottom">
    <td style="padding-left:0.125in;text-indent:-0.125in">&#160;</td>
    <td style="font-weight:bold;padding-bottom:1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom:Black 1.5pt solid;font-weight:bold;text-align:center">Year ended<br/>December&#160;31,</td>
    <td style="padding-bottom:1.5pt;font-weight:bold">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="padding-left:0.125in;text-indent:-0.125in">&#160;</td>
    <td style="font-weight:bold;padding-bottom:1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom:Black 1.5pt solid;font-weight:bold;text-align:center">2023</td>
    <td style="padding-bottom:1.5pt;font-weight:bold">&#160;</td>
    <td style="font-weight:bold;padding-bottom:1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom:Black 1.5pt solid;font-weight:bold;text-align:center">2022</td>
    <td style="padding-bottom:1.5pt;font-weight:bold">&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="padding-left:0.125in;text-indent:-0.125in;width:76%;text-align:left">Net profit for the year</td>
    <td style="width:1%">&#160;</td>
    <td style="width:1%;text-align:left">$</td>
    <td style="width:9%;text-align:right"><ix:nonFraction id="Fixv-38109" name="us-gaap:NetIncomeLoss" contextRef="C_20230101to20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">263,073</ix:nonFraction></td>
    <td style="width:1%;text-align:left">&#160;</td>
    <td style="width:1%">&#160;</td>
    <td style="width:1%;text-align:left">$</td>
    <td style="width:9%;text-align:right"><ix:nonFraction id="Fixv-38110" name="us-gaap:NetIncomeLoss" contextRef="C_20220101to20221231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">584,025</ix:nonFraction></td>
    <td style="width:1%;text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="padding-left:0.125in;text-indent:-0.125in;text-align:left;padding-bottom:1.5pt">Less&#160;&#8211;&#160;interest earned on Investment
        held in Trust Account</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right">(<ix:nonFraction id="Fixv-38111" name="us-gaap:InvestmentIncomeInterest" contextRef="C_20230101to20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,364,444</ix:nonFraction></td>
    <td style="padding-bottom:1.5pt;text-align:left">)</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right">(<ix:nonFraction id="Fixv-38112" name="us-gaap:InvestmentIncomeInterest" contextRef="C_20220101to20221231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,685,666</ix:nonFraction></td>
    <td style="padding-bottom:1.5pt;text-align:left">)</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="padding-left:0.125in;text-indent:-0.125in;text-align:left;padding-bottom:1.5pt">Net loss excluding interest</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">$</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right">(<ix:nonFraction id="Fixv-38113" name="us-gaap:GrossProfit" contextRef="C_20230101to20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">1,101,371</ix:nonFraction></td>
    <td style="padding-bottom:1.5pt;text-align:left">)</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">$</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right">(<ix:nonFraction id="Fixv-38114" name="us-gaap:GrossProfit" contextRef="C_20220101to20221231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">1,101,641</ix:nonFraction></td>
    <td style="padding-bottom:1.5pt;text-align:left">)</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="padding-left:0.125in;text-indent:-0.125in">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="padding-left:0.125in;text-indent:-0.125in;font-weight:bold;text-align:left">Class&#160;A ordinary shares subject to possible redemption:</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="padding-left:0.125in;text-indent:-0.125in">Numerator:</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="text-indent:-0.125in;padding-left:0.25in;text-align:left">Net loss excluding interest</td>
    <td>&#160;</td>
    <td style="text-align:left">$</td>
    <td style="text-align:right">(<ix:nonFraction id="Fixv-38115" name="us-gaap:TemporaryEquityAccretionOfInterest" contextRef="C_20230101to20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_slxnClassAOrdinaryShareSubjectToPossibleRedemptionMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">498,567</ix:nonFraction></td>
    <td style="text-align:left">)</td>
    <td>&#160;</td>
    <td style="text-align:left">$</td>
    <td style="text-align:right">(<ix:nonFraction id="Fixv-38116" name="us-gaap:TemporaryEquityAccretionOfInterest" contextRef="C_20220101to20221231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_slxnClassAOrdinaryShareSubjectToPossibleRedemptionMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">852,835</ix:nonFraction></td>
    <td style="text-align:left">)</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="text-indent:-0.125in;padding-left:0.25in;text-align:left;padding-bottom:1.5pt">Accretion to Class&#160;A ordinary shares subject
        to possible redemption to redemption amount (&#8220;Accretion&#8221;)</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right"><ix:nonFraction id="Fixv-38117" name="us-gaap:TemporaryEquityAccretionToRedemptionValue" contextRef="C_20230101to20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_slxnClassAOrdinaryShareSubjectToPossibleRedemptionMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,908,820</ix:nonFraction></td>
    <td style="padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right"><ix:nonFraction id="Fixv-38118" name="us-gaap:TemporaryEquityAccretionToRedemptionValue" contextRef="C_20220101to20221231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_slxnClassAOrdinaryShareSubjectToPossibleRedemptionMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,685,666</ix:nonFraction></td>
    <td style="padding-bottom:1.5pt;text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="padding-left:0.125in;text-indent:-0.125in">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">$</td>
    <td style="text-align:right"><ix:nonFraction id="Fixv-38119" name="slxn:TemporaryEquitySubjectToPossibleRedemption" contextRef="C_20230101to20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_slxnClassAOrdinaryShareSubjectToPossibleRedemptionMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,410,253</ix:nonFraction></td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">$</td>
    <td style="text-align:right"><ix:nonFraction id="Fixv-38120" name="slxn:TemporaryEquitySubjectToPossibleRedemption" contextRef="C_20220101to20221231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_slxnClassAOrdinaryShareSubjectToPossibleRedemptionMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">832,831</ix:nonFraction></td>
    <td style="text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="padding-left:0.125in;text-indent:-0.125in">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="padding-left:0.125in;text-indent:-0.125in">Denominator:</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="text-indent:-0.125in;padding-left:0.25in;padding-bottom:1.5pt">Weighted average number of shares</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right"><ix:nonFraction id="Fixv-38121" name="us-gaap:WeightedAverageNumberOfSharesIssuedBasic" contextRef="C_20230101to20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_slxnClassAOrdinaryShareSubjectToPossibleRedemptionMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">2,774,850</ix:nonFraction></td>
    <td style="padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right"><ix:nonFraction id="Fixv-38122" name="us-gaap:WeightedAverageNumberOfSharesIssuedBasic" contextRef="C_20220101to20221231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_slxnClassAOrdinaryShareSubjectToPossibleRedemptionMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">11,500,000</ix:nonFraction></td>
    <td style="padding-bottom:1.5pt;text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="padding-left:0.125in;text-indent:-0.125in">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="padding-left:0.125in;text-indent:-0.125in;font-weight:bold;text-align:left;padding-bottom:4pt">Basic and diluted net profit per
        Class&#160;A ordinary share subject to possible redemption</td>
    <td style="padding-bottom:4pt">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:left">$</td>
    <td style="border-bottom:Black 4pt double;text-align:right"><ix:nonFraction id="Fixv-38123" name="us-gaap:EarningsPerShareBasic" contextRef="C_20230101to20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_slxnClassAOrdinaryShareSubjectToPossibleRedemptionMember" unitRef="usdPershares" scale="0" decimals="2" format="ixt:num-dot-decimal">0.51</ix:nonFraction></td>
    <td style="padding-bottom:4pt;text-align:left">&#160;</td>
    <td style="padding-bottom:4pt">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:left">$</td>
    <td style="border-bottom:Black 4pt double;text-align:right"><ix:nonFraction id="Fixv-38124" name="us-gaap:EarningsPerShareBasic" contextRef="C_20220101to20221231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_slxnClassAOrdinaryShareSubjectToPossibleRedemptionMember" unitRef="usdPershares" scale="0" decimals="2" format="ixt:num-dot-decimal">0.07</ix:nonFraction></td>
    <td style="padding-bottom:4pt;text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="padding-left:0.125in;text-indent:-0.125in">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="padding-left:0.125in;text-indent:-0.125in;font-weight:bold;text-align:left">Non-redeemable Class&#160;A and B ordinary shares:</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="padding-left:0.125in;text-indent:-0.125in">Numerator:</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="text-indent:-0.125in;padding-left:0.25in;text-align:left">Net loss excluding interest</td>
    <td>&#160;</td>
    <td style="text-align:left">$</td>
    <td style="text-align:right">(<ix:nonFraction id="Fixv-38125" name="us-gaap:TemporaryEquityAccretionOfInterest" contextRef="C_20230101to20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_slxnNonredeemableClassAandBOrdinaryShareMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">602,804</ix:nonFraction></td>
    <td style="text-align:left">)</td>
    <td>&#160;</td>
    <td style="text-align:left">$</td>
    <td style="text-align:right">(<ix:nonFraction id="Fixv-38126" name="us-gaap:TemporaryEquityAccretionOfInterest" contextRef="C_20220101to20221231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_slxnNonredeemableClassAandBOrdinaryShareMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">248,806</ix:nonFraction></td>
    <td style="text-align:left">)</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="text-indent:-0.125in;padding-left:0.25in;padding-bottom:1.5pt">Accretion</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right">(<ix:nonFraction id="Fixv-38127" name="slxn:Accretion" contextRef="C_20230101to20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_slxnNonredeemableClassAandBOrdinaryShareMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">544,376</ix:nonFraction></td>
    <td style="padding-bottom:1.5pt;text-align:left">)</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right">-</td>
    <td style="padding-bottom:1.5pt;text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="padding-left:0.125in;text-indent:-0.125in">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">(1,147,180</td>
    <td style="text-align:left">)</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">(248,806</td>
    <td style="text-align:left">)</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="padding-left:0.125in;text-indent:-0.125in">Denominator:</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="text-indent:-0.125in;padding-left:0.25in;padding-bottom:1.5pt">Weighted average number of shares</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right"><ix:nonFraction id="Fixv-38128" name="us-gaap:WeightedAverageNumberOfSharesIssuedBasic" contextRef="C_20230101to20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_slxnNonredeemableClassAandBOrdinaryShareMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">3,355,000</ix:nonFraction></td>
    <td style="padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right"><ix:nonFraction id="Fixv-38129" name="us-gaap:WeightedAverageNumberOfSharesIssuedBasic" contextRef="C_20220101to20221231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_slxnNonredeemableClassAandBOrdinaryShareMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">3,355,000</ix:nonFraction></td>
    <td style="padding-bottom:1.5pt;text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="padding-left:0.125in;text-indent:-0.125in">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="padding-left:0.125in;text-indent:-0.125in;font-weight:bold;text-align:left;padding-bottom:4pt">Basic and diluted net loss per non-redeemable
        Class&#160;A and B ordinary share</td>
    <td style="padding-bottom:4pt">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:left">$</td>
    <td style="border-bottom:Black 4pt double;text-align:right">(<ix:nonFraction id="Fixv-38130" name="us-gaap:EarningsPerShareBasic" contextRef="C_20230101to20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_slxnNonredeemableClassAandBOrdinaryShareMember" unitRef="usdPershares" scale="0" decimals="2" format="ixt:num-dot-decimal" sign="-">0.34</ix:nonFraction></td>
    <td style="padding-bottom:2px;text-align:left">)</td>
    <td style="padding-bottom:4pt">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:left">$</td>
    <td style="border-bottom:Black 4pt double;text-align:right">(<ix:nonFraction id="Fixv-38131" name="us-gaap:EarningsPerShareBasic" contextRef="C_20220101to20221231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapStatementClassOfStockAxis_slxnNonredeemableClassAandBOrdinaryShareMember" unitRef="usdPershares" scale="0" decimals="2" format="ixt:num-dot-decimal" sign="-">0.07</ix:nonFraction></td>
    <td style="padding-bottom:2px;text-align:left">)</td> </tr>
  </table> </div> </div> </ix:nonNumeric>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">&#160;</span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">The
potential exercise of&#160;<ix:nonFraction id="Fixv-38132" name="us-gaap:DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1" contextRef="C_20230101to20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapDerivativeInstrumentRiskAxis_slxnPublicWarrantsMember" unitRef="shares" scale="0" decimals="0" format="ixt:num-dot-decimal">5,750,000</ix:nonFraction>&#160;Public
Warrants and&#160;<ix:nonFraction id="Fixv-38133" name="us-gaap:DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1" contextRef="C_20230101to20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapDerivativeInstrumentRiskAxis_slxnPrivateWarrantsMember" unitRef="shares" scale="0" decimals="0" format="ixt:num-dot-decimal">190,000</ix:nonFraction>&#160;Private
Warrants sold in the Public Offering and Private Placements as detailed in Note&#160;3 into&#160;<ix:nonFraction id="Fixv-38134" name="us-gaap:DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1" contextRef="C_20230101to20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="shares" scale="0" decimals="0" format="ixt:num-dot-decimal">5,940,000</ix:nonFraction>&#160;shares
has not been included in the calculation of diluted net profit (loss) per share, since the exercise of the warrants is contingent upon
the occurrence of a future event.</span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">&#160;</span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">Additionally,
the effect of the conversion of the Second, Third, Forth and Fifth Promissory Notes into an aggregate amount of&#160;<ix:nonFraction id="Fixv-38135" name="us-gaap:ConvertibleNotesPayable" contextRef="C_20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_srtTitleOfIndividualAxis_slxnSecondThirdForthAndFifthPromissoryNotesMember_usgaapDerivativeInstrumentRiskAxis_slxnPrivateWarrantsMember" unitRef="usd" scale="0" decimals="0" format="ixt:num-dot-decimal">1,500,000</ix:nonFraction>&#160;private
warrants (exercisable into <ix:nonFraction id="Fxbrl_20241206165959771" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="C_20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_srtTitleOfIndividualAxis_slxnSecondThirdForthAndFifthPromissoryNotesMember_usgaapDerivativeInstrumentRiskAxis_slxnPrivateWarrantsMember" unitRef="shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,500,000</ix:nonFraction>
shares) as detailed in Note&#160;4, has not been included in the calculation of diluted net profit (loss) per share, since the conversion
of the abovementioned promissory notes is contingent upon the occurrence of a future event.</span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">&#160;</span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">As
a result, diluted net profit (loss) per share is the same as basic net profit (loss) per share for each of the periods presented, and
for each class.</span></p> </ix:nonNumeric>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">&#160;</span></p>

<div style="margin-top:12pt;margin-bottom:6pt;border-bottom:Black 1.5pt solid">

<p style="font:10pt Times New Roman, Times, Serif;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">F-38</span></p>
</div>

<div style="break-before:page;margin-top:6pt;margin-bottom:12pt">

<p style="margin:0pt">&#160;</p> </div>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt"><strong>&#160;</strong></span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center">&#160;</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt"><strong>MORINGA
ACQUISITION CORP<br/>NOTES TO FINANCIAL STATEMENTS</strong></span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center">&#160;</p> </div>

<div style="font:10pt Times New Roman, Times, Serif"> <ix:nonNumeric id="Fixv-22462" name="slxn:GeneralAndAdministrativeTextBlock" contextRef="C_20230101to20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" escape="true">

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt"><strong>NOTE
9 &#8212;&#160;GENERAL AND ADMINISTRATIVE:</strong></span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">&#160;</span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">The
formation and other operating expenses for the years ended December 31, 2023 and 2022 are as follows:</span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">&#160;</span></p>
<ix:nonNumeric id="Fxbrl_20241003025614125" name="us-gaap:ScheduleOfOtherOperatingCostAndExpenseByComponentTextBlock" contextRef="C_20230101to20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" escape="true">

<table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width:100%;font:10pt Times New Roman, Times, Serif">
  <tr style="vertical-align:bottom">
    <td>&#160;</td>
    <td style="font-weight:bold;padding-bottom:1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom:Black 1.5pt solid;font-weight:bold;text-align:center">December&#160;31,<br/>2023</td>
    <td style="padding-bottom:1.5pt;font-weight:bold">&#160;</td>
    <td style="font-weight:bold;padding-bottom:1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom:Black 1.5pt solid;font-weight:bold;text-align:center">December&#160;31,<br/>2022</td>
    <td style="padding-bottom:1.5pt;font-weight:bold">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td>&#160;</td>
    <td style="font-weight:bold;padding-bottom:1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom:Black 1.5pt solid;font-weight:bold;text-align:center">U.S.&#160;dollars</td>
    <td style="padding-bottom:1.5pt">&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="width:76%;text-align:left">Legal expenses</td>
    <td style="width:1%">&#160;</td>
    <td style="width:1%;text-align:left">&#160;</td>
    <td style="width:9%;text-align:right"><ix:nonFraction id="Fixv-38136" name="slxn:GeneralAndAdministrativeExpenses" contextRef="C_20230101to20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_srtProductOrServiceAxis_slxnLegalExpensesMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">259,000</ix:nonFraction></td>
    <td style="width:1%;text-align:left">&#160;</td>
    <td style="width:1%">&#160;</td>
    <td style="width:1%;text-align:left">&#160;</td>
    <td style="width:9%;text-align:right"><ix:nonFraction id="Fixv-38137" name="slxn:GeneralAndAdministrativeExpenses" contextRef="C_20220101to20221231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_srtProductOrServiceAxis_slxnLegalExpensesMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">398,903</ix:nonFraction></td>
    <td style="width:1%;text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="text-align:left">Audit, bookkeeping and accounting</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right"><ix:nonFraction id="Fixv-38138" name="slxn:GeneralAndAdministrativeExpenses" contextRef="C_20230101to20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_srtProductOrServiceAxis_slxnAuditBookkeepingAndAccountingMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">146,600</ix:nonFraction></td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right"><ix:nonFraction id="Fixv-38139" name="slxn:GeneralAndAdministrativeExpenses" contextRef="C_20220101to20221231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_srtProductOrServiceAxis_slxnAuditBookkeepingAndAccountingMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">143,101</ix:nonFraction></td>
    <td style="text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="text-align:left">Professional services</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right"><ix:nonFraction id="Fixv-38140" name="slxn:GeneralAndAdministrativeExpenses" contextRef="C_20230101to20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_srtProductOrServiceAxis_slxnProfessionalServicesMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">245,538</ix:nonFraction></td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right"><ix:nonFraction id="Fixv-38141" name="slxn:GeneralAndAdministrativeExpenses" contextRef="C_20220101to20221231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_srtProductOrServiceAxis_slxnProfessionalServicesMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">115,651</ix:nonFraction></td>
    <td style="text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="text-align:left">Management fees</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right"><ix:nonFraction id="Fixv-38142" name="slxn:GeneralAndAdministrativeExpenses" contextRef="C_20230101to20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_srtProductOrServiceAxis_slxnManagementFeesMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">120,000</ix:nonFraction></td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right"><ix:nonFraction id="Fixv-38143" name="slxn:GeneralAndAdministrativeExpenses" contextRef="C_20220101to20221231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_srtProductOrServiceAxis_slxnManagementFeesMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">120,000</ix:nonFraction></td>
    <td style="text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td>Insurance</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right"><ix:nonFraction id="Fixv-38144" name="slxn:GeneralAndAdministrativeExpenses" contextRef="C_20230101to20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_srtProductOrServiceAxis_slxnInsuranceMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">281,044</ix:nonFraction></td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right"><ix:nonFraction id="Fixv-38145" name="slxn:GeneralAndAdministrativeExpenses" contextRef="C_20220101to20221231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_srtProductOrServiceAxis_slxnInsuranceMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">325,000</ix:nonFraction></td>
    <td style="text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="text-align:left">Nasdaq fees</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right"><ix:nonFraction id="Fixv-38146" name="slxn:GeneralAndAdministrativeExpenses" contextRef="C_20230101to20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_srtProductOrServiceAxis_slxnNasdaqFeesMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">70,000</ix:nonFraction></td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right"><ix:nonFraction id="Fixv-38147" name="slxn:GeneralAndAdministrativeExpenses" contextRef="C_20220101to20221231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_srtProductOrServiceAxis_slxnNasdaqFeesMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">129,500</ix:nonFraction></td>
    <td style="text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="padding-bottom:1.5pt">Other</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right"><ix:nonFraction id="Fixv-38148" name="slxn:GeneralAndAdministrativeExpenses" contextRef="C_20230101to20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_srtProductOrServiceAxis_slxnOtherExpensesMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">298</ix:nonFraction></td>
    <td style="padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right"><ix:nonFraction id="Fixv-38149" name="slxn:GeneralAndAdministrativeExpenses" contextRef="C_20220101to20221231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_srtProductOrServiceAxis_slxnOtherExpensesMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">187</ix:nonFraction></td>
    <td style="padding-bottom:1.5pt;text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="padding-bottom:4pt">&#160;</td>
    <td style="padding-bottom:4pt">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:left">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:right"><ix:nonFraction id="Fixv-38150" name="slxn:GeneralAndAdministrativeExpenses" contextRef="C_20230101to20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,122,480</ix:nonFraction></td>
    <td style="padding-bottom:4pt;text-align:left">&#160;</td>
    <td style="padding-bottom:4pt">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:left">&#160;</td>
    <td style="border-bottom:Black 4pt double;text-align:right"><ix:nonFraction id="Fixv-38151" name="slxn:GeneralAndAdministrativeExpenses" contextRef="C_20220101to20221231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,232,342</ix:nonFraction></td>
    <td style="padding-bottom:4pt;text-align:left">&#160;</td> </tr>
  </table> </ix:nonNumeric> </ix:nonNumeric>

<p style="margin:0pt">&#160;</p> </div>

<div style="font:10pt Times New Roman, Times, Serif"> <ix:nonNumeric id="Fixv-22575" name="us-gaap:SubsequentEventsTextBlock" contextRef="C_20230101to20231231_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember" escape="true">

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt"><strong>NOTE
10 &#8212;&#160;SUBSEQUENT EVENTS:</strong></span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in;text-indent:-24pt"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt"><strong>&#160;</strong></span></p>

<table cellpadding="0" cellspacing="0" style="font:10pt Times New Roman, Times, Serif;margin-top:0pt;margin-bottom:0pt;width:100%">
  <tr style="vertical-align:top;text-align:justify">
    <td style="width:0.25in">&#160;</td>
    <td style="width:0.25in;text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt"><strong>a.</strong></span></td>
    <td style="text-align:justify"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt"><strong>Nasdaq Deficiency Note</strong></span></td>
        </tr>
  </table>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">&#160;</span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">On
February&#160;20, 2024, the Company received a notice from the staff of the Listing Qualifications Department of The Nasdaq Stock Market
LLC indicating that unless the Company timely requests a hearing before the Nasdaq Hearings Panel (hereafter&#160;&#8212;&#160;the Panel),
trading of the Company&#8217;s securities on The Nasdaq Capital Market would be suspended at the opening of business on February&#160;29,
2024, due to the Company&#8217;s non-compliance with Nasdaq IM-5101-2, which requires that a special purpose acquisition company complete
one or more business combinations within 36&#160;months of the effectiveness of its IPO registration statement.</span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">&#160;</span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">The
Company timely requested a hearing before the Panel to request sufficient time to complete its previously disclosed proposed business
combination with Silexion. The hearing request has resulted in a stay of any suspension or delisting action pending the hearing, which
is scheduled to take place on April&#160;23, 2024.</span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in;text-indent:-24pt"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt"><strong>&#160;</strong></span></p>

<table cellpadding="0" cellspacing="0" style="font:10pt Times New Roman, Times, Serif;margin-top:0pt;margin-bottom:0pt;width:100%">
  <tr style="vertical-align:top;text-align:justify">
    <td style="width:0.25in">&#160;</td>
    <td style="width:0.25in;text-align:left"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt"><strong>b.</strong></span></td>
    <td style="text-align:justify"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt"><strong>Proposed Business Combination</strong></span></td>
        </tr>
  </table>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">&#160;</span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">On
February&#160;21, 2024, the Company, together with its wholly-owned Israeli subsidiary (hereafter&#160;&#8212;&#160;the Merger Sub), entered
into a business combination agreement (hereafter&#160;&#8212;&#160;the BCA) with Silexion Therapeutics Ltd., an Israeli company (hereafter&#160;&#8212;&#160;Silexion).</span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">&#160;</span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">The&#160;Business
Combination is expected to close in the third quarter of 2024, subject to the satisfaction of customary closing conditions under the BCA,
including the approval of the Business Combination by Silexion&#8217;s and the Company&#8217;s shareholders, and Nasdaq approval of the
initial listing of the combined company&#8217;s securities.</span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">&#160;</span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">Headquartered
in Israel, Silexion is a clinical-stage, oncology-focused biotechnology company that develops innovative treatments for unsatisfactorily
treated solid tumor cancers which have a mutated KRAS oncogene. The Business Combination values Silexion at a pre-transaction equity value
of $<ix:nonFraction id="Fixv-38152" name="slxn:PreTransactionEquity" contextRef="C_20240221_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapSubsequentEventTypeAxis_usgaapSubsequentEventMember" unitRef="usd" scale="6" decimals="-5" format="ixt:num-dot-decimal">62.5</ix:nonFraction>&#160;million,
based on a $<ix:nonFraction id="Fixv-38153" name="slxn:PreTransactionsEquity" contextRef="C_20240221_srtConsolidatedEntitiesAxis_slxnMoringaAcquisitionCorpMember_usgaapSubsequentEventTypeAxis_usgaapSubsequentEventMember" unitRef="usdPershares" scale="0" decimals="0" format="ixt:num-dot-decimal">10</ix:nonFraction>&#160;price
per share.</span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">&#160;</span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">The
BCA and the Business Combination have been unanimously approved by the boards of directors of the Company and&#160;Silexion.</span></p>
</ix:nonNumeric>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in">&#160;</p>

<div style="margin-top:12pt;margin-bottom:6pt;border-bottom:Black 1.5pt solid">

<p style="font:10pt Times New Roman, Times, Serif;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">F-39</span></p>
</div> </div>

<div>

<div style="font:10pt Times New Roman, Times, Serif">

<div style="font-family:'Times New Roman',Times,serif;font-size:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span id="f_012"></span></span></span></div>

<div style="clear:both;margin-top:10pt;margin-bottom:10pt">

<div style="page-break-after:always"><hr style="background-color:#ffffff;border-width:0px;clear:both;color:#ffffff;height:0px;margin:4px 0px;width:100%"/></div></div></div>

<div>

<div style="text-align:left;line-height:1.25;font-family:'Times New Roman',Times,serif;font-size:10pt;font-weight:400">&#160;</div>

<div style="text-align:left;line-height:1.25;font-family:'Times New Roman',Times,serif;font-size:10pt;font-weight:400">

<div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">SILEXION
THERAPEUTICS CORP</span></span></div>

<div style="text-align:center;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">UNAUDITED
CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></span></div>

<div style="text-align:center;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">SEPTEMBER
30, 2024</span></span></div>

<div style="line-height:1.25">&#160;</div>

<div style="clear:both;margin-top:10pt;margin-bottom:10pt">

<div style="text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="color:rgb(0, 0, 0);font-weight:normal;font-style:normal">F-40</span></span></span></div>

<div style="page-break-after:always"><hr style="border-width:0px;clear:both;margin:4px 0px;width:100%;height:2px;color:#000000;background-color:#000000"/></div></div>

<div style="line-height:1.25">&#160;</div>

<div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">SILEXION
THERAPEUTICS CORP</span></span></div>

<div style="text-align:center;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">INTERIM
FINANCIAL STATEMENTS</span></span></div>

<div style="text-align:center;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">SEPTEMBER
30, 2024</span></span></div>

<div style="text-align:center;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(Unaudited)</span></span></div>

<div style="line-height:1.25">&#160;</div>

<div style="text-align:center;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">TABLE
OF CONTENTS</span></span></div>

<div style="line-height:1.25">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%">
  <tr>
    <td style="vertical-align:top;width:91%">&#160;</td>
    <td style="vertical-align:top;width:9%">
        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Page</span></span></div></td></tr>
  <tr>
    <td style="vertical-align:bottom;width:91%">
        <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">CONSOLIDATED
        FINANCIAL STATEMENTS:</span></span></div></td>
    <td style="vertical-align:bottom;width:9%">&#160;</td></tr>
  <tr>
    <td style="vertical-align:top;width:91%">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="#BALANCESHEETS">Condensed
        Consolidated Balance Sheets (unaudited)</a></span></span></div></td>
    <td style="vertical-align:top;width:9%">
        <div style="text-align:center;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">F-42
        - F-44</span></span></div></td></tr>
  <tr>
    <td style="vertical-align:top;width:91%">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="#STATEMENTSOFOPERATIONS">Condensed
        Consolidated Statements of Operations (unaudited)</a></span></span></div></td>
    <td style="vertical-align:top;width:9%">
        <div style="text-align:center;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">F-45</span></span></div></td></tr>
  <tr>
    <td style="vertical-align:top;width:91%">
        <div style="text-indent:-8.7pt;margin-left:8.7pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="#CAPITALDEFICIENCY">Condensed
        Consolidated Statements of Changes in Redeemable Convertible Preferred Shares and Capital Deficiency (unaudited)</a></span></span></div></td>
    <td style="vertical-align:top;width:9%">
        <div style="text-align:center;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">F-46
        - F-47</span></span></div></td></tr>
  <tr>
    <td style="vertical-align:top;width:91%">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="#CASHFLOWS">Condensed
        Consolidated Statements of Cash Flows (unaudited)</a></span></span></div></td>
    <td style="vertical-align:top;width:9%">
        <div style="text-align:center;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">F-48
        - F-49</span></span></div></td></tr>
  <tr>
    <td style="vertical-align:top;width:91%">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="#FINANCIALSTATEMENTS">Notes
        to Condensed Consolidated Financial Statements (unaudited)</a></span></span></div></td>
    <td style="vertical-align:top;width:9%">
        <div style="text-align:center;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">F-50
        - F-64</span></span></div></td></tr>
  </table>

<div style="line-height:1.25;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">__________________________</span></span></div>

<div style="line-height:1.25;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">______________________________________</span></span></div>

<div style="line-height:1.25;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">__________________________</span></span></div>

<div style="line-height:1.25">&#160;</div>

<div style="clear:both;margin-top:10pt;margin-bottom:10pt">

<div style="text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="color:rgb(0, 0, 0);font-weight:normal;font-style:normal">F-41</span></span></span></div>

<div style="page-break-after:always"><hr style="border-width:0px;clear:both;margin:4px 0px;width:100%;height:2px;color:#000000;background-color:#000000;margin-top:4pt;margin-bottom:10pt"/></div></div>

<div style="line-height:1.25">&#160;</div></div></div></div>

<div>

<div>

<div style="text-align:center;margin-left:1pt;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">SILEXION
THERAPEUTICS CORP</span></span></div>

<div style="text-align:center;margin-left:1pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">UNAUDITED
CONDENSED CONSOLIDATED BALANCE SHEETS<span id="BALANCESHEETS"></span></span></span></div>

<div style="text-align:center;margin-left:1pt;line-height:1.25">&#160;</div>

<div style="text-align:center;margin-left:0pt;line-height:1.25">

<table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left;color:#000000;width:100%">
  <tr>
    <td style="vertical-align:top;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
    <td colspan="2" style="vertical-align:bottom;vertical-align:bottom">
        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">September
        30,</span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
    <td colspan="2" style="vertical-align:bottom;vertical-align:bottom">
        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">December
        31</span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2024</span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2023</span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
    <td colspan="6" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">U.S.
        dollars in thousands</span></span></div> </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:top;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Assets</span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:top;vertical-align:bottom">
        <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">CURRENT
        ASSETS:</span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
    <td colspan="2" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
    <td colspan="2" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:top;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="margin-left:9.6pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Cash
        and cash equivalents</span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="F20241205041230372_17" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="C_20240930" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,973</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="F20241205041230372_16" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,595</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align:top;width:76%;vertical-align:bottom">
        <div style="margin-left:9.6pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Restricted
        cash</span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="F20241205041230373_19" name="us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue" contextRef="C_20240930" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">50</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="F20241205041230373_18" name="us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">25</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:top;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="margin-left:9.6pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Prepaid
        expenses</span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="F20241205041230374_21" name="us-gaap:PrepaidExpenseCurrent" contextRef="C_20240930" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">944</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="F20241205041230373_20" name="us-gaap:PrepaidExpenseCurrent" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">335</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align:top;width:76%;vertical-align:bottom">
        <div style="margin-left:9.6pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Other
        current assets</span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="F20241205041230374_23" name="us-gaap:OtherAssetsCurrent" contextRef="C_20240930" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">80</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="F20241205041230374_22" name="us-gaap:OtherAssetsCurrent" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">24</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:top;width:76%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">TOTAL
        CURRENT ASSETS</span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="F20241205041230375_25" name="us-gaap:AssetsCurrent" contextRef="C_20240930" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,047</ix:nonFraction></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="F20241205041230375_24" name="us-gaap:AssetsCurrent" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,979</ix:nonFraction></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align:top;width:76%;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:top;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">NON-CURRENT
        ASSETS:</span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align:top;width:76%;vertical-align:bottom">
        <div style="margin-left:9.6pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Restricted
        cash</span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="F20241205041230376_27" name="us-gaap:RestrictedCashNoncurrent" contextRef="C_20240930" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="F20241205041230376_26" name="us-gaap:RestrictedCashNoncurrent" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">25</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:top;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="margin-left:9.6pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Long-term
        deposit</span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="F20241205041230377_29" name="us-gaap:DepositsAssetsNoncurrent" contextRef="C_20240930" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">5</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="F20241205041230376_28" name="us-gaap:DepositsAssetsNoncurrent" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">5</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align:top;width:76%;vertical-align:bottom">
        <div style="margin-left:9.6pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Property
        and equipment, net</span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="F20241205041230377_31" name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="C_20240930" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">35</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="F20241205041230377_30" name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">49</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:top;width:76%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="margin-left:9.6pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Operating
        lease right-of-use asset</span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="F20241205041230378_33" name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="C_20240930" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="F20241205041230378_32" name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">198</ix:nonFraction></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align:top;width:76%;padding-bottom:2px;vertical-align:bottom">
        <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">TOTAL
        NON-CURRENT ASSETS</span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="F20241205041230379_35" name="us-gaap:AssetsNoncurrent" contextRef="C_20240930" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">40</ix:nonFraction></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="F20241205041230378_34" name="us-gaap:AssetsNoncurrent" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">277</ix:nonFraction></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:top;width:76%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">TOTAL
        ASSETS</span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="F20241205041230380_37" name="us-gaap:Assets" contextRef="C_20240930" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,087</ix:nonFraction></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="F20241205041230379_36" name="us-gaap:Assets" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,256</ix:nonFraction></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        </tr>
  </table> </div>&#160;

<div style="text-align:center;margin-left:15.75pt;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The
accompanying notes are an integral part of the unaudited condensed consolidated financial statements.</span></span></div>

<div style="text-align:center;margin-left:15.75pt;line-height:1.25;font-weight:bold">&#160;</div>

<div style="clear:both;margin-top:10pt;margin-bottom:10pt">

<div style="text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:normal;font-style:normal">F-42</span></span></span></div>

<div style="page-break-after:always"> <hr style="border-width:0px;clear:both;margin:4px 0px;width:100%;height:2px;color:#000000;background-color:#000000"/>
</div> </div>

<div style="line-height:1.25">&#160;</div>

<div style="text-align:center;margin-left:1pt;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">SILEXION
THERAPEUTICS CORP</span></span></div>

<div style="text-align:center;margin-left:1pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">UNAUDITED
CONDENSED CONSOLIDATED BALANCE SHEETS</span></span></div>

<div style="line-height:1.25">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left;color:#000000;width:100%">
  <tr>
    <td style="vertical-align:top;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
    <td colspan="2" style="vertical-align:bottom;vertical-align:bottom">
        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">September
        30,</span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
    <td colspan="2" style="vertical-align:bottom;vertical-align:bottom">
        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">December
        31</span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2024</span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2023</span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
    <td colspan="6" style="vertical-align:top;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">U.S.
        dollars in thousands</span></span></div> </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td> </tr>
  <tr style="background-color:rgb(204, 238, 255)">
    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255)">
        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Liabilities
        and redeemable convertible preferred shares, net of capital deficiency</span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
    <td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;white-space:nowrap;background-color:rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
    <td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;white-space:nowrap;background-color:rgb(204, 238, 255)">&#160;</td> </tr>
  <tr style="background-color:rgb(255, 255, 255)">
    <td style="vertical-align:bottom;background-color:rgb(255, 255, 255)">
        <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">CURRENT
        LIABILITIES:</span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;background-color:rgb(255, 255, 255)">&#160;</td>
    <td colspan="2" style="vertical-align:bottom;background-color:rgb(255, 255, 255)">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;white-space:nowrap;background-color:rgb(255, 255, 255)">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;background-color:rgb(255, 255, 255)">&#160;</td>
    <td colspan="2" style="vertical-align:bottom;background-color:rgb(255, 255, 255)">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;white-space:nowrap;background-color:rgb(255, 255, 255)">&#160;</td> </tr>
  <tr style="background-color:rgb(204, 238, 255)">
    <td style="width:76%;vertical-align:bottom;background-color:rgb(204, 238, 255)">
        <div style="text-indent:-14.2pt;margin-left:23.8pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Trade
        payables</span></span></div> </td>
    <td colspan="1" style="text-align:right;width:1%;vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(204, 238, 255)">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
        </td>
    <td colspan="1" style="text-align:right;width:9%;vertical-align:bottom;background-color:rgb(204, 238, 255)">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="F20241205041230380_39" name="us-gaap:AccountsPayableCurrent" contextRef="C_20240930" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">799</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="width:1%;vertical-align:bottom;white-space:nowrap;background-color:rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" style="text-align:right;width:1%;vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(204, 238, 255)">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
        </td>
    <td colspan="1" style="text-align:right;width:9%;vertical-align:bottom;background-color:rgb(204, 238, 255)">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="F20241205041230380_38" name="us-gaap:AccountsPayableCurrent" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">319</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="width:1%;vertical-align:bottom;white-space:nowrap;background-color:rgb(204, 238, 255)">&#160;</td> </tr>
  <tr style="background-color:rgb(255, 255, 255)">
    <td style="width:76%;vertical-align:bottom;background-color:rgb(255, 255, 255)">
        <div style="text-indent:-14.2pt;margin-left:23.8pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Current
        maturities of operating lease liability</span></span></div> </td>
    <td colspan="1" style="text-align:right;width:1%;vertical-align:bottom;background-color:rgb(255, 255, 255)">&#160;</td>
    <td colspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(255, 255, 255)">&#160;</td>
    <td colspan="1" style="text-align:right;width:9%;vertical-align:bottom;background-color:rgb(255, 255, 255)">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="F20241205041230381_41" name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="C_20240930" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="width:1%;vertical-align:bottom;white-space:nowrap;background-color:rgb(255, 255, 255)">&#160;</td>
    <td colspan="1" style="text-align:right;width:1%;vertical-align:bottom;background-color:rgb(255, 255, 255)">&#160;</td>
    <td colspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(255, 255, 255)">&#160;</td>
    <td colspan="1" style="text-align:right;width:9%;vertical-align:bottom;background-color:rgb(255, 255, 255)">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="F20241205041230381_40" name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">112</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="width:1%;vertical-align:bottom;white-space:nowrap;background-color:rgb(255, 255, 255)">&#160;</td> </tr>
  <tr style="background-color:rgb(204, 238, 255)">
    <td style="width:76%;vertical-align:bottom;background-color:rgb(204, 238, 255)">
        <div style="margin-left:8.95pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Warrants
        to preferred shares&#160;(including $<ix:nonFraction id="F20241205041230363_0" name="us-gaap:OtherNotesPayableCurrent" contextRef="C_20240930_usgaapRelatedPartyTransactionsByRelatedPartyAxis_usgaapRelatedPartyMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">0</ix:nonFraction>
        and $<ix:nonFraction id="F20241205041230364_1" name="us-gaap:OtherNotesPayableCurrent" contextRef="C_20231231_usgaapRelatedPartyTransactionsByRelatedPartyAxis_usgaapRelatedPartyMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">186</ix:nonFraction>
        due to related party, as of September 30, 2024 and December 31, 2023, respectively)</span></span></div> </td>
    <td colspan="1" style="text-align:right;width:1%;vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" style="text-align:right;width:9%;vertical-align:bottom;background-color:rgb(204, 238, 255)">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="F20241205041230382_43" name="us-gaap:OtherLiabilitiesCurrent" contextRef="C_20240930" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="width:1%;vertical-align:bottom;white-space:nowrap;background-color:rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" style="text-align:right;width:1%;vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" style="text-align:right;width:9%;vertical-align:bottom;background-color:rgb(204, 238, 255)">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="F20241205041230382_42" name="us-gaap:OtherLiabilitiesCurrent" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">200</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="width:1%;vertical-align:bottom;white-space:nowrap;background-color:rgb(204, 238, 255)">&#160;</td> </tr>
  <tr style="background-color:rgb(255, 255, 255)">
    <td style="width:76%;vertical-align:bottom;background-color:rgb(255, 255, 255)">
        <div style="text-indent:-14.2pt;margin-left:23.8pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Employee
        related obligations</span></span></div> </td>
    <td colspan="1" style="text-align:right;width:1%;vertical-align:bottom;background-color:rgb(255, 255, 255)">&#160;</td>
    <td colspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(255, 255, 255)">&#160;</td>
    <td colspan="1" style="text-align:right;width:9%;vertical-align:bottom;background-color:rgb(255, 255, 255)">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="F20241205041230385_45" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" contextRef="C_20240930" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">687</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="width:1%;vertical-align:bottom;white-space:nowrap;background-color:rgb(255, 255, 255)">&#160;</td>
    <td colspan="1" style="text-align:right;width:1%;vertical-align:bottom;background-color:rgb(255, 255, 255)">&#160;</td>
    <td colspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(255, 255, 255)">&#160;</td>
    <td colspan="1" style="text-align:right;width:9%;vertical-align:bottom;background-color:rgb(255, 255, 255)">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="F20241205041230384_44" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">207</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="width:1%;vertical-align:bottom;white-space:nowrap;background-color:rgb(255, 255, 255)">&#160;</td> </tr>
  <tr style="background-color:rgb(204, 238, 255)">
    <td style="width:76%;vertical-align:bottom;background-color:rgb(204, 238, 255)">
        <div style="text-indent:-14.2pt;margin-left:23.8pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Accrued
        expenses and other account payable</span></span></div> </td>
    <td colspan="1" style="text-align:right;width:1%;vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" style="text-align:right;width:9%;vertical-align:bottom;background-color:rgb(204, 238, 255)">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="F20241205041230386_47" name="us-gaap:OtherAccountsPayableAndAccruedLiabilities" contextRef="C_20240930" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,858</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="width:1%;vertical-align:bottom;white-space:nowrap;background-color:rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" style="text-align:right;width:1%;vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" style="text-align:right;width:9%;vertical-align:bottom;background-color:rgb(204, 238, 255)">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="F20241205041230385_46" name="us-gaap:OtherAccountsPayableAndAccruedLiabilities" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,358</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="width:1%;vertical-align:bottom;white-space:nowrap;background-color:rgb(204, 238, 255)">&#160;</td> </tr>
  <tr style="background-color:rgb(255, 255, 255)">
    <td style="width:76%;vertical-align:bottom;background-color:rgb(255, 255, 255)">
        <div style="text-indent:-14.2pt;margin-left:23.8pt;line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Private warrants to purchase
        ordinary shares</span></span></div> </div> </td>
    <td colspan="1" style="text-align:right;width:1%;vertical-align:bottom;background-color:rgb(255, 255, 255)">&#160;</td>
    <td colspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(255, 255, 255)">&#160;</td>
    <td colspan="1" style="text-align:right;width:9%;vertical-align:bottom;background-color:rgb(255, 255, 255)">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20241111150050191_20241205041230386_47" name="slxn:PrivateWarrantToPurchaseOrdinaryShares" contextRef="C_20240930" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">10</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="width:1%;vertical-align:bottom;white-space:nowrap;background-color:rgb(255, 255, 255)">&#160;</td>
    <td colspan="1" style="text-align:right;width:1%;vertical-align:bottom;background-color:rgb(255, 255, 255)">&#160;</td>
    <td colspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(255, 255, 255)">&#160;</td>
    <td colspan="1" style="text-align:right;width:9%;vertical-align:bottom;background-color:rgb(255, 255, 255)">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20241111150050191_20241205041230385_46" name="slxn:PrivateWarrantToPurchaseOrdinaryShares" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="width:1%;vertical-align:bottom;white-space:nowrap;background-color:rgb(255, 255, 255)">&#160;</td> </tr>
  <tr style="background-color:rgb(204, 238, 255)">
    <td style="width:76%;padding-bottom:2px;vertical-align:bottom;background-color:rgb(204, 238, 255)">
        <div style="text-indent:-14.2pt;margin-left:23.8pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Underwriters
        Promissory Note</span></span></div> </td>
    <td colspan="1" style="text-align:right;width:1%;padding-bottom:2px;vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" style="width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" style="text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom;background-color:rgb(204, 238, 255)">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20241111150052183_20241205041230386_47" name="slxn:UnderwritersPromissoryNotesCurrentLiabilities" contextRef="C_20240930" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">229</ix:nonFraction></span></span></div>
        </div> </td>
    <td colspan="1" style="width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap;background-color:rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" style="text-align:right;width:1%;padding-bottom:2px;vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" style="width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" style="text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom;background-color:rgb(204, 238, 255)">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20241111150052183_20241205041230385_46" name="slxn:UnderwritersPromissoryNotesCurrentLiabilities" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
        </div> </td>
    <td colspan="1" style="width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap;background-color:rgb(204, 238, 255)">&#160;</td>
        </tr>
  <tr style="background-color:rgb(255, 255, 255)">
    <td style="width:76%;padding-bottom:2px;vertical-align:bottom;background-color:rgb(255, 255, 255)">
        <div style="line-height:1.25;margin-left:10pt"><strong><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">TOTAL
        CURRENT LIABILITIES</span></span></strong></div> </td>
    <td colspan="1" style="text-align:right;width:1%;padding-bottom:2px;vertical-align:bottom;background-color:rgb(255, 255, 255)">&#160;</td>
    <td colspan="1" style="width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom;background-color:rgb(255, 255, 255)">&#160;</td>
    <td colspan="1" style="text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom;background-color:rgb(255, 255, 255)">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="F20241205041230387_49" name="us-gaap:LiabilitiesCurrent" contextRef="C_20240930" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,583</ix:nonFraction></span></span></div>
        </div> </td>
    <td colspan="1" style="width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap;background-color:rgb(255, 255, 255)">&#160;</td>
    <td colspan="1" style="text-align:right;width:1%;padding-bottom:2px;vertical-align:bottom;background-color:rgb(255, 255, 255)">&#160;</td>
    <td colspan="1" style="width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom;background-color:rgb(255, 255, 255)">&#160;</td>
    <td colspan="1" style="text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom;background-color:rgb(255, 255, 255)">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="F20241205041230386_48" name="us-gaap:LiabilitiesCurrent" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,196</ix:nonFraction></span></span></div>
        </div> </td>
    <td colspan="1" style="width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap;background-color:rgb(255, 255, 255)">&#160;</td>
        </tr>
  <tr style="background-color:rgb(204, 238, 255)">
    <td style="width:76%;vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" style="text-align:right;width:1%;vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" style="text-align:right;width:9%;vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" style="width:1%;vertical-align:bottom;white-space:nowrap;background-color:rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" style="text-align:right;width:1%;vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" style="text-align:right;width:9%;vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" style="width:1%;vertical-align:bottom;white-space:nowrap;background-color:rgb(204, 238, 255)">&#160;</td> </tr>
  <tr style="background-color:rgb(255, 255, 255)">
    <td style="width:76%;vertical-align:bottom;background-color:rgb(255, 255, 255)">
        <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">NON-CURRENT
        LIABILITIES:</span></span></div> </td>
    <td colspan="1" style="text-align:right;width:1%;vertical-align:bottom;background-color:rgb(255, 255, 255)">&#160;</td>
    <td colspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(255, 255, 255)">&#160;</td>
    <td colspan="1" style="text-align:right;width:9%;vertical-align:bottom;background-color:rgb(255, 255, 255)">&#160;</td>
    <td colspan="1" style="width:1%;vertical-align:bottom;white-space:nowrap;background-color:rgb(255, 255, 255)">&#160;</td>
    <td colspan="1" style="text-align:right;width:1%;vertical-align:bottom;background-color:rgb(255, 255, 255)">&#160;</td>
    <td colspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(255, 255, 255)">&#160;</td>
    <td colspan="1" style="text-align:right;width:9%;vertical-align:bottom;background-color:rgb(255, 255, 255)">&#160;</td>
    <td colspan="1" style="width:1%;vertical-align:bottom;white-space:nowrap;background-color:rgb(255, 255, 255)">&#160;</td> </tr>
  <tr style="background-color:rgb(204, 238, 255)">
    <td style="width:76%;vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" style="text-align:right;width:1%;vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" style="text-align:right;width:9%;vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" style="width:1%;vertical-align:bottom;white-space:nowrap;background-color:rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" style="text-align:right;width:1%;vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" style="text-align:right;width:9%;vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" style="width:1%;vertical-align:bottom;white-space:nowrap;background-color:rgb(204, 238, 255)">&#160;</td> </tr>
  <tr style="background-color:rgb(255, 255, 255)">
    <td style="width:76%;vertical-align:bottom;background-color:rgb(255, 255, 255)">
        <div style="line-height:1.25;margin-left:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Long-term
        operating lease liability</span></span></div> </td>
    <td colspan="1" style="text-align:right;width:1%;vertical-align:bottom;background-color:rgb(255, 255, 255)">&#160;</td>
    <td colspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(255, 255, 255)">&#160;</td>
    <td colspan="1" style="text-align:right;width:9%;vertical-align:bottom;background-color:rgb(255, 255, 255)">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="F20241205041230387_51" name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="C_20240930" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="width:1%;vertical-align:bottom;white-space:nowrap;background-color:rgb(255, 255, 255)">&#160;</td>
    <td colspan="1" style="text-align:right;width:1%;vertical-align:bottom;background-color:rgb(255, 255, 255)">&#160;</td>
    <td colspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(255, 255, 255)">&#160;</td>
    <td colspan="1" style="text-align:right;width:9%;vertical-align:bottom;background-color:rgb(255, 255, 255)">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="F20241205041230387_50" name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">59</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="width:1%;vertical-align:bottom;white-space:nowrap;background-color:rgb(255, 255, 255)">&#160;</td> </tr>
  <tr style="background-color:rgb(204, 238, 255)">
    <td style="width:76%;vertical-align:bottom;background-color:rgb(204, 238, 255)">
        <div style="margin-left:9.6pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Underwriters
        Promissory Note</span></span></div> </td>
    <td colspan="1" style="text-align:right;width:1%;vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" style="text-align:right;width:9%;vertical-align:bottom;background-color:rgb(204, 238, 255)">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20241111150055119_20241205041230386_47" name="slxn:UnderwritersPromissoryNotesNonCurrentLiabilities" contextRef="C_20240930" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">977</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="width:1%;vertical-align:bottom;white-space:nowrap;background-color:rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" style="text-align:right;width:1%;vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" style="text-align:right;width:9%;vertical-align:bottom;background-color:rgb(204, 238, 255)">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20241111150055119_20241205041230385_46" name="slxn:UnderwritersPromissoryNotesNonCurrentLiabilities" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="width:1%;vertical-align:bottom;white-space:nowrap;background-color:rgb(204, 238, 255)">&#160;</td> </tr>
  <tr style="background-color:rgb(255, 255, 255)">
    <td style="width:76%;padding-bottom:2px;vertical-align:bottom;background-color:rgb(255, 255, 255)">
        <div style="margin-left:9.6pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Promissory
        note - related party</span></span></div> </td>
    <td colspan="1" style="text-align:right;width:1%;padding-bottom:2px;vertical-align:bottom;background-color:rgb(255, 255, 255)">&#160;</td>
    <td colspan="1" style="width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom;background-color:rgb(255, 255, 255)">&#160;</td>
    <td colspan="1" style="text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom;background-color:rgb(255, 255, 255)">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20241111150057503_20241205041230386_47" name="slxn:PromissoryNotesToRelatedParties" contextRef="C_20240930" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,106</ix:nonFraction></span></span></div>
        </div> </td>
    <td colspan="1" style="width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap;background-color:rgb(255, 255, 255)">&#160;</td>
    <td colspan="1" style="text-align:right;width:1%;padding-bottom:2px;vertical-align:bottom;background-color:rgb(255, 255, 255)">&#160;</td>
    <td colspan="1" style="width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom;background-color:rgb(255, 255, 255)">&#160;</td>
    <td colspan="1" style="text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom;background-color:rgb(255, 255, 255)">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20241111150057503_20241205041230385_46" name="slxn:PromissoryNotesToRelatedParties" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
        </div> </td>
    <td colspan="1" style="width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap;background-color:rgb(255, 255, 255)">&#160;</td>
        </tr>
  <tr style="background-color:rgb(204, 238, 255)">
    <td style="width:76%;padding-bottom:2px;vertical-align:bottom;background-color:rgb(204, 238, 255)">
        <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">TOTAL
        NON-CURRENT LIABILITIES</span></span></div> </td>
    <td colspan="1" style="text-align:right;width:1%;padding-bottom:2px;vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" style="width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom;background-color:rgb(204, 238, 255)">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
        </div> </td>
    <td colspan="1" style="text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom;background-color:rgb(204, 238, 255)">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="F20241205041230388_53" name="us-gaap:LiabilitiesNoncurrent" contextRef="C_20240930" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,083</ix:nonFraction></span></span></div>
        </div> </td>
    <td colspan="1" style="width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap;background-color:rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" style="text-align:right;width:1%;padding-bottom:2px;vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" style="width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom;background-color:rgb(204, 238, 255)">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
        </div> </td>
    <td colspan="1" style="text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom;background-color:rgb(204, 238, 255)">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="F20241205041230388_52" name="us-gaap:LiabilitiesNoncurrent" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">59</ix:nonFraction></span></span></div>
        </div> </td>
    <td colspan="1" style="width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap;background-color:rgb(204, 238, 255)">&#160;</td>
        </tr>
  <tr style="background-color:rgb(255, 255, 255)">
    <td rowspan="1" style="width:76%;vertical-align:bottom;background-color:rgb(255, 255, 255)">&#160;</td>
    <td colspan="1" rowspan="1" style="text-align:right;width:1%;vertical-align:bottom;background-color:rgb(255, 255, 255)">&#160;</td>
    <td colspan="1" rowspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(255, 255, 255)">&#160;</td>
    <td colspan="1" rowspan="1" style="text-align:right;width:9%;vertical-align:bottom;background-color:rgb(255, 255, 255)">&#160;</td>
    <td colspan="1" rowspan="1" style="width:1%;vertical-align:bottom;white-space:nowrap;background-color:rgb(255, 255, 255)">&#160;</td>
    <td colspan="1" rowspan="1" style="text-align:right;width:1%;vertical-align:bottom;background-color:rgb(255, 255, 255)">&#160;</td>
    <td colspan="1" rowspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(255, 255, 255)">&#160;</td>
    <td colspan="1" rowspan="1" style="text-align:right;width:9%;vertical-align:bottom;background-color:rgb(255, 255, 255)">&#160;</td>
    <td colspan="1" rowspan="1" style="width:1%;vertical-align:bottom;white-space:nowrap;background-color:rgb(255, 255, 255)">&#160;</td> </tr>
  <tr style="background-color:rgb(204, 238, 255)">
    <td style="width:76%;padding-bottom:2px;vertical-align:bottom;background-color:rgb(204, 238, 255)">
        <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">TOTAL
        LIABILITIES</span></span></div> </td>
    <td colspan="1" style="text-align:right;width:1%;padding-bottom:2px;vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" style="width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom;background-color:rgb(204, 238, 255)">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
        </div> </td>
    <td colspan="1" style="text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom;background-color:rgb(204, 238, 255)">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="F20241205041230389_55" name="us-gaap:Liabilities" contextRef="C_20240930" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,666</ix:nonFraction></span></span></div>
        </div> </td>
    <td colspan="1" style="width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap;background-color:rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" style="text-align:right;width:1%;padding-bottom:2px;vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" style="width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom;background-color:rgb(204, 238, 255)">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
        </div> </td>
    <td colspan="1" style="text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom;background-color:rgb(204, 238, 255)">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="F20241205041230388_54" name="us-gaap:Liabilities" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,255</ix:nonFraction></span></span></div>
        </div> </td>
    <td colspan="1" style="width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap;background-color:rgb(204, 238, 255)">&#160;</td>
        </tr>
  <tr style="background-color:rgb(255, 255, 255)">
    <td style="width:76%;vertical-align:bottom;background-color:rgb(255, 255, 255)">&#160;</td>
    <td colspan="1" style="text-align:right;width:1%;vertical-align:bottom;background-color:rgb(255, 255, 255)">&#160;</td>
    <td colspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(255, 255, 255)">&#160;</td>
    <td colspan="1" style="text-align:right;width:9%;vertical-align:bottom;background-color:rgb(255, 255, 255)">&#160;</td>
    <td colspan="1" style="width:1%;vertical-align:bottom;white-space:nowrap;background-color:rgb(255, 255, 255)">&#160;</td>
    <td colspan="1" style="text-align:right;width:1%;vertical-align:bottom;background-color:rgb(255, 255, 255)">&#160;</td>
    <td colspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(255, 255, 255)">&#160;</td>
    <td colspan="1" style="text-align:right;width:9%;vertical-align:bottom;background-color:rgb(255, 255, 255)">&#160;</td>
    <td colspan="1" style="width:1%;vertical-align:bottom;white-space:nowrap;background-color:rgb(255, 255, 255)">&#160;</td> </tr>
  <tr style="background-color:rgb(204, 238, 255)">
    <td style="width:76%;vertical-align:bottom;background-color:rgb(204, 238, 255)">
        <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">COMMITMENTS
        AND CONTINGENT LIABILITIES</span></span></div> </td>
    <td colspan="1" style="text-align:right;width:1%;vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" style="text-align:right;width:9%;vertical-align:bottom;background-color:rgb(204, 238, 255)"><ix:nonFraction id="F20241205041230405_96" name="us-gaap:CommitmentsAndContingencies" contextRef="C_20240930" unitRef="usd" xsi:nil="true"></ix:nonFraction></td>
    <td colspan="1" style="width:1%;vertical-align:bottom;white-space:nowrap;background-color:rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" style="text-align:right;width:1%;vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" style="text-align:right;width:9%;vertical-align:bottom;background-color:rgb(204, 238, 255)"><ix:nonFraction id="F20241205041230405_97" name="us-gaap:CommitmentsAndContingencies" contextRef="C_20231231" unitRef="usd" xsi:nil="true"></ix:nonFraction></td>
    <td colspan="1" style="width:1%;vertical-align:bottom;white-space:nowrap;background-color:rgb(204, 238, 255)">&#160;</td> </tr>
  <tr style="background-color:rgb(255, 255, 255)">
    <td style="width:76%;vertical-align:bottom;background-color:rgb(255, 255, 255)">
        <div style="text-indent:-9.6pt;margin-left:9.6pt;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">REDEEMABLE
        CONVERTIBLE PREFERRED SHARES&#160;AND NON-CONTROLLING INTERESTS:</span></span></div> </td>
    <td colspan="1" style="text-align:right;width:1%;vertical-align:bottom;background-color:rgb(255, 255, 255)">&#160;</td>
    <td colspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(255, 255, 255)">&#160;</td>
    <td colspan="1" style="text-align:right;width:9%;vertical-align:bottom;background-color:rgb(255, 255, 255)">&#160;</td>
    <td colspan="1" style="width:1%;vertical-align:bottom;white-space:nowrap;background-color:rgb(255, 255, 255)">&#160;</td>
    <td colspan="1" style="text-align:right;width:1%;vertical-align:bottom;background-color:rgb(255, 255, 255)">&#160;</td>
    <td colspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(255, 255, 255)">&#160;</td>
    <td colspan="1" style="text-align:right;width:9%;vertical-align:bottom;background-color:rgb(255, 255, 255)">&#160;</td>
    <td colspan="1" style="width:1%;vertical-align:bottom;white-space:nowrap;background-color:rgb(255, 255, 255)">&#160;</td> </tr>
  <tr style="background-color:rgb(204, 238, 255)">
    <td style="width:76%;vertical-align:bottom;background-color:rgb(204, 238, 255)">
        <div style="text-indent:-14.2pt;margin-left:23.8pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Convertible
        Series A Preferred Shares (NIS <ix:nonFraction id="Fxbrl_20241205155830289" name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="C_20231231_usgaapStatementClassOfStockAxis_slxnConvertibleSeriesAPreferredSharesMember" unitRef="ilsPershares" scale="0" decimals="2" format="ixt:num-dot-decimal"><ix:nonFraction id="F20241205041230396_74" name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="C_20240930_usgaapStatementClassOfStockAxis_slxnConvertibleSeriesAPreferredSharesMember" unitRef="ilsPershares" scale="0" decimals="2" format="ixt:num-dot-decimal">0.09</ix:nonFraction></ix:nonFraction>&#160;par
        value, <ix:nonFraction id="F20241205041230397_77" name="us-gaap:PreferredStockSharesAuthorized" contextRef="C_20240930_usgaapStatementClassOfStockAxis_slxnConvertibleSeriesAPreferredSharesMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">0</ix:nonFraction>
        and <ix:nonFraction id="F20241205041230396_75" name="us-gaap:PreferredStockSharesAuthorized" contextRef="C_20231231_usgaapStatementClassOfStockAxis_slxnConvertibleSeriesAPreferredSharesMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">56,667</ix:nonFraction>
        shares authorized as of September 30, 2024 and December 31, 2023, respectively; <ix:nonFraction id="F20241205041230412_114" name="us-gaap:PreferredStockSharesOutstanding" contextRef="C_20240930_usgaapStatementClassOfStockAxis_slxnConvertibleSeriesAPreferredSharesMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F20241205041230398_78" name="us-gaap:PreferredStockSharesIssued" contextRef="C_20240930_usgaapStatementClassOfStockAxis_slxnConvertibleSeriesAPreferredSharesMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">0</ix:nonFraction></ix:nonFraction>
        and <ix:nonFraction id="Fxbrl_20241205155808266" name="us-gaap:PreferredStockSharesOutstanding" contextRef="C_20231231_usgaapStatementClassOfStockAxis_slxnConvertibleSeriesAPreferredSharesMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F20241205041230397_76" name="us-gaap:PreferredStockSharesIssued" contextRef="C_20231231_usgaapStatementClassOfStockAxis_slxnConvertibleSeriesAPreferredSharesMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">43,121</ix:nonFraction></ix:nonFraction>&#160;shares
        issued and outstanding as of September 30, 2024 and December 31, 2023, respectively);</span></span></div> </td>
    <td colspan="1" style="text-align:right;width:1%;vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" style="text-align:right;width:9%;vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" style="width:1%;vertical-align:bottom;white-space:nowrap;background-color:rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" style="text-align:right;width:1%;vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" style="text-align:right;width:9%;vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" style="width:1%;vertical-align:bottom;white-space:nowrap;background-color:rgb(204, 238, 255)">&#160;</td> </tr>
  <tr style="background-color:rgb(255, 255, 255)">
    <td rowspan="1" style="width:76%;vertical-align:bottom;background-color:rgb(255, 255, 255)">
        <div style="text-indent:-14.2pt;margin-left:23.8pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Convertible
        Series A-1 Preferred Shares (NIS <ix:nonFraction id="Fxbrl_20241205155900331" name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="C_20231231_usgaapStatementClassOfStockAxis_slxnConvertibleSeriesAOnePreferredSharesMember" unitRef="ilsPershares" scale="0" decimals="2" format="ixt:num-dot-decimal"><ix:nonFraction id="F20241205041230364_2" name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="C_20240930_usgaapStatementClassOfStockAxis_slxnConvertibleSeriesAOnePreferredSharesMember" unitRef="ilsPershares" scale="0" decimals="2" format="ixt:num-dot-decimal">0.09</ix:nonFraction></ix:nonFraction>&#160;par
        value per share, <ix:nonFraction id="F20241205041230398_79" name="us-gaap:PreferredStockSharesAuthorized" contextRef="C_20240930_usgaapStatementClassOfStockAxis_slxnConvertibleSeriesAOnePreferredSharesMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">0</ix:nonFraction>
        and <ix:nonFraction id="F20241205041230365_3" name="us-gaap:PreferredStockSharesAuthorized" contextRef="C_20231231_usgaapStatementClassOfStockAxis_slxnConvertibleSeriesAOnePreferredSharesMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">13,334</ix:nonFraction>
        shares authorized as of September 30, 2024 and December 31, 2023, respectively; <ix:nonFraction id="F20241205041230412_115" name="us-gaap:PreferredStockSharesOutstanding" contextRef="C_20240930_usgaapStatementClassOfStockAxis_slxnConvertibleSeriesAOnePreferredSharesMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F20241205041230398_80" name="us-gaap:PreferredStockSharesIssued" contextRef="C_20240930_usgaapStatementClassOfStockAxis_slxnConvertibleSeriesAOnePreferredSharesMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">0</ix:nonFraction></ix:nonFraction>
        and <ix:nonFraction id="Fxbrl_20241205155911978" name="us-gaap:PreferredStockSharesOutstanding" contextRef="C_20231231_usgaapStatementClassOfStockAxis_slxnConvertibleSeriesAOnePreferredSharesMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F20241205041230365_4" name="us-gaap:PreferredStockSharesIssued" contextRef="C_20231231_usgaapStatementClassOfStockAxis_slxnConvertibleSeriesAOnePreferredSharesMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">10,136</ix:nonFraction></ix:nonFraction>
        shares issued and outstanding as of September 30, 2024 and December 31, 2023, respectively);</span></span></div> </td>
    <td colspan="1" rowspan="1" style="text-align:right;width:1%;vertical-align:bottom;background-color:rgb(255, 255, 255)">&#160;</td>
    <td colspan="1" rowspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(255, 255, 255)">&#160;</td>
    <td colspan="1" rowspan="1" style="text-align:right;width:9%;vertical-align:bottom;background-color:rgb(255, 255, 255)">&#160;</td>
    <td colspan="1" rowspan="1" style="width:1%;vertical-align:bottom;white-space:nowrap;background-color:rgb(255, 255, 255)">&#160;</td>
    <td colspan="1" rowspan="1" style="text-align:right;width:1%;vertical-align:bottom;background-color:rgb(255, 255, 255)">&#160;</td>
    <td colspan="1" rowspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(255, 255, 255)">&#160;</td>
    <td colspan="1" rowspan="1" style="text-align:right;width:9%;vertical-align:bottom;background-color:rgb(255, 255, 255)">&#160;</td>
    <td colspan="1" rowspan="1" style="width:1%;vertical-align:bottom;white-space:nowrap;background-color:rgb(255, 255, 255)">&#160;</td> </tr>
  <tr style="background-color:rgb(204, 238, 255)">
    <td rowspan="1" style="width:76%;vertical-align:bottom;background-color:rgb(204, 238, 255)">
        <div style="text-indent:-14.2pt;margin-left:23.8pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Convertible
        Series A-2 Preferred Shares (NIS <ix:nonFraction id="Fxbrl_20241205155927185" name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="C_20231231_usgaapStatementClassOfStockAxis_slxnConvertibleSeriesA2PreferredSharesMember" unitRef="ilsPershares" scale="0" decimals="2" format="ixt:num-dot-decimal"><ix:nonFraction id="F20241205041230366_5" name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="C_20240930_usgaapStatementClassOfStockAxis_slxnConvertibleSeriesA2PreferredSharesMember" unitRef="ilsPershares" scale="0" decimals="2" format="ixt:num-dot-decimal">0.09</ix:nonFraction></ix:nonFraction>&#160;par
        value per share, <ix:nonFraction id="F20241205041230399_81" name="us-gaap:PreferredStockSharesAuthorized" contextRef="C_20240930_usgaapStatementClassOfStockAxis_slxnConvertibleSeriesA2PreferredSharesMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">0</ix:nonFraction>
        and <ix:nonFraction id="F20241205041230366_6" name="us-gaap:PreferredStockSharesAuthorized" contextRef="C_20231231_usgaapStatementClassOfStockAxis_slxnConvertibleSeriesA2PreferredSharesMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">22,223</ix:nonFraction>
        shares authorized as of September 30, 2024 and December 31, 2023, respectively; <ix:nonFraction id="F20241205041230413_116" name="us-gaap:PreferredStockSharesOutstanding" contextRef="C_20240930_usgaapStatementClassOfStockAxis_slxnConvertibleSeriesA2PreferredSharesMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F20241205041230399_82" name="us-gaap:PreferredStockSharesIssued" contextRef="C_20240930_usgaapStatementClassOfStockAxis_slxnConvertibleSeriesA2PreferredSharesMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">0</ix:nonFraction></ix:nonFraction>
        and <ix:nonFraction id="Fxbrl_20241205155939178" name="us-gaap:PreferredStockSharesOutstanding" contextRef="C_20231231_usgaapStatementClassOfStockAxis_slxnConvertibleSeriesA2PreferredSharesMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F20241205041230367_7" name="us-gaap:PreferredStockSharesIssued" contextRef="C_20231231_usgaapStatementClassOfStockAxis_slxnConvertibleSeriesA2PreferredSharesMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">5,051</ix:nonFraction></ix:nonFraction>&#160;shares
        issued and outstanding as of September 30, 2024 and December 31, 2023, respectively);</span></span></div> </td>
    <td colspan="1" rowspan="1" style="text-align:right;width:1%;vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" rowspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" rowspan="1" style="text-align:right;width:9%;vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" rowspan="1" style="width:1%;vertical-align:bottom;white-space:nowrap;background-color:rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" rowspan="1" style="text-align:right;width:1%;vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" rowspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" rowspan="1" style="text-align:right;width:9%;vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" rowspan="1" style="width:1%;vertical-align:bottom;white-space:nowrap;background-color:rgb(204, 238, 255)">&#160;</td> </tr>
  <tr style="background-color:rgb(255, 255, 255)">
    <td rowspan="1" style="width:76%;vertical-align:bottom;background-color:rgb(255, 255, 255)">
        <div style="line-height:1.25">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">
        <div style="line-height:1.25">
        <div style="line-height:1.25;text-indent:-14.2pt;margin-left:23.8pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Convertible
        Series A-3 Preferred Shares (NIS <ix:nonFraction id="Fxbrl_20241205155952034" name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="C_20231231_usgaapStatementClassOfStockAxis_slxnConvertibleSeriesAThreePreferredSharesMember" unitRef="ilsPershares" scale="0" decimals="2" format="ixt:num-dot-decimal"><ix:nonFraction id="F20241205041230367_8" name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="C_20240930_usgaapStatementClassOfStockAxis_slxnConvertibleSeriesAThreePreferredSharesMember" unitRef="ilsPershares" scale="0" decimals="2" format="ixt:num-dot-decimal">0.09</ix:nonFraction></ix:nonFraction>&#160;par
        value per share, <ix:nonFraction id="F20241205041230399_83" name="us-gaap:PreferredStockSharesAuthorized" contextRef="C_20240930_usgaapStatementClassOfStockAxis_slxnConvertibleSeriesAThreePreferredSharesMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">0</ix:nonFraction>
        and <ix:nonFraction id="F20241205041230368_9" name="us-gaap:PreferredStockSharesAuthorized" contextRef="C_20231231_usgaapStatementClassOfStockAxis_slxnConvertibleSeriesAThreePreferredSharesMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">8,889</ix:nonFraction>
        shares authorized as of September 30, 2024 and December 31, 2023, respectively <ix:nonFraction id="F20241205041230413_117" name="us-gaap:PreferredStockSharesOutstanding" contextRef="C_20240930_usgaapStatementClassOfStockAxis_slxnConvertibleSeriesAThreePreferredSharesMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F20241205041230400_84" name="us-gaap:PreferredStockSharesIssued" contextRef="C_20240930_usgaapStatementClassOfStockAxis_slxnConvertibleSeriesAThreePreferredSharesMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">0</ix:nonFraction></ix:nonFraction>
        and <ix:nonFraction id="Fxbrl_20241205160004304" name="us-gaap:PreferredStockSharesOutstanding" contextRef="C_20231231_usgaapStatementClassOfStockAxis_slxnConvertibleSeriesAThreePreferredSharesMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F20241205041230368_10" name="us-gaap:PreferredStockSharesIssued" contextRef="C_20231231_usgaapStatementClassOfStockAxis_slxnConvertibleSeriesAThreePreferredSharesMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">7,037</ix:nonFraction></ix:nonFraction>&#160;shares
        issued and outstanding as of September 30, 2024 and December 31, 2023, respectively);</span></span></div> </div> </div> </div> </td>
    <td colspan="1" rowspan="1" style="text-align:right;width:1%;vertical-align:bottom;background-color:rgb(255, 255, 255)">&#160;</td>
    <td colspan="1" rowspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(255, 255, 255)">&#160;</td>
    <td colspan="1" rowspan="1" style="text-align:right;width:9%;vertical-align:bottom;background-color:rgb(255, 255, 255)">&#160;</td>
    <td colspan="1" rowspan="1" style="width:1%;vertical-align:bottom;white-space:nowrap;background-color:rgb(255, 255, 255)">&#160;</td>
    <td colspan="1" rowspan="1" style="text-align:right;width:1%;vertical-align:bottom;background-color:rgb(255, 255, 255)">&#160;</td>
    <td colspan="1" rowspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(255, 255, 255)">&#160;</td>
    <td colspan="1" rowspan="1" style="text-align:right;width:9%;vertical-align:bottom;background-color:rgb(255, 255, 255)">&#160;</td>
    <td colspan="1" rowspan="1" style="width:1%;vertical-align:bottom;white-space:nowrap;background-color:rgb(255, 255, 255)">&#160;</td> </tr>
  <tr style="background-color:rgb(204, 238, 255)">
    <td rowspan="1" style="text-indent:-14.2pt;margin-left:23.8pt;line-height:1.25;width:76%;vertical-align:bottom;background-color:rgb(204, 238, 255)">
        <div style="margin-left:23pt">
        <div style="margin-left:0pt">
        <div style="margin-left:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Convertible Series A-4
        Preferred Shares (NIS <ix:nonFraction id="Fxbrl_20241205160022264" name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="C_20231231_usgaapStatementClassOfStockAxis_slxnConvertibleSeriesAFourPreferredSharesMember" unitRef="ilsPershares" scale="0" decimals="2" format="ixt:num-dot-decimal"><ix:nonFraction id="F20241205041230369_11" name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="C_20240930_usgaapStatementClassOfStockAxis_slxnConvertibleSeriesAFourPreferredSharesMember" unitRef="ilsPershares" scale="0" decimals="2" format="ixt:num-dot-decimal">0.09</ix:nonFraction></ix:nonFraction>&#160;par
        value per share, <ix:nonFraction id="F20241205041230400_85" name="us-gaap:PreferredStockSharesAuthorized" contextRef="C_20240930_usgaapStatementClassOfStockAxis_slxnConvertibleSeriesAFourPreferredSharesMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">0</ix:nonFraction>
        and <ix:nonFraction id="F20241205041230370_12" name="us-gaap:PreferredStockSharesAuthorized" contextRef="C_20231231_usgaapStatementClassOfStockAxis_slxnConvertibleSeriesAFourPreferredSharesMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">90,556</ix:nonFraction>
        shares authorized as of September 30, 2024 and December 31, 2023, respectively; <ix:nonFraction id="F20241205041230413_118" name="us-gaap:PreferredStockSharesOutstanding" contextRef="C_20240930_usgaapStatementClassOfStockAxis_slxnConvertibleSeriesAFourPreferredSharesMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F20241205041230401_86" name="us-gaap:PreferredStockSharesIssued" contextRef="C_20240930_usgaapStatementClassOfStockAxis_slxnConvertibleSeriesAFourPreferredSharesMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">0</ix:nonFraction></ix:nonFraction>
        and <ix:nonFraction id="Fxbrl_20241205155736145" name="us-gaap:PreferredStockSharesOutstanding" contextRef="C_20231231_usgaapStatementClassOfStockAxis_slxnConvertibleSeriesAFourPreferredSharesMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F20241205041230370_13" name="us-gaap:PreferredStockSharesIssued" contextRef="C_20231231_usgaapStatementClassOfStockAxis_slxnConvertibleSeriesAFourPreferredSharesMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">2,413</ix:nonFraction></ix:nonFraction>**
        shares issued and outstanding as of September 30, 2024 and December 31, 2023, respectively); </span></span></div> </div> </div> </td>
    <td colspan="1" rowspan="1" style="text-align:right;width:1%;vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" rowspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" rowspan="1" style="text-align:right;width:9%;vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" rowspan="1" style="width:1%;vertical-align:bottom;white-space:nowrap;background-color:rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" rowspan="1" style="text-align:right;width:1%;vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" rowspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" rowspan="1" style="text-align:right;width:9%;vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" rowspan="1" style="width:1%;vertical-align:bottom;white-space:nowrap;background-color:rgb(204, 238, 255)">&#160;</td> </tr>
  <tr style="background-color:rgb(255, 255, 255)">
    <td rowspan="1" style="width:76%;vertical-align:bottom;background-color:rgb(255, 255, 255)">&#160;</td>
    <td colspan="1" rowspan="1" style="text-align:right;width:1%;vertical-align:bottom;background-color:rgb(255, 255, 255)">&#160;</td>
    <td colspan="1" rowspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(255, 255, 255)">&#160;</td>
    <td colspan="1" rowspan="1" style="text-align:right;width:9%;vertical-align:bottom;background-color:rgb(255, 255, 255)">&#160;</td>
    <td colspan="1" rowspan="1" style="width:1%;vertical-align:bottom;white-space:nowrap;background-color:rgb(255, 255, 255)">&#160;</td>
    <td colspan="1" rowspan="1" style="text-align:right;width:1%;vertical-align:bottom;background-color:rgb(255, 255, 255)">&#160;</td>
    <td colspan="1" rowspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(255, 255, 255)">&#160;</td>
    <td colspan="1" rowspan="1" style="text-align:right;width:9%;vertical-align:bottom;background-color:rgb(255, 255, 255)">&#160;</td>
    <td colspan="1" rowspan="1" style="width:1%;vertical-align:bottom;white-space:nowrap;background-color:rgb(255, 255, 255)">&#160;</td> </tr>
  <tr style="background-color:rgb(204, 238, 255)">
    <td style="width:76%;padding-bottom:2px;vertical-align:bottom;background-color:rgb(204, 238, 255)">
        <div style="text-indent:-9.6pt;margin-left:9.6pt;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">TOTAL
        REDEEMABLE CONVERTIBLE PREFERRED SHARES</span></span></div> </td>
    <td colspan="1" style="text-align:right;width:1%;padding-bottom:2px;vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" style="width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" style="text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom;background-color:rgb(204, 238, 255)">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="F20241205041230390_57" name="us-gaap:ConvertiblePreferredStockNonredeemableOrRedeemableIssuerOptionValue" contextRef="C_20240930" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
        </div> </td>
    <td colspan="1" style="width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap;background-color:rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" style="text-align:right;width:1%;padding-bottom:2px;vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" style="width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" style="text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom;background-color:rgb(204, 238, 255)">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="F20241205041230389_56" name="us-gaap:ConvertiblePreferredStockNonredeemableOrRedeemableIssuerOptionValue" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">15,057</ix:nonFraction></span></span></div>
        </div> </td>
    <td colspan="1" style="width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap;background-color:rgb(204, 238, 255)">&#160;</td>
        </tr>
  <tr style="background-color:rgb(255, 255, 255)">
    <td rowspan="1" style="width:76%;vertical-align:bottom;background-color:rgb(255, 255, 255)">&#160;</td>
    <td colspan="1" rowspan="1" style="text-align:right;width:1%;vertical-align:bottom;background-color:rgb(255, 255, 255)">&#160;</td>
    <td colspan="1" rowspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(255, 255, 255)">&#160;</td>
    <td colspan="1" rowspan="1" style="text-align:right;width:9%;vertical-align:bottom;background-color:rgb(255, 255, 255)">&#160;</td>
    <td colspan="1" rowspan="1" style="width:1%;vertical-align:bottom;white-space:nowrap;background-color:rgb(255, 255, 255)">&#160;</td>
    <td colspan="1" rowspan="1" style="text-align:right;width:1%;vertical-align:bottom;background-color:rgb(255, 255, 255)">&#160;</td>
    <td colspan="1" rowspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(255, 255, 255)">&#160;</td>
    <td colspan="1" rowspan="1" style="text-align:right;width:9%;vertical-align:bottom;background-color:rgb(255, 255, 255)">&#160;</td>
    <td colspan="1" rowspan="1" style="width:1%;vertical-align:bottom;white-space:nowrap;background-color:rgb(255, 255, 255)">&#160;</td> </tr>
  <tr style="background-color:rgb(204, 238, 255)">
    <td style="width:76%;padding-bottom:2px;vertical-align:bottom;background-color:rgb(204, 238, 255)">
        <div style="text-indent:-9.6pt;margin-left:9.6pt;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">CONTINGENTLY
        REDEEMABLE NON-CONTROLLING INTERESTS</span></span></div> </td>
    <td colspan="1" style="text-align:right;width:1%;padding-bottom:2px;vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" style="width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" style="text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom;background-color:rgb(204, 238, 255)">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="F20241205041230390_59" name="us-gaap:RedeemableNoncontrollingInterestEquityPreferredCarryingAmount" contextRef="C_20240930" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
        </div> </td>
    <td colspan="1" style="width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap;background-color:rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" style="text-align:right;width:1%;padding-bottom:2px;vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" style="width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" style="text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom;background-color:rgb(204, 238, 255)">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="F20241205041230390_58" name="us-gaap:RedeemableNoncontrollingInterestEquityPreferredCarryingAmount" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,420</ix:nonFraction></span></span></div>
        </div> </td>
    <td colspan="1" style="width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap;background-color:rgb(204, 238, 255)">&#160;</td>
        </tr>
  <tr style="background-color:rgb(255, 255, 255)">
    <td rowspan="1" style="width:76%;vertical-align:bottom;background-color:rgb(255, 255, 255)">&#160;</td>
    <td colspan="1" rowspan="1" style="text-align:right;width:1%;vertical-align:bottom;background-color:rgb(255, 255, 255)">&#160;</td>
    <td colspan="1" rowspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(255, 255, 255)">&#160;</td>
    <td colspan="1" rowspan="1" style="text-align:right;width:9%;vertical-align:bottom;background-color:rgb(255, 255, 255)">&#160;</td>
    <td colspan="1" rowspan="1" style="width:1%;vertical-align:bottom;white-space:nowrap;background-color:rgb(255, 255, 255)">&#160;</td>
    <td colspan="1" rowspan="1" style="text-align:right;width:1%;vertical-align:bottom;background-color:rgb(255, 255, 255)">&#160;</td>
    <td colspan="1" rowspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(255, 255, 255)">&#160;</td>
    <td colspan="1" rowspan="1" style="text-align:right;width:9%;vertical-align:bottom;background-color:rgb(255, 255, 255)">&#160;</td>
    <td colspan="1" rowspan="1" style="width:1%;vertical-align:bottom;white-space:nowrap;background-color:rgb(255, 255, 255)">&#160;</td> </tr>
  <tr style="background-color:rgb(204, 238, 255)">
    <td style="width:76%;padding-bottom:2px;vertical-align:bottom;background-color:rgb(204, 238, 255)">
        <div style="text-indent:-9.6pt;margin-left:9.6pt;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">TOTAL
        REDEEMABLE CONVERTIBLE PREFERRED SHARES AND CONTINGENTLY REDEEMABLE NON-CONTROLLING INTERESTS</span></span></div> </td>
    <td colspan="1" style="text-align:right;width:1%;padding-bottom:2px;vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" style="width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom;background-color:rgb(204, 238, 255)">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
        </div> </td>
    <td colspan="1" style="text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom;background-color:rgb(204, 238, 255)">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="F20241205041230391_61" name="us-gaap:PreferredStockRedemptionAmount" contextRef="C_20240930" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
        </div> </td>
    <td colspan="1" style="width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap;background-color:rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" style="text-align:right;width:1%;padding-bottom:2px;vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" style="width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom;background-color:rgb(204, 238, 255)">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
        </div> </td>
    <td colspan="1" style="text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom;background-color:rgb(204, 238, 255)">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="F20241205041230391_60" name="us-gaap:PreferredStockRedemptionAmount" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">18,477</ix:nonFraction></span></span></div>
        </div> </td>
    <td colspan="1" style="width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap;background-color:rgb(204, 238, 255)">&#160;</td>
        </tr>
  </table>

<div style="line-height:1.25">&#160;</div>

<div style="clear:both;margin-top:10pt;margin-bottom:10pt">

<div style="text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:normal;font-style:normal">F-43</span></span></span></div>

<div style="page-break-after:always"> <hr style="border-width:0px;clear:both;margin:4px 0px;width:100%;height:2px;color:#000000;background-color:#000000"/>
</div> </div>

<div style="line-height:1.25">&#160;</div>

<div style="text-align:center;margin-left:1pt;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">SILEXION
THERAPEUTICS CORP</span></span></div>

<div style="text-align:center;margin-left:1pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">UNAUDITED
CONDENSED CONSOLIDATED BALANCE SHEETS</span></span></div>

<div style="line-height:1.25">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left;color:#000000;width:100%">
  <tr>
    <td style="vertical-align:top;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
    <td colspan="2" style="vertical-align:bottom;vertical-align:bottom">
        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">September
        30,</span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
    <td colspan="2" style="vertical-align:bottom;vertical-align:bottom">
        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">December
        31,</span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2024</span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2023</span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
    <td colspan="6" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">U.S.
        dollars in thousands</span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td> </tr>
  <tr style="background-color:rgb(204, 238, 255)">
    <td rowspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255)">
        <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">CAPITAL
        DEFICIENCY:</span></span></div> </td>
    <td colspan="1" rowspan="1" style="text-align:right;vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
    <td colspan="2" rowspan="1" style="text-align:right;vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" rowspan="1" style="vertical-align:bottom;white-space:nowrap;background-color:rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" rowspan="1" style="text-align:right;vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
    <td colspan="2" rowspan="1" style="text-align:right;vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" rowspan="1" style="vertical-align:bottom;white-space:nowrap;background-color:rgb(204, 238, 255)">&#160;</td> </tr>
  <tr style="background-color:rgb(255, 255, 255)">
    <td style="width:76%;vertical-align:bottom;background-color:rgb(255, 255, 255)">
        <div style="line-height:1.25">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;margin-left:9pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Ordinary
        shares ($<ix:nonFraction id="Fxbrl_20241205160251436" name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="C_20231231" unitRef="usdPershares" scale="0" decimals="4" format="ixt:num-dot-decimal"><ix:nonFraction id="F20241205041230371_14" name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="C_20240930" unitRef="usdPershares" scale="0" decimals="4" format="ixt:num-dot-decimal">0.0009</ix:nonFraction></ix:nonFraction>&#160;par
        value per share, <ix:nonFraction id="Fxbrl_20241205161059757" name="us-gaap:CommonStockSharesAuthorized" contextRef="C_20231231" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F20241205041230406_98" name="us-gaap:CommonStockSharesAuthorized" contextRef="C_20240930" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">22,222,222</ix:nonFraction></ix:nonFraction>&#160;shares
        authorized as of September 30, 2024 and December 31, 2023;</span></span></div>
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">&#160;&#160;&#160;&#160;&#160;<ix:nonFraction id="Fxbrl_20241205161117827" name="us-gaap:CommonStockSharesOutstanding" contextRef="C_20240930" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F20241205041230371_15" name="us-gaap:CommonStockSharesIssued" contextRef="C_20240930" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">1,242,267</ix:nonFraction></ix:nonFraction>&#160;and
        <ix:nonFraction id="Fxbrl_20241205161142504" name="us-gaap:CommonStockSharesOutstanding" contextRef="C_20231231" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F20241205041230401_87" name="us-gaap:CommonStockSharesIssued" contextRef="C_20231231" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">97,120</ix:nonFraction></ix:nonFraction>&#160;shares
        issued and outstanding as of September 30, 2024 and December 31, 2023, respectively)</span></span></div> </div> </td>
    <td colspan="1" style="text-align:right;width:1%;vertical-align:bottom;background-color:rgb(255, 255, 255)">&#160;</td>
    <td colspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(255, 255, 255)">&#160;</td>
    <td colspan="1" style="text-align:right;width:9%;vertical-align:bottom;background-color:rgb(255, 255, 255)">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="F20241205041230392_63" name="us-gaap:CommonStockValue" contextRef="C_20240930" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="width:1%;vertical-align:bottom;white-space:nowrap;background-color:rgb(255, 255, 255)">&#160;</td>
    <td colspan="1" style="text-align:right;width:1%;vertical-align:bottom;background-color:rgb(255, 255, 255)">&#160;</td>
    <td colspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(255, 255, 255)">&#160;</td>
    <td colspan="1" style="text-align:right;width:9%;vertical-align:bottom;background-color:rgb(255, 255, 255)">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="-sec-ix-hidden:F20241205041230391_62">*</span></span></span></div>
        </td>
    <td colspan="1" style="width:1%;vertical-align:bottom;white-space:nowrap;background-color:rgb(255, 255, 255)">&#160;</td> </tr>
  <tr style="background-color:rgb(204, 238, 255)">
    <td style="width:76%;vertical-align:bottom;background-color:rgb(204, 238, 255)">
        <div style="margin-left:9.6pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Additional
        paid-in capital</span></span></div> </td>
    <td colspan="1" style="text-align:right;width:1%;vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" style="text-align:right;width:9%;vertical-align:bottom;background-color:rgb(204, 238, 255)">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="F20241205041230393_65" name="us-gaap:AdditionalPaidInCapital" contextRef="C_20240930" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">37,003</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="width:1%;vertical-align:bottom;white-space:nowrap;background-color:rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" style="text-align:right;width:1%;vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" style="text-align:right;width:9%;vertical-align:bottom;background-color:rgb(204, 238, 255)">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="F20241205041230392_64" name="us-gaap:AdditionalPaidInCapital" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">11,335</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="width:1%;vertical-align:bottom;white-space:nowrap;background-color:rgb(204, 238, 255)">&#160;</td> </tr>
  <tr style="background-color:rgb(255, 255, 255)">
    <td style="width:76%;padding-bottom:2px;vertical-align:bottom;background-color:rgb(255, 255, 255)">
        <div style="margin-left:9.6pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Accumulated
        deficit</span></span></div> </td>
    <td colspan="1" style="text-align:right;width:1%;padding-bottom:2px;vertical-align:bottom;background-color:rgb(255, 255, 255)">&#160;</td>
    <td colspan="1" style="width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom;background-color:rgb(255, 255, 255)">&#160;</td>
    <td colspan="1" style="text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom;background-color:rgb(255, 255, 255)">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="F20241205041230393_67" name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="C_20240930" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">41,583</ix:nonFraction></span></span></div>
        </div> </td>
    <td colspan="1" style="width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap;background-color:rgb(255, 255, 255)">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
        </div> </td>
    <td colspan="1" style="text-align:right;width:1%;padding-bottom:2px;vertical-align:bottom;background-color:rgb(255, 255, 255)">&#160;</td>
    <td colspan="1" style="width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom;background-color:rgb(255, 255, 255)">&#160;</td>
    <td colspan="1" style="text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom;background-color:rgb(255, 255, 255)">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="F20241205041230393_66" name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">26,811</ix:nonFraction></span></span></div>
        </div> </td>
    <td colspan="1" style="width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap;background-color:rgb(255, 255, 255)">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
        </div> </td> </tr>
  <tr style="background-color:rgb(204, 238, 255)">
    <td style="width:76%;padding-bottom:2px;vertical-align:bottom;background-color:rgb(204, 238, 255)">
        <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">TOTAL
        CAPITAL DEFICIENCY</span></span></div> </td>
    <td colspan="1" style="text-align:right;width:1%;padding-bottom:2px;vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" style="width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom;background-color:rgb(204, 238, 255)">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
        </div> </td>
    <td colspan="1" style="text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom;background-color:rgb(204, 238, 255)">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="F20241205041230394_69" name="us-gaap:StockholdersEquity" contextRef="C_20240930" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">4,579</ix:nonFraction></span></span></div>
        </div> </td>
    <td colspan="1" style="width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap;background-color:rgb(204, 238, 255)">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
        </div> </td>
    <td colspan="1" style="text-align:right;width:1%;padding-bottom:2px;vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" style="width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom;background-color:rgb(204, 238, 255)">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
        </div> </td>
    <td colspan="1" style="text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom;background-color:rgb(204, 238, 255)">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="F20241205041230394_68" name="us-gaap:StockholdersEquity" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">15,476</ix:nonFraction></span></span></div>
        </div> </td>
    <td colspan="1" style="width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap;background-color:rgb(204, 238, 255)">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
        </div> </td> </tr>
  <tr style="background-color:rgb(255, 255, 255)">
    <td style="width:76%;padding-bottom:2px;vertical-align:bottom;background-color:rgb(255, 255, 255)">
        <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">TOTAL
        REDEEMABLE CONVERTIBLE PREFERRED SHARES AND CONTINGENTLY REDEEMABLE NON-CONTROLLING INTERESTS, NET OF CAPITAL DEFICIENCY</span></span></div>
        </td>
    <td colspan="1" style="text-align:right;width:1%;padding-bottom:2px;vertical-align:bottom;background-color:rgb(255, 255, 255)">&#160;</td>
    <td colspan="1" style="width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom;background-color:rgb(255, 255, 255)">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
        </div> </td>
    <td colspan="1" style="text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom;background-color:rgb(255, 255, 255)">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="F20241205041230395_71" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_20240930" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">4,579</ix:nonFraction></span></span></div>
        </div> </td>
    <td colspan="1" style="width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap;background-color:rgb(255, 255, 255)">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
        </div> </td>
    <td colspan="1" style="text-align:right;width:1%;padding-bottom:2px;vertical-align:bottom;background-color:rgb(255, 255, 255)">&#160;</td>
    <td colspan="1" style="width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom;background-color:rgb(255, 255, 255)">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
        </div> </td>
    <td colspan="1" style="text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom;background-color:rgb(255, 255, 255)">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="F20241205041230394_70" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,001</ix:nonFraction></span></span></div>
        </div> </td>
    <td colspan="1" style="width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap;background-color:rgb(255, 255, 255)">&#160;</td>
        </tr>
  <tr style="background-color:rgb(204, 238, 255)">
    <td style="width:76%;padding-bottom:0px;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><strong><span style="font-size:10pt;font-family:Times New Roman, Times, serif">TOTAL
        LIABILITIES, REDEEMABLE CONVERTIBLE</span></strong></p> </td>
    <td colspan="1" style="text-align:right;width:1%;padding-bottom:0px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="width:1%;padding-bottom:0px;white-space:nowrap;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="text-align:right;width:1%;padding-bottom:0px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="width:1%;padding-bottom:0px;white-space:nowrap;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
        </tr>
  <tr style="background-color:rgb(255, 255, 255)">
    <td style="width:76%;padding-bottom:4px;vertical-align:bottom;background-color:rgb(255, 255, 255)">
        <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">PREFERRED
        SHARES AND NON-CONTROLLING INTEREST NET OF CAPITAL DEFICIENCY</span></span></div> </td>
    <td colspan="1" style="text-align:right;width:1%;padding-bottom:4px;vertical-align:bottom;background-color:rgb(255, 255, 255)">&#160;</td>
    <td colspan="1" style="width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom;background-color:rgb(255, 255, 255)">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
        </div> </td>
    <td colspan="1" style="text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom;background-color:rgb(255, 255, 255)">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="F20241205041230396_73" name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="C_20240930" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,087</ix:nonFraction></span></span></div>
        </div> </td>
    <td colspan="1" style="width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap;background-color:rgb(255, 255, 255)">&#160;</td>
    <td colspan="1" style="text-align:right;width:1%;padding-bottom:4px;vertical-align:bottom;background-color:rgb(255, 255, 255)">&#160;</td>
    <td colspan="1" style="width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom;background-color:rgb(255, 255, 255)">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
        </div> </td>
    <td colspan="1" style="text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom;background-color:rgb(255, 255, 255)">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="F20241205041230395_72" name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,256</ix:nonFraction></span></span></div>
        </div> </td>
    <td colspan="1" style="width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap;background-color:rgb(255, 255, 255)">&#160;</td>
        </tr>
  </table>

<div style="line-height:1.25">&#160;</div>

<div style="line-height:1.25;text-align:center;margin-left:15.5pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">*
Represents an amount less than $1</span></span></div>

<div style="line-height:1.25;text-align:center;margin-left:15.5pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">**
Net of 13,458 treasury shares held by the subsidiary as of December 31, 2023</span></span></div>

<div style="margin-left:15.75pt;line-height:1.25;font-weight:bold">&#160;</div>

<div style="text-align:center;margin-left:15.75pt;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The
accompanying notes are an integral part of the unaudited condensed consolidated financial statements.</span></span></div>

<div style="text-align:center;margin-left:15.75pt;line-height:1.25;font-weight:bold">&#160;</div> </div> </div>

<div style="line-height:1.25">

<div style="margin-top:10pt;margin-bottom:10pt">

<div style="text-align:center"><span style="font-size:10pt;font-family:Times New Roman, Times, serif;font-style:normal;font-weight:normal">F-44</span></div>

<div> <hr style="border-width:0px;clear:both;margin:4px 0px;width:100%;height:2px;color:#000000;background-color:#000000;page-break-after:always"/>
</div> </div>

<div style="line-height:1.25">&#160;</div> </div>

<div>

<div style="text-align:center;margin-left:1pt;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">SILEXION
THERAPEUTICS CORP</span></span></div>

<div style="text-align:center;margin-left:7.65pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">UNAUDITED
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS<span id="STATEMENTSOFOPERATIONS"></span></span></span></div>

<div style="line-height:1.25">&#160;</div>

<div style="line-height:1.25">

<div style="line-height:1.25">

<table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left;color:#000000;width:100%">
  <tr>
    <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
    <td colspan="6" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>Nine
        months ended</span></span></span></span></div>
        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>September
        30</span></span></span></span></div> </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
    <td colspan="6" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>Three
        months ended</span></span></span></span></div>
        <div style="line-height:1.25">
        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>September
        30,</span></span></span></span></div> </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>2024</span></span></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>2023</span></span></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>2024</span></span></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>2023</span></span></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
    <td colspan="2" style="border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">
        <div style="line-height:1.25;margin-top:0pt;margin-bottom:0pt">
        <div style="text-align:center;line-height:1.25;font-weight:bold;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">U.S.
        dollars in</span></span></span></span></div>
        <div style="text-align:center;line-height:1.25;font-weight:bold;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">thousands</span></span></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
    <td colspan="2" style="border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">
        <div style="line-height:1.25;margin-top:0pt;margin-bottom:0pt">
        <div style="text-align:center;line-height:1.25;font-weight:bold;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">U.S.
        dollars in</span></span></span></span></div>
        <div style="text-align:center;line-height:1.25;font-weight:bold;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">thousands</span></span></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
    <td colspan="6" style="border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom;margin-top:0pt;margin-bottom:0pt">
        <div style="line-height:1.25;margin-top:0pt;margin-bottom:0pt">
        <div style="text-align:center;line-height:1.25;font-weight:bold;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">U.S.
        dollars in </span></span></span></span></div>
        <div style="text-align:center;line-height:1.25;font-weight:bold;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">thousands</span></span></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">OPERATING
        EXPENSES:</span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="2" style="vertical-align:top;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:bottom;width:52%;vertical-align:bottom">
        <div style="text-indent:-7.05pt;margin-left:14.85pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Research
        and development (including $<ix:nonFraction id="F20241205041230427_0" name="us-gaap:OtherResearchAndDevelopmentExpense" contextRef="C_20240101to20240930_usgaapRelatedPartyTransactionsByRelatedPartyAxis_usgaapRelatedPartyMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,796</ix:nonFraction>
        and $<ix:nonFraction id="F20241205041230449_60" name="us-gaap:OtherResearchAndDevelopmentExpense" contextRef="C_20230101to20230930_usgaapRelatedPartyTransactionsByRelatedPartyAxis_usgaapRelatedPartyMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">51</ix:nonFraction>
        from related party for the nine months period ended September 30, 2024 and 2023, respectively, and including $<ix:nonFraction id="F20241205041230427_1" name="us-gaap:OtherResearchAndDevelopmentExpense" contextRef="C_20240701to20240930_usgaapRelatedPartyTransactionsByRelatedPartyAxis_usgaapRelatedPartyMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,762</ix:nonFraction>
        and $<ix:nonFraction id="F20241205041230450_61" name="us-gaap:OtherResearchAndDevelopmentExpense" contextRef="C_20230701to20230930_usgaapRelatedPartyTransactionsByRelatedPartyAxis_usgaapRelatedPartyMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">17</ix:nonFraction>
        from related party for the three months period ended September 30, 2024 and 2023, respectively)</span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="F20241205041230449_59" name="us-gaap:ResearchAndDevelopmentExpense" contextRef="C_20240101to20240930" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,944</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="F20241205041230427_2" name="us-gaap:ResearchAndDevelopmentExpense" contextRef="C_20230101to20230930" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,451</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="F20241205041230428_3" name="us-gaap:ResearchAndDevelopmentExpense" contextRef="C_20240701to20240930" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,217</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="F20241205041230428_4" name="us-gaap:ResearchAndDevelopmentExpense" contextRef="C_20230701to20230930" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">535</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:bottom;width:52%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="text-indent:-7.05pt;margin-left:14.85pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">General
        and administrative (including $<ix:nonFraction id="F20241205041230428_5" name="us-gaap:OtherGeneralAndAdministrativeExpense" contextRef="C_20240101to20240930_usgaapRelatedPartyTransactionsByRelatedPartyAxis_usgaapRelatedPartyMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,972</ix:nonFraction>
        and $<ix:nonFraction id="F20241205041230450_62" name="us-gaap:OtherGeneralAndAdministrativeExpense" contextRef="C_20230101to20230930_usgaapRelatedPartyTransactionsByRelatedPartyAxis_usgaapRelatedPartyMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">36</ix:nonFraction>
        from related party for the nine months period ended September 30, 2024 and 2023, respectively, and including $<ix:nonFraction id="F20241205041230429_6" name="us-gaap:OtherGeneralAndAdministrativeExpense" contextRef="C_20240701to20240930_usgaapRelatedPartyTransactionsByRelatedPartyAxis_usgaapRelatedPartyMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,948</ix:nonFraction>
        and $<ix:nonFraction id="F20241205041230450_63" name="us-gaap:OtherGeneralAndAdministrativeExpense" contextRef="C_20230701to20230930_usgaapRelatedPartyTransactionsByRelatedPartyAxis_usgaapRelatedPartyMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">12</ix:nonFraction>
        from related party for the three months period ended September 30, 2024 and 2023, respectively)</span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="F20241205041230429_7" name="us-gaap:GeneralAndAdministrativeExpense" contextRef="C_20240101to20240930" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,727</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="F20241205041230429_8" name="us-gaap:GeneralAndAdministrativeExpense" contextRef="C_20230101to20230930" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">502</ix:nonFraction></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="F20241205041230430_9" name="us-gaap:GeneralAndAdministrativeExpense" contextRef="C_20240701to20240930" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,819</ix:nonFraction></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="F20241205041230430_10" name="us-gaap:GeneralAndAdministrativeExpense" contextRef="C_20230701to20230930" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">196</ix:nonFraction></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align:bottom;width:52%;padding-bottom:2px;vertical-align:bottom">
        <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">TOTAL
        OPERATING EXPENSES</span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="F20241205041230430_11" name="us-gaap:OperatingExpenses" contextRef="C_20240101to20240930" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">10,671</ix:nonFraction></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="F20241205041230431_12" name="us-gaap:OperatingExpenses" contextRef="C_20230101to20230930" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,953</ix:nonFraction></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="F20241205041230431_13" name="us-gaap:OperatingExpenses" contextRef="C_20240701to20240930" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,036</ix:nonFraction></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="F20241205041230431_14" name="us-gaap:OperatingExpenses" contextRef="C_20230701to20230930" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">731</ix:nonFraction></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:bottom;width:52%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">OPERATING
        LOSS</span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="F20241205041230432_15" name="us-gaap:OperatingIncomeLoss" contextRef="C_20240101to20240930" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">10,671</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="F20241205041230432_16" name="us-gaap:OperatingIncomeLoss" contextRef="C_20230101to20230930" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">2,953</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="F20241205041230432_17" name="us-gaap:OperatingIncomeLoss" contextRef="C_20240701to20240930" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">8,036</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="F20241205041230433_18" name="us-gaap:OperatingIncomeLoss" contextRef="C_20230701to20230930" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">731</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align:bottom;width:52%;padding-bottom:2px;vertical-align:bottom">
        <div style="text-indent:-7.05pt;margin-left:14.85pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Financial
        expenses (income), (including $(<ix:nonFraction id="F20241205041230433_19" name="slxn:FinancialExpensesNetFromRelatedParty" contextRef="C_20240101to20240930_usgaapRelatedPartyTransactionsByRelatedPartyAxis_usgaapRelatedPartyMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">47</ix:nonFraction>)
        and $<ix:nonFraction id="F20241205041230434_20" name="slxn:FinancialExpensesNetFromRelatedParty" contextRef="C_20230101to20230930_usgaapRelatedPartyTransactionsByRelatedPartyAxis_usgaapRelatedPartyMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">40</ix:nonFraction>
        from related party for the nine months period ended September 30, 2024 and 2023, respectively, and including $(<ix:nonFraction id="F20241205041230434_21" name="slxn:FinancialExpensesNetFromRelatedParty" contextRef="C_20240701to20240930_usgaapRelatedPartyTransactionsByRelatedPartyAxis_usgaapRelatedPartyMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">182</ix:nonFraction>)
        and $<ix:nonFraction id="F20241205041230434_22" name="slxn:FinancialExpensesNetFromRelatedParty" contextRef="C_20230701to20230930_usgaapRelatedPartyTransactionsByRelatedPartyAxis_usgaapRelatedPartyMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">40</ix:nonFraction>
        from related party for the three months period ended September 30, 2024 and 2023, respectively)</span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="F20241205041230435_23" name="slxn:FinancialExpenses" contextRef="C_20240101to20240930" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,092</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="F20241205041230435_24" name="slxn:FinancialExpenses" contextRef="C_20230101to20230930" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">449</ix:nonFraction></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="F20241205041230435_25" name="slxn:FinancialExpenses" contextRef="C_20240701to20240930" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,822</ix:nonFraction></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="F20241205041230436_26" name="slxn:FinancialExpenses" contextRef="C_20230701to20230930" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">72</ix:nonFraction></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:bottom;width:52%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">LOSS
        BEFORE INCOME TAX</span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="F20241205041230436_27" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="C_20240101to20240930" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">14,763</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="F20241205041230436_28" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="C_20230101to20230930" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">3,402</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="F20241205041230437_29" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="C_20240701to20240930" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">11,858</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="F20241205041230437_30" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="C_20230701to20230930" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">803</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align:bottom;width:52%;padding-bottom:2px;vertical-align:bottom">
        <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">INCOME
        TAX</span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="F20241205041230439_31" name="us-gaap:IncomeTaxExpenseBenefit" contextRef="C_20240101to20240930" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">9</ix:nonFraction></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="F20241205041230440_32" name="us-gaap:IncomeTaxExpenseBenefit" contextRef="C_20230101to20230930" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">26</ix:nonFraction></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="F20241205041230440_33" name="us-gaap:IncomeTaxExpenseBenefit" contextRef="C_20240701to20240930" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">2</ix:nonFraction></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="F20241205041230441_34" name="us-gaap:IncomeTaxExpenseBenefit" contextRef="C_20230701to20230930" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">6</ix:nonFraction></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:bottom;width:52%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">NET
        LOSS</span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="F20241205041230441_35" name="us-gaap:NetIncomeLoss" contextRef="C_20240101to20240930" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">14,772</ix:nonFraction></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="F20241205041230441_36" name="us-gaap:NetIncomeLoss" contextRef="C_20230101to20230930" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">3,428</ix:nonFraction></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="F20241205041230442_37" name="us-gaap:NetIncomeLoss" contextRef="C_20240701to20240930" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">11,860</ix:nonFraction></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="F20241205041230442_38" name="us-gaap:NetIncomeLoss" contextRef="C_20230701to20230930" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">809</ix:nonFraction></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align:bottom;width:52%;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:bottom;width:52%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Attributable to:</span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align:bottom;width:52%;vertical-align:bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Equity holders of the
        Company</span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="F20241205041230442_39" name="slxn:EquityHoldersOfTheCompany" contextRef="C_20240101to20240930" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">14,696</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="F20241205041230443_40" name="slxn:EquityHoldersOfTheCompany" contextRef="C_20230101to20230930" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,214</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="F20241205041230443_41" name="slxn:EquityHoldersOfTheCompany" contextRef="C_20240701to20240930" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">11,851</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="F20241205041230443_42" name="slxn:EquityHoldersOfTheCompany" contextRef="C_20230701to20230930" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">787</ix:nonFraction></span></span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:bottom;width:52%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Non-controlling interests</span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="F20241205041230444_43" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" contextRef="C_20240101to20240930" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">76</ix:nonFraction></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="F20241205041230444_44" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" contextRef="C_20230101to20230930" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">214</ix:nonFraction></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="F20241205041230444_45" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" contextRef="C_20240701to20240930" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">9</ix:nonFraction></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="F20241205041230445_46" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" contextRef="C_20230701to20230930" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">22</ix:nonFraction></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align:bottom;width:52%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="F20241205041230445_47" name="us-gaap:NetIncomeLoss" contextRef="C_20240101to20240930" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">14,772</ix:nonFraction></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="F20241205041230445_48" name="us-gaap:NetIncomeLoss" contextRef="C_20230101to20230930" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">3,428</ix:nonFraction></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="F20241205041230446_49" name="us-gaap:NetIncomeLoss" contextRef="C_20240701to20240930" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">11,860</ix:nonFraction></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="F20241205041230446_50" name="us-gaap:NetIncomeLoss" contextRef="C_20230701to20230930" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">809</ix:nonFraction></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:bottom;width:52%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align:bottom;width:52%;vertical-align:bottom">
        <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">LOSS
        PER SHARE, BASIC AND DILUTED</span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20241205154915041" name="us-gaap:EarningsPerShareDiluted" contextRef="C_20240101to20240930" unitRef="usdPershares" scale="0" decimals="2" format="ixt:num-dot-decimal"><ix:nonFraction id="F20241205041230446_51" name="us-gaap:EarningsPerShareBasic" contextRef="C_20240101to20240930" unitRef="usdPershares" scale="0" decimals="2" format="ixt:num-dot-decimal">50.43</ix:nonFraction></ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20241205154931578" name="us-gaap:EarningsPerShareDiluted" contextRef="C_20230101to20230930" unitRef="usdPershares" scale="0" decimals="2" format="ixt:num-dot-decimal"><ix:nonFraction id="F20241205041230447_52" name="us-gaap:EarningsPerShareBasic" contextRef="C_20230101to20230930" unitRef="usdPershares" scale="0" decimals="2" format="ixt:num-dot-decimal">28.76</ix:nonFraction></ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20241205154943424" name="us-gaap:EarningsPerShareDiluted" contextRef="C_20240701to20240930" unitRef="usdPershares" scale="0" decimals="2" format="ixt:num-dot-decimal"><ix:nonFraction id="F20241205041230447_53" name="us-gaap:EarningsPerShareBasic" contextRef="C_20240701to20240930" unitRef="usdPershares" scale="0" decimals="2" format="ixt:num-dot-decimal">18.30</ix:nonFraction></ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20241205154957440" name="us-gaap:EarningsPerShareDiluted" contextRef="C_20230701to20230930" unitRef="usdPershares" scale="0" decimals="2" format="ixt:num-dot-decimal"><ix:nonFraction id="F20241205041230447_54" name="us-gaap:EarningsPerShareBasic" contextRef="C_20230701to20230930" unitRef="usdPershares" scale="0" decimals="2" format="ixt:num-dot-decimal">7.04</ix:nonFraction></ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:bottom;width:52%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align:bottom;width:52%;vertical-align:bottom">
        <div style="text-indent:-7.8pt;margin-left:7.8pt;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">WEIGHTED
        AVERAGE NUMBER OF ORDINARY SHARES OUTSTANDING USED IN COMPUTATION OF BASIC AND DILUTED LOSS PER SHARE</span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="F20241205041230448_55" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="C_20240101to20240930" unitRef="shares" scale="0" decimals="0" format="ixt:num-dot-decimal">291,407</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="F20241205041230448_56" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="C_20230101to20230930" unitRef="shares" scale="0" decimals="0" format="ixt:num-dot-decimal">111,726</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="F20241205041230449_57" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="C_20240701to20240930" unitRef="shares" scale="0" decimals="0" format="ixt:num-dot-decimal">647,568</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="F20241205041230449_58" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="C_20230701to20230930" unitRef="shares" scale="0" decimals="0" format="ixt:num-dot-decimal">111,726</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td> </tr>
  </table> </div>

<div style="line-height:1.25">&#160;</div> </div>

<div style="line-height:1.25"></div>

<div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The
accompanying notes are an integral part of the unaudited condensed consolidated financial statements.</span></span></div>

<div style="text-align:center;line-height:1.25;font-weight:bold">&#160;</div>

<div style="clear:both;margin-top:10pt;margin-bottom:10pt">

<div style="text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:normal;font-style:normal">F-45</span></span></span></div>

<div style="page-break-after:always"> <hr style="border-width:0px;clear:both;margin:4px 0px;width:100%;height:2px;color:#000000;background-color:#000000"/>
</div> </div>

<div>&#160;</div> </div>

<div style="text-align:center;margin-left:1pt;line-height:1.25;font-weight:bold"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span>SILEXION
THERAPEUTICS CORP</span></span></span></span></span></div>

<div style="text-align:center;line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span id="CAPITALDEFICIENCY"><span><span><span>UNAUDITED
CONDENSED CONSOLIDATED STATEMENTS</span></span></span></span><span><span><span> OF <span id="CHANGESINREDEEMABLECONVER"></span>CHANGES&#160;IN
REDEEMABLE CONVERTIBLE PREFERRED SHARES AND CAPITAL DEFICIENCY</span></span></span></span></span></div>

<div style="text-align:center;line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span>(U.S.
dollars in thousands, except per share data)</span></span></span></span></span></div>

<div style="text-align:center;line-height:1.25">&#160;</div>

<table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left;color:#000000;width:100%">
  <tr>
    <td style="vertical-align:top;padding-bottom:2px;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="42" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
        <div style="line-height:1.25;font-size:8pt">
        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">Redeemable
        Convertible Preferred Shares</span></span></div> </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;border-left:2px solid rgb(0, 0, 0);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="6" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
        <div style="line-height:1.25;font-size:8pt">
        <div style="line-height:1.25;font-weight:bold"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">Ordinary
        shares</span></span></div> </div> </td>
    <td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;font-size:8pt;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center;font-size:8pt">&#160;</td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
        <div style="line-height:1.25;font-weight:bold;font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">Additional<br/>paid-in
        Capital</span></span></div> </td>
    <td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;font-size:8pt;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center;font-size:8pt">&#160;</td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
        <div style="line-height:1.25;font-weight:bold;font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">Accumulated
        deficit</span></span></div> </td>
    <td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;font-size:8pt;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center;font-size:8pt">&#160;</td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center;margin-top:0pt;margin-bottom:0pt">
        <div style="line-height:1.25;font-size:8pt;margin-top:0pt;margin-bottom:0pt">
        <div style="line-height:1.25;font-weight:bold;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">Total</span></span></div>
        <div style="line-height:1.25;font-weight:bold;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">capital</span></span></div>
        <div style="line-height:1.25;font-weight:bold;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">deficiency</span></span></div>
        </div> </td>
    <td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;font-size:8pt;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center;font-size:8pt">&#160;</td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
        <div style="line-height:1.25;font-size:8pt">
        <div style="line-height:1.25;font-weight:bold"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">Total
        redeemable convertible preferred shares and contingently redeemable non-controlling interests, net of capital deficiency</span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:top;padding-bottom:2px;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="6" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
        <div style="line-height:1.25;font-size:8pt">
        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">Series
        A preferred shares</span></span></div> </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="6" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
        <div style="line-height:1.25;font-size:8pt">
        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">Series
        A-1 preferred shares</span></span></div> </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="6" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
        <div style="text-align:center;line-height:1.25;font-weight:bold;font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">Series
        A-2 preferred shares</span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="6" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
        <div style="line-height:1.25;font-size:8pt">
        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">Series
        A-3 preferred shares</span></span></div> </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="6" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
        <div style="line-height:1.25;font-size:8pt">
        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">Series
        A-4 preferred shares</span></span></div> </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="2" style="vertical-align:top;border-bottom:2px solid rgb(0, 0, 0);font-size:8pt;vertical-align:bottom">
        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">Contingently
        redeemable non-controlling</span></span></div>
        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">interests</span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;border-left:2px solid rgb(0, 0, 0);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="6" style="vertical-align:bottom;padding-bottom:2px;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="2" style="vertical-align:bottom;padding-bottom:2px;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="2" style="vertical-align:bottom;padding-bottom:2px;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="2" style="vertical-align:bottom;padding-bottom:2px;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="2" style="vertical-align:bottom;padding-bottom:2px;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:top;padding-bottom:2px;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="padding-bottom:2px;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="2" style="border-bottom:2px solid black;vertical-align:bottom">
        <div style="line-height:1.25;font-size:8pt">
        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">Shares</span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="padding-bottom:2px;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="2" style="border-bottom:2px solid black;vertical-align:bottom">
        <div style="line-height:1.25;font-size:8pt">
        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">Amount</span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="padding-bottom:2px;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="2" style="border-bottom:2px solid black;vertical-align:bottom">
        <div style="line-height:1.25;font-size:8pt">
        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">Shares</span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="padding-bottom:2px;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="2" style="border-bottom:2px solid black;vertical-align:bottom">
        <div style="line-height:1.25;font-size:8pt">
        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">Amount</span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="padding-bottom:2px;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="2" style="border-bottom:2px solid black;vertical-align:bottom">
        <div style="line-height:1.25;font-size:8pt">
        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">Shares</span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="padding-bottom:2px;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="2" style="border-bottom:2px solid black;vertical-align:bottom">
        <div style="line-height:1.25;font-size:8pt">
        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">Amount</span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="padding-bottom:2px;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="2" style="border-bottom:2px solid black;vertical-align:bottom">
        <div style="line-height:1.25;font-size:8pt">
        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">Shares</span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="padding-bottom:2px;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="2" style="border-bottom:2px solid black;vertical-align:bottom">
        <div style="line-height:1.25;font-size:8pt">
        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">Amount</span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="padding-bottom:2px;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="2" style="border-bottom:2px solid black;vertical-align:bottom">
        <div style="line-height:1.25;font-size:8pt">
        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">Shares</span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="padding-bottom:2px;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="2" style="border-bottom:2px solid black;vertical-align:bottom">
        <div style="line-height:1.25;font-size:8pt">
        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">Amount</span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="padding-bottom:2px;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="2" style="border-bottom:2px solid black;vertical-align:bottom">
        <div style="line-height:1.25;font-size:8pt">
        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">Amount</span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="padding-bottom:2px;border-left:2px solid rgb(0, 0, 0);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="2" style="border-bottom:2px solid black;vertical-align:bottom">
        <div style="line-height:1.25;font-size:8pt">
        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">Shares</span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="padding-bottom:2px;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="2" style="border-bottom:2px solid black;vertical-align:bottom">
        <div style="line-height:1.25;font-size:8pt">
        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">Amount</span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="padding-bottom:2px;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="2" style="padding-bottom:2px;font-size:8pt;vertical-align:bottom;border-bottom:2px solid black">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="padding-bottom:2px;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="2" style="padding-bottom:2px;font-size:8pt;vertical-align:bottom;border-bottom:2px solid black">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="padding-bottom:2px;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="2" style="padding-bottom:2px;font-size:8pt;vertical-align:bottom;border-bottom:2px solid black">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="padding-bottom:2px;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="2" style="padding-bottom:2px;font-size:8pt;vertical-align:bottom;border-bottom:2px solid black">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:bottom;width:0%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="text-indent:-6.9pt;margin-left:6.9pt;line-height:1.25;font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span style="font-weight:bold">BALANCE
        AT JANUARY 1, 2023</span></span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="width:1%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="text-align:right;width:3%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-weight:bold;font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><ix:nonFraction id="F20241205041230473_0" name="us-gaap:SharesOutstanding" contextRef="C_20221231_usgaapStatementClassOfStockAxis_usgaapSeriesAPreferredStockMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">43,121</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-weight:bold;font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">$</span></span></div>
        </td>
    <td colspan="1" style="text-align:right;width:3%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-weight:bold;font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><ix:nonFraction id="F20241205041230475_1" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_20221231_usgaapStatementClassOfStockAxis_usgaapSeriesAPreferredStockMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,307</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="width:1%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="text-align:right;width:3%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-weight:bold;font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><ix:nonFraction id="F20241205041230480_2" name="us-gaap:SharesOutstanding" contextRef="C_20221231_usgaapStatementClassOfStockAxis_slxnSeriesA1PreferredSharesMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">10,136</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-weight:bold;font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">$</span></span></div>
        </td>
    <td colspan="1" style="text-align:right;width:3%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-weight:bold;font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><ix:nonFraction id="F20241205041230482_3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_20221231_usgaapStatementClassOfStockAxis_slxnSeriesA1PreferredSharesMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,392</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="width:1%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="text-align:right;width:3%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-weight:bold;font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><ix:nonFraction id="F20241205041230484_4" name="us-gaap:SharesOutstanding" contextRef="C_20221231_usgaapStatementClassOfStockAxis_slxnSeriesA2PreferredSharesMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">5,051</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-weight:bold;font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">$</span></span></div>
        </td>
    <td colspan="1" style="text-align:right;width:3%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-weight:bold;font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><ix:nonFraction id="F20241205041230486_5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_20221231_usgaapStatementClassOfStockAxis_slxnSeriesA2PreferredSharesMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,264</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="width:1%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="text-align:right;width:3%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-weight:bold;font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><ix:nonFraction id="F20241205041230487_6" name="us-gaap:SharesOutstanding" contextRef="C_20221231_usgaapStatementClassOfStockAxis_slxnSeriesA3PreferredSharesMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">7,037</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-weight:bold;font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">$</span></span></div>
        </td>
    <td colspan="1" style="text-align:right;width:3%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-weight:bold;font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><ix:nonFraction id="F20241205041230489_7" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_20221231_usgaapStatementClassOfStockAxis_slxnSeriesA3PreferredSharesMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,683</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="width:1%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="text-align:right;width:3%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-weight:bold;font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><ix:nonFraction id="F20241205041230867_169" name="us-gaap:SharesOutstanding" contextRef="C_20221231_usgaapStatementClassOfStockAxis_slxnSeriesA4PreferredSharesMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember" unitRef="shares" decimals="INF" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="width:1%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="text-align:right;width:3%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-weight:bold;font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><ix:nonFraction id="F20241205041230866_168" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_20221231_usgaapStatementClassOfStockAxis_slxnSeriesA4PreferredSharesMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-weight:bold;font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">$</span></span></div>
        </td>
    <td colspan="1" style="text-align:right;width:3%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-weight:bold;font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><ix:nonFraction id="F20241205041230491_8" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_20221231_usgaapStatementEquityComponentsAxis_usgaapNoncontrollingInterestMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,586</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);border-left:2px solid rgb(0, 0, 0);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="width:1%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="text-align:right;width:3%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-weight:bold;font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><ix:nonFraction id="F20241205041230493_9" name="us-gaap:SharesOutstanding" contextRef="C_20221231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">97,120</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="width:1%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="text-align:right;width:3%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span style="-sec-ix-hidden:F20241205041230498_10">*</span></span></span></td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-weight:bold;font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">$</span></span></div>
        </td>
    <td colspan="1" style="text-align:right;width:3%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-weight:bold;font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><ix:nonFraction id="F20241205041230500_11" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_20221231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">11,204</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-weight:bold;font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">$</span></span></div>
        </td>
    <td colspan="1" style="text-align:right;width:3%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-weight:bold;font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">(<ix:nonFraction id="F20241205041230502_12" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_20221231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">21,869</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
        <div style="line-height:1.25;font-weight:bold;font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">)</span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-weight:bold;font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">$</span></span></div>
        </td>
    <td colspan="1" style="text-align:right;width:3%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-weight:bold;font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">(<ix:nonFraction id="F20241205041230503_13" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_20221231_usgaapStatementEquityComponentsAxis_usgaapParentMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">10,665</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
        <div style="line-height:1.25;font-weight:bold;font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">)</span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-weight:bold;font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">$</span></span></div>
        </td>
    <td colspan="1" style="text-align:right;width:3%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-weight:bold;font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><ix:nonFraction id="F20241205041230505_14" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,567</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align:bottom;width:0%;vertical-align:bottom">
        <div style="text-indent:-6.9pt;margin-left:6.9pt;line-height:1.25;font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span style="font-weight:bold">CHANGES
        DURING THE NINE MONTHS PERIOD ENDED SEPTEMBER 30, 2023</span> (unaudited):</span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:3%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:3%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:3%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:3%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:3%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:3%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:3%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:3%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:3%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:3%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:3%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-left:2px solid rgb(0, 0, 0);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:3%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:3%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:3%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:3%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:3%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:3%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:top;width:0%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="text-indent:-6.9pt;margin-left:6.9pt;line-height:1.25;font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">Issuance
        of Preferred A-4 shares, net of issuance cost</span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:3%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:3%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:3%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:3%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:3%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:3%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:3%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:3%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:3%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><ix:nonFraction id="F20241205041230507_15" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="C_20230101to20230930_usgaapStatementClassOfStockAxis_slxnSeriesA4PreferredSharesMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">2,413</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">$</span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:3%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><ix:nonFraction id="F20241205041230509_16" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="C_20230101to20230930_usgaapStatementClassOfStockAxis_slxnSeriesA4PreferredSharesMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">411</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:3%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);border-left:2px solid rgb(0, 0, 0);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:3%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:3%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:3%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><ix:nonFraction id="F20241205041230511_17" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="C_20230101to20230930_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:3%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:3%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><ix:nonFraction id="F20241205041230514_18" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="C_20230101to20230930_usgaapStatementEquityComponentsAxis_usgaapParentMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:3%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><ix:nonFraction id="F20241205041230517_19" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="C_20230101to20230930" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">412</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align:top;width:0%;vertical-align:bottom">
        <div style="text-indent:-6.9pt;margin-left:6.9pt;line-height:1.25;font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">Share-based
        compensation</span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:3%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:3%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:3%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:3%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:3%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:3%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:3%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:3%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:3%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:3%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:3%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-left:2px solid rgb(0, 0, 0);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:3%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:3%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:3%;vertical-align:bottom">
        <div style="line-height:1.25;font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><ix:nonFraction id="F20241205041230519_20" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="C_20230101to20230930_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">96</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:3%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:3%;vertical-align:bottom">
        <div style="line-height:1.25;font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><ix:nonFraction id="F20241205041230521_21" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="C_20230101to20230930_usgaapStatementEquityComponentsAxis_usgaapParentMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">96</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:3%;vertical-align:bottom">
        <div style="line-height:1.25;font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><ix:nonFraction id="F20241205041230523_22" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="C_20230101to20230930" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">96</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:top;width:0%;background-color:rgb(204, 238, 255);padding-bottom:2px;vertical-align:bottom">
        <div style="text-indent:-6.9pt;margin-left:6.9pt;line-height:1.25;font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">Net
        loss</span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);padding-bottom:2px;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="width:1%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="text-align:right;width:3%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);padding-bottom:2px;font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);padding-bottom:2px;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="width:1%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="text-align:right;width:3%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);padding-bottom:2px;font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);padding-bottom:2px;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="width:1%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="text-align:right;width:3%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);padding-bottom:2px;font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);padding-bottom:2px;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="width:1%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="text-align:right;width:3%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);padding-bottom:2px;font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);padding-bottom:2px;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="width:1%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="text-align:right;width:3%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);padding-bottom:2px;font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);padding-bottom:2px;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="width:1%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="text-align:right;width:3%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);padding-bottom:2px;font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);padding-bottom:2px;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="width:1%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="text-align:right;width:3%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);padding-bottom:2px;font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);padding-bottom:2px;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="width:1%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="text-align:right;width:3%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);padding-bottom:2px;font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);padding-bottom:2px;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="width:1%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="text-align:right;width:3%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);padding-bottom:2px;font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);padding-bottom:2px;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="width:1%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="text-align:right;width:3%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);padding-bottom:2px;font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);padding-bottom:2px;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="width:1%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="text-align:right;width:3%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">(<ix:nonFraction id="F20241205041230525_23" name="us-gaap:ProfitLoss" contextRef="C_20230101to20230930_usgaapStatementEquityComponentsAxis_usgaapNoncontrollingInterestMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">214</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);padding-bottom:2px;vertical-align:bottom;white-space:nowrap">
        <div style="line-height:1.25;font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">)</span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);border-left:2px solid rgb(0, 0, 0);padding-bottom:2px;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="width:1%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="text-align:right;width:3%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);padding-bottom:2px;font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);padding-bottom:2px;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="width:1%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="text-align:right;width:3%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);padding-bottom:2px;font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);padding-bottom:2px;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="width:1%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="text-align:right;width:3%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);padding-bottom:2px;font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);padding-bottom:2px;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="width:1%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="text-align:right;width:3%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">(<ix:nonFraction id="F20241205041230526_24" name="us-gaap:ProfitLoss" contextRef="C_20230101to20230930_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">3,214</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);padding-bottom:2px;vertical-align:bottom;white-space:nowrap">
        <div style="line-height:1.25;font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">)</span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);padding-bottom:2px;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="width:1%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="text-align:right;width:3%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">(<ix:nonFraction id="F20241205041230528_25" name="us-gaap:ProfitLoss" contextRef="C_20230101to20230930_usgaapStatementEquityComponentsAxis_usgaapParentMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">3,214</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);padding-bottom:2px;vertical-align:bottom;white-space:nowrap">
        <div style="line-height:1.25;font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">)</span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);padding-bottom:2px;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="width:1%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="text-align:right;width:3%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">(<ix:nonFraction id="F20241205041230531_26" name="us-gaap:ProfitLoss" contextRef="C_20230101to20230930" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">3,428</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);padding-bottom:2px;vertical-align:bottom;white-space:nowrap">
        <div style="line-height:1.25;font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">)</span></span></div>
        </td> </tr>
  <tr>
    <td style="vertical-align:bottom;width:0%;padding-bottom:4px;vertical-align:bottom">
        <div style="text-indent:-6.9pt;margin-left:6.9pt;line-height:1.25;font-weight:bold;font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">BALANCE
        AS OF SEPTEMBER 30, 2023</span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="text-align:right;width:3%;vertical-align:bottom">
        <div style="line-height:1.25;font-weight:bold;font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><ix:nonFraction id="F20241205041230533_27" name="us-gaap:SharesOutstanding" contextRef="C_20230930_usgaapStatementClassOfStockAxis_usgaapSeriesAPreferredStockMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">43,121</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="width:1%;vertical-align:bottom">
        <div style="line-height:1.25;font-weight:bold;font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">$</span></span></div>
        </td>
    <td colspan="1" style="text-align:right;width:3%;vertical-align:bottom">
        <div style="line-height:1.25;font-weight:bold;font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><ix:nonFraction id="F20241205041230535_28" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_20230930_usgaapStatementClassOfStockAxis_usgaapSeriesAPreferredStockMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,307</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="text-align:right;width:3%;vertical-align:bottom">
        <div style="line-height:1.25;font-weight:bold;font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><ix:nonFraction id="F20241205041230537_29" name="us-gaap:SharesOutstanding" contextRef="C_20230930_usgaapStatementClassOfStockAxis_slxnSeriesA1PreferredSharesMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">10,136</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="width:1%;vertical-align:bottom">
        <div style="line-height:1.25;font-weight:bold;font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">$</span></span></div>
        </td>
    <td colspan="1" style="text-align:right;width:3%;vertical-align:bottom">
        <div style="line-height:1.25;font-weight:bold;font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><ix:nonFraction id="F20241205041230539_30" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_20230930_usgaapStatementClassOfStockAxis_slxnSeriesA1PreferredSharesMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,392</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="text-align:right;width:3%;vertical-align:bottom">
        <div style="line-height:1.25;font-weight:bold;font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><ix:nonFraction id="F20241205041230541_31" name="us-gaap:SharesOutstanding" contextRef="C_20230930_usgaapStatementClassOfStockAxis_slxnSeriesA2PreferredSharesMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">5,051</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="width:1%;vertical-align:bottom">
        <div style="line-height:1.25;font-weight:bold;font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">$</span></span></div>
        </td>
    <td colspan="1" style="text-align:right;width:3%;vertical-align:bottom">
        <div style="line-height:1.25;font-weight:bold;font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><ix:nonFraction id="F20241205041230542_32" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_20230930_usgaapStatementClassOfStockAxis_slxnSeriesA2PreferredSharesMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,264</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="text-align:right;width:3%;vertical-align:bottom">
        <div style="line-height:1.25;font-weight:bold;font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><ix:nonFraction id="F20241205041230544_33" name="us-gaap:SharesOutstanding" contextRef="C_20230930_usgaapStatementClassOfStockAxis_slxnSeriesA3PreferredSharesMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">7,037</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="width:1%;vertical-align:bottom">
        <div style="line-height:1.25;font-weight:bold;font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">$</span></span></div>
        </td>
    <td colspan="1" style="text-align:right;width:3%;vertical-align:bottom">
        <div style="line-height:1.25;font-weight:bold;font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><ix:nonFraction id="F20241205041230547_34" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_20230930_usgaapStatementClassOfStockAxis_slxnSeriesA3PreferredSharesMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,683</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="text-align:right;width:3%;vertical-align:bottom">
        <div style="line-height:1.25;font-weight:bold;font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><ix:nonFraction id="F20241205041230549_35" name="us-gaap:SharesOutstanding" contextRef="C_20230930_usgaapStatementClassOfStockAxis_slxnSeriesA4PreferredSharesMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">2,413</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="width:1%;vertical-align:bottom">
        <div style="line-height:1.25;font-weight:bold;font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">$</span></span></div>
        </td>
    <td colspan="1" style="text-align:right;width:3%;vertical-align:bottom">
        <div style="line-height:1.25;font-weight:bold;font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><ix:nonFraction id="F20241205041230551_36" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_20230930_usgaapStatementClassOfStockAxis_slxnSeriesA4PreferredSharesMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">411</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="width:1%;vertical-align:bottom">
        <div style="line-height:1.25;font-weight:bold;font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">$</span></span></div>
        </td>
    <td colspan="1" style="text-align:right;width:3%;vertical-align:bottom">
        <div style="line-height:1.25;font-weight:bold;font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><ix:nonFraction id="F20241205041230553_37" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_20230930_usgaapStatementEquityComponentsAxis_usgaapNoncontrollingInterestMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,372</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-left:2px solid rgb(0, 0, 0);padding-bottom:4px;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="text-align:right;width:3%;vertical-align:bottom">
        <div style="line-height:1.25;font-weight:bold;font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><ix:nonFraction id="F20241205041230555_38" name="us-gaap:SharesOutstanding" contextRef="C_20230930_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">97,120</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:4px;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="text-align:right;width:3%;font-size:8pt;vertical-align:bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span style="-sec-ix-hidden:F20241205041230557_39">*</span></span></span></td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="width:1%;vertical-align:bottom">
        <div style="line-height:1.25;font-weight:bold;font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">$</span></span></div>
        </td>
    <td colspan="1" style="text-align:right;width:3%;vertical-align:bottom">
        <div style="line-height:1.25;font-weight:bold;font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><ix:nonFraction id="F20241205041230558_40" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_20230930_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">11,301</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="width:1%;vertical-align:bottom">
        <div style="line-height:1.25;font-weight:bold;font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">$</span></span></div>
        </td>
    <td colspan="1" style="text-align:right;width:3%;vertical-align:bottom">
        <div style="line-height:1.25;font-weight:bold;font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">(<ix:nonFraction id="F20241205041230560_41" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_20230930_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">25,083</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">
        <div style="line-height:1.25;font-weight:bold;font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">)</span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="width:1%;vertical-align:bottom">
        <div style="line-height:1.25;font-weight:bold;font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">$</span></span></div>
        </td>
    <td colspan="1" style="text-align:right;width:3%;vertical-align:bottom">
        <div style="line-height:1.25;font-weight:bold;font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">(<ix:nonFraction id="F20241205041230563_42" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_20230930_usgaapStatementEquityComponentsAxis_usgaapParentMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">13,782</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">
        <div style="line-height:1.25;font-weight:bold;font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">)</span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="width:1%;vertical-align:bottom">
        <div style="line-height:1.25;font-weight:bold;font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">$</span></span></div>
        </td>
    <td colspan="1" style="text-align:right;width:3%;vertical-align:bottom">
        <div style="line-height:1.25;font-weight:bold;font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><ix:nonFraction id="F20241205041230565_43" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_20230930" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">4,647</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align:top;width:0%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:3%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:3%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:3%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:3%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:3%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:3%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:3%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:3%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:3%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:3%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:3%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);border-left:2px solid rgb(0, 0, 0);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:3%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:3%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:3%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:3%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:3%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:3%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align:top;width:0%;vertical-align:bottom">
        <div style="text-indent:-6.9pt;margin-left:6.9pt;line-height:1.25;font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span style="font-weight:bold">BALANCE
        AT JANUARY 1, 2024</span></span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:3%;vertical-align:bottom">
        <div style="line-height:1.25;font-weight:bold;font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><ix:nonFraction id="F20241205041230567_44" name="us-gaap:SharesOutstanding" contextRef="C_20231231_usgaapStatementClassOfStockAxis_usgaapSeriesAPreferredStockMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">43,121</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">
        <div style="line-height:1.25;font-weight:bold;font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">$</span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:3%;vertical-align:bottom">
        <div style="line-height:1.25;font-weight:bold;font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><ix:nonFraction id="F20241205041230569_45" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_20231231_usgaapStatementClassOfStockAxis_usgaapSeriesAPreferredStockMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,307</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:3%;vertical-align:bottom">
        <div style="line-height:1.25;font-weight:bold;font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><ix:nonFraction id="F20241205041230571_46" name="us-gaap:SharesOutstanding" contextRef="C_20231231_usgaapStatementClassOfStockAxis_slxnSeriesA1PreferredSharesMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">10,136</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">
        <div style="line-height:1.25;font-weight:bold;font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">$</span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:3%;vertical-align:bottom">
        <div style="line-height:1.25;font-weight:bold;font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><ix:nonFraction id="F20241205041230573_47" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_20231231_usgaapStatementClassOfStockAxis_slxnSeriesA1PreferredSharesMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,392</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:3%;vertical-align:bottom">
        <div style="line-height:1.25;font-weight:bold;font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><ix:nonFraction id="F20241205041230574_48" name="us-gaap:SharesOutstanding" contextRef="C_20231231_usgaapStatementClassOfStockAxis_slxnSeriesA2PreferredSharesMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">5,051</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">
        <div style="line-height:1.25;font-weight:bold;font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">$</span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:3%;vertical-align:bottom">
        <div style="line-height:1.25;font-weight:bold;font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><ix:nonFraction id="F20241205041230576_49" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_20231231_usgaapStatementClassOfStockAxis_slxnSeriesA2PreferredSharesMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,264</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:3%;vertical-align:bottom">
        <div style="line-height:1.25;font-weight:bold;font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><ix:nonFraction id="F20241205041230579_50" name="us-gaap:SharesOutstanding" contextRef="C_20231231_usgaapStatementClassOfStockAxis_slxnSeriesA3PreferredSharesMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">7,037</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">
        <div style="line-height:1.25;font-weight:bold;font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">$</span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:3%;vertical-align:bottom">
        <div style="line-height:1.25;font-weight:bold;font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><ix:nonFraction id="F20241205041230581_51" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_20231231_usgaapStatementClassOfStockAxis_slxnSeriesA3PreferredSharesMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,683</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:3%;vertical-align:bottom">
        <div style="line-height:1.25;font-weight:bold;font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><ix:nonFraction id="F20241205041230583_52" name="us-gaap:SharesOutstanding" contextRef="C_20231231_usgaapStatementClassOfStockAxis_slxnSeriesA4PreferredSharesMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">2,413</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">
        <div style="line-height:1.25;font-weight:bold;font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">$</span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:3%;vertical-align:bottom">
        <div style="line-height:1.25;font-weight:bold;font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><ix:nonFraction id="F20241205041230585_53" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_20231231_usgaapStatementClassOfStockAxis_slxnSeriesA4PreferredSharesMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">411</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">
        <div style="line-height:1.25;font-weight:bold;font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">$</span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:3%;vertical-align:bottom">
        <div style="line-height:1.25;font-weight:bold;font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><ix:nonFraction id="F20241205041230587_54" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_20231231_usgaapStatementEquityComponentsAxis_usgaapNoncontrollingInterestMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,420</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-left:2px solid rgb(0, 0, 0);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:3%;vertical-align:bottom">
        <div style="line-height:1.25;font-weight:bold;font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><ix:nonFraction id="F20241205041230589_55" name="us-gaap:SharesOutstanding" contextRef="C_20231231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">97,120</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:3%;font-size:8pt;vertical-align:bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span style="-sec-ix-hidden:F20241205041230590_56">*</span></span></span></td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">
        <div style="line-height:1.25;font-weight:bold;font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">$</span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:3%;vertical-align:bottom">
        <div style="line-height:1.25;font-weight:bold;font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><ix:nonFraction id="F20241205041230592_57" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_20231231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">11,335</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">
        <div style="line-height:1.25;font-weight:bold;font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">$</span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:3%;vertical-align:bottom">
        <div style="line-height:1.25;font-weight:bold;font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">(<ix:nonFraction id="F20241205041230595_58" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_20231231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">26,811</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">
        <div style="line-height:1.25;font-weight:bold;font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">)</span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">
        <div style="line-height:1.25;font-weight:bold;font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">$</span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:3%;vertical-align:bottom">
        <div style="line-height:1.25;font-weight:bold;font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">(<ix:nonFraction id="F20241205041230597_59" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_20231231_usgaapStatementEquityComponentsAxis_usgaapParentMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">15,476</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">
        <div style="line-height:1.25;font-weight:bold;font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">)</span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">
        <div style="line-height:1.25;font-weight:bold;font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">$</span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:3%;vertical-align:bottom">
        <div style="line-height:1.25;font-weight:bold;font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><ix:nonFraction id="F20241205041230599_60" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,001</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:top;width:0%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="text-indent:-6.9pt;margin-left:6.9pt;line-height:1.25;font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span style="font-weight:bold">CHANGES
        DURING THE NINE MONTHS PERIOD ENDED SEPTEMBER 30, 2024</span>&#160;(unaudited):</span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:3%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:3%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:3%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:3%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:3%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:3%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:3%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:3%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:3%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:3%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:3%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);border-left:2px solid rgb(0, 0, 0);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:3%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:3%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:3%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:3%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:3%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:3%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align:top;width:0%;vertical-align:bottom">
        <div style="text-indent:-6.9pt;margin-left:6.9pt;line-height:1.25;font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">Exercise
        of options</span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:3%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:3%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:3%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:3%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:3%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:3%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:3%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:3%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:3%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:3%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:3%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-left:2px solid rgb(0, 0, 0);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:3%;vertical-align:bottom">
        <div style="line-height:1.25;font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><ix:nonFraction id="F20241205041230601_61" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="C_20240101to20240930_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">13,780</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom;white-space:nowrap"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">**</span></span></td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:3%;vertical-align:bottom">
        <div style="line-height:1.25;font-weight:bold;font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span style="-sec-ix-hidden:F20241205041230602_62">*</span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:3%;vertical-align:bottom">
        <div style="line-height:1.25;font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span style="-sec-ix-hidden:F20241205041230604_63">*</span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:3%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:3%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:3%;vertical-align:bottom">
        <div style="line-height:1.25;font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span style="-sec-ix-hidden:F20241205041230606_64">*</span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:top;width:0%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="text-indent:-6.9pt;margin-left:6.9pt;line-height:1.25;font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">Share-based
        compensation</span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:3%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:3%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:3%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:3%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:3%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:3%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:3%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:3%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:3%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:3%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:3%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);border-left:2px solid rgb(0, 0, 0);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:3%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><ix:nonFraction id="F20241205041230889_173" name="slxn:NumberOfSharesIncreaseToAdditionalPaidinCapitalOptionIncreaseForCostRecognition" contextRef="C_20240101to20240930_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">78,650</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:3%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-weight:bold;font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span style="-sec-ix-hidden:F20241205041230887_172">*</span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:3%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><ix:nonFraction id="F20241205041230608_65" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="C_20240101to20240930_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,862</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:3%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:3%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><ix:nonFraction id="F20241205041230611_66" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="C_20240101to20240930_usgaapStatementEquityComponentsAxis_usgaapParentMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,862</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:3%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><ix:nonFraction id="F20241205041230612_67" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="C_20240101to20240930" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,862</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align:top;width:0%;vertical-align:bottom">
        <div style="text-indent:-6.9pt;margin-left:6.9pt;line-height:1.25;font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">Issuance
        of convertible preferred shares upon net exercise of warrants</span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:3%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:3%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:3%;vertical-align:bottom">
        <div style="line-height:1.25;font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><ix:nonFraction id="F20241205041230934_194" name="slxn:StockIssuedDuringPeriodShareIssuanceOfConvertiblePreferredSharesNetExerciseOfWarrants" contextRef="C_20240101to20240930_usgaapStatementClassOfStockAxis_slxnSeriesA1PreferredSharesMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">140</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:3%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:3%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:3%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:3%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:3%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:3%;vertical-align:bottom">
        <div style="line-height:1.25;font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><ix:nonFraction id="F20241205041230937_195" name="slxn:StockIssuedDuringPeriodShareIssuanceOfConvertiblePreferredSharesNetExerciseOfWarrants" contextRef="C_20240101to20240930_usgaapStatementClassOfStockAxis_slxnSeriesA4PreferredSharesMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">925</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:3%;vertical-align:bottom">
        <div style="line-height:1.25;font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><ix:nonFraction id="F20241205041230938_196" name="slxn:StockIssuedDuringPeriodValueIssuanceOfConvertiblePreferredSharesNetExerciseOfWarrants" contextRef="C_20240101to20240930_usgaapStatementClassOfStockAxis_slxnSeriesA4PreferredSharesMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">334</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:3%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-left:2px solid rgb(0, 0, 0);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:3%;vertical-align:bottom">
        <div style="line-height:1.25;font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>-</span></span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:3%;font-size:8pt;vertical-align:bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>-</span></span></span></span></td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:3%;vertical-align:bottom">
        <div style="line-height:1.25;font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><ix:nonFraction id="F20241205041230945_197" name="slxn:StockIssuedDuringPeriodValueIssuanceOfConvertiblePreferredSharesNetExerciseOfWarrants" contextRef="C_20240101to20240930_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:3%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:3%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:3%;vertical-align:bottom">
        <div style="line-height:1.25;font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><ix:nonFraction id="F20241205041230947_198" name="slxn:StockIssuedDuringPeriodValueIssuanceOfConvertiblePreferredSharesNetExerciseOfWarrants" contextRef="C_20240101to20240930" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">334</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:top;width:0%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="text-indent:-6.9pt;margin-left:6.9pt;line-height:1.25;font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">Net
        loss</span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:3%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:3%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:3%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:3%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:3%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:3%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:3%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:3%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:3%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:3%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:3%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">(<ix:nonFraction id="F20241205041230614_68" name="us-gaap:ProfitLoss" contextRef="C_20240101to20240930_usgaapStatementEquityComponentsAxis_usgaapNoncontrollingInterestMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">76</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
        <div style="line-height:1.25;font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">)</span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);border-left:2px solid rgb(0, 0, 0);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:3%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:3%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:3%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><ix:nonFraction id="F20241205041230970_224" name="us-gaap:ProfitLoss" contextRef="C_20240101to20240930_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">76</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:3%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">(<ix:nonFraction id="F20241205041230616_69" name="us-gaap:ProfitLoss" contextRef="C_20240101to20240930_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">14,772</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
        <div style="line-height:1.25;font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">)</span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:3%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">(<ix:nonFraction id="F20241205041230618_70" name="us-gaap:ProfitLoss" contextRef="C_20240101to20240930_usgaapStatementEquityComponentsAxis_usgaapParentMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">14,696</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
        <div style="line-height:1.25;font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">)</span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:3%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">(<ix:nonFraction id="F20241205041230620_71" name="us-gaap:ProfitLoss" contextRef="C_20240101to20240930" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">14,772</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
        <div style="line-height:1.25;font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">)</span></span></div>
        </td> </tr>
  <tr>
    <td style="vertical-align:top;width:0%;vertical-align:bottom">
        <div style="text-indent:-6.9pt;margin-left:6.9pt;line-height:1.25;font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">Conversion
        of convertible preferred shares and noncontrolling interests upon the effectiveness of the SPAC Merger (see Note 1(d))</span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:3%;vertical-align:bottom">
        <div style="line-height:1.25;font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">(<ix:nonFraction id="F20241205041230622_72" name="slxn:ConversionOfConvertiblePreferredSharesAndNonControllingInterestShareIssued" contextRef="C_20240101to20240930_usgaapStatementClassOfStockAxis_usgaapSeriesAPreferredStockMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal" sign="-">43,121</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">
        <div style="line-height:1.25;font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">)</span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">
        <div style="line-height:1.25;font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">$</span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:3%;vertical-align:bottom">
        <div style="line-height:1.25;font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">(<ix:nonFraction id="F20241205041230623_73" name="slxn:ConversionOfConvertiblePreferredSharesAndNonControllingInterestShareIssuedValue" contextRef="C_20240101to20240930_usgaapStatementClassOfStockAxis_usgaapSeriesAPreferredStockMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">7,307</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">
        <div style="line-height:1.25;font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">)</span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:3%;vertical-align:bottom">
        <div style="line-height:1.25;font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">(<ix:nonFraction id="F20241205041230626_74" name="slxn:ConversionOfConvertiblePreferredSharesAndNonControllingInterestShareIssued" contextRef="C_20240101to20240930_usgaapStatementClassOfStockAxis_slxnSeriesA1PreferredSharesMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal" sign="-">10,276</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">
        <div style="line-height:1.25;font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">)</span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">
        <div style="line-height:1.25;font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">$</span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:3%;vertical-align:bottom">
        <div style="line-height:1.25;font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">(<ix:nonFraction id="F20241205041230628_75" name="slxn:ConversionOfConvertiblePreferredSharesAndNonControllingInterestShareIssuedValue" contextRef="C_20240101to20240930_usgaapStatementClassOfStockAxis_slxnSeriesA1PreferredSharesMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">2,392</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">
        <div style="line-height:1.25;font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">)</span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:3%;vertical-align:bottom">
        <div style="line-height:1.25;font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">(<ix:nonFraction id="F20241205041230630_76" name="slxn:ConversionOfConvertiblePreferredSharesAndNonControllingInterestShareIssued" contextRef="C_20240101to20240930_usgaapStatementClassOfStockAxis_slxnSeriesA2PreferredSharesMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal" sign="-">5,051</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">
        <div style="line-height:1.25;font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">)</span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">
        <div style="line-height:1.25;font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">$</span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:3%;vertical-align:bottom">
        <div style="line-height:1.25;font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">(<ix:nonFraction id="F20241205041230632_77" name="slxn:ConversionOfConvertiblePreferredSharesAndNonControllingInterestShareIssuedValue" contextRef="C_20240101to20240930_usgaapStatementClassOfStockAxis_slxnSeriesA2PreferredSharesMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">2,264</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">
        <div style="line-height:1.25;font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">)</span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:3%;vertical-align:bottom">
        <div style="line-height:1.25;font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">(<ix:nonFraction id="F20241205041230634_78" name="slxn:ConversionOfConvertiblePreferredSharesAndNonControllingInterestShareIssued" contextRef="C_20240101to20240930_usgaapStatementClassOfStockAxis_slxnSeriesA3PreferredSharesMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal" sign="-">7,037</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">
        <div style="line-height:1.25;font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">)</span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">
        <div style="line-height:1.25;font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">$</span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:3%;vertical-align:bottom">
        <div style="line-height:1.25;font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">(<ix:nonFraction id="F20241205041230635_79" name="slxn:ConversionOfConvertiblePreferredSharesAndNonControllingInterestShareIssuedValue" contextRef="C_20240101to20240930_usgaapStatementClassOfStockAxis_slxnSeriesA3PreferredSharesMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">2,683</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">
        <div style="line-height:1.25;font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">)</span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:3%;vertical-align:bottom">
        <div style="line-height:1.25;font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">(<ix:nonFraction id="F20241205041230637_80" name="slxn:ConversionOfConvertiblePreferredSharesAndNonControllingInterestShareIssued" contextRef="C_20240101to20240930_usgaapStatementClassOfStockAxis_slxnSeriesA4PreferredSharesMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal" sign="-">3,338</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">
        <div style="line-height:1.25;font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">)</span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">
        <div style="line-height:1.25;font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">$</span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:3%;vertical-align:bottom">
        <div style="line-height:1.25;font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">(<ix:nonFraction id="F20241205041230639_81" name="slxn:ConversionOfConvertiblePreferredSharesAndNonControllingInterestShareIssuedValue" contextRef="C_20240101to20240930_usgaapStatementClassOfStockAxis_slxnSeriesA4PreferredSharesMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">745</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">
        <div style="line-height:1.25;font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">)</span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">
        <div style="line-height:1.25;font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">$</span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:3%;vertical-align:bottom">
        <div style="line-height:1.25;font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">(<ix:nonFraction id="F20241205041230642_82" name="slxn:ConversionOfConvertiblePreferredSharesAndNonControllingInterestShareIssuedValue" contextRef="C_20240101to20240930_usgaapStatementEquityComponentsAxis_usgaapNoncontrollingInterestMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">3,344</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">
        <div style="line-height:1.25;font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">)</span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-left:2px solid rgb(0, 0, 0);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:3%;vertical-align:bottom">
        <div style="line-height:1.25;font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><ix:nonFraction id="F20241205041230644_83" name="slxn:ConversionOfConvertiblePreferredSharesAndNonControllingInterestShareIssued" contextRef="C_20240101to20240930_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">478,073</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:3%;font-size:8pt;vertical-align:bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><ix:nonFraction id="F20241205041230646_84" name="slxn:ConversionOfConvertiblePreferredSharesAndNonControllingInterestShareIssuedValue" contextRef="C_20240101to20240930_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1</ix:nonFraction></span></span></td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:3%;vertical-align:bottom">
        <div style="line-height:1.25;font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><ix:nonFraction id="F20241205041230647_85" name="slxn:ConversionOfConvertiblePreferredSharesAndNonControllingInterestShareIssuedValue" contextRef="C_20240101to20240930_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">18,734</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:3%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:3%;vertical-align:bottom">
        <div style="line-height:1.25;font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><ix:nonFraction id="F20241205041230649_86" name="slxn:ConversionOfConvertiblePreferredSharesAndNonControllingInterestShareIssuedValue" contextRef="C_20240101to20240930_usgaapStatementEquityComponentsAxis_usgaapParentMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">18,735</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:3%;vertical-align:bottom">
        <div style="line-height:1.25;font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><ix:nonFraction id="F20241205041230651_87" name="slxn:ConversionOfConvertiblePreferredSharesAndNonControllingInterestShareIssuedValue" contextRef="C_20240101to20240930" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:top;width:0%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="text-indent:-6.9pt;margin-left:6.9pt;line-height:1.25;font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">Issuance
        of ordinary shares upon Transactions (see Note 1(d))</span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:3%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:3%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:3%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:3%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:3%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:3%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:3%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:3%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:3%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:3%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:3%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);border-left:2px solid rgb(0, 0, 0);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:3%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><ix:nonFraction id="F20241205041230951_205" name="slxn:StockIssuedDuringPeriodShareIssuanceOfOrdinarySharesUponTransactions" contextRef="C_20240101to20240930_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">417,375</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:3%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-weight:bold;font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span style="-sec-ix-hidden:F20241205041230952_206">*</span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:3%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-size:8pt">&#160;</div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:3%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:3%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span style="-sec-ix-hidden:F20241205041230955_207">*</span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:3%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span style="-sec-ix-hidden:F20241205041230956_208">*</span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align:top;width:0%;padding-bottom:2px;vertical-align:bottom">
        <div style="text-indent:-6.9pt;margin-left:6.9pt;line-height:1.25;font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">Issuance
        of ordinary shares for ELOC holders</span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:3%;border-bottom:2px solid rgb(0, 0, 0);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:3%;border-bottom:2px solid rgb(0, 0, 0);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:3%;border-bottom:2px solid rgb(0, 0, 0);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:3%;border-bottom:2px solid rgb(0, 0, 0);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:3%;border-bottom:2px solid rgb(0, 0, 0);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:3%;border-bottom:2px solid rgb(0, 0, 0);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:3%;border-bottom:2px solid rgb(0, 0, 0);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:3%;border-bottom:2px solid rgb(0, 0, 0);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:3%;border-bottom:2px solid rgb(0, 0, 0);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:3%;border-bottom:2px solid rgb(0, 0, 0);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:3%;border-bottom:2px solid rgb(0, 0, 0);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-left:2px solid rgb(0, 0, 0);padding-bottom:2px;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:3%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
        <div style="line-height:1.25;font-size:8pt">
        <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><ix:nonFraction id="F20241205041230959_210" name="slxn:StockIssuedDuringPeriodShareIssuanceOfOrdinarySharesForElocHolders" contextRef="C_20240101to20240930_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">157,269</ix:nonFraction></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:3%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
        <div style="line-height:1.25;font-size:8pt">
        <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span style="-sec-ix-hidden:F20241205041230960_211">*</span></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:3%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
        <div style="line-height:1.25;font-size:8pt">
        <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><ix:nonFraction id="F20241205041230961_212" name="slxn:StockIssuedDuringPeriodValueIssuanceOfOrdinarySharesForElocHolders" contextRef="C_20240101to20240930_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">996</ix:nonFraction></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:3%;border-bottom:2px solid rgb(0, 0, 0);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:3%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
        <div style="line-height:1.25;font-size:8pt">
        <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><ix:nonFraction id="F20241205041230963_213" name="slxn:StockIssuedDuringPeriodValueIssuanceOfOrdinarySharesForElocHolders" contextRef="C_20240101to20240930_usgaapStatementEquityComponentsAxis_usgaapParentMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">996</ix:nonFraction></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:3%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
        <div style="line-height:1.25;font-size:8pt">
        <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><ix:nonFraction id="F20241205041230957_209" name="slxn:StockIssuedDuringPeriodValueIssuanceOfOrdinarySharesForElocHolders" contextRef="C_20240101to20240930" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">996</ix:nonFraction></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align:top;width:0%;background-color:rgb(204, 238, 255);padding-bottom:4px;vertical-align:bottom">
        <div style="text-indent:-6.9pt;margin-left:6.9pt;line-height:1.25;font-weight:bold;font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">BALANCE
        AS OF SEPTEMBER 30, 2024</span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);padding-bottom:4px;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);border-bottom:4px double rgb(0, 0, 0);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:3%;background-color:rgb(204, 238, 255);border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
        <div style="line-height:1.25;font-size:8pt">
        <div style="line-height:1.25;font-weight:bold"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><ix:nonFraction id="Fxbrl_20241111173429986_20241205041230792_151" name="us-gaap:SharesOutstanding" contextRef="C_20240930_usgaapStatementClassOfStockAxis_usgaapSeriesAPreferredStockMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember" unitRef="shares" decimals="INF" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);padding-bottom:4px;font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);padding-bottom:4px;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);border-bottom:4px double rgb(0, 0, 0);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:3%;background-color:rgb(204, 238, 255);border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
        <div style="line-height:1.25;font-size:8pt">
        <div style="line-height:1.25;font-weight:bold"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><ix:nonFraction id="Fxbrl_20241111173429986_20241205041230794_152" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_20240930_usgaapStatementClassOfStockAxis_usgaapSeriesAPreferredStockMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);padding-bottom:4px;font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);padding-bottom:4px;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);border-bottom:4px double rgb(0, 0, 0);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:3%;background-color:rgb(204, 238, 255);border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
        <div style="line-height:1.25;font-size:8pt">
        <div style="line-height:1.25;font-weight:bold"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><ix:nonFraction id="Fxbrl_20241111173429986_20241205041230804_153" name="us-gaap:SharesOutstanding" contextRef="C_20240930_usgaapStatementClassOfStockAxis_slxnSeriesA1PreferredSharesMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember" unitRef="shares" decimals="INF" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);padding-bottom:4px;font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);padding-bottom:4px;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);border-bottom:4px double rgb(0, 0, 0);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:3%;background-color:rgb(204, 238, 255);border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
        <div style="line-height:1.25;font-size:8pt">
        <div style="line-height:1.25;font-weight:bold"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><ix:nonFraction id="Fxbrl_20241111173429986_20241205041230808_154" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_20240930_usgaapStatementClassOfStockAxis_slxnSeriesA1PreferredSharesMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);padding-bottom:4px;font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);padding-bottom:4px;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);border-bottom:4px double rgb(0, 0, 0);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:3%;background-color:rgb(204, 238, 255);border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
        <div style="line-height:1.25;font-size:8pt">
        <div style="line-height:1.25;font-weight:bold"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><ix:nonFraction id="Fxbrl_20241111173429986_20241205041230811_155" name="us-gaap:SharesOutstanding" contextRef="C_20240930_usgaapStatementClassOfStockAxis_slxnSeriesA2PreferredSharesMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember" unitRef="shares" decimals="INF" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);padding-bottom:4px;font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);padding-bottom:4px;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);border-bottom:4px double rgb(0, 0, 0);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:3%;background-color:rgb(204, 238, 255);border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
        <div style="line-height:1.25;font-size:8pt">
        <div style="line-height:1.25;font-weight:bold"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><ix:nonFraction id="Fxbrl_20241111173429986_20241205041230813_156" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_20240930_usgaapStatementClassOfStockAxis_slxnSeriesA2PreferredSharesMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);padding-bottom:4px;font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);padding-bottom:4px;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);border-bottom:4px double rgb(0, 0, 0);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:3%;background-color:rgb(204, 238, 255);border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
        <div style="line-height:1.25;font-size:8pt">
        <div style="line-height:1.25;font-weight:bold"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><ix:nonFraction id="Fxbrl_20241111173429986_20241205041230815_157" name="us-gaap:SharesOutstanding" contextRef="C_20240930_usgaapStatementClassOfStockAxis_slxnSeriesA3PreferredSharesMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember" unitRef="shares" decimals="INF" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);padding-bottom:4px;font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);padding-bottom:4px;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);border-bottom:4px double rgb(0, 0, 0);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:3%;background-color:rgb(204, 238, 255);border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
        <div style="line-height:1.25;font-size:8pt">
        <div style="line-height:1.25;font-weight:bold"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><ix:nonFraction id="Fxbrl_20241111173429986_20241205041230817_158" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_20240930_usgaapStatementClassOfStockAxis_slxnSeriesA3PreferredSharesMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);padding-bottom:4px;font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);padding-bottom:4px;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);border-bottom:4px double rgb(0, 0, 0);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:3%;background-color:rgb(204, 238, 255);border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
        <div style="line-height:1.25;font-size:8pt">
        <div style="line-height:1.25;font-weight:bold"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><ix:nonFraction id="Fxbrl_20241111173429986_20241205041230819_159" name="us-gaap:SharesOutstanding" contextRef="C_20240930_usgaapStatementClassOfStockAxis_slxnSeriesA4PreferredSharesMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember" unitRef="shares" decimals="INF" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);padding-bottom:4px;font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);padding-bottom:4px;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);border-bottom:4px double rgb(0, 0, 0);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:3%;background-color:rgb(204, 238, 255);border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
        <div style="line-height:1.25;font-size:8pt">
        <div style="line-height:1.25;font-weight:bold"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><ix:nonFraction id="Fxbrl_20241111173429986_20241205041230821_160" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_20240930_usgaapStatementClassOfStockAxis_slxnSeriesA4PreferredSharesMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);padding-bottom:4px;font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);padding-bottom:4px;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);border-bottom:4px double rgb(0, 0, 0);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:3%;background-color:rgb(204, 238, 255);border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
        <div style="line-height:1.25;font-size:8pt">
        <div style="line-height:1.25;font-weight:bold"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><ix:nonFraction id="Fxbrl_20241111173429986_20241205041230824_161" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_20240930_usgaapStatementEquityComponentsAxis_usgaapNoncontrollingInterestMember" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);padding-bottom:4px;font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);border-left:2px solid rgb(0, 0, 0);padding-bottom:4px;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);border-bottom:4px double rgb(0, 0, 0);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:3%;background-color:rgb(204, 238, 255);border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
        <div style="line-height:1.25;font-size:8pt">
        <div style="line-height:1.25;font-weight:bold"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><ix:nonFraction id="Fxbrl_20241111173429986_20241205041230846_162" name="us-gaap:SharesOutstanding" contextRef="C_20240930_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">1,242,267</ix:nonFraction></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);padding-bottom:4px;font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);padding-bottom:4px;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
        <div style="line-height:1.25;font-size:8pt">
        <div style="line-height:1.25;font-weight:bold"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">$</span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:3%;background-color:rgb(204, 238, 255);border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
        <div style="line-height:1.25;font-size:8pt">
        <div style="line-height:1.25;font-weight:bold"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><ix:nonFraction id="Fxbrl_20241111173429986_20241205041230848_163" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_20240930_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1</ix:nonFraction></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);padding-bottom:4px;font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);padding-bottom:4px;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
        <div style="line-height:1.25;font-size:8pt">
        <div style="line-height:1.25;font-weight:bold"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">$</span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:3%;background-color:rgb(204, 238, 255);border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
        <div style="line-height:1.25;font-size:8pt">
        <div style="line-height:1.25;font-weight:bold"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><ix:nonFraction id="Fxbrl_20241111173429986_20241205041230850_164" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_20240930_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">37,003</ix:nonFraction></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);padding-bottom:4px;font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);padding-bottom:4px;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
        <div style="line-height:1.25;font-size:8pt">
        <div style="line-height:1.25;font-weight:bold"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">$</span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:3%;background-color:rgb(204, 238, 255);border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
        <div style="line-height:1.25;font-size:8pt">
        <div style="line-height:1.25;font-weight:bold"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">(<ix:nonFraction id="Fxbrl_20241111173429986_20241205041230853_165" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_20240930_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">41,583</ix:nonFraction></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);padding-bottom:4px;vertical-align:bottom;white-space:nowrap">
        <div style="line-height:1.25;font-size:8pt">
        <div style="line-height:1.25;font-weight:bold"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">)</span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);padding-bottom:4px;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
        <div style="line-height:1.25;font-size:8pt">
        <div style="line-height:1.25;font-weight:bold"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">$</span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:3%;background-color:rgb(204, 238, 255);border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
        <div style="line-height:1.25;font-size:8pt">
        <div style="line-height:1.25;font-weight:bold"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">(<ix:nonFraction id="Fxbrl_20241111173429986_20241205041230859_166" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_20240930_usgaapStatementEquityComponentsAxis_usgaapParentMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">4,579</ix:nonFraction></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);padding-bottom:4px;vertical-align:bottom;white-space:nowrap">
        <div style="line-height:1.25;font-size:8pt">
        <div style="line-height:1.25;font-weight:bold"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">)</span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);padding-bottom:4px;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
        <div style="line-height:1.25;font-size:8pt">
        <div style="line-height:1.25;font-weight:bold"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">$</span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:3%;background-color:rgb(204, 238, 255);border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
        <div style="line-height:1.25;font-size:8pt">
        <div style="line-height:1.25;font-weight:bold"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">(<ix:nonFraction id="Fxbrl_20241111173429986_20241205041230863_167" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_20240930" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">4,579</ix:nonFraction></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);padding-bottom:4px;vertical-align:bottom;white-space:nowrap">
        <div style="line-height:1.25;font-size:8pt">
        <div style="line-height:1.25;font-weight:bold"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">)</span></span></div>
        </div> </td> </tr>
  </table>

<div style="text-align:center;line-height:1.25">&#160;</div>

<div style="line-height:1.25;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span>*
Represents an amount less than $1</span></span></span></span></span></div>

<div style="line-height:1.25;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span>**
Represents fully vested pre-funded options for the Company&#8217;s ordinary shares at an exercise price of $0.0226 or 0.0226 NIS per share</span></span></span></span></span></div>

<div style="text-align:center;line-height:1.25;font-weight:bold">&#160;</div>

<div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span>The
accompanying notes are an integral part of the unaudited condensed consolidated financial statements.</span></span></span></span></span></div>

<div>&#160;</div>

<div style="clear:both;margin-top:10pt;margin-bottom:10pt">

<div style="text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span style="font-weight:normal;font-style:normal">F-46</span></span></span></span></span></div>

<div style="page-break-after:always"> <hr style="border-width:0px;clear:both;margin:4px 0px;width:100%;height:2px;color:#000000;background-color:#000000"/>
</div> </div>

<div>

<div style="line-height:1.25">&#160;</div> </div>

<div style="text-align:center;margin-left:1pt;line-height:1.25;font-weight:bold"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span>SILEXION
THERAPEUTICS CORP</span></span></span></span></span></span></div>

<div style="text-align:center;line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span><span>UNAUDITED
CONDENSED CONSOLIDATED STATEMENTS OF CHANGES&#160;IN REDEEMABLE CONVERTIBLE PREFERRED SHARES AND CAPITAL DEFICIENCY</span></span></span></span></span></span></span></div>

<div style="text-align:center;line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span>(U.S.
dollars in thousands, except per share data)</span></span></span></span></span></div>

<div style="text-align:center;line-height:1.25">&#160;</div>

<table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left;color:#000000;width:100%">
  <tr>
    <td style="vertical-align:top;padding-bottom:2px;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="42" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
        <div style="line-height:1.25;font-size:8pt">
        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">Redeemable
        Convertible Preferred Shares</span></span></div> </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;border-right:2px solid rgb(0, 0, 0);font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="6" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
        <div style="line-height:1.25;font-size:8pt">
        <div style="line-height:1.25;font-weight:bold"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">Ordinary
        shares</span></span></div> </div> </td>
    <td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;font-size:8pt;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center;font-size:8pt">&#160;</td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
        <div style="line-height:1.25;font-weight:bold;font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">Additional<br/>paid-in
        Capital</span></span></div> </td>
    <td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;font-size:8pt;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center;font-size:8pt">&#160;</td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
        <div style="line-height:1.25;font-weight:bold;font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">Accumulated
        deficit</span></span></div> </td>
    <td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;font-size:8pt;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center;font-size:8pt">&#160;</td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
        <div style="line-height:1.25;font-size:8pt">
        <div style="line-height:1.25;font-weight:bold"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">Total
        capital deficiency</span></span></div> </div> </td>
    <td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;font-size:8pt;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center;font-size:8pt">&#160;</td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
        <div style="line-height:1.25;font-size:8pt">
        <div style="line-height:1.25;font-weight:bold"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">Total
        redeemable convertible preferred shares and contingently redeemable non-controlling interests, net of capital deficiency</span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:top;padding-bottom:2px;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="6" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
        <div style="line-height:1.25;font-size:8pt">
        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">Series
        A preferred shares</span></span></div> </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="6" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
        <div style="line-height:1.25;font-size:8pt">
        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">Series
        A-1 preferred shares</span></span></div> </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="6" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
        <div style="text-align:center;line-height:1.25;font-weight:bold;font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">Series
        A-2 preferred shares</span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="6" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
        <div style="line-height:1.25;font-size:8pt">
        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">Series
        A-3 preferred shares</span></span></div> </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="6" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
        <div style="line-height:1.25;font-size:8pt">
        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">Series
        A-4 preferred shares</span></span></div> </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="2" style="vertical-align:top;border-bottom:2px solid rgb(0, 0, 0);font-size:8pt;vertical-align:bottom">
        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">Contingently
        redeemable non-controlling</span></span></div>
        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">interests</span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;border-right:2px solid rgb(0, 0, 0);font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="6" style="font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="2" style="vertical-align:bottom;padding-bottom:2px;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="2" style="vertical-align:bottom;padding-bottom:2px;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="2" style="vertical-align:bottom;padding-bottom:2px;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="2" style="vertical-align:bottom;padding-bottom:2px;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:top;padding-bottom:2px;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="padding-bottom:2px;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="2" style="border-bottom:2px solid black;vertical-align:bottom">
        <div style="line-height:1.25;font-size:8pt">
        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">Shares</span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="padding-bottom:2px;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="2" style="border-bottom:2px solid black;vertical-align:bottom">
        <div style="line-height:1.25;font-size:8pt">
        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">Amount</span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="padding-bottom:2px;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="2" style="border-bottom:2px solid black;vertical-align:bottom">
        <div style="line-height:1.25;font-size:8pt">
        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">Shares</span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="padding-bottom:2px;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="2" style="border-bottom:2px solid black;vertical-align:bottom">
        <div style="line-height:1.25;font-size:8pt">
        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">Amount</span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="padding-bottom:2px;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="2" style="border-bottom:2px solid black;vertical-align:bottom">
        <div style="line-height:1.25;font-size:8pt">
        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">Shares</span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="padding-bottom:2px;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="2" style="border-bottom:2px solid black;vertical-align:bottom">
        <div style="line-height:1.25;font-size:8pt">
        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">Amount</span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="padding-bottom:2px;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="2" style="border-bottom:2px solid black;vertical-align:bottom">
        <div style="line-height:1.25;font-size:8pt">
        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">Shares</span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="padding-bottom:2px;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="2" style="border-bottom:2px solid black;vertical-align:bottom">
        <div style="line-height:1.25;font-size:8pt">
        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">Amount</span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="padding-bottom:2px;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="2" style="border-bottom:2px solid black;vertical-align:bottom">
        <div style="line-height:1.25;font-size:8pt">
        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">Shares</span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="padding-bottom:2px;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="2" style="border-bottom:2px solid black;vertical-align:bottom">
        <div style="line-height:1.25;font-size:8pt">
        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">Amount</span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="padding-bottom:2px;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="2" style="border-bottom:2px solid black;vertical-align:bottom">
        <div style="line-height:1.25;font-size:8pt">
        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">Amount</span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;border-right:2px solid rgb(0, 0, 0);font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="padding-bottom:2px;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="2" style="border-bottom:2px solid black;vertical-align:bottom">
        <div style="line-height:1.25;font-size:8pt">
        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">Shares</span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="padding-bottom:2px;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="2" style="border-bottom:2px solid black;vertical-align:bottom">
        <div style="line-height:1.25;font-size:8pt">
        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">Amount</span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="padding-bottom:2px;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="2" style="padding-bottom:2px;font-size:8pt;vertical-align:bottom;border-bottom:2px solid black">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="padding-bottom:2px;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="2" style="padding-bottom:2px;font-size:8pt;vertical-align:bottom;border-bottom:2px solid black">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="padding-bottom:2px;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="2" style="padding-bottom:2px;font-size:8pt;vertical-align:bottom;border-bottom:2px solid black">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="padding-bottom:2px;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="2" style="padding-bottom:2px;font-size:8pt;vertical-align:bottom;border-bottom:2px solid black">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:0%;vertical-align:bottom">
        <div style="text-indent:-6.9pt;margin-left:6.9pt;line-height:1.25;font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span style="font-weight:bold">BALANCE
        AT JUNE 30, 2023</span></span></span></div> </td>
    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:3%;vertical-align:bottom">
        <div style="line-height:1.25;font-weight:bold;font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><ix:nonFraction id="F20241205041230653_88" name="us-gaap:SharesOutstanding" contextRef="C_20230630_usgaapStatementClassOfStockAxis_usgaapSeriesAPreferredStockMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">43,121</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom">
        <div style="line-height:1.25;font-weight:bold;font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">$</span></span></div>
        </td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:3%;vertical-align:bottom">
        <div style="line-height:1.25;font-weight:bold;font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><ix:nonFraction id="F20241205041230655_89" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_20230630_usgaapStatementClassOfStockAxis_usgaapSeriesAPreferredStockMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,307</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:3%;vertical-align:bottom">
        <div style="line-height:1.25;font-weight:bold;font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><ix:nonFraction id="F20241205041230658_90" name="us-gaap:SharesOutstanding" contextRef="C_20230630_usgaapStatementClassOfStockAxis_slxnSeriesA1PreferredSharesMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">10,136</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom">
        <div style="line-height:1.25;font-weight:bold;font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">$</span></span></div>
        </td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:3%;vertical-align:bottom">
        <div style="line-height:1.25;font-weight:bold;font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><ix:nonFraction id="F20241205041230659_91" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_20230630_usgaapStatementClassOfStockAxis_slxnSeriesA1PreferredSharesMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,392</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:3%;vertical-align:bottom">
        <div style="line-height:1.25;font-weight:bold;font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><ix:nonFraction id="F20241205041230661_92" name="us-gaap:SharesOutstanding" contextRef="C_20230630_usgaapStatementClassOfStockAxis_slxnSeriesA2PreferredSharesMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">5,051</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom">
        <div style="line-height:1.25;font-weight:bold;font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">$</span></span></div>
        </td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:3%;vertical-align:bottom">
        <div style="line-height:1.25;font-weight:bold;font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><ix:nonFraction id="F20241205041230663_93" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_20230630_usgaapStatementClassOfStockAxis_slxnSeriesA2PreferredSharesMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,264</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:3%;vertical-align:bottom">
        <div style="line-height:1.25;font-weight:bold;font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><ix:nonFraction id="F20241205041230665_94" name="us-gaap:SharesOutstanding" contextRef="C_20230630_usgaapStatementClassOfStockAxis_slxnSeriesA3PreferredSharesMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">7,037</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom">
        <div style="line-height:1.25;font-weight:bold;font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">$</span></span></div>
        </td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:3%;vertical-align:bottom">
        <div style="line-height:1.25;font-weight:bold;font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><ix:nonFraction id="F20241205041230667_95" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_20230630_usgaapStatementClassOfStockAxis_slxnSeriesA3PreferredSharesMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,683</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:3%;vertical-align:bottom">
        <div style="line-height:1.25;font-weight:bold;font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><ix:nonFraction id="F20241205041230886_171" name="us-gaap:SharesOutstanding" contextRef="C_20230630_usgaapStatementClassOfStockAxis_slxnSeriesA4PreferredSharesMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">2,413</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom">
        <div style="line-height:1.25;font-weight:bold;font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">$</span></span></div>
        </td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:3%;vertical-align:bottom">
        <div style="line-height:1.25;font-weight:bold;font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><ix:nonFraction id="F20241205041230884_170" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_20230630_usgaapStatementClassOfStockAxis_slxnSeriesA4PreferredSharesMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">411</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom">
        <div style="line-height:1.25;font-weight:bold;font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">$</span></span></div>
        </td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:3%;vertical-align:bottom">
        <div style="line-height:1.25;font-weight:bold;font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><ix:nonFraction id="F20241205041230668_96" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_20230630_usgaapStatementEquityComponentsAxis_usgaapNoncontrollingInterestMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,394</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;border-right:2px solid rgb(0, 0, 0);font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:3%;vertical-align:bottom">
        <div style="line-height:1.25;font-weight:bold;font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><ix:nonFraction id="F20241205041230670_97" name="us-gaap:SharesOutstanding" contextRef="C_20230630_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">97,120</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:3%;vertical-align:bottom">
        <div style="line-height:1.25;font-weight:bold;font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span style="-sec-ix-hidden:F20241205041230673_98">*</span></span></span></div>
        </td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom">
        <div style="line-height:1.25;font-weight:bold;font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">$</span></span></div>
        </td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:3%;vertical-align:bottom">
        <div style="line-height:1.25;font-weight:bold;font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><ix:nonFraction id="F20241205041230675_99" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_20230630_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">11,269</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom">
        <div style="line-height:1.25;font-weight:bold;font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">$</span></span></div>
        </td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:3%;vertical-align:bottom">
        <div style="line-height:1.25;font-weight:bold;font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">(<ix:nonFraction id="F20241205041230677_100" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_20230630_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">24,296</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">
        <div style="line-height:1.25;font-weight:bold;font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">)</span></span></div>
        </td>
    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom">
        <div style="line-height:1.25;font-weight:bold;font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">$</span></span></div>
        </td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:3%;vertical-align:bottom">
        <div style="line-height:1.25;font-weight:bold;font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">(<ix:nonFraction id="F20241205041230679_101" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_20230630_usgaapStatementEquityComponentsAxis_usgaapParentMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">13,027</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">
        <div style="line-height:1.25;font-weight:bold;font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">)</span></span></div>
        </td>
    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom">
        <div style="line-height:1.25;font-weight:bold;font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">$</span></span></div>
        </td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:3%;vertical-align:bottom">
        <div style="line-height:1.25;font-weight:bold;font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><ix:nonFraction id="F20241205041230681_102" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_20230630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,424</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align:bottom;width:0%;vertical-align:bottom">
        <div style="line-height:1.25;font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span style="font-weight:bold">CHANGES
        DURING THE THREE MONTHS PERIOD ENDED SEPTEMBER 30, 2023</span> (unaudited):</span></span></div> </td>
    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:3%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:3%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:3%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:3%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:3%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:3%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:3%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:3%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:3%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:3%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:3%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-right:2px solid rgb(0, 0, 0);font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:3%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:3%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:3%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:3%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:3%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:3%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:top;background-color:rgb(204, 238, 255);width:0%;vertical-align:bottom">
        <div style="text-indent:-4pt;margin-left:8.85pt;line-height:1.25;font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">Issuance
        of Preferred A-4 shares, net of issuance cost</span></span></div> </td>
    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:3%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:3%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:3%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:3%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:3%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:3%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:3%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:3%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:3%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:3%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:3%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;border-right:2px solid rgb(0, 0, 0);font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:3%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:3%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:3%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:3%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:3%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:3%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align:top;width:0%;vertical-align:bottom">
        <div style="text-indent:-11.1pt;margin-left:17.3pt;line-height:1.25;font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">Share-based
        compensation</span></span></div> </td>
    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:3%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:3%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:3%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:3%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:3%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:3%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:3%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:3%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:3%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:3%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:3%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-right:2px solid rgb(0, 0, 0);font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:3%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:3%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:3%;vertical-align:bottom">
        <div style="line-height:1.25;font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><ix:nonFraction id="F20241205041230682_103" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="C_20230701to20230930_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">32</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:3%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:3%;vertical-align:bottom">
        <div style="line-height:1.25;font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><ix:nonFraction id="F20241205041230684_104" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="C_20230701to20230930_usgaapStatementEquityComponentsAxis_usgaapParentMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">32</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:3%;vertical-align:bottom">
        <div style="line-height:1.25;font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><ix:nonFraction id="F20241205041230686_105" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="C_20230701to20230930" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">32</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:top;background-color:rgb(204, 238, 255);width:0%;padding-bottom:2px;vertical-align:bottom">
        <div style="text-indent:-11.1pt;margin-left:17.3pt;line-height:1.25;font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">Net
        loss</span></span></div> </td>
    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);padding-bottom:2px;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:3%;border-bottom:2px solid rgb(0, 0, 0);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;padding-bottom:2px;font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);padding-bottom:2px;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:3%;border-bottom:2px solid rgb(0, 0, 0);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;padding-bottom:2px;font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);padding-bottom:2px;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:3%;border-bottom:2px solid rgb(0, 0, 0);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;padding-bottom:2px;font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);padding-bottom:2px;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:3%;border-bottom:2px solid rgb(0, 0, 0);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;padding-bottom:2px;font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);padding-bottom:2px;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:3%;border-bottom:2px solid rgb(0, 0, 0);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;padding-bottom:2px;font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);padding-bottom:2px;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:3%;border-bottom:2px solid rgb(0, 0, 0);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;padding-bottom:2px;font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);padding-bottom:2px;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:3%;border-bottom:2px solid rgb(0, 0, 0);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;padding-bottom:2px;font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);padding-bottom:2px;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:3%;border-bottom:2px solid rgb(0, 0, 0);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;padding-bottom:2px;font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);padding-bottom:2px;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:3%;border-bottom:2px solid rgb(0, 0, 0);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;padding-bottom:2px;font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);padding-bottom:2px;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:3%;border-bottom:2px solid rgb(0, 0, 0);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;padding-bottom:2px;font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);padding-bottom:2px;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:3%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
        <div style="line-height:1.25;font-size:8pt">
        <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">(<ix:nonFraction id="F20241205041230689_106" name="us-gaap:ProfitLoss" contextRef="C_20230701to20230930_usgaapStatementEquityComponentsAxis_usgaapNoncontrollingInterestMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">22</ix:nonFraction></span></span></div>
        </div> </td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;padding-bottom:2px;border-right:2px solid rgb(0, 0, 0);vertical-align:bottom;white-space:nowrap">
        <div style="line-height:1.25;font-size:8pt">
        <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">)</span></span></div>
        </div> </td>
    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);padding-bottom:2px;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:3%;border-bottom:2px solid rgb(0, 0, 0);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;padding-bottom:2px;font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);padding-bottom:2px;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:3%;border-bottom:2px solid rgb(0, 0, 0);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;padding-bottom:2px;font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);padding-bottom:2px;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:3%;border-bottom:2px solid rgb(0, 0, 0);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;padding-bottom:2px;font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);padding-bottom:2px;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:3%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
        <div style="line-height:1.25;font-size:8pt">
        <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">(<ix:nonFraction id="F20241205041230691_107" name="us-gaap:ProfitLoss" contextRef="C_20230701to20230930_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">787</ix:nonFraction></span></span></div>
        </div> </td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">
        <div style="line-height:1.25;font-size:8pt">
        <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">)</span></span></div>
        </div> </td>
    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);padding-bottom:2px;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:3%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
        <div style="line-height:1.25;font-size:8pt">
        <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">(<ix:nonFraction id="F20241205041230693_108" name="us-gaap:ProfitLoss" contextRef="C_20230701to20230930_usgaapStatementEquityComponentsAxis_usgaapParentMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">787</ix:nonFraction></span></span></div>
        </div> </td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">
        <div style="line-height:1.25;font-size:8pt">
        <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">)</span></span></div>
        </div> </td>
    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);padding-bottom:2px;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:3%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
        <div style="line-height:1.25;font-size:8pt">
        <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">(<ix:nonFraction id="F20241205041230694_109" name="us-gaap:ProfitLoss" contextRef="C_20230701to20230930" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">809</ix:nonFraction></span></span></div>
        </div> </td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">
        <div style="line-height:1.25;font-size:8pt">
        <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">)</span></span></div>
        </div> </td> </tr>
  <tr>
    <td style="vertical-align:bottom;width:0%;font-weight:bold;padding-bottom:4px;vertical-align:bottom">
        <div style="text-indent:-6.9pt;margin-left:6.9pt;line-height:1.25;font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">BALANCE
        AS OF SEPTEMBER 30, 2023</span></span></div> </td>
    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:4px;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:3%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
        <div style="line-height:1.25;font-size:8pt">
        <div style="line-height:1.25;font-weight:bold"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><ix:nonFraction id="F20241205041230696_110" name="us-gaap:SharesOutstanding" contextRef="C_20230930_usgaapStatementClassOfStockAxis_usgaapSeriesAPreferredStockMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">43,121</ix:nonFraction></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:4px;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
        <div style="line-height:1.25;font-size:8pt">
        <div style="line-height:1.25;font-weight:bold"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">$</span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:3%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
        <div style="line-height:1.25;font-size:8pt">
        <div style="line-height:1.25;font-weight:bold"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><ix:nonFraction id="F20241205041230698_111" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_20230930_usgaapStatementClassOfStockAxis_usgaapSeriesAPreferredStockMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,307</ix:nonFraction></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:4px;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:3%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
        <div style="line-height:1.25;font-size:8pt">
        <div style="line-height:1.25;font-weight:bold"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><ix:nonFraction id="F20241205041230700_112" name="us-gaap:SharesOutstanding" contextRef="C_20230930_usgaapStatementClassOfStockAxis_slxnSeriesA1PreferredSharesMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">10,136</ix:nonFraction></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:4px;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
        <div style="line-height:1.25;font-size:8pt">
        <div style="line-height:1.25;font-weight:bold"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">$</span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:3%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
        <div style="line-height:1.25;font-size:8pt">
        <div style="line-height:1.25;font-weight:bold"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><ix:nonFraction id="F20241205041230701_113" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_20230930_usgaapStatementClassOfStockAxis_slxnSeriesA1PreferredSharesMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,392</ix:nonFraction></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:4px;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:3%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
        <div style="line-height:1.25;font-size:8pt">
        <div style="line-height:1.25;font-weight:bold"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><ix:nonFraction id="F20241205041230704_114" name="us-gaap:SharesOutstanding" contextRef="C_20230930_usgaapStatementClassOfStockAxis_slxnSeriesA2PreferredSharesMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">5,051</ix:nonFraction></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:4px;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
        <div style="line-height:1.25;font-size:8pt">
        <div style="line-height:1.25;font-weight:bold"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">$</span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:3%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
        <div style="line-height:1.25;font-size:8pt">
        <div style="line-height:1.25;font-weight:bold"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><ix:nonFraction id="F20241205041230706_115" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_20230930_usgaapStatementClassOfStockAxis_slxnSeriesA2PreferredSharesMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,264</ix:nonFraction></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:4px;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:3%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
        <div style="line-height:1.25;font-size:8pt">
        <div style="line-height:1.25;font-weight:bold"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><ix:nonFraction id="F20241205041230708_116" name="us-gaap:SharesOutstanding" contextRef="C_20230930_usgaapStatementClassOfStockAxis_slxnSeriesA3PreferredSharesMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">7,037</ix:nonFraction></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:4px;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
        <div style="line-height:1.25;font-size:8pt">
        <div style="line-height:1.25;font-weight:bold"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">$</span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:3%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
        <div style="line-height:1.25;font-size:8pt">
        <div style="line-height:1.25;font-weight:bold"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><ix:nonFraction id="F20241205041230710_117" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_20230930_usgaapStatementClassOfStockAxis_slxnSeriesA3PreferredSharesMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,683</ix:nonFraction></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:4px;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:3%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
        <div style="line-height:1.25;font-size:8pt">
        <div style="line-height:1.25;font-weight:bold"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><ix:nonFraction id="F20241205041230711_118" name="us-gaap:SharesOutstanding" contextRef="C_20230930_usgaapStatementClassOfStockAxis_slxnSeriesA4PreferredSharesMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">2,413</ix:nonFraction></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:4px;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
        <div style="line-height:1.25;font-size:8pt">
        <div style="line-height:1.25;font-weight:bold"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">$</span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:3%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
        <div style="line-height:1.25;font-size:8pt">
        <div style="line-height:1.25;font-weight:bold"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><ix:nonFraction id="F20241205041230713_119" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_20230930_usgaapStatementClassOfStockAxis_slxnSeriesA4PreferredSharesMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">411</ix:nonFraction></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:4px;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
        <div style="line-height:1.25;font-size:8pt">
        <div style="line-height:1.25;font-weight:bold"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">$</span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:3%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
        <div style="line-height:1.25;font-size:8pt">
        <div style="line-height:1.25;font-weight:bold"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><ix:nonFraction id="F20241205041230715_120" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_20230930_usgaapStatementEquityComponentsAxis_usgaapNoncontrollingInterestMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,372</ix:nonFraction></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;border-right:2px solid rgb(0, 0, 0);font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:4px;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:3%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
        <div style="line-height:1.25;font-size:8pt">
        <div style="line-height:1.25;font-weight:bold"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><ix:nonFraction id="F20241205041230717_121" name="us-gaap:SharesOutstanding" contextRef="C_20230930_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">97,120</ix:nonFraction></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:4px;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:3%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
        <div style="line-height:1.25;font-size:8pt">
        <div style="line-height:1.25;font-weight:bold"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span style="-sec-ix-hidden:F20241205041230720_122">*</span></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:4px;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
        <div style="line-height:1.25;font-size:8pt">
        <div style="line-height:1.25;font-weight:bold"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">$</span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:3%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
        <div style="line-height:1.25;font-size:8pt">
        <div style="line-height:1.25;font-weight:bold"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><ix:nonFraction id="F20241205041230722_123" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_20230930_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">11,301</ix:nonFraction></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:4px;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
        <div style="line-height:1.25;font-size:8pt">
        <div style="line-height:1.25;font-weight:bold"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">$</span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:3%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
        <div style="line-height:1.25;font-size:8pt">
        <div style="line-height:1.25;font-weight:bold"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">(<ix:nonFraction id="F20241205041230723_124" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_20230930_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">25,083</ix:nonFraction></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">
        <div style="line-height:1.25;font-size:8pt">
        <div style="line-height:1.25;font-weight:bold"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">)</span></span></div>
        </div> </td>
    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:4px;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
        <div style="line-height:1.25;font-size:8pt">
        <div style="line-height:1.25;font-weight:bold"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">$</span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:3%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
        <div style="line-height:1.25;font-size:8pt">
        <div style="line-height:1.25;font-weight:bold"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">(<ix:nonFraction id="F20241205041230725_125" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_20230930_usgaapStatementEquityComponentsAxis_usgaapParentMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">13,782</ix:nonFraction></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">
        <div style="line-height:1.25;font-size:8pt">
        <div style="line-height:1.25;font-weight:bold"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">)</span></span></div>
        </div> </td>
    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:4px;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
        <div style="line-height:1.25;font-size:8pt">
        <div style="line-height:1.25;font-weight:bold"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">$</span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:3%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
        <div style="line-height:1.25;font-size:8pt">
        <div style="line-height:1.25;font-weight:bold"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">(<ix:nonFraction id="F20241205041230727_126" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_20230930" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">4,647</ix:nonFraction></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">
        <div style="line-height:1.25;font-size:8pt">
        <div style="line-height:1.25;font-weight:bold"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">)</span></span></div>
        </div> </td> </tr>
  <tr>
    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:0%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:3%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:3%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:3%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:3%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:3%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:3%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:3%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:3%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:3%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:3%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:3%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;border-right:2px solid rgb(0, 0, 0);font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:3%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:3%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:3%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:3%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:3%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:3%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align:top;width:0%;vertical-align:bottom">
        <div style="text-indent:-6.9pt;margin-left:6.9pt;line-height:1.25;font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span style="font-weight:bold">BALANCE
        AT JUNE 30, 2024</span></span></span></div> </td>
    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:3%;vertical-align:bottom">
        <div style="line-height:1.25;font-weight:bold;font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><ix:nonFraction id="F20241205041230728_127" name="us-gaap:SharesOutstanding" contextRef="C_20240630_usgaapStatementClassOfStockAxis_usgaapSeriesAPreferredStockMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">43,121</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">
        <div style="line-height:1.25;font-weight:bold;font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">$</span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:3%;vertical-align:bottom">
        <div style="line-height:1.25;font-weight:bold;font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><ix:nonFraction id="F20241205041230730_128" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_20240630_usgaapStatementClassOfStockAxis_usgaapSeriesAPreferredStockMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,307</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:3%;vertical-align:bottom">
        <div style="line-height:1.25;font-weight:bold;font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><ix:nonFraction id="F20241205041230732_129" name="us-gaap:SharesOutstanding" contextRef="C_20240630_usgaapStatementClassOfStockAxis_slxnSeriesA1PreferredSharesMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">10,136</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">
        <div style="line-height:1.25;font-weight:bold;font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">$</span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:3%;vertical-align:bottom">
        <div style="line-height:1.25;font-weight:bold;font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><ix:nonFraction id="F20241205041230735_130" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_20240630_usgaapStatementClassOfStockAxis_slxnSeriesA1PreferredSharesMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,392</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:3%;vertical-align:bottom">
        <div style="line-height:1.25;font-weight:bold;font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><ix:nonFraction id="F20241205041230737_131" name="us-gaap:SharesOutstanding" contextRef="C_20240630_usgaapStatementClassOfStockAxis_slxnSeriesA2PreferredSharesMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">5,051</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">
        <div style="line-height:1.25;font-weight:bold;font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">$</span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:3%;vertical-align:bottom">
        <div style="line-height:1.25;font-weight:bold;font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><ix:nonFraction id="F20241205041230739_132" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_20240630_usgaapStatementClassOfStockAxis_slxnSeriesA2PreferredSharesMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,264</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:3%;vertical-align:bottom">
        <div style="line-height:1.25;font-weight:bold;font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><ix:nonFraction id="F20241205041230740_133" name="us-gaap:SharesOutstanding" contextRef="C_20240630_usgaapStatementClassOfStockAxis_slxnSeriesA3PreferredSharesMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">7,037</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">
        <div style="line-height:1.25;font-weight:bold;font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">$</span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:3%;vertical-align:bottom">
        <div style="line-height:1.25;font-weight:bold;font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><ix:nonFraction id="F20241205041230742_134" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_20240630_usgaapStatementClassOfStockAxis_slxnSeriesA3PreferredSharesMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,683</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:3%;vertical-align:bottom">
        <div style="line-height:1.25;font-weight:bold;font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><ix:nonFraction id="F20241205041230744_135" name="us-gaap:SharesOutstanding" contextRef="C_20240630_usgaapStatementClassOfStockAxis_slxnSeriesA4PreferredSharesMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">2,413</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">
        <div style="line-height:1.25;font-weight:bold;font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">$</span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:3%;vertical-align:bottom">
        <div style="line-height:1.25;font-weight:bold;font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><ix:nonFraction id="F20241205041230746_136" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_20240630_usgaapStatementClassOfStockAxis_slxnSeriesA4PreferredSharesMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">411</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">
        <div style="line-height:1.25;font-weight:bold;font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">$</span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:3%;vertical-align:bottom">
        <div style="line-height:1.25;font-weight:bold;font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><ix:nonFraction id="F20241205041230748_137" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_20240630_usgaapStatementEquityComponentsAxis_usgaapNoncontrollingInterestMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,353</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-right:2px solid rgb(0, 0, 0);font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:3%;vertical-align:bottom">
        <div style="line-height:1.25;font-weight:bold;font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><ix:nonFraction id="F20241205041230750_138" name="us-gaap:SharesOutstanding" contextRef="C_20240630_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">110,900</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:3%;font-size:8pt;vertical-align:bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span style="-sec-ix-hidden:F20241205041230752_139">*</span></span></span></td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">
        <div style="line-height:1.25;font-weight:bold;font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">$</span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:3%;vertical-align:bottom">
        <div style="line-height:1.25;font-weight:bold;font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><ix:nonFraction id="F20241205041230754_140" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_20240630_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">11,399</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">
        <div style="line-height:1.25;font-weight:bold;font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">$</span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:3%;vertical-align:bottom">
        <div style="line-height:1.25;font-weight:bold;font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">(<ix:nonFraction id="F20241205041230756_141" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_20240630_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">29,656</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">
        <div style="line-height:1.25;font-weight:bold;font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">)</span></span></div>
        </td>
    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">
        <div style="line-height:1.25;font-weight:bold;font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">$</span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:3%;vertical-align:bottom">
        <div style="line-height:1.25;font-weight:bold;font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">(<ix:nonFraction id="F20241205041230757_142" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_20240630_usgaapStatementEquityComponentsAxis_usgaapParentMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">18,257</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">
        <div style="line-height:1.25;font-weight:bold;font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">)</span></span></div>
        </td>
    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">
        <div style="line-height:1.25;font-weight:bold;font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">$</span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:3%;vertical-align:bottom">
        <div style="line-height:1.25;font-weight:bold;font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><ix:nonFraction id="F20241205041230759_143" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_20240630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">153</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:top;background-color:rgb(204, 238, 255);width:0%;vertical-align:bottom">
        <div style="text-indent:-6.9pt;margin-left:6.9pt;line-height:1.25;font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span style="font-weight:bold">CHANGES
        DURING THE THREE MONTHS PERIOD ENDED SEPTEMBER 30, 2024 </span>(unaudited)<span style="font-weight:bold">:</span></span></span></div>
        </td>
    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:3%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:3%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:3%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:3%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:3%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:3%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:3%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:3%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:3%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:3%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:3%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;border-right:2px solid rgb(0, 0, 0);font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:3%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:3%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:3%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:3%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:3%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:3%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align:top;width:0%;vertical-align:bottom">
        <div style="text-indent:-6.9pt;margin-left:6.9pt;line-height:1.25;font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">Share-based
        compensation</span></span></div> </td>
    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:3%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:3%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:3%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:3%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:3%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:3%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:3%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:3%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:3%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:3%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:3%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-right:2px solid rgb(0, 0, 0);font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:3%;vertical-align:bottom">
        <div style="line-height:1.25;font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><ix:nonFraction id="F20241205041230932_193" name="slxn:NumberOfSharesIncreaseToAdditionalPaidinCapitalOptionIncreaseForCostRecognition" contextRef="C_20240701to20240930_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">78,650</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:3%;font-size:8pt;vertical-align:bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span style="-sec-ix-hidden:F20241205041230912_192">*</span></span></span></td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:3%;vertical-align:bottom">
        <div style="line-height:1.25;font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><ix:nonFraction id="F20241205041230761_144" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="C_20240701to20240930_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,798</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:3%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:3%;vertical-align:bottom">
        <div style="line-height:1.25;font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><ix:nonFraction id="F20241205041230763_145" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="C_20240701to20240930_usgaapStatementEquityComponentsAxis_usgaapParentMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,798</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:3%;vertical-align:bottom">
        <div style="line-height:1.25;font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><ix:nonFraction id="F20241205041230769_146" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="C_20240701to20240930" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,798</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:top;background-color:rgb(204, 238, 255);width:0%;vertical-align:bottom">
        <div style="text-indent:-6.9pt;margin-left:6.9pt;line-height:1.25;font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">Issuance
        of convertible preferred shares upon net exercise of warrants</span></span></div> </td>
    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:3%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:3%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:3%;vertical-align:bottom">
        <div style="line-height:1.25;font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><ix:nonFraction id="Fxbrl_20241111193401285_20241205041230934_194" name="slxn:StockIssuedDuringPeriodShareIssuanceOfConvertiblePreferredSharesNetExerciseOfWarrants" contextRef="C_20240701to20240930_usgaapStatementClassOfStockAxis_slxnSeriesA1PreferredSharesMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">140</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:3%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:3%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:3%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:3%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:3%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:3%;vertical-align:bottom">
        <div style="line-height:1.25;font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><ix:nonFraction id="Fxbrl_20241111193401285_20241205041230937_195" name="slxn:StockIssuedDuringPeriodShareIssuanceOfConvertiblePreferredSharesNetExerciseOfWarrants" contextRef="C_20240701to20240930_usgaapStatementClassOfStockAxis_slxnSeriesA4PreferredSharesMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">925</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:3%;vertical-align:bottom">
        <div style="line-height:1.25;font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><ix:nonFraction id="Fxbrl_20241111193401285_20241205041230938_196" name="slxn:StockIssuedDuringPeriodValueIssuanceOfConvertiblePreferredSharesNetExerciseOfWarrants" contextRef="C_20240701to20240930_usgaapStatementClassOfStockAxis_slxnSeriesA4PreferredSharesMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">334</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:3%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;border-right:2px solid rgb(0, 0, 0);font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:3%;vertical-align:bottom">
        <div style="line-height:1.25;font-size:8pt">&#160;</div> </td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:3%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:3%;vertical-align:bottom">
        <div style="line-height:1.25;font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><ix:nonFraction id="Fxbrl_20241111193401285_20241205041230945_197" name="slxn:StockIssuedDuringPeriodValueIssuanceOfConvertiblePreferredSharesNetExerciseOfWarrants" contextRef="C_20240701to20240930_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:3%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:3%;vertical-align:bottom">
        <div style="line-height:1.25;font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><ix:nonFraction id="F20241205041230950_204" name="slxn:StockIssuedDuringPeriodValueIssuanceOfConvertiblePreferredSharesNetExerciseOfWarrants" contextRef="C_20240701to20240930_usgaapStatementEquityComponentsAxis_usgaapParentMember" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:3%;vertical-align:bottom">
        <div style="line-height:1.25;font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><ix:nonFraction id="Fxbrl_20241111193401285_20241205041230947_198" name="slxn:StockIssuedDuringPeriodValueIssuanceOfConvertiblePreferredSharesNetExerciseOfWarrants" contextRef="C_20240701to20240930" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">334</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align:top;width:0%;vertical-align:bottom">
        <div style="text-indent:-6.9pt;margin-left:6.9pt;line-height:1.25;font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">Net
        loss</span></span></div> </td>
    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:3%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:3%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:3%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:3%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:3%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:3%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:3%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:3%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:3%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:3%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:3%;vertical-align:bottom">
        <div style="line-height:1.25;font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">(<ix:nonFraction id="F20241205041230771_147" name="us-gaap:ProfitLoss" contextRef="C_20240701to20240930_usgaapStatementEquityComponentsAxis_usgaapNoncontrollingInterestMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">9</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-right:2px solid rgb(0, 0, 0);vertical-align:bottom;white-space:nowrap">
        <div style="line-height:1.25;font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">)</span></span></div>
        </td>
    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:3%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:3%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:3%;vertical-align:bottom">
        <div style="line-height:1.25;font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><ix:nonFraction id="F20241205041230891_174" name="us-gaap:ProfitLoss" contextRef="C_20240701to20240930_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">76</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:3%;vertical-align:bottom">
        <div style="line-height:1.25;font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">(<ix:nonFraction id="F20241205041230773_148" name="us-gaap:ProfitLoss" contextRef="C_20240701to20240930_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">11,927</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">
        <div style="line-height:1.25;font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">)</span></span></div>
        </td>
    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:3%;vertical-align:bottom">
        <div style="line-height:1.25;font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">(<ix:nonFraction id="F20241205041230775_149" name="us-gaap:ProfitLoss" contextRef="C_20240701to20240930_usgaapStatementEquityComponentsAxis_usgaapParentMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">11,851</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">
        <div style="line-height:1.25;font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">)</span></span></div>
        </td>
    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:3%;vertical-align:bottom">
        <div style="line-height:1.25;font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">(<ix:nonFraction id="F20241205041230789_150" name="us-gaap:ProfitLoss" contextRef="C_20240701to20240930" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">11,860</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">
        <div style="line-height:1.25;font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">)</span></span></div>
        </td> </tr>
  <tr>
    <td style="vertical-align:top;background-color:rgb(204, 238, 255);width:0%;vertical-align:bottom">
        <div style="text-indent:-6.9pt;margin-left:6.9pt;line-height:1.25;font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">Conversion
        of convertible preferred shares and noncontrolling interests upon the effectiveness of the SPAC Merger (see Note 1(d))</span></span></div>
        </td>
    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:3%;vertical-align:bottom">
        <div style="line-height:1.25;font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">(<ix:nonFraction id="Fxbrl_20241111205500124_20241205041230622_72" name="slxn:ConversionOfConvertiblePreferredSharesAndNonControllingInterestShareIssued" contextRef="C_20240701to20240930_usgaapStatementClassOfStockAxis_usgaapSeriesAPreferredStockMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal" sign="-">43,121</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">
        <div style="line-height:1.25;font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">)</span></span></div>
        </td>
    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom">
        <div style="line-height:1.25;font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">$</span></span></div>
        </td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:3%;vertical-align:bottom">
        <div style="line-height:1.25;font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">(<ix:nonFraction id="Fxbrl_20241111205500124_20241205041230623_73" name="slxn:ConversionOfConvertiblePreferredSharesAndNonControllingInterestShareIssuedValue" contextRef="C_20240701to20240930_usgaapStatementClassOfStockAxis_usgaapSeriesAPreferredStockMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">7,307</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">
        <div style="line-height:1.25;font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">)</span></span></div>
        </td>
    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:3%;vertical-align:bottom">
        <div style="line-height:1.25;font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">(<ix:nonFraction id="Fxbrl_20241111205500124_20241205041230626_74" name="slxn:ConversionOfConvertiblePreferredSharesAndNonControllingInterestShareIssued" contextRef="C_20240701to20240930_usgaapStatementClassOfStockAxis_slxnSeriesA1PreferredSharesMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal" sign="-">10,276</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">
        <div style="line-height:1.25;font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">)</span></span></div>
        </td>
    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom">
        <div style="line-height:1.25;font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">$</span></span></div>
        </td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:3%;vertical-align:bottom">
        <div style="line-height:1.25;font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">(<ix:nonFraction id="Fxbrl_20241111205500124_20241205041230628_75" name="slxn:ConversionOfConvertiblePreferredSharesAndNonControllingInterestShareIssuedValue" contextRef="C_20240701to20240930_usgaapStatementClassOfStockAxis_slxnSeriesA1PreferredSharesMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">2,392</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">
        <div style="line-height:1.25;font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">)</span></span></div>
        </td>
    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:3%;vertical-align:bottom">
        <div style="line-height:1.25;font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">(<ix:nonFraction id="Fxbrl_20241111205500124_20241205041230630_76" name="slxn:ConversionOfConvertiblePreferredSharesAndNonControllingInterestShareIssued" contextRef="C_20240701to20240930_usgaapStatementClassOfStockAxis_slxnSeriesA2PreferredSharesMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal" sign="-">5,051</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">
        <div style="line-height:1.25;font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">)</span></span></div>
        </td>
    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom">
        <div style="line-height:1.25;font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">$</span></span></div>
        </td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:3%;vertical-align:bottom">
        <div style="line-height:1.25;font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">(<ix:nonFraction id="Fxbrl_20241111205500124_20241205041230632_77" name="slxn:ConversionOfConvertiblePreferredSharesAndNonControllingInterestShareIssuedValue" contextRef="C_20240701to20240930_usgaapStatementClassOfStockAxis_slxnSeriesA2PreferredSharesMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">2,264</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">
        <div style="line-height:1.25;font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">)</span></span></div>
        </td>
    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:3%;vertical-align:bottom">
        <div style="line-height:1.25;font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">(<ix:nonFraction id="Fxbrl_20241111205500124_20241205041230634_78" name="slxn:ConversionOfConvertiblePreferredSharesAndNonControllingInterestShareIssued" contextRef="C_20240701to20240930_usgaapStatementClassOfStockAxis_slxnSeriesA3PreferredSharesMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal" sign="-">7,037</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">
        <div style="line-height:1.25;font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">)</span></span></div>
        </td>
    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom">
        <div style="line-height:1.25;font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">$</span></span></div>
        </td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:3%;vertical-align:bottom">
        <div style="line-height:1.25;font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">(<ix:nonFraction id="Fxbrl_20241111205500124_20241205041230635_79" name="slxn:ConversionOfConvertiblePreferredSharesAndNonControllingInterestShareIssuedValue" contextRef="C_20240701to20240930_usgaapStatementClassOfStockAxis_slxnSeriesA3PreferredSharesMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">2,683</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">
        <div style="line-height:1.25;font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">)</span></span></div>
        </td>
    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:3%;vertical-align:bottom">
        <div style="line-height:1.25;font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">(<ix:nonFraction id="Fxbrl_20241111205500124_20241205041230637_80" name="slxn:ConversionOfConvertiblePreferredSharesAndNonControllingInterestShareIssued" contextRef="C_20240701to20240930_usgaapStatementClassOfStockAxis_slxnSeriesA4PreferredSharesMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal" sign="-">3,338</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">
        <div style="line-height:1.25;font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">)</span></span></div>
        </td>
    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom">
        <div style="line-height:1.25;font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">$</span></span></div>
        </td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:3%;vertical-align:bottom">
        <div style="line-height:1.25;font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">(<ix:nonFraction id="Fxbrl_20241111205500124_20241205041230639_81" name="slxn:ConversionOfConvertiblePreferredSharesAndNonControllingInterestShareIssuedValue" contextRef="C_20240701to20240930_usgaapStatementClassOfStockAxis_slxnSeriesA4PreferredSharesMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">745</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">
        <div style="line-height:1.25;font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">)</span></span></div>
        </td>
    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom">
        <div style="line-height:1.25;font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">$</span></span></div>
        </td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:3%;vertical-align:bottom">
        <div style="line-height:1.25;font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">(<ix:nonFraction id="Fxbrl_20241111205500124_20241205041230642_82" name="slxn:ConversionOfConvertiblePreferredSharesAndNonControllingInterestShareIssuedValue" contextRef="C_20240701to20240930_usgaapStatementEquityComponentsAxis_usgaapNoncontrollingInterestMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">3,344</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;border-right:2px solid rgb(0, 0, 0);vertical-align:bottom;white-space:nowrap">
        <div style="line-height:1.25;font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">)</span></span></div>
        </td>
    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:3%;vertical-align:bottom">
        <div style="line-height:1.25;font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><ix:nonFraction id="Fxbrl_20241111205500124_20241205041230644_83" name="slxn:ConversionOfConvertiblePreferredSharesAndNonControllingInterestShareIssued" contextRef="C_20240701to20240930_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">478,073</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:3%;font-size:8pt;vertical-align:bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><ix:nonFraction id="Fxbrl_20241111205500124_20241205041230646_84" name="slxn:ConversionOfConvertiblePreferredSharesAndNonControllingInterestShareIssuedValue" contextRef="C_20240701to20240930_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1</ix:nonFraction></span></span></td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:3%;vertical-align:bottom">
        <div style="line-height:1.25;font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><ix:nonFraction id="Fxbrl_20241111205500124_20241205041230647_85" name="slxn:ConversionOfConvertiblePreferredSharesAndNonControllingInterestShareIssuedValue" contextRef="C_20240701to20240930_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">18,734</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:3%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:3%;vertical-align:bottom">
        <div style="line-height:1.25;font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><ix:nonFraction id="Fxbrl_20241111205500124_20241205041230649_86" name="slxn:ConversionOfConvertiblePreferredSharesAndNonControllingInterestShareIssuedValue" contextRef="C_20240701to20240930_usgaapStatementEquityComponentsAxis_usgaapParentMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">18,735</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:3%;vertical-align:bottom">
        <div style="line-height:1.25;font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><ix:nonFraction id="Fxbrl_20241111205500124_20241205041230651_87" name="slxn:ConversionOfConvertiblePreferredSharesAndNonControllingInterestShareIssuedValue" contextRef="C_20240701to20240930" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align:top;width:0%;vertical-align:bottom">
        <div style="text-indent:-6.9pt;margin-left:6.9pt;line-height:1.25;font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">Issuance
        of ordinary shares upon Transactions (see Note 1(d))</span></span></div> </td>
    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:3%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:3%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:3%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:3%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:3%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:3%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:3%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:3%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:3%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:3%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:3%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-right:2px solid rgb(0, 0, 0);font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:3%;vertical-align:bottom">
        <div style="line-height:1.25;font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><ix:nonFraction id="Fxbrl_20241111194750134_20241205041230951_205" name="slxn:StockIssuedDuringPeriodShareIssuanceOfOrdinarySharesUponTransactions" contextRef="C_20240701to20240930_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">417,375</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:3%;font-size:8pt;vertical-align:bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span style="-sec-ix-hidden:Fxbrl_20241111194750134_20241205041230952_206">*</span></span></span></td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:3%;vertical-align:bottom">
        <div style="line-height:1.25;font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span style="-sec-ix-hidden:F20241205041230967_216">*</span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:3%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:3%;vertical-align:bottom">
        <div style="line-height:1.25;font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span style="-sec-ix-hidden:Fxbrl_20241111194750134_20241205041230955_207">*</span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:3%;vertical-align:bottom">
        <div style="line-height:1.25;font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span style="-sec-ix-hidden:Fxbrl_20241111194750134_20241205041230956_208">*</span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:top;background-color:rgb(204, 238, 255);width:0%;padding-bottom:2px;vertical-align:bottom">
        <div style="text-indent:-6.9pt;margin-left:6.9pt;line-height:1.25;font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">Issuance
        of ordinary shares for ELOC holders, net of issuance cost, see Note 3(d)</span></span></div> </td>
    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);padding-bottom:2px;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:3%;border-bottom:2px solid rgb(0, 0, 0);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;padding-bottom:2px;font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);padding-bottom:2px;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:3%;border-bottom:2px solid rgb(0, 0, 0);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;padding-bottom:2px;font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);padding-bottom:2px;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:3%;border-bottom:2px solid rgb(0, 0, 0);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;padding-bottom:2px;font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);padding-bottom:2px;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:3%;border-bottom:2px solid rgb(0, 0, 0);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;padding-bottom:2px;font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);padding-bottom:2px;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:3%;border-bottom:2px solid rgb(0, 0, 0);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;padding-bottom:2px;font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);padding-bottom:2px;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:3%;border-bottom:2px solid rgb(0, 0, 0);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;padding-bottom:2px;font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);padding-bottom:2px;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:3%;border-bottom:2px solid rgb(0, 0, 0);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;padding-bottom:2px;font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);padding-bottom:2px;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:3%;border-bottom:2px solid rgb(0, 0, 0);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;padding-bottom:2px;font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);padding-bottom:2px;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:3%;border-bottom:2px solid rgb(0, 0, 0);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;padding-bottom:2px;font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);padding-bottom:2px;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:3%;border-bottom:2px solid rgb(0, 0, 0);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;padding-bottom:2px;font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);padding-bottom:2px;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:3%;border-bottom:2px solid rgb(0, 0, 0);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;padding-bottom:2px;border-right:2px solid rgb(0, 0, 0);font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);padding-bottom:2px;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:3%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
        <div style="line-height:1.25;font-size:8pt">
        <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><ix:nonFraction id="Fxbrl_20241111194811742_20241205041230959_210" name="slxn:StockIssuedDuringPeriodShareIssuanceOfOrdinarySharesForElocHolders" contextRef="C_20240701to20240930_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">157,269</ix:nonFraction></span></span></div>
        </div> </td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;padding-bottom:2px;font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);padding-bottom:2px;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:3%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
        <div style="line-height:1.25;font-size:8pt">
        <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span style="-sec-ix-hidden:Fxbrl_20241111194811742_20241205041230960_211">*</span></span></span></div>
        </div> </td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;padding-bottom:2px;font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);padding-bottom:2px;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:3%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
        <div style="line-height:1.25;font-size:8pt">
        <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><ix:nonFraction id="Fxbrl_20241111194811742_20241205041230961_212" name="slxn:StockIssuedDuringPeriodValueIssuanceOfOrdinarySharesForElocHolders" contextRef="C_20240701to20240930_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">996</ix:nonFraction></span></span></div>
        </div> </td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;padding-bottom:2px;font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);padding-bottom:2px;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:3%;border-bottom:2px solid rgb(0, 0, 0);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;padding-bottom:2px;font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);padding-bottom:2px;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:3%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
        <div style="line-height:1.25;font-size:8pt">
        <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><ix:nonFraction id="Fxbrl_20241111194811742_20241205041230963_213" name="slxn:StockIssuedDuringPeriodValueIssuanceOfOrdinarySharesForElocHolders" contextRef="C_20240701to20240930_usgaapStatementEquityComponentsAxis_usgaapParentMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">996</ix:nonFraction></span></span></div>
        </div> </td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;padding-bottom:2px;font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);padding-bottom:2px;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:3%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
        <div style="line-height:1.25;font-size:8pt">
        <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><ix:nonFraction id="Fxbrl_20241111194811742_20241205041230957_209" name="slxn:StockIssuedDuringPeriodValueIssuanceOfOrdinarySharesForElocHolders" contextRef="C_20240701to20240930" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">996</ix:nonFraction></span></span></div>
        </div> </td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;padding-bottom:2px;font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align:top;width:0%;padding-bottom:4px;vertical-align:bottom">
        <div style="text-indent:-6.9pt;margin-left:6.9pt;line-height:1.25;font-weight:bold;font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">BALANCE
        AS OF SEPTEMBER 30, 2024</span></span></div> </td>
    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:4px;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:3%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
        <div style="line-height:1.25;font-size:8pt">
        <div style="line-height:1.25;font-weight:bold"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><ix:nonFraction id="F20241205041230792_151" name="us-gaap:SharesOutstanding" contextRef="C_20240930_usgaapStatementClassOfStockAxis_usgaapSeriesAPreferredStockMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember" unitRef="shares" decimals="INF" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:4px;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:3%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
        <div style="line-height:1.25;font-size:8pt">
        <div style="line-height:1.25;font-weight:bold"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><ix:nonFraction id="F20241205041230794_152" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_20240930_usgaapStatementClassOfStockAxis_usgaapSeriesAPreferredStockMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:4px;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:3%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
        <div style="line-height:1.25;font-size:8pt">
        <div style="line-height:1.25;font-weight:bold"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><ix:nonFraction id="F20241205041230804_153" name="us-gaap:SharesOutstanding" contextRef="C_20240930_usgaapStatementClassOfStockAxis_slxnSeriesA1PreferredSharesMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember" unitRef="shares" decimals="INF" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:4px;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:3%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
        <div style="line-height:1.25;font-size:8pt">
        <div style="line-height:1.25;font-weight:bold"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><ix:nonFraction id="F20241205041230808_154" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_20240930_usgaapStatementClassOfStockAxis_slxnSeriesA1PreferredSharesMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:4px;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:3%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
        <div style="line-height:1.25;font-size:8pt">
        <div style="line-height:1.25;font-weight:bold"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><ix:nonFraction id="F20241205041230811_155" name="us-gaap:SharesOutstanding" contextRef="C_20240930_usgaapStatementClassOfStockAxis_slxnSeriesA2PreferredSharesMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember" unitRef="shares" decimals="INF" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:4px;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:3%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
        <div style="line-height:1.25;font-size:8pt">
        <div style="line-height:1.25;font-weight:bold"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><ix:nonFraction id="F20241205041230813_156" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_20240930_usgaapStatementClassOfStockAxis_slxnSeriesA2PreferredSharesMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:4px;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:3%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
        <div style="line-height:1.25;font-size:8pt">
        <div style="line-height:1.25;font-weight:bold"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><ix:nonFraction id="F20241205041230815_157" name="us-gaap:SharesOutstanding" contextRef="C_20240930_usgaapStatementClassOfStockAxis_slxnSeriesA3PreferredSharesMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember" unitRef="shares" decimals="INF" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:4px;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:3%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
        <div style="line-height:1.25;font-size:8pt">
        <div style="line-height:1.25;font-weight:bold"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><ix:nonFraction id="F20241205041230817_158" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_20240930_usgaapStatementClassOfStockAxis_slxnSeriesA3PreferredSharesMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:4px;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:3%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
        <div style="line-height:1.25;font-size:8pt">
        <div style="line-height:1.25;font-weight:bold"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><ix:nonFraction id="F20241205041230819_159" name="us-gaap:SharesOutstanding" contextRef="C_20240930_usgaapStatementClassOfStockAxis_slxnSeriesA4PreferredSharesMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember" unitRef="shares" decimals="INF" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:4px;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:3%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
        <div style="line-height:1.25;font-size:8pt">
        <div style="line-height:1.25;font-weight:bold"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><ix:nonFraction id="F20241205041230821_160" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_20240930_usgaapStatementClassOfStockAxis_slxnSeriesA4PreferredSharesMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:4px;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:3%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
        <div style="line-height:1.25;font-size:8pt">
        <div style="line-height:1.25;font-weight:bold"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><ix:nonFraction id="F20241205041230824_161" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_20240930_usgaapStatementEquityComponentsAxis_usgaapNoncontrollingInterestMember" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;border-right:2px solid rgb(0, 0, 0);font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:4px;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:3%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
        <div style="line-height:1.25;font-size:8pt">
        <div style="line-height:1.25;font-weight:bold"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><ix:nonFraction id="F20241205041230846_162" name="us-gaap:SharesOutstanding" contextRef="C_20240930_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">1,242,267</ix:nonFraction></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:4px;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
        <div style="line-height:1.25;font-size:8pt">
        <div style="line-height:1.25;font-weight:bold"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">$</span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:3%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
        <div style="line-height:1.25;font-size:8pt">
        <div style="line-height:1.25;font-weight:bold"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><ix:nonFraction id="F20241205041230848_163" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_20240930_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1</ix:nonFraction></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:4px;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
        <div style="line-height:1.25;font-size:8pt">
        <div style="line-height:1.25;font-weight:bold"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">$</span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:3%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
        <div style="line-height:1.25;font-size:8pt">
        <div style="line-height:1.25;font-weight:bold"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><ix:nonFraction id="F20241205041230850_164" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_20240930_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">37,003</ix:nonFraction></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;font-size:8pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:4px;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
        <div style="line-height:1.25;font-size:8pt">
        <div style="line-height:1.25;font-weight:bold"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">$</span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:3%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
        <div style="line-height:1.25;font-size:8pt">
        <div style="line-height:1.25;font-weight:bold"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">(<ix:nonFraction id="F20241205041230853_165" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_20240930_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">41,583</ix:nonFraction></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">
        <div style="line-height:1.25;font-size:8pt">
        <div style="line-height:1.25;font-weight:bold"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">)</span></span></div>
        </div> </td>
    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:4px;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
        <div style="line-height:1.25;font-size:8pt">
        <div style="line-height:1.25;font-weight:bold"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">$</span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:3%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
        <div style="line-height:1.25;font-size:8pt">
        <div style="line-height:1.25;font-weight:bold"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">(<ix:nonFraction id="F20241205041230859_166" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_20240930_usgaapStatementEquityComponentsAxis_usgaapParentMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">4,579</ix:nonFraction></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">
        <div style="line-height:1.25;font-size:8pt">
        <div style="line-height:1.25;font-weight:bold"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">)</span></span></div>
        </div> </td>
    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:4px;font-size:8pt;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
        <div style="line-height:1.25;font-size:8pt">
        <div style="line-height:1.25;font-weight:bold"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">$</span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:3%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
        <div style="line-height:1.25;font-size:8pt">
        <div style="line-height:1.25;font-weight:bold"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">(<ix:nonFraction id="F20241205041230863_167" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_20240930" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">4,579</ix:nonFraction></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">
        <div style="line-height:1.25;font-size:8pt">
        <div style="line-height:1.25;font-weight:bold"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">)</span></span></div>
        </div> </td> </tr>
  </table>

<div style="text-align:center;line-height:1.25">&#160;</div>

<div style="line-height:1.25;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span>*
Represents an amount less than $1</span></span></span></span></span></span></div>

<div style="line-height:1.25">&#160;</div>

<div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span><span>The
accompanying notes are an integral part of the unaudited condensed consolidated financial statements.</span></span></span></span></span></span></span></div>

<div>&#160;</div>

<div style="clear:both;margin-top:10pt;margin-bottom:10pt">

<div style="text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span><span style="font-weight:normal;font-style:normal">F-47</span></span></span></span></span></span></span></div>

<div style="page-break-after:always"> <hr style="border-width:0px;clear:both;margin:4px 0px;width:100%;height:2px;color:#000000;background-color:#000000"/>
</div> </div>

<div>&#160;</div>

<div style="font:10pt Times New Roman, Times, Serif">

<div>

<div>

<div style="margin-left:1pt;line-height:1.25;font-weight:bold;text-align:center">SILEXION THERAPEUTICS CORP</div>

<div>

<div>

<div style="text-align:center;margin-left:1pt;line-height:1.25"><span>UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</span><span id="CASHFLOWS"></span></div>

<div style="line-height:1.25">&#160;</div>

<div style="line-height:1.25">

<table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left;color:#000000;width:100%">
  <tr>
    <td colspan="1" style="vertical-align:top;padding-bottom:2px;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
    <td colspan="6" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
        <div style="text-align:center;line-height:1.25;font-weight:bold">Nine months ended</div>
        <div style="line-height:1.25">
        <div style="text-align:center;line-height:1.25;font-weight:bold">September 30,</div> </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
    <td colspan="6" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="text-align:center;line-height:1.25;font-weight:bold">Three months ended</div>
        <div style="text-align:center;line-height:1.25;font-weight:bold">September 30</div> </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td> </tr>
  <tr>
    <td colspan="1" style="vertical-align:top;padding-bottom:2px;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="text-align:center;line-height:1.25;font-weight:bold">2024</div> </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
    <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="text-align:center;line-height:1.25;font-weight:bold">2023</div> </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="text-align:center;line-height:1.25;font-weight:bold">2024</div> </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="text-align:center;line-height:1.25;font-weight:bold">2023</div> </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td> </tr>
  <tr>
    <td colspan="1" style="vertical-align:top;padding-bottom:2px;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
    <td colspan="6" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="text-align:center;line-height:1.25;font-weight:bold">U.S. dollars in thousands</div> </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
    <td colspan="6" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="text-align:center;line-height:1.25;font-weight:bold">U.S. dollars in thousands</div> </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:top;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-weight:bold">CASH FLOWS FROM OPERATING ACTIVITIES:</div> </td>
    <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="2" style="vertical-align:top;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:top;width:52%;background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="text-indent:-14.2pt;margin-left:28.75pt;line-height:1.25">Net loss</div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25">$</div> </td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25">(<ix:nonFraction id="F20241205041231014_0" name="us-gaap:ProfitLoss" contextRef="C_20240101to20240930" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">14,772</ix:nonFraction></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom;white-space:nowrap">
        <div style="line-height:1.25">)</div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25">$</div> </td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25">(<ix:nonFraction id="F20241205041231018_1" name="us-gaap:ProfitLoss" contextRef="C_20230101to20230930" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">3,428</ix:nonFraction></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom;white-space:nowrap">
        <div style="line-height:1.25">)</div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25">$</div> </td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25">(<ix:nonFraction id="F20241205041231018_2" name="us-gaap:ProfitLoss" contextRef="C_20240701to20240930" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">11,860</ix:nonFraction></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom;white-space:nowrap">
        <div style="line-height:1.25">)</div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25">$</div> </td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25">(<ix:nonFraction id="F20241205041231019_3" name="us-gaap:ProfitLoss" contextRef="C_20230701to20230930" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">809</ix:nonFraction></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom;white-space:nowrap">
        <div style="line-height:1.25">)</div> </td> </tr>
  <tr>
    <td style="vertical-align:top;width:52%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="text-indent:-14.2pt;margin-left:28.75pt;line-height:1.25">Adjustments required to reconcile loss to net cash used in operating
        activities:</div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align:top;width:52%;background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="margin-left:28.75pt;line-height:1.25">Depreciation</div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25"><ix:nonFraction id="F20241205041231020_4" name="us-gaap:Depreciation" contextRef="C_20240101to20240930" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">37</ix:nonFraction></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25"><ix:nonFraction id="F20241205041231021_5" name="us-gaap:Depreciation" contextRef="C_20230101to20230930" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">39</ix:nonFraction></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25"><ix:nonFraction id="F20241205041231022_6" name="us-gaap:Depreciation" contextRef="C_20240701to20240930" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">22</ix:nonFraction></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25"><ix:nonFraction id="F20241205041231023_7" name="us-gaap:Depreciation" contextRef="C_20230701to20230930" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">10</ix:nonFraction></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align:top;width:52%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="margin-left:28.75pt;line-height:1.25">Share-based compensation expenses</div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25"><ix:nonFraction id="F20241205041231023_8" name="us-gaap:ShareBasedCompensation" contextRef="C_20240101to20240930" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,862</ix:nonFraction></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25"><ix:nonFraction id="F20241205041231024_9" name="us-gaap:ShareBasedCompensation" contextRef="C_20230101to20230930" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">96</ix:nonFraction></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25"><ix:nonFraction id="F20241205041231025_10" name="us-gaap:ShareBasedCompensation" contextRef="C_20240701to20240930" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,798</ix:nonFraction></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25"><ix:nonFraction id="F20241205041231026_11" name="us-gaap:ShareBasedCompensation" contextRef="C_20230701to20230930" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">32</ix:nonFraction></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align:top;width:52%;background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="margin-left:28.75pt;line-height:1.25">Non-cash financial expenses</div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25"><ix:nonFraction id="F20241205041231027_12" name="us-gaap:OtherNoncashExpense" contextRef="C_20240101to20240930" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,968</ix:nonFraction></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25"><ix:nonFraction id="F20241205041231028_13" name="us-gaap:OtherNoncashExpense" contextRef="C_20230101to20230930" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">365</ix:nonFraction></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25"><ix:nonFraction id="F20241205041231029_14" name="us-gaap:OtherNoncashExpense" contextRef="C_20240701to20240930" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,749</ix:nonFraction></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25"><ix:nonFraction id="F20241205041231029_15" name="us-gaap:OtherNoncashExpense" contextRef="C_20230701to20230930" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">108</ix:nonFraction></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align:top;width:52%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="margin-left:28.75pt;line-height:1.25">Gain on disposal of property and equipment</div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25"><ix:nonFraction id="F20241205041231100_96" name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" contextRef="C_20240101to20240930" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25">(<ix:nonFraction id="F20241205041231100_97" name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" contextRef="C_20230101to20230930" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1</ix:nonFraction></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
        <div style="line-height:1.25">)</div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25"><ix:nonFraction id="F20241205041231101_98" name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" contextRef="C_20240701to20240930" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25">(<ix:nonFraction id="F20241205041231101_99" name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" contextRef="C_20230701to20230930" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1</ix:nonFraction></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
        <div style="line-height:1.25">)</div> </td> </tr>
  <tr>
    <td style="vertical-align:top;width:52%;background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="margin-left:28.75pt;line-height:1.25">Loss from lease termination</div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25"><ix:nonFraction id="F20241205041231102_100" name="us-gaap:GainLossOnTerminationOfLease" contextRef="C_20240101to20240930" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">68</ix:nonFraction></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25"><ix:nonFraction id="F20241205041231103_101" name="us-gaap:GainLossOnTerminationOfLease" contextRef="C_20230101to20230930" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25"><ix:nonFraction id="F20241205041231103_102" name="us-gaap:GainLossOnTerminationOfLease" contextRef="C_20240701to20240930" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">68</ix:nonFraction></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25"><ix:nonFraction id="F20241205041231104_103" name="us-gaap:GainLossOnTerminationOfLease" contextRef="C_20230701to20230930" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align:top;width:52%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align:top;width:52%;background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="text-indent:-14.2pt;margin-left:28.75pt;line-height:1.25">Changes in operating assets and liabilities:</div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align:top;width:52%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="text-indent:-14.15pt;margin-left:42.9pt;line-height:1.25">Increase (decrease) in prepaid expenses</div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25">(<ix:nonFraction id="F20241205041231030_16" name="us-gaap:IncreaseDecreaseInPrepaidExpense" contextRef="C_20240101to20240930" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">609</ix:nonFraction></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
        <div style="line-height:1.25">)</div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25">(<ix:nonFraction id="F20241205041231031_17" name="us-gaap:IncreaseDecreaseInPrepaidExpense" contextRef="C_20230101to20230930" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">200</ix:nonFraction></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
        <div style="line-height:1.25">)</div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25">(<ix:nonFraction id="F20241205041231032_18" name="us-gaap:IncreaseDecreaseInPrepaidExpense" contextRef="C_20240701to20240930" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">417</ix:nonFraction></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
        <div style="line-height:1.25">)</div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25">(<ix:nonFraction id="F20241205041231035_19" name="us-gaap:IncreaseDecreaseInPrepaidExpense" contextRef="C_20230701to20230930" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">198</ix:nonFraction></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
        <div style="line-height:1.25">)</div> </td> </tr>
  <tr>
    <td style="vertical-align:top;width:52%;background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="text-indent:-14.15pt;margin-left:42.9pt;line-height:1.25">Increase (decrease) in other receivables</div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25">(<ix:nonFraction id="F20241205041231036_20" name="us-gaap:IncreaseDecreaseInAccountsAndOtherReceivables" contextRef="C_20240101to20240930" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">59</ix:nonFraction></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom;white-space:nowrap">
        <div style="line-height:1.25">)</div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25"><ix:nonFraction id="F20241205041231037_21" name="us-gaap:IncreaseDecreaseInAccountsAndOtherReceivables" contextRef="C_20230101to20230930" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">15</ix:nonFraction></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25">(<ix:nonFraction id="F20241205041231038_22" name="us-gaap:IncreaseDecreaseInAccountsAndOtherReceivables" contextRef="C_20240701to20240930" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">17</ix:nonFraction></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom;white-space:nowrap">
        <div style="line-height:1.25">)</div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25"><ix:nonFraction id="F20241205041231039_23" name="us-gaap:IncreaseDecreaseInAccountsAndOtherReceivables" contextRef="C_20230701to20230930" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">24</ix:nonFraction></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align:top;width:52%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="text-indent:-14.15pt;margin-left:42.9pt;line-height:1.25">Increase (decrease) in trade payable</div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25"><ix:nonFraction id="F20241205041231039_24" name="us-gaap:IncreaseDecreaseInAccountsPayableTrade" contextRef="C_20240101to20240930" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">479</ix:nonFraction></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25"><ix:nonFraction id="F20241205041231040_25" name="us-gaap:IncreaseDecreaseInAccountsPayableTrade" contextRef="C_20230101to20230930" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">74</ix:nonFraction></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25"><ix:nonFraction id="F20241205041231041_26" name="us-gaap:IncreaseDecreaseInAccountsPayableTrade" contextRef="C_20240701to20240930" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">517</ix:nonFraction></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25"><ix:nonFraction id="F20241205041231042_27" name="us-gaap:IncreaseDecreaseInAccountsPayableTrade" contextRef="C_20230701to20230930" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">131</ix:nonFraction></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align:top;width:52%;background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="text-indent:-14.15pt;margin-left:42.9pt;line-height:1.25">Net change in operating lease</div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25">(<ix:nonFraction id="F20241205041231043_28" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" contextRef="C_20240101to20240930" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">40</ix:nonFraction></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom;white-space:nowrap">
        <div style="line-height:1.25">)</div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25">(<ix:nonFraction id="F20241205041231044_29" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" contextRef="C_20230101to20230930" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">7</ix:nonFraction></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom;white-space:nowrap">
        <div style="line-height:1.25">)</div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25">(<ix:nonFraction id="F20241205041231044_30" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" contextRef="C_20240701to20240930" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">44</ix:nonFraction></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom;white-space:nowrap">
        <div style="line-height:1.25">)</div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25">(<ix:nonFraction id="F20241205041231045_31" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" contextRef="C_20230701to20230930" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">2</ix:nonFraction></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom;white-space:nowrap">
        <div style="line-height:1.25">)</div> </td> </tr>
  <tr>
    <td style="vertical-align:top;width:52%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="text-indent:-14.15pt;margin-left:42.9pt;line-height:1.25">Increase (decrease) in employee related obligations</div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25"><ix:nonFraction id="F20241205041231046_32" name="us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities" contextRef="C_20240101to20240930" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">480</ix:nonFraction></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25">(<ix:nonFraction id="F20241205041231047_33" name="us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities" contextRef="C_20230101to20230930" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">75</ix:nonFraction></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
        <div style="line-height:1.25">)</div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25"><ix:nonFraction id="F20241205041231048_34" name="us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities" contextRef="C_20240701to20240930" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">436</ix:nonFraction></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25">(<ix:nonFraction id="F20241205041231049_35" name="us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities" contextRef="C_20230701to20230930" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">13</ix:nonFraction></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
        <div style="line-height:1.25">)</div> </td> </tr>
  <tr>
    <td style="vertical-align:top;width:52%;padding-bottom:2px;background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="text-indent:-14.15pt;margin-left:42.9pt;line-height:1.25">Increase (decrease) in accrued expenses</div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25">(<ix:nonFraction id="F20241205041231050_36" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" contextRef="C_20240101to20240930" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">884</ix:nonFraction></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(255, 255, 255);vertical-align:bottom;white-space:nowrap">
        <div style="line-height:1.25">
        <div style="line-height:1.25">)</div> </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25">(<ix:nonFraction id="F20241205041231051_37" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" contextRef="C_20230101to20230930" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">150</ix:nonFraction></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(255, 255, 255);vertical-align:bottom;white-space:nowrap">
        <div style="line-height:1.25">
        <div style="line-height:1.25">)</div> </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25">(<ix:nonFraction id="F20241205041231052_38" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" contextRef="C_20240701to20240930" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">905</ix:nonFraction></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(255, 255, 255);vertical-align:bottom;white-space:nowrap">
        <div style="line-height:1.25">
        <div style="line-height:1.25">)</div> </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><ix:nonFraction id="F20241205041231053_39" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" contextRef="C_20230701to20230930" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">33</ix:nonFraction></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(255, 255, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align:top;width:52%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="text-indent:-14.2pt;margin-left:28.75pt;line-height:1.25">Net cash used in operating activities</div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25">(<ix:nonFraction id="F20241205041231054_40" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="C_20240101to20240930" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">5,470</ix:nonFraction></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
        <div style="line-height:1.25">
        <div style="line-height:1.25">)</div> </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25">(<ix:nonFraction id="F20241205041231055_41" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="C_20230101to20230930" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">3,272</ix:nonFraction></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
        <div style="line-height:1.25">
        <div style="line-height:1.25">)</div> </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25">(<ix:nonFraction id="F20241205041231055_42" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="C_20240701to20240930" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">2,653</ix:nonFraction></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
        <div style="line-height:1.25">
        <div style="line-height:1.25">)</div> </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25">(<ix:nonFraction id="F20241205041231056_43" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="C_20230701to20230930" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">685</ix:nonFraction></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
        <div style="line-height:1.25">
        <div style="line-height:1.25">)</div> </div> </td> </tr>
  <tr>
    <td style="vertical-align:top;width:52%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align:top;width:52%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-weight:bold">CASH FLOWS FROM INVESTING ACTIVITIES:</div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align:top;width:52%;background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="text-indent:-14.2pt;margin-left:28.75pt;line-height:1.25">Proceeds from short-term deposit</div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25"><ix:nonFraction id="F20241205041231093_87" name="us-gaap:ProceedsFromSaleOfShortTermInvestments" contextRef="C_20240101to20240930" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25"><ix:nonFraction id="F20241205041231057_44" name="us-gaap:ProceedsFromSaleOfShortTermInvestments" contextRef="C_20230101to20230930" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">507</ix:nonFraction></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25"><ix:nonFraction id="F20241205041231093_88" name="us-gaap:ProceedsFromSaleOfShortTermInvestments" contextRef="C_20240701to20240930" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25"><ix:nonFraction id="F20241205041231094_89" name="us-gaap:ProceedsFromSaleOfShortTermInvestments" contextRef="C_20230701to20230930" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align:top;width:52%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="text-indent:-14.2pt;margin-left:28.75pt;line-height:1.25">Purchase of property and equipment</div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25">(<ix:nonFraction id="F20241205041231058_45" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="C_20240101to20240930" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">22</ix:nonFraction></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
        <div style="line-height:1.25">)</div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25">(<ix:nonFraction id="F20241205041231059_46" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="C_20230101to20230930" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">8</ix:nonFraction></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
        <div style="line-height:1.25">)</div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25">(<ix:nonFraction id="F20241205041231095_90" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="C_20240701to20240930" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">16</ix:nonFraction></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
        <div style="line-height:1.25">)</div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25">(<ix:nonFraction id="F20241205041231059_47" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="C_20230701to20230930" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">6</ix:nonFraction></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
        <div style="line-height:1.25">)</div> </td> </tr>
  <tr>
    <td style="vertical-align:top;width:52%;padding-bottom:2px;background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="text-indent:-14.2pt;margin-left:28.75pt;line-height:1.25">Proceeds from Sale of property and equipment</div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><ix:nonFraction id="Fxbrl_20241112095739815_20241205041231093_87" name="us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment" contextRef="C_20240101to20240930" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(255, 255, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><ix:nonFraction id="Fxbrl_20241112095739815_20241205041231057_44" name="us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment" contextRef="C_20230101to20230930" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">78</ix:nonFraction></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(255, 255, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><ix:nonFraction id="Fxbrl_20241112095739815_20241205041231093_88" name="us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment" contextRef="C_20240701to20240930" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(255, 255, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><ix:nonFraction id="F20241205041231108_131" name="us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment" contextRef="C_20230701to20230930" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">78</ix:nonFraction></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(255, 255, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align:top;width:52%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="text-indent:-14.2pt;margin-left:28.75pt;line-height:1.25">Net cash provided by (used in (investing activities</div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25">(<ix:nonFraction id="F20241205041231060_48" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="C_20240101to20240930" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">22</ix:nonFraction></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
        <div style="line-height:1.25">
        <div style="line-height:1.25">)</div> </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><ix:nonFraction id="F20241205041231061_49" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="C_20230101to20230930" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">577</ix:nonFraction></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25">(<ix:nonFraction id="F20241205041231096_91" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="C_20240701to20240930" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">16</ix:nonFraction></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
        <div style="line-height:1.25">
        <div style="line-height:1.25">)</div> </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><ix:nonFraction id="F20241205041231062_50" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="C_20230701to20230930" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">72</ix:nonFraction></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align:top;width:52%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align:top;width:52%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-weight:bold">CASH FLOWS FROM FINANCING ACTIVITIES:</div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align:top;width:52%;background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="text-indent:-14.2pt;margin-left:28.75pt;line-height:1.25">Proceeds from issuance of preferred shares and warrants, net of
        issuance costs</div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25"><ix:nonFraction id="F20241205041231098_94" name="us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" contextRef="C_20240101to20240930" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25"><ix:nonFraction id="F20241205041231063_51" name="us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" contextRef="C_20230101to20230930" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">522</ix:nonFraction></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25"><ix:nonFraction id="F20241205041231097_92" name="us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" contextRef="C_20240701to20240930" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25"><ix:nonFraction id="F20241205041231063_52" name="us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" contextRef="C_20230701to20230930" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align:top;width:52%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="text-indent:-14.2pt;margin-left:28.75pt;line-height:1.25">Proceeds from issuance of ordinary shares (ELOC)</div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25"><ix:nonFraction id="Fxbrl_20241112101420283_20241205041231098_94" name="us-gaap:ProceedsFromStockOptionsExercised" contextRef="C_20240101to20240930" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">620</ix:nonFraction></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25"><ix:nonFraction id="Fxbrl_20241112101420283_20241205041231063_51" name="us-gaap:ProceedsFromStockOptionsExercised" contextRef="C_20230101to20230930" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25"><ix:nonFraction id="Fxbrl_20241112101420283_20241205041231097_92" name="us-gaap:ProceedsFromStockOptionsExercised" contextRef="C_20240701to20240930" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">620</ix:nonFraction></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25"><ix:nonFraction id="Fxbrl_20241112101420283_20241205041231063_52" name="us-gaap:ProceedsFromStockOptionsExercised" contextRef="C_20230701to20230930" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align:top;width:52%;padding-bottom:2px;background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="text-indent:-14.2pt;margin-left:28.75pt;line-height:1.25">Cash received from Transactions upon the effectiveness of the SPAC
        Merger</div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><ix:nonFraction id="Fxbrl_20241112101606385_20241205041231098_94" name="us-gaap:CashAcquiredInExcessOfPaymentsToAcquireBusiness" contextRef="C_20240101to20240930" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,300</ix:nonFraction></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(255, 255, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><ix:nonFraction id="Fxbrl_20241112101606385_20241205041231063_51" name="us-gaap:CashAcquiredInExcessOfPaymentsToAcquireBusiness" contextRef="C_20230101to20230930" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(255, 255, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><ix:nonFraction id="Fxbrl_20241112101606385_20241205041231097_92" name="us-gaap:CashAcquiredInExcessOfPaymentsToAcquireBusiness" contextRef="C_20240701to20240930" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,300</ix:nonFraction></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(255, 255, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><ix:nonFraction id="Fxbrl_20241112101606385_20241205041231063_52" name="us-gaap:CashAcquiredInExcessOfPaymentsToAcquireBusiness" contextRef="C_20230701to20230930" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(255, 255, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align:top;width:52%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="text-indent:-14.2pt;margin-left:28.75pt;line-height:1.25">Net cash provided by financing activities</div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><ix:nonFraction id="F20241205041231099_95" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="C_20240101to20240930" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,920</ix:nonFraction></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><ix:nonFraction id="F20241205041231064_53" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="C_20230101to20230930" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">522</ix:nonFraction></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><ix:nonFraction id="F20241205041231098_93" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="C_20240701to20240930" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,920</ix:nonFraction></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><ix:nonFraction id="F20241205041231065_54" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="C_20230701to20230930" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align:top;width:52%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align:bottom;width:52%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="text-indent:-14.55pt;margin-left:14.55pt;line-height:1.25;font-weight:bold">DECREASE IN CASH AND CASH EQUIVALENTS AND RESTRICTED
        CASH</div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25">(<ix:nonFraction id="F20241205041231067_55" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" contextRef="C_20240101to20240930" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">2,572</ix:nonFraction></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
        <div style="line-height:1.25">)</div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25">(<ix:nonFraction id="F20241205041231068_56" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" contextRef="C_20230101to20230930" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">2,173</ix:nonFraction></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
        <div style="line-height:1.25">)</div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25"><ix:nonFraction id="F20241205041231068_57" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" contextRef="C_20240701to20240930" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">251</ix:nonFraction></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25">(<ix:nonFraction id="F20241205041231069_58" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" contextRef="C_20230701to20230930" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">613</ix:nonFraction></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
        <div style="line-height:1.25">)</div> </td> </tr>
  <tr>
    <td style="vertical-align:bottom;width:52%;background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="text-indent:-14.55pt;margin-left:14.55pt;line-height:1.25;font-weight:bold">EXCHANGE RATE DIFFERENCES ON CASH AND CASH EQUIVALENTS
        AND RESTRICTED CASH</div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25">(<ix:nonFraction id="F20241205041231070_59" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="C_20240101to20240930" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">50</ix:nonFraction></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom;white-space:nowrap">
        <div style="line-height:1.25">)</div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25">(<ix:nonFraction id="F20241205041231071_60" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="C_20230101to20230930" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">324</ix:nonFraction></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom;white-space:nowrap">
        <div style="line-height:1.25">)</div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25"><ix:nonFraction id="F20241205041231072_61" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="C_20240701to20240930" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">25</ix:nonFraction></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25">(<ix:nonFraction id="F20241205041231072_62" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="C_20230701to20230930" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">66</ix:nonFraction></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom;white-space:nowrap">
        <div style="line-height:1.25">)</div> </td> </tr>
  <tr>
    <td style="vertical-align:bottom;width:52%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="text-indent:-14.55pt;margin-left:14.55pt;line-height:1.25;font-weight:bold">BALANCE OF CASH, CASH EQUIVALENTS AND RESTRICTED
        CASH AT BEGINNING OF PERIOD</div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><ix:nonFraction id="F20241205041231073_63" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,645</ix:nonFraction></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><ix:nonFraction id="F20241205041231074_64" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,309</ix:nonFraction></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><ix:nonFraction id="F20241205041231075_65" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="C_20240630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,747</ix:nonFraction></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><ix:nonFraction id="F20241205041231075_66" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="C_20230630" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,491</ix:nonFraction></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align:bottom;width:52%;padding-bottom:4px;background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="text-indent:-14.55pt;margin-left:14.55pt;line-height:1.25;font-weight:bold">BALANCE OF CASH, CASH EQUIVALENTS AND RESTRICTED
        CASH AT END OF PERIOD</div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><ix:nonFraction id="F20241205041231076_67" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="C_20240930" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,023</ix:nonFraction></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(255, 255, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25">$</div> </div> </td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><ix:nonFraction id="F20241205041231077_68" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="C_20230930" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,812</ix:nonFraction></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(255, 255, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><ix:nonFraction id="F20241205041231078_69" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="C_20240930" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,023</ix:nonFraction></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(255, 255, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><ix:nonFraction id="F20241205041231079_70" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="C_20230930" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,812</ix:nonFraction></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(255, 255, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        </tr>
  </table>

<p style="margin:0pt 0pt 10pt">&#160;</p>

<p style="margin:0pt;text-align:center">F-48</p>

<div style="page-break-after:always"> <hr style="border-width:0px;clear:both;margin:4px 0px;width:100%;height:2px;color:#000000;background-color:#000000;margin-top:4pt;margin-bottom:10pt"/>
</div> </div>

<div style="line-height:1.25">&#160;</div>

<div style="line-height:1.25">

<p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:center"><strong>SILEXION
THERAPEUTICS CORP</strong><br/>UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</p> </div>

<div style="line-height:1.25">&#160;</div>

<table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left;color:#000000;width:100%">
  <tr>
    <td rowspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
    <td colspan="1" rowspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
    <td colspan="6" rowspan="1" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
        <div style="text-align:center;line-height:1.25;font-weight:bold">Nine months ended</div>
        <div style="line-height:1.25">
        <div style="text-align:center;line-height:1.25;font-weight:bold">September 30,</div> </div> </td>
    <td colspan="1" rowspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" rowspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
    <td colspan="6" rowspan="1" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="text-align:center;line-height:1.25;font-weight:bold">Three months ended</div>
        <div style="text-align:center;line-height:1.25;font-weight:bold">September 30</div> </div> </td>
    <td colspan="1" rowspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td> </tr>
  <tr>
    <td rowspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
    <td colspan="1" rowspan="1" style="font-weight:bold;text-align:center;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
    <td colspan="2" rowspan="1" style="vertical-align:bottom;font-weight:bold;text-align:center;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">2024</td>
    <td colspan="1" rowspan="1" style="font-weight:bold;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" rowspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
    <td colspan="2" rowspan="1" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="text-align:center;line-height:1.25;font-weight:bold">2023</div> </div> </td>
    <td colspan="1" rowspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" rowspan="1" style="font-weight:bold;text-align:center;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
    <td colspan="2" rowspan="1" style="vertical-align:bottom;font-weight:bold;text-align:center;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">2024</td>
    <td colspan="1" rowspan="1" style="font-weight:bold;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" rowspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
    <td colspan="2" rowspan="1" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="text-align:center;line-height:1.25;font-weight:bold">2023</div> </div> </td>
    <td colspan="1" rowspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td> </tr>
  <tr>
    <td rowspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
    <td colspan="1" rowspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
    <td colspan="6" rowspan="1" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="text-align:center;line-height:1.25;font-weight:bold">U.S. dollars in thousands</div> </div> </td>
    <td colspan="1" rowspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" rowspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
    <td colspan="6" rowspan="1" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="text-align:center;line-height:1.25;font-weight:bold;text-indent:8pt">U.S. dollars in thousands</div> </div> </td>
    <td colspan="1" rowspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-weight:bold"><span style="text-decoration:underline">Appendix A</span>&#160;&#8211; <span style="text-decoration:underline">RECONCILIATION
        OF CASH, CASH EQUIVALENTS AND RESTRICTED CASH REPORTED IN THE CONSOLIDATED BALANCE SHEETS:</span></div> </td>
    <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="2" style="vertical-align:top;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:bottom;width:52%;background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25">Cash and cash equivalents</div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25"><ix:nonFraction id="F20241205041231079_71" name="us-gaap:CashEquivalentsAtCarryingValue" contextRef="C_20240930" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,973</ix:nonFraction></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25"><ix:nonFraction id="F20241205041231080_72" name="us-gaap:CashEquivalentsAtCarryingValue" contextRef="C_20230930" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,764</ix:nonFraction></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25"><ix:nonFraction id="F20241205041231082_73" name="us-gaap:CashEquivalentsAtCarryingValue" contextRef="C_20240930" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,973</ix:nonFraction></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25"><ix:nonFraction id="F20241205041231083_74" name="us-gaap:CashEquivalentsAtCarryingValue" contextRef="C_20230930" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,764</ix:nonFraction></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align:bottom;width:52%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25">Restricted cash</div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><ix:nonFraction id="F20241205041231084_75" name="us-gaap:RestrictedCash" contextRef="C_20240930" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">50</ix:nonFraction></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><ix:nonFraction id="F20241205041231084_76" name="us-gaap:RestrictedCash" contextRef="C_20230930" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">48</ix:nonFraction></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><ix:nonFraction id="F20241205041231085_77" name="us-gaap:RestrictedCash" contextRef="C_20240930" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">50</ix:nonFraction></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><ix:nonFraction id="F20241205041231086_78" name="us-gaap:RestrictedCash" contextRef="C_20230930" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">48</ix:nonFraction></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align:bottom;width:52%;padding-bottom:4px;background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-weight:bold">TOTAL CASH, CASH EQUIVALENTS AND RESTRICTED CASH SHOWN IN STATEMENT OF CASH FLOWS</div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25">$</div> </div> </td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><ix:nonFraction id="F20241205041231087_79" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="C_20240930" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">2023</ix:nonFraction></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(255, 255, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25">$</div> </div> </td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><ix:nonFraction id="F20241205041231087_80" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="C_20230930" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,812</ix:nonFraction></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(255, 255, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25">$</div> </div> </td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><ix:nonFraction id="F20241205041231088_81" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="C_20240930" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">2023</ix:nonFraction></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(255, 255, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25">$</div> </div> </td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><ix:nonFraction id="F20241205041231089_82" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="C_20230930" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,812</ix:nonFraction></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(255, 255, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align:bottom;width:52%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align:bottom;width:52%;background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="text-align:justify;line-height:1.25"><span style="text-decoration:underline;font-weight:bold">Appendix B</span><span style="font-weight:bold">
        -</span>&#160;<span style="text-decoration:underline;font-weight:bold">SUPPLEMENTARY INFORMATION:</span></div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align:bottom;width:52%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-weight:bold">SUPPLEMENTARY INFORMATION ON INVESTING AND FINANCING ACTIVITIES NOT INVOLVING CASH FLOWS:</div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align:bottom;width:52%;background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25">Operating lease termination</div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25">$</div> </td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25">(<ix:nonFraction id="Fxbrl_20241112114431661_20241205041231099_95" name="slxn:OperatingLeaseTermination" contextRef="C_20240101to20240930" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">55</ix:nonFraction></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom;white-space:nowrap">
        <div style="line-height:1.25">)</div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25">$</div> </td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25"><ix:nonFraction id="Fxbrl_20241112114431661_20241205041231064_53" name="slxn:OperatingLeaseTermination" contextRef="C_20230101to20230930" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25">$</div> </td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25">(<ix:nonFraction id="Fxbrl_20241112114431661_20241205041231098_93" name="slxn:OperatingLeaseTermination" contextRef="C_20240701to20240930" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">55</ix:nonFraction></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom;white-space:nowrap">
        <div style="line-height:1.25">)</div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25">$</div> </td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25"><ix:nonFraction id="Fxbrl_20241112114431661_20241205041231065_54" name="slxn:OperatingLeaseTermination" contextRef="C_20230701to20230930" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align:bottom;width:52%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25">Conversion of preferred shares</div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25">$</div> </td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25"><ix:nonFraction id="Fxbrl_20241112114433728_20241205041231099_95" name="slxn:ConversionOfPreferredShares" contextRef="C_20240101to20240930" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">15,058</ix:nonFraction></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25">$</div> </td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25"><ix:nonFraction id="Fxbrl_20241112114433728_20241205041231064_53" name="slxn:ConversionOfPreferredShares" contextRef="C_20230101to20230930" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25">$</div> </td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25"><ix:nonFraction id="Fxbrl_20241112114433728_20241205041231098_93" name="slxn:ConversionOfPreferredShares" contextRef="C_20240701to20240930" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">15,058</ix:nonFraction></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25">$</div> </td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25"><ix:nonFraction id="Fxbrl_20241112114433728_20241205041231065_54" name="slxn:ConversionOfPreferredShares" contextRef="C_20230701to20230930" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align:bottom;width:52%;background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25">Conversion of warrants to preferred shares on a cashless basis</div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25">$</div> </td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25"><ix:nonFraction id="Fxbrl_20241112114435421_20241205041231099_95" name="slxn:ConversionOfWarrantsToPreferredSharesOnACashlessBasis" contextRef="C_20240101to20240930" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">334</ix:nonFraction></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25">$</div> </td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25"><ix:nonFraction id="Fxbrl_20241112114435421_20241205041231064_53" name="slxn:ConversionOfWarrantsToPreferredSharesOnACashlessBasis" contextRef="C_20230101to20230930" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25">$</div> </td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25"><ix:nonFraction id="Fxbrl_20241112114435421_20241205041231098_93" name="slxn:ConversionOfWarrantsToPreferredSharesOnACashlessBasis" contextRef="C_20240701to20240930" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">334</ix:nonFraction></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25">$</div> </td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25"><ix:nonFraction id="Fxbrl_20241112114435421_20241205041231065_54" name="slxn:ConversionOfWarrantsToPreferredSharesOnACashlessBasis" contextRef="C_20230701to20230930" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align:bottom;width:52%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25">Conversion of non-controlling interests</div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25">$</div> </td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25"><ix:nonFraction id="Fxbrl_20241112114436825_20241205041231099_95" name="us-gaap:ProceedsFromMinorityShareholders" contextRef="C_20240101to20240930" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,344</ix:nonFraction></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25">$</div> </td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25"><ix:nonFraction id="Fxbrl_20241112114436825_20241205041231064_53" name="us-gaap:ProceedsFromMinorityShareholders" contextRef="C_20230101to20230930" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25">$</div> </td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25"><ix:nonFraction id="Fxbrl_20241112114436825_20241205041231098_93" name="us-gaap:ProceedsFromMinorityShareholders" contextRef="C_20240701to20240930" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,344</ix:nonFraction></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25">$</div> </td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25"><ix:nonFraction id="Fxbrl_20241112114436825_20241205041231065_54" name="slxn:ConversionOfWarrantsToPreferredSharesOnACashlessBasis" contextRef="C_20230701to20230930" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align:bottom;width:52%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align:bottom;width:52%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25"><span style="font-weight:bold">SUPPLEMENTAL DISCLOSURES</span>&#160;<span style="font-weight:bold">OF CASH
        FLOW INFORMATION:</span></div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align:bottom;width:52%;padding-bottom:4px;background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25">Interest received</div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25">$</div> </div> </td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><ix:nonFraction id="F20241205041231090_83" name="us-gaap:InterestPaidNet" contextRef="C_20240101to20240930" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">25</ix:nonFraction></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(255, 255, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25">$</div> </div> </td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><ix:nonFraction id="F20241205041231090_84" name="us-gaap:InterestPaidNet" contextRef="C_20230101to20230930" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">120</ix:nonFraction></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(255, 255, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25">$</div> </div> </td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><ix:nonFraction id="F20241205041231091_85" name="us-gaap:InterestPaidNet" contextRef="C_20240701to20240930" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(255, 255, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25">$</div> </div> </td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><ix:nonFraction id="F20241205041231092_86" name="us-gaap:InterestPaidNet" contextRef="C_20230701to20230930" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">42</ix:nonFraction></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(255, 255, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        </tr>
  </table>

<p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:center">&#160;</p>

<p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:center"><strong>The accompanying
notes are an integral part of the unaudited condensed consolidated financial statements.</strong></p>

<p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:10pt;text-align:center">&#160;</p> </div>
</div> </div> </div> </div>

<p style="margin:0pt;text-align:center">F-49</p>

<div style="page-break-after:always"> <hr style="border-width:0px;clear:both;margin:4px 0px;width:100%;height:2px;color:#000000;background-color:#000000;margin-top:4pt;margin-bottom:10pt"/>
</div>

<div style="line-height:1.25">&#160;</div>

<div>

<div style="line-height:1.25">

<div>

<div style="text-align:center;margin-left:1pt;line-height:1.25">

<p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><strong><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>SILEXION
THERAPEUTICS CORP</span></span></span></span></span></span></strong></p>

<p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span id="FINANCIALSTATEMENTS"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>NOTES
TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) (continued)</span></span></span></span></span></span></span></p>

<p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>(U.S.
dollars in thousands)</span></span></span></span></span></span></p> </div> </div> </div>

<div>

<div style="text-align:center;line-height:1.25">&#160;</div> </div> <ix:nonNumeric id="F20241205041231125_10" name="us-gaap:NatureOfOperations" contextRef="C_20240101to20240930" escape="true">

<div>

<div style="line-height:1.25;font-weight:bold;margin-top:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">NOTE
1&#160; - GENERAL:</span></span></div>

<div>

<div>

<div style="line-height:1.25">&#160;</div>

<table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">
  <tr>
    <td style="width:72pt">&#160;</td>
    <td style="width:18pt;vertical-align:top;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">a.</span></span></td>
    <td style="width:auto;vertical-align:top;text-align:justify">
        <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Silexion Therapeutics Corp (&#8220;New Silexion&#8221;)
        (hereinafter -"the Company" or the &#8220;combined company&#8221;)&#160; is a newly formed entity that was formed for the purpose of effecting
        the Transactions (see below), and now serves as a publicly-traded holding company of its subsidiaries &#8212; including Moringa Acquisition
        Corp (&#8220;Moringa&#8221; or &#8220;the SPAC&#8221;), a Cayman Islands exempted company and Silexion Therapeutics Ltd. (formerly known
        as Silenseed Ltd.) (&#8220;Silexion&#8221;), an Israeli limited company&#8212; after the closing of the Transactions (the &#8220;Closing&#8221;).</span></span></div>
        </td> </tr>
  </table>

<div style="line-height:1.25">&#160;</div>

<table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">
  <tr>
    <td style="width:72pt">&#160;</td>
    <td style="width:18pt;vertical-align:top;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">b.</span></span></td>
    <td style="width:auto;vertical-align:top;text-align:justify">
        <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Financial Information Presented:</span></span></div>
        </td> </tr>
  </table>

<div style="text-align:justify;margin-left:90pt;line-height:1.25;font-family:'Times New Roman', Times, serif">&#160;</div>

<div style="text-align:justify;margin-left:90pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">From
its formation on April 2, 2024 until the consummation of the Transactions on August 15, 2024, the Company had no operations and had been
formed for the sole purpose of entering into the Transactions and serving as the publicly-traded company following the Transactions. Silexion,
on the other hand, as the accounting acquirer in the Transactions and the predecessor entity to the Company from an accounting perspective,
had active operations during earlier periods of time, prior to the Transactions. Consequently, these financial statements&#160;reflect
the information of Silexion (as the predecessor entity to the Company) until August 15, 2024 and the information of New Silexion (as the
combined company following the Transactions) from that date forward.</span></span></div>

<div style="line-height:1.25">&#160;</div>

<table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">
  <tr>
    <td style="width:72pt">&#160;</td>
    <td style="width:18pt;vertical-align:top;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">c.</span></span></td>
    <td style="width:auto;vertical-align:top;text-align:justify">
        <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Subsidiaries:</span></span></div> </td> </tr>
  </table>

<div style="text-align:justify;margin-left:90pt;line-height:1.25;font-family:'Times New Roman', Times, serif">&#160;</div>

<div style="text-align:justify;margin-left:90pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The
Company has three subsidiaries as of September 30, 2024:</span></span></div>

<div style="text-align:justify;margin-left:90pt;line-height:1.25;font-family:'Times New Roman', Times, serif">&#160;</div>

<table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">
  <tr>
    <td style="width:90pt">&#160;</td>
    <td style="width:18pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">1.</span></span></td>
    <td style="width:auto;vertical-align:top;text-align:justify">
        <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span style="text-decoration:underline">Silenseed
        (China) Ltd.</span> On April 28, 2021, Silexion (as the predecessor entity to the Company) signed an agreement with Guangzhou Sino-Israel
        Biotech Investment Fund (&#8220;GIBF&#8221;) to establish a new company in China. On June 15, 2021 a company was established in China,
        named Silenseed (China) Ltd. (hereinafter - the "Subsidiary"). As of September 30, 2024, following transfer of all interests in the Subsidiary
        to the Company as part of the Transactions, the Company owns (directly or indirectly) <ix:nonFraction id="F20241205041231125_1" name="us-gaap:MinorityInterestOwnershipPercentageByParent" contextRef="C_20240930_srtOwnershipAxis_slxnSilexionEquityFinancingMember" unitRef="pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">100</ix:nonFraction>%
        of the shares of the Subsidiary.&#160;The Subsidiary has no significant operations as of September 30, 2024 (see Note c).</span>&#160;</span></span></div>
        </td> </tr>
  </table>

<div style="line-height:1.25">&#160;</div>

<table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">
  <tr>
    <td style="width:90pt">&#160;</td>
    <td style="width:18pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2.</span></span></td>
    <td style="width:auto;vertical-align:top;text-align:justify">
        <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="text-decoration:underline">Moringa</span>.
        Prior to the Transactions, Moringa&#8217;s&#160; class A ordinary shares and warrants were listed for trading on the Nasdaq Capital Market
        (Nasdaq: MACA and MACAW). As part of the Transactions, Moringa merged with a wholly-owned subsidiary of the Company and now serves as
        an inactive, wholly-owned subsidiary of the Company.</span></span></div> </td> </tr>
  </table>

<div style="line-height:1.25">&#160;</div>

<table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">
  <tr>
    <td style="width:90pt">&#160;</td>
    <td style="width:18pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">3.</span></span></td>
    <td style="width:auto;vertical-align:top;text-align:justify">
        <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span style="text-decoration:underline">Silexion.</span>
        Silexion was incorporated in Israel and began its operations on November 30, 2008. Since its incorporation, Silexion has been engaged
        in <ix:nonFraction id="F20241205041231125_0" name="us-gaap:NumberOfOperatingSegments" contextRef="C_20240101to20240930" unitRef="Segment" scale="0" decimals="0" format="ixt-sec:numwordsen">one</ix:nonFraction>
        operating segment - the research and development of innovative treatments for pancreatic cancer based on siRNAs, aiming to stop the production
        of a specific pancreatic cancer-causing protein known as the KRAS mutation. Silexion&#8217;s long-lived assets are located in Israel.</span>.&#160;</span></span></div>
        </td> </tr>
  </table>

<div style="text-align:justify;text-indent:108pt;line-height:1.25">&#160;</div>

<table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">
  <tr>
    <td style="width:90pt">&#160;</td>
    <td style="width:18pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">4.</span></span></td>
    <td style="width:auto;vertical-align:top;text-align:justify">
        <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The Company, the Subsidiary, Moringa and Silexion
        are together referred to hereinafter as &#8220;the Group&#8221;.</span></span></div> </td> </tr>
  </table>

<div style="line-height:1.25">&#160;</div>

<table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">
  <tr>
    <td style="width:72pt">&#160;</td>
    <td style="width:18pt;vertical-align:top;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">d.</span></span></td>
    <td style="width:auto;vertical-align:top;text-align:justify">
        <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">On April 3, 2024, Silexion entered into an Amended
        and Restated Business Combination Agreement (hereinafter, &#8220;A&amp;R BCA&#8221;) with the SPAC, New Silexion, August M.S. Ltd. an
        Israeli company and wholly-owned subsidiary of New Silexion (&#8220;Merger Sub 1&#8221;), and Moringa Acquisition Merger Sub Corp, a Cayman
        Islands exempted company and wholly-owned subsidiary of New Silexion (&#8220;Merger Sub 2&#8221;). Under the A&amp;R BCA, both Silexion
        and the SPAC were toi become wholly-owned subsidiaries of New Silexion, which was to become&#160; a publicly-held, Nasdaq-listed entity
        (the A&amp;R BCA and related transactions: the &#8220;Transactions&#8221;).</span></span></div> </td> </tr>
  </table>

<div style="line-height:1.25">&#160;</div>

<div style="text-align:justify;margin-left:92.15pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">On
August 15, 2024, the parties completed the Transactions pursuant to which Merger Sub 2 merged with and into the SPAC, with the SPAC continuing
as the surviving company of such merger and a wholly-owned&#160;subsidiary of New Silexion (the &#8220;SPAC Merger&#8221;), and Merger
Sub 1 merged with and into Silexion, with Silexion continuing as the surviving company of such merger and a wholly-owned&#160;subsidiary
of New Silexion (the &#8220;Acquisition Merger&#8221;).</span></span></div>

<div><ix:exclude>

<div style="text-align:justify;margin-left:92.15pt;line-height:1.25;font-family:'Times New Roman', Times, serif">&#160;</div>

<div style="line-height:1.25;font-family:'Times New Roman', Times, serif">

<div style="margin-top:10pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">

<p style="text-align:center;margin-top:0pt;margin-bottom:3pt"><span style="width:34%;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">F-50</span></span></span></p></div><hr style="page-break-after:always;border-width:0px;clear:both;margin:4px 0px;width:100%;height:2px;color:#000000;background-color:#000000;margin-top:0pt;margin-bottom:10pt"/>

<p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:center">&#160;</p>

<p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:center"><strong>SILEXION
THERAPEUTICS CORP</strong><br/>NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) (continued)<br/>(U.S. dollars in thousands)</p>

<p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:center">&#160;</p><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">NOTE
1&#160; - GENERAL </span>(continued):</span></span> </div> </ix:exclude></div>

<div style="line-height:1.25">&#160;</div>

<div style="text-indent:-0.55pt;margin-left:92.7pt;line-height:1.25;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Upon
the effectiveness of the SPAC Merger, each outstanding SPAC Class&#160;A ordinary share and the sole outstanding SPAC Class&#160;B ordinary
share was converted into an ordinary share of New Silexion on a one-for-one&#160;basis. Each outstanding warrant to purchase one SPAC
Class&#160;A ordinary share was converted into a warrant to purchase one New Silexion ordinary share, at the same exercise price. Upon
the effectiveness of the Acquisition Merger, each outstanding ordinary share and each outstanding preferred share of Silexion was converted
into <ix:nonFraction id="Fxbrl_20241205122134930" name="us-gaap:DerivativeExchangeRateCap1" contextRef="C_20240815_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_slxnNewPubcoMember" unitRef="pure" scale="0" decimals="4" format="ixt:num-dot-decimal">3.9829</ix:nonFraction>
shares of New Silexion before adjustment for reverse share split (the &#8220;Silexion Equity Exchange Ratio&#8221;). See below for post
&#8211; reverse share split figures. Each outstanding Silexion warrant and Silexion option to purchase one Silexion share, and Silexion
restricted share unit (RSU) that may be potentially settled for one Silexion share, was to become exercisable for, or became subject to
settlement for (as applicable), such number of New Silexion ordinary shares as were equal to the Silexion Equity Exchange Ratio. The exercise
price per New Silexion ordinary share of each such converted Silexion option and Silexion warrant was to be adjusted based on dividing
the existing per share exercise price by the Silexion Equity Exchange Ratio. The terms of vesting, exercise and/or settlement, as applicable,
of such converted options, warrants and RSUs were to remain the same following such conversion, except that the vesting of each&#160;Silexion
option was to accelerate immediately prior to the Acquisition Merger, such that the New Silexion option into which it was to be converted
was to be fully vested, and all Silexion warrants were to be exercised (on a cashless basis) immediately prior to the Acquisition Merger.</span></span></div>

<div style="line-height:1.25">&#160;</div>

<div style="text-align:justify;margin-left:92.15pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Immediately
prior to the Closing seven directors were elected to New Silexion&#8217;s board of directors, of whom five were designated by Silexion
and two were designated by the SPAC&#8217;s sponsor (the &#8220;Sponsor&#8221;).</span></span></div>

<div style="line-height:1.25">&#160;</div>

<div style="text-align:justify;margin-left:92.15pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The
A&amp;R BCA also required, as a closing condition, the transfer of the remaining outstanding shares of the Subsidiary held by GIBF to
Silexion prior to the closing of the Business Combination in exchange for the issuance to GIBF of shares of Silexion, which were to be
converted into ordinary shares of New Silexion in accordance with the Silexion Equity Exchange Ratio upon the closing.</span></span></div>

<div style="line-height:1.25">&#160;</div>

<table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">
  <tr>
    <td style="width:72pt">&#160;</td>
    <td style="width:18pt;vertical-align:top;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">e.</span></span></td>
    <td style="width:auto;vertical-align:top;text-align:justify">
        <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">In connection with the closing of the Transactions,
        the ordinary shares and warrants of New Silexion are now listed on the Nasdaq Global Market and began trading under the symbols &#8220;SLXN&#8221;
        and &#8220;SLXNW&#8221;, respectively.</span></span></div> </td> </tr>
  </table>

<div style="line-height:1.25">&#160;</div>

<table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">
  <tr>
    <td style="width:72pt">&#160;</td>
    <td style="width:18pt;vertical-align:top;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">f.</span></span></td>
    <td style="width:auto;vertical-align:top;text-align:justify">
        <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">For more information on instruments issued as
        part of the Transactions, see Note 3.</span></span></div> </td> </tr>
  </table>

<div style="line-height:1.25">&#160;</div>

<table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">
  <tr>
    <td style="width:72pt">&#160;</td>
    <td style="width:18pt;vertical-align:top;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">g.</span></span></td>
    <td style="width:auto;vertical-align:top;text-align:justify">
        <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The Transactions were accounted for as a reverse
        recapitalization in accordance with US GAAP.&#160;Under this method of accounting, Silexion was treated as the accounting acquirer and
        the SPAC was treated as the &#8220;acquired&#8221; company for financial reporting purposes. Silexion was determined to be the accounting
        acquirer based on evaluation of the following facts and circumstances:</span></span></div> </td> </tr>
  </table>

<div style="line-height:1.25">&#160;</div>

<div style="text-indent:-21.25pt;margin-left:113.4pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">&#8226;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Silexion&#8217;s
shareholders were to hold approximately <ix:nonFraction id="F20241205041231125_2" name="us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired" contextRef="C_20240930_usgaapBusinessAcquisitionAxis_slxnNewPubcoMember" unitRef="pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">61.55</ix:nonFraction>%
of the outstanding voting interests in New Silexion upon the closing of the Transactions;</span></span></div>

<div style="text-indent:-21.25pt;margin-left:113.4pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">&#8226;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Silexion&#8217;s
senior management were to comprise the senior management of New Silexion;</span></span></div>

<div style="text-indent:-21.25pt;margin-left:113.4pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">&#8226;&#160;&#160;&#160;&#160;&#160;&#160;&#160;the
directors nominated by Silexion were to constitute a majority of the board of directors of New Silexion (five out of seven of the initial
directors);</span></span></div>

<div style="text-indent:-21.25pt;margin-left:113.4pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">&#8226;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Silexion&#8217;s
operations were to comprise the ongoing operations of New Silexion; and</span></span></div>

<div style="text-indent:-21.25pt;margin-left:113.4pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">&#8226;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Silexion&#8217;s
name was to be the name used by New Silexion (in replacement of Biomotion Sciences).</span></span></div>

<div style="line-height:1.25">&#160;</div>

<div style="text-align:justify;margin-left:90pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Under
the reverse recapitalization accounting method, the Transactions were deemed to be the equivalent of a capital transaction in which Silexion
issued shares for the net assets of the SPAC. The net assets of the SPAC were stated at fair value, with no goodwill or other intangible
assets recorded. Operations prior to the Transactions are those of Silexion.</span></span></div>

<div><ix:exclude>

<div style="text-align:justify;margin-left:90pt;line-height:1.25;font-family:'Times New Roman', Times, serif">&#160;</div>

<div style="line-height:1.25;font-family:'Times New Roman', Times, serif">

<div style="margin-top:10pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">

<p style="text-align:center;margin-top:0pt;margin-bottom:3pt"><span style="width:34%;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">F-51</span></span></span></p></div><hr style="page-break-after:always;border-width:0px;clear:both;margin:4px 0px;width:100%;height:2px;color:#000000;background-color:#000000;margin-top:0pt;margin-bottom:10pt"/>

<p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:center">&#160;</p>

<p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:center"><strong>SILEXION
THERAPEUTICS CORP</strong><br/>NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) (continued)<br/>(U.S. dollars in thousands)</p>

<p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:center">&#160;</p><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">NOTE
1&#160; - GENERAL </span>(continued):</span></span> </div> </ix:exclude></div>

<div style="line-height:1.25">&#160;</div>

<div style="text-align:justify;margin-left:90pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">In
accordance with the applicable guidance to reverse recapitalization, the equity structure has been retroactively adjusted in all comparative
periods up to the date of the Closing (the &#8220;Closing Date&#8221;), to reflect the number of New Silexion&#8217;s Ordinary Shares,
$<ix:nonFraction id="Fxbrl_20241205122726545" name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="C_20240930_usgaapBusinessAcquisitionAxis_slxnNewPubcoMember" unitRef="usdPershares" scale="0" decimals="4" format="ixt:num-dot-decimal">0.0001</ix:nonFraction>&#160;par
value per share issued to legacy Silexion shareholders in connection with the reverse recapitalization transaction. As such, the shares
and corresponding capital amounts and earnings per share related to legacy Silexion shareholders prior to the reverse recapitalization
have been retroactively restated as shares reflecting the exchange ratio established pursuant to the Transactions. In conjunction with
the reverse recapitalization, Silexion&#8217;s Ordinary Shares underwent a <ix:nonNumeric id="Fxbrl_20241205122737857" name="slxn:StockConversionRatio" contextRef="C_20240101to20240930">1-for-3.9829</ix:nonNumeric>&#160;conversion.
After adjustment for the reverse share split, the conversion rate is <ix:nonNumeric id="Fxbrl_20241205141009742" name="slxn:ReverseStockSplitConversionRate" contextRef="C_20240101to20240930">0.4425</ix:nonNumeric>
New Silexion Ordinary Shares, $<ix:nonFraction id="Fxbrl_20241205141033552" name="slxn:ReverseStockSplitConversionPrice" contextRef="C_20240101to20240930" unitRef="usdPershares" scale="0" decimals="4" format="ixt:num-dot-decimal">0.0009</ix:nonFraction>
par value, for each legacy Silexion share.</span></span></div>

<div style="line-height:1.25">&#160;</div>

<div style="text-align:justify;margin-left:90pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">On
November 19, 2024, the Company&#8217;s shareholders approved a <ix:nonNumeric id="Fxbrl_20241205141053798" name="slxn:ReverseStockSplitConversionRatio" contextRef="C_20240101to20240930">1-for-9</ix:nonNumeric>
reverse share split of the Company&#8217;s Ordinary Shares. On November 29, 2024, the reverse share split became effective. All references
made to Ordinary Shares, preferred shares and per share amounts (both of the Company and New Silexion) in these unaudited consolidated
financial statements, unless otherwise indicated, have been retroactively adjusted to reflect the reverse share split.</span></span></div>

<div style="line-height:1.25">&#160;</div>

<table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">
  <tr>
    <td style="width:72pt">&#160;</td>
    <td style="width:18pt;vertical-align:top;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">h.</span></span></td>
    <td style="width:auto;vertical-align:top;text-align:justify">
        <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">In October 2023, Hamas terrorists infiltrated
        Israel&#8217;s southern border from the Gaza Strip and conducted a series of attacks on civilian and military targets. Following the attack,
        Israel&#8217;s security cabinet declared war against Hamas and commenced a military campaign against Hamas and other terrorist organizations.</span></span></div>
        </td> </tr>
  </table>

<div style="line-height:1.25">&#160;</div>

<div style="text-align:justify;margin-left:92.15pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">In
parallel, there have been continued hostilities along Israel&#8217;s northern border, as the Hezbollah terrorist organization based in
Lebanon has conducted rocket, drone, and, more recently, missile attacks against Israel. The hostilities with Hezbollah have escalated
recently, prompting Israel to send its ground forces into southern Lebanon to destroy terrorist positions and infrastructure used by Hezbollah
for attacks on northern and&#160;</span></span><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">central
Israel, which had caused the displacement of residents in northern Israel since early in the war. There have also been rocket, drone and
missile attacks against Israel by the Houthi movement in Yemen and from Iran.&#160;</span></span></div>

<div style="line-height:1.25">&#160;</div>

<div style="text-align:justify;margin-left:90pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The
Company&#8217;s headquarters are located in the central region of Israel. As of the issuance date of these consolidated financial statements,
these conflicts have not had a material impact on the Company&#8217;s results of operations or financial position, if at all. The Company
cannot currently predict the intensity or duration of Israel&#8217;s war, however, as most of the Company&#8217;s trials are not executed
in Israel, the Company does not believe the recent terrorist attack and the subsequent escalation will have any material impact on its
ongoing operations. The Company continues to monitor its ongoing activities and will make any needed adjustments to ensure continuity
of its business, while supporting the safety and well-being of its employees.</span></span></div>

<div style="line-height:1.25">&#160;</div>

<div style="text-align:justify;margin-left:90pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Any
hostilities involving Israel, or the interruption or curtailment of trade within Israel or between Israel and its trading partners could
adversely affect the Company&#8217;s operations and results of operations and could make it more difficult for the Company to raise capital.</span></span></div>

<div style="line-height:1.25">&#160;</div>

<table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">
  <tr>
    <td style="width:72pt">&#160;</td>
    <td style="width:18pt;vertical-align:top;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">i.</span></span></td>
    <td style="width:auto;vertical-align:top;text-align:justify">
        <div style="font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Going concern:</span></span></div>
        </td> </tr>
  </table>

<div style="line-height:1.25">&#160;</div>

<div style="text-align:justify;margin-left:90pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Since
its inception, the Company (and, prior to the Transactions, its predecessor, Silexion) has devoted substantially all its efforts to research
and development, clinical trials, and capital raising activities. The Company is still in its development and clinical stage and has not
yet generated revenues.</span></span></div>

<div style="line-height:1.25">&#160;</div>

<div style="text-align:justify;margin-left:90pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The
Company (or, for those periods prior to the Transactions, its predecessor, Silexion) has incurred losses of $<ix:nonFraction id="F20241205041231125_3" name="us-gaap:InterestCostsIncurred" contextRef="C_20240101to20240930" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">14,772</ix:nonFraction>
and $<ix:nonFraction id="F20241205041231125_4" name="us-gaap:InterestCostsIncurred" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,108</ix:nonFraction>
for the nine-months period ended on September 30, 2024 and for the year ended December 31, 2023, respectively. During the nine-month period
ended on September 30, 2024, the Company (including Silexion, for periods prior to the Transactions) had negative operating cash flows
of $<ix:nonFraction id="F20241205041231125_5" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="C_20240101to20240930" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">5,470</ix:nonFraction>.
As of September 30, 2024, the Company had cash and cash equivalents of $<ix:nonFraction id="F20241205041231125_6" name="us-gaap:CashEquivalentsAtCarryingValue" contextRef="C_20240930" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,973</ix:nonFraction>.&#160;On
August 15, 2024, Silexion completed a business combination with the SPAC.</span></span></div>

<div><ix:exclude>

<div style="line-height:1.25">

<div style="line-height:1.25">&#160;</div>

<div style="margin-top:10pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">

<p style="text-align:center;margin-top:0pt;margin-bottom:3pt"><span style="width:34%;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">F-52</span></span></span></p></div><hr style="page-break-after:always;border-width:0px;clear:both;margin:4px 0px;width:100%;height:2px;color:#000000;background-color:#000000;margin-top:0pt;margin-bottom:10pt"/>

<p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:center">&#160;</p>

<p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:center"><strong>SILEXION
THERAPEUTICS CORP</strong><br/>NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) (continued)<br/>(U.S. dollars in thousands)</p>

<p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:center">&#160;</p> </div>

<div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">NOTE
1&#160; - GENERAL </span>(continued):</span></span></div> </ix:exclude></div>

<div style="line-height:1.25">

<div style="line-height:1.25">&#160;</div>

<table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">
  <tr>
    <td style="width:64.25pt">&#160;</td>
    <td style="width:28.45pt;vertical-align:top;font-weight:bold">&#160;</td>
    <td style="width:auto;vertical-align:top">
        <div style="font-family:'Times New Roman',Times,serif;font-weight:bold">
        <div style="text-align:justify;line-height:1.25;font-weight:normal"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The
        Company expects to continue incurring losses, and negative cash flows from operations. Management is in the process of evaluating various
        financing alternatives, as the Company will need to finance future research and development activities, general and administrative expenses
        and working capital through fund raising. However, there is no assurance that the Company will be successful in obtaining such funding.</span></span></div>
        <div style="line-height:1.25;font-weight:normal">&#160;</div>
        <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:normal">Under
        these circumstances, in accordance with the requirements of ASC 205-40, management has concluded that there is substantial doubt about
        the Company&#8217;s ability to continue as a going concern for at least 12 months from the date these financial statements are issued.
        The unaudited condensed consolidated financial statements do not include any adjustments that may be necessary should the Company be unable
        to continue as a going concern (see Note 1 (d)).</span></span></span></div> </div> </td> </tr>
  </table> </div> </div> </div> </div> </ix:nonNumeric>

<p style="margin:0pt">&#160;</p> </div>

<div> <ix:nonNumeric id="F20241205041231132_12" name="us-gaap:SignificantAccountingPoliciesTextBlock" contextRef="C_20240101to20240930" escape="true">

<div>

<div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">NOTE
2&#160; - SIGNIFICANT ACCOUNTING POLICIES:</span></span></div>

<div style="line-height:1.25">&#160;</div> <ix:nonNumeric id="F20241205041231132_8" name="slxn:UnauditedCondensedFinancialStatementsPolicyTextBlock" contextRef="C_20240101to20240930" escape="true">

<div>

<table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">
  <tr>
    <td style="width:64.25pt">&#160;</td>
    <td style="vertical-align:top;width:28.45pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">a.</span></span></span></td>
    <td style="vertical-align:top;width:auto">
        <div style="font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Unaudited Condensed Financial
        Statements</span></span></div> </td> </tr>
  </table>

<div style="line-height:1.25">&#160;</div>

<div style="margin:0px 0px 0px 92.7pt;line-height:1.25;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The
accompanying condensed financial statements are unaudited. These unaudited interim condensed consolidated financial statements have been
prepared in accordance with generally accepted accounting principles in the United States of America ("U.S. GAAP") for interim financial
statements and follow the requirements of the Securities and Exchange Commission (&#8220;SEC&#8221;) for interim financial reporting.
Accordingly, they do not include all of the information and notes required by U.S. GAAP for annual financial statements. In the opinion
of management, these unaudited condensed consolidated financial statements reflect all adjustments, which include normal recurring adjustments,
necessary for a fair statement of the Company&#8217;s consolidated financial position as of September 30, 2024, and the consolidated results
of operations, statements of changes in redeemable convertible preferred shares and capital deficiency and cash flows for the nine-month
and three-month periods ended September 30, 2024 and 2023.</span></span></div>

<div style="line-height:1.25;margin-left:92.7pt">&#160;</div>

<div style="margin:0px 0px 0px 92.7pt;line-height:1.25;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The
consolidated results for the nine-months ended September 30, 2024 are not necessarily indicative of the results to be expected for the
year ending December 31, 2024.</span></span></div>

<div style="text-align:justify;margin-left:92.7pt;line-height:1.25">&#160;</div>

<div style="margin:0px 0px 0px 92.7pt;line-height:1.25;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">These
unaudited interim condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements
of Silexion as of and for the year ended December 31, 2023, which are included in a current report on Form 8-K and in a registration statement
on Form S-1/A which the Company is filing with the SEC presently. The significant accounting policies adopted and used in the preparation
of the financial statements are consistent with those of the previous financial year.</span></span></div> </div> </ix:nonNumeric>

<div style="line-height:1.25">&#160;</div> <ix:nonNumeric id="F20241205041231131_2" name="us-gaap:UseOfEstimates" contextRef="C_20240101to20240930" escape="true">

<div>

<table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">
  <tr>
    <td style="width:64.25pt">&#160;</td>
    <td style="vertical-align:top;font-weight:bold;width:28.45pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">b.</span></span></td>
    <td style="vertical-align:top;width:auto">
        <div style="font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Use of estimates</span></span></div>
        </td> </tr>
  </table>

<div style="line-height:1.25">&#160;</div>

<div style="margin:0px 0px 0px 92.7pt;line-height:1.25;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The
preparation of the financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect
the amounts reported in the financial statements and accompanying notes. As applicable to these financial statements, the most significant
estimates and assumptions relate share-based compensation&#160;and to fair value of financial instruments. See Note 6 and Notes 4 and
7, respectively. These estimates and assumptions are based on current facts, future expectations, and various other factors believed to
be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and
liabilities and the recording of expenses that are not readily apparent from other sources. Actual results may differ materially and adversely
from these estimates.</span></span></div> </div> </ix:nonNumeric>

<div style="line-height:1.25">&#160;</div>

<div><ix:exclude>

<div style="text-align:justify;line-height:1.25">

<div style="line-height:1.25">

<div style="clear:both;margin-top:0pt;margin-bottom:0pt">

<div style="margin-top:10pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">

<p style="text-align:center;margin-top:0pt;margin-bottom:3pt"><span style="width:34%;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">F-53</span></span></span></p></div><hr style="page-break-after:always;border-width:0px;clear:both;margin:4px 0px;width:100%;height:2px;color:#000000;background-color:#000000;margin-top:0pt;margin-bottom:10pt"/>

<p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:center">&#160;</p>

<p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:center"><strong>SILEXION
THERAPEUTICS CORP</strong><br/>NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) (continued)<br/>(U.S. dollars in thousands)</p>

<p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:center">&#160;</p>

<div style="text-align:left;margin-top:0px;margin-bottom:0px"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">NOTE
2&#160; - SIGNIFICANT ACCOUNTING POLICIES </span>(continued):</span></span></div>

<div style="text-align:justify;line-height:1.25;margin-top:0px;margin-bottom:0px">&#160;</div> </div> </div> </div> </ix:exclude></div>
<ix:nonNumeric id="F20241205041231131_3" name="us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" contextRef="C_20240101to20240930" escape="true">

<div>

<table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">
  <tr>
    <td style="width:64.25pt">&#160;</td>
    <td style="vertical-align:top;font-weight:bold;width:28.45pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">c.</span></span></td>
    <td style="vertical-align:top;width:auto">
        <div style="font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Restricted cash</span></span></div>
        </td> </tr>
  </table>

<div style="margin:0px 0px 0px 69.15pt;line-height:1.25;text-align:justify">&#160;</div>

<div style="margin:0px 0px 0px 92.7pt;line-height:1.25;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">As
of September 30, 2024 and December 31, 2023, the Company pledged an amount of $<ix:nonFraction id="F20241205041231132_14" name="us-gaap:OperatingLeasePayments" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal"><ix:nonFraction id="F20241205041231132_9" name="us-gaap:OperatingLeasePayments" contextRef="C_20240101to20240930" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">25</ix:nonFraction></ix:nonFraction>
in favor of a bank as collateral for guarantees provided to secure the lease payments.</span></span></div>

<div style="line-height:1.25">&#160;</div>

<div style="margin:0px 0px 0px 92.7pt;line-height:1.25;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The
Company is required to hold a minimum amount of NIS <ix:nonFraction id="F20241205041231132_13" name="us-gaap:LineOfCredit" contextRef="C_20240930" unitRef="NIS" scale="3" decimals="-3" format="ixt:num-dot-decimal">85</ix:nonFraction>
in its bank account in order to maintain availability of a credit line from its credit card company.&#160;</span></span></div> </div>
</ix:nonNumeric>

<div style="margin-left:92.7pt;line-height:1.25">&#160;</div> <ix:nonNumeric id="F20241205041231132_4" name="us-gaap:FairValueMeasurementPolicyPolicyTextBlock" contextRef="C_20240101to20240930" escape="true">

<div>

<table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">
  <tr>
    <td style="width:64.25pt">&#160;</td>
    <td style="vertical-align:top;font-weight:bold;width:28.45pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">d.</span></span></td>
    <td style="vertical-align:top;width:auto">
        <div style="font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Fair value measurement</span></span></div>
        </td> </tr>
  </table>

<div style="line-height:1.25">&#160;</div>

<div style="margin:0px 0px 0px 92.7pt;line-height:1.25;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Fair
value is based on the price that would be received from the sale of an asset or that would be paid to transfer a liability in an orderly
transaction between market participants at the measurement date. In order to increase consistency and comparability in fair value measurements,
the guidance establishes a fair value hierarchy that prioritizes observable and unobservable inputs used to measure fair value into three
broad levels, which are described as follows:</span></span></div>

<div style="line-height:1.25">&#160;</div>

<table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">
  <tr>
    <td style="width:92pt">&#160;</td>
    <td style="vertical-align:top;width:63pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Level 1:</span></span></td>
    <td style="vertical-align:top;text-align:justify;width:auto">
        <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Quoted prices (unadjusted) in active markets that
        are accessible at the measurement date for assets or liabilities. The fair value hierarchy gives the highest priority to Level 1 inputs.</span></span></div>
        </td> </tr>
  </table>

<div style="line-height:1.25">&#160;</div>

<table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">
  <tr>
    <td style="width:92.7pt">&#160;</td>
    <td style="vertical-align:top;width:63pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Level 2:</span></span></td>
    <td style="vertical-align:top;text-align:justify;width:auto">
        <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Observable prices that are based on inputs not
        quoted on active markets, but corroborated by market data or active market data of similar or identical assets or liabilities.</span></span></div>
        </td> </tr>
  </table>

<div style="line-height:1.25">&#160;</div>

<table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">
  <tr>
    <td style="width:92.7pt">&#160;</td>
    <td style="vertical-align:top;width:63pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Level 3</span></span></td>
    <td style="vertical-align:top;text-align:justify;width:auto">
        <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Unobservable inputs are used when little or no
        market data is available. The fair value hierarchy gives the lowest priority to Level 3 inputs.</span></span></div> </td> </tr>
  </table>

<div style="line-height:1.25">&#160;</div>

<div style="margin:0px 0px 0px 92.7pt;line-height:1.25;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">In
determining fair value, the Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable
inputs to the extent possible and considers counterparty credit risk in its assessment of fair value.</span></span></div> </div> </ix:nonNumeric>

<div style="line-height:1.25">&#160;</div> <ix:nonNumeric id="F20241205041231132_5" name="us-gaap:ConcentrationRiskDisclosureTextBlock" contextRef="C_20240101to20240930" escape="true">

<div>

<table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">
  <tr>
    <td style="width:64.25pt">&#160;</td>
    <td style="vertical-align:top;font-weight:bold;width:28.45pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">e.</span></span></td>
    <td style="vertical-align:top;width:auto">
        <div style="font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Concentration of credit
        risks</span></span></div> </td> </tr>
  </table>

<div style="line-height:1.25">&#160;</div>

<div style="margin:0px 0px 0px 92.7pt;line-height:1.25;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Financial
instruments that potentially subject the Company to concentration of credit risk consist principally of cash and cash equivalents, restricted
cash and short-term deposits. The Company deposits cash and cash equivalents mostly with three low risk financial institution. The Company
has not experienced any material credit losses in these accounts and does not believe it is exposed to significant credit risk on these
instruments.</span></span></div> </div> </ix:nonNumeric>

<div style="line-height:1.25">&#160;</div> <ix:nonNumeric id="F20241205041231132_6" name="us-gaap:EarningsPerSharePolicyTextBlock" contextRef="C_20240101to20240930" escape="true">

<div>

<table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">
  <tr>
    <td style="width:64.25pt">&#160;</td>
    <td style="vertical-align:top;font-weight:bold;width:28.45pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">f.</span></span></td>
    <td style="vertical-align:top;width:auto">
        <div style="font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Loss per share</span></span></div>
        </td> </tr>
  </table>

<div style="line-height:1.25">&#160;</div>

<div style="margin:0px 0px 0px 92.7pt;line-height:1.25;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The
Company calculates loss per share using the two-class&#160;method required for participating securities. This method entails allocating
income available to ordinary shareholders for the period between ordinary shares and participating securities based on their respective
rights to receive dividends as if all income for the period had been distributed. Basic loss per share is computed by dividing net loss
by the weighted average number of ordinary shares outstanding during the year, and fully vested pre-funded&#160;options for the Company&#8217;s
ordinary shares at an exercise price of $<ix:nonFraction id="F20241205041231131_0" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" contextRef="C_20240101to20240930" unitRef="usdPershares" scale="0" decimals="3" format="ixt:num-dot-decimal">0.027</ix:nonFraction>
or <ix:nonFraction id="F20241205041231131_1" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" contextRef="C_20240101to20240930" unitRef="ilsPershares" scale="0" decimals="4" format="ixt:num-dot-decimal">0.0063</ix:nonFraction>
NIS per share. The Company considers these shares to be exercisable for little to no additional consideration. The Company also considers
its redeemable convertible preferred shares to be participating securities as the holders of the redeemable convertible preferred shares
would be entitled to dividends that would be distributed to the holders of ordinary shares, on a pro-rata&#160;basis assuming conversion
of all redeemable convertible preferred shares into ordinary shares. However, these participating securities do not contractually require
the holders to participate in the Company&#8217;s losses. Consequently, net loss for the periods presented was not allocated to the Company&#8217;s
participating securities.&#160;The Ordinary Shares issued as a result of the Redeemable Convertible Preferred Shares conversion on the
Closing Date were included in the basic net loss per share calculation on a prospective basis.</span></span></div> </div> </ix:nonNumeric>

<div style="line-height:1.25">&#160;</div>

<div><ix:exclude>

<div style="line-height:1.25">

<div style="margin-top:10pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">

<p style="text-align:center;margin-top:0pt;margin-bottom:3pt"><span style="width:34%;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">F-54</span></span></span></p></div><hr style="page-break-after:always;border-width:0px;clear:both;margin:4px 0px;width:100%;height:2px;color:#000000;background-color:#000000;margin-top:0pt;margin-bottom:10pt"/>

<p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:center">&#160;</p>

<p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:center"><strong>SILEXION
THERAPEUTICS CORP</strong><br/>NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) (continued)<br/>(U.S. dollars in thousands)</p>

<p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:center">&#160;</p> </div>

<div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">NOTE
2&#160; - SIGNIFICANT ACCOUNTING POLICIES </span>(continued):</span></span></div>

<div style="line-height:1.25">&#160;</div> </ix:exclude></div>

<div> <ix:nonNumeric id="F20241205041231132_11" name="slxn:ContractsOverOrdinarySharesPolicyTextBlock" contextRef="C_20240101to20240930" escape="true">

<div>

<table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">
  <tr>
    <td style="vertical-align:top;font-weight:bold;width:64.25pt">&#160;</td>
    <td style="vertical-align:top;font-weight:bold;width:28.45pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">g.</span></span></td>
    <td style="vertical-align:top;text-align:justify;width:auto">
        <div style="font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Contracts over Ordinary
        Shares</span></span></div> </td> </tr>
  </table>

<div style="line-height:1.25">&#160;</div>

<div style="margin:0px 0px 0px 92.7pt;line-height:1.25;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">When
the Company becomes party to freestanding convertible instruments, the Company first analyzes the provisions of ASC 480 in order to determine
whether the instrument should be classified as a liability, with subsequent changes in fair value recognized in the statements of operations
in each period. Warrants to purchase Ordinary Shares are not within the scope of ASC 480, and as such the Company further analyzes the
provisions of ASC 815-40 in order to determine whether the contract should be classified within equity or classified as a liability, with
subsequent changes in fair value recognized in the statements of operations in each period.</span></span></div>

<div style="text-align:justify;line-height:1.25;margin-left:92.7pt">&#160;</div>

<div style="margin:0px 0px 0px 92.7pt;line-height:1.25;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Under&#160;ASC
815-40, contracts that are not indexed to the Company&#8217;s own stock are classified as liabilities recorded at fair value, As such,
the Company classifies private warrants (see Note 3(e)) as liabilities and measures them at their fair value at each reporting period.
This liability is subject to re-measurement at each balance sheet date until the private warrants are exercised or expire, or upon reassessment
of classification. Similarly the Company classifies the ELOC Agreement entered into (see Note 3(d)) as a derivative instrument measured
at fair value at each reporting period, as settlement provisions under this agreement are not indexed to the Company&#8217;s own stock.</span></span></div>

<div style="line-height:1.25;margin-left:92.7pt">&#160;</div>

<div style="margin:0px 0px 0px 92.7pt;line-height:1.25;text-align:justify">

<p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The
Company reassesses the classification of a contract over its own equity under the guidance above at each balance sheet date. If classification
changes as a result of events during the reporting period, the Company reclassifies the contract as of the date of the event that caused
the reclassification. When a contract over own equity is reclassified from a liability to equity, gains or losses recorded to account
for the contract at fair value during the period that the contract was classified as a liability are not reversed, and the contract is
marked to fair value immediately before the reclassification. The Redeemable Convertible Preferred Shares were converted into Ordinary
Shares in the framework of the recapitalization transaction as described in note 1(d).</span></span></p> </div> </div> </ix:nonNumeric>
</div>

<div style="line-height:1.25">&#160;</div> <ix:nonNumeric id="F20241205041231132_10" name="slxn:PromissoryNotesPolicyTextBlock" contextRef="C_20240101to20240930" escape="true">

<div>

<table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">
  <tr>
    <td style="width:64.25pt">&#160;</td>
    <td style="vertical-align:top;font-weight:bold;width:28.45pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">h.</span></span></td>
    <td style="vertical-align:top;text-align:justify;width:auto">
        <div style="font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Promissory Notes</span></span></div>
        </td> </tr>
  </table>

<div style="line-height:1.25">&#160;</div>

<div style="margin:0px 0px 0px 92.7pt;line-height:1.25;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Under
the Fair Value Option Subsection of ASC Subtopic 825-10, the Company has an irrevocable option to designate certain financial liabilities
at fair value on an instrument-by-instrument basis, with changes in fair value reported in the statement of operations. The Company designated
Promissory Notes issued as part of the Transactions under the fair value option. See Note 3(a) and (b).</span></span></div> </div> </ix:nonNumeric>

<div style="line-height:1.25">&#160;</div>

<div><ix:exclude>

<div style="line-height:1.25">

<div>

<div style="line-height:1.25">

<div>

<div style="margin-top:10pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">

<p style="text-align:center;margin-top:0pt;margin-bottom:3pt"><span style="width:34%;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">F-55</span></span></span></p></div><hr style="page-break-after:always;border-width:0px;clear:both;margin:4px 0px;width:100%;height:2px;color:#000000;background-color:#000000;margin-top:0pt;margin-bottom:10pt"/>

<p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:center">&#160;</p>

<p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:center"><strong>SILEXION
THERAPEUTICS CORP</strong><br/>NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) (continued)<br/>(U.S. dollars in thousands)</p>

<p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:center">&#160;</p> </div>
</div>

<div style="line-height:1.25"><span style="font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-weight:bold">NOTE
2&#160; - SIGNIFICANT ACCOUNTING POLICIES </span>(continued):</span></div>

<div style="line-height:1.25">&#160;</div> </div> </div> </ix:exclude></div> <ix:nonNumeric id="F20241205041231132_7" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" contextRef="C_20240101to20240930" escape="true">

<div>

<table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">
  <tr>
    <td style="width:64.25pt">&#160;</td>
    <td style="vertical-align:top;font-weight:bold;width:28.45pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">i.</span></span></td>
    <td style="vertical-align:top;width:auto">
        <div style="font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">New accounting pronouncements:</span></span></div>
        </td> </tr>
  </table>

<div style="line-height:1.25">&#160;</div>

<div style="margin:0px 0px 0px 92.7pt;line-height:1.25;text-align:justify;font-weight:bold;font-style:italic"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="text-decoration:underline">Recently
issued accounting standards not yet adopted:</span></span></span></div>

<div style="line-height:1.25">&#160;</div>

<table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">
  <tr>
    <td style="width:92.7pt">&#160;</td>
    <td style="vertical-align:top;width:18pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">1)</span></span></td>
    <td style="vertical-align:top;text-align:justify;width:auto">
        <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">In November 2023, the FASB issued ASU No. 2023-07&#160;Segment
        Reporting (Topic 280): Improvements to Reportable Segment Disclosures. The ASU improves reportable segments disclosure requirements, primarily
        through enhanced disclosures about significant segment expenses.&#160; The ASU also require that a public entity that has a single reportable
        segment to provide all the disclosures required by the amendments and all existing segment disclosures in Topic 280.&#160;The ASU is effective
        for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024.&#160;The
        Company is currently evaluating this ASU to determine its impact on the Company's segment disclosures.</span></span></div> </td> </tr>
  </table>

<div style="line-height:1.25">&#160;</div>

<table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">
  <tr>
    <td style="width:92.7pt">&#160;</td>
    <td style="vertical-align:top;width:18pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2)</span></span></td>
    <td style="vertical-align:top;text-align:justify;width:auto">
        <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">In December 2023, the FASB issued ASU No. 2023-09,
        Improvements to Income Tax Disclosures, which requires disclosure of disaggregated income taxes paid, prescribes standard categories for
        the components of the effective tax rate reconciliation, and modifies other income tax-related disclosures. The ASU will be effective
        for fiscal years beginning after December 15, 2025, and allows adoption on a prospective basis, with a retrospective option. The Company
        is in the process of assessing the impacts and method of adoption.</span></span></div> </td> </tr>
  </table>

<div style="line-height:1.25">&#160;</div>

<table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">
  <tr>
    <td style="width:92.7pt">&#160;</td>
    <td style="vertical-align:top;width:18pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">3)</span></span></td>
    <td style="vertical-align:top;text-align:justify;width:auto">
        <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">In November 2024, the FASB issued ASU No. 2024-03&#160;Income
        Statement&#8212;Reporting Comprehensive Income&#8212;Expense Disaggregation Disclosures (Subtopic 220-40). The ASU improves the disclosures
        about a public business entity&#8217;s expenses and provides more detailed information about the types of expenses in commonly presented
        expense captions. The amendments require that at each interim and annual reporting period an entity will, inter alia, disclose amounts
        of purchases of inventory, employee compensation, depreciation and amortization included in each relevant expense caption (such as cost
        of sales, SG&amp;A and research and development). The ASU is effective for fiscal years beginning after December 15, 2026, and interim
        periods within fiscal years beginning after December 15, 2027.&#160;Early adoption is permitted. The Company is currently evaluating this
        ASU to determine its impact on the Company's disclosures.</span></span></div> </td> </tr>
  </table> </div> </ix:nonNumeric> </div> </ix:nonNumeric> </div>

<div style="font-size:10pt;margin-top:0pt;margin-bottom:0pt;font-family:'Times New Roman', Times, serif">&#160;</div>

<div>

<div>

<div>

<div> <ix:nonNumeric id="F20241205041231148_29" name="us-gaap:FinancialInstrumentsDisclosureTextBlock" contextRef="C_20240101to20240930" escape="true">

<div>

<div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">NOTE
3 - FINANCIAL INSTRUMENTS ISSUED AND ASSUMED IN TRANSACTIONS</span></span></div>

<div>

<div>

<div style="line-height:1.25">&#160;</div>

<table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">
  <tr>
    <td style="width:64.25pt">&#160;</td>
    <td style="vertical-align:top;font-weight:bold;width:28.45pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">a.</span></span></td>
    <td style="vertical-align:top;text-align:justify;width:auto">
        <div style="font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Underwriters Promissory
        Note</span></span></div>
        <div style="font-weight:bold">&#160;</div>
        <div style="font-family:'Times New Roman',Times,serif;font-weight:bold">
        <div style="line-height:1.25;font-weight:normal"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Prior
        to the Closing, Moringa reached agreement with EarlyBird Capital, Inc. (&#8220;EarlyBird&#8221;) on the reduction, to $<ix:nonFraction id="F20241205041231141_0" name="us-gaap:PaymentsForRepurchaseOfInitialPublicOffering" contextRef="C_20240101to20240930_usgaapInvestmentTypeAxis_slxnUnderwritersPromissoryNoteMember_usgaapTypeOfArrangementAxis_slxnEarlybirdCapitalIncMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,600</ix:nonFraction>,
        in the aggregate, of the fee payable to EarlyBird under the Marketing Agreement entered into by Moringa with EarlyBird at the time of
        Moringa&#8217;s initial public offering (&#8220;IPO&#8221;). At the Closing, Moringa paid $<ix:nonFraction id="F20241205041231141_1" name="slxn:ProceedsFromIssuanceInitialPublicOfferingNet" contextRef="C_20240101to20240930_usgaapInvestmentTypeAxis_slxnUnderwritersPromissoryNoteMember_usgaapTypeOfArrangementAxis_slxnEarlybirdCapitalIncMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">350</ix:nonFraction>
        of cash to EarlyBird from its Trust Account and New Silexion issued to EarlyBird a convertible promissory note, due December 31, 2025,
        in an amount of $<ix:nonFraction id="F20241205041231141_2" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="C_20240101to20240930_usgaapInvestmentTypeAxis_slxnUnderwritersPromissoryNoteMember_usgaapTypeOfArrangementAxis_slxnEarlybirdCapitalIncMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,250</ix:nonFraction>
        to be paid by New Silexion to EarlyBird in cash or via conversion of outstanding amounts into ordinary shares of New Silexion (the &#8220;EarlyBird
        Convertible Note&#8221;).</span></span></div>
        <div style="line-height:1.25;font-weight:normal">&#160;</div>
        <div style="line-height:1.25;font-weight:normal"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The
        EarlyBird Convertible Note bears interest at a rate of <ix:nonFraction id="F20241205041231141_3" name="us-gaap:DebtInstrumentConvertibleConversionRatio1" contextRef="C_20240101to20240930_usgaapInvestmentTypeAxis_slxnUnderwritersPromissoryNoteMember_usgaapTypeOfArrangementAxis_slxnEarlybirdCapitalIncMember" unitRef="pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">6</ix:nonFraction>%
        per annum and matures on December 31, 2025. If not repaid on or prior to that maturity date or such earlier date as to which the repayment
        obligation may be accelerated under the note, or not converted in accordance with the terms thereof, the rate of interest applicable to
        the unpaid principal amount would be adjusted to (<ix:nonFraction id="F20241205041231141_4" name="slxn:UnpaidInterestRatePrincipalAmount" contextRef="C_20240101to20240930_usgaapInvestmentTypeAxis_slxnUnderwritersPromissoryNoteMember_usgaapTypeOfArrangementAxis_slxnEarlybirdCapitalIncMember" unitRef="pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">15</ix:nonFraction>%)
        per annum. New Silexion is required to make mandatory prepayments on the note in amounts equal to <ix:nonFraction id="F20241205041231143_5" name="slxn:PercentageOfGrossProceedsByEquityFinancingsMaturityDate" contextRef="C_20240101to20240930_usgaapInvestmentTypeAxis_slxnUnderwritersPromissoryNoteMember_usgaapTypeOfArrangementAxis_slxnEarlybirdCapitalIncMember" unitRef="pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">10</ix:nonFraction>%
        of the gross proceeds received by New Silexion from any equity financings consummated by it prior to the maturity date.</span></span></div>
        <div style="line-height:1.25;font-weight:normal">&#160;</div>
        <div style="line-height:1.25;font-weight:normal"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">New
        Silexion is entitled to voluntarily prepay any additional part of, or all of, the principal and accrued interest, in one or more installments
        without penalty, prior to the maturity date.</span></span></div> </div> </td> </tr>
  </table>

<div style="font-size:10pt;margin-top:0pt;margin-bottom:0pt;font-family:'Times New Roman', Times, serif">&#160;</div>

<div><ix:exclude>

<div style="margin-top:10pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">

<p style="text-align:center;margin-top:0pt;margin-bottom:3pt"><span style="width:34%;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">F-56</span></span></span></p></div><hr style="page-break-after:always;border-width:0px;clear:both;margin:4px 0px;width:100%;height:2px;color:#000000;background-color:#000000;margin-top:0pt;margin-bottom:10pt"/>

<p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:center">&#160;</p>

<p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:center"><strong>SILEXION
THERAPEUTICS CORP</strong><br/>NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) (continued)<br/>(U.S. dollars in thousands)</p>

<p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:center">&#160;</p>

<div style="line-height:1.25;font-family:'Times New Roman', Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">NOTE
3 - FINANCIAL INSTRUMENTS ISSUED AND ASSUMED IN TRANSACTIONS </span>(continued):</span></span></div>

<div style="line-height:1.25;font-family:'Times New Roman', Times, serif">&#160;</div> </ix:exclude></div>

<div style="line-height:1.25">

<table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">
  <tr>
    <td style="width:64.25pt">&#160;</td>
    <td style="vertical-align:top;font-weight:bold;width:28.45pt">&#160;</td>
    <td style="vertical-align:top;text-align:justify;width:auto">
        <div style="font-family:'Times New Roman',Times,serif;font-weight:bold">
        <div style="line-height:1.25;font-weight:normal">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">EarlyBird, in turn, may
        elect, at its sole discretion, at any time on or prior to the maturity date, to elect to convert all or part of the then outstanding principal
        and/or accrued interest under the EarlyBird Convertible Note into New Silexion ordinary shares, at a per share conversion price equal
        to <ix:nonFraction id="F20241205041231144_6" name="slxn:WeightedAveragePriceOfOrdinaryShares" contextRef="C_20240101to20240930_usgaapInvestmentTypeAxis_slxnUnderwritersPromissoryNoteMember_usgaapTypeOfArrangementAxis_slxnEarlybirdCapitalIncMember" unitRef="pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">95</ix:nonFraction>%
        of the volume weighted average price of a New Silexion ordinary share for the five trading days immediately prior to the date of New Silexion&#8217;s
        receipt of a conversion notice.</span></span></div>
        <div style="line-height:1.25">&#160;</div>
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">As of the date of this
        report, the Company repaid $<ix:nonFraction id="F20241205041231144_7" name="slxn:UnderwritersPromissoryNote" contextRef="C_20240101to20240930_usgaapInvestmentTypeAxis_slxnUnderwritersPromissoryNoteMember_usgaapTypeOfArrangementAxis_slxnEarlybirdCapitalIncMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">100</ix:nonFraction>
        of the EarlyBird Convertible Note as a result of the share issuance under the ELOC Agreement; see Note 3(d).</span></span></div> </div>
        </div> </td> </tr>
  </table>

<div style="line-height:1.25">&#160;</div> </div>

<table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">
  <tr>
    <td style="width:64.25pt">&#160;</td>
    <td style="width:28.45pt;vertical-align:top;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">b.</span></span></td>
    <td style="width:auto;vertical-align:top">
        <div style="font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Sponsor Promissory Note</span></span></div>
        <div style="font-weight:bold">&#160;</div>
        <div style="font-family:'Times New Roman',Times,serif;font-weight:bold">
        <div style="text-align:justify;line-height:1.25;font-weight:normal"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Effective
        as of the Closing, New Silexion issued to the Sponsor in replacement in their entirety of all previously existing promissory notes issued
        by Moringa to the Sponsor from its IPO until the Closing, an amended and restated promissory note (the &#8220;A&amp;R Sponsor Promissory
        Note&#8221;) in an amount of $<ix:nonFraction id="F20241205041231144_8" name="slxn:ProceedsFromIssuanceInitialPublicOfferingNet" contextRef="C_20240101to20240930_usgaapInvestmentTypeAxis_slxnSponsorPromissoryNoteMember_usgaapTypeOfArrangementAxis_slxnAAndRSponsorPromissoryNoteMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,433</ix:nonFraction>.
        This reflected the total amount owed by Moringa to the Sponsor through the Closing Date. The maturity date of the A&amp;R Sponsor Promissory
        Note is the 30-month&#160;anniversary of the Closing Date (i.e., February 15, 2027). Amounts outstanding under the A&amp;R Sponsor Promissory
        Note may be repaid (unless otherwise decided by New Silexion) only by way of conversion into New Silexion ordinary shares (&#8220;Note
        Shares&#8221;). New Silexion and the Sponsor may also convert amounts outstanding under the A&amp;R Sponsor Promissory Note at the price
        per share at which New Silexion conducts an equity financing following the Closing, subject to a minimum conversion amount of $<ix:nonFraction id="F20241205041231145_10" name="us-gaap:DebtInstrumentAnnualPrincipalPayment" contextRef="C_20240930_usgaapInvestmentTypeAxis_slxnSponsorPromissoryNoteMember_usgaapTypeOfArrangementAxis_slxnAAndRSponsorPromissoryNoteMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">100</ix:nonFraction>,
        in an amount of Note Shares constituting up to thirty percent (<ix:nonFraction id="F20241205041231145_9" name="us-gaap:DebtInstrumentConvertibleConversionRatio1" contextRef="C_20240101to20240930_usgaapInvestmentTypeAxis_slxnSponsorPromissoryNoteMember_usgaapTypeOfArrangementAxis_slxnAAndRSponsorPromissoryNoteMember" unitRef="pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">30</ix:nonFraction>%)
        of the number of New Silexion ordinary shares issued and sold by New Silexion in such equity financing. The Sponsor may also elect to
        convert amounts of principal outstanding under the note into New Silexion ordinary shares at any time following the 24-month&#160;anniversary
        of the Closing Date, subject to a minimum conversion of $<ix:nonFraction id="F20241205041231145_11" name="us-gaap:CommonStockConvertibleConversionPriceDecrease" contextRef="C_20240101to20240930_usgaapInvestmentTypeAxis_slxnSponsorPromissoryNoteMember_usgaapTypeOfArrangementAxis_slxnAAndRSponsorPromissoryNoteMember" unitRef="usdPershares" scale="0" decimals="0" format="ixt:num-dot-decimal">10</ix:nonFraction>,
        at a price per share equal to the volume weighted average price of the New Silexion ordinary shares on the principal market on which they
        are traded during the <ix:nonFraction id="F20241205041231145_12" name="slxn:NumberOfConsecutiveTradingDaysPriorToConversionDate" contextRef="C_20240101to20240930_usgaapInvestmentTypeAxis_slxnSponsorPromissoryNoteMember_usgaapTypeOfArrangementAxis_slxnAAndRSponsorPromissoryNoteMember" unitRef="Days" scale="0" decimals="0" format="ixt:num-dot-decimal">20</ix:nonFraction>
        consecutive&#160;trading days prior to the conversion date.</span></span></div>
        <div style="line-height:1.25;font-weight:normal">&#160;</div>
        <div style="text-align:justify;line-height:1.25;font-weight:normal"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">As
        of the date of this report, the Company has neither repaid, nor converted into New Silexion ordinary shares, any principal amounts outstanding
        under the Sponsor Promissory Note.</span></span></div> </div> </td> </tr>
  </table>

<div style="line-height:1.25">&#160;</div>

<table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">
  <tr>
    <td style="width:64.25pt">&#160;</td>
    <td style="width:28.45pt;vertical-align:top;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">c.</span></span></td>
    <td style="width:auto;vertical-align:top">
        <div style="font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">PIPE Financing</span></span></div>
        <div style="font-weight:bold">&#160;</div>
        <div style="font-family:'Times New Roman',Times,serif;font-weight:bold">
        <div style="text-align:justify;line-height:1.25;font-weight:normal"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">In
        connection with, and immediately prior to the Closing of the Transactions, Moringa raised $<ix:nonFraction id="F20241205041231145_13" name="us-gaap:ProceedsFromIssuanceOfPrivatePlacement" contextRef="C_20240101to20240930_usgaapInvestmentTypeAxis_slxnPrivateInvestmentInPublicEntityMember_usgaapTypeOfArrangementAxis_slxnGreenstarLpMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,000</ix:nonFraction>
        via a private investment in public entity financing (the &#8220;PIPE Financing&#8221;), whereby Moringa sold to Greenstar, LP, an affiliate
        of the Moringa Sponsor (the &#8220;PIPE Investor&#8221;), <ix:nonFraction id="F20241205041231145_14" name="us-gaap:DebtConversionConvertedInstrumentSharesIssued1" contextRef="C_20240101to20240930_usgaapInvestmentTypeAxis_slxnPrivateInvestmentInPublicEntityMember_usgaapTypeOfArrangementAxis_slxnGreenstarLpMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">22,223</ix:nonFraction>
        newly issued Moringa ordinary shares at a price of $<ix:nonFraction id="F20241205041231146_15" name="us-gaap:SaleOfStockPricePerShare" contextRef="C_20240930_usgaapInvestmentTypeAxis_slxnPrivateInvestmentInPublicEntityMember_usgaapTypeOfArrangementAxis_slxnGreenstarLpMember" unitRef="usdPershares" scale="0" decimals="2" format="ixt:num-dot-decimal">90.00</ix:nonFraction>
        per share, pursuant to a subscription agreement, dated as of August 15, 2024, by and among Moringa, New Silexion and the PIPE Investor
        (the &#8220;PIPE Agreement&#8221;). Those <ix:nonFraction id="F20241205041231146_16" name="us-gaap:ConversionOfStockSharesConverted1" contextRef="C_20240101to20240930_usgaapInvestmentTypeAxis_slxnPrivateInvestmentInPublicEntityMember_usgaapTypeOfArrangementAxis_slxnGreenstarLpMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">22,223</ix:nonFraction>
        shares automatically converted upon the Closing of the Transactions into an equivalent number of New Silexion ordinary shares (the &#8220;PIPE
        Shares&#8221;).</span></span></div> </div> </td> </tr>
  </table>

<div style="line-height:1.25">&#160;</div>

<table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">
  <tr>
    <td style="width:64.25pt">&#160;</td>
    <td style="width:28.45pt;vertical-align:top;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">d.</span></span></td>
    <td style="width:auto;vertical-align:top">
        <div style="font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">ELOC Financing</span></span></div>
        <div style="font-weight:bold">&#160;</div>
        <div style="font-family:'Times New Roman',Times,serif;font-weight:bold">
        <div style="text-align:justify;line-height:1.25;font-weight:normal"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">In
        connection with the Closing, New Silexion entered into an ordinary share purchase agreement, effective as of the Closing Date (the &#8220;ELOC
        Agreement&#8221;), for an equity line of credit (the &#8220;ELOC&#8221;) with White Lion Capital, LLC (the &#8220;ELOC Investor&#8221;),
        whereby New Silexion will be able to request to sell to the ELOC Investor, and the ELOC Investor will be required to purchase, via private
        placement transactions, up to $<ix:nonFraction id="F20241205041231148_30" name="us-gaap:PaymentsForRepurchaseOfPrivatePlacement" contextRef="C_20240101to20240930_usgaapInvestmentTypeAxis_slxnEquityLineOfCreditMember_usgaapTypeOfArrangementAxis_slxnWhiteLionCapitalLlcMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">15,000</ix:nonFraction>
        of New Silexion ordinary shares from time to time after the Closing, up until December 31, 2025 (unless the agreement is terminated sooner),
        subject to certain limitations and conditions as described therein. The number of New Silexion ordinary shares that New Silexion may require
        the ELOC Investor to purchase in any single sales notice will depend on a number of factors, including the type of purchase notice that
        New Silexion delivers.&#160; Similarly, the purchase price to be paid by the ELOC Investor for any shares that New Silexion requires it
        to purchase will depend on the type of sales notice that New Silexion delivers.</span></span></div> </div> </td> </tr>
  </table>

<div style="line-height:1.25">&#160;</div>

<div><ix:exclude>

<div style="margin-top:10pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">

<p style="text-align:center;margin-top:0pt;margin-bottom:3pt"><span style="width:34%;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">F-57</span></span></span></p></div><hr style="page-break-after:always;border-width:0px;clear:both;margin:4px 0px;width:100%;height:2px;color:#000000;background-color:#000000;margin-top:0pt;margin-bottom:10pt"/>

<p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:center">&#160;</p>

<p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:center"><strong>SILEXION
THERAPEUTICS CORP</strong><br/>NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) (continued)<br/>(U.S. dollars in thousands)</p>

<p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:center">&#160;</p>

<div style="text-align:justify;line-height:1.25;font-family:'Times New Roman', Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">NOTE
3 - FINANCIAL INSTRUMENTS ISSUED AND ASSUMED IN TRANSACTIONS </span>(continued):</span></span></div>

<div style="text-align:justify;line-height:1.25;font-family:'Times New Roman', Times, serif">&#160;</div> </ix:exclude></div>

<div style="line-height:1.25">

<table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">
  <tr>
    <td style="width:64.25pt">&#160;</td>
    <td style="width:28.45pt;vertical-align:top;font-family:'Times New Roman',Times,serif;font-weight:bold">&#160;</td>
    <td style="width:auto;vertical-align:top">
        <div style="font-family:'Times New Roman',Times,serif;font-weight:bold">
        <div style="text-align:justify;line-height:1.25;font-weight:normal"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Purchase
        price is determined with reference to either the lowest daily volume-weighted average price of the Company&#8217;s Ordinary Shares during
        a period of three consecutive business days ending on the notice date times <ix:nonFraction id="F20241205041231148_31" name="slxn:PercentageOfOriginalIssuedPrice" contextRef="C_20240930_usgaapInvestmentTypeAxis_slxnEquityLineOfCreditMember_usgaapTypeOfArrangementAxis_slxnWhiteLionCapitalLlcMember" unitRef="pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">97</ix:nonFraction>%
        or lowest traded price of the Company&#8217;s Ordinary Shares on the notice date.</span></span></div>
        <div style="line-height:1.25;font-weight:normal">&#160;</div>
        <div style="text-align:justify;line-height:1.25;font-weight:normal"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Pursuant
        to the ELOC Agreement, New Silexion agreed, among other things, that if New Silexion&#8217;s sales to the ELOC Investor under the ELOC
        exceed <ix:nonFraction id="F20241205041231148_32" name="slxn:MinimumSalesPercentageOnTotalNumberOfOrdinarySharesOutstanding" contextRef="C_20240101to20240930_usgaapInvestmentTypeAxis_slxnEquityLineOfCreditMember_usgaapTypeOfArrangementAxis_slxnWhiteLionCapitalLlcMember" unitRef="pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">19.99</ix:nonFraction>%
        of New Silexion&#8217;s total number of ordinary shares outstanding, New Silexion will seek the approval of its shareholders for the issuance
        of any New Silexion ordinary shares under the ELOC in excess of that amount, in accordance with the Nasdaq Listing Rules, subject to certain
        exceptions based on the price of the New Silexion ordinary shares to be sold in excess of that limit.</span></span></div>
        <div style="line-height:1.25;font-weight:normal">&#160;</div>
        <div style="text-align:justify;line-height:1.25;font-weight:normal"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">In
        consideration for the commitments of the ELOC Investor, New Silexion agreed to issue to the ELOC Investor an aggregate of $<ix:nonFraction id="F20241205041231146_17" name="us-gaap:DebtConversionConvertedInstrumentAmount1" contextRef="C_20240101to20240930_usgaapInvestmentTypeAxis_slxnEquityLineOfCreditMember_usgaapTypeOfArrangementAxis_slxnWhiteLionCapitalLlcMember" unitRef="usd" scale="3" decimals="-2" format="ixt:num-dot-decimal">337.5</ix:nonFraction>
        of New Silexion ordinary shares (the &#8220;ELOC Commitment Shares&#8221;). On September 18, 2024 the Company issued <ix:nonFraction id="F20241205041231146_18" name="slxn:NumberOfOrdinaryCommitmentShares" contextRef="C_20240901to20240918_usgaapInvestmentTypeAxis_slxnEquityLineOfCreditMember_usgaapTypeOfArrangementAxis_slxnWhiteLionCapitalLlcMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">40,602</ix:nonFraction>
        ordinary shares to White Lion LLC as the Commitment Shares. Issuance expenses amounted to $<ix:nonFraction id="F20241205041231146_19" name="us-gaap:DebtRelatedCommitmentFeesAndDebtIssuanceCosts" contextRef="C_20240101to20240930_usgaapInvestmentTypeAxis_slxnEquityLineOfCreditMember_usgaapTypeOfArrangementAxis_slxnWhiteLionCapitalLlcMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">52</ix:nonFraction>.</span></span></div>
        <div style="line-height:1.25;font-weight:normal">&#160;</div>
        <div style="text-align:justify;line-height:1.25;font-weight:normal"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">During
        the&#160;three<span style="font-style:italic">&#160;</span>months ended&#160;September 30, 2024, the Company sold&#160;<ix:nonFraction id="F20241205041231146_20" name="slxn:EquityLineOfCreditFacilityNumberOfOrdinarySharesSold" contextRef="C_20240701to20240930_usgaapInvestmentTypeAxis_slxnEquityLineOfCreditMember_usgaapTypeOfArrangementAxis_slxnWhiteLionCapitalLlcMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">116,667</ix:nonFraction>&#160;ordinary
        shares under the ELOC at an average&#160;price of $<ix:nonFraction id="F20241205041231146_21" name="slxn:EquityLineOfCreditFacilityAveragePricePerShare" contextRef="C_20240701to20240930_usgaapInvestmentTypeAxis_slxnEquityLineOfCreditMember_usgaapTypeOfArrangementAxis_slxnWhiteLionCapitalLlcMember" unitRef="ilsPershares" scale="0" decimals="3" format="ixt:num-dot-decimal">6.255</ix:nonFraction>&#160;per
        share, net of fees of approximately $<ix:nonFraction id="F20241205041231147_22" name="slxn:EquityLineOfCreditFacilityNetFees" contextRef="C_20240701to20240930_usgaapInvestmentTypeAxis_slxnEquityLineOfCreditMember_usgaapTypeOfArrangementAxis_slxnWhiteLionCapitalLlcMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">20</ix:nonFraction>.
        The net proceeds from those sales were $<ix:nonFraction id="F20241205041231147_23" name="slxn:EquityLineOfCreditFacilityNetProceedsFromSale" contextRef="C_20240701to20240930_usgaapInvestmentTypeAxis_slxnEquityLineOfCreditMember_usgaapTypeOfArrangementAxis_slxnWhiteLionCapitalLlcMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">620</ix:nonFraction>.
        For further information see Note 11.</span></span></div> </div> </td> </tr>
  </table> </div>

<div style="font-size:10pt;margin-top:0pt;margin-bottom:0pt;font-family:'Times New Roman', Times, serif">&#160;</div>

<table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">
  <tr>
    <td style="width:64.25pt">&#160;</td>
    <td style="width:28.45pt;vertical-align:top;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">e.</span></span></td>
    <td style="width:auto;vertical-align:top">
        <div style="font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">SPAC Warrants</span></span></div>
        <div style="font-weight:bold">&#160;</div>
        <div style="font-family:'Times New Roman',Times,serif;font-weight:bold">
        <div style="line-height:1.25;font-weight:normal;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">On
        the Closing Date, Moringa, New Silexion and Continental Stock Transfer &amp; Trust Company (&#8220;CST&#8221;) entered into a certain
        Assignment, Assumption and Amendment Agreement (the &#8220;New Warrant Agreement&#8221;). The New Warrant Agreement amended Moringa&#8217;s
        Warrant Agreement, dated as of February 19, 2021, to provide for the assignment by Moringa of all its rights, title and interest in the
        warrants of Moringa to New Silexion.</span></span></div>
        <div style="line-height:1.25;font-weight:normal">&#160;</div>
        <div style="line-height:1.25;font-weight:normal;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Upon
        Closing, New Silexion assumed <ix:nonFraction id="F20241205041231147_24" name="slxn:NumberOfPublicWarrants" contextRef="C_20240101to20240930_usgaapInvestmentTypeAxis_slxnSpacWarrantsMember_usgaapTypeOfArrangementAxis_slxnNewWarrantAgreementMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">638,889</ix:nonFraction>
        warrants sold by Moringa in its IPO (&#8220;Public Warrants&#8221;) and <ix:nonFraction id="F20241205041231147_25" name="slxn:NumberOfPrivateWarrants" contextRef="C_20240101to20240930_usgaapInvestmentTypeAxis_slxnSpacWarrantsMember_usgaapTypeOfArrangementAxis_slxnNewWarrantAgreementMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">21,112</ix:nonFraction>
        warrants sold by Moringa to the Sponsor and EarlyBird concurrently with its IPO (the &#8220;Private Warrants&#8221;, and together with
        the Public Warrants, the &#8220;Warrants&#8221;). Each such Warrant entitles the holder thereof to purchase one Ordinary Share of New
        Silexion of $<ix:nonFraction id="F20241205041231147_26" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="C_20240930_usgaapInvestmentTypeAxis_slxnSpacWarrantsMember_usgaapTypeOfArrangementAxis_slxnNewWarrantAgreementMember" unitRef="usdPershares" scale="0" decimals="2" format="ixt:num-dot-decimal">103.50</ix:nonFraction>
        per share, subject to adjustment. No fractional shares will be issued upon exercise of the Warrants. <ix:nonNumeric id="F20241205041231147_27" name="slxn:WarrantExercisableDescpription" contextRef="C_20240101to20240930_usgaapInvestmentTypeAxis_slxnSpacWarrantsMember_usgaapTypeOfArrangementAxis_slxnNewWarrantAgreementMember">Each
        Warrant became exercisable 30 days after the Closing and will expire after five years after the completion of the Closing or earlier upon
        redemption (only in the case of the Public Warrants) or liquidation.</ix:nonNumeric></span></span></div>
        <div style="margin-left:72pt;line-height:1.25;font-weight:normal">&#160;</div>
        <div style="line-height:1.25;font-weight:normal;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonNumeric id="F20241205041231148_28" name="slxn:WarrantExercisableRedemptionDescpription" contextRef="C_20240101to20240930_usgaapInvestmentTypeAxis_slxnSpacWarrantsMember_usgaapTypeOfArrangementAxis_slxnNewWarrantAgreementMember">Once
        the Public Warrants became exercisable, the Company may redeem them in whole and not in part at a price of $0.09 per Warrant upon a minimum
        of 30 days&#8217; prior written notice of redemption, if and only if the last reported sale price of the Company&#8217;s ordinary shares
        equals or exceeds $162.00 per share (as adjusted) for any 20 trading days within a 30-trading day period ending on the third trading day
        prior to the date on which the Company sends the notice of redemption to the Public Warrant holders.</ix:nonNumeric></span></span></div>
        <div style="line-height:1.25;font-weight:normal">&#160;</div>
        <div style="line-height:1.25;font-weight:normal;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The
        Company recognized a net liability, measured at fair value through profit or loss, from the Transactions (see also Note 2). As such, transaction
        costs related to the Transactions were expensed as incurred.</span></span></div>
        <div style="line-height:1.25;font-weight:normal">&#160;</div>
        <div style="line-height:1.25;font-weight:normal;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The
        Private Warrants are identical to the Public Warrants except that, for so long as they are held by the Sponsor, EarlyBird or their respective
        affiliates, the Private Warrants: (1) will not be redeemable by the Company; (2) could not (subject to certain limited exceptions), be
        transferred, assigned or sold by the holders thereof until 30 days after the Closing; (3) may be exercised by the holders thereof on a
        cashless basis; and (4) are entitled to registration rights.</span></span></div> </div> </td> </tr>
  </table> </div> </div> </div> </ix:nonNumeric> </div> </div>

<div style="font-size:10pt;margin-top:0pt;margin-bottom:0pt;font-family:'Times New Roman', Times, serif">&#160;</div>

<div style="line-height:1.25;text-align:justify;margin-top:0pt;margin-bottom:0pt">

<div style="margin-top:10pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">

<p style="text-align:center;margin-top:0pt;margin-bottom:3pt"><span style="width:34%;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">F-58</span></span></span></p></div><hr style="page-break-after:always;border-width:0px;clear:both;margin:4px 0px;width:100%;height:2px;color:#000000;background-color:#000000;margin-top:0pt;margin-bottom:10pt"/>

<p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:center">&#160;</p>

<p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:center"><strong>SILEXION
THERAPEUTICS CORP</strong><br/>NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) (continued)<br/>(U.S. dollars in thousands)</p>

<p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:center">&#160;</p> </div>
</div> </div>

<div style="font:10pt Times New Roman, Times, Serif"> <ix:nonNumeric id="F20241205041231157_0" name="us-gaap:AdditionalFinancialInformationDisclosureTextBlock" contextRef="C_20240101to20240930" escape="true">

<div>

<div>

<div style="line-height:1.25;font-weight:bold;margin-top:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">NOTE
4 - SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION:</span></span></div>

<div style="line-height:1.25">&#160;</div>

<div style="text-align:justify;margin-left:31.65pt;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Statement
of operations:</span></span></div>

<div style="text-align:justify;margin-left:31.65pt;line-height:1.25;font-weight:bold">&#160;</div>

<table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">
  <tr>
    <td style="width:51pt">&#160;</td>
    <td style="width:18pt;vertical-align:top;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">a.</span></span></td>
    <td style="width:auto;vertical-align:top">
        <div style="font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Research and development
        expenses:</span></span></div> </td> </tr>
  </table> <ix:nonNumeric id="F20241205041231187_81" name="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersTextBlock" contextRef="C_20240101to20240930" escape="true">

<div>

<div>&#160;</div>

<div style="margin-left:72pt">

<table border="0" cellpadding="0" cellspacing="0" style="width:85%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left">
  <tr>
    <td colspan="1" style="vertical-align:top;padding-bottom:2px;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
    <td colspan="6" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
        <div style="text-align:center;line-height:1.25;font-weight:bold">Nine months ended</div>
        <div style="line-height:1.25">
        <div style="text-align:center;line-height:1.25;font-weight:bold">September 30,</div> </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
    <td colspan="6" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="text-align:center;line-height:1.25;font-weight:bold">Three months ended</div>
        <div style="text-align:center;line-height:1.25;font-weight:bold">September 30,</div> </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td> </tr>
  <tr>
    <td colspan="1" style="vertical-align:top;padding-bottom:2px;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="text-align:center;line-height:1.25;font-weight:bold">2024</div> </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
    <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="text-align:center;line-height:1.25;font-weight:bold">2023</div> </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="text-align:center;line-height:1.25;font-weight:bold">2024</div> </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="text-align:center;line-height:1.25;font-weight:bold">2023</div> </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td> </tr>
  <tr>
    <td colspan="1" style="vertical-align:top;padding-bottom:2px;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
    <td colspan="6" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="text-align:center;line-height:1.25;font-weight:bold">U.S. dollars in thousands</div> </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
    <td colspan="6" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="text-align:center;line-height:1.25;font-weight:bold">U.S. dollars in thousands</div> </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:bottom;width:52%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25">Payroll and related expenses</div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25">$</div> </td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25"><ix:nonFraction id="F20241205041231158_1" name="us-gaap:LaborAndRelatedExpense" contextRef="C_20240101to20240930_usgaapIncomeStatementLocationAxis_usgaapResearchAndDevelopmentExpenseMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">928</ix:nonFraction></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25">$</div> </td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25"><ix:nonFraction id="F20241205041231158_2" name="us-gaap:LaborAndRelatedExpense" contextRef="C_20230101to20230930_usgaapIncomeStatementLocationAxis_usgaapResearchAndDevelopmentExpenseMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">729</ix:nonFraction></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25">$</div> </td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25"><ix:nonFraction id="F20241205041231158_3" name="us-gaap:LaborAndRelatedExpense" contextRef="C_20240701to20240930_usgaapIncomeStatementLocationAxis_usgaapResearchAndDevelopmentExpenseMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">453</ix:nonFraction></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25">$</div> </td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25"><ix:nonFraction id="F20241205041231159_4" name="us-gaap:LaborAndRelatedExpense" contextRef="C_20230701to20230930_usgaapIncomeStatementLocationAxis_usgaapResearchAndDevelopmentExpenseMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">198</ix:nonFraction></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align:bottom;width:52%;vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25">Share-based compensation expenses</div> </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
        <div style="line-height:1.25"><ix:nonFraction id="F20241205041231188_84" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_20240101to20240930_usgaapIncomeStatementLocationAxis_usgaapResearchAndDevelopmentExpenseMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,424</ix:nonFraction></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
        <div style="line-height:1.25"><ix:nonFraction id="F20241205041231188_85" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_20230101to20230930_usgaapIncomeStatementLocationAxis_usgaapResearchAndDevelopmentExpenseMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">57</ix:nonFraction></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
        <div style="line-height:1.25"><ix:nonFraction id="F20241205041231189_86" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_20240701to20240930_usgaapIncomeStatementLocationAxis_usgaapResearchAndDevelopmentExpenseMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,385</ix:nonFraction></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
        <div style="line-height:1.25"><ix:nonFraction id="F20241205041231189_87" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_20230701to20230930_usgaapIncomeStatementLocationAxis_usgaapResearchAndDevelopmentExpenseMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">19</ix:nonFraction></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:bottom;width:52%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25">Subcontractors and consultants</div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25"><ix:nonFraction id="F20241205041231159_5" name="slxn:SubcontractorsAndConsultants" contextRef="C_20240101to20240930_usgaapIncomeStatementLocationAxis_usgaapResearchAndDevelopmentExpenseMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,425</ix:nonFraction></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25"><ix:nonFraction id="F20241205041231159_6" name="slxn:SubcontractorsAndConsultants" contextRef="C_20230101to20230930_usgaapIncomeStatementLocationAxis_usgaapResearchAndDevelopmentExpenseMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,444</ix:nonFraction></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25"><ix:nonFraction id="F20241205041231160_7" name="slxn:SubcontractorsAndConsultants" contextRef="C_20240701to20240930_usgaapIncomeStatementLocationAxis_usgaapResearchAndDevelopmentExpenseMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">297</ix:nonFraction></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25"><ix:nonFraction id="F20241205041231160_8" name="slxn:SubcontractorsAndConsultants" contextRef="C_20230701to20230930_usgaapIncomeStatementLocationAxis_usgaapResearchAndDevelopmentExpenseMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">236</ix:nonFraction></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align:bottom;width:52%;vertical-align:bottom">
        <div style="line-height:1.25">Materials</div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
        <div style="line-height:1.25"><ix:nonFraction id="F20241205041231160_9" name="slxn:MaterialsExpenses" contextRef="C_20240101to20240930_usgaapIncomeStatementLocationAxis_usgaapResearchAndDevelopmentExpenseMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">3</ix:nonFraction></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
        <div style="line-height:1.25"><ix:nonFraction id="F20241205041231161_10" name="slxn:MaterialsExpenses" contextRef="C_20230101to20230930_usgaapIncomeStatementLocationAxis_usgaapResearchAndDevelopmentExpenseMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">16</ix:nonFraction></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
        <div style="line-height:1.25"><ix:nonFraction id="F20241205041231190_92" name="slxn:MaterialsExpenses" contextRef="C_20240701to20240930_usgaapIncomeStatementLocationAxis_usgaapResearchAndDevelopmentExpenseMember" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
        <div style="line-height:1.25"><ix:nonFraction id="F20241205041231161_11" name="slxn:MaterialsExpenses" contextRef="C_20230701to20230930_usgaapIncomeStatementLocationAxis_usgaapResearchAndDevelopmentExpenseMember" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:bottom;width:52%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25">Rent and maintenance</div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25"><ix:nonFraction id="F20241205041231161_12" name="us-gaap:CostOfPropertyRepairsAndMaintenance" contextRef="C_20240101to20240930_usgaapIncomeStatementLocationAxis_usgaapResearchAndDevelopmentExpenseMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">106</ix:nonFraction></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25"><ix:nonFraction id="F20241205041231162_13" name="us-gaap:CostOfPropertyRepairsAndMaintenance" contextRef="C_20230101to20230930_usgaapIncomeStatementLocationAxis_usgaapResearchAndDevelopmentExpenseMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">124</ix:nonFraction></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25"><ix:nonFraction id="F20241205041231162_14" name="us-gaap:CostOfPropertyRepairsAndMaintenance" contextRef="C_20240701to20240930_usgaapIncomeStatementLocationAxis_usgaapResearchAndDevelopmentExpenseMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">57</ix:nonFraction></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25"><ix:nonFraction id="F20241205041231162_15" name="us-gaap:CostOfPropertyRepairsAndMaintenance" contextRef="C_20230701to20230930_usgaapIncomeStatementLocationAxis_usgaapResearchAndDevelopmentExpenseMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">46</ix:nonFraction></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align:bottom;width:52%;vertical-align:bottom">
        <div style="line-height:1.25">Travel expenses</div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
        <div style="line-height:1.25"><ix:nonFraction id="F20241205041231163_16" name="us-gaap:TravelAndEntertainmentExpense" contextRef="C_20240101to20240930_usgaapIncomeStatementLocationAxis_usgaapResearchAndDevelopmentExpenseMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">13</ix:nonFraction></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
        <div style="line-height:1.25"><ix:nonFraction id="F20241205041231163_17" name="us-gaap:TravelAndEntertainmentExpense" contextRef="C_20230101to20230930_usgaapIncomeStatementLocationAxis_usgaapResearchAndDevelopmentExpenseMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">27</ix:nonFraction></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
        <div style="line-height:1.25"><ix:nonFraction id="F20241205041231163_18" name="us-gaap:TravelAndEntertainmentExpense" contextRef="C_20240701to20240930_usgaapIncomeStatementLocationAxis_usgaapResearchAndDevelopmentExpenseMember" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
        <div style="line-height:1.25"><ix:nonFraction id="F20241205041231164_19" name="us-gaap:TravelAndEntertainmentExpense" contextRef="C_20230701to20230930_usgaapIncomeStatementLocationAxis_usgaapResearchAndDevelopmentExpenseMember" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:bottom;width:52%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25">Other</div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><ix:nonFraction id="F20241205041231164_20" name="us-gaap:OtherResearchAndDevelopmentExpense" contextRef="C_20240101to20240930_usgaapIncomeStatementLocationAxis_usgaapResearchAndDevelopmentExpenseMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">45</ix:nonFraction></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><ix:nonFraction id="F20241205041231165_21" name="us-gaap:OtherResearchAndDevelopmentExpense" contextRef="C_20230101to20230930_usgaapIncomeStatementLocationAxis_usgaapResearchAndDevelopmentExpenseMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">54</ix:nonFraction></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><ix:nonFraction id="F20241205041231165_22" name="us-gaap:OtherResearchAndDevelopmentExpense" contextRef="C_20240701to20240930_usgaapIncomeStatementLocationAxis_usgaapResearchAndDevelopmentExpenseMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">25</ix:nonFraction></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><ix:nonFraction id="F20241205041231165_23" name="us-gaap:OtherResearchAndDevelopmentExpense" contextRef="C_20230701to20230930_usgaapIncomeStatementLocationAxis_usgaapResearchAndDevelopmentExpenseMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">36</ix:nonFraction></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align:top;width:52%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25">$</div> </div> </td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><ix:nonFraction id="F20241205041231166_24" name="us-gaap:ResearchAndDevelopmentExpense" contextRef="C_20240101to20240930_usgaapIncomeStatementLocationAxis_usgaapResearchAndDevelopmentExpenseMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,944</ix:nonFraction></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25">$</div> </div> </td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><ix:nonFraction id="F20241205041231166_25" name="us-gaap:ResearchAndDevelopmentExpense" contextRef="C_20230101to20230930_usgaapIncomeStatementLocationAxis_usgaapResearchAndDevelopmentExpenseMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,451</ix:nonFraction></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25">$</div> </div> </td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><ix:nonFraction id="F20241205041231166_26" name="us-gaap:ResearchAndDevelopmentExpense" contextRef="C_20240701to20240930_usgaapIncomeStatementLocationAxis_usgaapResearchAndDevelopmentExpenseMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,217</ix:nonFraction></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25">$</div> </div> </td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><ix:nonFraction id="F20241205041231167_27" name="us-gaap:ResearchAndDevelopmentExpense" contextRef="C_20230701to20230930_usgaapIncomeStatementLocationAxis_usgaapResearchAndDevelopmentExpenseMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">535</ix:nonFraction></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td> </tr>
  </table> </div> </div> </ix:nonNumeric>

<div>&#160;</div>

<table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">
  <tr>
    <td style="width:51pt">&#160;</td>
    <td style="width:18pt;vertical-align:top;font-weight:bold">b.</td>
    <td style="width:auto;vertical-align:top">
        <div style="font-weight:bold">General and administrative expenses:</div> </td> </tr>
  </table> <ix:nonNumeric id="F20241205041231188_82" name="us-gaap:SellingGeneralAndAdministrativeExpensesPolicyTextBlock" contextRef="C_20240101to20240930" escape="true">

<div>

<div>&#160;</div>

<div style="margin-left:72pt">

<table border="0" cellpadding="0" cellspacing="0" style="width:85%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left">
  <tr>
    <td style="vertical-align:bottom;width:52%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25">Payroll and related expenses</div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25">$</div> </td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25"><ix:nonFraction id="F20241205041231167_28" name="us-gaap:LaborAndRelatedExpense" contextRef="C_20240101to20240930_usgaapIncomeStatementLocationAxis_usgaapGeneralAndAdministrativeExpenseMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">856</ix:nonFraction></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25">$</div> </td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25"><ix:nonFraction id="F20241205041231167_29" name="us-gaap:LaborAndRelatedExpense" contextRef="C_20230101to20230930_usgaapIncomeStatementLocationAxis_usgaapGeneralAndAdministrativeExpenseMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">190</ix:nonFraction></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25">$</div> </td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25"><ix:nonFraction id="F20241205041231168_30" name="us-gaap:LaborAndRelatedExpense" contextRef="C_20240701to20240930_usgaapIncomeStatementLocationAxis_usgaapGeneralAndAdministrativeExpenseMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">575</ix:nonFraction></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25">$</div> </td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25"><ix:nonFraction id="F20241205041231168_31" name="us-gaap:LaborAndRelatedExpense" contextRef="C_20230701to20230930_usgaapIncomeStatementLocationAxis_usgaapGeneralAndAdministrativeExpenseMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">71</ix:nonFraction></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align:bottom;width:52%;vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25">Share-based compensation expenses</div> </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
        <div style="line-height:1.25"><ix:nonFraction id="F20241205041231189_88" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_20240101to20240930_usgaapIncomeStatementLocationAxis_usgaapGeneralAndAdministrativeExpenseMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,438</ix:nonFraction></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
        <div style="line-height:1.25"><ix:nonFraction id="F20241205041231190_89" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_20230101to20230930_usgaapIncomeStatementLocationAxis_usgaapGeneralAndAdministrativeExpenseMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">39</ix:nonFraction></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
        <div style="line-height:1.25"><ix:nonFraction id="F20241205041231190_90" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_20240701to20240930_usgaapIncomeStatementLocationAxis_usgaapGeneralAndAdministrativeExpenseMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,413</ix:nonFraction></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
        <div style="line-height:1.25"><ix:nonFraction id="F20241205041231190_91" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_20230701to20230930_usgaapIncomeStatementLocationAxis_usgaapGeneralAndAdministrativeExpenseMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">13</ix:nonFraction></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:bottom;width:52%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25">Professional services</div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25"><ix:nonFraction id="F20241205041231168_32" name="us-gaap:ProfessionalAndContractServicesExpense" contextRef="C_20240101to20240930_usgaapIncomeStatementLocationAxis_usgaapGeneralAndAdministrativeExpenseMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,053</ix:nonFraction></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25"><ix:nonFraction id="F20241205041231169_33" name="us-gaap:ProfessionalAndContractServicesExpense" contextRef="C_20230101to20230930_usgaapIncomeStatementLocationAxis_usgaapGeneralAndAdministrativeExpenseMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">79</ix:nonFraction></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25"><ix:nonFraction id="F20241205041231169_34" name="us-gaap:ProfessionalAndContractServicesExpense" contextRef="C_20240701to20240930_usgaapIncomeStatementLocationAxis_usgaapGeneralAndAdministrativeExpenseMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">605</ix:nonFraction></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25"><ix:nonFraction id="F20241205041231169_35" name="us-gaap:ProfessionalAndContractServicesExpense" contextRef="C_20230701to20230930_usgaapIncomeStatementLocationAxis_usgaapGeneralAndAdministrativeExpenseMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">51</ix:nonFraction></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align:bottom;width:52%;vertical-align:bottom">
        <div style="line-height:1.25">Depreciation</div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
        <div style="line-height:1.25"><ix:nonFraction id="F20241205041231170_36" name="us-gaap:Depreciation" contextRef="C_20240101to20240930_usgaapIncomeStatementLocationAxis_usgaapGeneralAndAdministrativeExpenseMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">37</ix:nonFraction></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
        <div style="line-height:1.25"><ix:nonFraction id="F20241205041231170_37" name="us-gaap:Depreciation" contextRef="C_20230101to20230930_usgaapIncomeStatementLocationAxis_usgaapGeneralAndAdministrativeExpenseMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">39</ix:nonFraction></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
        <div style="line-height:1.25"><ix:nonFraction id="F20241205041231170_38" name="us-gaap:Depreciation" contextRef="C_20240701to20240930_usgaapIncomeStatementLocationAxis_usgaapGeneralAndAdministrativeExpenseMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">22</ix:nonFraction></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
        <div style="line-height:1.25"><ix:nonFraction id="F20241205041231171_39" name="us-gaap:Depreciation" contextRef="C_20230701to20230930_usgaapIncomeStatementLocationAxis_usgaapGeneralAndAdministrativeExpenseMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">10</ix:nonFraction></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:bottom;width:52%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25">Rent and maintenance</div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25"><ix:nonFraction id="F20241205041231173_40" name="us-gaap:CostOfPropertyRepairsAndMaintenance" contextRef="C_20240101to20240930_usgaapIncomeStatementLocationAxis_usgaapGeneralAndAdministrativeExpenseMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">90</ix:nonFraction></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25"><ix:nonFraction id="F20241205041231174_41" name="us-gaap:CostOfPropertyRepairsAndMaintenance" contextRef="C_20230101to20230930_usgaapIncomeStatementLocationAxis_usgaapGeneralAndAdministrativeExpenseMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">67</ix:nonFraction></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25"><ix:nonFraction id="F20241205041231174_42" name="us-gaap:CostOfPropertyRepairsAndMaintenance" contextRef="C_20240701to20240930_usgaapIncomeStatementLocationAxis_usgaapGeneralAndAdministrativeExpenseMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">18</ix:nonFraction></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25"><ix:nonFraction id="F20241205041231175_43" name="us-gaap:CostOfPropertyRepairsAndMaintenance" contextRef="C_20230701to20230930_usgaapIncomeStatementLocationAxis_usgaapGeneralAndAdministrativeExpenseMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">25</ix:nonFraction></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align:bottom;width:52%;vertical-align:bottom">
        <div style="line-height:1.25">Patent registration</div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
        <div style="line-height:1.25"><ix:nonFraction id="F20241205041231175_44" name="slxn:PatentRegistration" contextRef="C_20240101to20240930_usgaapIncomeStatementLocationAxis_usgaapGeneralAndAdministrativeExpenseMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">25</ix:nonFraction></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
        <div style="line-height:1.25"><ix:nonFraction id="F20241205041231175_45" name="slxn:PatentRegistration" contextRef="C_20230101to20230930_usgaapIncomeStatementLocationAxis_usgaapGeneralAndAdministrativeExpenseMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">18</ix:nonFraction></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
        <div style="line-height:1.25"><ix:nonFraction id="F20241205041231176_46" name="slxn:PatentRegistration" contextRef="C_20240701to20240930_usgaapIncomeStatementLocationAxis_usgaapGeneralAndAdministrativeExpenseMember" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
        <div style="line-height:1.25"><ix:nonFraction id="F20241205041231176_47" name="slxn:PatentRegistration" contextRef="C_20230701to20230930_usgaapIncomeStatementLocationAxis_usgaapGeneralAndAdministrativeExpenseMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">2</ix:nonFraction></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:bottom;width:52%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25">Travel expenses</div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25"><ix:nonFraction id="F20241205041231176_48" name="us-gaap:TravelAndEntertainmentExpense" contextRef="C_20240101to20240930_usgaapIncomeStatementLocationAxis_usgaapGeneralAndAdministrativeExpenseMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">72</ix:nonFraction></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25"><ix:nonFraction id="F20241205041231177_49" name="us-gaap:TravelAndEntertainmentExpense" contextRef="C_20230101to20230930_usgaapIncomeStatementLocationAxis_usgaapGeneralAndAdministrativeExpenseMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">31</ix:nonFraction></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25"><ix:nonFraction id="F20241205041231177_50" name="us-gaap:TravelAndEntertainmentExpense" contextRef="C_20240701to20240930_usgaapIncomeStatementLocationAxis_usgaapGeneralAndAdministrativeExpenseMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">56</ix:nonFraction></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25"><ix:nonFraction id="F20241205041231177_51" name="us-gaap:TravelAndEntertainmentExpense" contextRef="C_20230701to20230930_usgaapIncomeStatementLocationAxis_usgaapGeneralAndAdministrativeExpenseMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">15</ix:nonFraction></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align:bottom;width:52%;padding-bottom:2px;vertical-align:bottom">
        <div style="line-height:1.25">Other</div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><ix:nonFraction id="F20241205041231178_52" name="us-gaap:OtherGeneralAndAdministrativeExpense" contextRef="C_20240101to20240930_usgaapIncomeStatementLocationAxis_usgaapGeneralAndAdministrativeExpenseMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">156</ix:nonFraction></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><ix:nonFraction id="F20241205041231178_53" name="us-gaap:OtherGeneralAndAdministrativeExpense" contextRef="C_20230101to20230930_usgaapIncomeStatementLocationAxis_usgaapGeneralAndAdministrativeExpenseMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">39</ix:nonFraction></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><ix:nonFraction id="F20241205041231178_54" name="us-gaap:OtherGeneralAndAdministrativeExpense" contextRef="C_20240701to20240930_usgaapIncomeStatementLocationAxis_usgaapGeneralAndAdministrativeExpenseMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">130</ix:nonFraction></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><ix:nonFraction id="F20241205041231179_55" name="us-gaap:OtherGeneralAndAdministrativeExpense" contextRef="C_20230701to20230930_usgaapIncomeStatementLocationAxis_usgaapGeneralAndAdministrativeExpenseMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">9</ix:nonFraction></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:bottom;width:52%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25">$</div> </div> </td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><ix:nonFraction id="F20241205041231179_56" name="us-gaap:GeneralAndAdministrativeExpense" contextRef="C_20240101to20240930_usgaapIncomeStatementLocationAxis_usgaapGeneralAndAdministrativeExpenseMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,727</ix:nonFraction></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25">$</div> </div> </td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><ix:nonFraction id="F20241205041231179_57" name="us-gaap:GeneralAndAdministrativeExpense" contextRef="C_20230101to20230930_usgaapIncomeStatementLocationAxis_usgaapGeneralAndAdministrativeExpenseMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">502</ix:nonFraction></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25">$</div> </div> </td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><ix:nonFraction id="F20241205041231180_58" name="us-gaap:GeneralAndAdministrativeExpense" contextRef="C_20240701to20240930_usgaapIncomeStatementLocationAxis_usgaapGeneralAndAdministrativeExpenseMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,819</ix:nonFraction></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25">$</div> </div> </td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><ix:nonFraction id="F20241205041231180_59" name="us-gaap:GeneralAndAdministrativeExpense" contextRef="C_20230701to20230930_usgaapIncomeStatementLocationAxis_usgaapGeneralAndAdministrativeExpenseMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">196</ix:nonFraction></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        </tr>
  </table> </div> </div> </ix:nonNumeric>

<div style="line-height:1.25">&#160;</div>

<table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">
  <tr>
    <td style="width:51pt">&#160;</td>
    <td style="width:18pt;vertical-align:top;font-weight:bold">c.</td>
    <td style="width:auto;vertical-align:top">
        <div style="font-weight:bold">Financial expense, net:</div> </td> </tr>
  </table> <ix:nonNumeric id="F20241205041231188_83" name="slxn:ScheduleOfFinancialExpenseNetTableTextBlock" contextRef="C_20240101to20240930" escape="true">

<div>

<div>&#160;</div>

<div style="margin-left:72pt">

<table border="0" cellpadding="0" cellspacing="0" style="width:85%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left">
  <tr style="background-color:rgb(204, 238, 255)">
    <td style="width:52%;vertical-align:bottom;background-color:rgb(204, 238, 255)">
        <div style="line-height:1.25">Change in fair value of financial liabilities measured at fair value</div> </td>
    <td colspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(204, 238, 255)">
        <div style="line-height:1.25">$</div> </td>
    <td colspan="1" style="text-align:right;width:9%;vertical-align:bottom;background-color:rgb(204, 238, 255)">
        <div style="line-height:1.25">(<ix:nonFraction id="F20241205041231181_60" name="us-gaap:LiabilitiesFairValueAdjustment" contextRef="C_20240101to20240930" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">919</ix:nonFraction></div>
        </td>
    <td colspan="1" style="width:1%;vertical-align:bottom;white-space:nowrap;background-color:rgb(204, 238, 255)">
        <div style="line-height:1.25">)</div> </td>
    <td colspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(204, 238, 255)">
        <div style="line-height:1.25">$</div> </td>
    <td colspan="1" style="text-align:right;width:9%;vertical-align:bottom;background-color:rgb(204, 238, 255)">
        <div style="line-height:1.25">(<ix:nonFraction id="F20241205041231181_61" name="us-gaap:LiabilitiesFairValueAdjustment" contextRef="C_20230101to20230930" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">3</ix:nonFraction></div>
        </td>
    <td colspan="1" style="width:1%;vertical-align:bottom;white-space:nowrap;background-color:rgb(204, 238, 255)">
        <div style="line-height:1.25">)</div> </td>
    <td colspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(204, 238, 255)">
        <div style="line-height:1.25">$</div> </td>
    <td colspan="1" style="text-align:right;width:9%;vertical-align:bottom;background-color:rgb(204, 238, 255)">
        <div style="line-height:1.25">(<ix:nonFraction id="F20241205041231181_62" name="us-gaap:LiabilitiesFairValueAdjustment" contextRef="C_20240701to20240930" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">1,064</ix:nonFraction></div>
        </td>
    <td colspan="1" style="width:1%;vertical-align:bottom;white-space:nowrap;background-color:rgb(204, 238, 255)">
        <div style="line-height:1.25">)</div> </td>
    <td colspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(204, 238, 255)">
        <div style="line-height:1.25">$</div> </td>
    <td colspan="1" style="text-align:right;width:9%;vertical-align:bottom;background-color:rgb(204, 238, 255)">
        <div style="line-height:1.25"><ix:nonFraction id="F20241205041231182_63" name="us-gaap:LiabilitiesFairValueAdjustment" contextRef="C_20230701to20230930" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></div>
        </td>
    <td colspan="1" style="width:1%;vertical-align:bottom;white-space:nowrap;background-color:rgb(204, 238, 255)">&#160;</td> </tr>
  <tr style="background-color:rgb(255, 255, 255)">
    <td style="width:52%;vertical-align:bottom;background-color:rgb(255, 255, 255)">
        <div style="line-height:1.25">Issuance costs</div> </td>
    <td colspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(255, 255, 255)">&#160;</td>
    <td colspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(255, 255, 255)">&#160;</td>
    <td colspan="1" style="text-align:right;width:9%;vertical-align:bottom;background-color:rgb(255, 255, 255)">
        <div style="line-height:1.25"><ix:nonFraction id="F20241205041231191_93" name="us-gaap:PaymentsOfStockIssuanceCosts" contextRef="C_20240101to20240930" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">52</ix:nonFraction></div>
        </td>
    <td colspan="1" style="width:1%;vertical-align:bottom;white-space:nowrap;background-color:rgb(255, 255, 255)">&#160;</td>
    <td colspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(255, 255, 255)">&#160;</td>
    <td colspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(255, 255, 255)">&#160;</td>
    <td colspan="1" style="text-align:right;width:9%;vertical-align:bottom;background-color:rgb(255, 255, 255)">
        <div style="line-height:1.25"><ix:nonFraction id="F20241205041231182_64" name="us-gaap:PaymentsOfStockIssuanceCosts" contextRef="C_20230101to20230930" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">47</ix:nonFraction></div>
        </td>
    <td colspan="1" style="width:1%;vertical-align:bottom;white-space:nowrap;background-color:rgb(255, 255, 255)">&#160;</td>
    <td colspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(255, 255, 255)">&#160;</td>
    <td colspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(255, 255, 255)">&#160;</td>
    <td colspan="1" style="text-align:right;width:9%;vertical-align:bottom;background-color:rgb(255, 255, 255)">
        <div style="line-height:1.25"><ix:nonFraction id="F20241205041231191_94" name="us-gaap:PaymentsOfStockIssuanceCosts" contextRef="C_20240701to20240930" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">52</ix:nonFraction></div>
        </td>
    <td colspan="1" style="width:1%;vertical-align:bottom;white-space:nowrap;background-color:rgb(255, 255, 255)">&#160;</td>
    <td colspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(255, 255, 255)">&#160;</td>
    <td colspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(255, 255, 255)">&#160;</td>
    <td colspan="1" style="text-align:right;width:9%;vertical-align:bottom;background-color:rgb(255, 255, 255)">
        <div style="line-height:1.25"><ix:nonFraction id="F20241205041231182_65" name="us-gaap:PaymentsOfStockIssuanceCosts" contextRef="C_20230701to20230930" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">44</ix:nonFraction></div>
        </td>
    <td colspan="1" style="width:1%;vertical-align:bottom;white-space:nowrap;background-color:rgb(255, 255, 255)">&#160;</td> </tr>
  <tr style="background-color:rgb(204, 238, 255)">
    <td style="width:52%;vertical-align:bottom;background-color:rgb(204, 238, 255)">
        <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt">Loss upon entering Transactions</p>
        </td>
    <td colspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" style="text-align:right;width:9%;vertical-align:bottom;background-color:rgb(204, 238, 255)"><ix:nonFraction id="Fxbrl_20241112222806175_20241205041231191_93" name="slxn:LossUponEnteringTransactions" contextRef="C_20240101to20240930" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,783</ix:nonFraction></td>
    <td colspan="1" style="width:1%;vertical-align:bottom;white-space:nowrap;background-color:rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" style="text-align:right;width:9%;vertical-align:bottom;background-color:rgb(204, 238, 255)"><ix:nonFraction id="Fxbrl_20241112222806175_20241205041231182_64" name="slxn:LossUponEnteringTransactions" contextRef="C_20230101to20230930" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></td>
    <td colspan="1" style="width:1%;vertical-align:bottom;white-space:nowrap;background-color:rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" style="text-align:right;width:9%;vertical-align:bottom;background-color:rgb(204, 238, 255)"><ix:nonFraction id="Fxbrl_20241112222806175_20241205041231191_94" name="slxn:LossUponEnteringTransactions" contextRef="C_20240701to20240930" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,783</ix:nonFraction></td>
    <td colspan="1" style="width:1%;vertical-align:bottom;white-space:nowrap;background-color:rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" style="text-align:right;width:9%;vertical-align:bottom;background-color:rgb(204, 238, 255)"><ix:nonFraction id="Fxbrl_20241112222806175_20241205041231182_65" name="slxn:LossUponEnteringTransactions" contextRef="C_20230701to20230930" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></td>
    <td colspan="1" style="width:1%;vertical-align:bottom;white-space:nowrap;background-color:rgb(204, 238, 255)">&#160;</td> </tr>
  <tr style="background-color:rgb(255, 255, 255)">
    <td style="width:52%;vertical-align:bottom;background-color:rgb(255, 255, 255)">
        <div style="line-height:1.25">Interest income</div> </td>
    <td colspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(255, 255, 255)">&#160;</td>
    <td colspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(255, 255, 255)">&#160;</td>
    <td colspan="1" style="text-align:right;width:9%;vertical-align:bottom;background-color:rgb(255, 255, 255)">
        <div style="line-height:1.25">(<ix:nonFraction id="F20241205041231183_66" name="us-gaap:InterestRevenueExpenseNet" contextRef="C_20240101to20240930" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">25</ix:nonFraction></div>
        </td>
    <td colspan="1" style="width:1%;vertical-align:bottom;white-space:nowrap;background-color:rgb(255, 255, 255)">
        <div style="line-height:1.25">)</div> </td>
    <td colspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(255, 255, 255)">&#160;</td>
    <td colspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(255, 255, 255)">&#160;</td>
    <td colspan="1" style="text-align:right;width:9%;vertical-align:bottom;background-color:rgb(255, 255, 255)">
        <div style="line-height:1.25">(<ix:nonFraction id="F20241205041231183_67" name="us-gaap:InterestRevenueExpenseNet" contextRef="C_20230101to20230930" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">120</ix:nonFraction></div>
        </td>
    <td colspan="1" style="width:1%;vertical-align:bottom;white-space:nowrap;background-color:rgb(255, 255, 255)">
        <div style="line-height:1.25">)</div> </td>
    <td colspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(255, 255, 255)">&#160;</td>
    <td colspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(255, 255, 255)">&#160;</td>
    <td colspan="1" style="text-align:right;width:9%;vertical-align:bottom;background-color:rgb(255, 255, 255)">
        <div style="line-height:1.25"><ix:nonFraction id="F20241205041231183_68" name="us-gaap:InterestRevenueExpenseNet" contextRef="C_20240701to20240930" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></div>
        </td>
    <td colspan="1" style="width:1%;vertical-align:bottom;white-space:nowrap;background-color:rgb(255, 255, 255)">&#160;</td>
    <td colspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(255, 255, 255)">&#160;</td>
    <td colspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(255, 255, 255)">&#160;</td>
    <td colspan="1" style="text-align:right;width:9%;vertical-align:bottom;background-color:rgb(255, 255, 255)">
        <div style="line-height:1.25">(<ix:nonFraction id="F20241205041231191_95" name="us-gaap:InterestRevenueExpenseNet" contextRef="C_20230701to20230930" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">42</ix:nonFraction></div>
        </td>
    <td colspan="1" style="width:1%;vertical-align:bottom;white-space:nowrap;background-color:rgb(255, 255, 255)">
        <div style="line-height:1.25">)</div> </td> </tr>
  <tr style="background-color:rgb(204, 238, 255)">
    <td style="width:52%;vertical-align:bottom;background-color:rgb(204, 238, 255)">
        <div style="line-height:1.25">Foreign currency exchange loss, net</div> </td>
    <td colspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" style="text-align:right;width:9%;vertical-align:bottom;background-color:rgb(204, 238, 255)">
        <div style="line-height:1.25"><ix:nonFraction id="F20241205041231184_69" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" contextRef="C_20240101to20240930" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">196</ix:nonFraction></div>
        </td>
    <td colspan="1" style="width:1%;vertical-align:bottom;white-space:nowrap;background-color:rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" style="text-align:right;width:9%;vertical-align:bottom;background-color:rgb(204, 238, 255)">
        <div style="line-height:1.25"><ix:nonFraction id="F20241205041231184_70" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" contextRef="C_20230101to20230930" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">520</ix:nonFraction></div>
        </td>
    <td colspan="1" style="width:1%;vertical-align:bottom;white-space:nowrap;background-color:rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" style="text-align:right;width:9%;vertical-align:bottom;background-color:rgb(204, 238, 255)">
        <div style="line-height:1.25"><ix:nonFraction id="F20241205041231184_71" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" contextRef="C_20240701to20240930" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">48</ix:nonFraction></div>
        </td>
    <td colspan="1" style="width:1%;vertical-align:bottom;white-space:nowrap;background-color:rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" style="text-align:right;width:9%;vertical-align:bottom;background-color:rgb(204, 238, 255)">
        <div style="line-height:1.25"><ix:nonFraction id="F20241205041231185_72" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" contextRef="C_20230701to20230930" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">69</ix:nonFraction></div>
        </td>
    <td colspan="1" style="width:1%;vertical-align:bottom;white-space:nowrap;background-color:rgb(204, 238, 255)">&#160;</td> </tr>
  <tr style="background-color:rgb(255, 255, 255)">
    <td style="width:52%;padding-bottom:2px;vertical-align:bottom;background-color:rgb(255, 255, 255)">
        <div style="line-height:1.25">Other</div> </td>
    <td colspan="1" style="width:1%;padding-bottom:2px;vertical-align:bottom;background-color:rgb(255, 255, 255)">&#160;</td>
    <td colspan="1" style="width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom;background-color:rgb(255, 255, 255)">&#160;</td>
    <td colspan="1" style="text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom;background-color:rgb(255, 255, 255)">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><ix:nonFraction id="F20241205041231185_73" name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="C_20240101to20240930" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">5</ix:nonFraction></div>
        </div> </td>
    <td colspan="1" style="width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap;background-color:rgb(255, 255, 255)">&#160;</td>
    <td colspan="1" style="width:1%;padding-bottom:2px;vertical-align:bottom;background-color:rgb(255, 255, 255)">&#160;</td>
    <td colspan="1" style="width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom;background-color:rgb(255, 255, 255)">&#160;</td>
    <td colspan="1" style="text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom;background-color:rgb(255, 255, 255)">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><ix:nonFraction id="F20241205041231185_74" name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="C_20230101to20230930" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">5</ix:nonFraction></div>
        </div> </td>
    <td colspan="1" style="width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap;background-color:rgb(255, 255, 255)">&#160;</td>
    <td colspan="1" style="width:1%;padding-bottom:2px;vertical-align:bottom;background-color:rgb(255, 255, 255)">&#160;</td>
    <td colspan="1" style="width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom;background-color:rgb(255, 255, 255)">&#160;</td>
    <td colspan="1" style="text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom;background-color:rgb(255, 255, 255)">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><ix:nonFraction id="F20241205041231186_75" name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="C_20240701to20240930" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">3</ix:nonFraction></div>
        </div> </td>
    <td colspan="1" style="width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap;background-color:rgb(255, 255, 255)">&#160;</td>
    <td colspan="1" style="width:1%;padding-bottom:2px;vertical-align:bottom;background-color:rgb(255, 255, 255)">&#160;</td>
    <td colspan="1" style="width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom;background-color:rgb(255, 255, 255)">&#160;</td>
    <td colspan="1" style="text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom;background-color:rgb(255, 255, 255)">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><ix:nonFraction id="F20241205041231186_76" name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="C_20230701to20230930" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1</ix:nonFraction></div>
        </div> </td>
    <td colspan="1" style="width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap;background-color:rgb(255, 255, 255)">&#160;</td>
        </tr>
  <tr style="background-color:rgb(204, 238, 255)">
    <td style="width:52%;padding-bottom:4px;vertical-align:bottom;background-color:rgb(204, 238, 255)">
        <div style="line-height:1.25">Total financial expense, net</div> </td>
    <td colspan="1" style="width:1%;padding-bottom:4px;vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" style="width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom;background-color:rgb(204, 238, 255)">
        <div style="line-height:1.25">
        <div style="line-height:1.25">$</div> </div> </td>
    <td colspan="1" style="text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom;background-color:rgb(204, 238, 255)">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><ix:nonFraction id="F20241205041231186_77" name="us-gaap:NonoperatingIncomeExpense" contextRef="C_20240101to20240930" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,092</ix:nonFraction></div>
        </div> </td>
    <td colspan="1" style="width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap;background-color:rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" style="width:1%;padding-bottom:4px;vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" style="width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom;background-color:rgb(204, 238, 255)">
        <div style="line-height:1.25">
        <div style="line-height:1.25">$</div> </div> </td>
    <td colspan="1" style="text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom;background-color:rgb(204, 238, 255)">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><ix:nonFraction id="F20241205041231186_78" name="us-gaap:NonoperatingIncomeExpense" contextRef="C_20230101to20230930" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">449</ix:nonFraction></div>
        </div> </td>
    <td colspan="1" style="width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap;background-color:rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" style="width:1%;padding-bottom:4px;vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" style="width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom;background-color:rgb(204, 238, 255)">
        <div style="line-height:1.25">
        <div style="line-height:1.25">$</div> </div> </td>
    <td colspan="1" style="text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom;background-color:rgb(204, 238, 255)">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><ix:nonFraction id="F20241205041231187_79" name="us-gaap:NonoperatingIncomeExpense" contextRef="C_20240701to20240930" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,822</ix:nonFraction></div>
        </div> </td>
    <td colspan="1" style="width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap;background-color:rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" style="width:1%;padding-bottom:4px;vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" style="width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom;background-color:rgb(204, 238, 255)">
        <div style="line-height:1.25">
        <div style="line-height:1.25">$</div> </div> </td>
    <td colspan="1" style="text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom;background-color:rgb(204, 238, 255)">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><ix:nonFraction id="F20241205041231187_80" name="us-gaap:NonoperatingIncomeExpense" contextRef="C_20230701to20230930" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">72</ix:nonFraction></div>
        </div> </td>
    <td colspan="1" style="width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap;background-color:rgb(204, 238, 255)">&#160;</td>
        </tr>
  </table> </div> </div> </ix:nonNumeric> </div> </div> </ix:nonNumeric> </div>

<p style="margin:0pt">&#160;</p>

<div>

<div> <ix:nonNumeric id="F20241205041231200_0" name="us-gaap:LesseeOperatingLeasesTextBlock" contextRef="C_20240101to20240930" escape="true">

<div>

<div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Note
5 - LEASES</span></span></div>

<div style="line-height:1.25;font-weight:bold">&#160;</div>

<table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">
  <tr>
    <td style="width:51pt">&#160;</td>
    <td style="width:18pt;vertical-align:top;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">a.</span></span></td>
    <td style="width:auto;vertical-align:top;text-align:justify">
        <div>
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">On August 15, 2024, the
        Company vacated its office spaces and facilities in Israel. On September 8, 2024, an early termination agreement for the operating lease
        was signed with the landlord, which included a termination penalty. As a result, the Company derecognized the right-of-use asset and the
        lease liability in its financial statements, recording a loss of $<ix:nonFraction id="F20241205041231200_1" name="us-gaap:GainLossOnTerminationOfLease" contextRef="C_20240901to20240908" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">68</ix:nonFraction>
        from the lease termination and an additional $<ix:nonFraction id="F20241205041231200_3" name="slxn:DisposalOfLeaseholdImprovements" contextRef="C_20240901to20240908" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">18</ix:nonFraction>
        from the disposal of leasehold improvements.</span></span></div> </div> </td> </tr>
  </table>

<div style="line-height:1.25">&#160;</div>

<table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">
  <tr>
    <td style="width:51pt">&#160;</td>
    <td style="width:18pt;vertical-align:top;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">b.</span></span></td>
    <td style="width:auto;vertical-align:top;text-align:justify">
        <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">On September 26, 2024 the Company signed a new
        lease agreement for an office in Israel starting November 1, 2024 and ending on October 31, 2026. The Company will pay a monthly payment
        of $<ix:nonFraction id="F20241205041231200_2" name="us-gaap:OperatingLeasesRentExpenseMinimumRentals" contextRef="C_20240901to20240926" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">10</ix:nonFraction>
        to the lessor.</span></span></div> </td> </tr>
  </table> </div> </ix:nonNumeric>

<p style="margin:0pt">&#160;</p>

<div style="margin-top:10pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">

<p style="text-align:center;margin-top:0pt;margin-bottom:3pt"><span style="width:34%;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">F-59</span></span></span></p></div><hr style="page-break-after:always;border-width:0px;clear:both;margin:4px 0px;width:100%;height:2px;color:#000000;background-color:#000000;margin-top:0pt;margin-bottom:10pt"/>

<p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:center">&#160;</p>

<p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:center"><strong>SILEXION
THERAPEUTICS CORP</strong><br/>NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) (continued)<br/>(U.S. dollars in thousands)</p>

<p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:center">&#160;</p> </div>
</div>

<div style="font:10pt Times New Roman, Times, Serif"> <ix:nonNumeric id="F20241205041231203_0" name="us-gaap:PreferredStockTextBlock" contextRef="C_20240101to20240930" escape="true">

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0"><strong><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">NOTE
6&#160; - WARRANTS TO PURCHASE PREFERRED SHARES:</span></span></strong></p>

<div>

<div>

<div style="line-height:1.25">&#160;</div>

<div style="text-align:justify;line-height:1.25;margin-left:69pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">On
May 30, 2023, Silexion issued warrants to acquire <ix:nonFraction id="F20241205041231203_1" name="slxn:WarrantsIssued" contextRef="C_20230530" unitRef="shares" scale="0" decimals="0" format="ixt:num-dot-decimal">2,413</ix:nonFraction>
Series A-4 Preferred Shares to various investors, with an exercise price of $<ix:nonFraction id="F20241205041231203_2" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="C_20230530" unitRef="ilsPershares" scale="0" decimals="3" format="ixt:num-dot-decimal">222.921</ix:nonFraction>&#160;per
share and an expiration date of May 30, 2025. Issuance expenses amounted to $<ix:nonFraction id="F20241205041231203_3" name="us-gaap:OtherExpenses" contextRef="C_20230501to20230530" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">3</ix:nonFraction>.
On August 6, 2024, all of these warrants were exercised via a &#8216;cashless&#8217; manner for<ix:nonFraction id="F20241205041231203_4" name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="C_20240806" unitRef="shares" scale="0" decimals="0" format="ixt:num-dot-decimal">
913</ix:nonFraction> Preferred A4 shares of Silexion.</span></span></div>

<div style="line-height:1.25">&#160;</div>

<div style="text-align:justify;line-height:1.25;margin-left:69pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Silexion
classified the warrants for the purchase of shares of its convertible redeemable preferred shares as a liability in its consolidated balance
sheets, as these warrants were freestanding financial instruments which underlying shares were contingently redeemable and, therefore,
may have obligated the Company to transfer assets at some point in the future. The warrant liability was initially recorded at fair value
upon the date of issuance and was subsequently remeasured at fair value at each reporting date. The Company (or Silexion, as applicable)
recorded revaluation expenses amounting to $<ix:nonFraction id="F20241205041231203_5" name="slxn:RevaluationExpensesIncome" contextRef="C_20240101to20240930" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">134</ix:nonFraction>
and $<ix:nonFraction id="F20241205041231203_6" name="slxn:RevaluationExpensesIncome" contextRef="C_20230101to20230930" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">40</ix:nonFraction>
for the nine months periods ended September 30, 2024 and September 30, 2023 , respectively, and revaluation (income) expenses amounting
to $(<ix:nonFraction id="F20241205041231203_7" name="slxn:RevaluationExpensesIncome" contextRef="C_20240701to20240930" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">11</ix:nonFraction>)
and $<ix:nonFraction id="F20241205041231203_8" name="slxn:RevaluationExpensesIncome" contextRef="C_20230701to20230930" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">43</ix:nonFraction>
for the three months periods ended September 30, 2024 and September 30, 2023 and accounted for such revaluation expenses as part of its
financial (income) expense, net, in the statements of operations (see Note 8).</span></span></div>

<div style="line-height:1.25">&#160;</div>

<div style="text-align:justify;line-height:1.25;margin-left:69pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">For
further information in respect of warrants granted to a service provider and exercised, see Note 7.</span></span></div>

<div style="text-align:justify;line-height:1.25">&#160;</div>

<div style="text-align:justify;line-height:1.25;margin-left:69pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">For
cashless exercise of these warrants see Note 1(d).</span></span></div> </div> </div> </ix:nonNumeric>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p> </div>

<div style="font:10pt Times New Roman, Times, Serif"> <ix:nonNumeric id="F20241205041231223_37" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" contextRef="C_20240101to20240930" escape="true">

<div>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0"><strong><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">NOTE
7&#160; - SHARE-BASED COMPENSATION:</span></span></strong></p>

<div>

<div>

<div style="line-height:1.25">&#160;</div>

<div style="text-align:justify;margin-left:69pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The
Company's (or Silexion&#8217;s, as applicable) share-based expenses amounted to a total of&#160;$<ix:nonFraction id="F20241205041231208_0" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_20240101to20240930" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,862</ix:nonFraction>
and $<ix:nonFraction id="F20241205041231210_1" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_20230101to20230930" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">96</ix:nonFraction>
in the nine months periods ended September 30, 2024 and 2023, respectively.&#160;As of September 30, 2024, <ix:nonFraction id="F20241205041231210_2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" contextRef="C_20240930" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">63,953</ix:nonFraction>&#160;shares
remain available for grant under the Company&#8217;s 2013, 2023 and 2024 Equity Incentive Plans.</span></span></div>

<div style="line-height:1.25">&#160;</div>

<div style="text-align:justify;margin-left:69pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">On
July 4, 2024, Silexion&#8217;s board of directors approved granting fully vested <ix:nonFraction id="F20241205041231211_3" name="srt:StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased" contextRef="C_20240704_usgaapAwardTypeAxis_usgaapRestrictedStockUnitsRSUMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">78,650</ix:nonFraction>&#160;RSUs
to Silexion&#8217;s employees and directors amounting to a total of $<ix:nonFraction id="F20241205041231231_51" name="slxn:StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchasedValue" contextRef="C_20240701to20240704_usgaapAwardTypeAxis_usgaapRestrictedStockUnitsRSUMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,578</ix:nonFraction>.
For a description of the acceleration of the Company&#8217;s options prior to the Closing of the Transactions, see Note 1(d).</span></span></div>

<div style="line-height:1.25">&#160;</div>

<div style="text-align:justify;margin-left:69pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The
fair value for the RSUs granted is based on the following assumptions:</span></span></div>

<div style="text-align:justify;margin-left:63.8pt;line-height:1.25">&#160;</div>

<div style="margin-left:72pt"> <ix:nonNumeric id="F20241205041231225_45" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" contextRef="C_20240101to20240930" escape="true">

<table border="0" cellpadding="0" cellspacing="0" style="width:85%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left">
  <tr>
    <td style="vertical-align:top;width:88%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Expected volatility</span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="F20241205041231224_42" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="C_20240101to20240930" unitRef="pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">74.82</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">%</span></span></div>
        </td> </tr>
  <tr>
    <td style="vertical-align:top;width:88%;vertical-align:bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Assumptions regarding
        the price of the underlying shares:</span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:top;width:88%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Probability of an IPO
        scenario (including de-SPAC transaction)</span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="F20241205041231225_46" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="C_20240101to20240930_usgaapSubsidiarySaleOfStockAxis_usgaapIPOMember" unitRef="pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">67</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">%</span></span></div>
        </td> </tr>
  <tr>
    <td style="vertical-align:top;width:88%;padding-bottom:2px;vertical-align:bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Expected time to IPO
        (including de-SPAC transaction) (years)</span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonNumeric id="F20241205041231227_47" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" contextRef="C_20240101to20240930_usgaapSubsidiarySaleOfStockAxis_usgaapIPOMember" format="ixt-sec:duryear">0.137</ix:nonNumeric></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:top;width:88%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Probability of other
        liquidation events</span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="F20241205041231230_49" name="slxn:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsProbabilityOfOtherLiquidationEvents" contextRef="C_20240101to20240930" unitRef="pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">33</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">%</span></span></div>
        </td> </tr>
  <tr>
    <td style="vertical-align:top;width:88%;padding-bottom:2px;vertical-align:bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Expected time to liquidation
        (years)</span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonNumeric id="F20241205041231224_43" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" contextRef="C_20240101to20240930" format="ixt-sec:duryear">2.25</ix:nonNumeric></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:top;width:88%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Expected return on Equity</span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="F20241205041231230_48" name="slxn:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedReturnOnEquity" contextRef="C_20240101to20240930" unitRef="pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">22</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">%</span></span></div>
        </td> </tr>
  </table> </ix:nonNumeric> </div>&#160;

<div style="text-align:justify;margin-left:69pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">On
August 6, 2024, a service provider exercised the warrants in a &#8216;cashless&#8217; manner, resulting in the issuance of <ix:nonFraction id="F20241205041231225_44" name="slxn:WarrantsIssued" contextRef="C_20240806_usgaapStatementClassOfStockAxis_slxnSeriesA1PreferredSharesMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">140</ix:nonFraction>&#160;Series
A-1 Preferred Shares and 12 Series A-4 Preferred Shares of Silexion (see Note 11(1) to the audited financial statements of Silexion as
of December 31, 2023, which were published on May 9, 2024).</span></span><br/>&#160;</div>

<div><ix:exclude>

<div style="text-align:justify;line-height:1.25">

<div style="margin-top:10pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">

<p style="text-align:center;margin-top:0pt;margin-bottom:3pt"><span style="width:34%;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">F-60</span></span></span></p></div><hr style="page-break-after:always;border-width:0px;clear:both;margin:4px 0px;width:100%;height:2px;color:#000000;background-color:#000000;margin-top:0pt;margin-bottom:10pt"/>

<p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:center">&#160;</p>

<p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:center"><strong>SILEXION
THERAPEUTICS CORP</strong><br/>NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) (continued)<br/>(U.S. dollars in thousands)</p>

<p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:center">&#160;</p> </div>

<div style="line-height:1.25;margin-top:0pt"><span style="font-size:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">NOTE
7&#160; - SHARE-BASED COMPENSATION </span>(continued):</span></span></span>

<p style="margin:0pt">&#160;</p> </div> </ix:exclude></div>

<div style="text-align:justify;margin-left:69pt;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Summary
of outstanding and exercisable options:</span></span></div>

<div style="text-align:justify;margin-left:49.65pt;line-height:1.25">&#160;</div>

<div>

<div>

<div style="line-height:1.25">

<div style="line-height:1.25;clear:both">

<div style="line-height:1.25">

<div style="line-height:1.25">

<table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">
  <tr>
    <td style="width:auto;vertical-align:top;text-align:justify">
        <div style="font-family:'Times New Roman',Times,serif">
        <div style="line-height:1.25">
        <div style="line-height:1.25;font-weight:bold">
        <div style="line-height:1.25;font-weight:normal;margin-left:69pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Below
        is a summary of the Company's (or for periods prior to the Closing of the Transactions, Silexion&#8217;s) stock-based compensation activity
        and related information with respect to options granted to employees and non-employees for the nine month period ended September 30, 2024:</span></span></div>
        </div> </div> </div> </td> </tr>
  </table>

<div style="line-height:1.25">&#160;</div> </div> </div> </div> </div>

<div style="margin-left:72pt"> <ix:nonNumeric id="Fxbrl_20241205121432074" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" contextRef="C_20240101to20240930" escape="true">

<table border="0" cellpadding="0" cellspacing="0" style="color:#000000;font-family:'Times New Roman',Times,serif;font-size:10pt;text-align:left;width:85%">
  <tr>
    <td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Number
        of options</span></span></div> </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Weighted-average
        exercise price (in U.S. dollars)</span></span></div> </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Weighted-
        average remaining contractual term</span></span></div>
        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(in
        years)</span></span></div> </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Aggregate</span></span></div>
        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">intrinsic</span></span></div>
        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">value</span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:bottom;width:52%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Outstanding at January
        1, 2024</span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="F20241205041231211_4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="C_20231231_usgaapGranteeStatusAxis_slxnShareBasedPaymentArrangementEmployeeAndNonEmployeeMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">53,914</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="F20241205041231212_5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="C_20231231_usgaapGranteeStatusAxis_slxnShareBasedPaymentArrangementEmployeeAndNonEmployeeMember" unitRef="usdPershares" scale="0" decimals="2" format="ixt:num-dot-decimal">38.94</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonNumeric id="F20241205041231212_6" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" contextRef="C_20230101to20231231_usgaapGranteeStatusAxis_slxnShareBasedPaymentArrangementEmployeeAndNonEmployeeMember" format="ixt-sec:duryear">4.88</ix:nonNumeric></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="F20241205041231230_50" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" contextRef="C_20231231_usgaapGranteeStatusAxis_slxnShareBasedPaymentArrangementEmployeeAndNonEmployeeMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">316</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align:bottom;width:52%;background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Granted</span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="F20241205041231223_38" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="C_20240101to20240930_usgaapGranteeStatusAxis_slxnShareBasedPaymentArrangementEmployeeAndNonEmployeeMember" unitRef="shares" scale="0" decimals="0" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="F20241205041231223_39" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="C_20240101to20240930_usgaapGranteeStatusAxis_slxnShareBasedPaymentArrangementEmployeeAndNonEmployeeMember" unitRef="usdPershares" scale="0" decimals="0" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align:bottom;width:52%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Exercised</span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="F20241205041231212_7" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="C_20240101to20240930_usgaapGranteeStatusAxis_slxnShareBasedPaymentArrangementEmployeeAndNonEmployeeMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">13,780</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="F20241205041231213_8" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" contextRef="C_20240101to20240930_usgaapGranteeStatusAxis_slxnShareBasedPaymentArrangementEmployeeAndNonEmployeeMember" unitRef="usdPershares" scale="0" decimals="2" format="ixt:num-dot-decimal">0.03</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonNumeric id="F20241205041231213_9" name="slxn:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTermExercised" contextRef="C_20240101to20240930_usgaapGranteeStatusAxis_slxnShareBasedPaymentArrangementEmployeeAndNonEmployeeMember" format="ixt-sec:duryear">0.01</ix:nonNumeric></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="F20241205041231213_10" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" contextRef="C_20240930_usgaapGranteeStatusAxis_slxnShareBasedPaymentArrangementEmployeeAndNonEmployeeMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">490</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align:bottom;width:52%;background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Forfeited</span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="F20241205041231214_11" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" contextRef="C_20240101to20240930_usgaapGranteeStatusAxis_slxnShareBasedPaymentArrangementEmployeeAndNonEmployeeMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">326</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom;white-space:nowrap">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="F20241205041231214_12" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" contextRef="C_20240101to20240930_usgaapGranteeStatusAxis_slxnShareBasedPaymentArrangementEmployeeAndNonEmployeeMember" unitRef="usdPershares" scale="0" decimals="2" format="ixt:num-dot-decimal">60.52</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonNumeric id="F20241205041231214_13" name="slxn:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTermForfeited" contextRef="C_20240101to20240930_usgaapGranteeStatusAxis_slxnShareBasedPaymentArrangementEmployeeAndNonEmployeeMember" format="ixt-sec:duryear">6.02</ix:nonNumeric></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom;white-space:nowrap">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align:bottom;width:52%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Expired</span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="F20241205041231215_14" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" contextRef="C_20240101to20240930_usgaapGranteeStatusAxis_slxnShareBasedPaymentArrangementEmployeeAndNonEmployeeMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">13,492</ix:nonFraction></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="F20241205041231215_15" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" contextRef="C_20240101to20240930_usgaapGranteeStatusAxis_slxnShareBasedPaymentArrangementEmployeeAndNonEmployeeMember" unitRef="usdPershares" scale="0" decimals="2" format="ixt:num-dot-decimal">41.06</ix:nonFraction></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align:bottom;width:52%;padding-bottom:4px;background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Outstanding at September
        30, 2024</span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="F20241205041231215_16" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="C_20240930_usgaapGranteeStatusAxis_slxnShareBasedPaymentArrangementEmployeeAndNonEmployeeMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">26,316</ix:nonFraction></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(255, 255, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="F20241205041231216_17" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="C_20240930_usgaapGranteeStatusAxis_slxnShareBasedPaymentArrangementEmployeeAndNonEmployeeMember" unitRef="usdPershares" scale="0" decimals="2" format="ixt:num-dot-decimal">57.97</ix:nonFraction></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(255, 255, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonNumeric id="F20241205041231216_18" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" contextRef="C_20240101to20240930_usgaapGranteeStatusAxis_slxnShareBasedPaymentArrangementEmployeeAndNonEmployeeMember" format="ixt-sec:duryear">7.09</ix:nonNumeric></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(255, 255, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(255, 255, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align:bottom;width:52%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Exercisable at September
        30, 2024</span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="F20241205041231216_19" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextRef="C_20240930_usgaapGranteeStatusAxis_slxnShareBasedPaymentArrangementEmployeeAndNonEmployeeMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">26,316</ix:nonFraction></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="F20241205041231217_20" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" contextRef="C_20240930_usgaapGranteeStatusAxis_slxnShareBasedPaymentArrangementEmployeeAndNonEmployeeMember" unitRef="usdPershares" scale="0" decimals="2" format="ixt:num-dot-decimal">57.97</ix:nonFraction></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonNumeric id="F20241205041231217_21" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" contextRef="C_20240101to20240930_usgaapGranteeStatusAxis_slxnShareBasedPaymentArrangementEmployeeAndNonEmployeeMember" format="ixt-sec:duryear">7.09</ix:nonNumeric></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align:bottom;width:52%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align:bottom;width:52%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Vested and expected to
        vest at September 30, 2024</span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="F20241205041231217_22" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" contextRef="C_20240930_usgaapGranteeStatusAxis_slxnShareBasedPaymentArrangementEmployeeAndNonEmployeeMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">26,316</ix:nonFraction></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="F20241205041231218_23" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" contextRef="C_20240930_usgaapGranteeStatusAxis_slxnShareBasedPaymentArrangementEmployeeAndNonEmployeeMember" unitRef="usdPershares" scale="0" decimals="2" format="ixt:num-dot-decimal">57.97</ix:nonFraction></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonNumeric id="F20241205041231218_24" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" contextRef="C_20240101to20240930_usgaapGranteeStatusAxis_slxnShareBasedPaymentArrangementEmployeeAndNonEmployeeMember" format="ixt-sec:duryear">7.09</ix:nonNumeric></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        </tr>
  </table> </ix:nonNumeric> </div>

<div style="line-height:1.25;clear:both">

<div style="line-height:1.25">

<div style="line-height:1.25;clear:both">

<div style="line-height:1.25">

<div style="line-height:1.25">

<div style="line-height:1.25">&#160;</div>

<table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">
  <tr>
    <td style="width:51pt">&#160;</td>
    <td style="width:18pt;vertical-align:top;font-weight:bold">&#160;</td>
    <td style="width:auto;vertical-align:top;text-align:justify">
        <div style="font-family:'Times New Roman',Times,serif">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Up to September 30, 2024
        and for the year ended December 31, 2023 no options were granted.</span></span></div> </div> </div> </td> </tr>
  </table> </div> </div> </div> </div> </div> </div> </div>

<div style="text-align:justify;margin-left:49.65pt;line-height:1.25">&#160;</div>

<div style="text-align:justify;margin-left:69pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The
share-based compensation expense by line item in the accompanying consolidated statements of operations is summarized as follows:</span></span></div>

<div style="line-height:1.25">&#160;</div>

<div style="margin-left:72pt"> <ix:nonNumeric id="F20241205041231224_41" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" contextRef="C_20240101to20240930" escape="true">

<table border="0" cellpadding="0" cellspacing="0" style="width:85%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left">
  <tr>
    <td rowspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
    <td colspan="1" rowspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
    <td colspan="6" rowspan="1" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Nine
        months ended</span></span></div>
        <div style="line-height:1.25">
        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">September
        30,</span></span></div> </div> </td>
    <td colspan="1" rowspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" rowspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
    <td colspan="6" rowspan="1" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Three
        months ended</span></span></div>
        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">September
        30,</span></span></div> </div> </td>
    <td colspan="1" rowspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td> </tr>
  <tr>
    <td rowspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
    <td colspan="1" rowspan="1" style="font-weight:bold;text-align:center;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
    <td colspan="2" rowspan="1" style="vertical-align:bottom;font-weight:bold;text-align:center;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2024</span></span></td>
    <td colspan="1" rowspan="1" style="font-weight:bold;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" rowspan="1" style="font-weight:bold;text-align:center;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
    <td colspan="2" rowspan="1" style="vertical-align:top;font-weight:bold;text-align:center;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2023</span></span></td>
    <td colspan="1" rowspan="1" style="font-weight:bold;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" rowspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
    <td colspan="2" rowspan="1" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center;vertical-align:bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">2024</span></span></span></td>
    <td colspan="1" rowspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" rowspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
    <td colspan="2" rowspan="1" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center;vertical-align:bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">2023</span></span></span></td>
    <td colspan="1" rowspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:bottom;width:52%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Research and development</span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="F20241205041231218_25" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_20240101to20240930_usgaapIncomeStatementLocationAxis_usgaapResearchAndDevelopmentExpenseMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,424</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="F20241205041231219_26" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_20230101to20230930_usgaapIncomeStatementLocationAxis_usgaapResearchAndDevelopmentExpenseMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">57</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="F20241205041231219_27" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_20240701to20240930_usgaapIncomeStatementLocationAxis_usgaapResearchAndDevelopmentExpenseMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,385</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="F20241205041231220_28" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_20230701to20230930_usgaapIncomeStatementLocationAxis_usgaapResearchAndDevelopmentExpenseMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">19</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align:bottom;width:52%;padding-bottom:2px;vertical-align:bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">General and administrative</span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="F20241205041231220_29" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_20240101to20240930_usgaapIncomeStatementLocationAxis_usgaapGeneralAndAdministrativeExpenseMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,438</ix:nonFraction></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="F20241205041231220_30" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_20230101to20230930_usgaapIncomeStatementLocationAxis_usgaapGeneralAndAdministrativeExpenseMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">39</ix:nonFraction></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="F20241205041231221_31" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_20240701to20240930_usgaapIncomeStatementLocationAxis_usgaapGeneralAndAdministrativeExpenseMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,413</ix:nonFraction></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="F20241205041231221_32" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_20230701to20230930_usgaapIncomeStatementLocationAxis_usgaapGeneralAndAdministrativeExpenseMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">13</ix:nonFraction></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:bottom;width:52%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="F20241205041231221_33" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_20240101to20240930" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,862</ix:nonFraction></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="F20241205041231222_34" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_20230101to20230930" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">96</ix:nonFraction></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="F20241205041231222_35" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_20240701to20240930" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,798</ix:nonFraction></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="F20241205041231222_36" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_20230701to20230930" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">32</ix:nonFraction></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        </tr>
  </table> </ix:nonNumeric> </div> </div> </div> </div> </ix:nonNumeric>

<p style="margin:0pt">&#160;</p> </div> <ix:nonNumeric id="Fxbrl_20241205135723838" name="us-gaap:FairValueDisclosuresTextBlock" contextRef="C_20240101to20240930" escape="true">

<div>

<div style="font:10pt Times New Roman, Times, Serif">

<div>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0"><strong><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">NOTE
8&#160; - FAIR VALUE MEASUREMENTS:</span></span></strong></p>

<div>

<div>

<div style="line-height:1.25">

<div style="line-height:1.25;clear:both">

<div style="line-height:1.25">

<div style="line-height:1.25;clear:both">

<div style="line-height:1.25">

<div style="line-height:1.25">

<div style="line-height:1.25">&#160;</div>

<table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">
  <tr>
    <td style="width:51pt">&#160;</td>
    <td style="width:18pt;vertical-align:top;font-weight:bold">&#160;</td>
    <td style="width:auto;vertical-align:top;text-align:justify">
        <div style="font-family:'Times New Roman',Times,serif">
        <div style="line-height:1.25">
        <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Financial
        instruments measured at fair value on a recurring basis</span></span></div>
        <div style="line-height:1.25">&#160;</div>
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The Company&#8217;s (or,
        for periods prior to the Closing of the Transactions, Silexion&#8217;s) assets and liabilities that are measured at fair value as of September
        30, 2024, and December 31, 2023, are classified in the tables below in one of the three categories described in &#8220;Note 2 &#8211;
        Fair value measurement&#8221;:</span></span></div> </div> </div> </td> </tr>
  </table> </div> </div> </div> </div> </div> </div> </div>

<div style="font-size:10pt;margin-top:0pt;margin-bottom:0pt;font-family:'Times New Roman', Times, serif">&#160;</div> <ix:nonNumeric id="Fxbrl_20241205134547501" name="us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" contextRef="C_20240101to20240930" escape="true">

<div>

<div>

<div>

<div style="margin-left:72pt">

<table border="0" cellpadding="0" cellspacing="0" style="color:#000000;font-family:'Times New Roman',Times,serif;font-size:10pt;text-align:left;width:85%">
  <tr>
    <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
    <td colspan="6" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">September
        30, 2024</span></span></div> </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
    <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Level
        3</span></span></div> </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
    <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Total</span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:top;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="text-align:justify;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Financial
        Liabilities</span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="2" style="vertical-align:top;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="2" style="vertical-align:top;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:top;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="2" style="vertical-align:top;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;background-color:rgb(255, 255, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="2" style="vertical-align:top;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;background-color:rgb(255, 255, 255);vertical-align:bottom;white-space:nowrap">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:top;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="margin-left:14.2pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Private
        Warrants to purchase ordinary shares</span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20241111180500034_20241205041231239_0" name="us-gaap:OtherLiabilitiesCurrent" contextRef="C_20240930_usgaapFairValueByFairValueHierarchyLevelAxis_usgaapFairValueInputsLevel3Member_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">10</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20241111180500034_20241205041231240_1" name="us-gaap:OtherLiabilitiesCurrent" contextRef="C_20240930_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">10</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align:top;width:76%;background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="margin-left:14.2pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Promissory
        Notes</span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20241111180458001_20241205041231239_0" name="us-gaap:OtherLiabilitiesCurrent" contextRef="C_20240930_usgaapFairValueByFairValueHierarchyLevelAxis_usgaapFairValueInputsLevel3Member_usgaapStatementEquityComponentsAxis_slxnPromissoryNotesMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,312</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20241111180458001_20241205041231240_1" name="us-gaap:OtherLiabilitiesCurrent" contextRef="C_20240930_usgaapStatementEquityComponentsAxis_slxnPromissoryNotesMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,312</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        </tr>
  </table> </div>

<div style="font-size:10pt;margin-top:0pt;margin-bottom:0pt;font-family:'Times New Roman', Times, serif">&#160;</div>

<div style="margin-left:72pt">

<table border="0" cellpadding="0" cellspacing="0" style="width:85%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left;float:left">
  <tr>
    <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
    <td colspan="6" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">December
        31, 2023</span></span></div> </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
    <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25;font-weight:bold;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Level
        3</span></span></div> </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
    <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Total</span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:top;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="text-align:justify;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Financial
        Liabilities</span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="2" style="vertical-align:top;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="2" style="vertical-align:top;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:top;width:76%;background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="margin-left:14.2pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Warrants
        to preferred shares</span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="F20241205041231239_0" name="us-gaap:OtherLiabilitiesCurrent" contextRef="C_20231231_usgaapFairValueByFairValueHierarchyLevelAxis_usgaapFairValueInputsLevel3Member_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">200</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="F20241205041231240_1" name="us-gaap:OtherLiabilitiesCurrent" contextRef="C_20231231_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">200</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        </tr>
  </table> </div> </div> </div> </div> </ix:nonNumeric>

<div style="line-height:1.25;clear:both">&#160;</div>

<div><ix:exclude>

<div style="line-height:1.25">

<div style="margin-top:10pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">

<p style="text-align:center;margin-top:0pt;margin-bottom:3pt"><span style="width:34%;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">F-61</span></span></span></p></div><hr style="page-break-after:always;border-width:0px;clear:both;margin:4px 0px;width:100%;height:2px;color:#000000;background-color:#000000;margin-top:0pt;margin-bottom:10pt"/>

<p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:center">&#160;</p>

<p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:center"><strong>SILEXION
THERAPEUTICS CORP</strong><br/>NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) (continued)<br/>(U.S. dollars in thousands)</p>

<p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:center">&#160;</p> </div>

<div style="line-height:1.25;font-family:'Times New Roman', Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">NOTE
8&#160; - FAIR VALUE MEASUREMENTS </span>(continued)<span style="font-weight:bold">:</span></span></span></div>

<div style="line-height:1.25;font-family:'Times New Roman', Times, serif">&#160;</div> </ix:exclude></div> </div> </div>

<div style="line-height:1.25">

<div style="line-height:1.25">

<div style="line-height:1.25;clear:both">

<div style="line-height:1.25">

<div style="line-height:1.25;clear:both">

<div style="line-height:1.25">

<div style="line-height:1.25">

<table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">
  <tr>
    <td style="width:51pt">&#160;</td>
    <td style="width:18pt;vertical-align:top;font-weight:bold">&#160;</td>
    <td style="width:auto;vertical-align:top;text-align:justify">
        <div style="font-family:'Times New Roman',Times,serif">
        <div style="line-height:1.25">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The following is a roll
        forward of the fair value of liabilities classified under Level 3:</span></span></div> </div> </div> </div> </td> </tr>
  </table> </div> </div> </div> </div> </div> </div> </div> </div>

<div style="font-size:10pt;margin-top:0pt;margin-bottom:0pt;font-family:'Times New Roman', Times, serif">&#160;</div> <ix:nonNumeric id="Fxbrl_20241205135839113" name="us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" contextRef="C_20240101to20240930" escape="true">

<div>

<div>

<div>

<div>

<div style="margin-left:72pt">

<table border="0" cellpadding="0" cellspacing="0" style="color:#000000;font-family:'Times New Roman',Times,serif;font-size:10pt;text-align:left;width:85%">
  <tr>
    <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
    <td colspan="10" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
        <div style="line-height:1.25">
        <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Nine
        months ended</span></span></div>
        <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">September
        30, 2024</span></span></div> </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center">&#160;</td>
    <td colspan="10" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
        <div style="line-height:1.25">
        <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Three
        months ended</span></span></div>
        <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">September
        30, 2024</span></span></div> </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
        <div style="line-height:1.25">
        <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Warrants
        to preferred shares</span></span></div> </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center">&#160;</td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
        <div style="line-height:1.25">
        <div style="line-height:1.25;font-weight:bold;text-indent:0.2pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Warrants
        to Ordinary shares</span></span></div> </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center">&#160;</td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
        <div style="line-height:1.25">
        <div style="line-height:1.25">&#160;</div>
        <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Promissory
        Notes</span></span></div> </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center">&#160;</td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
        <div style="line-height:1.25">
        <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Warrants
        to preferred shares</span></span></div> </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center">&#160;</td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
        <div style="line-height:1.25">
        <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Warrants
        to Ordinary shares</span></span></div> </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center">&#160;</td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><strong><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Promissory</span></span></strong></div>
        <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Notes</span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td> </tr>
  <tr>
    <td colspan="1" style="vertical-align:bottom;width:28%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Fair value at the beginning
        of the period</span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="F20241205041231240_2" name="us-gaap:OtherLiabilitiesCurrent" contextRef="C_20231231_usgaapClassOfWarrantOrRightAxis_usgaapWarrantMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">200</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20241111174808356_20241205041231240_2" name="us-gaap:OtherLiabilitiesCurrent" contextRef="C_20231231_usgaapClassOfWarrantOrRightAxis_usgaapWarrantMember_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20241111174808356_xbrl_20241111174758445_20241205041231240_2" name="us-gaap:OtherLiabilitiesCurrent" contextRef="C_20231231_usgaapClassOfWarrantOrRightAxis_usgaapWarrantMember_usgaapStatementEquityComponentsAxis_slxnPromissoryNotesMember" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20241111174808356_xbrl_20241111174758445_xbrl_20241111174712541_20241205041231240_2" name="us-gaap:OtherLiabilitiesCurrent" contextRef="C_20240630_usgaapClassOfWarrantOrRightAxis_usgaapWarrantMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">345</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20241111174808356_xbrl_20241111174758445_xbrl_20241111174712541_xbrl_20241111174705885_20241205041231240_2" name="us-gaap:OtherLiabilitiesCurrent" contextRef="C_20240630_usgaapClassOfWarrantOrRightAxis_usgaapWarrantMember_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20241111174808356_xbrl_20241111174758445_xbrl_20241111174712541_xbrl_20241111174705885_xbrl_20241111174656654_20241205041231240_2" name="us-gaap:OtherLiabilitiesCurrent" contextRef="C_20240630_usgaapClassOfWarrantOrRightAxis_usgaapWarrantMember_usgaapStatementEquityComponentsAxis_slxnPromissoryNotesMember" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        </tr>
  <tr>
    <td colspan="1" style="vertical-align:bottom;width:28%;background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Issuance</span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="F20241205041231242_6" name="us-gaap:ProceedsFromDebtNetOfIssuanceCosts" contextRef="C_20240101to20240930_usgaapClassOfWarrantOrRightAxis_usgaapWarrantMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20241111174808366_20241205041231242_6" name="us-gaap:ProceedsFromDebtNetOfIssuanceCosts" contextRef="C_20240101to20240930_usgaapClassOfWarrantOrRightAxis_usgaapWarrantMember_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,130</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20241111174808366_xbrl_20241111174758454_20241205041231242_6" name="us-gaap:ProceedsFromDebtNetOfIssuanceCosts" contextRef="C_20240101to20240930_usgaapClassOfWarrantOrRightAxis_usgaapWarrantMember_usgaapStatementEquityComponentsAxis_slxnPromissoryNotesMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,622</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20241111174808366_xbrl_20241111174758454_xbrl_20241111174712548_20241205041231242_6" name="us-gaap:ProceedsFromDebtNetOfIssuanceCosts" contextRef="C_20240701to20240930_usgaapClassOfWarrantOrRightAxis_usgaapWarrantMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20241111174808366_xbrl_20241111174758454_xbrl_20241111174712548_xbrl_20241111174705888_20241205041231242_6" name="us-gaap:ProceedsFromDebtNetOfIssuanceCosts" contextRef="C_20240701to20240930_usgaapClassOfWarrantOrRightAxis_usgaapWarrantMember_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,130</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20241111174808366_xbrl_20241111174758454_xbrl_20241111174712548_xbrl_20241111174705888_xbrl_20241111174656655_20241205041231242_6" name="us-gaap:ProceedsFromDebtNetOfIssuanceCosts" contextRef="C_20240701to20240930_usgaapClassOfWarrantOrRightAxis_usgaapWarrantMember_usgaapStatementEquityComponentsAxis_slxnPromissoryNotesMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,622</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        </tr>
  <tr>
    <td colspan="1" style="vertical-align:bottom;width:28%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Change in fair value</span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="F20241205041231241_3" name="us-gaap:FairValueOptionChangesInFairValueGainLoss1" contextRef="C_20240101to20240930_usgaapClassOfWarrantOrRightAxis_usgaapWarrantMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">134</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fxbrl_20241111174808377_20241205041231241_3" name="us-gaap:FairValueOptionChangesInFairValueGainLoss1" contextRef="C_20240101to20240930_usgaapClassOfWarrantOrRightAxis_usgaapWarrantMember_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">1,120</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fxbrl_20241111174808377_xbrl_20241111174758463_20241205041231241_3" name="us-gaap:FairValueOptionChangesInFairValueGainLoss1" contextRef="C_20240101to20240930_usgaapClassOfWarrantOrRightAxis_usgaapWarrantMember_usgaapStatementEquityComponentsAxis_slxnPromissoryNotesMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">310</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="F20241205041231246_48" name="us-gaap:FairValueOptionChangesInFairValueGainLoss1" contextRef="C_20240701to20240930_usgaapClassOfWarrantOrRightAxis_usgaapWarrantMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">11</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fxbrl_20241111174808377_xbrl_20241111174758463_xbrl_20241111174712555_xbrl_20241111174705893_20241205041231241_3" name="us-gaap:FairValueOptionChangesInFairValueGainLoss1" contextRef="C_20240701to20240930_usgaapClassOfWarrantOrRightAxis_usgaapWarrantMember_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">1,120</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fxbrl_20241111174808377_xbrl_20241111174758463_xbrl_20241111174712555_xbrl_20241111174705893_xbrl_20241111174656657_20241205041231241_3" name="us-gaap:FairValueOptionChangesInFairValueGainLoss1" contextRef="C_20240701to20240930_usgaapClassOfWarrantOrRightAxis_usgaapWarrantMember_usgaapStatementEquityComponentsAxis_slxnPromissoryNotesMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">310</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
        </td> </tr>
  <tr>
    <td colspan="1" style="vertical-align:bottom;width:28%;background-color:rgb(255, 255, 255);padding-bottom:2px;vertical-align:bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Conversion</span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);padding-bottom:2px;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255);border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="F20241205041231242_7" name="slxn:FairValueConversion" contextRef="C_20240101to20240930_usgaapClassOfWarrantOrRightAxis_usgaapWarrantMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">334</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);padding-bottom:2px;vertical-align:bottom;white-space:nowrap">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);padding-bottom:2px;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255);border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="F20241205041231247_51" name="slxn:FairValueConversion" contextRef="C_20240101to20240930_usgaapClassOfWarrantOrRightAxis_usgaapWarrantMember_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);padding-bottom:2px;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255);border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="F20241205041231248_52" name="slxn:FairValueConversion" contextRef="C_20240101to20240930_usgaapClassOfWarrantOrRightAxis_usgaapWarrantMember_usgaapStatementEquityComponentsAxis_slxnPromissoryNotesMember" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);padding-bottom:2px;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255);border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="F20241205041231247_49" name="slxn:FairValueConversion" contextRef="C_20240701to20240930_usgaapClassOfWarrantOrRightAxis_usgaapWarrantMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">334</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);padding-bottom:2px;vertical-align:bottom;white-space:nowrap">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);padding-bottom:2px;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255);border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="F20241205041231248_53" name="slxn:FairValueConversion" contextRef="C_20240101to20240930_usgaapClassOfWarrantOrRightAxis_usgaapWarrantMember_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);padding-bottom:2px;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255);border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="F20241205041231248_54" name="slxn:FairValueConversion" contextRef="C_20240101to20240930_usgaapClassOfWarrantOrRightAxis_usgaapWarrantMember_usgaapStatementEquityComponentsAxis_slxnPromissoryNotesMember" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
        </tr>
  <tr>
    <td colspan="1" style="vertical-align:bottom;width:28%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Fair value at the end
        of the period</span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="F20241205041231241_4" name="us-gaap:OtherLiabilitiesCurrent" contextRef="C_20240930_usgaapClassOfWarrantOrRightAxis_usgaapWarrantMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20241111174808397_20241205041231241_4" name="us-gaap:OtherLiabilitiesCurrent" contextRef="C_20240930_usgaapClassOfWarrantOrRightAxis_usgaapWarrantMember_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">10</ix:nonFraction></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20241111174808397_xbrl_20241111174758478_20241205041231241_4" name="us-gaap:OtherLiabilitiesCurrent" contextRef="C_20240930_usgaapClassOfWarrantOrRightAxis_usgaapWarrantMember_usgaapStatementEquityComponentsAxis_slxnPromissoryNotesMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,312</ix:nonFraction></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="F20241205041231247_50" name="us-gaap:OtherLiabilitiesCurrent" contextRef="C_20240930_usgaapClassOfWarrantOrRightAxis_usgaapWarrantMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20241111174808397_xbrl_20241111174758478_xbrl_20241111174712561_xbrl_20241111174705897_20241205041231241_4" name="us-gaap:OtherLiabilitiesCurrent" contextRef="C_20240930_usgaapClassOfWarrantOrRightAxis_usgaapWarrantMember_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">10</ix:nonFraction></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20241111174808397_xbrl_20241111174758478_xbrl_20241111174712561_xbrl_20241111174705897_xbrl_20241111174656659_20241205041231241_4" name="us-gaap:OtherLiabilitiesCurrent" contextRef="C_20240930_usgaapClassOfWarrantOrRightAxis_usgaapWarrantMember_usgaapStatementEquityComponentsAxis_slxnPromissoryNotesMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,312</ix:nonFraction></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        </tr>
  </table> </div> </div> </div>

<div style="line-height:1.25;clear:both">&#160;</div> </div>

<div>

<div>

<div style="margin-left:72pt">

<table border="0" cellpadding="0" cellspacing="0" style="color:#000000;font-family:'Times New Roman',Times,serif;font-size:10pt;text-align:left;width:85%">
  <tr>
    <td colspan="1" style="vertical-align:top;padding-bottom:2px;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
        <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Nine
        months ended September 30, 2023</span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center">&#160;</td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
        <div style="line-height:1.25">
        <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Three
        months ended September 30, 2023</span></span></div> </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td> </tr>
  <tr>
    <td colspan="1" style="vertical-align:top;padding-bottom:2px;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
        <div style="line-height:1.25">
        <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Warrants
        to preferred share</span></span></div> </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center">&#160;</td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
        <div style="line-height:1.25">
        <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Warrants
        to preferred shares</span></span></div> </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Fair value at the beginning
        of the period</span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20241112104920276_xbrl_20241111174808356_xbrl_20241111174758445_xbrl_20241111174712541_xbrl_20241111174705885_20241205041231240_2" name="us-gaap:OtherLiabilitiesCurrent" contextRef="C_20221231_usgaapClassOfWarrantOrRightAxis_usgaapWarrantMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">3</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20241112104920276_xbrl_20241111174808356_xbrl_20241111174758445_xbrl_20241111174712541_xbrl_20241111174705885_xbrl_20241111174656654_20241205041231240_2" name="us-gaap:OtherLiabilitiesCurrent" contextRef="C_20230630_usgaapClassOfWarrantOrRightAxis_usgaapWarrantMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">111</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align:bottom;width:76%;background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Issuance</span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20241112104920279_xbrl_20241111174808366_xbrl_20241111174758454_xbrl_20241111174712548_xbrl_20241111174705888_20241205041231242_6" name="us-gaap:ProceedsFromDebtNetOfIssuanceCosts" contextRef="C_20230101to20230930_usgaapClassOfWarrantOrRightAxis_usgaapWarrantMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">111</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20241112104920279_xbrl_20241111174808366_xbrl_20241111174758454_xbrl_20241111174712548_xbrl_20241111174705888_xbrl_20241111174656655_20241205041231242_6" name="us-gaap:ProceedsFromDebtNetOfIssuanceCosts" contextRef="C_20230701to20230930_usgaapClassOfWarrantOrRightAxis_usgaapWarrantMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255);padding-bottom:2px;vertical-align:bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Change in fair value</span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);padding-bottom:2px;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20241112104920283_xbrl_20241111174808377_xbrl_20241111174758463_xbrl_20241111174712555_xbrl_20241111174705893_20241205041231241_3" name="us-gaap:FairValueOptionChangesInFairValueGainLoss1" contextRef="C_20230101to20230930_usgaapClassOfWarrantOrRightAxis_usgaapWarrantMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">40</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);padding-bottom:2px;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20241112104920283_xbrl_20241111174808377_xbrl_20241111174758463_xbrl_20241111174712555_xbrl_20241111174705893_xbrl_20241111174656657_20241205041231241_3" name="us-gaap:FairValueOptionChangesInFairValueGainLoss1" contextRef="C_20230701to20230930_usgaapClassOfWarrantOrRightAxis_usgaapWarrantMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">43</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align:bottom;width:76%;padding-bottom:2px;background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Fair value at the end
        of the period</span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20241112104920286_xbrl_20241111174808397_xbrl_20241111174758478_xbrl_20241111174712561_xbrl_20241111174705897_20241205041231241_4" name="us-gaap:OtherLiabilitiesCurrent" contextRef="C_20230930_usgaapClassOfWarrantOrRightAxis_usgaapWarrantMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">154</ix:nonFraction></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(255, 255, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20241112104920286_xbrl_20241111174808397_xbrl_20241111174758478_xbrl_20241111174712561_xbrl_20241111174705897_xbrl_20241111174656659_20241205041231241_4" name="us-gaap:OtherLiabilitiesCurrent" contextRef="C_20230930_usgaapClassOfWarrantOrRightAxis_usgaapWarrantMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">154</ix:nonFraction></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(255, 255, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        </tr>
  </table> </div> </div> </div> </div> </ix:nonNumeric>

<div style="line-height:1.25;clear:both">

<div style="line-height:1.25">

<div style="line-height:1.25">

<div style="line-height:1.25;clear:both">

<div style="line-height:1.25">

<div style="line-height:1.25;clear:both">

<div style="line-height:1.25">

<div style="line-height:1.25">

<div style="line-height:1.25">&#160;</div>

<table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">
  <tr>
    <td style="width:51pt">&#160;</td>
    <td style="width:18pt;vertical-align:top;font-weight:bold">&#160;</td>
    <td style="width:auto;vertical-align:top;text-align:justify">
        <div style="font-family:'Times New Roman',Times,serif">
        <div style="line-height:1.25">
        <div style="line-height:1.25">
        <div style="line-height:1.25">
        <div style="line-height:1.25;font-style:italic;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">ELOC
        agreement</span></span></div>
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">As the ELOC agreement
        is in substance a purchased call option over the Company&#8217;s own shares at a price mentioned in Note 3(d), the fair value of this
        agreement will generally be approximately zero, until the Company sells shares under the agreement. Once the Company sells share under
        the agreement, the difference between cash raised (net of transaction costs) and the closing price of the Ordinary Shares as of the date
        of their issuance is recognized as financing income or expenses.</span></span></div>
        <div style="line-height:1.25">&#160;</div>
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Fair value gain and losses
        arising from ELOC agreement are measured with reference to the spot price of the Company&#8217;s shares sold less consideration receivable
        from the investor.</span></span></div>
        <div style="line-height:1.25">&#160;</div>
        <div style="line-height:1.25;font-style:italic;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Warrant
        to preferred shares</span></span></div>
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The fair value of Silexion&#8217;s
        warrant to purchase preferred shares as of September 30, 2023 and December 31, 2023 was estimated using a hybrid model in order to reflect
        two scenarios: (1) an IPO event (including de-SPAC transaction) and (2) other liquidation events. For further details see Note 12 in the
        annual consolidated financial statements.</span></span></div>
        <div style="line-height:1.25">&#160;</div>
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The valuation under the
        &#8216;other liquidation events&#8217; scenario was assessed using an option pricing model (OPM) by implementing a Monte Carlo Simulation,
        which treats the financial instruments&#160;</span></span><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">in
        Silexion&#8217;s equity as contingent claims whose future payoff depends on Silexion&#8217;s future equity value. Silexion&#8217;s entire
        equity value in 2023 was calculated based, among others, on the financing round closest to the valuation date.</span></span></div>
        <div style="line-height:1.25">&#160;</div>
        <div style="line-height:1.25;font-style:italic;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Promissory
        Notes</span></span></div>
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">In measuring the fair
        value of the Company&#8217;s Promissory Notes, a discount rate of <ix:nonFraction id="F20241205041231245_44" name="slxn:FairValueOfPromissoryNotesDiscountRate" contextRef="C_20240101to20240930_srtRangeAxis_srtMinimumMember" unitRef="pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">11.4</ix:nonFraction>%-<ix:nonFraction id="F20241205041231245_45" name="slxn:FairValueOfPromissoryNotesDiscountRate" contextRef="C_20240101to20240930_srtRangeAxis_srtMaximumMember" unitRef="pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">13.1</ix:nonFraction>%
        was used, based on a B- rated US dollar zero-coupon discount curve, plus a credit spread of <ix:nonFraction id="F20241205041231246_46" name="slxn:CreditSpreadPercentage" contextRef="C_20240101to20240930" unitRef="pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">6.67</ix:nonFraction>%.
        The expected timing of conversion or redemption of the notes was determined using the Company&#8217;s forecasts.</span></span></div> </div>
        </div> </div> </div> </td> </tr>
  </table> </div> </div> </div> </div> </div> </div> </div> </div>

<div style="font-size:10pt;margin-top:0pt;margin-bottom:0pt;font-family:'Times New Roman', Times, serif">&#160;</div>

<div><ix:exclude>

<div style="line-height:1.25;clear:both">

<div style="line-height:1.25">

<div style="line-height:1.25">

<div style="line-height:1.25">

<div style="margin-top:10pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">

<p style="text-align:center;margin-top:0pt;margin-bottom:3pt"><span style="width:34%;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">F-62</span></span></span></p></div><hr style="page-break-after:always;border-width:0px;clear:both;margin:4px 0px;width:100%;height:2px;color:#000000;background-color:#000000;margin-top:0pt;margin-bottom:10pt"/>

<p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:center">&#160;</p>

<p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:center"><strong>SILEXION
THERAPEUTICS CORP</strong><br/>NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) (continued)<br/>(U.S. dollars in thousands)</p>

<p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:center">&#160;</p> </div>
</div> </div> </div>

<div style="line-height:1.25;font-family:'Times New Roman', Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">NOTE
8&#160; - FAIR VALUE MEASUREMENTS </span>(continued)<span style="font-weight:bold">:</span></span></span></div>

<div style="line-height:1.25;font-family:'Times New Roman', Times, serif">&#160;</div> </ix:exclude></div>

<div style="line-height:1.25">

<div style="line-height:1.25">

<div style="line-height:1.25">

<div style="line-height:1.25;clear:both">

<div style="line-height:1.25">

<div style="line-height:1.25;clear:both">

<div style="line-height:1.25">

<div style="line-height:1.25">

<table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">
  <tr>
    <td style="width:51pt">&#160;</td>
    <td style="width:18pt;vertical-align:top;font-weight:bold">&#160;</td>
    <td style="width:auto;vertical-align:top;text-align:justify">
        <div style="font-family:'Times New Roman',Times,serif">
        <div style="line-height:1.25">
        <div style="line-height:1.25">
        <div style="line-height:1.25">
        <div style="line-height:1.25;font-style:italic;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Warrants
        over ordinary shares</span></span></div>
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">A Black-Scholes-Merton
        model with Level 3 inputs was used to calculate the warrants&#8217; fair value. Inherent in a Black-Scholes-Merton model are assumptions
        related to expected life (term), expected stock price, volatility, risk-free interest rate and dividend yield. The Company estimates the
        volatility of its warrants based on implied volatility from the Company&#8217;s traded warrants and from historical volatility of selected
        peer companies&#8217; Class A ordinary shares that matches the expected remaining life of the warrants. The risk-free interest rate is
        based on the U.S. Treasury zero-coupon yield curve on the grant date for a maturity similar to the expected remaining life of the warrants.
        The expected life of the warrants is assumed to be equivalent to their remaining contractual term. The dividend rate is based on the historical
        rate, which the Company anticipates remaining at zero.</span></span></div>
        <div style="line-height:1.25">&#160;</div>
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The following table provides
        quantitative information regarding Level&#160;3 fair value measurements inputs of the warrants:</span></span></div> </div> </div> </div>
        </div> </td> </tr>
  </table> </div> </div> </div> </div> </div>

<div style="line-height:1.25">&#160;</div> </div> </div> </div>

<div>

<div style="margin-left:72pt"> <ix:nonNumeric id="Fxbrl_20241205135909319" name="us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" contextRef="C_20240101to20240930" escape="true">

<div>

<table border="0" cellpadding="0" cellspacing="0" style="color:#000000;font-family:'Times New Roman',Times,serif;font-size:10pt;text-align:left;width:85%">
  <tr>
    <td style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
    <td colspan="2" style="vertical-align:bottom;text-align:center">
        <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">September&#160;30,</span></span></div>
        </td>
    <td colspan="1" style="text-align:center;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:center">&#160;</td>
    <td colspan="2" style="vertical-align:bottom;text-align:center">
        <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">August&#160;15,</span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
        <div style="line-height:1.25">
        <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2024</span></span></div>
        </div> </td>
    <td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center">&#160;</td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
        <div style="line-height:1.25">
        <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2024</span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Volatility</span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="F20241205041231245_40" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="C_20240101to20240930_usgaapFairValueByFairValueHierarchyLevelAxis_usgaapFairValueInputsLevel3Member" unitRef="pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">76.86</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">%</span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="F20241205041231245_41" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="C_20240801to20240815_usgaapFairValueByFairValueHierarchyLevelAxis_usgaapFairValueInputsLevel3Member" unitRef="pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">80.23</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">%</span></span></div>
        </td> </tr>
  <tr>
    <td style="vertical-align:bottom;width:76%;background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Dividend yield</span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20241112113643974_20241205041231245_40" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="C_20240101to20240930_usgaapFairValueByFairValueHierarchyLevelAxis_usgaapFairValueInputsLevel3Member" unitRef="pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">0</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom;white-space:nowrap">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">%</span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20241112113643974_20241205041231245_41" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="C_20240801to20240815_usgaapFairValueByFairValueHierarchyLevelAxis_usgaapFairValueInputsLevel3Member" unitRef="pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">0</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom;white-space:nowrap">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">%</span></span></div>
        </td> </tr>
  </table> </div> </ix:nonNumeric> </div> </div>

<div style="text-align:justify;margin-left:54pt;line-height:1.25;clear:both">&#160;</div>

<div style="line-height:1.25">

<div style="line-height:1.25">

<div style="line-height:1.25">

<div style="line-height:1.25">

<div style="line-height:1.25;clear:both">

<div style="line-height:1.25">

<div style="line-height:1.25;clear:both">

<div style="line-height:1.25">

<div style="line-height:1.25">

<table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">
  <tr>
    <td style="width:51pt">&#160;</td>
    <td style="width:18pt;vertical-align:top;font-weight:bold">&#160;</td>
    <td style="width:auto;vertical-align:top;text-align:justify">
        <div style="font-family:'Times New Roman',Times,serif">
        <div style="line-height:1.25">
        <div style="line-height:1.25">
        <div style="line-height:1.25">
        <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Financial
        instruments not measured at fair value</span></span></div>
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The carrying amounts
        of cash and cash equivalents, restricted cash, receivables, trade payables and other liabilities approximate their fair value due to the
        short-term maturity of such instruments.</span></span></div> </div> </div> </div> </div> </td> </tr>
  </table> </div> </div> </div> </div> </div> </div> </div> </div> </div> </div> </ix:nonNumeric>

<div style="font-size:10pt;margin-top:0pt;margin-bottom:0pt;font-family:'Times New Roman', Times, serif">&#160;</div>

<div> <ix:nonNumeric id="F20241205041231258_5" name="us-gaap:EarningsPerShareTextBlock" contextRef="C_20240101to20240930" escape="true">

<div>

<div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">NOTE
9&#160; - NET LOSS PER SHARE:</span></span></div>

<div>

<div>

<div style="line-height:1.25">

<div style="line-height:1.25">

<div style="text-align:justify;margin-left:54pt;line-height:1.25">&#160;</div>

<div style="line-height:1.25">

<div style="line-height:1.25">

<div style="line-height:1.25">

<div style="line-height:1.25">

<div style="line-height:1.25;clear:both">

<div style="line-height:1.25">

<div style="line-height:1.25;clear:both">

<div style="line-height:1.25">

<div style="line-height:1.25">

<table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">
  <tr>
    <td style="width:51pt">&#160;</td>
    <td style="width:18pt;vertical-align:top;font-weight:bold">&#160;</td>
    <td style="width:auto;vertical-align:top;text-align:justify">
        <div style="font-family:'Times New Roman',Times,serif">
        <div style="line-height:1.25">
        <div style="line-height:1.25">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The following table sets
        forth the computation of basic and diluted net loss per share attributable to ordinary shareholders for the periods presented (USD in
        thousands, except per share data):</span></span></div> </div> </div> </div> </div> </td> </tr>
  </table> </div> </div> </div> </div> </div>

<div style="line-height:1.25">&#160;</div> </div> </div> </div> </div> </div> </div> <ix:nonNumeric id="Fxbrl_20241205122151833" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" contextRef="C_20240101to20240930" escape="true">

<div>

<div style="margin-left:72pt">

<table border="0" cellpadding="0" cellspacing="0" style="color:#000000;font-family:'Times New Roman',Times,serif;font-size:10pt;text-align:left;width:85%">
  <tr>
    <td rowspan="1" style="vertical-align:top;padding-bottom:2px;vertical-align:bottom">&#160;</td>
    <td colspan="1" rowspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
    <td colspan="6" rowspan="1" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Nine
        months ended</span></span></div>
        <div style="line-height:1.25">
        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">September
        30,</span></span></div> </div> </td>
    <td colspan="1" rowspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" rowspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
    <td colspan="6" rowspan="1" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Three
        months ended</span></span></div>
        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">September
        30,</span></span></div> </div> </td>
    <td colspan="1" rowspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td> </tr>
  <tr>
    <td rowspan="1" style="vertical-align:top;padding-bottom:2px;vertical-align:bottom">&#160;</td>
    <td colspan="1" rowspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
    <td colspan="2" rowspan="1" style="vertical-align:top;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2024</span></span></div>
        </div> </td>
    <td colspan="1" rowspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" rowspan="1" style="font-weight:bold;text-align:center;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
    <td colspan="2" rowspan="1" style="vertical-align:bottom;font-weight:bold;text-align:center;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2023</span></span></td>
    <td colspan="1" rowspan="1" style="font-weight:bold;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" rowspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
    <td colspan="2" rowspan="1" style="vertical-align:top;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2024</span></span></div>
        </div> </td>
    <td colspan="1" rowspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" rowspan="1" style="font-weight:bold;text-align:center;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
    <td colspan="2" rowspan="1" style="vertical-align:top;font-weight:bold;text-align:center;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2023</span></span></td>
    <td colspan="1" rowspan="1" style="font-weight:bold;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align:top;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Numerator:</span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="2" style="vertical-align:top;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="2" style="vertical-align:top;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="2" style="vertical-align:top;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:top;width:52%;background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="text-indent:-14.15pt;margin-left:23.1pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Net
        loss</span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="F20241205041231266_14" name="us-gaap:NetIncomeLoss" contextRef="C_20240101to20240930" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">14,772</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="F20241205041231266_15" name="us-gaap:NetIncomeLoss" contextRef="C_20230101to20230930" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">3,428</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="F20241205041231266_16" name="us-gaap:NetIncomeLoss" contextRef="C_20240701to20240930" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">11,860</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="F20241205041231267_17" name="us-gaap:NetIncomeLoss" contextRef="C_20230701to20230930" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">809</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align:top;width:52%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="text-indent:-14.15pt;margin-left:23.1pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Net
        loss attributable to ordinary shareholders, basic and diluted:</span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="F20241205041231270_26" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" contextRef="C_20240101to20240930" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal"><ix:nonFraction id="F20241205041231259_10" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" contextRef="C_20240101to20240930" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">14,696</ix:nonFraction></ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="F20241205041231270_27" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" contextRef="C_20230101to20230930" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal"><ix:nonFraction id="F20241205041231259_11" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" contextRef="C_20230101to20230930" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,214</ix:nonFraction></ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="F20241205041231270_28" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" contextRef="C_20240701to20240930" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal"><ix:nonFraction id="F20241205041231260_12" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" contextRef="C_20240701to20240930" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">11,851</ix:nonFraction></ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="F20241205041231270_29" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" contextRef="C_20230701to20230930" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal"><ix:nonFraction id="F20241205041231265_13" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" contextRef="C_20230701to20230930" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">787</ix:nonFraction></ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align:top;width:52%;background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Denominator:</span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align:top;width:52%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="text-indent:-14.15pt;margin-left:23.1pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Weighted-average
        shares used in computing net loss per share attributable to ordinary shareholders, basic and diluted</span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20241216110454468" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="C_20240101to20240930" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="Fxbrl_20241205123300025" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="C_20240101to20240930" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">291,407</ix:nonFraction></ix:nonFraction></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_s_20241205184949037" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="C_20230101to20230930" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="Fxbrl_20241205184949037" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="C_20230101to20230930" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">111,726</ix:nonFraction></ix:nonFraction></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20241216110351314" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="C_20240701to20240930" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="Fxbrl_20241205124112853" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="C_20240701to20240930" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">647,568</ix:nonFraction></ix:nonFraction></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20241205124155446" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="C_20230701to20230930" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="Fxbrl_20241205124150383" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="C_20230701to20230930" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">111,726</ix:nonFraction></ix:nonFraction></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align:top;width:52%;padding-bottom:4px;background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="text-indent:-14.15pt;margin-left:23.1pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Net
        loss per share attributable to ordinary shareholders, basic and diluted</span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20241205124314358" name="us-gaap:EarningsPerShareDiluted" contextRef="C_20240101to20240930" unitRef="usdPershares" scale="0" decimals="2" format="ixt:num-dot-decimal"><ix:nonFraction id="Fxbrl_20241205124309531" name="us-gaap:EarningsPerShareBasic" contextRef="C_20240101to20240930" unitRef="usdPershares" scale="0" decimals="2" format="ixt:num-dot-decimal">50.43</ix:nonFraction></ix:nonFraction></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(255, 255, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20241205124355840" name="us-gaap:EarningsPerShareDiluted" contextRef="C_20230101to20230930" unitRef="usdPershares" scale="0" decimals="2" format="ixt:num-dot-decimal"><ix:nonFraction id="Fxbrl_20241205124348399" name="us-gaap:EarningsPerShareBasic" contextRef="C_20230101to20230930" unitRef="usdPershares" scale="0" decimals="2" format="ixt:num-dot-decimal">28.76</ix:nonFraction></ix:nonFraction></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(255, 255, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20241205124433684" name="us-gaap:EarningsPerShareDiluted" contextRef="C_20240701to20240930" unitRef="usdPershares" scale="0" decimals="2" format="ixt:num-dot-decimal"><ix:nonFraction id="Fxbrl_20241205124426354" name="us-gaap:EarningsPerShareBasic" contextRef="C_20240701to20240930" unitRef="usdPershares" scale="0" decimals="2" format="ixt:num-dot-decimal">18.30</ix:nonFraction></ix:nonFraction></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(255, 255, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20241205124519590" name="us-gaap:EarningsPerShareBasic" contextRef="C_20230701to20230930" unitRef="usdPershares" scale="0" decimals="2" format="ixt:num-dot-decimal"><ix:nonFraction id="Fxbrl_20241205124515439" name="us-gaap:EarningsPerShareDiluted" contextRef="C_20230701to20230930" unitRef="usdPershares" scale="0" decimals="2" format="ixt:num-dot-decimal">7.04</ix:nonFraction></ix:nonFraction></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(255, 255, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        </tr>
  </table> </div> </div> </ix:nonNumeric>

<div style="line-height:1.25;clear:both">

<div style="line-height:1.25">

<div style="line-height:1.25">

<div style="text-align:justify;margin-left:54pt;line-height:1.25">&#160;</div>

<div style="line-height:1.25">

<div style="line-height:1.25">

<div style="line-height:1.25">

<div style="line-height:1.25">

<div style="line-height:1.25;clear:both">

<div style="line-height:1.25">

<div style="line-height:1.25;clear:both">

<div style="line-height:1.25">

<div style="line-height:1.25">

<table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">
  <tr>
    <td style="width:51pt">&#160;</td>
    <td style="width:18pt;vertical-align:top;font-weight:bold">&#160;</td>
    <td style="width:auto;vertical-align:top;text-align:justify">
        <div style="font-family:'Times New Roman',Times,serif">
        <div style="line-height:1.25">
        <div style="line-height:1.25">
        <div style="line-height:1.25">
        <div style="line-height:1.25">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Basic loss per share
        is computed on the basis of the net loss for the period divided by the weighted average number of ordinary shares outstanding during the
        period, including fully vested pre-funded options for the Company&#8217;s (or Silexion&#8217;s, as applicable) ordinary shares at an exercise
        price of $<ix:nonFraction id="F20241205041231257_1" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" contextRef="C_20240101to20240930" unitRef="usdPershares" scale="0" decimals="4" format="ixt:num-dot-decimal">0.027
        </ix:nonFraction>or <ix:nonFraction id="F20241205041231258_2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" contextRef="C_20240101to20240930" unitRef="ilsPershares" scale="0" decimals="5" format="ixt:num-dot-decimal">0.0063
        </ix:nonFraction>NIS per share, as the Company (or Silexion, as applicable) considers these shares to be exercised for little to no additional
        consideration.</span></span></div> </div>
        <div style="line-height:1.25">&#160;</div>
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">As of September 30, 2024
        and September 30, 2023, the basic loss per share calculation included a weighted average number of <ix:nonFraction id="F20241205041231258_3" name="us-gaap:WeightedAverageNumberOfSharesIssuedBasic" contextRef="C_20240101to20240930" unitRef="shares" scale="0" decimals="0" format="ixt:num-dot-decimal">133
        </ix:nonFraction>and <ix:nonFraction id="F20241205041231258_4" name="us-gaap:WeightedAverageNumberOfSharesIssuedBasic" contextRef="C_20230101to20230930" unitRef="shares" scale="0" decimals="0" format="ixt:num-dot-decimal">14,652</ix:nonFraction>,
        respectively, of fully vested pre-funded options. As the inclusion of other potential ordinary shares equivalents in the calculation would
        be anti-dilutive for all periods presented, diluted net loss per share is the same as basic net loss per share.</span></span></div>
        <div style="line-height:1.25">&#160;</div> </div> </div> </div> </div> </div> </div> </td> </tr>
  </table> </div> </div> </div> </div> </div> </div> </div> </div> </div> </div> </div>

<div><ix:exclude>

<div style="clear:both;margin-top:0pt;margin-bottom:0pt">

<div style="text-align:center">

<div style="margin-top:10pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">

<p style="text-align:center;margin-top:0pt;margin-bottom:3pt"><span style="width:34%;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">F-63</span></span></span></p></div><hr style="page-break-after:always;border-width:0px;clear:both;margin:4px 0px;width:100%;height:2px;color:#000000;background-color:#000000;margin-top:0pt;margin-bottom:10pt"/>

<p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:center">&#160;</p>

<p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:center"><strong>SILEXION
THERAPEUTICS CORP</strong><br/>NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) (continued)<br/>(U.S. dollars in thousands)</p>

<p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:center">&#160;</p>

<div style="font-size:10pt;margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman, Times, serif;text-align:left">

<p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span style="color:#000000;font-family:Times New Roman, Times, serif;font-size:13.3333px;font-style:normal;font-variant-ligatures:normal;text-align:left;white-space:normal;text-decoration-thickness:initial;text-decoration-style:initial;text-decoration-color:initial;font-weight:bold">NOTE
9&#160; - NET LOSS PER SHARE&#160;</span><span style="text-align:left;color:rgb(0, 0, 0);font-style:normal;font-weight:400">(continued)</span><span style="color:#000000;font-family:Times New Roman, Times, serif;font-size:13.3333px;font-style:normal;font-variant-ligatures:normal;text-align:left;white-space:normal;text-decoration-thickness:initial;text-decoration-style:initial;text-decoration-color:initial;font-weight:bold">:</span></span></span></p>

<p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt">&#160;</p> </div> </div> </div> </ix:exclude></div>
</div>

<div style="line-height:1.25">

<div style="line-height:1.25">

<div style="line-height:1.25">

<div style="line-height:1.25">

<div style="line-height:1.25">

<div style="line-height:1.25">

<div style="line-height:1.25">

<div style="line-height:1.25;clear:both">

<div style="line-height:1.25">

<div style="line-height:1.25;clear:both">

<div style="line-height:1.25">

<div style="line-height:1.25">

<table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">
  <tr>
    <td style="width:51pt">&#160;</td>
    <td style="width:18pt;vertical-align:top;font-weight:bold">&#160;</td>
    <td style="width:auto;vertical-align:top;text-align:justify">
        <div style="font-family:'Times New Roman',Times,serif">
        <div style="line-height:1.25">
        <div style="line-height:1.25">
        <div style="line-height:1.25">
        <div style="line-height:1.25">
        <div style="line-height:1.25">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The following instruments
        were not included in the computation of diluted earnings per share because of their anti-dilutive effect:</span></span></div> </div> </div>
        </div> </div> </div> </div> </div> </td> </tr>
  </table> </div> </div> </div> </div> </div> </div> </div> </div> </div> </div> </div> </div>

<div style="line-height:1.25">

<div style="margin-left:56.7pt;line-height:1.25">&#160;</div> </div>

<table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">
  <tr>
    <td style="width:74.7pt">&#160;</td>
    <td style="width:18pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></td>
    <td style="width:auto;vertical-align:top">
        <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Redeemable convertible preferred shares;</span></span></div>
        </td> </tr>
  </table>

<table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">
  <tr>
    <td style="width:74.7pt">&#160;</td>
    <td style="width:18pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></td>
    <td style="width:auto;vertical-align:top">
        <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Warrants to purchase redeemable convertible preferred
        shares;</span></span></div> </td> </tr>
  </table>

<table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">
  <tr>
    <td style="width:74.7pt">&#160;</td>
    <td style="width:18pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></td>
    <td style="width:auto;vertical-align:top">
        <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Share-based compensation issuable at substantial
        consideration;</span></span></div> </td> </tr>
  </table>

<table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">
  <tr>
    <td style="width:74.7pt">&#160;</td>
    <td style="width:18pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></td>
    <td style="width:auto;vertical-align:top">
        <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Private Warrants to purchase ordinary shares;</span></span></div>
        </td> </tr>
  </table>

<table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">
  <tr>
    <td style="width:74.7pt">&#160;</td>
    <td style="width:18pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></td>
    <td style="width:auto;vertical-align:top">
        <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Promissory Notes.</span></span></div> </td> </tr>
  </table> </div> </div> </div> </ix:nonNumeric>

<div style="font-size:10pt;margin-top:0pt;margin-bottom:0pt;font-family:'Times New Roman', Times, serif">&#160;</div> </div>

<div> <ix:nonNumeric id="F20241205041231277_13" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock" contextRef="C_20240101to20240930" escape="true">

<div>

<div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">NOTE
10&#160; - TRANSACTIONS AND BALANCES WITH RELATED PARTIES</span>:</span></span></div>

<div style="line-height:1.25">&#160;</div>

<div style="line-height:1.25">

<div style="margin-left:69pt;line-height:1.25;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Transactions
with related parties which are shareholders and directors of the Company (or Silexion, for periods prior to the Closing of the Transactions):</span></span></div>

<div style="line-height:1.25">&#160;</div> </div>

<table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">
  <tr>
    <td style="width:51pt">&#160;</td>
    <td style="width:18pt;vertical-align:top;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">a.</span></span></td>
    <td style="width:auto;vertical-align:top;margin-top:0pt;margin-bottom:0pt">
        <div style="font-weight:bold;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt">Transactions:</span></span></div>
        </td> </tr>
  </table>

<p style="margin-bottom:0px">&#160;</p> <ix:nonNumeric id="F20241205041231278_18" name="us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock" contextRef="C_20240101to20240930" escape="true">

<div>

<div style="margin-left:72pt">

<table border="0" cellpadding="0" cellspacing="0" style="width:85%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left">
  <tr>
    <td rowspan="1" style="vertical-align:top;padding-bottom:2px;vertical-align:bottom">&#160;</td>
    <td colspan="1" rowspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
    <td colspan="6" rowspan="1" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
        <div style="line-height:1.25;font-weight:bold;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>Nine
        months ended</span></span></span></span></div>
        <div style="line-height:1.25;font-weight:bold;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>September
        30,</span></span></span></span></div> </td>
    <td colspan="1" rowspan="1" style="padding-bottom:2px;vertical-align:bottom;white-space:nowrap;text-align:center">&#160;</td>
    <td colspan="1" rowspan="1" style="padding-bottom:2px;vertical-align:bottom;text-align:center">&#160;</td>
    <td colspan="6" rowspan="1" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25;font-weight:bold;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>Three
        months ended</span></span></span></span></div>
        <div style="line-height:1.25;font-weight:bold;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>September
        30</span></span></span></span></div> </div> </td>
    <td colspan="1" rowspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td> </tr>
  <tr>
    <td rowspan="1" style="vertical-align:top;padding-bottom:2px;vertical-align:bottom">&#160;</td>
    <td colspan="1" rowspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
    <td colspan="2" rowspan="1" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2024</span></span></div>
        </div> </td>
    <td colspan="1" rowspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" rowspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
    <td colspan="2" rowspan="1" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2023</span></span></div>
        </div> </td>
    <td colspan="1" rowspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" rowspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
    <td colspan="2" rowspan="1" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2024</span></span></div>
        </div> </td>
    <td colspan="1" rowspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" rowspan="1" style="font-weight:bold;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
    <td colspan="2" rowspan="1" style="font-weight:bold;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2023</span></span></td>
    <td colspan="1" rowspan="1" style="font-weight:bold;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align:top;width:52%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="text-indent:-10.75pt;margin-left:10.75pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Share-based
        compensation included in research and development expenses</span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="F20241205041231276_0" name="us-gaap:ResearchAndDevelopmentExpense" contextRef="C_20240101to20240930_usgaapRelatedPartyTransactionAxis_usgaapRelatedPartyMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,796</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="F20241205041231277_1" name="us-gaap:ResearchAndDevelopmentExpense" contextRef="C_20230101to20230930_usgaapRelatedPartyTransactionAxis_usgaapRelatedPartyMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">51</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="F20241205041231277_2" name="us-gaap:ResearchAndDevelopmentExpense" contextRef="C_20240701to20240930_usgaapRelatedPartyTransactionAxis_usgaapRelatedPartyMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,762</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="F20241205041231277_3" name="us-gaap:ResearchAndDevelopmentExpense" contextRef="C_20230701to20230930_usgaapRelatedPartyTransactionAxis_usgaapRelatedPartyMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">17</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align:top;width:52%;vertical-align:bottom">
        <div style="text-indent:-10.75pt;margin-left:10.75pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Share-based
        compensation included in general and administrative expenses</span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="F20241205041231277_4" name="us-gaap:GeneralAndAdministrativeExpense" contextRef="C_20240101to20240930_usgaapRelatedPartyTransactionAxis_usgaapRelatedPartyMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,972</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="F20241205041231277_5" name="us-gaap:GeneralAndAdministrativeExpense" contextRef="C_20230101to20230930_usgaapRelatedPartyTransactionAxis_usgaapRelatedPartyMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">36</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="F20241205041231277_6" name="us-gaap:GeneralAndAdministrativeExpense" contextRef="C_20240701to20240930_usgaapRelatedPartyTransactionAxis_usgaapRelatedPartyMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,948</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="F20241205041231277_7" name="us-gaap:GeneralAndAdministrativeExpense" contextRef="C_20230701to20230930_usgaapRelatedPartyTransactionAxis_usgaapRelatedPartyMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">12</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:top;width:52%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Financial expenses</span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="F20241205041231277_8" name="slxn:FinancialExpensesNetFromRelatedParty" contextRef="C_20240101to20240930_usgaapRelatedPartyTransactionAxis_usgaapRelatedPartyMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">47</ix:nonFraction></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="F20241205041231278_20" name="slxn:FinancialExpensesNetFromRelatedParty" contextRef="C_20230101to20230930_usgaapRelatedPartyTransactionAxis_usgaapRelatedPartyMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">40</ix:nonFraction></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="F20241205041231277_9" name="slxn:FinancialExpensesNetFromRelatedParty" contextRef="C_20240701to20240930_usgaapRelatedPartyTransactionAxis_usgaapRelatedPartyMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">182</ix:nonFraction></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="F20241205041231277_12" name="slxn:FinancialExpensesNetFromRelatedParty" contextRef="C_20230701to20230930_usgaapRelatedPartyTransactionAxis_usgaapRelatedPartyMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">40</ix:nonFraction></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        </tr>
  </table> </div> </div> </ix:nonNumeric>

<div style="line-height:1.25">&#160;</div>

<table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">
  <tr>
    <td style="width:51pt">&#160;</td>
    <td style="width:18pt;vertical-align:top;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">b.</span></span></td>
    <td style="width:auto;vertical-align:top">
        <div style="font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Balances:</span></span></div>
        </td> </tr>
  </table>

<div style="font-size:10pt;margin-top:0pt;margin-bottom:0pt;font-family:'Times New Roman', Times, serif">&#160;</div> <ix:nonNumeric id="F20241205041231278_19" name="us-gaap:ScheduleOfCompensatingBalancesTextBlock" contextRef="C_20240101to20240930" escape="true">

<div>

<div style="margin-left:72pt">

<table border="0" cellpadding="0" cellspacing="0" style="width:85%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left">
  <tr>
    <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
    <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">September&#160;30,
        2024</span></span></div> </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
    <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">December&#160;31,
        2023</span></span></div> </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="text-align:justify;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Non-Current
        liabilities -</span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:top;width:76%;vertical-align:bottom">
        <div style="text-align:justify;margin-left:17.45pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Warrants
        to purchase&#160;preferred shares&#160;&#160;</span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="F20241205041231277_10" name="us-gaap:OtherLiabilitiesNoncurrent" contextRef="C_20240930_usgaapRelatedPartyTransactionsByRelatedPartyAxis_usgaapRelatedPartyMember" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="F20241205041231277_11" name="us-gaap:OtherLiabilitiesNoncurrent" contextRef="C_20231231_usgaapRelatedPartyTransactionsByRelatedPartyAxis_usgaapRelatedPartyMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">186</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:top;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="text-align:justify;margin-left:17.45pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Private
        warrants to purchase ordinary shares</span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20241111171109305_20241205041231277_10" name="us-gaap:ConvertibleDebtNoncurrent" contextRef="C_20240930_usgaapRelatedPartyTransactionsByRelatedPartyAxis_usgaapRelatedPartyMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">10</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20241111171109305_20241205041231277_11" name="us-gaap:ConvertibleDebtNoncurrent" contextRef="C_20231231_usgaapRelatedPartyTransactionsByRelatedPartyAxis_usgaapRelatedPartyMember" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align:top;width:76%;padding-bottom:4px;vertical-align:bottom">
        <div style="text-align:justify;margin-left:17.45pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Promissory
        Note</span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20241111171111562_20241205041231277_10" name="us-gaap:LongTermNotesPayable" contextRef="C_20240930_usgaapRelatedPartyTransactionsByRelatedPartyAxis_usgaapRelatedPartyMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,106</ix:nonFraction></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20241111171111562_20241205041231277_11" name="us-gaap:LongTermNotesPayable" contextRef="C_20231231_usgaapRelatedPartyTransactionsByRelatedPartyAxis_usgaapRelatedPartyMember" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">&#160;</td> </tr>
  </table> </div> </div> </ix:nonNumeric> </div> </ix:nonNumeric> </div>

<div style="font-size:10pt;margin-top:0pt;margin-bottom:0pt;font-family:'Times New Roman', Times, serif">&#160;</div>

<div> <ix:nonNumeric id="F20241205041231281_0" name="us-gaap:SubsequentEventsTextBlock" contextRef="C_20240101to20240930" escape="true">

<div>

<div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">NOTE
11&#160; - SUBSEQUENT EVENTS:</span></span></div>

<div>

<div>

<div style="line-height:1.25">&#160;</div>

<table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">
  <tr>
    <td style="width:56.7pt">&#160;</td>
    <td style="width:18pt;vertical-align:top;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">a.</span></span></td>
    <td style="width:auto;vertical-align:top;text-align:justify">
        <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">On October 1, 2024, the Company completed an equity
        raise through the ELOC, issuing <ix:nonFraction id="F20241205041231281_1" name="us-gaap:CommonStockSharesIssued" contextRef="C_20241001_usgaapInvestmentTypeAxis_slxnEquityLineOfCreditMember_usgaapSubsequentEventTypeAxis_usgaapSubsequentEventMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">293,777
        </ix:nonFraction>ordinary shares for a total consideration of $<ix:nonFraction id="F20241205041231281_2" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" contextRef="C_20240901to20241001_usgaapInvestmentTypeAxis_slxnEquityLineOfCreditMember_usgaapSubsequentEventTypeAxis_usgaapSubsequentEventMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,658</ix:nonFraction>.</span></span></div>
        </td> </tr>
  </table>

<div style="line-height:1.25">&#160;</div>

<div style="line-height:1.25">

<table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">
  <tr>
    <td style="width:56.7pt">&#160;</td>
    <td style="width:18pt;vertical-align:top;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">b.</span></span></td>
    <td style="width:auto;vertical-align:top">
        <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">On October 22, 2024, the Company completed an
        equity raise through the ELOC, issuing <ix:nonFraction id="F20241205041231281_3" name="us-gaap:CommonStockSharesIssued" contextRef="C_20241022_usgaapInvestmentTypeAxis_slxnEquityLineOfCreditMember_usgaapSubsequentEventTypeAxis_usgaapSubsequentEventMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">66,667
        </ix:nonFraction>ordinary shares for a total consideration of $<ix:nonFraction id="F20241205041231281_4" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" contextRef="C_20241003to20241022_usgaapInvestmentTypeAxis_slxnEquityLineOfCreditMember_usgaapSubsequentEventTypeAxis_usgaapSubsequentEventMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">200</ix:nonFraction>.</span></span></div>
        </td> </tr>
  </table> </div>

<div style="line-height:1.25">

<div style="line-height:1.25">&#160;</div> </div>

<div style="line-height:1.25">

<table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">
  <tr>
    <td style="width:56.7pt">&#160;</td>
    <td style="width:18pt;vertical-align:top;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">c.</span></span></td>
    <td style="width:auto;vertical-align:top;text-align:justify">
        <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">On October 29, 2024, the Company received a deficiency
        letter from the Listing Qualifications Department (the &#8220;Staff&#8221;) of the Nasdaq Stock Market LLC (&#8220;Nasdaq&#8221;) notifying
        the Company that, for the 30 consecutive business days preceding the letter, the closing bid price of the Company&#8217;s Ordinary Shares
        was below the minimum $1.00 per share required for continued listing on The Nasdaq Stock Market.&#160;<ix:nonNumeric id="F20241205041231281_6" name="slxn:BidPriceCloseDescription" contextRef="C_20241003to20241029_usgaapSubsequentEventTypeAxis_usgaapSubsequentEventMember">The
        Company has been given 180 calendar days, or until April 28, 2025, to regain compliance. If at any time before April 28, 2025, the bid
        price of the Ordinary Shares closes at $1.00 per share or more for a minimum of 10 consecutive business days, the Staff will provide written
        confirmation that the Company has achieved compliance.</ix:nonNumeric></span></span></div> </td> </tr>
  </table> </div>

<div style="line-height:1.25">&#160;</div>

<div style="line-height:1.25">

<table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">
  <tr>
    <td style="width:56.7pt">&#160;</td>
    <td style="width:18pt;vertical-align:top;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">d.</span></span></td>
    <td style="width:auto;vertical-align:top;text-align:justify">
        <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">d. For information regarding the reverse share
        split, see Note 1 (g)</span></span></div> </td> </tr>
  </table> </div> </div> </div> </div> </ix:nonNumeric>

<div style="line-height:1.25">

<div style="line-height:1.25">

<div style="line-height:1.25;text-align:center">_______________________</div>

<div style="line-height:1.25;text-align:center">________________________________</div>

<div style="line-height:1.25;text-align:center">_______________________</div>

<div style="clear:both;margin-top:10pt;margin-bottom:10pt">

<div style="text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:normal;font-style:normal">F-64</span></span></span></div>

<div style="page-break-after:always"> <hr style="border-width:0px;clear:both;margin:4px 0px;width:100%;height:2px;color:#000000;background-color:#000000;margin-bottom:10pt"/>
</div> </div>

<div style="line-height:1.25">

<div style="line-height:1.25;font-weight:bold">&#160;</div> </div> </div> </div> </div>

<div>

<div>

<div>

<div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">SILEXION
THERAPEUTICS CORP</span></span></div>

<div style="text-align:center;line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">CONSOLIDATED
FINANCIAL STATEMENTS</span></span></div>

<div style="text-align:center;line-height:1.25;font-family:'Times New Roman', Times, serif"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>AS
OF DECEMBER 31</span>, 2023</span></span></div>

<div style="line-height:1.25">&#160;</div>

<div style="clear:both;margin-top:10pt;margin-bottom:10pt">

<div style="text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span style="color:rgb(0, 0, 0);font-weight:normal;font-style:normal">F-65</span></span></span></div>

<div style="page-break-after:always"><hr style="border-width:0px;clear:both;margin:4px 0px;width:100%;height:2px;color:#000000;background-color:#000000"/></div></div>

<div style="line-height:1.25">&#160;</div>

<div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">SILEXION
THERAPEUTICS CORP</span></span></div>

<div style="text-align:center;line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">CONSOLIDATED
FINANCIAL STATEMENTS</span></span></div>

<div style="text-align:center;line-height:1.25;font-family:'Times New Roman', Times, serif"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>AS
OF DECEMBER 31</span>, 2023</span></span></div>

<div style="line-height:1.25">&#160;</div>

<div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">TABLE
OF CONTENTS</span></span></div>

<div style="line-height:1.25">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%">
  <tr>
    <td style="vertical-align:top;width:91%">&#160;</td>
    <td style="vertical-align:top;width:9%">
        <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">Page</span></span></div></td></tr>
  <tr>
    <td style="vertical-align:bottom;width:91%">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><a href="#ACCOUNTINGFIRM">Report
        of Independent Registered Public Accounting Firm</a></span></span></div></td>
    <td style="vertical-align:bottom;width:9%">
        <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">F-67</span></span></div></td></tr>
  <tr>
    <td style="vertical-align:bottom;width:91%">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">CONSOLIDATED
        FINANCIAL STATEMENTS:</span></span></div></td>
    <td style="vertical-align:bottom;width:9%">&#160;</td></tr>
  <tr>
    <td style="vertical-align:top;width:91%">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><a href="#DBALANCESHEETS">Consolidated
        Balance Sheets</a></span></span></div></td>
    <td style="vertical-align:top;text-align:center;width:9%"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">F-68
        - F-69</span></span></td></tr>
  <tr>
    <td style="vertical-align:top;width:91%">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><a href="#DSTATEMENTSOFOPERATIONS">Consolidated
        Statements of Operations</a></span></span></div></td>
    <td style="vertical-align:top;text-align:center;width:9%"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">F-70</span></span></td></tr>
  <tr>
    <td style="vertical-align:top;width:91%">
        <div style="text-indent:-8.7pt;margin-left:8.7pt;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><a href="#DCAPITALDEFICIENCY">Consolidated
        Statements of Changes in Redeemable Convertible Preferred Shares and Capital Deficiency</a></span></span></div></td>
    <td style="vertical-align:top;width:9%">
        <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">F-71</span></span></div></td></tr>
  <tr>
    <td style="vertical-align:top;width:91%">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><a href="#FCASHFLOWS">Consolidated
        Statements of Cash Flows</a></span></span></div></td>
    <td style="vertical-align:top;text-align:center;width:9%"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">F-72
        - F-73</span></span></td></tr>
  <tr>
    <td style="vertical-align:top;width:91%">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><a href="#DFINANCIALSTATEMENTS">Notes
        to Consolidated Financial Statements</a></span></span></div></td>
    <td style="vertical-align:top;text-align:center;width:9%"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">F-74
        - F-99</span></span></td></tr>
  </table>

<div style="line-height:1.25">&#160;</div>

<div style="line-height:1.25">

<div style="line-height:1.25;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">_______________________</span></span></div>

<div style="line-height:1.25;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">________________________________</span></span></div>

<div style="line-height:1.25;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">_______________________</span></span></div>

<div style="clear:both;margin-top:10pt;margin-bottom:10pt">

<div style="text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span style="color:rgb(0, 0, 0);font-weight:normal;font-style:normal">F-66</span></span></span></div>

<div style="page-break-after:always"><hr style="border-width:0px;clear:both;margin:4px 0px;width:100%;height:2px;color:#000000;background-color:#000000"/></div></div></div>

<div style="line-height:1.25">&#160;</div>

<div>

<div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><img alt="image00014.jpg" src="slxn_img01.jpg" style="width:152px;height:129px"/></span></span></div></div>

<div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">REPORT
OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM<span id="ACCOUNTINGFIRM"></span></span></span></div>

<div style="text-align:center;line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">To
the board of directors and shareholders of</span></span></div>

<div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">SILEXION
THERAPEUTICS CORP</span></span></div>

<div style="line-height:1.25">&#160;</div>

<div style="line-height:1.25;font-style:italic;font-weight:bold"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">Opinion
on the Financial Statements</span></span></div>

<div style="line-height:1.25">&#160;</div>

<div style="text-align:justify;line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">We
have audited the accompanying consolidated balance sheets of Silexion Therapeutics Corp (formerly known as Silexion Therapeutics Ltd.)
and its subsidiaries (the &#8220;Company&#8221;) as of December 31, 2023 and 2022, and the related consolidated statements of operations,
changes in redeemable convertible preferred shares and capital deficiency and cash flows for the years then ended, including the related
notes (collectively referred to as the &#8220;consolidated financial statements&#8221;). In our opinion, the consolidated financial statements
present fairly, in all material respects, the financial position of the Company as of December 31, 2023 and 2022, and the results of its
operations and its cash flows for each of the years then ended, in conformity with accounting principles generally accepted in the United
States of America.</span></span></div>

<div style="line-height:1.25">&#160;</div>

<div style="line-height:1.25">

<div style="text-align:justify;line-height:1.25;font-style:italic"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">Substantial
Doubt about the Company&#8217;s Ability to Continue as a Going Concern</span></span></div>

<div style="text-align:justify;line-height:1.25">&#160;</div>

<div style="text-align:justify;line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">The
accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern. As discussed
in Note 1e to the consolidated financial statements, the Company has suffered recurring losses from operations and has cash outflows from
operating activities that raise substantial doubt about its ability to continue as a going concern. Management&#8217;s plans in regard
to these matters are also described in Note 1e. The consolidated financial statements do not include any adjustments that might result
from the outcome of this uncertainty.</span></span></div></div>

<div style="line-height:1.25">&#160;</div>

<div style="line-height:1.25;font-style:italic;font-weight:bold"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">Basis
for Opinion</span></span></div>

<div style="line-height:1.25">&#160;</div>

<div style="text-align:justify;line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">These
consolidated financial statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion
on the Company&#8217;s consolidated financial statements based on our audits. We are a public accounting firm registered with the Public
Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance
with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></span></div>

<div style="line-height:1.25">&#160;</div>

<div style="text-align:justify;line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">We
conducted our audits of these consolidated financial statements in accordance with the standards of the PCAOB. Those standards require
that we plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free of material
misstatement, whether due to error or fraud.</span></span></div>

<div style="text-align:justify;line-height:1.25">&#160;</div>

<div>

<div>

<div style="text-align:justify;line-height:1.25">Our audits included performing procedures to assess the risks of material misstatement
of the consolidated financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures
included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements. Our audits
also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall
presentation of the consolidated financial statements. We believe that our audits provide a reasonable basis for our opinion.</div>

<div style="line-height:1.25">&#160;</div>

<table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">
  <tr>
    <td style="width:37.39%;vertical-align:top">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">/s/Kesselman &amp; Kesselman</div></td>
    <td style="width:62.61%;vertical-align:top">&#160;</td></tr>
  <tr>
    <td style="width:37.39%;vertical-align:top">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">Certified Public Accountants (lsr.)</div></td>
    <td style="width:62.61%;vertical-align:top">&#160;</td></tr>
  <tr>
    <td colspan="2" style="width:100%;vertical-align:top">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">A member firm of PricewaterhouseCoopers International Limited</div></td></tr>
  <tr>
    <td colspan="2" style="width:100%;vertical-align:top">&#160;</td></tr>
  <tr>
    <td style="width:37.39%;vertical-align:top">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">Tel-Aviv, Israel</div></td>
    <td style="width:62.61%;vertical-align:top">&#160;</td></tr>
  <tr>
    <td colspan="2" style="width:100%;vertical-align:top">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">May 9, 2024, except for the effects of the reverse share split
        discussed in note 1c, and except for the effects of the merger exchange ratio discussed in note 1c, as to which the date is January 13,
        2025</div></td></tr>
  </table>

<div style="line-height:1.25">&#160;</div>

<div style="line-height:1.25">

<table border="0" cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;color:#000000;width:100%">
  <tr>
    <td colspan="1" rowspan="1" style="border-left:2px dotted;border-top:2px dotted #000000;width:1%">&#160;</td>
    <td rowspan="1" style="border-top:2px dotted #000000;width:99%">&#160;</td></tr>
  <tr>
    <td colspan="1" style="width:1%">&#160;</td>
    <td style="width:99%">
        <div style="line-height:1.25">
        <div style="text-align:left;line-height:1.25;font-style:italic">Kesselman &amp; Kesselman, 146 Derech Menachem Begin, Tel-Aviv 6492103,
        Israel,</div>
        <div style="text-align:left;line-height:1.25;font-style:italic">P.O Box 50005 Tel-Aviv 6150001, Telephone: +972 -3- 7954555, Fax:+972
        -3- 7954556, www.pwc.com/il</div></div></td></tr>
  </table></div>

<div style="line-height:1.25">&#160;</div>

<div style="clear:both;margin-top:10pt;margin-bottom:10pt">

<div style="text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span style="color:rgb(0, 0, 0);font-weight:normal;font-style:normal">F-67</span></span></span></div></div></div></div>

<div style="clear:both;margin-top:0pt;margin-bottom:0pt">

<div style="page-break-after:always"><hr style="border-width:0px;clear:both;margin:4px 0px;width:100%;height:2px;color:#000000;background-color:#000000;margin-top:4pt;margin-bottom:10pt"/></div></div>

<div>

<div style="line-height:1.25">&#160;</div></div></div></div></div>

<div>

<div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">SILEXION
THERAPEUTICS CORP</span></span></div>

<div style="text-align:center;margin-left:1pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">CONSOLIDATED
BALANCE SHEETS<span id="DBALANCESHEETS"></span></span></span></div>

<div style="text-align:center;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(U.S.
dollars in thousands, except share data)</span></span></div>

<div style="line-height:1.25">&#160;

<table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left;color:#000000;width:100%">
  <tr>
    <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
    <td colspan="6" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">December
        31</span></span></div> </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2023</span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2022</span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:top;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Assets</span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:top;background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">CURRENT
        ASSETS:</span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="2" style="vertical-align:bottom;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;background-color:rgb(255, 255, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="2" style="vertical-align:bottom;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;background-color:rgb(255, 255, 255);vertical-align:bottom;white-space:nowrap">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:top;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="margin-left:9.6pt;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Cash
        and cash equivalents</span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fixv-38866" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,595</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fixv-38867" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,259</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align:top;width:76%;background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="margin-left:9.6pt;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Restricted
        cash</span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fixv-38868" name="us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">25</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fixv-38869" name="us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">25</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align:top;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="margin-left:9.6pt;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Short
        term deposits</span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20241003052800808" name="us-gaap:ShortTermInvestments" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fixv-38870" name="us-gaap:ShortTermInvestments" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">507</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align:top;width:76%;background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="margin-left:9.6pt;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Prepaid
        expenses</span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fixv-38871" name="us-gaap:PrepaidExpenseCurrent" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">335</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fixv-38872" name="us-gaap:PrepaidExpenseCurrent" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">6</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align:top;width:76%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="margin-left:9.6pt;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Other
        current assets</span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fixv-38873" name="us-gaap:OtherAssetsCurrent" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">24</ix:nonFraction></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fixv-38874" name="us-gaap:OtherAssetsCurrent" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">42</ix:nonFraction></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align:top;width:76%;padding-bottom:2px;background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">TOTAL
        CURRENT ASSETS</span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fixv-38875" name="us-gaap:AssetsCurrent" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,979</ix:nonFraction></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(255, 255, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fixv-38876" name="us-gaap:AssetsCurrent" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,839</ix:nonFraction></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(255, 255, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align:top;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align:top;width:76%;background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">NON-CURRENT
        ASSETS:</span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align:top;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="margin-left:9.6pt;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Restricted
        cash</span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fixv-38877" name="us-gaap:RestrictedCashNoncurrent" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">25</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fixv-38878" name="us-gaap:RestrictedCashNoncurrent" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">25</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align:top;width:76%;background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="margin-left:9.6pt;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Long-term
        deposit</span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fixv-38879" name="us-gaap:DepositsAssetsNoncurrent" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">5</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fixv-38880" name="us-gaap:DepositsAssetsNoncurrent" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">5</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align:top;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="margin-left:9.6pt;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Property
        and equipment, net</span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fixv-38881" name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">49</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fixv-38882" name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">159</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align:top;width:76%;padding-bottom:2px;background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="margin-left:9.6pt;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Operating
        lease right-of-use asset</span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fixv-38883" name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">198</ix:nonFraction></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(255, 255, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fixv-38884" name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">305</ix:nonFraction></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(255, 255, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align:top;width:76%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">TOTAL
        NON-CURRENT ASSETS</span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fixv-38885" name="us-gaap:AssetsNoncurrent" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">277</ix:nonFraction></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fixv-38886" name="us-gaap:AssetsNoncurrent" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">494</ix:nonFraction></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align:top;width:76%;padding-bottom:4px;background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">TOTAL
        ASSETS</span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fixv-38887" name="us-gaap:Assets" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,256</ix:nonFraction></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(255, 255, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fixv-38888" name="us-gaap:Assets" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,333</ix:nonFraction></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(255, 255, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        </tr>
  </table> </div>

<div style="line-height:1.25">&#160;</div>

<div style="text-align:center;margin-left:15.75pt;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The
accompanying notes are an integral part of these consolidated financial statements.</span></span></div>

<div style="clear:both;margin-top:10pt;margin-bottom:10pt">

<div style="text-align:center">&#160;</div>

<div style="text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="color:rgb(0, 0, 0);font-weight:normal;font-style:normal">F-68</span></span></span></div>

<div style="page-break-after:always"> <hr style="border-width:0px;clear:both;margin:4px 0px;width:100%;height:2px;color:#000000;background-color:#000000"/>
</div> </div>

<div style="line-height:1.25">&#160;</div>

<div style="text-align:center;margin-left:1pt;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">SILEXION
THERAPEUTICS CORP</span></span></div>

<div style="text-align:center;margin-left:1pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">CONSOLIDATED
BALANCE SHEETS</span></span></div>

<div style="text-align:center;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(U.S.
dollars in thousands, except share data)</span></span></div>

<div style="line-height:1.25">&#160;</div>

<table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left;color:#000000;width:100%">
  <tr>
    <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
    <td colspan="6" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">December
        31</span></span></div> </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2023</span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2022</span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Liabilities
        and redeemable convertible preferred shares, net of capital deficiency</span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">CURRENT
        LIABILITIES:</span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="2" style="vertical-align:bottom;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;background-color:rgb(255, 255, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="2" style="vertical-align:bottom;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;background-color:rgb(255, 255, 255);vertical-align:bottom;white-space:nowrap">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:top;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="text-indent:-14.2pt;margin-left:23.8pt;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Trade
        payables</span></span></div> </td>
    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fixv-38889" name="us-gaap:AccountsPayableCurrent" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">319</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fixv-38890" name="us-gaap:AccountsPayableCurrent" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">240</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align:top;width:76%;background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="text-indent:-14.2pt;margin-left:23.8pt;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Current
        maturities of operating lease liability</span></span></div> </td>
    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fixv-38891" name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">112</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fixv-38892" name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">115</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align:top;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="text-indent:-14.2pt;margin-left:23.8pt;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Warrants
        to preferred shares&#160;(including $<ix:nonFraction id="Fixv-38893" name="us-gaap:OtherNotesPayableCurrent" contextRef="C_20231231_usgaapRelatedPartyTransactionsByRelatedPartyAxis_usgaapRelatedPartyMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">186</ix:nonFraction>
        and $<ix:nonFraction id="Fixv-38894" name="us-gaap:OtherNotesPayableCurrent" contextRef="C_20221231_usgaapRelatedPartyTransactionsByRelatedPartyAxis_usgaapRelatedPartyMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">0</ix:nonFraction>
        due to related party, respectively)</span></span></div> </td>
    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fixv-38895" name="us-gaap:OtherLiabilitiesCurrent" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">200</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fixv-38896" name="us-gaap:OtherLiabilitiesCurrent" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">3</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align:top;width:76%;background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="text-indent:-14.2pt;margin-left:23.8pt;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Employee
        related obligations</span></span></div> </td>
    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fixv-38897" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">207</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fixv-38898" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">253</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align:top;width:76%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="text-indent:-14.2pt;margin-left:23.8pt;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Accrued
        expenses</span></span></div> </td>
    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fixv-38899" name="us-gaap:OtherAccountsPayableAndAccruedLiabilities" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,358</ix:nonFraction></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fixv-38900" name="us-gaap:OtherAccountsPayableAndAccruedLiabilities" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">999</ix:nonFraction></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align:top;width:76%;padding-bottom:2px;background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">TOTAL
        CURRENT LIABILITIES</span></span></div> </td>
    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fixv-38901" name="us-gaap:LiabilitiesCurrent" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,196</ix:nonFraction></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(255, 255, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fixv-38902" name="us-gaap:LiabilitiesCurrent" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,610</ix:nonFraction></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(255, 255, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align:top;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align:top;width:76%;background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">NON-CURRENT
        LIABILITIES:</span></span></div> </td>
    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align:top;width:76%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="margin-left:9.6pt;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Long-term
        operating lease liability</span></span></div> </td>
    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fixv-38903" name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">59</ix:nonFraction></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fixv-38904" name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">156</ix:nonFraction></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align:top;width:76%;padding-bottom:2px;background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">TOTAL
        NON-CURRENT LIABILITIES</span></span></div> </td>
    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fixv-38905" name="us-gaap:LiabilitiesNoncurrent" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">59</ix:nonFraction></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(255, 255, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fixv-38906" name="us-gaap:LiabilitiesNoncurrent" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">156</ix:nonFraction></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(255, 255, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align:top;width:76%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">TOTAL
        LIABILITIES</span></span></div> </td>
    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fixv-38907" name="us-gaap:Liabilities" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,255</ix:nonFraction></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fixv-38908" name="us-gaap:Liabilities" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,766</ix:nonFraction></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align:top;width:76%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align:top;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">COMMITMENTS
        AND CONTINGENT LIABILITIES </span>(Note 6)</span></span></div> </td>
    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align:top;width:76%;background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="text-indent:-9.6pt;margin-left:9.6pt;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">REDEEMABLE
        CONVERTIBLE PREFERRED SHARES&#160;AND NON-CONTROLLING INTERESTS:</span></span></div> </td>
    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        </tr>
  <tr>
    <td rowspan="1" style="vertical-align:top;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="text-indent:-14.2pt;margin-left:23.8pt;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Convertible
        Series A Preferred Shares (NIS <ix:nonFraction id="Fxbrl_20241205160312546" name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="C_20221231_usgaapStatementClassOfStockAxis_slxnConvertibleSeriesAPreferredSharesMember" unitRef="ilsPershares" scale="0" decimals="2" format="ixt:num-dot-decimal"><ix:nonFraction id="Fxbrl_20241004103557538" name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="C_20231231_usgaapStatementClassOfStockAxis_slxnConvertibleSeriesAPreferredSharesMember" unitRef="ilsPershares" scale="0" decimals="2" format="ixt:num-dot-decimal">0.09</ix:nonFraction></ix:nonFraction>
        par value, <ix:nonFraction id="Fxbrl_s_20241004103620346" name="us-gaap:PreferredStockSharesAuthorized" contextRef="C_20221231_usgaapStatementClassOfStockAxis_slxnConvertibleSeriesAPreferredSharesMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="Fxbrl_20241004103620346" name="us-gaap:PreferredStockSharesAuthorized" contextRef="C_20231231_usgaapStatementClassOfStockAxis_slxnConvertibleSeriesAPreferredSharesMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">56,667</ix:nonFraction></ix:nonFraction>
        shares authorized as of December 31, 2023 and 2022, <ix:nonFraction id="Fxbrl_20241205160525463" name="us-gaap:PreferredStockSharesOutstanding" contextRef="C_20221231_usgaapStatementClassOfStockAxis_slxnConvertibleSeriesAPreferredSharesMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="Fxbrl_20241205160523312" name="us-gaap:PreferredStockSharesIssued" contextRef="C_20221231_usgaapStatementClassOfStockAxis_slxnConvertibleSeriesAPreferredSharesMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="Fxbrl_20241205160501739" name="us-gaap:PreferredStockSharesOutstanding" contextRef="C_20231231_usgaapStatementClassOfStockAxis_slxnConvertibleSeriesAPreferredSharesMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="Fxbrl_20241004103916322" name="us-gaap:PreferredStockSharesIssued" contextRef="C_20231231_usgaapStatementClassOfStockAxis_slxnConvertibleSeriesAPreferredSharesMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">43,121</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction>
        shares issued and outstanding as of December 31, 2023 and 2022); aggregate liquidation preference of $<ix:nonFraction id="Fxbrl_20241004104016075" name="us-gaap:PreferredStockLiquidationPreferenceValue" contextRef="C_20231231_usgaapStatementClassOfStockAxis_slxnConvertibleSeriesAPreferredSharesMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,162</ix:nonFraction>
        as of December 31, 2023;</span></span></div> </td>
    <td colspan="1" rowspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" rowspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" rowspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" rowspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" rowspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" rowspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" rowspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" rowspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        </tr>
  <tr>
    <td rowspan="1" style="vertical-align:top;width:76%;background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="text-indent:-14.2pt;margin-left:23.8pt;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Convertible
        Series A-1 Preferred Shares (NIS <ix:nonFraction id="Fxbrl_20241205160324842" name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="C_20221231_usgaapStatementClassOfStockAxis_slxnConvertibleSeriesAOnePreferredSharesMember" unitRef="ilsPershares" scale="0" decimals="2" format="ixt:num-dot-decimal"><ix:nonFraction id="Fxbrl_20241004104332441" name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="C_20231231_usgaapStatementClassOfStockAxis_slxnConvertibleSeriesAOnePreferredSharesMember" unitRef="ilsPershares" scale="0" decimals="2" format="ixt:num-dot-decimal">0.09</ix:nonFraction></ix:nonFraction>
        par value per share, <ix:nonFraction id="Fxbrl_20241211203543454" name="us-gaap:PreferredStockSharesAuthorized" contextRef="C_20221231_usgaapStatementClassOfStockAxis_slxnConvertibleSeriesAOnePreferredSharesMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="Fxbrl_20241004104338840" name="us-gaap:PreferredStockSharesAuthorized" contextRef="C_20231231_usgaapStatementClassOfStockAxis_slxnConvertibleSeriesAOnePreferredSharesMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">13,334</ix:nonFraction></ix:nonFraction>
        shares authorized as of December 31, 2023 and 2022, <ix:nonFraction id="Fxbrl_20241205160612031" name="us-gaap:PreferredStockSharesOutstanding" contextRef="C_20221231_usgaapStatementClassOfStockAxis_slxnConvertibleSeriesAOnePreferredSharesMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="Fxbrl_20241205160611110" name="us-gaap:PreferredStockSharesIssued" contextRef="C_20221231_usgaapStatementClassOfStockAxis_slxnConvertibleSeriesAOnePreferredSharesMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="Fxbrl_20241205160610353" name="us-gaap:PreferredStockSharesOutstanding" contextRef="C_20231231_usgaapStatementClassOfStockAxis_slxnConvertibleSeriesAOnePreferredSharesMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="Fxbrl_20241004120852041" name="us-gaap:PreferredStockSharesIssued" contextRef="C_20231231_usgaapStatementClassOfStockAxis_slxnConvertibleSeriesAOnePreferredSharesMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">10,136</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction>
        shares issued and outstanding as of December 31, 2023 and 2022); aggregate liquidation preference of $<ix:nonFraction id="Fxbrl_20241004104425728" name="us-gaap:PreferredStockLiquidationPreferenceValue" contextRef="C_20231231_usgaapStatementClassOfStockAxis_slxnConvertibleSeriesAOnePreferredSharesMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,443</ix:nonFraction>
        as of December 31, 2023;</span></span></div> </td>
    <td colspan="1" rowspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" rowspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" rowspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" rowspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" rowspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" rowspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" rowspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" rowspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        </tr>
  <tr>
    <td rowspan="1" style="vertical-align:top;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="text-indent:-14.2pt;margin-left:23.8pt;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Convertible
        Series A-2 Preferred Shares (NIS <ix:nonFraction id="Fxbrl_20241205160334219" name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="C_20221231_usgaapStatementClassOfStockAxis_slxnConvertibleSeriesA2PreferredSharesMember" unitRef="ilsPershares" scale="0" decimals="2" format="ixt:num-dot-decimal"><ix:nonFraction id="Fxbrl_20241004105239999" name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="C_20231231_usgaapStatementClassOfStockAxis_slxnConvertibleSeriesA2PreferredSharesMember" unitRef="ilsPershares" scale="0" decimals="2" format="ixt:num-dot-decimal">0.09</ix:nonFraction></ix:nonFraction>
        par value per share, <ix:nonFraction id="Fxbrl_20241211203632525" name="us-gaap:PreferredStockSharesAuthorized" contextRef="C_20221231_usgaapStatementClassOfStockAxis_slxnConvertibleSeriesA2PreferredSharesMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="Fxbrl_20241004105253199" name="us-gaap:PreferredStockSharesAuthorized" contextRef="C_20231231_usgaapStatementClassOfStockAxis_slxnConvertibleSeriesA2PreferredSharesMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">22,223</ix:nonFraction></ix:nonFraction>
        shares authorized as of December 31, 2023 and 2022, <ix:nonFraction id="Fxbrl_20241205160708609" name="us-gaap:PreferredStockSharesOutstanding" contextRef="C_20221231_usgaapStatementClassOfStockAxis_slxnConvertibleSeriesA2PreferredSharesMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="Fxbrl_20241205160708091" name="us-gaap:PreferredStockSharesIssued" contextRef="C_20221231_usgaapStatementClassOfStockAxis_slxnConvertibleSeriesA2PreferredSharesMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="Fxbrl_20241205160707222" name="us-gaap:PreferredStockSharesOutstanding" contextRef="C_20231231_usgaapStatementClassOfStockAxis_slxnConvertibleSeriesA2PreferredSharesMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="Fxbrl_20241004121434122" name="us-gaap:PreferredStockSharesIssued" contextRef="C_20231231_usgaapStatementClassOfStockAxis_slxnConvertibleSeriesA2PreferredSharesMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">5,051</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction>
        shares issued and outstanding as of December 31, 2023 and 2022); aggregate liquidation preference of $<ix:nonFraction id="Fxbrl_20241004105354587" name="us-gaap:PreferredStockLiquidationPreferenceValue" contextRef="C_20231231_usgaapStatementClassOfStockAxis_slxnConvertibleSeriesA2PreferredSharesMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,763</ix:nonFraction>
        as of December 31, 2023;</span></span></div> </td>
    <td colspan="1" rowspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" rowspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" rowspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" rowspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" rowspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" rowspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" rowspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" rowspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        </tr>
  <tr>
    <td rowspan="1" style="vertical-align:top;width:76%;background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="text-indent:-14.2pt;margin-left:23.8pt;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Convertible
        Series A-3 Preferred Shares (NIS <ix:nonFraction id="Fxbrl_20241205160343235" name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="C_20221231_usgaapStatementClassOfStockAxis_slxnConvertibleSeriesAThreePreferredSharesMember" unitRef="ilsPershares" scale="0" decimals="2" format="ixt:num-dot-decimal"><ix:nonFraction id="Fxbrl_20241004105243349" name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="C_20231231_usgaapStatementClassOfStockAxis_slxnConvertibleSeriesAThreePreferredSharesMember" unitRef="ilsPershares" scale="0" decimals="2" format="ixt:num-dot-decimal">0.09</ix:nonFraction></ix:nonFraction>
        par value per share, <ix:nonFraction id="Fxbrl_s_20241004105256279" name="us-gaap:PreferredStockSharesAuthorized" contextRef="C_20221231_usgaapStatementClassOfStockAxis_slxnConvertibleSeriesAThreePreferredSharesMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="Fxbrl_20241004105256279" name="us-gaap:PreferredStockSharesAuthorized" contextRef="C_20231231_usgaapStatementClassOfStockAxis_slxnConvertibleSeriesAThreePreferredSharesMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">8,889</ix:nonFraction></ix:nonFraction>
        shares authorized as of December 31, 2023 and 2022, <ix:nonFraction id="Fxbrl_20241205160801304" name="us-gaap:PreferredStockSharesOutstanding" contextRef="C_20221231_usgaapStatementClassOfStockAxis_slxnConvertibleSeriesAThreePreferredSharesMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="Fxbrl_20241205160800706" name="us-gaap:PreferredStockSharesIssued" contextRef="C_20221231_usgaapStatementClassOfStockAxis_slxnConvertibleSeriesAThreePreferredSharesMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="Fxbrl_20241205160759899" name="us-gaap:PreferredStockSharesOutstanding" contextRef="C_20231231_usgaapStatementClassOfStockAxis_slxnConvertibleSeriesAThreePreferredSharesMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="Fxbrl_20241004121610748" name="us-gaap:PreferredStockSharesIssued" contextRef="C_20231231_usgaapStatementClassOfStockAxis_slxnConvertibleSeriesAThreePreferredSharesMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">7,037</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction>
        shares issued and outstanding as of December 31, 2023 and 2022); aggregate liquidation preference of $<ix:nonFraction id="Fxbrl_20241004105358523" name="us-gaap:PreferredStockLiquidationPreferenceValue" contextRef="C_20231231_usgaapStatementClassOfStockAxis_slxnConvertibleSeriesAThreePreferredSharesMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,887</ix:nonFraction>
        as of December 31, 2023;</span></span></div> </td>
    <td colspan="1" rowspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" rowspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" rowspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" rowspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" rowspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" rowspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" rowspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" rowspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        </tr>
  <tr>
    <td rowspan="1" style="vertical-align:top;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="text-indent:-14.2pt;margin-left:23.8pt;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Convertible
        Series A-4 Preferred Shares (NIS <ix:nonFraction id="Fxbrl_20241205160353507" name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="C_20221231_usgaapStatementClassOfStockAxis_slxnConvertibleSeriesAFourPreferredSharesMember" unitRef="ilsPershares" scale="0" decimals="2" format="ixt:num-dot-decimal"><ix:nonFraction id="Fxbrl_20241004105246903" name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="C_20231231_usgaapStatementClassOfStockAxis_slxnConvertibleSeriesAFourPreferredSharesMember" unitRef="ilsPershares" scale="0" decimals="2" format="ixt:num-dot-decimal">0.09</ix:nonFraction></ix:nonFraction>
        par value per share, <ix:nonFraction id="Fxbrl_20241004105259703" name="us-gaap:PreferredStockSharesAuthorized" contextRef="C_20231231_usgaapStatementClassOfStockAxis_slxnConvertibleSeriesAFourPreferredSharesMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">90,556</ix:nonFraction>
        and <ix:nonFraction id="Fxbrl_20241004105729481" name="us-gaap:PreferredStockSharesAuthorized" contextRef="C_20221231_usgaapStatementClassOfStockAxis_slxnConvertibleSeriesAFourPreferredSharesMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">0</ix:nonFraction>
        shares authorized as of December 31, 2023 and 2022, respectively, <ix:nonFraction id="Fxbrl_20241205160916026" name="us-gaap:PreferredStockSharesOutstanding" contextRef="C_20231231_usgaapStatementClassOfStockAxis_slxnConvertibleSeriesAFourPreferredSharesMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="Fxbrl_20241004105335082" name="us-gaap:PreferredStockSharesIssued" contextRef="C_20231231_usgaapStatementClassOfStockAxis_slxnConvertibleSeriesAFourPreferredSharesMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">2,413</ix:nonFraction></ix:nonFraction>**
        and <ix:nonFraction id="Fxbrl_s_20241004105904225" name="us-gaap:PreferredStockSharesOutstanding" contextRef="C_20221231_usgaapStatementClassOfStockAxis_slxnConvertibleSeriesAFourPreferredSharesMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="Fxbrl_20241004105904225" name="us-gaap:PreferredStockSharesIssued" contextRef="C_20221231_usgaapStatementClassOfStockAxis_slxnConvertibleSeriesAFourPreferredSharesMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">0</ix:nonFraction></ix:nonFraction>
        shares issued and outstanding as of December 31, 2023 and 2022, respectively); aggregate liquidation preference of $<ix:nonFraction id="Fxbrl_20241004105405268" name="us-gaap:PreferredStockLiquidationPreferenceValue" contextRef="C_20231231_usgaapStatementClassOfStockAxis_slxnConvertibleSeriesAFourPreferredSharesMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,076</ix:nonFraction>
        as of December 31, 2023;</span></span></div> </td>
    <td colspan="1" rowspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" rowspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" rowspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" rowspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" rowspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" rowspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" rowspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" rowspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align:top;width:76%;padding-bottom:2px;background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="text-indent:-9.6pt;margin-left:9.6pt;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">TOTAL
        REDEEMABLE CONVERTIBLE PREFERRED SHARES</span></span></div> </td>
    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fixv-38954" name="us-gaap:ConvertiblePreferredStockNonredeemableOrRedeemableIssuerOptionValue" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">15,057</ix:nonFraction></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(255, 255, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fixv-38955" name="us-gaap:ConvertiblePreferredStockNonredeemableOrRedeemableIssuerOptionValue" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">14,646</ix:nonFraction></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(255, 255, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align:top;width:76%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="text-indent:-9.6pt;margin-left:9.6pt;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">CONTINGENTLY
        REDEEMABLE NON-CONTROLLING INTERESTS</span></span></div> </td>
    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fixv-38956" name="us-gaap:RedeemableNoncontrollingInterestEquityPreferredCarryingAmount" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,420</ix:nonFraction></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fixv-38957" name="us-gaap:RedeemableNoncontrollingInterestEquityPreferredCarryingAmount" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,586</ix:nonFraction></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align:top;width:76%;padding-bottom:2px;background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="text-indent:-9.6pt;margin-left:9.6pt;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">TOTAL
        REDEEMABLE CONVERTIBLE PREFERRED SHARES AND CONTINGENTLY REDEEMABLE NON-CONTROLLING INTERESTS</span></span></div> </td>
    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fixv-38958" name="us-gaap:PreferredStockRedemptionAmount" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">18,477</ix:nonFraction></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(255, 255, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fixv-38959" name="us-gaap:PreferredStockRedemptionAmount" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">18,232</ix:nonFraction></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(255, 255, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align:top;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">CAPITAL
        DEFICIENCY:</span></span></div>
        <div style="text-indent:-14.2pt;margin-left:23.8pt;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Ordinary
        shares (($<ix:nonFraction id="Fxbrl_20241205160404665" name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="C_20221231" unitRef="usdPershares" scale="0" decimals="4" format="ixt:num-dot-decimal"><ix:nonFraction id="Fixv-38960" name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="C_20231231" unitRef="usdPershares" scale="0" decimals="4" format="ixt:num-dot-decimal">0.0009</ix:nonFraction></ix:nonFraction>
        par value per share, <ix:nonFraction id="Fxbrl_20241205160947011" name="us-gaap:CommonStockSharesAuthorized" contextRef="C_20221231" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="Fxbrl_20241004101021924" name="us-gaap:CommonStockSharesAuthorized" contextRef="C_20231231" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">22,222,222</ix:nonFraction></ix:nonFraction>
        shares authorized as of December 31, 2023 and 2022; <ix:nonFraction id="Fxbrl_20241216111154979" name="us-gaap:CommonStockSharesOutstanding" contextRef="C_20221231" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="Fxbrl_20241216111154068" name="us-gaap:CommonStockSharesIssued" contextRef="C_20221231" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="Fxbrl_20241216111153185" name="us-gaap:CommonStockSharesOutstanding" contextRef="C_20231231" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="Fxbrl_20241004101334096" name="us-gaap:CommonStockSharesIssued" contextRef="C_20231231" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">97,120</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction>
        shares issued and outstanding as of December 31, 2023 and 2022)</span></span></div> </td>
    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="-sec-ix-hidden:Fixv-38968">*</span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="-sec-ix-hidden:Fixv-38969">*</span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align:top;width:76%;background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="margin-left:9.6pt;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Additional
        paid-in capital</span></span></div> </td>
    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fixv-38970" name="us-gaap:AdditionalPaidInCapital" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">11,335</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fixv-38971" name="us-gaap:AdditionalPaidInCapital" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">11,204</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align:top;width:76%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="margin-left:9.6pt;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Accumulated
        deficit</span></span></div> </td>
    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fixv-38972" name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">26,811</ix:nonFraction></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
        <div style="line-height:1.25">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
        </div> </td>
    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fixv-38973" name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">21,869</ix:nonFraction></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
        <div style="line-height:1.25">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
        </div> </td> </tr>
  <tr>
    <td style="vertical-align:top;width:76%;padding-bottom:2px;background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">TOTAL
        CAPITAL DEFICIENCY</span></span></div> </td>
    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fixv-38974" name="us-gaap:StockholdersEquity" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">15,476</ix:nonFraction></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(255, 255, 255);vertical-align:bottom;white-space:nowrap">
        <div style="line-height:1.25">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
        </div> </td>
    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fixv-38975" name="us-gaap:StockholdersEquity" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">10,665</ix:nonFraction></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(255, 255, 255);vertical-align:bottom;white-space:nowrap">
        <div style="line-height:1.25">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
        </div> </td> </tr>
  <tr>
    <td style="vertical-align:top;width:76%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">TOTAL
        REDEEMABLE CONVERTIBLE PREFERRED SHARES AND CONTINGENTLY REDEEMABLE NON-CONTROLLING INTERESTS, NET OF CAPITAL DEFICIENCY</span></span></div>
        </td>
    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fixv-38976" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,001</ix:nonFraction></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fixv-38977" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,567</ix:nonFraction></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align:top;width:76%;padding-bottom:4px;background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;TOTAL
        LIABILITIES, REDEEMABLE CONVERTIBLE</span></span></div>
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;PREFERRED
        SHARES AND NON-CONTROLLING INTEREST NET OF CAPITAL DEFICIENCY</span></span></div> </td>
    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fixv-38978" name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,256</ix:nonFraction></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(255, 255, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fixv-38979" name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,333</ix:nonFraction></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(255, 255, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        </tr>
  </table>

<div style="text-align:center;margin-left:15.75pt;line-height:1.25;font-family:'Times New Roman', Times, serif">&#160;</div>

<div style="text-align:center;margin-left:15.75pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">*
Represents an amount less than $1</span></span></div>

<div style="text-align:center;text-indent:-9.6pt;margin-left:9.6pt;line-height:1.25;font-family:'Times New Roman', Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">**
</span>Net of 13,458 treasury shares held by a subsidiary as of December 31, 2023 (see Note 9(b)(2))</span></span></div>

<div style="text-align:center;text-indent:-9.6pt;margin-left:9.6pt;line-height:1.25;font-family:'Times New Roman', Times, serif">&#160;</div>

<div style="text-align:center;margin-left:15.75pt;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The
accompanying notes are an integral part of these consolidated financial statements.</span></span></div>

<div style="clear:both;margin-top:10pt;margin-bottom:10pt">

<div style="text-align:center">&#160;</div>

<div style="text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="color:rgb(0, 0, 0);font-weight:normal;font-style:normal">F-69</span></span></span></div>

<div style="page-break-after:always"> <hr style="border-width:0px;clear:both;margin:4px 0px;width:100%;height:2px;color:#000000;background-color:#000000;margin-top:4pt;margin-bottom:10pt"/>
</div> </div>

<div style="text-align:center;margin-left:1pt;line-height:1.25;font-weight:bold">&#160;</div> </div>

<div style="font:10pt Times New Roman, Times, Serif">

<div>

<div>

<div style="text-align:center;margin-left:1pt;line-height:1.25;font-weight:bold">SILEXION THERAPEUTICS CORP</div>

<div style="text-align:center;margin-left:7.65pt;line-height:1.25">CONSOLIDATED STATEMENTS OF OPERATIONS<span id="DSTATEMENTSOFOPERATIONS"></span></div>

<div style="text-align:center;line-height:1.25">(U.S. dollars in thousands, except share data)</div>

<div style="line-height:1.25">&#160;</div>

<div style="line-height:1.25">

<table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left;color:#000000;width:100%">
  <tr>
    <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
    <td colspan="6" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold">Year ended December 31</div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold">2023</div> </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold">2022</div> </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold">OPERATING EXPENSES:</div> </td>
    <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="6" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:bottom;width:76%;background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="text-indent:-7.05pt;margin-left:14.85pt;line-height:1.25;font-family:'Times New Roman',Times,serif">Research and development,
        net (including $<ix:nonFraction id="Fixv-38981" name="us-gaap:OtherResearchAndDevelopmentExpense" contextRef="C_20230101to20231231_usgaapRelatedPartyTransactionsByRelatedPartyAxis_usgaapRelatedPartyMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">69
        </ix:nonFraction>and $<ix:nonFraction id="Fixv-38982" name="us-gaap:OtherResearchAndDevelopmentExpense" contextRef="C_20220101to20221231_usgaapRelatedPartyTransactionsByRelatedPartyAxis_usgaapRelatedPartyMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">49
        </ix:nonFraction>from related party, respectively)</div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">$</div> </td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><ix:nonFraction id="Fixv-38983" name="us-gaap:ResearchAndDevelopmentExpense" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,708</ix:nonFraction></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">$</div> </td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><ix:nonFraction id="Fixv-38984" name="us-gaap:ResearchAndDevelopmentExpense" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,226</ix:nonFraction></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align:bottom;width:76%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="text-indent:-7.05pt;margin-left:14.85pt;line-height:1.25;font-family:'Times New Roman',Times,serif">General and administrative
        (including $<ix:nonFraction id="Fixv-38985" name="us-gaap:OtherGeneralAndAdministrativeExpense" contextRef="C_20230101to20231231_usgaapRelatedPartyTransactionsByRelatedPartyAxis_usgaapRelatedPartyMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">48
        </ix:nonFraction>and $<ix:nonFraction id="Fixv-38986" name="us-gaap:OtherGeneralAndAdministrativeExpense" contextRef="C_20220101to20221231_usgaapRelatedPartyTransactionsByRelatedPartyAxis_usgaapRelatedPartyMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">37
        </ix:nonFraction>from related party, respectively)</div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><ix:nonFraction id="Fixv-38987" name="us-gaap:GeneralAndAdministrativeExpense" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">973</ix:nonFraction></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><ix:nonFraction id="Fixv-38988" name="us-gaap:GeneralAndAdministrativeExpense" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">634</ix:nonFraction></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align:bottom;width:76%;padding-bottom:2px;background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold">TOTAL OPERATING EXPENSES</div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><ix:nonFraction id="Fixv-38989" name="us-gaap:OperatingExpenses" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,681</ix:nonFraction></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(255, 255, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><ix:nonFraction id="Fixv-38990" name="us-gaap:OperatingExpenses" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,860</ix:nonFraction></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(255, 255, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold">OPERATING LOSS</div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><ix:nonFraction id="Fixv-38991" name="us-gaap:OperatingIncomeLoss" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">4,681</ix:nonFraction></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><ix:nonFraction id="Fixv-38992" name="us-gaap:OperatingIncomeLoss" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">3,860</ix:nonFraction></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align:bottom;width:76%;padding-bottom:2px;background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">Financial expenses (income), net (including $<ix:nonFraction id="Fixv-38993" name="slxn:FinancialExpensesNetFromRelatedParty" contextRef="C_20230101to20231231_usgaapRelatedPartyTransactionsByRelatedPartyAxis_usgaapRelatedPartyMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">83
        </ix:nonFraction>and $<ix:nonFraction id="Fixv-38994" name="slxn:FinancialExpensesNetFromRelatedParty" contextRef="C_20220101to20221231_usgaapRelatedPartyTransactionsByRelatedPartyAxis_usgaapRelatedPartyMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">0
        </ix:nonFraction>from related party, respectively)</div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><ix:nonFraction id="Fixv-38995" name="slxn:FinancialExpenses" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">395</ix:nonFraction></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(255, 255, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">(<ix:nonFraction id="Fixv-38996" name="slxn:FinancialExpenses" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">396</ix:nonFraction></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(255, 255, 255);vertical-align:bottom;white-space:nowrap">
        <div style="line-height:1.25">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">)</div> </div> </td> </tr>
  <tr>
    <td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold">LOSS BEFORE INCOME TAX</div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">$</div> </td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><ix:nonFraction id="Fixv-38997" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">5,076</ix:nonFraction></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">$</div> </td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><ix:nonFraction id="Fixv-38998" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">3,464</ix:nonFraction></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align:bottom;width:76%;padding-bottom:2px;background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold">INCOME TAX</div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><ix:nonFraction id="Fixv-38999" name="us-gaap:IncomeTaxExpenseBenefit" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">32</ix:nonFraction></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(255, 255, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><ix:nonFraction id="Fixv-39000" name="us-gaap:IncomeTaxExpenseBenefit" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">24</ix:nonFraction></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(255, 255, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align:bottom;width:76%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold">NET LOSS FOR THE YEAR</div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">$</div> </div> </td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><ix:nonFraction id="Fixv-39001" name="us-gaap:NetIncomeLoss" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">5,108</ix:nonFraction></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">$</div> </div> </td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><ix:nonFraction id="Fixv-39002" name="us-gaap:NetIncomeLoss" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">3,488</ix:nonFraction></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align:bottom;width:76%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">Attributable to:</div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align:bottom;width:76%;background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">Equity holders of the Company</div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><ix:nonFraction id="Fixv-39003" name="slxn:EquityHoldersOfTheCompany" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,942</ix:nonFraction></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><ix:nonFraction id="Fixv-39004" name="slxn:EquityHoldersOfTheCompany" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,215</ix:nonFraction></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align:bottom;width:76%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">Non-controlling interests</div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><ix:nonFraction id="Fixv-39005" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">166</ix:nonFraction></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><ix:nonFraction id="Fixv-39006" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">273</ix:nonFraction></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align:bottom;width:76%;padding-bottom:2px;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">$</div> </div> </td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><ix:nonFraction id="Fixv-39007" name="us-gaap:NetIncomeLoss" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">5,108</ix:nonFraction></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(255, 255, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">$</div> </div> </td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><ix:nonFraction id="Fixv-39008" name="us-gaap:NetIncomeLoss" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">3,488</ix:nonFraction></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(255, 255, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align:bottom;width:76%;background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold">LOSS PER SHARE, BASIC AND DILUTED</div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">$</div> </td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><ix:nonFraction id="Fxbrl_20241205160041718" name="us-gaap:EarningsPerShareDiluted" contextRef="C_20230101to20231231" unitRef="usdPershares" scale="0" decimals="2" format="ixt:num-dot-decimal"><ix:nonFraction id="Fixv-39009" name="us-gaap:EarningsPerShareBasic" contextRef="C_20230101to20231231" unitRef="usdPershares" scale="0" decimals="2" format="ixt:num-dot-decimal">44.23</ix:nonFraction></ix:nonFraction></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">$</div> </td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><ix:nonFraction id="Fxbrl_20241205160055658" name="us-gaap:EarningsPerShareDiluted" contextRef="C_20220101to20221231" unitRef="usdPershares" scale="0" decimals="2" format="ixt:num-dot-decimal"><ix:nonFraction id="Fixv-39010" name="us-gaap:EarningsPerShareBasic" contextRef="C_20220101to20221231" unitRef="usdPershares" scale="0" decimals="2" format="ixt:num-dot-decimal">28.79</ix:nonFraction></ix:nonFraction></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align:bottom;width:76%;background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="text-indent:-7.8pt;margin-left:7.8pt;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold">WEIGHTED
        AVERAGE NUMBER OF ORDINARY SHARES OUTSTANDING USED IN COMPUTATION OF BASIC AND DILUTED LOSS PER SHARE</div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><ix:nonFraction id="Fxbrl_20241205160355220" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="C_20230101to20231231" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="Fixv-39011" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="C_20230101to20231231" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">111,726</ix:nonFraction></ix:nonFraction></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><ix:nonFraction id="Fxbrl_20241205160409522" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="C_20220101to20221231" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="Fixv-39012" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="C_20220101to20221231" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">111,686</ix:nonFraction></ix:nonFraction></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        </tr>
  </table> </div>

<div style="line-height:1.25">&#160;</div>

<div style="text-align:center;margin-left:15.75pt;line-height:1.25;font-weight:bold">The accompanying notes are an integral part of these
consolidated financial statements.</div> </div> </div>

<div>

<p style="font:10pt Times New Roman, Times, Serif;text-align:center;margin-top:0pt;margin-bottom:0pt">&#160;</p>

<p style="font:10pt Times New Roman, Times, serif;text-align:center;margin-top:10pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, Serif;font-size:10pt">F-70</span></p>
</div> <hr style="page-break-after:always;border-width:0px;clear:both;margin:4px 0px;width:100%;height:2px;color:#000000;background-color:#000000;margin-top:4pt;margin-bottom:10pt"/>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0pt;text-align:center">&#160;</p>

<div><span id="f_021"></span></div> </div>

<div style="font:10pt Times New Roman, Times, Serif">

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><strong>SILEXION
THERAPEUTICS CORP</strong></span></span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center"><span id="DCAPITALDEFICIENCY"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">CONSOLIDATED
STATEMENTS OF CHANGES IN REDEEMABLE CONVERTIBLE PREFERRED&#160;SHARES AND CAPITAL DEFICIENCY</span></span></span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">(U.S.&#160;dollars
in thousands, except per share data)</span></span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center">&#160;</p>

<table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width:100%;font:10pt Times New Roman, Times, Serif">
  <tr style="vertical-align:bottom">
    <td style="text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="text-align:center;font-weight:bold;border-bottom:2px solid black"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td colspan="42" rowspan="1" style="border-bottom:2px solid black;text-align:center;font-weight:bold"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span><span>Re<strong>deemable
        Convertible Preferred Shares</strong></span></span></span></span></span></span></span><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span><span><strong>&#160;</strong></span></span></span></span></span></span></span><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span><span><strong>&#160;</strong></span></span></span></span></span></span></span><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span><span><strong>&#160;</strong></span></span></span></span></span></span></span></td>
    <td style="text-align:center;font-weight:bold;border-right:2px solid black"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span><span><strong>&#160;</strong></span></span></span></span></span></span></span></td>
    <td style="text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span><span><strong>&#160;</strong></span></span></span></span></span></span></span></td>
    <td colspan="6" rowspan="1" style="text-align:center;border-bottom:2px solid black">
        <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><strong>Ordinary
        shares</strong></span></span></span></span></span></p> </td>
    <td style="text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span><span><strong>&#160;</strong></span></span></span></span></span></span></span></td>
    <td style="text-align:center;font-weight:bold"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span><span><strong>&#160;</strong></span></span></span></span></span></span></span></td>
    <td colspan="2" style="text-align:center;font-weight:bold;margin-top:0pt;margin-bottom:0pt;border-bottom:2px solid black">
        <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span style="margin-top:0pt;margin-bottom:0pt">Additional
        paid-in</span></span></span></span></span></p>
        <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span style="margin-top:0pt;margin-bottom:0pt"><strong style="margin-top:0pt;margin-bottom:0pt">Capital</strong></span><strong style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</strong></span></span></span></span></p>
        </td>
    <td style="text-align:center;font-weight:bold"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span><span><strong>&#160;</strong></span></span></span></span></span></span></span></td>
    <td style="text-align:center;font-weight:bold"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span><span><strong>&#160;</strong></span></span></span></span></span></span></span></td>
    <td colspan="2" style="text-align:center;font-weight:bold;margin-top:0pt;margin-bottom:0pt;border-bottom:2px solid black">
        <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span style="margin-top:0pt;margin-bottom:0pt">Accumulated</span></span></span></span></span></p>
        <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span style="margin-top:0pt;margin-bottom:0pt">deficit</span><strong style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</strong></span></span></span></span></p>
        </td>
    <td style="text-align:center;font-weight:bold"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span><span><strong>&#160;</strong></span></span></span></span></span></span></span></td>
    <td style="text-align:center;font-weight:bold"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span><span><strong>&#160;</strong></span></span></span></span></span></span></span></td>
    <td colspan="2" style="text-align:center;font-weight:bold;margin-top:0pt;margin-bottom:0pt;border-bottom:2px solid black">Total
        <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">capital</span></span></span></span></span></p>
        <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">deficiency</span></span></span></span></span></p>
        </td>
    <td style="text-align:center;font-weight:bold"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span><span><strong>&#160;</strong></span></span></span></span></span></span></span></td>
    <td style="text-align:center;font-weight:bold"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span><span><strong>&#160;</strong></span></span></span></span></span></span></span></td>
    <td colspan="2" style="text-align:center;font-weight:bold;vertical-align:bottom;margin-top:0pt;margin-bottom:0pt;border-bottom:2px solid black">
        <p style="text-align:center;margin-top:0pt;font:10pt Times New Roman, Times, Serif;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt"><strong style="margin-top:0pt;margin-bottom:0pt">Total<br/>redeemable<br/>convertible<br/>preferred<br/>shares
        and<br/>contingently</strong></span></span></span></span></span></span></span></p>
        <p style="text-align:center;font:10pt Times New Roman, Times, Serif;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt"><strong style="margin-top:0pt;margin-bottom:0pt">redeemable&#160;</strong></span></span></span></span></span></span></span></p>
        <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span style="margin-top:0pt;margin-bottom:0pt">non-
        </span></span></span></span></span></p>
        <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span style="margin-top:0pt;margin-bottom:0pt">controlling
        </span></span></span></span></span></p>
        <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span style="margin-top:0pt;margin-bottom:0pt">interests,
        </span></span></span></span></span></p>
        <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span style="margin-top:0pt;margin-bottom:0pt">net
        of </span></span></span></span></span></p>
        <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span style="margin-top:0pt;margin-bottom:0pt">capital</span></span></span></span></span></p>
        <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span style="margin-top:0pt;margin-bottom:0pt">deficiency</span></span></span></span></span></p>
        </td>
    <td style="text-align:center;font-weight:bold"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span>&#160;</span></span></span></span></span></td>
        </tr>
  <tr style="vertical-align:bottom">
    <td style="text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="text-align:center;font-weight:bold"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td colspan="6" style="border-bottom:1.5pt solid black;text-align:center;font-weight:bold;margin-top:0pt;margin-bottom:0pt">
        <p style="margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">Series&#160;A</span></span></span></span></span></span></span></p>
        <p style="margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">preferred&#160;shares</span></span></span></span></span></span></span></p>
        </td>
    <td style="text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span><span>&#160;</span></span></span></span></span></span></span></td>
    <td style="text-align:center;font-weight:bold"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span><span>&#160;</span></span></span></span></span></span></span></td>
    <td colspan="6" style="border-bottom:1.5pt solid black;text-align:center;font-weight:bold;margin-top:0pt;margin-bottom:0pt">
        <p style="margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">Series&#160;A-1</span></span></span></span></span></span></span></p>
        <p style="margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">preferred&#160;shares</span></span></span></span></span></span></span></p>
        </td>
    <td style="text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span><span>&#160;</span></span></span></span></span></span></span></td>
    <td style="text-align:center;font-weight:bold"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span><span>&#160;</span></span></span></span></span></span></span></td>
    <td colspan="6" style="border-bottom:1.5pt solid black;text-align:center;font-weight:bold;margin-top:0pt;margin-bottom:0pt">
        <p style="margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">Series&#160;A-2</span></span></span></span></span></span></span></p>
        <p style="margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">preferred&#160;shares</span></span></span></span></span></span></span></p>
        </td>
    <td style="text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span><span>&#160;</span></span></span></span></span></span></span></td>
    <td style="text-align:center;font-weight:bold"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span><span>&#160;</span></span></span></span></span></span></span></td>
    <td colspan="6" style="border-bottom:1.5pt solid black;text-align:center;font-weight:bold;margin-top:0pt;margin-bottom:0pt">
        <p style="margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">Series&#160;A-3</span></span></span></span></span></span></span></p>
        <p style="margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">preferred&#160;shares</span></span></span></span></span></span></span></p>
        </td>
    <td style="text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span><span>&#160;</span></span></span></span></span></span></span></td>
    <td style="text-align:center;font-weight:bold"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span><span>&#160;</span></span></span></span></span></span></span></td>
    <td colspan="6" style="border-bottom:1.5pt solid black;text-align:center;font-weight:bold;margin-top:0pt;margin-bottom:0pt">
        <p style="margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">Series&#160;A-4</span></span></span></span></span></span></span></p>
        <p style="margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">preferred&#160;shares</span></span></span></span></span></span></span></p>
        </td>
    <td style="text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span><span>&#160;</span></span></span></span></span></span></span></td>
    <td style="text-align:center;font-weight:bold"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span><span>&#160;</span></span></span></span></span></span></span></td>
    <td colspan="2" style="text-align:center;font-weight:bold;border-bottom:2px solid black"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span><span>Contingently
        redeemable non- controlling interests</span></span></span></span></span></span></span></td>
    <td style="text-align:center;font-weight:bold;border-right:2px solid black"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span><span>&#160;</span></span></span></span></span></span></span></td>
    <td style="text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span><span>&#160;</span></span></span></span></span></span></span></td>
    <td colspan="6" style="text-align:center">&#160;</td>
    <td style="text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span><span>&#160;</span></span></span></span></span></span></span></td>
    <td style="text-align:center;font-weight:bold"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span><span>&#160;</span></span></span></span></span></span></span></td>
    <td colspan="2" style="text-align:center;font-weight:bold">&#160;</td>
    <td style="text-align:center;font-weight:bold"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span><span>&#160;</span></span></span></span></span></span></span></td>
    <td style="text-align:center;font-weight:bold"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span><span>&#160;</span></span></span></span></span></span></span></td>
    <td colspan="2" style="text-align:center;font-weight:bold">&#160;</td>
    <td style="text-align:center;font-weight:bold"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span><span>&#160;</span></span></span></span></span></span></span></td>
    <td style="text-align:center;font-weight:bold"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span><span>&#160;</span></span></span></span></span></span></span></td>
    <td colspan="2" style="text-align:center;font-weight:bold">&#160;</td>
    <td style="text-align:center;font-weight:bold"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span><span>&#160;</span></span></span></span></span></span></span></td>
    <td style="text-align:center;font-weight:bold"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span><span>&#160;</span></span></span></span></span></span></span></td>
    <td colspan="2" style="text-align:center;font-weight:bold;margin-top:0pt;margin-bottom:0pt">
        <p style="margin-top:0pt;margin-bottom:0pt">&#160;</p> </td>
    <td style="text-align:center;font-weight:bold"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span>&#160;</span></span></span></span></span></td>
        </tr>
  <tr style="vertical-align:bottom">
    <td style="text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="text-align:center;font-weight:bold"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td colspan="2" style="border-bottom:1.5pt solid black;text-align:center;font-weight:bold"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span><span>Shares</span></span></span></span></span></span></span></td>
    <td style="text-align:center;font-weight:bold"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span><span>&#160;</span></span></span></span></span></span></span></td>
    <td style="text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span><span>&#160;</span></span></span></span></span></span></span></td>
    <td colspan="2" style="border-bottom:1.5pt solid black;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span><span><strong>Amount</strong></span></span></span></span></span></span></span></td>
    <td style="text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span><span>&#160;</span></span></span></span></span></span></span></td>
    <td style="text-align:center;font-weight:bold"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span><span>&#160;</span></span></span></span></span></span></span></td>
    <td colspan="2" style="border-bottom:1.5pt solid black;text-align:center;font-weight:bold"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span><span>Shares</span></span></span></span></span></span></span></td>
    <td style="text-align:center;font-weight:bold"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span><span>&#160;</span></span></span></span></span></span></span></td>
    <td style="text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span><span>&#160;</span></span></span></span></span></span></span></td>
    <td colspan="2" style="border-bottom:1.5pt solid black;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span><span><strong>Amount</strong></span></span></span></span></span></span></span></td>
    <td style="text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span><span>&#160;</span></span></span></span></span></span></span></td>
    <td style="text-align:center;font-weight:bold"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span><span>&#160;</span></span></span></span></span></span></span></td>
    <td colspan="2" style="border-bottom:1.5pt solid black;text-align:center;font-weight:bold"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span><span>Shares</span></span></span></span></span></span></span></td>
    <td style="text-align:center;font-weight:bold"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span><span>&#160;</span></span></span></span></span></span></span></td>
    <td style="text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span><span>&#160;</span></span></span></span></span></span></span></td>
    <td colspan="2" style="border-bottom:1.5pt solid black;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span><span><strong>Amount</strong></span></span></span></span></span></span></span></td>
    <td style="text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span><span>&#160;</span></span></span></span></span></span></span></td>
    <td style="text-align:center;font-weight:bold"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span><span>&#160;</span></span></span></span></span></span></span></td>
    <td colspan="2" style="border-bottom:1.5pt solid black;text-align:center;font-weight:bold"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span><span>Shares</span></span></span></span></span></span></span></td>
    <td style="text-align:center;font-weight:bold"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span><span>&#160;</span></span></span></span></span></span></span></td>
    <td style="text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span><span>&#160;</span></span></span></span></span></span></span></td>
    <td colspan="2" style="border-bottom:1.5pt solid black;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span><span><strong>Amount</strong></span></span></span></span></span></span></span></td>
    <td style="text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span><span>&#160;</span></span></span></span></span></span></span></td>
    <td style="text-align:center;font-weight:bold"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span><span>&#160;</span></span></span></span></span></span></span></td>
    <td colspan="2" style="border-bottom:1.5pt solid black;text-align:center;font-weight:bold"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span><span>Shares</span></span></span></span></span></span></span></td>
    <td style="text-align:center;font-weight:bold"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span><span>&#160;</span></span></span></span></span></span></span></td>
    <td style="text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span><span>&#160;</span></span></span></span></span></span></span></td>
    <td colspan="2" style="border-bottom:1.5pt solid black;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span><span><strong>Amount</strong></span></span></span></span></span></span></span></td>
    <td style="text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span><span>&#160;</span></span></span></span></span></span></span></td>
    <td style="text-align:center;font-weight:bold"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span><span>&#160;</span></span></span></span></span></span></span></td>
    <td colspan="2" style="border-bottom:1.5pt solid black;text-align:center;font-weight:bold"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span><span>Amount</span></span></span></span></span></span></span></td>
    <td style="text-align:center;font-weight:bold;border-right:2px solid black"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span><span>&#160;</span></span></span></span></span></span></span></td>
    <td style="text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span><span>&#160;</span></span></span></span></span></span></span></td>
    <td colspan="2" style="border-bottom:1.5pt solid black;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span><span>&#160;<strong>Shares</strong></span></span></span></span></span></span></span></td>
    <td style="text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span><span>&#160;</span></span></span></span></span></span></span></td>
    <td style="text-align:center;font-weight:bold"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span><span>&#160;</span></span></span></span></span></span></span></td>
    <td colspan="2" style="border-bottom:1.5pt solid black;text-align:center;font-weight:bold"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span><span>Amount</span></span></span></span></span></span></span></td>
    <td style="text-align:center;font-weight:bold"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span><span>&#160;</span></span></span></span></span></span></span></td>
    <td style="text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span><span>&#160;</span></span></span></span></span></span></span></td>
    <td colspan="2" style="border-bottom:1.5pt solid black;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span><span>&#160;</span></span></span></span></span></span></span></td>
    <td style="text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span><span>&#160;</span></span></span></span></span></span></span></td>
    <td style="text-align:center;font-weight:bold"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span><span>&#160;</span></span></span></span></span></span></span></td>
    <td colspan="2" style="border-bottom:1.5pt solid black;text-align:center;font-weight:bold">&#160;</td>
    <td style="text-align:center;font-weight:bold"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span><span>&#160;</span></span></span></span></span></span></span></td>
    <td style="text-align:center;font-weight:bold"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span><span>&#160;</span></span></span></span></span></span></span></td>
    <td colspan="2" style="border-bottom:1.5pt solid black;text-align:center;font-weight:bold">&#160;</td>
    <td style="text-align:center;font-weight:bold"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span><span>&#160;</span></span></span></span></span></span></span></td>
    <td style="text-align:center;font-weight:bold"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span><span>&#160;</span></span></span></span></span></span></span></td>
    <td colspan="2" style="border-bottom:1.5pt solid black;text-align:center;font-weight:bold">&#160;</td>
    <td style="text-align:center;font-weight:bold"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span>&#160;</span></span></span></span></span></td>
        </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="padding-left:0.125in;text-indent:-0.125in;font-weight:bold;width:4.8%"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>BALANCE
        AT JANUARY 1, 2022</span></span></span></td>
    <td style="width:0.2%"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="width:0.2%;text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="width:5%;text-align:right"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><ix:nonFraction id="Fixv-39013" name="us-gaap:SharesOutstanding" contextRef="C_20211231_usgaapStatementClassOfStockAxis_usgaapSeriesAPreferredStockMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">43,121</ix:nonFraction></span></span></span></td>
    <td style="width:0.2%;text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="width:0.2%"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="width:0.2%;text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>$</span></span></span></td>
    <td style="width:5%;text-align:right"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><ix:nonFraction id="Fixv-39014" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_20211231_usgaapStatementClassOfStockAxis_usgaapSeriesAPreferredStockMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,307</ix:nonFraction></span></span></span></td>
    <td style="width:0.2%;text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="width:0.2%"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="width:0.2%;text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="width:5%;text-align:right"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><ix:nonFraction id="Fixv-39015" name="us-gaap:SharesOutstanding" contextRef="C_20211231_usgaapStatementClassOfStockAxis_slxnSeriesA1PreferredSharesMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">10,136</ix:nonFraction></span></span></span></td>
    <td style="width:0.2%;text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="width:0.2%"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="width:0.2%;text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>$</span></span></span></td>
    <td style="width:5%;text-align:right"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><ix:nonFraction id="Fixv-39016" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_20211231_usgaapStatementClassOfStockAxis_slxnSeriesA1PreferredSharesMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,392</ix:nonFraction></span></span></span></td>
    <td style="width:0.2%;text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="width:0.2%"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="width:0.2%;text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="width:5%;text-align:right"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><ix:nonFraction id="Fhidden-fact-98" name="us-gaap:SharesOutstanding" contextRef="C_20211231_usgaapStatementClassOfStockAxis_slxnSeriesA2PreferredSharesMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember" unitRef="shares" decimals="INF" format="ixt:fixed-zero">-</ix:nonFraction></span></span></td>
    <td style="width:0.2%;text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="width:0.2%"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="width:0.2%;text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="width:5%;text-align:right"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><ix:nonFraction id="Fhidden-fact-99" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_20211231_usgaapStatementClassOfStockAxis_slxnSeriesA2PreferredSharesMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></td>
    <td style="width:0.2%;text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="width:0.2%"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="width:0.2%;text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="width:5%;text-align:right"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><ix:nonFraction id="Fhidden-fact-100" name="us-gaap:SharesOutstanding" contextRef="C_20211231_usgaapStatementClassOfStockAxis_slxnSeriesA3PreferredSharesMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember" unitRef="shares" decimals="INF" format="ixt:fixed-zero">-</ix:nonFraction></span></span></td>
    <td style="width:0.2%;text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="width:0.2%"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="width:0.2%;text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="width:5%;text-align:right"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><ix:nonFraction id="Fhidden-fact-101" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_20211231_usgaapStatementClassOfStockAxis_slxnSeriesA3PreferredSharesMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></td>
    <td style="width:0.2%;text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="width:0.2%"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="width:0.2%;text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="width:5%;text-align:right"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><ix:nonFraction id="Fhidden-fact-102" name="us-gaap:SharesOutstanding" contextRef="C_20211231_usgaapStatementClassOfStockAxis_slxnSeriesA4PreferredSharesMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember" unitRef="shares" decimals="INF" format="ixt:fixed-zero">-</ix:nonFraction></span></span></td>
    <td style="width:0.2%;text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="width:0.2%"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="width:0.2%;text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="width:5%;text-align:right"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><ix:nonFraction id="Fhidden-fact-103" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_20211231_usgaapStatementClassOfStockAxis_slxnSeriesA4PreferredSharesMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></td>
    <td style="width:0.2%;text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="width:0.2%"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="width:0.2%;text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>$</span></span></span></td>
    <td style="width:5%;text-align:right"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><ix:nonFraction id="Fixv-39017" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_20211231_usgaapStatementEquityComponentsAxis_usgaapNoncontrollingInterestMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,859</ix:nonFraction></span></span></span></td>
    <td style="width:0.2%;text-align:left;border-right:2px solid black"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="width:0.2%"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="width:0.2%;text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="width:5%;text-align:right"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><ix:nonFraction id="Fixv-39018" name="us-gaap:SharesOutstanding" contextRef="C_20211231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">97,074</ix:nonFraction></span></span></span></td>
    <td style="width:0.2%;text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="width:0.2%"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="width:0.2%;text-align:left">&#160;</td>
    <td style="width:5%;text-align:right"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span style="-sec-ix-hidden:Fixv-39019">*</span></span></span></span></td>
    <td style="width:0.2%;text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="width:0.2%"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="width:0.2%;text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>$</span></span></span></td>
    <td style="width:5%;text-align:right"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><ix:nonFraction id="Fixv-39020" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_20211231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">11,007</ix:nonFraction></span></span></span></td>
    <td style="width:0.2%;text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="width:0.2%"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="width:0.2%;text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>$</span></span></span></td>
    <td style="width:5%;text-align:right"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>(<ix:nonFraction id="Fixv-39021" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_20211231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">18,654</ix:nonFraction></span></span></span></td>
    <td style="width:0.2%;text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>)</span></span></span></td>
    <td style="width:0.2%"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="width:0.2%;text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>$</span></span></span></td>
    <td style="width:5%;text-align:right"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>(<ix:nonFraction id="Fixv-39022" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_20211231_usgaapStatementEquityComponentsAxis_usgaapParentMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">7,647</ix:nonFraction></span></span></span></td>
    <td style="width:0.2%;text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>)</span></span></span></td>
    <td style="width:0.2%"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="width:0.2%;text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>$</span></span></span></td>
    <td style="width:5%;text-align:right"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><ix:nonFraction id="Fixv-39023" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,911</ix:nonFraction></span></span></span></td>
    <td style="width:0.2%;text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
        </tr>
  <tr style="vertical-align:bottom">
    <td style="padding-left:0.125in;text-indent:-0.125in;font-weight:bold;text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>CHANGES
        DURING 2022:</span></span></span></td>
    <td><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="text-align:right"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="text-align:right"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="text-align:right"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="text-align:right"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="text-align:right"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="text-align:right"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="text-align:right"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="text-align:right"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="text-align:right"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="text-align:right"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="text-align:right"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="text-align:left;border-right:2px solid black"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="text-align:right"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="text-align:right"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="text-align:right"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="text-align:right"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="text-align:right"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="text-align:right"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
        </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="padding-left:0.25in;text-indent:-0.125in;text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>Issuance
        of Preferred A-2 shares, net of issuance cost, see Note&#160;9(b)</span></span></span></td>
    <td><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="text-align:right"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="text-align:right"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="text-align:right"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="text-align:right"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="text-align:right"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><ix:nonFraction id="Fixv-39024" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="C_20220101to20221231_usgaapStatementClassOfStockAxis_slxnSeriesA2PreferredSharesMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">5,051</ix:nonFraction></span></span></span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="text-align:right"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><ix:nonFraction id="Fixv-39025" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="C_20220101to20221231_usgaapStatementClassOfStockAxis_slxnSeriesA2PreferredSharesMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,264</ix:nonFraction></span></span></span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="text-align:right"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="text-align:right"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="text-align:right"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="text-align:right"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="text-align:right"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="text-align:left;border-right:2px solid black"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="text-align:right"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="text-align:right"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="text-align:right"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="text-align:right"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="text-align:right"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="text-align:right"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><ix:nonFraction id="Fixv-39026" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,264</ix:nonFraction></span></span></span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
        </tr>
  <tr style="vertical-align:bottom">
    <td style="padding-left:0.25in;text-indent:-0.125in;text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>Conversion
        of simple agreements for future equity (SAFE) to Preferred A-3 shares, see Note&#160;7</span></span></span></td>
    <td><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="text-align:right"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="text-align:right"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="text-align:right"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="text-align:right"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="text-align:right"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="text-align:right"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="text-align:right"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><ix:nonFraction id="Fixv-39027" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits" contextRef="C_20220101to20221231_usgaapStatementClassOfStockAxis_slxnSeriesA3PreferredSharesMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">7,037</ix:nonFraction></span></span></span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="text-align:right"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><ix:nonFraction id="Fixv-39028" name="us-gaap:StockIssuedDuringPeriodValueConversionOfUnits" contextRef="C_20220101to20221231_usgaapStatementClassOfStockAxis_slxnSeriesA3PreferredSharesMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,683</ix:nonFraction></span></span></span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="text-align:right"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="text-align:right"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="text-align:right"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="text-align:left;border-right:2px solid black"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="text-align:right"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="text-align:right"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="text-align:right"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><ix:nonFraction id="Fixv-39029" name="us-gaap:StockIssuedDuringPeriodValueConversionOfUnits" contextRef="C_20220101to20221231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">69</ix:nonFraction></span></span></span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="text-align:right"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="text-align:right"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><ix:nonFraction id="Fixv-39030" name="us-gaap:StockIssuedDuringPeriodValueConversionOfUnits" contextRef="C_20220101to20221231_usgaapStatementEquityComponentsAxis_usgaapParentMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">69</ix:nonFraction></span></span></span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="text-align:right"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><ix:nonFraction id="Fixv-39031" name="us-gaap:StockIssuedDuringPeriodValueConversionOfUnits" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,752</ix:nonFraction></span></span></span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
        </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="padding-left:0.25in;text-indent:-0.125in"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>Exercise
        of options</span></span></span></td>
    <td><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="text-align:right"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="text-align:right"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="text-align:right"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="text-align:right"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="text-align:right"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="text-align:right"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="text-align:right"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="text-align:right"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="text-align:right"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="text-align:right"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="text-align:right"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="text-align:left;border-right:2px solid black"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="text-align:right"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><ix:nonFraction id="Fixv-39032" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="C_20220101to20221231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">46</ix:nonFraction></span></span></span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="text-align:right"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span style="-sec-ix-hidden:Fhidden-fact-104">*</span></span></span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="text-align:right"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><ix:nonFraction id="Fixv-39033" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="C_20220101to20221231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">3</ix:nonFraction></span></span></span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="text-align:right"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="text-align:right"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><ix:nonFraction id="Fixv-39034" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="C_20220101to20221231_usgaapStatementEquityComponentsAxis_usgaapParentMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">3</ix:nonFraction></span></span></span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="text-align:right"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><ix:nonFraction id="Fixv-39035" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">3</ix:nonFraction></span></span></span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
        </tr>
  <tr style="vertical-align:bottom">
    <td style="padding-left:0.25in;text-indent:-0.125in;text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>Share-based
        compensation</span></span></span></td>
    <td><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="text-align:right"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="text-align:right"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="text-align:right"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="text-align:right"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="text-align:right"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="text-align:right"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="text-align:right"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="text-align:right"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="text-align:right"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="text-align:right"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="text-align:right"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="text-align:left;border-right:2px solid black"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="text-align:right"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="text-align:right"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="text-align:right"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><ix:nonFraction id="Fixv-39036" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="C_20220101to20221231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">125</ix:nonFraction></span></span></span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="text-align:right"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="text-align:right"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><ix:nonFraction id="Fixv-39037" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="C_20220101to20221231_usgaapStatementEquityComponentsAxis_usgaapParentMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">125</ix:nonFraction></span></span></span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="text-align:right"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><ix:nonFraction id="Fixv-39038" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">125</ix:nonFraction></span></span></span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
        </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="padding-left:0.25in;text-indent:-0.125in;text-align:left;padding-bottom:1.5pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>Net
        loss</span></span></span></td>
    <td style="padding-bottom:1.5pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="border-bottom:1.5pt solid black;text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="border-bottom:1.5pt solid black;text-align:right"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="padding-bottom:1.5pt;text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="padding-bottom:1.5pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="border-bottom:1.5pt solid black;text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="border-bottom:1.5pt solid black;text-align:right"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="padding-bottom:1.5pt;text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="padding-bottom:1.5pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="border-bottom:1.5pt solid black;text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="border-bottom:1.5pt solid black;text-align:right"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="padding-bottom:1.5pt;text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="padding-bottom:1.5pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="border-bottom:1.5pt solid black;text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="border-bottom:1.5pt solid black;text-align:right"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="padding-bottom:1.5pt;text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="padding-bottom:1.5pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="border-bottom:1.5pt solid black;text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="border-bottom:1.5pt solid black;text-align:right"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="padding-bottom:1.5pt;text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="padding-bottom:1.5pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="text-align:left;border-bottom:2px solid black"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="text-align:right;border-bottom:2px solid black"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="padding-bottom:1.5pt;text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="padding-bottom:1.5pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="padding-bottom:1.5pt;text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="border-bottom:1.5pt solid black;text-align:right"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="padding-bottom:1.5pt;text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="padding-bottom:1.5pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="border-bottom:1.5pt solid black;text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="border-bottom:1.5pt solid black;text-align:right"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="padding-bottom:1.5pt;text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="padding-bottom:1.5pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="border-bottom:1.5pt solid black;text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="border-bottom:1.5pt solid black;text-align:right"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="padding-bottom:1.5pt;text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="padding-bottom:1.5pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="border-bottom:1.5pt solid black;text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="border-bottom:1.5pt solid black;text-align:right"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="padding-bottom:1.5pt;text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="padding-bottom:1.5pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="border-bottom:2px solid black;text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="border-bottom:2px solid black;text-align:right"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>(<ix:nonFraction id="Fixv-39039" name="us-gaap:ProfitLoss" contextRef="C_20220101to20221231_usgaapStatementEquityComponentsAxis_usgaapNoncontrollingInterestMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">273</ix:nonFraction></span></span></span></td>
    <td style="padding-bottom:1.5pt;text-align:left;border-right:2px solid black"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>)</span></span></span></td>
    <td style="padding-bottom:1.5pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="border-bottom:1.5pt solid black;text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="border-bottom:1.5pt solid black;text-align:right"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="padding-bottom:1.5pt;text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="padding-bottom:1.5pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="border-bottom:1.5pt solid black;text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="border-bottom:1.5pt solid black;text-align:right"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="padding-bottom:1.5pt;text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="padding-bottom:1.5pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="border-bottom:1.5pt solid black;text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="border-bottom:1.5pt solid black;text-align:right"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="padding-bottom:1.5pt;text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="padding-bottom:1.5pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="border-bottom:2px solid black;text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="border-bottom:2px solid black;text-align:right"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>(<ix:nonFraction id="Fixv-39040" name="us-gaap:ProfitLoss" contextRef="C_20220101to20221231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">3,215</ix:nonFraction></span></span></span></td>
    <td style="padding-bottom:1.5pt;text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>)</span></span></span></td>
    <td style="padding-bottom:1.5pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="border-bottom:2px solid black;text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="border-bottom:2px solid black;text-align:right"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>(<ix:nonFraction id="Fixv-39041" name="us-gaap:ProfitLoss" contextRef="C_20220101to20221231_usgaapStatementEquityComponentsAxis_usgaapParentMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">3,215</ix:nonFraction></span></span></span></td>
    <td style="padding-bottom:1.5pt;text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>)</span></span></span></td>
    <td style="padding-bottom:1.5pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="border-bottom:2px solid black;text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="border-bottom:2px solid black;text-align:right"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>(<ix:nonFraction id="Fixv-39042" name="us-gaap:ProfitLoss" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">3,488</ix:nonFraction></span></span></span></td>
    <td style="padding-bottom:1.5pt;text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>)</span></span></span></td>
        </tr>
  <tr style="vertical-align:bottom">
    <td style="padding-left:0.125in;text-indent:-0.125in;font-weight:bold"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>BALANCE
        AT DECEMBER&#160;31, 2022</span></span></span></td>
    <td style="font-weight:bold"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="font-weight:bold;text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="font-weight:bold;text-align:right"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><ix:nonFraction id="Fixv-39043" name="us-gaap:SharesOutstanding" contextRef="C_20221231_usgaapStatementClassOfStockAxis_usgaapSeriesAPreferredStockMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">43,121</ix:nonFraction></span></span></span></td>
    <td style="font-weight:bold;text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="font-weight:bold"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="font-weight:bold;text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>$</span></span></span></td>
    <td style="font-weight:bold;text-align:right"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><ix:nonFraction id="Fixv-39044" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_20221231_usgaapStatementClassOfStockAxis_usgaapSeriesAPreferredStockMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,307</ix:nonFraction></span></span></span></td>
    <td style="font-weight:bold;text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="font-weight:bold"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="font-weight:bold;text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="font-weight:bold;text-align:right"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><ix:nonFraction id="Fixv-39045" name="us-gaap:SharesOutstanding" contextRef="C_20221231_usgaapStatementClassOfStockAxis_slxnSeriesA1PreferredSharesMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">10,136</ix:nonFraction></span></span></span></td>
    <td style="font-weight:bold;text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="font-weight:bold"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="font-weight:bold;text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>$</span></span></span></td>
    <td style="font-weight:bold;text-align:right"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><ix:nonFraction id="Fixv-39046" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_20221231_usgaapStatementClassOfStockAxis_slxnSeriesA1PreferredSharesMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,392</ix:nonFraction></span></span></span></td>
    <td style="font-weight:bold;text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="font-weight:bold"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="font-weight:bold;text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="font-weight:bold;text-align:right"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><ix:nonFraction id="Fixv-39047" name="us-gaap:SharesOutstanding" contextRef="C_20221231_usgaapStatementClassOfStockAxis_slxnSeriesA2PreferredSharesMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">5,051</ix:nonFraction></span></span></span></td>
    <td style="font-weight:bold;text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="font-weight:bold"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="font-weight:bold;text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>$</span></span></span></td>
    <td style="font-weight:bold;text-align:right"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><ix:nonFraction id="Fixv-39048" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_20221231_usgaapStatementClassOfStockAxis_slxnSeriesA2PreferredSharesMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,264</ix:nonFraction></span></span></span></td>
    <td style="font-weight:bold;text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="font-weight:bold"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="font-weight:bold;text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="font-weight:bold;text-align:right"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><ix:nonFraction id="Fixv-39049" name="us-gaap:SharesOutstanding" contextRef="C_20221231_usgaapStatementClassOfStockAxis_slxnSeriesA3PreferredSharesMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">7,037</ix:nonFraction></span></span></span></td>
    <td style="font-weight:bold;text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="font-weight:bold"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="font-weight:bold;text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>$</span></span></span></td>
    <td style="font-weight:bold;text-align:right"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><ix:nonFraction id="Fixv-39050" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_20221231_usgaapStatementClassOfStockAxis_slxnSeriesA3PreferredSharesMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,683</ix:nonFraction></span></span></span></td>
    <td style="font-weight:bold;text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="font-weight:bold"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="font-weight:bold;text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="font-weight:bold;text-align:right"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><ix:nonFraction id="Fhidden-fact-105" name="us-gaap:SharesOutstanding" contextRef="C_20221231_usgaapStatementClassOfStockAxis_slxnSeriesA4PreferredSharesMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember" unitRef="shares" decimals="INF" format="ixt:fixed-zero">-</ix:nonFraction></span></span></td>
    <td style="font-weight:bold;text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="font-weight:bold"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="font-weight:bold;text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="font-weight:bold;text-align:right"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><ix:nonFraction id="Fhidden-fact-106" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_20221231_usgaapStatementClassOfStockAxis_slxnSeriesA4PreferredSharesMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></td>
    <td style="font-weight:bold;text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="font-weight:bold"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="font-weight:bold;text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>$</span></span></span></td>
    <td style="font-weight:bold;text-align:right"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><ix:nonFraction id="Fixv-39051" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_20221231_usgaapStatementEquityComponentsAxis_usgaapNoncontrollingInterestMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,586</ix:nonFraction></span></span></span></td>
    <td style="font-weight:bold;text-align:left;border-right:2px solid black"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="font-weight:bold"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="font-weight:bold;text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="font-weight:bold;text-align:right"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><ix:nonFraction id="Fixv-39052" name="us-gaap:SharesOutstanding" contextRef="C_20221231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">97,120</ix:nonFraction></span></span></span></td>
    <td style="font-weight:bold;text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="font-weight:bold"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="font-weight:bold;text-align:left">&#160;</td>
    <td style="font-weight:bold;text-align:right"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span style="-sec-ix-hidden:Fixv-39053">*</span></span></span></span></td>
    <td style="font-weight:bold;text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="font-weight:bold"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="font-weight:bold;text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>$</span></span></span></td>
    <td style="font-weight:bold;text-align:right"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><ix:nonFraction id="Fixv-39054" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_20221231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">11,204</ix:nonFraction></span></span></span></td>
    <td style="font-weight:bold;text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="font-weight:bold"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="font-weight:bold;text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>$</span></span></span></td>
    <td style="font-weight:bold;text-align:right"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>(<ix:nonFraction id="Fixv-39055" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_20221231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">21,869</ix:nonFraction></span></span></span></td>
    <td style="font-weight:bold;text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>)</span></span></span></td>
    <td style="font-weight:bold"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="font-weight:bold;text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>$</span></span></span></td>
    <td style="font-weight:bold;text-align:right"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>(<ix:nonFraction id="Fixv-39056" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_20221231_usgaapStatementEquityComponentsAxis_usgaapParentMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">10,665</ix:nonFraction></span></span></span></td>
    <td style="font-weight:bold;text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>)</span></span></span></td>
    <td style="font-weight:bold"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="font-weight:bold;text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>$</span></span></span></td>
    <td style="font-weight:bold;text-align:right"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><ix:nonFraction id="Fixv-39057" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,567</ix:nonFraction></span></span></span></td>
    <td style="font-weight:bold;text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
        </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="padding-left:0.125in;text-indent:-0.125in;font-weight:bold;text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>CHANGES
        DURING 2023:</span></span></span></td>
    <td><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="text-align:right"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="text-align:right"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="text-align:right"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="text-align:right"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="text-align:right"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="text-align:right"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="text-align:right"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="text-align:right"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="text-align:right"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="text-align:right"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="text-align:right"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="text-align:left;border-right:2px solid black"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="text-align:right"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="text-align:right"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="text-align:right"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="text-align:right"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="text-align:right"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="text-align:right"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
        </tr>
  <tr style="vertical-align:bottom">
    <td style="padding-left:0.125in;text-indent:-0.125in;text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>Issuance
        of Preferred A-4 shares, net of issuance cost, see Note&#160;9(b)</span></span></span></td>
    <td><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="text-align:right"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="text-align:right"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="text-align:right"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="text-align:right"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="text-align:right"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="text-align:right"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="text-align:right"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="text-align:right"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="text-align:right"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><ix:nonFraction id="Fixv-39058" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="C_20230101to20231231_usgaapStatementClassOfStockAxis_slxnSeriesA4PreferredSharesMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">2,413</ix:nonFraction></span></span></span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="text-align:right"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><ix:nonFraction id="Fixv-39059" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="C_20230101to20231231_usgaapStatementClassOfStockAxis_slxnSeriesA4PreferredSharesMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">411</ix:nonFraction></span></span></span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="text-align:right"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="text-align:left;border-right:2px solid black"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="text-align:right"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="text-align:right"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="text-align:right"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><ix:nonFraction id="Fixv-39060" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="C_20230101to20231231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1</ix:nonFraction></span></span></span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="text-align:right"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="text-align:right"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><ix:nonFraction id="Fixv-39061" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="C_20230101to20231231_usgaapStatementEquityComponentsAxis_usgaapParentMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1</ix:nonFraction></span></span></span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="text-align:right"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><ix:nonFraction id="Fixv-39062" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">412</ix:nonFraction></span></span></span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
        </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="padding-left:0.125in;text-indent:-0.125in;text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>Share-based
        compensation</span></span></span></td>
    <td><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="text-align:right"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="text-align:right"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="text-align:right"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="text-align:right"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="text-align:right"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="text-align:right"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="text-align:right"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="text-align:right"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="text-align:right"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="text-align:right"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="text-align:right"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="text-align:left;border-right:2px solid black"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="text-align:right"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="text-align:right"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="text-align:right"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><ix:nonFraction id="Fixv-39063" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="C_20230101to20231231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">130</ix:nonFraction></span></span></span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="text-align:right"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="text-align:right"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><ix:nonFraction id="Fixv-39064" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="C_20230101to20231231_usgaapStatementEquityComponentsAxis_usgaapParentMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">130</ix:nonFraction></span></span></span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="text-align:right"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><ix:nonFraction id="Fixv-39065" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">130</ix:nonFraction></span></span></span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
        </tr>
  <tr style="vertical-align:bottom">
    <td style="padding-left:0.125in;text-indent:-0.125in;text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>Net
        loss</span></span></span></td>
    <td><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="text-align:right"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="text-align:right"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="text-align:right"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="text-align:right"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="text-align:right"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="text-align:right"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="text-align:right"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="text-align:right"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="text-align:right"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="text-align:right"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="text-align:right"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>(<ix:nonFraction id="Fixv-39066" name="us-gaap:ProfitLoss" contextRef="C_20230101to20231231_usgaapStatementEquityComponentsAxis_usgaapNoncontrollingInterestMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">166</ix:nonFraction></span></span></span></td>
    <td style="text-align:left;border-right:2px solid black"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>)</span></span></span></td>
    <td><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="text-align:right"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="text-align:right"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="text-align:right"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="text-align:right"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>(<ix:nonFraction id="Fixv-39067" name="us-gaap:ProfitLoss" contextRef="C_20230101to20231231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">4,942</ix:nonFraction></span></span></span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>)</span></span></span></td>
    <td><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="text-align:right"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>(<ix:nonFraction id="Fixv-39068" name="us-gaap:ProfitLoss" contextRef="C_20230101to20231231_usgaapStatementEquityComponentsAxis_usgaapParentMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">4,942</ix:nonFraction></span></span></span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>)</span></span></span></td>
    <td><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="text-align:right"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>(<ix:nonFraction id="Fixv-39069" name="us-gaap:ProfitLoss" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">5,108</ix:nonFraction></span></span></span></td>
    <td style="text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>)</span></span></span></td>
        </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="padding-left:0.125in;text-indent:-0.125in;font-weight:bold"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>BALANCE
        AT DECEMBER&#160;31, 2023</span></span></span></td>
    <td style="font-weight:bold"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="font-weight:bold;text-align:left;border-bottom:2px solid black"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="font-weight:bold;text-align:right;border-bottom:2px solid black"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><ix:nonFraction id="Fixv-39070" name="us-gaap:SharesOutstanding" contextRef="C_20231231_usgaapStatementClassOfStockAxis_usgaapSeriesAPreferredStockMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">43,121</ix:nonFraction></span></span></span></td>
    <td style="font-weight:bold;text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="font-weight:bold"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="font-weight:bold;text-align:left;border-bottom:2px solid black"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>$</span></span></span></td>
    <td style="font-weight:bold;text-align:right;border-bottom:2px solid black"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><ix:nonFraction id="Fixv-39071" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_20231231_usgaapStatementClassOfStockAxis_usgaapSeriesAPreferredStockMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,307</ix:nonFraction></span></span></span></td>
    <td style="font-weight:bold;text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="font-weight:bold"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="font-weight:bold;text-align:left;border-bottom:2px solid black"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="font-weight:bold;text-align:right;border-bottom:2px solid black"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><ix:nonFraction id="Fixv-39072" name="us-gaap:SharesOutstanding" contextRef="C_20231231_usgaapStatementClassOfStockAxis_slxnSeriesA1PreferredSharesMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">10,136</ix:nonFraction></span></span></span></td>
    <td style="font-weight:bold;text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="font-weight:bold"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="font-weight:bold;text-align:left;border-bottom:2px solid black"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>$</span></span></span></td>
    <td style="font-weight:bold;text-align:right;border-bottom:2px solid black"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><ix:nonFraction id="Fixv-39073" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_20231231_usgaapStatementClassOfStockAxis_slxnSeriesA1PreferredSharesMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,392</ix:nonFraction></span></span></span></td>
    <td style="font-weight:bold;text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="font-weight:bold"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="font-weight:bold;text-align:left;border-bottom:2px solid black"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="font-weight:bold;text-align:right;border-bottom:2px solid black"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><ix:nonFraction id="Fixv-39074" name="us-gaap:SharesOutstanding" contextRef="C_20231231_usgaapStatementClassOfStockAxis_slxnSeriesA2PreferredSharesMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">5,051</ix:nonFraction></span></span></span></td>
    <td style="font-weight:bold;text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="font-weight:bold"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="font-weight:bold;text-align:left;border-bottom:2px solid black"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>$</span></span></span></td>
    <td style="font-weight:bold;text-align:right;border-bottom:2px solid black"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><ix:nonFraction id="Fixv-39075" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_20231231_usgaapStatementClassOfStockAxis_slxnSeriesA2PreferredSharesMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,264</ix:nonFraction></span></span></span></td>
    <td style="font-weight:bold;text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="font-weight:bold"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="font-weight:bold;text-align:left;border-bottom:2px solid black"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="font-weight:bold;text-align:right;border-bottom:2px solid black"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><ix:nonFraction id="Fixv-39076" name="us-gaap:SharesOutstanding" contextRef="C_20231231_usgaapStatementClassOfStockAxis_slxnSeriesA3PreferredSharesMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">7,037</ix:nonFraction></span></span></span></td>
    <td style="font-weight:bold;text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="font-weight:bold"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="font-weight:bold;text-align:left;border-bottom:2px solid black"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>$</span></span></span></td>
    <td style="font-weight:bold;text-align:right;border-bottom:2px solid black"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><ix:nonFraction id="Fixv-39077" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_20231231_usgaapStatementClassOfStockAxis_slxnSeriesA3PreferredSharesMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,683</ix:nonFraction></span></span></span></td>
    <td style="font-weight:bold;text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="font-weight:bold"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="font-weight:bold;text-align:left;border-bottom:2px solid black"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="font-weight:bold;text-align:right;border-bottom:2px solid black"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><ix:nonFraction id="Fixv-39078" name="us-gaap:SharesOutstanding" contextRef="C_20231231_usgaapStatementClassOfStockAxis_slxnSeriesA4PreferredSharesMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">2,413</ix:nonFraction></span></span></span></td>
    <td style="font-weight:bold;text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="font-weight:bold"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="font-weight:bold;text-align:left;border-bottom:2px solid black"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>$</span></span></span></td>
    <td style="font-weight:bold;text-align:right;border-bottom:2px solid black"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><ix:nonFraction id="Fixv-39079" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_20231231_usgaapStatementClassOfStockAxis_slxnSeriesA4PreferredSharesMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">411</ix:nonFraction></span></span></span></td>
    <td style="font-weight:bold;text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="font-weight:bold"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="font-weight:bold;text-align:left;border-bottom:2px solid black"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>$</span></span></span></td>
    <td style="font-weight:bold;text-align:right;border-bottom:2px solid black"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><ix:nonFraction id="Fixv-39080" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_20231231_usgaapStatementEquityComponentsAxis_usgaapNoncontrollingInterestMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,420</ix:nonFraction></span></span></span></td>
    <td style="font-weight:bold;text-align:left;border-right:2px solid black"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="font-weight:bold"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="font-weight:bold;text-align:left;border-bottom:2px solid black"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="font-weight:bold;text-align:right;border-bottom:2px solid black"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><ix:nonFraction id="Fixv-39081" name="us-gaap:SharesOutstanding" contextRef="C_20231231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">97,120</ix:nonFraction></span></span></span></td>
    <td style="font-weight:bold;text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="font-weight:bold"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="font-weight:bold;text-align:left;border-bottom:2px solid black">&#160;</td>
    <td style="font-weight:bold;text-align:right;border-bottom:2px solid black"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span style="-sec-ix-hidden:Fixv-39082">*</span></span></span></span></td>
    <td style="font-weight:bold;text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="font-weight:bold"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="font-weight:bold;text-align:left;border-bottom:2px solid black"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>$</span></span></span></td>
    <td style="font-weight:bold;text-align:right;border-bottom:2px solid black"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><ix:nonFraction id="Fixv-39083" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_20231231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">11,335</ix:nonFraction></span></span></span></td>
    <td style="font-weight:bold;text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="font-weight:bold"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="font-weight:bold;text-align:left;border-bottom:2px solid black"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>$</span></span></span></td>
    <td style="font-weight:bold;text-align:right;border-bottom:2px solid black"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>(<ix:nonFraction id="Fixv-39084" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_20231231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">26,811</ix:nonFraction></span></span></span></td>
    <td style="font-weight:bold;text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>)</span></span></span></td>
    <td style="font-weight:bold"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="font-weight:bold;text-align:left;border-bottom:2px solid black"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>$</span></span></span></td>
    <td style="font-weight:bold;text-align:right;border-bottom:2px solid black"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>(<ix:nonFraction id="Fixv-39085" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_20231231_usgaapStatementEquityComponentsAxis_usgaapParentMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">15,476</ix:nonFraction></span></span></span></td>
    <td style="font-weight:bold;text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>)</span></span></span></td>
    <td style="font-weight:bold"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
    <td style="font-weight:bold;text-align:left;border-bottom:2px solid black"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>$</span></span></span></td>
    <td style="font-weight:bold;text-align:right;border-bottom:2px solid black"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><ix:nonFraction id="Fixv-39086" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,001</ix:nonFraction></span></span></span></td>
    <td style="font-weight:bold;text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>&#160;</span></span></span></td>
        </tr>
  </table>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font:10pt Times New Roman, Times, Serif;margin-top:0pt;margin-bottom:0pt;width:100%">
  <tr style="vertical-align:top;text-align:justify">
    <td style="width:0.25in;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">*&#160;</span></span><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">Represents
        an amount less than $1</span></span></td> </tr>
  </table>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><strong>&#160;</strong></span></span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><strong>The
accompanying notes are an integral part of these consolidated financial statements.</strong></span></span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center">&#160;</p>

<div>

<p style="font:10pt Times New Roman, Times, serif;text-align:center;margin-top:10pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>F-71</span></span></span></p>
</div> <hr style="page-break-after:always;border-width:0px;clear:both;margin:4px 0px;width:100%;height:2px;color:#000000;background-color:#000000;margin-top:4pt;margin-bottom:10pt"/>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center">&#160;</p>

<div><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span id="f_022"></span></span></span></div>
</div>

<div style="font:10pt Times New Roman, Times, Serif">

<div>

<div>

<div style="text-align:center;margin-left:1pt;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">SILEXION
THERAPEUTICS CORP</span></span></div>

<div style="text-align:center;margin-left:1pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">CONSOLIDATED
STATEMENTS OF CASH FLOWS<span id="FCASHFLOWS"></span></span></span></div>

<div style="text-align:center;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(U.S.
dollars in thousands)</span></span></div>

<div style="text-align:center;line-height:1.25;font-family:'Times New Roman', Times, serif">&#160;</div>

<div style="line-height:1.25">

<table border="0" cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left;color:#000000;width:100%">
  <tr>
    <td colspan="1" style="vertical-align:top;padding-bottom:2px;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
    <td colspan="6" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Year
        ended December 31</span></span></div> </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td> </tr>
  <tr>
    <td colspan="1" style="vertical-align:top;padding-bottom:2px;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2023</span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2022</span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td> </tr>
  <tr>
    <td colspan="1" style="vertical-align:top;padding-left:9pt;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">CASH
        FLOWS FROM OPERATING ACTIVITIES:</span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td> </tr>
  <tr>
    <td colspan="1" style="vertical-align:top;padding-left:9pt;width:76%;background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="text-indent:-14.2pt;margin-left:28.75pt;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Net
        loss</span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fixv-39087" name="us-gaap:ProfitLoss" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">5,108</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom;white-space:nowrap">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fixv-39088" name="us-gaap:ProfitLoss" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">3,488</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom;white-space:nowrap">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
        </td> </tr>
  <tr>
    <td colspan="1" style="vertical-align:top;padding-left:9pt;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="text-indent:-14.2pt;margin-left:28.75pt;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Adjustments
        required to reconcile loss to net cash used in operating activities:</span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        </tr>
  <tr>
    <td colspan="1" style="vertical-align:top;padding-left:9pt;width:76%;background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="margin-left:28.75pt;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Depreciation</span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fixv-39089" name="us-gaap:Depreciation" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">45</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fixv-39090" name="us-gaap:Depreciation" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">57</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        </tr>
  <tr>
    <td colspan="1" style="vertical-align:top;padding-left:9pt;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="margin-left:28.75pt;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Share-based
        compensation expenses</span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fixv-39091" name="us-gaap:ShareBasedCompensation" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">130</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fixv-39092" name="us-gaap:ShareBasedCompensation" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">125</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        </tr>
  <tr>
    <td colspan="1" style="vertical-align:top;padding-left:9pt;width:76%;background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="margin-left:28.75pt;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Non-cash
        financial expenses</span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fixv-39093" name="us-gaap:OtherNoncashExpense" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">318</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fixv-39094" name="us-gaap:OtherNoncashExpense" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">268</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom;white-space:nowrap">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
        </td> </tr>
  <tr>
    <td colspan="1" style="vertical-align:top;padding-left:9pt;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="margin-left:28.75pt;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Gain
        on disposal of property and equipment</span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fixv-39095" name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20241004174837231" name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        </tr>
  <tr>
    <td colspan="1" style="vertical-align:top;padding-left:9pt;width:76%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        </tr>
  <tr style="background-color:rgb(204, 238, 255)">
    <td colspan="1" style="padding-left:9pt;width:76%;vertical-align:bottom;background-color:rgb(204, 238, 255)">
        <div style="text-indent:-14.2pt;margin-left:28.75pt;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Changes
        in operating assets and liabilities:</span></span></div> </td>
    <td colspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" style="text-align:right;width:9%;vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" style="width:1%;vertical-align:bottom;white-space:nowrap;background-color:rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" style="text-align:right;width:9%;vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" style="width:1%;vertical-align:bottom;white-space:nowrap;background-color:rgb(204, 238, 255)">&#160;</td> </tr>
  <tr style="background-color:rgb(255, 255, 255)">
    <td colspan="1" style="padding-left:9pt;width:76%;vertical-align:bottom;background-color:rgb(255, 255, 255)">
        <div style="text-indent:-14.15pt;margin-left:42.9pt;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Increase
        (decrease) in prepaid expenses</span></span></div> </td>
    <td colspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(255, 255, 255)">&#160;</td>
    <td colspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(255, 255, 255)">&#160;</td>
    <td colspan="1" style="text-align:right;width:9%;vertical-align:bottom;background-color:rgb(255, 255, 255)">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fixv-39096" name="us-gaap:IncreaseDecreaseInPrepaidExpense" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">329</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="width:1%;vertical-align:bottom;white-space:nowrap;background-color:rgb(255, 255, 255)">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
        </td>
    <td colspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(255, 255, 255)">&#160;</td>
    <td colspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(255, 255, 255)">&#160;</td>
    <td colspan="1" style="text-align:right;width:9%;vertical-align:bottom;background-color:rgb(255, 255, 255)">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fixv-39097" name="us-gaap:IncreaseDecreaseInPrepaidExpense" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">415</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="width:1%;vertical-align:bottom;white-space:nowrap;background-color:rgb(255, 255, 255)">&#160;</td> </tr>
  <tr style="background-color:rgb(204, 238, 255)">
    <td colspan="1" style="padding-left:9pt;width:76%;vertical-align:bottom;background-color:rgb(204, 238, 255)">
        <div style="text-indent:-14.15pt;margin-left:42.9pt;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Increase
        (decrease) in other receivables</span></span></div> </td>
    <td colspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" style="text-align:right;width:9%;vertical-align:bottom;background-color:rgb(204, 238, 255)">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fixv-39098" name="us-gaap:IncreaseDecreaseInAccountsAndOtherReceivables" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">18</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="width:1%;vertical-align:bottom;white-space:nowrap;background-color:rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" style="text-align:right;width:9%;vertical-align:bottom;background-color:rgb(204, 238, 255)">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fixv-39099" name="us-gaap:IncreaseDecreaseInAccountsAndOtherReceivables" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">40</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="width:1%;vertical-align:bottom;white-space:nowrap;background-color:rgb(204, 238, 255)">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
        </td> </tr>
  <tr style="background-color:rgb(255, 255, 255)">
    <td colspan="1" style="padding-left:9pt;width:76%;vertical-align:bottom;background-color:rgb(255, 255, 255)">
        <div style="text-indent:-14.15pt;margin-left:42.9pt;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Increase
        (decrease) in trade payable</span></span></div> </td>
    <td colspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(255, 255, 255)">&#160;</td>
    <td colspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(255, 255, 255)">&#160;</td>
    <td colspan="1" style="text-align:right;width:9%;vertical-align:bottom;background-color:rgb(255, 255, 255)">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fixv-39100" name="us-gaap:IncreaseDecreaseInAccountsPayableTrade" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">79</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="width:1%;vertical-align:bottom;white-space:nowrap;background-color:rgb(255, 255, 255)">&#160;</td>
    <td colspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(255, 255, 255)">&#160;</td>
    <td colspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(255, 255, 255)">&#160;</td>
    <td colspan="1" style="text-align:right;width:9%;vertical-align:bottom;background-color:rgb(255, 255, 255)">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fixv-39101" name="us-gaap:IncreaseDecreaseInAccountsPayableTrade" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">38</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="width:1%;vertical-align:bottom;white-space:nowrap;background-color:rgb(255, 255, 255)">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
        </td> </tr>
  <tr style="background-color:rgb(204, 238, 255)">
    <td colspan="1" style="padding-left:9pt;width:76%;vertical-align:bottom;background-color:rgb(204, 238, 255)">
        <div style="text-indent:-14.15pt;margin-left:42.9pt;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Net
        change in operating lease</span></span></div> </td>
    <td colspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" style="text-align:right;width:9%;vertical-align:bottom;background-color:rgb(204, 238, 255)">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fixv-39102" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">6</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="width:1%;vertical-align:bottom;white-space:nowrap;background-color:rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" style="text-align:right;width:9%;vertical-align:bottom;background-color:rgb(204, 238, 255)">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fixv-39103" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">34</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="width:1%;vertical-align:bottom;white-space:nowrap;background-color:rgb(204, 238, 255)">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
        </td> </tr>
  <tr style="background-color:rgb(255, 255, 255)">
    <td colspan="1" style="padding-left:9pt;width:76%;vertical-align:bottom;background-color:rgb(255, 255, 255)">
        <div style="text-indent:-14.15pt;margin-left:42.9pt;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Increase
        (decrease) in employee related obligations</span></span></div> </td>
    <td colspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(255, 255, 255)">&#160;</td>
    <td colspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(255, 255, 255)">&#160;</td>
    <td colspan="1" style="text-align:right;width:9%;vertical-align:bottom;background-color:rgb(255, 255, 255)">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fixv-39104" name="us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">46</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="width:1%;vertical-align:bottom;white-space:nowrap;background-color:rgb(255, 255, 255)">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
        </td>
    <td colspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(255, 255, 255)">&#160;</td>
    <td colspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(255, 255, 255)">&#160;</td>
    <td colspan="1" style="text-align:right;width:9%;vertical-align:bottom;background-color:rgb(255, 255, 255)">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fixv-39105" name="us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">53</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="width:1%;vertical-align:bottom;white-space:nowrap;background-color:rgb(255, 255, 255)">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
        </td> </tr>
  <tr style="background-color:rgb(204, 238, 255)">
    <td colspan="1" style="padding-left:9pt;width:76%;padding-bottom:2px;vertical-align:bottom;background-color:rgb(204, 238, 255)">
        <div style="text-indent:-14.15pt;margin-left:42.9pt;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Increase
        (decrease) in accrued expenses</span></span></div> </td>
    <td colspan="1" style="width:1%;padding-bottom:2px;vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" style="width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" style="text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom;background-color:rgb(204, 238, 255)">
        <div style="line-height:1.25">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fixv-39106" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">359</ix:nonFraction></span></span></div>
        </div> </td>
    <td colspan="1" style="width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap;background-color:rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" style="width:1%;padding-bottom:2px;vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" style="width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" style="text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom;background-color:rgb(204, 238, 255)">
        <div style="line-height:1.25">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fixv-39107" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">11</ix:nonFraction></span></span></div>
        </div> </td>
    <td colspan="1" style="width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap;background-color:rgb(204, 238, 255)">
        <div style="line-height:1.25">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
        </div> </td> </tr>
  <tr style="background-color:rgb(255, 255, 255)">
    <td colspan="1" style="padding-left:9pt;width:76%;padding-bottom:2px;vertical-align:bottom;background-color:rgb(255, 255, 255)">
        <div style="text-indent:-14.2pt;margin-left:28.75pt;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Net
        cash used in operating activities</span></span></div> </td>
    <td colspan="1" style="width:1%;padding-bottom:2px;vertical-align:bottom;background-color:rgb(255, 255, 255)">&#160;</td>
    <td colspan="1" style="width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom;background-color:rgb(255, 255, 255)">&#160;</td>
    <td colspan="1" style="text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom;background-color:rgb(255, 255, 255)">
        <div style="line-height:1.25">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fixv-39108" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">4,529</ix:nonFraction></span></span></div>
        </div> </td>
    <td colspan="1" style="width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap;background-color:rgb(255, 255, 255)">
        <div style="line-height:1.25">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
        </div> </td>
    <td colspan="1" style="width:1%;padding-bottom:2px;vertical-align:bottom;background-color:rgb(255, 255, 255)">&#160;</td>
    <td colspan="1" style="width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom;background-color:rgb(255, 255, 255)">&#160;</td>
    <td colspan="1" style="text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom;background-color:rgb(255, 255, 255)">
        <div style="line-height:1.25">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fixv-39109" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">3,335</ix:nonFraction></span></span></div>
        </div> </td>
    <td colspan="1" style="width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap;background-color:rgb(255, 255, 255)">
        <div style="line-height:1.25">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
        </div> </td> </tr>
  <tr style="background-color:rgb(204, 238, 255)">
    <td colspan="1" style="padding-left:9pt;width:76%;vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" style="text-align:right;width:9%;vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" style="width:1%;vertical-align:bottom;white-space:nowrap;background-color:rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" style="text-align:right;width:9%;vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" style="width:1%;vertical-align:bottom;white-space:nowrap;background-color:rgb(204, 238, 255)">&#160;</td> </tr>
  <tr style="background-color:rgb(255, 255, 255)">
    <td colspan="1" style="padding-left:9pt;width:76%;vertical-align:bottom;background-color:rgb(255, 255, 255)">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">CASH
        FLOWS FROM INVESTING ACTIVITIES:</span></span></div> </td>
    <td colspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(255, 255, 255)">&#160;</td>
    <td colspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(255, 255, 255)">&#160;</td>
    <td colspan="1" style="text-align:right;width:9%;vertical-align:bottom;background-color:rgb(255, 255, 255)">&#160;</td>
    <td colspan="1" style="width:1%;vertical-align:bottom;white-space:nowrap;background-color:rgb(255, 255, 255)">&#160;</td>
    <td colspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(255, 255, 255)">&#160;</td>
    <td colspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(255, 255, 255)">&#160;</td>
    <td colspan="1" style="text-align:right;width:9%;vertical-align:bottom;background-color:rgb(255, 255, 255)">&#160;</td>
    <td colspan="1" style="width:1%;vertical-align:bottom;white-space:nowrap;background-color:rgb(255, 255, 255)">&#160;</td> </tr>
  <tr style="background-color:rgb(204, 238, 255)">
    <td colspan="1" style="padding-left:9pt;width:76%;vertical-align:bottom;background-color:rgb(204, 238, 255)">
        <div style="text-indent:-14.2pt;margin-left:28.75pt;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Proceeds
        from long-term deposits</span></span></div> </td>
    <td colspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" style="text-align:right;width:9%;vertical-align:bottom;background-color:rgb(204, 238, 255)">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20241004174925943" name="us-gaap:ProceedsFromSaleOfLongtermInvestments" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="width:1%;vertical-align:bottom;white-space:nowrap;background-color:rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" style="text-align:right;width:9%;vertical-align:bottom;background-color:rgb(204, 238, 255)">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fixv-39110" name="us-gaap:ProceedsFromSaleOfLongtermInvestments" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">16</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="width:1%;vertical-align:bottom;white-space:nowrap;background-color:rgb(204, 238, 255)">&#160;</td> </tr>
  <tr style="background-color:rgb(255, 255, 255)">
    <td colspan="1" style="padding-left:9pt;width:76%;vertical-align:bottom;background-color:rgb(255, 255, 255)">
        <div style="text-indent:-14.2pt;margin-left:28.75pt;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Investment
        in short-term deposit</span></span></div> </td>
    <td colspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(255, 255, 255)">&#160;</td>
    <td colspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(255, 255, 255)">&#160;</td>
    <td colspan="1" style="text-align:right;width:9%;vertical-align:bottom;background-color:rgb(255, 255, 255)">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20241004175002634" name="us-gaap:PaymentsToAcquireShortTermInvestments" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="width:1%;vertical-align:bottom;white-space:nowrap;background-color:rgb(255, 255, 255)">&#160;</td>
    <td colspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(255, 255, 255)">&#160;</td>
    <td colspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(255, 255, 255)">&#160;</td>
    <td colspan="1" style="text-align:right;width:9%;vertical-align:bottom;background-color:rgb(255, 255, 255)">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fixv-39111" name="us-gaap:PaymentsToAcquireShortTermInvestments" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">500</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="width:1%;vertical-align:bottom;white-space:nowrap;background-color:rgb(255, 255, 255)">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
        </td> </tr>
  <tr style="background-color:rgb(204, 238, 255)">
    <td colspan="1" style="padding-left:9pt;width:76%;vertical-align:bottom;background-color:rgb(204, 238, 255)">
        <div style="text-indent:-14.2pt;margin-left:28.75pt;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Proceeds
        from short-term deposit</span></span></div> </td>
    <td colspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" style="text-align:right;width:9%;vertical-align:bottom;background-color:rgb(204, 238, 255)">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fixv-39112" name="us-gaap:ProceedsFromSaleOfShortTermInvestments" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">507</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="width:1%;vertical-align:bottom;white-space:nowrap;background-color:rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" style="text-align:right;width:9%;vertical-align:bottom;background-color:rgb(204, 238, 255)">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20241004175020438" name="us-gaap:ProceedsFromSaleOfShortTermInvestments" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="width:1%;vertical-align:bottom;white-space:nowrap;background-color:rgb(204, 238, 255)">&#160;</td> </tr>
  <tr style="background-color:rgb(255, 255, 255)">
    <td colspan="1" style="padding-left:9pt;width:76%;vertical-align:bottom;background-color:rgb(255, 255, 255)">
        <div style="text-indent:-14.2pt;margin-left:28.75pt;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Purchase
        of property and equipment</span></span></div> </td>
    <td colspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(255, 255, 255)">&#160;</td>
    <td colspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(255, 255, 255)">&#160;</td>
    <td colspan="1" style="text-align:right;width:9%;vertical-align:bottom;background-color:rgb(255, 255, 255)">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fixv-39113" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">12</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="width:1%;vertical-align:bottom;white-space:nowrap;background-color:rgb(255, 255, 255)">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
        </td>
    <td colspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(255, 255, 255)">&#160;</td>
    <td colspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(255, 255, 255)">&#160;</td>
    <td colspan="1" style="text-align:right;width:9%;vertical-align:bottom;background-color:rgb(255, 255, 255)">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fixv-39114" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">40</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="width:1%;vertical-align:bottom;white-space:nowrap;background-color:rgb(255, 255, 255)">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
        </td> </tr>
  <tr style="background-color:rgb(204, 238, 255)">
    <td colspan="1" style="padding-left:9pt;width:76%;padding-bottom:2px;vertical-align:bottom;background-color:rgb(204, 238, 255)">
        <div style="text-indent:-14.2pt;margin-left:28.75pt;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Proceeds
        from sale of property and equipment</span></span></div> </td>
    <td colspan="1" style="width:1%;padding-bottom:2px;vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" style="width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" style="text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom;background-color:rgb(204, 238, 255)">
        <div style="line-height:1.25">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fixv-39115" name="us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">78</ix:nonFraction></span></span></div>
        </div> </td>
    <td colspan="1" style="width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap;background-color:rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" style="width:1%;padding-bottom:2px;vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" style="width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" style="text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom;background-color:rgb(204, 238, 255)">
        <div style="line-height:1.25">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20241004175034871" name="us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
        </div> </td>
    <td colspan="1" style="width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap;background-color:rgb(204, 238, 255)">&#160;</td>
        </tr>
  <tr style="background-color:rgb(255, 255, 255)">
    <td colspan="1" style="padding-left:9pt;width:76%;padding-bottom:2px;vertical-align:bottom;background-color:rgb(255, 255, 255)">
        <div style="text-indent:-14.2pt;margin-left:28.75pt;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Net
        cash provided by (used in (investing activities</span></span></div> </td>
    <td colspan="1" style="width:1%;padding-bottom:2px;vertical-align:bottom;background-color:rgb(255, 255, 255)">&#160;</td>
    <td colspan="1" style="width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom;background-color:rgb(255, 255, 255)">&#160;</td>
    <td colspan="1" style="text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom;background-color:rgb(255, 255, 255)">
        <div style="line-height:1.25">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fixv-39116" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">573</ix:nonFraction></span></span></div>
        </div> </td>
    <td colspan="1" style="width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap;background-color:rgb(255, 255, 255)">&#160;</td>
    <td colspan="1" style="width:1%;padding-bottom:2px;vertical-align:bottom;background-color:rgb(255, 255, 255)">&#160;</td>
    <td colspan="1" style="width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom;background-color:rgb(255, 255, 255)">&#160;</td>
    <td colspan="1" style="text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom;background-color:rgb(255, 255, 255)">
        <div style="line-height:1.25">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fixv-39117" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">524</ix:nonFraction></span></span></div>
        </div> </td>
    <td colspan="1" style="width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap;background-color:rgb(255, 255, 255)">
        <div style="line-height:1.25">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
        </div> </td> </tr>
  <tr style="background-color:rgb(204, 238, 255)">
    <td colspan="1" style="padding-left:9pt;width:76%;vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" style="text-align:right;width:9%;vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" style="width:1%;vertical-align:bottom;white-space:nowrap;background-color:rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" style="text-align:right;width:9%;vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" style="width:1%;vertical-align:bottom;white-space:nowrap;background-color:rgb(204, 238, 255)">&#160;</td> </tr>
  <tr style="background-color:rgb(255, 255, 255)">
    <td colspan="1" style="padding-left:9pt;width:76%;vertical-align:bottom;background-color:rgb(255, 255, 255)">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">CASH
        FLOWS FROM FINANCING ACTIVITIES:</span></span></div> </td>
    <td colspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(255, 255, 255)">&#160;</td>
    <td colspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(255, 255, 255)">&#160;</td>
    <td colspan="1" style="text-align:right;width:9%;vertical-align:bottom;background-color:rgb(255, 255, 255)">&#160;</td>
    <td colspan="1" style="width:1%;vertical-align:bottom;white-space:nowrap;background-color:rgb(255, 255, 255)">&#160;</td>
    <td colspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(255, 255, 255)">&#160;</td>
    <td colspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(255, 255, 255)">&#160;</td>
    <td colspan="1" style="text-align:right;width:9%;vertical-align:bottom;background-color:rgb(255, 255, 255)">&#160;</td>
    <td colspan="1" style="width:1%;vertical-align:bottom;white-space:nowrap;background-color:rgb(255, 255, 255)">&#160;</td> </tr>
  <tr style="background-color:rgb(204, 238, 255)">
    <td colspan="1" style="padding-left:9pt;width:76%;vertical-align:bottom;background-color:rgb(204, 238, 255)">
        <div style="text-indent:-14.2pt;margin-left:28.75pt;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Proceeds
        from issuance of preferred shares and warrants, net of issuance costs</span></span></div> </td>
    <td colspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" style="text-align:right;width:9%;vertical-align:bottom;background-color:rgb(204, 238, 255)">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fixv-39118" name="us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">522</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="width:1%;vertical-align:bottom;white-space:nowrap;background-color:rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" style="text-align:right;width:9%;vertical-align:bottom;background-color:rgb(204, 238, 255)">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fixv-39119" name="us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,749</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="width:1%;vertical-align:bottom;white-space:nowrap;background-color:rgb(204, 238, 255)">&#160;</td> </tr>
  <tr style="background-color:rgb(255, 255, 255)">
    <td colspan="1" style="padding-left:9pt;width:76%;padding-bottom:2px;vertical-align:bottom;background-color:rgb(255, 255, 255)">
        <div style="text-indent:-14.2pt;margin-left:28.75pt;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Exercise
        of options</span></span></div> </td>
    <td colspan="1" style="width:1%;padding-bottom:2px;vertical-align:bottom;background-color:rgb(255, 255, 255)">&#160;</td>
    <td colspan="1" style="width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom;background-color:rgb(255, 255, 255)">&#160;</td>
    <td colspan="1" style="text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom;background-color:rgb(255, 255, 255)">
        <div style="line-height:1.25">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20241004175054514" name="us-gaap:ProceedsFromStockOptionsExercised" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
        </div> </td>
    <td colspan="1" style="width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap;background-color:rgb(255, 255, 255)">&#160;</td>
    <td colspan="1" style="width:1%;padding-bottom:2px;vertical-align:bottom;background-color:rgb(255, 255, 255)">&#160;</td>
    <td colspan="1" style="width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom;background-color:rgb(255, 255, 255)">&#160;</td>
    <td colspan="1" style="text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom;background-color:rgb(255, 255, 255)">
        <div style="line-height:1.25">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fixv-39120" name="us-gaap:ProceedsFromStockOptionsExercised" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">3</ix:nonFraction></span></span></div>
        </div> </td>
    <td colspan="1" style="width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap;background-color:rgb(255, 255, 255)">&#160;</td>
        </tr>
  <tr style="background-color:rgb(204, 238, 255)">
    <td colspan="1" style="padding-left:9pt;width:76%;padding-bottom:2px;vertical-align:bottom;background-color:rgb(204, 238, 255)">
        <div style="text-indent:-14.2pt;margin-left:28.75pt;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Net
        cash provided by financing activities</span></span></div> </td>
    <td colspan="1" style="width:1%;padding-bottom:2px;vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" style="width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" style="text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom;background-color:rgb(204, 238, 255)">
        <div style="line-height:1.25">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fixv-39121" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">522</ix:nonFraction></span></span></div>
        </div> </td>
    <td colspan="1" style="width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap;background-color:rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" style="width:1%;padding-bottom:2px;vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" style="width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" style="text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom;background-color:rgb(204, 238, 255)">
        <div style="line-height:1.25">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fixv-39122" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,752</ix:nonFraction></span></span></div>
        </div> </td>
    <td colspan="1" style="width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap;background-color:rgb(204, 238, 255)">&#160;</td>
        </tr>
  <tr style="background-color:rgb(255, 255, 255)">
    <td colspan="1" style="padding-left:9pt;width:76%;vertical-align:bottom;background-color:rgb(255, 255, 255)">&#160;</td>
    <td colspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(255, 255, 255)">&#160;</td>
    <td colspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(255, 255, 255)">&#160;</td>
    <td colspan="1" style="text-align:right;width:9%;vertical-align:bottom;background-color:rgb(255, 255, 255)">&#160;</td>
    <td colspan="1" style="width:1%;vertical-align:bottom;white-space:nowrap;background-color:rgb(255, 255, 255)">&#160;</td>
    <td colspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(255, 255, 255)">&#160;</td>
    <td colspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(255, 255, 255)">&#160;</td>
    <td colspan="1" style="text-align:right;width:9%;vertical-align:bottom;background-color:rgb(255, 255, 255)">&#160;</td>
    <td colspan="1" style="width:1%;vertical-align:bottom;white-space:nowrap;background-color:rgb(255, 255, 255)">&#160;</td> </tr>
  <tr style="background-color:rgb(204, 238, 255)">
    <td colspan="1" style="padding-left:9pt;width:76%;vertical-align:bottom;background-color:rgb(204, 238, 255)">
        <div style="text-indent:-14.55pt;margin-left:14.55pt;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">DECREASE
        IN CASH AND CASH EQUIVALENTS AND RESTRICTED CASH</span></span></div> </td>
    <td colspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" style="text-align:right;width:9%;vertical-align:bottom;background-color:rgb(204, 238, 255)">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fixv-39123" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">3,434</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="width:1%;vertical-align:bottom;white-space:nowrap;background-color:rgb(204, 238, 255)">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
        </td>
    <td colspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" style="text-align:right;width:9%;vertical-align:bottom;background-color:rgb(204, 238, 255)">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fixv-39124" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">1,107</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="width:1%;vertical-align:bottom;white-space:nowrap;background-color:rgb(204, 238, 255)">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
        </td> </tr>
  <tr style="background-color:rgb(255, 255, 255)">
    <td colspan="1" style="padding-left:9pt;width:76%;vertical-align:bottom;background-color:rgb(255, 255, 255)">
        <div style="text-indent:-14.55pt;margin-left:14.55pt;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">EXCHANGE
        RATE DIFFERENCES ON CASH AND CASH EQUIVALENTS AND RESTRICTED CASH</span></span></div> </td>
    <td colspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(255, 255, 255)">&#160;</td>
    <td colspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(255, 255, 255)">&#160;</td>
    <td colspan="1" style="text-align:right;width:9%;vertical-align:bottom;background-color:rgb(255, 255, 255)">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fixv-39125" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">230</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="width:1%;vertical-align:bottom;white-space:nowrap;background-color:rgb(255, 255, 255)">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
        </td>
    <td colspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(255, 255, 255)">&#160;</td>
    <td colspan="1" style="width:1%;vertical-align:bottom;background-color:rgb(255, 255, 255)">&#160;</td>
    <td colspan="1" style="text-align:right;width:9%;vertical-align:bottom;background-color:rgb(255, 255, 255)">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fixv-39126" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">667</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="width:1%;vertical-align:bottom;white-space:nowrap;background-color:rgb(255, 255, 255)">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
        </td> </tr>
  <tr style="background-color:rgb(204, 238, 255)">
    <td colspan="1" style="padding-left:9pt;width:76%;padding-bottom:2px;vertical-align:bottom;background-color:rgb(204, 238, 255)">
        <div style="text-indent:-14.55pt;margin-left:14.55pt;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">BALANCE
        OF CASH, CASH EQUIVALENTS AND RESTRICTED CASH AT BEGINNING OF YEAR</span></span></div> </td>
    <td colspan="1" style="width:1%;padding-bottom:2px;vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" style="width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" style="text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom;background-color:rgb(204, 238, 255)">
        <div style="line-height:1.25">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fixv-39127" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,309</ix:nonFraction></span></span></div>
        </div> </td>
    <td colspan="1" style="width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap;background-color:rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" style="width:1%;padding-bottom:2px;vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" style="width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom;background-color:rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" style="text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom;background-color:rgb(204, 238, 255)">
        <div style="line-height:1.25">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fixv-39128" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="C_20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">10,083</ix:nonFraction></span></span></div>
        </div> </td>
    <td colspan="1" style="width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap;background-color:rgb(204, 238, 255)">&#160;</td>
        </tr>
  <tr style="background-color:rgb(255, 255, 255)">
    <td colspan="1" style="padding-left:9pt;width:76%;padding-bottom:4px;vertical-align:bottom;background-color:rgb(255, 255, 255)">
        <div style="text-indent:-14.55pt;margin-left:14.55pt;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">BALANCE
        OF CASH, CASH EQUIVALENTS AND RESTRICTED CASH AT END OF YEAR</span></span></div> </td>
    <td colspan="1" style="width:1%;padding-bottom:4px;vertical-align:bottom;background-color:rgb(255, 255, 255)">&#160;</td>
    <td colspan="1" style="width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom;background-color:rgb(255, 255, 255)">
        <div style="line-height:1.25">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
        </div> </td>
    <td colspan="1" style="text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom;background-color:rgb(255, 255, 255)">
        <div style="line-height:1.25">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fixv-39129" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,645</ix:nonFraction></span></span></div>
        </div> </td>
    <td colspan="1" style="width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap;background-color:rgb(255, 255, 255)">&#160;</td>
    <td colspan="1" style="width:1%;padding-bottom:4px;vertical-align:bottom;background-color:rgb(255, 255, 255)">&#160;</td>
    <td colspan="1" style="width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom;background-color:rgb(255, 255, 255)">
        <div style="line-height:1.25">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
        </div> </td>
    <td colspan="1" style="text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom;background-color:rgb(255, 255, 255)">
        <div style="line-height:1.25">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fixv-39130" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,309</ix:nonFraction></span></span></div>
        </div> </td>
    <td colspan="1" style="width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap;background-color:rgb(255, 255, 255)">&#160;</td>
        </tr>
  </table> </div>

<div style="line-height:1.25">&#160;</div>

<div style="text-align:center;margin-left:7.65pt;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The
accompanying notes are an integral part of these consolidated financial statements.</span></span></div>

<div style="clear:both;margin-top:10pt;margin-bottom:10pt">

<div style="text-align:center">&#160;</div>

<div style="text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="color:rgb(0, 0, 0);font-weight:normal;font-style:normal">F-72</span></span></span></div>

<div style="page-break-after:always"> <hr style="border-width:0px;clear:both;margin:4px 0px;width:100%;height:2px;color:#000000;background-color:#000000;margin-top:4pt;margin-bottom:10pt"/>
</div> </div>

<div style="line-height:1.25">&#160;</div>

<div style="text-align:center;margin-left:1pt;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">SILEXION
THERAPEUTICS CORP</span></span></div>

<div style="text-align:center;margin-left:1pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">CONSOLIDATED
STATEMENTS OF CASH FLOWS</span></span></div>

<div style="text-align:center;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(U.S.
dollars in thousands)</span></span></div>

<div style="line-height:1.25">&#160;</div>

<table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left;color:#000000;width:100%">
  <tr>
    <td colspan="1" rowspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
    <td colspan="1" rowspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
    <td colspan="6" rowspan="1" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Year
        ended December 31</span></span></div> </div> </td>
    <td colspan="1" rowspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td> </tr>
  <tr>
    <td colspan="1" rowspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
    <td colspan="1" rowspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
    <td colspan="2" rowspan="1" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2023</span></span></div>
        </div> </td>
    <td colspan="1" rowspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" rowspan="1" style="font-weight:bold;text-align:center;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
    <td colspan="2" rowspan="1" style="vertical-align:bottom;font-weight:bold;text-align:center;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2022</span></span></td>
    <td colspan="1" rowspan="1" style="font-weight:bold;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
        </tr>
  <tr>
    <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="text-decoration:underline">Appendix
        A</span>&#160;&#8211; <span style="text-decoration:underline">RECONCILIATION OF CASH, CASH EQUIVALENTS AND RESTRICTED CASH REPORTED IN
        THE CONSOLIDATED BALANCE SHEETS:</span></span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td> </tr>
  <tr>
    <td colspan="1" style="vertical-align:bottom;width:76%;background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Cash
        and cash equivalents</span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fixv-39131" name="us-gaap:CashEquivalentsAtCarryingValue" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,595</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fixv-39132" name="us-gaap:CashEquivalentsAtCarryingValue" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,259</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        </tr>
  <tr>
    <td colspan="1" style="vertical-align:bottom;width:76%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Restricted
        cash</span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fixv-39133" name="us-gaap:RestrictedCash" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">50</ix:nonFraction></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fixv-39134" name="us-gaap:RestrictedCash" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">50</ix:nonFraction></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        </tr>
  <tr>
    <td colspan="1" style="vertical-align:bottom;width:76%;padding-bottom:4px;background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">TOTAL
        CASH, CASH EQUIVALENTS AND RESTRICTED CASH SHOWN IN STATEMENT OF CASH FLOWS</span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fixv-39135" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,645</ix:nonFraction></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(255, 255, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fixv-39136" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,309</ix:nonFraction></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(255, 255, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        </tr>
  <tr>
    <td colspan="1" style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        </tr>
  <tr>
    <td colspan="1" style="vertical-align:bottom;width:76%;background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="text-decoration:underline;font-weight:bold">Appendix
        B</span><span style="font-weight:bold"> -</span>&#160;<span style="text-decoration:underline;font-weight:bold">SUPPLEMENTARY INFORMATION:</span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        </tr>
  <tr>
    <td colspan="1" style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">SUPPLEMENTARY
        INFORMATION ON INVESTING AND FINANCING ACTIVITIES NOT INVOLVING CASH FLOWS:</span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        </tr>
  <tr>
    <td colspan="1" style="vertical-align:bottom;padding-left:9pt;width:76%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        </tr>
  <tr>
    <td colspan="1" style="vertical-align:bottom;width:76%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Transition
        to ASC 842 - recognition of operating right of use assets and operating lease liabilities</span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20241003023320197" name="slxn:RecognitionOfOperatingRightOfUseAssetsAndOperatingLeaseLiabilities" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fixv-39137" name="slxn:RecognitionOfOperatingRightOfUseAssetsAndOperatingLeaseLiabilities" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">391</ix:nonFraction></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        </tr>
  <tr>
    <td colspan="1" style="vertical-align:bottom;width:76%;padding-bottom:2px;background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Conversion
        of SAFEs to preferred shares and warrants</span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20241003023343093" name="slxn:ConversionOfSAFEsToPreferredSharesAndWarrants" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(255, 255, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fixv-39138" name="slxn:ConversionOfSAFEsToPreferredSharesAndWarrants" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,683</ix:nonFraction></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(255, 255, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        </tr>
  <tr>
    <td colspan="1" style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        </tr>
  <tr>
    <td colspan="1" style="vertical-align:bottom;width:76%;background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">SUPPLEMENTAL
        DISCLOSURES</span>&#160;<span style="font-weight:bold">OF CASH FLOW INFORMATION:</span></span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        </tr>
  <tr>
    <td colspan="1" style="vertical-align:bottom;width:76%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Interest
        received</span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fixv-39139" name="us-gaap:InterestPaidNet" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">153</ix:nonFraction></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fixv-39140" name="us-gaap:InterestPaidNet" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">114</ix:nonFraction></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        </tr>
  </table>

<div style="line-height:1.25">&#160;</div>

<div style="clear:both;margin-top:10pt;margin-bottom:10pt">

<div style="text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="color:rgb(0, 0, 0);font-weight:normal;font-style:normal">F-73</span></span></span></div>

<div style="page-break-after:always"> <hr style="border-width:0px;clear:both;margin:4px 0px;width:100%;height:2px;color:#000000;background-color:#000000;margin-top:4pt;margin-bottom:10pt"/>
</div> </div>

<div style="line-height:1.25">&#160;</div>

<div style="line-height:1.25">

<div style="text-align:center;margin-left:1pt;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">SILEXION
THERAPEUTICS CORP</span></span></div>

<div style="text-align:center;margin-left:1pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS<span id="DFINANCIALSTATEMENTS"></span> (continued)</span></span></div>

<div style="text-align:center;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">U.S.
DOLLARS IN THOUSANDS</span></span></div> </div> </div> </div>

<p style="font:10pt Times New Roman, Times, serif;margin:0pt 0px 0pt;text-align:center">&#160;</p> </div>

<div> <ix:nonNumeric id="Fxbrl_20241205181417025" name="us-gaap:NatureOfOperations" contextRef="C_20230101to20231231" escape="true">

<div>

<div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>NOTE
1&#160; - GENERAL:</span></span></span></span></div>

<div style="line-height:1.25">&#160;</div>

<table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">
  <tr>
    <td style="width:72pt">&#160;</td>
    <td style="width:18pt;vertical-align:top;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>a.</span></span></span></span></td>
    <td style="width:auto;vertical-align:top;text-align:justify">
        <div style="font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Silexion
        Therapeutics Ltd. (formerly known as Silenseed Ltd.) (hereinafter -"the Company") was incorporated in Israel and began its operations
        on November 30, 2008. Since its incorporation, the Company has been engaged in <ix:nonFraction id="Fixv-39141" name="us-gaap:NumberOfOperatingSegments" contextRef="C_20230101to20231231" unitRef="Segment" scale="0" decimals="0" format="ixt-sec:numwordsen">one</ix:nonFraction>
        operating segment &#8211; the research and development of innovative treatments for pancreatic cancer based on siRNAs, aiming to stop
        the production of a specific pancreatic cancer-causing protein known as the KRAS mutation. The Company&#8217;s long-lived assets are located
        in Israel.</span></span></span></span></div> </td> </tr>
  </table>

<div style="line-height:1.25">&#160;</div>

<table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">
  <tr>
    <td style="width:72pt">&#160;</td>
    <td style="width:18pt;vertical-align:top;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>b.</span></span></span></span></td>
    <td style="width:auto;vertical-align:top;text-align:justify">
        <div style="font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>On
        April 28, 2021, the Company signed an agreement with Guangzhou Sino-Israel Biotech Investment Fund (GIBF) to establish a new company in
        China. On June 15, 2021 a company was established in China, named Silenseed (China) Ltd (hereinafter - the "Subsidiary"). The Company
        owns <ix:nonFraction id="Fixv-39142" name="us-gaap:MinorityInterestOwnershipPercentageByParent" contextRef="C_20231231_srtOwnershipAxis_slxnSilexionEquityFinancingMember" unitRef="pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">51</ix:nonFraction>%
        of the shares of the Subsidiary.&#160;The Subsidiary has not yet started significant operations as of December 31, 2023. The Company and
        Silenseed (China) Ltd., together - &#8220;the Group&#8221; (see Note 9d).</span></span></span></span></div> </td> </tr>
  </table>

<div style="line-height:1.25">&#160;</div>

<table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">
  <tr>
    <td style="width:72pt">&#160;</td>
    <td style="width:18pt;vertical-align:top;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>c.</span></span></span></span></td>
    <td style="width:auto;vertical-align:top;text-align:justify">
        <div style="font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>On
        April 3, 2024, the Company entered into an Amended and Restated Business Combination Agreement (hereinafter, &#8220;A&amp;R BCA&#8221;)
        with Moringa acquisition Corp (the &#8220;SPAC&#8220;), Biomotion Sciences, August M.S. Ltd. and Moringa Acquisition Merger Sub Corp (hereinafter
        - the &#8220;Business Combination&#8221;) which replaced an earlier business combination agreement,&#160;for further information see Note
        15(a) and (b). Subsequently, Biomotion Sciences changed its name to Silexion Therapeutics Corp (&#8220;New Silexion&#8221;).</span></span></span></span></div>
        </td> </tr>
  </table>

<div style="line-height:1.25">&#160;</div>

<div style="text-align:justify;margin-left:90pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>The
A&amp;R BCA was accounted for as a reverse recapitalization in accordance with US GAAP.&#160;Under this method of accounting, the Company
was treated as the accounting acquirer and the SPAC was treated as the &#8220;acquired&#8221; company for financial reporting purposes.</span></span></span></span></div>

<div style="text-align:justify;margin-left:90pt;line-height:1.25">&#160;</div>

<div style="text-align:justify;margin-left:90pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Under
the reverse recapitalization accounting method, the A&amp;R BCA was deemed to be the equivalent of a capital transaction in which Silexion
issued shares for the net assets of the SPAC. Operations prior to the A&amp;R BCA are those of Silexion.</span></span></span></span></div>

<div style="line-height:1.25">&#160;</div>

<div style="text-align:justify;margin-left:90pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>In
accordance with the applicable guidance to reverse recapitalization, the equity structure has been retroactively adjusted in all comparative
periods up to the date of the Closing (the &#8220;Closing Date&#8221;), to reflect the number of New Silexion&#8217;s Ordinary Shares,
$<ix:nonFraction id="Fxbrl_20241205181924000" name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="C_20231231" unitRef="ilsPershares" scale="0" decimals="4" format="ixt:num-dot-decimal">0.0001</ix:nonFraction>
par value per share (prior to reverse share split, see below) issued to legacy Silexion shareholders in connection with the reverse recapitalization
transaction. As such, the shares and corresponding capital amounts and earnings per share related to legacy Silexion shareholders prior
to the reverse recapitalization have been retroactively restated as shares reflecting the exchange ratio established pursuant to the Transactions.
In conjunction with the reverse recapitalization, Silexion&#8217;s Ordinary Shares underwent a 1-for-3.9829&#160;conversion (prior to
reverse share split, see below). Also, under ASC 250, the reporting entity changed such that financial statements covering periods prior
to the Closing Date are now deemed to be those of New Silexion.</span></span></span></span></div>

<div style="line-height:1.25">&#160;</div>

<div style="text-align:justify;margin-left:90pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>On
November 22, 2024, New Silexion announced a prospective 1-for-9 reverse share split of all of its issued and outstanding, and authorized
but unissued, Ordinary Shares. See Note 13. The reverse share split was to result in a corresponding increase in the par value of New
Silexion&#8217;s Ordinary Shares, from $<ix:nonFraction id="Fxbrl_20241205181957844" name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="C_20231231" unitRef="ilsPershares" scale="0" decimals="4" format="ixt:num-dot-decimal">0.0001</ix:nonFraction>
per share to $<ix:nonFraction id="Fxbrl_20241205182005513" name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="C_20241122" unitRef="ilsPershares" scale="0" decimals="4" format="ixt:num-dot-decimal">0.0009</ix:nonFraction>
per share. No fractional shares were to be issued as a result of the reverse split, as any fractional share totals to which shareholders
became entitled were to be rounded up to the nearest whole number of shares. The reverse share split became effective after market close
on November 27, 2024 and was reflected at the start of trading in New Silexion&#8217;s Ordinary Shares on November 29, 2024. Unless otherwise
noted, all Ordinary Shares, preferred shares and per share amounts contained in these consolidated financial statements (both of the Company
and New Silexion) have been retroactively adjusted to reflect a 1-for-9 reverse share split.</span></span></span></span></div>

<div style="line-height:1.25">&#160;</div>

<table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">
  <tr>
    <td style="width:72pt">&#160;</td>
    <td style="width:18pt;vertical-align:top;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>d.</span></span></span></span></td>
    <td style="width:auto;vertical-align:top;text-align:justify">
        <div style="font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>In
        October 2023, Hamas terrorists infiltrated Israel&#8217;s southern border from the Gaza Strip and conducted a series of attacks on civilian
        and military targets. Following the attack, Israel&#8217;s security cabinet declared war against Hamas and commenced a military campaign
        against Hamas and other terrorist organizations.</span></span></span></span></div> </td> </tr>
  </table>

<div style="line-height:1.25">&#160;</div>

<div><ix:exclude>

<div style="margin-top:10pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">

<p style="text-align:center;margin-top:0pt;margin-bottom:3pt"><span style="width:34%;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">F-74</span></span></span></p></div><hr style="page-break-after:always;border-width:0px;clear:both;margin:4px 0px;width:100%;height:2px;color:#000000;background-color:#000000;margin-top:0pt;margin-bottom:10pt"/>

<p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:center">&#160;</p>

<p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:center"><strong>S<span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">ILEXION
THERAPEUTICS CORP</span></span></strong><br/><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS (continued)</span></span></p>

<p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">U.S.
DOLLARS IN THOUSANDS</span></span></p>

<p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:center">&#160;</p>

<div style="line-height:1.25;font-family:'Times New Roman', Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span style="font-weight:bold">NOTE
1&#160; - GENERAL</span> (continued):</span></span></span></span></div>

<div style="line-height:1.25;font-family:'Times New Roman', Times, serif">&#160;</div> </ix:exclude></div>

<div style="text-align:justify;margin-left:90pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>The
Company&#8217;s headquarters are located in Modiin, Israel. As of the issuance date of these consolidated financial statements, the conflict
between Israel and Hamas has not had a material impact on the Company&#8217;s results of operations or financial position, if at all.
The Company cannot currently predict the intensity or duration of Israel&#8217;s war against Hamas, however, as most of the Company&#8217;s
trials are not executed in Israel, the Company does not believe the recent terrorist attack and the subsequent declaration of war by the
Israeli government against the Hamas terrorist organization will have any material impact on its ongoing operations. The Company continues
to monitor its ongoing activities and will make any needed adjustments to ensure continuity of its business, while supporting the safety
and well-being of its employees.</span></span></span></span></div>

<div style="line-height:1.25">&#160;</div>

<div style="text-align:justify;margin-left:90pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Any
hostilities involving Israel, or the interruption or curtailment of trade within Israel or between Israel and its trading partners could
adversely affect the Company&#8217;s operations and results of operations and could make it more difficult for the Company to raise capital.</span></span></span></span></div>

<div style="line-height:1.25">&#160;</div>

<table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">
  <tr>
    <td style="width:72pt">&#160;</td>
    <td style="width:18pt;vertical-align:top;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>e.</span></span></span></span></td>
    <td style="width:auto;vertical-align:top;text-align:justify">
        <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span style="text-decoration:underline">Going
        concern</span>:</span></span></span></span></span></div> </td> </tr>
  </table>

<div style="line-height:1.25">&#160;</div>

<div style="text-align:justify;margin-left:90pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Since
its inception, the Company has devoted substantially all its efforts to research and development, clinical trials, and capital raising
activities. The Company is still in its development and clinical stage and has not yet generated revenues.</span></span></span></span></div>

<div style="line-height:1.25">&#160;</div>

<div style="text-align:justify;margin-left:90pt;line-height:1.25;font-family:'Times New Roman', Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>The</span>
Company has incurred losses of $<ix:nonFraction id="Fixv-39143" name="us-gaap:InterestCostsIncurred" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,108</ix:nonFraction>
and $<ix:nonFraction id="Fixv-39144" name="us-gaap:InterestCostsIncurred" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,488</ix:nonFraction>
for the years ended on December 31, 2023&#160; and 2022, respectively.<span> During the years ended on December 31, 2023 and 2022, the
Company had negative operating cash flows of $<ix:nonFraction id="Fixv-39145" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">4,529</ix:nonFraction>
and $<ix:nonFraction id="Fixv-39146" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">3,335</ix:nonFraction>,
respectively.&#160; As of December 31, 2023, the Company had cash and cash equivalents of $<ix:nonFraction id="Fixv-39147" name="us-gaap:CashEquivalentsAtCarryingValue" contextRef="C_20231231" unitRef="usd" scale="6" decimals="-5" format="ixt:num-dot-decimal">4.6</ix:nonFraction>
million. The Company expects to continue incurring losses, and negative cash flows from operations. Management is in the process of evaluating
various financing alternatives, as the Company will need to finance future research and development activities, general and administrative
expenses and working capital through fund raising. However, there is no assurance that the Company will be successful in obtaining such
funding.</span></span></span></span></span></div>

<div style="line-height:1.25">&#160;</div>

<div style="text-align:justify;margin-left:90pt;line-height:1.25;font-family:'Times New Roman', Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>Under
these circumstances, in accordance with the requirements of ASC 205-40, management has concluded that there is substantial doubt about
the Company&#8217;s ability to continue as a going concern for at least 12 months from the date these financial statements are issued.
The financial statements do not include any adjustments that may be necessary should the Company be unable to continue as a going concern.</span></span></span></span></span></div>
</div> </ix:nonNumeric> </div>

<div style="font-size:10pt;margin-top:0pt;margin-bottom:0pt;font-family:'Times New Roman', Times, serif">&#160;</div> <ix:nonNumeric id="Fxbrl_20241003121255356" name="us-gaap:SignificantAccountingPoliciesTextBlock" contextRef="C_20230101to20231231" escape="true">

<div>

<div style="font:10pt Times New Roman, Times, Serif">

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>NOTE
2&#160; - SIGNIFICANT ACCOUNTING POLICIES:</strong></span></span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.75in;text-indent:-24pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>&#160;</strong></span></span></p>
<ix:nonNumeric id="Fxbrl_20241003121336690" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" contextRef="C_20230101to20231231" escape="true">

<div>

<table cellpadding="0" cellspacing="0" style="font:10pt Times New Roman, Times, Serif;margin-top:0pt;margin-bottom:0pt;width:100%">
  <tr style="vertical-align:top;text-align:justify">
    <td style="width:64.25pt">&#160;</td>
    <td style="text-align:left;width:28.45pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>a.</strong></span></span></td>
    <td style="text-align:justify;width:auto"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>Basis
        of presentation</strong></span></span></td> </tr>
  </table>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.75in">&#160;</p>

<p style="font:10pt Times New Roman, Times, serif;margin:0pt 0px 0pt 92.7pt;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The
Company&#8217;s consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the
United&#160;States (&#8220;U.S.&#160;GAAP&#8221;).</span></span></p> </div> </ix:nonNumeric>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.75in;text-indent:-24pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>&#160;</strong></span></span></p>
<ix:nonNumeric id="Fxbrl_20241003121355171" name="us-gaap:UseOfEstimates" contextRef="C_20230101to20231231" escape="true">

<div>

<table cellpadding="0" cellspacing="0" style="font:10pt Times New Roman, Times, Serif;margin-top:0pt;margin-bottom:0pt;width:100%">
  <tr style="vertical-align:top;text-align:justify">
    <td style="width:64.25pt">&#160;</td>
    <td style="text-align:left;width:28.45pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>b.</strong></span></span></td>
    <td style="text-align:justify;width:auto"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>Use of
        estimates</strong></span></span></td> </tr>
  </table>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.75in">&#160;</p>

<p style="font:10pt Times New Roman, Times, serif;margin:0pt 0px 0pt 92.7pt;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The
preparation of the financial statements in conformity with U.S.&#160;GAAP requires management to make estimates and assumptions that affect
the amounts reported in the financial statements and accompanying notes. Actual results could differ from those estimates. As applicable
to these financial statements, the most significant estimates and assumptions relate to fair value of financial instruments and share-based
compensation see Notes 12 and 11, respectively.</span></span></p> </div> </ix:nonNumeric>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.75in;text-indent:-24pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>&#160;</strong></span></span></p>
<ix:nonNumeric id="Fxbrl_20241003121416790" name="us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" contextRef="C_20230101to20231231" escape="true">

<div>

<table cellpadding="0" cellspacing="0" style="font:10pt Times New Roman, Times, Serif;margin-top:0pt;margin-bottom:0pt;width:100%">
  <tr style="vertical-align:top;text-align:justify">
    <td style="width:64.25pt">&#160;</td>
    <td style="text-align:left;width:28.45pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>c.</strong></span></span></td>
    <td style="text-align:justify;width:auto"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>Functional
        currency</strong></span></span></td> </tr>
  </table>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.75in">&#160;</p>

<p style="font:10pt Times New Roman, Times, serif;margin:0pt 0px 0pt 92.7pt;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The
Company&#8217;s operations are currently conducted in Israel and some of the Company&#8217;s expenses are currently paid in new Israeli
shekels (&#8220;NIS&#8221;); however, the markets for the Company&#8217;s future products are located outside of Israel. Financing activities
are conducted in U.S.&#160;dollar (&#8220;dollar&#8221; or &#8220;$&#8221;). The Company&#8217;s management believes that the US dollar
is the currency of the primary economic environment in which the Company operates. Thus, the functional and reporting currency of the
Company is the dollar. The functional currency of the Subsidiary is U.S.&#160;dollar, inter alia, in light of the composition of expenses
and expected volume of intercompany transactions with the Company.</span></span></p>

<p style="font:10pt Times New Roman, Times, serif;margin:0pt 0px 0pt 92.7pt;text-align:justify">&#160;</p>

<div><ix:exclude>

<div style="margin-top:10pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">

<p style="text-align:center;margin-top:0pt;margin-bottom:3pt"><span style="width:34%;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">F-75</span></span></span></p></div><hr style="page-break-after:always;border-width:0px;clear:both;margin:4px 0px;width:100%;height:2px;color:#000000;background-color:#000000;margin-top:0pt;margin-bottom:10pt"/>

<p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:center">&#160;</p>

<p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:center"><strong>S<span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">ILEXION
THERAPEUTICS CORP</span></span></strong><br/><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS (continued)</span></span></p>

<p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">U.S.
DOLLARS IN THOUSANDS</span></span></p>

<p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:center">&#160;</p>

<p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt;font-family:Times New Roman, Times, serif"><strong>NOTE
2&#160; - SIGNIFICANT ACCOUNTING POLICIES</strong>&#160;(continued):</span></p>

<p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt">&#160;</p> </ix:exclude></div>

<p style="font:10pt Times New Roman, Times, serif;margin:0pt 0px 0pt 92.7pt;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Transactions
and balances originally denominated in dollars are presented at their original amounts. Balances in non- U.S.&#160;dollar currencies are
translated into dollars using historical and current exchange rates for non-monetary and monetary balances, respectively. For non-dollar
transactions and other items in the statements of operations (indicated below), the following exchange rates are used: (i)&#160;for transactions&#160;&#8212;&#160;exchange
rates at transaction dates or average exchange rates; and (ii)&#160;for other items (derived from non-monetary balance sheet items such
as depreciation and amortization) &#8212;&#160;historical exchange rates. Currency transaction gains and losses are presented in financial
income or expenses, as appropriate.</span></span></p> </div> </ix:nonNumeric>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.75in;text-indent:-24pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>&#160;</strong></span></span></p>
<ix:nonNumeric id="Fxbrl_20241003121435804" name="us-gaap:ConsolidationPolicyTextBlock" contextRef="C_20230101to20231231" escape="true">

<div>

<table cellpadding="0" cellspacing="0" style="font:10pt Times New Roman, Times, Serif;margin-top:0pt;margin-bottom:0pt;width:100%">
  <tr style="vertical-align:top;text-align:justify">
    <td style="width:64.25pt">&#160;</td>
    <td style="text-align:left;width:28.45pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>d.</strong></span></span></td>
    <td style="text-align:justify;width:auto"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>Principles
        of consolidation</strong></span></span></td> </tr>
  </table>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.75in">&#160;</p>

<p style="font:10pt Times New Roman, Times, serif;margin:0pt 0px 0pt 92.7pt;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The
accompanying consolidated financial statements include the accounts of the Company and its subsidiary. All intercompany balances and transactions
have been eliminated in consolidation.</span></span></p>

<p style="font:10pt Times New Roman, Times, serif;margin:0pt 0px 0pt 92.7pt;text-align:justify">&#160;</p>

<p style="font:10pt Times New Roman, Times, serif;margin:0pt 0px 0pt 92.7pt;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The
financial statements of the Company and of the Subsidiary are prepared as of the same dates and periods. The consolidated financial statements
are prepared using uniform accounting policies by all companies in the Group.</span></span></p> </div> </ix:nonNumeric>

<p style="text-align:left;font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.75in;text-indent:-24pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>&#160;</strong></span></span></p>
<ix:nonNumeric id="Fxbrl_20241003121455773" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" contextRef="C_20230101to20231231" escape="true">

<div>

<table cellpadding="0" cellspacing="0" style="font:10pt Times New Roman, Times, Serif;margin-top:0pt;margin-bottom:0pt;width:100%">
  <tr style="vertical-align:top;text-align:justify">
    <td style="text-align:left;width:64.25pt">&#160;</td>
    <td style="text-align:left;width:28.45pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>e.</strong></span></span></td>
    <td style="text-align:left;width:auto"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>Cash and
        cash equivalents</strong></span></span></td> </tr>
  </table>

<p style="text-align:left;font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.75in">&#160;</p>

<p style="font:10pt Times New Roman, Times, serif;margin:0pt 0px 0pt 92.7pt;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The
Company considers as cash equivalents all short-term, highly liquid investments, which include short-term bank deposits with original
maturities of three&#160;months or less from the date of purchase that are not restricted as to withdrawal or use and are readily convertible
to known amounts of cash.</span></span></p>

<p style="font:10pt Times New Roman, Times, serif;margin:0pt 0px 0pt 92.7pt;text-align:justify">&#160;</p>

<p style="font:10pt Times New Roman, Times, serif;margin:0pt 0px 0pt 92.7pt;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Bank
balances for which use by the Company is subject to third party contractual restrictions are included as part of cash unless the restrictions
result in a bank balance no longer meeting the definition of cash. If the contractual restrictions to use the cash extend beyond 12&#160;months
after the end of the reporting period, the related amounts are classified as non-current in Balance sheets.</span></span></p> </div> </ix:nonNumeric>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.75in;text-indent:-24pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>&#160;</strong></span></span></p>
<ix:nonNumeric id="Fxbrl_20241003121512277" name="us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" contextRef="C_20230101to20231231" escape="true">

<div>

<table cellpadding="0" cellspacing="0" style="font:10pt Times New Roman, Times, Serif;margin-top:0pt;margin-bottom:0pt;width:100%">
  <tr style="vertical-align:top;text-align:justify">
    <td style="width:64.25pt">&#160;</td>
    <td style="text-align:left;width:28.45pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>f.</strong></span></span></td>
    <td style="text-align:justify;width:auto"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>Restricted
        cash</strong></span></span></td> </tr>
  </table>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.75in">&#160;</p>

<p style="font:10pt Times New Roman, Times, serif;margin:0pt 0px 0pt 92.7pt;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">As
of December&#160;31, 2023 and 2022, the Company pledged an amount of $<ix:nonFraction id="Fxbrl_20241003122849698" name="us-gaap:OperatingLeasePayments" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal"><ix:nonFraction id="Fixv-39148" name="us-gaap:OperatingLeasePayments" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">25</ix:nonFraction></ix:nonFraction>
in favor of a bank as collateral for guarantees provided to secure the lease payments.</span></span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.75in">&#160;</p>

<p style="font:10pt Times New Roman, Times, serif;margin:0pt 0px 0pt 92.7pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The
Company is required to hold a minimum amount of NIS <ix:nonFraction id="Fxbrl_20241205180208916" name="us-gaap:LineOfCredit" contextRef="C_20231231" unitRef="NIS" scale="3" decimals="-3" format="ixt:num-dot-decimal">85</ix:nonFraction>
in its bank account in order to maintain availability of a credit line from its credit card company.</span></span></p> </div> </ix:nonNumeric>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.75in;text-indent:-24pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>&#160;</strong></span></span></p>
</div> <ix:nonNumeric id="Fxbrl_20241003121627821" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" contextRef="C_20230101to20231231" escape="true">

<div>

<div style="font:10pt Times New Roman, Times, Serif">

<table cellpadding="0" cellspacing="0" style="font:10pt Times New Roman, Times, Serif;margin-top:0pt;margin-bottom:0pt;width:100%">
  <tr style="vertical-align:top;text-align:justify">
    <td style="width:64.25pt">&#160;</td>
    <td style="text-align:left;width:28.45pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>g.</strong></span></span></td>
    <td style="text-align:justify;width:auto"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>Property
        and equipment:</strong></span></span></td> </tr>
  </table>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.75in">&#160;</p>

<p style="font:10pt Times New Roman, Times, serif;margin:0pt 0px 0pt 92.7pt;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Property
and equipment are stated at cost, net of accumulated depreciation.</span></span></p>

<p style="font:10pt Times New Roman, Times, serif;margin:0pt 0px 0pt 0.75in;text-align:justify">&#160;</p> </div> <ix:nonNumeric id="Fxbrl_20241004042437827" name="slxn:ScheduleOfEstimatedUsefulLivesTableTextBlock" contextRef="C_20230101to20231231" escape="true">

<div>

<div style="font:10pt Times New Roman, Times, Serif">

<p style="font:10pt Times New Roman, Times, serif;margin:0pt 0px 0pt 92.7pt;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Depreciation
is calculated using the straight-line method over the estimated useful lives of the assets, at the following annual rates:</span></span></p>
</div>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.75in">&#160;</p>

<div>

<div style="font:10pt Times New Roman, Times, Serif;margin-lefft:90pt">

<div style="margin-left:90pt">

<table cellpadding="0" cellspacing="0" style="border-collapse:collapse;font:10pt Times New Roman, Times, serif;width:85%">
  <tr style="vertical-align:bottom">
    <td>&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;font-weight:bold">&#160;</td>
    <td colspan="2" style="border-bottom:Black 1.5pt solid;font-weight:bold;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">%</span></span></td>
    <td style="padding-bottom:1.5pt;font-weight:bold">&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="width:88%;text-align:left;text-indent:-10pt;padding-left:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Computers
        and software</span></span></td>
    <td style="width:1%">&#160;</td>
    <td style="width:1%;text-align:left">&#160;</td>
    <td style="width:9%;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonNumeric id="Fixv-39151" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" contextRef="C_20231231_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapComputerEquipmentMember" format="ixt-sec:duryear">33</ix:nonNumeric></span></span></td>
    <td style="width:1%;text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="text-align:left;text-indent:-10pt;padding-left:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Laboratory
        and electronic equipment</span></span></td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonNumeric id="Fixv-39152" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" contextRef="C_20231231_usgaapPropertyPlantAndEquipmentByTypeAxis_slxnLaboratoryAndElectronicEquipmentMember" format="ixt-sec:duryear">15</ix:nonNumeric></span></span></td>
    <td style="text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="text-align:left;text-indent:-10pt;padding-left:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Leasehold
        improvements*</span></span></td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><ix:nonNumeric id="Fxbrl_20241206144615742" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" contextRef="C_20231231_srtRangeAxis_srtMinimumMember_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapLeaseholdImprovementsMember" format="ixt-sec:duryear">15</ix:nonNumeric>-<ix:nonNumeric id="Fix_8_fact" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" contextRef="C_20231231_srtRangeAxis_srtMaximumMember_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapLeaseholdImprovementsMember" format="ixt-sec:duryear">40</ix:nonNumeric></span></span></span></td>
    <td style="text-align:left">&#160;</td> </tr>
  </table> </div>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 24pt;text-indent:-24pt">&#160;</p> </div>

<div><ix:exclude>

<div style="margin-top:0pt;margin-bottom:0pt">

<div style="margin-top:10pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">

<p style="text-align:center;margin-top:0pt;margin-bottom:3pt"><span style="width:34%;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">F-76</span></span></span></p></div><hr style="page-break-after:always;border-width:0px;clear:both;margin:4px 0px;width:100%;height:2px;color:#000000;background-color:#000000;margin-top:0pt;margin-bottom:10pt"/>

<p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:center">&#160;</p>

<p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:center"><strong>S<span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">ILEXION
THERAPEUTICS CORP</span></span></strong><br/><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS (continued)</span></span></p>

<p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">U.S.
DOLLARS IN THOUSANDS</span></span></p>

<p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:center">&#160;</p> </div>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>NOTE
2&#160; - SIGNIFICANT ACCOUNTING POLICIES</strong>&#160;(continued):</span></span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">&#160;</p> </ix:exclude></div>

<div style="margin-top:0pt;margin-bottom:0pt;width:25%">

<div style="font-size:1pt">&#160;</div> </div>

<div style="margin-left:92.7pt">

<table cellpadding="0" cellspacing="0" style="font:10pt Times New Roman, Times, Serif;margin-top:0pt;margin-bottom:0pt;width:100%">
  <tr style="vertical-align:top;text-align:justify">
    <td style="width:10pt">
        <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">*</span></p>
        </td>
    <td style="width:auto"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Leasehold improvements are amortized
        by the straight-line method over the expected lease term, which is shorter than the estimated useful life of the&#160;improvements.</span></span></td>
        </tr>
  </table> </div> </div> </div> </ix:nonNumeric> </div> </ix:nonNumeric>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.75in;text-indent:-24pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>&#160;</strong></span></span></p>
<ix:nonNumeric id="Fxbrl_20241003121713762" name="us-gaap:PostemploymentBenefitPlansPolicy" contextRef="C_20230101to20231231" escape="true">

<div>

<table cellpadding="0" cellspacing="0" style="font:10pt Times New Roman, Times, Serif;margin-top:0pt;margin-bottom:0pt;width:100%">
  <tr style="vertical-align:top;text-align:justify">
    <td style="width:64.25pt">&#160;</td>
    <td style="text-align:left;width:28.45pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>h.</strong></span></span></td>
    <td style="text-align:justify;width:auto"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>Employee
        rights upon retirement</strong></span></span></td> </tr>
  </table>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.75in">&#160;</p>

<p style="font:10pt Times New Roman, Times, serif;margin:0pt 0px 0pt 92.7pt;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The
Company is required to make severance payments upon dismissal of an employee or upon termination of employment in certain circumstances.</span></span></p>

<p style="font:10pt Times New Roman, Times, serif;margin:0pt 0px 0pt 92.7pt;text-align:justify">&#160;</p>

<p style="font:10pt Times New Roman, Times, serif;margin:0pt 0px 0pt 92.7pt;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">In
accordance with the current employment terms with all of its employees located in Israel, and pursuant to Section&#160;14 of the Israeli
Severance Pay Law, 1963, the Company makes and has been continuously making, since the beginning of employment of each of its current
employees, regular deposits, at a rate of <ix:nonFraction id="Fixv-39156" name="slxn:RegularDepositsByEmployee" contextRef="C_20230101to20231231" unitRef="pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">8.33</ix:nonFraction>%
of their monthly salary, with certain insurance companies for accounts controlled by each applicable employee in order to secure the employee&#8217;s
full severance pay obligation.</span></span></p>

<p style="font:10pt Times New Roman, Times, serif;margin:0pt 0px 0pt 92.7pt;text-align:justify">&#160;</p>

<p style="font:10pt Times New Roman, Times, serif;margin:0pt 0px 0pt 92.7pt;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Under
these circumstances, the Company is currently relieved from any severance pay liability with respect to each such employee. Neither the
liability in respect of these employees nor the credit for the amounts funded are reflected on the Company&#8217;s consolidated balance
sheets, as the amounts funded are not under the control or management of the Company and the severance pay risks have been irrevocably
transferred to the applicable insurance companies.</span></span></p>

<p style="font:10pt Times New Roman, Times, serif;margin:0pt 0px 0pt 92.7pt;text-align:justify">&#160;</p>

<p style="font:10pt Times New Roman, Times, serif;margin:0pt 0px 0pt 92.7pt;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The
amounts of severance payment expenses were $<ix:nonFraction id="Fixv-39157" name="us-gaap:SeveranceCosts1" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">74</ix:nonFraction>
and $<ix:nonFraction id="Fixv-39158" name="us-gaap:SeveranceCosts1" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">82</ix:nonFraction>
for the&#160;years ended December&#160;31, 2023 and 2022, respectively.</span></span></p> </div> </ix:nonNumeric>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.75in;text-indent:-24pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>&#160;</strong></span></span></p>
<ix:nonNumeric id="Fxbrl_20241003121737303" name="us-gaap:FairValueMeasurementPolicyPolicyTextBlock" contextRef="C_20230101to20231231" escape="true">

<div>

<table cellpadding="0" cellspacing="0" style="font:10pt Times New Roman, Times, Serif;margin-top:0pt;margin-bottom:0pt;width:100%">
  <tr style="vertical-align:top;text-align:justify">
    <td style="width:64.25pt">&#160;</td>
    <td style="text-align:left;width:28.45pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>i.</strong></span></span></td>
    <td style="text-align:justify;width:auto"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>Fair
        value measurement</strong></span></span></td> </tr>
  </table>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.75in">&#160;</p>

<p style="font:10pt Times New Roman, Times, serif;margin:0pt 0px 0pt 92.7pt;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Fair
value is based on the price that would be received from the sale of an asset or that would be paid to transfer a liability in an orderly
transaction between market participants at the measurement date. In order to increase consistency and comparability in fair value measurements,
the guidance establishes a fair value hierarchy that prioritizes observable and unobservable inputs used to measure fair value into three
broad levels, which are described as follows:</span></span></p>

<p style="font:10pt Times New Roman, Times, serif;margin:0pt 0px 0pt 0.75in;text-align:justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font:10pt Times New Roman, Times, Serif;width:100%;border-collapse:collapse">
  <tr style="vertical-align:top">
    <td style="padding-bottom:2.25pt;width:92.7pt;text-align:justify">&#160;</td>
    <td style="padding-left:10pt;text-indent:-10pt;width:55pt;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>Level&#160;1:</span></span></span></td>
    <td style="width:auto;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>Quoted
        prices (unadjusted) in active markets that are accessible at the measurement date for assets or liabilities. The fair value hierarchy
        gives the highest priority to Level 1 inputs.</span></span></span></td> </tr>
  <tr style="vertical-align:top">
    <td style="padding-bottom:2.25pt;width:92.7pt;text-align:justify">&#160;</td>
    <td style="padding-left:10pt;text-indent:-10pt;width:55pt;text-align:justify">&#160;</td>
    <td style="width:auto;text-align:justify">&#160;</td> </tr>
  <tr style="vertical-align:top">
    <td style="padding-bottom:2.25pt;width:92.7pt;text-align:justify">&#160;</td>
    <td style="padding-left:10pt;text-indent:-10pt;width:55pt;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>Level&#160;2:</span></span></span></td>
    <td style="width:auto;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>Observable
        prices that are based on inputs not quoted on active markets, but corroborated by market data or active market data of similar or identical
        assets or liabilities.</span></span></span></td> </tr>
  <tr style="vertical-align:top">
    <td style="padding-bottom:2.25pt;width:92.7pt;text-align:justify">&#160;</td>
    <td style="padding-left:10pt;text-indent:-10pt;width:55pt;text-align:justify">&#160;</td>
    <td style="width:auto;text-align:justify">&#160;</td> </tr>
  <tr style="vertical-align:top">
    <td style="padding-bottom:2.25pt;width:92.7pt;text-align:justify">&#160;</td>
    <td style="padding-left:10pt;text-indent:-10pt;width:55pt;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>Level&#160;3:</span></span></span></td>
    <td style="width:auto;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>Unobservable
        inputs are used when little or no market data is available. The fair value hierarchy gives the lowest priority to Level 3 inputs.</span></span></span></td>
        </tr>
  </table>

<p style="margin-top:0;margin-bottom:0">&#160;</p>

<p style="font:10pt Times New Roman, Times, serif;margin:0pt 0px 0pt 92.7pt;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">In
determining fair value, the Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable
inputs to the extent possible and considers counterparty credit risk in its assessment of fair value.</span></span></p> </div> </ix:nonNumeric>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.75in;text-indent:-24pt">&#160;</p> <ix:nonNumeric id="Fxbrl_20241003121754966" name="us-gaap:FairValueOfFinancialInstrumentsPolicy" contextRef="C_20230101to20231231" escape="true">

<div>

<table cellpadding="0" cellspacing="0" style="font:10pt Times New Roman, Times, Serif;margin-top:0pt;margin-bottom:0pt;width:100%">
  <tr style="vertical-align:top;text-align:justify">
    <td style="width:64.25pt">&#160;</td>
    <td style="text-align:left;width:28.45pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>j.</strong></span></span></td>
    <td style="text-align:justify;width:auto"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>Financial
        instruments issued</strong></span></span></td> </tr>
  </table>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.75in">&#160;</p>

<p style="font:10pt Times New Roman, Times, serif;margin:0pt 0px 0pt 92.7pt;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">When
the Company issues preferred shares, it first considers the provisions of ASC&#160;480, Distinguishing Liabilities from Equity (&#8220;ASC&#160;480&#8221;)
in order to determine whether the preferred share should be classified as a liability. If the instrument is not within the scope of ASC&#160;480,
the Company further analyzes the instrument&#8217;s characteristics in order to determine whether it should be classified within temporary
equity (mezzanine) or within permanent equity in accordance with the provisions of ASC&#160;480-10-S99. The Company&#8217;s redeemable
convertible preferred shares are not mandatorily or currently redeemable. However, they include clauses that could constitute as in-substance
redemption clauses that are outside of the Company&#8217;s control. As such, all shares of redeemable convertible preferred shares have
been presented outside of permanent equity.</span></span></p>

<p style="font:10pt Times New Roman, Times, serif;margin:0pt 0px 0pt 92.7pt;text-align:justify">&#160;</p>

<div><ix:exclude>

<div style="margin-top:10pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">

<p style="text-align:center;margin-top:0pt;margin-bottom:3pt"><span style="width:34%;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">F-77</span></span></span></p></div><hr style="page-break-after:always;border-width:0px;clear:both;margin:4px 0px;width:100%;height:2px;color:#000000;background-color:#000000;margin-top:0pt;margin-bottom:10pt"/>

<p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:center">&#160;</p>

<p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:center"><strong>S<span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">ILEXION
THERAPEUTICS CORP</span></span></strong><br/><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS (continued)</span></span></p>

<p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">U.S.
DOLLARS IN THOUSANDS</span></span></p>

<p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:center">&#160;</p>

<p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>NOTE
2&#160; -&#160;SIGNIFICANT ACCOUNTING POLICIES</strong>&#160;(continued):</span></span></p>

<p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt">&#160;</p> </ix:exclude></div>

<p style="font:10pt Times New Roman, Times, serif;margin:0pt 0px 0pt 92.7pt;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">When
the Company issues other freestanding instruments, the Company first analyzes the provisions of ASC&#160;480 in order to determine whether
the instrument should be classified as a liability, with subsequent changes in fair value recognized in the statements of operations in
each period. If the instrument is not within the scope of ASC&#160;480, the Company further analyzes the provisions of ASC&#160;815-40
in order to determine whether the instrument should be classified within equity or classified as an asset or liability, with subsequent
changes in fair value recognized in the statements of operations in each period.</span></span></p>

<p style="font:10pt Times New Roman, Times, serif;margin:0pt 0px 0pt 92.7pt;text-align:justify">&#160;</p>

<p style="font:10pt Times New Roman, Times, serif;margin:0pt 0px 0pt 92.7pt;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The
Company&#8217;s issued financial instruments convertible to preferred shares are in the scope of ASC&#160;480. For further details see
Note&#160;7 and Note&#160;8.</span></span></p> </div> </ix:nonNumeric>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.75in">&#160;</p> <ix:nonNumeric id="Fxbrl_20241003121815634" name="slxn:RedeemableNoncontrollingInterestPolicyTextBlock" contextRef="C_20230101to20231231" escape="true">

<div>

<table cellpadding="0" cellspacing="0" style="font:10pt Times New Roman, Times, Serif;margin-top:0pt;margin-bottom:0pt;width:100%">
  <tr style="vertical-align:top;text-align:justify">
    <td style="width:64.25pt">&#160;</td>
    <td style="text-align:left;width:28.45pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>k.</strong></span></span></td>
    <td style="text-align:justify;width:auto"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>Redeemable
        Non-controlling Interest</strong></span></span></td> </tr>
  </table>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.75in">&#160;</p>

<p style="font:10pt Times New Roman, Times, serif;margin:0pt 0px 0pt 92.7pt;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Non-controlling
interests with embedded redemption features, whose settlement is not at the Company&#8217;s discretion, are considered redeemable non-controlling
interest. Redeemable non-controlling interests are considered to be temporary equity and are therefore presented as a mezzanine section
between liabilities and equity on the Company&#8217;s consolidated balance sheets. Redeemable non-controlling interests are measured at
the greater of the initial carrying amount adjusted for the non-controlling interest&#8217;s share of comprehensive income or loss or
its redemption value. Subsequent adjustment of the amount presented in temporary equity is currently not required because the Company&#8217;s
management estimates that it is not probable that the instrument will become redeemable. Adjustments of redeemable non-controlling interest
to its redemption value are recorded through additional paid-in capital.</span></span></p> </div> </ix:nonNumeric>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.75in;text-indent:-24pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>&#160;</strong></span></span></p>
<ix:nonNumeric id="Fxbrl_20241003121845954" name="us-gaap:ResearchAndDevelopmentExpensePolicy" contextRef="C_20230101to20231231" escape="true">

<div>

<table cellpadding="0" cellspacing="0" style="font:10pt Times New Roman, Times, Serif;margin-top:0pt;margin-bottom:0pt;width:100%">
  <tr style="vertical-align:top;text-align:justify">
    <td style="width:64.25pt">&#160;</td>
    <td style="text-align:left;width:28.45pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>l.</strong></span></span></td>
    <td style="text-align:justify;width:auto"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>Research
        and development expenses</strong></span></span></td> </tr>
  </table>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.75in">&#160;</p>

<p style="font:10pt Times New Roman, Times, serif;margin:0pt 0px 0pt 92.7pt;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Research
and development costs are charged to the statements of operations as incurred. Research and development expenses include costs directly
attributable to the conduct of research and development programs, including the cost of payroll and subcontractors, as well as share-based
payments. Advance payments for goods or services that will be used or rendered for future research and development activities are deferred.
Such amounts are recognized as an expense as the related goods are used or the services are rendered.</span></span></p>

<p style="font:10pt Times New Roman, Times, serif;margin:0pt 0px 0pt 92.7pt;text-align:justify">&#160;</p>

<p style="font:10pt Times New Roman, Times, serif;margin:0pt 0px 0pt 92.7pt;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Grants
received from the Israeli Innovation Authority (&#8220;IIA&#8221;) for approved research and development projects are recognized at the
time the Company is entitled to such grants, on the basis of the costs incurred and included as a deduction from research and development
expenses, see Note&#160;5(a). The Company did not receive any grants during 2022 and 2023.</span></span></p> </div> </ix:nonNumeric>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">&#160;</p> <ix:nonNumeric id="Fxbrl_20241003121909842" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" contextRef="C_20230101to20231231" escape="true">

<div>

<table cellpadding="0" cellspacing="0" style="font:10pt Times New Roman, Times, Serif;margin-top:0pt;margin-bottom:0pt;width:100%">
  <tr style="vertical-align:top;text-align:justify">
    <td style="width:64.25pt">&#160;</td>
    <td style="text-align:left;width:28.45pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>m.</strong></span></span></td>
    <td style="text-align:justify;width:auto"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>Share-based
        compensation</strong></span></span></td> </tr>
  </table>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.75in">&#160;</p>

<p style="font:10pt Times New Roman, Times, serif;margin:0pt 0px 0pt 92.7pt;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The
Company&#8217;s employees and non-employees share-based payment awards are classified as equity awards. The Company accounts for these
awards using the grant-date fair value method. The fair value of share-based payment transactions is recognized as an expense over the
requisite service period using the straight-line method.</span></span></p>

<p style="font:10pt Times New Roman, Times, serif;margin:0pt 0px 0pt 92.7pt;text-align:justify">&#160;</p>

<p style="font:10pt Times New Roman, Times, serif;margin:0pt 0px 0pt 92.7pt;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The
Company elected to recognize compensation costs for awards conditioned only on continued service that have a graded vesting schedule using
the straight-line method based on the multiple-option award approach. Forfeitures are recognized as they occur.</span></span></p>

<p style="font:10pt Times New Roman, Times, serif;margin:0pt 0px 0pt 92.7pt;text-align:justify">&#160;</p>

<p style="font:10pt Times New Roman, Times, serif;margin:0pt 0px 0pt 92.7pt;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The
Company accounts for its non-employees&#8217; equity-classified share-based payment in a similar manner.</span></span></p>

<p style="font:10pt Times New Roman, Times, serif;margin:0pt 0px 0pt 92.7pt;text-align:justify">&#160;</p> </div> </ix:nonNumeric>

<div><ix:exclude>

<div style="margin-top:10pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">

<p style="text-align:center;margin-top:0pt;margin-bottom:3pt"><span style="width:34%;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">F-78</span></span></span></p></div><hr style="page-break-after:always;border-width:0px;clear:both;margin:4px 0px;width:100%;height:2px;color:#000000;background-color:#000000;margin-top:0pt;margin-bottom:10pt"/>

<p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:center">&#160;</p>

<p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:center"><strong>S<span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">ILEXION
THERAPEUTICS CORP</span></span></strong><br/><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS (continued)</span></span></p>

<p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">U.S.
DOLLARS IN THOUSANDS</span></span></p>

<p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:center">&#160;</p>

<p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>NOTE
2&#160; - SIGNIFICANT ACCOUNTING POLICIES</strong>&#160;(continued):</span></span></p>

<p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt">&#160;</p> </ix:exclude></div> <ix:nonNumeric id="Fxbrl_20241003121932023" name="us-gaap:LesseeLeasesPolicyTextBlock" contextRef="C_20230101to20231231" escape="true">

<div>

<table cellpadding="0" cellspacing="0" style="font:10pt Times New Roman, Times, Serif;margin-top:0pt;margin-bottom:0pt;width:100%">
  <tr style="vertical-align:top;text-align:justify">
    <td style="width:64.25pt">&#160;</td>
    <td style="text-align:left;width:28.45pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>n.</strong></span></span></td>
    <td style="text-align:justify;width:auto"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>Leases</strong></span></span></td>
        </tr>
  </table>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.75in">&#160;</p>

<p style="font:10pt Times New Roman, Times, serif;margin:0pt 0px 0pt 92.7pt;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The
Company adopted the ASC&#160;842, Leases accounting guidance. The Company recognized new right-of-use assets and operating lease liabilities
of $<ix:nonFraction id="Fixv-39159" name="us-gaap:OperatingLeaseLiability" contextRef="C_20220101" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">391</ix:nonFraction>
as of January&#160;1, 2022. The Company does not have any finance leases.</span></span></p>

<p style="font:10pt Times New Roman, Times, serif;margin:0pt 0px 0pt 92.7pt;text-align:justify">&#160;</p>

<p style="font:10pt Times New Roman, Times, serif;margin:0pt 0px 0pt 92.7pt;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The
Company recognizes operating lease payments in the consolidated statements of operations on a straight-line basis over the lease term.
Right-of-use (&#8220;ROU&#8221;) assets represent the right to use an underlying asset for the lease term and lease liabilities represent
the obligation to make minimum lease payments arising from the lease. ROU assets are initially measured at amounts representing the discounted
present value of the lease payments over the lease, plus any initial direct costs incurred. The lease liability is initially measured
at lease commencement date based on the discounted present value of minimum lease payments over the lease term. The discount rate for
the lease is the rate in the lease unless that rate cannot readily determined. As the Company&#8217;s leases do not provide an implicit
rate, the Company uses an estimated incremental borrowing rate (&#8220;IBR&#8221;) based on the information available at commencement
date in determining the present value of lease payments. The Company&#8217;s IBR is estimated to approximate the interest rate for collateralized
borrowing with similar terms and payments and in economic environments where the leased asset is located. The lease agreement included
an option to extend or terminate the lease. The Company exercised its option to extend the lease period up to July&#160;2025.</span></span></p>

<p style="font:10pt Times New Roman, Times, serif;margin:0pt 0px 0pt 92.7pt;text-align:justify">&#160;</p>

<p style="font:10pt Times New Roman, Times, serif;margin:0pt 0px 0pt 92.7pt;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Payments
under the Company&#8217;s lease arrangements are primarily fixed, however, certain lease agreements contain variable payments, which are
expensed as incurred and not included in the operating lease right-of-use assets and liabilities. The Company elected the practical expedient
not to separate lease and non-lease components.</span></span></p> </div> </ix:nonNumeric>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.75in;text-indent:-24pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>&#160;</strong></span></span></p>
<ix:nonNumeric id="Fxbrl_20241003122016949" name="us-gaap:EarningsPerSharePolicyTextBlock" contextRef="C_20230101to20231231" escape="true">

<div>

<table cellpadding="0" cellspacing="0" style="font:10pt Times New Roman, Times, Serif;margin-top:0pt;margin-bottom:0pt;width:100%">
  <tr style="vertical-align:top;text-align:justify">
    <td style="width:64.25pt">&#160;</td>
    <td style="text-align:left;width:28.45pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>o.</strong></span></span></td>
    <td style="text-align:justify;width:auto"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>Loss
        per share</strong></span></span></td> </tr>
  </table>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.75in">&#160;</p>

<p style="font:10pt Times New Roman, Times, serif;margin:0pt 0px 0pt 92.7pt;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The
Company calculates loss per share using the two-class method required for participating securities. This method entails allocating income
available to ordinary shareholders for the period between ordinary shares and participating securities based on their respective rights
to receive dividends as if all income for the period had been distributed. Basic loss per share is computed by dividing net loss by the
weighted average number of shares of Ordinary shares outstanding during the year, and fully vested pre-funded options for the Company's
Ordinary shares at an exercise price of $<ix:nonFraction id="Fxbrl_20241206144755033" name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="C_20231231_usgaapAwardTypeAxis_slxnOptionPreFundedMember" unitRef="usdPershares" scale="0" decimals="3" format="ixt:num-dot-decimal">0.027</ix:nonFraction>
or <ix:nonFraction id="Fxbrl_20241206144804593" name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="C_20231231_usgaapAwardTypeAxis_slxnOptionPreFundedMember" unitRef="ilsPershares" scale="0" decimals="4" format="ixt:num-dot-decimal">0.0063</ix:nonFraction>
NIS per share. The Company considers these shares to be exercised for little to no additional consideration. The Company also considers
its redeemable convertible preferred shares to be participating securities, as the holders of the redeemable convertible preferred shares
would be entitled to dividends that would be distributed to the holders of ordinary shares, on a pro-rata basis assuming conversion of
all redeemable convertible preferred shares into ordinary shares. However, these participating securities do not contractually require
the holders to participate in the Company's losses. Consequently, net loss for the periods presented was not allocated to the Company's
participating securities.</span></span></p> </div> </ix:nonNumeric>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">&#160;</p> <ix:nonNumeric id="Fxbrl_20241003122036976" name="us-gaap:IncomeTaxPolicyTextBlock" contextRef="C_20230101to20231231" escape="true">

<div>

<table cellpadding="0" cellspacing="0" style="font:10pt Times New Roman, Times, Serif;margin-top:0pt;margin-bottom:0pt;width:100%">
  <tr style="vertical-align:top;text-align:justify">
    <td style="width:64.25pt">&#160;</td>
    <td style="text-align:left;width:28.45pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>p.</strong></span></span></td>
    <td style="text-align:justify;width:auto"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>Income
        taxes:</strong></span></span></td> </tr>
  </table>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in;text-indent:-24pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font:10pt Times New Roman, Times, Serif;margin-top:0pt;margin-bottom:0pt;width:100%">
  <tr style="vertical-align:top;text-align:justify">
    <td style="width:92.7pt">&#160;</td>
    <td style="text-align:left;width:17.3pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">1)</span></span></td>
    <td style="text-align:justify;width:auto"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Deferred taxes</span></span></td>
        </tr>
  </table>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in">&#160;</p>

<p style="font:10pt Times New Roman, Times, serif;margin:0pt 0px 0pt 110pt;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Income
taxes are computed using the asset and liability method. Under the asset and liability method, deferred income tax assets and liabilities
are determined based on the differences between the financial reporting and tax bases of assets and liabilities and are measured using
the currently enacted tax rates and laws. A valuation allowance is recognized to the extent that it is more likely than not that the deferred
taxes will not be realized in the foreseeable future. Given the Company&#8217;s losses, the Company has provided a full valuation allowance
with respect to its deferred tax assets.</span></span></p>

<p style="font:10pt Times New Roman, Times, serif;margin:0pt 0px 0pt 1in;text-align:justify">&#160;</p>

<div><ix:exclude>

<div style="margin-top:10pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">

<p style="text-align:center;margin-top:0pt;margin-bottom:3pt"><span style="width:34%;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">F-79</span></span></span></p></div><hr style="page-break-after:always;border-width:0px;clear:both;margin:4px 0px;width:100%;height:2px;color:#000000;background-color:#000000;margin-top:0pt;margin-bottom:10pt"/>

<p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:center">&#160;</p>

<p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:center"><strong>S<span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">ILEXION
THERAPEUTICS CORP</span></span></strong><br/><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS (continued)</span></span></p>

<p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">U.S.
DOLLARS IN THOUSANDS</span></span></p>

<p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:center">&#160;</p>

<p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>NOTE
2&#160; -&#160;SIGNIFICANT ACCOUNTING POLICIES</strong>&#160;(continued):</span></span></p>

<p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt">&#160;</p> </ix:exclude></div>

<table cellpadding="0" cellspacing="0" style="font:10pt Times New Roman, Times, Serif;margin-top:0pt;margin-bottom:0pt;width:100%">
  <tr style="vertical-align:top;text-align:justify">
    <td style="width:92.7pt">&#160;</td>
    <td style="text-align:left;width:17.3pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2)</span></span></td>
    <td style="text-align:justify;width:auto"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Uncertainty in
        income tax</span></span></td> </tr>
  </table>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in">&#160;</p>

<p style="font:10pt Times New Roman, Times, serif;margin:0pt 0px 0pt 110pt;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The
Company follows a two-step approach in recognizing and measuring uncertain tax positions. The first step is to evaluate the tax position
for recognition by determining if the available evidence indicates that it is more likely than not that the tax position will be sustained
upon examination, including resolution of any related appeals or litigation processes, based on the technical merits of the position.
If this threshold is met, the second step is to measure the tax position as the largest amount that has more than a 50% likelihood of
being realized upon ultimate settlement.</span></span></p> </div> </ix:nonNumeric>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.75in;text-indent:-24pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>&#160;</strong></span></span></p>
<ix:nonNumeric id="Fxbrl_20241003122054801" name="us-gaap:ConcentrationRiskCreditRisk" contextRef="C_20230101to20231231" escape="true">

<div>

<table cellpadding="0" cellspacing="0" style="font:10pt Times New Roman, Times, Serif;margin-top:0pt;margin-bottom:0pt;width:100%">
  <tr style="vertical-align:top;text-align:justify">
    <td style="width:64.25pt">&#160;</td>
    <td style="text-align:left;width:28.46pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>q.</strong></span></span></td>
    <td style="text-align:justify;width:auto"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>Concentration
        of credit risks</strong></span></span></td> </tr>
  </table>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.75in">&#160;</p>

<p style="font:10pt Times New Roman, Times, serif;margin:0pt 0px 0pt 92.7pt;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Financial
instruments that potentially subject the Company to concentration of credit risk consist principally of cash and cash equivalents, restricted
cash and short-term deposits. The Company deposits cash and cash equivalents mostly with three low risk financial institution. The Company
has not experienced any material credit losses in these accounts and does not believe it is exposed to significant credit risk on these
instruments.</span></span></p> </div> </ix:nonNumeric>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.75in;text-indent:-24pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>&#160;</strong></span></span></p>
<ix:nonNumeric id="Fxbrl_20241003122121074" name="us-gaap:SegmentReportingPolicyPolicyTextBlock" contextRef="C_20230101to20231231" escape="true">

<div>

<table cellpadding="0" cellspacing="0" style="font:10pt Times New Roman, Times, Serif;margin-top:0pt;margin-bottom:0pt;width:100%">
  <tr style="vertical-align:top;text-align:justify">
    <td style="width:64.25pt">&#160;</td>
    <td style="text-align:left;width:28.45pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>r.</strong></span></span></td>
    <td style="text-align:justify;width:auto"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>Operating
        segments and geographical information:</strong></span></span></td> </tr>
  </table>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.75in">&#160;</p>

<p style="font:10pt Times New Roman, Times, serif;margin:0pt 0px 0pt 92.7pt;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The
Company is managed as one R&amp;D department during its startup phase that has yet to earn revenues. The Company&#8217;s Chief Executive
Office (&#8220;CEO&#8221;) was identified as the chief operating decision maker (&#8220;CODM&#8221;). The CODM reviews the financial information
every quarter. Accordingly, the company had determined to operate under one reportable&#160;segment.</span></span></p>

<p style="font:10pt Times New Roman, Times, serif;margin:0pt 0px 0pt 92.7pt">&#160;</p>

<p style="font:10pt Times New Roman, Times, serif;margin:0pt 0px 0pt 92.7pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">All
of the Company long-lived assets are located in Israel.</span></span></p> </div> </ix:nonNumeric>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.75in;text-indent:-24pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>&#160;</strong></span></span></p>
<ix:nonNumeric id="Fxbrl_20241003122151287" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" contextRef="C_20230101to20231231" escape="true">

<div>

<table cellpadding="0" cellspacing="0" style="font:10pt Times New Roman, Times, Serif;margin-top:0pt;margin-bottom:0pt;width:100%">
  <tr style="vertical-align:top;text-align:justify">
    <td style="width:64.25pt">&#160;</td>
    <td style="text-align:left;width:28.45pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>s.</strong></span></span></td>
    <td style="text-align:justify;width:auto"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>New accounting
        pronouncements:</strong></span></span></td> </tr>
  </table>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.75in">&#160;</p>

<p style="font:10pt Times New Roman, Times, serif;margin:0pt 0px 0pt 92.7pt;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The
Company qualifies as an emerging growth company (&#8220;EGC&#8221;) as defined under the Jumpstart Our Business Startups Act (the &#8220;JOBS
Act&#8221;). Using exemptions provided under the JOBS Act for EGCs, the Company has elected to defer compliance with new or revised ASUs
until it is required to comply with such updates, which is generally consistent with the adoption dates of private companies.</span></span></p>

<p style="font:10pt Times New Roman, Times, serif;margin:0pt 0px 0pt 92.7pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><i>&#160;</i></span></span></p>

<p style="font:10pt Times New Roman, Times, serif;margin:0pt 0px 0pt 92.7pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><i><span style="text-decoration:underline">Recently
Adopted accounting pronouncements:</span></i></span></span></p>

<p style="font:10pt Times New Roman, Times, serif;margin:0pt 0px 0pt 92.7pt">&#160;</p>

<p style="font:10pt Times New Roman, Times, serif;margin:0pt 0px 0pt 92.7pt;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">In
June&#160;2016, the FASB issued ASU&#160;2016-13, &#8220;Financial Instruments&#160;-&#160;Credit Losses (Topic&#160;326): Measurement
of Credit Losses on Financial Instruments&#8221;, which replaces the existing incurred loss model with a current expected credit loss
(&#8220;CECL&#8221;) model that requires consideration of a broader range of reasonable and supportable information to inform credit loss
estimates. Subsequent to the issuance of ASU&#160;2016-13, the FASB issued several additional Accounting Standard Updates to clarify implementation
guidance, provide narrow-scope improvements and provide additional disclosure guidance. Under the ASU, the Company is required to use
a forward-looking CECL model for accounts receivables and other financial instruments. The Company adopted the ASU on January&#160;1,
2023 and it did not have a material impact on its consolidated financial statement.</span></span></p>

<p style="font:10pt Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt">&#160;</p>

<p style="font:10pt Times New Roman, Times, serif;margin:0pt 0px 0pt 92.7pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong><span style="text-decoration:underline">Recently
issued accounting standards not yet adopted:</span></strong></span></span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 1in;text-indent:-24pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font:10pt Times New Roman, Times, Serif;margin-top:0pt;margin-bottom:0pt;width:100%">
  <tr style="vertical-align:top;text-align:justify">
    <td style="width:92.7pt">&#160;</td>
    <td style="text-align:left;width:18pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">1)</span></span></td>
    <td style="width:auto">
        <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">In
        June 2022, the FASB issued ASU 2022-03 &#8220;Fair Value Measurement of Equity Securities Subject to Contractual Sale Restrictions&#8221;.
        The ASU clarifies that a contractual restriction on the sale of an equity security is not considered part of the unit of account of the
        equity security and, therefore, is not considered in measuring</span></span></p>
        <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt">&#160;</p> </td> </tr>
  </table>

<div><ix:exclude>

<div style="margin-top:10pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">

<p style="text-align:center;margin-top:0pt;margin-bottom:3pt"><span style="width:34%;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">F-80</span></span></span></p></div><hr style="page-break-after:always;border-width:0px;clear:both;margin:4px 0px;width:100%;height:2px;color:#000000;background-color:#000000;margin-top:0pt;margin-bottom:10pt"/>

<p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:center">&#160;</p>

<p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:center"><strong>S<span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">ILEXION
THERAPEUTICS CORP</span></span></strong><br/><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS (continued)</span></span></p>

<p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">U.S.
DOLLARS IN THOUSANDS</span></span></p>

<p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:center">&#160;</p>

<p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>NOTE
2&#160; - SIGNIFICANT ACCOUNTING POLICIES</strong>&#160;(continued):</span></span></p>

<p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt">&#160;</p> </ix:exclude></div>

<table cellpadding="0" cellspacing="0" style="font:10pt Times New Roman, Times, Serif;margin-top:0pt;margin-bottom:0pt;width:100%">
  <tr style="vertical-align:top;text-align:justify">
    <td style="width:92.7pt">&#160;</td>
    <td style="width:18pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2)</span></span></td>
    <td style="width:auto">
        <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">its
        fair value. The ASU also clarifies that an entity cannot, as a separate unit of account, recognize and measure a contractual sale restriction.
        The ASU also introduces new disclosure requirements for equity securities subject to contractual sale restrictions. As an Emerging Growth
        Company, the ASU is effective for fiscal years beginning after December 15, 2024, and interim periods within those fiscal years. Early
        adoption is permitted for both interim and annual financial statements that have not yet been issued or made available for issuance. The
        Company is currently evaluating the effect that ASU 2022-03 will have on its consolidated financial statements and related disclosures.</span></span></p>
        </td> </tr>
  </table>

<p style="font:10pt Times New Roman, Times, serif;margin:0pt 0px 0pt 1in;text-indent:-24pt;text-align:justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font:10pt Times New Roman, Times, Serif;margin-top:0pt;margin-bottom:0pt;width:100%">
  <tr style="vertical-align:top;text-align:justify">
    <td style="width:92.7pt">&#160;</td>
    <td style="width:18pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">3)</span></span></td>
    <td style="width:auto">
        <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">In
        November 2023, the FASB issued ASU No. 2023-07 Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures. The ASU
        improves reportable segments disclosure requirements, primarily through enhanced disclosures about significant segment expenses. &#160;The
        ASU also require that a public entity that has a single reportable segment to provide all the disclosures required by the amendments and
        all existing segment disclosures in Topic 280. The ASU is effective for fiscal years beginning after December 15, 2023, and interim periods
        within fiscal years beginning after December 15, 2024. The Company is currently evaluating this ASU to determine its impact on the Company's
        segment disclosures.</span></span></p> </td> </tr>
  <tr>
    <td style="width:92.7pt">&#160;</td>
    <td style="width:18pt">&#160;</td>
    <td style="width:auto">&#160;</td> </tr>
  <tr>
    <td style="width:92.7pt">&#160;</td>
    <td style="width:18pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">4)</span></span></td>
    <td style="width:auto">
        <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">In
        December, 2023, the FASB issued ASU 2023-09, Improvements to Income Tax Disclosures, which requires disclosure of disaggregated income
        taxes paid, prescribes standard categories for the components of the effective tax rate reconciliation, and modifies other income tax-related
        disclosures. The ASU will be effective for fiscal years beginning after December 15, 2025, and allows adoption on a prospective basis,
        with a retrospective option. The Company is in the process of assessing the impacts and method of adoption.</span></span></p> </td> </tr>
  </table> </div> </ix:nonNumeric> </div> </ix:nonNumeric>

<div style="font-size:10pt;margin-top:0pt;margin-bottom:0pt;font-family:'Times New Roman', Times, serif">&#160;</div>

<div style="margin-top:10pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">

<p style="text-align:center;margin-top:0pt;margin-bottom:3pt"><span style="width:34%;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">F-81</span></span></span></p></div><hr style="page-break-after:always;border-width:0px;clear:both;margin:4px 0px;width:100%;height:2px;color:#000000;background-color:#000000;margin-top:0pt;margin-bottom:10pt"/>

<p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:center">&#160;</p>

<p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:center"><strong>S<span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">ILEXION
THERAPEUTICS CORP</span></span></strong><br/><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS (continued)</span></span></p>

<p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">U.S.
DOLLARS IN THOUSANDS</span></span></p>

<p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:center">&#160;</p>

<div style="font:10pt Times New Roman, Times, Serif"> <ix:nonNumeric id="Fixv-33153" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" contextRef="C_20230101to20231231" escape="true">

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0"><strong>NOTE 3&#160; - PROPERTY AND EQUIPMENT, NET:</strong></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in">&#160;</p>

<p style="font:10pt Times New Roman, Times, serif;margin:0pt 0px 0pt 49.65pt">Composition of property and equipment, grouped by major
classifications, is as follows:</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in">&#160;</p> <ix:nonNumeric id="Fxbrl_20241003035115303" name="us-gaap:PropertyPlantAndEquipmentTextBlock" contextRef="C_20230101to20231231" escape="true">

<div style="margin-left:54pt">

<table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width:85%;font:10pt Times New Roman, Times, Serif">
  <tr style="vertical-align:bottom">
    <td>&#160;</td>
    <td style="font-weight:bold;padding-bottom:1.5pt">&#160;</td>
    <td colspan="6" style="font-weight:bold;text-align:center;border-bottom:Black 1.5pt solid">December&#160;31</td>
    <td style="padding-bottom:1.5pt;font-weight:bold">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td>&#160;</td>
    <td style="font-weight:bold;padding-bottom:1.5pt">&#160;</td>
    <td colspan="2" style="font-weight:bold;text-align:center;border-bottom:Black 1.5pt solid">2023</td>
    <td style="padding-bottom:1.5pt;font-weight:bold">&#160;</td>
    <td style="font-weight:bold;padding-bottom:1.5pt">&#160;</td>
    <td colspan="2" style="font-weight:bold;text-align:center;border-bottom:Black 1.5pt solid">2022</td>
    <td style="padding-bottom:1.5pt;font-weight:bold">&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="width:76%;font-weight:bold">Cost:</td>
    <td style="width:1%">&#160;</td>
    <td style="width:1%;text-align:left">&#160;</td>
    <td style="width:9%;text-align:right">&#160;</td>
    <td style="width:1%;text-align:left">&#160;</td>
    <td style="width:1%">&#160;</td>
    <td style="width:1%;text-align:left">&#160;</td>
    <td style="width:9%;text-align:right">&#160;</td>
    <td style="width:1%;text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="padding-left:0.145in">Computers</td>
    <td>&#160;</td>
    <td style="text-align:left">
        <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt">$</p> </td>
    <td style="text-align:right">
        <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><ix:nonFraction id="Fxbrl_20241206163512992_ixv-39163" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="C_20231231_usgaapPropertyPlantAndEquipmentByTypeAxis_slxnCostMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">75</ix:nonFraction></p>
        </td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">
        <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt">$</p> </td>
    <td style="text-align:right">
        <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><ix:nonFraction id="Fxbrl_20241206163512992_ixv-39164" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="C_20221231_usgaapPropertyPlantAndEquipmentByTypeAxis_slxnCostMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">67</ix:nonFraction></p>
        </td>
    <td style="text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="padding-left:0.145in;text-align:left">Laboratory and electronic equipment</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right"><ix:nonFraction id="Fxbrl_20241004175308131" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="C_20231231_usgaapPropertyPlantAndEquipmentByTypeAxis_slxnLaboratoryAndElectronicEquipmentMember" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right"><ix:nonFraction id="Fixv-39165" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="C_20221231_usgaapPropertyPlantAndEquipmentByTypeAxis_slxnLaboratoryAndElectronicEquipmentMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">274</ix:nonFraction></td>
    <td style="text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="padding-left:0.145in;text-align:left">Office furniture</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right"><ix:nonFraction id="Fixv-39166" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="C_20231231_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapOfficeEquipmentMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">2</ix:nonFraction></td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right"><ix:nonFraction id="Fixv-39167" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="C_20221231_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapOfficeEquipmentMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">2</ix:nonFraction></td>
    <td style="text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="padding-left:0.145in;text-align:left">Communication equipment</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right"><ix:nonFraction id="Fixv-39168" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="C_20231231_usgaapPropertyPlantAndEquipmentByTypeAxis_slxnCommunicationEquipmentMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">3</ix:nonFraction></td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right"><ix:nonFraction id="Fixv-39169" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="C_20221231_usgaapPropertyPlantAndEquipmentByTypeAxis_slxnCommunicationEquipmentMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">3</ix:nonFraction></td>
    <td style="text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="padding-left:0.145in;text-align:left;padding-bottom:1.5pt">Leasehold improvements</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right"><ix:nonFraction id="Fixv-39170" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="C_20231231_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapLeaseholdImprovementsMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">56</ix:nonFraction></td>
    <td style="padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right"><ix:nonFraction id="Fixv-39171" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="C_20221231_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapLeaseholdImprovementsMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">52</ix:nonFraction></td>
    <td style="padding-bottom:1.5pt;text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="padding-bottom:4pt">&#160;</td>
    <td style="padding-bottom:4pt">&#160;</td>
    <td style="text-align:left;border-bottom:1.5pt solid black">$</td>
    <td style="text-align:right;border-bottom:1.5pt solid black"><ix:nonFraction id="Fixv-39172" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">136</ix:nonFraction></td>
    <td style="padding-bottom:4pt;text-align:left">&#160;</td>
    <td style="padding-bottom:4pt">&#160;</td>
    <td style="text-align:left;border-bottom:1.5pt solid black">$</td>
    <td style="text-align:right;border-bottom:1.5pt solid black"><ix:nonFraction id="Fixv-39173" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">398</ix:nonFraction></td>
    <td style="padding-bottom:4pt;text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="font-weight:bold;text-align:left">Accumulated depreciation:</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">&#160;</td>
    <td style="text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td>Computers</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right"><ix:nonFraction id="Fixv-39174" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" contextRef="C_20231231_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapComputerEquipmentMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">55</ix:nonFraction></td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right"><ix:nonFraction id="Fixv-39175" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" contextRef="C_20221231_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapComputerEquipmentMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">41</ix:nonFraction></td>
    <td style="text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="padding-left:0.125in;text-align:left">Laboratory and electronic equipment</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right"><ix:nonFraction id="Fxbrl_20241004175326636" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" contextRef="C_20231231_usgaapPropertyPlantAndEquipmentByTypeAxis_slxnLaboratoryAndElectronicEquipmentMember" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right"><ix:nonFraction id="Fixv-39176" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" contextRef="C_20221231_usgaapPropertyPlantAndEquipmentByTypeAxis_slxnLaboratoryAndElectronicEquipmentMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">179</ix:nonFraction></td>
    <td style="text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="padding-left:0.125in;text-align:left">Office furniture</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right"><ix:nonFraction id="Fixv-39177" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" contextRef="C_20231231_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapOfficeEquipmentMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">2</ix:nonFraction></td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right"><ix:nonFraction id="Fixv-39178" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" contextRef="C_20221231_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapOfficeEquipmentMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1</ix:nonFraction></td>
    <td style="text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="padding-left:0.125in;text-align:left">Communication equipment</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right"><ix:nonFraction id="Fixv-39179" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" contextRef="C_20231231_usgaapPropertyPlantAndEquipmentByTypeAxis_slxnCommunicationEquipmentMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">3</ix:nonFraction></td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right"><ix:nonFraction id="Fixv-39180" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" contextRef="C_20221231_usgaapPropertyPlantAndEquipmentByTypeAxis_slxnCommunicationEquipmentMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">3</ix:nonFraction></td>
    <td style="text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="padding-left:0.125in;text-align:left;padding-bottom:1.5pt">Leasehold improvements</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right"><ix:nonFraction id="Fixv-39181" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" contextRef="C_20231231_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapLeaseholdImprovementsMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">27</ix:nonFraction></td>
    <td style="padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right"><ix:nonFraction id="Fixv-39182" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" contextRef="C_20221231_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapLeaseholdImprovementsMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">15</ix:nonFraction></td>
    <td style="padding-bottom:1.5pt;text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">$</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right"><ix:nonFraction id="Fixv-39183" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">87</ix:nonFraction></td>
    <td style="padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">$</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right"><ix:nonFraction id="Fixv-39184" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">239</ix:nonFraction></td>
    <td style="padding-bottom:1.5pt;text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="padding-left:0.125in;text-align:left;padding-bottom:4pt">Property and equipment, net</td>
    <td style="padding-bottom:4pt">&#160;</td>
    <td style="text-align:left;border-bottom:4px double black">$</td>
    <td style="text-align:right;border-bottom:4px double black"><ix:nonFraction id="Fixv-39185" name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">49</ix:nonFraction></td>
    <td style="padding-bottom:4pt;text-align:left">&#160;</td>
    <td style="padding-bottom:4pt">&#160;</td>
    <td style="text-align:left;border-bottom:4px double black">$</td>
    <td style="text-align:right;border-bottom:4px double black"><ix:nonFraction id="Fixv-39186" name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">159</ix:nonFraction></td>
    <td style="padding-bottom:4pt;text-align:left">&#160;</td> </tr>
  </table> </div> </ix:nonNumeric>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in">&#160;</p>

<p style="font:10pt Times New Roman, Times, serif;margin:0pt 0px 0pt 49.65pt">Depreciation expenses were $<ix:nonFraction id="Fixv-39187" name="us-gaap:Depreciation" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">45</ix:nonFraction>
and $<ix:nonFraction id="Fixv-39188" name="us-gaap:Depreciation" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">57</ix:nonFraction>
in the&#160;years ended December&#160;31, 2023 and 2022, respectively.</p> </ix:nonNumeric>

<p style="font:10pt Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt">&#160;</p> </div>

<div style="font:10pt Times New Roman, Times, Serif"> <ix:nonNumeric id="Fixv-33352" name="us-gaap:LesseeOperatingLeasesTextBlock" contextRef="C_20230101to20231231" escape="true">

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><strong>NOTE
4&#160; - LEASES:</strong></span></span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in">&#160;</p>

<p style="font:10pt Times New Roman, Times, serif;margin:0pt 0px 0pt 49.65pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">The
Company leases offices for its facilities in Israel by way of an operating lease. The lease agreement for such offices is denominated
in NIS and linked to the Israeli consumer price index (&#8220;CPI&#8221;).</span></span></p>

<p style="font:10pt Times New Roman, Times, serif;margin:0pt 0px 0pt 49.65pt">&#160;</p>

<p style="font:10pt Times New Roman, Times, serif;margin:0pt 0px 0pt 49.65pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">The
Company provided the lessor with a bank guarantee as a rental security. The bank in turn placed a pledge over restricted cash of $<ix:nonFraction id="Fixv-39189" name="us-gaap:RestrictedCashCurrent" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">25</ix:nonFraction>.</span></span></p>

<p style="font:10pt Times New Roman, Times, serif;margin:0pt 0px 0pt 49.65pt">&#160;</p>

<p style="font:10pt Times New Roman, Times, serif;margin:0pt 0px 0pt 49.65pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">The
lease for the offices expires on July&#160;31, 2025. The remaining lease term is up to <ix:nonNumeric id="Fixv-39190" name="us-gaap:LesseeOperatingLeaseRemainingLeaseTerm" contextRef="C_20231231" format="ixt-sec:duryear">1.58</ix:nonNumeric>&#160;years
as of December&#160;31, 2023.</span></span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in">&#160;</p> <ix:nonNumeric id="Fxbrl_20241003040442835" name="us-gaap:LeaseCostTableTextBlock" contextRef="C_20230101to20231231" escape="true">

<div>

<p style="font:10pt Times New Roman, Times, serif;margin:0pt 0px 0pt 49.65pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">Operating
lease costs for the&#160;years ended December&#160;31, 2022 and 2023 are as follows:</span></span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in">&#160;</p>

<div style="margin-left:54pt">

<table cellpadding="0" cellspacing="0" style="border-collapse:collapse;font:10pt Times New Roman, Times, serif;width:85%">
  <tr style="vertical-align:bottom">
    <td>&#160;</td>
    <td style="font-weight:bold;padding-bottom:1.5pt">&#160;</td>
    <td colspan="6" style="font-weight:bold;text-align:center;border-bottom:Black 1.5pt solid"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">Year
        Ended&#160;December&#160;31,</span></span></td>
    <td style="padding-bottom:1.5pt;font-weight:bold">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td>&#160;</td>
    <td style="font-weight:bold;padding-bottom:1.5pt">&#160;</td>
    <td colspan="2" style="font-weight:bold;text-align:center;border-bottom:Black 1.5pt solid"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">2023</span></span></td>
    <td style="padding-bottom:1.5pt;font-weight:bold">&#160;</td>
    <td style="font-weight:bold;padding-bottom:1.5pt">&#160;</td>
    <td colspan="2" style="font-weight:bold;text-align:center;border-bottom:Black 1.5pt solid"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">2022</span></span></td>
    <td style="padding-bottom:1.5pt;font-weight:bold">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">Fixed payments and variable payments that depend on
        an index or rate:</span></span></td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="width:76%;text-align:left;text-indent:-10pt;padding-left:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">Office
        and operational lease expenses</span></span></td>
    <td style="width:1%">&#160;</td>
    <td style="width:1%;text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">$</span></span></td>
    <td style="width:9%;text-align:right"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><ix:nonFraction id="Fixv-39191" name="us-gaap:OperatingLeaseExpense" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">131</ix:nonFraction></span></span></td>
    <td style="width:1%;text-align:left">&#160;</td>
    <td style="width:1%">&#160;</td>
    <td style="width:1%;text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">$</span></span></td>
    <td style="width:9%;text-align:right"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><ix:nonFraction id="Fixv-39192" name="us-gaap:OperatingLeaseExpense" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">132</ix:nonFraction></span></span></td>
    <td style="width:1%;text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="text-align:left;padding-bottom:1.5pt;text-indent:-10pt;padding-left:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">Variable
        lease cost (included in the operating lease costs)</span></span></td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">$</span></span></td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><ix:nonFraction id="Fixv-39193" name="us-gaap:VariableLeaseCost" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">9</ix:nonFraction></span></span></td>
    <td style="padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">$</span></span></td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><ix:nonFraction id="Fixv-39194" name="us-gaap:VariableLeaseCost" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">3</ix:nonFraction></span></span></td>
    <td style="padding-bottom:1.5pt;text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="text-align:left;padding-bottom:4pt;text-indent:-10pt;padding-left:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">Total
        operating lease costs</span></span></td>
    <td style="padding-bottom:4pt">&#160;</td>
    <td style="text-align:left;border-bottom:4px double black"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">$</span></span></td>
    <td style="text-align:right;border-bottom:4px double black"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><ix:nonFraction id="Fixv-39195" name="us-gaap:OperatingLeaseCost" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">140</ix:nonFraction></span></span></td>
    <td style="padding-bottom:4pt;text-align:left">&#160;</td>
    <td style="padding-bottom:4pt">&#160;</td>
    <td style="text-align:left;border-bottom:4px double black"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">$</span></span></td>
    <td style="text-align:right;border-bottom:4px double black"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><ix:nonFraction id="Fixv-39196" name="us-gaap:OperatingLeaseCost" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">135</ix:nonFraction></span></span></td>
    <td style="padding-bottom:4pt;text-align:left">&#160;</td> </tr>
  </table> </div>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in">&#160;</p>

<p style="font:10pt Times New Roman, Times, serif;margin:0pt 0px 0pt 49.65pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">Operating
cash flows, for amounts included in the measurement of lease liabilities, are as follows:</span></span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in">&#160;</p>

<div style="margin-left:54pt">

<table cellpadding="0" cellspacing="0" style="border-collapse:collapse;font:10pt Times New Roman, Times, serif;width:85%">
  <tr style="vertical-align:bottom">
    <td>&#160;</td>
    <td style="font-weight:bold;padding-bottom:1.5pt">&#160;</td>
    <td colspan="6" style="font-weight:bold;text-align:center;border-bottom:Black 1.5pt solid"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">Year
        Ended&#160;December&#160;31,</span></span></td>
    <td style="padding-bottom:1.5pt;font-weight:bold">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td>&#160;</td>
    <td style="font-weight:bold;padding-bottom:1.5pt">&#160;</td>
    <td colspan="2" style="font-weight:bold;text-align:center;border-bottom:Black 1.5pt solid"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">2023</span></span></td>
    <td style="padding-bottom:1.5pt;font-weight:bold">&#160;</td>
    <td style="font-weight:bold;padding-bottom:1.5pt">&#160;</td>
    <td colspan="2" style="font-weight:bold;text-align:center;border-bottom:Black 1.5pt solid"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">2022</span></span></td>
    <td style="padding-bottom:1.5pt;font-weight:bold">&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="width:76%;text-align:left;padding-bottom:4pt;text-indent:-10pt;padding-left:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">Office
        and operational spaces lease expenses</span></span></td>
    <td style="width:1%;padding-bottom:4pt">&#160;</td>
    <td style="width:1%;text-align:left;border-bottom:4px double black"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">$</span></span></td>
    <td style="width:9%;text-align:right;border-bottom:4px double black"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><ix:nonFraction id="Fixv-39198" name="us-gaap:LeaseAndRentalExpense" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">101</ix:nonFraction></span></span></td>
    <td style="width:1%;padding-bottom:4pt;text-align:left">&#160;</td>
    <td style="width:1%;padding-bottom:4pt">&#160;</td>
    <td style="width:1%;text-align:left;border-bottom:4px double black"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">$</span></span></td>
    <td style="width:9%;text-align:right;border-bottom:4px double black"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><ix:nonFraction id="Fixv-39199" name="us-gaap:LeaseAndRentalExpense" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">119</ix:nonFraction></span></span></td>
    <td style="width:1%;padding-bottom:4pt;text-align:left">&#160;</td> </tr>
  </table> </div>

<div style="font-size:10pt;margin-top:0pt;margin-bottom:0pt;font-family:'Times New Roman', Times, serif">&#160;</div>

<div><ix:exclude>

<div style="margin-top:10pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">

<p style="text-align:center;margin-top:0pt;margin-bottom:3pt"><span style="width:34%;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">F-82</span></span></span></p></div><hr style="page-break-after:always;border-width:0px;clear:both;margin:4px 0px;width:100%;height:2px;color:#000000;background-color:#000000;margin-top:0pt;margin-bottom:10pt"/>

<p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:center">&#160;</p>

<p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:center"><strong>S<span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">ILEXION
THERAPEUTICS CORP</span></span></strong><br/><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS (continued)</span></span></p>

<p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">U.S.
DOLLARS IN THOUSANDS</span></span></p>

<p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:center">&#160;</p>

<p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><strong><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">NOTE
4 &#160;- LEASES</span></span></strong><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"> (continued):</span></span></p>

<p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt">&#160;</p> </ix:exclude></div>

<p style="font:10pt Times New Roman, Times, serif;margin:0pt 0px 0pt 49.65pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">Supplemental
information related to operating leases is as follows:</span></span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in">&#160;</p>

<div style="margin-left:54pt">

<table cellpadding="0" cellspacing="0" style="border-collapse:collapse;font:10pt Times New Roman, Times, serif;width:85%">
  <tr style="vertical-align:bottom">
    <td>&#160;</td>
    <td style="font-weight:bold;padding-bottom:1.5pt">&#160;</td>
    <td colspan="6" style="font-weight:bold;text-align:center;border-bottom:Black 1.5pt solid"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">Year
        Ended&#160;December&#160;31,</span></span></td>
    <td style="padding-bottom:1.5pt;font-weight:bold">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td>&#160;</td>
    <td style="font-weight:bold;padding-bottom:1.5pt">&#160;</td>
    <td colspan="2" style="font-weight:bold;text-align:center;border-bottom:Black 1.5pt solid"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">2023</span></span></td>
    <td style="padding-bottom:1.5pt;font-weight:bold">&#160;</td>
    <td style="font-weight:bold;padding-bottom:1.5pt">&#160;</td>
    <td colspan="2" style="font-weight:bold;text-align:center;border-bottom:Black 1.5pt solid"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">2022</span></span></td>
    <td style="padding-bottom:1.5pt;font-weight:bold">&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="width:76%;text-align:left;padding-bottom:4pt;text-indent:-10pt;padding-left:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">Operating
        lease right-of-use assets</span></span></td>
    <td style="width:1%;padding-bottom:4pt">&#160;</td>
    <td style="width:1%;text-align:left;border-bottom:4px double black"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">$</span></span></td>
    <td style="width:9%;text-align:right;border-bottom:4px double black"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><ix:nonFraction id="Fixv-39201" name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">198</ix:nonFraction></span></span></td>
    <td style="width:1%;padding-bottom:4pt;text-align:left">&#160;</td>
    <td style="width:1%;padding-bottom:4pt">&#160;</td>
    <td style="width:1%;text-align:left;border-bottom:4px double black"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">$</span></span></td>
    <td style="width:9%;text-align:right;border-bottom:4px double black"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><ix:nonFraction id="Fixv-39202" name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">305</ix:nonFraction></span></span></td>
    <td style="width:1%;padding-bottom:4pt;text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="text-align:left;padding-bottom:4pt;text-indent:-10pt;padding-left:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">Operating
        lease liabilities</span></span></td>
    <td style="padding-bottom:4pt">&#160;</td>
    <td style="text-align:left;border-bottom:4px double black"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">$</span></span></td>
    <td style="text-align:right;border-bottom:4px double black"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><ix:nonFraction id="Fixv-39203" name="us-gaap:OperatingLeaseLiability" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">171</ix:nonFraction></span></span></td>
    <td style="padding-bottom:4pt;text-align:left">&#160;</td>
    <td style="padding-bottom:4pt">&#160;</td>
    <td style="text-align:left;border-bottom:4px double black"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">$</span></span></td>
    <td style="text-align:right;border-bottom:4px double black"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><ix:nonFraction id="Fixv-39204" name="us-gaap:OperatingLeaseLiability" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">271</ix:nonFraction></span></span></td>
    <td style="padding-bottom:4pt;text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="text-align:left;padding-bottom:4pt;text-indent:-10pt;padding-left:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">Weighted
        average remaining lease term (years)</span></span></td>
    <td style="padding-bottom:4pt">&#160;</td>
    <td style="text-align:left;border-bottom:4px double black">&#160;</td>
    <td style="text-align:right;border-bottom:4px double black"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><ix:nonNumeric id="Fixv-39205" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" contextRef="C_20231231" format="ixt-sec:duryear">1.58</ix:nonNumeric></span></span></td>
    <td style="padding-bottom:4pt;text-align:left">&#160;</td>
    <td style="padding-bottom:4pt">&#160;</td>
    <td style="text-align:left;border-bottom:4px double black">&#160;</td>
    <td style="text-align:right;border-bottom:4px double black"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><ix:nonNumeric id="Fixv-39206" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" contextRef="C_20221231" format="ixt-sec:duryear">2.58</ix:nonNumeric></span></span></td>
    <td style="padding-bottom:4pt;text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="padding-bottom:4pt;text-indent:-10pt;padding-left:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">Weighted
        average discount rate</span></span></td>
    <td style="padding-bottom:4pt">&#160;</td>
    <td style="text-align:left;border-bottom:4px double black">&#160;</td>
    <td style="text-align:right;border-bottom:4px double black"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><ix:nonFraction id="Fixv-39207" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" contextRef="C_20231231" unitRef="pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">12.69</ix:nonFraction></span></span></td>
    <td style="padding-bottom:2px;text-align:left;vertical-align:bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">%</span></span></td>
    <td style="padding-bottom:4pt">&#160;</td>
    <td style="text-align:left;border-bottom:4px double black">&#160;</td>
    <td style="text-align:right;border-bottom:4px double black"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><ix:nonFraction id="Fixv-39208" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" contextRef="C_20221231" unitRef="pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">12.69</ix:nonFraction></span></span></td>
    <td style="padding-bottom:2px;text-align:left;vertical-align:bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">%</span></span></td>
        </tr>
  </table> </div> </div> </ix:nonNumeric>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in">&#160;</p>

<p style="font:10pt Times New Roman, Times, serif;margin:0pt 0px 0pt 49.65pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">As
of December&#160;31, 2023, the Company has not entered into lease agreements that include options to extend them that are not included
in the measurement of the lease liability.</span></span></p>

<p style="font:10pt Times New Roman, Times, serif;margin:0pt 0px 0pt 49.65pt">&#160;</p>

<p style="font:10pt Times New Roman, Times, serif;margin:0pt 0px 0pt 49.65pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">The
following table outlines maturities of the Company&#8217;s operating lease liabilities as of December&#160;31, 2023:</span></span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in">&#160;</p> <ix:nonNumeric id="Fxbrl_20241003040330164" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" contextRef="C_20230101to20231231" escape="true">

<div style="margin-left:54pt">

<table cellpadding="0" cellspacing="0" style="border-collapse:collapse;font:10pt Times New Roman, Times, serif;width:85%">
  <tr style="vertical-align:bottom">
    <td style="text-align:left">&#160;</td>
    <td style="font-weight:bold;padding-bottom:1.5pt">&#160;</td>
    <td colspan="2" style="text-align:center;font-weight:bold;border-bottom:1.5pt solid black;margin-top:0pt;margin-bottom:0pt">
        <p style="margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">Operating</span></span></span></span></p>
        <p style="margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">lease&#160;liabilities</span></span></span></span></p>
        </td>
    <td style="padding-bottom:1.5pt;font-weight:bold">&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="width:88%;text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">2024</span></span></td>
    <td style="width:1%">&#160;</td>
    <td style="width:1%;text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">$</span></span></td>
    <td style="width:9%;text-align:right"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><ix:nonFraction id="Fixv-39210" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">117</ix:nonFraction></span></span></td>
    <td style="width:1%;text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="text-align:left;padding-bottom:1.5pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">2025</span></span></td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><ix:nonFraction id="Fixv-39211" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">68</ix:nonFraction></span></span></td>
    <td style="padding-bottom:1.5pt;text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">Total undiscounted lease payments</span></span></td>
    <td>&#160;</td>
    <td style="text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">$</span></span></td>
    <td style="text-align:right"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><ix:nonFraction id="Fixv-39212" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">185</ix:nonFraction></span></span></td>
    <td style="text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="text-align:left;padding-bottom:1.5pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">Less&#160;&#8211;&#160;imputed
        interest</span></span></td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">$</span></span></td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><ix:nonFraction id="Fixv-39213" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">14</ix:nonFraction></span></span></td>
    <td style="padding-bottom:1.5pt;text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="text-align:left;padding-bottom:4pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">Present
        value of lease liabilities</span></span></td>
    <td style="padding-bottom:4pt">&#160;</td>
    <td style="text-align:left;border-bottom:4px double black"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">$</span></span></td>
    <td style="text-align:right;border-bottom:4px double black"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><ix:nonFraction id="Fixv-39214" name="us-gaap:OperatingLeaseLiability" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">171</ix:nonFraction></span></span></td>
    <td style="padding-bottom:4pt;text-align:left">&#160;</td> </tr>
  </table> </div> </ix:nonNumeric> </ix:nonNumeric>

<div style="font-size:10pt;margin-top:0pt;margin-bottom:0pt;font-family:'Times New Roman', Times, serif">&#160;</div> </div>

<div> <ix:nonNumeric id="Fxbrl_20241205144556277" name="us-gaap:AdditionalFinancialInformationDisclosureTextBlock" contextRef="C_20230101to20231231" escape="true">

<div>

<div style="text-align:justify;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong><span>NOTE
5&#160; - SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION:</span></strong></span></span></div>

<div style="line-height:1.25">&#160;</div>

<div style="text-align:justify;margin-left:31.65pt;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong><span>Statement
of operations:</span></strong></span></span></div>

<div style="line-height:1.25">&#160;</div>

<table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">
  <tr>
    <td style="width:51pt">&#160;</td>
    <td style="vertical-align:top;font-family:Times New Roman, Times, serif;font-weight:bold;width:18pt"><span style="font-family:Times New Roman,Times,serif">a.</span></td>
    <td style="vertical-align:top;width:auto">
        <div style="font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-family:Times New Roman,Times,serif">Research
        and development expenses, net:</span></div> </td> </tr>
  </table>

<div style="line-height:1.25">&#160;</div>

<div style="line-height:1.25;margin-left:72pt"> <ix:nonNumeric id="Fxbrl_20241205144625992" name="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersTextBlock" contextRef="C_20230101to20231231" escape="true">

<table border="0" cellpadding="0" cellspacing="0" style="color:#000000;font-family:'Times New Roman',Times,serif;font-size:10pt;text-align:left;width:85%">
  <tr>
    <td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
    <td colspan="6" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-family:Times New Roman,Times,serif">Year&#160;ended&#160;December&#160;31,</span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-family:Times New Roman,Times,serif">2023</span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-family:Times New Roman,Times,serif">2022</span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-family:Times New Roman,Times,serif">Payroll
        and related expenses</span></div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-family:Times New Roman,Times,serif">$</span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fixv-39215" name="us-gaap:LaborAndRelatedExpense" contextRef="C_20230101to20231231_usgaapIncomeStatementLocationAxis_usgaapResearchAndDevelopmentExpenseMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">973</ix:nonFraction></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-family:Times New Roman,Times,serif">$</span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fixv-39216" name="us-gaap:LaborAndRelatedExpense" contextRef="C_20220101to20221231_usgaapIncomeStatementLocationAxis_usgaapResearchAndDevelopmentExpenseMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,192</ix:nonFraction></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align:bottom;width:76%;background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-family:Times New Roman,Times,serif">Subcontractors
        and consultants</span></div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fixv-39217" name="slxn:SubcontractorsAndConsultants" contextRef="C_20230101to20231231_usgaapIncomeStatementLocationAxis_usgaapResearchAndDevelopmentExpenseMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,467</ix:nonFraction></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fixv-39218" name="slxn:SubcontractorsAndConsultants" contextRef="C_20220101to20221231_usgaapIncomeStatementLocationAxis_usgaapResearchAndDevelopmentExpenseMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,595</ix:nonFraction></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-family:Times New Roman,Times,serif">Materials</span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fixv-39219" name="slxn:MaterialsExpenses" contextRef="C_20230101to20231231_usgaapIncomeStatementLocationAxis_usgaapResearchAndDevelopmentExpenseMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">13</ix:nonFraction></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fixv-39220" name="slxn:MaterialsExpenses" contextRef="C_20220101to20221231_usgaapIncomeStatementLocationAxis_usgaapResearchAndDevelopmentExpenseMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">191</ix:nonFraction></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align:bottom;width:76%;background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-family:Times New Roman,Times,serif">Rent and
        maintenance</span></div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fixv-39221" name="us-gaap:CostOfPropertyRepairsAndMaintenance" contextRef="C_20230101to20231231_usgaapIncomeStatementLocationAxis_usgaapResearchAndDevelopmentExpenseMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">160</ix:nonFraction></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fixv-39222" name="us-gaap:CostOfPropertyRepairsAndMaintenance" contextRef="C_20220101to20221231_usgaapIncomeStatementLocationAxis_usgaapResearchAndDevelopmentExpenseMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">175</ix:nonFraction></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-family:Times New Roman,Times,serif">Travel expenses</span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fixv-39223" name="us-gaap:TravelAndEntertainmentExpense" contextRef="C_20230101to20231231_usgaapIncomeStatementLocationAxis_usgaapResearchAndDevelopmentExpenseMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">37</ix:nonFraction></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fixv-39224" name="us-gaap:TravelAndEntertainmentExpense" contextRef="C_20220101to20221231_usgaapIncomeStatementLocationAxis_usgaapResearchAndDevelopmentExpenseMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">42</ix:nonFraction></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align:bottom;width:76%;padding-bottom:2px;background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-family:Times New Roman,Times,serif">Other</span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fixv-39225" name="us-gaap:OtherResearchAndDevelopmentExpense" contextRef="C_20230101to20231231_usgaapIncomeStatementLocationAxis_usgaapResearchAndDevelopmentExpenseMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">58</ix:nonFraction></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(255, 255, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fixv-39226" name="us-gaap:OtherResearchAndDevelopmentExpense" contextRef="C_20220101to20221231_usgaapIncomeStatementLocationAxis_usgaapResearchAndDevelopmentExpenseMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">31</ix:nonFraction></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(255, 255, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align:top;width:76%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-family:Times New Roman,Times,serif">$</span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fixv-39227" name="us-gaap:ResearchAndDevelopmentExpense" contextRef="C_20230101to20231231_usgaapIncomeStatementLocationAxis_usgaapResearchAndDevelopmentExpenseMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,708</ix:nonFraction></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-family:Times New Roman,Times,serif">$</span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fixv-39228" name="us-gaap:ResearchAndDevelopmentExpense" contextRef="C_20220101to20221231_usgaapIncomeStatementLocationAxis_usgaapResearchAndDevelopmentExpenseMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,226</ix:nonFraction></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        </tr>
  </table> </ix:nonNumeric> </div>

<div style="line-height:1.25;clear:both">&#160;</div>

<table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">
  <tr>
    <td style="width:51pt">&#160;</td>
    <td style="width:18pt;vertical-align:top;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-family:Times New Roman,Times,serif">b.</span></td>
    <td style="width:auto;vertical-align:top">
        <div style="font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-family:Times New Roman,Times,serif">General
        and administrative expenses:</span></div> </td> </tr>
  </table>

<div style="line-height:1.25">&#160;</div>

<div style="margin-left:72pt"> <ix:nonNumeric id="Fxbrl_20241205144637236" name="us-gaap:SellingGeneralAndAdministrativeExpensesPolicyTextBlock" contextRef="C_20230101to20231231" escape="true">

<table border="0" cellpadding="0" cellspacing="0" style="color:#000000;font-family:'Times New Roman',Times,serif;font-size:10pt;text-align:left;width:85%">
  <tr>
    <td style="vertical-align:top;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-family:Times New Roman,Times,serif">Payroll
        and related expenses</span></div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-family:Times New Roman,Times,serif">$</span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fixv-39229" name="us-gaap:LaborAndRelatedExpense" contextRef="C_20230101to20231231_usgaapIncomeStatementLocationAxis_usgaapGeneralAndAdministrativeExpenseMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">356</ix:nonFraction></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-family:Times New Roman,Times,serif">$</span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fixv-39230" name="us-gaap:LaborAndRelatedExpense" contextRef="C_20220101to20221231_usgaapIncomeStatementLocationAxis_usgaapGeneralAndAdministrativeExpenseMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">219</ix:nonFraction></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align:top;width:76%;background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-family:Times New Roman,Times,serif">Professional
        services</span></div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fixv-39231" name="us-gaap:ProfessionalAndContractServicesExpense" contextRef="C_20230101to20231231_usgaapIncomeStatementLocationAxis_usgaapGeneralAndAdministrativeExpenseMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">386</ix:nonFraction></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fixv-39232" name="us-gaap:ProfessionalAndContractServicesExpense" contextRef="C_20220101to20221231_usgaapIncomeStatementLocationAxis_usgaapGeneralAndAdministrativeExpenseMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">197</ix:nonFraction></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align:top;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-family:Times New Roman,Times,serif">Depreciation</span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fixv-39233" name="us-gaap:Depreciation" contextRef="C_20230101to20231231_usgaapIncomeStatementLocationAxis_usgaapGeneralAndAdministrativeExpenseMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">45</ix:nonFraction></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fixv-39234" name="us-gaap:Depreciation" contextRef="C_20220101to20221231_usgaapIncomeStatementLocationAxis_usgaapGeneralAndAdministrativeExpenseMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">57</ix:nonFraction></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align:top;width:76%;background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-family:Times New Roman,Times,serif">Rent and
        maintenance</span></div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fixv-39235" name="us-gaap:CostOfPropertyRepairsAndMaintenance" contextRef="C_20230101to20231231_usgaapIncomeStatementLocationAxis_usgaapGeneralAndAdministrativeExpenseMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">86</ix:nonFraction></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fixv-39236" name="us-gaap:CostOfPropertyRepairsAndMaintenance" contextRef="C_20220101to20221231_usgaapIncomeStatementLocationAxis_usgaapGeneralAndAdministrativeExpenseMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">71</ix:nonFraction></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align:top;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-family:Times New Roman,Times,serif">Patent registration</span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fixv-39237" name="slxn:PatentRegistration" contextRef="C_20230101to20231231_usgaapIncomeStatementLocationAxis_usgaapGeneralAndAdministrativeExpenseMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">22</ix:nonFraction></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fixv-39238" name="slxn:PatentRegistration" contextRef="C_20220101to20221231_usgaapIncomeStatementLocationAxis_usgaapGeneralAndAdministrativeExpenseMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">32</ix:nonFraction></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align:top;width:76%;background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-family:Times New Roman,Times,serif">Travel expenses</span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fixv-39239" name="us-gaap:TravelAndEntertainmentExpense" contextRef="C_20230101to20231231_usgaapIncomeStatementLocationAxis_usgaapGeneralAndAdministrativeExpenseMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">31</ix:nonFraction></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20241004175518529" name="us-gaap:TravelAndEntertainmentExpense" contextRef="C_20220101to20221231_usgaapIncomeStatementLocationAxis_usgaapGeneralAndAdministrativeExpenseMember" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align:top;width:76%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-family:Times New Roman,Times,serif">Other</span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fixv-39240" name="us-gaap:OtherGeneralAndAdministrativeExpense" contextRef="C_20230101to20231231_usgaapIncomeStatementLocationAxis_usgaapGeneralAndAdministrativeExpenseMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">47</ix:nonFraction></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fixv-39241" name="us-gaap:OtherGeneralAndAdministrativeExpense" contextRef="C_20220101to20221231_usgaapIncomeStatementLocationAxis_usgaapGeneralAndAdministrativeExpenseMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">58</ix:nonFraction></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align:bottom;width:76%;padding-bottom:4px;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-family:Times New Roman,Times,serif">$</span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fixv-39242" name="us-gaap:GeneralAndAdministrativeExpense" contextRef="C_20230101to20231231_usgaapIncomeStatementLocationAxis_usgaapGeneralAndAdministrativeExpenseMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">973</ix:nonFraction></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(255, 255, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-family:Times New Roman,Times,serif">$</span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fixv-39243" name="us-gaap:GeneralAndAdministrativeExpense" contextRef="C_20220101to20221231_usgaapIncomeStatementLocationAxis_usgaapGeneralAndAdministrativeExpenseMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">634</ix:nonFraction></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(255, 255, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        </tr>
  </table> </ix:nonNumeric> </div>

<div style="font-size:10pt;margin-top:0pt;margin-bottom:0pt;font-family:'Times New Roman', Times, serif">&#160;</div>

<div><ix:exclude>

<div style="line-height:1.25;clear:both">

<div style="margin-top:10pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">

<p style="text-align:center;margin-top:0pt;margin-bottom:3pt"><span style="width:34%;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">F-83</span></span></span></p></div><hr style="page-break-after:always;border-width:0px;clear:both;margin:4px 0px;width:100%;height:2px;color:#000000;background-color:#000000;margin-top:0pt;margin-bottom:10pt"/>

<p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:center">&#160;</p>

<p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:center"><strong>S<span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">ILEXION
THERAPEUTICS CORP</span></span></strong><br/><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS (continued)</span></span></p>

<p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">U.S.
DOLLARS IN THOUSANDS</span></span></p>

<p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:center">&#160;</p> </div>

<div style="line-height:1.25;font-family:'Times New Roman', Times, serif"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">NOTE
5&#160; - SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION </span>(continued):</span></div>

<div style="line-height:1.25;font-family:'Times New Roman', Times, serif">&#160;</div> </ix:exclude></div>

<table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">
  <tr>
    <td style="width:51pt">&#160;</td>
    <td style="width:18pt;vertical-align:top;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-family:Times New Roman,Times,serif">c.</span></td>
    <td style="width:auto;vertical-align:top">
        <div style="font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-family:Times New Roman,Times,serif">Financial
        expense, net:</span></div> </td> </tr>
  </table>

<div style="line-height:1.25">&#160;</div>

<div style="margin-left:72pt"> <ix:nonNumeric id="Fxbrl_20241205144648397" name="slxn:ScheduleOfFinancialExpenseNetTableTextBlock" contextRef="C_20230101to20231231" escape="true">

<table border="0" cellpadding="0" cellspacing="0" style="color:#000000;font-family:'Times New Roman',Times,serif;font-size:10pt;text-align:left;width:85%">
  <tr>
    <td style="vertical-align:top;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-family:Times New Roman,Times,serif">Change
        in fair value of financial liabilities measured at fair value</span></div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-family:Times New Roman,Times,serif">$</span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fixv-39244" name="us-gaap:LiabilitiesFairValueAdjustment" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">86</ix:nonFraction></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-family:Times New Roman,Times,serif">$</span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fixv-39245" name="us-gaap:LiabilitiesFairValueAdjustment" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">1,017</ix:nonFraction></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-family:Times New Roman,Times,serif">)</span></div>
        </td> </tr>
  <tr>
    <td style="vertical-align:top;width:76%;background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-family:Times New Roman,Times,serif">Issuance
        costs</span></div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fixv-39246" name="us-gaap:PaymentsOfStockIssuanceCosts" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">3</ix:nonFraction></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fixv-39247" name="us-gaap:PaymentsOfStockIssuanceCosts" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">84</ix:nonFraction></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align:top;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-family:Times New Roman,Times,serif">Interest
        income</span></div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fixv-39248" name="us-gaap:InterestRevenueExpenseNet" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">153</ix:nonFraction></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-family:Times New Roman,Times,serif">)</span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fixv-39249" name="us-gaap:InterestRevenueExpenseNet" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">114</ix:nonFraction></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-family:Times New Roman,Times,serif">)</span></div>
        </td> </tr>
  <tr>
    <td style="vertical-align:top;width:76%;background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-family:Times New Roman,Times,serif">Foreign
        currency exchange loss, net</span></div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fixv-39250" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">453</ix:nonFraction></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fixv-39251" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">650</ix:nonFraction></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align:top;width:76%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-family:Times New Roman,Times,serif">Other</span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fixv-39252" name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">6</ix:nonFraction></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fixv-39253" name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1</ix:nonFraction></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align:top;width:76%;padding-bottom:4px;background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-family:Times New Roman,Times,serif">Total
        financial expense (income), net</span></div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-family:Times New Roman,Times,serif">$</span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fixv-39254" name="us-gaap:NonoperatingIncomeExpense" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">395</ix:nonFraction></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(255, 255, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-family:Times New Roman,Times,serif">$</span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fixv-39255" name="us-gaap:NonoperatingIncomeExpense" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">396</ix:nonFraction></span></div>
        </div> </td>
    <td colspan="1" style="width:1%;padding-bottom:2.8px;background-color:rgb(255, 255, 255);vertical-align:bottom;white-space:nowrap;padding-top:0px">
        <div style="line-height:1.25">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">)</div> </div> </td> </tr>
  </table> </ix:nonNumeric> </div> </div> </ix:nonNumeric> </div>

<div style="font-size:10pt;margin-top:0pt;margin-bottom:0pt;font-family:'Times New Roman', Times, serif">&#160;</div>

<div style="font:10pt Times New Roman, Times, Serif"> <ix:nonNumeric id="Fixv-33847" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" contextRef="C_20230101to20231231" escape="true">

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0"><strong>NOTE 6&#160; - COMMITMENTS AND CONTINGENT LIABILITIES:</strong></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in">&#160;</p>

<p style="font:10pt Times New Roman, Times, serif;margin:0pt 0px 0pt 64.34pt;text-align:justify">During 2009 to 2020, the Company received
several approvals from the IIA for participation in research and development activities performed by the Company (&#8220;Support Grants&#8221;)
in a total amount of $<ix:nonFraction id="Fixv-39256" name="us-gaap:ResearchAndDevelopmentExpense" contextRef="C_20230101to20231231_usgaapLongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_usgaapResearchAndDevelopmentArrangementMember" unitRef="usd" scale="6" decimals="-5" format="ixt:num-dot-decimal">5.8</ix:nonFraction>&#160;million.</p>

<p style="font:10pt Times New Roman, Times, serif;margin:0pt 0px 0pt 64.34pt;text-align:justify">&#160;</p>

<p style="font:10pt Times New Roman, Times, serif;margin:0pt 0px 0pt 64.34pt;text-align:justify">The Company is obligated to pay royalties
to the IIA amounting to <ix:nonFraction id="Fixv-39257" name="slxn:PaymentsForRoyaltiesInterest" contextRef="C_20231231_srtRangeAxis_srtMinimumMember" unitRef="pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">3</ix:nonFraction>%-<ix:nonFraction id="Fixv-39258" name="slxn:PaymentsForRoyaltiesInterest" contextRef="C_20231231_srtRangeAxis_srtMaximumMember" unitRef="pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">5</ix:nonFraction>%
of the sales of the core products and other related revenues generated from such projects, up to <ix:nonFraction id="Fixv-39259" name="us-gaap:InvestmentInterestRate" contextRef="C_20231231" unitRef="pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">100</ix:nonFraction>%
of the Support Grants received, linked to the U.S.&#160;dollar and bearing interest at the rate of LIBOR.&#160;The obligation to pay these
royalties is contingent upon actual sales of the products and, in the absence of such sales, no payment is required. In October&#160;2023,
it was published that the interest rate on the Support Grants will be replaced with the <ix:nonNumeric id="Fixv-39260" name="slxn:SupportGrantsTerms" contextRef="C_20230101to20231231" format="ixt-sec:durmonth">12</ix:nonNumeric>-month
term Secured Overnight Financing Rate (SOFR) published on the first&#160;trading day of each calendar year.</p>

<p style="font:10pt Times New Roman, Times, serif;margin:0pt 0px 0pt 64.34pt;text-align:justify">&#160;</p>

<p style="font:10pt Times New Roman, Times, serif;margin:0pt 0px 0pt 64.34pt;text-align:justify">As of December&#160;31, 2023, the total
royalty amount that may be payable by the Company is approximately $<ix:nonFraction id="Fixv-39261" name="us-gaap:PaymentsForRoyalties" contextRef="C_20230101to20231231" unitRef="usd" scale="6" decimals="-5" format="ixt:num-dot-decimal">5.8</ix:nonFraction>&#160;million
($<ix:nonFraction id="Fixv-39262" name="us-gaap:PaymentsForRoyalties" contextRef="C_20230101to20231231_usgaapRelatedPartyTransactionsByRelatedPartyAxis_slxnSupportGrantsMember" unitRef="usd" scale="6" decimals="-5" format="ixt:num-dot-decimal">6.4</ix:nonFraction>&#160;million
including interest).</p> </ix:nonNumeric>

<p style="font:10pt Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt">&#160;</p> </div>

<div style="font:10pt Times New Roman, Times, Serif"> <ix:nonNumeric id="Fxbrl_20241004130933045" name="slxn:SimpleAgreementForFutureEquityTextBlock" contextRef="C_20230101to20231231" escape="true">

<div>

<div>

<div>

<div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">NOTE
7&#160; - SIMPLE AGREEMENT FOR FUTURE EQUITY</span></span></div>

<div style="line-height:1.25">&#160;</div>

<div style="text-align:justify;margin-left:64.34pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">On
March 15, 2021, a Simple Agreement for Future Equity ("SAFE") was signed between the Company and a group of investors, for an aggregate
amount of up to $<ix:nonFraction id="Fixv-39263" name="slxn:AgreementAggregateAmount" contextRef="C_20210315to20210315_usgaapRelatedPartyTransactionsByRelatedPartyAxis_usgaapInvestorMember" unitRef="usd" scale="0" decimals="0" format="ixt:num-dot-decimal">4,000</ix:nonFraction>,
of which $<ix:nonFraction id="Fixv-39264" name="us-gaap:AssetAcquisitionConsiderationTransferred" contextRef="C_20210315to20210315_usgaapRelatedPartyTransactionsByRelatedPartyAxis_usgaapInvestorMember" unitRef="usd" scale="0" decimals="0" format="ixt:num-dot-decimal">2,887</ix:nonFraction>
were actually raised. The SAFE was for a period of 9 months and was convertible into preferred shares with the most senior class of rights
issued&#160;&#160; by the Company at the time of conversion.</span></span></div>

<div style="line-height:1.25">&#160;</div>

<div style="text-align:justify;margin-left:64.3pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The
conversion rate and timing were subject to events as determined in the SAFE, the principal amount thereon was to be converted to the most
senior class of shares of the Company in accordance with the terms mentioned in the SAFE, as follows: in an event that the Company consummates
an equity investment of at least $<ix:nonFraction id="Fixv-39265" name="us-gaap:InvestmentOwnedBalancePrincipalAmount" contextRef="C_20231231" unitRef="usd" scale="0" decimals="0" format="ixt:num-dot-decimal">2,000</ix:nonFraction>,
the principal amount will be converted automatically to the most senior class of equity at the lower of (i) the price per share of the
most senior shares issued in such equity investment less a <ix:nonFraction id="Fixv-39266" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" contextRef="C_20231231_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_slxnSAFEMember" unitRef="pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">25</ix:nonFraction>%
discount, or (ii) a price per share reflecting a fully diluted pre-money Company valuation of $<ix:nonFraction id="Fixv-39267" name="slxn:PreMoneyValuationAmount" contextRef="C_20230101to20231231_srtRangeAxis_srtMaximumMember" unitRef="usd" scale="0" decimals="0" format="ixt:num-dot-decimal">70,000</ix:nonFraction>.
However, in no event was the price per share to be lower than a price per share reflecting a fully-diluted pre-money valuation of the
Company of $<ix:nonFraction id="Fixv-39268" name="slxn:PreMoneyValuationAmount" contextRef="C_20230101to20231231_srtRangeAxis_srtMinimumMember" unitRef="usd" scale="0" decimals="0" format="ixt:num-dot-decimal">30,000</ix:nonFraction>.</span></span></div>

<div style="line-height:1.25">&#160;</div>

<div style="text-indent:36pt;margin-left:28.3pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Total
consideration for the SAFE agreements was $<ix:nonFraction id="Fixv-39269" name="us-gaap:AssetAcquisitionConsiderationTransferred" contextRef="C_20230101to20231231" unitRef="usd" scale="0" decimals="0" format="ixt:num-dot-decimal">2,887</ix:nonFraction>.</span></span></div>

<div style="line-height:1.25">&#160;</div>

<div style="text-align:justify;margin-left:64.3pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">On
January 14, 2022, the Company converted the SAFE in the total amount of $<ix:nonFraction id="Fixv-39270" name="us-gaap:InvestmentOwnedAtFairValue" contextRef="C_20220114" unitRef="usd" scale="0" decimals="0" format="ixt:num-dot-decimal">3,204</ix:nonFraction>
(its fair value as of conversion date) into <ix:nonFraction id="Fixv-39271" name="us-gaap:ConversionOfStockSharesConverted1" contextRef="C_20220114to20220114" unitRef="shares" scale="0" decimals="0" format="ixt:num-dot-decimal">7,037</ix:nonFraction>
Series A-3 Preferred Shares and <ix:nonFraction id="Fixv-39272" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="C_20220114_usgaapClassOfWarrantOrRightAxis_usgaapWarrantMember" unitRef="shares" scale="0" decimals="0" format="ixt:num-dot-decimal">5,278</ix:nonFraction>
warrants exercisable into Series A-2 Preferred Shares. In accordance with ASC 480 the Company recorded financial expenses in amount of
$<ix:nonFraction id="Fixv-39273" name="us-gaap:CostsAndExpenses" contextRef="C_20230101to20231231" unitRef="usd" scale="0" decimals="0" format="ixt:num-dot-decimal">317</ix:nonFraction>
with respect to the discount on the SAFE conversion.</span></span></div> </div> </div> </div> </ix:nonNumeric>

<div style="font-size:10pt;margin-top:0pt;margin-bottom:0pt;font-family:'Times New Roman', Times, serif">&#160;</div>

<div style="margin-top:10pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">

<p style="text-align:center;margin-top:0pt;margin-bottom:3pt"><span style="width:34%;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">F-84</span></span></span></p></div><hr style="page-break-after:always;border-width:0px;clear:both;margin:4px 0px;width:100%;height:2px;color:#000000;background-color:#000000;margin-top:0pt;margin-bottom:10pt"/>

<p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:center">&#160;</p>

<p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:center"><strong>S<span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">ILEXION
THERAPEUTICS CORP</span></span></strong><br/><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS (continued)</span></span></p>

<p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">U.S.
DOLLARS IN THOUSANDS</span></span></p>

<p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:center">&#160;</p> </div>

<div style="font:10pt Times New Roman, Times, Serif"> <ix:nonNumeric id="Fixv-33895" name="us-gaap:PreferredStockTextBlock" contextRef="C_20230101to20231231" escape="true">

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0"><strong>NOTE 8&#160; - WARRANTS TO PURCHASE PREFERRED SHARES:</strong></p>

<div>

<div>

<div style="line-height:1.25">&#160;</div>

<table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">
  <tr>
    <td style="width:31.65pt">&#160;</td>
    <td style="vertical-align:top;font-family:Times New Roman, Times, serif;font-weight:bold;width:18pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">a.</span></span></td>
    <td style="vertical-align:top;text-align:justify;width:auto">
        <div style="font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">In
        connection with the Series A-2 Preferred Shares (see Note 9(b)), the Company issued warrants to acquire <ix:nonFraction id="Fixv-39274" name="slxn:WarrantsIssued" contextRef="C_20231231_usgaapStatementClassOfStockAxis_slxnSeriesA2PreferredSharesMember" unitRef="shares" scale="0" decimals="0" format="ixt:num-dot-decimal">10,329</ix:nonFraction>
        Series A-2 Preferred Shares to various investors, including <ix:nonFraction id="Fixv-39275" name="slxn:WarrantsIssued" contextRef="C_20231231" unitRef="shares" scale="0" decimals="0" format="ixt:num-dot-decimal">5,278</ix:nonFraction>
        warrants issued as part of the converted SAFE (see Note 9(b)). These warrants feature an exercise price of $<ix:nonFraction id="Fixv-39276" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="C_20231231" unitRef="usdPershares" scale="0" decimals="3" format="ixt:num-dot-decimal">547.047</ix:nonFraction>
        per share and expired during 2023. As of December 31, 2022, there are <ix:nonFraction id="Fixv-39277" name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="C_20221231" unitRef="shares" scale="0" decimals="0" format="ixt:num-dot-decimal">10,329</ix:nonFraction>
        outstanding warrants. As of December 31, 2023, all warrants are expired.</span></span></div> </td> </tr>
  </table>

<div style="line-height:1.25">&#160;</div>

<table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">
  <tr>
    <td style="width:31.65pt">&#160;</td>
    <td style="width:18pt;vertical-align:top;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">b.</span></span></td>
    <td style="width:auto;vertical-align:top;text-align:justify">
        <div style="font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Concerning
        the Series A-4 Preferred Shares (see Note 9(b)), the Company issued warrants to acquire <ix:nonFraction id="Fixv-39278" name="slxn:WarrantsIssued" contextRef="C_20231231_usgaapClassOfWarrantOrRightAxis_usgaapWarrantMember_usgaapStatementClassOfStockAxis_slxnSeriesA4PreferredSharesMember" unitRef="shares" scale="0" decimals="0" format="ixt:num-dot-decimal">2,413</ix:nonFraction>
        Series A-4 Preferred Shares to various investors, with an exercise price of $<ix:nonFraction id="Fixv-39279" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="C_20231231_usgaapStatementClassOfStockAxis_slxnSeriesA4PreferredSharesMember" unitRef="usdPershares" scale="0" decimals="3" format="ixt:num-dot-decimal">222.921</ix:nonFraction>
        per share and an expiration date of May 30, 2025. Issuance expenses amounted to $<ix:nonFraction id="Fixv-39280" name="us-gaap:OtherExpenses" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">3</ix:nonFraction>.
        As of December 31, 2023, there are outstanding warrants of <ix:nonFraction id="Fixv-39281" name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="C_20231231" unitRef="shares" scale="0" decimals="0" format="ixt:num-dot-decimal">2,413</ix:nonFraction>.
        Regarding the warrants issued to the subsidiary see Note 9(b)(2).</span></span></div> </td> </tr>
  </table> </div> </div>

<p style="text-align:left;font:10pt Times New Roman, Times, serif;margin:0pt 0px 0pt 49.65pt">&#160;</p>

<p style="font:10pt Times New Roman, Times, serif;margin:0pt 0px 0pt 49.65pt;text-align:justify"><span style="font-size:10pt">The Company
classified the warrants for the purchase of shares of its convertible redeemable preferred shares as a liability in its consolidated balance
sheets, as these warrants were freestanding financial instruments which underlying shares are contingently redeemable and, therefore,
may obligate the Company to transfer assets at some point in the future. The warrant liability was initially recorded at fair value upon
the date of issuance and was subsequently remeasured at fair value at each reporting date. The Company recorded revaluation expenses (income)
amounting to $(</span><ix:nonFraction id="Fixv-39282" name="slxn:RevaluationExpensesIncome" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">86</ix:nonFraction><span style="font-size:10pt">)&#160;and
$</span><ix:nonFraction id="Fixv-39283" name="slxn:RevaluationExpensesIncome" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,017</ix:nonFraction><span style="font-size:10pt">&#160;for
the&#160;years ended 2023 and 2022, respectively, and accounted for such revaluation expenses as part of its financial income (expense),
net, in the statements of operations.</span></p>

<p style="font:10pt Times New Roman, Times, serif;margin:0pt 0px 0pt 49.65pt">&#160;</p>

<p style="font:10pt Times New Roman, Times, serif;margin:0pt 0px 0pt 49.65pt;text-align:justify">For further information in respect of
warrants issuance to service provider see Note&#160;11(1).</p> </ix:nonNumeric>

<p style="font:10pt Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt">&#160;</p> </div>

<div> <ix:nonNumeric id="Fxbrl_20241205112310308" name="slxn:RedeemableConvertiblePreferredSharesAndShareholdersEquityTextBlock" contextRef="C_20230101to20231231" escape="true">

<div>

<div style="text-indent:-49.65pt;margin-left:49.65pt;line-height:1.25;font-weight:bold"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>NOTE
9 - REDEEMABLE CONVERTIBLE PREFERRED SHARES AND SHAREHOLDERS&#8217; EQUITY:</span></span></span></div>

<div style="line-height:1.25">&#160;</div>

<table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">
  <tr>
    <td style="width:31.65pt">&#160;</td>
    <td style="width:18pt;vertical-align:top;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>a.</span></span></span></td>
    <td style="width:auto;vertical-align:top">
        <div style="font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>As
        of December 31, 2023 and 2022, the share capital is composed of 0.09 NIS par value shares, as follows:</span></span></span></div> </td>
        </tr>
  </table> <ix:nonNumeric id="Fxbrl_20241205112415949" name="us-gaap:ScheduleOfStockholdersEquityTableTextBlock" contextRef="C_20230101to20231231" escape="true">

<div>

<div>&#160;</div>

<div style="margin-left:54pt">

<table border="0" cellpadding="0" cellspacing="0" style="width:85%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left;float:left">
  <tr>
    <td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
    <td colspan="14" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>December
        31, 2023</span></span></span></div> </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong><span><span><span>Authorized</span></span></span></strong></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong><span><span><span>Issued
        and paid</span></span></span></strong></span></span></div> </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong><span><span><span>Carrying</span></span></span></strong></span></span></div>
        <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong><span><span><span>Value</span></span></span></strong></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong><span><span><span>Liquidation</span></span></span></strong></span></span></div>
        <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong><span><span><span>Preference</span></span></span></strong></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:bottom;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>Ordinary
        Shares</span></span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><ix:nonFraction id="Fixv-39286" name="us-gaap:CommonStockSharesAuthorized" contextRef="C_20231231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">22,222,222</ix:nonFraction></span></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><ix:nonFraction id="Fixv-39287" name="us-gaap:CommonStockSharesIssued" contextRef="C_20231231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">97,120</ix:nonFraction></span></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>$</span></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><ix:nonFraction id="Fixv-39288" name="us-gaap:CommonStockValue" contextRef="C_20231231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,685</ix:nonFraction></span></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align:bottom;width:52%;padding-bottom:4px;background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>Preferred
        A Shares</span></span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><ix:nonFraction id="Fixv-39289" name="us-gaap:PreferredStockSharesAuthorized" contextRef="C_20231231_usgaapStatementClassOfStockAxis_usgaapSeriesAPreferredStockMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">56,667</ix:nonFraction></span></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(255, 255, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><ix:nonFraction id="Fixv-39290" name="us-gaap:PreferredStockSharesIssued" contextRef="C_20231231_usgaapStatementClassOfStockAxis_usgaapSeriesAPreferredStockMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">43,121</ix:nonFraction></span></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(255, 255, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>$</span></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><ix:nonFraction id="Fixv-39291" name="us-gaap:PreferredStockValue" contextRef="C_20231231_usgaapStatementClassOfStockAxis_usgaapSeriesAPreferredStockMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,307</ix:nonFraction></span></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(255, 255, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>$</span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><ix:nonFraction id="Fixv-39292" name="us-gaap:PreferredStockLiquidationPreferenceValue" contextRef="C_20231231_usgaapStatementClassOfStockAxis_usgaapSeriesAPreferredStockMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,162</ix:nonFraction></span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(255, 255, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align:bottom;width:52%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>Preferred
        A-1 Shares</span></span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><ix:nonFraction id="Fixv-39293" name="us-gaap:PreferredStockSharesAuthorized" contextRef="C_20231231_usgaapStatementClassOfStockAxis_slxnSeriesA1PreferredSharesMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">13,334</ix:nonFraction></span></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><ix:nonFraction id="Fixv-39294" name="us-gaap:PreferredStockSharesIssued" contextRef="C_20231231_usgaapStatementClassOfStockAxis_slxnSeriesA1PreferredSharesMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">10,136</ix:nonFraction></span></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>$</span></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><ix:nonFraction id="Fixv-39295" name="us-gaap:PreferredStockValue" contextRef="C_20231231_usgaapStatementClassOfStockAxis_slxnSeriesA1PreferredSharesMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,392</ix:nonFraction></span></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>$</span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><ix:nonFraction id="Fixv-39296" name="us-gaap:PreferredStockLiquidationPreferenceValue" contextRef="C_20231231_usgaapStatementClassOfStockAxis_slxnSeriesA1PreferredSharesMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,443</ix:nonFraction></span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align:bottom;width:52%;padding-bottom:4px;background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>Preferred
        A-2 Shares</span></span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><ix:nonFraction id="Fixv-39297" name="us-gaap:PreferredStockSharesAuthorized" contextRef="C_20231231_usgaapStatementClassOfStockAxis_slxnSeriesA2PreferredSharesMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">22,223</ix:nonFraction></span></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(255, 255, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><ix:nonFraction id="Fixv-39298" name="us-gaap:PreferredStockSharesIssued" contextRef="C_20231231_usgaapStatementClassOfStockAxis_slxnSeriesA2PreferredSharesMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">5,051</ix:nonFraction></span></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(255, 255, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>$</span></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><ix:nonFraction id="Fixv-39299" name="us-gaap:PreferredStockValue" contextRef="C_20231231_usgaapStatementClassOfStockAxis_slxnSeriesA2PreferredSharesMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,264</ix:nonFraction></span></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(255, 255, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>$</span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><ix:nonFraction id="Fixv-39300" name="us-gaap:PreferredStockLiquidationPreferenceValue" contextRef="C_20231231_usgaapStatementClassOfStockAxis_slxnSeriesA2PreferredSharesMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,763</ix:nonFraction></span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(255, 255, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align:bottom;width:52%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>Preferred
        A-3 Shares</span></span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><ix:nonFraction id="Fixv-39301" name="us-gaap:PreferredStockSharesAuthorized" contextRef="C_20231231_usgaapStatementClassOfStockAxis_slxnSeriesA3PreferredSharesMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">8,889</ix:nonFraction></span></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><ix:nonFraction id="Fixv-39302" name="us-gaap:PreferredStockSharesIssued" contextRef="C_20231231_usgaapStatementClassOfStockAxis_slxnSeriesA3PreferredSharesMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">7,037</ix:nonFraction></span></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>$</span></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><ix:nonFraction id="Fixv-39303" name="us-gaap:PreferredStockValue" contextRef="C_20231231_usgaapStatementClassOfStockAxis_slxnSeriesA3PreferredSharesMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,683</ix:nonFraction></span></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>$</span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><ix:nonFraction id="Fixv-39304" name="us-gaap:PreferredStockLiquidationPreferenceValue" contextRef="C_20231231_usgaapStatementClassOfStockAxis_slxnSeriesA3PreferredSharesMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,887</ix:nonFraction></span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align:bottom;width:52%;padding-bottom:4px;background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>Preferred
        A-4 Shares</span></span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><ix:nonFraction id="Fixv-39305" name="us-gaap:PreferredStockSharesAuthorized" contextRef="C_20231231_usgaapStatementClassOfStockAxis_slxnSeriesA4PreferredSharesMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">90,556</ix:nonFraction></span></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(255, 255, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><ix:nonFraction id="Fixv-39306" name="us-gaap:PreferredStockSharesIssued" contextRef="C_20231231_usgaapStatementClassOfStockAxis_slxnSeriesA4PreferredSharesMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">2,413</ix:nonFraction></span></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(255, 255, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>$</span></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><ix:nonFraction id="Fixv-39307" name="us-gaap:PreferredStockValue" contextRef="C_20231231_usgaapStatementClassOfStockAxis_slxnSeriesA4PreferredSharesMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">411</ix:nonFraction></span></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(255, 255, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>$</span></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><ix:nonFraction id="Fixv-39308" name="us-gaap:PreferredStockLiquidationPreferenceValue" contextRef="C_20231231_usgaapStatementClassOfStockAxis_slxnSeriesA4PreferredSharesMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,076</ix:nonFraction></span></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(255, 255, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        </tr>
  </table> </div>

<div style="line-height:1.25;clear:both">&#160;</div>

<div style="margin-left:54pt">

<table border="0" cellpadding="0" cellspacing="0" style="width:85%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left;float:left">
  <tr>
    <td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
    <td colspan="14" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>December
        31, 2022</span></span></span></div> </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong><span><span><span>Authorized</span></span></span></strong></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong><span><span><span>Issued
        and paid</span></span></span></strong></span></span></div> </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong><span><span><span>Carrying</span></span></span></strong></span></span></div>
        <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong><span><span><span>Value</span></span></span></strong></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong><span><span><span>Liquidation</span></span></span></strong></span></span></div>
        <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong><span><span><span>Preference</span></span></span></strong></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:bottom;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>Ordinary
        Shares</span></span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><ix:nonFraction id="Fxbrl_20241004135423058_ixv-39286" name="us-gaap:CommonStockSharesAuthorized" contextRef="C_20221231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">22,222,222</ix:nonFraction></span></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><ix:nonFraction id="Fxbrl_20241004135423058_ixv-39287" name="us-gaap:CommonStockSharesIssued" contextRef="C_20221231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">97,120</ix:nonFraction></span></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>$</span></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><ix:nonFraction id="Fxbrl_20241004135423058_ixv-39288" name="us-gaap:CommonStockValue" contextRef="C_20221231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,685</ix:nonFraction></span></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align:bottom;width:52%;padding-bottom:4px;background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>Preferred
        A Shares</span></span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><ix:nonFraction id="Fixv-39312" name="us-gaap:PreferredStockSharesAuthorized" contextRef="C_20221231_usgaapStatementClassOfStockAxis_usgaapSeriesAPreferredStockMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">56,667</ix:nonFraction></span></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(255, 255, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><ix:nonFraction id="Fixv-39313" name="us-gaap:PreferredStockSharesIssued" contextRef="C_20221231_usgaapStatementClassOfStockAxis_usgaapSeriesAPreferredStockMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">43,121</ix:nonFraction></span></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(255, 255, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>$</span></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><ix:nonFraction id="Fixv-39314" name="us-gaap:PreferredStockValue" contextRef="C_20221231_usgaapStatementClassOfStockAxis_usgaapSeriesAPreferredStockMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,307</ix:nonFraction></span></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(255, 255, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>$</span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><ix:nonFraction id="Fixv-39315" name="us-gaap:PreferredStockLiquidationPreferenceValue" contextRef="C_20221231_usgaapStatementClassOfStockAxis_usgaapSeriesAPreferredStockMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,162</ix:nonFraction></span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(255, 255, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align:bottom;width:52%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>Preferred
        A-1 Shares</span></span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><ix:nonFraction id="Fixv-39316" name="us-gaap:PreferredStockSharesAuthorized" contextRef="C_20221231_usgaapStatementClassOfStockAxis_slxnSeriesA1PreferredSharesMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">13,334</ix:nonFraction></span></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><ix:nonFraction id="Fixv-39317" name="us-gaap:PreferredStockSharesIssued" contextRef="C_20221231_usgaapStatementClassOfStockAxis_slxnSeriesA1PreferredSharesMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">10,136</ix:nonFraction></span></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>$</span></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><ix:nonFraction id="Fixv-39318" name="us-gaap:PreferredStockValue" contextRef="C_20221231_usgaapStatementClassOfStockAxis_slxnSeriesA1PreferredSharesMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,392</ix:nonFraction></span></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>$</span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><ix:nonFraction id="Fixv-39319" name="us-gaap:PreferredStockLiquidationPreferenceValue" contextRef="C_20221231_usgaapStatementClassOfStockAxis_slxnSeriesA1PreferredSharesMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,443</ix:nonFraction></span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align:bottom;width:52%;padding-bottom:4px;background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>Preferred
        A-2 Shares</span></span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><ix:nonFraction id="Fixv-39320" name="us-gaap:PreferredStockSharesAuthorized" contextRef="C_20221231_usgaapStatementClassOfStockAxis_slxnSeriesA2PreferredSharesMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">22,223</ix:nonFraction></span></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(255, 255, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><ix:nonFraction id="Fixv-39321" name="us-gaap:PreferredStockSharesIssued" contextRef="C_20221231_usgaapStatementClassOfStockAxis_slxnSeriesA2PreferredSharesMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">5,051</ix:nonFraction></span></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(255, 255, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>$</span></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><ix:nonFraction id="Fixv-39322" name="us-gaap:PreferredStockValue" contextRef="C_20221231_usgaapStatementClassOfStockAxis_slxnSeriesA2PreferredSharesMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,264</ix:nonFraction></span></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(255, 255, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>$</span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><ix:nonFraction id="Fixv-39323" name="us-gaap:PreferredStockLiquidationPreferenceValue" contextRef="C_20221231_usgaapStatementClassOfStockAxis_slxnSeriesA2PreferredSharesMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,763</ix:nonFraction></span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(255, 255, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align:bottom;width:52%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>Preferred
        A-3 Shares</span></span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><ix:nonFraction id="Fixv-39324" name="us-gaap:PreferredStockSharesAuthorized" contextRef="C_20221231_usgaapStatementClassOfStockAxis_slxnSeriesA3PreferredSharesMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">8,889</ix:nonFraction></span></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><ix:nonFraction id="Fixv-39325" name="us-gaap:PreferredStockSharesIssued" contextRef="C_20221231_usgaapStatementClassOfStockAxis_slxnSeriesA3PreferredSharesMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">7,037</ix:nonFraction></span></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>$</span></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><ix:nonFraction id="Fixv-39326" name="us-gaap:PreferredStockValue" contextRef="C_20221231_usgaapStatementClassOfStockAxis_slxnSeriesA3PreferredSharesMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,683</ix:nonFraction></span></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>$</span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><ix:nonFraction id="Fixv-39327" name="us-gaap:PreferredStockLiquidationPreferenceValue" contextRef="C_20221231_usgaapStatementClassOfStockAxis_slxnSeriesA3PreferredSharesMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,887</ix:nonFraction></span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        </tr>
  </table> </div> </div>

<div style="text-indent:-49.65pt;margin-left:49.65pt;line-height:1.25;clear:both">&#160;</div> </ix:nonNumeric>

<div><ix:exclude>

<div style="line-height:1.25">

<div style="margin-top:10pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">

<p style="text-align:center;margin-top:0pt;margin-bottom:3pt"><span style="width:34%;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">F-85</span></span></span></p></div><hr style="page-break-after:always;border-width:0px;clear:both;margin:4px 0px;width:100%;height:2px;color:#000000;background-color:#000000;margin-top:0pt;margin-bottom:10pt"/>

<p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:center">&#160;</p>

<p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:center"><strong>S<span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">ILEXION
THERAPEUTICS CORP</span></span></strong><br/><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS (continued)</span></span></p>

<p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">U.S.
DOLLARS IN THOUSANDS</span></span></p>

<p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:center">&#160;</p> </div>

<div style="text-indent:-49.65pt;margin-left:49.65pt;line-height:1.25;font-family:'Times New Roman', Times, serif"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span style="font-weight:bold">NOTE
9 - REDEEMABLE CONVERTIBLE PREFERRED SHARES AND SHAREHOLDERS&#8217; EQUITY </span>(continued):</span></span></span></div>

<div style="text-indent:-49.65pt;margin-left:49.65pt;line-height:1.25;font-family:'Times New Roman', Times, serif">&#160;</div> </ix:exclude></div>

<table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">
  <tr>
    <td style="width:64.25pt">&#160;</td>
    <td style="vertical-align:top;font-family:Times New Roman, Times, serif;font-weight:bold;width:28.45pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>b.</span></span></span></td>
    <td style="vertical-align:top;width:auto">
        <div style="font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>Issuance
        of shares:</span></span></span></div> </td> </tr>
  </table>

<div style="line-height:1.25">&#160;</div>

<table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">
  <tr>
    <td style="width:92.7pt">&#160;</td>
    <td style="width:18pt;vertical-align:top;font-family:'Times New Roman',Times,serif"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>1)</span></span></span></td>
    <td style="width:auto;vertical-align:top;text-align:justify">
        <div style="font-family:'Times New Roman',Times,serif"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>On
        January 14, 2022, the Company signed an agreement to issue shares in consideration for an investment in the amount of $<ix:nonFraction id="Fixv-39328" name="us-gaap:PreferredStockLiquidationPreferenceValue" contextRef="C_20220114" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,763</ix:nonFraction>.
        In return for this investment, the Company issued <ix:nonFraction id="Fixv-39329" name="us-gaap:PreferredStockSharesIssued" contextRef="C_20220114_usgaapStatementClassOfStockAxis_slxnSeriesA2PreferredSharesMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">5,051</ix:nonFraction>
        Series A-2 Preferred Shares with a par value of NIS <ix:nonFraction id="Fixv-39330" name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="C_20231231_usgaapStatementClassOfStockAxis_slxnSeriesA2PreferredSharesMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember" unitRef="ilsPershares" scale="0" decimals="2" format="ixt:num-dot-decimal">0.09</ix:nonFraction>.
        Issuance expenses amounted to $<ix:nonFraction id="Fixv-39331" name="us-gaap:OtherExpenses" contextRef="C_20230101to20231231_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">14</ix:nonFraction>.</span></span></span></div>
        </td> </tr>
  </table>

<div style="line-height:1.25">&#160;</div>

<div style="text-align:justify;margin-left:108pt;line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>Following
this investment, the Company converted the SAFE in the total amount of $<ix:nonFraction id="Fixv-39332" name="us-gaap:PreferredStockLiquidationPreferenceValue" contextRef="C_20231231_usgaapStatementClassOfStockAxis_slxnSeriesA3PreferredSharesMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,204</ix:nonFraction>
into <ix:nonFraction id="Fixv-39333" name="us-gaap:PreferredStockSharesIssued" contextRef="C_20231231_usgaapStatementClassOfStockAxis_slxnSeriesA3PreferredSharesMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">7,037</ix:nonFraction>
Series A-3 Preferred Shares.</span></span></span></div>

<div style="line-height:1.25">&#160;</div>

<div style="text-align:justify;margin-left:108pt;line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>In
addition, the Company issued <ix:nonFraction id="Fixv-39334" name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="C_20231231_usgaapClassOfWarrantOrRightAxis_usgaapWarrantMember_usgaapStatementClassOfStockAxis_slxnSeriesA2PreferredSharesMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">10,329</ix:nonFraction>
warrants for Series A-2 Preferred Shares NIS <ix:nonFraction id="Fixv-39335" name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="C_20231231_usgaapClassOfWarrantOrRightAxis_usgaapWarrantMember_usgaapStatementClassOfStockAxis_slxnSeriesA2PreferredSharesMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember" unitRef="ilsPershares" scale="0" decimals="2" format="ixt:num-dot-decimal">0.09</ix:nonFraction>
par value per share, including <ix:nonFraction id="Fixv-39336" name="slxn:WarrantsIssued" contextRef="C_20231231_usgaapClassOfWarrantOrRightAxis_usgaapWarrantMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">5,278</ix:nonFraction>
warrants issued as part of the converted SAFE (see Note 8(a)), each exercisable at a price &#160; &#160; of $<ix:nonFraction id="Fixv-39337" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="C_20231231_usgaapClassOfWarrantOrRightAxis_usgaapWarrantMember" unitRef="usdPershares" scale="0" decimals="2" format="ixt:num-dot-decimal">547.02</ix:nonFraction>
per share.</span></span></span></div>

<div style="line-height:1.25">&#160;</div>

<table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">
  <tr>
    <td style="width:92.7pt">&#160;</td>
    <td style="width:18pt;vertical-align:top;font-family:'Times New Roman',Times,serif"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>2)</span></span></span></td>
    <td style="width:auto;vertical-align:top;text-align:justify">
        <div style="font-family:'Times New Roman',Times,serif"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>On
        May 30, 2023, the Company entered into an agreement to receive an investment in a total amount of $<ix:nonFraction id="Fixv-39338" name="us-gaap:ProceedsFromSaleOfInvestmentProjects" contextRef="C_20230530to20230530" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">538</ix:nonFraction>.
        In exchange for this investment, the Company issued <ix:nonFraction id="Fixv-39339" name="us-gaap:PreferredStockSharesIssued" contextRef="C_20230530_usgaapStatementClassOfStockAxis_slxnSeriesA4PreferredSharesMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember" unitRef="shares" scale="0" decimals="0" format="ixt:num-dot-decimal">2,413</ix:nonFraction>
        Series A-4 Preferred Shares with a par value of NIS <ix:nonFraction id="Fixv-39340" name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="C_20230530_usgaapStatementClassOfStockAxis_slxnSeriesA4PreferredSharesMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember" unitRef="ilsPershares" scale="0" decimals="2" format="ixt:num-dot-decimal">0.09</ix:nonFraction>.
        Issuance expenses amounted to $<ix:nonFraction id="Fixv-39341" name="us-gaap:OtherExpenses" contextRef="C_20230530to20230530_usgaapStatementClassOfStockAxis_slxnSeriesA4PreferredSharesMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">16</ix:nonFraction>.</span></span></span></div>
        </td> </tr>
  </table>

<div style="line-height:1.25">&#160;</div>

<div style="text-align:justify;margin-left:113.4pt;line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>Additionally,
the Company issued <ix:nonFraction id="Fixv-39342" name="us-gaap:PreferredStockSharesIssued" contextRef="C_20231231_usgaapStatementClassOfStockAxis_slxnSeriesA4PreferredSharesMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">2,413</ix:nonFraction>
warrants for Series A-4 Preferred Shares, each with a par value of NIS <ix:nonFraction id="Fixv-39343" name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="C_20231231_usgaapStatementClassOfStockAxis_slxnSeriesA4PreferredSharesMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember" unitRef="ilsPershares" scale="0" decimals="2" format="ixt:num-dot-decimal">0.09</ix:nonFraction>,
exercisable at a price of $<ix:nonFraction id="Fixv-39344" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="C_20231231_usgaapStatementClassOfStockAxis_slxnSeriesA4PreferredSharesMember_usgaapStatementEquityComponentsAxis_usgaapPreferredStockMember" unitRef="usdPershares" scale="0" decimals="3" format="ixt:num-dot-decimal">222.921</ix:nonFraction>
per share.</span></span></span></div>

<div style="line-height:1.25">&#160;</div>

<div style="text-align:justify;margin-left:113.4pt;line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>In
addition, on May 30, 2023, the Subsidiary made an investment totaling $<ix:nonFraction id="Fixv-39345" name="us-gaap:ProceedsFromSaleOfInvestmentProjects" contextRef="C_20230530to20230530_usgaapRelatedPartyTransactionsByRelatedPartyAxis_srtSubsidiariesMember" unitRef="usd" scale="6" decimals="-6" format="ixt:num-dot-decimal">3</ix:nonFraction>
million in the Company. This investment resulted in the acquisition by the Subsidiary of <ix:nonFraction id="Fixv-39346" name="us-gaap:StockIssuedDuringPeriodSharesAcquisitions" contextRef="C_20230530to20230530_usgaapRelatedPartyTransactionsByRelatedPartyAxis_srtSubsidiariesMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">13,458</ix:nonFraction>
Series A-4 Preferred Shares and <ix:nonFraction id="Fixv-39347" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits" contextRef="C_20230530to20230530_usgaapRelatedPartyTransactionsByRelatedPartyAxis_srtSubsidiariesMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">13,458</ix:nonFraction>
warrants convertible into series A-4 Preferred Shares. Each warrant is exercisable into one series A-4 Preferred Share at an exercise
price of $<ix:nonFraction id="Fixv-39348" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="C_20230530" unitRef="usdPershares" scale="0" decimals="3" format="ixt:num-dot-decimal">222.921</ix:nonFraction>
per share.&#160;As the acquisition was eliminated in consolidation, it had no impact on the consolidated financial statement.</span></span></span></div>

<div style="line-height:1.25">&#160;</div>

<table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">
  <tr>
    <td style="width:64.25pt">&#160;</td>
    <td style="width:28.45pt;vertical-align:top;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>c.</span></span></span></td>
    <td style="width:auto;vertical-align:top">
        <div style="font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>Shareholders
        rights:</span></span></span></div> </td> </tr>
  </table>

<div style="line-height:1.25">&#160;</div>

<table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">
  <tr>
    <td style="width:90pt">&#160;</td>
    <td style="width:18pt;vertical-align:top;font-family:'Times New Roman',Times,serif"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>1)</span></span></span></td>
    <td style="width:auto;vertical-align:top;text-align:justify">
        <div style="font-family:'Times New Roman',Times,serif"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>The
        Ordinary shares confer upon their holders the right to participate and vote in general shareholders meetings of the Company and to share
        in the distribution of dividends, if any declared by the Company.</span></span></span></div> </td> </tr>
  </table>

<div style="line-height:1.25">&#160;</div>

<div style="text-align:justify;margin-left:108pt;line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>The
Series A Preferred Shares, Series A-1 Preferred Shares, Series A-2 Preferred Shares, Series A-3 Preferred Shares and Series A-4 Preferred
Shares (collectively, the "Preferred A Shares") confer upon their holders all of the rights conferred upon the holders of Ordinary Shares
in the Company, as well as the following rights:</span></span></span></div>

<div style="line-height:1.25">&#160;</div>

<table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">
  <tr>
    <td style="width:108pt">&#160;</td>
    <td style="width:18pt;vertical-align:top;font-family:'Times New Roman',Times,serif"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>a)</span></span></span></td>
    <td style="width:auto;vertical-align:top;text-align:justify">
        <div style="font-family:'Times New Roman',Times,serif"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>Distribution
        Preference</span></span></span></div> </td> </tr>
  </table>

<div style="line-height:1.25">&#160;</div>

<div style="text-align:justify;margin-left:126pt;line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>First,
the holders of Series A-4 Preferred Shares shall be entitled to receive, prior and in preference to any holders of Series A-3 Preferred
Shares, Series A-2 Preferred Shares, Series A-1 Preferred Shares, Series A Preferred Shares, Ordinary Shares or any other equity securities
of the Company, for each outstanding Series A-4 Preferred Share held by them, an amount equal to (i) <ix:nonFraction id="Fixv-39349" name="slxn:PercentageOfOriginalIssuedPrice" contextRef="C_20231231_usgaapStatementClassOfStockAxis_slxnSeriesA4PreferredSharesMember" unitRef="pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">200</ix:nonFraction>%
of the Original Issue Price per each Series A-4 Preferred Share (in cash, cash equivalents or, if applicable, securities) plus (ii) declared
and unpaid dividend in respect of such share (the "Series A-4 Preference Amount").</span></span></span></div>

<div style="line-height:1.25">&#160;</div>

<div style="text-align:justify;margin-left:126pt;line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>In
the event that the distributable proceeds are insufficient for the distribution of the Series A-4 Preference Amount in full to all holders
of Series A-4 Preferred Shares, then the Distributable Proceeds shall be distributed pari passu among such holders of Series A-4 Preferred
Shares in proportion to the respective full Series A-4 Preference Amount such holders would otherwise be entitled to receive.</span></span></span></div>

<div style="line-height:1.25">&#160;</div>

<div><ix:exclude>

<div style="clear:both;margin-top:0pt;margin-bottom:0pt">

<div>

<div style="margin-top:10pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">

<p style="text-align:center;margin-top:0pt;margin-bottom:3pt"><span style="width:34%;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">F-86</span></span></span></p></div><hr style="page-break-after:always;border-width:0px;clear:both;margin:4px 0px;width:100%;height:2px;color:#000000;background-color:#000000;margin-top:0pt;margin-bottom:10pt"/>

<p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:center">&#160;</p>

<p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:center"><strong>S<span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">ILEXION
THERAPEUTICS CORP</span></span></strong><br/><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS (continued)</span></span></p>

<p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">U.S.
DOLLARS IN THOUSANDS</span></span></p>

<p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:center">&#160;</p> </div>
</div>

<div style="text-indent:-49.65pt;margin-left:49.65pt;line-height:1.25;font-family:'Times New Roman', Times, serif"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span style="font-weight:bold">NOTE
9 - REDEEMABLE CONVERTIBLE PREFERRED SHARES AND SHAREHOLDERS&#8217; EQUITY </span>(continued):</span></span></span></div>

<div style="text-indent:-49.65pt;margin-left:49.65pt;line-height:1.25;font-family:'Times New Roman', Times, serif">&#160;</div> </ix:exclude></div>

<div style="text-align:justify;margin-left:126pt;line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>Second,
the holders of Series A Preferred Shares, Series A-1 Preferred Shares, Series A-2 Preferred Shares and Series A-3 Preferred Shares, shall
be entitled to receive, prior and in preference to any holders of Ordinary Shares, for each outstanding Preferred A Share held by them,
an amount equal to: (a) Series A and Series A-1 Shares - the issue price paid for such share; (b) Series A-2 preferred share - US$ <ix:nonFraction id="Fixv-39350" name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="C_20231231_usgaapStatementClassOfStockAxis_slxnSeriesA2PreferredSharesMember" unitRef="usdPershares" scale="0" decimals="3" format="ixt:num-dot-decimal">547.047</ix:nonFraction>
per each Series A-2 share, and (c) Series A-3 Preferred Shares - US$<ix:nonFraction id="Fixv-39351" name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="C_20231231_usgaapStatementClassOfStockAxis_slxnSeriesA3PreferredSharesMember" unitRef="usdPershares" scale="0" decimals="3" format="ixt:num-dot-decimal">410.283</ix:nonFraction>
per each Preferred A-3 share; plus any declared and unpaid dividend in respect of such share (the "Series A, A-1, A-2 and A-3 Preference
Amount", and together with the Series A-4 Preference Amount, the "Preference Amounts").</span></span></span></div>

<div style="line-height:1.25">&#160;</div>

<div style="text-align:justify;margin-left:126pt;line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>In
the event that the distributable proceeds are insufficient for the distribution of the Series A, A-1, A-2 and A-3 Preference Amount in
full to all holders of Preferred A Shares, then the Distributable Proceeds shall be distributed pari passu among such holders of Series
A Preferred Shares, Series A-1 Preferred Shares, Series A-2 Preferred Shares and Series A-3 Preferred Shares in proportion to the respective
full Series A, A-1, A-2 and A-3 Preference Amount such holders would otherwise be entitled to receive.</span></span></span></div>

<div style="line-height:1.25">&#160;</div>

<div style="text-align:justify;margin-left:126pt;line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>Third,
following the distribution of the Preference Amounts, any remaining distributable proceeds shall be distributed pro rata among all the
holders of Ordinary Shares and Preferred A Shares, based on their respective holdings of outstanding shares of the Company, on a pari
passu and as converted basis.</span></span></span></div>

<div style="line-height:1.25">&#160;</div>

<table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">
  <tr>
    <td style="width:108pt">&#160;</td>
    <td style="width:18pt;vertical-align:top;font-family:'Times New Roman',Times,serif"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>b)</span></span></span></td>
    <td style="width:auto;vertical-align:top;text-align:justify">
        <div style="font-family:'Times New Roman',Times,serif"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>Liquidation
        Preference:</span></span></span></div> </td> </tr>
  </table>

<div style="line-height:1.25">&#160;</div>

<div style="text-align:justify;margin-left:126pt;line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>If
the Company is liquidated, dissolved or wound up (including, without limitation, upon appointment of a receiver or liquidator to all or
substantially all of the Company's assets, whether voluntary or involuntary), then all the assets and funds of the Company available for
distribution shall first be distributed in accordance with the Preference Amounts, and thereafter among all shareholders of the Company
pro rata based on the number of Ordinary Shares and Series A Preferred Shares held by each, on an as-converted basis.</span></span></span></div>

<div style="line-height:1.25">&#160;</div>

<div style="text-align:justify;margin-left:126pt;line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>For
the purpose of this clause, a liquidation event also includes (a) a merger of the Company into another corporation(s) in which the holders
of the Company&#8217;s shares do not, immediately after such merger, represent a majority of the voting power of the surviving corporation
(other than a merger with a company in which the shareholders of the Company receive stock of the surviving company which is publicly
traded at the time of such merger); (b) a sale of all or substantially all of the assets of the Company to entities not controlled by
the Company&#8217;s existing shareholders; and (c) a grant of an exclusive, irrevocable licensing of all or substantially all of the Company&#8217;s
intellectual property to a third party<span style="font-style:italic">.</span></span></span></span></div>

<div style="line-height:1.25">&#160;</div>

<table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">
  <tr>
    <td style="width:108pt">&#160;</td>
    <td style="width:18pt;vertical-align:top;font-family:'Times New Roman',Times,serif"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>c)</span></span></span></td>
    <td style="width:auto;vertical-align:top;text-align:justify">
        <div style="font-family:'Times New Roman',Times,serif"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>Dividend
        Preference:</span></span></span></div> </td> </tr>
  </table>

<div style="text-align:justify;margin-left:126pt;line-height:1.25;font-family:'Times New Roman', Times, serif">&#160;</div>

<div style="text-align:justify;margin-left:126pt;line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>In
the event that the Company distributes a dividend in respect of its shares, the holders of Preferred A Shares shall be entitled to receive
the Preference Amounts prior to and in preference to the distribution of dividends to all shareholders of the Company.</span></span></span></div>

<div style="text-align:justify;margin-left:126pt;line-height:1.25">&#160;</div>

<div><ix:exclude>

<div style="line-height:1.25">

<div style="margin-top:10pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">

<p style="text-align:center;margin-top:0pt;margin-bottom:3pt"><span style="width:34%;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">F-87</span></span></span></p></div><hr style="page-break-after:always;border-width:0px;clear:both;margin:4px 0px;width:100%;height:2px;color:#000000;background-color:#000000;margin-top:0pt;margin-bottom:10pt"/>

<p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:center">&#160;</p>

<p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:center"><strong>S<span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">ILEXION
THERAPEUTICS CORP</span></span></strong><br/><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS (continued)</span></span></p>

<p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">U.S.
DOLLARS IN THOUSANDS</span></span></p>

<p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:center">&#160;</p> </div>

<div style="text-indent:-49.65pt;margin-left:49.65pt;line-height:1.25;font-family:'Times New Roman', Times, serif"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span style="font-weight:bold">NOTE
9 - REDEEMABLE CONVERTIBLE PREFERRED SHARES AND SHAREHOLDERS&#8217; EQUITY </span>(continued):</span></span></span></div>

<div style="text-indent:-49.65pt;margin-left:49.65pt;line-height:1.25;font-family:'Times New Roman', Times, serif">&#160;</div> </ix:exclude></div>

<table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">
  <tr>
    <td style="width:108pt">&#160;</td>
    <td style="width:18pt;vertical-align:top;font-family:'Times New Roman',Times,serif"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>d)</span></span></span></td>
    <td style="width:auto;vertical-align:top;text-align:justify">
        <div style="font-family:'Times New Roman',Times,serif"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>Conversion
        Rights:</span></span></span></div> </td> </tr>
  </table>

<div style="line-height:1.25">&#160;</div>

<div style="text-align:justify;margin-left:126pt;line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>Each
Preferred A Share is convertible into Ordinary Shares. Their number is determined by multiplying such Preferred A Share by a quotient
equal to (a) the applicable Original Issue Price for such share divided by (b) the Conversion Price (as defined below) at the time in
effect for such share. The Preferred A Shares are convertible without payment of additional consideration by the holder thereof, upon
each of the following events: (i) at the option of the holder thereof, at any time and from time to time; (ii) upon the consent of, or
conversion by, the holders of a majority of the Preferred A Shares; or (iii) immediately before the consummation of an initial public
offering of the Company's securities.</span></span></span></div>

<div style="line-height:1.25">&#160;</div>

<div style="text-align:justify;margin-left:126pt;line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>The
initial conversion price per each Preferred A Share is the applicable Original Issue Price for such share (the "Conversion Price"). The
Conversion Price per each Preferred A Share shall be adjusted in the event of a share combination or subdivision, share split, distribution
of bonus shares or any other reclassification, reorganization or recapitalization (each, a "Recapitalization Event"), so that the holder
of each Preferred A Share shall be entitled to receive, upon conversion, such number of Ordinary Shares they would have been entitled
to receive following the Recapitalization Event had each Preferred A Share been converted into Ordinary Shares prior to the Recapitalization
Event.</span></span></span></div>

<div style="line-height:1.25">&#160;</div>

<div style="text-align:justify;margin-left:126pt;line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>Additionally,
in the event that the Company issues Additional Shares (as such term is defined in the Company's articles of association), for a consideration
per share lower than the applicable Conversion Price for Series A-4 Preferred Shares in effect immediately prior to such issuance (the
"Reduced Price"), then the Conversion Price for Series A-4 Preferred Shares shall be reduced, for no additional consideration, concurrently
with such issuance, to the Reduced Price.</span></span></span></div>

<div style="line-height:1.25">&#160;</div>

<table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">
  <tr>
    <td style="width:64pt">&#160;</td>
    <td style="vertical-align:top;font-family:Times New Roman, Times, serif;font-weight:bold;width:28pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>d.</span></span></span></td>
    <td style="vertical-align:top;width:auto">
        <div style="font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>Silenseed
        China Minority Equityholder Rights:</span></span></span></div> </td> </tr>
  </table>

<div style="line-height:1.25">&#160;</div>

<div style="text-align:justify;margin-left:92.7pt;line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>The
articles of association of Silenseed (China) Ltd. (the " Subsidiary&#8217;s Articles") provide the minority shareholder, Guangzhou Sino-Israel
Bio-industry Investment Fund (LLP) ("GIBF") with the following minority shareholder protections:</span></span></span></div>

<div style="line-height:1.25">&#160;</div>

<table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">
  <tr>
    <td style="width:92.7pt">&#160;</td>
    <td style="width:18pt;vertical-align:top;font-family:'Times New Roman',Times,serif"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>a.</span></span></span></td>
    <td style="width:auto;vertical-align:top;text-align:justify">
        <div style="font-family:'Times New Roman',Times,serif"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>Conversion
        ("Put/Call") Option: Either GIBF or the Company may elect that the equity rights of GIBF in the Subsidiary shall be exchanged for the
        most senior shares (i.e., preferred shares) of the Company, consequently turning the Subsidiary into a wholly-owned subsidiary of the
        Company. The number of shares to be issued to GIBF upon such exchange shall be calculated by converting the total cash amount invested
        by GIBF in the Subsidiary (the "Contribution Amount"), into the most senior class of shares of the Company as of May 30, 2023, based on
        a pre-money valuation of the Company of US$<ix:nonFraction id="Fixv-39352" name="us-gaap:OptionContractIndexedToEquitySettlementShareFairValue" contextRef="C_20230530" unitRef="usd" scale="6" decimals="-6" format="ixt:num-dot-decimal">20</ix:nonFraction>
        million on a fully diluted basis as of September 1, 2023, or later, as shall be mutually agreed between the parties.</span></span></span></div>
        </td> </tr>
  </table>

<div style="line-height:1.25">&#160;</div>

<table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">
  <tr>
    <td style="width:92.7pt">&#160;</td>
    <td style="width:18pt;vertical-align:top;font-family:'Times New Roman',Times,serif"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>b.</span></span></span></td>
    <td style="width:auto;vertical-align:top;text-align:justify">
        <div style="font-family:'Times New Roman',Times,serif"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>"Company
        Exit Event" means the consummation of: (i) an initial public offering of Company, in a stock exchange, directly or via a SPAC (or similar
        methods); (ii) the sale of all or substantially all of the securities or assets of the Company (or an exclusive license with respect to
        all or substantially all of the assets of Company); (iii) a merger or acquisition of the Company (following which existing shareholders
        as of immediately prior to such transaction hold less than <ix:nonFraction id="Fixv-39353" name="us-gaap:VariableInterestEntityOwnershipPercentage" contextRef="C_20230101to20231231" unitRef="pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">50</ix:nonFraction>%
        of the voting power of the surviving or acquiring entity); (iv) sale of at least <ix:nonFraction id="Fixv-39354" name="slxn:PercentageOfSaleOfAssets" contextRef="C_20230101to20231231" unitRef="pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">50</ix:nonFraction>%
        of the means of control or assets of the Company; (v) liquidation, dissolution or winding up of the Company; or (vi) at any time upon
        a party&#8217;s written notice, provided, however that the exercise of such right by the Company shall be subject to GIBF&#8217;s written
        consent, which shall not be unreasonably withheld.</span></span></span></div> </td> </tr>
  </table>

<div style="line-height:1.25">&#160;</div>

<div><ix:exclude>

<div style="clear:both;margin-top:0pt;margin-bottom:0pt">

<div>

<div style="margin-top:10pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">

<p style="text-align:center;margin-top:0pt;margin-bottom:3pt"><span style="width:34%;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">F-88</span></span></span></p></div><hr style="page-break-after:always;border-width:0px;clear:both;margin:4px 0px;width:100%;height:2px;color:#000000;background-color:#000000;margin-top:0pt;margin-bottom:10pt"/>

<p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:center">&#160;</p>

<p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:center"><strong>S<span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">ILEXION
THERAPEUTICS CORP</span></span></strong><br/><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS (continued)</span></span></p>

<p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">U.S.
DOLLARS IN THOUSANDS</span></span></p>

<p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:center">&#160;</p> </div>
</div>

<div style="text-indent:-49.65pt;margin-left:49.65pt;line-height:1.25;font-family:'Times New Roman', Times, serif"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span style="font-weight:bold">NOTE
9 - REDEEMABLE CONVERTIBLE PREFERRED SHARES AND SHAREHOLDERS&#8217; EQUITY </span>(continued):</span></span></span></div>

<div style="text-indent:-49.65pt;margin-left:49.65pt;line-height:1.25;font-family:'Times New Roman', Times, serif">&#160;</div> </ix:exclude></div>

<table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">
  <tr>
    <td style="width:90pt">&#160;</td>
    <td style="width:18pt;vertical-align:top;font-family:'Times New Roman',Times,serif"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>1)</span></span></span></td>
    <td style="width:auto;vertical-align:top;text-align:justify">
        <div><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span style="text-decoration:underline">Anti-Dilution
        Protection</span>: If the Subsidiary issues any additional equity rights in the Subsidiary to a third-party investor in the next two equity
        investment rounds of the Subsidiary, reflecting a purchase price per equity right lower than the purchase price per equity right paid
        by GIBF, GIBF will be issued additional equity rights of the Subsidiary for no consideration, based on a broad based weighted average
        formula.</span></span></span></div> </td> </tr>
  </table>

<div style="line-height:1.25">&#160;</div>

<table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">
  <tr>
    <td style="width:90pt">&#160;</td>
    <td style="width:18pt;vertical-align:top;font-family:'Times New Roman',Times,serif"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>2)</span></span></span></td>
    <td style="width:auto;vertical-align:top;text-align:justify">
        <div><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span style="text-decoration:underline">Registration
        Rights</span>: GIBF shall be entitled to the same rights to register its equity rights in the Subsidiary as part of an IPO of the Subsidiary,
        as granted to Company, on a pro-rata basis.</span></span></span></div> </td> </tr>
  </table>

<div style="line-height:1.25">&#160;</div>

<table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">
  <tr>
    <td style="width:90pt">&#160;</td>
    <td style="width:18pt;vertical-align:top;font-family:'Times New Roman',Times,serif"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>3)</span></span></span></td>
    <td style="width:auto;vertical-align:top;text-align:justify">
        <div><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span style="text-decoration:underline">Liquidation
        Preference</span>: In the event of an IPO in which the Subsidiary's valuation is at least $<ix:nonFraction id="Fixv-39355" name="us-gaap:GainLossOnSaleOfStockInSubsidiaryOrEquityMethodInvestee" contextRef="C_20230101to20231231_usgaapSubsidiarySaleOfStockAxis_usgaapIPOMember" unitRef="usd" scale="6" decimals="-6" format="ixt:num-dot-decimal">200</ix:nonFraction>
        million or an Exit Event (as defined in the Subsidiary&#8217;s Articles), GIBF shall be entitled to be paid out of the assets legally
        available for distribution to equity holders of the Subsidiary (the "Distributable Proceeds"), prior to any payment made to any other
        equity holder, an amount in cash equal to the Contribution Amount (the "Preference Amount"). Following payment of the Preference Amount,
        any remaining Distributable Proceeds shall be distributed among all holders of equity rights excluding GIBF, on a pro-rata basis, provided
        that GIBF shall have the right to waive its right to receive the Preference Amount, in which case all Distributable Proceeds shall be
        distributed among all equity holders of the Subsidiary on a pari passu and pro rata basis.</span></span></span></span></div> </td> </tr>
  </table>

<div style="line-height:1.25">&#160;</div>

<table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">
  <tr>
    <td style="width:90pt">&#160;</td>
    <td style="width:18pt;vertical-align:top;font-family:'Times New Roman',Times,serif"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>4)</span></span></span></td>
    <td style="width:auto;vertical-align:top;text-align:justify">
        <div style="font-family:'Times New Roman',Times,serif"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>Other
        rights, such as right of first refusal for GIBF to purchase the Company&#8217;s equity rights in the Subsidiary if the Company proposes
        to sell or receives an offer to sell its equity rights; a right of co-sale for GIBF to participate in a proposed sale of the Company&#8217;s
        equity rights in the Subsidiary on a pro-rata basis; a preemptive right for both investors to participate in the issuance of new securities
        by the Subsidiary until the consummation of an IPO or an Exit Event (as defined in the Subsidiary&#8217;s Articles).</span></span></span></div>
        </td> </tr>
  </table> </div> </ix:nonNumeric> </div>

<div style="font-size:10pt;margin-top:0pt;margin-bottom:0pt;font-family:'Times New Roman', Times, serif">&#160;</div> <ix:nonNumeric id="Fxbrl_20241003125143189" name="us-gaap:IncomeTaxDisclosureTextBlock" contextRef="C_20230101to20231231" escape="true">

<div>

<div style="font:10pt Times New Roman, Times, Serif">

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0"><strong><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">NOTE
10&#160; - INCOME TAXES:</span></span></strong></p> </div>

<div>

<div>

<div style="line-height:1.25">&#160;</div>

<table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">
  <tr>
    <td style="width:64.25pt">&#160;</td>
    <td style="width:28.45pt;vertical-align:top;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">a.</span></span></td>
    <td style="width:auto;vertical-align:top">
        <div style="font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Corporate
        taxation in Israel</span></span></div> </td> </tr>
  </table>

<div style="line-height:1.25">&#160;</div>

<div style="text-align:justify;margin-left:92.7pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The
Company is taxed according to the regular corporate income tax in Israel.&#160; The corporate tax rate is <ix:nonFraction id="Fxbrl_20241003125013334" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" contextRef="C_20220101to20221231" unitRef="pure" scale="-2" decimals="2" format="ixt:num-dot-decimal"><ix:nonFraction id="Fixv-39356" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" contextRef="C_20230101to20231231" unitRef="pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">23</ix:nonFraction></ix:nonFraction>%
in 2023 and 2022.</span></span></div>

<div style="line-height:1.25">&#160;</div>

<table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">
  <tr>
    <td style="width:64.25pt">&#160;</td>
    <td style="width:28.45pt;vertical-align:top;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">b.</span></span></td>
    <td style="width:auto;vertical-align:top;text-align:justify">
        <div style="font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Income
        taxes on non-Israeli&#160;subsidiary</span></span></div> </td> </tr>
  </table>

<div style="line-height:1.25">&#160;</div>

<div style="text-align:justify;margin-left:92.7pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The
Subsidiary is taxed under the tax laws of China and the corporate tax rate is&#160; <ix:nonFraction id="Fixv-39358" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" contextRef="C_20230101to20231231_srtStatementGeographicalAxis_countryCN" unitRef="pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">25</ix:nonFraction>%.</span></span></div>

<div style="line-height:1.25">&#160;</div>

<table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">
  <tr>
    <td style="width:64.25pt">&#160;</td>
    <td style="width:28.45pt;vertical-align:top;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">c.</span></span></td>
    <td style="width:auto;vertical-align:top">
        <div style="font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Tax
        loss carryforwards</span></span></div> </td> </tr>
  </table>

<div style="line-height:1.25">&#160;</div>

<div style="text-align:justify;margin-left:92.7pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">As
of December 31, 2023, the expected tax loss carryforwards of the Company were approximately $<ix:nonFraction id="Fixv-39359" name="us-gaap:OperatingLossCarryforwards" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">19,151</ix:nonFraction>,
which may be carried forward and offset against taxable income in the future for an indefinite period. The Company has recognized valuation
allowance for the full amount in respect of these tax loss carryforwards since their utilization is not expected in the foreseeable future.</span></span></div>

<div style="line-height:1.25">&#160;</div>

<div><ix:exclude>

<div style="clear:both;margin-top:0pt;margin-bottom:0pt">

<div>

<div style="margin-top:10pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">

<p style="text-align:center;margin-top:0pt;margin-bottom:3pt"><span style="width:34%;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">F-89</span></span></span></p></div><hr style="page-break-after:always;border-width:0px;clear:both;margin:4px 0px;width:100%;height:2px;color:#000000;background-color:#000000;margin-top:0pt;margin-bottom:10pt"/>

<p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:center">&#160;</p>

<p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:center"><strong>S<span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">ILEXION
THERAPEUTICS CORP</span></span></strong><br/><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS (continued)</span></span></p>

<p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">U.S.
DOLLARS IN THOUSANDS</span></span></p>

<p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:center">&#160;</p> </div>
</div>

<div style="line-height:1.25;font-family:'Times New Roman', Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">NOTE
10&#160; - INCOME TAXES </span>(continued):</span></span></div>

<div style="line-height:1.25;font-family:'Times New Roman', Times, serif">&#160;</div> </ix:exclude></div>

<div style="text-align:justify;margin-left:92.7pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Israel
and foreign components of loss from continuing operations, before income taxes consisted of:</span></span></div>

<div style="line-height:1.25">&#160;</div>

<div style="margin-left:99pt"> <ix:nonNumeric id="Fxbrl_20241205142224631" name="us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" contextRef="C_20230101to20231231" escape="true">

<table border="0" cellpadding="0" cellspacing="0" style="color:#000000;font-family:'Times New Roman',Times,serif;font-size:10pt;text-align:left;width:85%">
  <tr>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
    <td colspan="6" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Year&#160;ended&#160;December&#160;31</span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td> </tr>
  <tr>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2023</span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2022</span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:top;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Israel</span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fixv-39361" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="C_20230101to20231231_srtStatementGeographicalAxis_countryIL" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">4,769</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fixv-39362" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="C_20220101to20221231_srtStatementGeographicalAxis_countryIL" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">2,929</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align:top;width:76%;padding-bottom:2px;background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Subsidiary
        outside of Israel</span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fixv-39363" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="C_20230101to20231231_srtStatementGeographicalAxis_slxnSubsidiaryOutsideOfIsraelMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">307</ix:nonFraction></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(255, 255, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fixv-39364" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="C_20220101to20221231_srtStatementGeographicalAxis_slxnSubsidiaryOutsideOfIsraelMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">535</ix:nonFraction></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(255, 255, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align:top;width:76%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Total</span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fixv-39365" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">5,076</ix:nonFraction></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fixv-39366" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">3,464</ix:nonFraction></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        </tr>
  </table> </ix:nonNumeric> </div>

<div style="line-height:1.25;clear:both">&#160;</div>

<table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">
  <tr>
    <td style="width:64.25pt">&#160;</td>
    <td style="width:28.45pt;vertical-align:top;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">d.</span></span></td>
    <td style="width:auto;vertical-align:top;text-align:justify">
        <div style="font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Uncertainty
        in income tax</span></span></div> </td> </tr>
  </table>

<div style="line-height:1.25">&#160;</div>

<div style="text-align:justify;margin-left:92.7pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">As
of December&#160;31, 2023 and 2022, no liability for unrecognized tax benefits was recorded due to immateriality.</span></span></div>

<div style="line-height:1.25">&#160;</div>

<table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">
  <tr>
    <td style="width:64.25pt">&#160;</td>
    <td style="width:28.45pt;vertical-align:top;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">e.</span></span></td>
    <td style="width:auto;vertical-align:top;text-align:justify">
        <div style="font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Tax
        rate reconciliation</span></span></div> </td> </tr>
  </table>

<div style="line-height:1.25">&#160;</div>

<div style="text-align:justify;margin-left:92.15pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Income
tax expense attributable to income from continuing operations was $<ix:nonFraction id="Fixv-39367" name="us-gaap:IncomeTaxExpenseBenefit" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">32</ix:nonFraction>
and $<ix:nonFraction id="Fixv-39368" name="us-gaap:IncomeTaxExpenseBenefit" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">24</ix:nonFraction>
for the years ended December 31, 2023 and 2022, respectively, and differed from the amounts computed by applying an Israeli Statutory
income tax rate of <ix:nonFraction id="Fixv-39369" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" contextRef="C_20230101to20231231" unitRef="pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">23</ix:nonFraction>%
to pretax income from continuing operations, mainly as a result of changes in valuation allowance of $<ix:nonFraction id="Fixv-39370" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">922</ix:nonFraction>
and $<ix:nonFraction id="Fixv-39371" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">268</ix:nonFraction>
respectively, as well as nondeductible expenses.</span></span></div>

<div style="line-height:1.25">&#160;</div>

<div style="text-align:justify;margin-left:92.15pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The
reconciliation of&#160;the theoretical tax benefit (expense) by the Israeli statutory tax rate to the Company's effective benefit (expense)
taxes are as follows:</span></span></div>

<div style="line-height:1.25">&#160;</div>

<div style="margin-left:99pt"> <ix:nonNumeric id="Fxbrl_20241205142243270" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" contextRef="C_20230101to20231231" escape="true">

<table border="0" cellpadding="0" cellspacing="0" style="color:#000000;font-family:'Times New Roman',Times,serif;font-size:10pt;text-align:left;width:85%">
  <tr>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
    <td colspan="6" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Year&#160;ended&#160;December&#160;31</span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td> </tr>
  <tr>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2023</span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2022</span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:top;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Loss
        before income taxes</span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fixv-39373" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">5,076</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fixv-39374" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">3,464</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
        </td> </tr>
  <tr>
    <td style="vertical-align:top;width:76%;padding-bottom:2px;background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Statutory
        tax rate</span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fixv-39375" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" contextRef="C_20230101to20231231" unitRef="pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">23</ix:nonFraction></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(255, 255, 255);vertical-align:bottom;white-space:nowrap">
        <div style="line-height:1.25">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">%</span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fixv-39376" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" contextRef="C_20220101to20221231" unitRef="pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">23</ix:nonFraction></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(255, 255, 255);vertical-align:bottom;white-space:nowrap">
        <div style="line-height:1.25">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">%</span></span></div>
        </div> </td> </tr>
  <tr>
    <td style="vertical-align:top;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Computed
        &#8220;expected&#8221; tax income</span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fixv-39377" name="us-gaap:IncomeTaxReconciliationOtherAdjustments" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">1,167</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fixv-39378" name="us-gaap:IncomeTaxReconciliationOtherAdjustments" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">797</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
        </td> </tr>
  <tr>
    <td style="vertical-align:top;width:76%;background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Exchange
        rate differences</span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fixv-39379" name="us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">120</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fixv-39380" name="us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">588</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align:top;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Non-deductible
        share-based compensation</span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fixv-39381" name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">30</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fixv-39382" name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">29</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align:top;width:76%;background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Non-deductible
        financial instruments valuation</span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fixv-39383" name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseOther" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">21</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fixv-39384" name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseOther" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">215</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom;white-space:nowrap">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
        </td> </tr>
  <tr>
    <td style="vertical-align:top;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Effect
        of other non-deductible differences</span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fixv-39385" name="us-gaap:IncomeTaxReconciliationNondeductibleExpense" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">112</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fixv-39386" name="us-gaap:IncomeTaxReconciliationNondeductibleExpense" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">162</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align:top;width:76%;background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Change
        in valuation allowance</span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fixv-39387" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">922</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fixv-39388" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">268</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align:top;width:76%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Subsidiary
        tax rate differences</span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fixv-39389" name="us-gaap:IncomeLossFromSubsidiariesTaxExpenseBenefit" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">6</ix:nonFraction></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
        <div style="line-height:1.25">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fixv-39390" name="us-gaap:IncomeLossFromSubsidiariesTaxExpenseBenefit" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">11</ix:nonFraction></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
        <div style="line-height:1.25">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
        </div> </td> </tr>
  <tr>
    <td style="vertical-align:top;width:76%;padding-bottom:4px;background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Reported
        taxes&#160;on income</span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fixv-39391" name="us-gaap:IncomeTaxExpenseBenefit" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">32</ix:nonFraction></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(255, 255, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fixv-39392" name="us-gaap:IncomeTaxExpenseBenefit" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">24</ix:nonFraction></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(255, 255, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        </tr>
  </table> </ix:nonNumeric> </div>

<div style="line-height:1.25;clear:both">&#160;</div>

<div><ix:exclude>

<div style="line-height:1.25">

<div style="margin-top:10pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">

<p style="text-align:center;margin-top:0pt;margin-bottom:3pt"><span style="width:34%;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">F-90</span></span></span></p></div><hr style="page-break-after:always;border-width:0px;clear:both;margin:4px 0px;width:100%;height:2px;color:#000000;background-color:#000000;margin-top:0pt;margin-bottom:10pt"/>

<p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:center">&#160;</p>

<p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:center"><strong>S<span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">ILEXION
THERAPEUTICS CORP</span></span></strong><br/><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS (continued)</span></span></p>

<p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">U.S.
DOLLARS IN THOUSANDS</span></span></p>

<p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:center">&#160;</p> </div>

<div style="line-height:1.25;font-family:'Times New Roman', Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">NOTE
10&#160; - INCOME TAXES </span>(continued):</span></span></div>

<div style="line-height:1.25;font-family:'Times New Roman', Times, serif">&#160;</div> </ix:exclude></div>

<table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">
  <tr>
    <td style="width:64.25pt">&#160;</td>
    <td style="width:28.45pt;vertical-align:top;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">f.</span></span></td>
    <td style="width:auto;vertical-align:top;text-align:justify">
        <div style="font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Deferred
        tax</span></span></div> </td> </tr>
  </table>

<div style="line-height:1.25">&#160;</div>

<div style="text-align:justify;margin-left:92.7pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Deferred
taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting
purposes and the amounts used for income tax purposes. Significant components of the Company&#8217;s deferred tax assets are as follows:</span></span></div>

<div style="line-height:1.25">&#160;</div>

<div style="margin-left:99pt"> <ix:nonNumeric id="Fxbrl_20241205142500390" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" contextRef="C_20230101to20231231" escape="true">

<table border="0" cellpadding="0" cellspacing="0" style="color:#000000;font-family:'Times New Roman',Times,serif;font-size:10pt;text-align:left;width:85%">
  <tr>
    <td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
    <td colspan="6" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">December
        31</span></span></div> </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2023</span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2022</span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:top;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Deferred
        tax assets</span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:top;width:76%;background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="margin-left:18pt;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Operating
        loss carryforwards</span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fixv-39394" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,405</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fixv-39395" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,752</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align:top;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="margin-left:18pt;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Research
        and development</span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fixv-39396" name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">780</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fixv-39397" name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">592</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align:top;width:76%;background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="margin-left:18pt;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Accrued
        expenses</span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fixv-39398" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">304</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fixv-39399" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">219</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align:top;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="margin-left:18pt;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Lease
        liability</span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fixv-39400" name="slxn:DeferredTaxAssetsLeaseLiability" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">39</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fixv-39401" name="slxn:DeferredTaxAssetsLeaseLiability" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">62</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align:top;width:76%;padding-bottom:2px;background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="margin-left:18pt;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Other</span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fixv-39402" name="us-gaap:DeferredTaxAssetsOther" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">25</ix:nonFraction></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(255, 255, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fixv-39403" name="us-gaap:DeferredTaxAssetsOther" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">30</ix:nonFraction></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(255, 255, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align:top;width:76%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Total
        deferred tax assets</span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fixv-39404" name="us-gaap:DeferredTaxAssetsGross" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,553</ix:nonFraction></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fixv-39405" name="us-gaap:DeferredTaxAssetsGross" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,655</ix:nonFraction></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align:top;width:76%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align:top;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Deferred
        tax liabilities</span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align:bottom;width:76%;padding-bottom:2px;background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="margin-left:17.25pt;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Right
        of use asset</span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fixv-39406" name="us-gaap:DeferredTaxLiabilitiesOtherFiniteLivedAssets" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">46</ix:nonFraction></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(255, 255, 255);vertical-align:bottom;white-space:nowrap">
        <div style="line-height:1.25">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fixv-39407" name="us-gaap:DeferredTaxLiabilitiesOtherFiniteLivedAssets" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">70</ix:nonFraction></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(255, 255, 255);vertical-align:bottom;white-space:nowrap">
        <div style="line-height:1.25">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
        </div> </td> </tr>
  <tr>
    <td style="vertical-align:top;width:76%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Total
        deferred tax liabilities</span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fixv-39408" name="us-gaap:DeferredIncomeTaxLiabilities" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">46</ix:nonFraction></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
        <div style="line-height:1.25">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fixv-39409" name="us-gaap:DeferredIncomeTaxLiabilities" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">70</ix:nonFraction></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
        <div style="line-height:1.25">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
        </div> </td> </tr>
  <tr>
    <td style="vertical-align:top;width:76%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align:top;width:76%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Valuation
        allowance</span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fixv-39410" name="us-gaap:DeferredTaxAssetsValuationAllowance" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,507</ix:nonFraction></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
        <div style="line-height:1.25">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fixv-39411" name="us-gaap:DeferredTaxAssetsValuationAllowance" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,585</ix:nonFraction></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
        <div style="line-height:1.25">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
        </div> </td> </tr>
  <tr>
    <td style="vertical-align:top;width:76%;padding-bottom:4px;background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="text-indent:-12.85pt;margin-left:12.85pt;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Deferred
        tax assets, net of valuation allowance</span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20241004175710019" name="us-gaap:DeferredTaxAssetsNet" contextRef="C_20231231" unitRef="usd" scale="0" decimals="0" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(255, 255, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20241004175729646" name="us-gaap:DeferredTaxAssetsNet" contextRef="C_20221231" unitRef="usd" scale="0" decimals="0" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(255, 255, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        </tr>
  </table> </ix:nonNumeric> </div>

<div style="line-height:1.25;clear:both">&#160;</div>

<table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">
  <tr>
    <td style="width:64.25pt">&#160;</td>
    <td style="width:28.45pt;vertical-align:top;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">g.</span></span></td>
    <td style="width:auto;vertical-align:top;text-align:justify">
        <div style="font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Roll
        forward of valuation allowance:</span></span></div> </td> </tr>
  </table>

<div style="line-height:1.25">&#160;</div>

<div style="text-align:justify;margin-left:92.7pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The
following table presents a reconciliation of the beginning and ending valuation allowance:</span></span></div>

<div style="line-height:1.25">&#160;</div>

<div style="margin-left:99pt"> <ix:nonNumeric id="Fxbrl_20241205142524357" name="us-gaap:SummaryOfValuationAllowanceTextBlock" contextRef="C_20230101to20231231" escape="true">

<table border="0" cellpadding="0" cellspacing="0" style="color:#000000;font-family:'Times New Roman',Times,serif;font-size:10pt;text-align:left;width:85%">
  <tr>
    <td style="vertical-align:top;width:88%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Balance
        as of December 31, 2021</span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fixv-39413" name="us-gaap:DeferredTaxAssetsValuationAllowance" contextRef="C_20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,317</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
        </td> </tr>
  <tr>
    <td style="vertical-align:top;width:88%;padding-bottom:2px;background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Additions</span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fixv-39414" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">268</ix:nonFraction></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(255, 255, 255);vertical-align:bottom;white-space:nowrap">
        <div style="line-height:1.25">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
        </div> </td> </tr>
  <tr>
    <td style="vertical-align:top;width:88%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Balance
        as of December 31, 2022</span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fixv-39415" name="us-gaap:DeferredTaxAssetsValuationAllowance" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,585</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
        </td> </tr>
  <tr>
    <td style="vertical-align:top;width:88%;padding-bottom:2px;background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Additions</span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fixv-39416" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">922</ix:nonFraction></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(255, 255, 255);vertical-align:bottom;white-space:nowrap">
        <div style="line-height:1.25">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
        </div> </td> </tr>
  <tr>
    <td style="vertical-align:top;width:88%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Balance
        as of December 31, 2023</span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fixv-39417" name="us-gaap:DeferredTaxAssetsValuationAllowance" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,507</ix:nonFraction></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
        <div style="line-height:1.25">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
        </div> </td> </tr>
  </table> </ix:nonNumeric> </div>

<div style="line-height:1.25;clear:both">&#160;</div>

<div style="text-align:justify;margin-left:92.7pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">In
assessing the realization of deferred tax assets, management considers whether it is more likely than not that all or some portion of
the deferred tax assets will not be realized. The ultimate realization of the deferred tax assets is dependent upon the generation of
future taxable income during the periods in which temporary differences are deductible and net operating losses are utilized. Based on
these factors, the Company recorded a full valuation allowance on December 31, 2023 and 2022.</span></span></div>

<div style="line-height:1.25">&#160;</div>

<table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">
  <tr>
    <td style="width:64.25pt">&#160;</td>
    <td style="width:28.45pt;vertical-align:top;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">h.</span></span></td>
    <td style="width:auto;vertical-align:top">
        <div style="font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Income
        tax assessments</span></span></div> </td> </tr>
  </table>

<div style="line-height:1.25">&#160;</div>

<div style="text-align:justify;margin-left:92.7pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The
Company has tax assessments that are considered to be final through tax year 2018.</span></span></div>

<div style="text-align:justify;margin-left:92.7pt;line-height:1.25">&#160;</div>

<div style="text-align:justify;margin-left:92.7pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The
subsidiary does not have final tax assessments.</span></span></div> </div> </div> </div> </ix:nonNumeric>

<div style="font-size:10pt;margin-top:0pt;margin-bottom:0pt;font-family:'Times New Roman', Times, serif">&#160;</div>

<div style="margin-top:10pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">

<p style="text-align:center;margin-top:0pt;margin-bottom:3pt"><span style="width:34%;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">F-91</span></span></span></p></div><hr style="page-break-after:always;border-width:0px;clear:both;margin:4px 0px;width:100%;height:2px;color:#000000;background-color:#000000;margin-top:0pt;margin-bottom:10pt"/>

<p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:center">&#160;</p>

<p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:center"><strong>S<span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">ILEXION
THERAPEUTICS CORP</span></span></strong><br/><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS (continued)</span></span></p>

<p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">U.S.
DOLLARS IN THOUSANDS</span></span></p>

<p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:center">&#160;</p>

<div style="font:10pt Times New Roman, Times, Serif"> <ix:nonNumeric id="Fxbrl_20241003133934065" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" contextRef="C_20230101to20231231" escape="true">

<div>

<div>

<div>

<div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">NOTE
11&#160; - SHARE-BASED COMPENSATION:</span></span></div>

<div style="line-height:1.25">&#160;</div>

<table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">
  <tr>
    <td style="width:63.8pt">&#160;</td>
    <td style="width:18pt;vertical-align:top;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">1)</span></span></td>
    <td style="width:auto;vertical-align:top;text-align:justify">
        <div style="font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Warrants
        to service provider</span></span></div> </td> </tr>
  </table>

<div style="text-align:justify;margin-left:85.05pt;line-height:1.25">&#160;</div>

<div style="text-align:justify;margin-left:85.05pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">In
conjunction with the issuance of Series A-1 Preferred Shares, the Company issued warrants to acquire <ix:nonFraction id="Fixv-39418" name="slxn:WarrantsIssued" contextRef="C_20231231_usgaapStatementClassOfStockAxis_slxnSeriesA1PreferredSharesMember" unitRef="shares" scale="0" decimals="0" format="ixt:num-dot-decimal">427</ix:nonFraction>
Series A-1 Preferred Shares to a service provider who assisted in raising the&#160;funds, which warrants were classified as part of the
issue expenses. These warrants carry an exercise price of $<ix:nonFraction id="Fixv-39419" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="C_20231231_usgaapStatementClassOfStockAxis_slxnSeriesA1PreferredSharesMember" unitRef="usdPershares" scale="0" decimals="2" format="ixt:num-dot-decimal">241.02</ix:nonFraction>
per share and are set to expire on January 31, 2027. As of December 31, 2023 and 2022, all <ix:nonFraction id="Fxbrl_20241003172646605" name="us-gaap:WarrantsAndRightsOutstanding" contextRef="C_20221231_usgaapStatementClassOfStockAxis_slxnSeriesA1PreferredSharesMember" unitRef="usd" scale="0" decimals="0" format="ixt:num-dot-decimal"><ix:nonFraction id="Fixv-39420" name="us-gaap:WarrantsAndRightsOutstanding" contextRef="C_20231231_usgaapStatementClassOfStockAxis_slxnSeriesA1PreferredSharesMember" unitRef="usd" scale="0" decimals="0" format="ixt:num-dot-decimal">427</ix:nonFraction></ix:nonFraction>
of such warrants remained outstanding.</span></span></div>

<div style="text-align:justify;margin-left:85.05pt;line-height:1.25">&#160;</div>

<div style="text-align:justify;margin-left:85.05pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">In
conjunction with the issuance of Series A-2 Preferred Shares, the Company issued warrants to acquire <ix:nonFraction id="Fixv-39422" name="slxn:WarrantsIssued" contextRef="C_20231231_usgaapStatementClassOfStockAxis_slxnSeriesA3PreferredSharesMember" unitRef="shares" scale="0" decimals="0" format="ixt:num-dot-decimal">446</ix:nonFraction>
Series A-3 Preferred Shares to a service provider who assisted in raising the&#160;funds, which were recorded as part of issue expenses.
These warrants carry an exercise price of $<ix:nonFraction id="Fixv-39423" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="C_20231231_usgaapStatementClassOfStockAxis_slxnSeriesA3PreferredSharesMember" unitRef="usdPershares" scale="0" decimals="3" format="ixt:num-dot-decimal">410.283</ix:nonFraction>
per share and are set to expire on January 14, 2029. As of December 31, 2023 and 2022, all <ix:nonFraction id="Fxbrl_20241003172656716" name="us-gaap:WarrantsAndRightsOutstanding" contextRef="C_20221231_usgaapStatementClassOfStockAxis_slxnSeriesA3PreferredSharesMember" unitRef="usd" scale="0" decimals="0" format="ixt:num-dot-decimal"><ix:nonFraction id="Fixv-39424" name="us-gaap:WarrantsAndRightsOutstanding" contextRef="C_20231231_usgaapStatementClassOfStockAxis_slxnSeriesA3PreferredSharesMember" unitRef="usd" scale="0" decimals="0" format="ixt:num-dot-decimal">446</ix:nonFraction></ix:nonFraction>
of such warrants remained outstanding.</span></span></div>

<div style="text-align:justify;margin-left:85.05pt;line-height:1.25">&#160;</div>

<div style="text-align:justify;margin-left:85.05pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The
warrants for both the Series A-1 Preferred Shares and Series A-3 Preferred Shares were recognized as issuance costs of the SAFE round
and recognized as financial expenses.</span></span></div>

<div style="text-align:justify;margin-left:85.05pt;line-height:1.25">&#160;</div>

<div style="text-align:justify;margin-left:85.05pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">In
conjunction with the issuance of Series A-4 Preferred Shares, the Company issued warrants to acquire <ix:nonFraction id="Fixv-39426" name="slxn:WarrantsIssued" contextRef="C_20231231_usgaapStatementClassOfStockAxis_slxnSeriesA4PreferredSharesMember" unitRef="shares" scale="0" decimals="0" format="ixt:num-dot-decimal">12</ix:nonFraction>
Series A-4 Preferred Shares to a service provider who assisted in raising the&#160;funds, which were recorded as part of issue expenses.
These warrants carry an exercise price as those issued to the investors in such round, and expire on May 30, 2030. As of December 31,
2023, all <ix:nonFraction id="Fixv-39427" name="us-gaap:WarrantsAndRightsOutstanding" contextRef="C_20231231_usgaapStatementClassOfStockAxis_slxnSeriesA4PreferredSharesMember" unitRef="usd" scale="0" decimals="0" format="ixt:num-dot-decimal">12</ix:nonFraction>
of such warrants remained outstanding.&#160;The warrants were recognized as issuance costs and the portion attributed to the issuance
of Series A-4 Preferred Shares was classified as part of the shareholders&#8217; equity. The portion attributed to the issuance of the
warrants was recognized as financial expenses.</span></span></div>

<div style="text-align:justify;margin-left:85.05pt;line-height:1.25">&#160;</div>

<table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">
  <tr>
    <td style="width:63.8pt">&#160;</td>
    <td style="width:18pt;vertical-align:top;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2)</span></span></td>
    <td style="width:auto;vertical-align:top;text-align:justify">
        <div style="font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Employee
        Stock Option Plan</span></span></div> </td> </tr>
  </table>

<div style="text-align:justify;margin-left:85.05pt;line-height:1.25">&#160;</div>

<div style="text-align:justify;margin-left:85.05pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">As
of December 31, 2023, the&#160;Board of Directors approved a pool of&#160;<ix:nonFraction id="Fixv-39428" name="srt:StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased" contextRef="C_20231231" unitRef="shares" scale="0" decimals="0" format="ixt:num-dot-decimal">57,925</ix:nonFraction>
Ordinary Shares for grant to Company employees, consultants, directors and other service providers.</span></span></div>

<div style="text-align:justify;margin-left:85.05pt;line-height:1.25">&#160;</div>

<div style="text-align:justify;margin-left:85.05pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Under
the Company's 2013 and 2023 Incentive Option Plans (collectively "the Plan"), options to purchase Ordinary Shares may be granted to certain
entities and individuals. Each option granted under the Plan is exercisable until <ix:nonNumeric id="Fixv-39429" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" contextRef="C_20230101to20231231" format="ixt-sec:durwordsen">10
years</ix:nonNumeric> from the date of grant, or earlier upon cessation of employment or engagement of the grantee and certain other occurrences.</span></span></div>

<div style="text-align:justify;margin-left:85.05pt;line-height:1.25">&#160;</div>

<div style="text-align:justify;margin-left:85.05pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Grants
to employees are made in accordance with the Plan and are carried out within the provisions of Section&#160;102 of the Israel Income Tax
Ordinance, under the capital gains track described in subsection (b)(2) of Section 102. In accordance with such track selected by the
Company and the provisions associated with it, the Company is not entitled to claim a tax deduction for the employee benefits.</span></span></div>

<div style="text-align:justify;margin-left:85.05pt;line-height:1.25">&#160;</div>

<div style="text-align:justify;margin-left:85.05pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The
Company's options expenses amounted to a total of $<ix:nonFraction id="Fixv-39430" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">130</ix:nonFraction>
and $<ix:nonFraction id="Fixv-39431" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">125</ix:nonFraction>
in 2023 and 2022, respectively.&#160;As of December 31, 2023, <ix:nonFraction id="Fixv-39432" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" contextRef="C_20231231" unitRef="shares" scale="0" decimals="0" format="ixt:num-dot-decimal">4,019</ix:nonFraction>
shares remain available for grant under the Plan.</span></span></div> </div> </div>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.75in">&#160;</p>

<div><ix:exclude>

<div style="margin-top:0pt;margin-bottom:0pt">

<div style="margin-top:10pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">

<p style="text-align:center;margin-top:0pt;margin-bottom:3pt"><span style="width:34%;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">F-92</span></span></span></p></div><hr style="page-break-after:always;border-width:0px;clear:both;margin:4px 0px;width:100%;height:2px;color:#000000;background-color:#000000;margin-top:0pt;margin-bottom:10pt"/>

<p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:center">&#160;</p>

<p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:center"><strong>S<span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">ILEXION
THERAPEUTICS CORP</span></span></strong><br/><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS (continued)</span></span></p>

<p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">U.S.
DOLLARS IN THOUSANDS</span></span></p>

<p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:center">&#160;</p> </div>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify"><strong>NOTE 11&#160; -&#160;SHARE-BASED COMPENSATION</strong>&#160;(continued):</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">&#160;</p> </ix:exclude></div>

<div>

<div>

<div style="text-align:justify;margin-left:63.8pt;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Summary
of outstanding and exercisable options:</span></span></div>

<div style="line-height:1.25">&#160;</div>

<div style="text-align:justify;margin-left:63.8pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Below
is a summary of the Company's stock-based compensation activity and related information with respect to options granted to employees and
non-employees for the year ended December 31, 2023 and 2022:</span></span></div>

<div style="line-height:1.25">&#160;</div> <ix:nonNumeric id="Fxbrl_20241205123915344" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" contextRef="C_20230101to20231231" escape="true">

<div>

<div style="margin-left:63pt">

<table border="0" cellpadding="0" cellspacing="0" style="color:#000000;font-family:'Times New Roman',Times,serif;font-size:10pt;text-align:left;width:85%">
  <tr>
    <td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Number
        of options</span></span></div> </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
    <td colspan="2" style="verical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Weighted-average
        exercise price (in U.S. dollars)</span></span></div> </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Weighted-
        average remaining contractual term</span></span></div>
        <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(in
        years)</span></span></div> </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Aggregate</span></span></div>
        <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">intrinsic</span></span></div>
        <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">value</span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
    <td colspan="2" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
    <td colspan="2" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
    <td colspan="2" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
    <td colspan="2" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:bottom;width:52%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Outstanding
        at December 31, 2022</span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fixv-39434" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="C_20221231_usgaapGranteeStatusAxis_slxnShareBasedPaymentArrangementEmployeeAndNonEmployeeMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">54,135</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fixv-39435" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="C_20221231_usgaapGranteeStatusAxis_slxnShareBasedPaymentArrangementEmployeeAndNonEmployeeMember" unitRef="usdPershares" scale="0" decimals="2" format="ixt:num-dot-decimal">38.93</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonNumeric id="Fixv-39436" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" contextRef="C_20220101to20221231_usgaapGranteeStatusAxis_slxnShareBasedPaymentArrangementEmployeeAndNonEmployeeMember" format="ixt-sec:duryear">5.88</ix:nonNumeric></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fixv-39437" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" contextRef="C_20221231_usgaapGranteeStatusAxis_slxnShareBasedPaymentArrangementEmployeeAndNonEmployeeMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">144</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align:bottom;width:52%;background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Granted</span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20241004180038872" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="C_20230101to20231231_usgaapGranteeStatusAxis_slxnShareBasedPaymentArrangementEmployeeAndNonEmployeeMember" unitRef="shares" decimals="INF" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20241004180346232" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="C_20230101to20231231_usgaapGranteeStatusAxis_slxnShareBasedPaymentArrangementEmployeeAndNonEmployeeMember" unitRef="usdPershares" scale="0" decimals="0" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="-sec-ix-hidden:Fxbrl_20241004180444170">-</span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align:bottom;width:52%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Exercised</span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20241004181103978" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="C_20230101to20231231_usgaapGranteeStatusAxis_slxnShareBasedPaymentArrangementEmployeeAndNonEmployeeMember" unitRef="shares" decimals="INF" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20241004180400355" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" contextRef="C_20230101to20231231_usgaapGranteeStatusAxis_slxnShareBasedPaymentArrangementEmployeeAndNonEmployeeMember" unitRef="usdPershares" scale="0" decimals="0" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="-sec-ix-hidden:Fxbrl_20241004180513328">-</span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align:bottom;width:52%;background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Forfeited</span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20241004180121864" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" contextRef="C_20230101to20231231_usgaapGranteeStatusAxis_slxnShareBasedPaymentArrangementEmployeeAndNonEmployeeMember" unitRef="shares" decimals="INF" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20241004180418757" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" contextRef="C_20230101to20231231_usgaapGranteeStatusAxis_slxnShareBasedPaymentArrangementEmployeeAndNonEmployeeMember" unitRef="usdPershares" scale="0" decimals="0" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="-sec-ix-hidden:Fxbrl_20241004180602489">-</span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align:bottom;width:52%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Expired</span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fixv-39438" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" contextRef="C_20230101to20231231_usgaapGranteeStatusAxis_slxnShareBasedPaymentArrangementEmployeeAndNonEmployeeMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">221</ix:nonFraction></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
        <div style="line-height:1.25">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fixv-39439" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" contextRef="C_20230101to20231231_usgaapGranteeStatusAxis_slxnShareBasedPaymentArrangementEmployeeAndNonEmployeeMember" unitRef="usdPershares" scale="0" decimals="2" format="ixt:num-dot-decimal">38.41</ix:nonFraction></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
        <div style="line-height:1.25">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="-sec-ix-hidden:Fxbrl_20241004180730561">-</span></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align:bottom;width:52%;padding-bottom:4px;background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Outstanding
        at December 31, 2023</span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fixv-39440" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="C_20231231_usgaapGranteeStatusAxis_slxnShareBasedPaymentArrangementEmployeeAndNonEmployeeMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">53,914</ix:nonFraction></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(255, 255, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fixv-39441" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="C_20231231_usgaapGranteeStatusAxis_slxnShareBasedPaymentArrangementEmployeeAndNonEmployeeMember" unitRef="usdPershares" scale="0" decimals="2" format="ixt:num-dot-decimal">38.94</ix:nonFraction></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(255, 255, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonNumeric id="Fixv-39442" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" contextRef="C_20230101to20231231_usgaapGranteeStatusAxis_slxnShareBasedPaymentArrangementEmployeeAndNonEmployeeMember" format="ixt-sec:duryear">4.88</ix:nonNumeric></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(255, 255, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fixv-39443" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" contextRef="C_20231231_usgaapGranteeStatusAxis_slxnShareBasedPaymentArrangementEmployeeAndNonEmployeeMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">316</ix:nonFraction></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(255, 255, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align:bottom;width:52%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align:bottom;width:52%;padding-bottom:4px;background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Exercisable
        at December 31, 2023</span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fixv-39444" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextRef="C_20231231_usgaapGranteeStatusAxis_slxnShareBasedPaymentArrangementEmployeeAndNonEmployeeMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">39,340</ix:nonFraction></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(255, 255, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fixv-39445" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" contextRef="C_20231231_usgaapGranteeStatusAxis_slxnShareBasedPaymentArrangementEmployeeAndNonEmployeeMember" unitRef="usdPershares" scale="0" decimals="2" format="ixt:num-dot-decimal">30.95</ix:nonFraction></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(255, 255, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonNumeric id="Fixv-39446" name="slxn:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTermExercisable" contextRef="C_20230101to20231231_usgaapGranteeStatusAxis_slxnShareBasedPaymentArrangementEmployeeAndNonEmployeeMember" format="ixt-sec:duryear">3.62</ix:nonNumeric></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(255, 255, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fixv-39447" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" contextRef="C_20231231_usgaapGranteeStatusAxis_slxnShareBasedPaymentArrangementEmployeeAndNonEmployeeMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">316</ix:nonFraction></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(255, 255, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align:bottom;width:52%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align:bottom;width:52%;padding-bottom:4px;background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Vested
        and expected to vest at December 31, 2023</span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fixv-39448" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" contextRef="C_20231231_usgaapGranteeStatusAxis_slxnShareBasedPaymentArrangementEmployeeAndNonEmployeeMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">53,914</ix:nonFraction></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(255, 255, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fixv-39449" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" contextRef="C_20231231_usgaapGranteeStatusAxis_slxnShareBasedPaymentArrangementEmployeeAndNonEmployeeMember" unitRef="usdPershares" scale="0" decimals="2" format="ixt:num-dot-decimal">38.94</ix:nonFraction></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(255, 255, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonNumeric id="Fixv-39450" name="slxn:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTermVestedAndExpectedToVest" contextRef="C_20230101to20231231_usgaapGranteeStatusAxis_slxnShareBasedPaymentArrangementEmployeeAndNonEmployeeMember" format="ixt-sec:duryear">4.88</ix:nonNumeric></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(255, 255, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fixv-39451" name="slxn:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAggregateIntrinsicValue" contextRef="C_20231231_usgaapGranteeStatusAxis_slxnShareBasedPaymentArrangementEmployeeAndNonEmployeeMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">316</ix:nonFraction></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(255, 255, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        </tr>
  </table> </div>

<div style="line-height:1.25;clear:both">&#160;</div>

<div style="margin-left:63pt">

<table border="0" cellpadding="0" cellspacing="0" style="color:#000000;font-family:'Times New Roman',Times,serif;font-size:10pt;text-align:left;width:85%">
  <tr>
    <td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Number
        of options</span></span></div> </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Weighted-average
        exercise price (in U.S. dollars)</span></span></div> </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Weighted-
        average remaining contractual term</span></span></div>
        <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(in
        years)</span></span></div> </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Aggregate</span></span></div>
        <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">intrinsic</span></span></div>
        <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">value</span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
    <td colspan="2" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
    <td colspan="2" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
    <td colspan="2" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
    <td colspan="2" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:bottom;width:52%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Outstanding
        at December 31, 2021</span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fixv-39452" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="C_20211231_usgaapGranteeStatusAxis_slxnShareBasedPaymentArrangementEmployeeAndNonEmployeeMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">31,897</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fixv-39453" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="C_20211231_usgaapGranteeStatusAxis_slxnShareBasedPaymentArrangementEmployeeAndNonEmployeeMember" unitRef="usdPershares" scale="0" decimals="2" format="ixt:num-dot-decimal">23.88</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonNumeric id="Fixv-39454" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" contextRef="C_20210101to20211231_usgaapGranteeStatusAxis_slxnShareBasedPaymentArrangementEmployeeAndNonEmployeeMember" format="ixt-sec:duryear">4.46</ix:nonNumeric></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fixv-39455" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" contextRef="C_20211231_usgaapGranteeStatusAxis_slxnShareBasedPaymentArrangementEmployeeAndNonEmployeeMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">493</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align:bottom;width:52%;background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Granted</span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fixv-39456" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="C_20220101to20221231_usgaapGranteeStatusAxis_slxnShareBasedPaymentArrangementEmployeeAndNonEmployeeMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">24,119</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fixv-39457" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="C_20220101to20221231_usgaapGranteeStatusAxis_slxnShareBasedPaymentArrangementEmployeeAndNonEmployeeMember" unitRef="usdPershares" scale="0" decimals="2" format="ixt:num-dot-decimal">60.51</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonNumeric id="Fixv-39458" name="slxn:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTermGranted" contextRef="C_20220101to20221231_usgaapGranteeStatusAxis_slxnShareBasedPaymentArrangementEmployeeAndNonEmployeeMember" format="ixt-sec:duryear">9.98</ix:nonNumeric></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align:bottom;width:52%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Exercised</span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fixv-39459" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="C_20220101to20221231_usgaapGranteeStatusAxis_slxnShareBasedPaymentArrangementEmployeeAndNonEmployeeMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">46</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fixv-39460" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" contextRef="C_20220101to20221231_usgaapGranteeStatusAxis_slxnShareBasedPaymentArrangementEmployeeAndNonEmployeeMember" unitRef="usdPershares" scale="0" decimals="2" format="ixt:num-dot-decimal">60.49</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonNumeric id="Fixv-39461" name="slxn:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTermExercised" contextRef="C_20220101to20221231_usgaapGranteeStatusAxis_slxnShareBasedPaymentArrangementEmployeeAndNonEmployeeMember" format="ixt-sec:duryear">8.22</ix:nonNumeric></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align:bottom;width:52%;background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Forfeited</span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fixv-39462" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" contextRef="C_20220101to20221231_usgaapGranteeStatusAxis_slxnShareBasedPaymentArrangementEmployeeAndNonEmployeeMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">1,128</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom;white-space:nowrap">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fixv-39463" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" contextRef="C_20220101to20221231_usgaapGranteeStatusAxis_slxnShareBasedPaymentArrangementEmployeeAndNonEmployeeMember" unitRef="usdPershares" scale="0" decimals="2" format="ixt:num-dot-decimal">60.50</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonNumeric id="Fixv-39464" name="slxn:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTermForfeited" contextRef="C_20220101to20221231_usgaapGranteeStatusAxis_slxnShareBasedPaymentArrangementEmployeeAndNonEmployeeMember" format="ixt-sec:duryear">9.18</ix:nonNumeric></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom;white-space:nowrap">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align:bottom;width:52%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Expired</span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fixv-39465" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" contextRef="C_20220101to20221231_usgaapGranteeStatusAxis_slxnShareBasedPaymentArrangementEmployeeAndNonEmployeeMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">707</ix:nonFraction></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
        <div style="line-height:1.25">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fixv-39466" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" contextRef="C_20220101to20221231_usgaapGranteeStatusAxis_slxnShareBasedPaymentArrangementEmployeeAndNonEmployeeMember" unitRef="usdPershares" scale="0" decimals="2" format="ixt:num-dot-decimal">61.01</ix:nonFraction></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
        <div style="line-height:1.25">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="-sec-ix-hidden:Fxbrl_20241004180813329">-</span></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align:bottom;width:52%;padding-bottom:4px;background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Outstanding
        at December 31, 2022</span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fixv-39467" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="C_20221231_usgaapGranteeStatusAxis_slxnShareBasedPaymentArrangementEmployeeAndNonEmployeeMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">54,135</ix:nonFraction></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(255, 255, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fixv-39468" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="C_20221231_usgaapGranteeStatusAxis_slxnShareBasedPaymentArrangementEmployeeAndNonEmployeeMember" unitRef="usdPershares" scale="0" decimals="2" format="ixt:num-dot-decimal">38.93</ix:nonFraction></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(255, 255, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonNumeric id="Fixv-39469" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" contextRef="C_20220101to20221231_usgaapGranteeStatusAxis_slxnShareBasedPaymentArrangementEmployeeAndNonEmployeeMember" format="ixt-sec:duryear">5.88</ix:nonNumeric></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(255, 255, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fixv-39470" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" contextRef="C_20221231_usgaapGranteeStatusAxis_slxnShareBasedPaymentArrangementEmployeeAndNonEmployeeMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">144</ix:nonFraction></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(255, 255, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align:bottom;width:52%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align:bottom;width:52%;padding-bottom:4px;background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Exercisable
        at December 31, 2022</span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fixv-39471" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextRef="C_20221231_usgaapGranteeStatusAxis_slxnShareBasedPaymentArrangementEmployeeAndNonEmployeeMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">30,677</ix:nonFraction></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(255, 255, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fixv-39472" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" contextRef="C_20221231_usgaapGranteeStatusAxis_slxnShareBasedPaymentArrangementEmployeeAndNonEmployeeMember" unitRef="usdPershares" scale="0" decimals="2" format="ixt:num-dot-decimal">22.46</ix:nonFraction></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(255, 255, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonNumeric id="Fixv-39473" name="slxn:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTermExercisable" contextRef="C_20220101to20221231_usgaapGranteeStatusAxis_slxnShareBasedPaymentArrangementEmployeeAndNonEmployeeMember" format="ixt-sec:duryear">3.29</ix:nonNumeric></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(255, 255, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fixv-39474" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" contextRef="C_20221231_usgaapGranteeStatusAxis_slxnShareBasedPaymentArrangementEmployeeAndNonEmployeeMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">144</ix:nonFraction></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(255, 255, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align:bottom;width:52%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align:bottom;width:52%;padding-bottom:4px;background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Vested
        and expected to vest at December 31, 2022</span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fixv-39475" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" contextRef="C_20221231_usgaapGranteeStatusAxis_slxnShareBasedPaymentArrangementEmployeeAndNonEmployeeMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">54,135</ix:nonFraction></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(255, 255, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fixv-39476" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" contextRef="C_20221231_usgaapGranteeStatusAxis_slxnShareBasedPaymentArrangementEmployeeAndNonEmployeeMember" unitRef="usdPershares" scale="0" decimals="2" format="ixt:num-dot-decimal">38.93</ix:nonFraction></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(255, 255, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonNumeric id="Fixv-39477" name="slxn:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTermVestedAndExpectedToVest" contextRef="C_20220101to20221231_usgaapGranteeStatusAxis_slxnShareBasedPaymentArrangementEmployeeAndNonEmployeeMember" format="ixt-sec:duryear">5.88</ix:nonNumeric></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(255, 255, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fixv-39478" name="slxn:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAggregateIntrinsicValue" contextRef="C_20221231_usgaapGranteeStatusAxis_slxnShareBasedPaymentArrangementEmployeeAndNonEmployeeMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">144</ix:nonFraction></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(255, 255, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        </tr>
  </table> </div> </div> </ix:nonNumeric>

<div style="line-height:1.25;clear:both">&#160;</div> </div> </div>

<div><ix:exclude>

<div style="margin-top:0pt;margin-bottom:0pt">

<div style="margin-top:10pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">

<p style="text-align:center;margin-top:0pt;margin-bottom:3pt"><span style="width:34%;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">F-93</span></span></span></p></div><hr style="page-break-after:always;border-width:0px;clear:both;margin:4px 0px;width:100%;height:2px;color:#000000;background-color:#000000;margin-top:0pt;margin-bottom:10pt"/>

<p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:center">&#160;</p>

<p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:center"><strong>S<span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">ILEXION
THERAPEUTICS CORP</span></span></strong><br/><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS (continued)</span></span></p>

<p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">U.S.
DOLLARS IN THOUSANDS</span></span></p>

<p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:center">&#160;</p> </div>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify"><strong>NOTE 11&#160; - SHARE-BASED COMPENSATION</strong>&#160;(continued):</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">&#160;</p> </ix:exclude></div>

<div>

<div>

<div style="text-align:justify;margin-left:63.8pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The
fair value for options granted in 2022 is estimated at the date of grant using a Black-Scholes option pricing model based on the following
assumptions:</span></span></div>

<div style="line-height:1.25">&#160;</div>

<div style="margin-left:63pt"> <ix:nonNumeric id="Fxbrl_20241205125232139" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" contextRef="C_20230101to20231231" escape="true">

<table border="0" cellpadding="0" cellspacing="0" style="width:85%">
  <tr>
    <td style="padding-bottom:2px;vertical-align:bottom;width:86%">&#160;</td>
    <td colspan="1" style="padding-bottom:2px;vertical-align:bottom;width:1%">&#160;</td>
    <td style="border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom;width:12%;margin-top:0pt;margin-bottom:0pt">
        <div style="line-height:1.25;margin-top:0pt;margin-bottom:0pt">
        <div style="text-align:center;line-height:1.25;font-family:Times New Roman, Times, serif;font-weight:bold;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt">Year&#160;ended</span></span></div>
        <div style="text-align:center;line-height:1.25;font-family:Times New Roman, Times, serif;font-weight:bold;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt">December&#160;31,&#160;2022</span></span></div>
        </div> </td>
    <td colspan="1" style="padding-bottom:2px;vertical-align:bottom;white-space:nowrap;width:1%">&#160;</td> </tr>
  <tr>
    <td style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:86%">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Employees</span></span></div>
        </td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%">&#160;</td>
    <td style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:12%">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap;width:1%">&#160;</td> </tr>
  <tr>
    <td style="background-color:rgb(255, 255, 255);vertical-align:bottom;width:86%">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Expected
        term (in years)</span></span></div> </td>
    <td colspan="1" style="background-color:rgb(255, 255, 255);vertical-align:bottom;width:1%">&#160;</td>
    <td colspan="1" style="text-align:right;background-color:rgb(255, 255, 255);vertical-align:bottom;width:12%">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonNumeric id="Fixv-39480" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" contextRef="C_20220101to20221231_srtRangeAxis_srtMinimumMember_usgaapGranteeStatusAxis_usgaapShareBasedPaymentArrangementEmployeeMember" format="ixt-sec:duryear">6.05</ix:nonNumeric>
        - <ix:nonNumeric id="Fixv-39481" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" contextRef="C_20220101to20221231_srtRangeAxis_srtMaximumMember_usgaapGranteeStatusAxis_usgaapShareBasedPaymentArrangementEmployeeMember" format="ixt-sec:duryear">10.00</ix:nonNumeric></span></span></div>
        </td>
    <td colspan="1" style="background-color:rgb(255, 255, 255);vertical-align:bottom;white-space:nowrap;width:1%">&#160;</td> </tr>
  <tr>
    <td style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:86%">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Expected
        volatility</span></span></div> </td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%">&#160;</td>
    <td colspan="1" style="text-align:right;background-color:rgb(204, 238, 255);vertical-align:bottom;width:12%">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fixv-39482" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="C_20220101to20221231_srtRangeAxis_srtMinimumMember_usgaapGranteeStatusAxis_usgaapShareBasedPaymentArrangementEmployeeMember" unitRef="pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">82.97</ix:nonFraction>%
        - <ix:nonFraction id="Fixv-39483" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="C_20220101to20221231_srtRangeAxis_srtMaximumMember_usgaapGranteeStatusAxis_usgaapShareBasedPaymentArrangementEmployeeMember" unitRef="pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">88.45</ix:nonFraction>%</span></span></div>
        </td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap;width:1%">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div> </td> </tr>
  <tr>
    <td style="background-color:rgb(255, 255, 255);vertical-align:bottom;width:86%">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Risk-free
        interest rate</span></span></div> </td>
    <td colspan="1" style="background-color:rgb(255, 255, 255);vertical-align:bottom;width:1%">&#160;</td>
    <td colspan="1" style="text-align:right;background-color:rgb(255, 255, 255);vertical-align:bottom;width:12%">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fixv-39484" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="C_20220101to20221231_srtRangeAxis_srtMinimumMember_usgaapGranteeStatusAxis_usgaapShareBasedPaymentArrangementEmployeeMember" unitRef="pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">2.31</ix:nonFraction>%
        - <ix:nonFraction id="Fixv-39485" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="C_20220101to20221231_srtRangeAxis_srtMaximumMember_usgaapGranteeStatusAxis_usgaapShareBasedPaymentArrangementEmployeeMember" unitRef="pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">2.90</ix:nonFraction>%</span></span></div>
        </td>
    <td colspan="1" style="background-color:rgb(255, 255, 255);vertical-align:bottom;white-space:nowrap;width:1%">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div> </td> </tr>
  <tr>
    <td style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:86%">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Expected
        dividend yield</span></span></div> </td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%">&#160;</td>
    <td colspan="1" style="text-align:right;background-color:rgb(204, 238, 255);vertical-align:bottom;width:12%">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fixv-39486" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="C_20220101to20221231_usgaapGranteeStatusAxis_usgaapShareBasedPaymentArrangementEmployeeMember" unitRef="pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">0.00</ix:nonFraction>%</span></span></div>
        </td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap;width:1%">&#160;</td> </tr>
  <tr>
    <td style="background-color:rgb(255, 255, 255);vertical-align:bottom;width:86%">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Exercise
        price</span></span></div> </td>
    <td colspan="1" style="background-color:rgb(255, 255, 255);vertical-align:bottom;width:1%">&#160;</td>
    <td colspan="1" style="text-align:right;background-color:rgb(255, 255, 255);vertical-align:bottom;width:12%">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$<ix:nonFraction id="Fixv-39487" name="us-gaap:SharePrice" contextRef="C_20221231_usgaapGranteeStatusAxis_usgaapShareBasedPaymentArrangementEmployeeMember" unitRef="usdPershares" scale="0" decimals="2" format="ixt:num-dot-decimal">60.51</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="background-color:rgb(255, 255, 255);vertical-align:bottom;white-space:nowrap;width:1%">&#160;</td> </tr>
  <tr>
    <td rowspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:86%">&#160;</td>
    <td colspan="1" rowspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%">&#160;</td>
    <td colspan="1" rowspan="1" style="text-align:center;background-color:rgb(204, 238, 255);vertical-align:bottom;width:12%">&#160;</td>
    <td colspan="1" rowspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap;width:1%">&#160;</td> </tr>
  <tr>
    <td style="background-color:rgb(255, 255, 255);vertical-align:bottom;width:86%">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Non-Employees</span></span></div>
        </td>
    <td colspan="1" style="background-color:rgb(255, 255, 255);vertical-align:bottom;width:1%">&#160;</td>
    <td colspan="1" style="text-align:center;background-color:rgb(255, 255, 255);vertical-align:bottom;width:12%">&#160;</td>
    <td colspan="1" style="background-color:rgb(255, 255, 255);vertical-align:bottom;white-space:nowrap;width:1%">&#160;</td> </tr>
  <tr>
    <td style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:86%">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Expected
        term (in years)</span></span></div> </td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%">&#160;</td>
    <td colspan="1" style="text-align:right;background-color:rgb(204, 238, 255);vertical-align:bottom;width:12%">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonNumeric id="Fixv-39488" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" contextRef="C_20220101to20221231_usgaapGranteeStatusAxis_usgaapShareBasedPaymentArrangementNonemployeeMember" format="ixt-sec:duryear">9.78</ix:nonNumeric></span></span></div>
        </td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap;width:1%">&#160;</td> </tr>
  <tr>
    <td style="background-color:rgb(255, 255, 255);vertical-align:bottom;width:86%">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Expected
        volatility</span></span></div> </td>
    <td colspan="1" style="background-color:rgb(255, 255, 255);vertical-align:bottom;width:1%">&#160;</td>
    <td colspan="1" style="text-align:right;background-color:rgb(255, 255, 255);vertical-align:bottom;width:12%">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fixv-39489" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="C_20220101to20221231_usgaapGranteeStatusAxis_usgaapShareBasedPaymentArrangementNonemployeeMember" unitRef="pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">88.46</ix:nonFraction>%</span></span></div>
        </td>
    <td colspan="1" style="background-color:rgb(255, 255, 255);vertical-align:bottom;white-space:nowrap;width:1%">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div> </td> </tr>
  <tr>
    <td style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:86%">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Risk-free
        interest rate</span></span></div> </td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%">&#160;</td>
    <td colspan="1" style="text-align:right;background-color:rgb(204, 238, 255);vertical-align:bottom;width:12%">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fixv-39490" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="C_20220101to20221231_usgaapGranteeStatusAxis_usgaapShareBasedPaymentArrangementNonemployeeMember" unitRef="pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">2.31</ix:nonFraction>%</span></span></div>
        </td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap;width:1%">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div> </td> </tr>
  <tr>
    <td style="background-color:rgb(255, 255, 255);vertical-align:bottom;width:86%">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Expected
        dividend yield</span></span></div> </td>
    <td colspan="1" style="background-color:rgb(255, 255, 255);vertical-align:bottom;width:1%">&#160;</td>
    <td colspan="1" style="text-align:right;background-color:rgb(255, 255, 255);vertical-align:bottom;width:12%">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fixv-39491" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="C_20220101to20221231_usgaapGranteeStatusAxis_usgaapShareBasedPaymentArrangementNonemployeeMember" unitRef="pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">0.00</ix:nonFraction>%</span></span></div>
        </td>
    <td colspan="1" style="background-color:rgb(255, 255, 255);vertical-align:bottom;white-space:nowrap;width:1%">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div> </td> </tr>
  <tr>
    <td style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:86%">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Exercise
        price</span></span></div> </td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%">&#160;</td>
    <td colspan="1" style="text-align:right;background-color:rgb(204, 238, 255);vertical-align:bottom;width:12%">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$<ix:nonFraction id="Fixv-39492" name="us-gaap:SharePrice" contextRef="C_20221231_usgaapGranteeStatusAxis_usgaapShareBasedPaymentArrangementNonemployeeMember" unitRef="usdPershares" scale="0" decimals="2" format="ixt:num-dot-decimal">60.51</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap;width:1%">&#160;</td> </tr>
  </table> </ix:nonNumeric> </div>

<div style="line-height:1.25;clear:both">&#160;</div>

<div style="text-align:justify;margin-left:63.8pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The
option-pricing model requires a number of assumptions, of which the most significant are the expected stock price volatility and the expected
option term. Since the Company is not traded, the expected volatility was based on the average volatility rate of <ix:nonFraction id="Fixv-39493" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" contextRef="C_20230101to20231231" unitRef="pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">8</ix:nonFraction>
public companies in the healthcare industry.</span></span></div>

<div style="line-height:1.25">&#160;</div>

<div style="text-align:justify;margin-left:63.8pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The
expected term of options granted represents the period during which options granted are expected to remain outstanding. The risk-free
interest rate is based on the yield from U.S. treasury bonds with an equivalent term. The Company has historically not paid dividends
and has no foreseeable plans to pay dividends. The Company uses the simplified method for nonexecutive employees, due to insufficient
historical exercise experience&#8221;.</span></span></div>

<div style="line-height:1.25">&#160;</div>

<div style="text-align:justify;margin-left:63.8pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The
fair value of options granted during 2022 was $<ix:nonFraction id="Fixv-39494" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" contextRef="C_20221231" unitRef="usd" scale="0" decimals="0" format="ixt:num-dot-decimal">529</ix:nonFraction>.</span></span></div>

<div style="line-height:1.25">&#160;</div>

<div style="text-align:justify;margin-left:63.8pt;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Options
granted to employees and non-employees:</span></span></div>

<div style="line-height:1.25">&#160;</div>

<div style="text-align:justify;margin-left:63.8pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">In
2023 no options were granted, neither to employees nor to non-employees.</span></span></div>

<div style="line-height:1.25">&#160;</div>

<div style="text-align:justify;margin-left:63.8pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">In
the year ended December 31, 2022, the Company granted options as follows:</span></span></div>

<div style="line-height:1.25">&#160;</div>

<div style="margin-left:63pt"> <ix:nonNumeric id="Fxbrl_20241205125428885" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock" contextRef="C_20230101to20231231" escape="true">

<table border="0" cellpadding="0" cellspacing="0" style="color:#000000;font-family:'Times New Roman',Times,serif;font-size:10pt;text-align:left;width:85%">
  <tr>
    <td rowspan="1" style="vertical-align:top;padding-bottom:2px;width:57.13%;vertical-align:bottom">&#160;</td>
    <td colspan="1" rowspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1.04%;vertical-align:bottom">&#160;</td>
    <td colspan="9" rowspan="1" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Year
        ended December 31, 2022</span></span></div> </div> </td> </tr>
  <tr>
    <td style="vertical-align:top;padding-bottom:2px;width:57.13%;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1.04%;vertical-align:bottom">&#160;</td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Award
        amount</span></span></div> </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1.04%;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Exercise
        price</span></span></div> </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1.04%;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td style="vertical-align:bottom;width:9.21%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Vesting
        period</span></span></div> </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1.04%;vertical-align:bottom">&#160;</td>
    <td style="vertical-align:bottom;width:9.21%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Expiration</span></span></div>
        </div> </td> </tr>
  <tr>
    <td style="vertical-align:top;width:57.13%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Employees</span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1.04%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1.04%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9.21%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fixv-39496" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="C_20220101to20221231_usgaapGranteeStatusAxis_usgaapShareBasedPaymentArrangementEmployeeMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">23,234</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1.04%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1.04%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9.21%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fixv-39497" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="C_20220101to20221231_usgaapGranteeStatusAxis_usgaapShareBasedPaymentArrangementEmployeeMember" unitRef="usdPershares" scale="0" decimals="2" format="ixt:num-dot-decimal">60.51</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1.04%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td style="vertical-align:middle;width:9.21%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="text-align:center;text-indent:-4.95pt;margin-left:9.35pt;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonNumeric id="Fixv-39498" name="slxn:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod" contextRef="C_20220101to20221231_usgaapGranteeStatusAxis_usgaapShareBasedPaymentArrangementEmployeeMember">up
        to 4 years</ix:nonNumeric></span></span></div> </td>
    <td colspan="1" style="vertical-align:middle;width:1.04%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td style="vertical-align:middle;width:9.21%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="text-align:center;text-indent:-4.95pt;margin-left:9.35pt;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonNumeric id="Fixv-39499" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" contextRef="C_20220101to20221231_usgaapGranteeStatusAxis_usgaapShareBasedPaymentArrangementEmployeeMember" format="ixt-sec:duryear">10</ix:nonNumeric>
        years</span></span></div> </td> </tr>
  <tr>
    <td style="vertical-align:top;width:57.13%;padding-bottom:2px;background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Non-employees</span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1.04%;padding-bottom:2px;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1.04%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9.21%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fixv-39500" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="C_20220101to20221231_usgaapGranteeStatusAxis_usgaapShareBasedPaymentArrangementNonemployeeMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">886</ix:nonFraction></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1.04%;padding-bottom:2px;background-color:rgb(255, 255, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1.04%;padding-bottom:2px;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9.21%;padding-bottom:2px;background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fixv-39501" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="C_20220101to20221231_usgaapGranteeStatusAxis_usgaapShareBasedPaymentArrangementNonemployeeMember" unitRef="usdPershares" scale="0" decimals="2" format="ixt:num-dot-decimal">60.51</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1.04%;padding-bottom:2px;background-color:rgb(255, 255, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td style="vertical-align:middle;width:9.21%;padding-bottom:2px;background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="text-align:center;text-indent:-4.95pt;margin-left:9.35pt;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonNumeric id="Fixv-39502" name="slxn:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod" contextRef="C_20220101to20221231_usgaapGranteeStatusAxis_usgaapShareBasedPaymentArrangementNonemployeeMember">Immediate</ix:nonNumeric></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:middle;width:1.04%;padding-bottom:2px;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td style="vertical-align:middle;width:9.21%;padding-bottom:2px;background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="text-align:center;text-indent:-4.95pt;margin-left:9.35pt;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonNumeric id="Fixv-39503" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" contextRef="C_20220101to20221231_usgaapGranteeStatusAxis_usgaapShareBasedPaymentArrangementNonemployeeMember" format="ixt-sec:duryear">10</ix:nonNumeric>
        years</span></span></div> </td> </tr>
  <tr>
    <td style="vertical-align:top;width:57.13%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="text-indent:-4.95pt;margin-left:9.35pt;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Total
        granted</span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1.04%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1.04%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9.21%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fixv-39504" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="C_20220101to20221231" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">24,120</ix:nonFraction></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1.04%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1.04%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9.21%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1.04%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td style="vertical-align:bottom;width:9.21%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1.04%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td style="vertical-align:top;width:9.21%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">&#160;&#160;&#160;</span></span></td>
        </tr>
  </table> </ix:nonNumeric> </div>

<div style="line-height:1.25;clear:both">&#160;</div> </div> </div>

<div><ix:exclude>

<div style="margin-top:0pt;margin-bottom:0pt">

<div style="margin-top:10pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">

<p style="text-align:center;margin-top:0pt;margin-bottom:3pt"><span style="width:34%;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">F-94</span></span></span></p></div><hr style="page-break-after:always;border-width:0px;clear:both;margin:4px 0px;width:100%;height:2px;color:#000000;background-color:#000000;margin-top:0pt;margin-bottom:10pt"/>

<p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:center">&#160;</p>

<p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:center"><strong>S<span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">ILEXION
THERAPEUTICS CORP</span></span></strong><br/><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS (continued)</span></span></p>

<p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">U.S.
DOLLARS IN THOUSANDS</span></span></p>

<p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:center">&#160;</p> </div>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify"><strong>NOTE 11&#160; - SHARE-BASED COMPENSATION</strong>&#160;(continued):</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">&#160;</p> </ix:exclude></div>

<div>

<div>

<div style="text-align:justify;margin-left:63.8pt;line-height:1.25;font-style:italic;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Summary
of status of the Company&#8217;s nonvested employee options:</span></span></div>

<div style="line-height:1.25">&#160;</div>

<div style="text-align:justify;margin-left:63.8pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The
following table summarizes the number of options outstanding for the years ended December 31, 2023 and December 31, 2022, and related
information:</span></span></div> <ix:nonNumeric id="Fxbrl_20241206004113711" name="us-gaap:ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingTableTextBlock" contextRef="C_20230101to20231231" continuedAt="F20241206004253925" escape="true">

<div>

<div style="line-height:1.25">&#160;</div>

<div style="margin-left:63pt">

<table border="0" cellpadding="0" cellspacing="0" style="color:#000000;font-family:'Times New Roman',Times,serif;font-size:10pt;text-align:left;width:85%">
  <tr>
    <td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Number
        of</span></span></div>
        <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">options</span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Weighted-average
        grant-date fair</span></span></div>
        <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">value
        price</span></span></div> </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
    <td colspan="2" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
    <td colspan="2" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Outstanding
        at December 31, 2022</span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fixv-39506" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="C_20221231_usgaapGranteeStatusAxis_usgaapShareBasedPaymentArrangementEmployeeMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">23,393</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fixv-39507" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" contextRef="C_20221231_usgaapGranteeStatusAxis_usgaapShareBasedPaymentArrangementEmployeeMember" unitRef="usdPershares" scale="0" decimals="2" format="ixt:num-dot-decimal">21.67</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align:bottom;width:76%;background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Granted</span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20241004181710958" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="C_20230101to20231231_usgaapGranteeStatusAxis_usgaapShareBasedPaymentArrangementEmployeeMember" unitRef="shares" decimals="INF" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20241004181721280" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="C_20230101to20231231_usgaapGranteeStatusAxis_usgaapShareBasedPaymentArrangementEmployeeMember" unitRef="usdPershares" scale="0" decimals="0" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Vested</span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fixv-39508" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" contextRef="C_20230101to20231231_usgaapGranteeStatusAxis_usgaapShareBasedPaymentArrangementEmployeeMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">8,827</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fixv-39509" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" contextRef="C_20230101to20231231_usgaapGranteeStatusAxis_usgaapShareBasedPaymentArrangementEmployeeMember" unitRef="usdPershares" scale="0" decimals="2" format="ixt:num-dot-decimal">21.60</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align:bottom;width:76%;background-color:rgb(255, 255, 255);padding-bottom:2px;vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Forfeited</span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);padding-bottom:2px;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255);border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20241004181746879" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" contextRef="C_20230101to20231231_usgaapGranteeStatusAxis_usgaapShareBasedPaymentArrangementEmployeeMember" unitRef="shares" decimals="INF" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);padding-bottom:2px;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255);border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20241004181757727" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" contextRef="C_20230101to20231231_usgaapGranteeStatusAxis_usgaapShareBasedPaymentArrangementEmployeeMember" unitRef="usdPershares" scale="0" decimals="0" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align:bottom;width:76%;padding-bottom:4px;background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Outstanding
        at December 31, 2023</span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fixv-39510" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="C_20231231_usgaapGranteeStatusAxis_usgaapShareBasedPaymentArrangementEmployeeMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">14,566</ix:nonFraction></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(255, 255, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fixv-39511" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" contextRef="C_20231231_usgaapGranteeStatusAxis_usgaapShareBasedPaymentArrangementEmployeeMember" unitRef="usdPershares" scale="0" decimals="2" format="ixt:num-dot-decimal">21.72</ix:nonFraction></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(255, 255, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align:bottom;width:76%;background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Outstanding
        at December 31, 2021</span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fixv-39512" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="C_20211231_usgaapGranteeStatusAxis_usgaapShareBasedPaymentArrangementEmployeeMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">1,976</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fixv-39513" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" contextRef="C_20211231_usgaapGranteeStatusAxis_usgaapShareBasedPaymentArrangementEmployeeMember" unitRef="usdPershares" scale="0" decimals="2" format="ixt:num-dot-decimal">17.33</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Granted</span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fixv-39514" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="C_20220101to20221231_usgaapGranteeStatusAxis_usgaapShareBasedPaymentArrangementEmployeeMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">23,234</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fixv-39515" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="C_20220101to20221231_usgaapGranteeStatusAxis_usgaapShareBasedPaymentArrangementEmployeeMember" unitRef="usdPershares" scale="0" decimals="2" format="ixt:num-dot-decimal">21.76</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align:bottom;width:76%;background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Vested</span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fixv-39516" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" contextRef="C_20220101to20221231_usgaapGranteeStatusAxis_usgaapShareBasedPaymentArrangementEmployeeMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">690</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom;white-space:nowrap">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fixv-39517" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" contextRef="C_20220101to20221231_usgaapGranteeStatusAxis_usgaapShareBasedPaymentArrangementEmployeeMember" unitRef="usdPershares" scale="0" decimals="2" format="ixt:num-dot-decimal">16.04</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255);padding-bottom:2px;vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Forfeited</span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);padding-bottom:2px;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fixv-39518" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" contextRef="C_20220101to20221231_usgaapGranteeStatusAxis_usgaapShareBasedPaymentArrangementEmployeeMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">1,127</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);padding-bottom:2px;vertical-align:bottom;white-space:nowrap">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);padding-bottom:2px;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fixv-39519" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" contextRef="C_20220101to20221231_usgaapGranteeStatusAxis_usgaapShareBasedPaymentArrangementEmployeeMember" unitRef="usdPershares" scale="0" decimals="2" format="ixt:num-dot-decimal">19.34</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align:bottom;width:76%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align:bottom;width:76%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Outstanding
        at December 31, 2022</span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fixv-39520" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="C_20221231_usgaapGranteeStatusAxis_usgaapShareBasedPaymentArrangementEmployeeMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">23,393</ix:nonFraction></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fixv-39521" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" contextRef="C_20221231_usgaapGranteeStatusAxis_usgaapShareBasedPaymentArrangementEmployeeMember" unitRef="usdPershares" scale="0" decimals="2" format="ixt:num-dot-decimal">21.67</ix:nonFraction></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        </tr>
  </table> </div>

<div style="line-height:1.25;clear:both">&#160;</div> </div> </ix:nonNumeric>

<div style="text-align:justify;margin-left:63.8pt;line-height:1.25;font-style:italic;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Summary
of status of the Company&#8217;s nonvested nonemployee options:</span></span></div>

<div style="line-height:1.25">&#160;</div>

<div style="text-align:justify;margin-left:63.8pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The
following table summarizes the number of options outstanding for the years ended December 31, 2023 and December 31, 2022, and related
information:</span></span></div> <ix:continuation id="F20241206004253925">

<div>

<div>

<div style="line-height:1.25">&#160;</div>

<div style="margin-left:63pt">

<table border="0" cellpadding="0" cellspacing="0" style="color:#000000;font-family:'Times New Roman',Times,serif;font-size:10pt;text-align:left;width:85%">
  <tr>
    <td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Number
        of</span></span></div>
        <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">options</span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Weighted-average
        grant-date fair</span></span></div>
        <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">value
        price</span></span></div> </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
    <td colspan="2" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
    <td colspan="2" style="vertical-align:bottom;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Outstanding
        at December 31, 2022</span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fixv-39523" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="C_20221231_usgaapGranteeStatusAxis_usgaapShareBasedPaymentArrangementNonemployeeMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">59</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fixv-39524" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" contextRef="C_20221231_usgaapGranteeStatusAxis_usgaapShareBasedPaymentArrangementNonemployeeMember" unitRef="usdPershares" scale="0" decimals="2" format="ixt:num-dot-decimal">11.21</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align:bottom;width:76%;background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Granted</span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20241004181903463" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="C_20230101to20231231_usgaapGranteeStatusAxis_usgaapShareBasedPaymentArrangementNonemployeeMember" unitRef="shares" decimals="INF" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20241004182010410" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="C_20230101to20231231" unitRef="usdPershares" scale="0" decimals="0" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Vested</span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fixv-39525" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" contextRef="C_20230101to20231231_usgaapGranteeStatusAxis_usgaapShareBasedPaymentArrangementNonemployeeMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">59</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fixv-39526" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" contextRef="C_20230101to20231231_usgaapGranteeStatusAxis_usgaapShareBasedPaymentArrangementNonemployeeMember" unitRef="usdPershares" scale="0" decimals="2" format="ixt:num-dot-decimal">11.21</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align:bottom;width:76%;background-color:rgb(255, 255, 255);padding-bottom:2px;vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Forfeited</span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);padding-bottom:2px;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255);border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20241004182039944" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" contextRef="C_20230101to20231231_usgaapGranteeStatusAxis_usgaapShareBasedPaymentArrangementNonemployeeMember" unitRef="shares" decimals="INF" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);padding-bottom:2px;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255);border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20241004182203466" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" contextRef="C_20230101to20231231_usgaapGranteeStatusAxis_usgaapShareBasedPaymentArrangementNonemployeeMember" unitRef="usdPershares" scale="0" decimals="0" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align:bottom;width:76%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Outstanding
        at December 31, 2023</span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20241004154226870" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="C_20231231_usgaapGranteeStatusAxis_usgaapShareBasedPaymentArrangementNonemployeeMember" unitRef="shares" decimals="INF" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20241004154221174" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" contextRef="C_20231231_usgaapGranteeStatusAxis_usgaapShareBasedPaymentArrangementNonemployeeMember" unitRef="usdPershares" scale="0" decimals="0" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align:bottom;width:76%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Outstanding
        at December 31, 2021</span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fixv-39527" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="C_20211231_usgaapGranteeStatusAxis_usgaapShareBasedPaymentArrangementNonemployeeMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">135</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fixv-39528" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" contextRef="C_20211231_usgaapGranteeStatusAxis_usgaapShareBasedPaymentArrangementNonemployeeMember" unitRef="usdPershares" scale="0" decimals="2" format="ixt:num-dot-decimal">11.09</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align:bottom;width:76%;background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Granted</span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fixv-39529" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="C_20220101to20221231_usgaapGranteeStatusAxis_usgaapShareBasedPaymentArrangementNonemployeeMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">886</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fixv-39530" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="C_20220101to20221231_usgaapGranteeStatusAxis_usgaapShareBasedPaymentArrangementNonemployeeMember" unitRef="usdPershares" scale="0" decimals="2" format="ixt:num-dot-decimal">26.96</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Vested</span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fixv-39531" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" contextRef="C_20220101to20221231_usgaapGranteeStatusAxis_usgaapShareBasedPaymentArrangementNonemployeeMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">962</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fixv-39532" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" contextRef="C_20220101to20221231_usgaapGranteeStatusAxis_usgaapShareBasedPaymentArrangementNonemployeeMember" unitRef="usdPershares" scale="0" decimals="2" format="ixt:num-dot-decimal">25.69</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align:bottom;width:76%;background-color:rgb(255, 255, 255);padding-bottom:2px;vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Forfeited</span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);padding-bottom:2px;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255);border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20241004182247732" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" contextRef="C_20220101to20221231_usgaapGranteeStatusAxis_usgaapShareBasedPaymentArrangementNonemployeeMember" unitRef="shares" decimals="INF" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);padding-bottom:2px;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255);border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20241004182309732" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" contextRef="C_20220101to20221231_usgaapGranteeStatusAxis_usgaapShareBasedPaymentArrangementNonemployeeMember" unitRef="usdPershares" scale="0" decimals="0" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align:bottom;width:76%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Outstanding
        at December 31, 2022</span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fixv-39533" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="C_20221231_usgaapGranteeStatusAxis_usgaapShareBasedPaymentArrangementNonemployeeMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">59</ix:nonFraction></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fixv-39534" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" contextRef="C_20221231_usgaapGranteeStatusAxis_usgaapShareBasedPaymentArrangementNonemployeeMember" unitRef="usdPershares" scale="0" decimals="2" format="ixt:num-dot-decimal">11.21</ix:nonFraction></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        </tr>
  </table> </div> </div> </div> </ix:continuation>

<div style="text-align:justify;margin-left:63.8pt;line-height:1.25">&#160;</div>

<div style="text-align:justify;margin-left:63.8pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">On
December 31, 2023, there was $<ix:nonFraction id="Fixv-39535" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">284</ix:nonFraction>
of total unrecognized compensation cost related to unvested stock options granted under the Plan. That cost is expected to be recognized
over a weighted-average period of <ix:nonNumeric id="Fixv-39536" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" contextRef="C_20230101to20231231" format="ixt-sec:duryear">2.22</ix:nonNumeric>
years.</span></span></div>

<div style="line-height:1.25">&#160;</div>

<div style="text-align:justify;margin-left:63.8pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">On
December 31, 2022, there was $<ix:nonFraction id="Fixv-39537" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">414</ix:nonFraction>
of total unrecognized compensation cost related to unvested stock options granted under the Plan. That cost is expected to be recognized
over a weighted-average period of <ix:nonNumeric id="Fixv-39538" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" contextRef="C_20220101to20221231" format="ixt-sec:duryear">3.20</ix:nonNumeric>
years.</span></span></div> </div> </div>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in">&#160;</p>

<div><ix:exclude>

<div style="margin-top:0pt;margin-bottom:0pt">

<div style="margin-top:10pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">

<p style="text-align:center;margin-top:0pt;margin-bottom:3pt"><span style="width:34%;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">F-95</span></span></span></p></div><hr style="page-break-after:always;border-width:0px;clear:both;margin:4px 0px;width:100%;height:2px;color:#000000;background-color:#000000;margin-top:0pt;margin-bottom:10pt"/>

<p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:center">&#160;</p>

<p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:center"><strong>S<span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">ILEXION
THERAPEUTICS CORP</span></span></strong><br/><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS (continued)</span></span></p>

<p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">U.S.
DOLLARS IN THOUSANDS</span></span></p>

<p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:center">&#160;</p> </div>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify"><strong>NOTE 11&#160; - SHARE-BASED COMPENSATION</strong>&#160;(continued):</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">&#160;</p> </ix:exclude></div>

<p style="font:10pt Times New Roman, Times, serif;margin:0pt 0px 0pt 54pt">The share-based compensation expense by line item in the accompanying
consolidated statements of operations is summarized as follows:</p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in">&#160;</p> <ix:nonNumeric id="Fxbrl_20241003133829697" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" contextRef="C_20230101to20231231" escape="true">

<div style="margin-left:54pt">

<table cellpadding="0" cellspacing="0" style="border-collapse:collapse;font:10pt Times New Roman, Times, serif;width:85%">
  <tr style="vertical-align:bottom">
    <td>&#160;</td>
    <td style="font-weight:bold;padding-bottom:1.5pt">&#160;</td>
    <td colspan="6" style="font-weight:bold;text-align:center;border-bottom:Black 1.5pt solid">Year ended&#160;December&#160;31</td>
    <td style="padding-bottom:1.5pt;font-weight:bold">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td>&#160;</td>
    <td style="font-weight:bold;padding-bottom:1.5pt">&#160;</td>
    <td colspan="2" style="font-weight:bold;text-align:center;border-bottom:Black 1.5pt solid">2023</td>
    <td style="padding-bottom:1.5pt;font-weight:bold">&#160;</td>
    <td style="font-weight:bold;padding-bottom:1.5pt">&#160;</td>
    <td colspan="2" style="font-weight:bold;text-align:center;border-bottom:Black 1.5pt solid">2022</td>
    <td style="padding-bottom:1.5pt;font-weight:bold">&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="width:76%;text-align:left;text-indent:-10pt;padding-left:10pt">Research and development</td>
    <td style="width:1%">&#160;</td>
    <td style="width:1%;text-align:left">$</td>
    <td style="width:9%;text-align:right"><ix:nonFraction id="Fixv-39540" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_20230101to20231231_usgaapIncomeStatementLocationAxis_usgaapResearchAndDevelopmentExpenseMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">78</ix:nonFraction></td>
    <td style="width:1%;text-align:left">&#160;</td>
    <td style="width:1%">&#160;</td>
    <td style="width:1%;text-align:left">$</td>
    <td style="width:9%;text-align:right"><ix:nonFraction id="Fixv-39541" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_20220101to20221231_usgaapIncomeStatementLocationAxis_usgaapResearchAndDevelopmentExpenseMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">60</ix:nonFraction></td>
    <td style="width:1%;text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom">
    <td style="text-align:left;padding-bottom:1.5pt;text-indent:-10pt;padding-left:10pt">General and administrative</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right"><ix:nonFraction id="Fixv-39542" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_20230101to20231231_usgaapIncomeStatementLocationAxis_usgaapGeneralAndAdministrativeExpenseMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">52</ix:nonFraction></td>
    <td style="padding-bottom:1.5pt;text-align:left">&#160;</td>
    <td style="padding-bottom:1.5pt">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1.5pt solid;text-align:right"><ix:nonFraction id="Fixv-39543" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_20220101to20221231_usgaapIncomeStatementLocationAxis_usgaapGeneralAndAdministrativeExpenseMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">65</ix:nonFraction></td>
    <td style="padding-bottom:1.5pt;text-align:left">&#160;</td> </tr>
  <tr style="vertical-align:bottom;background-color:rgb(204,238,255)">
    <td style="padding-bottom:4pt">&#160;</td>
    <td style="padding-bottom:4pt">&#160;</td>
    <td style="text-align:left;border-bottom:4px double black">$</td>
    <td style="text-align:right;border-bottom:4px double black"><ix:nonFraction id="Fixv-39544" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">130</ix:nonFraction></td>
    <td style="padding-bottom:4pt;text-align:left">&#160;</td>
    <td style="padding-bottom:4pt">&#160;</td>
    <td style="text-align:left;border-bottom:4px double black">$</td>
    <td style="text-align:right;border-bottom:4px double black"><ix:nonFraction id="Fixv-39545" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">125</ix:nonFraction></td>
    <td style="padding-bottom:4pt;text-align:left">&#160;</td> </tr>
  </table> </div> </ix:nonNumeric> </div> </ix:nonNumeric>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p> </div>

<div style="font:10pt Times New Roman, Times, Serif"> <ix:nonNumeric id="Fxbrl_20241003134215050" name="us-gaap:FairValueDisclosuresTextBlock" contextRef="C_20230101to20231231" escape="true">

<div>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong><span>NOTE
12&#160; - FAIR VALUE MEASUREMENTS:</span></strong></span></span></p>

<div>

<div>

<div style="line-height:1.25">&#160;</div>

<div style="margin-left:54pt;line-height:1.25;font-weight:bold"><strong><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>Financial
instruments measured at fair value on a recurring basis</span></span></span></strong></div>

<div style="line-height:1.25">&#160;</div>

<div style="text-align:justify;margin-left:54pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>The
Company&#8217;s assets and liabilities that are measured at fair value as of December 31, 2023, and December 31, 2022, are classified
in the tables below in one of the three categories described in &#8220;Note 2 &#8211; Fair value measurement&#8221; above:</span></span></span></div>

<div style="text-align:justify;margin-left:54pt;line-height:1.25">&#160;</div> <ix:nonNumeric id="Fxbrl_20241003134027716" name="us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" contextRef="C_20230101to20231231" escape="true">

<div>

<div style="margin-left:54pt">

<table border="0" cellpadding="0" cellspacing="0" style="width:85%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left;float:left">
  <tr>
    <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
    <td colspan="6" style="vertical-align:top;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-family:Times New Roman,Times,serif">December
        31, 2023</span></div> </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
    <td colspan="2" style="vertical-align:top;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-family:Times New Roman,Times,serif">Level
        3</span></div> </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
    <td colspan="2" style="vertical-align:top;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-family:Times New Roman,Times,serif">Total</span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:top;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-family:Times New Roman,Times,serif">Financial
        Liabilities</span></div> </td>
    <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="2" style="vertical-align:middle;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="2" style="vertical-align:middle;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:top;width:76%;background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="margin-left:14.2pt;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-family:Times New Roman,Times,serif">Warrants
        to preferred shares</span></div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-family:Times New Roman,Times,serif">$</span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25"><span style="font-family:Times New Roman,Times,serif"><span><ix:nonFraction id="Fixv-39547" name="us-gaap:OtherLiabilitiesCurrent" contextRef="C_20231231_usgaapFairValueByFairValueHierarchyLevelAxis_usgaapFairValueInputsLevel3Member" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">200</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-family:Times New Roman,Times,serif">$</span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fixv-39548" name="us-gaap:OtherLiabilitiesCurrent" contextRef="C_20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">200</ix:nonFraction></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        </tr>
  </table> </div>

<div style="line-height:1.25;clear:both">&#160;</div>

<div style="margin-left:54pt">

<table border="0" cellpadding="0" cellspacing="0" style="color:#000000;font-family:'Times New Roman',Times,serif;font-size:10pt;text-align:left;width:85%">
  <tr>
    <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
    <td colspan="6" style="vertical-align:top;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-family:Times New Roman,Times,serif">December
        31, 2022</span></div> </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
    <td colspan="2" style="vertical-align:top;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-family:Times New Roman,Times,serif">Level
        3</span></div> </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
    <td colspan="2" style="vertical-align:top;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-family:Times New Roman,Times,serif">Total</span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:top;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-family:Times New Roman,Times,serif">Financial
        Liabilities</span></div> </td>
    <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="2" style="vertical-align:middle;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="2" style="vertical-align:middle;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:top;width:76%;background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="margin-left:14.2pt;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-family:Times New Roman,Times,serif">Warrants
        to preferred shares</span></div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-family:Times New Roman,Times,serif">$</span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fixv-39549" name="us-gaap:OtherLiabilitiesCurrent" contextRef="C_20221231_usgaapFairValueByFairValueHierarchyLevelAxis_usgaapFairValueInputsLevel3Member" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">3</ix:nonFraction></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-family:Times New Roman,Times,serif">$</span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fixv-39550" name="us-gaap:OtherLiabilitiesCurrent" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">3</ix:nonFraction></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        </tr>
  </table> </div> </div> </ix:nonNumeric>

<div style="line-height:1.25;clear:both">&#160;</div>

<div style="text-align:justify;margin-left:54pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>The
following is a roll forward of the fair value of liabilities classified under Level 3:</span></span></span></div>

<div style="text-align:justify;margin-left:54pt;line-height:1.25">&#160;</div> <ix:nonNumeric id="Fxbrl_20241003134051076" name="us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" contextRef="C_20230101to20231231" escape="true">

<div>

<div style="margin-left:54pt">

<table border="0" cellpadding="0" cellspacing="0" style="color:#000000;font-family:'Times New Roman',Times,serif;font-size:10pt;text-align:left;width:85%">
  <tr>
    <td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-family:Times New Roman,Times,serif">2023</span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
    <td colspan="6" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-family:Times New Roman,Times,serif">2022</span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-family:Times New Roman,Times,serif">Warrants</span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-family:Times New Roman,Times,serif">Warrants</span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-family:Times New Roman,Times,serif">SAFE</span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-family:Times New Roman,Times,serif">Fair value
        at the beginning of the year</span></div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-family:Times New Roman,Times,serif">$</span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fixv-39552" name="us-gaap:OtherLiabilitiesCurrent" contextRef="C_20221231_usgaapClassOfWarrantOrRightAxis_usgaapWarrantMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">3</ix:nonFraction></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-family:Times New Roman,Times,serif">$</span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20241003165238872" name="us-gaap:OtherLiabilitiesCurrent" contextRef="C_20211231_usgaapClassOfWarrantOrRightAxis_usgaapWarrantMember" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-family:Times New Roman,Times,serif">$</span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fixv-39553" name="us-gaap:OtherLiabilitiesCurrent" contextRef="C_20211231_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_slxnSAFEMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,204</ix:nonFraction></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align:bottom;width:64%;background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-family:Times New Roman,Times,serif">Issuance</span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fixv-39554" name="us-gaap:ProceedsFromDebtNetOfIssuanceCosts" contextRef="C_20230101to20231231_usgaapClassOfWarrantOrRightAxis_usgaapWarrantMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">111</ix:nonFraction></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fixv-39555" name="us-gaap:ProceedsFromDebtNetOfIssuanceCosts" contextRef="C_20220101to20221231_usgaapClassOfWarrantOrRightAxis_usgaapWarrantMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,020</ix:nonFraction></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20241003164939845" name="us-gaap:ProceedsFromDebtNetOfIssuanceCosts" contextRef="C_20220101to20221231_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_slxnSAFEMember" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-family:Times New Roman,Times,serif">Change in
        fair value</span></div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fixv-39556" name="us-gaap:FairValueOptionChangesInFairValueGainLoss1" contextRef="C_20230101to20231231_usgaapClassOfWarrantOrRightAxis_usgaapWarrantMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">86</ix:nonFraction></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fixv-39557" name="us-gaap:FairValueOptionChangesInFairValueGainLoss1" contextRef="C_20220101to20221231_usgaapClassOfWarrantOrRightAxis_usgaapWarrantMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">1,017</ix:nonFraction></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-family:Times New Roman,Times,serif">)</span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20241003164951094" name="us-gaap:FairValueOptionChangesInFairValueGainLoss1" contextRef="C_20220101to20221231_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_slxnSAFEMember" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align:bottom;width:64%;background-color:rgb(255, 255, 255);padding-bottom:2px;vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-family:Times New Roman,Times,serif">Conversion
        to equity</span></div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);padding-bottom:2px;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255);border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20241003165006518" name="us-gaap:InvestmentOwnedAtFairValue" contextRef="C_20231231_usgaapClassOfWarrantOrRightAxis_usgaapWarrantMember" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);padding-bottom:2px;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255);border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20241003165002830" name="us-gaap:InvestmentOwnedAtFairValue" contextRef="C_20221231_usgaapClassOfWarrantOrRightAxis_usgaapWarrantMember" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);padding-bottom:2px;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255);border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fixv-39558" name="us-gaap:InvestmentOwnedAtFairValue" contextRef="C_20221231_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_slxnSAFEMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">3,204</ix:nonFraction></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);padding-bottom:2px;vertical-align:bottom;white-space:nowrap"><span style="font-family:Times New Roman,Times,serif">)</span></td>
        </tr>
  <tr>
    <td style="vertical-align:bottom;width:64%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-family:Times New Roman,Times,serif">Fair value
        at the end of the year</span></div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-family:Times New Roman,Times,serif">$</span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fixv-39559" name="us-gaap:OtherLiabilitiesCurrent" contextRef="C_20231231_usgaapClassOfWarrantOrRightAxis_usgaapWarrantMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">200</ix:nonFraction></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-family:Times New Roman,Times,serif">$</span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fixv-39560" name="us-gaap:OtherLiabilitiesCurrent" contextRef="C_20221231_usgaapClassOfWarrantOrRightAxis_usgaapWarrantMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">3</ix:nonFraction></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-family:Times New Roman,Times,serif">$</span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20241003165050663" name="us-gaap:OtherLiabilitiesCurrent" contextRef="C_20221231_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_slxnSAFEMember" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        </tr>
  </table> </div> </div> </ix:nonNumeric>

<div style="line-height:1.25;clear:both">&#160;</div>

<div style="text-align:justify;margin-left:54pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>The
fair value of the Company&#8217;s warrant liabilities as of December 31, 2023 was estimated using a hybrid model in order to reflect two
scenarios: (1) an IPO event (including de-SPAC transaction) and (2) other liquidation events.</span></span></span></div>

<div style="line-height:1.25">&#160;</div>

<div style="text-align:justify;margin-left:54pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>The
IPO scenario (including de-SPAC transaction) was based on management estimation regarding the expected value of the Company&#8217;s entire
equity at the IPO event (including de-SPAC transaction). Valuation under this scenario was assessed using the probability-weighted expected
return method (PWERM).</span></span></span></div>

<div style="line-height:1.25">&#160;</div>

<div style="text-align:justify;margin-left:54pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>The
valuation under the &#8216;other liquidation events&#8217; scenario was assessed using an option pricing model (OPM) by implementing a
Monte Carlo Simulation, which treats the financial instruments in the Company's equity as contingent claims whose future payoff depends
on the Company's future equity value. The Company&#8217;s entire equity value in 2023 was calculated based, among others, on the financing
round closest to the valuation date.</span></span></span></div>

<div style="line-height:1.25">&#160;</div>

<div style="text-align:justify;margin-left:54pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>The
fair value of the Company&#8217;s warrant liabilities as of December 31, 2022 was estimated using only the &#8216;other liquidation events&#8217;
scenario.</span></span></span></div>

<div style="line-height:1.25">&#160;</div>

<div><ix:exclude>

<div style="line-height:1.25">

<div style="margin-top:10pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">

<p style="text-align:center;margin-top:0pt;margin-bottom:3pt"><span style="width:34%;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">F-96</span></span></span></p></div><hr style="page-break-after:always;border-width:0px;clear:both;margin:4px 0px;width:100%;height:2px;color:#000000;background-color:#000000;margin-top:0pt;margin-bottom:10pt"/>

<p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:center">&#160;</p>

<p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:center"><strong>S<span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">ILEXION
THERAPEUTICS CORP</span></span></strong><br/><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS (continued)</span></span></p>

<p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">U.S.
DOLLARS IN THOUSANDS</span></span></p>

<p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:center">&#160;</p> </div>

<div style="line-height:1.25;font-family:'Times New Roman', Times, serif"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">NOTE
12&#160; - FAIR VALUE MEASUREMENTS </span>(continued):</span></div>

<div style="line-height:1.25;font-family:'Times New Roman', Times, serif">&#160;</div> </ix:exclude></div>

<div style="text-align:justify;margin-left:54pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>Application
of these approaches and methodologies involves the use of estimates, judgments and assumptions that are highly complex and subjective,
such as those regarding discount rates, the&#160;</span><span>selection of comparable public companies, and the probability of and timing
associated with possible future events.</span></span></span></div>

<div style="line-height:1.25">&#160;</div>

<div style="text-align:justify;margin-left:54pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>The
following table presents the main assumptions used in the hybrid model for the periods presented:</span></span></span></div>

<div style="text-align:justify;margin-left:54pt;line-height:1.25">&#160;</div> <ix:nonNumeric id="Fxbrl_20241003134106325" name="us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock" contextRef="C_20230101to20231231" escape="true">

<div>

<div style="margin-left:54pt">

<table border="0" cellpadding="0" cellspacing="0" style="color:#000000;font-family:'Times New Roman',Times,serif;font-size:10pt;text-align:left;width:85%">
  <tr>
    <td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
    <td colspan="6" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-family:Times New Roman,Times,serif">December
        31</span></div> </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">
        <div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-family:Times New Roman,Times,serif">2023</span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-family:Times New Roman,Times,serif">2022</span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-family:Times New Roman,Times,serif">Expected
        volatility</span></div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fixv-39562" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="C_20230101to20231231" unitRef="pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">73.8</ix:nonFraction></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-family:Times New Roman,Times,serif">%</span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20241205141000815" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="C_20220101to20221231" unitRef="pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">87.3</ix:nonFraction></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-family:Times New Roman,Times,serif">%</span></div>
        </td> </tr>
  <tr>
    <td style="vertical-align:bottom;width:76%;background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-family:Times New Roman,Times,serif">Assumptions
        regarding the price of the underlying shares:</span></div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-family:Times New Roman,Times,serif">Probability
        of an IPO scenario (including de-SPAC transaction)</span></div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fixv-39564" name="slxn:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedProbabilityRate" contextRef="C_20230101to20231231_usgaapMeasurementInputTypeAxis_slxnProbabilityOfAnIPOScenarioMember" unitRef="pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">25</ix:nonFraction></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-family:Times New Roman,Times,serif">%</span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20241004181405487" name="slxn:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedProbabilityRate" contextRef="C_20220101to20221231_usgaapMeasurementInputTypeAxis_slxnProbabilityOfAnIPOScenarioMember" unitRef="pure" scale="-2" decimals="2" format="ixt:fixed-zero">-</ix:nonFraction></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align:bottom;width:76%;background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-family:Times New Roman,Times,serif">Expected
        time to IPO (including de-SPAC transaction) (years)</span></div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-family:Times New Roman,Times,serif"><ix:nonNumeric id="Fixv-39565" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" contextRef="C_20230101to20231231_usgaapMeasurementInputTypeAxis_slxnExpectedTimeToIPOMember" format="ixt-sec:duryear">0.414</ix:nonNumeric></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-family:Times New Roman,Times,serif"><span style="-sec-ix-hidden:Fxbrl_20241004181424317">-</span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-family:Times New Roman,Times,serif">Probability
        of other liquidation events</span></div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fixv-39566" name="slxn:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedProbabilityRate" contextRef="C_20230101to20231231_usgaapMeasurementInputTypeAxis_slxnProbabilityOfOtherLiquidationEventsMember" unitRef="pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">75</ix:nonFraction></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-family:Times New Roman,Times,serif">%</span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fixv-39567" name="slxn:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedProbabilityRate" contextRef="C_20220101to20221231_usgaapMeasurementInputTypeAxis_slxnProbabilityOfOtherLiquidationEventsMember" unitRef="pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">100</ix:nonFraction></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-family:Times New Roman,Times,serif">%</span></div>
        </td> </tr>
  <tr>
    <td style="vertical-align:bottom;width:76%;background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-family:Times New Roman,Times,serif">Expected
        time to liquidation (years)</span></div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-family:Times New Roman,Times,serif"><ix:nonNumeric id="Fixv-39568" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" contextRef="C_20230101to20231231_usgaapMeasurementInputTypeAxis_slxnExpectedTimeToLiquidationMember" format="ixt-sec:duryear">2.75</ix:nonNumeric></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-family:Times New Roman,Times,serif"><ix:nonNumeric id="Fixv-39569" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" contextRef="C_20220101to20221231_usgaapMeasurementInputTypeAxis_slxnExpectedTimeToLiquidationMember" format="ixt-sec:duryear">3.00</ix:nonNumeric></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-family:Times New Roman,Times,serif">Expected
        return on Equity</span></div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fixv-39570" name="slxn:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedProbabilityRate" contextRef="C_20230101to20231231_usgaapMeasurementInputTypeAxis_slxnExpectedReturnOnEquityMember" unitRef="pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">22</ix:nonFraction></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-family:Times New Roman,Times,serif">%</span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fixv-39571" name="slxn:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedProbabilityRate" contextRef="C_20220101to20221231_usgaapMeasurementInputTypeAxis_slxnExpectedReturnOnEquityMember" unitRef="pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">23</ix:nonFraction></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-family:Times New Roman,Times,serif">%</span></div>
        </td> </tr>
  </table> </div> </div> </ix:nonNumeric>

<div style="text-align:justify;margin-left:54pt;line-height:1.25;clear:both">&#160;</div>

<div style="text-align:justify;margin-left:54pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>A
significant increase in the expected volatility, or in the probability of an IPO (including de-SPAC transaction) (in 2023), could each
increase the fair value of the related instruments. A significant decrease in the expected term of the warrants or expected time to IPO
(including de-SPAC transaction), could each decrease the fair value of related instruments. In combination, changes in these inputs could
result in a significantly higher or lower fair value measurement if the input changes were to be compounding, or could result in a minimally
higher or lower fair value measurement if the input changes were of opposite effects and consequently offset each other.&#160;</span></span></span></div>

<div style="line-height:1.25">&#160;</div>

<div style="line-height:1.25;font-weight:bold;margin-left:54pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>Financial
instruments not measured at fair value</span></span></span></div>

<div style="line-height:1.25">&#160;</div>

<div style="text-align:justify;margin-left:56.7pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>The
carrying amounts of cash and cash equivalents, restricted cash, receivables, trade payables and other liabilities approximate their fair
value due to the short-term maturity of such instruments.</span></span></span></div> </div> </div> </div> </ix:nonNumeric>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p> </div>

<div style="font:10pt Times New Roman, Times, Serif"> <ix:nonNumeric id="Fxbrl_20241003134506355" name="us-gaap:EarningsPerShareTextBlock" contextRef="C_20230101to20231231" escape="true">

<div>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0"><strong><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">NOTE
13&#160; - NET LOSS PER SHARE:</span></span></strong></p>

<div>

<div>

<div style="line-height:1.25">

<div style="line-height:1.25">&#160;</div>

<div style="margin-left:56.7pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The
following table sets forth the computation of basic and diluted net loss per share attributable to ordinary shareholders for the periods
presented (USD in thousands, except per share data):</span></span></div>

<div style="margin-left:56.7pt;line-height:1.25">&#160;</div> </div> <ix:nonNumeric id="Fxbrl_20241205125521330" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" contextRef="C_20230101to20231231" escape="true">

<div>

<div style="margin-left:54pt">

<table border="0" cellpadding="0" cellspacing="0" style="color:#000000;font-family:'Times New Roman',Times,serif;font-size:10pt;text-align:left;width:85%">
  <tr>
    <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
    <td colspan="6" style="vertical-align:middle;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Year
        ended December 31</span></span></div> </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
    <td colspan="2" style="vertical-align:middle;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2023</span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
    <td colspan="2" style="vertical-align:middle;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2022</span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:top;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Numerator:</span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="2" style="vertical-align:top;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="2" style="vertical-align:top;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:top;width:76%;background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="text-indent:-14.15pt;margin-left:23.1pt;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Net
        loss for the year</span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fixv-39573" name="us-gaap:NetIncomeLoss" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">5,108</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fixv-39574" name="us-gaap:NetIncomeLoss" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">3,488</ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align:top;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="text-indent:-14.15pt;margin-left:23.1pt;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Net
        loss attributable to ordinary shareholders, basic and diluted:</span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20241205125612980" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal"><ix:nonFraction id="Fixv-39575" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" contextRef="C_20230101to20231231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,942</ix:nonFraction></ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20241205125654977" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal"><ix:nonFraction id="Fixv-39576" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,215</ix:nonFraction></ix:nonFraction></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align:top;width:76%;background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Denominator:</span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align:top;width:76%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="text-indent:-14.15pt;margin-left:23.1pt;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Weighted-average
        shares used in computing net loss per share attributable to ordinary shareholders, basic and diluted</span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20241205125712203" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="C_20230101to20231231" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="Fixv-39577" name="us-gaap:WeightedAverageNumberOfSharesIssuedBasic" contextRef="C_20230101to20231231" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">111,726</ix:nonFraction></ix:nonFraction></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20241205125727228" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="C_20220101to20221231" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="Fixv-39578" name="us-gaap:WeightedAverageNumberOfSharesIssuedBasic" contextRef="C_20220101to20221231" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">111,686</ix:nonFraction></ix:nonFraction></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align:top;width:76%;padding-bottom:4px;background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="text-indent:-14.15pt;margin-left:23.1pt;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Net
        loss per share attributable to ordinary shareholders, basic and diluted</span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20241205125740457" name="us-gaap:EarningsPerShareDiluted" contextRef="C_20230101to20231231" unitRef="usdPershares" scale="0" decimals="2" format="ixt:num-dot-decimal"><ix:nonFraction id="Fixv-39579" name="us-gaap:EarningsPerShareBasic" contextRef="C_20230101to20231231" unitRef="usdPershares" scale="0" decimals="2" format="ixt:num-dot-decimal">44.23</ix:nonFraction></ix:nonFraction></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(255, 255, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20241205125754354" name="us-gaap:EarningsPerShareDiluted" contextRef="C_20220101to20221231" unitRef="usdPershares" scale="0" decimals="2" format="ixt:num-dot-decimal"><ix:nonFraction id="Fixv-39580" name="us-gaap:EarningsPerShareBasic" contextRef="C_20220101to20221231" unitRef="usdPershares" scale="0" decimals="2" format="ixt:num-dot-decimal">28.79</ix:nonFraction></ix:nonFraction></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(255, 255, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        </tr>
  </table> </div> </div> </ix:nonNumeric>

<div style="line-height:1.25;clear:both">

<div style="line-height:1.25">&#160;</div> </div>

<div><ix:exclude>

<div style="clear:both;margin-top:0pt;margin-bottom:0pt">

<div>

<div style="margin-top:10pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">

<p style="text-align:center;margin-top:0pt;margin-bottom:3pt"><span style="width:34%;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">F-97</span></span></span></p></div><hr style="page-break-after:always;border-width:0px;clear:both;margin:4px 0px;width:100%;height:2px;color:#000000;background-color:#000000;margin-top:0pt;margin-bottom:10pt"/>

<p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:center">&#160;</p>

<p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:center"><strong>S<span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">ILEXION
THERAPEUTICS CORP</span></span></strong><br/><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS (continued)</span></span></p>

<p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">U.S.
DOLLARS IN THOUSANDS</span></span></p>

<p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:center">&#160;</p> </div>
</div>

<div style="line-height:1.25;font-family:'Times New Roman', Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">NOTE
13&#160; - NET LOSS PER SHARE </span>(continued)<span style="font-weight:bold">:</span></span></span></div>

<div style="line-height:1.25;font-family:'Times New Roman', Times, serif">&#160;</div> </ix:exclude></div>

<div style="line-height:1.25">

<div style="margin-left:56.7pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Basic
loss per share is computed on the basis of the net loss for the period divided by the weighted average number of ordinary shares outstanding
during the period, and fully vested Pre-Funded options for the Company&#8217;s ordinary shares at an exercise price of $<ix:nonFraction id="Fxbrl_20241206052618182" name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="C_20231231_usgaapAwardTypeAxis_slxnPreFundedOptionsMember" unitRef="usdPershares" scale="0" decimals="4" format="ixt:num-dot-decimal">0.0226</ix:nonFraction>
or <ix:nonFraction id="Fxbrl_20241206052632303" name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="C_20231231_usgaapAwardTypeAxis_slxnPreFundedOptionsMember" unitRef="ilsPershares" scale="0" decimals="4" format="ixt:num-dot-decimal">0.0226</ix:nonFraction>
NIS per share, as the Company considers these shares to be exercised for little to no additional consideration.</span></span></div>

<div style="line-height:1.25">&#160;</div>

<div style="margin-left:56.7pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">As
of December 31, 2023 and 2022, the basic loss per share calculation included a weighted average number of <ix:nonFraction id="Fxbrl_s_20241206052644020" name="us-gaap:WeightedAverageNumberOfSharesIssuedBasic" contextRef="C_20220101to20221231_usgaapAwardTypeAxis_slxnPreFundedOptionsMember" unitRef="shares" scale="0" decimals="0" format="ixt:num-dot-decimal"><ix:nonFraction id="Fxbrl_20241206052644020" name="us-gaap:WeightedAverageNumberOfSharesIssuedBasic" contextRef="C_20230101to20231231_usgaapAwardTypeAxis_slxnPreFundedOptionsMember" unitRef="shares" scale="0" decimals="0" format="ixt:num-dot-decimal">14,652</ix:nonFraction></ix:nonFraction>
of fully vested Pre-Funded options. As the inclusion of shares of ordinary shares equivalents in the calculation would be anti-dilutive
for all periods presented, diluted net loss per share is the same as basic net loss per share.</span></span></div>

<div style="line-height:1.25">&#160;</div>

<div style="margin-left:56.7pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The
following instruments were not included in the computation of diluted earnings per share because of their anti-dilutive effect:</span></span></div>

<div style="margin-left:56.7pt;line-height:1.25;font-family:'Times New Roman', Times, serif">&#160;</div> </div>

<table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">
  <tr>
    <td style="width:56.7pt">&#160;</td>
    <td style="width:18pt;vertical-align:top;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></td>
    <td style="width:auto;vertical-align:top">
        <div style="font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Redeemable
        convertible preferred shares (see Note 9);</span></span></div> </td> </tr>
  </table>

<table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">
  <tr>
    <td style="width:56.7pt">&#160;</td>
    <td style="width:18pt;vertical-align:top;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></td>
    <td style="width:auto;vertical-align:top">
        <div style="font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Warrants
        to purchase redeemable convertible preferred shares (see Note 8);</span></span></div> </td> </tr>
  </table>

<table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">
  <tr>
    <td style="width:56.7pt">&#160;</td>
    <td style="width:18pt;vertical-align:top;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></td>
    <td style="width:auto;vertical-align:top">
        <div style="font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Simple
        agreements for future equity (see Note 7);</span></span></div> </td> </tr>
  </table>

<table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">
  <tr>
    <td style="width:56.7pt">&#160;</td>
    <td style="width:18pt;vertical-align:top;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></td>
    <td style="width:auto;vertical-align:top">
        <div style="font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Share-based
        compensation issuable at substantial consideration (see Note 11).</span></span></div> </td> </tr>
  </table> </div> </div> </div> </ix:nonNumeric>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p> </div>

<div style="font:10pt Times New Roman, Times, Serif"> <ix:nonNumeric id="Fixv-36481" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock" contextRef="C_20230101to20231231" escape="true">

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">NOTE
14&#160; - TRANSACTIONS AND BALANCES WITH RELATED PARTIES</span>:</span></p>

<div>

<div>

<div style="line-height:1.25">&#160;</div>

<div style="line-height:1.25">

<div style="margin-left:56.7pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>Transactions
with related parties which are shareholders and directors of the Company:</span></span></span></div>

<div style="line-height:1.25">&#160;</div> </div>

<table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">
  <tr>
    <td style="width:52.9pt">&#160;</td>
    <td style="width:18pt;vertical-align:top;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-family:Times New Roman,Times,serif">a.</span></td>
    <td style="width:auto;vertical-align:top">
        <div style="font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-family:Times New Roman,Times,serif">Transactions:</span></div>
        </td> </tr>
  </table>

<div style="line-height:1.25">&#160;</div> <ix:nonNumeric id="Fxbrl_20241003134535671" name="us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock" contextRef="C_20230101to20231231" escape="true">

<div>

<div style="margin-left:72pt">

<table border="0" cellpadding="0" cellspacing="0" style="color:#000000;font-family:'Times New Roman',Times,serif;font-size:10pt;text-align:left;width:85%">
  <tr>
    <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
    <td colspan="6" style="vertical-align:top;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-family:Times New Roman,Times,serif">Year
        ended December 31</span></div> </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
    <td colspan="2" style="vertical-align:top;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-family:Times New Roman,Times,serif">2023</span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
    <td colspan="2" style="vertical-align:top;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-family:Times New Roman,Times,serif">2022</span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:top;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-family:Times New Roman,Times,serif">Share-based
        compensation included in research and development expenses</span></div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-family:Times New Roman,Times,serif">$</span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fixv-39585" name="us-gaap:ResearchAndDevelopmentExpense" contextRef="C_20230101to20231231_usgaapRelatedPartyTransactionAxis_usgaapRelatedPartyMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">69</ix:nonFraction></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-family:Times New Roman,Times,serif">$</span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fixv-39586" name="us-gaap:ResearchAndDevelopmentExpense" contextRef="C_20220101to20221231_usgaapRelatedPartyTransactionAxis_usgaapRelatedPartyMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">49</ix:nonFraction></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align:top;width:76%;background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-family:Times New Roman,Times,serif">Share-based
        compensation included in general and administrative expenses</span></div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-family:Times New Roman,Times,serif">$</span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fixv-39587" name="us-gaap:GeneralAndAdministrativeExpense" contextRef="C_20230101to20231231_usgaapRelatedPartyTransactionAxis_usgaapRelatedPartyMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">48</ix:nonFraction></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-family:Times New Roman,Times,serif">$</span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fixv-39588" name="us-gaap:GeneralAndAdministrativeExpense" contextRef="C_20220101to20221231_usgaapRelatedPartyTransactionAxis_usgaapRelatedPartyMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">37</ix:nonFraction></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align:top;width:76%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-family:Times New Roman,Times,serif">Financial
        expenses</span></div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-family:Times New Roman,Times,serif">$</span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fixv-39589" name="slxn:FinancialExpensesNetFromRelatedParty" contextRef="C_20230101to20231231_usgaapRelatedPartyTransactionAxis_usgaapRelatedPartyMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">83</ix:nonFraction></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-family:Times New Roman,Times,serif">$</span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20241004095132391" name="slxn:FinancialExpensesNetFromRelatedParty" contextRef="C_20220101to20221231_usgaapRelatedPartyTransactionAxis_usgaapRelatedPartyMember" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        </tr>
  </table> </div> </div> </ix:nonNumeric>

<div style="line-height:1.25;clear:both">&#160;</div>

<table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">
  <tr>
    <td style="width:52.9pt">&#160;</td>
    <td style="width:18pt;vertical-align:top;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-family:Times New Roman,Times,serif">b.</span></td>
    <td style="width:auto;vertical-align:top">
        <div style="font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-family:Times New Roman,Times,serif">Balances:</span></div>
        </td> </tr>
  </table>

<div>&#160;</div> <ix:nonNumeric id="Fxbrl_20241205115501092" name="us-gaap:ScheduleOfCompensatingBalancesTextBlock" contextRef="C_20230101to20231231" escape="true">

<div>

<div style="margin-left:72pt">

<table border="0" cellpadding="0" cellspacing="0" style="color:#000000;font-family:'Times New Roman',Times,serif;font-size:10pt;text-align:left;width:85%">
  <tr>
    <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
    <td colspan="6" style="vertical-align:top;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-family:Times New Roman,Times,serif">December
        31</span></div> </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
    <td colspan="2" style="vertical-align:top;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-family:Times New Roman,Times,serif">2023</span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom">&#160;</td>
    <td colspan="2" style="vertical-align:top;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-family:Times New Roman,Times,serif">2022</span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-family:Times New Roman,Times,serif">Non-Current
        liabilities &#8212;</span></div> </td>
    <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:top;width:76%;padding-bottom:4px;background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-family:Times New Roman,Times,serif">Warrants
        to preferred shares&#160;&#160;</span></div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-family:Times New Roman,Times,serif">$</span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fixv-39590" name="us-gaap:OtherLiabilitiesNoncurrent" contextRef="C_20231231_usgaapRelatedPartyTransactionsByRelatedPartyAxis_usgaapRelatedPartyMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">186</ix:nonFraction></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(255, 255, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-family:Times New Roman,Times,serif">$</span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20241004095054139" name="us-gaap:OtherLiabilitiesNoncurrent" contextRef="C_20221231_usgaapRelatedPartyTransactionsByRelatedPartyAxis_usgaapRelatedPartyMember" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(255, 255, 255);vertical-align:bottom;white-space:nowrap">&#160;</td>
        </tr>
  </table> </div> </div> </ix:nonNumeric> </div> </div> </ix:nonNumeric>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</p> </div>

<div style="font:10pt Times New Roman, Times, Serif"> <ix:nonNumeric id="Fxbrl_20241003130955369" name="us-gaap:SubsequentEventsTextBlock" contextRef="C_20230101to20231231" escape="true">

<div>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><strong>NOTE
15&#160; - SUBSEQUENT EVENT:</strong></span></span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.5in">&#160;</p>

<p style="font:10pt Times New Roman, Times, serif;margin:0pt 0px 0pt 56.7pt;text-align:justify"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">The
Company&#8217;s management has performed an evaluation of subsequent events through May 09<sup>th</sup>, 2024, the date the financial
statements were available to be issued.</span></span></p>

<p style="text-align:left;font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.75in;text-indent:-24pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font:10pt Times New Roman, Times, Serif;margin-top:0pt;margin-bottom:0pt;width:100%">
  <tr style="vertical-align:top;text-align:justify">
    <td style="text-align:left;width:60pt">&#160;</td>
    <td style="text-align:left;width:18pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">a.</span></span></td>
    <td style="width:auto"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">On February&#160;21, 2024, the Company
        entered into a business combination agreement with Moringa Acquisition Corp. (the &#8220;SPAC&#8221;), an exempted company incorporated
        under the Laws of the Cayman Islands whose class A ordinary shares (as well as other instruments) are listed for trade on the Nasdaq Global
        Market (NASDAQ:MACA), and April.M.G.&#160;Ltd. (the &#8220;April Merger Sub&#8221;), a limited liability company organized under the laws
        of the State of Israel and a wholly-owned subsidiary of the SPAC (the &#8220;Original BCA&#8221;). According to the Original BCA, April
        Merger Sub would merge with and into the Company, with the Company continuing as the surviving entity and a wholly-owned subsidiary of
        the SPAC, and with the SPAC continuing as a public company following the completion of the merger and with its securities continuing to
        be traded on Nasdaq.</span></span></td> </tr>
  </table>

<p style="text-align:left;font:10pt Times New Roman, Times, Serif;margin:0pt 0 0pt 0.75in;text-indent:-24pt">&#160;</p>

<div><ix:exclude>

<div style="margin-top:0pt;margin-bottom:0pt">

<div style="margin-top:10pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">

<p style="text-align:center;margin-top:0pt;margin-bottom:3pt"><span style="width:34%;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">F-98</span></span></span></p></div><hr style="page-break-after:always;border-width:0px;clear:both;margin:4px 0px;width:100%;height:2px;color:#000000;background-color:#000000;margin-top:0pt;margin-bottom:10pt"/>

<p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:center">&#160;</p>

<p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:center"><strong>S<span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">ILEXION
THERAPEUTICS CORP</span></span></strong><br/><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS (continued)</span></span></p>

<p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">U.S.
DOLLARS IN THOUSANDS</span></span></p>

<p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:center">&#160;</p> </div>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><strong>NOTE
15&#160; - SUBSEQUENT EVENT</strong> (continued):</span></span></p>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">&#160;</p> </ix:exclude></div>

<table cellpadding="0" cellspacing="0" style="font:10pt Times New Roman, Times, Serif;margin-top:0pt;margin-bottom:0pt;width:100%">
  <tr style="vertical-align:top;text-align:justify">
    <td style="text-align:left;width:60pt">&#160;</td>
    <td style="text-align:left;width:18pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">b.</span></span></td>
    <td style="width:auto"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">On April&#160;3, 2024, the SPAC
        and the Company restructured the transactions contemplated under the Original BCA by entering into the A&amp;R BCA by and among Biomotion
        Sciences, a Cayman Islands exempted company (the &#8220;New Pubco&#8221;), August M.S.&#160;Ltd., an Israeli company and a wholly owned
        subsidiary of New Pubco (the &#8220;Merger Sub 1&#8221;), Moringa Acquisition Merger Sub Corp, a Cayman Islands exempted company and a
        wholly owned subsidiary of New Pubco (the &#8220;Merger Sub 2&#8221;), the SPAC and the Company. The A&amp;R BCA amends and restates,
        in its entirety, the Original BCA.</span></span></td> </tr>
  </table>

<p style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">&#160;</p>

<p style="font:10pt Times New Roman, Times, serif;margin:0pt 0px 0pt 78pt;text-align:justify"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">Pursuant
to the A&amp;R BCA, Merger Sub 2 will merge with and into the SPAC, with the SPAC continuing as the surviving company of such merger and
a wholly-owned subsidiary of New Pubco (the &#8220;SPAC Merger&#8221;), and Merger Sub 1 will merge with and into the Company, with the
Company continuing as the surviving company of such merger and a wholly-owned subsidiary of New Pubco (the &#8220;Acquisition Merger&#8221;).</span></span></p>

<p style="font:10pt Times New Roman, Times, serif;margin:0pt 0px 0pt 78pt;text-align:justify">&#160;</p>

<p style="font:10pt Times New Roman, Times, serif;margin:0pt 0px 0pt 78pt;text-align:justify"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">Upon
the effectiveness of the SPAC Merger, each outstanding SPAC Class&#160;A ordinary share and the sole outstanding SPAC Class&#160;B ordinary
share will convert into an ordinary share of New Pubco on a one-for-one basis, and each outstanding warrant to purchase <ix:nonFraction id="Fixv-39591" name="us-gaap:CommonStockSharesIssued" contextRef="C_20231231_usgaapRelatedPartyTransactionsByRelatedPartyAxis_slxnSPACMember_usgaapSubsequentEventTypeAxis_usgaapSubsequentEventMember" unitRef="shares" decimals="INF" format="ixt-sec:numwordsen">one</ix:nonFraction>
SPAC Class&#160;A ordinary share will convert into a warrant to purchase <ix:nonFraction id="Fixv-39592" name="us-gaap:CommonStockSharesIssued" contextRef="C_20231231_usgaapRelatedPartyTransactionsByRelatedPartyAxis_slxnNewPubcoMember_usgaapSubsequentEventTypeAxis_usgaapSubsequentEventMember" unitRef="shares" decimals="INF" format="ixt-sec:numwordsen">one</ix:nonFraction>
New Pubco ordinary share, at the same exercise price.</span></span></p>

<p style="font:10pt Times New Roman, Times, serif;margin:0pt 0px 0pt 78pt;text-align:justify">&#160;</p>

<p style="font:10pt Times New Roman, Times, serif;margin:0pt 0px 0pt 78pt;text-align:justify"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">Upon
the effectiveness of the Acquisition Merger, each outstanding ordinary share and preferred share of the Company will convert into such
number of ordinary shares of New Pubco as is equal to the quotient obtained by dividing (x)&#160;the quotient obtained by dividing (1)&#160;$<ix:nonFraction id="Fixv-39593" name="us-gaap:StockIssuedDuringPeriodValueAcquisitions" contextRef="C_20230101to20231231_usgaapRelatedPartyTransactionsByRelatedPartyAxis_slxnNewPubcoMember_usgaapSubsequentEventTypeAxis_usgaapSubsequentEventMember" unitRef="usd" scale="0" decimals="0" format="ixt:num-dot-decimal">62,500,000</ix:nonFraction>
by (2)&#160;the number of fully diluted Company equity securities, by (y)&#160;$<ix:nonFraction id="Fixv-39594" name="us-gaap:SharesIssuedPricePerShare" contextRef="C_20231231_usgaapRelatedPartyTransactionsByRelatedPartyAxis_slxnNewPubcoMember_usgaapSubsequentEventTypeAxis_usgaapSubsequentEventMember" unitRef="usdPershares" scale="0" decimals="2" format="ixt:num-dot-decimal">10.00</ix:nonFraction>
(the &#8220;Company Equity Exchange Ratio&#8221;). Each outstanding Company warrant and Company option to purchase one Company share,
and Company restricted share unit (RSU) that may be potentially settled for one Company share, will become exercisable for, or will be
subject to settlement for (as applicable), such number of New Pubco ordinary shares as are equal to the Company Equity Exchange Ratio.
The exercise price per New Pubco ordinary share of each such converted Company options and Company warrants will be adjusted based on
dividing the existing per share exercise price by the Company Equity Exchange Ratio. The terms of vesting, exercise and/or settlement,
as applicable, of such converted options, warrants and RSUs shall remain the same following such conversion, except that the vesting of
each Company option will accelerate immediately prior to the Acquisition Merger, such that the New Pubco option into which it has been
converted will be fully vested.</span></span></p>

<p style="font:10pt Times New Roman, Times, serif;margin:0pt 0px 0pt 78pt;text-align:justify">&#160;</p>

<p style="font:10pt Times New Roman, Times, serif;margin:0pt 0px 0pt 78pt;text-align:justify"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">The
completion of the A&amp;R BCA is subject to the satisfaction of certain conditions, including obtaining the consent of the shareholders
of each of the SPAC and the Company and the declaration of effectiveness of a registration statement on form S-4 by the U.S.&#160;Securities
and Exchange Commission in relation to issuance of New Pubco ordinary shares to be issued or issuable to the SPAC&#8217;s and the Company&#8217;s
respective security holders pursuant to the A&amp;R BCA.&#160;To facilitate the A&amp;R BCA, the parties further entered into certain
ancillary agreements.</span></span></p>

<p style="font:10pt Times New Roman, Times, serif;margin:0pt 0px 0pt 78pt;text-align:justify">&#160;</p>

<p style="font:10pt Times New Roman, Times, serif;margin:0pt 0px 0pt 78pt;text-align:justify"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">The
A&amp;R BCA further imposes various restrictions on the total liabilities which the SPAC may incur prior to closing, including the total
indebtedness toward the sponsor of the SPAC, and the terms on which such indebtedness will be repaid or converted, whereas such conversion,
if and when it occurs, will further dilute the holdings of all shareholders of New Pubco at that time, including the former shareholders
of the Company.</span></span></p>

<p style="font:10pt Times New Roman, Times, serif;margin:0pt 0px 0pt 78pt;text-align:justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font:10pt Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;width:100%;border:0px">
  <tr style="vertical-align:top;text-align:justify">
    <td style="text-align:left;width:60pt">&#160;</td>
    <td style="text-align:left;width:18pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">c.</span></span></td>
    <td style="width:auto">
        <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">For
        information regarding the reverse share split, see Note 1 (c)</span></span></p> </td> </tr>
  </table> </div> </ix:nonNumeric>

<div style="line-height:1.25;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">_______________________</span></span></div>

<div style="line-height:1.25;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">________________________________</span></span></div>

<div style="line-height:1.25;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">_______________________</span></span></div>

<div style="margin-top:10pt;margin-bottom:0pt">

<p style="font:10pt Times New Roman, Times, Serif;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>F-99</span></span></span></p>
</div> <hr style="page-break-after:always;border-width:0px;clear:both;margin:4px 0px;width:100%;height:2px;color:#000000;background-color:#000000;margin-top:4pt;margin-bottom:10pt"/>
</div>

<div>

<div style="text-align:center;line-height:1.25;font-family:'Times New Roman', Times, serif;font-size:10pt;font-weight:bold">

<div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold">

<div style="line-height:1.25;font-family:'Times New Roman', Times, serif;font-weight:bold">

<p style="margin:0pt">&#160;</p>Silexion Therapeutics Corp</div>

<div style="line-height:1.25;font-family:'Times New Roman', Times, serif;font-weight:bold">&#160;</div>

<div style="line-height:1.25;font-family:'Times New Roman', Times, serif;font-weight:bold">Up to 2,377,030 Ordinary Shares</div>

<div style="line-height:1.25;font-family:'Times New Roman', Times, serif;font-weight:bold">&#160;</div>

<div style="line-height:1.25;font-family:'Times New Roman', Times, serif;font-weight:bold">PROSPECTUS</div>

<div style="line-height:1.25;font-family:'Times New Roman', Times, serif;font-weight:bold">&#160;</div></div></div>

<div style="text-align:center;line-height:1.25;font-family:'Times New Roman', Times, serif;font-size:10pt">&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;,
2025</div></div>

<div style="clear:both;margin-top:10pt;margin-bottom:10pt">

<div style="page-break-after:always"><hr style="border-width:0px;clear:both;margin:4px 0px;width:100%;height:2px;color:#000000;background-color:#000000"/></div></div>

<div style="font:10pt Times New Roman, Times, Serif">&#160;

<div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-size:10pt;font-weight:bold">PART II</div>

<div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-size:10pt;font-weight:bold">&#160;</div>

<div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-size:10pt;font-weight:bold">INFORMATION
NOT REQUIRED IN PROSPECTUS</div>

<div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-size:10pt;font-weight:bold">&#160;</div>

<div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif;font-size:10pt;font-weight:bold">Item 13. Other
Expenses of Issuance and Distribution.</div>

<div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif;font-size:10pt;font-weight:bold">&#160;</div>

<div style="text-align:left;text-indent:36pt;line-height:1.25;font-family:'Times New Roman', Times, serif;font-size:10pt">

<div style="text-indent:36pt;line-height:1.25;font-family:'Times New Roman',Times,serif">

<div style="text-indent:36pt;line-height:1.25;font-family:'Times New Roman', Times, serif">

<div style="text-indent:36pt;line-height:1.25">The following table sets forth all costs and expenses, other than underwriting discounts
and commissions, payable by us in connection with the sale of the securities being registered. All amounts shown are estimates, except
for the&#160;SEC registration fee.</div></div></div></div>

<div style="text-align:left;line-height:1.25;font-family:'Times New Roman',Times,serif;font-size:10pt">

<div>&#160;</div>

<div>

<table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left;color:#000000;width:100%">
  <tr>
    <td style="vertical-align:bottom;padding-bottom:2px;width:88%;vertical-align:bottom">
        <div style="line-height:1.25">&#160;</div></td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%;vertical-align:bottom">&#160;</td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
        <div style="text-align:center;line-height:1.25;font-weight:bold">Amount</div></td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td></tr>
  <tr>
    <td rowspan="1" style="vertical-align:bottom;width:88%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25">SEC registration fee</div></td>
    <td colspan="1" rowspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" rowspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">$</td>
    <td colspan="1" rowspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom">
        <div style="line-height:1.25">517</div></td>
    <td colspan="1" rowspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">&#160;</td></tr>
  <tr>
    <td style="vertical-align:bottom;width:88%;background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25">Accountants&#8217; fees and expenses</div></td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25">$</div></td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25">40,000</div></td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom;white-space:nowrap">&#160;</td></tr>
  <tr>
    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:88%;vertical-align:bottom">
        <div style="line-height:1.25">Legal fees and expenses</div></td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom">
        <div style="line-height:1.25">$</div></td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">
        <div style="line-height:1.25">10,000</div></td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">&#160;</td></tr>
  <tr>
    <td style="vertical-align:bottom;width:88%;background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25">Printing fees</div></td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25">$</div></td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25">2,500</div></td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255);vertical-align:bottom;white-space:nowrap">&#160;</td></tr>
  <tr>
    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:88%;padding-bottom:2px;vertical-align:bottom">
        <div style="line-height:1.25">Miscellaneous</div></td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
        <div style="line-height:1.25">$</div></td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">
        <div style="line-height:1.25">1,983</div></td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">&#160;</td></tr>
  <tr>
    <td style="vertical-align:bottom;width:88%;padding-bottom:4px;background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25">Total expenses</div></td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(255, 255, 255);vertical-align:bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25">$</div></td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(255, 255, 255);vertical-align:bottom">
        <div style="line-height:1.25">55,000</div></td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(255, 255, 255);vertical-align:bottom;white-space:nowrap">&#160;</td></tr>
  </table></div>

<div>&#160;</div></div></div>

<div style="font:10pt Times New Roman, Times, Serif">

<div style="text-align:left;text-indent:36pt;line-height:1.25;font-family:'Times New Roman', Times, serif;font-size:10pt">

<div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif">

<div style="text-align:left;line-height:1.25">

<div style="text-indent:36pt;line-height:1.25;font-family:'Times New Roman', Times, serif">Discounts, concessions, commissions and similar
selling expenses attributable to the sale of ordinary shares covered by this prospectus will be borne by the Selling Securityholders.
We will pay all expenses (other than discounts, concessions, commissions and similar selling expenses) relating to the registration of
the shares with the SEC, as estimated in the table above.</div></div></div></div>

<div style="text-align:justify;text-indent:18pt;line-height:1.25;font-family:'Times New Roman',Times,serif;font-size:10pt">&#160;</div>

<div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif;font-size:10pt;font-weight:bold">Item 14. Indemnification
of Directors and Officers.</div>

<div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif;font-size:10pt">&#160;</div>

<div style="text-align:left;text-indent:36pt;line-height:1.25;font-family:'Times New Roman',Times,serif;font-size:10pt">

<div style="text-indent:36pt;line-height:1.25;font-family:'Times New Roman', Times, serif">Cayman Islands law does not limit the extent
to which a company&#8217;s memorandum and articles of association may provide for indemnification of officers and directors, except to
the extent any such provision may be held by the Cayman Islands courts to be contrary to public policy, such as to provide indemnification
against willful default, willful neglect, actual fraud or the consequences of committing a crime. New Silexion&#8217;s amended and restated
memorandum and articles of association provide for indemnification of its officers and directors to the maximum extent permitted by law,
including for any liability incurred in their capacities as such, except through their own actual fraud, willful default or willful neglect.
New Silexion has purchased a policy of directors&#8217; and officers&#8217; liability insurance that insures its officers and directors
against the cost of defense, settlement or payment of a judgment in some circumstances and insures it against its obligations to indemnify
its officers and directors.</div></div>

<div style="text-align:left;text-indent:36pt;line-height:1.25;font-family:'Times New Roman',Times,serif;font-size:10pt">&#160;</div>

<div style="text-align:left;text-indent:36pt;line-height:1.25;font-family:'Times New Roman',Times,serif;font-size:10pt">We believe that
these provisions and the insurance are necessary to attract and retain talented and experienced officers and directors.</div>

<div style="text-align:left;text-indent:36pt;line-height:1.25;font-family:'Times New Roman',Times,serif;font-size:10pt">&#160;</div>

<div style="text-align:left;text-indent:36pt;line-height:1.25;font-family:'Times New Roman',Times,serif;font-size:10pt">Insofar as indemnification
for liabilities arising under the Securities Act may be permitted to directors, officers or persons controlling us pursuant to the foregoing
provisions, we have been informed that in the opinion of the SEC such indemnification is against public policy as expressed in the Securities
Act and is therefore unenforceable.</div>

<div style="text-align:left;text-indent:36pt;line-height:1.25;font-family:'Times New Roman',Times,serif;font-size:10pt">&#160;</div>

<div style="text-align:left;text-indent:36pt;line-height:1.25;font-family:'Times New Roman',Times,serif;font-size:10pt">

<div style="text-indent:36pt;line-height:1.25;font-family:'Times New Roman', Times, serif">New Silexion has entered into indemnity agreements
with each of its officers and directors. These agreements require New Silexion to indemnify these individuals and entity to the fullest
extent permitted under applicable Cayman Islands law and to hold harmless, exonerate and advance expenses incurred as a result of any
proceeding against them as to which they could be indemnified.</div></div>

<div style="text-align:left;text-indent:36pt;line-height:1.25;font-family:'Times New Roman',Times,serif;font-size:10pt">&#160;</div>

<div style="text-align:left;text-indent:36pt;line-height:1.25;font-family:'Times New Roman',Times,serif;font-size:10pt">

<div style="text-indent:36pt;line-height:1.25;font-family:'Times New Roman', Times, serif">Insofar as indemnification for liabilities
arising under the Securities Act may be permitted to New Silexion&#8217;s directors, officers, and controlling persons pursuant to the
foregoing provisions, or otherwise, New Silexion has been advised that, in the opinion of the SEC, such indemnification is against public
policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such
liabilities (other than the payment of expenses incurred or paid by a director, officer or controlling person in a successful defense
of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being
registered, New Silexion will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to the
court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities
Act and will be governed by the final adjudication of such issue.</div></div>

<div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-size:10pt"><br/>II-1</div>

<div style="clear:both;margin-top:10pt;margin-bottom:10pt">

<div style="page-break-after:always"><hr style="border-width:0px;clear:both;margin:4px 0px;width:100%;height:2px;color:#000000;background-color:#000000"/></div></div>

<div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif;font-size:10pt;font-weight:bold">Item 15. Recent
Sales of Unregistered Securities.</div>

<div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif;font-size:10pt">&#160;</div>

<div style="text-align:justify;text-indent:36pt;line-height:1.25;font-family:'Times New Roman',Times,serif;font-size:10pt">Since our formation
on April 2, 2024, we have sold securities in transactions not registered under the Securities Act as described below:</div>

<div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif;font-size:10pt">&#160;</div>

<div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif;font-size:10pt;font-style:italic;font-weight:bold">Initial
Issuance Upon Formation</div>

<div style="text-align:left;text-indent:36pt;line-height:1.25;font-family:'Times New Roman',Times,serif;font-size:10pt">&#160;</div>

<div style="text-align:left;text-indent:36pt;line-height:1.25;font-family:'Times New Roman',Times,serif;font-size:10pt">Upon its formation
on April 2, 2024, the Company initially sold one ordinary share to its initial shareholder, Maples Corporate Services Limited, in exchange
for corporate services provided by that initial shareholder. That issuance was effected without registration under the Securities Act
in an offshore transaction pursuant to the exemption provided by Regulation S under the Securities Act.</div>

<div style="text-align:left;line-height:1.25;font-family:'Times New Roman',Times,serif;font-size:10pt">&#160;</div>

<div style="text-align:left;line-height:1.25;font-family:'Times New Roman',Times,serif;font-size:10pt;font-style:italic;font-weight:bold">Unregistered
Issuances Upon Closing of Business Combination</div>

<div style="text-align:left;line-height:1.25;font-family:'Times New Roman',Times,serif;font-size:10pt">&#160;</div>

<div style="text-align:left;line-height:1.25;font-family:'Times New Roman',Times,serif;font-size:10pt;font-style:italic">Issuance of EarlyBird
Convertible Note and Underlying Ordinary Shares</div>

<div style="text-align:left;line-height:1.25;font-family:'Times New Roman',Times,serif;font-size:10pt;font-style:italic;font-weight:bold">&#160;</div>

<div style="text-align:left;text-indent:36pt;line-height:1.25;font-family:'Times New Roman', Times, serif;font-size:10pt">

<div style="line-height:1.25;font-family:'Times New Roman',Times,serif">

<div style="text-indent:36pt;line-height:1.25;font-family:'Times New Roman', Times, serif">Prior to the Closing of the Business Combination,
on August 11, 2024, Moringa reached agreement with EarlyBird on the reduction, to $1.6 million, in the aggregate, of the fee payable to
EarlyBird under the Business Combination Marketing Agreement, dated as of February 19, 2021, entered into by Moringa with EarlyBird at
the time of Moringa&#8217;s initial public offering. As part of that agreement, New Silexion issued to EarlyBird the EarlyBird Convertible
Note, in an amount of $1.25 million to be paid by New Silexion to EarlyBird in cash and/or via conversion of outstanding amounts into
ordinary shares of New Silexion, which convertible note bears interest at a rate of 6% per annum and is due on December 31, 2025.</div></div></div>

<div style="text-align:left;text-indent:36pt;line-height:1.25;font-family:'Times New Roman',Times,serif;font-size:10pt">&#160;</div>

<div style="text-align:left;text-indent:36pt;line-height:1.25;font-family:'Times New Roman', Times, serif;font-size:10pt">

<div style="text-indent:36pt;line-height:1.25;font-family:'Times New Roman',Times,serif">

<div style="text-indent:36pt;line-height:1.25;font-family:'Times New Roman', Times, serif">EarlyBird may elect, at its sole discretion,
at any time on or prior to the maturity date of the EarlyBird Convertible Note, to convert all or part of the then outstanding principal
and/or accrued interest under the note into New Silexion ordinary shares, at a per share conversion price equal to 95% of the volume weighted
average price of a New Silexion ordinary share for the five trading days immediately prior to the date of New Silexion&#8217;s receipt
of a conversion notice, provided, however, that New Silexion is not required to issue, and EarlyBird may not elect to convert the principal
and/or accrued interest into an aggregate number of New Silexion ordinary shares that would exceed the maximum number of ordinary shares
permitted by Section 5635 of the Nasdaq Listing Rules to be issued without the approval of New Silexion&#8217;s shareholders, unless such
approval is obtained.</div></div>

<div style="text-indent:36pt;line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div></div>

<div style="text-align:left;text-indent:36pt;line-height:1.25;font-family:'Times New Roman',Times,serif;font-size:10pt">Under the EarlyBird
Convertible Note, New Silexion agreed to promptly file a registration statement with the SEC covering the resale of the ordinary shares
that may be issued upon conversion of the note and use its best efforts to have such registration statement declared effective as soon
thereafter as possible. In the event such registration statement is not declared effective by the SEC within 180 days from the date hereof,
then an event of default shall have occurred under the note, triggering all amounts under the note to become due and payable immediately
and automatically.</div>

<div style="text-align:left;line-height:1.25;font-family:'Times New Roman',Times,serif;font-size:10pt">&#160;</div>

<div style="text-align:left;text-indent:36pt;line-height:1.25;font-family:'Times New Roman',Times,serif;font-size:10pt">The issuance of
the EarlyBird Convertible Note and the potential issuance of New Silexion ordinary shares upon conversion of amounts outstanding under
the EarlyBird Convertible Note, has been, and will be (respectively), effected in reliance upon the exemption from registration provided
under Section 4(a)(2) and/or Rule 506 of Regulation D of the Securities Act in a transaction not requiring registration under the Securities
Act.</div>

<div style="text-align:left;line-height:1.25;font-family:'Times New Roman',Times,serif;font-size:10pt">&#160;</div>

<div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-size:10pt">II-2</div>

<div style="clear:both;margin-top:10pt;margin-bottom:10pt">

<div style="page-break-after:always"><hr style="border-width:0px;clear:both;margin:4px 0px;width:100%;height:2px;color:#000000;background-color:#000000"/></div></div>

<div style="text-align:left;line-height:1.25;font-family:'Times New Roman',Times,serif;font-size:10pt;font-style:italic">Issuance of PIPE
Financing Shares</div>

<div style="text-align:left;line-height:1.25;font-family:'Times New Roman',Times,serif;font-size:10pt">&#160;</div>

<div style="text-align:left;text-indent:36pt;line-height:1.25;font-family:'Times New Roman', Times, serif;font-size:10pt">

<div style="line-height:1.25;font-family:'Times New Roman',Times,serif">

<div style="text-indent:36pt;line-height:1.25;font-family:'Times New Roman', Times, serif">

<div style="text-indent:36pt;line-height:1.25">As described under &#8220;<span style="font-style:italic">Certain Relationships and Related
Party Transactions&#8212;PIPE Financing</span>&#8221; above, in connection with, and immediately prior to the Closing of, the Business
Combination, Moringa raised $2.0 million via the PIPE Financing, whereby Moringa sold to the PIPE Investor 200,000 newly issued Moringa
Class A ordinary shares at a price of $10.00 per share, pursuant to the PIPE Agreement. Upon the Closing of the Business Combination,
the Company issued 200,000 New Silexion ordinary shares to the PIPE Investor upon conversion of those 200,000 Moringa Class A ordinary
shares.</div></div></div></div>

<div style="text-align:left;text-indent:36pt;line-height:1.25;font-family:'Times New Roman',Times,serif;font-size:10pt">&#160;</div>

<div style="text-align:left;text-indent:36pt;line-height:1.25;font-family:'Times New Roman', Times, serif;font-size:10pt">

<div style="line-height:1.25;font-family:'Times New Roman',Times,serif">

<div style="text-indent:36pt;line-height:1.25;font-family:'Times New Roman', Times, serif">The issuance of those 200,000 PIPE Shares by
the Company to the PIPE Investor (a Cayman Islands exempted limited partnership) was effected without registration under the Securities
Act in an offshore transaction pursuant to the exemption provided by Regulation S under the Securities Act.</div></div></div>

<div style="text-align:left;text-indent:36pt;line-height:1.25;font-family:'Times New Roman',Times,serif;font-size:10pt">&#160;</div>

<div style="text-align:left;line-height:1.25;font-family:'Times New Roman',Times,serif;font-size:10pt;font-style:italic">Issuances of
Equity Line of Credit Financing Shares to White Lion</div>

<div style="text-align:left;line-height:1.25;font-family:'Times New Roman',Times,serif;font-size:10pt">&#160;</div>

<div style="text-align:left;text-indent:28.35pt;line-height:1.25;font-family:'Times New Roman', Times, serif;font-size:10pt">

<div style="line-height:1.25;font-family:'Times New Roman',Times,serif">

<div style="text-indent:28.35pt;line-height:1.25;font-family:'Times New Roman', Times, serif">As described above in this registration
statement under &#8220;<span style="font-style:italic">White Lion Transaction</span>&#8221;, also in connection with the Closing of the
Business Combination, New Silexion entered into the White Lion Purchase Agreement, under which it will be able to request to sell to White
Lion, and White Lion will be required to purchase, under an equity line of credit, up to $15.0 million of New Silexion ordinary shares&#8212;
the Purchase Notice Shares&#8212; from time to time after the Closing, up until December 31, 2025 (unless the agreement is terminated
sooner), subject to certain limitations and conditions as described therein. New Silexion is furthermore required to issue to White Lion
ordinary shares constituting the Commitment Shares, having a value equal to $337,500, as a commitment fee under the White Lion Purchase
Agreement The issuance of all ordinary shares to White Lion under the White Lion Purchase Agreement will be effected in reliance upon
the exemption from registration provided under Section 4(a)(2) and/or Rule 506 of Regulation D of the Securities Act in a transaction
not requiring registration under the Securities Act.</div></div></div>

<div style="text-align:left;line-height:1.25;font-family:'Times New Roman',Times,serif;font-size:10pt">&#160;</div>

<div style="text-align:left;line-height:1.25;font-family:'Times New Roman',Times,serif;font-size:10pt;font-style:italic">Issuance of Amended
and Restated Sponsor Promissory Note and Underlying Shares to Moringa Sponsor</div>

<div style="text-align:left;line-height:1.25;font-family:'Times New Roman',Times,serif;font-size:10pt;font-style:italic;font-weight:bold">&#160;</div>

<div style="text-align:left;text-indent:36pt;line-height:1.25;font-family:'Times New Roman',Times,serif;font-size:10pt">As described above
in this registration statement under &#8220;<span style="font-style:italic">Certain Relationships and Related Party Transactions</span>&#8212;
<span style="font-style:italic">Amended and Restated Sponsor Promissory Note</span>&#8221;, upon the Closing of the Business Combination,
New Silexion issued to the Sponsor, in amendment and restatement, and replacement, in their entirety, of all existing promissory notes
issued by Moringa to the Sponsor from Moringa&#8217;s initial public offering until the Closing, the A&amp;R Sponsor Promissory Note in
an amount of $3,433,000, which matures on February 15, 2027. Amounts outstanding under the A&amp;R Sponsor Promissory Note may be repaid
only by way of conversion by either the Company or the Sponsor into ordinary shares, under various circumstances.</div>

<div style="text-align:left;text-indent:36pt;line-height:1.25;font-family:'Times New Roman',Times,serif;font-size:10pt">&#160;</div>

<div style="text-align:left;text-indent:36pt;line-height:1.25;font-family:'Times New Roman',Times,serif;font-size:10pt">The issuance by
the Company to the Sponsor (a Cayman Islands exempted limited partnership) of the A&amp;R Sponsor Promissory Note, and the prospective
issuance by the Company to the Sponsor of underlying Note Shares, was or will be (as applicable), effected without registration under
the Securities Act in an offshore transaction pursuant to the exemption provided by Regulation S under the Securities Act.</div>

<div style="text-align:left;text-indent:36pt;line-height:1.25;font-family:'Times New Roman',Times,serif;font-size:10pt">&#160;</div>

<div style="text-align:left;text-indent:36pt;line-height:1.25;font-family:'Times New Roman',Times,serif;font-size:10pt">None of the foregoing
transactions described in this &#8220;Recent Sales of Unregistered Securities&#8221; section involved any underwriters, underwriting discounts
or commissions, or any public offering. The recipients of the securities in each of these transactions represented their intentions to
acquire the securities for investment only and not with a view to or for sale in connection with the distribution thereof (absent registration
under the Securities Act), and appropriate legends were placed on the securities certificates issued in these transactions. All recipients
had adequate access, through their relationships with us, to information about us. The sales of these securities were made without any
general solicitation or advertising.</div>

<div style="text-align:justify;text-indent:18pt;line-height:1.25;font-family:'Times New Roman',Times,serif;font-size:10pt">&#160;</div>

<div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-size:10pt">II-3</div>

<div style="clear:both;margin-top:10pt;margin-bottom:10pt">

<div style="page-break-after:always"><hr style="border-width:0px;clear:both;margin:4px 0px;width:100%;height:2px;color:#000000;background-color:#000000"/></div></div>

<div>

<div>

<div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif;font-size:10pt;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Item&#8201;16.
Exhibits and Financial Statement Schedules</span></span></div>

<div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif;font-size:10pt">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">
  <tr>
    <td style="width:9%;vertical-align:bottom;border-bottom:#000000 2px solid">
        <div style="line-height:1.25;font-weight:bold;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Exhibit
        No.</span></span></div></td>
    <td style="width:10px;vertical-align:middle">&#160;</td>
    <td style="width:889px;vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0)">
        <div style="line-height:1.25;font-weight:bold;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Description</span></span></div></td></tr>
  <tr style="background-color:rgb(204, 238, 255)">
    <td style="width:9%;vertical-align:top;background-color:rgb(204, 238, 255)">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="https://www.sec.gov/Archives/edgar/data/1835416/000121390024029646/ea020320401ex2-1_moringaacq.htm">2.1.1&#8224;</a></span></span></div></td>
    <td style="width:10px;vertical-align:top;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="width:889px;vertical-align:top;background-color:rgb(204, 238, 255)">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="https://www.sec.gov/Archives/edgar/data/1835416/000121390024029646/ea020320401ex2-1_moringaacq.htm">Amended
        and Restated Business Combination Agreement, dated as of April 3, 2024, by and among Biomotion Sciences (now known as Silexion Therapeutics
        Corp), August M.S. Ltd., Moringa Acquisition Merger Sub Corp, Silexion Therapeutics Ltd. and Moringa Acquisition Corp (incorporated by
        reference to Exhibit 2.1 to Moringa Acquisition Corp&#8217;s Current Report on Form 8-K, filed with the SEC on April 3, 2024)</a></span></span></div></td></tr>
  <tr style="background-color:rgb(255, 255, 255)">
    <td style="width:9%;vertical-align:top;background-color:rgb(255, 255, 255)">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="https://www.sec.gov/Archives/edgar/data/1835416/000121390024055254/ea020833801ex10-1_moringa.htm">2.1.2</a></span></span></div></td>
    <td style="width:10px;vertical-align:top;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="width:889px;vertical-align:top;background-color:rgb(255, 255, 255)">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="https://www.sec.gov/Archives/edgar/data/1835416/000121390024055254/ea020833801ex10-1_moringa.htm">Waiver
        letter, dated June 18, 2024, under Amended and Restated Business Combination Agreement (incorporated by reference to Exhibit 10.1 to Moringa
        Acquisition Corp&#8217;s Current Report on Form 8-K filed with the SEC on June 24, 2024)</a></span></span></div></td></tr>
  <tr style="background-color:rgb(204, 238, 255)">
    <td style="width:9%;vertical-align:top;background-color:rgb(204, 238, 255)">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="https://www.sec.gov/Archives/edgar/data/2022416/000121390024071491/ea021197601ex2-2_silexion.htm">2.2</a></span></span></div></td>
    <td style="width:10px;vertical-align:top;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="width:889px;vertical-align:top;background-color:rgb(204, 238, 255)">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="https://www.sec.gov/Archives/edgar/data/2022416/000121390024071491/ea021197601ex2-2_silexion.htm">Plan
        of Merger for merger of Moringa Acquisition Corp and Moringa Acquisition Merger Sub Corp (incorporated by reference to Exhibit 2.2 to
        Silexion Therapeutics Corp&#8217;s Current Report on Form 8-K filed with the SEC on August 21, 2024)</a></span></span></div></td></tr>
  <tr style="background-color:rgb(255, 255, 255)">
    <td style="width:9%;vertical-align:top;background-color:rgb(255, 255, 255)">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="https://www.sec.gov/Archives/edgar/data/2022416/000121390024071491/ea021197601ex3-1_silexion.htm">3.1</a></span></span></div></td>
    <td style="width:10px;vertical-align:top;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="width:889px;vertical-align:top;background-color:rgb(255, 255, 255)">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="https://www.sec.gov/Archives/edgar/data/2022416/000121390024071491/ea021197601ex3-1_silexion.htm">Amended
        and Restated Memorandum and Articles of Association of Silexion Therapeutics Corp (formerly Biomotion Sciences) (incorporated by reference
        to Exhibit 3.1 to Silexion Therapeutics Corp&#8217;s Current Report on Form 8-K filed with the SEC on August 21, 2024)</a></span></span></div></td></tr>
  <tr style="background-color:rgb(204, 238, 255)">
    <td rowspan="1" style="width:9%;vertical-align:top;background-color:rgb(204, 238, 255)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="https://www.sec.gov/Archives/edgar/data/2022416/000117891324003866/exhibit_3-1.htm">3.2</a></span></span></td>
    <td rowspan="1" style="width:10px;vertical-align:top;background-color:rgb(204, 238, 255)">&#160;</td>
    <td rowspan="1" style="width:889px;vertical-align:top;background-color:rgb(204, 238, 255)">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="https://www.sec.gov/Archives/edgar/data/2022416/000117891324003866/exhibit_3-1.htm">Ordinary
        Resolution Effecting 1-for-9 Reverse Share Split to Share Capital of Silexion Therapeutics Corp (incorporated by reference to Exhibit
        3.1 to Silexion Therapeutics Corp&#8217;s Current Report on Form 8-K filed with the SEC on November 29, 2024) </a></span></span></div></td></tr>
  <tr style="background-color:rgb(255, 255, 255)">
    <td style="width:9%;vertical-align:top;background-color:rgb(255, 255, 255)">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="https://www.sec.gov/Archives/edgar/data/1835416/000121390021010849/ea136177ex4-1_moringaacq.htm">4.1</a></span></span></div></td>
    <td style="width:10px;vertical-align:top;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="width:889px;vertical-align:top;background-color:rgb(255, 255, 255)">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="https://www.sec.gov/Archives/edgar/data/1835416/000121390021010849/ea136177ex4-1_moringaacq.htm">Warrant
        Agreement, dated February&#160;19, 2021, by and between Moringa Acquisition Corp and Continental Stock Transfer&#160;&amp; Trust Company,
        as warrant agent (incorporated by reference to Exhibit&#160;4.1 to Moringa Acquisition Corp&#8217;s Current Report on Form&#160;8-K, filed
        with the SEC on February&#160;22, 2021)</a></span></span></div></td></tr>
  <tr style="background-color:rgb(204, 238, 255)">
    <td style="width:9%;vertical-align:top;background-color:rgb(204, 238, 255)">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="https://www.sec.gov/Archives/edgar/data/2022416/000121390024071491/ea021197601ex4-1_silexion.htm">4.2</a></span></span></div></td>
    <td style="width:10px;vertical-align:top;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="width:889px;vertical-align:top;background-color:rgb(204, 238, 255)">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="https://www.sec.gov/Archives/edgar/data/2022416/000121390024071491/ea021197601ex4-1_silexion.htm">Assignment,
        Assumption and Amendment Agreement, dated as of August 15, 2024, by and among Moringa Acquisition Corp, Silexion Therapeutics Corp (formerly
        known as Biomotion Sciences) and Continental Stock Transfer &amp; Trust Company (incorporated by reference to Exhibit 4.1 to Silexion
        Therapeutics Corp&#8217;s Current Report on Form 8-K filed with the SEC on August 21, 2024)</a></span></span></div></td></tr>
  <tr style="background-color:rgb(255, 255, 255)">
    <td rowspan="1" style="width:9%;vertical-align:top;background-color:rgb(255, 255, 255)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="https://www.sec.gov/Archives/edgar/data/2022416/000117891324003866/exhibit_4-1.htm">4.3</a></span></span></td>
    <td rowspan="1" style="width:10px;vertical-align:top;background-color:rgb(255, 255, 255)">&#160;</td>
    <td rowspan="1" style="width:889px;vertical-align:top;background-color:rgb(255, 255, 255)">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="https://www.sec.gov/Archives/edgar/data/2022416/000117891324003866/exhibit_4-1.htm">Warrant
        Adjustment Notice, dated November 29, 2024, in respect of 1-for-9 Reverse Share Split of Silexion Therapeutics Corp (incorporated by reference
        to Exhibit 4.1 to Silexion Therapeutics Corp&#8217;s Current Report on Form 8-K filed with the SEC on November 29, 2024) </a></span></span></div></td></tr>
  <tr style="background-color:rgb(204, 238, 255)">
    <td style="width:9%;vertical-align:top;background-color:rgb(204, 238, 255)">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><a href="exhibit_5-1.htm"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">5.1*</span></span></a></div></td>
    <td style="width:10px;vertical-align:top;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="width:889px;vertical-align:top;background-color:rgb(204, 238, 255)">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">
        <div style="line-height:1.25"><a href="exhibit_5-1.htm"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Opinion
        of Conyers Dill&#160;&amp; Pearman LLP, Cayman legal counsel to Silexion Therapeutics Corp</span></span></a></div></div></td></tr>
  <tr style="background-color:rgb(255, 255, 255)">
    <td style="width:9%;vertical-align:top;background-color:rgb(255, 255, 255)">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="https://www.sec.gov/Archives/edgar/data/2022416/000121390024071491/ea021197601ex10-1i_silexion.htm">10.1.1</a></span></span></div></td>
    <td style="width:10px;vertical-align:top;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="width:889px;vertical-align:top;background-color:rgb(255, 255, 255)">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="https://www.sec.gov/Archives/edgar/data/2022416/000121390024071491/ea021197601ex10-1i_silexion.htm">Final
        invoice issued by EarlyBirdCapital, Inc. to Moringa Acquisition Corp under the Business Combination Marketing Agreement, dated February
        16, 2021, by and between EarlyBirdCapital, Inc. and Moringa Acquisition Corp (incorporated by reference to Exhibit 10.1.1 to Silexion
        Therapeutics Corp&#8217;s Current Report on Form 8-K filed with the SEC on August 21, 2024)</a></span></span></div></td></tr>
  <tr style="background-color:rgb(204, 238, 255)">
    <td style="width:9%;vertical-align:top;background-color:rgb(204, 238, 255)">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="https://www.sec.gov/Archives/edgar/data/2022416/000121390024071491/ea021197601ex10-1ii_silexion.htm">10.1.2</a></span></span></div></td>
    <td style="width:10px;vertical-align:top;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="width:889px;vertical-align:top;background-color:rgb(204, 238, 255)">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="https://www.sec.gov/Archives/edgar/data/2022416/000121390024071491/ea021197601ex10-1ii_silexion.htm">Convertible
        Promissory Note, dated August 15, 2024, in an amount of $1,250,000, issued by Silexion Therapeutics Corp (formerly known as Biomotion
        Sciences) to EarlyBirdCapital, Inc. (incorporated by reference to Exhibit 10.1.2 to Silexion Therapeutics Corp&#8217;s Current Report
        on Form 8-K filed with the SEC on August 21, 2024)</a></span></span></div></td></tr>
  <tr style="background-color:rgb(255, 255, 255)">
    <td style="width:9%;vertical-align:top;background-color:rgb(255, 255, 255)">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="https://www.sec.gov/Archives/edgar/data/2022416/000121390024071491/ea021197601ex10-2_silexion.htm">10.2</a></span></span></div></td>
    <td style="width:10px;vertical-align:top;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="width:889px;vertical-align:top;background-color:rgb(255, 255, 255)">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="https://www.sec.gov/Archives/edgar/data/2022416/000121390024071491/ea021197601ex10-2_silexion.htm">Subscription
        Agreement, dated August 15, 2024, by and among Moringa Acquisition Corp, Silexion Therapeutics Corp (formerly known as Biomotion Sciences)
        and Greenstar, L.P. (incorporated by reference to Exhibit 10.2 to Silexion Therapeutics Corp&#8217;s Current Report on Form 8-K filed
        with the SEC on August 21, 2024)</a></span></span></div></td></tr>
  <tr style="background-color:rgb(204, 238, 255)">
    <td style="width:9%;vertical-align:top;background-color:rgb(204, 238, 255)">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="https://www.sec.gov/Archives/edgar/data/2022416/000121390024071491/ea021197601ex10-3i_silexion.htm">10.3.1</a></span></span></div></td>
    <td style="width:10px;vertical-align:top;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="width:889px;vertical-align:top;background-color:rgb(204, 238, 255)">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="https://www.sec.gov/Archives/edgar/data/2022416/000121390024071491/ea021197601ex10-3i_silexion.htm">Ordinary
        Share Purchase Agreement, dated August 13, 2024 and effective as of the closing date of the Business Combination, by and between Silexion
        Therapeutics Corp (formerly known as Biomotion Sciences) and White Lion Capital, LLC (incorporated by reference to Exhibit 10.3.1 to Silexion
        Therapeutics Corp&#8217;s Current Report on Form 8-K filed with the SEC on August 21, 2024)</a></span></span></div></td></tr>
  <tr style="background-color:rgb(255, 255, 255)">
    <td rowspan="1" style="width:9%;vertical-align:top;background-color:rgb(255, 255, 255)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="exhibit10_3-2.htm">10.3.2*</a></span></span></td>
    <td rowspan="1" style="width:10px;vertical-align:top;background-color:rgb(255, 255, 255)">&#160;</td>
    <td rowspan="1" style="width:889px;vertical-align:top;background-color:rgb(255, 255, 255)">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="exhibit10_3-2.htm">Amendment
        No. 1, effective January 14, 2025, to Ordinary Share Purchase Agreement, dated August 13, 2024 and effective as of the closing date of
        the Business Combination, by and between Silexion Therapeutics Corp and White Lion Capital, LLC</a></span></span></div></td></tr>
  <tr style="background-color:rgb(204, 238, 255)">
    <td style="width:9%;vertical-align:top;background-color:rgb(204, 238, 255)">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="https://www.sec.gov/Archives/edgar/data/2022416/000121390024071491/ea021197601ex10-3ii_silexion.htm">10.3.3</a></span></span></div></td>
    <td style="width:10px;vertical-align:top;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="width:889px;vertical-align:top;background-color:rgb(204, 238, 255)">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="https://www.sec.gov/Archives/edgar/data/2022416/000121390024071491/ea021197601ex10-3ii_silexion.htm">Registration
        Rights Agreement, dated August 13, 2024 and effective as of the closing date of the Business Combination, by and between Silexion Therapeutics
        Corp (formerly known as Biomotion Sciences) and White Lion Capital, LLC (incorporated by reference to Exhibit 10.3.2 to Silexion Therapeutics
        Corp&#8217;s Current Report on Form 8-K filed with the SEC on August 21, 2024)</a></span></span></div></td></tr>
  <tr style="background-color:rgb(255, 255, 255)">
    <td style="width:9%;vertical-align:top;background-color:rgb(255, 255, 255)">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="https://www.sec.gov/Archives/edgar/data/2022416/000121390024071491/ea021197601ex10-4_silexion.htm">10.4</a></span></span></div></td>
    <td style="width:10px;vertical-align:top;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="width:889px;vertical-align:top;background-color:rgb(255, 255, 255)">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="https://www.sec.gov/Archives/edgar/data/2022416/000121390024071491/ea021197601ex10-4_silexion.htm">Amended
        and Restated Registration Rights and Lock-Up Agreement, dated August 14, 2024 and effective as of the Closing Date, by and among Silexion
        Therapeutics Corp (formerly known as Biomotion Sciences), Moringa Acquisition Corp, Moringa Sponsor, L.P., the distributees of Sponsor
        Investment Shares that were issuable to Moringa Sponsor, L.P., EarlyBirdCapital, Inc., certain of Silexion Therapeutics Ltd.&#8217;s pre-Business
        Combination shareholders and Greenstar, L.P. (incorporated by reference to Exhibit 10.4 to Silexion Therapeutics Corp&#8217;s Current
        Report on Form 8-K filed with the SEC on August 21, 2024)</a></span></span></div></td></tr>
  <tr style="background-color:rgb(204, 238, 255)">
    <td style="width:9%;vertical-align:top;background-color:rgb(204, 238, 255)">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="https://www.sec.gov/Archives/edgar/data/2022416/000121390024071491/ea021197601ex10-5_silexion.htm">10.5</a></span></span></div></td>
    <td style="width:10px;vertical-align:top;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="width:889px;vertical-align:top;background-color:rgb(204, 238, 255)">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="https://www.sec.gov/Archives/edgar/data/2022416/000121390024071491/ea021197601ex10-5_silexion.htm">Amended
        and Restated Promissory Note, dated August 15, 2024, issued by Silexion Therapeutics Corp (formerly known as Biomotion Sciences) to Moringa
        Sponsor, L.P. (incorporated by reference to Exhibit 10.5 to Silexion Therapeutics Corp&#8217;s Current Report on Form 8-K filed with the
        SEC on August 21, 2024)</a></span></span></div></td></tr>
  <tr style="background-color:rgb(255, 255, 255)">
    <td style="width:9%;vertical-align:top;background-color:rgb(255, 255, 255)">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="https://www.sec.gov/Archives/edgar/data/2022416/000121390024071491/ea021197601ex10-6_silexion.htm">10.6</a></span></span></div></td>
    <td style="width:10px;vertical-align:top;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="width:889px;vertical-align:top;background-color:rgb(255, 255, 255)">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="https://www.sec.gov/Archives/edgar/data/2022416/000121390024071491/ea021197601ex10-6_silexion.htm">Form
        of Director and Officer Indemnification Agreement, dated August 15, 2024, by and between Silexion Therapeutics Corp (formerly known as
        Biomotion Sciences) and each of its executive officers and directors (incorporated by reference to Exhibit 10.6 to Silexion Therapeutics
        Corp&#8217;s Current Report on Form 8-K filed with the SEC on August 21, 2024)</a></span></span></div></td></tr>
  <tr style="background-color:rgb(204, 238, 255)">
    <td style="width:9%;vertical-align:top;background-color:rgb(204, 238, 255)">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="https://www.sec.gov/Archives/edgar/data/2022416/000121390024041383/ea020533401ex10-12i_bio.htm">10.11.1#</a></span></span></div></td>
    <td style="width:10px;vertical-align:middle;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="width:889px;vertical-align:middle;background-color:rgb(204, 238, 255)">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="https://www.sec.gov/Archives/edgar/data/2022416/000121390024041383/ea020533401ex10-12i_bio.htm">Employment
        Agreement, dated April 1, 2022, by and between Silexion Therapeutics Ltd. and Ilan Hadar (incorporated by reference to Exhibit 10.12.1
        to Amendment No. 3 to the Company&#8217;s Registration Statement on Form S-4 (File No. 333-279281), filed with the SEC on July 12, 2024)</a>.</span></span></div></td></tr>
  <tr style="background-color:rgb(255, 255, 255)">
    <td style="width:9%;vertical-align:top;background-color:rgb(255, 255, 255)">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="https://www.sec.gov/Archives/edgar/data/2022416/000121390024041383/ea020533401ex10-12ii_bio.htm">10.11.2#</a></span></span></div></td>
    <td style="width:10px;vertical-align:middle;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="width:889px;vertical-align:middle;background-color:rgb(255, 255, 255)">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="https://www.sec.gov/Archives/edgar/data/2022416/000121390024041383/ea020533401ex10-12ii_bio.htm">Amendment
        No. 1 to Employment Agreement, dated May 2024, by and between Silexion Therapeutics Ltd. and Ilan Hadar ((incorporated by reference to
        Exhibit 10.12.2 to Amendment No. 3 to the Company&#8217;s Registration Statement on Form S-4 (File No. 333-279281), filed with the SEC
        on July 12, 2024)</a></span></span></div></td></tr>
  <tr style="background-color:rgb(204, 238, 255)">
    <td style="width:9%;vertical-align:top;background-color:rgb(204, 238, 255)">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="https://www.sec.gov/Archives/edgar/data/2022416/000121390024071491/ea021197601ex10-12_silexion.htm">10.12#</a></span></span></div></td>
    <td style="width:10px;vertical-align:middle;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="width:889px;vertical-align:middle;background-color:rgb(204, 238, 255)">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="https://www.sec.gov/Archives/edgar/data/2022416/000121390024071491/ea021197601ex10-12_silexion.htm">Silexion
        Therapeutics Corp 2024 Equity Incentive Plan (incorporated by reference to Exhibit 10.12 to Silexion Therapeutics Corp&#8217;s Current
        Report on Form 8-K filed with the SEC on August 21, 2024)</a></span></span></div></td></tr>
  <tr style="background-color:rgb(255, 255, 255)">
    <td style="width:9%;vertical-align:top;background-color:rgb(255, 255, 255)">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="https://www.sec.gov/Archives/edgar/data/2022416/000121390024077039/ea021365401ex10-13_silexion.htm">10.13#</a></span></span></div></td>
    <td style="width:10px;vertical-align:middle;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="width:889px;vertical-align:middle;background-color:rgb(255, 255, 255)">
        <div style="line-height:1.25">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="https://www.sec.gov/Archives/edgar/data/2022416/000121390024077039/ea021365401ex10-13_silexion.htm"><span style="text-decoration:underline">Silexion
        Therapeutics Ltd. 2023 Equity Incentive Plan</span>&#160;(incorporated by reference to Exhibit 10.13 to Silexion Therapeutics Corp&#8217;s
        Registration Statement on Form S-1 (File No. 333-282017), filed with the SEC on September 10, 2024)</a></span></span></div></div></div></td></tr>
  <tr style="background-color:rgb(204, 238, 255)">
    <td style="width:9%;vertical-align:top;background-color:rgb(204, 238, 255)">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="https://www.sec.gov/Archives/edgar/data/2022416/000121390024077039/ea021365401ex10-14_silexion.htm">10.14#</a></span></span></div></td>
    <td style="width:10px;vertical-align:middle;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="width:889px;vertical-align:middle;background-color:rgb(204, 238, 255)">
        <div style="line-height:1.25">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="https://www.sec.gov/Archives/edgar/data/2022416/000121390024077039/ea021365401ex10-14_silexion.htm"><span style="text-decoration:underline">Silexion
        Therapeutics Ltd. 2013 Share Option Plan</span>&#160;(incorporated by reference to Exhibit 10.14 to Silexion Therapeutics Corp&#8217;s
        Registration Statement on Form S-1 (File No. 333-282017), filed with the SEC on September 10, 2024)</a></span></span></div></div></div></td></tr>
  <tr style="background-color:rgb(255, 255, 255)">
    <td rowspan="1" style="width:9%;vertical-align:top;background-color:rgb(255, 255, 255)">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="https://www.sec.gov/Archives/edgar/data/2022416/000117891325000143/exhibit_10-1.htm">10.15</a></span></span></div></td>
    <td rowspan="1" style="width:10px;vertical-align:middle;background-color:rgb(255, 255, 255)">&#160;</td>
    <td rowspan="1" style="width:889px;vertical-align:middle;background-color:rgb(255, 255, 255)">
        <div style="line-height:1.25">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="https://www.sec.gov/Archives/edgar/data/2022416/000117891325000143/exhibit_10-1.htm">Securities
        Purchase Agreement, dated January 15, 2025, by and between the Company and each investor party thereto (incorporated by reference to Exhibit
        10.1 to Silexion Therapeutics Corp&#8217;s Current Report on Form 8-K filed with the SEC on January 17, 2025)</a></span></span></div></div></td></tr>
  <tr style="background-color:rgb(204, 238, 255)">
    <td rowspan="1" style="width:9%;vertical-align:top;background-color:rgb(204, 238, 255)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="https://www.sec.gov/Archives/edgar/data/2022416/000117891325000143/exhibit_4-1.htm">10.16</a></span></span></td>
    <td rowspan="1" style="width:10px;vertical-align:middle;background-color:rgb(204, 238, 255)">&#160;</td>
    <td rowspan="1" style="width:889px;vertical-align:middle;background-color:rgb(204, 238, 255)">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="https://www.sec.gov/Archives/edgar/data/2022416/000117891325000143/exhibit_4-1.htm">Form
        of Ordinary Warrant (incorporated by reference to Exhibit 4.1 to Silexion Therapeutics Corp&#8217;s Current Report on Form 8-K filed with
        the SEC on January 17, 2025)</a></span></span></div></td></tr>
  <tr style="background-color:rgb(255, 255, 255)">
    <td rowspan="1" style="width:9%;vertical-align:top;background-color:rgb(255, 255, 255)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="https://www.sec.gov/Archives/edgar/data/2022416/000117891325000143/exhibit_4-2.htm">10.17</a></span></span></td>
    <td rowspan="1" style="width:10px;vertical-align:middle;background-color:rgb(255, 255, 255)">&#160;</td>
    <td rowspan="1" style="width:889px;vertical-align:middle;background-color:rgb(255, 255, 255)">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="https://www.sec.gov/Archives/edgar/data/2022416/000117891325000143/exhibit_4-2.htm">Form
        of Pre-Funded Warrant (incorporated by reference to Exhibit 4.2 to Silexion Therapeutics Corp&#8217;s Current Report on Form 8-K filed
        with the SEC on January 17, 2025)</a></span></span></div></td></tr>
  <tr style="background-color:rgb(204, 238, 255)">
    <td rowspan="1" style="width:9%;vertical-align:top;background-color:rgb(204, 238, 255)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="https://www.sec.gov/Archives/edgar/data/2022416/000117891325000143/exhibit_4-3.htm">10.18</a></span></span></td>
    <td rowspan="1" style="width:10px;vertical-align:middle;background-color:rgb(204, 238, 255)">&#160;</td>
    <td rowspan="1" style="width:889px;vertical-align:middle;background-color:rgb(204, 238, 255)">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="https://www.sec.gov/Archives/edgar/data/2022416/000117891325000143/exhibit_4-3.htm">Form
        of Placement Agent Warrant (incorporated by reference to Exhibit 4.3 to Silexion Therapeutics Corp&#8217;s Current Report on Form 8-K
        filed with the SEC on January 17, 2025)</a></span></span></div></td></tr>
  <tr style="background-color:rgb(255, 255, 255)">
    <td rowspan="1" style="width:9%;vertical-align:top;background-color:rgb(255, 255, 255)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="https://www.sec.gov/Archives/edgar/data/2022416/000117891325000259/exhibit_10-1.htm">10.19</a></span></span></td>
    <td rowspan="1" style="width:10px;vertical-align:middle;background-color:rgb(255, 255, 255)">&#160;</td>
    <td rowspan="1" style="width:889px;vertical-align:middle;background-color:rgb(255, 255, 255)">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="https://www.sec.gov/Archives/edgar/data/2022416/000117891325000259/exhibit_10-1.htm">Form
        of Inducement Letter (incorporated by reference to Exhibit 10.1 to Silexion Therapeutics Corp&#8217;s Current Report on Form 8-K filed
        with the SEC on January 30, 2025)</a></span></span></div></td></tr>
  <tr style="background-color:rgb(204, 238, 255)">
    <td rowspan="1" style="width:9%;vertical-align:top;background-color:rgb(204, 238, 255)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="https://www.sec.gov/Archives/edgar/data/2022416/000117891325000259/exhibit_10-2.htm">10.20</a></span></span></td>
    <td rowspan="1" style="width:10px;vertical-align:middle;background-color:rgb(204, 238, 255)">&#160;</td>
    <td rowspan="1" style="width:889px;vertical-align:middle;background-color:rgb(204, 238, 255)">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="https://www.sec.gov/Archives/edgar/data/2022416/000117891325000259/exhibit_10-2.htm">Form
        of New Warrant (incorporated by reference to Exhibit 10.2 to Silexion Therapeutics Corp&#8217;s Current Report on Form 8-K filed with
        the SEC on January 30, 2025)</a></span></span></div></td></tr>
  <tr style="background-color:rgb(255, 255, 255)">
    <td rowspan="1" style="width:9%;vertical-align:top;background-color:rgb(255, 255, 255)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="https://www.sec.gov/Archives/edgar/data/2022416/000117891325000259/exhibit_10-3.htm">10.21</a></span></span></td>
    <td rowspan="1" style="width:10px;vertical-align:middle;background-color:rgb(255, 255, 255)">&#160;</td>
    <td rowspan="1" style="width:889px;vertical-align:middle;background-color:rgb(255, 255, 255)">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="https://www.sec.gov/Archives/edgar/data/2022416/000117891325000259/exhibit_10-3.htm">Form
        of Placement Agent Warrant (incorporated by reference to Exhibit 10.3 to Silexion Therapeutics Corp&#8217;s Current Report on Form 8-K
        filed with the SEC on January 30, 2025)</a></span></span></div></td></tr>
  <tr style="background-color:rgb(204, 238, 255)">
    <td style="width:9%;vertical-align:top;white-space:nowrap;background-color:rgb(204, 238, 255)">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="https://www.sec.gov/Archives/edgar/data/2022416/000121390024071491/ea021197601ex21-1_silexion.htm">21.1</a></span></span></div></td>
    <td style="width:10px;vertical-align:middle;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="width:889px;vertical-align:middle;background-color:rgb(204, 238, 255)">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="https://www.sec.gov/Archives/edgar/data/2022416/000121390024071491/ea021197601ex21-1_silexion.htm">List
        of Subsidiaries (incorporated by reference to Exhibit 21.1 to Silexion Therapeutics Corp&#8217;s Current Report on Form 8-K filed with
        the SEC on August 21, 2024)</a></span></span></div></td></tr>
  <tr style="background-color:rgb(255, 255, 255)">
    <td style="width:9%;vertical-align:top;white-space:nowrap;background-color:rgb(255, 255, 255)">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><a href="exhibit_23-1.htm"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">23.1*</span></span></a></div></td>
    <td style="width:10px;vertical-align:middle;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="width:889px;vertical-align:middle;background-color:rgb(255, 255, 255)">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">
        <div style="line-height:1.25;font-family:'Times New Roman', Times, serif">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><a href="exhibit_23-1.htm"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Consent
        of Kesselman&#160;&amp; Kesselman, a member firm of PricewaterhouseCoopers International Limited, independent registered public accounting
        firm of Moringa Acquisition Corp</span></span></a></div></div></div></td></tr>
  <tr style="background-color:rgb(204, 238, 255)">
    <td style="width:9%;vertical-align:top;white-space:nowrap;background-color:rgb(204, 238, 255)">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><a href="exhibit_23-2.htm"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">23.2*</span></span></a></div></td>
    <td style="width:10px;vertical-align:middle;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="width:889px;vertical-align:middle;background-color:rgb(204, 238, 255)">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">
        <div style="line-height:1.25"><a href="exhibit_23-2.htm"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Consent
        of Kesselman &amp; Kesselman, a member firm of PricewaterhouseCoopers International Limited, independent registered public accounting
        firm of Silexion Therapeutics Corp</span></span></a></div></div></td></tr>
  <tr style="background-color:rgb(255, 255, 255)">
    <td style="width:9%;vertical-align:top;white-space:nowrap;background-color:rgb(255, 255, 255)">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><a href="exhibit_5-1.htm"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">23.3*</span></span></a></div></td>
    <td style="width:10px;vertical-align:middle;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="width:889px;vertical-align:middle;background-color:rgb(255, 255, 255)">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><a href="exhibit_5-1.htm"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Consent
        of Conyers Dill &amp; Pearman LLP (included in Exhibit 5.1)</span></span></a></div></td></tr>
  <tr style="background-color:rgb(204, 238, 255)">
    <td style="width:9%;vertical-align:top;white-space:nowrap;background-color:rgb(204, 238, 255)">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="#SIGNATURES">24.1</a></span></span></div></td>
    <td style="width:10px;vertical-align:middle;background-color:rgb(204, 238, 255)">&#160;</td>
    <td style="width:889px;vertical-align:middle;background-color:rgb(204, 238, 255)">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="#SIGNATURES">Power
        of attorney (included on the signature page to this registration statement)</a></span></span></div></td></tr>
  <tr style="background-color:rgb(255, 255, 255)">
    <td style="width:9%;vertical-align:top;white-space:nowrap;background-color:rgb(255, 255, 255)">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="exhibit_107.htm">107*</a></span></span></div></td>
    <td style="width:10px;vertical-align:middle;font-family:Times New Roman, Times, serif;background-color:rgb(255, 255, 255)">&#160;</td>
    <td style="width:889px;vertical-align:middle;background-color:rgb(255, 255, 255)">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="exhibit_107.htm">Filing
        fee table</a></span></span></div></td></tr>
  </table>

<div style="text-align:left;line-height:1.25;font-family:'Times New Roman',Times,serif;font-size:10pt">&#160;</div>

<table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">
  <tr>
    <td style="width:3.85%;vertical-align:top">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">*</span></span></div></td>
    <td style="width:96.15%;vertical-align:top">
        <div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Filed
        herewith.</span></span></div></td></tr>
  </table>

<div>&#160;</div>

<table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">
  <tr>
    <td style="width:3.85%;vertical-align:top">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">&#8224;</span></span></div></td>
    <td style="width:96.15%;vertical-align:top">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Certain
        of the exhibits and schedules to this Exhibit have been omitted in accordance with Regulation S-K Item 601(a)(5). The registrant agrees
        to furnish a copy of all omitted exhibits and schedules to the SEC upon its request.</span></span></div></td></tr>
  </table>

<div style="text-align:left;line-height:1.25;font-family:'Times New Roman',Times,serif;font-size:10pt">&#160;</div>

<table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">
  <tr>
    <td style="width:3.85%;vertical-align:top">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">#</span></span></div></td>
    <td style="width:96.15%;vertical-align:top">
        <div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Indicates
        management contract or compensatory plan, contract or arrangement.</span></span></div></td></tr>
  </table></div></div>

<div style="text-align:justify;text-indent:-18pt;margin-left:18pt;line-height:1.25;font-family:'Times New Roman',Times,serif;font-size:10pt">&#160;</div>

<div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif;font-size:10pt;font-weight:bold">Item&#8201;17.
Undertakings</div>

<div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif;font-size:10pt;font-weight:bold">&#160;</div>

<div style="text-align:justify;text-indent:18pt;line-height:1.25;font-family:'Times New Roman',Times,serif;font-size:10pt">The undersigned
Registrant hereby undertakes<span style="font-style:italic">:</span>&#160;</div>

<div style="text-align:justify;text-indent:18pt;line-height:1.25;font-family:'Times New Roman',Times,serif;font-size:10pt">&#160;</div>

<div style="text-align:left;text-indent:18pt;line-height:1.25;font-family:'Times New Roman',Times,serif;font-size:10pt">(a) To file, during
any period in which offers or sales are being made, a post-effective amendment to this Registration Statement:</div>

<div style="text-align:justify;text-indent:18pt;line-height:1.25;font-family:'Times New Roman',Times,serif;font-size:10pt">&#160;</div>

<div style="text-align:justify;text-indent:36pt;line-height:1.25;font-family:'Times New Roman',Times,serif;font-size:10pt">(i) To include
any prospectus required by section 10(a)(3) of the Securities Act of 1933;</div>

<div style="text-align:justify;text-indent:36pt;line-height:1.25;font-family:'Times New Roman',Times,serif;font-size:10pt">&#160;</div>

<div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-size:10pt">II-4</div>

<div style="clear:both;margin-top:10pt;margin-bottom:10pt">

<div style="page-break-after:always"><hr style="border-width:0px;clear:both;margin:4px 0px;width:100%;height:2px;color:#000000;background-color:#000000"/></div></div>

<div style="text-align:left;text-indent:36pt;line-height:1.25;font-family:'Times New Roman',Times,serif;font-size:10pt">(ii) To reflect
in the prospectus any facts or events arising after the effective date of this Registration Statement (or the most recent post-effective
amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in this Registration
Statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities
offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range
may be reflected in the form of prospectus filed with the Commission pursuant to Rule 424(b) if, in the aggregate, the changes in volume
and price represent no more than 20% change in the maximum aggregate offering price set forth in the &#8220;Calculation of Registration
Fee&#8221; table in the effective registration statement; and</div>

<div style="text-align:justify;text-indent:36pt;line-height:1.25;font-family:'Times New Roman',Times,serif;font-size:10pt">&#160;&#160;</div>

<div style="text-align:left;text-indent:36pt;line-height:1.25;font-family:'Times New Roman',Times,serif;font-size:10pt">(iii) To include
any material information with respect to the plan of distribution not previously disclosed in this Registration Statement or any material
change to such information in this Registration Statement.</div>

<div style="text-align:justify;text-indent:36pt;line-height:1.25;font-family:'Times New Roman',Times,serif;font-size:10pt">&#160;</div>

<div style="text-align:left;text-indent:18pt;line-height:1.25;font-family:'Times New Roman',Times,serif;font-size:10pt">(b) That, for
the purpose of determining any liability under the Securities Act of 1933, each such post-effective amendment that contains a form of
prospectus shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities
at that time shall be deemed to be the initial bona fide offering thereof.</div>

<div style="text-align:justify;text-indent:18pt;line-height:1.25;font-family:'Times New Roman',Times,serif;font-size:10pt">&#160;</div>

<div style="text-align:left;text-indent:18pt;line-height:1.25;font-family:'Times New Roman',Times,serif;font-size:10pt">(c) To remove
from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination
of the offering.</div>

<div style="text-align:justify;text-indent:18pt;line-height:1.25;font-family:'Times New Roman',Times,serif;font-size:10pt">&#160;</div>

<div style="text-align:left;text-indent:18pt;line-height:1.25;font-family:'Times New Roman',Times,serif;font-size:10pt">(d) That, for
the purpose of determining liability under the Securities Act of 1933 to any purchaser, each prospectus filed pursuant to Rule 424(b)
as part of a registration statement relating to an offering, other than registration statements relying on Rule 430B or other than prospectuses
filed in reliance on Rule 430A, shall be deemed to be part of and included in the registration statement as of the date it is first used
after effectiveness. Provided, however, that no statement made in a registration statement or prospectus that is part of the registration
statement or made in a document incorporated or deemed incorporated by reference into the registration statement or prospectus that is
part of the registration statement will, as to a purchaser with a time of contract of sale prior to such first use, supersede or modify
any statement that was made in the registration statement or prospectus that was part of the registration statement or made in any such
document immediately prior to such date of first use.</div>

<div style="text-align:justify;text-indent:18pt;line-height:1.25;font-family:'Times New Roman',Times,serif;font-size:10pt">&#160;</div>

<div style="text-align:left;text-indent:18pt;line-height:1.25;font-family:'Times New Roman',Times,serif;font-size:10pt">(e) That, for
the purpose of determining liability of the registrant under the Securities Act of 1933 to any purchaser in the initial distribution of
the securities, the undersigned registrant undertakes that in a primary offering of securities of the undersigned registrant pursuant
to this registration statement, regardless of the underwriting method used to sell the securities to the purchaser, if the securities
are offered or sold to such purchaser by means of any of the following communications,</div>

<div style="text-align:justify;text-indent:18pt;line-height:1.25;font-family:'Times New Roman',Times,serif;font-size:10pt">&#160;</div>

<div style="text-align:left;text-indent:36pt;line-height:1.25;font-family:'Times New Roman',Times,serif;font-size:10pt">(i) Any preliminary
prospectus or prospectus of the undersigned registrant relating to the offering required to be filed pursuant to Rule 424;</div>

<div style="text-align:left;text-indent:36pt;line-height:1.25;font-family:'Times New Roman',Times,serif;font-size:10pt">&#160;</div>

<div style="text-align:left;text-indent:36pt;line-height:1.25;font-family:'Times New Roman',Times,serif;font-size:10pt">(ii) Any free
writing prospectus relating to the offering prepared by or on behalf of the undersigned registrant or used or referred to by the undersigned
registrant;</div>

<div style="text-align:left;text-indent:36pt;line-height:1.25;font-family:'Times New Roman',Times,serif;font-size:10pt">&#160;</div>

<div style="text-align:left;text-indent:36pt;line-height:1.25;font-family:'Times New Roman',Times,serif;font-size:10pt">(iii) The portion
of any other free writing prospectus relating to the offering containing material information about the undersigned registrant or its
securities provided by or on behalf of the undersigned registrant; and</div>

<div style="text-align:left;text-indent:36pt;line-height:1.25;font-family:'Times New Roman',Times,serif;font-size:10pt">&#160;</div>

<div style="text-align:left;text-indent:36pt;line-height:1.25;font-family:'Times New Roman',Times,serif;font-size:10pt">(iv) Any other
communication that is an offer in the offering made by the undersigned registrant to the purchaser.</div>

<div style="text-align:left;text-indent:36pt;line-height:1.25;font-family:'Times New Roman',Times,serif;font-size:10pt">&#160;</div>

<div style="text-align:left;text-indent:18pt;line-height:1.25;font-family:'Times New Roman',Times,serif;font-size:10pt">Insofar as indemnification
for liabilities arising under the Securities Act of 1933 may be permitted to directors, officers and controlling persons of the Registrant
pursuant to the foregoing provisions, or otherwise, the Registrant has been advised that in the opinion of the SEC such indemnification
is against public policy as expressed in the Securities Act of 1933 and is, therefore, unenforceable. In the event that a claim for indemnification
against such liabilities (other than the payment by the Registrant of expenses incurred or paid by a director, officer or controlling
person of the Registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling
person in connection with the securities being registered, the Registrant will, unless in the opinion of its counsel the matter has been
settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by them is against
public policy as expressed in the Securities Act of 1933 and will be governed by the final adjudication of such issue.</div>

<div style="text-align:justify;text-indent:18pt;line-height:1.25;font-family:'Times New Roman',Times,serif;font-size:10pt;font-weight:bold">&#160;</div>

<div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-size:10pt">II-5</div>

<div style="clear:both;margin-top:10pt;margin-bottom:10pt">

<div style="page-break-after:always"><hr style="border-width:0px;clear:both;margin:4px 0px;width:100%;height:2px;color:#000000;background-color:#000000"/></div></div>

<div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-size:10pt;font-weight:bold"><span id="SIGNATURES"></span>SIGNATURES</div>

<div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-size:10pt;font-weight:bold">&#160;</div>

<div style="text-align:left;text-indent:36pt;line-height:1.25;font-family:'Times New Roman', Times, serif;font-size:10pt">

<div style="line-height:1.25;font-family:'Times New Roman',Times,serif">

<div style="text-indent:25.2pt;margin-left:8.15pt;line-height:1.25">

<div style="text-indent:25.2pt;line-height:1.25;font-family:'Times New Roman', Times, serif">

<div style="text-indent:36pt;line-height:1.25">Pursuant to the requirements of the Securities Act, the registrant has duly caused this
registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in Ramat Gan, Israel, on February 12,
2025.</div></div></div></div></div>

<div style="text-align:justify;text-indent:18pt;line-height:1.25;font-family:'Times New Roman',Times,serif;font-size:10pt">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">
  <tr>
    <td colspan="3" style="vertical-align:top">
        <div style="line-height:1.25;font-weight:bold;font-family:'Times New Roman',Times,serif">SILEXION THERAPEUTICS CORP</div></td>
    <td style="width:62%;vertical-align:top">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div></td></tr>
  <tr>
    <td style="width:3%;vertical-align:middle">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div></td>
    <td colspan="2" style="vertical-align:middle">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div></td>
    <td style="width:62%;vertical-align:middle">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div></td></tr>
  <tr>
    <td style="width:3%;vertical-align:top">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">By:</div></td>
    <td colspan="2" style="vertical-align:top;border-bottom:2px solid rgb(0, 0, 0)">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">/s/ Ilan Hadar</div></td>
    <td style="width:62%;vertical-align:middle">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div></td></tr>
  <tr>
    <td style="width:3%;vertical-align:top">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div></td>
    <td style="width:4%;vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">Name:&#160;</div></td>
    <td style="width:30.59%;vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">Ilan Hadar</div></td>
    <td style="width:62%;vertical-align:middle">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div></td></tr>
  <tr>
    <td style="width:3%;vertical-align:top">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div></td>
    <td style="width:4%;vertical-align:top">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">Title:</div></td>
    <td style="width:30.59%;vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">Chairman and Chief Executive Officer</div></td>
    <td style="width:62%;vertical-align:middle">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div></td></tr>
  </table>

<div>

<div style="text-align:center;line-height:1.25;font-family:'Times New Roman', Times, serif;font-size:10pt;font-weight:bold">&#160;</div>

<div style="text-align:center;line-height:1.25;font-family:'Times New Roman', Times, serif;font-size:10pt;font-weight:bold">POWER OF ATTORNEY</div>

<div style="text-align:center;line-height:1.25;font-family:'Times New Roman', Times, serif;font-size:10pt;font-weight:bold">&#160;</div>

<div style="text-align:left;text-indent:36pt;line-height:1.25;font-family:'Times New Roman', Times, serif;font-size:10pt">KNOW ALL BY
THESE PRESENTS, that each person whose signature appears below hereby constitutes and appoints Ilan Hadar and Mirit Horenshtein Hadar,
and each of them, as his true and lawful agents, proxies and attorneys-in-fact, with full power of substitution and resubstitution, for
him or her and in his or her name, place and stead, in any and all capacities, to (i) act on, sign and file with the Securities and Exchange
Commission any and all amendments (including post-effective amendments) to this registration statement together with all schedules and
exhibits thereto and any subsequent registration statement filed pursuant to Rule 462(b) under the Securities Act of 1933, as amended,
together with all schedules and exhibits thereto, (ii) act on, sign and file such certificates, instruments, agreements and other documents
as may be necessary or appropriate in connection therewith, (iii) act on and file any supplement to any prospectus included in this registration
statement or any such amendment or any subsequent registration statement filed pursuant to Rule 462(b) under the Securities Act of 1933,
as amended, and (iv) take any and all actions which may be necessary or appropriate to be done, as fully for all intents and purposes
as he might or could do in person, hereby approving, ratifying and confirming all that such agent, proxy and attorney-in-fact or any of
his substitutes may lawfully do or cause to be done by virtue thereof.</div></div>

<div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-size:10pt;font-weight:bold">&#160;</div>

<div style="text-align:left;text-indent:36pt;line-height:1.25;font-family:'Times New Roman',Times,serif;font-size:10pt">Pursuant to the
requirements of the Securities Act of 1933, this registration statement has been signed by the following persons in the capacities and
on the dates indicated.</div>

<div style="text-align:justify;text-indent:18pt;line-height:1.25;font-family:'Times New Roman',Times,serif;font-size:10pt">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">
  <tr>
    <td style="width:30%;vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);white-space:nowrap">
        <div style="line-height:1.25;font-weight:bold;font-family:'Times New Roman',Times,serif">Signature</div></td>
    <td style="width:0.68%;vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div></td>
    <td style="width:50.22%;vertical-align:bottom;border-bottom:#000000 2px solid">
        <div style="text-align:center;line-height:1.25;font-weight:bold;font-family:'Times New Roman',Times,serif">Title</div></td>
    <td style="width:0.68%;vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div></td>
    <td style="width:17.85%;vertical-align:bottom;border-bottom:#000000 2px solid">
        <div style="text-align:center;line-height:1.25;font-weight:bold;font-family:'Times New Roman',Times,serif">Date</div></td></tr>
  <tr>
    <td style="width:30%;vertical-align:middle">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div></td>
    <td style="width:0.68%;vertical-align:middle">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div></td>
    <td style="width:50.22%;vertical-align:middle">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div></td>
    <td style="width:0.68%;vertical-align:middle">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div></td>
    <td style="width:17.85%;vertical-align:middle">
        <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div></td></tr>
  <tr>
    <td style="width:30%;vertical-align:top;border-bottom:2px solid rgb(0, 0, 0)">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">/s/ Ilan Hadar</div></td>
    <td style="width:0.68%;vertical-align:middle">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div></td>
    <td style="width:50.22%;vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">Chairman and Chief Executive Officer</div></td>
    <td style="width:0.68%;vertical-align:middle">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div></td>
    <td style="width:17.85%;vertical-align:bottom;text-align:center">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">
        <div style="line-height:1.25">
        <div style="line-height:1.25">
        <div style="line-height:1.25">
        <div style="line-height:1.25">February 12, 2025</div></div></div></div></div></td></tr>
  <tr>
    <td style="width:30%;vertical-align:top">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">Ilan Hadar</div></td>
    <td style="width:0.68%;vertical-align:middle">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div></td>
    <td style="width:50.22%;vertical-align:bottom">
        <div style="line-height:1.25;font-style:italic;font-family:'Times New Roman',Times,serif">(Principal Executive Officer)</div></td>
    <td style="width:0.68%;vertical-align:middle">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div></td>
    <td style="width:17.85%;vertical-align:bottom">
        <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div></td></tr>
  <tr>
    <td style="width:30%;vertical-align:middle">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div></td>
    <td style="width:0.68%;vertical-align:middle">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div></td>
    <td style="width:50.22%;vertical-align:middle">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div></td>
    <td style="width:0.68%;vertical-align:middle">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div></td>
    <td style="width:17.85%;vertical-align:middle">
        <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div></td></tr>
  <tr>
    <td style="width:30%;vertical-align:top;border-bottom:2px solid rgb(0, 0, 0)">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">/s/ Mirit Horenshtein Hadar</div></td>
    <td style="width:0.68%;vertical-align:middle">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div></td>
    <td style="width:50.22%;vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">Chief Financial Officer and Secretary</div></td>
    <td style="width:0.68%;vertical-align:middle">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div></td>
    <td style="width:17.85%;vertical-align:bottom">
        <div style="text-align:center;line-height:1.25">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">
        <div style="line-height:1.25">
        <div style="line-height:1.25">
        <div style="line-height:1.25">
        <div style="line-height:1.25">
        <div style="line-height:1.25">
        <div style="line-height:1.25">
        <div style="line-height:1.25">
        <div style="line-height:1.25">
        <div style="line-height:1.25">
        <div style="line-height:1.25">February 12, 2025</div></div></div></div></div></div></div></div></div></div></div></div></td></tr>
  <tr>
    <td style="width:30%;vertical-align:top">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">Mirit Horenshtein Hadar</div></td>
    <td style="width:0.68%;vertical-align:middle">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div></td>
    <td style="width:50.22%;vertical-align:bottom">
        <div style="line-height:1.25;font-style:italic;font-family:'Times New Roman',Times,serif">(Principal Financial and Accounting Officer)</div></td>
    <td style="width:0.68%;vertical-align:middle">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div></td>
    <td style="width:17.85%;vertical-align:bottom">
        <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div></td></tr>
  <tr>
    <td style="width:30%;vertical-align:middle">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div></td>
    <td style="width:0.68%;vertical-align:middle">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div></td>
    <td style="width:50.22%;vertical-align:middle">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div></td>
    <td style="width:0.68%;vertical-align:middle">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div></td>
    <td style="width:17.85%;vertical-align:middle">
        <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div></td></tr>
  <tr>
    <td style="width:30%;vertical-align:top;border-bottom:2px solid rgb(0, 0, 0)">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">
        <div style="line-height:1.25">/s/ Dror J. Abramov</div></div></td>
    <td style="width:0.68%;vertical-align:middle">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div></td>
    <td style="width:50.22%;vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">Director</div></td>
    <td style="width:0.68%;vertical-align:middle">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div></td>
    <td style="width:17.85%;vertical-align:bottom">
        <div style="text-align:center;line-height:1.25">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">
        <div style="line-height:1.25">
        <div style="line-height:1.25">
        <div style="line-height:1.25">
        <div style="line-height:1.25">
        <div style="line-height:1.25">
        <div style="line-height:1.25">
        <div style="line-height:1.25">
        <div style="line-height:1.25">
        <div style="line-height:1.25">
        <div style="line-height:1.25">
        <div style="line-height:1.25">
        <div style="line-height:1.25">February 12, 2025</div></div></div></div></div></div></div></div></div></div></div></div></div></div></td></tr>
  <tr>
    <td style="width:30%;vertical-align:top">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">Dror J. Abramov</div></td>
    <td style="width:0.68%;vertical-align:middle">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div></td>
    <td style="width:50.22%;vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div></td>
    <td style="width:0.68%;vertical-align:middle">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div></td>
    <td style="width:17.85%;vertical-align:bottom">
        <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div></td></tr>
  <tr>
    <td style="width:30%;vertical-align:middle">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div></td>
    <td style="width:0.68%;vertical-align:middle">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div></td>
    <td style="width:50.22%;vertical-align:middle">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div></td>
    <td style="width:0.68%;vertical-align:middle">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div></td>
    <td style="width:17.85%;vertical-align:middle">
        <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div></td></tr>
  <tr>
    <td style="width:30%;vertical-align:top;border-bottom:2px solid rgb(0, 0, 0)">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">
        <div style="line-height:1.25">/s/ Ruth Alon</div></div></td>
    <td style="width:0.68%;vertical-align:middle">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div></td>
    <td style="width:50.22%;vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">Director</div></td>
    <td style="width:0.68%;vertical-align:middle">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div></td>
    <td style="width:17.85%;vertical-align:bottom">
        <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif">
        <div style="line-height:1.25">
        <div style="line-height:1.25">
        <div style="line-height:1.25">
        <div style="line-height:1.25">
        <div style="line-height:1.25">
        <div style="line-height:1.25">
        <div style="line-height:1.25">
        <div style="line-height:1.25">
        <div style="line-height:1.25">
        <div style="line-height:1.25">
        <div style="line-height:1.25">
        <div style="line-height:1.25">February 12, 2025</div></div></div></div></div></div></div></div></div></div></div></div></div></td></tr>
  <tr>
    <td style="width:30%;vertical-align:top">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">Ruth Alon</div></td>
    <td style="width:0.68%;vertical-align:middle">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div></td>
    <td style="width:50.22%;vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div></td>
    <td style="width:0.68%;vertical-align:middle">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div></td>
    <td style="width:17.85%;vertical-align:bottom">
        <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div></td></tr>
  <tr>
    <td style="width:30%;vertical-align:middle">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div></td>
    <td style="width:0.68%;vertical-align:middle">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div></td>
    <td style="width:50.22%;vertical-align:middle">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div></td>
    <td style="width:0.68%;vertical-align:middle">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div></td>
    <td style="width:17.85%;vertical-align:middle">
        <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div></td></tr>
  <tr>
    <td style="width:30%;vertical-align:top;border-bottom:2px solid rgb(0, 0, 0)">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">
        <div style="line-height:1.25">/s/ Ilan Levin</div></div></td>
    <td style="width:0.68%;vertical-align:middle">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div></td>
    <td style="width:50.22%;vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">Director</div></td>
    <td style="width:0.68%;vertical-align:middle">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div></td>
    <td style="width:17.85%;vertical-align:bottom">
        <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif">
        <div style="line-height:1.25">
        <div style="line-height:1.25">
        <div style="line-height:1.25">
        <div style="line-height:1.25">
        <div style="line-height:1.25">
        <div style="line-height:1.25">
        <div style="line-height:1.25">
        <div style="line-height:1.25">
        <div style="line-height:1.25">
        <div style="line-height:1.25">
        <div style="line-height:1.25">
        <div style="line-height:1.25">February 12, 2025</div></div></div></div></div></div></div></div></div></div></div></div></div></td></tr>
  <tr>
    <td style="width:30%;vertical-align:top">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">Ilan Levin</div></td>
    <td style="width:0.68%;vertical-align:middle">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div></td>
    <td style="width:50.22%;vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div></td>
    <td style="width:0.68%;vertical-align:middle">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div></td>
    <td style="width:17.85%;vertical-align:bottom">
        <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div></td></tr>
  <tr>
    <td style="width:30%;vertical-align:middle">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div></td>
    <td style="width:0.68%;vertical-align:middle">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div></td>
    <td style="width:50.22%;vertical-align:middle">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div></td>
    <td style="width:0.68%;vertical-align:middle">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div></td>
    <td style="width:17.85%;vertical-align:middle">
        <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div></td></tr>
  <tr>
    <td style="width:30%;vertical-align:top;border-bottom:2px solid rgb(0, 0, 0)">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">
        <div style="line-height:1.25">/s/ Avner Lushi</div></div></td>
    <td style="width:0.68%;vertical-align:middle">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div></td>
    <td style="width:50.22%;vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">Director</div></td>
    <td style="width:0.68%;vertical-align:middle">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div></td>
    <td style="width:17.85%;vertical-align:bottom">
        <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif">
        <div style="line-height:1.25">
        <div style="line-height:1.25">
        <div style="line-height:1.25">
        <div style="line-height:1.25">
        <div style="line-height:1.25">
        <div style="line-height:1.25">
        <div style="line-height:1.25">
        <div style="line-height:1.25">
        <div style="line-height:1.25">
        <div style="line-height:1.25">
        <div style="line-height:1.25">
        <div style="line-height:1.25">February 12, 2025</div></div></div></div></div></div></div></div></div></div></div></div></div></td></tr>
  <tr>
    <td style="width:30%;vertical-align:top">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">Avner Lushi</div></td>
    <td style="width:0.68%;vertical-align:middle">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div></td>
    <td style="width:50.22%;vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div></td>
    <td style="width:0.68%;vertical-align:middle">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div></td>
    <td style="width:17.85%;vertical-align:bottom">
        <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div></td></tr>
  <tr>
    <td style="width:30%;vertical-align:middle">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div></td>
    <td style="width:0.68%;vertical-align:middle">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div></td>
    <td style="width:50.22%;vertical-align:middle">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div></td>
    <td style="width:0.68%;vertical-align:middle">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div></td>
    <td style="width:17.85%;vertical-align:middle">
        <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div></td></tr>
  <tr>
    <td style="width:30%;vertical-align:top;border-bottom:2px solid rgb(0, 0, 0)">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">
        <div style="line-height:1.25">/s/ Shlomo Noy</div></div></td>
    <td style="width:0.68%;vertical-align:middle">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div></td>
    <td style="width:50.22%;vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">Director</div></td>
    <td style="width:0.68%;vertical-align:middle">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div></td>
    <td style="width:17.85%;vertical-align:bottom">
        <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif">
        <div style="line-height:1.25">
        <div style="line-height:1.25">
        <div style="line-height:1.25">
        <div style="line-height:1.25">
        <div style="line-height:1.25">
        <div style="line-height:1.25">
        <div style="line-height:1.25">
        <div style="line-height:1.25">
        <div style="line-height:1.25">
        <div style="line-height:1.25">
        <div style="line-height:1.25">
        <div style="line-height:1.25">February 12, 2025</div></div></div></div></div></div></div></div></div></div></div></div></div></td></tr>
  <tr>
    <td style="width:30%;vertical-align:top">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">Shlomo Noy</div></td>
    <td style="width:0.68%;vertical-align:middle">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div></td>
    <td style="width:50.22%;vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div></td>
    <td style="width:0.68%;vertical-align:middle">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div></td>
    <td style="width:17.85%;vertical-align:bottom">
        <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div></td></tr>
  <tr>
    <td rowspan="1" style="width:30%;vertical-align:top">&#160;</td>
    <td rowspan="1" style="width:0.68%;vertical-align:middle">&#160;</td>
    <td rowspan="1" style="width:50.22%;vertical-align:bottom">&#160;</td>
    <td rowspan="1" style="width:0.68%;vertical-align:middle">&#160;</td>
    <td rowspan="1" style="width:17.85%;vertical-align:bottom">&#160;</td></tr>
  <tr>
    <td rowspan="1" style="width:30%;vertical-align:top;border-bottom:2px solid rgb(0, 0, 0)">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;/s/ Amnon Peled</div></td>
    <td rowspan="1" style="width:0.68%;vertical-align:middle;padding-bottom:2px">&#160;</td>
    <td rowspan="1" style="width:50.22%;vertical-align:bottom;padding-bottom:2px">Director</td>
    <td rowspan="1" style="width:0.68%;vertical-align:middle;padding-bottom:2px">&#160;</td>
    <td rowspan="1" style="width:17.85%;vertical-align:bottom;padding-bottom:2px">
        <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif">
        <div style="line-height:1.25">
        <div style="line-height:1.25">
        <div style="line-height:1.25">
        <div style="line-height:1.25">
        <div style="line-height:1.25">
        <div style="line-height:1.25">
        <div style="line-height:1.25">
        <div style="line-height:1.25">
        <div style="line-height:1.25">
        <div style="line-height:1.25">
        <div style="line-height:1.25">
        <div style="line-height:1.25">February 12, 2025</div></div></div></div></div></div></div></div></div></div></div></div></div></td></tr>
  <tr>
    <td rowspan="1" style="width:30%;vertical-align:top">Amnon Peled</td>
    <td rowspan="1" style="width:0.68%;vertical-align:middle">&#160;</td>
    <td rowspan="1" style="width:50.22%;vertical-align:bottom">&#160;</td>
    <td rowspan="1" style="width:0.68%;vertical-align:middle">&#160;</td>
    <td rowspan="1" style="width:17.85%;vertical-align:bottom">&#160;</td></tr>
  </table>

<div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif;font-size:10pt">&#160;</div>

<div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-size:10pt">II-6</div>

<div style="clear:both;margin-top:10pt;margin-bottom:10pt">

<div style="page-break-after:always"><hr style="border-width:0px;clear:both;margin:4px 0px;width:100%;height:2px;color:#000000;background-color:#000000"/></div></div>

<div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-size:10pt;font-weight:bold">AUTHORIZED REPRESENTATIVE</div>

<div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-size:10pt;font-weight:bold">&#160;</div>

<div style="text-align:left;text-indent:36pt;line-height:1.25;font-family:'Times New Roman', Times, serif;font-size:10pt">

<div style="line-height:1.25;font-family:'Times New Roman',Times,serif">

<div style="text-indent:25.2pt;margin-left:8.15pt;line-height:1.25">

<div style="text-indent:25.2pt;line-height:1.25;font-family:'Times New Roman', Times, serif">

<div style="line-height:1.25;font-family:'Times New Roman',Times,serif">Pursuant to the requirements of the&#160;Securities Act&#160;of&#160;1933,
as amended, the undersigned, the duly authorized representative of the Registrant in the United&#160;States, has signed registration statement
in Newark, Delaware, on February 12, 2025.</div></div></div></div></div>

<div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif;font-size:10pt">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">
  <tr>
    <td style="width:50%;vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div></td>
    <td colspan="2" style="vertical-align:bottom">
        <div style="text-align:justify;line-height:1.25;font-weight:bold;font-family:'Times New Roman',Times,serif">PUGLISI&#160;&amp; ASSOCIATES</div></td></tr>
  <tr>
    <td style="width:50%;vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div></td>
    <td colspan="2" style="vertical-align:bottom">
        <div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div></td></tr>
  <tr>
    <td style="width:50%;vertical-align:bottom">
        <div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div></td>
    <td style="width:4%;vertical-align:bottom">
        <div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif">By:</div></td>
    <td style="width:46%;vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0)">
        <div style="text-align:justify;line-height:1.25;font-style:normal;font-family:'Times New Roman',Times,serif">/s/ Donald J.&#160;Puglisi</div></td></tr>
  <tr>
    <td style="width:50%;vertical-align:bottom">
        <div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div></td>
    <td style="width:4%;vertical-align:bottom">
        <div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif">Name:&#160;</div></td>
    <td style="width:46%;vertical-align:bottom">
        <div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif">Donald J.&#160;Puglisi</div></td></tr>
  <tr>
    <td style="width:50%;vertical-align:bottom">
        <div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div></td>
    <td style="width:4%;vertical-align:bottom">
        <div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif">Title:</div></td>
    <td style="width:46%;vertical-align:bottom">
        <div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif">Authorized Representative</div></td></tr>
  </table>

<div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-size:10pt">&#160;</div>

<div style="text-align:center;line-height:1.25;font-family:'Times New Roman', Times, serif;font-size:10pt"><span style="font-family:'Times New Roman',Times,serif">II-7
</span><hr style="border:none;border-bottom:4px solid black;border-top:1px solid black;height:10px;color:#ffffff;background-color:#ffffff;margin-left:auto;margin-right:auto;text-align:center"/></div></div></div>

</div></body>
</html>
[{"type": "S-1", "sequence": "1", "filename": "zk2532684.htm", "description": "S-1", "secsgml_size_bytes": 5750427}]
{"company-data": {"conformed-name": "Silexion Therapeutics Corp", "cik": "0002022416", "assigned-sic": "2836", "organization-name": "03 Life Sciences", "irs-number": "000000000", "state-of-incorporation": "E9", "fiscal-year-end": "1231"}, "filing-values": {"form-type": "S-1", "act": "33", "file-number": "333-284873", "film-number": "25615378"}, "business-address": {"street1": "12 ABBA HILLEL ROAD", "city": "RAMAT GAN", "state": "L3", "zip": "5250606", "phone": "972-8-6286005"}, "mail-address": {"street1": "12 ABBA HILLEL ROAD", "city": "RAMAT GAN", "state": "L3", "zip": "5250606"}, "former-company": {"former-conformed-name": "Biomotion Sciences", "date-changed": "20240506"}}
Silexion Therapeutics Corp - 2022416 - 2025
As filed with the United States Securities and Exchange Commission on February 12, 2025.
Registration No. 333-
UNITED STATES
SECURITIES AND
EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
S-1
REGISTRATION
STATEMENT UNDER
THE
SECURITIES ACT OF 1933
Silexion
Therapeutics Corp
(Exact name of registrant as
specified in its charter)
Cayman
        Islands
8731
N/A
(State or other jurisdiction of
incorporation or organization)
(Primary Standard Industrial
Classification
        Code Number)
(I.R.S. Employer
Identification Number)
12 Abba Hillel
Road
Ramat Gan,
Israel 5250606
+972-8-6286005
(Address, Including Zip Code,
and Telephone Number, Including Area Code, of Registrant's Principal Executive Offices)
Puglisi &
Associates
850 Library Avenue, Suite 204
Newark, DE 19711
Telephone:
(302) 738-6680
(Name, Address, Including Zip
Code, and Telephone Number, Including Area Code, of Agent For Service)
Copies to:
Jonathan M. Nathan, Adv.
Meitar Law Offices
16 Abba Hillel Road
Ramat Gan, Israel 5251608
Tel: +972-3-610-3100
Mark S. Selinger, Esq.
Gary Emmanuel,
        Esq.
Greenberg
        Traurig, LLP
One Vanderbilt Avenue
New York, New York 10017-5404
Tel: (212) 801-9200
Approximate date of commencement
of proposed sale to the public:
From time to time on or after this registration statement is declared effective.
If
any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the
Securities Act of 1933, check the following box. ☒
If
this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, please check the
following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.
☐
If
this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities
Act registration statement number of the earlier effective registration statement for the same offering. ☐
If
this Form is a post-effective amendment filed pursuant to Rule 462(d) under the Securities Act, check the following box and list the Securities
Act registration statement number of the earlier effective registration statement for the same offering. ☐
Indicate
by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting
company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer,"
"smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.
Large accelerated filer
☐
Accelerated filer
☐
Non-accelerated
        filer
☒
Smaller reporting company
☒
Emerging growth company
☒
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act.
☐
The Registrant hereby amends this Registration
Statement on such date or dates as may be necessary to delay its effective date until the Registrant shall file a further amendment which
specifically states that this Registration Statement shall thereafter become effective in accordance with Section 8(a) of the
Securities Act of 1933, as amended ("Securities Act"), or until the Registration Statement shall become effective
on such date as the SEC, acting pursuant to Section 8(a), may determine.
The information in this preliminary
prospectus is not complete and may be changed. The securities described herein may not be sold until the registration statement filed
with the U.S. Securities and Exchange Commission is declared effective. This preliminary prospectus is not an offer to sell these securities
and it is not soliciting an offer to buy these securities in any jurisdiction where the offer or sale is not permitted.
PRELIMINARY
PROSPECTUS
SUBJECT TO COMPLETION, DATED FEBRUARY 12, 2025
Up to 2,377,030 Ordinary Shares
This prospectus relates to the resale, from time to time, by the securityholders named
herein (the "
Selling Securityholders
")of up to 2,377,030 ordinary shares, par value
$0.0009 per share ("
ordinary shares
" or "
New
Silexion ordinary shares
") of Silexion Therapeutics Corp, a Cayman Islands exempted company ("
New
Silexion
", the "
Company
", "
our company
",
"
we
" or "
us
"), issuable upon the
exercise of warrants, as further described below under "Prospectus Summary — Recent Developments — Warrant Repricing."
The Selling Securityholders are identified in the table commencing on page 131. We will
not receive any proceeds from the sale of the ordinary shares by the Selling Securityholders. All net proceeds from the sale of the ordinary
shares covered by this prospectus will go to the Selling Securityholders. However, we may receive the proceeds from any exercise of warrants
if the holders do not exercise the warrants on a cashless basis. See "Use of Proceeds."
The Selling Securityholders may sell all or a portion of the ordinary
shares from time to time in market transactions through any market on which our ordinary shares are then traded, in negotiated transactions
or otherwise, and at prices and on terms that will be determined by the then prevailing market price or at negotiated prices directly
or through a broker or brokers, who may act as agent or as principal or by a combination of such methods of sale. The Selling Securityholders
will pay all brokerage fees and commissions and similar expenses attributable to their sales of securities. We will pay the expenses (except
brokerage fees and commissions and similar expenses) incurred in registering the sale of the securities offered hereby, including legal
and accounting fees. See "
Plan of Distribution
."
On November 27, 2024, we effected a 1-for-9 reverse share split of our authorized
ordinary shares, including our issued and outstanding ordinary shares, with a market effectiveness date of November 29, 2024. Unless specifically
provided otherwise herein, all of our (but not that of Moringa Acquisition Corp) share, per share and related option and warrant information
presented in this prospectus has been retroactively adjusted to reflect the reduced number of shares and the increase in the share price
which resulted from the reverse share split.
Our ordinary shares and warrants are listed on The Nasdaq Stock Market under the symbols
"SLXN" and "SLXNW," respectively. On February 11, 2025, the last reported sales price of our ordinary shares was
$1.38 per share and the last reported sales price of our warrants was $0.0684 per warrant.
We are an "emerging
growth company" as defined under U.S. federal securities laws and, as such, have elected to comply with reduced public company reporting
requirements. This prospectus complies with the requirements that apply to an issuer that is an emerging growth company.
Investing in our securities
involves a high degree of risk. You should review carefully the risks and uncertainties described in the section titled "Risk Factors"
beginning on page 6 of this prospectus, and under similar headings in any amendments or supplements to this prospectus.
Neither the Securities
and Exchange Commission nor any state securities commission has approved or disapproved of these securities, or passed upon the accuracy
or adequacy of this prospectus. Any representation to the contrary is a criminal offense.
Prospectus dated        , 2025
ABOUT THIS PROSPECTUS
This
prospectus is part of a registration statement on Form S-1 that we filed with the Securities and Exchange Commission (the "SEC")
using the "shelf" registration process. Under this shelf registration process, the Selling Securityholders may, from time
to time, sell the ordinary shares offered by them described in this prospectus. We will not receive any proceeds from the sale by such
Selling Securityholders of the ordinary shares offered by them described in this prospectus, except with respect to amounts received by
us upon exercise of warrants to the extent such warrants are exercised for cash. Given the current price level of our ordinary shares,
there is no certainty that warrant holders will exercise their warrants and, accordingly, we may not receive any proceeds in relation
to our outstanding warrants.
Neither
we nor the Selling Securityholders have authorized anyone to provide you with any information or to make any representations other than
those contained in this prospectus or any applicable prospectus supplement or any free writing prospectuses prepared by or on behalf of
us or to which we have referred you. Neither we nor the Selling Securityholders take responsibility for, and can provide no assurance
as to the reliability of, any other information that others may give you. Neither we nor the Selling Securityholders will make an offer
to sell these ordinary shares in any jurisdiction where the offer or sale is not permitted.
We
may also provide a prospectus supplement or post-effective amendment to the registration statement to add information to, or update or
change information contained in, this prospectus. You should read both this prospectus and any applicable prospectus supplement or post-effective
amendment to the registration statement together with the additional information to which we refer you in the section of this prospectus
titled
"Where You Can Find
More Information."
Unless the context indicates otherwise, references in
this prospectus to "
New Silexion
", "
we
",
"
us,
" "
our
," "
the
Company
", "
our company
" and similar terms refer to Silexion Therapeutics
Corp (formerly known as Biomotion Sciences), a Cayman Islands exempted company, and its consolidated subsidiaries. References to "
Silexion
"
refer to Silexion Therapeutics Ltd., an Israeli company and wholly-owned subsidiary of the Company, and references to "
Moringa
"
refer to Moringa Acquisition Corp, a Cayman Islands exempted company and wholly-owned subsidiary of the Company. References to the "
Business
Combination
" refer collectively to the transactions completed on August 15, 2024 pursuant to that certain Amended and Restated
Business Combination Agreement, dated as of April 3, 2024 (as amended, the "
Business Combination
Agreement
"), by and among New Silexion, August M.S. Ltd., an Israeli company and a wholly-owned subsidiary of New
Silexion ("
Merger Sub 1
"), Moringa Acquisition Merger Sub Corp, a Cayman Islands exempted
company and a wholly-owned subsidiary of New Silexion ("
Merger Sub 2
"), Moringa
and Silexion. Pursuant to the Business Combination Agreement, among other things, (i) Merger Sub 2 merged with and into Moringa, with
Moringa continuing as the surviving company and a wholly-owned subsidiary of New Silexion (the "
SPAC
Merger
") and (ii) Merger Sub 1 merged with and into Silexion, with Silexion continuing as the surviving company and a wholly-owned
subsidiary of New Silexion (the "
Acquisition Merger
"). In connection with the consummation
of the Business Combination (the "
Closing
"), New Silexion changed its name from "Biomotion
Sciences" to "Silexion Therapeutics Corp", and the ordinary shares and warrants of New Silexion commenced trading on
the Nasdaq Global Market ("
Nasdaq
") under the symbols "SLXN" and "SLXNW",
respectively, on August 16, 2024.
This prospectus contains summaries of certain provisions
contained in some of the documents described herein, but reference is made to the actual documents for complete information. All of the
summaries are qualified in their entirety by the actual documents. Copies of some of the documents referred to herein have been filed,
will be filed or will be incorporated by reference as exhibits to the registration statement of which this prospectus is a part, and you
may obtain copies of those documents as described below under "
Where You Can Find More Information
".
SPECIAL NOTE REGARDING FORWARD-LOOKING
STATEMENTS
The statements contained in this prospectus that are not
purely historical are forward-looking statements. Certain statements in this prospectus may constitute "forward-looking statements"
for purposes of the federal securities laws. These forward-looking statements include, but are not limited to, statements regarding the
Company's and the Company's management team's expectations, hopes, beliefs, intentions or strategies regarding the future,
including statements regarding our future results of operations or financial condition, business strategy and plans, and objectives of
management for future operations. In addition, any statements that refer to projections, forecasts or other characterizations of future
events or circumstances, including any underlying assumptions, are forward-looking statements. The words "anticipate," "believe,"
"continue," "could," "estimate," "expect," "intends," "may," "might,"
"plan," "possible," "potential," "predict," "project," "should,"
"will," "would" and similar expressions may identify forward-looking statements, but the absence of these words
does not mean that a statement is not forward-looking. Forward-looking statements in this prospectus may include, for example, statements
about:
●
the ability to maintain the listing of our ordinary shares and our warrants
        on Nasdaq;
●
our future performance, including our projected timeline for regulatory approvals
        of its product candidates;
●
our market opportunity;
●
our strategy, future operations, financial position, projected costs, prospects
        and plans;
●
expectations regarding the time during which we will be an emerging growth
        company under the JOBS Act;
●
our ability to retain or recruit officers, key employees and directors;
●
the impact of the regulatory environment and complexities with compliance
        related to such environment;
●
expectations regarding future partnerships or other relationships with third
        parties; and
●
our future capital requirements and sources and uses of cash, including the
        our ability to obtain additional capital in the future.
The forward-looking statements contained in this prospectus
and in any document incorporated by reference are based on current expectations, forecasts and beliefs concerning future developments
and their potential effects on us. There can be no assurance that future developments affecting we will be those that we have anticipated.
These forward-looking statements involve a number of risks, uncertainties, some of which are beyond our control, or other assumptions
that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements.
These risks and uncertainties include, but are not limited to, the following factors:
●
we are a development-stage company and have a limited operating history on
        which to assess our business;
●
we have never generated any revenue from product sales and may never be profitable;
●
we will need to raise substantial additional funding, which may not be available
        on acceptable terms, or at all, and which will cause dilution to our shareholders;
●
the approach we are taking to discover and develop novel RNAi therapeutics
        is unproven for oncology and may never lead to marketable products;
●
we do not have experience producing our product candidates at commercial
        levels, currently have no marketing and sales organization, have an uncertain market receptiveness to our product candidates, and are
        uncertain as to whether there will be insurance coverage and reimbursement for our potential products;
●
we may be unable to attract, develop and/or retain our key personnel or additional
        employees required for our development and future success;
●
we may issue additional ordinary shares or other equity securities without your approval, including: (a)
        up to $15,337,500 of ordinary shares issuable under the Ordinary Share Purchase Agreement, dated August 13, 2024 and effective as of August
        15, 2024, by and between the Company and White Lion Capital, LLC ("White Lion") (the "White Lion Purchase Agreement"
        or "ELOC Agreement"), which established an equity line of credit for the Company; (b) ordinary shares underlying
659,999
outstanding warrants; and (c) ordinary shares underlying convertible promissory notes that the Company has issued to (i) Moringa's
        sponsor, Moringa Sponsor, LP, a Cayman Islands exempted limited partnership (the "Sponsor" or "Moringa Sponsor"),
        in a principal amount of $3,433,000 (the "A&R Sponsor Promissory Note"), in amendment and restatement of all promissory
        notes previously issued by Moringa to the Sponsor for funds borrowed between Moringa's initial public offering and the completion
        of the Business Combination, and (ii) EarlyBird Capital, Inc. ("EarlyBird"), which served as the representative of the underwriters
        for Moringa's initial public offering, in an amount of $1,250,000 (the "EarlyBird Convertible Note"), each of which
        would dilute your ownership interest and may depress the market price of our ordinary shares; and
●
those additional factors described or incorporated by reference under the
        heading "
Risk Factors
" below.
Should one or more of these risks or uncertainties materialize,
or should any of our assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking
statements. It is not possible to predict or identify all such risks. Accordingly, forward-looking statements in this prospectus and in
any document incorporated herein by reference should not be relied upon as representing our views as of any subsequent date, and we undertake
no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise,
except as may be required under applicable securities laws.
These forward-looking statements are based on information
available as of the date of this prospectus, and current expectations, forecasts and assumptions, and involve a number of judgments, risks
and uncertainties. Accordingly, forward-looking statements should not be relied upon as representing our views as of any subsequent date,
and we do not undertake any obligation to update forward-looking statements to reflect events or circumstances after the date they were
made, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws.
You should read this prospectus and the documents that
we reference in this prospectus and have filed as exhibits to the registration statement of which this prospectus is a part, completely
and with the understanding that our actual future results may be materially different from what we expect. We qualify all of our forward-looking
statements by these cautionary statements.
In addition, statements that "we believe"
and similar statements reflect our beliefs and opinions on the relevant subject. Those statements are based upon information available
to us as of the date of this prospectus and while we believe such information forms a reasonable basis for such statements, such information
may be limited or incomplete, and such statements should not be read to indicate that we have conducted an exhaustive inquiry into, or
review of, all potentially available relevant information. Those statements are inherently uncertain, and investors are cautioned not
to unduly rely upon those statements.
TABLE OF CONTENTS
Page
Prospectus Summary
1
Risk Factors
6
Transactions Related to Offering Under This Prospectus
42
Market and Industry Data
42
Use of Proceeds
43
Determination of Offering Price
44
Market Information for Securities and Dividend Policy
44
Unaudited Pro Forma Condensed Combined Financial Information
44
Management's Discussion and Analysis of Financial Condition and Results of
        Operations
57
Business
80
Management
109
Executive Compensation
115
Certain Relationships and Related Party Transactions
126
Beneficial Ownership of Securities
129
Selling Securityholders
131
Description of Share Capital
135
Material U.S. Federal Income Tax Consequences
142
Plan of Distribution
149
Legal Matters
151
Experts
151
Where You Can Find More Information
152
Index to Financial Statements
F-1
You should rely only on the information
contained in this prospectus, any supplement to this prospectus or in any free writing prospectus, filed with the Securities and Exchange
Commission. Neither we nor the Selling Securityholders have authorized anyone to provide you with additional information or information
different from that contained in this prospectus filed with the Securities and Exchange Commission. We take no responsibility for, and
can provide no assurance as to the reliability of, any other information that others may give you. The Selling Securityholders is offering
to sell, and seeking offers to buy, our securities only in jurisdictions where offers and sales are permitted. The information contained
in this prospectus is accurate only as of the date of this prospectus, regardless of the time of delivery of this prospectus or any sale
of our securities. Our business, financial condition, results of operations and prospects may have changed since that date.
For investors outside of the United States:
Neither we nor the Selling Securityholders have done anything that would permit this offering or possession or distribution of this prospectus
in any jurisdiction where action for that purpose is required, other than in the United States. Persons outside the United States who
come into possession of this prospectus must inform themselves about, and observe any restrictions relating to, the offering of our securities
and the distribution of this prospectus outside the United States.
PROSPECTUS
SUMMARY
This summary highlights information
contained elsewhere in this prospectus and does not contain all of the information that you should consider in making your investment
decision. Before investing in our securities, you should carefully read this entire prospectus, including our consolidated financial statements
and the related notes thereto and the information set forth in the sections titled "Risk Factors" and "Management's
Discussion and Analysis of Financial Condition and Results of Operations."
Our Business
We are a clinical-stage, oncology-focused biotechnology
company engaged in the discovery and development of proprietary treatments for KRAS-driven cancers. The KRAS gene is an oncogene that
is involved in the regulation of cell division as a result of its ability to relay external signals to the cell nucleus. Based on our
research of refractory solid tumor cancers, we are actively developing a platform focused on the silencing of the KRAS oncogene using
RNA-interference therapeutics. Our lead product candidate, SIL-204B, consists of locally administered small interfering RNAs, or siRNA,
in an extended-release formulation, as a first-line treatment of locally advanced pancreatic cancer patients, or LAPC, in combination
with standard-of-care chemotherapy.
The KRAS oncogene is considered to be the most common
oncogenic gene driver in human cancers, and the most notable in pancreatic, lung, and gastrointestinal (GI) (including colorectal, esophagus,
stomach, small bowel, and appendix) cancers. Considered a challenging therapeutic target due to its intrinsic characteristics, recent
advances have been made at directly inhibiting the KRAS proteins produced by the mutated gene. Our platform is designed to silence the
gene, and thus prevent the production of the harmful mutated KRAS proteins driving the growth of cancerous tumors.
We are currently focused on treatment for pancreatic cancer
(PC) tumors bearing the KRAS G12D or KRAS G12V mutations where metastases have not been detected and are non-resectable, i.e., they are
not able to be surgically removed. For our first indication, we are targeting the largest and least treatable form of localized pancreatic
tumors referred to as locally advanced pancreatic cancer. LAPC represents approximately 30% of the total pancreatic cancer population.
We are currently developing SIL-204B, a second-generation siRNA product candidate following a Phase 1 and Phase 2 clinical trial with
our first-generation siRNA product candidate, siG12D-LODER, which we also refer to as Loder. Results from the Phase 2 clinical trial showed
a trend for differences between treatment groups in patients with the KRAS G12D/V mutation, with the Loder arm suggesting an overall survival
advantage of 9.3 months.
SIL-204B has been designed to optimize Loder with the
aim of improving uptake into tumor cells, enhancing stability, and improving the delivery system. We plan to conduct a Phase 2/3 prospective,
randomized, controlled, multinational, two-arm, open-label trial in LAPC subjects that harbor the KRAS G12D/V mutations to evaluate the
efficacy, safety and tolerability of SIL-204B administered intratumorally in combination with standard of care (SoC) chemotherapy versus
SoC chemotherapy only. In support of our planned Phase 2/3 trial, we held a meeting with the Federal Institute for Drugs and Medical Devices
in Germany (BfArM) to discuss the planned design of the Phase 2/3 trial at which BfArM agreed, in principle, to the design. In preparation
for the study, we plan to initiate toxicology studies of SIL-204B in 2025 followed by the regulatory submission in the second half of
2025 to initiate the Phase 2/3 trial and trial initiation in the first half of 2026 . At this time, we are focused on the further development
of the core siRNA technology underlying the Loder and SIL-204B as well as the clinical development of SIL-204B as the most optimized version
of the technology.
Corporate Information
We were originally known as Biomotion Sciences, a Cayman Islands exempted
company. On April 3, 2024, we entered into an amended and restated business combination agreement (the "Business Combination Agreement"),
dated April 3, 2024, by and among our company (whose name was subsequently changed to Silexion Therapeutics Corp) ("New Silexion"),
August M.S. Ltd., an Israeli company and a wholly owned subsidiary of New Silexion ("Merger Sub 1"), Moringa Acquisition Merger
Sub Corp, a Cayman Islands exempted company and a wholly owned subsidiary of Silexion ("Merger Sub 2"), Moringa Acquisition
Corp ("Moringa") and Silexion Therapeutics Ltd., an Israeli company ("Silexion"). On August 15, 2024 (the "Closing
Date"), the transactions contemplated by the Business Combination Agreement (collectively, the "Business Combination")
were completed (the "Closing"), following the approval of the Business Combination on August 6, 2024 by the extraordinary
general meeting of Moringa.
1
Our principal executive offices are located at 12 Abba
Hillel Road, Ramat Gan, Israel 5250606, Israel and our phone number is +972-8-6286005. Our corporate website address is www.silexion.com.
Information contained on or accessible through our website is not a part of this prospectus, and the inclusion of our website address
in this prospectus is an inactive textual reference only.
This prospectus contains trademarks, service marks, trade
names and copyrights of other companies, which are the property of their respective owners. Solely for convenience, trademarks and trade
names referred to in this prospectus may appear without the ® or ™ symbols, but such references are not intended to indicate,
in any way, that the applicable licensor will not assert, to the fullest extent under applicable law, its rights to these trademarks and
trade names. We do not intend our use or display of other companies' trade names, trademarks or service marks to imply a relationship
with, or endorsement or sponsorship of us by, any other companies.
Reverse Share Split
On November 27, 2024, we effected a 1-for-9
reverse share split of our authorized ordinary shares, including our issued and outstanding ordinary shares, with a market effectiveness
date of November 29, 2024. Unless specifically provided otherwise herein, all of our (but not that of Moringa Acquisition Corp) share,
per share and related option and warrant information presented in this prospectus, has been retroactively adjusted to reflect the reduced
number of shares and the increase in the share price which resulted from the reverse share split.
Nasdaq Market Value-Related Deficiencies
On November 19, 2024, we received two letters from the Nasdaq Listing
Qualifications Department, each addressing a separate compliance deficiency of the Company under the Nasdaq Listing Rules. The first letter
from the Nasdaq Listing Qualifications Department notified us of our non-compliance with Nasdaq Listing Rule 5450(b)(2)(A), which requires
a company such as ours whose securities are listed on the Nasdaq Global Market under the "Market Value Standard" to maintain
a minimum Market Value of Listed Securities (an "MVLS") of $50,000,000. The deficiency was triggered by our MVLS having closed
below the minimum level for a period of 30 consecutive business days. Under Nasdaq Listing Rule 5810(c)(3)(C), we are entitled to a 180-day
period, ending on May 19, 2025, to rectify the deficiency. In order to do so, we must achieve and maintain an MVLS of $50,000,000 or more
for at least 10 consecutive business days. Failure to regain compliance within the 180-day period would result in the delisting of our
securities from Nasdaq, although we would have the right to appeal such a delisting to a Nasdaq hearings panel.
The second letter informed us of our deficiency in complying with
Nasdaq Listing Rule 5450(b)(2)(C), which requires a minimum Market Value of Publicly Held Shares (an "MVPHS") of $15,000,000
for continued listing on the Nasdaq Global Market under the "Market Value Standard". This deficiency was caused by our MVPHS
having fallen below the minimum threshold for the prior 30 consecutive business days. Under Nasdaq Listing Rule 5810(c)(3)(D), we have
180 calendar days, or until May 19, 2025, to regain compliance, which we can achieve if its MVPHS closes at or above $15,000,000 for at
least 10 consecutive business days. Failure to regain compliance within that 180-day period would result in the delisting of our securities
from Nasdaq, subject to our right to appeal to a Nasdaq hearings panel.
We intend to actively monitor the market value of our securities
and explore available options to resolve both market value-related deficiencies. As part of our strategy, we may consider applying to
transfer the listing of our securities to the Nasdaq Capital Market, subject to meeting one set of listing requirements for that market.
There can be no assurance, however, that we will successfully regain compliance with either rule within the allotted timeframe or that
any appeal, if necessary, will be successful.
Implications of Being a Smaller Reporting
Company and Emerging Growth Company
We are a "smaller reporting company" as defined
in Item 10(f)(1) of Regulation S-K. Smaller reporting companies may take advantage of certain reduced disclosure obligations, including,
among other things, providing only two years of audited financial statements and reduced disclosure obligations regarding executive compensation.
We will remain a smaller reporting company until the last day of any fiscal year for so long as either (1) the market value of our ordinary
shares held by non-affiliates does not equal or exceed $250 million as of the prior June 30th, or (2) our annual revenues did not equal
or exceed $100 million during such completed fiscal year and the market value of our ordinary shares held by non-affiliates did not equal
or exceed $700 million as of the prior June 30th. To the extent we take advantage of any reduced disclosure obligations, it may make the
comparison of our financial statements with other public companies difficult or impossible.
We are an "emerging growth company," as defined
in the Jumpstart Our Business Startups Act of 2012 (t
he "JOBS Act"). A
s an emerging
growth company, we are exempt from certain requirements related to executive compensation, including the requirements to hold a nonbinding
advisory vote on executive compensation and to provide information relating to the ratio of total compensation of our Chief Executive
Officer to the median of the annual total compensation of all of our employees, each as required by the Investor Protection and Securities
Reform Act of 2010, which is part of the Dodd-Frank Act.
Section 102(b)(1) of the JOBS Act exempts
emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that
is, those that have not had a registration statement under the Securities Act of 1933, as amended (the "
Securities
Act
") declared effective or do not have a class of securities registered under the Exchange Act) are required to comply with
the new or revised financial accounting standards. The JOBS Act provides that a company can elect to opt out of the extended transition
period and comply with the requirements that apply to non-emerging growth companies but any such an election to opt out is irrevocable.
We have elected not to opt out of such extended transition period, which means that when a standard is issued or revised and it has different
application dates for public or private companies, we, as an emerging growth company, can adopt the new or revised standard at the time
private companies adopt the new or revised standard. This may make comparison of New Silexion's financial statements with those
of another public company that is neither an emerging growth company nor an emerging growth company that has opted out of using the extended
transition period difficult or impossible because of the potential differences in accounting standards used.
We will remain an emerging growth company
until the earlier of: (1) the last day of the fiscal year (a) following the fifth anniversary of the date on which New Silexion ordinary
shares were offered in exchange for ordinary shares of each of Moringa and Silexion, (b) in which we have total annual gross revenue of
at least $1.235 billion, or (c) in which we are deemed to be a large accelerated filer, which means the market value of our common equity
that is held by non-affiliates exceeds $700 million as of the end of the prior fiscal year's second fiscal quarter; and (2) the
date on which we have issued more than $1.00 billion in non-convertible debt securities during the prior three-year period. References
herein to "emerging growth company" are to its meaning under the Securities Act, as modified by the JOBS Act.
2
Summary Risk Factors
Investing in our securities involves risks.
You should carefully consider the risks described in "
Risk Factors
" before making
a decision to invest in our securities. If any of these risks is actualized, our business, financial condition and results of operations
would likely be materially adversely affected. In such case, the trading price of our securities would likely decline, and you may lose
all or part of your investment. In particular, you should consider the risk factors described under "
Risk
Factors
" beginning on page 6. Such risks include, but are not limited to:
●
We are a development-stage company and have a limited operating history on
        which to assess our business. The approach we are taking to discover and develop novel RNAi therapeutics is unproven for oncology and
        may never lead to marketable products.
●
We have never generated any revenue from product sales and may never be profitable.
●
We will need to raise substantial additional funding, which may not be available
        on acceptable terms, or at all, and which will cause dilution to our shareholders.
●
Our independent registered public accounting firm's report contains
        an explanatory paragraph that expresses substantial doubt about our ability to continue as a "going concern.".
●
The approach we are taking to discover and develop novel RNAi therapeutics
        is unproven for oncology and may never lead to marketable products.
●
We are heavily dependent on the success of our product candidates, which
        are in the early stages of preclinical or clinical development. We cannot give any assurance that any of our product candidates will receive
        regulatory approval, which is necessary before they can be commercialized.
●
The regulatory approval processes of the FDA and comparable foreign authorities
        are lengthy, time consuming, and inherently unpredictable. If we are ultimately unable to obtain regulatory approval for our product candidates,
        our business will be substantially harmed.
●
Clinical drug development involves a lengthy and expensive process with an
        uncertain outcome, and results of preclinical activity or earlier studies may not be predictive of future study results.
●
We may find it difficult to enroll patients in our clinical studies, which
        could delay or prevent clinical studies of our product candidates.
●
Our product candidates and the administration of our product candidates may
        cause undesirable side effects or have other properties that could delay or prevent their regulatory approval, limit the commercial profile
        of an approved label, or result in significant negative consequences following marketing approval, if any.
●
Even if we obtain regulatory approval for a product candidate, our products
        will remain subject to regulatory scrutiny.
●
We are subject to a multitude of manufacturing risks, any of which could
        substantially increase our costs and limit supply of our product candidates.
●
We rely on third parties to conduct our preclinical and clinical studies,
        and to manufacture the raw materials and products that we use to create our product candidates and to supply us with the medical devices
        used to administer such products, which entails regulatory and trade secrets-related risks.
●
We do not have experience producing our product candidates at commercial
        levels, currently have no marketing and sales organization, have an uncertain market receptiveness to our product candidates, and is uncertain
        as to whether there will be insurance coverage and reimbursement for our potential products.
●
We face intense competition and rapid technological change and the possibility
        that our competitors may develop therapies that are similar, more advanced, or more effective than ours, which may adversely affect our
        financial condition and our ability to successfully commercialize our product candidates.
●
If we are unable to obtain and maintain effective patent rights for our product
        candidates or any future product candidates, we may not be able to compete effectively in our markets.
●
Third-party claims of intellectual property infringement may prevent or delay
        our development and commercialization efforts.
●
We may be unable to attract, develop and/or retain our key personnel or additional
        employees required for our development and future success.
3
●
Conditions in the Middle East and in Israel may harm our operations.
●
If we fail to maintain compliance with Nasdaq's continued
        listing requirements, our securities may be delisted from the Nasdaq Global Market.
●
A substantial number of our ordinary shares may be issued pursuant
        to the conversion terms of the A&R Sponsor Promissory Note and the EarlyBird Convertible Note, which could cause the price of the
        ordinary shares to decline
●
The price of our ordinary shares and our warrants may be volatile.
●
A substantial number of our ordinary shares may be issued pursuant to the
        White Lion Purchase Agreement and/or the conversion terms of the A&R Sponsor Promissory Note and the EarlyBird Convertible Note, which
        could cause (i) substantial dilution and (ii) the market price of the ordinary shares to decline.
●
We have no current plans to pay cash dividends on our ordinary shares for
        the foreseeable future.
●
Our reverse share split may negatively impact the market for our ordinary
        shares.
4
The Offering
Ordinary shares currently outstanding
8,414,615 ordinary shares.
Securities offered by the selling securityholders
Up to 2,377,030 our ordinary shares, par value $0.0009 per share, consisting of (i) 2,221,523 ordinary
        shares issuable upon the exercise of the New Warrants (as defined below), and (ii) 155,507 ordinary shares issuable upon the exercise
        of the Placement Agent Warrants (as defined below).
Ordinary shares to be outstanding assuming exercise of the warrants
10,791,645 ordinary shares.
Use of proceeds
We will not receive any proceeds from the sale of the ordinary shares issuable upon the exercise of the
        warrants by the selling securityholders. All net proceeds from the sale of the ordinary shares issuable upon the exercise of the warrants
        covered by this prospectus will go to the selling securityholders. However, we may receive the proceeds from any exercise of the warrants
        and placement agent warrants if the holders do not exercise the warrants on a cashless basis. See the section of this prospectus titled
        "
Use of Proceeds
."
Risk factors
Before investing in our securities, you should carefully read
        and consider the information set forth in "Risk Factors" beginning on page 6.
Nasdaq ticker symbols
New Silexion ordinary shares and New Silexion warrants are listed on Nasdaq under the symbols "SLXN"
        and "SLXNW", respectively.
For additional information concerning the offering, see "
Plan of
Distribution
" beginning on page 149.
5
RISK
FACTORS
Investing in our securities involves a high degree of risk. You
should carefully consider the risks and uncertainties described below together with all of the other information contained in this prospectus,
including our financial statements and related notes appearing at the end of this prospectus and in the section titled "Management's
Discussion and Analysis of Financial Condition and Results of Operations," before deciding to invest in our securities. If any of
the events or developments described below were to occur, our business, prospects, operating results and financial condition could suffer
materially, the trading price of our ordinary shares could decline, and you could lose all or part of your investment. The risks and uncertainties
described below are not the only ones we face. Additional risks and uncertainties not presently known to us or that we currently believe
to be immaterial may also adversely affect our business.
Risks Related to Our Financial Condition and Capital Requirements
We are a development-stage company
and have a limited operating history on which to assess our business. We have incurred significant losses since our inception and anticipate
that we will continue to incur significant losses for the foreseeable future.
We are a development stage company with a limited operating history focused
on the discovery and development of treatments based on the emerging therapeutic modality RNA interference (RNAi), a biological process
in which ribonucleic acid (RNA) molecules inhibit gene expression. Our proposed treatment, which we refer to as SIL-204B, consists of
locally administered small interfering RNAs, or siRNA, to KRAS G12D- or KRAS G12V-mutations (G12D/V), which is the gene driver that causes
development of tumors and human cancer (oncogenic). We have incurred net losses since our inception in November 2008, including net losses
of $5.1 million for the year ended December 31, 2023 and $14.8 million for the nine months ended September 30, 2024. As of September 30,
2024, we have an accumulated deficit of $41.6 million.
We have devoted substantially all of our financial resources to design and
develop our product candidates, including conducting preclinical and clinical studies and providing general and administrative support
for these operations. To date, we have financed our operations primarily through the sale of equity securities and through royalty-bearing
grants that we received from Israel's Innovation Authority, or the IIA. The amount of our future net losses will depend, in part,
on the rate of our future expenditures and our ability to obtain funding through equity or debt financings, strategic collaborations,
or grants. Biopharmaceutical product development is a highly speculative undertaking and involves a substantial degree of risk. We are
the early stages of clinical and preclinical development for our product candidates, we have we have not yet commenced pivotal clinical
studies for any product candidate and it may be several years, if ever, before we complete pivotal clinical studies and have a product
candidate approved for commercialization. Even if we obtain regulatory approval to market a product candidate, our future revenue will
depend upon the size of any markets in which our product candidates may receive approval, and our ability to achieve sufficient market
acceptance, pricing, reimbursement from third-party payors, and adequate market share for our product candidates in those markets.
We expect to continue to incur significant expenses and increasing operating
losses for the foreseeable future. We anticipate that our expenses will increase substantially if and as we:
●
continue and expand our research and preclinical and clinical development
        of our product candidates;
●
initiate additional preclinical, toxicology, clinical, or other studies for
        our product candidates;
●
continue to improve our quality standards and change or add additional manufacturers
        or suppliers;
●
seek regulatory and marketing approvals for our product candidates that successfully
        complete clinical studies;
6
●
establish a sales, marketing, and distribution infrastructure to commercialize
        any products for which we may obtain marketing approval;
●
seek to identify, assess, acquire, license, and/or develop other product
        candidates;
●
enter into license agreements;
●
seek to maintain, protect, and expand our intellectual property portfolio;
●
seek to attract and retain skilled personnel;
●
create additional infrastructure to support our operations as a public company
        and our product development and planned future commercialization efforts; and
●
experience any delays or encounter issues with any of the above, including
        but not limited to failed studies, complex results, safety issues, or other regulatory challenges that require longer follow-up of
        existing studies, additional major studies, or additional supportive studies in order to pursue marketing approval.
Further, the net losses we incur may fluctuate significantly
from quarter to quarter and year to year, such that a period-to-period comparison of our results of operations may not be a good indication
of our future performance.
We have never generated any revenue
from product sales and may never be profitable.
We have we have no products approved for commercialization and has never
generated any revenue. Our ability to generate revenue and achieve profitability depends on our ability, alone or with strategic collaboration
partners, to successfully complete the development of, and obtain the regulatory and marketing approvals necessary to commercialize, one
or more of our product candidates. We do not anticipate generating revenue from product sales for the foreseeable future. Our ability
to generate future revenue from product sales depends heavily on our success in many areas, including but not limited to:
●
completing research and preclinical and toxicology and clinical development
        of our product candidates;
●
obtaining regulatory and marketing approvals for our product candidates,
        if and when we complete clinical studies;
●
developing a sustainable and scalable in-house manufacturing process,
        meeting all regulatory standards for approved product candidates, and in some instances, establishing and maintaining supply and manufacturing
        relationships with third parties that can conduct the process and provide adequate (in amount and quality) products to support clinical
        development and the market demand for product candidates, if approved;
●
launching and commercializing product candidates, if and when we obtain regulatory
        and marketing approval, either directly or with a collaborator or distributor;
●
exposing, educating and training physicians to use our products;
●
obtaining market acceptance of our product candidates as viable treatment
        options;
●
addressing any competing technological and market developments;
●
identifying, assessing, acquiring and/or developing new product candidates;
7
●
negotiating favorable terms in any collaboration, licensing, or other arrangements
        into which we may enter;
●
maintaining, protecting, and expanding our portfolio of intellectual property
        rights, including patents, trade secrets, and know-how; and
●
attracting, hiring, and retaining qualified personnel.
Even if one or more of the product candidates that we develop is approved
for commercial sale, we anticipate incurring significant costs associated with commercializing any approved product candidate. Our expenses
could increase beyond expectations if we are required by the FDA, the European Medicines Agency (EMA) or other regulatory agencies, domestic
or foreign, or ethical committees in medical centers, to change our manufacturing processes or assays or to perform clinical, nonclinical,
or other types of studies in addition to those that we currently anticipate. In cases where we are successful in obtaining regulatory
approvals to market one or more of our product candidates, our revenue will be dependent, in part, upon the size of the markets in the
territories for which we gain regulatory approval, the accepted price for the product, the ability to get reimbursement at any price,
and whether we own the commercial rights for that territory. If the number of our addressable disease patients is not as significant as
we estimate, the indication approved by regulatory authorities is narrower than we expect, or the reasonably accepted population for treatment
is narrowed by competition, physician choice or treatment guidelines, we may not generate significant revenue from sales of such products,
even if approved. Additionally, there might be changes in supply or other changes in the approved drugs of which our products will be
administrated in combination, where such changes can affect our revenues. Further, if we are not able to generate revenue from the sale
of any approved products, we may be forced to cease operations.
We will need to raise substantial
additional funding before we can expect to become profitable from product sales. This additional financing may not be available on acceptable
terms, or at all. Failure to obtain this necessary capital when needed may force us to delay, limit, or terminate our product development
efforts or other operations.
We are currently advancing our SIL-204B platform product through preclinical
and clinical development. Developing our product candidates is expensive, and we expect our research and development expenses to increase
substantially in connection with our ongoing activities, particularly as we advance pour product candidates through clinical studies.
If our product candidates enter and advance through preclinical studies and
clinical trials, we will need substantial additional funds to expand our development, regulatory, manufacturing, marketing and sales capabilities
or contract with other organizations to provide those capabilities for it. We have used substantial funds to develop our product candidates
and delivery technologies and will require significant funds to conduct further research and development and preclinical testing and clinical
trials of our product candidates, to seek regulatory approvals for our product candidates and to manufacture and market products, if any,
which are approved for commercial sale.
As of September 30, 2024, our cash and cash equivalents were $1.97 million.
Based upon our then-expected level of operating expenditures, we have substantial doubt about our ability to continue as a going concern
as of such date. Please see the risk factor below titled "
our independent registered public accounting
firm's report contains an explanatory paragraph
…" Beyond our activities for the next 12 months, we furthermore
expect that we will require substantial additional capital to advance manufacturing capabilities for, to obtain regulatory approval for,
and to commercialize, our product candidates. In addition, our operating plans may change as a result of many factors that may currently
be unknown to it, and we may need to seek additional funds sooner than planned. Our future funding requirements will depend on many factors,
including but not limited to:
●
the scope, rate of progress, results and cost of our clinical studies, preclinical
        testing, toxicology studies, and other related activities;
8
●
the cost of manufacturing clinical supplies, and establishing commercial
        supplies of our product candidates and any future products;
●
the number and characteristics of product candidates that we pursue;
●
the cost, timing, and outcomes of regulatory approvals;
●
the cost and timing of establishing sales, marketing, and distribution capabilities;
        and
●
the terms and timing of any collaborative, licensing, and other arrangements
        that we may establish.
Any additional fundraising efforts may divert our management
from our day-to-day activities, which may adversely affect our abilities to develop and commercialize our product candidates.
In addition, we cannot guarantee that future financing will be available in sufficient amounts or on terms acceptable to us, if at all.
Moreover, the terms of any financing may adversely affect the holdings or the rights of our shareholders, and the issuance of additional
securities, whether equity or debt, by us, or the possibility of such issuance, may cause the market price of our ordinary shares to decline
due to expected or actual dilution. The incurrence of indebtedness could result in increased fixed payment obligations, and we may be
required to agree to certain restrictive covenants, such as limitations on our ability to incur additional debt, limitations on our ability
to acquire, sell, or license intellectual property rights, and other operating restrictions that could adversely impact our ability to
conduct our business. We could also be required to seek funds through arrangements with collaborative partners or otherwise at an earlier
stage than otherwise would be desirable, and we may be required to relinquish rights to some of our technologies or product candidates
or otherwise agree to terms unfavorable to it, any of which may have a material adverse effect on our business, operating results, and
prospects. Even if we believe we have sufficient funds for our current or future operating plans, we may seek additional capital if market
conditions are favorable or if we have specific strategic considerations.
If we are unable to obtain funding on a timely basis, we may be required
to significantly curtail, delay, or discontinue one or more of our research, development or manufacturing programs or the commercialization
of any product candidates, or be unable to expand our operations or otherwise capitalize on our business opportunities, as desired, which
could materially affect our business, financial condition, and results of operations.
Our independent registered public
accounting firm's report contains an explanatory paragraph that expresses substantial doubt about our ability to continue as a "going
concern."
We have limited cash resources and will need to obtain
additional funds in order to satisfy our liquidity needs. Silexion will require significant funds to conduct further research and development
and preclinical testing and clinical trials of our product candidates, to seek regulatory approvals for our product candidates and to
manufacture and market products, if any, which are approved for commercial sale. In light of our significant working capital needs and
the absence of any committed source of financing to meet those needs, there may be substantial doubt raised about our ability to continue
as a "going concern." Please see the explanatory paragraph under the heading "Substantial Doubt about the Company's
Ability to Continue as a Going Concern" in our independent auditors' report on our financial statements that appear in this
prospectus. Those financial statements do not include any adjustments that might result from our inability to continue as a "going
concern."
The historical financial results of
Silexion and unaudited pro forma financial information included herein may not be indicative of what our actual financial position or
results of operations would have been.
The historical financial results of Silexion included in this prospectus
do not reflect the financial condition, results of operations or cash flows we would have achieved as a public company during the periods
presented or those the Company will achieve in the future. Our financial condition and future results of operations could be materially
different from amounts reflected in certain of our historical financial statements included elsewhere in this prospectus, and it may be
difficult for investors to compare our future results to historical results or to evaluate our relative performance or trends in our business.
9
Similarly, the unaudited pro forma financial information
included herein is presented for illustrative purposes only and has been prepared based on a number of assumptions. Accordingly, such
pro forma financial information is not necessarily indicative of what our actual financial position or results of operations would have
been had the Business Combination been completed on the dates indicated, and our actual financial condition and results of operations
may vary materially from such pro forma financial information, including as a result of such assumptions not being accurate. See "Unaudited
Pro Forma Condensed Combined Financial Information."
Risks Related to the Research and Development
of Silexion's Product Candidates
The approach we are taking to discover
and develop novel RNAi therapeutics is unproven for oncology and may never lead to marketable products.
We have concentrated our efforts and therapeutic product
research on RNAi technology, and RNAi drug delivery and our future success depends on the successful development of this technology and
products based on it. We have not received regulatory approval to market therapeutics utilizing RNAi based drugs, including siRNAs, the
class of molecule we are trying to develop into products. The scientific discoveries that form the basis for our efforts to discover and
develop new drugs are relatively new. The scientific evidence to support the feasibility of developing drugs and the delivery of such
drugs based on these discoveries is both preliminary and limited. Skepticism as to the feasibility of developing RNAi therapeutics for
oncology has been expressed in scientific literature. For example, there are potential challenges to achieving safe RNAi therapeutics
based on the so-called off-target effects and activation of the interferon response, and other potential challenges to achieve
safe and potent levels of RNAi drugs due to complications associated with drug delivery. In addition, decisions by other companies with
respect to their RNAi development efforts may increase skepticism in the marketplace regarding the potential for RNAi therapeutics.
Relatively few product candidates based on these discoveries
have ever been tested in animals or humans. siRNAs may not naturally possess the inherent properties typically required of drugs, such
as the ability to be stable in the body long enough to reach the tissues in which their effects are required, or the ability to enter
cells within these tissues in order to exert their effects. We are currently has only limited data, and no conclusive evidence, to suggest
that it can introduce these drug-like properties into siRNAs. We may spend large amounts of money trying to introduce these properties,
and may never succeed in doing so. In addition, these compounds may not demonstrate in patients the chemical and pharmacological properties
ascribed to them in laboratory studies, and they may interact with human biological systems in unforeseen, ineffective or harmful ways.
As a result, we may never succeed in developing a marketable product, we may not become profitable and the value of our ordinary shares
may decline.
The FDA has relatively limited experience with RNAi and
siRNA based therapeutics. Limited granted approvals to any person or entity, including us, to market and commercialize therapeutics using
RNAi based drugs including siRNA, which may increase the complexity, uncertainty and length of the regulatory approval process for our
product candidates. Further, siRNA therapies are part of a broader therapeutic category called oligonueciotides, and there are only a
few approved drugs based on this therapeutic category. We may never receive approval to market and commercialize any product candidate.
Further, our focus on RNAi technology for developing drugs,
as opposed to multiple, more proven technologies for drug development, increases the risks associated with the ownership of our ordinary
shares. If we are not successful in developing a product candidate using RNAi technology, we may be required to change the scope and direction
of our product development activities. In that case, we may not be able to identify and implement successfully an alternative product
development strategy.
We are heavily dependent on the success
of our product candidates, which are in the early stages of preclinical or clinical development. We cannot give any assurance that any
of our product candidates will receive regulatory approval, which is necessary before they can be commercialized.
To date, we have invested a substantial amount of our
efforts and financial resources to: (i) identify and develop our product candidates, including conducting preclinical and clinical
studies and providing general and administrative support for these operations; and (ii) develop and secure our intellectual property
portfolio for our product candidates. Our future success is dependent on our ability to successfully develop, obtain regulatory approval
for, and then successfully commercialize one or more product candidates. We currently generate no revenue from sales of any drugs or technology
platforms, and we may never be able to develop or commercialize a marketable drug.
10
Each of our product candidates is in the early stages
of development and will require additional clinical development (and in some cases additional preclinical development), management of
nonclinical, clinical and manufacturing activities, regulatory approval, obtaining adequate manufacturing supply, building of a commercial
organization, and significant marketing efforts before we generate any revenue from product sales. We have concluded Phase II study
on first-generation Loder and moved on to SIL-204B. Silexion hopes to initiate the next clinical trial with SIL-204B during
the first half of 2026 for locally advanced pancreatic cancer. We are not permitted to market or promote any of our product candidates
before we receive regulatory approval from the FDA or comparable foreign regulatory authorities, and we may never receive such regulatory
approval for any of our product candidates.
We have never submitted marketing applications to the FDA or comparable foreign
regulatory authorities. We cannot be certain that any of our product candidates will be successful in clinical studies or receive regulatory
approval. Further, our product candidates may not receive regulatory approval even if they are successful in clinical studies. If we do
not receive regulatory approvals for our product candidates, we may not be able to continue our operations.
We generally plans to seek regulatory approval to commercialize our product
candidates in the United States, the EU and in additional foreign countries. To obtain regulatory approval in other countries, we must
comply with numerous and varying regulatory requirements of such other countries regarding safety, efficacy, chemistry, manufacturing
and controls, clinical studies, commercial sales, pricing, and distribution of our product candidates. Even if we are successful in obtaining
approval in one jurisdiction, it cannot ensure that we will obtain approval in any other jurisdictions. If we are unable to obtain approval
for our product candidates in multiple jurisdictions, our revenue and results of operations could be negatively affected.
The regulatory approval processes
of the FDA and comparable foreign authorities are lengthy, time consuming, and inherently unpredictable. If we are ultimately unable to
obtain regulatory approval for our product candidates, our business will be substantially harmed.
The time required to develop a drug and obtain approval by the FDA and comparable
foreign authorities is unpredictable, typically takes many years following the commencement of clinical studies, and depends upon numerous
factors. In addition, approval policies, regulations, or the type and amount of clinical data necessary to gain approval may change during
the course of a product candidate's clinical development and may vary among jurisdictions, which may cause delays in the approval
or the decision not to approve an application. We have we have not obtained regulatory approval for any product candidate, and it is possible
that none of our existing product candidates or any product candidates we may seek to develop in the future will ever obtain regulatory
approval.
Applications for our product candidates could fail to
receive regulatory approval for many reasons, including but not limited to the following:
●
the FDA or comparable foreign regulatory authorities may disagree with the
        design or implementation of our clinical studies;
●
We may be unable to demonstrate to the FDA or comparable foreign regulatory
        authorities that a product candidate's benefit to risk ratio for our proposed indication is acceptable;
●
the population studied in the clinical program may not be sufficiently broad
        or representative to assure safety in the full population for which we seek approval;
●
the FDA or comparable foreign regulatory authorities may disagree with our
        interpretation of data from preclinical studies or clinical studies;
11
●
the data collected from clinical studies of our product candidates may not
        be sufficient to support the submission of a new drug application (NDA) or a biologics license application (BLA) or other submission or
        to obtain regulatory approval in the United States or elsewhere;
●
the FDA or comparable foreign regulatory authorities may fail to approve
        the manufacturing processes, test procedures and specifications, or facilities of third-party manufacturers with which we contract
        for clinical and commercial supplies; and
●
the approval policies or regulations of the FDA or comparable foreign regulatory
        authorities may significantly change in a manner rendering our clinical data insufficient for approval.
This lengthy development and approval process, as well as the unpredictability
of the results of clinical studies, may result in our failing to obtain regulatory approval to market any of our product candidates, which
would significantly harm our business, and our consolidated results of operations and prospects.
Clinical drug development involves
a lengthy and expensive process with an uncertain outcome, and results of preclinical activity or earlier studies may not be predictive
of future study results.
Before obtaining marketing approval from regulatory authorities for the sale
of our product candidates, we must conduct extensive clinical studies to demonstrate the safety and efficacy of the product candidates
in humans. Clinical testing is expensive and can take many years to complete, and its outcome is inherently uncertain. Failure can occur
at any time during the clinical study process. The results of preclinical studies and early clinical studies of product candidates often
are not predictive of the results of later-stage clinical studies. In general, even product candidates that have shown promising results
in preclinical activities or early-stage clinical studies may still suffer significant setbacks in subsequent registration clinical studies.
For example, the safety or efficacy results generated to date in preclinical and clinical studies for siG12DLoder or preclinical studies
with SIL-204B do not ensure that later clinical studies will demonstrate similar results. There is a high failure rate for drugs and biologics
proceeding through clinical studies, and product candidates in later stages of clinical studies may fail to show the desired safety and
efficacy traits despite having progressed through preclinical studies and initial clinical studies. A number of companies in the biopharmaceutical
industry have suffered significant setbacks in advanced clinical studies due to lack of efficacy or adverse safety profiles, notwithstanding
promising results in earlier studies. Moreover, preclinical and clinical data are often susceptible to varying interpretations and analyses.
We do not know whether any Phase 1, Phase 2, Phase 3 or other clinical studies we may conduct will demonstrate consistent or adequate
efficacy and safety sufficient to obtain regulatory approval to market our drug candidates.
Events that may prevent successful or timely completion
of clinical development include but are not limited to:
●
inability to generate sufficient preclinical, toxicology, or other
in
        vivo
or
in vitro
data to support the initiation of human clinical studies;
●
delays in reaching a consensus with regulatory agencies on study design;
●
delays in reaching agreement on acceptable terms with prospective contract
        research organizations (CROs) and clinical study sites, the terms of which can be subject to extensive negotiation and may vary significantly
        among different CROs and clinical study sites;
●
delays in obtaining required Institutional Review Board (IRB) or Ethics Committee
        approval at each clinical study site;
●
imposition of a clinical hold by regulatory agencies, after review of an
        investigational new drug (IND) application, or equivalent application, or an inspection of our clinical study operations or study sites;
●
difficulty collaborating with patient groups and investigators;
●
failure by our CROs, other third parties, or us to adhere to clinical study
        requirements;
●
failure to perform in accordance with the FDA's good clinical practices
        requirements or applicable regulatory guidelines in other countries;
12
●
occurrence of serious adverse events associated with the product candidate
        that are viewed to outweigh our potential benefits;
●
the cost of clinical studies of our drug candidates being greater than we
        anticipate;
●
clinical studies of our drug candidates producing negative or inconclusive
        results, which may result in us deciding, or regulators requiring us, to conduct additional clinical studies or abandon drug development
        programs; and
●
failures associated with data interpretation, data management and data storage
        of such studies.
If we ultimately is unable to successfully complete clinical development
of our product candidates, we would be forced to cease operations. Clinical study delays could also shorten any periods during which our
products have patent protection and may allow our competitors to bring products to market before we do, which could impair our ability
to obtain orphan exclusivity and to successfully commercialize our product candidates.
We may find it difficult to enroll
patients in our clinical studies. Difficulty in enrolling patients could delay or prevent clinical studies of our product candidates.
Identifying and qualifying patients to participate in clinical studies of
our product candidates is critical to our success. The timing of our clinical studies depends in part on the speed at which we can recruit
patients to participate in testing our product candidates, and we may experience delays in our clinical studies if we encounter difficulties
in enrollment.
Some of the conditions for which we plan to evaluate our current product
candidates are relatively rare diseases. For example, according to the National Cancer Institute, approximately 61,000 patients were diagnosed
with pancreatic cancer in the U.S. in 2020. Accordingly, there are limited patient pools from which to draw for clinical studies. In addition
to the relative rarity of these diseases, the eligibility criteria of our clinical studies will further limit the pool of available study
participants as we will require that patients have specific characteristics that we can measure or to assure their disease is either severe
enough or not too advanced to include them in a study. We also may not be able to identify, recruit, and enroll a sufficient number of
patients to complete our clinical studies because of the perceived risks and benefits of the product candidate under study, the availability
and efficacy of competing therapies and clinical studies, the proximity and availability of clinical study sites for prospective patients,
and the patient referral practices of physicians.
In addition, even for the more prevalent diseases which we target, such as
prostate and breast cancer, enrolling patients in our clinical studies may be difficult. There may be several ongoing clinical studies
for these diseases (both RNAi based and otherwise), and we may face competition in enrolling patients. The number of patients in such
clinical studies might be significantly large. In addition, the time period required to achieve indications of safety and efficacy in
such studies may be very long. Some of these competing studies may be conducted by other biopharmaceutical companies with more experience
in clinical testing and with much greater financial, technical and human resources than we have.
If patients are unwilling to participate in our studies for any reason, the
timeline for recruiting patients, conducting studies, and obtaining regulatory approval of our potential products will be delayed.
Our product candidates and the administration
of our product candidates may cause undesirable side effects or have other properties that could delay or prevent their regulatory approval,
limit the commercial profile of an approved label, or result in significant negative consequences following marketing approval, if any.
Undesirable side effects including toxicology caused by our product candidates
could cause us or regulatory authorities to interrupt, delay, or halt clinical studies and could result in a more restrictive label or
the delay or denial of regulatory approval by the FDA or other comparable foreign authorities. For example, there are known immune stimulation
and other side effects associated with RNAi. The implantation of SIL-204B may entail the use of endoscopic ultrasound (EUS) needles, which
may cause pancreatitis, bleeding or other procedural related safety issues. The Phase 2 clinical study with siG12DLoder indicated that
Loder treatment was well tolerated. Safety events that were observed were primarily related to procedure, mainly reversible abdominal
pain. In addition, the presence of a foreign body such as our SIL-204B) in human tissue may cause inflammation. Results of our studies
could reveal a high and unacceptable severity and prevalence of these or other side effects. In such an event, such studies could be suspended
or terminated, and the FDA or comparable foreign regulatory authorities could order us to cease further development of or deny or withdraw
approval of our product candidates for any or all targeted indications.
13
The drug-related, drug-product related, and administration
related side effects could affect patient recruitment, the ability of enrolled patients to complete the study, or result in potential
product liability claims. we do not currently have product liability insurance and does not anticipate obtaining product liability insurance
until such time as we have received FDA or other comparable foreign authority approval for a product and there is a product that is being
provided to patients outside of clinical trials.
Additionally,
if one or more of our product candidates receives marketing approval, and we or others later identify undesirable side effects caused
by such products, a number of potentially significant negative consequences could result, including but not limited to:
●
regulatory authorities may withdraw approvals of such product;
●
regulatory authorities may require additional warnings on the label;
●
We may be required to create a Risk Evaluation and Mitigation Strategy (REMS)
        plan or similar plan in other jurisdictions, which could include a medication guide outlining the risks of such side effects for distribution
        to patients, a communication plan for healthcare providers, and/or other elements to assure safe use;
●
We could be sued and held liable for harm caused to patients; and
●
Our reputation may suffer.
Any of these
events could prevent us from achieving or maintaining market acceptance of the particular product candidate, if approved, and could significantly
harm our business, results of operations, and prospects.
Even if we obtain regulatory approval
for a product candidate, our products will remain subject to regulatory scrutiny.
If our product candidates are approved, they will be subject to ongoing regulatory
requirements for manufacturing, labeling, packaging, storage, advertising, promotion, sampling, record-keeping, conduct of post-marketing
studies, and submission of safety, efficacy, and other post-market information, including both federal and state requirements in the United
States and other jurisdictions, where the product might be marketed. Accordingly, we and others with whom we work must continue to expend
time, money, and effort in all areas of regulatory compliance, including manufacturing, production, and quality control.
Any regulatory approvals that we receive for our product candidates may also
be subject to limitations on the approved indicated uses for which the product may be marketed or to the conditions of approval, or contain
requirements for potentially costly post-marketing testing, including Phase 4 clinical trials, and surveillance to monitor the safety
and efficacy of the product candidate. We will also be required to report certain adverse reactions and production problems, if any, to
the FDA, and to comply with requirements concerning advertising and promotion for our products. Promotional communications with respect
to prescription drugs are subject to a variety of legal and regulatory restrictions and must be consistent with the information in the
product's approved label. As such, we may not promote our products for indications or uses for which they do not have FDA approval.
The holder of an approved NDA or BLA must also submit new or supplemental applications and obtain FDA approval for certain changes to
the approved product, product labeling, or manufacturing process. We could also be asked to conduct post-marketing clinical studies to
verify the safety and efficacy of our products in general or in specific patient subsets. If we obtain original marketing approval via
the accelerated approval pathway, we could be required to conduct a successful post-marketing clinical study to confirm clinical benefit
for our products. An unsuccessful post-marketing study or failure to complete such a study could result in the withdrawal of marketing
approval. Furthermore, any new legislation addressing drug safety issues could result in delays in product development or commercialization
or increased costs to assure compliance. Foreign regulatory authorities impose similar requirements.
14
If a regulatory agency discovers previously unknown problems
with a product, such as adverse events of unanticipated severity or frequency, or disagrees with the promotion, marketing or labeling
of a product, such regulatory agency may impose restrictions on that product or us, including requiring withdrawal of the product from
the market. If we fail to comply with applicable regulatory requirements, a regulatory agency or enforcement authority may, among other
things:
●
issue warning letters;
●
impose civil or criminal penalties;
●
suspend or withdraw regulatory approval;
●
suspend any of our ongoing clinical studies;
●
refuse to approve pending applications or supplements
        to approved applications submitted by Silexion; or
●
seize or detain products, or require a product recall.
Any government investigation of alleged violations of law could require us
to expend significant time and resources in response, and could generate negative publicity. Any failure to comply with ongoing regulatory
requirements may significantly and adversely affect our ability to commercialize and generate revenue from our products. If regulatory
sanctions are applied or if regulatory approval is withdrawn, the value of the Company and our operating results will be adversely affected.
The FDA and other regulatory agencies
actively enforce the laws and regulations prohibiting the promotion of off-label uses.
If any of our product candidates are approved and they are found to have
been improperly promoted for unapproved uses of those products, we may become subject to significant liability. The FDA and other regulatory
agencies or other governmental bodies strictly regulate the promotional claims that may be made about prescription products, such as our
product candidates, if approved. In particular, a product may not be promoted for uses that are not approved by the FDA or such other
regulatory agencies as reflected in the product's approved labeling. If we receive marketing approval for a product candidate, physicians
may nevertheless prescribe it to their patients in a manner that is inconsistent with the approved label. If we are found to have promoted
such unapproved, or off-label, uses, they may become subject to significant liability. The U.S. federal government has levied large civil
and criminal fines against companies for alleged improper promotion of off-label use and has enjoined several companies from engaging
in off-label promotion. The FDA has also requested that companies enter into consent decrees or permanent injunctions under which specified
promotional conduct is changed or curtailed. If we cannot successfully manage the promotion of our product candidates, if approved, we
could become subject to significant liability, which would materially adversely affect our business and financial condition.
We and our collaborators are subject
to significant regulation with respect to manufacturing our product candidates. The facilities we subcontract to for manufacturing may
not meet regulatory requirements and may have limited capacity.
All entities involved in the preparation of therapeutics for clinical studies
or commercial sale are subject to extensive regulation. Components of a finished therapeutic product approved for commercial sale or used
in late-stage clinical studies must be manufactured in accordance with current GMP (cGMP) or, in other countries, GMP. These regulations
govern manufacturing processes and procedures (including record keeping) and the implementation and operation of quality systems to control
and assure the quality of investigational products and products approved for sale. Poor control of production processes can lead to the
introduction of contaminants or to inadvertent changes in the properties or stability of our product candidates that may not be detectable
in final product testing. Us, our collaborators, or any contract manufacturers must supply all necessary documentation in support of an
NDA, BLA, or Marketing Authorization Application (MAA) on a timely basis and must adhere to Good Laboratory Practices (GLP) and cGMP/GMP
regulations enforced by the FDA and other regulatory agencies through their facilities and data and documentation inspection programs.
We have never produced a commercially approved pharmaceutical product and therefore have not obtained the requisite regulatory authority
approvals to do so. Our facilities and quality systems, and those of our collaborators and any third-party contractors, must pass a pre-approval
inspection for compliance with the applicable regulations as a condition of regulatory approval of our product candidates or any of our
other potential products. In addition, the regulatory authorities may, at any time, inspect a manufacturing facility involved with the
preparation of our product candidates or our other potential products or the associated quality systems for compliance with the regulations
applicable to the activities being conducted. If these facilities do not pass a preapproval plant inspection, regulatory approval of the
products may not be granted or may be substantially delayed until any violations are corrected to the satisfaction of the regulatory authority,
if ever.
15
The regulatory authorities also may, at any time following approval of a
product for sale, audit a manufacturing facility. If any such inspection or audit identifies a failure to comply with applicable regulations
or if a violation of our product specifications or applicable regulations occurs independent of such an inspection or audit, we or the
relevant regulatory authority may require remedial measures that may be costly and/or time consuming for us or a third party to implement,
and that may include the temporary or permanent suspension of a clinical study or commercial sales or the temporary or permanent closure
of a facility. Any such remedial measures imposed upon us, or third parties with whom we contract could materially harm our business.
If we, our collaborators, or any of our third-party manufacturers
fail to maintain regulatory compliance, the FDA or other applicable regulatory authorities can impose regulatory sanctions including,
among other things, refusal to approve a pending application for a new drug product or biologic product, withdrawal of an approval, or
suspension of production. As a result, our business, financial condition, and results of operations may be materially harmed.
These factors could cause us to incur higher costs and
could cause the delay or termination of clinical studies, regulatory submissions, required approvals, or commercialization of our product
candidates.
We are subject to a multitude of manufacturing
risks, any of which could substantially increase our costs and limit supply of our product candidates.
The process of manufacturing our product candidates is
complex, highly regulated, and subject to several risks, including but not limited to:
●
the process of manufacturing RNAi-drugs, drug substances, and RNAi-delivery
        vehicles, such as our product candidates, is extremely susceptible to product loss due to contamination, equipment failure or improper
        installation or operation of equipment, or vendor or operator error. Even minor deviations from normal manufacturing processes for any
        of our product candidates could result in reduced production yields, product defects, and other supply disruptions. If microbial, viral,
        or other contaminations are discovered in our product candidates or in the manufacturing facilities in which our product candidates are
        made, such manufacturing facilities may need to be closed for an extended period of time to investigate and remedy the contamination;
        and
●
the manufacturing facilities in which our product candidates are made could
        be adversely affected by equipment failures, labor shortages, natural disasters, power failures, and numerous other factors.
Any adverse developments affecting manufacturing operations
for our product candidates may result in shipment delays, inventory shortages, lot failures, withdrawals or recalls, or other interruptions
in the supply of our product candidates. We may also have to take inventory write-offs and incur other charges and expenses for product
candidates that fail to meet specifications, undertake costly remediation efforts, or seek more costly manufacturing alternatives.
16
Risks Related to Our Reliance on Third Parties
We rely on third parties to conduct
its preclinical and clinical studies and perform other tasks for us. If these third parties do not successfully carry out their contractual
duties, meet expected deadlines, or comply with regulatory requirements, we may not be able to obtain regulatory approval for or commercialize
its product candidates, and our business could be substantially harmed
We have relied upon and plans to continue to rely upon third-party CROs to
monitor and manage data for our ongoing preclinical and clinical programs. We rely on these parties for execution of our preclinical and
clinical studies, and control only certain aspects of their activities. Nevertheless, we are responsible for ensuring that each of our
studies is conducted in accordance with the applicable protocol, legal, regulatory, and scientific standards and our reliance on the CROs
does not relieve us of our regulatory responsibilities. we and our CROs and other vendors are required to comply with cGMP and GLP, which
are regulations and guidelines enforced by the FDA, the Competent Authorities of the Member States of the European Economic Area (EEA)
and comparable foreign regulatory authorities for all of our product candidates in clinical development. Regulatory authorities enforce
these regulations through periodic inspections of study sponsors, principal and other investigators, study sites, and other contractors.
If we or any of our CROs or vendors fail to comply with applicable regulations, the clinical data generated in our clinical studies may
be deemed unreliable and the FDA, EMA, or comparable foreign regulatory authorities may require us to perform additional clinical studies
before approving our marketing applications. We cannot assure you that upon inspection by a given regulatory authority, such regulatory
authority will determine that any of our clinical studies comply with Good Clinical Practices (GCP) regulations. In addition, our clinical
studies must be conducted with product produced under cGMP/GMP regulations. Our failure to comply with these regulations may require us
to repeat clinical studies, which would delay the regulatory approval process.
If any of our relationships with these third-party CROs terminate, we may
not be able to enter into arrangements with alternative CROs or do so on commercially reasonable terms. In addition, our CROs are not
our employees, and, except for remedies available to us under our agreements with such CROs, we cannot control whether or not they devote
sufficient time and resources to our on-going clinical, nonclinical, and preclinical programs. If CROs do not successfully carry out their
contractual duties or obligations or meet expected deadlines, if they need to be replaced or if the quality or accuracy of the clinical
data they obtain is compromised due to the failure to adhere to our clinical protocols, regulatory requirements, or for other reasons,
our clinical studies may be extended, delayed, or terminated, and we may not be able to obtain regulatory approval for or successfully
commercialize our product candidates. CROs may also generate higher costs than anticipated. As a result, our results of operations and
the commercial prospects for our product candidates would be harmed, our costs could increase, and our ability to generate revenue could
be delayed.
Switching or adding additional CROs involves additional cost and requires
management time and focus. In addition, there is a natural transition period when a new CRO commences work. As a result, delays occur,
which can materially impact our ability to meet our desired clinical development timelines. Though we carefully manage our relationships
with our CROs, there can be no assurance that we will not encounter similar challenges or delays in the future or that these delays or
challenges will not have a material adverse impact on our business, financial condition, and prospects.
17
We currently rely on third parties
to manufacture the raw materials and products that we use to create our product candidates and to supply us with the medical devices used
to administer such product. This reliance requires us to share our trade secrets with these third parties, which increases the possibility
that a competitor will discover them or that our trade secrets will be misappropriated or disclosed.
Because we rely on third parties to provide us with the materials that we
use to develop and manufacture our product candidates, we may, at times, share trade secrets with such third parties. We seek to protect
our proprietary technology in part by entering into confidentiality agreements and, if applicable, material transfer agreements, collaborative
research agreements, consulting agreements, or other similar agreements with our collaborators, advisors, employees, and consultants prior
to beginning research or disclosing proprietary information. These agreements typically limit the rights of the third parties to use or
disclose our confidential information, such as trade secrets. Despite the contractual provisions employed when working with third parties,
the need to share trade secrets and other confidential information increases the risk that such trade secrets become known by our competitors,
are inadvertently incorporated into the technology of others, or are disclosed or used in violation of these agreements. Given that our
proprietary position is based, in part, on our know- how and trade secrets, a competitor's discovery of our trade secrets or other
unauthorized use or disclosure would impair our competitive position and may have a material adverse effect on our business.
Our reliance on third parties to manufacture
the raw materials and products that are used to create our product candidates and to supply us with the medical devices used to administer
such product might cause our business harm if manufacturers fail to provide us with sufficient quantities of these materials and products
or fail to do so at acceptable quality levels or prices.
We do not currently have the infrastructure or capability internally to develop
the raw materials and other products that we use to manufacture our product candidates, and we lack the resources and the capability to
manufacture the medical devices which we use to administer our products. There are a limited number of suppliers for these raw materials,
products and devices, and there may be a need to identify alternate suppliers to prevent a possible disruption to our clinical studies,
and, if approved, ultimately for commercial sale. We cannot assure you that we will be able to identify alternate suppliers if the need
arises at acceptable quality levels or prices.
Risks Related to Commercialization of Our Product Candidates
If the market opportunities for our
product candidates are smaller than we believe they are, our revenue may be adversely affected, and our business may suffer. Because some
of the target patient populations of our product candidates are small, we must be able to successfully identify patients and achieve a
significant market share to maintain profitability and growth.
We focus a substantial part of our research and product development on treatments
for locally advanced pancreatic cancer with certain specific mutations. Given the small number of patients who have this disease with
these mutations, it is critical to Silexion's ability to grow and become profitable that we continue to successfully identify effected
patients. Our projections of both the number of people who have these diseases, as well as the subset of people with these diseases who
have the potential to benefit from treatment with our product candidates, are based on our beliefs and estimates. These estimates have
been derived from a variety of sources, including the scientific literature, surveys of clinics, patient foundations, or market research,
and may prove to be incorrect. Further, new studies may change the estimated incidence or prevalence of these diseases. The number of
patients may turn out to be lower than expected. The effort to identify patients with diseases we seek to treat is in its early stages,
and we cannot accurately predict the number of patients for whom treatment might be possible. Additionally, the potentially addressable
patient population for each of our product candidates may be limited or may not be amenable to treatment with its product candidates,
and new patients may become increasingly difficult to identify or gain access to, which would adversely affect our results of operations
and business.
18
We do not have experience producing
our product candidates at commercial levels and may not achieve the necessary regulatory approvals or produce product candidates at the
quality, quantities, locations, and timing needed to support commercialization. Additionally, we intend to rely on third-party manufacturers
to produce the raw materials and products that we use to manufacture our product candidates, but we have not entered into binding agreements
with any such manufacturers to support commercialization.
We do not currently have the experience or ability to
produce product candidates at commercial levels. We may run into technical or scientific issues related to manufacturing or development
that we may be unable to resolve in a timely manner or with available funds. We also have not completed all of the characterization and
validation activities necessary for commercialization and regulatory approvals. If we do not conduct all such necessary activities, our
commercialization efforts will be harmed.
Although we intend to rely on third-party manufacturers for the raw materials
and products to support our own manufacturing of our product candidates for commercialization, we have not yet entered into agreements
with such manufacturers. We may be unable to negotiate binding agreements with the manufacturers to support our commercialization activities
at commercially reasonable terms. Additionally, these third party manufacturers may not be able to supply us with the necessary quantities
of these raw materials and products to support our own manufacturing process, or in compliance with cGMP or other pertinent regulatory
requirements, and within our planned timeframe and cost parameters, and the development and sales of our products, if approved, may be
materially harmed.
We face intense competition and rapid
technological change and the possibility that our competitors may develop therapies that are similar, more advanced, or more effective
than ours, which may adversely affect our financial condition and our ability to successfully commercialize our product candidates.
The biotechnology and pharmaceutical industries are intensely competitive
and subject to rapid and significant technological change. We are currently aware of various existing therapies in the market and in development
that may in the future compete with our product candidates. For example, there is an increasing number of companies commercializing treatments
and/or developing programs specifically targeting KRAS mutations, including KRAS G12D and KRAS G12V, in a variety of manners and for a
variety of indications, including cancer, including Bristol-Myers Squibb Company (through the recently acquired Mirati Therapeutics, Inc.),
Revolution Medicines, Inc., AstraZeneca (in collaboration with Usynova), Boehringer and Gilead. Smaller and other early-stage companies
may also prove to be significant competitors. Treatments for cancer currently include surgery, radiation therapy, chemotherapy, hormone
therapy, immunotherapy and combined treatment modalities such as chemo-radiotherapy. Other approaches may also emerge for the treatment
of any of the disease areas in which we focus.
We have competitors both in the United States and internationally, including
major multinational pharmaceutical companies, specialty pharmaceutical companies, and biotechnology companies. Our competitors may succeed
in developing, acquiring, or licensing on an exclusive basis, products that are more effective or less costly than any product candidate
that Silexion may develop, or achieve earlier patent protection, regulatory approval, product commercialization, and market penetration
than we do. Additionally, technologies developed by our competitors may render our potential product candidates uneconomical or obsolete,
and we may not be successful in marketing our product candidates against competitors.
We currently have no marketing and
sales organization. If we are unable to establish sales and marketing capabilities or enter into agreements with third parties to market
and sell our product candidates, we may be unable to generate any revenue.
We as a company have no experience selling and marketing our product candidates,
and currently have no marketing or sales organization. To successfully commercialize any products that may result from our development
programs, we will need to develop these capabilities, either on our own or with others. If our product candidates receive regulatory approval,
we intend to establish a sales and marketing organization with technical expertise and supporting distribution capabilities to commercialize
our product candidates in major markets, which will be expensive, difficult, and time consuming. Any failure or delay in the development
of our internal sales, marketing, and distribution capabilities would adversely impact the commercialization of our products.
19
Further, given our lack of prior experience in marketing and selling biopharmaceutical
products, our initial estimate of the size of the required sales force may be materially more or less than the size of the sales force
actually required to effectively commercialize our product candidates. As such, we may be required to hire the commercialization of our
product candidates, or we may incur excess costs as a result of hiring more sales representatives than necessary. With respect to certain
geographical markets, we may enter into collaborations with other entities to utilize their local marketing and distribution capabilities,
but we may be unable to enter into such agreements on favorable terms, if at all. If our future collaborators do not commit sufficient
resources to commercialize our future products, if any, and we are unable to develop the necessary marketing capabilities on our own,
we will be unable to generate sufficient product revenue to sustain our business. We may be competing with companies that currently have
extensive and well-funded marketing and sales operations. Without an internal team or the support of a third party to perform marketing
and sales functions, we may be unable to compete successfully against these more established companies.
The market may not be receptive to
our product candidates based on a novel therapeutic modality, and we may not generate any future revenue from the sale or licensing of
product candidates.
Even if approval is obtained for a product candidate,
we may not generate or sustain revenue from sales or licensing of the product due to factors such as whether the product can be sold at
a competitive cost and otherwise accepted in the market. The product candidates that we are developing are based on new technologies and
therapeutic approaches. Market participants with significant influence over acceptance of new treatments, such as physicians and third-party payors,
may not adopt a treatment based on RNAi, including siRNA technology, and we may not be able to convince the medical community and third-party payors
to accept and use, or to provide favorable reimbursement for, our product candidates. Market acceptance of Silexion's product candidates
will depend on, among other factors:
●
the timing of our receipt of any marketing and commercialization approvals;
●
the terms of any approvals and the countries in which approvals are obtained;
●
the safety and efficacy of our product candidates;
●
the prevalence and severity of any adverse side effects associated with our
        product candidates;
●
limitations or warnings contained in any labeling approved by the FDA or
        other regulatory authorities;
●
relative convenience and ease of administration of our product candidates;
●
the willingness of patients to accept any new methods of administration;
●
the success of our physician education programs;
●
the availability of adequate government and third-party payor reimbursement;
●
the pricing of our products, particularly as compared to alternative treatments;
        and
●
availability of alternative effective treatments for the disease indications
        our product candidates are intended to treat and the relative risks, benefits and costs of those treatments.
With Silexion's focus on the emerging therapeutic modality RNAi, these
risks may increase to the extent the space becomes more competitive or less favored in the commercial marketplace. Some of Silexion's
target diseases, such as pancreatic cancer, are relatively rare. Because of the small patient population for a rare disease, if pricing
is not approved or accepted in the market at an appropriate level for an approved product, such product may not generate enough revenue
to offset costs of development, manufacturing, marketing and commercialization. Market size is also a variable in disease indications
not classified as rare. Our estimates regarding potential market size for any indication may be materially different from what we discover
to exist at the time we commence commercialization, if any, for a product, which could result in significant changes in our business plan
and have a material adverse effect on our business, financial condition, results of operations and prospects.
20
Even if a potential product displays a favorable efficacy and safety profile
in preclinical and clinical studies, market acceptance of the product will not be fully known until after it is launched. Our efforts
to educate the medical community and third-party payors on the benefits of the product candidates may require significant resources and
may never be successful. If our product candidates are approved but fail to achieve an adequate level of acceptance by physicians, patients,
third-party payors, and others in the medical community, we will not be able to generate sufficient revenue for us to become or remain
profitable.
The insurance coverage and reimbursement
status of newly-approved products is uncertain. Failure to obtain or maintain adequate coverage and reimbursement for new or
current products could limit our ability to market those products and decrease our ability to generate revenue.
Some of our target patient populations are small, and,
accordingly, the pricing, coverage, and reimbursement of our respective product candidates, if approved, must be adequate to support our
commercial infrastructure. Our per-patient prices must be sufficient to recover our development and manufacturing costs and potentially
achieve profitability. Accordingly, the availability and adequacy of coverage and reimbursement by governmental and private payors are
essential for most patients to be able to afford expensive treatments such as our, assuming approval. Sales of our product candidates
will depend substantially, both domestically and abroad, on the extent to which the costs of our product candidates will be paid for by
health maintenance, managed care, pharmacy benefit, and similar healthcare management organizations, or reimbursed by government authorities,
private health insurers, and other third-party payors. If coverage and reimbursement are not available, or are available only to
limited levels, Silexion may not be able to successfully commercialize our product candidates. Even if coverage is provided, the approved
reimbursement amount may not be high enough to allow us to establish or maintain pricing sufficient to realize a return on our investment.
There is significant uncertainty related to the insurance
coverage and reimbursement of newly approved products. In the United States, the principal decisions about coverage and reimbursement
for new drugs are typically made by the Centers for Medicare & Medicaid Services, or CMS, an agency within the U.S. Department
of Health and Human Services, as CMS decides whether and to what extent a new drug will be covered and reimbursed under Medicare. Private
payors tend to follow the coverage reimbursement policies established by CMS to a substantial degree. It is difficult to predict what
CMS will decide with respect to reimbursement for products such as our's.
Outside the United States, international operations
are generally subject to extensive governmental price controls and other market regulations, and we believe the increasing emphasis on
cost-containment initiatives in Europe, Canada, and other countries has, and will continue to, put pressure on the pricing and usage
of our product candidates. In many countries, the prices of medical products are subject to varying price control mechanisms as part of
national health systems. In general, the prices of medicines under such systems are substantially lower than in the United States.
Other countries allow companies to fix their own prices for medicinal products, but monitor and control company profits. Additional foreign
price controls or other changes in pricing regulation could restrict the amount that we are able to charge for our product candidates.
Accordingly, in markets outside the United States, the reimbursement for our products may be reduced compared with the United States
and may be insufficient to generate commercially reasonable revenue and profits.
Moreover, increasing efforts by governmental and third-party payors
in the United States and abroad to cap or reduce healthcare costs may cause such organizations to limit both coverage and the level
of reimbursement for new products approved, and, as a result, they may not cover or provide adequate payment for our product candidates.
We expect to experience pricing pressures in connection with the sale of any of our product candidates due to the trend toward managed
healthcare, the increasing influence of health maintenance organizations, and additional legislative changes like the Inflation Reduction
Act. The downward pressure on healthcare costs in general, particularly prescription drugs and surgical procedures and other treatments,
has become very intense. As a result, increasingly high barriers are being erected to the entry of new products.
21
Healthcare legislative reform measures
may have a material adverse effect on our business and results of operations.
The business and financial condition of pharmaceutical
and biotechnology companies are affected by the efforts of governmental and third-party payors to contain or reduce the costs of
health care. The U.S. Congress has enacted legislation to reform the health care system. While we anticipate that this legislation
may, over time, increase the number of patients who have insurance coverage for pharmaceutical products, it also imposes cost containment
measures that may adversely affect the amount of reimbursement for pharmaceutical products. These measures include increasing the minimum
rebates for products covered by Medicaid programs and extending such rebates to drugs dispensed to Medicaid beneficiaries enrolled in
Medicaid managed care organizations as well as expansion of the 340(B) Public Health Services drug discount program. In addition,
such legislation contains a number of provisions designed to generate the revenues necessary to fund the coverage expansion. In foreign
jurisdictions there have been, and we expect that there will continue to be, a number of legislative and regulatory proposals aimed at
changing the health care system. For example, in some countries other than the United States, pricing of prescription drugs is subject
to government control and we expect to see continued efforts to reduce healthcare costs in international markets.
Some U.S. states are also considering legislation
that would control the prices of drugs, and state Medicaid programs are increasingly requesting manufacturers to pay supplemental rebates
and requiring prior authorization by the state program for use of any drug for which supplemental rebates are not being paid. Managed
care organizations continue to seek price discounts and, in some cases, to impose restrictions on the coverage of particular drugs. Government
efforts to reduce Medicaid expenses may lead to increased use of managed care organizations by Medicaid programs. This may result in managed
care organizations influencing prescription decisions for a larger segment of the population and a corresponding constraint on prices
and reimbursement for drugs. It is likely that federal and state legislatures and health agencies will continue to focus on additional
health care reform in the future although we are unable to predict what additional legislation or regulation, if any, relating to the
health care industry or third-party coverage and reimbursement may be enacted in the future or what effect such legislation or regulation
would have on our business. Our ability to commercialize any product candidates that Silexion may seek to commercialize, is highly dependent
on the extent to which coverage and reimbursement for these product candidates will be available from government payors, such as Medicare
and Medicaid, private health insurers, including managed care organizations, and other third-party payors, and any change in reimbursement
levels could materially and adversely affect our business. Further, the pendency or approval of future proposals or reforms could result
in a decrease in our share price or limit our ability to raise capital or to obtain strategic partnerships or licenses.
Our product candidates may be approved
and/or commercialized only in part, only as neoadjuvant therapy, or as an adjuvant therapy.
Our product candidates may be approved by the FDA or other
regulatory agencies only as a treatment to be provided in association with other treatments, if at all. For example, it may be possible
that our SIL-204B be used as adjunct therapy with chemotherapy treatments. Limitation in commercialization of such treatments, including
limitations in supply, call-back, clinical holds, changes in medical trends, changes in cost and/or reimbursement policy, may limit our
ability to commercialize our product candidates, either directly or via third parties.
22
Risks Related to Competition
The pharmaceutical market is intensely
competitive. If we are unable to compete effectively with existing drugs, new treatment methods and new technologies, we may be unable
to commercialize successfully any drugs that we develop.
The pharmaceutical market is intensely competitive and
rapidly changing. Many large pharmaceutical and biotechnology companies, academic institutions, governmental agencies and other public
and private research organizations are pursuing the development of novel drugs for the same diseases that we are targeting or expect to
target. Many of our competitors have:
●
much greater financial, technical and human resources than we have at every
        stage of the discovery, development, manufacture and commercialization of products;
●
more extensive experience in pre-clinical testing, conducting clinical
        trials, obtaining regulatory approvals, and in manufacturing, marketing and selling pharmaceutical products;
●
product candidates that are based on previously tested or accepted technologies;
●
products that have been approved or are in late stages of development; and
●
collaborative arrangements in our target markets with leading companies and
        research institutions.
We will face intense competition from drugs that have
already been, or may in the future become, approved and accepted by the medical community for the treatment of the conditions for which
we may develop drugs. We also expect to face competition from new drugs that enter the market. We believe a significant number of drugs
are currently under development, and may become commercially available in the future, for the treatment of conditions for which we may
try to develop drugs and therapies. These drugs may be more effective, safer, less expensive, or marketed and sold more effectively, than
any product we develop.
If we successfully develop our product candidates, and
obtains approval for them, we will face competition based on many different factors, including:
●
the safety and effectiveness of our product;
●
the ease with which our product can be administered and the extent to which
        patients accept relatively new routes of administration;
●
the timing and scope of regulatory approvals for our product;
●
the availability and cost of manufacturing, marketing and sales capabilities;
●
price;
●
reimbursement coverage; and
●
patent position.
Our competitors may develop or commercialize products
with significant advantages over any products we develop based on any of the factors listed above or on other factors. Our competitors
may therefore be more successful in commercializing their products than us, which could adversely affect our competitive position and
business. Competitive products may make any products we develop obsolete or noncompetitive before we can recover the expenses of developing
and commercializing our product candidates. Such competitors could also recruit our employees, which could negatively impact our level
of expertise and the ability to execute on our business plan.
We face competition from other companies
that are working to develop novel drugs and technology platforms using technology similar or in the same field as our's. If these
companies develop drugs more rapidly than us, or their technologies, including delivery technologies, are more effective, our ability
to successfully commercialize drugs may be adversely affected.
In addition to the competition we face from competing
drugs in general, we also face competition from other companies working to develop novel drugs using technology that competes more directly
with our own. We are aware of multiple companies that are working in the field of RNAi therapeutics and or KRAS inhibition, including
major pharmaceutical companies such as Bristol Myers Squibb/Mirati; Amgen; AstraZeneca; E.I. Lilly; Pfizer, Novartis International
AG, Takeda Pharmaceutical Company Limited and, and biopharmaceutical/pharmaceutical companies such as Alnylam, Revolutions Medicines;
Boehringer Ingelheim; Biomea Fusion Inc; Tekmira Pharmaceuticals Corporation, Arrowhead Research Corporation, Silence Therapeutics plc,
RXi Pharmaceuticals Corporation, Quark Pharmaceuticals, Inc. and Marina Biotech, Inc.
23
We also compete with companies working to develop antisense-based drugs.
Like RNAi therapeutics, antisense drugs target mRNAs in order to suppress the activity of specific genes. Ionis Pharmaceuticals, Inc.
is currently marketing an antisense drug and has several antisense product candidates in clinical trials, albeit none in the oncology
area at this time.
In addition to competition with respect to RNAi and with
respect to specific products, we face substantial competition to discover and develop safe and effective means to deliver RNAi based drugs
to the relevant cell and tissue types. Safe and effective means to deliver RNAi based drugs and to the relevant cell and tissue types
may be developed by our competitors, and our ability to successfully commercialize a competitive product would be adversely affected.
In addition, substantial resources are being expended by third parties in the effort to discover and develop a safe and effective means
of delivering RNAi based drugs and into the relevant cell and tissue types, both in academic laboratories and in the corporate sector.
Some of our competitors have substantially greater resources than we do, and if our competitors are able to negotiate exclusive access
to those delivery solutions developed by third parties, we may be unable to successfully commercialize our product candidates. Also, we
compete with companies working to develop non RNAi based treatments for solid tumor cancers. For example, Novartis is working on a SHP2
inhibitor, and Boehringer Ingelheim and Bayer SOS1 inhibitors; Threshold Pharmaceuticals (Threshold) is working to develop therapies that
target tumor hypoxia, a common characteristic of the tumor microenvironment. Even if we successfully develop our product candidates, and
obtain approval for them, other non RNAi treatments may be preferred, and we may not be successful in commercializing our product candidates
Also, we compete with companies commercializing and/or
working to develop drug delivery systems, including drug delivery systems for local (or regional) release. For example, various companies
are working on nanoparticle technologies, although these products would not give the extended-release delivery of SIL-204B, and other
companies on PLGA microparticles. In addition other companies such as SurModics, Inc. is a provider of drug delivery and surface modification
technologies to the healthcare industry, including local delivery of drugs from drug eluting stents. We compete with many companies commercializing
and/or working to develop drug delivery systems for specific indications, for example for local ocular (in the eye) release of drugs,
including degradable and non-degradable products.
Risks Related to Our Intellectual Property
If we are unable to obtain and maintain
effective patent rights for our product candidates or any future product candidates, we may not be able to compete effectively in our
markets.
We rely upon a combination of trade secret protection and confidentiality
agreements to protect the intellectual property related to our technologies and product candidates. As further described in detail below,
we have pending PCT application in several international (i.e. non-U.S.) locations relating the SIL-204B, which upon grant will provide
patent protection in the U.S., E.U. and other international jurisdictions. Our success depends in large part on our ability to obtain
and maintain patent and other intellectual property protection in the United States and in other countries with respect to our proprietary
technology and products.
We have sought to protect our proprietary position by
filing patent applications in the United States and in other countries, with respect to our novel technologies and products, which
are important to our business. This process is expensive and time consuming, and we may not be able to file and prosecute all necessary
or desirable patent applications at a reasonable cost or in a timely manner. It is also possible that we will fail to identify patentable
aspects of our research and development output before it is too late to obtain patent protection.
The patent position of biotechnology and pharmaceutical
companies generally is highly uncertain and involves complex legal and factual questions for which legal principles remain unsolved. The
patent applications that we own may fail to result in issued patents with claims that cover our product candidates in the United States
or in other foreign countries. There is no assurance that all potentially relevant prior art relating to our patents and patent applications
has been found, which can invalidate a patent or prevent a patent from issuing from a pending patent application. Even if patents do successfully
issue, and even if such patents cover our product candidates, third parties may challenge their validity, enforceability, or scope, which
may result in such patents being narrowed, found unenforceable or invalidated. Furthermore, even if they are unchallenged, our patents
and patent applications may not adequately protect our intellectual property, provide exclusivity for our product candidates, or prevent
others from designing around our claims. Any of these outcomes could impair our ability to prevent competition from third parties, which
may have an adverse impact on our business.
24
We cannot offer any assurances about which,
if any, patents will issue, the breadth of any such patent or whether any issued patents will be found invalid and unenforceable or will
be threatened by third parties. Any successful opposition to these patents or any other patents owned by or licensed to us after patent
issuance could deprive us of rights necessary for the successful commercialization of any product candidates that we may develop. Further,
if we encounter delays in regulatory approvals, the period of time during which we could market a product candidate under patent protection
could be reduced.
If we cannot obtain and maintain effective patent rights
for our product candidates, we may not be able to compete effectively, and our business and results of operations would be harmed.
We may not have sufficient patent
terms to effectively protect our products and business.
In the pharmaceutical and biotechnology industries, the
majority of an innovative product's commercial value is realized during our market exclusivity period. In the United States
and in some other countries, when market exclusivity expires and generic versions are approved and marketed or when biosimilars are introduced
(even if only for a competing product), there are usually very substantial and rapid declines in a product's revenues.
Patents have a limited lifespan. In the United States,
the natural expiration of a patent is generally 20 years after it is filed. Although various extensions may be available, the life
of a patent, and the protection it affords, is limited.
While patent term extensions under the Hatch-Waxman Act
in the United States and under supplementary protection certificates in Europe may be available to extend the patent exclusivity
term, we cannot provide any assurances that any such patent term extension will be obtained and, if so, for how long. In addition, upon
issuance in the United States, any patent term can be adjusted based on certain delays caused by the applicant(s) or the USPTO. For
example, a patent term can be reduced based on certain delays caused by the patent applicant during patent prosecution. If we do not have
sufficient patent terms or regulatory exclusivity to protect our products, our business and results of operations will be adversely affected.
Furthermore, manufacturers of innovative products as well as generic drug manufacturers may be able to design their products around our
patents and compete with Silexion using the resulting alternative technology. Absent relevant patent protection for a product, once the
exclusivity period expires, generic or alternative versions can be approved and marketed.
Generic and biosimilar product manufacturers as well as
other groups seeking financial gain are also increasingly seeking to challenge patents before they expire, and we could face earlier-than-expected competition
for any products at any time. Patents covering our key products may be subject to validity, enforceability and infringement challenges
in patent litigations and post-grant review patent office proceedings. It may be possible for these parties to successfully challenge
our rights and launch their versions of our drugs prior to the expiration of our intellectual property rights.
In addition, both the U.S. Congress and the U.S. FDA
have taken steps to promote the development and approval of generic drugs and biosimilar biologics, including by providing generic and
biosimilar developers a private right of action to obtain sufficient quantities of drug samples from the reference product's manufacturer
in order to conduct testing necessary to obtain approval for generic or biosimilar products.
25
Further, in December 2023, the Biden Administration
released a proposed framework that for the first time proposed that a drug's price can be a factor in determining that the drug
is not accessible to the public and therefore that the government could exercise "march-in rights" and license it to
a third party to manufacture. A comment period on the proposal ran through February 6, 2024, and we are not able to predict whether
a final rule will be adopted along the lines proposed and, if adopted, whether the government would seek to exercise march-in rights
for any of our products.
Patent law, policy or
rule changes could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or
defense of any issued patent.
Changes in either the patent laws or interpretation of the patent laws in
the United States and other countries may diminish the value of our patent or narrow the scope of our patent protection. The laws of foreign
countries may not protect our rights to the same extent as the laws of the United States. Publications of discoveries in the scientific
literature often lag behind the actual discoveries, and patent applications in the United States and other jurisdictions are typically
not published until 18 months after filing, or in some cases not at all. We therefore cannot be certain that we or our licensors were
the first to make the invention claimed in our owned and licensed patent or pending applications, or that it or our licensor were the
first to file for patent protection of such inventions. Assuming the other requirements for patentability are met, in the United States
prior to March 15, 2013, the first to make the claimed invention is entitled to the patent, while outside the United States, the first
to file a patent application is entitled to the patent. After March 15, 2013, under the Leahy-Smith America Invents Act, or the Leahy-Smith
Act, enacted on September 16, 2011, the United States has moved to a first to file system. The Leahy-Smith Act also includes a number
of significant changes that affect the way patent applications will be prosecuted and may also affect patent litigation. The USPTO recently
developed new regulations and procedures to govern administration of the Leahy-Smith Act, and accordingly, it is not clear what, if any,
impact the Leahy-Smith Act will have on the operation of our business. The Leahy-Smith Act and our implementation could increase the uncertainties
and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents, all of which could
have a material adverse effect on our business and financial condition.
In addition, patent reform legislation may pass in the
future that could lead to additional uncertainties and increased costs surrounding the prosecution, enforcement and defense of our patents
and pending patent applications. Recent U.S. Supreme Court rulings have narrowed the scope of patent protection available in certain
circumstances and weakened the rights of patent owners in certain situations. Furthermore, the U.S. Supreme Court and the U.S. Court
of Appeals for the Federal Circuit have made, and will likely continue to make, changes in how the patent laws of the United States
are interpreted. Similarly, foreign countries have made, and will likely continue to make, changes in how the patent laws in their respective
jurisdictions are interpreted. We cannot predict future changes in the interpretation of patent laws or changes to patent laws that might
be enacted into law by United States and foreign legislative bodies. Those changes may materially affect our patents or patent applications
and our ability to obtain additional patent protection in the future.
The United States federal government retains certain
rights in inventions produced with our financial assistance under the Patent and Trademark Law Amendments Act, or the Bayh-Dole Act.
The federal government retains a "nonexclusive, nontransferable, irrevocable, paid-up license" for our own benefit. The
Bayh-Dole Act also provides federal agencies with "march-in rights." March-in rights allow the government,
in specified circumstances, to require the contractor or successors in title to the patent to grant a "nonexclusive, partially exclusive,
or exclusive license" to a "responsible applicant or applicants." If the patent owner refuses to do so, the government
may grant the license itself.
If we are unable to maintain effective
proprietary rights for our product candidates or any future product candidates, Silexion may not be able to compete effectively in our
markets.
In addition to the protection afforded by any patents
that may be granted, we rely on trade secret protection and confidentiality agreements to protect proprietary know-how that is not
patentable or that we elect not to patent, processes for which patents are difficult to enforce and any other elements of our product
candidate discovery and development processes that involve proprietary know-how, information or technology that is not covered by patents.
However, trade secrets can be difficult to protect. we seek to protect our proprietary technology and processes, in part, by entering
into confidentiality agreements with our employees, consultants, scientific advisors, and contractors. We also seek to preserve the integrity
and confidentiality of our data and trade secrets by maintaining physical security of our premises and physical and electronic security
of our information technology systems. While we have confidence in these individuals, organizations and systems, agreements or security
measures may be breached, and we may not have adequate remedies for any breach. In addition, our trade secrets may otherwise become known
or be independently discovered by competitors.
26
Although we expect all of our employees and consultants
to assign their inventions to it, and all of our employees, consultants, advisors, and any third parties who have access to our proprietary
know-how, information, or technology to enter into confidentiality agreements, we cannot provide any assurances that all such agreements
have been duly executed or that our trade secrets and other confidential proprietary information will not be disclosed or that competitors
will not otherwise gain access to our trade secrets or independently develop substantially equivalent information and techniques. Misappropriation
or unauthorized disclosure of our trade secrets could impair our competitive position and may have a material adverse effect on our business.
Additionally, if the steps taken to maintain our trade secrets are deemed inadequate, we may have insufficient recourse against third
parties for misappropriating the trade secret.
Intellectual property rights of third
parties could adversely affect our ability to commercialize our product candidates, and we might be required to litigate or obtain licenses
from third parties in order to develop or market our product candidate. Such litigation or licenses could be costly or not available on
commercially reasonable terms.
Because the RNAi intellectual property landscape is still evolving, it is
difficult to conclusively assess our freedom to operate without infringing on third party rights. There are numerous companies that have
pending patent applications and issued patents broadly directed to RNAi generally and to RNAi delivery technologies. Our competitive
position may suffer if patents issued to third parties or other third party intellectual property rights cover our products or elements
thereof, or our manufacture or uses relevant to our development plans. In such cases, we may not be in a position to develop or commercialize
products or our product candidate unless we successfully pursue litigation to nullify or invalidate the third party intellectual property
right concerned, or enter into a license agreement with the intellectual property right holder, if available on commercially reasonable
terms. we are also aware of pending patent applications, and there may be others of which we are not aware, that if they result in issued
patents, could be alleged to be infringed by our product candidates. If such an infringement claim should be brought and be successful,
we may be required to pay substantial damages, be forced to abandon our product candidates or seek a license from any patent holders.
No assurances can be given that a license will be available on commercially reasonable terms, if at all. It is also possible that we have
failed to identify relevant third party patents or applications. For example, U.S. applications filed before November 29, 2000 and certain
U.S. applications filed after that date that will not be filed outside the U.S. remain confidential until patents issue. Patent applications
in the U.S. and elsewhere are published approximately 18 months after the earliest filing for which priority is claimed, with such earliest
filing date being commonly referred to as the priority date. Therefore, patent applications covering our product candidates or platform
technology could have been filed by others without our knowledge. Additionally, pending patent applications which have been published
can, subject to certain limitations, be later amended in a manner that could cover our platform technologies, our product candidates or
the use of our product candidates. Third party intellectual property right holders may also actively bring infringement claims against
Us. We cannot guarantee that we will be able to successfully settle or otherwise resolve such infringement claims. If we are unable to
successfully settle future claims on terms acceptable to us, we may be required to engage in or continue costly, unpredictable and time-consuming
litigation and may be prevented from or experience substantial delays in pursuing the development of and/or marketing of our product candidates.
If we fail in any such dispute, in addition to being forced to pay damages, we may be temporarily or permanently prohibited from commercializing
our product candidates that are held to be infringing. We might, if possible, also be forced to redesign our product candidates so that
we no longer infringes the third party intellectual property rights. Any of these events, even if we were ultimately to prevail, could
require us to divert substantial financial and management resources that we would otherwise be able to devote to our business.
27
Third-party claims of intellectual
property infringement may prevent or delay our development and commercialization efforts.
Our commercial success depends in part on our avoiding
infringement of the patents and proprietary rights of third parties. There have been many lawsuits and other proceedings involving patent
and other intellectual property rights in the biotechnology and pharmaceutical industries, including patent infringement lawsuits, interferences,
oppositions, and reexamination proceedings before the USPTO and corresponding foreign patent offices. Numerous U.S. and foreign issued
patents and pending patent applications, which are owned by third parties, exist in the fields in which we are developing product candidates.
As the biotechnology and pharmaceutical industries expand and more patents are issued, the risk increases that our product candidates
may be subject to claims of infringement of the patent rights of third parties.
Third parties may assert that we are employing our proprietary technology
without authorization. There may be third-party patents or patent applications with claims to materials, formulations, methods of manufacture,
or methods for treatment related to the use or manufacture of our product candidates. Because patent applications can take many years
to issue, there may be currently pending patent applications that may later result in issued patents that our product candidates may infringe.
In addition, third parties may obtain patents in the future and claim that use of our technologies infringes upon these patents. If any
third-party patents were held by a court of competent jurisdiction to cover the manufacturing process of any of our product candidates,
any molecules formed during the manufacturing process or any final product itself, the holders of any such patents may be able to block
our ability to commercialize such product candidates unless we obtain a license under the applicable patents, or until such patents expire
or are finally determined to be invalid or unenforceable.
Similarly, if any third-party patents were held by a court of competent jurisdiction
to cover aspects of our formulations, processes for manufacture, or methods of use, the holders of any such patents may be able to block
our ability to develop and commercialize the applicable product candidate unless we obtain a license or until such patent expires or is
finally determined to be invalid or unenforceable. In either case, such a license may not be available on commercially reasonable terms
or at all.
Parties making claims against us may obtain injunctive or other equitable
relief, which could effectively block our ability to further develop and commercialize one or more of our product candidates. Defense
of these claims, regardless of their merit, would involve substantial litigation expense and would be a substantial diversion of employee
resources from our business. In the event of a successful claim of infringement against us, we may have to pay substantial damages, including
treble damages and attorneys' fees for willful infringement, pay royalties, redesign our infringing products or obtain one or more
licenses from third parties, which may be impossible or require substantial time and monetary expenditure.
We may not be successful in obtaining
or maintaining necessary rights to our product candidates through acquisitions and in-licenses.
Because our programs may require the use of proprietary rights held by third
parties, the growth of our business will likely depend in part on our ability to acquire, in-license, or use these proprietary rights.
In addition, our product candidates may require specific formulations to work effectively and efficiently and the rights to these formulations
may be held by others. We may be unable to acquire or in-license any compositions, methods of use, processes, or other third-party intellectual
property rights from third parties that we identify as necessary for our product candidates. The licensing and acquisition of third-party
intellectual property rights is a competitive area, and a number of more established companies are also pursuing strategies to license
or acquire third-party intellectual property rights that we may consider attractive. These established companies may have a competitive
advantage over us due to their size, cash resources, and greater clinical development and commercialization capabilities.
28
For example, we sometimes collaborates with U.S. and foreign academic institutions
to accelerate our preclinical research or development under written agreements with these institutions. Typically, these institutions
provide we with an option to negotiate a license to any of the institution's rights in technology resulting from the collaboration.
Regardless of such option, we may be unable to negotiate a license within the specified timeframe or under terms that are acceptable to
us. If we are unable to do so, the institution may offer the intellectual property rights to other parties, potentially blocking our ability
to pursue our program.
In addition, companies that perceive us to be a competitor
may be unwilling to assign or license rights to us. We also may be unable to license or acquire third-party intellectual property
rights on terms that would allow us to make an appropriate return on our investment. If we are unable to successfully obtain rights to
required third-party intellectual property rights, we may have to abandon development of that program and our business and financial
condition could suffer.
We may be involved in lawsuits to
protect or enforce our current patent applications or future patents, which could be expensive, time consuming, and unsuccessful.
Competitors may infringe our current patent
applications, future patents or the patents of our licensors. If we or a future licensing partner were to initiate legal proceedings against
a third party to enforce a patent covering one of our product candidates, the defendant could counterclaim that the patent covering our
product candidate is invalid and/or unenforceable. In patent litigation in the United States, defendant counterclaims alleging invalidity
and/or unenforceability are commonplace. Grounds for a validity challenge could be an alleged failure to meet any of several statutory
requirements, including lack of novelty, obviousness, or non-enablement. Grounds for an unenforceability assertion could be an allegation
that someone connected with prosecution of the patent withheld relevant information from the USPTO, or made a misleading statement, during
prosecution. The outcome following legal assertions of invalidity and unenforceability is unpredictable.
Interference proceedings provoked by third parties or brought by us or declared
by the USPTO may be necessary to determine the priority of inventions with respect to our patent or patent applications or those of our
licensors. An unfavorable outcome could require us to cease using the related technology or to attempt to license rights to us from the
prevailing party. Our business could be harmed if the prevailing party does not offer us a license on commercially reasonable terms. Our
defense of litigation or interference proceedings may fail and, even if successful, may result in substantial costs and distract our management
and other employees. In addition, the uncertainties associated with litigation could have a material adverse effect on our ability to
raise the funds necessary to continue our clinical trials, continue our research programs, license necessary technology from third parties,
or enter into development partnerships that would help us bring our product candidates to market.
Furthermore, because of the substantial amount of discovery
required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised
by disclosure during this type of litigation. There could also be public announcements of the results of hearings, motions, or other interim
proceedings or developments. If securities analysts or investors perceive these results to be negative, it could have a material adverse
effect on the price of our ordinary shares.
We may be subject to claims that our
employees, consultants, or independent contractors have wrongfully used or disclosed confidential information of third parties or that
our employees have wrongfully used or disclosed alleged trade secrets of their former employers.
We employ or engage as consultants or subcontractors individuals who were
previously employed at universities or other biotechnology or pharmaceutical companies, including our competitors or potential competitors.
Although we try to ensure that our employees, consultants, and independent contractors do not use the proprietary information or know-how
of others in their work for us, we may be subject to claims that we or our employees, consultants, or independent contractors have inadvertently
or otherwise used or disclosed intellectual property, including trade secrets or other proprietary information, of any of our employees'
former employers or other third parties. Litigation may be necessary to defend against these claims. If we fail in defending any such
claims, in addition to paying monetary damages, we may lose valuable intellectual property rights or personnel, which could adversely
impact our business. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a
distraction to management and other employees.
29
We may be subject to
claims challenging the inventorship of our current patent application or future patents and other intellectual property.
We
may be subject to claims that former employees, collaborators or other third parties have an interest in or right to compensation with
respect to our current patent application, future patents or other intellectual property as an inventor or co-inventor. For example, we
may have inventorship disputes arise from conflicting obligations of consultants or others who are involved in developing our product
candidates. Litigation may be necessary to defend against these and other claims challenging inventorship or claiming the right to compensation.
If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights, such
as exclusive ownership of, or right to use, valuable intellectual property. Such an outcome could have a material adverse effect on our
business. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction
to management and other employees. To the extent that our employees have not effectively waived the right to compensation with respect
to inventions that they helped create, they may be able to assert claims for compensation with respect to our future revenue. As a result,
we may receive less revenue from future products if such claims are successful which in turn could impact our future profitability.
We may not be able to protect our
intellectual property rights throughout the world.
Filing, prosecuting, and defending patents on product
candidates in all countries throughout the world would be prohibitively expensive, and our intellectual property rights in some countries
outside the United States can be less extensive than those in the United States. In addition, the laws of some foreign countries
do not protect intellectual property rights to the same extent as federal and state laws in the United States.
Competitors may use our technologies in
jurisdictions where we have not obtained patent protection to develop their own products and may also export otherwise infringing products
to territories where we have patent protection but where enforcement is not as strong as that in the United States. These products
may compete with Silexion's products and our current patent application, future patents or other intellectual property rights may
not be effective or sufficient to prevent them from competing.
Many companies have encountered significant problems in protecting and defending intellectual
property rights in foreign jurisdictions. The legal systems of certain countries, particularly certain developing countries, do not favor
the enforcement of patents, trade secrets, and other intellectual property protection, particularly those relating to biotechnology products,
which could make it difficult for us to stop the infringement of our patents or marketing of competing products in violation of our proprietary
rights generally. Proceedings to enforce our patent rights in foreign jurisdictions, whether or not successful, could result in substantial
costs and divert our efforts and attention from other aspects of our business, could put our current patent applications or future patents
at risk of being invalidated or interpreted narrowly and our patent applications at risk of not issuing and could provoke third parties
to assert claims against us. We may not prevail in any lawsuits that we initiate and the damages or other remedies awarded, if any, may
not be commercially meaningful. Accordingly, our efforts to enforce our intellectual property rights around the world may be inadequate
to obtain a significant commercial advantage from the intellectual property that we develop or license.
Risks Related to our Human Resources
The loss of the services of our key
personnel would negatively affect our business.
To successfully develop our drug candidates, we must be
able to attract and retain highly skilled personnel, including consultants and employees. The retention of their services cannot be guaranteed.
Our failure to retain or recruit such professionals might impair our performance and materially affect our technological and product development
capabilities and our product marketing ability. Our future success depends to a large extent on the continued services of our senior management
and key personnel, including in particular, Ilan Hadar, Dr. Mitchell Shirvan, Dr. Racheli Malka and Michal Yaron. Any loss of
the services of members of our senior management or key employees would adversely affect our business. We do not currently maintain key-person insurance
on the lives of any of our key personnel.
30
We may be unable to attract, develop
and retain additional employees required for our development and future success.
Our success is largely dependent on the
performance of our management team and certain key employees and our continuing ability to attract, develop, motivate and retain highly
qualified and skilled employees. Qualified individuals are in high demand, and we may incur significant costs to attract and retain them.
The inability to attract suitably qualified persons when needed, could prevent us from executing on our business plan and strategy, and
we may be unable to find adequate replacements on a timely basis, or at all.
Risks Related to Our Operations
Our business and operations, or those
of our CROs or third parties, may suffer in the event of computer system failures, cyberattacks or deficiencies in our cybersecurity,
which could materially affect our results.
We receive, generate and store significant and increasing
volumes of sensitive information, such as health information, insurance information and other potentially personally identifiable information.
We faces a number of risks relative to protecting the computer systems we rely on and this critical information, including loss of access
risk, inappropriate use or disclosure, inappropriate modification and the risk of being unable to adequately monitor, audit and modify
our controls over our critical information. This risk extends to the computer systems and information of any collaboration partners, medical
institutions, clinical investigators, CROs, contract laboratories, or other third parties involved in our business.
Despite the implementation of security measures, our information
technology systems, as well as those of CROs or other third parties with which we have relationships, are vulnerable to attack and damage
from computer viruses and malware (e.g., ransomware), unauthorized access, natural and manmade disasters, terrorism, war and telecommunication
and electrical failures, malfeasance by external or internal parties, and human error (e.g., social engineering, phishing). Attacks upon
information technology systems are increasing in their frequency, levels of persistence, sophistication and intensity, and are being conducted
by sophisticated and organized groups and individuals with a wide range of motives and expertise. Furthermore, because the technologies
used to obtain unauthorized access to, or to sabotage or disrupt, systems change frequently and often are not recognized until launched
against a target, we may be unable to anticipate these techniques or implement adequate preventative measures. we may also experience
security breaches that may remain undetected for an extended period. We may not be able to anticipate all types of security threats, and
even if identified, we may be unable to adequately investigate or remediate incidents or breaches due to attackers increasingly using
tools and techniques that are designed to circumvent controls, to avoid detection, and to remove or obfuscate forensic evidence. We may
also face increased cybersecurity risks due to our reliance on internet technology and the number of our and our service providers'
employees who are (and may continue to be) working remotely, which may create additional opportunities for cybercriminals to exploit vulnerabilities.
The White House, SEC and other regulators have also increased their focus on companies' cybersecurity vulnerabilities and risks.
Our CROs and certain of our service providers are from
time to time, subject to cyberattacks and security incidents. While we have not to our knowledge experienced any significant system failure,
accident or security breach to date, if such an event were to occur and cause interruptions in our or our critical third parties'
operations, it could result in delays and/or material disruptions of our research and development programs, our operations and ultimately,
our financial results. For example, the loss of trial data from completed, ongoing or planned trials could result in delays in our regulatory
approval efforts and significantly increase our costs to recover or reproduce the data. Likewise, we rely on third parties for the manufacture
of our product candidates and to conduct clinical trials, and similar events relating to their computer systems could also adversely impact
our business. Further, due to the current political uncertainty involving Hamas in Gaza, Hezbollah in Lebanon, Russia and Ukraine, there
is an increased likelihood that the tensions could result in cyberattacks or cybersecurity incidents that could either directly or indirectly
impact our or our critical third parties' operations. To the extent that any disruption or security breach were to result in a loss
of or damage to data or applications, or inappropriate disclosure of personal, confidential or proprietary information, we could incur
liability due to delays in the development and commercialization of our product candidates or other business activities and/or due to
reputational harm, litigation, regulatory investigations and enforcement, fines and penalties, or increased costs of compliance and system
remediation.
31
Our existing general liability and cyber
liability insurance policies may not cover, or may cover only a portion of, any potential claims related to security breaches to which
we are exposed or may not be adequate to indemnify us for all or any portion of liabilities that may be imposed. We also cannot be certain
that our existing insurance coverage will continue to be available on acceptable terms or in amounts sufficient to cover the potentially
significant losses that may result from a security incident or breach or that the insurer will not deny coverage of any future claim.
If the information technology systems of our CROs or other service providers become subject to disruptions or security breaches, we may
have insufficient recites against such third parties and we may have to expend significant resources to mitigate the impact of such an
event, and to develop and implement protections to prevent future events of this nature from occurring.
If product liability lawsuits are
brought against us, we may incur substantial liabilities and may be required to limit commercialization of any approved products.
We face an inherent risk of product liability as a result of the clinical
testing of product candidates and will face an even greater risk if we commercialize any products. For example, we may be sued if any
product candidate we develop causes or is perceived to cause injury or is found to be otherwise unsuitable during clinical testing, manufacturing,
marketing or sale. Any such product liability claims may include allegations of defects in manufacturing, defects in design, a failure
to warn of dangers inherent in the product, negligence, strict liability or a breach of warranties. Claims could also be asserted under
state consumer protection acts. If we cannot successfully defend itself against product liability claims, we may incur substantial liabilities
or be required to limit commercialization of any approved products. Even successful defense would require significant financial and management
resources.
Regardless of the merits or eventual outcome, liability
claims may result in:
●
decreased demand for any approved product;
●
injury to our reputation;
●
withdrawal of clinical trial participants;
●
initiation of investigations by regulators;
●
costs to defend the related litigation;
●
a diversion of management's time and our resources;
●
substantial monetary awards to trial participants or patients;
●
product recalls, withdrawals or labeling, marketing or promotional restrictions;
●
exhaustion of any available insurance and our capital resources and potential
        increase in our insurance premiums and/or retention amounts; and
●
the inability to commercialize any product candidate.
Our inability to obtain sufficient product liability insurance
at an acceptable cost to protect against potential product liability claims could prevent or inhibit the commercialization of products
we develop, alone or with collaboration partners.
32
Insurance coverage is increasingly expensive.
we may not be able to maintain insurance at a reasonable cost or in an amount adequate to satisfy any liability that may arise, if at
all. Our insurance policy contains various exclusions, and we may be subject to a product liability claim for which we have no coverage.
We may have to pay any amounts awarded by a court or negotiated in a settlement that exceed our coverage limitations or that are not covered
by our insurance, and we may not have, or be able to obtain, sufficient capital to pay such amounts. Even if our agreements with any current
or future collaborator entitle us to indemnification against losses, such indemnification is limited and may not be available or adequate
should any claim arise.
We may not be able to successfully
identify and execute strategic alliances or other relationships with third parties or to successfully manage the impacts of acquisitions,
dispositions or relationships on our operations.
We currently have, and may expand the scope of, and may in the future enter
into, strategic alliances with third parties that it believes will complement or augment our existing business. Our ability to complete
further such strategic alliances is dependent upon, and may be limited by, among other things, the availability of suitable candidates
and capital. In addition, strategic alliances could present unforeseen integration obstacles or costs, may not enhance our business and
may involve risks that could adversely affect us, including the investment of significant amounts of management time that may be diverted
from operations in order to pursue and complete such transactions or maintain such strategic alliances. Future strategic alliances could
result in the incurrence of debt, costs and contingent liabilities, and there can be no assurance that future strategic alliances will
achieve, or that our existing strategic alliances will continue to achieve, the expected benefits to our business or that we will be able
to consummate future strategic alliances on satisfactory terms, or at all.
Although
we do not currently plan to engage in other material strategic transactions, such as acquisitions, we may from time to time consider such
transactions. Material strategic transactions involve a number of risks, including:
●
the potential disruption of our ongoing business;
●
the distraction of management away from the ongoing oversight of our existing
        business activities;
●
incurring additional indebtedness;
●
the anticipated benefits and cost savings of those transactions not being
        realized fully, or at all, or taking longer to realize than anticipated;
●
an increase in the scope and complexity of our operations; and
●
the loss or reduction of control over certain of our assets.
A strategic transaction may result in a significant change
in the nature of our business, operations and strategy, and we may encounter unforeseen obstacles or costs in implementing a strategic
transaction or integrating any acquired business into our operations.
Risks Related to our Operations in Israel and
China
Conditions in the Middle East and
in Israel may harm our operations.
Our executive offices and research and development facilities are located
in Israel. Most of our officers and directors are residents of Israel. Since the establishment of the State of Israel in 1948, a number
of armed conflicts have taken place between Israel and its neighboring countries, and between Israel and neighboring terrorist organizations,
including Hamas (an Islamist terrorist and political group in the Gaza Strip) and Hezbollah (an Islamist terrorist and political group
in Lebanon).
33
In particular, on October 7, 2023, Hamas terrorists
infiltrated Israel's southern border from the Gaza Strip and conducted a series of attacks on civilian and military targets. Hamas
also launched extensive rocket attacks on the Israeli population and industrial centers located along Israel's border with the Gaza
Strip and in other areas within the State of Israel. These attacks resulted in thousands of deaths and injuries, and Hamas additionally
kidnapped many Israeli civilians and soldiers. Following the attack, Israel's security cabinet declared war against Hamas and commenced
a military campaign against Hamas and these terrorist organizations, in parallel to continued rocket and terror attacks against Israel
by Hamas. Upon the start of the war, the Israeli military began to call-up reservists for active duty.
In parallel with the war against Hamas that began in October 2023, there have been continued
hostilities along Israel's northern border, as the Hezbollah terrorist organization based in Lebanon has conducted rocket, drone,
and, more recently, missile attacks against Israel, and there have also been rocket, drone and missile attacks against Israel by the Houthi
movement in Yemen as well continued hostilities with various rebel militia groups in Syria and Iraq. The hostilities with Hezbollah
have escalated recently, prompting Israel to send its ground forces into southern Lebanon to destroy terrorist positions and infrastructure
used by Hezbollah for attacks on northern and central Israel, which had caused the displacement of residents in northern Israel since
early in the war. In November 2024, a ceasefire was brokered between Israel and Hezbollah.
Iran has furthermore entered the conflict against Israel, shooting ballistic missiles
at Israel twice during the current war (on April 13, 2024 and October 1, 2024). Iran is furthermore widely believed to be developing
nuclear weapons, with which it has threatened Israel and is also believed to have a strong influence among extremist groups in the
region, such as Hamas in Gaza, Hezbollah in Lebanon, the Houthi movement in Yemen and various rebel militia groups in Syria and Iraq.
There is a risk that other terrorist organizations, including Palestinian military organizations in the West Bank as well as other hostile
countries will join the hostilities against Israel. Such clashes may escalate into a greater regional conflict.
Armed conflicts, terrorist activities or political instability in Israel
or in the broader Middle East have been, and could continue to, in a more severe way, adversely affect business conditions in Israel,
and could harm our results of operations and make it more difficult for us to raise capital. Parties with whom we do business may decline
to travel to Israel during periods of heightened unrest or tension, forcing Silexion to make alternative arrangements when necessary in
order to meet our business partners face to face. In addition, the political and security situation in Israel may result in parties with
whom we have agreements involving performance in Israel claiming that they are not obligated to perform their commitments under those
agreements pursuant to force majeure provisions in such agreements. Further, in the past, the State of Israel and Israeli companies have
been subjected to economic boycotts. Several countries still restrict business with the State of Israel and with Israeli companies. These
restrictive laws and policies may have an adverse impact on our operating results, financial condition or the expansion of our business.
The interruption or curtailment of trade between Israel and its trading partners could adversely affect our operations and results of
operations.
Our commercial insurance does not cover losses that may
occur as a result of events associated with the security situation in the Middle East. Although the Israeli government currently covers
the reinstatement value of direct damages that are caused by terrorist attacks or acts of war, we cannot assure you that this government
coverage will be maintained. Any losses or damages incurred by us could have a material adverse effect on our business.
Finally, political conditions within Israel may also affect
our operations. Israel held five general elections between 2019 and 2022, and prior to October 2023, the Israeli government pursued
extensive changes to Israel's judicial system, which sparked extensive political debate and unrest. To date, these initiatives have
been substantially put on hold. Actual or perceived political instability in Israel or any negative changes in the political environment,
may individually or in the aggregate adversely affect the Israeli economy and, in turn, our business, financial condition, results of
operations and growth prospects.
34
It may be difficult to enforce a U.S. judgment
against us, our officers or our directors or to assert U.S. securities law claims in Israel.
Service of process upon us and upon our directors and
officers, who reside outside the U.S., may be difficult to obtain within the U.S. In addition, because substantially all of our assets
and most of our directors and officers are located outside the U.S., any judgment obtained in the U.S. against us or any of our directors
and officers may not be collectible within the U.S. There is a doubt as to the enforceability of civil liabilities under the Securities
Act or the Exchange Act pursuant to original actions instituted in Israel. Subject to particular time limitations and provided certain
conditions are met, executory judgments of a U.S. court for monetary damages in civil matters may be enforced by an Israeli court.
Under applicable U.S. and Israeli
law, we may not be able to enforce covenants not to compete and therefore may be unable to prevent our competitors from benefiting from
the expertise of some of our former employees. In addition, employees may be entitled to seek compensation for their inventions irrespective
of their agreements with us, which in turn could impact our future profitability.
We generally enter into non-competition agreements
with our employees and key consultants. These agreements prohibit our employees and key consultants, if they cease working for us, from
competing directly with it or working for our competitors or clients for a limited period of time. We may be unable to enforce these agreements
under the laws of the jurisdictions in which our employees work and it may be difficult for it to restrict our competitors from benefitting
from the expertise our former employees or consultants developed while working for us. For example, Israeli courts have required employers
seeking to enforce non-compete undertakings of a former employee to demonstrate that the competitive activities of the former employee
will harm one of a limited number of material interests of the employer which have been recognized by the courts, such as the secrecy
of a company's confidential commercial information or the protection of our intellectual property. If it cannot demonstrate that
such interests will be harmed, we may be unable to prevent our competitors from benefiting from the expertise of our former employees
or consultants and our ability to remain competitive may be diminished.
In addition, Chapter 8 of the Israeli Patents Law, 5727-1967,
or the Patents Law, deals with inventions made in the course of an employee's service and during his or her term of employment,
whether or not the invention is patentable, or service inventions. Section 134 of the Patents Law, sets forth that if there is no
agreement which explicitly determines whether the employee is entitled to compensation for the service inventions and the extent and terms
of such compensation, such determination will be made by the Compensation and Rewards Committee, a statutory committee of the Israeli
Patents Office. As a result, it is unclear if, and to what extent, our research and development employees may be able to claim compensation
with respect to our future revenue. As a result, Silexion may receive less revenue from future products if such claims are successful,
which in turn could impact our future profitability.
Governmental control of currency conversion
in China may limit us our ability to utilize our cash balance effectively and affect the value of our investment.
We may be reliant on dividend payments, equity investments,
or other forms of cash infusion from PRC subsidiaries to fund any cash and financing requirements it may have. The PRC government imposes
controls on the convertibility of the Renminbi into foreign currencies and, in certain cases, the remittance of currency out of China.
Under existing PRC foreign exchange regulations, payments of current account items, including profit distributions, interest payments
and trade and service-related foreign exchange transactions, can be made in foreign currencies without prior approval of the State
Administration of Foreign Exchange ("SAFE") (the foreign exchange management administrative body of the People's Bank
of China) by complying with certain procedural requirements. Specifically, under the existing exchange restrictions, without prior approval
of SAFE, cash generated from the operations of PRC subsidiaries in China may be used to pay dividends to parent companies. However, approval
from or registration with appropriate government authorities is required where Renminbi is to be converted into foreign currency and remitted
out of China to pay capital expenses such as the repayment of loans denominated in foreign currencies. As a result, we would need to obtain
SAFE approval to use cash held at PRC subsidiaries to pay outside China, or to make other capital expenditure payments outside China in
a currency other than Renminbi. The PRC government may at its discretion restrict access to foreign currencies for current account transactions
in the future. If the foreign exchange control system prevents us from obtaining sufficient foreign currencies to satisfy its foreign
currency demands, it may not be able to pay dividends in foreign currencies to our shareholders.
35
PRC regulations relating to dividends may restrict the
ability of our PRC subsidiaries to make payments to New Silexion, which may have an adverse effect on our ability to conduct our business.
Under PRC laws and regulations, our PRC subsidiaries (which
are each "wholly foreign-owned enterprises" incorporated in Mainland China) are only permitted to pay dividends out of
their respective accumulated profits, as determined in accordance with PRC accounting standards and regulations. In addition, prior to
distribution of any dividends, our subsidiaries in China are each required to compensate their past losses with after-tax profits
each year, if any, and then set aside at least 10% of their after-tax profits each year to fund a statutory reserve until such reserve
reaches 50% of the subsidiary's total registered capital. Additionally, if our PRC subsidiaries incur debt on their own behalf in
the future, the instruments governing their debt may restrict their ability to pay dividends or make other distributions to us.
Any limitation on the ability of our PRC subsidiaries
to pay dividends or make other distributions to us could adversely limit our ability to grow, make investments or acquisitions that could
be beneficial to our business, pay dividends, or otherwise fund and conduct our business.
Risks Related to this Offering
The
        sale of a substantial amount of our ordinary shares, including resale of the ordinary shares held by the Selling Securityholders in the
        public market could adversely affect the prevailing market price of our ordinary shares.
We are registering for resale 2,377,030 ordinary shares. Sales
of substantial amounts of shares of our ordinary shares in the public market, or the perception that such sales might occur, could adversely
affect the market price of our ordinary shares, and the market value of our other securities. We cannot predict if and when the Selling
Securityholders may sell such shares in the public markets. Furthermore, in the future, we may issue additional ordinary shares or other
equity or debt securities convertible into ordinary shares. Any such issuance could result in substantial dilution to our existing shareholders
and could cause our share price to decline.
36
Investors who buy shares at different times from the Selling Securityholders
will likely pay different prices.
The Selling Securityholders will have discretion, subject to market demand, to vary
the timing, prices, and numbers of ordinary shares issuable upon the exercise of the warrants sold by them pursuant to this prospectus.
If and when they do elect to sell ordinary shares issuable upon the exercise of the warrants, the Selling Securityholders may sell all,
some or none of such shares at any time or from time to time at their discretion and at different prices. As a result, investors who purchase
our securities from Selling Securityholders in this offering at different times will likely pay different prices for those securities,
and so may experience different levels of dilution and in some cases substantial dilution and different outcomes in their investment results.
Investors may experience a decline in the value of the securities they purchase from the Selling Securityholders as a result of future
sales made by Selling Securityholders to other investors at prices lower than the prices such earlier investors paid for their securities
from the Selling Securityholders.
There can be no assurance that the New Warrants will ever be in
the money at the time they become exercisable or otherwise, and they may expire worthless.
The exercise price of the New Warrants is $1.50 per ordinary share. There is no guarantee
that the  warrants will ever be in the money prior to their expiration, and as such, the warrants may expire worthless. We believe
that the likelihood that warrant holders determine to exercise their warrants, and therefore the amount of cash proceeds that we would
receive, is dependent upon the market price of our New Silexion ordinary shares. If the market price for our New Silexion ordinary shares
is less than the exercise price of the warrants (on a per share basis), we believe that warrant holders will be very unlikely to exercise
any of their warrants, and accordingly, we will not receive any such exercise proceeds. There is no assurance that the warrants will be
"in the money" prior to their expiration or that the warrant holders will exercise their warrants. As of February 11, 2025,
the closing price of our ordinary shares was $1.38 per share.
37
Risks Related to Owning Our Ordinary Shares
The price of our ordinary shares and
our warrants may be volatile, and the value of our ordinary shares and our warrants may decline.
We cannot predict the prices at which our ordinary
shares or warrants will trade. The price of our ordinary shares and our warrants may not bear any relation to any established criteria
of the value of our business and prospects. In addition, the trading price of our ordinary shares and warrants is likely to be volatile
and could be subject to fluctuations in response to various factors, some of which are beyond our control. These fluctuations could cause
you to lose all or part of your investment in our ordinary shares and our warrants as you might be unable to sell your shares at or above
the price you paid. Factors that could cause fluctuations in the trading price of our ordinary shares and our warrants include the following:
●
actual or anticipated fluctuations in our financial condition or results
        of operations;
●
variance in the projected timeline for regulatory approvals of our product
        candidates from expectations of securities analysts;
●
changes in laws or regulations applicable to our business;
●
announcements by us or our competitors of significant business developments;
●
significant data breaches, disruptions to or other incidents involving our
        company;
●
conditions or developments affecting the biotechnology industry;
●
future sales of New Silexion ordinary shares by us or our shareholders, as
        well as the anticipation of lock-up releases;
●
changes in senior management or key personnel;
●
the trading volume of our securities;
●
changes in the anticipated future size and growth rate of our markets;
●
publication of research reports or news stories about us, our competitors
        or our industry, or positive or negative recommendations or withdrawal of research coverage by securities analysts;
●
general economic and market conditions; and
●
other events or factors, including those resulting from war, incidents of
        terrorism, global pandemics or responses to those events.
Broad market and industry fluctuations, as well as
general economic, political, regulatory and market conditions, may also negatively impact the market price of our ordinary shares. In
the past, companies that have experienced volatility in the market price of their securities have been subject to securities class action
litigation. We may be the target of this type of litigation in the future, which could result in substantial expenses and divert our management's
attention.
A substantial number of our ordinary
shares may be issued pursuant to the White Lion Purchase Agreement, as well as the conversion terms of our outstanding convertible notes
(consisting of the A&R Sponsor Promissory Note and the EarlyBird Convertible Note), which could cause (i) the price of the ordinary
shares to decline, and (ii) substantial dilution to our existing shareholders.
The purchase price per ordinary share to be paid by White
Lion for shares that we may elect to issue and sell to it under the White Lion Purchase Agreement will fluctuate based on the market price
of our ordinary shares at the time we elect to sell such shares. Depending on market liquidity at the time, resales of such ordinary shares
by White Lion may cause the trading price of our ordinary shares to decrease, and any such decrease could be substantial.
If and when we elect to issue and sell ordinary shares
to White Lion, those issuances and sales will result in dilution to the interests of existing holders of our ordinary shares, which dilution
may be substantial. Additionally, the sale of a substantial number of ordinary shares to White Lion, or the anticipation of such sales,
could make it more difficult for us to sell equity or equity-related securities in the future at a time and at a price that we might otherwise
wish to effect sales.
In addition to ordinary shares that may be issued under
the White Lion Purchase Agreement, ordinary shares may also be issued upon conversion of amounts outstanding under two convertible promissory
notes that we issued in connection with the consummation of the Business Combination— consisting of the A&R Sponsor Promissory
Note, in an amount of $3,433,000, that we issued to the Moringa Sponsor, due February 15, 2027, and the EarlyBird Convertible Note, due
December 31, 2025, in an amount of $1,250,000 that we issued to EarlyBird (together, the "Convertible Notes"). The conversion
prices under the Convertible Notes relate to the market price of our ordinary shares and/or the price at which we raise capital from equity
financings. The issuance of additional shares under the Convertible Notes will dilute our other equity holders, which could cause the
price of our ordinary shares to decline.
38
The ordinary shares (including ordinary
shares underlying warrants) that are being offered by selling securityholders under another registration statement that we currently have
in effect represent a substantial percentage of our outstanding ordinary shares, and the sale of such shares, or the perception that such
sales may occur, could cause the price of our ordinary shares to be more volatile or decrease.
On October 9, 2024, we filed, and on October
16, 2024, the SEC declared effective, a registration statement on Form S-1 (SEC file number 333-282556), in which we registered with the
SEC the sale by selling securityholders named therein of up to 1,705,798 of our ordinary shares and up to 21,112 of our warrants (constituting
our private warrants).
Depending on market liquidity, resales of ordinary shares and warrants
by those selling securityholders may cause the trading price of our ordinary shares and warrants to decrease, and any such decrease could
be substantial. Additionally, the sale of a substantial number of ordinary shares or warrants by those selling securityholders, or the
perception that such sales may take place, could increase the volatility of the market price of the ordinary shares and warrants and depress
the trading price of the ordinary shares and warrants and thereby make it more difficult for us to raise capital by selling equity or
equity-related securities in the future at a time and at a price that we might otherwise wish to effect sales.
The requirement that we repay the
EarlyBird Convertible Note could adversely affect our business plan, liquidity, financial condition, and results of operations.
If not converted, we are required to repay, in cash, principal
that is outstanding under the EarlyBird Convertible Note, as well as interest thereon, in connection with equity financings by us, or
upon the maturity of the note on December 31, 2025. That obligation could have important consequences on our business. In particular,
it could:
●
limit our flexibility in planning the payment of expenditures that arise
        in our clinical program and our business and operations generally;
●
increase our vulnerability to general adverse economic conditions that hinder
        our ability to obtain equity financings; and
●
place us at a competitive disadvantage compared to our competitors.
No assurances can be given that we will be successful
in making the required payments under the EarlyBird Convertible Note. If we are unable to make the required cash payments, there could
be a default under the EarlyBird Convertible Note. In such event, or if a default otherwise occurs under the EarlyBird Convertible Note:
●
the interest rate payable under the EarlyBird Convertible Note could be increased,
        and EarlyBird, as the holder of the EarlyBird Convertible Note, could declare all outstanding principal and interest to be due and payable;
        and/or
●
we could be forced into bankruptcy or liquidation.
Because we have no current plans to
pay cash dividends on our ordinary shares for the foreseeable future, you may not receive any return on investment unless you sell New
Silexion ordinary shares for a price greater than that which you paid for it.
We will likely retain future earnings, if any, for future
operations, expansion and debt repayment and have no current plans to pay any cash dividends for the foreseeable future. Any decision
to declare and pay dividends as a public company in the future will be made at the discretion of our board of directors and will depend
on, among other things, our results of operations, financial condition, cash requirements, contractual restrictions, funds lawfully available
therefor and other factors that our board of directors may deem relevant. In addition, our ability to pay dividends may be limited by
covenants of any existing and future outstanding indebtedness we or our subsidiaries incur. As a result, you may not receive any return
on an investment in our ordinary shares unless you sell our ordinary shares for a price greater than that which you paid for it.
Our reverse share split may negatively
impact the market for our ordinary shares.
There can be no assurance that the total market capitalization of our ordinary
shares after our reverse share split will be equal to or greater than the total market capitalization before the reverse share split,
or that the per share market price of our ordinary shares following the reverse share split will increase in proportion to the reduction
in the number of ordinary shares outstanding before the reverse share split. Factors such as the results of our pre-clinical and clinical
trials, progress in seeking regulatory approval for our product candidates, our financial results, developments involving our competitors,
market conditions and the market perception of our product candidates may adversely affect the market price of our ordinary shares. As
a result, a decline in the market price of our ordinary shares after the reverse share split may result in a greater percentage decline
than would occur in the absence of a reverse share split.
39
In addition to market price, the liquidity of our ordinary
shares may also be adversely affected by the reverse share split, given the reduced number of ordinary shares that will be outstanding
following the reverse share split.
The reverse share split may furthermore increase the number of our shareholders
who own odd lots (less than 100 shares). Any shareholder who owns fewer than 900 ordinary shares, prior to the reverse share split will
own fewer than 100 ordinary shares following the reverse share split. Shareholders who hold odd lots may experience an increase in the
cost of selling their shares and may have greater difficulty in effecting sales.
Following, and as a partial result
of, our reverse share split, our ordinary shares may experience extreme price volatility unrelated to our actual or expected operating
performance, financial condition or prospects, making it difficult for prospective investors to assess the rapidly changing value of our
ordinary shares.
Recently, there have been instances of extreme share price run-ups followed
by rapid price declines and strong share price volatility with a number of relatively new public companies, especially among companies
with relatively smaller public floats. As a relatively small-capitalization company with relatively small public float, we may experience
greater share price volatility, extreme price run-ups, lower trading volume and less liquidity than large-capitalization companies. The
potential for decrease in liquidity due to our reverse share split may heighten our exposure to those trading trends. In particular, following
the reverse share split, our ordinary shares may be subject to rapid and substantial price volatility, low volume of trades, and large
spreads in bid and ask prices. Such volatility, including any stock run up, may be unrelated to our actual or expected operating performance,
financial condition or prospects, making it difficult for prospective investors to assess the rapidly changing value of our ordinary shares.
In addition, if the trading volumes of our ordinary
shares are low, persons buying or selling in relatively small quantities may easily influence prices of our ordinary shares. This low
volume of trades could also cause the price of our ordinary shares to fluctuate greatly, with large percentage changes in price occurring
in any trading day session. Holders of our ordinary shares may also not be able to readily liquidate their investment or may be forced
to sell at depressed prices due to low volume trading. If high spreads between the bid and ask prices of our ordinary shares exist at
the time of a purchase, the shares would have to appreciate substantially on a relative percentage basis for an investor to recoup their
investment. Broad market fluctuations and general economic and political conditions (including in Israel, where our operations are centered)
may also adversely affect the market price of our ordinary shares.
As a result of this volatility, investors may experience
losses on their investment in our ordinary shares. A volatile market price of our ordinary shares also could adversely affect our ability
to issue additional ordinary shares or other securities and our ability to obtain additional financing in the future, which is a key strategic
goal for us, thereby frustrating our ability to achieve one of the key purposes of our reverse share split.
Following our reverse share split,
the resulting higher market price of our ordinary shares may not attract new investors, including institutional investors, and may not
satisfy the investing requirements of those investors. Consequently, the trading liquidity of our ordinary shares may not improve.
Although we believe that a higher market price of our ordinary shares, which
is expected to result from our reverse share split, may help generate greater or broader investor interest, there can be no assurance
that the reverse share split will result in a share price that will attract new investors, including institutional investors. In addition,
there can be no assurance that the market price of our ordinary shares will satisfy the investing requirements of those investors. As
a result, the trading liquidity of our ordinary shares may not necessarily improve.
We qualify as an "emerging growth
company" as well as a "smaller reporting company" within the meaning of the Securities Act, and if we take advantage
of certain exemptions from disclosure requirements available to emerging growth companies or smaller reporting companies, it could make
our securities less attractive to investors and may make it more difficult to compare our performance to the performance of other public
companies.
We qualify as an "emerging growth company" as defined in Section
2(a)(19) of the Securities Act, as modified by the JOBS Act. As such, we will be eligible for and intend to take advantage of certain
exemptions from various reporting requirements applicable to other public companies that are not emerging growth companies for as long
as we continue to be an emerging growth company, including (a) the exemption from the auditor attestation requirements with respect to
internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act, (b) the exemptions from say-on-pay, say-on-frequency
and say-on-golden parachute voting requirements and (c) reduced disclosure obligations regarding executive compensation in its periodic
reports and proxy statements. We will remain an emerging growth company until the earliest of (i) the last day of the fiscal year in which
the market value of our ordinary shares that are held by non-affiliates is equal to or exceeds $700 million as of the end of that year's
second fiscal quarter, (ii) the last day of the fiscal year in which we have total annual gross revenue of $1.235 billion or more during
such fiscal year (as indexed for inflation), (iii) the date on which we have issued more than $1 billion in non-convertible debt in the
prior three-year period or (iv) the last day of the fiscal year following the fifth anniversary of the date of the first issuance of our
ordinary shares in the Business Combination. In addition, Section 107 of the JOBS Act also provides that an emerging growth company can
take advantage of the exemption from complying with new or revised accounting standards provided in Section 7(a)(2)(B) of the Securities
Act as long as the Company is an emerging growth company. An emerging growth company can therefore delay the adoption of certain accounting
standards until those standards would otherwise apply to private companies. We have elected not to opt out of such extended transition
period and, therefore, the Company may not be subject to the same new or revised accounting standards as other public companies that are
not emerging growth companies. Investors may find our ordinary shares less attractive because we rely on these exemptions, which may result
in a less active trading market for our ordinary shares and its price may be more volatile.
40
Additionally, we qualify as a "smaller
reporting company" as defined in Item 10(f)(1) of Regulation S-K promulgated by the SEC. Smaller reporting
companies may take advantage of certain reduced disclosure obligations, including, among other things, providing only two years of
audited financial statements. The Company will remain a smaller reporting company until the last day of the fiscal year in which
(i) the market value of our ordinary shares held by non-affiliates is equal to or exceeds $250 million as of the end of
that year's second fiscal quarter, or (ii) our annual revenues is equal to or exceeds $100 million during such completed
fiscal year and the market value of our ordinary shares held by non-affiliates is equal to or exceeds $700 million as of the
end of that year's second fiscal quarter. To the extent the Company takes advantage of such reduced disclosure obligations, it may
also make comparison of our financial statements with other public companies difficult or impossible.
Risks Related to U.S. Federal Income Taxation
The PFIC status of New Silexion could
result in adverse U.S. federal income tax consequences to U.S. Holders.
In general, a non-U.S. corporation is a PFIC for
U.S. federal income tax purposes for any taxable year in which, after applying certain look-through rules, either (i) 50%
or more of the average value of its assets (generally determined on the basis of a weighted quarterly average) consists of assets that
produce, or are held for the production of, passive income, or (ii) 75% or more of its gross income consists of passive income. Passive
income generally includes dividends, interest, rents and royalties (other than rents or royalties derived from the active conduct of a
trade or business) and gains from the disposition of passive assets. Cash and cash equivalents generally are passive assets. The value
of goodwill will generally be treated as an active or passive asset based on the nature of the income produced in the activity to which
the goodwill is attributable. For purposes of the PFIC rules, a non-U.S. corporation that owns, directly or indirectly, at least
25% by value of the stock of another corporation is treated as if it held its proportionate share of the assets of the other corporation
and received directly its proportionate share of the income of the other corporation.
The annual PFIC income and asset tests in respect of New Silexion will be
applied based on the assets and activities of the combined business. Based on the composition of our income and assets, it cannot be determined
whether we will be classified as a PFIC for our current taxable year or in any future taxable year. Further, changes in the composition
of our income or composition of our assets may cause us to be or become a PFIC for the current or subsequent taxable years. Whether we
are treated as a PFIC for U.S. federal income tax purposes is a factual determination that must be made annually at the close of each
taxable year and, thus, is subject to significant uncertainty.
If we are treated as a PFIC for any taxable year, or portion thereof, that
is included in the holding period of a U.S. Holder, such U.S. Holder may be subject to certain adverse U.S. federal income tax consequences
and may be subject to additional reporting requirements. For a further discussion, see "
Certain
Material U.S. Federal Income Tax Considerations — PFIC Rules
." U.S. Holders are strongly encouraged to consult their
own advisors regarding the potential application of these rules to the ownership of our ordinary shares, pre-funded warrants and/or our
ordinary warrants.
If a U.S. person is treated as
owning at least 10% of the shares of New Silexion, such person may be subject to adverse U.S. federal income tax consequences.
If a U.S. Holder is treated as owning (directly, indirectly or constructively)
at least 10% of the value or voting power of our shares, such holder may be treated as a "United States shareholder" with
respect to each of New Silexion and our direct and indirect subsidiaries (the "
New Silexion Group
")
that is a "controlled foreign corporation," (a "CFC"), for U.S. federal income tax purposes. A non-U.S. corporation
is considered a CFC if more than 50% of (1) the total combined voting power of all classes of stock of such corporation entitled to vote,
or (2) the total value of the stock of such corporation is owned, or is considered as owned by applying certain constructive ownership
rules, by United States shareholders on any day during the taxable year of such non-U.S. corporation. If the New Silexion Group includes
one or more non-U.S. subsidiaries, certain of our non-U.S. subsidiaries could be treated as CFCs regardless of whether we are treated
as a CFC.
If we or any of our non-U.S. subsidiaries is a CFC, 10% "United States
shareholders" will be subject to adverse income inclusion and reporting requirements with respect to such CFC. No assurance can
be provided that we will assist holders in determining whether we or any of our non-U.S. subsidiaries is treated as a CFC or whether any
holder is treated as a United States shareholder with respect to any of such CFCs, or furnish to any holder information that may be necessary
to comply with reporting and tax payment obligations with respect to such CFCs.
41
General Risks
The Company may be subject to securities
litigation, which is expensive and could divert management attention, including securities class action and derivative lawsuits which
could result in substantial costs.
Our share price may be volatile and, in the past, companies
that have experienced volatility in the market price of their stock or shares have been subject to securities litigation, including class
action litigation. The Company may be the target of this type of litigation in the future. Litigation of this type could result in substantial
costs and diversion of management's attention and resources, which could have a material adverse effect on our business, financial
condition, and results of operations. Any adverse determination in litigation could also subject the Company to significant liabilities.
Securities class action lawsuits and derivative lawsuits
are often brought against public companies that have entered into merger or business combination agreements. Even if the lawsuits are
without merit, defending against these claims can result in substantial costs and divert management time and resources. An adverse judgment
could result in monetary damages, which could have a negative impact on our liquidity and financial condition. We cannot predict whether
any such lawsuits will be filed.
TRANSACTIONS RELATED
        TO OFFERING UNDER THIS PROSPECTUS
The New Silexion securities to be offered
by the Selling Securityholders under this prospectus include, in large part, New Silexion ordinary shares and New Silexion ordinary warrants
that were issued pursuant to a number of transactions completed in connection with the Closing of the Business Combination. We describe
those transactions below:
January 2025 Warrant
Inducement Transaction
On January 29, 2025,
New Silexion entered into an inducement offer letter agreement (the "
Inducement Letter
")
with certain holders (each a "
Holder
") of certain of New Silexion's existing
warrants to purchase up to 2,221,523 shares of New Silexion ordinary shares issued on January 17, 2025 with a five year term at an exercise
price of $1.35 per share (the "
Existing Warrants
").
Pursuant to the Inducement
Letter, the Holders agreed to exercise for cash their Existing Warrants to purchase an aggregate of 2,221,523 of New Silexion's
ordinary shares at the exercise price of $1.35 per share in consideration of New Silexion's agreement to issue new ordinary share
purchase warrants (the "
New Warrants
") to purchase up to an aggregate of 2,221,523
of New Silexion's ordinary shares (the "
New Warrant Shares
"), at an exercise
price of $1.50 per share. The Holders also paid New Silexion an additional $0.125 per New Warrant issued in the offering. New Silexion
received aggregate gross proceeds of approximately $3.3 million from the exercise of the Existing Warrants by the Holders, before deducting
placement agent fees and other offering expenses payable by New Silexion.
New Silexion engaged
H.C. Wainwright & Co., LLC (the "
Wainwright
") to act as its exclusive placement
agent in connection with the transactions contemplated by the Inducement Letter. New Silexion  also issued to Wainwright or its designees
warrants (the "
Placement Agent Warrants
") to purchase up to 155,507 ordinary shares
(representing 7.0% of the Existing Warrants being exercised), which have the same terms as the New Warrants except the Placement Agent
Warrants have an exercise price equal to $1.8438 per share (125% of the sum of the exercise price of the Existing Warrants and the additional
$0.125 paid per New Warrant). Similar to the New Warrants, the Placement Agent Warrants will be immediately exercisable from the date
of issuance until the twenty-four month anniversary of the effective date of the Resale Registration Statement (as defined below).
The closing of the
transactions contemplated pursuant to the Inducement Letter occurred on January 30, 2025 (the "
Closing
Date
"), subject to satisfaction of customary closing conditions. New Silexion also agreed to file this registration statement
(this "
Resale Registration Statement
") within thirty (30) calendar days of the date
of the Inducement Letter, and to use commercially reasonable efforts to have such Resale Registration Statement declared effective by
the SEC within sixty (60) calendar days following the date of the Inducement Letter (or within ninety (90) calendar days following the
date of the Inducement Letter in case of "full review" of the Resale Registration Statement by the SEC) and to keep the Resale
Registration Statement effective at all times until no holder of the New Warrants owns any New Warrants or New Warrant Shares. In the
Inducement Letter, New Silexion agreed not to issue any shares of ordinary shares or ordinary share equivalents or to file any other registration
statement with the SEC (in each case, subject to certain exceptions) until March 18, 2025. New Silexion also agreed not to effect or agree
to effect any Variable Rate Transaction (as defined in the Inducement Letter) until one (1) year after the Closing Date (subject to certain
exceptions).
MARKET AND INDUSTRY
DATA
Information contained in this prospectus
concerning the market and the industries in which New Silexion competes, including its market position, general expectations of market
opportunities and market size, is based on information from various third-party sources, publicly available information, various industry
publications, internal data and estimates, and assumptions made by New Silexion based on such sources. Internal data and estimates are
based upon information obtained from trade and business organizations and other contacts in the markets in which New Silexion operates
and New Silexion management's understanding of industry conditions. This information and any estimates provided herein involve numerous
assumptions and limitations, and you are cautioned not to give undue weight to such information. Third-party sources generally state that
the information contained in such sources has been obtained from sources believed to be reliable. Although we believe that such information
is reliable, there can be no assurance as to the accuracy or completeness of such information. Industry and market data could be wrong
because of the method by which sources obtained their data and because information cannot always be verified with complete certainty due
to the limits on the availability and reliability of raw data, the voluntary nature of the data gathering process and other limitations
and uncertainties. Although we are responsible for all of the disclosure contained in this prospectus and we believe the third-party market
position, general expectations of market opportunity and market size data included in this prospectus are reliable, we have not independently
verified any third-party information and each publication speaks as of its original publication date (and not as of the date of this prospectus).
In addition, we do not know all of the assumptions regarding general economic conditions or growth that were used in preparing the forecasts
from the sources relied upon or cited herein.
42
USE OF
PROCEEDS
All of the ordinary shares issuable upon
the exercise of the warrants offered by the Selling Securityholders pursuant to this prospectus will be sold by the Selling Securityholders
for their respective own accounts. We will not receive any of the proceeds from the resale of the ordinary shares issuable upon the exercise
of the warrants by the Selling Securityholders. However, we may receive up to up to an aggregate of approximately $3.6 million from the
exercise of the outstanding warrants, assuming the exercise in full of all such warrants for cash. There is no assurance that the holders
of the warrants will elect to exercise any or all of the warrants. Given the relative lack of liquidity in our ordinary shares, there
is no certainty that warrant holders will exercise their warrants and, accordingly, we may not receive any proceeds in relation to our
outstanding warrants. We believe that the likelihood that warrant holders determine to exercise their warrants, and therefore the amount
of cash proceeds that we would receive, is dependent upon the market price of our New Silexion ordinary shares. If the market price for
our ordinary shares is less than the exercise price of the warrants (on a per share basis), we believe that warrant holders will be very
unlikely to exercise any of their warrants, and accordingly, we will not receive any such proceeds. There is no assurance that the warrants
will be "in the money" prior to their expiration or that the warrant holders will exercise their warrants. As of February
11, 2025, the closing price of our ordinary shares was $1.38 per share.
We expect to use the net proceeds received
from the exercise of the warrants, if any, for general corporate purposes, including working capital. Accordingly, we retain broad discretion
over the use of the proceeds from the exercise of the warrants. The precise amount and timing of the application of such proceeds will
depend upon our liquidity needs and the availability and cost of other capital over which we have little or no control. As of the date
hereof, we cannot specify with certainty the particular uses for the proceeds, if any, from the exercise of the warrants See "
Plan
of Distribution
" elsewhere in this prospectus for more information.
​
43
DETERMINATION OF OFFERING
PRICE
We cannot currently determine the price
or prices at which ordinary shares issuable upon the exercise of the warrants may be sold by the Selling Securityholders under this prospectus.
MARKET INFORMATION FOR
SECURITIES AND DIVIDEND
POLICY
Market Information
Our ordinary shares and warrants are currently
listed on Nasdaq under the symbols "SLXN" and "SLXNW," respectively. On December 31, 2024, there were 26 holders
of record of the ordinary shares and three holders of record of our warrants.
Dividend Policy
We have never declared or paid any dividends on ordinary
shares. We anticipate that we will retain all of our future earnings, if any, for use in the operation and expansion of our business and
do not anticipate paying cash dividends in the foreseeable future. Any decision to declare and pay dividends in the future will depend
on, among other things, the consent of our lender(s), our results of operations, cash requirements, financial condition, contractual restrictions,
funds lawfully available therefor and other factors that our board of directors may deem relevant.
UNAUDITED PRO FORMA CONDENSED
COMBINED FINANCIAL
INFORMATION
Introduction
The registrant, Silexion Therapeutics Corp (formerly known
as Biomotion Sciences), a Cayman Islands exempted company ("
New Silexion
") is providing
the following unaudited pro forma condensed combined financial information to aid you in your analysis of the financial aspects of the
business combination and related transactions (collectively, the "
Transactions
") involving
Moringa Acquisition Corp ("
Moringa
") and Silexion Therapeutics Ltd. ("
Silexion
").
The following unaudited pro forma condensed combined financial information presents the combination of the financial information of Moringa
and Silexion, as adjusted to give effect to the Transactions. Capitalized terms included in this section containing unaudited pro forma
condensed combined financial information and not otherwise defined in this section have the same meaning as is provided elsewhere in this
prospectus.
Parties to the Transaction
Moringa is a Cayman Islands exempted company that was
originally a blank check company that was formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase,
recapitalization, reorganization or similar business combination with one or more businesses. As of June 30, 2024 and December 31, 2023,
there was approximately $5.924 million and $5.698 million, respectively, held in Moringa's trust account, which was held for the
benefit of Moringa's public shareholders (the "
Trust Account
"). The Trust Account
was liquidated upon the completion of the Transactions, as described below.
Silexion, an Israeli company that was known previously
as Silenseed Ltd., is a pioneering biopharma developmental-stage company dedicated to the development of innovative treatments for pancreatic
cancer.
New Silexion is a newly formed entity that was formed
for the purpose of effecting the Transactions, and now serves as a publicly-traded holding company of its subsidiaries — including
Moringa and Silexion — after the Closing of the Transactions.
44
Description of the Transactions
On August 15, 2024, the parties completed the previously-reported
Transactions pursuant to that certain amended and restated business combination agreement, dated April 3, 3024 (the "
Business
Combination Agreement
") by and among New Silexion (then known as Biomotion Sciences), August M.S. Ltd., an Israeli company
and a wholly owned subsidiary of New Silexion ("
Merger Sub 1
"), Moringa Acquisition
Merger Sub Corp, a Cayman Islands exempted company and a wholly owned subsidiary of New Silexion ("
Merger
Sub 2
"), Moringa and Silexion.
Pursuant to the Transactions, Merger Sub 2 merged with and into Moringa,
with Moringa continuing as the surviving company of such merger and a wholly-owned subsidiary of New Silexion (the "
SPAC
Merger
"), and Merger Sub 1 merged with and into Silexion, with Silexion continuing as the surviving company of such merger
and a wholly-owned subsidiary of New Silexion (the "
Acquisition Merger
"). Upon the
effectiveness of the SPAC Merger, each outstanding Moringa Class A ordinary share and the sole outstanding Moringa Class B ordinary share
converted into an ordinary share of New Silexion on a one-for-one basis. Each outstanding warrant to purchase one Moringa Class A ordinary
share converted into a warrant to purchase one New Silexion ordinary share, at the same exercise price. Upon the effectiveness of the
Acquisition Merger, each outstanding ordinary share and preferred share of Silexion converted into such number of ordinary shares of New
Silexion as is equal to the quotient obtained by dividing (x) the quotient obtained by dividing (1) $62,500,000 by (2) the number of fully
diluted Silexion equity securities, by (y) $90.00 (the "
Silexion Equity Exchange Ratio
").
Each outstanding Silexion warrant and Silexion option to purchase one Silexion share, and Silexion restricted share unit (RSU) that may
be potentially settled for one Silexion share, became exercisable for, or became subject to settlement for (as applicable), such number
of New Silexion ordinary shares as are equal to the Silexion Equity Exchange Ratio. The exercise price per New Silexion ordinary share
of each such converted Silexion option and Silexion warrant were adjusted based on dividing the existing per share exercise price by the
Silexion Equity Exchange Ratio. The terms of vesting, exercise and/or settlement, as applicable, of such converted options, warrants and
RSUs remain the same following such conversion, except that the vesting of each Silexion option accelerated immediately prior to the Acquisition
Merger, such that the New Silexion option into which it has been converted was fully vested, and all Silexion warrants were exercised
(on a cashless basis) immediately prior to the Acquisition Merger.
Immediately prior to the Closing, seven directors were
appointed to New Silexion's board of directors, of whom five were designated by Silexion and two were designated by Moringa's
sponsor (Moringa Sponsor, LP, a Cayman Islands exempted limited partnership and/or its wholly-owned subsidiary, Moringa Sponsor US L.P.,
a Delaware limited partnership) (collectively, the "
Moringa Sponsor
").
In connection with the Closing, the ordinary shares and
warrants of New Silexion were approved for listing on the Nasdaq Global Market and began trading under the symbols "SLXN"
and "SLXNW", respectively.
The Business Combination was accounted for as a reverse
recapitalization in accordance with US GAAP. Under this method of accounting, Silexion was treated as the accounting acquirer and Moringa
was treated as the "acquired" company for financial reporting purposes. Silexion was determined to be the accounting acquirer
based on evaluation of the following facts and circumstances:
●
Silexion's shareholders holding approximately 61.55% of the outstanding
        voting interests in New Silexion upon the Closing of the Transactions;
●
Silexion's senior management comprise the senior management of New
        Silexion;
●
the directors nominated by Silexion constitute the majority of the board
        of directors of New Silexion (five out of seven of the initial directors); and
45
●
Silexion's operations comprise the ongoing operations of New Silexion.
Under the reverse recapitalization accounting method,
the Business Combination is deemed to be the equivalent of a capital transaction in which Silexion has issued shares for the net assets
of Moringa. The net assets of Moringa are stated at fair value, with no goodwill or other intangible assets recorded. Operations prior
to the Business Combination are of Silexion.
The unaudited pro forma condensed combined financial statements
were prepared in accordance with Article 11 of SEC Regulation S-X, as amended by the final rule, SEC Release No. 33-10786 "Amendments
to Financial Disclosures About Acquired and Disposed Businesses". The adjustments presented in the unaudited pro forma condensed
combined financial statements (collectively, the "
Pro Forma Adjustments
") have been
identified and presented to provide relevant information necessary for an understanding of New Silexion upon consummation of the Business
Combination and related transactions.
The unaudited pro forma combined statements of operations for
the nine-months period ended September 30, 2024 and for the year ended December 31, 2023 combine the historical statements of operations
of Moringa for the year ended December 31, 2023 (audited), and for the period from January 1 to August 14, 2024 (unaudited), and
the updated financial statements of New Silexion (formerly: Silexion) that show the effects of the reverse share split and reverse recapitalization
for the year ended December 31, 2023 (audited), and for the nine-months period ended September 30, 2024 (unaudited), subject to the Pro
Forma Adjustments, giving effect to the Business Combination as if it had been consummated on January 1, 2023.
Unaudited Condensed Combined Pro Forma Financial Statements
The unaudited pro forma condensed combined financial statements have been
derived from, are qualified in their entirety by, and should be read in conjunction with:
●
the accompanying notes to the unaudited pro forma condensed combined financial
        statements;
●
the historical unaudited financial statements of Moringa as of and for the
        six-months period ended June 30, 2024 and the related notes included elsewhere in this prospectus;
●
the historical unaudited financial statements of New Silexion as of and for
        the nine-months period ended September 30, 2024 and the related notes included elsewhere in this prospectus;
●
the historical audited financial statements of Moringa as of and for the
        year ended December 31, 2023 and the related notes included elsewhere in this prospectus;
●
the historical audited financial statements of New Silexion as of and for
        the year ended December 31, 2023 and the related notes included elsewhere in this prospectus;
●
the sections entitled "Management's Discussion
        and Analysis of Financial Condition and Results of Operations" included in Moringa's annual report on Form 10-K for the year
        ended December 31, 2023 and quarterly report on Form 10-Q for the quarter ended June 30, 2024, filed with the SEC on April 1, 2024 and
        August 13, 2024, respectively (the "
Moringa 2023 Form 10-K
" and "
Moringa
        Q2 Form 10-Q
," respectively), and "Management's Discussion and Analysis of Financial Condition and Results of
        Operations" included in this prospectus;
●
the other financial information relating to Moringa and New Silexion included
        in this prospectus; and
●
factors detailed under the section entitled "
Risk
        Factors
" in this prospectus.
The unaudited pro forma condensed combined financial information
is for illustrative purposes only and is not necessarily indicative of what the actual results of operations and financial position would
have been had the Transactions included in the Pro Forma Adjustments taken place on the dates indicated, nor are they indicative of the
future results of operations or financial position of New Silexion. The Pro Forma Adjustments are based on currently available information
and certain assumptions and estimates that New Silexion believes are reasonable under the circumstances. Management performed a comprehensive
review of the accounting policies between the two entities. Management is not aware of any significant accounting policy differences and
has therefore not made any adjustments to the pro forma condensed combined financial information related to any potential differences.
46
SILEXION
THERAPEUTICS CORP
UNAUDITED
PRO FORMA CONDENSED COMBINED STATEMENT OF OPERATIONS
FOR NINE-MONTHS
PRIOD ENDED SEPTEMBER 30, 2024
(in thousands, except share and per share amounts)
Historical
Historical
Actual Redemption
Moringa Acquisition
Corp (Period between January 1 and August
        14, 2024)
New Silexion
Business Combination
Adjustments
Pro Forma Statement of Operations
Research and development expenses, net
$
—
$
4,944
A
$
(2,424
)
$
2,520
General and administrative expenses
551
5,727
A
(3,438
)
2,449
—
—
B
75
—
—
C
(466
)
OPERATING LOSS
551
10,671
(6,253
)
4,969
Financial expenses (income), net
(155
)
4,092
D
(134
)
(740
)
—
—
E
(4,783
)
F
123
G
(337
)
H
454
Loss before income tax
396
14,763
(10,930
)
4,229
Tax on Income
—
9
—
9
LOSS FOR THE PERIOD
$
396
$
14,772
$
(10,930
)
$
4,238
Attributable to:
Equity holders of the Company
—
14,696
I
76
4,238
Non-controlling interests
—
76
I
(76
)
—
PROFIT (LOSS) PER SHARE, BASIC AND DILUTED
Ordinary share subject to possible redemption
$
0.39
$
—
$
(0.39
)
$
—
Non-redeemable ordinary shares
$
(0.18
)
$
(50.43
)
$
46.85
$
(3.76
)
WEIGHTED AVERAGE NUMBER OF SHARES OUTSTANDING USED IN
COMPUTATION OF BASIC AND DILUTED LOSS PER SHARE
Ordinary shares subject to possible redemption
87,722
—
(87,722
)
Non-redeemable ordinary shares
3,355,000
291,407
(2,519,042
)
J
1,127,365
See accompanying notes to the unaudited pro forma condensed
combined financial information.
47
SILEXION THERAPEUTICS CORP
UNAUDITED
PRO FORMA CONDENSED COMBINED STATEMENT OF OPERATIONS
FOR THE YEAR ENDED DECEMBER 31, 2023
(in thousands, except share and
per share amounts)
Moringa Acquisition
Corp
New Silexion
Business Combination
Adjustments
Pro Forma Statement
of Operations
Research and development expenses, net
$
—
$
3,708
A
$
2,424
$
6,132
—
—
-
General and administrative expenses
1,122
973
A
3,438
6,119
—
—
-
—
—
B
120
—
—
C
466
—
—
-
OPERATING LOSS
1,122
4,681
6,448
12,251
Financial expenses (income), net
(1,385
)
395
D
(86
)
6,047
E
4,783
F
1,364
G
337
H
639
Loss before income tax
(263
)
5,076
13,485
18,298
Tax on Income
—
32
—
32
LOSS FOR THE PERIOD
$
(263
)
$
5,108
$
13,485
$
18,330
Attributable to:
Equity holders of the Company
—
4,942
I
166
18,330
Non-controlling interests
—
166
I
(166
)
—
PROFIT (LOSS) PER SHARE, BASIC AND DILUTED
Ordinary share subject to possible redemption
$
0.51
$
—
$
(0.51
)
$
—
Non-redeemable ordinary shares
$
(0.34
)
$
(44.23
)
$
28.30
$
(16.27
)
WEIGHTED AVERAGE NUMBER OF SHARES OUTSTANDING USED IN COMPUTATION OF BASIC AND DILUTED LOSS PER SHARE
Ordinary shares subject to possible redemption
2,774,850
—
(2,774,850
)
—
Non-redeemable ordinary shares
3,355,000
111,726
(2,340,293
)
J
1,126,433
See accompanying notes to the unaudited pro forma condensed
combined financial information.
48
NOTES TO UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL
INFORMATION
1. Description of the Business Combination
On August 15, 2024, the parties completed the previously-reported
transactions (the "
Transactions
" or "
Business
Combination
") pursuant to that certain amended and restated business combination agreement, dated April 3, 3024 (the "Business
Combination Agreement") by and among the registrant ("
New Silexion
", which was
then known as Biomotion Sciences), August M.S. Ltd., an Israeli company and a wholly owned subsidiary of New Silexion ("
Merger
Sub 1
"), Moringa Acquisition Merger Sub Corp, a Cayman Islands exempted company and a wholly owned subsidiary of New Silexion
("
Merger Sub 2
"), Moringa and Silexion.
Pursuant to the Transactions, Merger Sub 2 merged with and into
Moringa, with Moringa continuing as the surviving company of such merger and a wholly-owned subsidiary of New Silexion (the "
SPAC
Merger
"), and Merger Sub 1 merged with and into Silexion, with Silexion continuing as the surviving company of such merger
and a wholly-owned subsidiary of New Silexion (the "
Acquisition Merger
"). Upon the
effectiveness of the SPAC Merger, each outstanding Moringa Class A ordinary share and the sole outstanding Moringa Class B ordinary share
converted into an ordinary share of New Silexion on a nine-to-one basis (after adjustments for the reverse share split described below).
Each outstanding warrant to purchase nine Moringa Class A ordinary share converted into a warrant to purchase one New Silexion ordinary
share, at the same exercise price. Upon the effectiveness of the Acquisition Merger, each outstanding ordinary share and preferred share
of Silexion converted into such number of ordinary shares of New Silexion as is equal to the quotient obtained by dividing (x) the quotient
obtained by dividing (1) $62,500,000 by (2) the number of fully diluted Silexion equity securities, by (y) $90.00 (after adjustment for
the subsequent New Silexion 1-for-9 reverse share split, as described below) (the "
Silexion Equity
Exchange Ratio
"). Each outstanding Silexion warrant and Silexion option to purchase one Silexion share, and Silexion restricted
share unit (RSU) that may be potentially settled for one Silexion share, became exercisable for, or will be subject to settlement for
(as applicable), such number of New Silexion ordinary shares as are equal to the Silexion Equity Exchange Ratio. The exercise price per
New Silexion ordinary share of each such converted Silexion option and Silexion warrant was adjusted based on dividing the existing per
share exercise price by the Silexion Equity Exchange Ratio. The terms of vesting, exercise and/or settlement, as applicable, of such converted
options, warrants and RSUs remains the same following that conversion, except that the vesting of each Silexion option accelerated immediately
prior to the Acquisition Merger, such that the New Silexion option into which it has been converted is fully vested, and all Silexion
warrants were exercised (on a cashless basis) immediately prior to the Acquisition Merger.
Unless indicated otherwise
in these notes to the Pro Forma Condensed Combined Financial Information, all share and per share numbers of New Silexion have been adjusted
retroactively to reflect the one-for-nine reverse share split effected by New Silexion with respect to its ordinary shares on November
27, 2024 (which reverse share split was reflected in trading prices at the start of trading on November 29, 2024). All share and per share
numbers of Moringa and Silexion have not been so adjusted.
Immediately prior to the closing of the Business Combination
(the "
Closing
"), seven directors were appointed to New Silexion's board of directors,
of whom five were designated by Silexion and two were designated by Moringa's sponsor (Moringa Sponsor, LP, a Cayman Islands exempted
limited partnership and/or its wholly-owned subsidiary, Moringa Sponsor US L.P., a Delaware limited partnership) (collectively, the "
Moringa
Sponsor
"). Also upon Closing, New Silexion's articles of association were amended and restated as appears in Exhibit
3.1 to the registration statement of which this prospectus forms a part. In connection with the Closing, the ordinary shares and warrants
of New Silexion were approved for listing on the Nasdaq Global Market and began trading under the symbols "SLXN" and "SLXNW",
respectively.
In addition, at the Closing, each of the following additional
actions was taken, in accordance with the terms of the Business Combination Agreement (in certain cases, as modified by subsequent agreements):
●
Moringa Sponsor forfeited for retirement 1,308,000 of the Moringa founders
        shares held by it, while 1,567,000 of the Moringa founders shares were transferred to non-affiliated third-party investors (including
        316,750 founders shares to certain security holders) as Backstop Shares (as defined in the Business Combination Agreement);
49
●
New Silexion issued to the Moringa Sponsor the A&R Sponsor Promissory
        Note in an amount of $3,433,000, in replacement of all promissory notes that Moringa had issued to the Moringa Sponsor for amounts owed
        by Moringa to the Moringa Sponsor prior to the Closing;
●
New Silexion, Moringa Sponsor, the investor in the PIPE financing
        (described below) and certain additional shareholders of New Silexion entered into an Amended and Restated Registration Rights and Lock-Up
        Agreement granting them registration rights with respect to the ordinary shares of New Silexion issued to them; and
●
Guangzhou Sino-Israel Bio-Industry Investment Fund I ("
GIBF
"),
        a shareholder of Silexion, transferred its noncontrolling interest in Silexion's Chinese subsidiary, Silenseed (China) Ltd., directly
        to New Silexion, such that the subsidiary became a wholly-owned subsidiary of New Silexion, and was issued 203,971 ordinary shares of
        New Silexion as consideration for that transfer (the "
Chinese Subsidiary Transfer
")
        (in addition to the 16,817 New Silexion ordinary shares that GIBF received upon the accelerated vesting of RSUs granted to it).
In connection with the Moringa extraordinary general meeting
at which the three proposals related to the Business Combination—the Business Combination Proposal, the Merger Proposal and the
Articles Amendment Proposal— were approved by the requisite majorities of Moringa's shareholders, holders of an aggregate
of 427,297 Moringa public shares properly exercised their right to have their shares redeemed for a full pro rata portion of the Trust
Account holding the proceeds from Moringa's IPO, which was approximately $11.575 per share, or $4,946,046 in the aggregate. Also
prior to the Closing, Moringa reached agreement with EarlyBird on a reduction, from $4.025 million to $1.6 million, in the aggregate,
of the fee payable to EarlyBird under the Business Combination Marketing Agreement, dated February 19, 2021 (the "
Marketing
Agreement
"), entered into by Moringa with EarlyBird at the time of Moringa's initial public offering. Pursuant to the
final invoice provided by EarlyBird under the Marketing Agreement at the Closing, Moringa paid $350,000 of cash to EarlyBird at the Closing,
and New Silexion issued to EarlyBird a convertible promissory note, due December 31, 2025, in an amount of $1.25 million to be paid by
New Silexion to EarlyBird in cash and/or via conversion of outstanding amounts into ordinary shares of New Silexion. After the redemption
payments, the payment to EarlyBird, and the satisfaction of amounts due to parties that arranged financing and/or capital markets advisory
services in connection with the Closing, the remaining balance of the Trust Account immediately prior to the Closing of $333,936 was used
to partially fund the Business Combination.
In connection with, and immediately prior
to the Closing of, the Business Combination, Moringa raised $2.0 million via a private investment in public entity (PIPE) financing, whereby
Moringa sold to Greenstar, L.P. 200,000 Moringa ordinary shares (which does not reflect the reverse share split) at a price of $10.00
per share. Those funds, together with remaining funds in Moringa's Trust Account after payments to redeeming public shareholders,
were used for financing support for Moringa and New Silexion, as well as for payment to service providers to whom outstanding amounts
were owed by Moringa, including parties that had provided financial advisory services and capital markets advisory services to Moringa
during the period leading up to the Closing.
Also in connection with the Closing, New Silexion entered
into an ordinary share purchase agreement for an equity line of credit with White Lion, whereby New Silexion will be able to request to
sell to White Lion, and White Lion will be required to purchase, via private placement transactions, up to $15.0 million of New Silexion
ordinary shares from time to time after the Closing, up until December 31, 2025 (unless the agreement is terminated sooner), subject to
certain limitations and conditions as described therein. The number of New Silexion ordinary shares that New Silexion may require White
Lion to purchase in any single sales notice will depend on a number of factors, including the type of purchase notice that New Silexion
delivers. Similarly, the purchase price to be paid by White Lion for any shares that New Silexion requires them to purchase will depend
on the type of sales notice that New Silexion delivers. New Silexion has also granted registration rights to White Lion pursuant to an
accompanying registration rights agreement.
50
In consideration for the commitments of White Lion, New Silexion
agreed to issue to White Lion an aggregate of $337,500 of New Silexion ordinary shares based on the closing price of the New Silexion
ordinary shares on September 16, 2024. Based on the closing price of the ordinary shares on September 16, 2024, New Silexion issued to
White Lion, on September 18, 2024, 40,602 ordinary shares in respect of White Lion's commitments under the White Lion Purchase Agreement.
Separately, the Moringa Sponsor transferred to third-party investors (in
lieu of forfeiting) all 1,567,000 Moringa founders shares that had been designated to serve as Backstop Shares under the Business Combination
Agreement, including 316,750 founders shares to certain security holders.
Various issuances and other actions impacted the final
number of New Silexion ordinary shares that were issued upon the Closing of the Business Combination, including the following:
●
the redemption of the 427,297 Moringa public shares described above;
●
the separation of each former Moringa unit into one Moringa Class A ordinary
        share and one-half of a Moringa warrant;
●
t1he Sponsor Founder Shares Forfeiture (as defined in the Business Combination Agreement) of 1,308,000
        Moringa founders shares, and the transfer of the remaining 1,567,000 Moringa founders shares to third parties (including 316,750 Moringa
        founders shares to certain securityholders) as Backstop Shares, which resulted in the issuance of 174,112 ordinary shares of New Silexion;
●
the issuance of 9,747 New Silexion ordinary shares in exchange for 87,722
        Moringa public shares that remained outstanding immediately prior to the Closing (following the redemptions described above);
●
the issuance of 42,223 New Silexion ordinary shares in exchange
        for 380,000 Moringa private shares;
●
the issuance of 11,112 New Silexion ordinary shares to EarlyBird
        in exchange for 100,000 Moringa representative shares;
●
the issuance by New Silexion to the Sponsor and/or its limited
        partners to whom the Sponsor distributed such shares of the 153,592 Sponsor Investment Shares (as defined in the Business Combination
        Agreement);
●
the issuance of 22,223 New Silexion ordinary shares to Greenstar, L.P. in
        exchange for 200,000 Moringa shares that were purchased in the $2.0 million PIPE financing, as described above;
●
the issuance of 446,835 New Silexion ordinary shares as the
        Silexion Merger Consideration (as defined in the Business Combination Agreement) to security holders of Silexion;
●
the issuance of 203,971 New Silexion ordinary shares to GIBF in respect of
        the Chinese Subsidiary Transfer (in addition to 16,817 New Silexion ordinary shares issued to GIBF upon the accelerated vesting of RSUs
        granted to it), as described above; and
●
the issuance of 4,370 New Silexion ordinary shares to a non-employee director
        of New Silexion upon acceleration of vesting, and settlement, of an equivalent number of New Silexion RSUs granted to the director.
As a result of each of the foregoing, upon
the Closing, there were 1,084,998 New Silexion ordinary shares issued and outstanding.
51
Upon the Closing, the ownership structure
for New Silexion was as set forth in the table below, based on actual number of redemptions of Moringa public shares (with the numbers
of New Silexion shares in the table retroactively reflecting the one-for-nine reverse share split of New Silexion):
Equity Holders
Shares
Percentage of
Outstanding
Shares
Moringa Public Shareholders(1)
9,747
0.88
%
Silexion Shareholders(2)
694,491
62.46
%
Moringa Sponsor Shares(3)
187,798
16.89
%
Distributees of Sponsor Investment Shares
5,000
0.45
%
PIPE investor
22,223
2.00
%
Founders Shares/ Backstop Shares
174,112
15.66
%
EarlyBird(3)
14,127
1.27
%
Director receiving RSU grant upon Closing
4,370
0.39
%
Total
1,111,868
100
%
(1)
Excludes 638,889 public warrants held by Moringa's public
        shareholders, which will be exercisable for New Silexion ordinary shares at an exercise price of $103.50 per share beginning 30 days after
        the Closing of the Business Combination.
(2)
Includes all securities issuable to security holders of Silexion on a fully-diluted
        basis, including New Silexion ordinary shares, New Silexion warrants, New Silexion options and New Silexion RSUs, and also includes 203,971
        New Silexion ordinary shares issued directly to GIBF in respect of the Chinese Subsidiary Transfer, as well as 16,817 New Silexion ordinary
        shares issued to GIBF upon the accelerated vesting of RSUs granted to it.
(3)
Excludes 21,112 private warrants held, in the aggregate, by
        the Moringa Sponsor and EarlyBird, which will be exercisable for New Silexion ordinary shares at an exercise price of $103.50 per share
        beginning 30 days after the Closing of the Business Combination.
2. Basis of Pro Forma Presentation
The unaudited pro forma condensed combined financial statements
were prepared in accordance with Article 11 of SEC Regulation S-X, as amended by the final rule, SEC Release No. 33-10786 "Amendments
to Financial Disclosures About Acquired and Disposed Businesses". The adjustments presented in the unaudited pro forma condensed
combined financial statements (collectively, the "
Pro Forma Adjustments
") have been
identified and presented to provide relevant information necessary for an understanding of New Silexion upon consummation of the Business
Combination and related transactions.
The unaudited pro forma combined statements of operations for
the nine-months period ended September 30, 2024 and for the year ended December 31, 2023 combine the historical statements of operations
of Moringa for the year ended December 31, 2023 (audited), and for the period from January 1 to August 14, 2024 (unaudited), and
the updated financial statements of New Silexion (formerly: Silexion) that show the effects of the reverse share split and reverse recapitalization
for the year ended December 31, 2023 (audited), and for the nine-months period ended September 30, 2024 (unaudited), subject to the Pro
Forma Adjustments, giving effect to the Business Combination as if it had been consummated on January 1, 2023.
The historical financial information has been adjusted
to reflect the Pro Forma Adjustments giving effect to the Business Combination and related transactions as described in more detail below.
52
The unaudited pro forma condensed combined financial information
is for illustrative purposes only. The financial results may have been different had New Silexion and Moringa been always combined. You
should not rely on the unaudited pro forma condensed combined financial information as being indicative of the historical results that
would have been achieved had Moringa always been combined or the future results that the Company will experience.
The unaudited pro forma condensed combined financial information
does not give effect to any anticipated synergies, operating efficiencies, tax savings, or cost savings that may be associated with the
Business Combination and related transactions as described in more detail below. Moringa and Silexion have not had any historical relationship
prior to the Business Combination. Accordingly, no pro forma adjustments were required to eliminate activities between the companies.
However, the unaudited pro forma condensed combined financial information includes certain share-based compensation that was granted upon
the consummation of the Business Combination, as well as net exercise of all Silexion warrants outstanding for New Silexion ordinary shares,
which occurred upon the consummation of the Business Combination.
Pro forma adjustments giving effect
to the Business Combination and related transactions:
A) Immediately prior to the Effective Time of the Acquisition
Merger, the vesting of all outstanding Silexion share-based incentive awards was accelerated and those awards became fully vested. At
the Effective Time of the Acquisition Merger, all of Silexion's share-based incentive awards were assumed by New Silexion and converted
into options to purchase New Silexion ordinary shares, based on the Equity Exchange Ratio. These pro forma financial statements reflect
the acceleration of the awards as a 2023 adjustment and subsequent elimination of remaining expenses in 2024.
In addition, the adjustment reflects the
issuance of 177,736 new RSUs of Silexion (before adjustment for reverse share split), which converted into 78,650 new RSUs of New Silexion
and issuance of 4,370 new RSU's of New Silexion, in the aggregate, at the Closing, to directors of New Silexion and employees of
New Silexion and its subsidiaries (of which 22,070 RSUs were granted to New Silexion directors) with a grant date fair value of $70.908
per RSU (each such number of RSUs of New Silexion retroactively reflects the reverse share split). All of the foregoing new RSUs were
vested upon the Closing, and the RSUs were settled for equivalent numbers of underlying New Silexion ordinary shares. In these pro
forma statements of operations, this expense was eliminated from the period ended September 30, 2024 and was moved back to 2023 as a pro
forma adjustment.
B) To reflect additional cash compensation to be paid
to Ilan Levin, a director of New Silexion, in an amount of $10 thousand per month, commencing on Closing and for a period of 36 months.
C) To reflect Transactions-related costs in an amount of $466. In the pro
forma statement of operations, it was assumed that the expenses were incurred in 2023 rather than 2024.
53
Therefore, Transactions-related expenses recorded in
New Silexion's statements of operations for the period ended September 30, 2024 were moved back to 2023 as a pro forma adjustment.
D) These unaudited pro forma financial statements reflect net exercise of all Silexion warrants over Preferred Shares outstanding and
their conversion to New Silexion ordinary shares, which occurred upon the consummation of the Business Combination. Related fair value
measurement gains or losses of those warrants were eliminated from the pro forma combined statements of operations.
E) To reflect financing loss recorded by New Silexion
upon Closing, equal to the difference between Moringa's net assets and liability-classified instruments measured at fair value issued
by New Silexion as part of the Business Combination. This loss was recorded in New Silexion's statements of operations for the period
ended September 30, 2024 and was moved back to 2023 as a pro forma adjustment.
F) To reflect the elimination of unrealized interest income
on investments held in the Trust Account.
G) Represents an obligation to issue ordinary shares of
New Silexion with a value of $337,500 (the "
ELOC Commitment Shares
") to White Lion
as a fee in consideration of White Lion's commitment to purchase New Silexion ordinary shares from New Silexion under the ordinary
share purchase agreement for New Silexion's equity line of credit.
H) To reflect fair value changes of New Silexion's A&R Sponsor Promissory
Note and EarlyBird Convertible Note (the "Notes"). See also Note 3(a) and (b) of New Silexion's interim financial statements
for the period ended September 30, 2024. It was assumed that fair value changes of the Notes until August 15, 2024 are equal to the unwinding
of the Notes' discount, using the discount rates in the Notes' valuation work.
I) To reflect the transfer by GIBF of its noncontrolling interest in Silexion's
Chinese subsidiary, Silenseed (China) Ltd., to New Silexion in exchange for 203,971 New Silexion ordinary shares upon the completion of
the Business Combination.
Pro forma weighted average shares outstanding
:
J) As the Business Combination is being reflected as if it had occurred at the beginning
of the earliest period presented, the calculation of weighted average shares outstanding for basic and diluted net loss per share assumes
that the shares issuable in connection with the Pro Forma Adjustments have been outstanding for the entirety of the periods presented.
Weighted average shares outstanding - basic and diluted (excluding a combined 660,001 ordinary shares underlying outstanding public warrants
and private placement warrants because including them would have had an anti-dilutive effect on net loss per share) for the nine-months
period ended September 30, 2024, and for the year ended December 31, 2023 are calculated based on the actual pro forma number of New Silexion
ordinary shares that were issued and outstanding upon the Closing, after taking into account actual redemptions of Moringa public shares.
54
Comparative Share Information
The following table sets forth selected historical comparative share information for
each of Moringa and New Silexion and unaudited pro forma condensed combined per share information for New Silexion after giving effect
to the Business Combination.
The weighted average shares outstanding and net earnings per share information reflect
the Business Combination as if it had occurred on January 1, 2023.
This information is only a summary and should be read together with the historical financial
statements of Moringa and New Silexion and related notes. The unaudited pro forma condensed combined per share information of Moringa
and New Silexion is derived from, and should be read in conjunction with, the unaudited pro forma combined financial statements and related
notes included above.
The unaudited pro forma combined earnings per share information below does not purport
to represent the earnings per share which would have occurred had Moringa and New Silexion been combined during the periods presented,
nor the earnings per share for any future date or period. Historically, Moringa's statement of operations included a presentation
of profit (loss) per share in a manner similar to the two-class method of income (loss) per ordinary shares. The two-class method is not
required in the pro forma income (loss) per ordinary shares as the Moringa Class A ordinary shares are no longer subject to redemption.
Moringa has included the effect of the warrants to purchase an aggregate of 660,001 Class A ordinary shares, in the aggregate, sold in
the IPO and the concurrent private placement in the calculation of diluted earnings per share, as they became exercisable commencing 30
days following the Closing. As a result, diluted earnings per ordinary share differs from basic earnings per ordinary share for the periods
presented. The share and per share information appearing in the table below does not reflect the reverse share split with respect to Moringa
historical data, but does reflect the reverse share split for the New Silexion historical data and for the pro forma combined data of
New Silexion.
55
Moringa Acquisition Corp (Period between January 1 and August 14,
        2024)
(Historical)
For the nine-months period ended September 30, 2024
Class A
subject to
Possible
Redemption
Non-
redeemable
Class A and
Class B
New Silexion
(Historical)
Pro Forma
Combined
(Actual
Redemption)
Weighted average shares outstanding – basic and diluted
87,722
3,355,000
291,407
1,127,365
Net profit (loss) per share – basic
$
0.39
$
(0.18
)
$
(50.43
)
$
(3.76
)
Moringa Acquisition Corp
(Historical)
For the year ended December 31, 2023
Class A
subject to
Possible
Redemption
Non-
redeemable
Class A and
Class B
New Silexion
(Historical)
Pro Forma
Combined
(Actual
Redemption)
Weighted average shares outstanding – basic and diluted
2,774,850
3,355,000
111,726
1,126,433
Net profit (loss) per share – basic
$
0.51
$
(0.34
)
$
(44.23
)
$
(16.27
)
56
MANAGEMENT'S DISCUSSION
AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF
OPERATIONS
Introductory Note
The following discussion and analysis
of our financial condition and results of operations (this "
MD&A
") should be read
in conjunction with the financial statements and the related notes included elsewhere in this prospectus. Some of the information contained
in this discussion and analysis or set forth in this prospectus, including information with respect to our plans, objectives, expectations,
projections, and strategy for our business and related financing, includes forward-looking statements that involve risks and uncertainties.
As a result of many factors, including those factors set out in the "Risk Factors" sections of this prospectus, our actual
results could differ materially from the results described in or implied by these forward-looking statements. See also the section entitled
"Special Note Regarding Forward-Looking Statements" in this prospectus.
Unless the context otherwise requires,
references to the "Company," "we," "us" and "our" in this MD&A generally refer to
Silexion Therapeutics Ltd., an Israeli company ("Silexion"), or, from and after the Business Combination, Silexion Therapeutics
Corp (formerly known as Biomotion Sciences), a Cayman Islands exempted company (also referred to herein as "New Silexion").
On August 15, 2024, New Silexion,
Silexion and Moringa completed the Business Combination pursuant to the Business Combination Agreement.
Overview
We are a Cayman Islands exempted company that was originally
formed for the purpose of effectuating the Business Combination and that now serves as a publicly-traded holding company for each of Silexion
(through which our operations are carried out) and Moringa (which has no operations). Our ordinary shares and warrants are listed on the
Nasdaq Global Market under the trading symbols "SLXN" and "SLXNW", respectively.
We conduct operations primarily through our principal subsidiary— Silexion—
which is a clinical-stage, oncology-focused biotechnology company engaged in the discovery and development of proprietary treatments for
KRAS-driven cancers. The KRAS gene is an oncogene that is involved in the regulation of cell division as a result of its ability to relay
external signals to the cell nucleus. Based on its research of refractory solid tumor cancers, Silexion is actively developing a platform
focused on the silencing of the KRAS oncogene using RNA-interference therapeutics. Silexion's lead product candidate, SIL-204B,
consists of locally administered small interfering RNAs, or siRNA, in an extended-release formulation, as a first-line treatment of locally
advanced pancreatic cancer patients, in combination with standard-of-care chemotherapy.
To date, Silexion has financed its operations primarily
with the net proceeds from private offerings of its ordinary shares and convertible preferred shares, grants from the Israeli Innovation
Authority (the "IIA"), convertible financing agreements and Simple Agreement for Future Equity (SAFE) financings, and royalty-bearing
grants from the IIA (which totaled $5.8 million through September 30, 2024). Since its inception, Silexion has incurred significant operating
losses. Silexion's net losses were $5.1 million and $3.5 million for the years ended December 31, 2023 and December 31, 2022, respectively.
The combined company's net losses (consisting of Silexion's net losses for all periods through the Business Combination, and
the combined company's net losses for all periods after) were $14.8 million and $3.4 million for the nine-month periods ended September
30, 2024, and 2023, respectively. As of September 30, 2024, we had an accumulated deficit of $41.6 million (reflecting Silexion's accumulated
deficit for all periods through August 15, 2024 and the combined company's accumulated deficit from August 16, 2024 through September
30, 2024). Silexion has not recognized any revenue to date.
We expect to continue to incur significant expenses and operating losses
for the foreseeable future. The net losses it incurs may fluctuate significantly from quarter to quarter. Our expenses will depend on
many factors, including the timing and extent of spending to further develop SIL-204 and initiate pre-clinical and clinical trials, support
research and development efforts, investments in potential additional pipe-line products, and increased overall compensation as we continue
to hire additional personnel. We anticipate that our expenses will increase if and as we:
●
apply for Orphan Drug Designation in both the U.S. and EU for its SIL-204B
        product;
●
initiate a clinical trial powered for statistical significance with respect
        to SIL-204B;
●
initiate toxicological studies with respect to SIL-204B;
●
seek marketing approvals for SIL-204B in various territories;
●
maintain, expand and protect our intellectual property portfolio;
●
hire additional operational, clinical, quality control and scientific personnel;
●
add operational, financial and management information systems and personnel,
        including personnel to support our product development, any future commercialization efforts and our prospective transition to a public
        company; and
●
invest in research and development and regulatory approval efforts in order
        to utilize our technology as a platform focused on the silencing of the KRAS oncogene using RNA-interference therapeutics.
57
Reverse Share Split
On November 27, 2024, we effected a 1-for-9
reverse share split of our authorized ordinary shares, including our issued and outstanding ordinary shares, with a market effective date
of November 29, 2024. Unless specifically provided otherwise herein, all share, per share and related option and warrant information for
New Silexion (but not Moringa) presented in this prospectus has been retroactively adjusted to reflect the reduced number of shares and
the increase in the share price which resulted from the reverse share split.
Recent Developments
Our prospective financial condition and
results of operations in the period following the Closing of the Business Combination will be impacted by the following transactions,
all of which were entered into at or around the time of the Closing:
January 2025 Warrant
Inducement Transaction
For a description of the Warrant Inducement
Transaction, please see "
January 2025
Transactions
Related to Offering Under This Prospectus—January 2025 Warrant Inducement Transaction
" above in this prospectus, which
description is incorporated by reference herein.
January 2025 Financing
On January 15, 2025, New Silexion offered
and sold in a public offering on a best efforts basis (the "
January 2025
Offering
")
(i) 2,145,998 of New Silexion ordinary shares, (ii) 1,557,705 pre-funded warrants to purchase up to 1,557,705 New Silexion ordinary shares
(the "
January 2025 Pre-Funded Warrants
"), and (iii) 3,703,703 warrants to purchase
up to 3,703,703 New Silexion ordinary shares (the "
January 2025
Investor
Warrants
" and together with the Pre-Funded Warrants, the "
January 2025
Warrants
"),
at a purchase price of $1.35 per share and accompanying January 2025 Investor Warrant, and $1.3499 per January 2025 Pre-Funded Warrant
and accompanying January 2025 Investor Warrant. Aggregate gross proceeds from the January 2025 Offering (without taking into account any
proceeds from any future exercises of January 2025 Warrants) were approximately $5 million. The January Offering closed on January 17,
2025, subject to the satisfaction of customary closing conditions.
The January 2025 Pre-Funded Warrants are
immediately exercisable at an exercise price of $0.0001 per share and will not expire until exercised in full. The January 2025 Investor
Warrants have an exercise price of $1.35 per share, are immediately exercisable, and may be exercised for five years from issuance.
A holder of the January 2025 Warrants will
not have the right to exercise any portion of its Pre-Funded Warrants and Investor Warrants if the holder (together with such holder's
affiliates, and any persons acting as a group together with such holder or any of such holder's affiliates or any other persons
whose beneficial ownership of ordinary shares would be aggregated with the holder's or any of the holder's affiliates), would
beneficially own ordinary shares in excess of 4.99% (or, at the election of the holder, 9.99%) of the number of the ordinary shares outstanding
immediately after giving effect to such exercise.
58
Certain investors in the January 2025 Offering
entered into a definitive securities purchase agreement with the Company (the "
January 2025 Purchase
Agreement
"). The Purchase Agreement contains representations, warranties, indemnification and other provisions customary
for transactions of this nature. Pursuant to the January 2025 Purchase Agreement, New Silexion agreed to abide by certain customary standstill
restrictions for a period of sixty (60) days following the closing of the January 2025 Offering. In addition, subject to limited exceptions,
the January 2025 Purchase Agreement provides that for a period of one year following the closing of the January 2025 Offering, the Company
will not effect or enter into an agreement to effect a "variable rate transaction" as defined in the January 2025 Purchase
Agreement.
Wainwright acted as the sole placement agent
(the "
Placement Agent
"), on a "best efforts" basis, in connection with
the January 2025 Offering. Pursuant to an engagement agreement that New Silexion entered into with Wainwright, New Silexion issued to
Wainwright or its designees 259,259 warrants to purchase up to 259,259 New Silexion ordinary shares, representing 7.0% of the sum of the
shares and January 2025 Pre-Funded Warrants sold in the January 2025 Offering (the "
January 2025
Placement
Agent Warrants
"). The January 2025 Placement Agent Warrants have an exercise price of $1.6875 per share (representing 125%
of the public offering price per share and accompanying January 2025 Investor Warrant), are exercisable for five years from the date
of the commencement of sales in this offering, and otherwise reflect substantially the same terms as the January 2025 Investor Warrants.
The net proceeds to
New Silexion from the January 2025 Offering were approximately $4.26 million before deducting estimated offering expenses payable by New
Silexion.
Prior to the January 2025 Warrant Inducement Transaction, a total of 640,257 January
2025 Investor Warrants were exercised into 640,257 New Silexion ordinary shares and 1,557,705 January 2025 Pre-Funded Warrants were exercised
into 1,557,705 New Silexion ordinary shares, for a total net proceeds of $0.86 million. As of February 11, 2025, the January 2025 Pre-Funded
Warrants have been exercised in full and 841,923 January 2025 Investor Warrants remain unexercised at an exercise price of $1.35 per share.
Completion of Business
Combination Transaction
On August 15, 2024, New Silexion, Silexion
and Moringa completed the previously-announced Business Combination pursuant to the Amended and Restated Business Combination Agreement,
dated April 3, 2024, by and among New Silexion, Merger Sub 1, Merger Sub 2, Moringa and Silexion. In connection with the Closing of the
Business Combination, New Silexion changed its name from "Biomotion Sciences" to "Silexion Therapeutics Corp".
Pursuant to the Business Combination Agreement,
among other things, (i) Merger Sub 2 merged with and into Moringa, with Moringa continuing as the surviving company and a wholly-owned
subsidiary of New Silexion and (ii) Merger Sub 1 merged with and into Silexion, with Silexion continuing as the surviving company and
a wholly-owned subsidiary of New Silexion.
Upon the effectiveness of the SPAC Merger,
each outstanding Moringa Class A ordinary share, that had not been redeemed and the sole outstanding Moringa Class B ordinary
share converted into a New Silexion ordinary share on a one-for-one basis. Each outstanding Moringa warrant converted into a New
Silexion warrant, exercisable at the same exercise price. Upon the effectiveness of the Acquisition Merger, each outstanding ordinary
share and preferred share of Silexion converted into such number of New Silexion ordinary shares as is equal to the quotient obtained
by dividing (x) the quotient obtained by dividing (1) $62,500,000 by (2) the number of fully diluted Silexion equity securities,
by (y) $10.00 (the "
Silexion Equity Exchange Ratio
"). Each outstanding Silexion
warrant and Silexion option to purchase one Silexion share, and Silexion restricted share unit (RSU) that may be potentially settled for
one Silexion share, became exercisable for, or became subject to settlement for (as applicable), such number of New Silexion ordinary
shares as are equal to the Silexion Equity Exchange Ratio. The exercise price per New Silexion ordinary share of each such converted Silexion
option and Silexion warrant were adjusted based on dividing the existing per share exercise price by the Silexion Equity Exchange Ratio.
The terms of vesting, exercise and/or settlement, as applicable, of such converted options, warrants and RSUs remain the same following
such conversion, except that the vesting of each Silexion option accelerated immediately prior to the Acquisition Merger, such that the
New Silexion option into which it has been converted was fully vested, and all Silexion warrants were exercised (on a cashless basis)
immediately prior to the Acquisition Merger.
59
In connection with the Moringa shareholder
vote to approve the Business Combination Agreement and the Business Combination, holders of an aggregate of 427,297 Moringa ordinary shares
properly exercised their right to have their shares redeemed for a full pro rata portion of the Trust Account holding the proceeds from
Moringa's IPO, which was approximately $11.575 per share, or $4,946,046 in the aggregate.
As a result of the redemptions of Moringa
ordinary shares, a total of 87,722 Moringa public shares remained outstanding at the Closing. After giving effect to the Business Combination
and additional changes to share capital, immediately following the Closing, there were 9,768,396 New Silexion ordinary shares issued and
outstanding.
PIPE Financing
In connection with, and immediately prior
to the Closing of, the Business Combination, Moringa raised $2.0 million via a private investment in public entity financing (the "
PIPE
Financing
"), whereby Moringa sold to Greenstar, LP, an affiliate of the Moringa Sponsor (the "
PIPE
Investor
"), 200,000 newly issued Moringa ordinary shares at a price of $10.00 per share, pursuant to a subscription agreement,
dated as of August 15, 2024, by and among Moringa, New Silexion and the PIPE Investor (the "
PIPE
Agreement
"). Those 200,000 shares automatically converted upon the Closing of the Business Combination into an equivalent
number of New Silexion ordinary shares (the "
PIPE Shares
"). The PIPE Investor is entitled
to customary registration rights in respect of the PIPE Shares under the PIPE Agreement, pursuant to which New Silexion has agreed that,
within 60 days after the date of the Closing, it will file with the SEC a registration statement registering the resale of the PIPE Shares
by the PIPE Investor, and use its commercially reasonable efforts to have that registration statement declared effective by 180 days after
the Closing (or 90 days after the Closing if the SEC does not review that filing).
The funds raised from the PIPE Financing,
together with remaining funds in Moringa's Trust Account after payments to redeeming public shareholders, were used for financing
support for Moringa and New Silexion, as well as for payment to service providers to whom outstanding amounts were owed by Moringa, including
parties that had provided financial advisory services and capital markets advisory services to Moringa during the period leading up to
the Closing.
The foregoing summary provides only a
brief description of the PIPE Agreement and does not purport to be complete. The summary is qualified in its entirety by the full text
of the PIPE Agreement, which serves as Exhibit 10.2 to the registration statement of which this prospectus forms a part, and which is
incorporated herein by reference.
Settlement of Amounts
Due Under Marketing Agreement with EarlyBird
Prior to the Closing, Moringa reached agreement
with EarlyBird on the reduction, to $1.6 million, in the aggregate, of the fee payable to EarlyBird under the Business Combination Marketing
Agreement entered into by Moringa with EarlyBird at the time of Moringa's initial public offering (the "
Marketing
Agreement
"). Pursuant to the final invoice provided by EarlyBird under the Marketing Agreement at the Closing, Moringa paid
$350,000 of cash to EarlyBird from Moringa's trust account holding the proceeds from Moringa's IPO and its concurrent private
placement (the "
Trust Account
") at the Closing, and New Silexion issued to EarlyBird
the EarlyBird Convertible Note, which is due on December 31, 2025, in an amount of $1,250,000 to be paid by New Silexion to EarlyBird
in cash and/or via conversion of outstanding amounts into New Silexion ordinary shares.
The EarlyBird Convertible Note bears interest
at a rate of 6% per annum and matures on December 31, 2025 (the "
Maturity Date
"). If
not repaid on or prior to the Maturity Date or such earlier date as to which the repayment obligation may be accelerated under the note,
or not converted in accordance with the terms thereof, the rate of interest applicable to the unpaid principal amount would be adjusted
to (15%) per annum. New Silexion is required to make mandatory prepayments on the note (which shall first be applied to accrued interest
and then to principal) from time to time in amounts equal to ten percent (10%) of the gross proceeds received by New Silexion from any
equity financings consummated by it prior to the Maturity Date. New Silexion is entitled to voluntarily prepay any additional part of,
or all of, the principal and accrued interest, in one or more installments without penalty, prior to the Maturity Date.
60
EarlyBird, in turn, may elect, at its sole
discretion, at any time on or prior to the Maturity Date, to elect to convert all or part of the then outstanding principal and/or accrued
interest under the EarlyBird Convertible Note into New Silexion ordinary shares, at a per share conversion price equal to 95% of the volume
weighted average price of a New Silexion ordinary share for the five trading days immediately prior to the date of New Silexion's
receipt of a conversion notice, provided, however, New Silexion is not required to issue, and EarlyBird may not elect to convert the principal
and/or accrued interest into an aggregate number of New Silexion ordinary shares that would exceed the maximum number of ordinary shares
permitted by Section 5635 of the Nasdaq Listing Rules to be issued without the approval of New Silexion's shareholders, unless such
approval is obtained.
Under the EarlyBird Convertible Note, New
Silexion agreed to promptly file a registration statement with the SEC covering the resale of the ordinary shares that may be issued upon
conversion of the note and use its best efforts to have such registration statement declared effective as soon thereafter as possible.
In the event such registration statement is not declared effective by the SEC within 180 days from the date hereof, then an event of default
shall have occurred under the note, triggering all amounts under the note to become due and payable immediately and automatically. The
registration statement of which this prospectus forms a part is being filed, in part, to comply with that registration requirement.
The foregoing summary provides only a brief
description and does not purport to be complete. The summary is qualified in its entirety by the full text of the final invoice provided
by EarlyBird under the Marketing Agreement at the Closing, and the EarlyBird Convertible Note, which serve as Exhibits 10.1.1 and 10.1.2
to the registration statement of which this prospectus forms a part, and which are incorporated herein by reference.
Amended and Restated
Sponsor Promissory Note
Effective as of the Closing, New Silexion
issued to the Sponsor, and Sponsor accepted, in amendment and restatement, and replacement, in their entirety, of all existing promissory
notes issued by Moringa to the Sponsor from the IPO until the Closing (and as to which the obligations of Moringa were assigned to New
Silexion upon the Closing), the A&R Sponsor Promissory Note, in an amount of $3,433,000, which reflected the total amount owed by
Moringa to the Sponsor through the Closing. The maturity date of the A&R Sponsor Promissory Note is the 30-month anniversary of the
Closing (i.e., February 15, 2027). Amounts outstanding under the A&R Sponsor Promissory Note may be repaid (unless otherwise decided
by New Silexion) only by way of conversion into New Silexion ordinary shares ("
Note Shares
")
in accordance with the terms set forth in the form of A&R Sponsor Promissory Note. New Silexion and the Sponsor may also convert amounts
outstanding under the A&R Sponsor Promissory Note at the price per share at which New Silexion conducts an equity financing following
the Closing, subject to a minimum conversion amount of $100,000, in an amount of Note Shares constituting up to thirty percent (30%) of
the number of New Silexion ordinary shares issued and sold by New Silexion in such equity financing. The Sponsor may also elect to convert
amounts of principal outstanding under the note into New Silexion ordinary shares at any time following the 24-month anniversary of the
Closing, subject to a minimum conversion of $10,000, at a price per share equal to the volume weighted average price of the New Silexion
ordinary shares on the principal market on which they are traded during the 20 consecutive trading days prior to the conversion date.
The foregoing summary provides only a brief
description of the A&R Sponsor Promissory Note and does not purport to be complete. The summary is qualified in its entirety by the
full text of the A&R Sponsor Promissory Note, which serves as Exhibit 10.5 to the registration statement of which this prospectus
forms a part, and which is incorporated herein by reference.
ELOC Financing
Also in connection with the Closing, New
Silexion entered into the White Lion Purchase Agreement with White Lion, for an equity line of credit, whereby New Silexion will be able
to request to sell to White Lion, and White Lion, which agreement was amended as of January 14, 2025, will be required to purchase, via
private placement transactions, up to $15.0 million of New Silexion ordinary shares from time to time after the Closing, up until December
31, 2025 (unless the agreement is terminated sooner), subject to certain limitations and conditions as described therein. The number of
New Silexion ordinary shares that New Silexion may require White Lion to purchase in any single sales notice will depend on a number of
factors, including the type of purchase notice that New Silexion delivers. Similarly, the purchase price to be paid by White Lion for
any shares that New Silexion requires it to purchase will depend on the type of sales notice that New Silexion delivers. New Silexion
has also granted registration rights to White Lion pursuant to an accompanying registration rights agreement.
61
In consideration for the commitments of
White Lion, New Silexion agreed to issue to White Lion an aggregate of $337,500 of New Silexion ordinary shares based on the closing price
of the New Silexion ordinary shares on the day that is the earlier of (i) the business day prior to effectiveness of the registration
statement registering the resale of the shares issuable under the White Lion Purchase Agreement and (ii) the business day prior to the
180
th
day following the Closing Date of the Business Combination.
Based on the closing price of the ordinary shares on September 16, 2024, we have issued to White Lion, on September 18, 2024, 365,418
ordinary shares in respect of White Lion's commitments under the White Lion Purchase Agreement.
Amended and Restated
Registration Rights and Lock-Up Agreement
Prior to the Closing under the Business
Combination Agreement, on August 14, 2024, New Silexion, Moringa, Moringa Sponsor, the distributees of Sponsor Investment Shares, certain
of Silexion's pre-Business Combination shareholders and the PIPE Investor entered into (and EarlyBird will be bound by) the A&R
Registration Rights and Lock-Up Agreement, which became effective as of the Closing. Under the agreement, New Silexion has assumed Moringa's
existing obligations under Moringa's prior registration rights agreement (entered into in connection with its IPO) and has granted
registration rights to the Moringa Sponsor, the distributees of Sponsor Investment Shares, certain of Silexion's pre-Business Combination
shareholders, the PIPE Investor and EarlyBird with respect to certain securities of New Silexion.
Under the A&R Registration Rights and
Lock-Up Agreement, New Silexion has agreed to provide the holders party thereto customary demand and shelf registration rights (subject
to certain minimum size offerings) and piggy-back rights on primary and secondary offerings, subject to customary cut-back provisions.
Under the lock-up provisions of the agreement,
lock-up periods will apply following the Closing to securities of New Silexion that are held by the holders who are party to the agreement,
subject to permitted transfers to certain categories of "Permitted Transferees". Specifically, those lock-up periods will
apply to the following categories of securities for the following periods of time post-Closing:
●
Sponsor/Silexion Lock-Up Period
: (A) 50% of the Sponsor Investment
        Shares held by the Sponsor and its distributees and 50% of the New Silexion securities held by the former Silexion shareholders who are
        party to the agreement, in each case, upon the Closing, are subject to a lock-up period ending on the earlier of (i) six (6) months after
        the completion of the Business Combination, and (ii) the date on which New Silexion will consummate a liquidation, merger, amalgamation,
        share exchange, reorganization, or other similar transaction after the Business Combination that results in all of New Silexion's
        shareholders having the right to exchange their ordinary shares for cash, securities or other property, and (B) the other 50% of the Sponsor
        Investment Shares held by the Sponsor and its distributees and 50% of the New Silexion securities held by the former Silexion shareholders
        party to the agreement, in each case, upon the Closing, will be subject to a lock-up period that will end on the earliest of (x) six (6)
        months after the date of the consummation of the Business Combination, (y) the date on which New Silexion consummates a liquidation, merger,
        amalgamation, share exchange, reorganization, or other similar transaction after the Business Combination that results in all of New Silexion's
        shareholders having the right to exchange their ordinary shares for cash, securities or other property, or (z) the date on which the last
        reported sale price of New Silexion's ordinary shares equals or exceeds $12.00 per share (as adjusted for share splits, share dividends,
        rights issuances, subdivisions, reorganizations, recapitalizations and the like) for any 20 trading days within any 30-trading day period.
62
●
Private Shares and Private Warrants Lock-Up Period:
The lock-up
        period on all New Silexion ordinary shares issued pursuant to the Business Combination in exchange for private placement shares and private
        placement warrants purchased by or issued to the Sponsor and EarlyBird concurrently with Moringa's initial public offering will
        remain (as provided in the documentation for Moringa's initial public offering) 30 days after the Closing.
●
Representative Shares
Lock-Up
        Period
. The lock-up period on all representative shares that are held by EarlyBird will remain (as provided in the documentation
        for Moringa's initial public offering) three months after the Closing.
●
Note Shares and PIPE Shares
Lock-Up
        Period
. Note Shares (as defined under "
Amended and Restated Sponsor Promissory Note
"
        below) issued to the Sponsor upon conversion of amounts due under the A&R Sponsor Promissory Note and PIPE Shares issued to the PIPE
        Investor are not subject to any lock-up periods following the Closing.
The foregoing summary provides only a brief
description of the A&R Registration Rights and Lock-Up Agreement and does not purport to be complete. The summary is qualified in
its entirety by the full text of the A&R Registration Rights and Lock-Up Agreement, which serves as Exhibit 10.4 to the registration
statement of which this prospectus forms a part, and which is incorporated herein by reference.
Components of our Results of Operations
Operating Expenses
Research and Development Expenses
Research and development expenses include costs directly
attributable to the conduct of research and development programs, including the cost of payroll and related expenses, payroll taxes and
other employee benefits including share-based compensation related to employees, subcontractors, lab expenses, preclinical and clinical
trials cost, material costs and consulting fees.
We expect to continue to invest in research and development
to develop SIL-204, including hiring additional employees and continuing the research and development of that product candidate. As a
result, we expect that our research and development expenses will continue to increase in the future.
General and Administrative Expenses
General and administrative expenses consist primarily
of personnel costs, including share-based compensation related to directors and employees, patent application fees, office space rental
costs, and maintenance expenses, external professional service costs, including legal, accounting, audit, finance, human resource services,
travel expenses and other consulting fees.
We expect that our general and administrative expenses
will increase in the future to fund our continued research and development activities, primarily due to increased headcount to support
anticipated growth in the business and due to incremental costs associated with operating as a public company, including costs to comply
with the rules and regulations applicable to public companies such as costs related to compliance and reporting obligations pursuant to
the rules and regulations of the SEC and stock exchange listing standards, public relations, insurance and professional services.
Financial expenses (income), net
The finance expenses consisted primarily of change in
fair value of warrants and financial liabilities measured at fair value, interest income and exchange rate differences expenses.
63
Results of Operations
Comparison of nine-month period ended
September 30, 2024 and 2023
The following table summarizes our results of operations
for the nine-month periods ended September 30, 2024 and 2023:
Nine-month period ended
September
        30,
2024
2023
(U.S. dollars, in thousands)
Operating expenses:
Research and development, net
$
4,944
$
2,451
General and administrative
5,727
502
Total operating expenses
10,671
2,953
Operating loss
10,671
2,953
Financial expenses, net
4,092
449
Loss before income tax
14,763
3,402
Income tax
9
26
Net loss for the nine-month period
$
14,772
$
3,428
Research and Development Expenses
The following table summarizes our research and development
expenses for the nine-month periods ended September 30, 2024 and 2023:
Nine-month period ended
September
        30,
2024
2023
(U.S. dollars, in thousands)
Payroll and related expenses
$
928
$
729
Share-based compensation expenses
2,424
57
Subcontractors and consultants
1,425
1,444
Materials
3
16
Rent and maintenance
106
124
Travel expenses
13
27
Other
45
54
Total research and development expenses
$
4,944
$
2,451
Research and development expenses increased by approximately
$2.4 million, or 96%, to $4.9 million for the nine-month period ended September 30, 2024, compared to $2.5 million for the nine-month
period ended September 30, 2023. The increase resulted mainly from an increase in non-cash share-based compensation expenses in an amount
of $2.4 million and from an increase in payroll and related expenses in an amount of $0.2 million.
Research and development expenses for the nine-month
periods ended September 30, 2024 and September 30, 2023 included approximately $0.2 million and $0.9 million, respectively, related to
the development of Loder, and $4.7 million and $1.6 million, respectively, related to the development of SIL-204B. Aggregate research
and development expenses since inception for our Loder program, as of September 30, 2024 and as of September 30, 2023, were approximately
$18.4 million and $18.3 million, respectively. Aggregate research and development expenses since inception for the SIL-204B program, as
of September 30, 2024 and as of September 30, 2023, were approximately $8.3 million and $2.2 million, respectively.
64
General and Administrative Expenses
The following table summarizes our general and administrative
expenses for the nine-month periods ended September 30, 2024 and 2023:
Nine-month periods ended
September
        30,
2024
2023
(U.S. dollars, in thousands)
Payroll and related expenses
$
856
$
190
Share-based compensation expenses
3,438
39
Professional services
1,053
79
Depreciation
37
39
Rent and maintenance
90
67
Patent registration
25
18
Travel expenses
72
31
Other
156
39
Total general and administrative expenses
$
5,727
$
502
General and administrative expenses increased by approximately
$5.2 million, or 1,040%, to $5.7 million for the nine-month period ended September 30, 2024, compared to $0.5 million for the nine-month
period ended September 30, 2023. The increase resulted mainly from an increase in non-cash share-based compensation expenses in an amount
of $3.4 million, an increase in professional services costs primarily related to one-time legal, accounting, and other expenses associated
with the costs of becoming a public company and the SPAC merger in an amount of $1.0 million, and an increase in payroll and related expenses
in an amount of $0.7 million.
Financial expenses, net
Financial expenses, net increased by approximately
$3.7 million, or 925%, to an expense of $4.1 million for the nine-months ended September 30, 2024 compared to an expense of $0.4 million
for the nine months ended September 30, 2023. This increase was mainly due to an increase in an amount of $4.8 million in one-time loss
upon entering Transactions expenses, offset in part by (i) an increase in revaluation income of financial instruments (warrants and promissory
notes) in an amount of $0.9 million, and (ii) a decrease in foreign exchange loss in an amount of $0.3 million for the nine-month period
ended September 30, 2024.
65
Net loss
Net loss increased by approximately $11.4 million,
or 335.3%, to $14.8 million for the nine-month period ended September 30, 2024, compared to $3.4 million for the nine-month period ended
September 30, 2023. The increase was mainly due to an increase in our research and development expenses, general and administrative expenses,
and financial expenses including significant non-cash items related to share-based compensation, transaction costs and costs related to
becoming a public company.
Comparison of three-month periods
ended September 30, 2024 and 2023
The following table summarizes our results of operations
for the three-month periods ended September 30, 2024 and 2023:
Three-month period ended
September
        30,
2024
2023
Operating expenses:
(U.S. dollars, in thousands)
Research and development, net
$
3,217
$
535
General and administrative
4,819
196
Total operating expenses
8,036
731
Operating loss
8,036
731
Financial expenses, net
3,822
72
Loss before income tax
11,858
803
Income tax
2
6
Net loss for the three-month period
$
11,860
$
809
Research and Development Expenses
The following table summarizes our research and development
expenses for the three-month periods ended September 30, 2024 and 2023:
Three-month period ended
September
        30,
2024
2023
(U.S. dollars, in thousands)
Payroll and related expenses
$
453
$
198
Share-based compensation expenses
2,385
19
Subcontractors and consultants
297
236
Materials
-
-
Rent and maintenance
57
46
Travel expenses
-
-
Other
25
36
Total research and development expenses
$
3,217
$
535
Research and Development Expenses
Research and development expenses increased by approximately
$2.7 million, or 540%, to $3.2 million for the three-month period ended September 30, 2024, compared to $0.5 million for the three-month
period ended September 30, 2023. The increase resulted mainly from an increase in non-cash share-based compensation expenses in an amount
of $2.4 million and from an increase in payroll and related expenses in an amount of $0.3 million.
Research and development expenses for the three-month
periods ended September 30, 2024 and September 30, 2023 included approximately $0.01 million and $0.4 million, respectively, related to
the development of Loder, and $3.2 million and $0.2 million, respectively, related to the development of SIL-204B.
66
General and Administrative Expenses
The following table summarizes our general and administrative
expenses for the three-month periods ended September 30, 2024 and 2023:
Three-month period ended
September
        30,
2024
2023
(U.S. dollars, in thousands)
Payroll and related expenses
$
575
$
71
Share-based compensation expenses
3,413
13
Professional services
605
51
Depreciation
22
10
Rent and maintenance
18
25
Patent registration
-
2
Travel expenses
56
15
Other
130
9
Total general and administrative expenses
$
4,819
$
196
General and administrative expenses increased by approximately
$4.6 million, or 2,300%, to $4.8 million for the three-month period ended September 30, 2024, compared to $0.2 million for the three-month
period ended September 30, 2023. The increase resulted mainly from an increase in non-cash share-based compensation expenses in an amount
of $3.4 million, an increase in professional services costs primarily related to one-time legal, accounting, and other expenses associated
with the costs of becoming a public company and the SPAC merger in an amount of $0.6 million, and an increase in payroll and related expenses
in an amount of $0.5 million.
Financial expenses, net
Financial
expenses, net increased by approximately $3.7 million, or 3,700% to expense of $3.8 million for the three-month period ended September
30, 2024 compared to financial expenses, net of $0.1 million for the three-month period ended September 30, 2023. This increase was mainly
due to an increase in an amount of $4.8 million in one-time loss upon entering Transactions, offset, in part, by an increase in revaluation
income of financial instruments (warrants and promissory notes) in the amount of $1.1 million.
67
Net loss
Net loss increased by approximately $11.1 million,
or 1,387.5%, to $11.9 million for the three-month period ended September 30, 2024, compared to $0.8 million for the three-month period
ended September 30, 2023. The increase was mainly due to an increase in our research and development expenses, general and administrative
expenses, and financial expenses including significant non-cash items related to share-based compensation, transaction costs and costs
related to becoming a public company.
Comparison of Years
        ended December 31, 2023 and 2022
The following table summarizes our results of operations for the years ended
December 31, 2023 and 2022:
Years ended December 31,
2023
2022
Operating expenses:
Research and development, net
$
3,708
$
3,226
General and administrative
973
634
Total operating expenses
4,681
3,860
Operating loss
4,681
3,860
Financial expenses (income), net
395
(396
)
Loss before income tax
5,076
3,464
Income tax
32
24
Net loss for the year
$
5,108
$
3,488
Research and Development Expenses
The following table summarizes our research and development expenses for
the years ended December 31, 2023 and 2022:
Years ended December 31,
2023
2022
Payroll and related expenses
$
973
$
1,192
Subcontractors and consultants
2,467
1,595
Materials
13
191
Rent and maintenance
160
175
Travel expenses
37
42
Other
58
31
Total research and development expenses
$
3,708
$
3,226
Research and development expenses increased by approximately
$0.5 million, or 15.6% to $3.7 million for the year ended December 31, 2023, compared to $3.2 million for the year ended December 31,
2022. The increase resulted mainly from an increase in subcontractors in the amount of $0.9 million partially offset by a decrease in
payroll and related expenses in the amount of $0.2 million and a decrease in materials costs in the amount of $0.2 million.
Research and development expenses for the year ended December 31, 2023 and
December 31, 2022 included approximately $0.8 million and $2.6 million related to the development of Loder, respectively, and $2.9 million
and $0.6 million related to the development of SIL-204B, respectively. Aggregate research and development expenses since inception for
Loder program, as of December 31, 2023 and as of December 31, 2022, were approximately $18.2 million and $17.4 million, respectively.
Aggregate research and development expenses since inception for SIL-204B program, as of December 31, 2023 and as of December 31, 2022,
were approximately $3.6 million and $0.6 million, respectively.
68
The following table summarizes our general and administrative expenses for
the years ended December 31, 2023 and 2022:
Years ended December 31,
2023
2022
Payroll and related expenses
$
356
$
219
Professional Services
386
197
Depreciation
45
57
Rent and maintenance
86
71
Patent registration
22
32
Travel expenses
31
—
Other
47
58
Total general and administrative expenses
$
973
$
634
General and administrative expenses increased by approximately $0.4 million,
or 66.7% to approximately $1.0 million for year ended December 31, 2023, compared to approximately $0.6 million for the year ended December
31, 2022. The increase resulted mainly from an increase in payroll and related expenses in the amount of $0.1 million and from an increase
of professional services costs in the amount of $0.2 million.
Financial expenses, net
Financial expenses (income), net increased by approximately $0.8 million,
or 200.0% to expense of $0.4 million for the year ended December 31, 2023 compared to income of $0.4 million for the year ended December
31, 2022. This increase was mainly due to revaluation of warrants in the amount of $1.0 million for the year ended December 31, 2022 offset
by a decrease of $0.2 million in foreign exchange loss.
Net loss
Net loss increased by approximately $1.6 million, or 45.7% to $5.1 million
for the year ended December 31, 2023, compared to $3.5 million for the year ended December 31, 2022. The increase was mainly due to increase
in our research and development expenses, general and administrative expenses and financial expenses.
Liquidity and Capital Resources
Overview
Our capital requirements will depend on many factors, including the timing
and extent of spending to further develop SIL-204 and initiate pre-clinical and clinical trials, support research and development efforts,
investments in potential additional pipe-line products, and increased overall compensation as we continue to hire additional personnel.
For the nine-month periods ended September 30, 2024 and 2023, and for the years ended December 31, 2023 and 2022, we had net losses of
$14.8 million and $3.4 million, and $5.1 million and $3.5 million, respectively. As of September 30, 2024, our cash and cash equivalents
totaled $2.0 million.
69
To date, our principal sources of liquidity have been
proceeds from private offerings of our ordinary shares and convertible preferred shares, grants from the Israeli Innovation Authority,
and issuance of convertible financing agreements (CFA) and Simple Agreement for Future Equity (SAFE).
Based on our current business plan, we believe our current cash and cash
equivalents, and anticipated cash flow from operations, will not be sufficient to meet our anticipated cash requirements for the next
12 months from the date of this prospectus. We will need to raise additional capital to finance our operations, expand our business and
pipeline, or for other reasons.
Our audited consolidated financial statements for the year ended December
31, 2023 and our unaudited condensed financial statements for the nine-month period ended September 30, 2024 included in this prospectus
note that there is substantial doubt about our ability to continue as a going concern as of such date; and in its report accompanying
our audited consolidated financial statements included herein, our independent registered public accounting firm included an explanatory
paragraph stating that our recurring losses from operations and our cash outflows from operating activities raise substantial doubt as
to our ability to continue as a going concern. This means that our management and our independent registered public accounting firm have
expressed substantial doubt about our ability to continue our operations without an additional infusion of capital from external sources.
Our audited consolidated financial statements have been prepared on a going concern basis and do not include any adjustments that may
be necessary should we be unable to continue as a going concern. If we are unable to finance our operations, our business would be in
jeopardy and we might not be able to continue operations and might have to liquidate our assets. In that case, investors might receive
less than the value at which those assets are carried on our unaudited condensed financial statements for the nine-month period ended
September 30, 2024 and year ended December 31, 2023, and it is likely that investors would lose all or a part of their investment.
We have lease obligations and other contractual obligations
and commitments as part of our ordinary course of business. See "
Note 4: Operating Leases
"
and "
Note 6: Commitments and Contingent Liabilities"
to our consolidated financial
statements for the year ended December 31, 2023 for information about our lease obligations.
We did not have during the periods presented, and we do
not currently have, any off-balance sheet arrangements involving commitments or obligations, including contingent obligations, arising
from arrangements with unconsolidated entities or persons that have or are reasonably likely to have a material current or future effect
on our financial condition, results of operations, liquidity, cash requirements or capital resources.
January
2025 Warrant Inducement Transaction
On January 29, 2025, New Silexion entered
into the Inducement Letter with certain Holders of certain of New Silexion's existing warrants to purchase up to 2,221,523 shares
of New Silexion ordinary shares issued on January 17, 2025 with a five year term at an exercise price of $1.35 per share (the "
Existing
Warrants
").
70
Pursuant to the Inducement Letter, the Holders
agreed to exercise for cash their Existing Warrants to purchase an aggregate of 2,221,523 of New Silexion's ordinary shares at the
exercise price of $1.35 per share in consideration of New Silexion's agreement to issue new ordinary share purchase warrants (the
"
New Warrants
") to purchase up to an aggregate of 2,221,523 of New Silexion's
ordinary shares (the "
New Warrant Shares
"), at an exercise price of $1.50 per share.
The Holders also paid New Silexion an additional $0.125 per New Warrant issued in the offering. New Silexion received aggregate gross
proceeds of approximately $3.3 million from the exercise of the Existing Warrants by the Holders, before deducting placement agent fees
and other offering expenses payable by New Silexion.
New Silexion engaged Wainwright to act as
its exclusive placement agent in connection with the transactions contemplated by the Inducement Letter. New Silexion  also issued
to Wainwright or its designees warrants (the "
Placement Agent Warrants
") to purchase
up to 155,507 ordinary shares (representing 7.0% of the Existing Warrants being exercised), which have the same terms as the New Warrants
except the Placement Agent Warrants have an exercise price equal to $1.8438 per share (125% of the sum of the exercise price of the Existing
Warrants and the additional $0.125 paid per New Warrant). Similar to the New Warrants, the Placement Agent Warrants will be immediately
exercisable from the date of issuance until the twenty-four month anniversary of the effective date of the Resale Registration Statement
(as defined below).
The closing of the transactions contemplated
pursuant to the Inducement Letter occurred on January 30, 2025 (the "
Closing Date
"),
subject to satisfaction of customary closing conditions. New Silexion also agreed to file this registration statement (this "
Resale
Registration Statement
") within thirty (30) calendar days of the date of the Inducement Letter, and to use commercially reasonable
efforts to have such Resale Registration Statement declared effective by the SEC within sixty (60) calendar days following the date of
the Inducement Letter (or within ninety (90) calendar days following the date of the Inducement Letter in case of "full review"
of the Resale Registration Statement by the SEC) and to keep the Resale Registration Statement effective at all times until no holder
of the New Warrants owns any New Warrants or New Warrant Shares. In the Inducement Letter, New Silexion agreed not to issue any shares
of ordinary shares or ordinary share equivalents or to file any other registration statement with the SEC (in each case, subject to certain
exceptions) until March 18, 2025. New Silexion also agreed not to effect or agree to effect any Variable Rate Transaction (as defined
in the Inducement Letter) until one (1) year after the Closing Date (subject to certain exceptions).
January
2025 Financing
On January 15, 2025, New Silexion offered and sold in a public offering on a best efforts
basis (the "
January 2025
Offering
") (i)
2,145,998 of New Silexion ordinary shares, (ii) 1,557,705 pre-funded warrants to purchase up to 1,557,705 New Silexion ordinary shares
(the "
January 2025 Pre-Funded Warrants
"), and (iii) 3,703,703 warrants to purchase
up to 3,703,703 New Silexion ordinary shares (the "
January 2025
Investor
Warrants
" and together with the Pre-Funded Warrants, the "
January 2025
Warrants
"),
at a purchase price of $1.35 per share and accompanying January 2025 Investor Warrant, and $1.3499 per January 2025 Pre-Funded Warrant
and accompanying January 2025 Investor Warrant. Aggregate gross proceeds from the January 2025 Offering (without taking into account any
proceeds from any future exercises of January 2025 Warrants) were approximately $5 million. The January Offering closed on January 17,
2025, subject to the satisfaction of customary closing conditions.
The January 2025 Pre-Funded Warrants are immediately exercisable at an exercise price
of $0.0001 per share and will not expire until exercised in full. The January 2025 Investor Warrants have an exercise price of $1.35 per
share, are immediately exercisable, and may be exercised for five years from issuance.
A holder of the January 2025 Warrants will not have the right to exercise any portion
of its Pre-Funded Warrants and Investor Warrants if the holder (together with such holder's affiliates, and any persons acting as
a group together with such holder or any of such holder's affiliates or any other persons whose beneficial ownership of ordinary
shares would be aggregated with the holder's or any of the holder's affiliates), would beneficially own ordinary shares in
excess of 4.99% (or, at the election of the holder, 9.99%) of the number of the ordinary shares outstanding immediately after giving effect
to such exercise.
71
Certain investors in the January 2025 Offering entered into a definitive securities
purchase agreement with the Company (the "
January 2025 Purchase Agreement
"). The Purchase
Agreement contains representations, warranties, indemnification and other provisions customary for transactions of this nature. Pursuant
to the January 2025 Purchase Agreement, New Silexion agreed to abide by certain customary standstill restrictions for a period of sixty
(60) days following the closing of the January 2025 Offering. In addition, subject to limited exceptions, the January 2025 Purchase Agreement
provides that for a period of one year following the closing of the January 2025 Offering, the Company will not effect or enter into an
agreement to effect a "variable rate transaction" as defined in the January 2025 Purchase Agreement.
Wainwright acted as the sole placement agent (the "
Placement
Agent
"), on a "best efforts" basis, in connection with the January 2025 Offering. Pursuant to an engagement agreement
that New Silexion entered into with Wainwright, New Silexion issued to Wainwright or its designees 259,259 warrants to purchase up to
259,259 New Silexion ordinary shares, representing 7.0% of the sum of the shares and January 2025 Pre-Funded Warrants sold in the January
2025 Offering (the "
January 2025
Placement Agent Warrants
").
The January 2025 Placement Agent Warrants have an exercise price of $1.6875 per share (representing 125% of the public offering price
per share and accompanying January 2025 Investor Warrant), are exercisable for five years from the date of the commencement of sales
in this offering, and otherwise reflect substantially the same terms as the January 2025 Investor Warrants.
The net proceeds to New Silexion from the January 2025 Offering were approximately $4.26
million before deducting estimated offering expenses payable by New Silexion.
Prior to the January 2025 Warrant Inducement
Transaction, a total of 640,257 January 2025 Investor Warrants were exercised into 640,257 New Silexion ordinary shares and 1,557,705
January 2025 Pre-Funded Warrants were exercised into 1,557,705 New Silexion ordinary shares, for a total net proceeds of $0.86 million.
As of February 11, 2025, the January 2025 Pre-Funded Warrants have been exercised in full and 841,923 January 2025 Investor Warrants remain
unexercised at an exercise price of $1.35 per share.
ELOC Financing
In connection with the Closing of the Business
Combination, we entered into an ordinary share purchase agreement, dated August 13, 2024, but effective as of the Closing (the "ELOC
Agreement"), for an equity line of credit (the "ELOC") with White Lion Capital, LLC (the "ELOC Investor").
The agreement was amended as of January 14, 2025. Under the ELOC, we have the right to request to sell to the ELOC Investor, and the ELOC
Investor is required to purchase, via private placement transactions, up to $15.0 million of our ordinary shares from time to time after
the Closing, up until December 31, 2025 (unless the agreement is terminated sooner), subject to certain limitations and conditions as
described therein. The number of ordinary shares that we may require the ELOC Investor to purchase in any single sales notice depends
on a number of factors, including the type of purchase notice that we deliver. Similarly, the purchase price to be paid by the ELOC Investor
for any shares that we require it to purchase depends on the type of sales notice that we deliver, and is derived from the market price
of our ordinary shares for a certain period of time following our purchase request or as of the date of our purchase request. We also
granted registration rights to the ELOC Investor pursuant to an accompanying registration rights agreement, also dated August 15, 2024,
by and between New Silexion and the ELOC Investor (the "ELOC Registration Rights Agreement"), for which we filed a registration
statement on Form S-1 (SEC file number 333-282017), which was declared effective by the SEC on September 17, 2024.
Pursuant to the ELOC Agreement, New Silexion agreed, among
other things, that if our sales to the ELOC Investor under the ELOC exceed 19.99% of our total number of ordinary shares outstanding,
we will seek the approval of our shareholders for the issuance of any ordinary shares under the ELOC in excess of that amount, in accordance
with the Nasdaq Listing Rules, subject to certain exceptions based on the price of our ordinary shares to be sold in excess of that limit.
In consideration for the commitments of
the ELOC Investor, we agreed to issue to the ELOC Investor an aggregate of $337,500 of our ordinary shares (the "ELOC Commitment
Shares") based on the closing price of the ordinary shares on the day that is the earlier of (i) the business day prior to effectiveness
of the registration statement registering the resale of the shares issuable under the ELOC ordinary share purchase agreement and (ii)
the business day prior to the 180th day following the date of Closing of the Business Combination. In fulfillment of that commitment fee,
we issued to the ELOC Investor 40,602 ordinary shares as the ELOC Commitment Shares on September 18, 2024.
Through February 11, 2025, we have issued and sold an aggregate of 763,713 ordinary
shares (which includes the foregoing 40,602 ordinary shares issued as a commitment fee) to White Lion under the White Lion Purchase Agreement
for aggregate proceeds to us of approximately $3.1 million.
Settlement of Amounts Due Under Marketing
Agreement with EarlyBirdCapital
Prior to the Closing of the Business Combination, Moringa
reached agreement with EarlyBirdCapital on the reduction, to $1.6 million, in the aggregate, of the fee payable to EarlyBirdCapital under
the Marketing Agreement. Pursuant to the final invoice provided by EarlyBirdCapital under the Marketing Agreement at the Closing, Moringa
paid $350,000 of cash to EarlyBirdCapital from the trust account at the Closing, and we issued to EarlyBirdCapital a convertible promissory
note, due December 31, 2025, in an amount of $1.25 million to be paid by us to EarlyBirdCapital in cash and/or via conversion of outstanding
amounts into ordinary shares (the "EarlyBird Convertible Note").
The EarlyBird Convertible Note bears interest at a rate
of 6% per annum and matures on December 31, 2025. If not repaid on or prior to that maturity date or such earlier date as to which the
repayment obligation may be accelerated under the note, or not converted in accordance with the terms thereof, the rate of interest applicable
to the unpaid principal amount would be adjusted to (15%) per annum. We are required to make mandatory prepayments on the note (which
shall first be applied to accrued interest and then to principal) from time to time in amounts equal to ten percent (10%) of the gross
proceeds received by us from any equity financings consummated by us prior to the maturity date. We are entitled to voluntarily prepay
any additional part of, or all of, the principal and accrued interest, in one or more installments without penalty, prior to the maturity
date.
EarlyBirdCapital, in turn, may elect, at its sole discretion,
at any time on or prior to the maturity date, to elect to convert all or part of the then outstanding principal and/or accrued interest
under the EarlyBird Convertible Note into ordinary shares, at a per share conversion price equal to 95% of the volume weighted average
price of an ordinary share for the five trading days immediately prior to the date of our receipt of a conversion notice, provided, however,
we are not required to issue, and EarlyBirdCapital may not elect to convert the principal and/or accrued interest into an aggregate number
of ordinary shares that would exceed the maximum number of ordinary shares permitted by Section 5635 of the Nasdaq Listing Rules to be
issued without the approval of our shareholders, unless such approval is obtained.
Through the date hereof, we have made
one payment of $407,556 to EarlyBirdCapital due to amounts raised by us.
72
PIPE Financing
In connection with, and immediately prior
to the Closing of, the Business Combination, Moringa raised $2.0 million via a private investment in public entity financing (the "PIPE
Financing"), whereby Moringa sold to Greenstar, LP, an affiliate of the Moringa sponsor (the "PIPE Investor"), 200,000
newly issued Moringa ordinary shares (which does not reflect the reverse share split) at a price of $10.00 per share, pursuant to a subscription
agreement, dated as of August 15, 2024, by and among Moringa, New Silexion and the PIPE Investor (the "PIPE Agreement"). Those
200,000 shares automatically converted upon the Closing of the Business Combination 22,223 New Silexion ordinary shares (the "PIPE
Shares").
The funds raised from the PIPE Financing, together with
remaining funds in the trust account after payments to redeeming public shareholders, were used for financing support for Moringa and
New Silexion, as well as for payment to service providers to whom outstanding amounts were owed by Moringa, including parties that had
provided financial advisory services and capital markets advisory services to Moringa during the period leading up to the Closing.
Issuance of Amended and Restated Sponsor
Promissory Note
Effective as of the Closing, we issued to the sponsor,
and the sponsor accepted, in amendment and restatement, and replacement, in their entirety, of all existing promissory notes issued by
Moringa to the sponsor from the IPO until the Closing (and as to which the obligations of Moringa were assigned to New Silexion upon the
Closing), an amended and restated promissory note (the "A&R Sponsor Promissory Note") in an amount of $3,433,000, which
reflected the total amount owed by Moringa to the sponsor through the Closing Date. The maturity date of the A&R Sponsor Promissory
Note is the 30-month anniversary of the Closing Date (i.e., February 15, 2027). Amounts outstanding under the A&R Sponsor Promissory
Note may be repaid (unless otherwise decided by us) only by way of conversion into ordinary shares ("Note Shares") in accordance
with the terms set forth in the form of A&R Sponsor Promissory Note. New Silexion and the Sponsor may also convert amounts outstanding
under the A&R Sponsor Promissory Note at the price per share at which we conduct an equity financing following the Closing, subject
to a minimum conversion amount of $100,000, in an amount of Note Shares constituting up to thirty percent (30%) of the number of ordinary
shares issued and sold by us in such equity financing. The sponsor may also elect to convert amounts of principal outstanding under the
note into ordinary shares at any time following the 24-month anniversary of the date of the Closing, subject to a minimum conversion of
$10,000, at a price per share equal to the volume weighted average price of the ordinary shares on the principal market on which they
are traded during the 20 consecutive trading days prior to the conversion date.
Government Grants
Our research
and development efforts were financed, in part, through royalty-bearing grants from the Israeli Innovation Authority, or the IIA. As of
September 30, 2024, we received IIA royalty-bearing grants totaling approximately $5.8 million.
We are committed to pay royalties to the IIA at a rate
of approximately 3.0% to 5.0% of the sales of all of our product candidates and other related revenues generated from such projects, that
were developed, in whole or in part, using the IIA royalty-bearing grants we received under IIA programs up to the total amount of royalty-bearing
grants received, linked to the U.S. dollar and bearing annual interest at rates prescribed by the IIA's rules and guidelines.
We may in the future apply to receive additional grants
from the IIA. However, we cannot predict whether we will be entitled to any future grants, or the amounts of any such grants.
Under the Israeli Innovation Law, research and development
programs that meet specified criteria and are approved by a committee of the IIA are eligible for grants. A company that receives a royalty-bearing
grant from the IIA is typically required to pay royalties to the IIA on income generated from products incorporating IIA-funded know-how
(including income derived from services associated with such products and from IIA-funded know-how), up to 100% of the U.S. dollar-linked
royalty-bearing grant amount plus interest.
73
The obligation to pay royalties is contingent on actual
income generated from such products and services. In the absence of such income, no payment of royalties is required.
As of September 30, 2024, the total royalty amount that may be payable by
the Company is approximately $5.8 million ($6.5 million including interest).
Cash Flows
Cash flows for the nine-month period
ended September 30, 2024 and 2023
The following table summarizes our cash flows for the periods indicated:
Nine-month period ended
September 30,
2024
2023
(U.S. dollars, in thousands)
Cash and cash equivalents and restricted cash at beginning
        of the period
$
4,645
$
8,309
Net cash used in operating activities
(5,470
)
(3,272
)
Net cash provided by (used in) investing activities
(22
)
577
Net cash provided by financing activities
2,920
522
Net decrease in cash and cash equivalents and restricted
        cash
$
(2,572
)
$
(2,173
)
Translation adjustments on cash and cash equivalents and
        restricted cash
(50
)
(324
)
Cash and cash equivalents and restricted cash at end of
        the period
$
2,023
$
5,812
Cash Flows from Operating Activities
Net cash used in operating activities increased
by approximately $2.2 million, or 66.7%, to $5.5 million for the nine-month period ended September 30, 2024, compared to $3.3 million
for the nine-month period ended September 30, 2023. This increase was mainly due to an increase of $11.3 million in the net loss for the
nine-month period ended September 30, 2024, and from an increase in net working capital in an amount of $0.3 million, subject to reduction,
in part, to account for non-cash items included in net loss, including an increase of $5.8 million in share-based compensation expenses
and an increase of $3.6 million in non-cash financial expenses.
Cash Flows from Investing Activities
Net cash provided by (used in) investing activities decreased by $0.6 million,
or 100%, to $0 million for the nine-month period ended September 30, 2024, compared to $0.6 million of cash provided by investing activities
in the nine-month period ended September 30, 2023. This decrease was mainly due to a reduction in short-term deposits in an amount of
$0.5 million, which cash was used for operating activities.
Cash Flows from Financing Activities
Net cash provided by financing activities increased by $2.4 million, or 480%,
to approximately $2.9 million for the nine-month period ended September 30, 2024, compared to $0.5 million the nine-month period ended
September 30, 2023. This increase was mainly due to an increase in cash received from transactions upon the closing of the Business Combination
in an amount of $2.3 million and from an increase in proceeds from issuance of ordinary shares under the ELOC in an amount of $0.6 million,
offset by a decrease of $0.5 million in proceeds from issuance of preferred shares, occurred in the nine-month period ended September
30, 2023.
74
Cash flows for the three-month periods
ended September 30, 2024 and 2023
The following table summarizes our cash flows for the periods indicated:
Three-month period ended
September
        30,
2024
2023
(U.S. dollars, in thousands)
Cash and cash equivalents and restricted cash at the beginning
        of the period
$
1,747
$
6,491
Net cash used in operating activities
(2,653
)
(685
)
Net cash provided by (used in) investing activities
(16
)
72
Net cash provided by financing activities
2,920
-
Net decrease in cash and cash equivalents and restricted
        cash
$
251
$
(613
)
Translation adjustments on cash and cash equivalents and
        restricted cash
25
(66
)
Cash and cash equivalents and restricted cash at the end
        of the period
$
2,023
$
5,812
Cash Flows from Operating Activities
Net cash used in operating activities increased by approximately $2 million,
or 285.7%, to $2.7 million for the three-month period ended September 30, 2024, compared to $0.7 million for the three-month period ended
September 30, 2023. This increase was mainly from an increase of $11.1 million in the net loss for the three-month period ended September
30, 2024, and from an increase of $0.4 million in change of net working capital, offset by (i) an increase of $5.8 million in share-based
compensation and (ii) an increase of $3.6 million in non-cash financial expenses included in the net loss.
Cash Flows from Financing Activities
Net cash provided by financing activities increased by $2.9 million, to approximately
$2.9 million for the three-month period ended September 30, 2024, compared to $0 for the three-month period ended September 30, 2023.
This increase was mainly due to an increase in cash received from transactions in connection with the closing of the Business Combination
in an amount of $2.3 million and from an increase in proceeds from issuance of ordinary shares under the ELOC in an amount of $0.6 million.
Cash flows for the Years ended
December 31, 2023 and 2022
The following table summarizes our cash flows for the
years ended December 31, 2023 and 2022:
Year ended December 31,
2023
2022
Cash and cash equivalents and restricted cash at beginning
        of the period
$
8,309
$
10,083
Net cash used in operating activities
(4,529
)
(3,335
)
Net cash provided by (used in) investing activities
573
(524
)
Net cash provided by financing activities
522
2,752
Net decrease in cash and cash equivalents and restricted
        cash
$
(3,434
)
$
(1,107
)
Translation adjustments on cash and cash equivalents and
        restricted cash
(230
)
(667
)
Cash and cash equivalents and restricted cash at the end
        of the period
$
4,645
$
8,309
75
Cash Flows from Operating Activities
Net cash used in operating activities increased by approximately
$1.2 million, or 36.4%, to $4.5 million for the year ended December 31, 2023, compared to $3.3 million for the year
ended December 31, 2022. This increase was mainly from an increase of $1.6 million in the loss for the year, offset by a decrease
of $0.6 million in non-cash financial expenses.
Cash Flows from Investing Activities
Net cash provided by (used in) investing activities increased
by $1.1 million, or 220.0%, to $0.6 million for the year ended December 31, 2023, compared to investment of $0.5 million
for the year ended December 31, 2022. This increase was mainly due to change short-term deposit in the amount of $1.0 million.
Cash Flows from Financing Activities
Net cash provided by financing activities decreased by
$2.3 million, or 82.1%, to approximately $0.5 million for the year ended December 31, 2023, compared to $2.8 million
for the year ended December 31, 2022. This decrease was mainly due to a decrease in proceeds from issuance of preferred shares which
was higher in the amount of $2.2 million in 2022.
Funding Requirements
We expect to devote substantial financial resources to
our ongoing and planned activities, particularly further development of SIL-204 and as we conduct our planned pre-clinical and clinical
trials.
Identifying potential product candidates and conducting
pre-clinical testing and clinical trials is a time-consuming, expensive, and uncertain process that takes years to complete, and we may
never generate the necessary data or results required to obtain marketing approval and achieve product sales. In addition, our product
candidates, if approved, may not achieve commercial success. For additional information please refer to the "
Risk
Factors
" section of this prospectus, including "
Risks Related to Our Financial Condition
and Capital Requirements
—
we have never generated any revenue from product sales and may
never be profitable" and "Risks Related to the Research and Development of our Product Candidates — Silexion is heavily
dependent on the success of its product candidates
…".
We expect our expenses to increase substantially in connection
with our ongoing activities, particularly as we advance our pre-clinical studies and clinical trials. In addition, if we obtain marketing
approval for SIL-204 in any indication or for any other product candidate we are developing or may develop in the future, we expect to
incur significant commercialization expenses related to product manufacturing, sales, marketing, and distribution. Furthermore, upon the
closing of the Business Combination, we expect to incur additional costs associated with operating as a public company. Accordingly, we
will need to obtain substantial additional funding.
Our future capital requirements will depend on many factors,
including:
●
Material cost.
●
Regulatory pathway; and
●
Human clinical trial costs.
As of September 30, 2024, we had cash and cash equivalents of $2.0 million.
Based on our current cash balance, as well as its history of operating losses and negative cash flows from operation, combined with its
anticipated use of cash to, among other things, (i) fund the preclinical and clinical development of our products, (ii) identify and develop
new product candidates, and (iii) seek approval for SIL-204 and any other product candidates we may develop, our management has concluded
that we do not have sufficient cash to fund our operations for 12 months from the date of its unaudited condensed financial statements
for the nine-month period ended September 30, 2024 included in this prospectus without additional financing, and as a result, there is
substantial doubt about our ability to continue as a going concern.
76
In making this determination, applicable accounting standards prohibited
us from considering the potential mitigating effect of plans that have not been fully implemented as of the date of our unaudited condensed
financial statements for the nine-month period ended September 30, 2024, including, without limitation, plans to consummate the Business
Combination discussed below and to raise additional capital. Our financial information throughout this prospectus, and our unaudited condensed
financial statements for the nine -month period ended September 30, 2024 contained herein have been prepared on a basis that assumes that
we will continue as a going concern, which contemplates the realization of assets and the satisfaction of liabilities and commitments
in the normal course of business. This financial information and our unaudited condensed financial statements for the nine -month period
ended September 30, 2024 do not include any adjustments that may result from an unfavorable outcome of this uncertainty.
Without giving effect to the receipt of any proceeds from this offering, we currently
estimate that our existing cash and cash equivalents are sufficient to fund business operations through the end of first quarter of 2025.
We have based these estimates and expectations on assumptions that may prove
to be wrong, and our operating plan may change as a result of many factors currently unknown to us. We could not, as of the September
30, 2024 balance sheet date of the unaudited condensed financial statements for the three and nine-month periods ended September 30, 2024,
determine the exact level of funds that will be available to us upon potential equity financings. Our expected use of funds represents
our intentions based upon our current plans and business condition, which could change in the future as our plans and business condition
evolve and the level of funding available to us becomes clear. In addition, changing circumstances could cause us to consume capital significantly
faster than we currently anticipate, and we may need to spend more than currently expected because of circumstances beyond our control.
As a result, we could deplete our capital resources sooner than we currently expect. In addition, because the successful development of
SIL-204 and any studies or other product candidates that we pursue is highly uncertain, at this time we cannot reasonably estimate or
know the nature, timing and costs of the efforts that will be necessary to complete the development of any product candidate.
Until such time, if ever, as we can generate substantial
revenues from product sales, we expect to finance our cash needs through a combination of public and private equity offerings and debt
financings, including the private placement of ordinary shares pursuant to the White Lion Purchase Agreement, strategic alliances, collaborations,
and marketing, distribution, or licensing arrangements. However, adequate additional financing may not be available to us on acceptable
terms, or at all, and may be impacted by the economic climate and market conditions.
Reliance on
the ELOC or other similar types of equity financings as a source of ongoing funding for our operations following the Business Combination
could involve significant issuances of ordinary shares by us that could cause the following impacts (among others):
●
significant dilution to the equity interests of our current shareholders;
●
a deemed change of control of our company due to the issuance of a substantial number of ordinary
        shares, which may affect, among other things, our ability to use our net operating loss carry forwards, if any, and could result in a
        change in the officers and directors of our company relative to our current officers and directors, to the extent any shareholders build
        up significant beneficial ownership from ordinary shares issued pursuant to the ELOC;
●
may have the effect of delaying or preventing a change of control of our company by diluting
        the share ownership or voting rights of a person seeking to obtain control; and
●
may adversely affect prevailing market prices for our ordinary shares or
        warrants.
Critical Accounting Policies and Estimates
For a description of our significant accounting policies, see Note 2 to our
consolidated financial statements for the year ended December 31, 2023 and unaudited condensed consolidated financial statements for the
nine-month period ended September 30, 2024 included in this prospectus.
The preparation of our consolidated financial statements for the year ended
December 31, 2023 and unaudited condensed consolidated financial statements for the nine-month period ended September 30, 2024 in conformity
with U.S. GAAP requires management to make estimates and assumptions in certain circumstances that affect the amounts reported in the
accompanying consolidated financial statements for the year ended December 31, 2023 and unaudited condensed consolidated financial statements
for the nine-month period ended September 30, 2024 and related footnotes. Actual results may differ from these estimates. We base our
judgments on our experience and on various assumptions that we believe to be reasonable under the circumstances.
77
Of our policies, the following are considered critical to an understanding
of our consolidated financial statements for the year ended December 31, 2023 and unaudited condensed consolidated financial statements
for the nine-month period ended September 30, 2024 as they require the application of subjective and complex judgment, involving critical
accounting estimates and assumptions impacting our consolidated financial statements for the year ended December 31, 2023 and unaudited
condensed consolidated financial statements for the nine-month period ended September 30, 2024.
The critical accounting estimates relate to the following:
Share-Based
Compensation
Share-based compensation expense related to share awards
is recognized based on the fair value of the awards granted. The fair value of each option award is estimated on the grant date using
the Black-Scholes option pricing model. The Black-Scholes option pricing model requires the input of highly subjective assumptions, including
the fair value of the underlying ordinary shares (see below), the expected term of the option, and the expected volatility of the price
of our ordinary shares. These estimates involve inherent uncertainties and the application of management's judgment. The related
share-based compensation expense is recognized on a straight-line basis over the requisite service period of the awards, including awards
with graded vesting and no additional conditions for vesting other than service conditions. Forfeitures are accounted for as they occur
instead of estimating the number of awards expected to be forfeited.
Our use of the Black-Scholes option-pricing model requires
the input of highly subjective assumptions. If factors change and different assumptions are used, our share-based compensation expense
could be materially different in the future.
We will continue to use judgment in evaluating the assumptions
related to our share-based compensation on a prospective basis. As we continue to accumulate additional data related to our ordinary shares,
we may refine our estimation process, which could materially impact our future share-based compensation expense.
Valuations of instruments convertible
to our Ordinary and Preferred Shares
Our preferred shares are classified as temporary equity,
as they include clauses that could constitute as in-substance redemption clauses that are outside our control. Warrants and other instruments
over our Preferred Shares are classified as liabilities under ASC 480 and measured at fair value, with subsequent changes in fair value
recognized in the statements of operations in each period.
The fair value of our preferred shares underlying our
convertible instruments was determined by our board of directors, after considering contemporaneous third-party valuations and input from
management. In the absence of a public trading market, our board of directors, with input from management, exercised significant judgment
and considered various objective and subjective factors to determine the fair value of our equity including the following factors:
●
History of transactions in our preferred shares;
●
Probability of an IPO scenario (including de SPAC transaction);
●
Probability of other liquidation events;
●
Expected time to liquidation; and
●
Expected return on equity.
The resulting equity value was then allocated to each
share class based on differences in liquidation preferences of the various share classes using an Option Pricing Model ("OPM")
through the use of a series of call options and by implementing a Monte Carlo simulation. The OPM allocates the overall company value
to the various share classes based on differences in liquidation preferences, using a series of call options. The OPM is appropriate to
use when the range of possible future outcomes is difficult to predict. Starting from 2023, for the IPO scenario (including de SPAC transaction)
we utilized a probability-weighted expected return method ("PWERM") to allocate value among the various share classes. The
PWERM involves the estimation of the value of our company under multiple future potential outcomes and estimates the probability of each
potential outcome. After the value of each applicable class of shares was determined, a discount for lack of marketability ("DLOM")
was applied to arrive at the fair value of the ordinary shares on a non-marketable basis. A DLOM is applied in order to reflect the lack
of a recognized market for a closely held interest and the fact that a non-controlling equity interest may not be readily transferable.
A market participant purchasing this share would recognize this illiquidity associated with the shares, which would reduce the overall
fair market value.
78
In some cases, we considered the amount of time between
rounds of financing to determine whether to use a mid price calculation between two dates.
Upon completion of the Business Combination, our ordinary
shares are publicly traded, and we rely on the closing price of our ordinary shares as reported on the date of the applicable valuations.
The fair value of the warrants for the purchase of preferred
shares was calculated using the OPM as part of the allocation of the equity value to the various share classes (as described above). The
critical accounting estimates for the valuation of those warrants include (a) the fair value of the underlying preferred shares, as mentioned
above, and (b) volatility — based on peer companies' volatility.
Recent Accounting Pronouncements
See Note 2 on page F-75 to our financial statements for
the year ended December 31, 2023 included in this prospectus for a description of recent accounting pronouncements applicable to our financial
statements for the year ended December 31, 2023.
Smaller Reporting Company Status
We are a "smaller reporting company," meaning
that the market value of our ordinary shares held by non-affiliates is less than $700 million and our (via its Silexion subsidiary) annual
revenue was less than $100 million during the most recently completed fiscal year. We will continue to be a smaller reporting company
if either (i) the market value of our shares held by non-affiliates is less than $250 million or (ii) our annual revenue was less than
$100 million during the most recently completed fiscal year and the market value of our shares held by non-affiliates is less than $700
million. As a smaller reporting company, we may choose to present only the two most recent fiscal years of audited financial statements
and we have reduced disclosure obligations regarding executive compensation.
Emerging Growth Company Status
Section 102(b)(1) of the Jumpstart Our Business Startups
Act of 2012, or the JOBS Act, exempts emerging growth companies from being required to comply with new or revised financial accounting
standards until private companies are required to comply with the new or revised financial accounting standards. The JOBS Act provides
that a company can choose not to take advantage of the extended transition period and comply with the requirements that apply to non-emerging
growth companies, and any such election to not take advantage of the extended transition period is irrevocable.
We are an "emerging growth company" as defined
in Section 2(a) of the Securities Act, and has elected to take advantage of the benefits of the extended transition period for new or
revised financial accounting standards. We will remain an emerging growth company until the earliest of (i) the last day of the fiscal
year in which the market value of ordinary shares that is held by non-affiliates exceeds $700 million as of the end of that year's
second fiscal quarter, (ii) the last day of the fiscal year in which we have total annual gross revenue of $1.235 billion or more during
such fiscal year (as indexed for inflation), (iii) the date on which we have issued more than $1.0 billion in non-convertible debt in
the prior three-year period, or (iv) December 31, 2025. We expect to continue to take advantage of the benefits of the extended transition
period, although it may decide to early adopt such new or revised accounting standards to the extent permitted by such standards. This
may make it difficult or impossible to compare our financial results with the financial results of another public company that is either
not an emerging growth company or is an emerging growth company that has chosen not to take advantage of the extended transition period
exemptions because of the potential differences in accounting standards used.
79
BUSINESS
Unless the context otherwise requires,
in this "Business" section, the terms "we," "us" and "our" generally refer to Silexion
Therapeutics Ltd., an Israeli company ("Silexion"), or, from and after the Business Combination, to Silexion Therapeutics
Corp (formerly known as Biomotion Sciences), a Cayman Islands exempted company ("New Silexion").
Business Overview
We are a clinical-stage, oncology-focused biotechnology
company engaged in the discovery and development of proprietary treatments for KRAS-driven cancers. The KRAS gene is an oncogene
that is involved in the regulation of cell division as a result of its ability to relay external signals to the cell nucleus. Based
on our research of refractory solid tumor cancers, we are actively developing a platform focused on the silencing of the KRAS oncogene
using RNA-interference therapeutics. Our lead product candidate, SIL-204B, consists of locally administered small interfering RNAs,
or siRNA, in an extended-release formulation, as a first-line treatment of locally advanced pancreatic cancer patients, or LAPC,
in combination with standard-of-care chemotherapy.
The KRAS oncogene is considered to be the most common
oncogenic gene driver in human cancers, and the most notable in pancreatic, lung, and gastrointestinal (GI) (including colorectal, esophagus,
stomach, small bowel, and appendix) cancers. Considered a challenging therapeutic target due to its intrinsic characteristics, recent
advances have been made at directly inhibiting the KRAS proteins produced by the mutated gene. Our platform is designed to silence the
gene, and thus prevent the production of the harmful mutated KRAS proteins driving the growth of cancerous tumors.
We are currently focused on treatment for pancreatic cancer
(PC) tumors bearing the KRAS G12D or KRAS G12V mutations where metastases have not been detected and are non-resectable, i.e. they are
not able to be surgically removed. For our first indication, we are targeting the largest and least treatable form of localized pancreatic
tumors referred to as locally advanced pancreatic cancer. LAPC represents approximately 30% of the total pancreatic cancer population.
We are currently developing SIL-204B, a second-generation siRNA product candidate following a Phase 1 and Phase 2 clinical trial
with our first-generation siRNA product candidate, siG12D-LODER, which we also refer to as Loder. Results from the Phase 2 clinical
trial showed a trend for differences between treatment groups in patients with the KRAS G12D/V mutation, with the Loder arm suggesting
an overall survival advantage of 9.3 months.
SIL-204B has been designed to optimize Loder with the
aim of improving uptake into tumor cells, enhancing stability, and improving the delivery system. We plan to conduct a Phase 2/3 prospective,
randomized, controlled, multinational, two-arm, open-label trial in LAPC subjects that harbor the KRAS G12D/V mutations to evaluate the
efficacy, safety and tolerability of SIL-204B administered intratumorally in combination with standard of care (SoC) chemotherapy versus
SoC chemotherapy only. In support of our planned Phase 2/3 trial, we held a meeting with the Federal Institute for Drugs and Medical Devices
in Germany (BfArM) to discuss the planned design of the Phase 2/3 trial at which BfArM agreed, in principle, to the design. In preparation
for the study, we plan to initiate toxicology studies of SIL-204B in 2025 followed by the regulatory submission in the second half of
2025  to initiate the Phase 2/3 trial and trial initiation in the first half of 2026. At this time, we are focused on the further
development of the core siRNA technology underlying the Loder and SIL-204B as well as the clinical development of SIL-204B as the most
optimized version of the technology.
80
Our Market Opportunity
Activating mutations in KRAS are among the most
prevalent oncogenic driver mutations in human cancers. In a recent study of over 400,000 patients with various cancer type malignancies,
23% of adult pan-cancer samples had KRAS alterations, 88% of which were mutations, most commonly G12D, G12V, G12C, G13D and G12R,
making the KRAS target a sought-out target in for many cancers ("Comprehensive pan-cancer genomic landscape of KRAS altered
cancers and real-world outcomes in solid tumors", by Jessica K. Lee, etc., NPJ Precision Oncology 2022; 6: 91). In
addition, the study found that various cancers have an amplification of the non-mutated KRAS protein. Tumor types with a high prevalence
of KRAS mutations included pancreatic ductal adenocarcinoma (PDAC) (92%), colorectal cancer (CRC) (49%), and non-squamous non-small cell
lung cancer (NSCLC) (35%). These three cancers represent 71% of the KRAS mutant pan-tumor population studied.
The following chart shows the distribution of various
alternations of the KRAS oncogene in various type of cancers:
81
Pancreatic Cancer
By the next decade, pancreatic cancer is expected to become
the second most deadly cancer. Every year in the U.S. approximately 50,000 people die from pancreatic cancer, while approximately
61,000 new patients are diagnosed with pancreatic cancer annually (American Cancer Society Statistics 2023).
Studies have shown that pancreatic cancer patients have
short survival rates compared to other cancer types (see, for example, "Prognosis and survival analysis of patients with pancreatic
cancer: retrospective experience of a single institution", by Qi Li and others, World Journal of Surgical Oncology, 2022; 20:11).
There are four basic forms of pancreatic cancer: Resectable, those where a surgeon can remove a tumor; Borderline Resectable (BRPC) where
the tumor is not currently permissible for surgery but prior treatment with chemotherapy or radiation could in some cases allow for surgical
removal; LAPC where the tumor has surrounded more than half of a major artery or vein and is not surgically removable; and Metastatic
where the cancerous tumor has spread to other organs. Of the forms of pancreatic cancer that are localized (those which have not yet spread),
the largest and most life threatening is LAPC, which constitutes approximately 30% of pancreatic cancers ("Locally Advanced Pancreatic
Cancer: A Review of Local Ablative Therapies", by Alette Ruarus and others, Cancers BaseI, January 2018; 10(1):16).
82
Below is a curve of overall survival in LAPC patients:
Fig. Comparison of overall survival between different
chemotherapy regimens in non-resected locally advanced pancreatic cancer patients. CHT indicates chemotherapy; FFX, FOLFIRINOX; Gem,
gemcitabine. Reference Gemenetzis, G et al. 2019. Annals of Surgery. 270 (2):340
KRAS mutations across their various forms are responsible
for approximately 92% of all pancreatic cancers, of which the KRAS G12D and KRAS12V mutations account for over 70% of the cases traced
to KRAS mutations (Bailey, P.
et al.
Genomic analyses identify molecular subtypes of
pancreatic cancer.
Nature
531(7592), 47 – 52.
https://doi.org/10.1038/nature16965
(2016) (Art.
No. 7592)). Unfortunately, those with LAPC have a short survival time, about 17 months, and constitute about 30% of the total pancreatic
cancer population ("Survival in Locally Advanced Pancreatic Cancer After Neoadjuvant Therapy and Surgical Resection", by Georgio
Gemenetzis, MD, and others, Annals of Surgery. 270 (2):1, March 2018). Among those patients with KRAS mutations, those with the mutation
type G12D and G12V show the shortest OS among the G12x mutation type.
83
Distribution of KRAS Mutations in Pancreatic Cancer
Our Technology
Our research is focused on the development of a platform
of therapeutics that is designed to silence the KRAS oncogene using small interfering RNA, or siRNA. This function is called interference
RNA (RNAi). When the RNAi is double stranded of 19-25 nucleotides (NTs), in length, it is referred to as siRNA. This class of siRNA
therapeutics exert their effect by inducing the enzymatic breakdown of the messenger (mRNA) of a targeted gene inhibiting the process
called translation, which turns the message (mRNA) into a protein. The general mechanism for the silencing the oncogene is actually an
evolutionary process developed by cells to protect against viruses.
We believe our approach also builds upon the validation
of our target KRAS mutations as a target for cancers, as seen with the two small molecule KRAS inhibitors currently on the market for
non-small cell lung cancer, and the validation of siRNA technology, as it is currently on the market for five non-oncological indications.
None of these agents is appropriate for our intended primary indication, but we believe they do support our premises regarding target
(KRAS) and basic technology (siRNA) for use in the oncological area. A key distinction between our technology and the existing inhibitors
of KRAS is that our siRNA technology prevents the production of the protein, as indicated by a decrease in the mRNA and physiological
decrease in human tumor cell line growth shown in our preclinical studies. By contrast, the existing inhibitors and to our knowledge,
those in development inhibit its activity, and clinical use of the existing inhibitors has shown that they potentially leave large unmet
needs.
The specific mechanism of this silencing activity is depicted
in the figure below. siRNAs, usually 19-25 NTs, enter the cell as a double-standard complex. Once in the inner cell matrix,
they bind to an RNA-induced silencing complex of enzymes (RISC), which splits the siRNA into two single RNA strands referred to as
the passenger (sense) strand and the guide (antisense) strand. It is the antisense which is the active part. The single guide strand has
complementary binding to the target mRNA and thereby acts as an inducing guide for other enzymes in the RISC complex to bind and
induce specific cleavage of the now double stranded target mRNA. As the siRNA guide strand is designed to be complementary to the RNA
message around the site of the mutation of the gene to be silenced, in our case the mutated KRAS oncogene, once the message (mRNA) is
destroyed, the oncogene is silenced. As the sense-strand of the siRNA is designed to be specific for the KRAS, there is a specificity
to the silencing of this driver of cancer.
84
Our first-generation siRNA product candidate, siG12D,
is an extended-release formulation of siRNA. While originally designed to combat the KRAS G12D mutation in patients with LAPC, siG12D
was shown to have silencing activity in other KRAS mutations including G12V as well as to a lesser degree in G12C and G12R. The product
candidate is comprised of the anti-KRAS(G12D) siRNA drug substance (siG12D), formulated in a biodegradable polymeric matrix (PLGA) as
solid rods in order to obtain an extended-release profile. To overcome the difficulties of a systemic drug to enter the pancreatic
tumor environment and to obtain a sufficiently high level of siRNA in the pancreatic cell without inducing unnecessary side effects, the
siRNA is directly delivered intratumorally using a standard ultrasound guided endoscopy (EUS). Since patients should undergo anesthesia
prior to the endoscopy, the same as that required for a biopsy, the siRNA has been formulated as an extended-release formulation
to increase the time between administrations. We refer to this product formulation as siG12D-LODER or Loder. Loder has undergone
extensive pre-clinical testing as well as two open-label clinical trials.
Our second-generation siRNA product candidate, SIL-204B,
is an optimized form of the first-generation Loder comprised of an anti-KRAS siRNA drug substance (SIL-204) encapsulated into
a biodegradable polymeric matrix (PLGA). While pre-clinical testing of SIL-204B has shown silencing activity of KRAS mutations
including G12D, G12V, G12C and G12R in varying degrees, it is designed to mainly combat the KRAS G12D and KRAS G12V mutations in patients
with LAPC where silencing activity is more enhanced. The second-generation siRNA drug substance aims to provide improved uptake into
tumor cells by introduction of a hydrophobic tail that enhances movement across the cell membrane. Additionally, second-generation siRNA
drug substance includes modified nucleotides in the siRNA that enhance stability and corresponding half life. Most significantly, the
delivery system has been improved in which PLGA-rods used in Loder have been replaced by PLGA-microparticles, allowing the drug substance
to be injected as a suspension, facilitating administration through smaller needles. As with Loder, the administration is by ultrasound
guided endoscopy (EUS), of the type typically used for pancreatic biopsies to diagnose pancreatic cancer and can be done by a typical
gastrointestinal endoscopist.
85
As discussed further below, Silexion plans to conduct
a Phase 2/3 clinical trial of SIL-204B targeting KRAS G12D and G12V mutations. The targeting of additional mutations is expected
to require additional clinical trials.
We believe the optimization of Loder allows for more of
a personalized medicine approach to the dosing, allowing the siRNA dose to be adjusted to the tumor size. The small volume of suspension
is expected to allow for treatment of smaller tumors than those treated with Loder, and to continue treatment for a longer period of time
with tumors shrinking in size. Furthermore, delivery of the extended-release PLGA formulated siRNA, SIL-204B, to be administered
using a much smaller needle is expected to allow more flexibility and decrease the risk associated with administration.
Pre-Clinical Studies
We have conducted the evaluation of our first-generation siRNA
product candidate, Loder, in pharmacology, pharmacokinetics (PK), and toxicology studies with both the siG12D and siG12D-LODER. The results
of the extensive in vitro and in vivo nonclinical studies conducted with Loder have demonstrated its effects on the KRAS oncogene, tumor
development, and the development of new metastases. In these studies, the mechanism of action (MOA) was elucidated and the effect of Loder
on a variety of downstream processes, ultimately leading to cell apoptosis, tumor necrosis, and halting of new metastases, was investigated.
Pre-clinical data show that the siG12D silencing
is very specific and effective (peak mRNA degradation effect in vivo was found to be 98%), can down-regulate signaling pathways,
reduce pancreatic cancer cell viability, decelerate cancer cell migration, and suppress expression of genes involved in Epithelial-to-Mesenchymal Transition
(EMT). It was demonstrated in vivo that Loder protects siG12D against degradation. The product candidate induces apoptosis and necrosis
throughout the entire tumor, hinders the appearance of metastases, decelerates the development and growth of pancreatic tumors, induces
an innate immune response locally within the tumor and extends survival.
siG12D was also found to be additive with FOLFIRINOX,
Gemcitabine, and Gemcitabine+nab-Paclitaxel. When administered into the tumor, siG12D molecules are in part spontaneously taken up into
tumor cells; the siG12D drug is distributed from the siG12D-LODER throughout the entire tumor, by diffusion and convection, and covers
the entire tumor after about a week, increasing the "void volume" in the tumor microenvironment.
PK studies yielded validated methods for detecting siG12D
in rat and human plasma, and confirmed distribution and absorption at the local tissue level.
The toxicological study confirmed siG12D tolerability,
with minimal, not drug related, focal effect at the implantation site and No Observed Adverse Effect Level (NOAEL) 24.2 times higher than
the dose in the Loder Phase 2 trial.
Taken together, these converging effects on multiple genetic,
cellular, tumor tissue, tumor microenvironment, systemic levels and survival aspects act to produce a durable and prolonged anti-tumor effect
both in in vitro and in vivo pancreatic cancer models.
We have also conducted pre-clinical studies of our
second-generation siRNA product candidate, SIL-204B. There are three key preclinical studies which support our advancing SIL-204B into
a planned Phase 2/3 clinical trial.
The first key clinical study was a dose response analysis
of SIL-204 in mouse Hepa1-6 cells together with a relevant Dual Glo reporter plasmid. SIL-204 in this study showed inhibition
of the drug substance across KRAS mutations G12D, G12V, G12C and G12R and the wild type to cover the KRAS amplifications. Similar to the
results found with the siRNA in the Loder (siG12D) three of the mutations (G12D, G12V, and G12R) were highly inhibited. However, whereas
G12C was mildly silenced (inhibited) with siG12D, it was significantly more inhibited with SIL-204 which has implications for potentially
broadening the indications for SIL-204B to include all four of the major KRAS mutations and the wild-type. Additionally in this model,
when a prototype of SIL-204 was tested for its silencing activity with and without the lipid lead we are conjugating to the siRNA
with SIL-204, the results showed that the lipid-conjugated siRNA enhanced the silencing activity of the siRNA by two-fold. The siG12D
(siRNA in the Loder) does not have the lipid conjugate.
86
The second key pre-clinical study examined the stability
of the guide strand of SIL-204 in human serum. Whereas siG12D was completely broken down (enzymatically cleaved) in < 1 hour,
SIL-204 showed complete stability at 48 hours. Consistently, when SIL-204 was administered to rats via subcutaneous injection,
the plasma half-life was 5 hours. In contrast when siG12D was administered systemically to mice the half life was 1 minute.
In a third key pre-clinical study, the human pancreatic
cell line CAPAN-1 harboring the KRAS G12V mutation was xenografted (transplanted) to mice and the tumor growth and necrosis (death
of body tissue) in the tumor was observed following daily treatments of SIL-204 compared to the controls (untreated and vehicle treated
mice). Results showed a significant growth of the tumor in the control mice while in the SIL-204-treated mice, the tumor growth was
significantly curtailed, as indicated by a significant reduction in the tumor volume and weight. In addition, when analyzing tumor slices
from the center of the tumor, the results showed a statistically significant increase in tumor necrosis in SIL-204 treated mice compared
to untreated- and vehicle-treated mice.
Clinical Studies
Phase 1 Clinical Study
An escalating dose, multicenter Phase 1 clinical study
of Loder was conducted in Israel from 2011 to 2015 at three sites enrolling a total of 15 patients with unresectable LAPC. The study was
designed as an open-label, single-arm, single-administration of siG12D-LODER (concomitantly with standard of care chemotherapy),
dose-escalating Phase 1 study, enrolling LAPC patients with a target tumor accessible for intra-tumor administration, with a
Karnofsky performance status equal or greater than 70% and with a life expectancy of at least three months. Single escalating doses of
LODER (0.025, 0.75, 1.5 or 3 mg) by insertion into the tumor were administered by standard EUS procedures. Following insertion, patients
received standard of care chemotherapy as first line treatment in accordance with treating physician recommendation, Gemcitabine (nine
patients) or modified FOLFIRINOX (four patients), while one patient refused to receive any chemotherapy. After study drug administration,
the patients were to be monitored for signs of systemic or local treatment- related toxicity. Active follow-up comprised scheduled
physical and clinical examinations, vital sign measurements, laboratory tests, abdominal CT and disease assessments.
The primary endpoint of the study was to assess the safety
and tolerability of siG12D-LODER, and to define the dose-limiting toxicities (DLT) of siG12D-LODER. Secondary endpoints included
the recommended Phase 2 dose and defining the maximum tolerated dose (MTD). In the event of surgery, assessment of siG12D-LODER local
distribution and efficacy were to be based on histopathology measurements and RNA analysis. Progression free survival (PFS) and overall
survival (OS) were to be assessed only by long term follow-up. Due to the small size of the trial, it was not powered for statistical
significance. The study met its primary endpoints. The 15 patients reported a total of 125 adverse events (AEs). 111 of the reported AEs
(89%) were grade 1 and 2, which were transient and resolved. The most common AE (grade 1-2) was diarrhea which was reported by seven
(46.7%) patients, abdominal pain and nausea were both reported by six (40%) patients, whereas fatigue was reported by five (33.3%) patients.
Thirteen severe AEs of grade 3 and one grade 4 severe were reported by 10 (66.7%) patients. The most common grade 3-4 AEs were neutropenia
and cholangitis reported by three patients and two patients, respectively. Pancreatitis was reported by the investigator as possibly related
to the procedure. One adverse event (cholangitis) in one patient was considered as definitely related to the EUS intervention. At the
doses tested, no DLTs were observed and therefore if there was a DLT it was defined as being greater than 3mg, the highest dose administered.
The study also met the secondary endpoint of establishing the Phase 2 dose of up to 3mg however the MTD was not determined.
Evidence of tumor response was observed, noting that none
of the patients presented progressive disease (PD) and tumor response durability was demonstrated. The tumor marker CA19-9 decreased
in 70% of relevant cases soon after siG12D-LODER administration and time to metastasis (TTM) and overall survival were comparable
to (or better than) the historical data of the disease in a similar population. However, no clear dose response was observed between the
dose of siG12D-LODER and OS or TTM probably due to several factors, including the small size of the study, the single dosing administration,
without repeat dosing, and the level of dose at the low-dose cohort, which was selected to be ~5 times higher than then the minimal
effective dose level as predicted in pre-clinical studies.
87
Phase 2 Clinical Study
From 2018 to 2023, we conducted a prospective, multi-center,
Phase II, open label study to evaluate the efficacy, safety and tolerability of siG12D-LODER in two separate cohorts across five
sites in Israel and four in the U.S.
Cohort 1 was a randomized and controlled two-arm study
of 37 subjects with unresectable LAPC to assess the efficacy, safety, tolerability and pharmacokinetics of siG12D-LODER when used
in combination with standard chemotherapy treatment (gemcitabine + nab-Paclitaxel) compared to gemcitabine + nab-Paclitaxel alone
in subjects. Cohort 2 was a single arm study of 22 subjects with unresectable and borderline resectable LAPC to assess the efficacy, safety,
and tolerability of siG12D-LODER in combination with standard of care chemotherapy treatment (gemcitabine + nab-paclitaxel or
FOLFIRINOX or modified FOLFIRINOX).
For comparative purposes, we evaluated the randomized
section of the trial for efficacy (Cohort 1) and both cohorts (Cohort 1 and Cohort 2) for safety. All patients who met the inclusion criteria
were accepted to the trial, regardless of whether they had a KRAS mutation or which specific mutation they had.
The KRAS mutation status was however determined post-hoc in
a sample of 31 patients (21 of whom were Loder treated) in the table below:
KRAS
G12x
Mutation
Cohort 1
Arm 2
(Control)
Cohort 1
Arm 1
(Treatment)
Cohort 1
% Arm 1
Tx
Cohort 2
(Treatment)
All
Treated
%
R
5/10
1/12
8
2/9
26 (8/31)
D
2/10
3/12
25
2/9
23 (7/31)
V
3/10
8/12
67
5/9
52 (16/31)
A total of up to eight Loders (2.8 mg) were inserted into
the pancreatic tumor per single administration. Insertion was done using EUS. The trial consisted of a screening period (28 days), a treatment
phase (12-week Loder treatment cycles at investigator's discretion with concomitant chemotherapy treatment cycles) and a follow-up phase
(up to six months until end of study which is defined as death, withdrawn consent or lost to follow-up). For efficacy, the primary endpoint
in the randomized section of the trial (Cohort 1) was overall survival (OS), defined as the time that passed from study entry (screening
visit) until death from any cause. For Cohort 2, the primary endpoint was the overall response rate (ORR) by end of treatment; ORR
was defined as the proportion of subjects with best overall confirmed response (BOCR) of either a complete response (CR) or partial response
(PR). Concerning the secondary endpoint of safety, the endpoints were incidence of adverse events (AEs), and serious adverse events (SAEs)
overall, by severity, by relationship to each study intervention, and those that led to discontinuation of study interventions. Other
secondary endpoints included ORR for Cohort 1, progression free survival, time to metastatis, time to response, duration of response
and rate of disease control.
Overall, a total of 59 subjects with LAPC were enrolled
in the study, 38 were treated with Loder and 48 subjects overall (81.3%) completed the study. In Cohort 1, 15/19 (78.9%) completed
the Loder arm and 11/18 (61.1%) completed the standard of care arm. In Cohort 2, 21/22 (95.5%) completed the study.
In Cohort 1, OS was comparable between the two treatment
arms. Median time to death was 691 days in the Loder-treated group, compared with 666 days in the standard of care group. The Hazard
Ratio (Loder/SoC) was 1.47 (95% CI; 0.643, 3.365) with a non-significant p-value of 0.361 for the treatment difference. In the
sub-group of subjects with D or V KRAS mutation (n=16), the median OS was 691 days for the 11 Loder treated subjects, compared to
409 days for the five SoC subjects. The Hazard Ratio was 0.59 (95% CI; 0.179, 1.963) with a non-significant p-value of 0.393.
In the subjects who were not found to have D or V KRAS mutation (n=13), the median OS in the seven Loder treated subjects was 637 days
compared to 937 days in the six SoC treated subjects. The hazard ratio was 2.87 (95% CI; 0.705, 11.650) with a p-value of 0.141.
The ORR was 44.4% (8/18) in the Loder group compared to 27.3% in the SoC group (3/11). No subject had a CR in either group. The ORR in
subjects with D or V KRAS mutation was 63.6% (7/11) in the Loder group compared to 20% in the SoC group (1/5).
88
In Cohort 2, the ORR was 31.6% reflecting 6/19 subjects
with partial responses. No subject had CR. In subjects with D or V KRAS mutation, the ORR was 57.1% (4/7), however, these subjects also
had a shorter median OS compared to subjects without these mutations (414 days vs. 671 days).
As depicted below, the survival probability in subjects
of Cohort 1 bearing a KRAS G12D/V mutation compared to the control group, showed a median survival in the Loder group (n=11) of 22.8 months
compared to 13.8 months in the control group (n=5).
Based on the above, although the primary endpoints of
all patients were not met, the results showed a trend for differences between treatment groups in patients with the KRAS G12D/V mutation,
with the Loder arm suggesting an overall survival advantage of 9.3 months. With respect to the secondary efficacy endpoints, no statistically
significant differences were observed or there was insufficient data to evaluate although with respect to ORR in Cohort 1, a positive
trend in the KRAS G12D/V mutation subgroup was observed. Due to the small size of the trial, it was not powered for statistical significance.
The secondary safety endpoints were met. In Cohort 1,
all subjects in the Loder treatment group reported at least one moderate or severe treatment emergent adverse event (TEAE) (18 subjects).
One subject was reported with a TEAE leading to death (sepsis). This event was deemed as not related to the Loder or the EUS procedure.
Of the remaining 17 subjects, one subject was reported with a life-threatening TEAE, gastrointestinal disorders (colitis). The majority
of moderate and severe TEAEs reported in the Loder treatment group were attributed to gastrointestinal disorders (10), blood/lymphatic
disorders (14), general disorders and administration site conditions (11), metabolism and nutrition disorders (11), and investigations
(10). In the SoC treatment group, all subjects reported at least one moderate or severe TEAE (11 subjects). No subjects were reported
with a TEAE leading to death. Two subjects were reported with a life- threatening TEAE. The majority of moderate and severe TEAEs reported
in the SoC treatment group were attributed to gastrointestinal disorders (10), blood/lymphatic disorders (9), general disorders and administration
site conditions (9), metabolism and nutrition disorders (8), and investigations (9).
In Cohort 2, all subjects in the Loder treatment
group reported at least one moderate or severe TEAE (20 subjects). One subject was reported with a TEAE leading to death (gastrointestinal
disorder). This event was deemed as not related to the Loder or the EUS procedure. Three subjects were reported with a life-threatening TEAE.
Of the three subjects, one subject was investigation (neutrophil count decreased) and two subjects were metabolism/nutrition (hyperglycaemia,
hyperkalaemia). The majority of moderate and severe TEAEs reported in the Loder treatment group were attributed to gastrointestinal disorders
(13), nervous system disorder (10) and investigations (11).
89
Manufacturing
We rely on and intend to continue to rely on third-party contract
manufacturing organizations for drug substance and drug products for our clinical trials. We have agreements with contract manufacturers
for the manufacturing of SIL-204B for clinical development.
Future Development Plans
We plan to conduct a Phase 2/3 prospective, randomized,
controlled, multinational, two-arm, open-label trial in LAPC subjects that harbor the KRAS G12D/V mutations to evaluate the efficacy,
safety and tolerability of SIL-204B administered intratumorally in combination with SoC chemotherapy versus SoC chemotherapy only.
The study design, including the dose and dosing frequency, the combination with SoC chemotherapy, the proposed target population and safety
monitoring is based on the experience with the preceding Phase 1 and 2 clinical studies with the first-generation siRNA product candidate,
Loder.
The study is initially planned to enroll approximately
350 subjects and has an adaptive design with several segments; a screening period which includes a biopsy eligibility test for G12D/V
mutations, a CT scan and physiologic profiling to ensure subjects are qualified for treatment; concurrent with this, all subjects will
receive run-in SoC chemotherapy; a Phase 2 safety run-in and treatment period where initially 30 subjects will be randomized
2:1 to receive SIL-204B and SoC Chemotherapy or SoC Chemotherapy at which point a Data and Safety Monitoring Board (DSMB) will perform
a safety review and recommend whether the study is safe to proceed; a Phase 2 expansion period to continue enrollment; and when approximately
60 events have occurred, an unblinded interim analysis for sample size re-estimation and futility will be conducted, to expand the
trial from Phase 2 to Phase 3, which is expected to happen approximately one year from start of enrollment. Following the interim
analysis, the study will continue into a Phase 3 treatment period to complete the enrollment of the remaining subjects for a total treatment
period of 24 months. The study design is powered for statistical significance.
In support of our planned Phase 2/3 trial of SIL-204B,
we held a meeting with the Federal Institute for Drugs and Medical Devices in Germany (BfArM) to discuss the planned design of the Phase
2/3 trial, at which BfArM agreed, in principle, to the design. In preparation for the study, we plan to initiate toxicology studies of
SIL-204B in 2025 followed by the regulatory submission in late 2025 to initiate the Phase 2/3 trial. Currently, we are upscaling
SIL-204 and planning for GMP production. At this time, Silexion is focused on the further development of the core siRNA technology
underlying the Loder and SIL-204B as well as the clinical development of SIL-204B as the most optimized version of the technology.
We expect to apply in 2024 for Orphan Drug Designation
in both the U.S. and EU. In the U.S., Orphan Drug designation by the FDA gives a company exclusive marketing rights for a seven-year period,
along with other benefits to recoup the costs of researching and developing drugs to treat rare diseases. In the EU, a company receives
data exclusivity for 10 years which provides protection from similar drugs being approved. We believe the size of the localized pancreatic
cancer market fits the requirements for this designation however there can be no assurance that we will be granted such designation and
such designation neither shortens the development time or regulatory review time of a drug nor does it increase the likelihood for any
approval in the regulatory review process. Our continued development plans for SIL-204B are not dependent on whether we are granted
Orphan Drug Designation.
90
Our Strategy
Our goal is to have a positive impact on the health and
treatment of KRAS driven cancer patients, in general and initially with pancreatic cancer through the continued development and commercialization
of our pipeline. Key elements of our strategy to advance toward this goal include the following:
●
Advancing the clinical
        development of SIL-204B for the treatment of LAPC
.    Our Phase 2
        trial with our first-generation siRNA product, Loder in LAPC patients acts as a validation of approach and foundation for our continued
        development efforts. As further described in "Future Development Plans", Silexion plans to initiate toxicology studies of
        SIL-204B in 2025 followed by the regulatory submission in late 2025 to initiate a Phase 2/3 trial of SIL-204B powered for statistical
        significance. At this time, Silexion is focused on the further development of the core siRNA technology underlying the Loder and SIL-204B as
        well as the clinical development of SIL-204B as the most optimized version of the technology.
●
Leveraging our platform
        to other oncological indications
harboring the KRASG12D/V mutation.
●
Advancing SIL-204B to
        commercialization.
We have assembled a world class clinical advisory
        board for better understanding the market in the U.S. and EU.
●
Forming strategic alliances
        and collaborating with partners to augment our capabilities
.    We
        may pursue strategic alliances with other biopharmaceutical companies with well-established presences in the specialties we aim to
        target for our indications. This may include co-marketing, co-promotion, and co-development relationships, or a partnership with
        a diagnostics company to help improve availability of rapid testing. We also intend to explore options to work with partners to augment
        the study and treatment of patients and the impact of our product candidates, including medical professionals, healthcare professional
        networks, pharmacy benefit managers, insurance companies, and artificial intelligence companies.
Our History
Silexion was established as Silenseed Ltd in 2008 as an Israeli company which
underwent a name change to Silexion Therapeutics Ltd. in May 2023. On June 13, 2014, Silexion filed a registration statement on Form F-1
with the SEC, in contemplation of an initial public offering, and the listing of its shares on Nasdaq. Subsequently, the public offering
process was abandoned because our board of directors was not satisfied with our valuation in the offering, and no securities were sold
under the registration statement. During April 2022, our management was replaced following a health condition of the then-founder and
CEO of Silexion, and the new management, after evaluating the viability of commercializing the Loder, has decided to pivot from the first-generation
siRNA product candidate to the second-generation siRNA product candidate and develop SIL-204.
Competition
The biotechnology and pharmaceutical industries, and the
oncology sector, are characterized by a rapid evolution of technologies, fierce competition and strong defense of intellectual property
rights. While we believe that our discovery programs and technology provide us with competitive advantages, we face competition from major
biotechnology and pharmaceutical companies, academic institutions, governmental agencies and public and private research institutions,
among others.
Any product candidates that we successfully develop and
commercialize will compete with currently approved therapies and new therapeutics that may become available in the future. Key product
features that would affect our ability to effectively compete with other therapeutics include efficacy, safety and convenience of our
products as compared to other available therapeutics.
There are a large number of companies developing or marketing
treatments for cancer, including major biotechnology and pharmaceutical companies. These treatments consist of novel treatments based
on small molecule drug products, cell-based therapies, as well as traditional chemotherapy treatments. There are also an increasing
number of companies commercializing treatments and/or developing programs specifically targeting KRAS mutations, including KRAS G12D and
KRAS G12V, in a variety of manners and for a variety of indications, including cancer, including Amgen Inc., Bristol-Myers Squibb
Company (through the recently acquired Mirati Therapeutics, Inc.), Revolution Medicines, Inc., AstraZeneca (in collaboration with Usynova),
BioNTech, Roche, Merck/Moderna, Boehringer and Gilead. Smaller and other early-stage companies may also prove to be significant competitors.
In addition, academic research departments and public and private research institutions may be conducting research on compounds that could
prove to be competitive.
91
Many of the companies against which we may compete have
significantly greater financial resources and expertise in the research and development, manufacturing, preclinical testing, conducting
clinical trials, obtaining regulatory approvals and marketing approved products than we do. Similar or early-stage companies may
also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. These
competitors also compete with us in recruiting and retaining qualified scientific and management personnel, and establishing clinical
trial sites and patient registration for clinical trials, as well as acquiring technologies complementary to, or necessary for, our programs.
Our competitors have already and/or may obtain more rapidly
than we may obtain approval FDA, or other regulatory approval for commercialization of product. As a result, our competitors could establish
a strong market position before we are able to enter the market with our products. The availability of coverage and reimbursement from
government and other third-party payors for competing products at the time of commercialization of our products will also significantly
affect the pricing and competitiveness of our products.
Intellectual Property
Our business depends, in part, on our ability to develop and maintain the proprietary
aspects of our products.
We are seeking patent protection for our product (SIL-204) in International Patent Application
No. PCT/IL2023/051276 filed on December 14, 2023 (the "276 Application")
The minimum expiration date of any patent that is issued from the 276 Application is
December 14, 2043. However, given typical practice with respect to regulatory-related patent term extensions, this date may be extended
up to an additional five years in many countries, depending on the length of the regulatory process, to a maximum final expiration date
of December 14, 2048.
The 276 Application was published on June 20, 2024 as International Patent Publication
No. WO 2024/127405.
In addition to patent laws, we rely on copyright and trade secret laws to protect our
proprietary rights. We also attempt to protect our trade secrets and other proprietary information through agreements with vendors, employees,
and consultants.
92
Property and Facilities
Our principal executive officers are currently
located in Ramat-Gan, Israel, where we lease a space of 464 square meters consisting of offices, under a lease agreement that will expire
on October 31, 2026.
Employees
As of the date of this prospectus, we have
eleven full time and three part time employees. All of our employees are based in Israel. None of our employees are represented by labor
unions or covered by collective bargaining agreements. We believe that we maintain good relations with all of our employees.
Grants from the Israeli Innovation Authority
During 2009 to 2020, we received several approvals from
the IIA for participation in research and development activities performed by us in a total amount of $5.8 million.
The Company is obligated to pay royalties to the IIA amounting
to 3%-5% of the sales of all of its product candidates and other related revenues generated from such projects, up to 100% of the grants
received, linked to the U.S. dollar and bearing interest at the rate of LIBOR. The obligation to pay these royalties is contingent
upon actual sales of the products and, in the absence of such sales, no payment is required. In October 2023, it was published that
the interest rate of the grants will be replaced with the 12-month term SOFR published on the first trading day of each calendar
year.
As of December 31, 2023, the total royalty amount
that may be payable by the Company is approximately $5.8 million ($6.4 million including interest).
Legal Proceedings
From time to time, we may become involved in actions,
claims, suits, and other legal proceedings arising in the ordinary course of our business, including assertions by third parties relating
to intellectual property infringement, breaches of contract or warranties, or employment-related matters. We are not currently subject
to any material legal proceedings.
Regulatory Environment
Government Regulation
Clinical trials, the drug approval process, and the marketing
of drugs are intensively regulated in the United States and in all major foreign countries. Government authorities in the United States
(including federal, state, and local authorities) and in other countries (including federal, state, and local authorities) extensively
regulate, among other things, the manufacturing, research and clinical development, marketing, labeling and packaging, storage, distribution,
post-approval monitoring and reporting, advertising and promotion, pricing, and export and import of pharmaceutical products, such
as those we are developing. The process of obtaining regulatory approvals and the subsequent compliance with appropriate federal, state,
local, and foreign statutes and regulations require the expenditure of substantial time and financial resources.
U.S. Government Regulation
In the United States, the Food and Drug Administration,
or FDA, regulates drugs under the Federal Food, Drug, and Cosmetic Act (FDCA) and related regulations and biologics under the FDCA and
the Public Health Service Act (PHSA) and its implementing regulations. FDA approval is required before any new unapproved drug or dosage
form, including a new use of a previously approved drug, can be marketed in the United States. Drugs and biologics are also subject
to other federal, state and local statutes and regulations. Failure to comply with the applicable United States regulatory requirements
at any time during the product development process, approval process or after approval may subject an applicant to administrative or judicial
sanctions. These sanctions could include the imposition by the FDA or an Institutional Review Board, or IRB, of a clinical hold on trials,
the FDA's refusal to approve pending applications or supplements, license suspension or revocation, withdrawal of an approval, warning
letters, product recalls, product seizures, total or partial suspension of production or distribution, injunctions, fines, civil penalties
or criminal prosecution. Any agency or judicial enforcement action could have a material adverse effect on us.
93
The FDA and comparable regulatory agencies in state and
local jurisdictions and in foreign countries impose substantial requirements upon the clinical development, manufacture and marketing
of pharmaceutical products. These agencies and other federal, state and local entities regulate research and development activities and
the testing, manufacture, quality control, safety, effectiveness, labeling, storage, distribution, record keeping, approval, advertising
and promotion of our products.
The FDA's policies may change and additional government
regulations may be enacted that could prevent or delay regulatory approval of our platforms and candidate products or any future product
candidates or approval of new disease indications or label changes. We cannot predict the likelihood, nature or extent of adverse governmental
regulation that might arise from future legislative or administrative action, either in the United States or abroad.
Marketing Approval
The process required by the FDA before product candidates
may be marketed in the United States, the European Medicines Agency, or EMA, before a product can be marketed in Europe, and Medicines &
Healthcare products Regulatory Agency (MHRA) for the United Kingdom. Generally involves the following:
●
completion of extensive preclinical laboratory tests and preclinical animal
        studies, all performed in accordance with the GLP regulations;
●
submission to the FDA of an investigational new drug application, or IND,
        Clinical Trial Application (CTA) for Europe which must become effective or approved before human clinical studies may begin and must be
        updated on a regular basis;
●
approval by an independent institutional review board, or IRB, or ethics
        committee representing each clinical site before each clinical study may be initiated;
●
performance of adequate and well-controlled human clinical studies to
        establish the safety and efficacy of the product candidate for each proposed indication;
●
preparation of and submission to the FDA of a new drug application, or NDA,
        or biologics license application, or BLA, or for Europe a Marketing Authorization Application (MAA) after completion of all pivotal clinical
        studies;
●
potential review of the product application by an FDA advisory committee,
        where appropriate and if applicable. In the EU, the Committee for Medicinal Products for Human Use (CHMP) issues a scientific opinion
        to the European Commission which issues the marketing authorization;
●
a determination by the FDA within 60 days of its receipt of an NDA or
        BLA to file the application for review;
●
satisfactory completion of an FDA pre-approval inspection of the manufacturing
        facilities where the proposed product drug substance is produced to assess compliance with cGMP; and
●
FDA review and approval of an NDA or BLA or marketing authorization in the
        European Union (EU) in all European Union Member States plus Norway, Iceland and Liechtenstein, prior to any commercial marketing or sale
        of the drug in the United States. Note that if the centralized procedure is used, which is mandatory for all new anticancer products,
        a marketing authorization is issued centrally by the EU commission, which is valid immediately in all member states of the EEA (EU plus
        Iceland, Norway, and Liechtenstein).
The testing and approval process requires substantial
time and financial resources, and we cannot be certain that any approvals for our candidate products will be granted on a timely basis,
if at all.
94
An IND/CTA is a request for authorization from the FDA/national
regulatory authorities in Europe to administer an investigational new drug product to humans. The central focus of an IND/CTA submission
is on the general investigational plan and the protocol(s) for human studies. The IND and CTA also include results of animal and
in
vitro
studies assessing the toxicology, pharmacokinetics, pharmacology, and pharmacodynamic characteristics of the product;
chemistry, manufacturing, and controls information; and any available human data or literature to support the use of the investigational
new drug. An IND or a CTA must become effective before human clinical trials may begin. An IND will automatically become effective 30 days
after receipt by the FDA, unless before that time the FDA raises concerns or questions related to the proposed clinical studies. In such
a case, the IND may be placed on clinical hold and the IND sponsor and the FDA must resolve any outstanding concerns or questions before
clinical studies can begin. Accordingly, submission of an IND may or may not result in the FDA allowing clinical studies to commence.
In Europe, a CTA is required to be approved by regulators, which may take several months. Accordingly, submission of a CTA to European
regulators may or may not result in permission to commence clinical studies in Europe.
We will need to successfully complete an extensive additional
clinical trial or some clinical trials in order to be in a position to submit a new drug application to the FDA. Our planned future
clinical trials for our candidate products may not begin or be completed on schedule, if at all. Clinical trials can be delayed for a
variety of reasons, including delays in:
●
obtaining regulatory approval to commence a study;
●
reaching agreement with third-party clinical trial sites and their subsequent
        performance in conducting accurate and reliable studies on a timely basis;
●
obtaining institutional review board approval or an Ethics Committee approval
        to conduct a study at a prospective site;
●
recruiting patients to participate in a study; and
●
supply of the drug.
We must reach agreement with the FDA/European national
authorities on the proposed protocols for our future clinical trials in the United States and EU. A separate submission apart
from any IND or initial CTA application we submit must be made for each successive clinical trial to be conducted during product development.
Further, an independent IRB or EC for each site proposing to conduct the clinical trial must review and approve the plan for any clinical
trial before it commences at that site. Informed consent must also be obtained from each study subject. Regulatory authorities, an IRB
or EC, a data safety monitoring board or the Sponsor may suspend or terminate a clinical trial at any time on various grounds, including
a finding that the participants are being exposed to an unacceptable health risk.
Clinical Studies
Clinical studies involve the administration of the investigational
new drug to human subjects under the supervision of qualified investigators in accordance with current cGCP/GCP, which include the requirement
that all research subjects provide their informed consent for their participation in any clinical study. Clinical studies are conducted
under protocols detailing, among other things, the objectives of the study, the parameters to be used in monitoring safety, and the efficacy
criteria to be evaluated. A protocol for each clinical study and any subsequent protocol amendments must be submitted to the FDA and/or
European national authorities as part of the IND or CTA. Additionally, approval must also be obtained from each clinical study site's
IRB or EC before the studies may be initiated, and the IRB/EC must monitor the study until completed. There are also requirements governing
the reporting of ongoing clinical studies and clinical study results to public registries.
Our objective is to conduct additional clinical trials
for our candidate products and, if those trials are successful, seek marketing approval from the FDA and other worldwide regulatory bodies.
95
For purposes of NDA approval, human clinical trials are
typically conducted in phases that may overlap.
●
Phase 1.
The
        drug is initially introduced into healthy human subjects and tested for safety, dosage tolerance, absorption, metabolism, distribution
        and excretion. In the case of some products for severe or life-threatening diseases, especially when the product may be too inherently
        toxic to ethically administer to healthy volunteers, the initial human testing is often conducted in patients.
●
Phase 2.
This
        phase involves trials in a limited patient population to identify possible adverse effects and safety risks, to preliminarily evaluate
        the efficacy of the product for specific targeted diseases and to determine dosage tolerance and optimal dosage.
●
Phase 3.
This
        phase involves trials undertaken to further evaluate dosage, clinical efficacy and safety in an expanded patient population, often at
        geographically dispersed clinical trial sites. These trials are intended to establish the overall risk/benefit ratio of the product and
        provide an adequate basis for product labeling.
●
Phase 4.
In
        some cases, the FDA or the EMA may condition approval of an NDA or BLA or MAA for a product candidate on the Sponsor's agreement
        to conduct additional clinical studies after approval. In other cases, a sponsor may voluntarily conduct additional clinical studies after
        approval to gain more information about the drug. Such post-approval studies are typically referred to as Phase 4 clinical studies.
A pivotal study is a clinical study that adequately meets
regulatory agency requirements for the evaluation of a drug candidate's efficacy and safety such that it can be used to justify
the approval of the product. Generally, pivotal studies are Phase 3 studies, but the FDA or EMA may accept results from a Phase 2
study if such study's design provides a well-controlled and reliable assessment of clinical benefit, particularly in situations
where there is an unmet medical need and the results are sufficiently robust.
The FDA/EMA, the IRB/EC, or the clinical study sponsor
may suspend or terminate a clinical study at any time on various grounds, including a finding that the research subjects are being exposed
to an unacceptable health risk.
Additionally, some clinical studies are overseen by an
independent group of qualified experts organized by the clinical study sponsor, known as a data safety monitoring board or committee.
This group provides authorization or recommendation for whether or not a study may move forward at designated check points based on access
to certain data from the study. We may also suspend or terminate a clinical study based on evolving business objectives and/or competitive
climate. All of these trials must be conducted in accordance with cGCP requirements in order for the data to be considered reliable for
regulatory purposes.
The clinical study process can take several (2- 12 or
more) years to complete, and there can be no assurance that the data collected will support FDA or EU Commission approval or licensure
of the product. Government regulation may delay or prevent marketing of product candidates or new drugs for a considerable period of time
and impose costly procedures upon our activities. We cannot be certain that the FDA or any other regulatory agency will grant approvals
for our candidate products or any future product candidates on a timely basis, if at all. Success in early stage clinical trials does
not ensure success in later stage clinical trials. Data obtained from clinical activities is not always conclusive and may be susceptible
to varying interpretations, which could delay, limit or prevent regulatory approval.
The NDA Approval Process
Assuming successful completion of all required testing
in accordance with all applicable regulatory requirements, detailed investigational new drug product information is submitted to the FDA
in the form of an NDA or BLA requesting approval to market the product for one or more indications. Under federal law, the submission
of most NDAs and BLAs is subject to an application user fee. For fiscal year 2014, the application user fee exceeds $2.1 million,
and the Sponsor of an approved NDA or BLA is also subject to annual product and establishment user fees, set at $104,060 per product and
$554,600 per establishment. These fees are typically increased annually. Applications for orphan drug products are exempted from the NDA
and BLA user fees and may be exempted from product and establishment user fees, unless the application includes an indication for other
than a rare disease or condition.
96
An NDA or BLA must include all relevant data available
from pertinent preclinical and clinical studies, including negative or ambiguous results as well as positive findings, together with detailed
information relating to the product's chemistry, manufacturing, controls, and proposed labeling, among other things. Data can come
from company-sponsored clinical studies intended to test the safety and effectiveness of a use of a product, or from a number of
alternative sources, including studies initiated by investigators. To support marketing approval, the data submitted must be sufficient
in quality and quantity to establish the safety and effectiveness of the investigational new drug product to the satisfaction of the FDA.
The FDA will initially review the NDA for completeness
before it accepts it for filing. The FDA has 60 days from its receipt of an NDA to determine whether the application will be accepted
for filing based on the agency's threshold determination that the application is sufficiently complete to permit substantive review.
After the NDA submission is accepted for filing, the FDA reviews the NDA to determine, among other things, whether the proposed product
is safe and effective for its intended use, and whether the product is being manufactured in accordance with cGMP to assure and preserve
the product's identity, strength, quality and purity. The FDA may refer applications for novel drug products or drug products that
present difficult questions of safety or efficacy to an advisory committee, typically a panel that includes clinicians and other experts,
for review, evaluation and a recommendation as to whether the application should be approved and, if so, under what conditions. The FDA
is not bound by the recommendations of an advisory committee, but it considers such recommendations carefully when making decisions.
Based on pivotal Phase 3 trial results submitted
in an NDA, upon the request of an applicant, the FDA may grant a priority review designation to a product, which sets the target date
for FDA action on the application at six months, rather than the standard ten months. Priority review is given where preliminary
estimates indicate that a product, if approved, has the potential to provide a significant improvement compared to marketed products or
offers a therapy where no satisfactory alternative therapy exists. Priority review designation does not change the scientific/medical
standard for approval or the quality of evidence necessary to support approval.
After the FDA completes its initial review of an NDA,
it will communicate to the sponsor that the drug will either be approved, or it will issue a complete response letter to communicate that
the NDA will not be approved in its current form and inform the sponsor of changes that must be made or additional clinical, nonclinical
or manufacturing data that must be received before the application can be approved, with no implication regarding the ultimate approvability
of the application.
Before approving an NDA or BLA, the FDA will typically
inspect the facilities at which the product is manufactured. The FDA will not approve the product unless it determines that the manufacturing
processes and facilities are in compliance with cGMP requirements and adequate to assure consistent production of the product within required
specifications.
Additionally, before approving an NDA, the FDA may inspect
one or more clinical sites to assure compliance with GCPs. If the FDA determines the application, manufacturing process or manufacturing
facilities are not acceptable, it typically will outline the deficiencies and often will request additional testing or information. This
may significantly delay further review of the application. If the FDA finds that a clinical site did not conduct the clinical trial in
accordance with GCP, the FDA may determine the data generated by the clinical site should be excluded from the primary efficacy analyses
provided in the NDA. Additionally, notwithstanding the submission of any requested additional information, the FDA ultimately may
decide that the application does not satisfy the regulatory criteria for approval.
The testing and approval process for a drug requires substantial
time, effort and financial resources, and this process may take several years to complete. Data obtained from clinical activities
are not always conclusive and may be susceptible to varying interpretations, which could delay, limit or prevent regulatory approval.
The FDA may not grant approval on a timely basis, or at all. We may encounter difficulties or unanticipated costs in our efforts to secure
necessary governmental approvals, which could delay or preclude us from marketing our products.
97
The FDA may require, or companies may pursue, additional
clinical trials after a product is approved. These so-called Phase 4 studies may be made a condition to be satisfied for continuing
drug approval. The results of Phase 4 studies can confirm the effectiveness of a product candidate and can provide important safety
information. In addition, the FDA now has express statutory authority to require sponsors to conduct post-market studies to specifically
address safety issues identified by the agency.
Any approvals that we may ultimately receive could be
withdrawn if required post-marketing trials or analyses do not meet the FDA requirements, which could materially harm the commercial
prospects for our candidate products.
The FDA also has authority to require a Risk Evaluation
and Mitigation Strategy, or REMS, from manufacturers to ensure that the benefits of a drug or biological product outweigh its risks. A
sponsor may also voluntarily propose a REMS as part of the NDA submission. The need for a REMS is determined as part of the review of
the NDA. Based on statutory standards, elements of a REMS may include "dear doctor letters," a medication guide, more
elaborate targeted educational programs, and in some cases restrictions on distribution. These elements are negotiated as part of the
NDA approval, and in some cases if consensus is not obtained until after the PDUFA review cycle, the approval date may be delayed. Once
adopted, REMS are subject to periodic assessment and modification.
Even if a product candidate receives regulatory approval,
the approval may be limited to specific disease states, patient populations and dosages, or might contain significant limitations on use
in the form of warnings, precautions or contraindications, or in the form of onerous risk management plans, restrictions on distribution,
or post-marketing study requirements. Further, even after regulatory approval is obtained, later discovery of previously unknown
problems with a product may result in restrictions on the product or even complete withdrawal of the product from the market. Delay in
obtaining, or failure to obtain, regulatory approval for our candidate products, or obtaining approval but for significantly limited use,
would harm our business. In addition, we cannot predict what adverse governmental regulations may arise from future U.S. or foreign
governmental action.
Expedited Review and Accelerated Approval Programs
A sponsor may seek approval of its product candidate under
programs designed to accelerate FDA's review and approval of NDAs and BLAs. For example, Fast Track Designation may be granted to
a drug intended for treatment of a serious or life-threatening disease or condition that has potential to address unmet medical needs
for the disease or condition. The key benefits of fast track designation are the eligibility for priority review, rolling review (submission
of portions of an application before the complete marketing application is submitted), and accelerated approval, if relevant criteria
are met. Based on results of the Phase 3 clinical study(ies) submitted in an NDA or BLA, upon the request of an applicant, the FDA
may grant the NDA or BLA a priority review designation, which sets the target date for FDA action on the application at six months
after the FDA accepts the application for filing. Priority review is granted where there is evidence that the proposed product would be
a significant improvement in the safety or effectiveness of the treatment, diagnosis, or prevention of a serious condition. If criteria
are not met for priority review, the application is subject to the standard FDA review period of ten months after FDA accepts the
application for filing. Priority review designation does not change the scientific/medical standard for approval or the quality of evidence
necessary to support approval.
Under the accelerated approval program, the FDA may approve
an NDA or a BLA on the basis of either a surrogate endpoint that is reasonably likely to predict clinical benefit, or on a clinical endpoint
that can be measured earlier than irreversible morbidity or mortality, that is reasonably likely to predict an effect on irreversible
morbidity or mortality or other clinical benefit, taking into account the severity, rarity, or prevalence of the condition and the availability
or lack of alternative treatments. Post-marketing studies or completion of ongoing studies after marketing approval are generally
required to verify the drug's clinical benefit in relationship to the surrogate endpoint or ultimate outcome in relationship to
the clinical benefit. In addition, the Food and Drug Administration Safety and Innovation Act (FDASIA), which was enacted and signed into
law in 2012, established the new "breakthrough therapy" designation. A sponsor may seek FDA designation of its product candidate
as a breakthrough therapy if the drug is intended, alone or in combination with one or more other drugs, to treat a serious or life-threatening disease
or condition and preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over existing therapies
on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development.
98
FDA Post-Approval Requirements
Drugs manufactured or distributed pursuant to FDA approvals
are subject to pervasive and continuing regulation by the FDA, including, among other things, requirements relating to recordkeeping,
periodic reporting, product sampling and distribution, advertising and promotion and reporting of adverse experiences with the product.
After approval, most changes to the approved product, such as adding new indications or other labeling claims are subject to prior FDA
review and approval. There also are continuing, annual user fee requirements for any marketed products and the establishments at which
such products are manufactured, as well as new application fees for supplemental applications with clinical data.
Drug manufacturers are subject to periodic unannounced
inspections by the FDA and state agencies for compliance with cGMP requirements. Changes to the manufacturing process are strictly regulated,
and, depending on the significance of the change, may require prior FDA approval before being implemented. FDA regulations also require
investigation and correction of any deviations from cGMP and impose reporting and documentation requirements upon us and any third-party manufacturers
that we may decide to use. Accordingly, manufacturers must continue to expend time, money and effort in the area of production and quality
control to maintain compliance with cGMP and other aspects of regulatory compliance.
We rely, and expect to continue to rely, on third parties
for the production of clinical quantities of our product candidates, and expect to rely in the future on third parties for the production
of commercial quantities. Future FDA and state inspections may identify compliance issues at our facilities or at the facilities of our
contract manufacturers that may disrupt production or distribution, or require substantial resources to correct. In addition, discovery
of previously unknown problems with a product or the failure to comply with applicable requirements may result in restrictions on a product,
manufacturer or holder of an approved NDA or BLA, including withdrawal or recall of the product from the market or other voluntary, FDA-initiated or
judicial action that could delay or prohibit further marketing. Also, new government requirements, including those resulting from new
legislation, may be established, or the FDA's policies may change, which could delay or prevent regulatory approval of our products
under development.
The FDA may withdraw approval if compliance with regulatory
requirements and standards is not maintained or if problems occur after the product reaches the market. Later discovery of previously
unknown problems with a product, including adverse events of unanticipated severity or frequency, or with manufacturing processes, or
failure to comply with regulatory requirements, may result in revisions to the approved labeling to add new safety information, imposition
of post-market studies or clinical studies to assess new safety risks, or imposition of distribution restrictions or other restrictions
under a REMS program. Other potential consequences include, among other things:
●
restrictions on the marketing or manufacturing of the product, complete withdrawal
        of the product from the market or product recalls;
●
fines, warning letters or holds on post-approval clinical studies;
●
refusal of the FDA to approve pending NDAs or supplements to approved NDAs,
        or suspension or revocation of product license approvals;
●
injunctions or the imposition of civil or criminal penalties; or
●
product seizure or detention, or refusal to permit the import or export of
        products.
The FDA strictly regulates marketing, labeling, advertising,
and promotion of products that are placed on the market. Drugs may be promoted only for the approved indications and in accordance with
the provisions of the approved label. The FDA and other agencies actively enforce the laws and regulations prohibiting the promotion of
off-label uses, and a company that is found to have improperly promoted off-label uses may be subject to significant liability.
99
Orphan Designation and Exclusivity
The FDA may grant orphan drug designation to drugs intended
to treat a rare disease or condition that affects fewer than 200,000 individuals in the United States, or, if it affects more than
200,000 individuals in the United States, when there is no reasonable expectation that the cost of developing and making the drug
for this type of disease or condition will be recovered from sales in the United States.
Orphan drug designation entitles a party to financial
incentives such as opportunities for grant funding of clinical study costs, tax advantages, and user-fee waivers. In addition, if
a product receives FDA approval for the indication for which it has orphan designation, the product is entitled to orphan drug exclusivity,
which means the FDA may not approve any other application to market the same drug for the same indication for a period of seven years,
except in limited circumstances, such as a showing of clinical superiority over the product with orphan exclusivity.
Patent Term Restoration
Depending upon the timing, duration, and specifics of
the FDA approval of the use of our product candidates, U.S. patents that may be granted to us in the future may be eligible for limited
patent term extension under the Drug Price Competition and Patent Term Restoration Act of 1984, commonly referred to as the
Hatch-Waxman Amendments. The Hatch-Waxman Amendments permit a patent restoration term of up to five years as compensation
for patent term lost during product development and the FDA regulatory review process. However, patent term restoration cannot extend
the remaining term of a patent beyond a total of 14 years from the product's approval date. The patent term restoration period
is generally one-half the time between the effective date of an IND and the submission date of an NDA or BLA, plus the time between
the submission date and the approval of that application. Only one patent applicable to an approved product is eligible for the extension
and the application for the extension must be submitted prior to the expiration of the patent. The USPTO, in consultation with the FDA,
reviews and approves the application for any patent term extension or restoration. In the future, we may apply for restoration of patent
term for one of our currently owned or licensed patents to add patent life beyond its current expiration date, depending on the expected
length of the clinical studies and other factors involved in the filing of the relevant NDA or BLA.
Biosimilars and Exclusivity
The Patient Protection and Affordable Care Act, or Affordable
Care Act, signed into law on March 23, 2010, includes a subtitle called the Biologics Price Competition and Innovation Act of 2009
(BPCI Act), which created an abbreviated approval pathway for biological products shown to be similar to, or interchangeable with, an
FDA-licensed reference biological product. This amendment to the PHSA attempts to minimize duplicative testing. Biosimilarity, which
requires that there be no clinically meaningful differences between the biological product and the reference product in terms of safety,
purity, and potency, can be shown through analytical studies, animal studies, and a clinical study or studies. Interchangeability requires
that a product is biosimilar to the reference product and the product must demonstrate that it can be expected to produce the same clinical
results as the reference product and, for products administered multiple times, the biologic and the reference biologic may be switched
after one has been previously administered without increasing safety risks or risks of diminished efficacy relative to exclusive use of
the reference biologic. However, complexities associated with the larger, and often more complex, structure of biological products, as
well as the process by which such products are manufactured, pose significant hurdles to implementation that are still being worked out
by the FDA.
A reference biologic is granted twelve years of exclusivity
from the time of first licensure of the reference product. The first biologic product submitted under the abbreviated approval pathway
that is determined to be interchangeable with the reference product has exclusivity against other biologics submitting under the abbreviated
approval pathway for the lesser of (i) one year after the first commercial marketing, (ii) eighteen months after approval
if there is no legal challenge, (iii) eighteen months after the resolution in the applicant's favor of a lawsuit challenging
the biologics' patents if an application has been submitted, or (iv) 42 months after the application has been approved
if a lawsuit is ongoing within the 42-month period.
100
Abbreviated New Drug Applications for Generic Drugs
In 1984, with passage of the Hatch-Waxman Act, Congress
authorized the FDA to approve generic drugs that are the same as drugs previously approved by the FDA under the NDA provisions of the
statute. To obtain approval of a generic drug, an applicant must submit an abbreviated new drug application (ANDA) to the agency. In support
of such applications, a generic manufacturer may rely on the preclinical and clinical testing previously conducted for a drug product
previously approved under an NDA, known as the reference listed drug (RLD).
Specifically, in order for an ANDA to be approved, the
FDA must find that the generic version is identical to the RLD with respect to the active ingredients, the route of administration, the
dosage form, and the strength of the drug. At the same time, the FDA must also determine that the generic drug is "bioequivalent"
to the innovator drug. Under the statute, a generic drug is bioequivalent to an RLD if "the rate and extent of absorption of the
[generic] drug do not show a significant difference from the rate and extent of absorption of the listed drug. . . ."
Upon approval of an ANDA, the FDA indicates that the generic
product is "therapeutically equivalent" to the RLD and it assigns a therapeutic equivalence rating to the approved generic
drug in its publication "Approved Drug Products with Therapeutic Equivalence Evaluations," also referred to as the "Orange
Book." Physicians and pharmacists consider an "AB" therapeutic equivalence rating to mean that a generic drug is fully
substitutable for the RLD. In addition, by operation of certain state laws and numerous health insurance programs, the FDA's
designation of an "AB" rating often results in substitution of the generic drug without the knowledge or consent of either
the prescribing physician or patient.
The FDCA provides a period of five years of non-patent exclusivity
for a new drug containing a new chemical entity. In cases where such exclusivity has been granted, an ANDA may not be filed with the FDA
until the expiration of five years unless the submission is accompanied by a Paragraph IV certification, in which case the applicant
may submit its application four years following the original product approval. The FDCA also provides for a period of three years
of exclusivity if the NDA includes reports of one or more new clinical investigations, other than bioavailability or bioequivalence studies,
that were conducted by or for the applicant and are essential to the approval of the application. This three-year exclusivity period
often protects changes to a previously approved drug product, such as a new dosage form, route of administration, combination or indication.
Hatch-Waxman Patent Certification and the 30-Month Stay
Upon approval of an NDA or a supplement thereto, NDA sponsors
are required to list with the FDA each patent with claims that cover the applicant's product or a method of using the product. Each
of the patents listed by the NDA sponsor is published in the Orange Book. When an ANDA applicant files its application with the FDA, the
applicant is required to certify to the FDA concerning any patents listed for the reference product in the Orange Book, except for patents
covering methods of use for which the ANDA applicant is not seeking approval.
Specifically, the applicant must certify with respect
to each patent that:
●
the required patent information has not been filed;
●
the listed patent has expired;
●
the listed patent has not expired, but will expire on a particular date and
        approval is sought after patent expiration; or
●
the listed patent is invalid, unenforceable or will not be infringed by the
        new product.
A certification that the new product will not infringe
the already approved product's listed patents or that such patents are invalid or unenforceable is called a Paragraph IV certification.
If the applicant does not challenge the listed patents or indicates that it is not seeking approval of a patented method of use, the ANDA
application will not be approved until all the listed patents claiming the referenced product have expired.
101
If the ANDA applicant has provided a Paragraph IV
certification to the FDA, the applicant must also send notice of the Paragraph IV certification to the NDA and patent holders once
the ANDA has been accepted for filing by the FDA. The NDA and patent holders may then initiate a patent infringement lawsuit in response
to the notice of the Paragraph IV certification. The filing of a patent infringement lawsuit within 45 days after the receipt
of a Paragraph IV certification automatically prevents the FDA from approving the ANDA until the earlier of 30 months after
the receipt of the Paragraph IV notice, expiration of the patent, or a decision in the infringement case that is favorable to the
ANDA applicant.
European Union/Rest of World Government
Regulation
In addition to regulations in the United States,
we will be subject to a variety of regulations in other jurisdictions governing, among other things, clinical studies and any commercial
sales and distribution of our products.
Whether or not we obtain FDA approval for a product, we
must obtain the requisite approvals from regulatory authorities in foreign countries prior to the commencement of clinical studies or
marketing of the product in those countries. Certain countries outside of the United States have a similar process that requires
the submission of a clinical study application much like the IND prior to the commencement of human clinical studies. In the European
Union, for example, a clinical study application, or CTA, must be submitted for each clinical protocol to each country's national
health authority and an independent ethics committee, much like the FDA and IRB, respectively. Once the CTA is accepted in accordance
with a country's requirements, the clinical study may proceed.
The requirements and process governing the conduct of
clinical studies vary from country to country. In all cases, the clinical studies are conducted in accordance with cGCP, the applicable
regulatory requirements, and the ethical principles that have their origin in the Declaration of Helsinki.
To obtain regulatory approval of an investigational medicinal
product under European Union regulatory systems, we must submit a marketing authorization application. The content of the NDA or BLA filed
in the United States is similar to that required in the European Union, with the exception of, among other things, country-specific document
requirements.
For other countries outside of the European Union, such
as countries in Eastern Europe, Latin America or Asia, the requirements governing product licensing, pricing, and reimbursement vary from
country to country.
Countries that are part of the European Union, as well
as countries outside of the European Union, have their own governing bodies, requirements, and processes with respect to the approval
of pharmaceutical products. If we fail to comply with applicable foreign regulatory requirements, we may be subject to, among other things,
fines, suspension or withdrawal of regulatory approvals, product recalls, seizure of products, operating restrictions and criminal prosecution.
Authorization Procedures in the European Union
Medicines can be authorized in the European Union by using
either the centralized authorization procedure or national authorization procedures.
Centralized procedure
The EMA implemented the centralized procedure for the
approval of human medicines to facilitate marketing authorizations that are valid throughout the European Economic Area, or EEA, which
is comprised of the 27 member states of the European Union plus Norway, Iceland, and Lichtenstein. This procedure results in a single
marketing authorization issued by the EMA that is valid across the EEA. The centralized procedure is compulsory for human medicines
that are: derived from biotechnology processes, such as genetic engineering, contain a new active substance indicated for the treatment
of certain diseases, such as HIV/AIDS, cancer, diabetes, neurodegenerative disorders or autoimmune diseases and other immune dysfunctions,
and officially designated orphan medicines.
102
For medicines that do not fall within these categories,
an applicant has the option of submitting an application for a centralized marketing authorization to the European Commission following
a favorable opinion by the EMA, as long as the medicine concerned is a significant therapeutic, scientific or technical innovation, or
if its authorization would be in the interest of public health.
National authorization procedures
There are also two other possible routes to authorize
medicinal products in several European Union countries, which are available for investigational medicinal products that fall outside the
scope of the centralized procedure:
●
Decentralized procedure
.    Using
        the decentralized procedure, an applicant may apply for simultaneous authorization in more than one European Union country of medicinal
        products that have not yet been authorized in any European Union country and that do not fall within the mandatory scope of the centralized
        procedure.
●
Mutual recognition procedure.
In
        the mutual recognition procedure, a medicine is first authorized in one European Union Member State, in accordance with the national procedures
        of that country. Following this, further marketing authorizations can be sought from other European Union countries in a procedure whereby
        the countries concerned agree to recognize the validity of the original, national marketing authorization.
In most cases, a Pediatric Investigation Plan, and/or
a request for waiver or deferral, is required for submission prior to submitting a marketing authorization application. A PIP describes,
among other things, proposed pediatric studies and their timing relative to clinical studies in adults.
New Chemical Entity Exclusivity
In the European Union, new chemical entities, sometimes
referred to as new active substances, qualify for eight years of data exclusivity upon marketing authorization and an additional
two years of market exclusivity. This data exclusivity, if granted, prevents regulatory authorities in the European Union from referencing
the innovator's data to assess a generic (abbreviated) application for eight years, after which generic marketing authorization
can be submitted, and the innovator's data may be referenced, but not approved for two years. The overall ten-year period
will be extended to a maximum of eleven years if, during the first eight years of those ten years, the marketing authorization
holder obtains an authorization for one or more new therapeutic indications which, during the scientific evaluation prior to their authorization,
are held to bring a significant clinical benefit in comparison with existing therapies.
Orphan Designation and Exclusivity
In the European Union, the EMA's Committee for Orphan
Medicinal Products, or COMP, grants orphan drug designation to promote the development of products that are intended for the diagnosis,
prevention or treatment of life-threatening or chronically debilitating conditions affecting not more than 5 in 10,000 persons
in the European Union Community and for which no satisfactory method of diagnosis, prevention, or treatment has been authorized (or the
product would be a significant benefit to those affected). Additionally, designation is granted for products intended for the diagnosis,
prevention, or treatment of a life-threatening, seriously debilitating or serious and chronic condition and when, without incentives,
it is unlikely that sales of the drug in the European Union would be sufficient to justify the necessary investment in developing the
medicinal product.
In the European Union, orphan drug designation entitles
a party to financial incentives such as reduction of fees or fee waivers and 10 years of market exclusivity is granted following
medicinal product approval. This period may be reduced to six years if the orphan drug designation criteria are no longer met, including
where it is shown that the product is sufficiently profitable not to justify maintenance of market exclusivity, and may be prolonged to
a total of 12 years, if pediatric studies in accordance with a PIP are being performed.
103
Orphan drug designation must be requested before submitting
an application for marketing approval. Orphan drug designation does not convey any advantage in, or shorten the duration of, the regulatory
review and approval process.
Exceptional Circumstances/Conditional Approval
Orphan drugs or drugs with unmet medical needs may be
eligible for EU approval under exceptional circumstances or with conditional approval. Approval under exceptional circumstances is applicable
to orphan and non-orphan products and is used when an applicant is unable to provide comprehensive data on the efficacy and safety
under normal conditions of use because the indication for which the product is intended is encountered so rarely that the applicant cannot
reasonably be expected to provide comprehensive evidence, when the present state of scientific knowledge does not allow comprehensive
information to be provided, or when it is medically unethical to collect such information. Conditional marketing authorization is applicable
to orphan medicinal products, medicinal products for seriously debilitating or life-threatening diseases, or medicinal products to
be used in emergency situations in response to recognized public threats. Conditional marketing authorization can be granted on the basis
of less complete data than is normally required in order to meet unmet medical needs and in the interest of public health, provided the
risk-benefit balance is positive, it is likely that the applicant will be able to provide the comprehensive clinical data, and unmet
medical needs will be fulfilled. Conditional marketing authorization is subject to certain specific obligations to be reviewed annually.
Accelerated Review
Under the Centralized Procedure in the European Union,
the maximum timeframe for the evaluation of a marketing authorization application is 210 days (excluding clock stops, when additional
written or oral information is to be provided by the applicant in response to questions asked by the EMA's Committee for Medicinal
Products for Human Use (CHMP)). Accelerated evaluation might be granted by the CHMP in exceptional cases, when a medicinal product is
expected to be of a major public health interest, particularly from the point of view of therapeutic innovation. In this circumstance,
EMA ensures that the opinion of the CHMP is given within 150 days, excluding clock stops.
Pharmaceutical Coverage, Pricing and
Reimbursement
Significant uncertainty exists as to the coverage and
reimbursement status of any drug products for which we obtain regulatory approval. In the United States and markets in other countries,
sales of any products for which we receive regulatory approval for commercial sale will depend in part on the availability of coverage
and reimbursement from third-party payors. Third-party payors include government authorities, managed care providers, private
health insurers and other organizations. The process for determining whether a payor will provide coverage for a drug product may be separate
from the process for setting the reimbursement rate that the payor will pay for the drug product. Third-party payors may limit coverage
to specific drug products on an approved list, or formulary, which might not include all of the FDA-approved drugs for a particular
indication. Moreover, a payor's decision to provide coverage for a drug product does not imply that an adequate reimbursement rate
will be approved. Adequate third-party reimbursement may not be available to enable us to maintain price levels sufficient to realize
an appropriate return on our investment in product development.
Third-party payors are increasingly challenging the
price and examining the medical necessity and cost-effectiveness of medical products and services, in addition to their safety and
efficacy. In order to obtain coverage and reimbursement for any product that might be approved for sale, we may need to conduct expensive
pharmacoeconomic studies in order to demonstrate the medical necessity and cost-effectiveness of our products, in addition to the
costs required to obtain regulatory approvals. Our product candidates may not be considered medically necessary or cost-effective. If
third-party payors do not consider a product to be cost-effective compared to other available therapies, they may not cover
the product after approval as a benefit under their plans or, if they do, the level of payment may not be sufficient to allow a company
to sell its products at a profit.
104
The U.S. government, state legislatures and foreign
governments have shown significant interest in implementing cost containment programs to limit the growth of government-paid health
care costs, including price controls, restrictions on reimbursement and requirements for substitution of generic products for branded
prescription drugs. By way of example, the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation
Act, collectively, the Healthcare Reform Law, contains provisions that may reduce the profitability of drug products, including, for example,
increased rebates for drugs sold to Medicaid programs, extension of Medicaid rebates to Medicaid managed care plans, mandatory discounts
for certain Medicare Part D beneficiaries and annual fees based on pharmaceutical companies' share of sales to federal health
care programs. Adoption of government controls and measures, and tightening of restrictive policies in jurisdictions with existing controls
and measures, could limit payments for pharmaceuticals.
In the European Community, governments influence the price
of pharmaceutical products through their pricing and reimbursement rules and control of national health care systems that fund a large
part of the cost of those products to consumers. Some jurisdictions operate positive and negative list systems under which products may
only be marketed once a reimbursement price has been agreed to by the government. To obtain reimbursement or pricing approval, some of
these countries may require the completion of clinical studies that compare the cost-effectiveness of a particular product candidate
to currently available therapies. Other member states allow companies to fix their own prices for medicines, but monitor and control company
profits. The downward pressure on health care costs in general, particularly prescription drugs, has become very intense. As a result,
increasingly high barriers are being erected to the entry of new products. In addition, in some countries, cross-border imports from
low-priced markets exert a commercial pressure on pricing within a country.
The marketability of any products for which we receive
regulatory approval for commercial sale may suffer if the government and third-party payors fail to provide adequate coverage and
reimbursement. In addition, an increasing emphasis on cost containment measures in the United States and other countries has increased
and we expect will continue to increase the pressure on pharmaceutical pricing. Coverage policies and third-party reimbursement rates
may change at any time. Even if favorable coverage and reimbursement status is attained for one or more products for which we receive
regulatory approval, less favorable coverage policies and reimbursement rates may be implemented in the future.
Other Healthcare Laws and Compliance
Requirements
If we obtain regulatory approval for any of our product
candidates, we may be subject to various federal and state laws targeting fraud and abuse in the healthcare industry. These laws may impact,
among other things, our proposed sales, marketing and education programs. In addition, we may be subject to patient privacy regulation
by both the federal government and the states in which we conduct our business. The laws that may affect our ability to operate include:
●
the federal Anti-Kickback Statute, which prohibits, among other things,
        persons from knowingly and willfully soliciting, receiving, offering or paying remuneration, directly or indirectly, to induce, or in
        return for, the purchase or recommendation of an item or service reimbursable under a federal healthcare program, such as the Medicare
        and Medicaid programs;
●
federal civil and criminal false claims laws and civil monetary penalty laws,
        which prohibit, among other things, individuals or entities from knowingly presenting, or causing to be presented, claims for payment
        from Medicare, Medicaid, or other third-party payers that are false or fraudulent;
●
the federal Health Insurance Portability and Accountability Act of 1996,
        or HIPAA, which created new federal criminal statutes that prohibit executing a scheme to defraud any healthcare benefit program and making
        false statements relating to healthcare matters;
105
●
the federal transparency laws, including the federal Physician Payment Sunshine
        Act, that requires drug manufacturers to disclose payments and other transfers of value provided to physicians and teaching hospitals;
●
HIPAA, as amended by HITECH and its implementing regulations, which imposes
        certain requirements relating to the privacy, security and transmission of individually identifiable health information; and
●
state law equivalents of each of the above federal laws, such as anti-kickback and
        false claims laws which may apply to items or services reimbursed by any third-party payer, including commercial insurers, and state
        laws governing the privacy and security of health information in certain circumstances, many of which differ from each other in significant
        ways and may not have the same effect, thus complicating compliance efforts.
The Healthcare Reform Law broadened the reach of the fraud
and abuse laws by, among other things, amending the intent requirement of the federal Anti-Kickback Statute and the applicable criminal
healthcare fraud statutes contained within 42 U.S.C. § 1320a-7b, effective March 23, 2010. Pursuant to the statutory
amendment, a person or entity no longer needs to have actual knowledge of this statute or specific intent to violate it in order to have
committed a violation. In addition, the Healthcare Reform Law provides that the government may assert that a claim including items or
services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of
the civil False Claims Act (discussed below) or the civil monetary penalties statute. Many states have adopted laws similar to the federal
Anti-Kickback Statute, some of which apply to the referral of patients for healthcare items or services reimbursed by any source,
not only the Medicare and Medicaid programs.
We are also subject to the Foreign Corrupt Practices Act,
or FCPA, which prohibits improper payments or offers of payments to foreign governments and their officials for the purpose of obtaining
or retaining business.
Safeguards we implement to discourage improper payments
or offers of payments by our employees, consultants, and others may be ineffective, and violations of the FCPA and similar laws may result
in severe criminal or civil sanctions, or other liabilities or proceedings against us, any of which would likely harm our reputation,
business, financial condition and result of operations.
If our operations are found to be in violation of any
of the laws described above or any other governmental regulations that apply to us, we may be subject to penalties, including civil and
criminal penalties, exclusion from participation in government healthcare programs, such as Medicare and Medicaid and imprisonment, damages,
fines and the curtailment or restructuring of our operations, any of which could adversely affect our ability to operate our business
and our results of operations.
Labeling, Marketing and Promotion
The FDA closely regulates the labeling, marketing and
promotion of drugs. While doctors are free to prescribe any drug approved by the FDA for any use, a company can only make claims relating
to safety and efficacy of a drug that are consistent with FDA approval, and the Company is allowed to actively market a drug only for
the particular use and treatment approved by the FDA. In addition, any claims we make for our products in advertising or promotion
must be appropriately balanced with important safety information and otherwise be adequately substantiated. Failure to comply with these
requirements can result in adverse publicity, warning letters, corrective advertising, injunctions and potential civil and criminal penalties.
Government regulators recently have increased their scrutiny of the promotion and marketing of drugs.
Pediatric Research Equity Act
The Pediatric Research Equity Act (PREA) amended the FDCA
to authorize the FDA to require certain research into drugs used in pediatric patients. The intent of PREA is to compel sponsors whose
drugs have pediatric applicability to study those drugs in pediatric populations, rather than ignoring pediatric indications for adult
indications that could be more economically desirable. The Secretary of Health and Human Services may defer or waive these requirements
under specified circumstances.
106
Anti-Kickback and False Claims Laws
In the United States, the research, manufacturing,
distribution, sale and promotion of drug products and medical devices are potentially subject to regulation by various federal, state
and local authorities in addition to the FDA, including the Centers for Medicare & Medicaid Services, other divisions of the
U.S. Department of Health and Human Services (e.g., the Office of Inspector General), the U.S. Department of Justice, state
Attorneys General, and other state and local government agencies. For example, sales, marketing and scientific/educational grant programs
must comply with the Medicare-Medicaid Anti-Fraud and Abuse Act, as amended (the "Anti-Kickback Statute"),
the False Claims Act, as amended, the privacy regulations promulgated under the Health Insurance Portability and Accountability Act, or
HIPAA, and similar state laws. Pricing and rebate programs must comply with the Medicaid Drug Rebate Program requirements of the Omnibus
Budget Reconciliation Act of 1990, as amended, and the Veterans Health Care Act of 1992, as amended. If products are
made available to authorized users of the Federal Supply Schedule of the General Services Administration, additional laws and requirements
apply. All of these activities are also potentially subject to federal and state consumer protection and unfair competition laws.
In the United States, we are subject to complex laws
and regulations pertaining to healthcare "fraud and abuse," including, but not limited to, the Anti-Kickback Statute,
the federal False Claims Act, and other state and federal laws and regulations. The Anti-Kickback Statute makes it illegal for any
person, including a prescription drug manufacturer (or a party acting on its behalf) to knowingly and willfully solicit, receive, offer,
or pay any remuneration that is intended to induce the referral of business, including the purchase, order, or prescription of a particular
drug, for which payment may be made under a federal healthcare program, such as Medicare or Medicaid.
The federal False Claims Act prohibits anyone from knowingly
presenting, or causing to be presented, for payment to federal programs (including Medicare and Medicaid) claims for items or services,
including drugs, that are false or fraudulent, claims for items or services not provided as claimed, or claims for medically unnecessary
items or services.
There are also an increasing number of state laws that
require manufacturers to make reports to states on pricing and marketing information. Many of these laws contain ambiguities as to what
is required to comply with the laws. In addition, as discussed below, beginning in 2013, a similar federal requirement will require manufacturers
to track and report to the federal government certain payments made to physicians and teaching hospitals made in the previous calendar
year. These laws may affect our sales, marketing, and other promotional activities by imposing administrative and compliance burdens on
us. In addition, given the lack of clarity with respect to these laws and their implementation, our reporting actions could be subject
to the penalty provisions of the pertinent state, and soon federal, authorities.
Patient Protection and Affordable
Health Care Act
In March 2010, the Patient Protection and Affordable
Health Care Act, as amended by the Health Care and Education Reconciliation Act of 2010 (collectively, PPACA) was enacted, which
includes measures that have or will significantly change the way health care is financed by both governmental and private insurers. The
fees, discounts and other provisions of this law are expected to have a significant negative effect on the profitability of pharmaceuticals.
Many of the details regarding the implementation of PPACA
are yet to be determined, and at this time, it remains unclear the full effect that PPACA would have on our business.
Other Regulations
We are also subject to numerous federal, state and local
laws relating to such matters as safe working conditions, manufacturing practices, environmental protection, fire hazard control, and
disposal of hazardous or potentially hazardous substances. We may incur significant costs to comply with such laws and regulations now
or in the future.
107
Israel
Clinical Testing in Israel
In order to conduct clinical testing on humans in the
State of Israel, special authorization must first be obtained from the ethics committee and general manager of the institution in which
the clinical studies are scheduled to be conducted, as required under the Guidelines for Clinical Trials in Human Subjects implemented
pursuant to the Israeli Public Health Regulations (Clinical Trials in Human Subjects) 5741-1980, as amended from time to time, and
other applicable legislation. These regulations require authorization by the institutional ethics committee and general manager as well
as from the Israeli Ministry of Health, except in certain circumstances, and in the case of genetic trials, special fertility trials and
complex clinical trials, an additional authorization of the Ministry of Health's overseeing ethics committee. The institutional
ethics committee must, among other things, evaluate the anticipated benefits that are likely to be derived from the project to determine
if it justifies the risks and inconvenience to be inflicted on the human subjects, and the committee must ensure that adequate protection
exists for the rights and safety of the participants as well as the accuracy of the information gathered in the course of the clinical
testing. Since we perform a portion of the clinical studies on certain of our therapeutic candidates in Israel, we are required to obtain
authorization from the ethics committee and general manager of each institution in which we intend to conduct our clinical trials, and
in most cases, from the Israeli Ministry of Health.
New Silexion Corporate Information
New Silexion was formed on April 2, 2024 under the name
Biomotion Sciences as a Cayman Islands exempted limited company for the purpose of effecting a business combination with Moringa and Silexion.
On April 3, 2024, New Silexion entered into the Business Combination Agreement by and among New Silexion, Moringa, Silexion, and New Silexion's
two wholly-owned subsidiaries— Merger Sub 1 and Merger Sub 2. On the Closing Date of August 15, 2024, following the approval of
the Business Combination (among other matters) at Moringa's extraordinary general meeting that was held on August 6, 2024, the transactions
contemplated by the Business Combination Agreement were completed. As a result, Moringa and Silexion merged with Merger Sub 2 and Merger
Sub 1 pursuant to the SPAC Merger and Acquisition Merger, respectively, and became New Silexion's wholly-owned subsidiaries, and
their securityholders became securityholders of New Silexion at previously agreed-upon exchange ratios. In addition, New Silexion's
ordinary shares and warrants were listed, and began trading, on the Nasdaq Global Market on August 16, 2024, and its name was changed
to Silexion Therapeutics Corp.
New Silexion's principal executive offices are located at 12 Abba Hillel
Road, Ramat Gan, Israel 5250606, and its phone number is +972-8-6286005. New Silexion's corporate website address is www.silexion.com.
Information contained on or accessible through that website is not a part of this prospectus, and the inclusion of that website address
in this prospectus is an inactive textual reference only.
Properties
We currently lease 464 square meters of
office space at
12 Abba Hillel Silver St
, Ramat Gan, Israel. The lease term is for 24 months beginning
on November 1, 2024 and ending on 31 October 2026, with an option to extend for an additional 24 months. Monthly rent payments, including
utilities, amount to approximately $12,839 per month
Access to Company Information
The Company files or furnishes periodic reports and amendments
thereto, including its Annual Reports on Form 10-K, its Quarterly Reports on Form 10-Q and Current Reports on Form 8-K, proxy statements
and other information with the SEC. In addition, the SEC maintains a website (www.sec.gov) that contains reports, proxy and information
statements, and other information regarding issuers that file electronically. New Silexion's internet address is https://www.silexion.com.
The Company makes available, free of charge, its Annual Report on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K,
and all amendments to those reports as soon as reasonably practicable after such reports have been filed with or furnished to the SEC
through its internet website.
108
MANAGEMENT
Management and Board of Directors
Our board of directors (sometimes referred to as the "New
Silexion Board") is comprised of the six directors listed below.
Each director will hold office until his or her successor
is duly elected or appointed and qualified in accordance with applicable law or until his or her death, resignation or removal in accordance
with law and our governing documents, including our Amended and Restated Memorandum and Articles of Association (the "Articles"),
which went into effect upon the Closing of the Business Combination.
The following sets forth certain information known as
of the date hereof concerning the persons who currently serve as directors and executive officers of New Silexion (who have served as
such since the consummation of the Business Combination):
Name
Age
Position(s)
Directors
Ilan Hadar
55
Chairman and Chief Executive Officer
Dror J. Abramov
63
Director
Ruth Alon
72
Director
Ilan Levin
58
Director
Avner Lushi
57
Director
Shlomo Noy
71
Director
Amnon Peled
65
Director
Executive Officers (who are not also directors)
Dr. Mitchell Shirvan
70
Chief Scientific and Development Officer
Mirit Horenshtein Hadar, CPA
40
EVP of Finance Affairs, Chief Financial Officer and Secretary
Directors
Ilan Hadar
, 55,
was
appointed as Chief Executive Officer of New Silexion, serving on a full-time basis, effective upon the Business Combination, and
has served as our (previously, Silexion's) Chairman of the Board since May 2024. Previously, he served as Managing Director of Silexion
from April 2022 until the Business Combination. Mr. Hadar has over 20 years of multinational managerial and corporate experience
with pharmaceutical and high-tech companies, as described below, over which time period he has acquired the experience and skills
to serve as a valuable member of the board of directors of a company such as Biomotion Sciences. In addition to his current role at Silexion,
Mr. Hadar has served as the Chief Executive Officer of Painreform Ltd (Nasdaq: PRFX) since November 2020, a position he will
relinquish following the consummation of the Business Combination. Prior to joining Painreform and Silexion, Mr. Hadar served as
Country Manager Israel and Chief Financial Officer at Foamix Pharmaceuticals Ltd. (currently, Nasdaq: VYNE) from 2014 until August 2020,
where he was instrumental in building the organization and launching new innovative topical drugs in the U.S., and also focused on capital
markets and mergers and acquisitions. Prior to his role at Foamix, Mr. Hadar was Finance Director at Pfizer PFR Pharmaceuticals Israel
Ltd., where he oversaw all commercial, financial and operational activities of the local entity of the large pharmaceutical company. Before
his tenure at Pfizer, Mr. Hadar served as Finance Manager at HP Indigo Ltd., a world-leading company in digital printing and,
prior to that, served as Finance Director at BAE Systems, the third-largest defense company in the world, where he was responsible
for all financial activities of BAE Systems Israel. From 1998 to 2006, Mr. Hadar was Chief Financial Officer at Mango DSP, a global
leader of Intelligent Video Solutions. Mr. Hadar served on the board of directors of Kadimastem, a public Israeli biopharmaceutical
company from 2019 to 2022. He received his MBA in Finance and Business Entrepreneurship and BA from The Hebrew University in Jerusalem,
Israel. We believe Mr. Hadar is qualified to serve on our board of directors due to his extensive knowledge as Silexion's Managing
Director, and his extensive commercial, financial and managerial experience with high-tech and pharmaceutical companies, both private
and public.
109
Dror J. Abramov,
63,
was appointed as a director of New Silexion effective upon the consummation of the Business Combination. Mr. Abramov's experience
of over 15 years in multiple roles in changing and growing companies and markets within dynamic environments, and in particular his multi-disciplinary experience
in R&D, consulting, taxes, sales, business development, finance and government, lend to his being an appropriate board member of Biomotion
Sciences. Mr. Abramov has served as Managing Director of Hewlett Packard Inc. Israel since 2015. Mr. Abramov held several other
management positions in Hewlett Packard Inc. Israel from 2006 to 2015, including finance director, general manager of imaging and printing
divisions and general manager of printing and personal systems division. From 2002 through 2006, Mr. Abramov served as Chief Financial
Officer of Applied Materials UK and Applied Materials Israel, both part of Applied Materials, Inc. (Nasdaq: AMAT), a nanomanufacturing
company that supplies equipment, services and software for the manufacture of semiconductor chips for electronics. From 2000 through 2002,
Mr. Abramov served as Vice President of business management at Avaya Communication, a cloud communications and workstream collaboration
technology company. From 1997 until 2000, Mr. Abramov held positions in Mainsoft Corporation, first as director of finance and operations
and later as general manager. From 1991 through 1997, Mr. Abramov served as consultant and manager at Maron, Sobel, Shor & Co.,
an Israeli CPA firm. Mr. Abramov is a licensed CPA and holds a Bachelor of Accounting, Master of Business Administration and Bachelor
of Science in physics and computer sciences, all three degrees from Tel Aviv University. We believe Mr. Abramov is qualified to serve
on our board of directors due to his extensive financial and business management experience.
Ruth Alon
, 72,
became
a director of New Silexion effective upon the consummation of the Business Combination. Ms. Alon's international experience of over
30 years in the high-tech medical industry and with Israeli life sciences companies, in particular, make her a prospective valuable
member of the board of directors of Biomotion Sciences. Ms. Alon is the Founder and Chief Executive Officer of Medstrada, which was started
in 2016. From 1997 until 2016, Ms. Alon served as a General Partner in Pitango Venture Capital, where she headed the life sciences activities
and helped to facilitate the acquisition of several of the company'sportfolio companies. Currently, Ms. Alon also serves on the
board of directors of a number of private and public companies as a member or chairperson, including Vascular Biogenics Ltd. (Nasdaq:
VBLT), Brainsgate and KadimaStem. Ms. Alon previously worked on Wall Street where she held senior positions as a senior medical device
analyst with Montgomery Securities (from 1981 to 1987) and Kidder Peabody & Co. (from 1987 to 1993). She also managed her own
independent consulting business in San Francisco from 1995 to 1996, providing broad-based services to early-stage companies
and venture capitalists in the medical devices industry. Ms. Alon was also instrumental in the establishment, in 2005, of Israel Life
Science Industry (ILSI), a not-for-profit organization which represented, as of 2005, the mutual goals of approximately 700 Israeli
life science companies. She is the Co-Founder of IATI, an umbrella organization established in 2012, representing Israel's
High Tech and Life Sciences industries. Ms. Alon holds a B.A. in Economics from the Hebrew University of Jerusalem, an M.B.A. from Boston
University, and an M.Sc. from the Columbia University School of Physicians and Surgeons. We believe Ms. Alon is qualified to serve on
our board of directors given her above-described extensive experience in the high-tech medical industry and with Israeli life
sciences companies, in particular.
Ilan Levin
, 58,
who
was the co-founder, Chairman and Chief Executive Officer of Moringa, was appointed as a director of New Silexion after its formation in
April 2024 and has continued as a director following the consummation of the Business Combination. Mr. Levin has been involved, for
approximately 25 years, as an executive and venture capital/private equity investor in high-tech, Israel-related ventures. His
experience as an executive and board member in managing growth companies that develop technology, and his knowledge of that industry in
Israel in particular, suit him well to serve as a director of Biomotion Sciences. From 2000 to 2018, Mr. Levin was a member of the
Board and Executive Committee of Objet Ltd., which as a result of a merger with Stratasys, Inc. in 2012, formed Stratasys Ltd. (Nasdaq:
SSYS), the pioneer and global leader in 3D printing. During his tenure at Objet/Stratasys, Mr. Levin held various positions including
President, Vice Chairman and from 2016 to 2018, Chief Executive Officer. From 2004 to 2009, Mr. Levin was the Chief Executive Officer
of CellGuide, a developer of software-based GPS for mobile devices. Since 1997, Mr. Levin has also served as a member of the
board of directors and as an advisor for a wide variety of Israel-based technology-related companies, including currently serving
as Chairman of Vision Sigma (TLV: VISN: IT), an Israel-based real estate and investment company. Early in his career, Mr. Levin
was a practicing attorney focusing on corporate and securities related matters. In addition to his role as our Chairman and Chief Executive
Officer, Mr. Levin also serves as the sole director and sole equity owner of an Israeli company that serves as the sole general partner
of the Sponsor. Mr. Levin earned an LL.B. from Tel Aviv University and a B.A.Sc. in Industrial Engineering from the University of
Toronto. We believe Mr. Levin is qualified to serve on our board of directors given his above-described experience in managing
growth companies that develop technology, and his knowledge of that industry in Israel in particular.
110
Avner Lushi
, 57,
was
appointed as a director of New Silexion effective upon the consummation of the Business Combination. His experience of over 20 years and
skills acquired in his managing roles at an Israeli life sciences venture capital fund and in life sciences investment banking make him
suitable to provide similar support as a member of the board of directors of Biomotion Sciences. Mr. Lushi co-founded Guangzhou
Sino-Israel Bio-industry Investment Fund (GIBF), which currently includes two approximately $100 million funds focused on introducing
Israeli and other foreign companies in the field of life sciences to the Chinese market, in which he also serves as a Managing Partner &
CEO of the GP since 2016. From 2004 to 2015, Mr. Lushi served as a Partner and Managing Director of Israel Healthcare Ventures (IHCV),
a prominent Israeli life sciences venture capital fund. Before joining IHCV, Mr. Lushi was the Co-Founder & CEO of Life
Sciences Transaction Support Ltd. (LTS), a PwC subsidiary dealing with life sciences investment banking. Since 2005, Mr. Lushi has
served as an independent director on the boards of nine public companies, including, currently, Brainsway Ltd. (Nasdaq: BWAY) and Ginegar
Plastic Products Ltd. In addition, he serves as a board member of several private companies as part of his role at GIBF. From 1997
to 2001, prior to turning to the private sector, he held increasingly senior roles within the Israeli Prime Minister's Chamber and
the Israeli Supreme Court. Mr. Lushi holds an LLM in Law from the Hebrew University of Jerusalem, LLB in Law and a BA in Economics
from the Haifa University. We believe Mr. Lushi is qualified to serve on our board of directors due to his extensive executive and
board experience with life sciences companies.
Shlomo Noy
,
MD PhD, 71,
was appointed as a director of New Silexion effective upon the consummation
of the Business Combination. Professor Noy's international-level expertise in healthcare management, tech transfer, building
ecosystems and focusing hospitals on research and clinical trials will provide important knowledge to the Biomotion Sciences board of
directors in the realm of Israeli research and clinical trial activities. Professor Noy has served as Chief Medical Officer of GIBF since
January 2017. Professor Noy served as the Director of the Rehabilitation Hospital at Sheba Medical Center from 1993 to
2017 and Vice President of Research and Development and Academic Affairs at Sheba Medical Center from 2000 to 2017. Prof. Noy was a Professor
at Sackler School of Medicine at Tel-Aviv University from 1993 to 2016. Prof. Noy serves as a board member of several private
companies as part of his role at GIBF. Prof. Noy possesses 25 years' experience in health care management and is active
in promoting research and education at an Israeli national level as well as at an international level. Prof. Noy received his MD from
the Hebrew University, Hadassah Medical School, Jerusalem, Israel, and completed his MBA at the European School of Business Administration
(INSEAD) Fontainebleau, France, and holds a PhD degree from Tel-Aviv University, Faculty of Medicine and Management. We believe Mr. Noy
is qualified to serve on our board of directors due to his extensive medical and health care management experience.
Amnon Peled
,
PhD, 65, was appointed as a director in December 2024. Professor Peled has served as an associate professor at Hadassah Medical Center,
Jerusalem since August 2000. Professor Peled also served as Director of the Gene Therapy Institute at Hadassah Medical Center from October
2021 to February 2024. He specializes in cytokine research, hematopoietic stem cell biology, inflammation, and cancer, leading the development
of therapies now in Phase II/III trials. Professor Peled served as Founder and CEO of Biokine Therapeutics, and as its Chief Scientific
Officer, from July 2000 to February 2024, where he advanced the CXCR4 antagonist BKT140/BL8040. Prof. Peled is an author of over 100 publications
and holder of 200+ patents and patent applications, and holds a Bachelor's degree in agriculture from the Hebrew University of Jerusalem,
a Master's degree in cell biology and histology from Tel Aviv University, and a Ph.D. from the Weizmann Institute. He completed
postdoctoral training at Harvard Medical School and the Weizmann Institute.
Executive Officers
Mitchell Shirvan
, 70,
has served as the Chief Scientific and Development Officer of New Silexion since the Business Combination, and, before the Business Combination,
of Silexion, since April 2022. Prior to joining Silexion, Dr. Shirvan served as the Senior Vice President of R&D and V.P. Innovation
and Discovery at Foamix Pharmaceuticals Ltd. from 2014 to 2019. Dr. Shirvan has over 25 years of industry experience, previously
holding positions as Chief Executive Officer at Macrocure Ltd. from 2008 to 2012. From 1992 until 2008, Dr. Shirvan held various
positions of increasing responsibility at Teva Pharmaceutical Industries, including Senior Director, Strategic Business Planning and Senior
Manager, Research & Development. Prior to his tenure at Teva, he was a research fellow at the U.S. National Institutes of
Health. Dr. Shirvan holds a Ph.D. in microbiology from The Hebrew University of Jerusalem and an MBA from the University of Bradford.
Mirit Horenshtein Hadar
, 40,
has served as the Chief Financial Officer and Secretary of New Silexion since the Business Combination, and served as the Executive Vice
President of Finance Affairs at Silexion before the Business Combination, beginning in January 2024. From August 2023 to January
2024, Ms. Horenshtein Hadar served as a part-time consultant in a Strategy & Corporate Finance Advisory capacity. Ms. Horenshtein
Hadar has over 15 years of corporate finance experience in senior financial positions of public companies and privately held companies,
in the pharmaceutical and high-tech industries, where she has been instrumental in building financial infrastructures for growth,
U.S. GAAP financial reporting and FP&A functions, and has led the accounting and reporting of complex M&A transactions, integration
processes and public offerings. Prior to joining Silexion, from January 2021 to December 2022, Ms. Horenshtein Hadar served
as VP of Finance and then CFO Israel of Gauzy Ltd. (currently, Nasdaq: GAUZ), a nanotechnology company that develops and markets smart
glass and vision control technologies. Since December 2022, Ms. Horenshtein Hadar continues to serve as an external advisor to the
finance department at Gauzy. Prior to Gauzy, Ms. Horenshtein Hadar served as Senior Director of Finance and Head of FP&A, Accounting
and Financial Reporting at Foamix Pharmaceuticals Ltd. (currently, Nasdaq: VYNE) from July 2016 until December 2020. Prior to
Foamix, Ms. Horenshtein Hadar was a Senior Manager at PwC Israel, as an external auditor, from 2008 to 2016. Ms. Horenshtein Hadar became
a Qualified CPA in 2011 and received a BA in Accounting, Economics and Business Management from Tel Aviv University.
111
Family Relationships
Mirit Horenshtein Hadar and Ilan Hadar are married to
one another. There are no other family relationships between the individuals who serve as directors and executive officers of the Company.
Corporate Governance Practices
Overall
The Company does not qualify as a "foreign private
issuer" under U.S. securities laws and is therefore not currently eligible to exempt itself from any of the Nasdaq listing
rule requirements in a manner that other non-U.S. issuers often do.
Composition of the New Silexion Board
After the Business Combination
New Silexion's business and affairs are managed
under the direction of the New Silexion Board. Under the terms of the Articles, the New Silexion Board may be composed of between three
and nine directors, as may be amended from time to time exclusively by ordinary resolution under Cayman Islands law, being a resolution
passed by a simple majority of the shareholders of New Silexion as, being entitled to do so, vote in person or by proxy at a general meeting
(an "
Ordinary Resolution
"). The size of the New Silexion Board was set by our shareholders
as seven members effective upon the Closing. Ilan Hadar serves as Chairman of the New Silexion Board. Subsequent to the Closing, Ilan
Shiloah stepped down from the Board, citing competing demands on his time, thereby leaving the current size of the Board as six members.
Pursuant to the Articles, New Silexion's directors are appointed by
an Ordinary Resolution at an annual general meeting. Unless the Board resolves that the election of nominees of the Board (referred to
as "
Nominees
") or of nominees of any shareholders entitled to present such nomination
(referred to as "
Alternate Nominees
") will be determined by plurality vote, the Nominees
or Alternate Nominees shall be appointed by Ordinary Resolution at the annual general meeting at which they are proposed for election.
Officers
New Silexion's Chief Executive Officer is responsible
for the company's day-to-day management. The Chief Executive Officer is appointed by, and serves at the discretion of,
the New Silexion Board, subject to his employment agreement. All other executive officers are proposed for appointment by the Chief Executive
Officer, subject to approval by the New Silexion Board, and will be subject to the terms of any applicable employment or consulting agreements
that Silexion may enter into with them.
Director Independence
Nasdaq listing standards require that a majority of the
New Silexion Board be independent. An "independent director" is defined generally as a person who has no material relationship
with the listed company (either directly or as a partner, shareholder or officer of an organization that has a relationship with the listed
company) that would interfere with the exercise of independent judgment in carrying out the responsibilities of a director. In making
these determinations, the New Silexion Board considers the current and prior relationships that each non-employee director has with the
Company and all other facts and circumstances the New Silexion Board deems relevant in determining their independence, including the beneficial
ownership of our securities by each non-employee director and the transactions described in the section titled "
Certain
Relationships and Related Party Transactions
."
The New Silexion Board has determined that
each of Messrs. Dror J. Abramov, Ilan Levin, Avner Lushi, Amon Peled and Shlomo Noy, and Ms. Ruth Alon, meets the definition of "independent
director" as defined in Nasdaq listing standards. For purposes of SEC rules applicable to members of the audit committee and compensation
committee, each of Messrs Abramov and Peled and Ms. Alon are deemed independent.
112
Board Committees
The New Silexion Board has established an audit committee,
a compensation committee and a nominating and corporate governance committee, each of which has the composition and the responsibilities
described below. Each of these committees operates under a written charter, approved by the New Silexion Board and effective upon the
Closing, that satisfies the applicable Nasdaq rules, copies of which are available on the investor relations portion of our website. Members
will serve on these committees until their resignation or until otherwise determined by the New Silexion Board. The New Silexion Board
may establish other committees as it deems necessary or appropriate from time to time.
Audit Committee
Our audit committee consists of Dror J.
Abramov, Amnon Peled and Ruth Alon, with Mr. Abramov serving as chair. Ilan Shiloah had served as the third member of the audit committee
from the Closing until his resignation from the New Silexion Board on September 16, 2024. Rule 10A-3 of the Exchange Act
and the Nasdaq listing standards require that our audit committee be composed entirely of independent members. The Nasdaq listing standards
require that the audit committee be composed of at least three members. With the resignation of Mr. Siloah from the New Silexion Board
and its audit committee, we will have until the earlier of our 2025 annual general meeting or one year after Mr. Shiloah's resignation
to restore the size of the audit committee to three members. The New Silexion Board has determined that each of Messrs Abramov and Peled
and Ms. Alon meets the definition of "independent director" for purposes of serving on the audit committee under Rule 10A-3 of
the Exchange Act and the Nasdaq listing standards and also meets the financial literacy requirements of the Nasdaq listing standards.
In addition, the New Silexion Board has determined that Mr. Abramov qualifies as an "audit committee financial expert"
within the meaning of the SEC regulations.
The primary purpose of the audit committee is to discharge
the responsibilities of the New Silexion Board with respect to our corporate accounting and financial reporting processes, systems of
internal control and financial statement audits and to oversee our independent registered public accounting firm. The principal functions
of the audit committee include, among other things:
●
helping the New Silexion Board oversee our corporate accounting and financial
        reporting processes;
113
●
managing the selection, engagement, qualifications, independence, and performance
        of a qualified firm to serve as the independent registered public accounting firm to audit our financial statements;
●
reviewing and discussing the scope and results of the audit with the independent
        registered public accounting firm, and reviewing, with management and the independent accountants, our interim and year-end operating
        results;
●
obtaining and reviewing a report by the independent registered public accounting
        firm at least annually that describes our internal quality control procedures, any material issues with such procedures and any steps
        taken to deal with such issues when required by applicable law;
●
establishing procedures for employees to submit concerns anonymously about
        questionable accounting or audit matters;
●
overseeing our policies on risk assessment and risk management;
●
overseeing compliance with our code of business conduct and ethics;
●
reviewing related person transactions; and
●
approving or, as required, pre-approving audit and permissible non-audit services
        to be performed by the independent registered public accounting firm.
Compensation Committee
Our compensation committee consists of Dror
J. Abramov, Amon Peled and Ruth Alon. The chair of the compensation committee will be chosen from among the committee's members.
The New Silexion Board has determined that each of Messrs. Abramov and Peled and Ms. Alon meets the definition of "independent
director" for purposes of serving on the compensation committee under the Nasdaq listing standards, including the heightened independence
standards for members of a compensation committee.
The primary purpose of our compensation committee is to
discharge the responsibilities of the New Silexion Board in overseeing our compensation policies, plans and programs and to review and
determine the compensation to be paid to our executive officers, directors and other senior management, as appropriate. The principal
functions of the compensation committee include, among other things:
●
reviewing, approving and determining, or making recommendations to the New
        Silexion Board regarding the compensation of our chief executive officer, other executive officers and senior management;
●
reviewing, evaluating and recommending to the New Silexion Board succession
        plans for our executive officers;
●
reviewing and recommending to the New Silexion Board the compensation paid
        to our non-employee directors;
●
administering our equity incentive plans and other benefit programs;
●
reviewing, adopting, amending and terminating incentive compensation and
        equity plans, severance agreements, profit sharing plans, bonus plans, change-of-control protections and any other compensatory arrangements
        for our executive officers and other senior management; and
●
reviewing and establishing general policies relating to compensation and
        benefits of our employees, including our overall compensation philosophy.
114
Corporate Governance and Nominating
Committee
We have appointed a corporate governance
and nominating committee that currently consists of Dror J. Abramov, Ilan Levin, Amnon Peled and Ruth Alon. The chair of the committee
will be chosen from among the committee's members. The New Silexion Board has determined that each of Messrs. Abramov, Peled and
Levin, and Ms. Alon, meets the definition of "independent director" under the Nasdaq listing standards.
Our corporate governance and nominating committee is responsible
for, among other things:
●
identifying and evaluating candidates, including the nomination of incumbent
        directors for reelection and nominees recommended by shareholders, to serve on the New Silexion Board;
●
considering and making recommendations to the New Silexion Board regarding
        the composition and chairmanship of the committees of the New Silexion Board;
●
instituting plans or programs for the continuing education of the New Silexion
        Board and the orientation of new directors;
●
developing and making recommendations to the New Silexion Board regarding
        corporate governance guidelines and matters;
●
overseeing our corporate governance practices;
●
overseeing periodic evaluations of the New Silexion Board's performance,
        including committees of the New Silexion Board; and
●
contributing to succession planning.
Compensation Committee Interlocks
and Insider Participation
None of the members of Silexion's compensation committee
is currently, or has been at any time, one of Silexion's, Moringa's or Silexion's executive officers or employees. None
of our executive officers serves as a member of the board of directors or compensation committee (or other committee performing equivalent
functions) of any entity that had one or more executive officers serving on our board of directors or compensation committee during 2023.
Code of Business Conduct and Ethics
Prior to the completion of the Business Combination, we
adopted a written code of business conduct and ethics that applies to our directors, officers and employees, including our principal executive
officer, principal financial officer, principal accounting officer or controller, or persons performing similar functions. A copy of the
code is posted on the investor relations portion of our website. In addition, we intend to post on our website all disclosures that are
required by law or Nasdaq listing standards concerning any amendments to, or waivers from, any provision of the code.
EXECUTIVE
COMPENSATION
Silexion
Unless the context requires
otherwise, references in this "Executive Compensation" section to "we," "our," "us" and
the "Company" generally refer to our company on a consolidated basis, for all periods following the completion of the Business
Combination (on August 15, 2024), and to our wholly-owned subsidiary, Silexion Therapeutics Ltd., an Israeli company ("Silexion"),
and its subsidiaries, for all periods prior to the completion of the Business Combination.
115
Overview
The following tables and accompanying narrative
set forth information about the compensation, for 2024, provided to our chief executive officer (or person serving in an equivalent position)
and the two most highly compensated executive officers (other than our chief executive officer) who were serving as executive officers
as of December 31, 2024, each of whom served as an executive officer of Silexion prior to the completion of the Business Combination.
These executive officers consist of: Ilan Hadar, who was Silexion's Managing Director and now serves as New Silexion's Chairman
and Chief Executive Officer; Mirit Horenshtein Hadar, who was Silexion's EVP Finance and now serves as New Silexion's Chief
Financial Officer; and Dr. Mitchell Shirvan, who was Silexion's— and is now New Silexion's— Chief Scientific
and Development Officer. These executive officers are referred to in this section as our "named executive officers" or "NEOs."
This discussion may contain forward-looking statements
that are based on our current plans, considerations, expectations and determinations regarding future compensation programs, in the period
immediately following the Business Combination. Actual compensation programs that we adopt in the future may differ materially from the
plans summarized in this discussion.
Summary Compensation Table
The following table presents summary information
regarding the total compensation for services rendered in all capacities that was awarded to, earned by, or paid to our named executive
officers for 2024.
Name and Principal Position
Year
Base Gross
Salary
($)
(1)
Stock
Awards
($)
All Other
Compensation
($)
(1)(2)
Total
($)
(1)
Ilan Hadar
Chief Executive Officer (formerly Managing Director of
        Silexion)
(3)
2024
240,560
1,192,785
107,283
1,540,628
2023
182,976
-
70,638
253,614
Mirit Horenshtein Hadar
Chief Financial Officer (formerly EVP Finance
        of Silexion)
(4)
2024
233,532
447,291
89,267
770,090
2023
26,238
-
-
26,238
Dr. Mitchell Shirvan
Chief Scientific and Development Officer
(5)
2024
190,286
1,043,699
67,505
1,301,490
2023
156,140
-
50,660
206,800
(1)
Amounts reported for the named executive officer and paid in New Israeli Shekels are converted from New
        Israeli Shekels to U.S. dollars using the 2024 and 2023 (as applicable) average exchange rates as published by Bank of Israel of
        3.699 and 3.689 New Israeli Shekels, respectively, to 1 U.S. Dollar.
(2)
The amounts in this column include payments for a leased car or car maintenance, contributions to a pension
        fund, compensation fund, and continuing education fund, or payments in lieu of a continuing education fund.
(3)
This was for a part-time (75%) position prior to, and a full-time position following, completion of
        the Business Combination.
(4)
For 2023, Ms. Horenshtein Hadar's compensation was for a period of 4.5 months during which she
        served as a part-time consultant in a Strategy & Corporate Finance Advisory capacity.
(5)
This was for a part-time (80%) position prior to, and a full-time position following, completion of
        the Business Combination.
Narrative Disclosure to Summary Compensation Table
Base Salary
The named executive officers receive base salaries to compensate
them for services rendered to us. The base gross salary payable to each named executive officer is intended to provide a fixed component
of compensation reflecting the executive's skill set, experience, role, and responsibilities. The annual base salaries for Ilan
Hadar, Mirit Horenshtein Hadar and Dr. Mitchell Shirvan, for 2024 and 2023 were $1,540,628 and $253,614 for Mr. Hadar, $770,090 and
$26,238 for Ms. Horenshtein Hadar, and $1,301,490 and $206,800 for Dr. Shirvan, respectively.
116
Equity Compensation
From time to time, we have granted equity awards under the Silexion Therapeutics Ltd.
2013 Equity Incentive Plan, which was replaced by the Silexion Therapeutics Ltd. 2023 Equity Incentive Plan (the "2013 Plan"
and "2023 Plan", respectively, collectively referred to as the "Silexion Plans"), as incentives to attract, retain
and motivate our named executive officers. During 2024, we granted restricted share units (RSUs) that could be settled for 16,821, 6,308 
and 14,718 ordinary shares of Silexion, to Ilan Hadar, Mirit Horenshtein Hadar, and Dr. Mitchell Shirvan, respectively (each such number
of Silexion ordinary shares does not reflect the exchange ratio in the Business Combination or the subsequent reverse share split of New
Silexion). The vesting of those RSUs accelerated upon the Closing of the Business Combination, entitling each such officer to receive
New Silexion ordinary shares in accordance with the exchange ratio upon the Closing.
During 2022, Silexion granted 32,400 and 16,200 options to purchase Silexion ordinary
shares to Ilan Hadar and Dr. Mitchell Shirvan, respectively (each such number of options does not reflect the equity exchange ratio
in the Business Combination or the subsequent reverse share split of New Silexion). Vesting of those options was to occur over a period
of 48 months, provided that Ilan Hadar or Dr. Mitchell Shirvan, as applicable, remains engaged by Silexion (or a Silexion affiliate),
and is subject to the Silexion
Plans. Upon consummation of an initial public offering of Silexion's
securities or an M&A Transaction (as defined in Silexion's articles of association), which included the Business Combination,
the vesting of those options was to accelerate, such that all unvested options were to immediately vest, provided that such IPO or M&A
Transaction was to be consummated after January 1, 2023.
Employment Agreements
Following the Closing, Silexion has entered or will enter into employment agreements
with each of its NEOs.
Silexion 2013 Equity Incentive Plan and Silexion 2023 Equity Incentive
Plan
Silexion (and, following the Business Combination, New Silexion) has maintained the
Silexion Plans in order to provide additional incentives for employees, directors and consultants, and to provide incentives to attract,
retain and motivate eligible persons whose present and potential contributions are important to Silexion's (and New Silexion's)
success. The 2013 Plan was adopted on July 25, 2013 and was replaced by the 2023 Plan, which was adopted on April 4, 2023. For
a complete description of the 2013 Plan and the 2023 Plan, please see "
Silexion Share Incentive
Plans
" below.
The Silexion Plans provide for grants of options to purchase ordinary shares of Silexion
(following the Business Combination, New Silexion), shares, restricted shares and RSUs. As described above, during 2022, Silexion granted
option awards under the Silexion Plans to Ilan Hadar and Dr. Mitchell Shirvan and during 2024, Silexion granted RSUs to Ilan Hadar,
Mirit Horenshtein Hadar, and Dr. Mitchell Shirvan, respectively.
Immediately prior to the effective time of the Acquisition Merger, all outstanding Silexion
options and Silexion RSUs accelerated and became fully vested (and, in the case of RSUs, settled for underlying shares). At the effective
time of the Acquisition Merger, all Silexion options outstanding immediately prior to the Acquisition Merger automatically and without
any action on the part of any Silexion option holder or beneficiary thereof, were assumed by New Silexion, and each such Silexion option
was converted into an option to purchase New Silexion ordinary shares (based on the equity exchange ratio for Silexion under the Business
Combination Agreement).
In addition, immediately prior to the completion of the Business Combination, New Silexion
adopted the 2024 Equity Incentive Plan (described below), which provides for the grant of equity-based incentive awards to its employees,
directors, office holders, service providers and consultants in order to incentivize them to increase their efforts on behalf of New Silexion
and to promote the success of New Silexion's business.
117
Outstanding Equity Awards at Fiscal Year-End
The following table provides information
regarding equity awards held by Silexion's named executive officers that were outstanding as of December 31, 2024. The awards
listed in this table were granted under the Silexion Plans, which are summarized above under "
— Narrative
Disclosure to Summary Compensation Table — Silexion 2013 Equity Incentive Plan and Silexion 2023 Equity Incentive Plan
."
Option awards
Name
Number of securities underlying unexercised options
(#)
        exercisable
Number of securities
underlying
unexercised
options
(#) unexercisable
Equity
incentive
plan awards: Number of
securities
underlying
unexercised
unearned
options
(#)
Option
exercise price
($)
Option expiration date
Ilan Hadar
Chief Executive Officer (formerly Managing Director of
        Silexion
14,339
-
-
60.51
24/03/2032
Mirit Horenshtein Hadar
Chief Financial Officer (formerly EVP Finance
        of Silexion
--
-
-
-
-
Dr. Mitchell Shirvan
Chief Scientific and Development Officer
(
7,170
-
-
60.51
07/06/2032
Director Compensation
Name
Fees earned or paid in cash
($)
Stock awards
($)
Option awards
($)
All other compensation
($)
Total
($)
Ilan Hadar
See Summary Compensation Table above
See Summary Compensation Table above
See Summary Compensation Table above
See Summary Compensation Table above
See Summary Compensation Table above
Dror Abramov
-
313,800
-
-
313,800
Ruth Alon
-
-
-
-
-
Ilan Levin
-
-
-
45,000
45,000
Avner Lushi
-
313,800
-
-
313,800
Shlomo Noy
-
313,800
-
-
313,800
Amnon Peled
-
-
-
-
-
Ilan Shiloah (
former director
)
-
313,800
-
-
313,800
In the year ended December 31, 2024, we did not pay any cash fees to, but we did
grant equity awards, consisting of 22,070 RSUs that could be settled for New Silexion ordinary shares (such number of RSUs reflects
the one-for-nine reverse share split of New Silexion), all of which became fully vested at the Closing, to  each non-employee member
of our board of directors for his or her service as a director.
New Silexion Executive Compensation
Following the Closing, we are developing an executive compensation program that is designed
to align compensation with our business objectives and the creation of shareholder value, while enabling us to attract, retain, incentivize
and reward individuals who contribute to the long-term success of New Silexion. Decisions regarding the executive compensation program
will be made by our compensation committee.
New Silexion Equity Compensation
It is anticipated that equity-based compensation
will continue to be an important element of executive compensation following the consummation of the Business Combination in order to
maintain a strong link between executive incentives and the creation of shareholder value. Upon the consummation of the Business Combination,
we granted 78,650 RSUs, in the aggregate, to directors of New Silexion and employees of New Silexion and its subsidiaries (of which 22,070
RSUs were granted to New Silexion directors) as a means of incentivizing them and aligning their interests with those of the shareholders
of the Company. We furthermore expect that the additional 63,953 New Silexion ordinary shares that will be available under the 2024 Equity
Incentive Plan (as referenced below) following the consummation of the Business Combination will be an important element of the new compensation
arrangements for New Silexion.
Silexion Share Incentive Plans
2013 Share Option Plan
Shares Reserved under the 2013 Share Option Plan.
The
total number of authorized but unissued Silexion ordinary shares available for issuance under Silexion's 2013 Share Option Plan
(the "
2013 Plan
") is 33,828 (which number does not reflect the exchange ratio in the
Business Combination or New Silexion's one-for-nine reverse share split). Any option which has expired or has been cancelled, without
having been exercised in full, is available again for issuance under the 2013 Plan. Upon the termination of the 2013 Plan, any unissued
New Silexion ordinary shares available under the 2013 Plan shall cease to be reserved for the purpose of the 2013 Plan, other than New
Silexion ordinary shares underlying then-outstanding options under the 2013 Plan.
Administration.
Our
board of directors, or a duly authorized compensation committee of the board of directors, has the power to administer the 2013 Plan.
Subject to applicable laws and the relevant provisions of the 2013 Plan, any member of the designated committee is eligible to receive
options under the 2013 Plan. The committee has the authority, subject to applicable law and our articles of association, to interpret
the terms of the 2013 Plan and any option agreements granted thereunder, designate participants in the 2013 Plan, determine and amend
the terms of respective option agreements, including the exercise price of an option, the fair market value of the New Silexion ordinary
shares, the time and vesting schedule applicable to the option, accelerate or amend the vesting schedule applicable to an option, prescribe
the forms of option agreement for use under the 2013 Plan and take all other actions and make all other determinations necessary for the
administration of the 2013 Plan.
118
Eligibility.
The
2013 Plan provides for granting options under various tax regimes, including, without limitation, in compliance with Section 102
or Section 3(i) of the Israeli Tax Ordinance (the "
Ordinance
"), and for awards
granted to Silexion's United States employees or service providers, including those who are deemed to be residents of the United States
for tax purposes, Section 422 of the U.S. Internal Revenue Code of 1986, as amended (the "
Code
")
and Section 409A of the Code.
Options.
All
options granted pursuant to the 2013 Plan are evidenced by an option agreement, in a form approved, from time to time, by the committee
in its sole discretion. The option agreement sets forth the terms and conditions of the number of shares to which the option relates and
the type of option granted thereunder, the purchase price per share and the vesting schedule to which such option shall become exercisable.
Unless otherwise determined by the committee or the board
of directors and as stated in the option agreement, and subject to the conditions of the 2013 Plan, options become exercisable under the
following schedule: 25% of the shares covered by the option on the first anniversary of the date on which such option was granted and
12.5% of the shares covered by the option at the end of each subsequent six-month period during the second, third and fourth years
from the date of grant, with the committee and/or board of directors reserving the exclusive authority to accelerate the periods for exercising
an option.
Each option shall expire after ten years from the
date of the grant thereof, or five years with respect to incentive stock options unless a shorter term of expiration is otherwise
designated by the committee.
Grants.
The
2013 Plan provides for the grant of options (including incentive stock options and nonqualified stock options).
Options granted under the 2013 Plan to Silexion employees
who are U.S. residents may qualify as "incentive stock options" within the meaning of Section 422 of the Code, or
may be non-qualified stock options. The exercise price of an option may not be less than the par value of the shares (if the shares
bear a par value) for which such option is exercisable. The exercise price of an Incentive Stock Option may not be less than 100% of the
fair market value of the underlying share on the date of grant or such other amount as may be required pursuant to the Code, and in the
case of Incentive Stock Options granted to ten percent (10%) shareholders, not less than 110%.
Exercise.
An
option under the 2013 Plan may be exercised by providing us with a written notice of exercise and full payment of the exercise price for
such shares underlying the award, if applicable, in such form and method as may be determined by the committee and the trustee and permitted
by applicable law.
Transferability.
No
option shall be assignable, transferable or given as collateral or any right with respect to them given to any third party whatsoever,
and during the lifetime of the option-holder each and all of such option-holder's rights to purchase New Silexion ordinary
shares thereunder shall be exercisable only by the option-holder.
Termination of Employment.
An
option may be exercised after the date of termination of option-holder's service or employment with Silexion or any of its affiliates
or termination of an affiliate's status as such only with respect to the number of options already vested and unexpired at the time
of such termination according to the vesting and expiration periods of the options set forth in the 2013 Plan, or under a different period
prescribed by the committee or by the board of directors and specified in relevant option agreement, provided however, that (i) such
termination is without cause, in which case the options shall be exercisable within not more than 90 days from the effective date
of such termination, or (ii) such termination is the result of death or disability of the option-holder, in which case the options
shall be exercisable within 12 months, and in the event of death, the option shall be exercisable by the option-holder's estate,
all in accordance the 2013 Plan. If termination of employment or service is for cause, any outstanding unexercised option (whether vested
or non-vested), will immediately expire and terminate, and the option-holder shall not have any right in connection to such outstanding
options.
119
Voting Rights.
Option-holders shall
not have any of the rights or privileges of shareholders of New Silexion in respect of any New Silexion ordinary shares purchasable upon
the exercise of any part of an option unless and until, following exercise in accordance with the terms of the 2013 Plan and the option,
registration of the option-holder as holder of such New Silexion ordinary shares in New Silexion's register of members, but
in case of options and New Silexion ordinary shares held by the trustee, subject to the provisions of the 2013 Plan.
Dividends.
With
respect to all New Silexion ordinary shares (in contrast to options not exercised for New Silexion ordinary shares) issued upon the exercise
of options purchased by an option holder, the option holder, as a shareholder of New Silexion shall be entitled to receive dividends in
accordance with the quantity of such New Silexion ordinary shares and the amended and restated memorandum and articles of association
of New Silexion, and subject to any applicable taxation on distribution of dividends.
Transactions.
If
the outstanding shares of New Silexion shall at any time be changed or exchanged by declaration of a dividend, split, share subdivision,
combination or exchange of shares, recapitalization, or any other like event of New Silexion, then in such event only and as often as
the same shall occur, the number, class and kind of New Silexion ordinary shares (including New Silexion ordinary shares issuable pursuant
to the 2013 Plan, in respect of which options have not yet been exercised) subject to the 2013 Plan or subject to any options granted
thereunder, and the purchase prices of the options, shall be appropriately and equitably adjusted so as to maintain the proportionate
number of New Silexion ordinary shares without changing the aggregate purchase price of the options.
In the event of a merger or consolidation of New Silexion
or a sale of all, or substantially all, of our shares or assets or other transaction having a similar effect on New Silexion, or change
in the composition of the board of directors, or such other transaction or circumstances that the New Silexion Board determines to be
a relevant transaction, the merger agreement will provide for one or more of the following, without the consent of the option-holder:
(i) any outstanding option will be assumed or substituted by the successor corporation; (ii) the cancellation of such options
and a payment to the option-holder, as provided in the 2013 Plan; and (iii) the full exercisability of the option and full vesting
of the New Silexion ordinary shares subject to the option, followed by the cancellation of the option.
2023 Equity Incentive Plan
The 2023 Equity Incentive (the
"2023
Plan"
) was adopted by our board of directors in 2023. The purpose of the 2023 Plan is to provide equity-based incentive
awards in order to link the compensation and benefits of the individuals and entities providing services to Silexion or its affiliates
with the success of Silexion and long-term shareholder value. The 2023 Plan enabled Silexion to grant options to purchase ordinary
shares of Silexion (currently, following the Business Combination, New Silexion ordinary shares), restricted shares and restricted share
units, all of which are referred to as "awards".
Shares Available for
Grants.
The total number of shares available for issuance under
the 2023 Plan was determined from time to time by our board of directors, subject to certain adjustments as described in the 2023 Plan.
If any shares subject to awards under the 2023 Plan expires or otherwise terminates in accordance with the terms thereunder, such shares
shall become available for future grants thereunder.
Administration.
our
board of directors (currently, following the Business Combination, the board of directors of New Silexion), or a duly authorized committee
of its board of directors (the
"Administrator"
), is authorized to administer the
2023 Plan. Under the 2023 Plan, the Administrator has the authority, subject to applicable law, to interpret the terms of the 2023 Plan
and any award agreements or awards granted thereunder, designate recipients of awards, determine and amend the terms of awards, including
the number of awards granted, the exercise price of an award, the time and vesting schedule applicable to an award or the method of payment
for an award, accelerate or amend the vesting schedule applicable to an award, prescribe the forms of agreement for use under the 2023
Plan and take all other actions and make all other determinations necessary for the administration of the 2023 Plan.
The Administrator also has the authority to determine
the circumstances under which awards may be settled, cancelled, forfeited, exchanged, or surrendered under and in accordance with the
2023 Plan of any or all awards or shares, and the authority to prescribe, amend and rescind rules and regulations relating to the 2023
Plan, including the form of award agreements and rules governing the grant of awards in jurisdictions in which Silexion or any affiliate
operate, or to terminate the 2023 Plan at any time before the date of expiration of its ten-year term, provided that such termination
shall not materially affect the rights of grantees, to whom awards have already been granted.
120
Eligibility.
The
2023 Plan provides for granting awards under the Israeli tax regime, including compliance with Section 102 or Section 3(i) of
the Ordinance.
Grants.
All
awards granted pursuant to the 2023 Plan are evidenced by an award letter, in a form approved, from time to time, by the administrator
in its sole discretion. The award letter sets forth the terms and conditions of the award, including the type of award, number of shares
subject to such award, vesting schedule and conditions (including performance goals or measures) and the exercise price, if applicable.
Unless otherwise determined by the Administrator and stated
in the award letter, and subject to the conditions of the 2023 Plan, awards vest and become exercisable under the following schedule:
25% of the shares covered by the award on the first anniversary of the vesting commencement date determined by the Administrator (and
in the absence of such determination, the date on which such award was granted) and the remaining 75% of the award shall vest (equally)
on a quarterly basis, over 12 quarters as of the commencement date's first annual anniversary; provided that the grantee remains
continuously as an employee or provides services to Silexion throughout such vesting dates.
Each award will expire ten years from the date of
the grant thereof, unless a shorter term of expiration is otherwise designated by the Administrator.
Awards.
The
2023 Plan provides for the grant of options, shares, restricted shares, RSUs, and other share-based awards.
Exercise.
An
award under the 2023 Plan may be exercised by providing Silexion (currently, New Silexion) a written notice of exercise and full payment
of the exercise price for such shares underlying the award, if applicable, in such form and method as may be determined by the Administrator
and permitted by applicable law. The 2023 Plan allows for a net exercise of awards (as may be included in the award letter or otherwise
approved by the Administrator). An award may not be exercised for a fraction of a share.
Transferability.
No
person other than the grantee shall have any right with respect to any award granted under the 2023 Plan. No transfer of any right to
any award or its underlying shares, by will or by the laws of descent, shall effectively bind Silexion (currently, New Silexion) unless
and until furnished with the certain signed and notarized documents, as described in the 2023 Plan.
Termination of Engagement.
In
the event of termination of a grantee's employment or service with Silexion or any of its affiliates, for any reason other than
death, retirement, disability or cause, any vested and unexercised awards held by such grantee as of the date of termination may be exercised
within 90-days after such date of termination, unless otherwise determined by the Administrator, but in no event later than the date
of expiration of the award as set forth in the award letter. After such 90-days period, all such unexercised awards will terminate
and the shares covered by such awards become available for issuance under the 2023 Plan.
In the event of termination of a grantee's employment
or service with Silexion or any of its affiliates due to such grantee's death, retirement or permanent disability, any vested but
unexercised awards shall be exercisable (a) in the case of death, by such grantee's estate, personal representative or beneficiary,
or (b) in the case of retirement or Disability, by such grantee or his/her personal representative (as the case may be), until the
earlier of (i) 180 days following the date of termination for any such reason; or (ii) the date of expiration of each such
as set forth in the award letter. All such grantee's other awards shall expire upon the date of such termination.
Notwithstanding any of the foregoing, if a grantee's
employment or services with Silexion or any of its affiliates is terminated for "cause" (as defined in the 2023 Plan), all
outstanding awards held by such grantee (whether vested or unvested) shall expire. With respect to any and all shares owned by such grantee
pursuant to the exercise of any and all awards granted under the 2023 Plan, the board of directors of Silexion may convert such shares
into deferred shares of Silexion.
121
Voting Rights.
Until
consummation of our initial public offering (or equivalent transaction, such as the Business Combination), shares underlying awards held
by grantees or the trustee, as applicable, were to be voted by an irrevocable proxy assigned to a person appointed by the board of directors.
Dividends.
Grantees
holding shares issuable or issued upon exercise of awards granted under the 2023 Plan will, as a shareholder of New Silexion, be entitled
to receive dividends and other distributions with respect to the underlying shares.
Transactions.
In
the event of any division or subdivision of Silexion's (currently, New Silexion's) issued and outstanding share capital, any
distribution of bonus shares (share split or subdivision), consolidation or combination of the share capital (reverse share split), reclassification
of the shares or any similar recapitalization event, as well as any reorganization, merger, consolidation, split-up, spin-off, combination,
repurchase, or exchange of the shares or other securities of Silexion (currently, New Silexion), or any other change in Silexion's
(currently, New Silexion's) corporate structure affecting the shares, the administrator may, in order to prevent diminution or enlargement
of the benefits or potential benefits intended to be made available under the 2023 Plan, adjust (A) the number and class of shares
that may be issued under the 2023 Plan; (B) the number, class, and exercise price of underlying shares for each outstanding award;
(C) any other term of the awards that in the administrator's opinion should be adjusted (including those concerning the vesting,
exercisability and term of outstanding awards); provided, that no adjustment shall be made by reason of the distribution of subscription
rights (rights offering) on outstanding shares.
Upon any such adjustment, references herein to shares
and underlying shares shall be construed to mean those shares of Silexion (currently, New Silexion) subject to the 2023 Plan as determined
by the Administrator following such adjustment. Any fractional shares resulting from such adjustment shall be rounded down to the nearest
whole number of share and Silexion (currently, New Silexion) shall have no obligation to make any cash or other payment with respect to
such fractional shares. The adjustments shall be made by the Administrator. If the applicable awards or underlying shares are deposited
with a trustee, all of the shares formed by such adjustments shall also be deposited with the trustee on the same terms as such awards
or underlying shares.
In the event of a merger, reorganization or consolidation
of Silexion (currently, New Silexion) with or into another incorporated entity, or its acquisition by another incorporated entity by means
of any transaction or series of related transactions, except any such merger, reorganization or consolidation in which the issued shares
of Silexion (currently, New Silexion) as of immediately prior to such transaction continue to represent, or are converted into or exchanged
for shares that represent, immediately following such merger, reorganization, or consolidation, at least a majority, by voting power,
of the outstanding shares of the surviving or acquiring incorporated entity; or a sale of all, or substantially all, of our shares or
assets or other transaction having a similar effect on our company, or change in the composition of the board of directors, or liquidation
or dissolution, or such other transaction or circumstances that our board of directors determines to be a relevant transaction, then without
the consent of the grantee, (i) unless otherwise determined by the Administrator, any outstanding award will be assumed or substituted
by such successor corporation or substituted by our company or by any affiliate of the successor corporation, as determined by the Administrator,
and (ii) regardless of whether or not the award is assumed or substituted, the Administrator may:
(a)
entitle a grantee to exercise an award, or to otherwise provide for the acceleration
        of such award's vesting schedule, as to all or part of its underlying shares, including with respect to awards that would not otherwise
        be exercisable or vested, under such terms and conditions as the Administrator shall determine, including the cancellation of all unexercised
        awards upon or immediately prior to the closing of a transaction or as of such other date (the
"Cut-Off Date"
),
        and/or the termination of all awards (whether vested but un-exercised or un-vested) as of the relevant Cut-Off Date, as of which
        they shall no longer be exercisable by the applicable grantees; and/or
(b)
provide for the cancellation of outstanding awards at or immediately prior
        to the closing of a transaction, and payment to the applicable grantee of a consideration determined by the Administrator to be fair in
        the circumstances (whether in shares, cash, other securities, property, or any combination thereof), taking into account the value of
        each underlying share of any such award's vested portion as reflected by the terms of such transaction, and the exercise price of
        each such underlying share, and subject to such terms and conditions as determined by the Administrator.
The Administrator shall have full authority to select
the method for determining the payment to the grantees, as well as to set such payment to zero, with respect to underlying shares valued
at less than their exercise price or to those of awards that would not otherwise be exercisable or vested, or to determine that such payment
be made only in excess of the exercise price.
122
New Silexion Share Incentive Plans
2024 Equity Incentive Plan
Pursuant to written resolutions adopted by our board of
directors and shareholders prior to the Closing, we have approved and adopted the 2024 Equity Incentive Plan (the "
2024
Plan
"), which became effective immediately upon the Closing.
Upon the Closing, a total of 63,953 New Silexion ordinary shares were reserved
for issuance under the terms of the 2024 Plan, which, together with New Silexion ordinary shares allocated for issuance under the existing
2013 Plan and 2023 Plan, equaled 10% of the total number of New Silexion ordinary shares on a fully diluted basis immediately following
the Closing. A summary of the other material terms of the 2024 Incentive Plan is provided below:
Administration
The compensation committee of our board of directors is
the administrator of the 2024 Plan. Except as provided otherwise under the 2024 Plan, the administrator has plenary authority to grant
awards pursuant to the terms of the 2024 Plan to eligible individuals, determine the types of awards and the number of shares covered
by the awards, establish the terms and conditions for awards and take all other actions necessary or desirable to carry out the purpose
and intent of the 2024 Plan.
Eligibility and Participation
The administrator selects the individuals who participate
in the 2024 Plan. Eligibility to participate is open to officers, directors and employees of, and other individuals who provide bona fide
services to or for, us or any of our subsidiaries. Our board of directors may also select as participants prospective officers, employees
and individual service providers who have accepted an offer of employment or another service relationship from us or one of our subsidiaries.
Any awards granted to such a prospect before the individual's start date may not become vested or exercisable, and no shares may
be issued to such individual, before the date the individual first commences performance of services with us.
Share Pool Under the 2024 Plan
The initial number of New Silexion ordinary shares allocated to the 2024
Plan is 63,953. The number of New Silexion ordinary shares available under the 2024 Plan (the "
Share
Pool
") will be subject to the following annual allocations and adjustments:
The Share Pool will be increased automatically on January
1 of each calendar year, beginning on January 1, 2025 and for each of the subsequent nine calendar years, through (and including) January
1, 2034, in an amount equal to the lesser of (i) 5% of the number of New Silexion ordinary shares issued and outstanding as of that January
1 date, or (ii) an amount determined by our board of directors prior to such date.
The following additional rules apply to the number of
New Silexion ordinary shares available under the Share Pool on an ongoing basis:
●
The Share Pool will be reduced by one share for each share made subject to
        an award granted under the 2024 Plan;
●
The Share Pool will be increased by the number of unissued shares underlying
        or used as a reference measure for any award or portion of an award granted under the 2024 Plan that is cancelled, forfeited, expired,
        terminated unearned or settled in cash, in any such case without the issuance of shares;
●
The Share Pool will be increased by the number of shares that are forfeited
        back or surrendered for no consideration to us after issuance due to a failure to meet an award contingency or condition with respect
        to any award or portion of an award granted under the 2024 Plan;
123
●
The Share Pool shall be increased, on the exercise date, by the number of
        shares withheld by or surrendered (either actually or through attestation) to the Company in payment of the exercise price of any award
        granted under the 2024 Plan; and
●
The Share Pool shall be increased, on the relevant date, by the number of
        shares withheld by or surrendered (either actually or through attestation) to the Company in payment of any tax withholding obligation
        that arises in connection with any award granted under the 2024 Plan.
In the event of a merger, consolidation, share rights
offering, statutory share exchange or similar event affecting the Company or a share dividend, share split, reverse share split, separation,
spinoff, reorganization, extraordinary dividend of cash or other property, share combination or subdivision, or recapitalization or similar
event affecting the capital structure of the Company, our board of directors will make equitable and appropriate substitutions or proportionate
adjustments to the Share Pool to reflect the transaction or event. Similar adjustments will be made to the award limitations described
below and to the terms of outstanding awards.
ISO Award Limit
The maximum number of New Silexion ordinary shares that may be issued in
connection with awards granted under the 2024 Plan that are intended to qualify as incentive stock options under Section 422 of the Code
is 63,953.
Types of Awards
General
.
The 2024 Plan enables the grant of share awards, performance shares, restricted share units, cash-based performance units, other share-based
awards, share options, share appreciation rights, and share unit awards, each of which may be granted separately or in tandem with other
awards. The administrator may establish sub-plans under the 2024 Plan under which awards that qualify for preferred tax treatment for
recipients in jurisdictions outside the U.S. may be granted.
We have adopted a sub-plan for Israeli participants, which
provides for granting awards in compliance with Section 102 ("
Section 102
") and Section
3(i) of the Israeli Income Tax Ordinance (New Version), 5721-1961, as amended (the "
ITO
").
Section 102 allows employees, directors and officers who are not controlling shareholders and who are considered Israeli residents for
tax purposes to receive favorable tax treatment for compensation in the form of shares, options or certain other types of equity awards,
subject to certain terms and conditions. Our non-employee service providers and controlling shareholders who are considered Israeli residents
for tax purposes may be granted awards under Section 3(i) of the ITO, which do not provide for similar tax benefits as Section 102.
Out of the three tax tracks that are available under Section
102 ((i) the "ordinary income track" with a trustee, (ii) the "capital gains track" with a trustee and (iii) grants
without a trustee and without a trust period), we have elected the "capital gain track" for grants to eligible Israeli grantees
as provided above, which may allow favorable tax treatment for such grantees.
Adjustments to Awards for Corporate Transactions and
Other Events
Mandatory Adjustments
.
In the event of a merger, amalgamation, consolidation,
share rights offering, share exchange or similar event affecting the Company (a "
Corporate Event
")
or a share dividend, share split, reverse share split, separation, spinoff, reorganization, extraordinary dividend of cash or other property,
share combination or subdivision, or recapitalization, capital reduction distribution or similar event affecting the capital structure
of the Company, the administrator will make equitable and appropriate substitutions or proportionate adjustments to:
●
the aggregate number and kind of shares or other securities that may be granted
        to eligible individuals under the 2024 Plan;
124
●
the maximum number of shares or other securities that may be issued with
        respect to incentive share options granted under the 2024 Plan;
●
the number of shares or other securities covered by each outstanding award
        and the exercise price, base price or other price per share, if any, and other relevant terms of each outstanding award; and
●
all other numerical limitations relating to awards, whether contained in
        the 2024 Plan or in award agreements.
Notwithstanding the foregoing, any fractional shares resulting
from the above mandatory adjustments will be eliminated.
Discretionary Adjustments
.
In addition to the adjustments specified above, in the
case of Corporate Events, the administrator may make such other adjustments to outstanding awards as it determines to be appropriate and
desirable, which adjustments may include, without limitation, (i) the cancellation of outstanding awards in exchange for payments of cash,
securities or other property or a combination thereof having an aggregate value equal to the value of such awards, (ii) the substitution
of securities or other property (including, without limitation, cash or other securities of the Company and securities of entities other
than the Company) for the shares subject to outstanding awards, and (iii) the substitution of equivalent awards, as determined in the
sole discretion of the administrator, of the surviving or successor entity or a parent thereof. The administrator may, in its discretion,
adjust the performance goals applicable to any awards to reflect any unusual or non-recurring events and other extraordinary items, impact
of charges for restructurings, discontinued operations and the cumulative effects of accounting or tax changes.
Repricing
.
The administrator may reprice any share options or share
appreciation rights without the approval of the shareholders of the Company. For this purpose, "reprice" means (i) any of
the following or any other action that has the same effect: (A) lowering the exercise price or base price of an option or share appreciation
right after it is granted other than an adjustment made pursuant to the provisions of the 2024 Plan, (B) any other action that is treated
as a repricing under applicable accounting principles; (C) cancelling a share option or share appreciation right at a time when its exercise
price or base price exceeds the fair market value of the underlying share, in exchange for another share option, share appreciation right,
restricted share or other equity, unless the cancellation and exchange occurs in connection with a merger, acquisition, spin-off or other
similar corporate transaction; and (ii) any other action that is considered to be a repricing under formal or informal guidance issued
by the primary securities market or exchange on which the shares are listed or admitted for trading.
Treatment of Awards upon Dissolution or Liquidation or
a Change in Control
Dissolution or Liquidation
.
Unless the administrator determines otherwise, all awards
outstanding under the 2024 Plan will terminate upon the winding up, liquidation or dissolution of the Company.
Amendment and Termination
Our board of directors or the compensation committee may
terminate, amend or modify the 2024 Plan or any portion of it at any time; provided, that, (i) if required to comply with Cayman Islands
law and any other applicable laws or marketplace or listing rules of a securities market or securities exchange (other than any requirement
from which the Company may opt out based on any available home country exemption), the Company shall obtain shareholder approval of any
2024 Plan amendment in such a manner and to such a degree as required, and (ii) no such termination or amendment may materially impair
the rights of a participant with respect to a previously granted award (other than as required to comply with applicable law or the rules
of any securities exchange or market on which the shares are listed or to prevent adverse tax or accounting consequences to the Company
or the participant) without such participant's consent.
125
The 2024 Plan is scheduled to expire on August 14, 2034,
which is ten years after the effective date of its adoption by our board of directors. After that time, no further grants may be made
under the 2024 Plan, but any then-outstanding grants will remain subject to the terms of the plan.
The foregoing description of the 2024 Incentive Plan is
qualified in its entirety by the full text of the 2024 Incentive Plan, which is attached to the registration statement of which this prospectus
forms a part as Exhibit 10.12 and incorporated herein by reference.
Rule 10b5-1 Sales Plans
Our directors and executive officers may adopt written
plans, known as Rule 10b5-1 plans, in which they will contract with a broker to buy or sell ordinary shares on a periodic basis. Under
a Rule 10b5-1 plan, a broker executes trades pursuant to parameters established by the director or executive officer when entering into
the plan, without further direction from them. The director or executive officer may amend a Rule 10b5-1 plan in some circumstances and
may terminate a plan at any time. Our directors and executive officers also may buy or sell additional shares outside of a Rule 10b5-1
plan when they are not in possession of material nonpublic information, subject to compliance with the terms of our insider trading policy.
Emerging Growth Company Status
We are an "emerging growth company," as defined
in the JOBS Act. As an emerging growth company, it is exempt from certain requirements related to executive compensation, including the
requirements to hold a nonbinding advisory vote on executive compensation and to provide information relating to the ratio of total compensation
of its chief executive officer to the median of the annual total compensation of all of its employees, each as required by the Investor
Protection and Securities Reform Act of 2010, which is part of the Dodd-Frank Wall Street Reform and Consumer Protection Act.
CERTAIN
RELATIONSHIPS AND RELATED PARTY TRANSACTIONS
Other than the compensation arrangements for our directors
and executive officers, which are described in the section titled "Executive Compensation", below is a description of transactions
since our formation on April 2, 2024 to which we have been a party, in which:
●
the amounts involved exceeded or will exceed $120,000; and
●
any of our directors, executive officers or holders of more than 5% of our
        share capital, or any member of the immediate family of, or person sharing the household with, the foregoing persons, had or will have
        a direct or indirect material interest.
Related Party Transactions
Arrangements with Executive Officers
Ilan Hadar serves as our Chief Executive Officer and Chairman of the our
Board. Mr. Hadar's employment agreement with us, as to be amended in the period following the Closing of the Business Combination,
subject to corporate approvals, will provide for him to receive an annual base salary of $357,820 (based on the average exchange rate
for 2023, as published by the Bank of Israel), customary disbursements toward his providence fund, further education fund and severance
pay fund, and other fringe benefits commensurate with such position. During 2022, Silexion granted Mr. Hadar 14,339 options to purchase
New Silexion ordinary shares, vesting over a period of 48 months, provided that Mr. Hadar remains engaged by us (or a Silexion affiliate)
at the end of each vesting period and subject to the Silexion Plan. Upon completion of the Business Combination, the vesting of all such
options is expected to accelerate, such that all unvested options shall become fully vested at that time.
Mirit Horenshtein Hadar, our Executive VP of Finance, Chief Financial Officer
and Secretary, is Mr. Hadar's spouse. Ms. Horenshtein Hadar's employment agreement with us provides for her to receive an
annual base salary of $234,210 (based on the average exchange rate for 2023, as published by the Bank of Israel), as well as customary
disbursements toward her providence fund, further education fund and severance pay fund, and other fringe benefits commensurate with such
position.
126
Indemnification Agreements
On the date of, and in connection with, the Closing of
the Business Combination, the Company entered into indemnification agreements with each of its directors and executive officers, which
provide for indemnification and advancements by the Company of certain expenses and costs under certain circumstances. The indemnification
agreements provide that we will indemnify each of its directors and executive officers against any and all expenses incurred by that director
or executive officer because of his or her status as a director or officer of New Silexion, to the fullest extent permitted under Cayman
law and the Articles.
The foregoing description of the indemnification agreements does not purport
to be complete and is qualified in its entirety by reference to the text of the form of indemnification agreement that is filed as Exhibit
10.6 to the registration statement of which this prospectus forms a part, which is incorporated herein by reference.
Conversion Transaction with GIBF
Immediately following the Closing of the Business Combination, Guangzhou
Sino-Israel Bio-Industry Investment Fund I ("GIBF") beneficially owned 20.3% of our issued and outstanding share capital.
GIBF had held the remaining 49% of the issued and outstanding share capital of our 51%-held Chinese subsidiary, Silenseed (China) Ltd.
(which 49% interest had been received by it in return for its equity investments in the Chinese subsidiary, rather than equity investments
directly in us). In connection with the consummation of the Business Combination, GIBF was to exchange its entire holdings in the Chinese
subsidiary for preferred shares of Silexion according to the terms set out in the contract for the establishment of the Chinese subsidiary,
dated August 30, 2021, as amended, which preferred shares were to be automatically converted into 203,971 New Silexion ordinary shares
in accordance with the equity exchange ratio for our shareholders' exchange of shares of Silexion for our shares under the Business
Combination Agreement.
However, in order to simplify the transfer of GIBF's 49% interest in
our Chinese subsidiary to our company, in lieu of transferring that interest to Silexion, GIBF instead transferred the interest directly
to New Silexion pursuant to an Agreement on Arrangements Related to Equity Interest Conversion, dated as of August 5, 2024 (the "GIBF
Conversion Agreement"). As consideration for its transfer of that 49% interest to us, GIBF received 203,971 New Silexion ordinary
shares at the Closing. GIBF furthermore received an additional 16,817 of our ordinary shares upon consummation of the Business Combination
due to the conversion of our shares that were issued to it upon settlement of RSUs of Silexion that were subject to accelerated vesting
at the Closing. Those RSUs were granted to GIBF subject to GIBF's providing certain services to us in connection with the transfer
of funds from our Chinese subsidiary to us. Avner Lushi and Shlomo Noy, both of whom serve as our directors since the Closing, share voting
and investment power over the 220,788 of our ordinary shares beneficially owned by GIBF after the Closing.
PIPE Financing
In connection with, and immediately prior
to the Closing of, the Business Combination, Moringa raised $2.0 million via a private investment in public entity financing (the "PIPE
Financing"), whereby Moringa sold to Greenstar, LP (the "PIPE Investor"), a Cayman Islands exempted limited partnership
and affiliate of the Moringa Sponsor, 200,000 newly issued Moringa ordinary shares (the "PIPE Shares") (which does not reflect
the reverse share split) at a price of $10.00 per share, pursuant to the PIPE Agreement, dated as of August 15, 2024, by and among Moringa,
us and the PIPE Investor. Those 200,000 shares automatically converted upon the Closing of the Business Combination into an equivalent
number of our ordinary shares (at a number prior to the effectiveness of the reverse share split), or the PIPE Shares. The PIPE Investor
is entitled to customary registration rights in respect of the PIPE Shares under the PIPE Agreement, pursuant to which we have agreed
that, within 60 days after the Closing Date, it will file with the SEC a registration statement registering the resale of the PIPE Shares
by the PIPE Investor, and use its commercially reasonable efforts to have that registration statement be declared effective by 180 days
after the Closing Date (or 90 days after the Closing Date if the SEC does not review that filing).
127
The funds raised from the PIPE Financing, together with
remaining funds in Moringa's trust account after payments to redeeming public shareholders of Moringa, were used for financing support
for Moringa and New Silexion, as well as for payment to service providers to whom outstanding amounts were owed by Moringa, including
parties that had provided financial advisory services and capital markets advisory services to Moringa during the period leading up to
the Closing.
The foregoing summary provides only a brief description
of the PIPE Agreement and does not purport to be complete. The summary is qualified in its entirety by the full text of the PIPE Agreement,
a copy of which serves as Exhibit 10.2 to the registration statement of which this prospectus forms a part, and which is incorporated
herein by reference.
Amended and Restated Sponsor Promissory
Note
Effective as of the Closing, we issued to the Sponsor,
and Sponsor accepted, in amendment and restatement, and replacement, in their entirety, of all existing promissory notes issued by Moringa
to the Sponsor from the IPO until the Closing (and as to which the obligations of Moringa were assigned to us upon the Closing), the A&R
Sponsor Promissory Note in an amount of $3,433,000, which reflected the total amount owed by Moringa to the Sponsor through the Closing
Date. The maturity date of the A&R Sponsor Promissory Note is the 30-month anniversary of the Closing Date (i.e., February 15, 2027).
Amounts outstanding under the A&R Sponsor Promissory Note may be repaid (unless otherwise decided by us) only by way of conversion
into our ordinary shares ("
Note Shares
") in accordance with the terms set forth in
the form of A&R Sponsor Promissory Note. Us and the Sponsor may also convert amounts outstanding under the A&R Sponsor Promissory
Note at the price per share at which we conduct an equity financing following the Closing, subject to a minimum conversion amount of $100,000,
in an amount of Note Shares constituting up to thirty percent (30%) of the number of our ordinary shares issued and sold by us in such
equity financing. The Sponsor may also elect to convert amounts of principal outstanding under the note into our ordinary shares at any
time following the 24-month anniversary of the Closing Date, subject to a minimum conversion of $10,000, at a price per share equal to
the volume weighted average price of the our ordinary shares on the principal market on which they are traded during the 20 consecutive
trading days prior to the conversion date.
The foregoing summary provides only a brief description
of the A&R Sponsor Promissory Note and does not purport to be complete. The summary is qualified in its entirety by the full text
of the A&R Sponsor Promissory Note, a copy of which serves as Exhibit 10.5 to the registration statement of which this prospectus
forms a part, and which is incorporated herein by reference.
Amended and Restated Registration
Rights and Lock-Up Agreement
Prior to the Closing under the Business Combination Agreement,
on August 14, 2024, us, Moringa, Moringa Sponsor, the distributees of the Sponsor Investment Shares (as defined under the Business Combination
Agreement), certain of our pre-Business Combination shareholders and the PIPE Investor entered into (and EarlyBird will be bound by) an
amended and restated registration rights and lock-up agreement which became effective as of the Closing of the Business Combination
(the "A&R Registration Rights and Lock-Up Agreement"). Under the agreement, we have assumed Moringa's existing obligations
under Moringa's prior registration rights agreement (entered into in connection with Moringa's initial public offering, or
IPO) and has granted registration rights to the Moringa Sponsor, the distributees of Sponsor Investment Shares, certain of our pre-Business
Combination shareholders, the PIPE Investor and EarlyBird with respect to certain securities of ours.
Under the A&R Registration Rights and Lock-Up Agreement,
we have agreed to provide the holders party thereto customary demand and shelf registration rights (subject to certain minimum size offerings)
and piggy-back rights on primary and secondary offerings, subject to customary cut-back provisions.
128
Under the lock-up provisions of the agreement, lock-up
periods apply following the Closing to of our securities that are held by the holders who are party to the agreement, subject to permitted
transfers to certain categories of "Permitted Transferees". Specifically, those lock-up periods apply to the following categories
of securities for the following periods of time post-Closing:
●
Sponsor Investment Shares and securities held by former Silexion shareholders
:
        (A) 50% of the Sponsor Investment Shares held by the Sponsor and its distributees and 50% of the New Silexion securities held by the former
        Silexion shareholders who are party to the agreement, in each case, upon the Closing, are subject to a lock-up period ending on the earlier
        of (i) six (6) months after the completion of the Business Combination, and (ii) the date on which New Silexion will consummate a liquidation,
        merger, amalgamation, share exchange, reorganization, or other similar transaction after the Business Combination that results in all
        of our shareholders having the right to exchange their ordinary shares for cash, securities or other property, and (B) the other 50% of
        the Sponsor Investment Shares held by the Sponsor and its distributees and 50% of the our securities held by the former Silexion shareholders
        party to the agreement, in each case, upon the Closing, will be subject to a lock-up period that will end on the earliest of (x) six (6)
        months after the date of the consummation of the Business Combination, (y) the date on which we consummate a liquidation, merger, amalgamation,
        share exchange, reorganization, or other similar transaction after the Business Combination that results in all of our shareholders having
        the right to exchange their ordinary shares for cash, securities or other property, or (z) the date on which the closing price of our
        ordinary shares equals or exceeds $12.00 per share (as adjusted for share splits, share dividends, rights issuances, subdivisions, reorganizations,
        recapitalizations and the like) for any 20 trading days within any 30-trading day period.
●
Private Shares and Private Warrants:
The lock-up period on all New Silexion ordinary shares issued pursuant to the SPAC Merger in exchange for private placement shares and
        private placement warrants purchased by or issued to the Sponsor and EarlyBird concurrently with Moringa's initial public offering
        will remain (as provided in the documentation for Moringa's initial public offering) 30 days after the Closing.
●
Representative Shares
.
        The lock-up period on all Representative Shares (as defined in the Amended and Restated Registration Rights and Lock-Up Agreement) that
        are held by EarlyBird will remain (as provided in the documentation for Moringa's initial public offering) three months after the
        Closing.
●
Note Shares and PIPE Shares
.
        Note Shares issued to the Sponsor upon conversion of amounts due under the A&R Sponsor Promissory Note and PIPE Shares issued to the
        PIPE Investor will not be subject to any lock-up periods following the Closing.
The foregoing summary provides only a brief description
of the A&R Registration Rights and Lock-Up Agreement and does not purport to be complete. The summary is qualified in its entirety
by the full text of the A&R Registration Rights and Lock-Up Agreement, which serves as Exhibit 10.4 to the registration statement
of which this prospectus forms a part, and which is incorporated herein by reference.
BENEFICIAL
OWNERSHIP OF SECURITIES
The following table sets forth information known to the Company regarding the beneficial
ownership of New Silexion ordinary shares as of February 11, 2025 by:
●
each person who is the beneficial owner of more than
        5% of the outstanding New Silexion ordinary shares;
●
our named executive officer and directors; and
●
all of our executive officers and directors as a group.
129
Beneficial ownership is determined according to the rules of the SEC, which generally
provide that a person has beneficial ownership of a security if he, she or it possesses sole or shared voting or investment power over
that security, including options and warrants that are currently exercisable or exercisable within 60 days. In computing the number of
ordinary shares beneficially owned by a person and the percentage ownership, we include, as outstanding, those ordinary shares that are
subject to warrants held by that person that are currently exercisable or exercisable within 60 days of February 11, 2025. We do not deem
those shares to be outstanding, however, for the purpose of computing the percentage ownership of any other person.
Unless otherwise indicated, we believe that all persons named in the table have sole
voting and investment power with respect to all New Silexion ordinary shares beneficially owned by them.
The percentage ownership of New Silexion ordinary shares is based on 8,414,615
New Silexion ordinary shares outstanding as of February 11, 2025.
Name and Address of Beneficial Owner(1)
Number of Shares
Beneficially Owned
Approximate
Percentage of
Outstanding
Ordinary Shares
Directors and Executive Officers of New Silexion:
Ilan Hadar
31,160
(2)
*
Dror Abramov
4,425
*
Ruth Alon
6,037
*
Ilan Levin(3)
229,624
(4)
2.7
%
Avner Lushi(5)
220,788
(6)
2.6
%
Shlomo Noy(7)
220,788
(6)
2.6
%
Amnon Peled
-
-
Dr. Mitchell Shirvan
21,888
(8)
*
%
Mirit Horenshtein Hadar, CPA
6,308
*
All executive officers and directors as a group (8 individuals)
520,230
6.2
%
Five Percent Holders:
Hudson Bay Master Fund (9)
740,741
8.1
%
Entities affiliated with Anson Advisors Inc and Anson Funds Management LP (10)
740,741
6.4
%
CVI Investments, Inc. (11)
740,766
8.1
%
*
Less than 1%.
(1)
Unless otherwise noted, the business address of each beneficial owner listed
        in the above table is c/o Silexion Therapeutics Corp, 12 Abba Hillel Road, Ramat Gan, Israel 5250606.
(2)
Includes 14,339 New Silexion ordinary shares issuable upon exercise of options,
        at an exercise price of $60.48 per share, all of which are vested and currently exercisable.
(3)
The shares reported in this row are held of record by the Sponsor, Moringa
        Sponsor, LP, and/or by the PIPE Investor, Greenstar, L.P., each a Cayman Islands exempted limited partnership, as described in footnote
        (4) below. Moringa Partners Ltd., an Israeli company that is wholly-owned by Mr. Ilan Levin, serves as the sole general partner of each
        of the Sponsor and the PIPE Investor. Mr. Levin, a director of New Silexion, is the sole director of that general partner. As a result
        of his ownership of that general partner, Mr. Levin possesses sole voting and investment authority with respect to the shares indirectly
        held by the Sponsor and the PIPE Investor. The limited partnership interests of the Sponsor and the PIPE Investor are held by various
        individuals and entities, including Mr. Levin. Mr. Levin disclaims beneficial ownership of the securities held by the Sponsor and the
        PIPE Investor other than to the extent of his direct or indirect pecuniary interest in such securities. The address of each of the entities
        beneficially owning the shares that are reported in this row is c/o Moringa Acquisition Corp, 250 Park Avenue, 7
th
floor, New York, NY 10177.
130
(4)
Consists of the total of: (i) 148,592 New Silexion ordinary shares issued
        to the Sponsor as Sponsor Investment Shares (as defined under the Business Combination Agreement); (ii) 39,206 New Silexion ordinary shares
        issued to the Sponsor upon the Closing of the Business Combination due to the conversion, on a one-for-one basis, of the 352,857 Moringa
        private shares held by it; (iii) 19,603 New Silexion ordinary shares underlying New Silexion warrants issued to the Sponsor upon the Closing
        of the Business Combination due to the conversion, on a one-for-one basis, of the 176,429 Moringa private warrants held by the Sponsor
        (which New Silexion warrants will be exercisable beginning 30 days after the Closing Date); and (iv) 22,223 New Silexion ordinary shares
        issued to Greenstar, L.P., the PIPE Investor, as PIPE Shares in respect of the PIPE Financing. The foregoing beneficial ownership of New
        Silexion ordinary shares by the Sponsor does not include any Note Shares that may be issued to the Sponsor following the Closing upon
        conversion of amounts owed by New Silexion to the Sponsor under the A&R Sponsor Promissory Note, as the potential number of Note Shares,
        and the timing of issuance of Note Shares, cannot be determined in advance.
(5)
The shares reported in this row consist entirely of New Silexion ordinary
        shares held of record by Guangzhou Sino-Israel Biotech Fund ("
GIBF
"), with respect
        to which Mr. Lushi possesses shared voting and investment authority as a result of his serving as a Managing Partner and CEO of GIBF.
(6)
Includes 203,971 New Silexion ordinary shares issued to GIBF at the Closing
        in respect of its transfer of its noncontrolling interest in our Chinese subsidiary, Silenseed (China) Ltd., to New Silexion pursuant
        to the Chinese Subsidiary Transfer.
(7)
The shares reported in this row consist entirely of New Silexion ordinary
        shares held of record by GIBF, with respect to which Mr. Noy possesses shared voting and investment authority as a result of his serving
        as Chief Medical Officer of GIBF.
(8)
Includes 7,170 New Silexion ordinary shares issuable upon exercise of options,
        at an exercise price of $60.48 per share, all of which are vested and currently exercisable.
(9)
Represents 740,741 ordinary shares issuable upon exercise of
        warrants issued in connection with the Warrant Repricing. Hudson Bay Capital Management LP, the investment manager of Hudson Bay Master
        Fund Ltd., has voting and investment power over these securities. Sander Gerber is the managing member of Hudson Bay Capital GP LLC, which
        is the general partner of Hudson Bay Capital Management LP. Each of Hudson Bay Master Fund Ltd. and Sander Gerber disclaims beneficial
        ownership over these securities.
(10)
Represents (i) 577,778 ordinary shares issuable upon exercise
        of warrants issued in connection with the Warrant Repricing held by Anson Investments Master Fund LP ("AIMF") and (ii) 162,963
        ordinary shares issuable upon exercise of warrants issued in connection with the Warrant Repricing held by Anson East Master Fund LP ("AEMF").
        Anson Advisors Inc and Anson Funds Management LP, the Co-Investment Advisers of AIMF and AEMF, hold voting and dispositive power over
        the ordinary shares held by each of AIMF and AEMF. Tony Moore is the managing member of Anson Management GP LLC, which is the general
        partner of Anson Funds Management LP. Moez Kassam and Amin Nathoo are directors of Anson Advisors Inc. Mr. Moore, Mr. Kassam and Mr. Nathoo
        each disclaim beneficial ownership of these ordinary shares except to the extent of their pecuniary interest therein. The principal business
        address of each of AIMF and AEMF is Maples Corporate Services Limited, PO Box 309, Ugland House, Grand Cayman, KY1-1104, Cayman Islands.
(11)
Represents (i) 463,741 ordinary shares issuable upon exercise
        of warrant issued in our January 2025 financing, (ii) 277,000 ordinary shares issuable upon exercise of warrants issued in connection
        with the Warrant Repricing and (iii) 25 ordinary shares issuable upon the exercise of warrants issued by Moringa that the Company assumed
        in connection with the Business Combination. Heights Capital Management, Inc., the authorized agent of CVI Investments, Inc. ("CVI"),
        has discretionary authority to vote and dispose of the shares held by CVI and may be deemed to be the beneficial owner of these shares.
        Martin Kobinger, in his capacity as President of Heights Capital Management, Inc., may also be deemed to have investment discretion and
        voting power over the shares held by CVI. Mr. Kobinger disclaims any such beneficial ownership of the shares. CVI Investments, Inc.is
        affiliated with one or more FINRA member, none of whom are currently expected to participate in the sale pursuant to the prospectus contained
        in the Registration Statement of shares purchased by the investor in this offering.
SELLING
SECURITYHOLDERS
The ordinary shares
being offered by the Selling Securityholders are ordinary shares issuable upon exercise of the New Warrants and Placement Agent Warrants
previously issued in connection with the January 2025 Warrant Inducement Transaction. For additional information regarding the issuance
of those shares of common stock and warrants, see "
January 2025
Transactions
Related to Offering Under This Prospectus—January 2025 Warrant Inducement Transaction
" above. We are registering the
ordinary shares in order to permit the selling stockholders to offer the shares of common stock for resale from time to time. Other than
with respect to Wainwright, which acted as our placement agent in the January 2025 Warrant Inducement Transaction and January 2025 financing
and the other Selling Securityholders (excluding Wainwright), which was an investor in our January 2025 financing, except for the ownership
of the warrants and Placement Agent Warrants issued, and the ordinary shares issued and issuable pursuant to prior financings, the Selling
Securityholders have not had any material relationship with us within the past three years.
The table below lists the Selling Securityholders and other information regarding the
beneficial ownership of the ordinary shares by each of the Selling Securityholders. The second column lists the number the ordinary shares
beneficially owned by each selling stockholder, based on its ownership of the ordinary shares, including shares underlying the New Warrants
or Placement Agent Warrants, as of February 11, 2025, assuming exercise of the New Warrants or Placement Agent Warrants held by the Selling
Securityholders on that date, without regard to any limitations on conversions or exercises. The third column lists the maximum number
of ordinary shares being offered in this prospectus by the Selling Securityholders. The fourth and fifth columns list the amount of ordinary
shares owned after the offering, by number of ordinary shares and percentage of outstanding the shares of common stock (assuming for the
purpose of such percentage, 8,414,615 shares outstanding as of February 11, 2025) assuming in both cases the sale of all of the ordinary
shares offered by the Selling Securityholders pursuant to this prospectus, and without regard to any limitations on conversions or exercises.
Under the terms of
the New Warrants and Placement Agent Warrants issued in the January 2025 Warrant Inducement Transaction, a Selling Securityholder may
not exercise the warrants to the extent such exercise would cause such Selling Securityholder, together with its affiliates, to beneficially
own a number of ordinary shares which would exceed 4.99% or 9.99%, as applicable, of our then outstanding ordinary shares following such
exercise, excluding for purposes of such determination ordinary shares not yet issuable upon exercise of the warrants which have not been
exercised. The number of shares does not reflect this limitation. The Selling Securityholder may sell all, some or none of their ordinary
shares or New Warrants or Placement Agent Warrants in this offering. See "
Plan of Distribution
."
131
Number of Shares of Ordinary Owned Prior to Offering
Maximum Number of Ordinary Shares to be Sold Pursuant to this Prospectus
Number of Ordinary Shares Owned After the Offering
Percentage of Ordinary Shares Owned After the Offering
CVI Investments, Inc.
(1)
740,766
(2)
277,000
(3)
463,766
(4)
5.5
%
Anson Investments Master Fund LP
(5)
577,778
(6)
577,778
(6)
-
-
Anson East Master Fund LP
(7)
162,963
(8)
162,963
(8)
-
-
Hudson Bay Master Fund Ltd.
(9)
740,741
(10)
740,741
(10)
-
-
3i, LP
(11)
150,000
(12)
150,000
(12)
-
-
Intracoastal Capital LLC
(13)
240,741
(14)
240,741
(14)
-
-
Boothbay Absolute Return Strategies, LP
(15)
15,300
(16)
15,300
(16)
-
-
%
Orca Capital AG
(17)
37,000
(18)
37,000
(18)
-
-
%
KBB Asset Management, LLC
(19)
20,000
(20)
20,000
(20)
-
-
%
Michael Vasinkevich
(21)
265,969
(22)
99,719
(23)
166,250
(24)
1.2
%
Noam Rubinstein
(21)
130,651
(25)
48,985
(26)
81,666
(27)
*
%
Craig Schwabe
(21)
13,998
(28)
5,248
(29)
8,750
(30)
*
%
Charles Worthman
(21)
4,148
(31)
1,555
(32)
2,593
(33)
*
%
*
Less than 1%
(1)
Heights Capital Management, Inc., the authorized agent of CVI Investments, Inc. ("CVI"),
        has discretionary authority to vote and dispose of the shares held by CVI and may be deemed to be the beneficial owner of these shares.
        Martin Kobinger, in his capacity as President of Heights Capital Management, Inc., may also be deemed to have investment discretion and
        voting power over the shares held by CVI. Mr. Kobinger disclaims any such beneficial ownership of the shares. CVI Investments, Inc.is
        affiliated with one or more FINRA member, none of whom are currently expected to participate in the sale pursuant to the prospectus contained
        in the Registration Statement of shares purchased by the investor in this offering.
(2)
Represents (i) 463,741 ordinary shares issuable upon exercise of warrant issued in
        our January 2025 financing, (ii) 277,000 ordinary shares issuable upon exercise of warrants issued in connection with the Warrant Repricing
        and (iii) 25 ordinary shares issuable upon the exercise of warrants issued by Moringa that the Company assumed in connection with the
        Business Combination.
(3)
Represents 277,000 ordinary shares issuable upon exercise of warrants issued in connection
        with the Warrant Repricing.
(4)
Represents (i) 463,741 ordinary shares issuable upon exercise of warrant issued in
        our January 2025 financing and (ii) 25 ordinary shares issuable upon the exercise of warrants issued by Moringa that the Company assumed
        in connection with the Business Combination.
(5)
Anson Advisors Inc and Anson Funds Management LP, the Co-Investment Advisers of Anson
        Investments Master Fund LP ("Anson"), hold voting and dispositive power over the ordinary shares held by Anson. Tony Moore
        is the managing member of Anson Management GP LLC, which is the general partner of Anson Funds Management LP. Moez Kassam and Amin Nathoo
        are directors of Anson Advisors Inc. Mr. Moore, Mr. Kassam and Mr. Nathoo each disclaim beneficial ownership of these ordinary shares
        except to the extent of their pecuniary interest therein. The principal business address of Anson is Maples Corporate Services Limited,
        PO Box 309, Ugland House, Grand Cayman, KY1-1104, Cayman Islands.
132
(6)
Represents 577,778 ordinary shares issuable upon exercise of warrants issued in connection
        with the Warrant Repricing.
(7)
Anson Advisors Inc and Anson Funds Management LP, the Co-Investment Advisers of Anson
        East Master Fund LP ("Anson"), hold voting and dispositive power over the ordinary shares held by Anson. Tony Moore is the
        managing member of Anson Management GP LLC, which is the general partner of Anson Funds Management LP. Moez Kassam and Amin Nathoo are
        directors of Anson Advisors Inc. Mr. Moore, Mr. Kassam and Mr. Nathoo each disclaim beneficial ownership of these ordinary shares except
        to the extent of their pecuniary interest therein. The principal business address of Anson is Maples Corporate Services Limited, PO Box
        309, Ugland House, Grand Cayman, KY1-1104, Cayman Islands.
(8)
Represents 162,963 ordinary shares issuable upon exercise of warrants issued in connection
        with the Warrant Repricing.
(9)
Hudson Bay Capital Management LP, the investment manager of Hudson Bay Master Fund
        Ltd., has voting and investment power over these securities. Sander Gerber is the managing member of Hudson Bay Capital GP LLC, which
        is the general partner of Hudson Bay Capital Management LP. Each of Hudson Bay Master Fund Ltd. and Sander Gerber disclaims beneficial
        ownership over these securities.
(10)
Represents 740,741 ordinary shares issuable upon exercise of warrants issued in connection
        with the Warrant Repricing.
(11)
3i Management LLC is the general partner of 3i, LP, and Maier Joshua Tarlow is the
        manager of 3i Management LLC. As such, Mr. Tarlow exercises sole voting and investment discretion over securities beneficially owned directly
        or indirectly by 3i, LP and 3i Management LLC. Mr. Tarlow disclaims beneficial ownership of the securities beneficially owned directly
        by 3i, LP and indirectly by 3i Management LLC. The business address of each of the aforementioned parties is 2 Wooster Street, 2nd Floor,
        New York, NY 10013. We have been advised that none of Mr. Tarlow, 3i Management LLC, or 3i, LP is a member of the Financial Industry Regulatory
        Authority, or FINRA, or an independent broker-dealer, or an affiliate or associated person of a FINRA member or independent broker-dealer.
(12)
Represents 150,000 ordinary shares issuable upon exercise of warrants issued in connection
        with the Warrant Repricing.
(13)
Mitchell P. Kopin ("Mr. Kopin") and Daniel B. Asher ("Mr. Asher"),
        each of whom are managers of Intracoastal Capital LLC ("Intracoastal"), have shared voting control and investment discretion
        over the securities reported herein that are held by Intracoastal. Asa result, each of Mr. Kopin and Mr. Asher may be deemed to have beneficial
        ownership (as determined under Section 13(d) of the Securities Exchange Act of 1934, as amended(the "Exchange Act")) of the
        securities reported herein that are held by Intracoastal.
(14)
Represents 240,741 ordinary shares issuable upon exercise of warrants issued in connection
        with the Warrant Repricing.
(15)
Boothbay Absolute Return Strategies LP, a Delaware limited partnership (the "Fund"),
        is managed by Boothbay Fund Management, LLC, a Delaware limited liability company (the "Adviser"). The Adviser, in its capacity
        as the investment manager of the Fund, has the power to vote and the power to direct the disposition of all securities held by the Fund. 
        Ari Glass is the Managing Member of the Adviser.   Each of the Fund, the Adviser and Mr. Glass disclaim beneficial ownership
        of these securities, except to the extent of any pecuniary interest therein.
(16)
Represents 15,300 ordinary shares issuable upon exercise of warrants issued in connection
        with the Warrant Repricing.
(17)
Roman Grodon, Thomas Koenig, and Beate Ruhle-Burkhardt have shared voting control
        and investment discretion over the securities reported herein that are held by Orca Capital AG ("Orca Capital"). As a result,
        each of Roman Grodon, Thomas Koenig, and Beate Ruhle-Burkhardt may be deemed to have beneficial ownership (as determined under Section
        13(d) of the Securities and Exchange Act of 1934, as amended (the "Exchange Act")) of the securities reported herein that
        are held by Orca Capital. The principal business address of Orca Capital is Sperl-Ring 2, 85276 Hettenshausen, Germany.
(18)
Represents 37,000 ordinary shares issuable upon exercise of warrants issued in connection
        with the Warrant Repricing.
(19)
Steven Segal is the natural person voting control and investment discretion over the
        securities reported herein. The address of the selling shareholder is 47 Calle Del Sur Palm Coast Fl 32137.
(20)
Represents 20,000 ordinary shares issuable upon exercise of warrants issued in connection
        with the Warrant Repricing.
133
(21)
Referenced person is affiliated with Wainwright, a registered broker-dealer with a
        registered address of H.C. Wainwright & Co., LLC, 430 Park Ave, 3rd Floor, New York, NY 10022. Wainwright acted as our placement agent
        in our January 2025 financing. Referenced person has sole voting and dispositive power over the securities held, acquired the securities
        in the ordinary course of business and, at the time the securities were acquired, the selling stockholder had no agreement or understanding,
        directly or indirectly, with any person to distribute such securities.
(22)
Represents (i) 166,250 ordinary shares issuable upon exercise of placement agent warrants
        issued in connection with our January 2025 financing and (ii) 99,719 ordinary shares issuable upon exercise of placement agent warrants
        issued in connection with the Warrant Repricing.
(23)
Represents 99,719 ordinary shares issuable upon exercise of placement agent warrants
        issued in connection with the Warrant Repricing.
(24)
Represents 166,250 ordinary shares issuable upon exercise of placement agent warrants
        issued in connection with our January 2025 financing.
(25)
Represents (i) 81,666 ordinary shares issuable upon exercise of placement agent warrants
        issued in connection with our January 2025 financing and (ii) 48,985 ordinary shares issuable upon exercise of placement agent warrants
        issued in connection with the Warrant Repricing.
(26)
Represents 48,985 ordinary shares issuable upon exercise of placement agent warrants
        issued in connection with the Warrant Repricing.
(27)
Represents 81,666 ordinary shares issuable upon exercise of placement agent warrants
        issued in connection with our January 2025 financing.
(28)
Represents (i) 8,750 ordinary shares issuable upon exercise of placement agent warrants
        issued in connection with our January 2025 financing and (ii) 5,248 ordinary shares issuable upon exercise of placement agent warrants
        issued in connection with the Warrant Repricing.
(29)
Represents 5,248 ordinary shares issuable upon exercise of placement agent warrants
        issued in connection with the Warrant Repricing.
(30)
Represents 8,750 ordinary shares issuable upon exercise of placement agent warrants
        issued in connection with our January 2025 financing.
(31)
Represents (i) 2,593 ordinary shares issuable upon exercise of placement agent warrants
        issued in connection with our January 2025 financing and (ii) 1,555 ordinary shares issuable upon exercise of placement agent warrants
        issued in connection with the Warrant Repricing.
(32)
Represent 1,555 ordinary shares issuable upon exercise of placement agent warrants
        issued in connection with the Warrant Repricing.
(33)
Represents 2,593 ordinary shares issuable upon exercise of placement agent warrants
        issued in connection with our January 2025 financing.
134
DESCRIPTION OF SHARE
CAPITAL
In connection with the consummation of the Business Combination,
New Silexion adopted the Articles. The following summary of the material terms of New Silexion's securities is not intended to be
a complete summary of the rights and preferences of such securities. You are encouraged to read the Articles and the agreements governing
New Silexion's warrants in their entirety, which serve as Exhibit 3.1 and Exhibits 4.1 and 4.2, respectively, to the registration
statement of which this prospectus forms a part, along with the applicable provisions of Cayman Islands law, for a complete description
of the rights and preferences of New Silexion's securities.
Authorized and Outstanding Share Capital
The Articles of New Silexion authorize the issuance of 22,222,222 shares, consisting
of 22,222,222 ordinary shares, $0.0009 par value per share. As of February 11, 2025, there were 8,414,615 New Silexion ordinary shares
outstanding. All of such outstanding New Silexion ordinary shares were validly issued, fully paid and non-assessable.
135
Ordinary Shares
Voting Power
Holders of New Silexion ordinary shares are entitled to
one vote in respect of each share held of record by such holder on all matters to be voted on by shareholders.
Dividends
Subject to applicable law, holders of New Silexion ordinary
shares are entitled to receive dividends when, as and if declared by the New Silexion Board, payable in cash, property or shares.
Winding Up, Liquidation and Dissolution
Upon New Silexion's winding up and liquidation and after payment in
full of all amounts required to be paid to creditors, the holders of New Silexion ordinary shares are entitled to receive a pro rata share
of New Silexion's remaining assets available for distribution.
Preemptive or Other Rights
Holders of New Silexion ordinary shares will not be entitled
to preemptive rights, and New Silexion ordinary shares will not be subject to conversion, redemption or sinking fund provisions.
Appointment of Directors
The New Silexion Board will consist of up to nine (9) directors and not less
than three (3) directors, unless increased or decreased from time to time by Ordinary Resolution in a general meeting.
Directors will generally be appointed by an Ordinary Resolution
passed at each annual general meeting.
Prior to each annual general meeting, the New Silexion
Board (or a nominating committee established by the New Silexion Board for such purpose) may select, via a resolution adopted by a majority
of the New Silexion Board or such committee, a number of persons to be proposed to the shareholders for appointment as directors at such
annual general meeting, for service until the next annual general meeting (the "Nominees"). Any shareholder entitled under
applicable law to propose one or more persons as nominees for appointment as directors at an annual general meeting (each such nominee,
an "Alternate Nominee") may make such proposal only if a written notice of such shareholder's intent to that effect
has been given to the Secretary of the Company (or, if there is no such Secretary, the chief executive officer) within the periods set
out in the Articles.
Unless the New Silexion Board resolves that the appointment
of Nominees or Alternate Nominees will be determined based on those Nominees or Alternate Nominees receiving the highest number of votes
of Members in favor of their appointment— even if less than a majority of all Members' votes that are cast, the Nominees or
Alternate Nominees shall be appointed by Ordinary Resolution at the annual general meeting at which they are proposed for appointment.
If the appointment of the Nominees or Alternate Nominees proposed to be appointed would cause the total number of directors (including
those then in office) to exceed the maximum number, then any directors then in office who are not named as Nominees or Alternate Nominees
will cease to hold office following the conclusion of such annual general, if any such Nominees or Alternate Nominees are appointed in
such meeting, and upon such Nominees or Alternate Nominees taking office. If (a) the appointment of the Nominees or Alternate Nominees
proposed to be appointed would not cause the total number of directors to exceed the maximum, or (b) no Nominees or Alternate Nominees
are proposed to be appointed at an annual general meeting by either the Board or Members, or (c) no Nominees or Alternate Nominees are
eventually appointed in such annual general meeting — all directors then in office shall continue to hold office until the convening
of a general meeting at which Nominees or Alternate Nominees shall be proposed and appointed, and where such appointment would cause the
total number of directors to exceed the maximum.
136
Each director will hold office until the next succeeding
annual general meeting and until his or her successor is appointed and qualified, or until such director's earlier death, resignation,
disqualification or removal. The Articles will not provide for cumulative voting for the appointment of directors.
New Silexion Warrants
Following the Closing of the Business Combination
and as of October 1, 2024, there were 660,001 New Silexion warrants to purchase New Silexion ordinary shares outstanding, consisting of
638,889 New Silexion public warrants issued upon conversion of an equivalent number of Moringa public warrants and 21,112 New Silexion
private warrants issued upon conversion of an equivalent number of Moringa private warrants (of which 19,603 and 1,508 private warrants
are held by the Sponsor and EarlyBird, respectively). In connection with the Closing, each Moringa warrant was exchanged for a New Silexion
warrant on substantially similar terms, including exercise price.
Each New Silexion public warrant entitles the registered holder to purchase
one New Silexion ordinary share at a price of $103.50 per share, subject to adjustment as discussed below, at any time commencing one
month after the Closing. However, no New Silexion public warrants will be exercisable for cash unless there is an effective and current
registration statement covering the New Silexion ordinary shares issuable upon exercise of the New Silexion public warrants and a current
prospectus relating to such New Silexion ordinary shares. Notwithstanding the foregoing, if a registration statement covering the New
Silexion ordinary shares issuable upon exercise of the New Silexion public warrants is not effective within 60 business days from the
closing of the Business Combination, warrant holders may, until such time as there is an effective registration statement and during any
period when the Company shall have failed to maintain an effective registration statement, exercise New Silexion public warrants on a
cashless basis pursuant to the exemption provided by Section 3(a)(9) of the Securities Act, provided that such exemption is available.
If that exemption, or another exemption, is not available, holders will not be able to exercise their warrants on a cashless basis. In
the case of a cashless exercise, each holder would pay the exercise price by surrendering the warrants for that number of New Silexion
ordinary shares equal to the quotient obtained by dividing (x) the product of the number of New Silexion ordinary shares underlying the
warrants, multiplied by the difference between the exercise price of the warrants and the "fair market value" (defined below)
by (y) the fair market value. The "fair market value" for this purpose will mean the average reported last sale price of the
ordinary shares for the five trading days ending on the trading day prior to the date of exercise. The New Silexion public warrants will
expire five years from the Closing of the Business Combination (i.e., on August 15, 2029) at 5:00 p.m., New York City time.
The New Silexion private warrants are identical to the
New Silexion public warrants, except that each New Silexion private warrant will be exercisable for cash (even if a registration statement
covering the New Silexion ordinary shares issuable upon exercise of such warrants is not effective) or on a cashless basis, at the holder's
option, and will not be redeemable by the Company, in each case so long as they are still held by the Sponsor, EarlyBird or their respective
affiliates.
From and after the time the New Silexion warrants become
exercisable, we may call them for redemption (excluding the New Silexion private warrants), in whole and not in part, at a price of $0.01
per warrant, upon not less than 30 days' prior written notice of redemption to each warrant holder, if and only if
●
the reported last sale price of the ordinary shares equals or exceeds $162.00
        per share (as adjusted for share sub-divisions, share capitalizations, reorganizations and recapitalizations), for any 20 trading days
        within a 30 trading day period commencing after the warrants become exercisable and ending on the third business day prior to the notice
        of redemption to warrant holders; and
●
a registration statement is then in effect with respect to the New Silexion
        ordinary shares underlying such warrants.
The right to exercise will be forfeited unless the New
Silexion warrants are exercised prior to the date specified in the notice of redemption. On and after the redemption date, a record holder
of a New Silexion warrant will have no further rights except to receive the redemption price for such holder's warrant upon surrender
of such warrant.
137
The redemption criteria for New Silexion warrants have
been established at a price which is intended to provide warrant holders a reasonable premium to the initial exercise price and provide
a sufficient differential between the then-prevailing share price and the warrant exercise price so that if the share price declines
as a result of our redemption call, the redemption will not cause the share price to drop below the exercise price of the warrants.
If New Silexion calls the New Silexion warrants for redemption
as described above, its management will have the option to require all holders that wish to exercise warrants prior to redemption to do
so on a "cashless basis." In such event, each holder would pay the exercise price by surrendering the warrants for that number
of New Silexion ordinary shares equal to the quotient obtained by dividing (x) the product of the number of New Silexion ordinary
shares underlying the warrants, multiplied by the difference between the exercise price of the warrants and the "fair market value"
(defined below) by (y) the fair market value. The "fair market value" shall mean the average reported last sale price
of the New Silexion ordinary shares for the 5 trading days ending on the third trading day prior to the date on which the notice
of redemption is sent to the holders of warrants.
The New Silexion warrants will be issued in registered
form under a warrant agreement between Continental Stock Transfer & Trust Company, as warrant agent, and New Silexion (as assignee
of Moringa). The warrant agreement provides that the terms of the warrants may be amended without the consent of any holder to cure any
ambiguity or correct any defective provision, but requires the approval, by written consent or vote, of the holders of at least 50% of
the then outstanding public warrants in order to make any change that adversely affects the interests of the registered holders.
The exercise price and number of New Silexion ordinary
shares issuable on exercise of the warrants may be adjusted in certain circumstances including in the event of a share capitalization
or our recapitalization, reorganization, merger or consolidation. However, the warrants will not be adjusted for issuances of New Silexion
ordinary shares at a price below their respective exercise prices.
The New Silexion warrants may be exercised upon surrender
of the warrant certificate on or prior to the expiration date at the offices of the warrant agent, with the exercise form on the reverse
side of the warrant certificate completed and executed as indicated, accompanied by full payment of the exercise price, by certified or
official bank check payable to us, for the number of warrants being exercised. The warrant holders do not have the rights or privileges
of holders of New Silexion ordinary shares and any voting rights until they exercise their warrants and receive New Silexion ordinary
shares. After the issuance of New Silexion ordinary shares upon exercise of the warrants, each holder will be entitled to one vote for
each share held of record on all matters to be voted on by shareholders.
Under the terms of the warrant agreement, New Silexion
(as assignee of Moringa) has agreed to use its best efforts to have declared effective a registration statement relating to the New Silexion
ordinary shares issuable upon exercise of the warrants and keep such registration statement and its included prospectus current until
the expiration of the warrants. However, we cannot assure you that we will be able to do so and, if we do not maintain a current prospectus
relating to the New Silexion ordinary shares issuable upon exercise of the warrants, holders will be unable to exercise their warrants
for cash and we will not be required to net cash settle or cash settle the warrant exercise.
Warrant holders may elect to be subject to a restriction
on the exercise of their warrants such that an electing warrant holder would not be able to exercise their warrants to the extent that,
after giving effect to such exercise, such holder would beneficially own in excess of 9.9% of the New Silexion ordinary shares outstanding.
No fractional shares will be issued upon exercise of the
New Silexion warrants. If, upon exercise of the warrants, a holder would be entitled to receive a fractional interest in a share, we will,
upon exercise, round up to the nearest whole number the number of New Silexion ordinary shares to be issued to the warrant holder.
Contractual Arrangements with respect
to the New Silexion private warrants
So long as the New Silexion private warrants are still
held by the Sponsor, EarlyBird or their affiliates, the Company will not redeem such warrants, and the Company will allow the holders
to exercise such warrants on a cashless basis (even if a registration statement covering the New Silexion ordinary shares issuable upon
exercise of such warrants is not effective). However, once any of the New Silexion private warrants are transferred from the Sponsor,
EarlyBird or their affiliates, these arrangements will no longer apply. Furthermore, because the New Silexion private warrants were issued
in a private transaction, the holders and their transferees will be allowed to exercise the New Silexion private warrants for cash even
if a registration statement covering the New Silexion ordinary shares issuable upon exercise of such warrants is not effective and receive
unregistered New Silexion ordinary shares.
138
Listing of Securities
Our ordinary shares and New Silexion warrants are listed
on the Nasdaq under the symbols "SLXN" and "SLXNW", respectively.
Transfer Agent and Registrar
The transfer agent and registrar for the New Silexion
ordinary shares and warrant agent for the New Silexion warrants is Continental Stock Transfer & Trust Company.
Anti-Takeover Provisions in Our Articles.
Some provisions of our Articles may discourage, delay
or prevent a change in control of our company or management that shareholders may consider favorable.
However, under Cayman Islands law, our directors may only
exercise the rights and powers granted to them under our Articles, as amended and restated from time to time, for a proper purpose and
for what they believe in good faith to be in the best interests of our company.
Authorized but Unissued Shares
The authorized but unissued New Silexion ordinary shares
are available for future issuance without shareholder approval, subject to any limitations imposed by the listing standards of the Nasdaq
and the Articles. These additional shares may be used for a variety of corporate finance transactions, acquisitions and employee benefit
plans. The existence of authorized but unissued and unreserved New Silexion ordinary shares could make more difficult or discourage an
attempt to obtain control of New Silexion by means of a proxy contest, tender offer, merger or otherwise.
Shareholder Action; Extraordinary General Meetings
Our Articles provide that shareholders may take action
by unanimous written resolutions or at annual or extraordinary general meetings. As a result, a holder controlling a majority of New Silexion
ordinary shares would not be able to amend the Articles or remove directors without holding a meeting of shareholders called in accordance
with the Articles or the shareholders of New Silexion passing unanimous written resolutions to approve the same. Further, the Articles
provide that only the chairperson of the Board, or the New Silexion Board pursuant to a resolution adopted by a majority of the directors
then in office — and not shareholders — may call extraordinary general meetings of shareholders, thus
prohibiting a holder of New Silexion ordinary shares from calling an extraordinary general meeting. These provisions might delay the ability
of shareholders to force consideration of a proposal or for shareholders controlling a majority of New Silexion to take any action, including
the removal of directors.
Advance Notice Requirements for Shareholder Proposals
and Director Nominations
The Articles provide that shareholders seeking to bring
business before our annual general meeting, or to nominate candidates for appointment as directors at its annual general meeting, must
provide timely notice. To be timely, a shareholder's notice will need to be delivered to the Secretary of New Silexion at its principal
executive offices not less than 90 days nor more than 120 calendar days prior to the one-year anniversary of the preceding
year's annual general meeting. In the event that no annual general meeting was held during the preceding year or the date of the
annual general meeting is more than 30 days before or more than 60 days after such anniversary date, to be timely, a shareholder's
notice must be so delivered no earlier than the close of business on the 120
th
day
prior to such annual general meeting and not later than the 90
th
day
prior to such annual general meeting or, if later, the 10
th
day
following the day on which public disclosure of the date of such annual general meeting is first made by New Silexion. The Articles
also specify certain requirements as to the form and content of a shareholders' notice. These provisions may preclude New Silexion
shareholders from bringing matters before our annual general meeting or from making nominations for directors at our annual general meeting.
139
Supermajority Requirements for the Amendment of the Articles
Under the Companies Act (As Revised) of the Cayman Islands,
the Articles may be amended by a special resolution of shareholders, being a resolution passed by not less than two-thirds (2/3)
of our shareholders as being entitled to do so, vote in person or by proxy at a general meeting.
Board Vacancies
The Articles provide that any vacancy on the New Silexion
Board may be filled by the affirmative vote of a majority of the directors then in office, even if less than a quorum, or by a sole remaining
director, and not by our shareholders. Any director chosen to fill a vacancy will hold office until the next annual general meeting and
until his or her successor is duly appointed and qualified, or until his or her earlier death, resignation, disqualification or removal.
In addition, the number of directors constituting the then-authorized size of the New Silexion Board is permitted to be set only
by a resolution adopted by the Board.
Exclusive Forum Selection
The Articles provide that, unless New Silexion consents
in writing to the selection of an alternative forum and to the fullest extent permitted by law, the courts of the Cayman Islands have
exclusive jurisdiction over any claim or dispute arising out of or in connection with the Articles or otherwise related in any way to
each shareholder's shareholding in the Company, including but not limited to (i) any derivative action or proceeding brought
on behalf of the Company, (ii) any action asserting a claim of breach of a fiduciary duty owed by any director, officer or other
employee of the Company to the Company or our shareholders, or (iii) any action asserting a claim arising pursuant to any provision
of the Companies Act (As Revised) of the Cayman Islands or the Articles, and each shareholder shall be deemed to have irrevocably submitted
to the exclusive jurisdiction of the courts of the Cayman Islands over all such claims or disputes.
However, such forum selection provisions will not apply
to suits brought to enforce any liability or duty created by the Securities Act or the Exchange Act. The Articles also provide that,
unless New Silexion consents in writing to the selection of an alternative forum, the federal district courts of the United States
of America will be the exclusive forum for the resolution of any complaint asserting a cause of action arising under the Securities Act
or the Exchange Act. There is uncertainty as to whether a court would enforce that exclusivity provision. Furthermore, investors cannot
waive compliance with the U.S. federal securities laws and the rules and regulations thereunder.
Any person or entity purchasing or otherwise acquiring
any interest in New Silexion shares shall be deemed to have notice of and consented to the forum selection provisions in the Articles.
The choice of forum provisions may limit a shareholder's
ability to bring a claim in a judicial forum that it finds favorable for disputes with New Silexion or its directors, officers, or other
employees, which may discourage such lawsuits against New Silexion and its directors, officers, and other employees. Alternatively, if
a court were to find the choice of forum provisions contained in the Articles to be inapplicable or unenforceable in an action, New Silexion
may incur additional costs associated with resolving such action in other jurisdictions, which could harm its business, results of operations,
and financial condition.
140
Transactions with Interested Shareholders.
Cayman Islands law does not have a business combination
statute (like in Delaware) applicable to public companies prohibiting them from engaging in certain business combinations with an "interested
shareholder". As a result, we cannot avail ourselves of the types of protections afforded by a business combination statute. However,
although Cayman Islands law does not regulate transactions between a company and its significant shareholders, it does provide that such
transactions must be entered into bona fide in the best interests of the company and for a proper corporate purpose and not with the effect
of constituting a fraud on the minority shareholders.
Limitation on Liability and Indemnification of Directors
and Officers
Cayman Islands law does not limit the extent to which a company's memorandum
and articles of association may provide for indemnification of officers and directors, except to the extent any such provision may be
held by the Cayman Islands courts to be contrary to public policy, such as to provide indemnification against willful default, willful
neglect, actual fraud or the consequences of committing a crime. Our Articles provide that our directors and officers shall be indemnified
out of the assets of New Silexion against any liability, action, proceeding, claim, demand, costs, damages or expenses, including legal
expenses, whatsoever which they or any of them may incur as a result of any act or failure to act in carrying out their functions other
than such liability (if any) that they may incur by reason of their own actual fraud, willful neglect or willful default. No such indemnified
person shall be liable to New Silexion for any loss or damage incurred by New Silexion as a result (whether direct or indirect) of the
carrying out of their functions unless that liability arises through the actual fraud, willful neglect or willful default of such indemnified
person. No person shall be found to have committed actual fraud, willful neglect or willful default under the foregoing unless or until
a court of competent jurisdiction shall have made a finding to that effect.. In addition, the Articles provide for the advancing of certain
fees and costs to such indemnified persons and the purchase by New Silexion for insurance for the benefit of its directors and officers
as further described in the Articles.
Insofar as indemnification for liabilities arising under
the Securities Act may be permitted to New Silexion directors, officers and controlling persons pursuant to the foregoing provisions,
or otherwise, in the opinion of the SEC, such indemnification is against public policy as expressed in the Securities Act and is, therefore,
unenforceable.
141
MATERIAL U.S. FEDERAL INCOME TAX
CONSEQUENCES
The following discussion
is a summary of certain material U.S. federal income tax considerations generally applicable to the ownership and disposition of our ordinary
shares and the exercise, disposition and lapse of our warrants. The ordinary shares and the warrants are referred to collectively herein
as our securities. All prospective holders of our securities should consult their tax advisors with respect to the U.S. federal, state,
local and non-U.S. tax consequences of the ownership and disposition of our securities.
This discussion is not
a complete analysis of all potential U.S. federal income tax consequences relating to the ownership and disposition of our securities.
This summary is based upon current provisions of the Code, existing U.S. Treasury Regulations promulgated thereunder, published administrative
pronouncements and rulings of the U.S. Internal Revenue Service (the "
IRS
"), and judicial
decisions, all as in effect as of the date of this prospectus. These authorities are subject to change and differing interpretation, possibly
with retroactive effect. Any change or differing interpretation could alter the tax consequences to holders described in this discussion.
There can be no assurance that a court or the IRS will not challenge one or more of the tax consequences described herein, and we have
not obtained, nor do we intend to obtain, a ruling with respect to the U.S. federal income tax consequences to a holder of the ownership
or disposition of our securities.
Tax Consequences of
Ownership and Disposition of New Silexion Securities
Distributions on New
Silexion ordinary shares
Subject to the PFIC rules
discussed below, the gross amount of any distribution on New Silexion ordinary shares that is made out of New Silexion's current
or accumulated earnings and profits (as determined for U.S. federal income tax purposes) generally will be taxable to a U.S. Holder
as ordinary dividend income on the date such distribution is actually or constructively received. Any such dividends generally will not
be eligible for the dividends received deduction allowed to corporations in respect of dividends received from U.S. corporations.
To the extent that the amount of the distribution exceeds New Silexion's current and accumulated earnings and profits (as determined
under U.S. federal income tax principles), such excess amount will be treated first as a non-taxable return of capital to the
extent of the U.S. Holder's tax basis in its New Silexion ordinary shares, and thereafter as capital gain recognized on a sale
or exchange. However, it is not expected that New Silexion will maintain calculations of its earnings and profits principles. U.S. Holders
should therefore assume that any distribution by New Silexion with respect to New Silexion ordinary shares will be reported as dividend
income.
U.S. Holders should consult their own
tax advisors with respect to the appropriate U.S. federal income tax treatment of any distribution received from New Silexion.
142
Subject to the PFIC rules
discussed below, dividends received by non-corporate U.S. Holders (including individuals) from a "qualified foreign corporation"
may be eligible for reduced rates of taxation, provided that certain holding period requirements and other conditions are satisfied. For
these purposes, a non-U.S. corporation will be treated as a qualified foreign corporation if it is eligible for the benefits of a
comprehensive income tax treaty with the United States that meets certain requirements. A non-U.S. corporation is also treated
as a qualified foreign corporation with respect to dividends it pays on shares that are readily tradable on an established securities
market in the United States. U.S. Treasury guidance indicates that shares listed on Nasdaq (such as the New Silexion ordinary
shares) will be considered readily tradable on an established securities market in the United States. There can be no assurance that
New Silexion ordinary shares will be considered readily tradable on an established securities market in future years. Further, New
Silexion will not constitute a qualified foreign corporation for purposes of these rules if it is a PFIC for the taxable year in which
it pays a dividend or for the preceding taxable year.
Subject to certain conditions and limitations,
non-refundable withholding taxes (at a rate not in excess of any applicable income tax treaty rate), if any, on dividends paid by
New Silexion may be treated as foreign taxes eligible for credit against a U.S. Holder's U.S. federal income tax liability
under the U.S. foreign tax credit rules. However, as a result of recent changes to the U.S. foreign tax credit rules, a withholding
tax generally may need to satisfy certain additional requirements in order to be considered a creditable tax for a U.S. Holder. New
Silexion has not determined whether these requirements have been met with respect to any withholding tax that may apply to dividends paid
by New Silexion and, accordingly, no assurance can be given that any such withholding tax will be creditable. For purposes of calculating
the U.S. foreign tax credit, dividends paid on New Silexion ordinary shares will generally be treated as income from sources outside
the United States and will generally constitute passive category income. The rules governing the U.S. foreign tax credit are
complex. U.S. Holders should consult their tax advisors regarding the availability of the U.S. foreign tax credit under their
particular circumstances.
Sale, Taxable Exchange
or Other Taxable Disposition of New Silexion Securities
Subject to the PFIC rules
discussed below, upon any sale, exchange or other taxable disposition of any New Silexion security, a U.S. Holder generally will
recognize gain or loss in an amount equal to the difference between (i) the sum of (x) the amount cash and (y) the fair
market value of any other property, received in such sale, taxable exchange or other taxable disposition and (ii) the U.S. Holder's
adjusted tax basis in such New Silexion security. Any such gain or loss generally will be capital gain or loss and will be long-term capital
gain or loss if the U.S. Holder's holding period for such New Silexion security exceeds one year. Long-term capital gain
realized by a non-corporate U.S. Holder generally will be taxable at a reduced rate. The deductibility of capital losses is
subject to limitations.
This gain or loss generally will
be treated as U.S. source gain or loss. Accordingly, in the event that any non-U.S. tax (including withholding tax) is imposed
upon such sale, exchange or other taxable disposition, a U.S. Holder may not be able to utilize foreign tax credits in respect of
such non-U.S. tax. In addition, there may be other limitations on utilizing foreign tax credits even if a U.S. Holder has foreign
source income or gain in the same category from other sources. The rules governing foreign tax credits are complex and U.S. Holders
are urged to consult their tax advisers regarding the creditability of foreign taxes in their particular circumstances.
Exercise, Lapse or Redemption
of a New Silexion Public Warrant
Subject to the PFIC rules
discussed below, a U.S. Holder generally will not recognize gain or loss upon the acquisition of a New Silexion ordinary share on
the exercise of a New Silexion public warrant for cash. A U.S. Holder's tax basis in a New Silexion ordinary share received
upon exercise of the New Silexion public warrant generally will equal the sum of the U.S. Holder's tax basis in such New Silexion
public warrant and the exercise price. It is unclear whether a U.S. Holder's holding period for the New Silexion ordinary share
received will commence on the date of exercise of the New Silexion public warrant or the day following the date of exercise of the
New Silexion public warrant; in either case, the holding period will not include the period during which the U.S. Holder held the
New Silexion public warrant. If a New Silexion public warrant is allowed to lapse unexercised, a U.S. Holder generally will recognize
a capital loss equal to such holder's tax basis in the New Silexion public warrant.
143
The tax consequences of
a cashless exercise of a warrant are not clear under current law. Subject to the PFIC rules discussed below, a cashless exercise may not
be taxable, either because the exercise is not a realization event or because the exercise is treated as a recapitalization for U.S. federal
income tax purposes. In either situation, a U.S. Holder's tax basis in New Silexion ordinary shares received generally should
equal the U.S. Holder's tax basis in the New Silexion public warrants exercised therefor. If the cashless exercise was not
a realization event, it is unclear whether a U.S. Holder's holding period for the New Silexion ordinary shares received would
be treated as commencing on the date of exercise of the New Silexion public warrants or the day following the date of exercise of
the New Silexion public warrants; in either case, the holding period will not include the period during which the U.S. Holder held
the New Silexion public warrants. If the cashless exercise were treated as a recapitalization, the holding period of the New Silexion
ordinary shares received would include the holding period of the New Silexion public warrants.
It is also possible that
a cashless exercise could be treated in part as a taxable exchange in which gain or loss would be recognized. In such event, a U.S. Holder
could be deemed to have surrendered a number of New Silexion public warrants equal to the number of New Silexion ordinary shares having
a value equal to the exercise price for the total number of New Silexion public warrants to be exercised. In such case, subject to the
PFIC rules discussed below, the U.S. Holder would recognize capital gain or loss with respect to the New Silexion public warrants
deemed surrendered in an amount equal to the difference between the fair market value of the New Silexion ordinary shares that would have
been received in a regular exercise of the New Silexion public warrants deemed surrendered and the U.S. Holder's tax basis
in the New Silexion public warrants deemed surrendered. In this case, a U.S. Holder's aggregate tax basis in the New Silexion
ordinary shares received would equal the sum of the U.S. Holder's tax basis in the New Silexion public warrants deemed exercised
and the aggregate exercise price of such New Silexion public warrants. It is unclear whether a U.S. Holder's holding period
for the New Silexion ordinary shares would commence on the date of exercise of the New Silexion public warrants or the day following
the date of exercise of the New Silexion public warrants; in either case, the holding period will not include the period during which
the U.S. Holder held the New Silexion public warrants.
Due to the absence of
authority on the U.S. federal income tax treatment of a cashless exercise, including when a U.S. Holder's holding period
would commence with respect to New Silexion ordinary shares received, there can be no assurance regarding which, if any, of the alternative
tax consequences and holding periods described above would be adopted by the IRS or a court of law. Accordingly, U.S. Holders should
consult their tax advisors regarding the tax consequences of a cashless exercise.
Possible Constructive Distributions
The terms of each New
Silexion public warrant provide for an adjustment to the number of New Silexion ordinary shares for which the New Silexion public warrant
may be exercised or to the exercise price of the New Silexion public warrant in certain events, as discussed in the section of this prospectus
entitled "
Description of New Silexion Securities — Warrants.
" An adjustment
which has the effect of preventing dilution generally is not taxable. U.S. Holders of New Silexion public warrants would, however,
be treated as receiving a constructive distribution from New Silexion if, for example, the adjustment increases such U.S. Holders'
proportionate interest in New Silexion's assets or earnings and profits (e.g., through an increase in the number of New Silexion
ordinary shares that would be obtained upon exercise or through a decrease in the exercise price of the New Silexion public warrants),
which adjustment may be made as a result of a distribution of cash or other property to the holders of New Silexion ordinary shares. Such
constructive distribution to a U.S. Holder of New Silexion public warrants would be treated as if such U.S. Holder had received
a cash distribution from New Silexion generally equal to the fair market value of such increased interest (taxed as described above under
"—
Distributions on New Silexion ordinary shares
").
144
PFIC Rules
In General
The treatment of U.S. Holders
of New Silexion securities could be materially different from that described above if New Silexion is treated as a PFIC for U.S. federal
income tax purposes.
In general, a non-U.S. corporation
is a PFIC for U.S. federal income tax purposes for any taxable year in which, after applying certain look-through rules, (i) 50%
or more of the value of its assets (generally determined on the basis of a weighted quarterly average) consists of assets that produce,
or are held for the production of, passive income, or (ii) 75% or more of its gross income consists of passive income. Passive income
generally includes dividends, interest, rents and royalties (other than rents or royalties derived from the active conduct of a trade
or business) and gains from the disposition of passive assets. Cash and cash equivalents generally are passive assets. The value of goodwill
will generally be treated as an active or passive asset based on the nature of the income produced in the activity to which the goodwill
is attributable. For purposes of the PFIC rules, a non-U.S. corporation that owns, directly or indirectly, at least 25% by value
of the stock of another corporation is treated as if it held its proportionate share of the assets of the other corporation and directly
received its proportionate share of the income of the other corporation.
The application of the
PFIC rules to warrants is uncertain. The Code provides that, to the extent provided in Treasury Regulations, if any person has an option
to acquire shares of a PFIC, the shares will be considered as owned by that person for purposes of the PFIC rules. Under proposed Treasury
Regulations that have a retroactive effective date, an option to acquire shares of a PFIC is generally treated as ownership of those PFIC
shares. The remainder of this discussion assumes that the PFIC rules will apply to New Silexion public warrants if New Silexion was a
PFIC. However, U.S. Holders should consult their tax advisers regarding the application of the PFIC rules to New Silexion public
warrants prior to the finalization of the proposed Treasury Regulations.
If non-U.S. corporation is treated as a PFIC during
a U.S. Holder's holding period, it will, with respect to such U.S. Holder, always be treated as a PFIC, regardless of
whether it satisfied either of the qualification tests in subsequent years, subject to certain exceptions (such as upon making a
"deemed sale" election).
The adverse impact of
the PFIC rules on a U.S. Holder that holds shares in a PFIC may generally be mitigated if the U.S. Holder makes a timely qualified
electing fund ("
QEF
") election or mark-to-market election for the PFIC's
first taxable year as a PFIC in which the U.S. Holder held (or was deemed to hold) shares, or a QEF election along with an applicable
purging election (collectively, "
PFIC Elections
"). Further detail about the PFIC Elections
is provided below under "—
New Silexion Securities
".
New Silexion Securities
The annual PFIC income
and asset tests in respect of New Silexion will be applied based on the assets and activities of the combined business. Based on the projected
composition of New Silexion's income and assets, it cannot be determined whether New Silexion will be classified as a PFIC for its
taxable year that includes the date of the Business Combination or in any future taxable year. Further, changes in the composition of
New Silexion's income or composition of New Silexion's assets may cause New Silexion to be or become a PFIC for the current
or subsequent taxable years. Whether New Silexion is treated as a PFIC for U.S. federal income tax purposes is a factual determination
that must be made annually at the close of each taxable year and, thus, is subject to significant uncertainty.
145
If Moringa is determined to be a PFIC with
respect to any U.S. Holder who exchanges Moringa securities for New Silexion securities in connection with the SPAC Merger, the U.S. Holder
did not make any of the PFIC Elections, and the U.S. Holder is not subject to tax on the receipt of the New Silexion securities under
Section 1291(f) of the Code or otherwise, then, although not free from doubt, New Silexion may also be treated as a PFIC as
to the New Silexion ordinary shares received by such U.S. Holder in the SPAC Merger, even if New Silexion is not a PFIC in its own
right. In addition, it is possible that proposed Treasury Regulations could be finalized in a manner that would treat any New Silexion
public warrants that are received in the SPAC Merger as subject to the PFIC rules.
If New Silexion is or becomes a PFIC during any year in
which a U.S. Holder holds New Silexion securities, there are three separate taxation regimes that could apply to such U.S. Holder
under the PFIC rules: (i) the excess distribution regime (which is the default regime), (ii) the QEF regime, or (iii) the
mark-to-market regime. A U.S. Holder who holds (actually or constructively) stock in a non-U.S. corporation during any
year in which such corporation qualifies as a PFIC is subject to U.S. federal income taxation under one of these three regimes. The
effect of the PFIC rules on a U.S. Holder will depend upon which of these regimes applies to such U.S. Holder. However, dividends
paid by a PFIC are not eligible for the lower rates of taxation applicable to qualified dividend income under any of the foregoing regimes.
Excess
Distribution Regime
.    If a U.S. Holder does not make or is not eligible to make a QEF election or a
mark-to-market election, as described below, the U.S. Holder will be subject to the default "excess distribution regime"
under the PFIC rules with respect to (i) any gain realized on a sale or other disposition (including a pledge) of New Silexion securities,
and (ii) any "excess distribution" on New Silexion securities (generally, any distributions in excess of 125% of the
average of the annual distributions on New Silexion securities during the preceding three taxable years or the U.S. Holder's
Holding period, for the New Silexion securities that preceded the taxable year of the distribution whichever is shorter). Generally, under
this excess distribution regime
●
the U.S. Holder's gain or excess
        distribution will be allocated ratably over the U.S. Holder's holding period for the New Silexion securities;
●
the amount allocated to the U.S. Holder's
        taxable year in which the U.S. Holder recognized the gain or received the excess distribution, or to the period in the U.S. Holder's
        holding period before the first day of New Silexion's first taxable year in which New Silexion is a PFIC, will be taxed as
        ordinary income;
●
the amount allocated to other taxable years (or
        portions thereof) of the U.S. Holder and included in its holding period will be taxed at the highest tax rate in effect for that
        year and applicable to the U.S. Holder without regard to the U.S. Holder's other items of income and loss for such year;
        and
●
an additional amount equal to the interest charge generally
        applicable to underpayments of tax will be imposed on the U.S. Holder with respect to the tax attributable to each such other taxable
        year of the U.S. Holder.
The tax liability for
amounts allocated to years prior to the year of disposition or excess distribution will be payable generally without regard to offsets
from deductions, losses and expenses. In addition, gains (but not losses) realized on the sale of a U.S. Holder's New Silexion
securities cannot be treated as capital gains, even if such securities are held as capital assets. Further, no portion of any distribution
will be treated as qualified dividend income.
If New Silexion is, or
is treated as, a PFIC for any taxable year during which a U.S. Holder owns New Silexion securities and any entity in which New Silexion
owns equity interests is also a PFIC (a "lower-tier PFIC"), the U.S. Holder will be deemed to own their proportionate
amount (by value) of the shares of each lower-tier PFIC and will be subject to U.S. federal income tax according to the rules
described above on (i) certain distributions by a lower-tier PFIC and (ii) dispositions of shares of lower-tier PFICs,
in each case, as if the U.S. Holder held such shares directly, even though the U.S. Holder will not receive any proceeds of
those distributions or dispositions.
QEF
Regime
. A valid QEF election is effective for the taxable year for which the election is made and all subsequent taxable years
and may not be revoked without the consent of the IRS. If a U.S. Holder makes a timely QEF election with respect to its direct
or indirect interest in a PFIC, the U.S. Holder will be required to include in income each year its allocable portion of the ordinary
earnings and net capital gains of the PFIC as QEF income inclusions, even if such portion is not distributed to the U.S. Holder.
Thus, the U.S. Holder may be required to report taxable income as a result of QEF income inclusions without corresponding receipts
of cash. U.S. Holders of New Silexion securities should not expect that they will receive cash distributions from New Silexion sufficient
to cover their respective U.S. tax liability with respect to such QEF income inclusions. In addition, U.S. Holders of New Silexion
public warrants will not be able to make a QEF election with respect to their New Silexion public warrants.
146
The timely QEF election also allows
the electing U.S. Holder to: (i) generally treat any gain recognized on the disposition of its shares of the PFIC as capital
gain; (ii) treat its share of the PFIC's net capital gain, if any, as long-term capital gain instead of ordinary income;
and (iii) either avoid interest charges resulting from PFIC status, or make an annual election, subject to certain limitations, to
defer payment of current taxes on its undistributed QEF income inclusions, subject to an interest charge on the deferred tax computed
by using the statutory rate of interest applicable to an extension of time for payment of tax. In addition, net losses (if any) of a PFIC
will not pass through to its shareholders and may not be carried back or forward in computing such PFIC's ordinary earnings and
net capital gain in other taxable years.
A U.S. Holder's
tax basis in New Silexion ordinary shares will be increased to reflect QEF income inclusions and will be decreased to reflect distributions
of amounts previously included in income as QEF income inclusions. No portion of the QEF income inclusions attributable to ordinary income
will be treated as qualified dividend income. Amounts included as QEF income inclusions with respect to direct and indirect PFICs generally
will not be taxed again when distributed by such PFICs.
A U.S. Holder may make a QEF election with respect to its
New Silexion ordinary shares only if New Silexion provides U.S. Holders on an annual basis with certain information, including a
"PFIC annual information statement" as described in the Treasury Regulations. If New Silexion determines that it is a PFIC
for any taxable year, it will endeavor to provide to a U.S. Holder such information as the IRS may require, including a PFIC annual
information statement, in order to enable a U.S. Holder to make and maintain a QEF election. However, there can be no assurance that
New Silexion will have timely knowledge of its status as a PFIC in the future or that New Silexion will timely provide U.S. Holders
with the required information on an annual basis to allow U.S. Holders to make and maintain a QEF election with respect to the New
Silexion ordinary shares in the event New Silexion is treated as a PFIC for any taxable year. The failure to provide such information
on an annual basis could prevent a U.S. Holder from making a QEF election or result in the invalidation or termination of a U.S. Holder's
prior QEF election. In addition, as mentioned above, U.S. Holders of New Silexion public warrants will not be able to make a QEF
election with respect to their warrants.
If a U.S. Holder makes a QEF election with respect to its New Silexion ordinary
shares in a year after New Silexion's first taxable year as a PFIC in which the U.S. Holder held (or was deemed to hold) New
Silexion ordinary shares, then notwithstanding such QEF election, the excess distribution regime discussed above, adjusted to take into
account the QEF income inclusions resulting from the QEF election, will continue to apply with respect to such U.S. Holder's
New Silexion ordinary shares, unless the U.S. Holder makes a purging election under the PFIC rules. Under one type of purging election,
the U.S. Holder will be deemed to have sold such New Silexion ordinary shares at their fair market value and any gain recognized
on such deemed sale will be treated as an excess distribution, as described above. As a result of such purging election, the U.S. Holder
will have additional basis (to the extent of any gain recognized on the deemed sale) and, solely for purposes of the PFIC rules, a new
holding period in the New Silexion ordinary shares.
In addition, as mentioned
above, U.S. Holders of New Silexion public warrants will not be able to make a QEF election with respect to their warrants. As a
result, if a U.S. Holder sells or otherwise disposes of such New Silexion public warrants (other than upon exercise of such New Silexion
public warrants) and New Silexion were a PFIC at any time during the U.S. Holder's holding period of such New Silexion public
warrants, any gain recognized generally will be treated as an excess distribution, taxed as described above. If a U.S. Holder that
exercises such New Silexion public warrants properly makes and maintains a QEF election with respect to the newly acquired New Silexion
ordinary shares (or has previously made a QEF election with respect to New Silexion ordinary shares), the QEF election will apply to the
newly acquired New Silexion ordinary shares. Notwithstanding such QEF election, the excess distribution rules discussed above, adjusted
to take into account the current income inclusions resulting from the QEF election, will continue to apply with respect to such newly
acquired New Silexion ordinary shares (which, while not entirely clear, generally will be deemed to have a holding period for purposes
of the PFIC rules that includes the period the U.S. Holder held the New Silexion public warrants), unless the U.S. Holder makes
a purging election under the PFIC rules. U.S. Holders are urged to consult their tax advisors as to the application of the rules
governing purging elections to their particular circumstances.
147
Mark-to-Market Regime
. 
Alternatively, a U.S. Holder may make an election to mark marketable shares in a PFIC to market on an annual basis. PFIC shares generally
are marketable if they are "regularly traded" on a national securities exchange that is registered with the SEC, such as Nasdaq.
New Silexion ordinary shares are listed on Nasdaq but there can be no assurance that New Silexion ordinary shares will continue to be
so listed or will be "regularly traded" for purposes of these rules. Pursuant to such an election, a U.S. Holder of New
Silexion ordinary shares would include in each year as ordinary income the excess, if any, of the fair market value of such stock or shares
over its adjusted basis at the end of the taxable year. A U.S. Holder may treat as ordinary loss any excess of the adjusted basis
of the New Silexion ordinary shares over its fair market value at the end of the year, but only to the extent of the net amount previously
included in income as a result of the election in prior years. A U.S. Holder's adjusted tax basis in the New Silexion
ordinary shares will be increased to reflect any amounts included in income, and decreased to reflect any amounts deducted, as a result
of a mark-to-market election. Any gain recognized on a disposition of New Silexion ordinary shares in a taxable year in which New
Silexion is a PFIC will be treated as ordinary income and any loss will be treated as ordinary loss (but only to the extent of the net
amount of income previously included as a result of a mark-to-market election, and any loss in excess of such prior inclusions generally
would be treated as a capital loss). A mark-to-market election applies for the taxable year in which the election was made, and for
each subsequent taxable year, unless the PFIC shares cease to be marketable or the IRS consents to the revocation of the election. U.S. Holders
should also be aware that the Code and the Treasury Regulations do not allow a mark-to-market election with respect to stock of lower-tier PFICs
that is non-marketable. There is also no provision in the Code, Treasury Regulations or other published authority that specifically provides
that a mark-to-market election with respect to the stock of a publicly traded holding company (such as New Silexion) effectively
exempts stock of any lower-tier PFICs from the negative tax consequences arising from the general PFIC rules. U.S. Holders are
advised to consult their own tax advisor to determine whether the mark-to-market tax election is available to them and the consequences
resulting from such election. In addition, U.S. Holders of New Silexion public warrants will not be able to make a mark-to-market election
with respect to their New Silexion public warrants.
PFIC Reporting Requirements
A U.S. Holder that owns (or
is deemed to own) shares in a PFIC during any taxable year of the U.S. Holder generally is required to file an IRS Form 8621
with such U.S. Holder's U.S. federal income tax return and provide such other information as the IRS may require. Failure
to file IRS Form 8621 for each applicable taxable year may result in substantial penalties and result in the U.S. Holder's
taxable years being open to audit by the IRS until such forms are properly filed.
THE RULES DEALING WITH
PFICS AND PFIC ELECTIONS ARE VERY COMPLEX AND ARE AFFECTED BY VARIOUS FACTORS IN ADDITION TO THOSE DESCRIBED ABOVE. ACCORDINGLY, U.S. HOLDERS
OF NEW SILEXION SECURITIES ARE URGED TO CONSULT THEIR OWN TAX ADVISORS CONCERNING THE APPLICATION OF THE PFIC RULES TO NEW SILEXION SECURITIES
UNDER THEIR PARTICULAR CIRCUMSTANCES.
Additional Reporting Requirements
Certain U.S. Holders
may be required to file an IRS Form 926 (Return by a U.S. Transferor of Property to a Foreign Corporation) to report a transfer
of property (including cash) to New Silexion. Substantial penalties may be imposed on a U.S. Holder that fails to comply with this
reporting requirement, and the period of limitations on assessment and collection of U.S. federal income taxes will be extended in
the event of a failure to comply. Furthermore, certain U.S. Holders who are individuals and certain entities will be required to
report information with respect to such U.S. Holder's investment in "specified foreign financial assets" on IRS
Form 8938 (Statement of Specified Foreign Financial Assets), subject to certain exceptions. Specified foreign financial assets generally
include any financial account maintained with a non-U.S. financial institution and should also include New Silexion ordinary shares
and New Silexion public warrants if they are not held in an account maintained with a U.S. financial institution. Persons who are
required to report specified foreign financial assets and fail to do so may be subject to substantial penalties, and the period of limitations
on assessment and collection of U.S. federal income taxes may be extended in the event of a failure to comply. U.S. Holders
are urged to consult their tax advisors regarding the foreign financial asset and other reporting obligations and their application to
an investment in New Silexion ordinary shares and New Silexion public warrants.
148
Information Reporting and Backup Withholding
Dividend payments with
respect to New Silexion ordinary shares and proceeds from the sale, exchange or redemption of New Silexion securities may be subject to
information reporting to the IRS and possible backup withholding. Backup withholding will not apply, however, to a U.S. Holder who
furnishes a correct taxpayer identification number and makes other required certifications, or who is otherwise exempt from backup withholding
and establishes such exempt status.
Backup withholding is not an additional
tax. Amounts withheld as backup withholding may be credited against a U.S. Holder's U.S. federal income tax liability,
and a U.S. Holder generally may obtain a refund of any excess amounts withheld under the backup withholding rules by timely filing
the appropriate claim for refund with the IRS and furnishing any required information.
PLAN
OF DISTRIBUTION
We are registering the issuance by us of up to 2,377,030 New Silexion ordinary shares,
consisting of (i) 2,221,523 New Silexion ordinary shares issuable upon the exercise of the New Warrants, and (ii) 155,507 New Silexion
ordinary shares issuable upon the exercise of the Placement Agent Warrants.
The Selling Securityholders, which as used herein includes donees, pledgees, transferees
or other successors-in-interest selling New Silexion ordinary shares or New Silexion warrants received after the date of this prospectus
from a Selling Securityholder as a gift, pledge, partnership distribution or other transfer, may, from time to time, sell, transfer or
otherwise dispose of any or all of their New Silexion ordinary shares and New Silexion warrants (including New Silexion ordinary shares
underlying such New Silexion warrants once issued upon the exercise of such warrants) on any stock exchange, market or trading facility
on which the New Silexion ordinary shares or New Silexion warrants are traded or in private transactions. These dispositions may be at
fixed prices, at prevailing market prices at the time of sale, at prices related to the prevailing market price, at varying prices determined
at the time of sale, or at negotiated prices.
The Selling Securityholders may use any one or more of the following methods when
disposing of New Silexion ordinary shares or New Silexion warrants:
●
ordinary brokerage transactions and transactions in which the broker-dealer solicits purchasers;
●
block trades in which the broker-dealer will attempt to sell the shares as agent, but may position and
        resell a portion of the block as principal to facilitate the transaction;
●
purchases by a broker-dealer as principal and resale by the broker-dealer for their account;
●
an exchange distribution in accordance with the rules of the applicable exchange;
●
privately negotiated transactions;
●
short sales effected after the date the registration statement of which this prospectus is a part is declared
        effective by the SEC;
●
through the writing or settlement of options or other hedging transactions, whether through an options
        exchange or otherwise;
●
broker-dealers may agree with the Selling Securityholders  to sell a specified number of such shares
        at a stipulated price per share;
●
a combination of any such methods of sale; and
●
any other method permitted by applicable law.
149
The Selling Securityholders may, from
time to time, pledge or grant a security interest in some or all of the New Silexion ordinary shares or New Silexion warrants owned by
them and, if they default in the performance of their secured obligations, the pledgees or secured parties may offer and sell the New
Silexion ordinary shares or New Silexion warrants, from time to time, under this prospectus, or under an amendment to this prospectus
under Rule 424(b)(3) or other applicable provision of the Securities Act amending the list of Selling Securityholders to include the pledgee,
transferee or other successors in interest as Selling Securityholders under this prospectus. The Selling Securityholders also may transfer
the New Silexion ordinary shares or New Silexion warrants in other circumstances, in which case the transferees, pledgees or other successors
in interest will be the selling beneficial owners for purposes of this prospectus.
In connection with the sale of New Silexion ordinary shares or New Silexion warrants,
the Selling Securityholders may enter into hedging transactions with broker-dealers or other financial institutions, which may in turn
engage in short sales of New Silexion ordinary shares or New Silexion warrants in the course of hedging the positions they assume. The
Selling Securityholders may also sell New Silexion ordinary shares or New Silexion warrants short and deliver these securities to close
out their short positions, or loan or pledge New Silexion ordinary shares or New Silexion warrants to broker-dealers that in turn may
sell these securities. The Selling Securityholders may also enter into option or other transactions with broker-dealers or other financial
institutions or the creation of one or more derivative securities which require the delivery to such broker-dealer or other financial
institution of New Silexion ordinary shares or New Silexion warrants offered by this prospectus, which New Silexion ordinary shares or
New Silexion warrants such broker-dealer or other financial institution may resell pursuant to this prospectus (as supplemented or amended
to reflect such transaction).
Each of the Selling Securityholders reserves the right to accept and, together with
their agents from time to time, to reject, in whole or in part, any proposed purchase of New Silexion ordinary shares or New Silexion
warrants to be made directly or through agents. We will not receive any of the proceeds from this offering. Upon any exercise of New Silexion
warrants by payment of cash, however, we will receive the exercise price of the warrants.
The Selling Securityholders and any underwriters, broker-dealers or agents that participate
in the sale of the ordinary shares or interests therein may be "underwriters" within the meaning of Section 2(11) of the Securities
Act. Any discounts, commissions, concessions or profit they earn on any resale of the shares may be underwriting discounts and commissions
under the Securities Act. Selling Securityholders who are "underwriters" within the meaning of Section 2(11) of the Securities
Act will be subject to the prospectus delivery requirements of the Securities Act.
In addition, a Selling Securityholder that is an entity may elect to make a pro rata
in-kind distribution of securities to its members, partners or shareholders pursuant to the registration statement of which this prospectus
is a part by delivering a prospectus with a plan of distribution. Such members, partners or shareholders would thereby receive freely
tradeable securities pursuant to the distribution through a registration statement.
To the extent required, the New Silexion ordinary shares or New Silexion warrants
to be sold, the names of the Selling Securityholders, the respective purchase prices and public offering prices, the names of any agents,
dealer or underwriter, any applicable commissions or discounts with respect to a particular offer will be set forth in an accompanying
prospectus supplement or, if appropriate, a post-effective amendment to the registration statement that includes this prospectus.
In order to comply with the securities laws of some states, if applicable, the New
Silexion ordinary shares or New Silexion warrants may be sold in these jurisdictions only through registered or licensed brokers or dealers.
In addition, in some states the New Silexion ordinary shares or New Silexion warrants may not be sold unless they have been registered
or qualified for sale or an exemption from registration or qualification requirements is available and is complied with.
We have advised the Selling Securityholders that the anti-manipulation rules of Regulation
M under the Exchange Act may apply to sales of New Silexion ordinary shares or New Silexion warrants in the market and to the activities
of the Selling Securityholders and their affiliates. In addition, to the extent applicable we will make copies of this prospectus (as
it may be supplemented or amended from time to time) available to the Selling Securityholders for the purpose of satisfying the prospectus
delivery requirements of the Securities Act. The Selling Securityholders may indemnify any broker-dealer that participates in transactions
involving the sale of the shares against certain liabilities, including liabilities arising under the Securities Act.
A holder of New Silexion warrants may exercise its New Silexion warrants in accordance
with the applicable governing warrant agreement on or before the expiration date set forth therein by surrendering, at the office of the
warrant agent, Continental Stock Transfer & Trust Company, the certificate evidencing such Freightos Warrant, with the form of election
to purchase set forth thereon, properly completed and duly executed, accompanied by full payment of the exercise price and any and all
applicable taxes due in connection with the exercise of the Freightos Warrant, subject to any applicable provisions relating to cashless
exercises in accordance with the applicable warrant agreement.
We have agreed to indemnify the Selling Securityholders against liabilities, including
liabilities under the Securities Act and state securities laws, relating to the registration of the New Silexion ordinary shares or New
Silexion warrants offered by this prospectus.
We have agreed with the Selling Securityholders to keep the registration statement
of which this prospectus constitutes a part effective until all of the New Silexion ordinary shares or New Silexion warrants covered by
this prospectus have been disposed of pursuant to and in accordance with the registration statement or the securities have been withdrawn.
Our ordinary shares and warrants are currently listed
on the Nasdaq Global Market under the symbols "SLXN" and "SLXNW", respectively.
150
LEGAL
MATTERS
Conyers Dill & Pearman LLP will pass upon the validity of the ordinary shares of
the Company to be offered pursuant to the offering under this prospectus and matters of Cayman Islands law.
EXPERTS
The financial statements of Moringa Acquisition Corp as of December 31, 2023
and 2022, and for the two years ended December 31, 2023, included in this prospectus, have been so included in reliance on the report
(which contains an explanatory paragraph relating to the Company's ability to continue as a going concern as described in Note 1E
to the financial statements) of Kesselman & Kesselman, a member firm of PricewaterhouseCoopers International Limited, an independent
registered public accounting firm, given on the authority of said firm as experts in auditing and accounting.
The financial statements of Silexion Therapeutics
Corp (formerly known as Silexion Therapeutics Ltd.) as of December 31, 2023 and 2022, and for the two years ended December 31, 2023, included
in this prospectus have been so included in reliance on the report (which contains an explanatory paragraph relating to the Company's
ability to continue as a going concern as described in Note 1e to the financial statements) of Kesselman & Kesselman, a member firm
of PricewaterhouseCoopers International Limited, an independent registered public accounting firm, given on the authority of said firm
as experts in auditing and accounting.
151
WHERE
YOU CAN FIND MORE INFORMATION
We have filed with the SEC a registration statement on
Form S-1 under the Securities Act, with respect to the securities being offered by this prospectus. This prospectus, which constitutes
part of the registration statement, does not contain all of the information in the registration statement and its exhibits. For further
information with respect to New Silexion and the securities offered by this prospectus, we refer you to the registration statement and
its exhibits. Statements contained in this prospectus as to the contents of any contract or any other document referred to are not necessarily
complete, and in each instance, we refer you to the copy of the contract or other document filed as an exhibit to the registration statement.
Each of these statements is qualified in all respects by this reference. You can read our SEC filings, including the registration statement,
over the internet at the SEC's website at
www.sec.gov
.
We are subject to the information reporting requirements
of the Exchange Act, and we file reports, proxy statements and other information with the SEC. These reports, proxy statements and other
information will be available for review at the SEC's website at www.sec.gov. We also maintain a website at https://www.completesolaria.com/,
at which you may access these materials free of charge as soon as reasonably practicable after they are electronically filed with, or
furnished to, the SEC. The information contained in, or that can be accessed through, our website is not part of this prospectus.
152
INDEX
TO FINANCIAL STATEMENTS
TABLE
OF CONTENTS
MORINGA
ACQUISITION CORP
Page
Moringa
        Acquisition Corp Condensed Consolidated Financial Statements
Condensed
        Consolidated Balance Sheets
F-2
Condensed
        Consolidated Statements of Operations
F-3
Condensed
        Consolidated Statements of Changes in Capital Deficiency
F-4
Condensed
        Consolidated Statements of Cash Flows
F-5
Notes
        to the Condensed Consolidated Financial Statements
F-6
        - F-21
Moringa
        Acquisition Corp Audited Financial Statements
Report
        of Independent Registered Public Accounting Firm (PCAOB ID # 1309)
F-22
Balance
        Sheets
F-23
Statements
        of Operations
F-24
Statements
        of Changes in Capital Deficiency
F-25
Statements
        of Cash Flows
F-26
Notes
        to Financial Statements
F-27
        - F-39
SILEXION
THERAPEUTICS CORP
CONSOLIDATED
FINANCIAL STATEMENTS
Page
S
ilexion
        Therapeutics Corp Condensed Consolidated Financial Statements
Condensed
        Consolidated Balance Sheets (unaudited)
F-42
        - F-44
Condensed
        Consolidated Statements of Operations (unaudited)
F-45
Condensed
        Consolidated Statements of Changes in Redeemable Convertible Preferred Shares and Capital Deficiency (unaudited)
F-46
        - F-47
Condensed
        Consolidated Statements of Cash Flows (unaudited)
F-48
        -F-49
Notes
        to Condensed Consolidated Financial Statements (unaudited)
F-50
        - F64
S
ilexion
        Therapeutics
Corp
Audited Financial Statements
Report
        of Independent Registered Public Accounting Firm
F-67
CONSOLIDATED
        FINANCIAL STATEMENTS:
Consolidated
        Balance Sheets
F-68
        -F-69
Consolidated
        Statements of Operations
F-70
Consolidated
        Statements of Changes in Redeemable Convertible Preferred Shares and Capital Deficiency
F-71
Consolidated
        Statements of Cash Flows
F-72
        - F-73
Notes
        to Consolidated Financial Statements
F-74
F-1
MORINGA
ACQUISITION CORP
UNAUDITED
CONDENSED CONSOLIDATED BALANCE SHEETS
June 30,
December 31,
Note
2024
2023
U.S.
        Dollars
Assets
ASSETS:
Cash
        and cash equivalents
17,880
108,278
Investments
        held in Trust Account
5,924,118
5,697,632
Prepaid
        expenses
24,808
28,305
TOTAL
        ASSETS
5,966,806
5,834,215
Liabilities
        and shares subject to possible redemption net of capital deficiency
LIABILITIES:
Accrued
        expenses
55,191
115,560
Related
        party
4
3,346,000
2,861,000
Private
        warrant liability
27,284
8,531
TOTAL
        LIABILITIES
3,428,475
2,985,091
COMMITMENTS
        AND CONTINGENCIES
5
-
-
CLASS
        A ORDINARY SHARES SUBJECT TO POSSIBLE REDEMPTION:
515,019
shares at redemption value of $
11.50
and $
11.06
as of June 30, 2024 and December 31, 2023, respectively
5,924,118
5,697,632
CAPITAL
        DEFICIENCY:
7
Class
        A Ordinary Shares, $
0.0001
par value;
500,000,000
shares authorized,
3,354,999
issued and outstanding (excluding 515,019 shares subject to possible redemption) as of June 30, 2024 and December 31, 2023;
336
336
Class
        B Ordinary Shares, $
0.0001
par value;
50,000,000
shares authorized,
1
issued and outstanding as of June 30, 2024 and December 31, 2023;
*
*
Preferred
        Shares, $
0.0001
par value;
5,000,000
shares authorized,
no
shares issued and outstanding as of June 30, 2024 and December 31, 2023.
-
-
Accumulated
        deficit
(
3,386,123
)
(
2,848,844
)
TOTAL
        CAPITAL DEFICIENCY
(
3,385,787
)
(
2,848,508
)
TOTAL
        LIABILITIES AND SHARES SUBJECT TO POSSIBLE REDEMPTION NET OF CAPITAL DEFICIENCY
5,966,806
5,834,215
*
Less than one US dollar
The
accompanying notes are an integral part of these unaudited condensed consolidated financial statements
.
F-2
MORINGA
ACQUISITION CORP
UNAUDITED
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
Note
Six months ended
June
        30,
Three
        months ended
June 30,
2024
2023
2024
2023
U.S.
        Dollars
U.S.
        Dollars
Except
        share data
Except
        share data
INTEREST
        EARNED ON INVESTMENTS HELD IN TRUST ACCOUNT
149,236
1,063,043
75,305
318,002
GENERAL
        AND ADMINISTRATIVE
(
441,276
)
(
592,201
)
(
179,135
)
(
155,472
)
CHANGE
        IN FAIR VALUE OF WARRANT LIABILITY
(
18,753
)
5,301
(
6,745
)
418
NET
        PROFIT (LOSS) FOR THE PERIOD
(
310,793
)
476,143
(
110,575
)
162,948
WEIGHTED
        AVERAGE NUMBER OF CLASS A ORDINARY SHARES SUBJECT TO POSSIBLE REDEMPTION
8
515,019
5,015,185
515,019
2,589,567
NET
        PROFIT PER CLASS A ORDINARY SHARE SUBJECT TO POSSIBLE REDEMPTION – BASIC AND DILUTED
0.32
$
0.22
0.17
$
0.19
WEIGHTED
        AVERAGE NUMBER OF NON-REDEEMABLE CLASS A AND CLASS B ORDINARY SHARES
8
3,355,000
3,355,000
3,355,000
3,355,000
NET
        LOSS PER NON-REDEEMABLE CLASS A AND CLASS B ORDINARY SHARES – BASIC AND DILUTED
(
0.14
)
$
(
0.19
)
(
0.06
)
$
(
0.10
)
The
accompanying notes are an integral part of these unaudited condensed consolidated financial statements.
F-3
MORINGA ACQUISITION CORP
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CHANGES
IN CAPITAL DEFICIENCY
Class A
ordinary shares
Class B
ordinary shares
Total
Number of
shares
Par value
Number of
shares
Par value
Accumulated
deficit
capital
deficiency
BALANCE AT December 31, 2022
480,000
48
2,875,000
288
(
1,203,097
)
(
1,202,761
)
Subsequent accretion of Class A Ordinary Shares subject to possible redemption
        to amount as of March 31, 2023
(
905,040
)
(
905,040
)
Net profit for the period
313,195
313,195
BALANCE AT March 31, 2023
480,000
48
2,875,000
288
(
1,794,942
)
(
1,794,606
)
Subsequent accretion of Class A Ordinary Shares subject to possible redemption
        to amount as of June 30, 2023
(
558,002
)
(
558,002
)
Net profit for the period
162,948
162,948
BALANCE AT June 30, 2023
480,000
48
2,875,000
288
(
2,189,996
)
(
2,189,660
)
BALANCE AT December 31, 2023
3,354,999
336
1
*
(
2,848,844
)
(
2,848,508
)
Subsequent accretion of Class A Ordinary Shares subject to possible redemption
        to amount as of March 31, 2024
(
112,558
)
(
112,558
)
Net loss for the period
(
200,218
)
(
200,218
)
BALANCE AT March 31, 2024
3,354,999
336
1
*
(
3,161,620
)
(
3,161,284
)
Subsequent accretion of Class A Ordinary Shares subject to possible redemption
        to amount as of June 30, 2024
(
113,928
)
(
113,928
)
Net loss for the period
(
110,575
)
(
110,575
)
BALANCE AT June 30, 2024
3,354,999
336
1
*
(
3,386,123
)
(
3,385,787
)
*
Less than one US dollar
The accompanying notes are an integral part
of these unaudited condensed consolidated financial statements.
F-4
MORINGA ACQUISITION CORP
UNAUDITED
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
Six
        months ended
June 30,
2024
2023
CASH FLOWS
        FROM OPERATING ACTIVITIES:
Net
        profit (loss) for the period
(
310,793
)
476,143
Adjustments
        to reconcile net profit (loss) to net cash provided by (used in) operating activities:
Change
        in the fair value of the private warrant liability
18,753
(
5,301
)
Changes
        in operating assets and liabilities:
Decrease
        in prepaid expenses
3,497
2,023
Increase
        (decrease) in related party
(
20,000
)
30,000
Increase
        (decrease) in accrued expenses
(
60,369
)
14,993
Net
        cash provided by (used in) operating activities
(
368,912
)
517,858
CASH
        FLOWS FROM FINANCING ACTIVITIES:
Partial
        redemption of Class A ordinary shares subject to possible redemption
-
(
90,750,217
)
Proceeds
        from promissory notes – related party
505,000
920,000
Net
        cash provided by (used in) financing activities
505,000
(
89,830,217
)
INCREASE
        (DECREASE) IN CASH, CASH EQUIVALENTS AND INVESTMENTS HELD IN A TRUST ACCOUNT
136,088
(
89,312,359
)
CASH,
        CASH EQUIVALENTS AND INVESTMENTS HELD IN A TRUST ACCOUNT AT BEGINNING OF PERIOD
5,805,910
116,751,752
CASH,
        CASH EQUIVALENTS AND INVESTMENTS HELD IN A TRUST ACCOUNT AT END OF PERIOD
5,941,998
27,439,393
RECONCILIATION
        OF CASH, CASH EQUIVALENTS AND INVESTMENTS HELD IN A TRUST ACCOUNT:
Cash
        and cash equivalents
17,880
34,530
Investments
        held in trust account
5,924,118
27,404,863
Total
        cash, cash equivalents and investments held in a trust account
5,941,998
27,439,393
The
accompanying notes are an integral part of these unaudited condensed consolidated financial statements.
F-5
MORINGA ACQUISITION CORP
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)
NOTE 1 - DESCRIPTION OF ORGANIZATION AND BUSINESS OPERATIONS:
a.
Organization and General
Moringa Acquisition Corp (hereafter – the
Company) is a blank check company, incorporated on September 24, 2020 as a Cayman Islands exempted company, formed for the purpose of
effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination (hereafter –
the Business Combination). The Company is an emerging growth company, as defined in Section 2(a) of the Securities Act of 1933, as
amended (the "Securities Act"), as modified by the Jumpstart Our Business Startups Act of 2012 (the "JOBS Act").
The Company has selected December 31 as its fiscal
year end.
b.
Sponsor and Financing
The Company's sponsor is Moringa Sponsor,
L.P., a Cayman exempted limited partnership (which is referred to herein, together with its wholly-owned subsidiary, Moringa Sponsor (US)
LP, a Delaware limited partnership, as the "Sponsor").
Refer to Note 7(a) for information regarding the
aggregate withdrawals of approximately $
113
million, due to partial redemptions.
c.
The Trust Account
The proceeds held in the Trust Account are invested
in money market funds registered under the Investment Company Act and compliant with Rule 2a-7 thereof that maintain a stable net asset
value of $
1.00
.
The Company complies with the provisions of ASU
2016-18, under which changes in Investments held in the Trust Account are accounted for as Changes in Cash, Cash Equivalents and Investments
Held in a Trust Account in the Company's Statements of Cash Flows.
Refer to Note 4(a) for information regarding proceeds
received from the Sponsor under the Sixth and Eighth Promissory Notes, deposited into the Trust Account.
F-6
MORINGA ACQUISITION CORP
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)
(CONTINUED)
NOTE 1 - DESCRIPTION OF ORGANIZATION AND BUSINESS OPERATIONS
(continued)
:
d.
Initial Business Combination
The Company's management has broad discretion
with respect to the specific application of the net proceeds of the Public Offering, although substantially all of the net proceeds of
the Public Offering and the Private Placement are intended to be generally applied toward consummating an initial Business Combination.
The initial Business Combination must occur with one or more operating businesses or assets with a fair market value equal to at least
80
%
of the net assets held in the Trust Account (excluding taxes payable on the income accrued in the Trust Account). There is no assurance
that the Company will be able to successfully consummate an initial Business Combination.
The Company, after signing a definitive agreement
for an Initial Business Combination, will provide its public shareholders the opportunity to redeem all or a portion of their shares upon
the completion of the initial Business Combination, either (i) in connection with a shareholder meeting called to approve the business
combination or (ii) by means of a tender offer.
If the Company holds a shareholder vote or there
is a tender offer for shares in connection with an initial Business Combination, a public shareholder will have the right to redeem its
shares for an amount in cash equal to its pro rata share of the aggregate amount then on deposit in the Trust Account, calculated as of
two days prior to the general meeting or commencement of the Company's tender offer, including interest but less taxes payable.
As a result, the Company's Public Class A ordinary shares are classified as temporary equity upon the completion of the Public Offering,
in accordance with the Financial Accounting Standards Board ("FASB") Accounting Standards Codification ("ASC")
480, "Distinguishing Liabilities from Equity."
Pursuant to the Company's amended and restated
memorandum and articles of association, as amended, if the Company is unable to complete the initial Business Combination within 42 months
from the Closing of the Public Offering, the Company will (i) cease all operations except for the purpose of winding up, (ii) as promptly
as reasonably possible but not more than ten business days thereafter, redeem the public shares, at a per-share price, payable in cash,
equal to the aggregate amount then on deposit in the Trust Account, including interest (which interest shall be net of taxes payable,
and less up to $
100,000
of interest to pay dissolution expenses), divided by the number of then outstanding public shares, which redemption will completely extinguish
public shareholders' rights as shareholders (including the right to receive further liquidating distributions, if any), and (iii)
as promptly as reasonably possible following such redemption, subject to the approval of the Company's remaining shareholders and
the Company's board of directors, liquidate and dissolve, subject in each case to the Company's obligations under Cayman Islands
law to provide for claims of creditors and the requirements of other applicable law.
The Sponsor and the Company's officers and
directors have entered into a letter agreement with the Company, pursuant to which they have waived their rights to liquidating distributions
from the Trust Account with respect to any Class B ordinary share (as described in Note 7) held by them if the Company fails to complete
the initial Business Combination within 24 months of the Closing of the Public Offering or during any extended time that the Company has
to consummate an initial Business Combination beyond 24 months as a result of a shareholder vote to amend its amended and restated memorandum
and articles of association. However, if the Sponsor or any of the Company's directors or officers acquire any Class A ordinary
shares, they will be entitled to liquidating distributions from the Trust Account with respect to such shares if the Company fails to
complete the Initial Business Combination within the prescribed time period.
F-7
MORINGA ACQUISITION CORP
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)
(CONTINUED)
NOTE 1 - DESCRIPTION OF ORGANIZATION AND BUSINESS OPERATIONS
(continued)
:
In the event of a liquidation, dissolution or
winding up of the Company after an initial Business Combination, the Company's shareholders are entitled to share ratably in all
assets remaining available for distribution to them after payment of liabilities and after provision is made for each class of stock,
if any, having preference over the ordinary shares. The Company's shareholders have no preemptive or other subscription rights.
There are no sinking fund provisions applicable to the ordinary shares, except that the Company will provide its shareholders with the
opportunity to redeem their public shares for cash equal to their pro rata share of the aggregate amount then on deposit in the Trust
Account, under the circumstances, and, subject to the limitations, described herein.
On February 9, 2023 the Company held an extraordinary
general meeting in lieu of the 2022 annual general meeting of the Company (hereafter – the First Extension Meeting). At the First
Extension Meeting, the Company's shareholders approved the proposal to adopt, by way of special resolution, an amendment to the
Amended and Restated Articles to extend the date by which the Company has to consummate a business combination from the 24 month anniversary
of the Closing of the Public Offering – i.e., February 19, 2023 to August 19, 2023 (hereafter – the Extended Mandatory Liquidation
Date) or such earlier date as may be determined by the Board in its sole discretion.
On August 18, 2023 the Company held an extraordinary
general meeting in lieu of the 2023 annual general meeting of the Company (hereafter – the Second Extension Meeting). At the Second
Extension Meeting, the Company's shareholders approved, among other proposals, an amendment to the Amended and Restated Memorandum
and Articles of Association to further extend the date by which the Company has to consummate a business combination from the Extended
Mandatory Liquidation Date to August 19, 2024 (hereafter – the Second Extended Mandatory Liquidation Date) or such earlier date
as may be determined by the Board in its sole discretion.
Refer to Note 7(a) for information regarding the
partial redemptions of Class A ordinary shares subject to possible redemption, following the First and Second Extensions, and for information
regarding the conversion of Class B ordinary shares into Class A ordinary shares, following the Second Extension Meeting.
e.
Substantial Doubt about the Company's Ability to
        Continue as a Going Concern
As of June 30, 2024, the Company had approximately
$
18
thousand of cash and an accumulated deficit of $
3,386
thousand. In connection with the Company's assessment of going concern considerations in accordance with Financial Accounting Standard
Board's Accounting Standard Codification 205-40, "Going Concern", the Company will need to obtain additional funds in
order to satisfy its liquidity needs in its current endeavors to consummate the Proposed Silexion Merger, as detailed in Note 1(f), or
a different Initial Business Combination, if the former does not occur.
F-8
MORINGA ACQUISITION CORP
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)
(CONTINUED)
NOTE 1 - DESCRIPTION OF ORGANIZATION AND BUSINESS OPERATIONS
(continued)
:
Since its inception date and through the issuance
date of these unaudited condensed consolidated financial statements, the Company's liquidity needs were satisfied through an initial
capital injection from the Sponsor, followed by net Private Placement proceeds, as well as several withdrawals of the Sponsor promissory
notes. Management has determined that it will need to continue to rely and is significantly dependent on both outstanding and future promissory
notes, or other forms of financial support (all of which the Sponsor is not obligated to provide). Moreover, following the Second Extension
Meeting, the Company has until August 19, 2024 to consummate an Initial Business Combination. If a business combination is not consummated
by this date, there will be a mandatory liquidation and subsequent dissolution of the Company. There can be no assurance that the Company
will be able to consummate any business combination ahead of the Second Extended Mandatory Liquidation Date, nor will it be able to raise
sufficient funds to complete an Initial Business Combination. These matters raise substantial doubt about the Company's ability
to continue as a going concern, for the subsequent twelve months following the issuance date of these unaudited condensed consolidated
financial statements.
In February 2024, the Company entered into a Business
Combination Agreement with Silexion Therapeutics Ltd. (hereafter – Silexion), an Israeli company which is in its developmental stage,
dedicated to the development of innovative treatments for pancreatic cancer. Refer to Note 1(f) for further information regarding the
Proposed Silexion Merger.
No adjustments have been made to the carrying
amounts of assets or liabilities should the company fail to obtain financial support in its pursuit to consummate an Initial Business
Combination, nor if it is required to liquidate after the Second Extended Mandatory Liquidation Date.
f.
Proposed Business Combination
On February 21, 2024, the Company, together with
its wholly-owned Israeli subsidiary
April M.G. Ltd
. – which was incorporated due to the original business combination
structure, entered into a business combination agreement with Silexion (hereafter – the Proposed Silexion Merger).
The Proposed Silexion Merger is expected
to close in the third quarter of 2024, subject to the satisfaction of customary closing conditions under the Business Combination Agreement,
including the approval of the business combination by Silexion's and the Company's shareholders, as well as Nasdaq's
approval of the initial listing of the combined company's securities.
The Proposed Silexion Merger have been unanimously
approved by the boards of directors of the Company and Silexion.
On April 3, 2024, the Proposed Silexion Merger
contemplated under the original Proposed Silexion Merger agreement was restructured pursuant to the Business Combination Agreement, by
and among New Pubco (a newly formed Cayman Islands exempted company), its two newly-formed subsidiaries – Merger Sub 1 and Merger
Sub 2 – the Company and Silexion.
F-9
MORINGA ACQUISITION CORP
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)
(CONTINUED)
NOTE 1 - DESCRIPTION OF ORGANIZATION AND BUSINESS OPERATIONS
(continued)
:
As contemplated under the Business Combination
Agreement, Merger Sub 2 will merge with and into the Company, with the Company continuing as the surviving company and a wholly-owned
subsidiary of New Pubco, and Merger Sub 1 will merge with and into Silexion, with Silexion continuing as the surviving company and a wholly-owned
subsidiary of New Pubco. The shareholders and other equity holders of each of the Company and Silexion will receive corresponding securities
of New Pubco as consideration in the Prospective Business Combination at set ratios in exchange for their securities of Company and Silexion,
respectively. New Pubco will serve as the public company upon completion of the Proposed Business Combination, with its ordinary
shares and warrants listed for trading on Nasdaq.
The foregoing description of the Proposed Business
Combination, as amended, does not purport to be complete. For further information and access to the full agreement and all other related
agreements, refer to the Company's Current Report on Form 8-K filed with the SEC on April 3, 2024.
In connection with the Proposed Silexion Merger, on May 9,
2024, New Pubco filed with the SEC a Registration Statement on Form S-4, and has subsequently filed amendments on June 24, 2024, July
7, 2024 and July 12, 2024, that include a document that will serve as both a prospectus for the securities to be issued by New Pubco in
the Prospective Business Combination to security holders of the Company and Silexion, as well as a proxy statement of the Company for
the Company's extraordinary general meeting at which the Prospective Business Combination and the Business Combination Agreement
(among other matters) was presented for approval (see note 9). The SEC staff declared the New Pubco Registration Statement effective on
July 16, 2024.
g.
Impact of War in Israel
Israel's current war against the terrorist
organization Hamas continued to rage during the second quarter of 2024. The intensity and duration of the war has varied since it began
on October 7, 2023. Up to the balance sheet date and subsequently, the war has not had a material effect on the Company. However, the
war may cause wider macroeconomic deterioration in Israel, which may have a material adverse effect on the Company's ability to
effectively complete the Proposed Business Combination.
F-10
MORINGA ACQUISITION CORP
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)
(CONTINUED)
NOTE 2 - SIGNIFICANT ACCOUNTING POLICIES:
a.
Basis of Presentation
The condensed consolidated financial statements
herein are unaudited; however, such information reflects all adjustments (consisting of normal, recurring adjustments), which are, in
the opinion of the management, necessary for a fair statement of results for the interim period. The results of the operation for the
six and three-month periods ended June 30, 2024, are not necessarily indicative of the results to be expected for the full year. The year-end
condensed consolidated balance sheet data was derived from audited financial statements for the year ended December 31, 2023 as filed
on April 1, 2024, but does not include all disclosures required by accounting principles generally accepted in the United States of America
("U.S. GAAP"). These unaudited condensed consolidated financial statements should be read in conjunction with the audited
financial statements and related notes thereto of Moringa Acquisition Corp.
b.
Emerging Growth Company
Section 102(b)(1) of the JOBS Act exempts emerging
growth companies from being required to comply with new or revised financial accounting standards until private companies (that is, those
that have not had a Securities Act registration statement declared effective or do not have a class of securities registered under the
Exchange Act) are required to comply with the new or revised financial accounting standards.
The JOBS Act provides that a company can elect
to opt out of the extended transition period and comply with the requirements that apply to non-emerging growth companies but any such
election to opt out is irrevocable. The Company has elected not to opt out of such extended transition period which means that when a
standard is issued or revised and it has different application dates for public or private companies, the Company, as an emerging growth
company, can adopt the new or revised standard at the time private companies adopt the new or revised standard.
This may make comparison of the Company's
unaudited condensed consolidated financial statements with another public company which is neither an emerging growth company nor an emerging
growth company which has opted out of using the extended transition period difficult or impossible, because of the potential differences
in accounting standards used.
F-11
MORINGA ACQUISITION CORP
NOTES TO CONDENSED CONSOLIDATED
FINANCIAL STATEMENTS (UNAUDITED)
(CONTINUED)
NOTE 2 - SIGNIFICANT ACCOUNTING POLICIES
(continued)
:
c.
Cash and cash
        equivalents
The Company considers as cash equivalents all
short-term, highly liquid investments, which include short-term bank deposits with original maturities of three months or less from the
date of purchase that are not restricted as to withdrawal or use by nature of the account and are readily convertible to known amounts
of cash.
d.
Class A Ordinary Shares
        subject to possible redemption
As discussed in Note 1, all of the
11,500,000
shares of Class A ordinary shares sold as parts of the Units in the Public Offering contain a redemption feature. In accordance with
the Accounting Standards Codification 480-10-S99-3A "Classification and Measurement of Redeemable Securities", redemption
provisions not solely within the control of the Company require the security to be classified outside of permanent equity. The Company
has classified all of the shares sold under the Public Units as subject to possible redemption.
Refer to Note 7(a) for information regarding the
partial redemptions of Class A ordinary shares subject to possible redemption, following the First and Second Extensions. Also, refer
to Note 9(c) regarding an additional redemption after the balance sheet date.
e.
Net profit (loss) per share
The Company complies with accounting and disclosure
requirements of FASB ASC Topic 260, Earnings Per Share. Net profit (loss) per share is computed by dividing net profit (loss) by the weighted
average number of shares outstanding during the period. The Company applies the two-class method in calculating net profit (loss) per
each class of shares: the non-redeemable shares, which include the Private Class A Ordinary Shares, as defined in Note 7, and the Class
B ordinary shares (hereafter and collectively – Non-Redeemable class A and B ordinary shares); and the Class A ordinary shares subject
to possible redemption.
In order to determine the net profit (loss) attributable
to each class, the Company first considered the total profit (loss) allocable to both sets of shares. This is calculated using the total
net profit (loss) less any interest earned on investments held in trust account. Then, the accretion is fully allocated to the Class A
ordinary shares subject to redemption.
f.
Concentration of credit risk
Financial instruments that potentially
subject the Company to concentrations of credit risk consist of cash accounts in a financial institution, which, at times, may exceed
the Federal Depository Insurance Coverage of $
250,000
.
From the Company's incorporation and through June 30, 2024, the Company has not experienced any losses on these accounts.
As of June 30, 2024, the Company held its cash
and cash equivalents in an SVB bank account, and its investments Held in Trust Account in Goldman Sachs money market funds. Money market
funds are characterized as Level 1 investments within the fair value hierarchy under ASC 820.
F-12
MORINGA ACQUISITION CORP
NOTES TO CONDENSED CONSOLIDATED
FINANCIAL STATEMENTS (UNAUDITED)
(CONTINUED)
NOTE 2 - SIGNIFICANT ACCOUNTING POLICIES
(continued)
:
g.
Public Warrants
The Company applied the provisions of ASC 815-40
and classified its public warrants, issued as part of the Public Units as detailed in Note 3, as equity securities.
h.
Private Warrant liability
The Company accounts for the warrants in accordance
with the guidance contained in Accounting Standards Codification 815 ("ASC 815"), "Derivatives and Hedging", under
which the warrants do not meet the criteria for equity treatment and must be recorded as derivative liabilities. Accordingly, the Company
classifies the private warrants as liabilities at their fair value and adjusts the private warrants to fair value at each reporting period.
This liability is subject to re-measurement at each balance sheet date until the private warrants are exercised or expire, and any change
in fair value is recognized in the Company's statements of operations. Refer to Note 6 for information regarding the model used
to estimate the fair value of the Private Warrants (as defined in Note 3).
i.
Financial instruments
The fair value of the Company's assets and
liabilities, which qualify as financial instruments under the FASB ASC 820, "Fair Value Measurements and Disclosures", approximates
the carrying amounts represented in the balance sheet, primarily due to their short-term nature.
j.
Use of estimates in the preparation of financial statements
The preparation of the financial statements in
conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities,
the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during
the reporting period. Actual results may differ from those estimates and such differences may have a material impact on the Company's
financial statements.
m.
Income tax
The Company accounts for income taxes in accordance
with ASC 740, "Income Taxes (hereafter – ASC 740). ASC 740 prescribes the use of the liability method whereby deferred
tax asset and liability account balances are determined based on differences between the financial reporting and tax bases of assets and
liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse.
The Company provides a valuation allowance, if necessary, to reduce deferred tax assets to their estimated realizable value if it is more
likely than not that a portion or all of the deferred tax assets will not be realized, based on the weight of available positive and negative
evidence. Deferred tax liabilities and assets are classified as non-current in accordance with ASU 2015-17.
F-13
MORINGA ACQUISITION CORP
NOTES TO CONDENSED CONSOLIDATED
FINANCIAL STATEMENTS (UNAUDITED)
(CONTINUED)
NOTE 2 - SIGNIFICANT ACCOUNTING POLICIES
(continued)
:
n.
Recent accounting pronouncements
Management does not believe that any recently
issued, but not yet effective, accounting pronouncements, if currently adopted would have a material effect on the Company's financial
statements.
NOTE 3 - PUBLIC OFFERING AND PRIVATE PLACEMENTS:
In the Initial Public Offering, the Company issued
and sold
11,500,000
units (including
1,500,000
units sold at a second closing pursuant to the underwriters' exercise of their over-allotment option in full) at an offering price
of $
10.00
per unit (hereafter – the Units). The Sponsor and EarlyBirdCapital, Inc. (the representative of the underwriters) purchased, in
a private placement that occurred simultaneously with the two closings of the initial Public Offering (hereafter – the Private Placement),
an aggregate of
352,857
and
27,143
Units, respectively, at a price of $
10.00
per Unit.
Once the Public Warrants become exercisable, the
Company may redeem them in whole and not in part at a price of $
0.01
per Warrant upon a minimum of 30 days' prior written notice of redemption, if and only if the last reported sale price of the Company's
Class A ordinary shares equals or exceeds $
18.00
per share (as adjusted) for any 20 trading days within a 30-trading day period ending on the third trading day prior to the date on which
the Company sends the notice of redemption to the Public Warrant holders.
The Private Warrants are identical to the Public
Warrants except that, for so long as they are held by the Sponsor, EarlyBirdCapital, Inc. or their respective affiliates: (1) will not
be redeemable by the Company; (2) may not (including the Class A ordinary shares issuable upon exercise thereof), subject to certain limited
exceptions, be transferred, assigned or sold by the holders thereof until 30 days after the completion of the Company's Initial
Business Combination; (3) may be exercised by the holders thereof on a cashless basis; and (4) they (including the Class A ordinary shares
issuable upon exercise thereof) are entitled to registration rights.
The Company paid an underwriting commission of
2.0
%
of the gross proceeds of the Public Offering and the full exercise of the underwriters' over-allotment, or $
2,300,000
,
in the aggregate, to the underwriters at the two closings of the Public Offering. Refer to Notes 5(a) and 9(a) for more information regarding
an additional fee payable to the underwriters upon the consummation of an Initial Business Combination, and an amendment to the agreement.
F-14
MORINGA ACQUISITION CORP
NOTES TO CONDENSED CONSOLIDATED
FINANCIAL STATEMENTS (UNAUDITED)
(CONTINUED)
NOTE 4 - RELATED PARTY TRANSACTIONS:
a.
Promissory Notes
The Company has issued several promissory note
agreements to its Sponsor throughout its life term, in order to fulfil its ongoing operational needs or preparations towards an Initial
Business Combination. All outstanding promissory notes bear no interest and are repayable in full upon the earlier of (a) the date of
the consummation of the Company's Initial Business Combination, or (b) Second Extended Mandatory Liquidation Date (hereafter and
collectively – the Maturity Date).
Second to Fifth Promissory Notes
On August 9, 2021 the Company issued its Second
Promissory Note to the Sponsor, according to which the former may withdraw up to $
1
million – which has been withdrawn in full in several installments up until June 2022.
In December 2022 the Company issued its Third
and Fourth Promissory Notes, according to which the Company may withdraw up to an aggregate amount of $
190
thousand – which were withdrawn in full on the same month.
On February 8, 2023 the Company issued its Fifth
Promissory Note to the Sponsor, in an amount of up to $
310
thousand, which were withdrawn in full in several installments between February and June 2023.
According to the terms of the outstanding Second,
Third, Fourth and Fifth Promissory Notes, which comprise an aggregate principal of $
1.5
million, the Sponsor may elect to convert any portion of the amounts outstanding into private warrants to purchase Class A ordinary shares
at a conversion price of $
1
per private warrant on the Maturity Date. Such private warrants will have an exercise price of $
11.5
and shall be identical to the private warrants included in the private units.
Sixth Promissory Note
On February 9, 2023 the Company issued its Sixth
Promissory Note to the Sponsor, in an amount of $
480
thousand – under which the funds that were loaned by the Sponsor were deposited into the Company's Trust Account, in connection
with the First Extension. The Sponsor provided six monthly injections of $
80
thousand into the Company's Trust Account under the Sixth Promissory Note, starting February 19, 2023.
Seventh Promissory Note
On June 14, 2023 the Company issued its Seventh
Promissory Note to the Sponsor in an amount of up to $
1
million, which were withdrawn in full in several installments between June 2023 and March 2024.
F-15
MORINGA
ACQUISITION CORP
NOTES
TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)
(CONTINUED)
NOTE 4 - RELATED PARTY TRANSACTIONS
(continued)
:
Eighth Promissory Note
On August 18, 2023 the Company issued its Eighth
Promissory Note to the Sponsor, in an amount of approximately $
154
thousand – under which the funds that were loaned by the Sponsor were deposited into the Company's Trust Account, in connection
with the Second Extension. The Sponsor shall make monthly injections of approximately $
13
thousand into the Company's Trust Account, starting August 19, 2023 and up until the earlier of the Second Extended Mandatory Liquidation
Date (or such earlier date that the Board determines to liquidate the Company) or the date on which an Initial Business Combination is
completed. During the six months ended June 30, 2024, approximately $
77
thousand have been injected into the trust account in six monthly installments.
Ninth Promissory Note
On March 27, 2024, the Company issued its Ninth
Promissory Note, according to which the Company may withdraw up to an aggregate amount of $
180
thousand. As of June 30, 2024 the Ninth Promissory Note has been fully withdrawn.
Tenth Promissory Note
On June 27, 2024, the Company issued its Tenth
Promissory Note, according to which the Company may withdraw up to an aggregate amount of $
250
thousand. The Company has made partial withdrawals in June and July 2024.
A&R Promissory Note
Upon the closing of the proposed business combination,
and according to the terms of the amended Silexion Business Combination agreement, all promissory notes shall be converted into one sponsor
promissory note – the A&R Sponsor Promissory Note, which will be subject to a cap of (i) $
5.5
million, minus (ii) any fee that may be paid or owed under the amended Business Marketing Agreement (See Notes 5(a) and 9(a)). Any outstanding
amount loaned by the sponsor to the Company in excess of the cap, will be attributed to the conversion shares issuable under the A&R
Sponsor Promissory Note as additional paid-in capital.
b.
Administrative Services Agreement
On December 16, 2020, the Company signed an agreement
with the Sponsor, under which the Company shall pay the Sponsor a fixed $
10
thousand per month for office space, utilities and other administrative expenses. The monthly payments under this administrative services
agreement commenced on the effective date of the registration statement for the initial Public Offering and will continue until the earlier
of (i) the consummation of the Company's initial Business Combination, or (ii) the Company's liquidation.
The composition of the Related Party balance as
of June 30, 2024 and December 31, 2023 is as follows:
June 30,
2024
December 31,
2023
In U.S. dollars
Promissory notes
3,346,000
2,841,000
Accrual for Administrative Services Agreement
-
20,000
3,346,000
2,861,000
F-16
MORINGA
ACQUISITION CORP
NOTES
TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)
(CONTINUED)
NOTE 5 - COMMITMENTS AND CONTINGENCIES:
a.
Underwriters' deferred discount
Under the Business Combination
Marketing Agreement, the Company shall pay an additional fee (hereafter – the Deferred Commission) of
3.5
%
of the gross proceeds of the Public Offering (or $
4,025,000
)
payable upon the Company's completion of the Initial Business Combination. The Deferred Commission will become payable to the underwriters
from the amounts held in the Trust Account solely in the event the Company completes an Initial Business Combination.
b.
Advisory and Placement Agent Agreement with Cohen & Company
Refer to Note 9(d) for information
regarding the agreement entered into after the balance sheet date.
c.
Nasdaq Deficiency Notice
Third Deficiency Notice
On February 20, 2024, the Company received a notice
from the staff of the Listing Qualifications Department of The Nasdaq Stock Market LLC indicating that unless the Company timely requests
a hearing before the Nasdaq Hearings Panel (hereafter - the Panel), trading of the Company's securities on The Nasdaq Capital Market
would be suspended at the opening of business on February 29, 2024, due to the Company's non-compliance with Nasdaq IM-5101-2, which
requires that a special purpose acquisition company complete one or more business combinations within 36 months of the effectiveness of
its IPO registration statement.
The Company timely requested a hearing before
the Panel to request sufficient time to complete its previously disclosed proposed business combination with Silexion. The hearing request
has resulted in a stay of any suspension or delisting action pending the hearing, which was held on April 23, 2024.
On April 23, 2024, the Company participated in
a hearing with Nasdaq in which the Company presented its request that Nasdaq provide the Company an additional six months to remedy the
Company's non-compliance with Nasdaq IM-5101-2, which requires that a special purpose acquisition company complete one or more business
combinations within 36 months of the effectiveness of its IPO registration statement. The Company's plan for regaining compliance
focused on the Company's efforts to complete its previously disclosed Proposed Business Combination with Silexion. On May 10, 2024,
the Company received the results of the hearing, under which Nasdaq approved the Company's request for a six-month extension—
until the Second Extension Date— to remain listed on Nasdaq and complete its proposed business combination.
F-17
MORINGA ACQUISITION CORP
NOTES TO CONDENSED CONSOLIDATED
FINANCIAL STATEMENTS (UNAUDITED)
(CONTINUED)
NOTE 6 - FAIR VALUE MEASUREMENTS:
The fair value of a financial instrument is the
amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at
the measurement date (i.e., the exit price).
The fair value hierarchy under ASC 820 prioritizes
the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in
active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements).
The three levels of the fair value hierarchy are as follows:
Basis for Fair Value Measurement
Level 1: Unadjusted quoted prices in active markets
that are accessible at the measurement date for identical, unrestricted assets or liabilities;
Level 2: Quoted prices in markets that are not
active or financial instruments for which significant inputs to models are observable (including but not limited to quoted prices for
similar securities, interest rates, foreign exchange rates, volatility and credit risk), either directly or indirectly;
Level 3: Prices or valuations that require significant
unobservable inputs (including the Management's assumptions in determining fair value measurement).
The following table presents information about
the Company's assets and liabilities that are measured at fair value on a recurring basis at June 30, 2024 and December 31, 2023
by level within the fair value hierarchy:
Level
June 30,
2024
December 31,
2023
Assets:
Money market funds held in Trust Account
1
5,924,118
5,697,632
Liabilities:
Private Warrant Liability
3
27,284
8,531
The estimated fair value of the Private Placement
Warrants was determined using a binomial model to extract the market's implied probability for an Initial Business Combination,
using the Public Warrant's market price. Once probability was extracted, a Black-Scholes-Merton model with Level 3 inputs was used
to calculate the Private Warrants' fair value. Inherent in a Black-Scholes-Merton model are assumptions related to expected life
(term), expected stock price, volatility, risk-free interest rate and dividend yield. The Company estimates the volatility of its warrants
based on implied volatility from the Company's traded warrants and from historical volatility of selected peer companies'
Class A ordinary shares that matches the expected remaining life of the warrants. The risk-free interest rate is based on the U.S. Treasury
zero-coupon yield curve on the grant date for a maturity similar to the expected remaining life of the warrants. The expected life of
the warrants is assumed to be equivalent to their remaining contractual term. The dividend rate is based on the historical rate, which
the Company anticipates remaining at zero.
The following table provides quantitative information
regarding Level 3 fair value measurements inputs:
As of
June 30,
2024
As of
December 31,
2023
Share price
$
10.0
$
10.0
Strike price
$
11.5
$
11.5
Volatility
60
%
60
%
Risk-free interest rate
4.34
%
4.78
%
Dividend yield
0.00
%
0.00
%
Public warrant market price
$
0.08
$
0.03
In U.S dollars
Value of warrant liability measured with Level 3 inputs at December
        31, 2023
8,531
Change in fair value of private warrant liability measured
        with Level 3 inputs
18,753
Value of warrant liability measured with Level 3 inputs at
        June 30, 2024
27,284
F-18
MORINGA ACQUISITION CORP
NOTES TO CONDENSED CONSOLIDATED
FINANCIAL STATEMENTS (UNAUDITED)
(CONTINUED)
NOTE 7 - CAPITAL DEFICIENCY:
a.
Ordinary Shares
Class A Ordinary Shares
On November 20, 2020 the Company issued
100,000
Class A ordinary shares of $
0.0001
par value each to designees of the Representative (hereafter – the Representative Shares) for a consideration equal to the par value
of the shares. The Representative Shares are deemed to be underwriters' compensation by FINRA pursuant to Rule 5110 of the FINRA
Manual.
The Company accounted for the issuance of the
Representative Shares as compensation expenses amounting to $
860
,
with a corresponding credit to Additional Paid-In Capital, for the excess value over the consideration paid. The Company estimated the
fair value of the issuance based upon the price of Class B Ordinary Shares that were issued to the Sponsor.
Pursuant to the initial Public Offering and the
concurrent Private Placement that were each effected in two closings – on February 19, 2021 and March 3, 2021 – the Company
issued and sold an aggregate of
11,500,000
and
380,000
Class A ordinary shares as part of the Units sold in those respective transactions. The Units (which also included Warrants) were sold
at a price of $
10
per Unit, and for an aggregate consideration of $
115
million and $
3.8
million in the Public Offering and Private Placement, respectively. See Note 3 above for further information regarding those share issuances.
The Company classified its
11,500,000
Public Class A ordinary shares as temporary equity. The remaining
480,000
Private Class A ordinary shares were classified as permanent equity.
In conjunction with the First and Second
Extensions,
8,910,433
and
2,074,548
Class A Ordinary Shares subject to possible redemption were redeemed, respectively, for their redemption value, including accrued interest.
As part of the partial redemptions approximately $
113
million has been withdrawn from the Investments held in Trust Account.
Class B Ordinary Shares
On November 20, 2020, the Company issued
2,875,000
Class B ordinary shares of $
0.0001
par value each for a total consideration of $
25
thousand to the Sponsor's wholly-owned Delaware subsidiary.
Class B ordinary shares are convertible into non-redeemable
Class A ordinary shares, on a one-for-one basis, automatically on the day of the Business Combination or at the election of the holder
thereof at any time prior to the Business Combination. Class B ordinary shares also possess the sole right to vote for the election or
removal of directors, until the consummation of an Initial Business Combination.
Following the Second Extension Meeting, the Sponsor
converted
2,874,999
of its
Class
B ordinary shares into Class A ordinary shares on a one to one basis
.
b.
Preferred shares
The Company is authorized to issue up to
5,000,000
Preferred Shares of $
0.0001
par value each. As of June 30, 2024, the Company has no preferred shares issued and outstanding.
F-19
MORINGA ACQUISITION CORP
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)
(CONTINUED)
NOTE 8 - NET PROFIT (LOSS) PER SHARE:
The following table reflects the calculation
of basic and diluted net profit (loss) per share (in dollars, except share amounts):
Six months ended
June 30,
Three months ended
June 30,
2024
2023
2024
2023
Net profit (loss) for the period
$
(
310,793
)
$
476,143
$
(
110,575
)
$
162,948
Less – interest earned on Investment held in Trust
        Account
(
149,236
)
(
1,063,043
)
(
75,305
)
(
318,002
)
Net loss excluding interest
$
(
460,029
)
$
(
586,900
)
$
(
185,880
)
$
(
155,054
)
Class A ordinary shares subject to possible redemption:
Numerator:
Net loss excluding interest
$
(
61,220
)
$
(
351,654
)
$
(
24,737
)
$
(
67,544
)
Accretion to Class A ordinary shares subject to possible
        redemption to redemption amount ("Accretion")
226,486
1,463,043
113,930
558,002
$
165,266
$
1,111,389
$
89,193
$
490,458
Denominator:
weighted average number of shares
515,019
5,015,185
515,019
2,589,567
Net profit per Class A ordinary share subject
        to possible redemption – basic and diluted
$
0.32
$
0.22
$
0.17
$
0.19
Non-redeemable Class A and B ordinary shares:
Numerator:
Net loss excluding interest
$
(
398,809
)
$
(
235,246
)
$
(
161,143
)
$
(
87,510
)
Accretion
(
77,250
)
(
400,000
)
(
38,625
)
(
240,000
)
(
476,059
)
(
635,246
)
(
199,768
)
(
327,510
)
Denominator:
weighted average number of shares
3,355,000
3,355,000
3,355,000
3,355,000
Net loss per non-redeemable Class A and
        B ordinary share – basic and diluted
$
(
0.14
)
$
(
0.19
)
$
(
0.06
)
$
(
0.10
)
The potential exercise of
5,750,000
Public Warrants and
190,000
Private Warrants sold in the Public Offering and Private Placements as detailed in Note 3 into
5,940,000
shares has not been included in the calculation of diluted net profit (loss) per share, since the exercise of the warrants is contingent
upon the occurrence of a future event.
Additionally, the effect of the conversion
of the Second, Third, Fourth and Fifth Promissory Notes into an aggregate amount of
1,500,000
private warrants (exercisable into
1,500,000
shares) as detailed in Note 4, has not been included in the calculation of diluted net profit (loss) per share, since the conversion of
the abovementioned promissory notes is contingent upon the occurrence of a future event.
As a result, diluted net profit (loss) per
share is the same as basic net profit (loss) per share for each of the periods presented, and for each class.
F-20
MORINGA ACQUISITION CORP
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)
(CONTINUED)
NOTE
9 - SUBSEQUENT EVENTS:
a.
Additional withdrawals under the Promissory Notes
Since the balance sheet date and up until the
filing date of these financial statements, an aggregate amount of $
62
thousand has been withdrawn under the Tenth Promissory Note, and a final injection into the trust account of approximately $
13
thousand has been withdrawn under the Eighth Promissory Note – rendering the latter fully withdrawn.
b.
Extraordinary General Meeting and redemption of Class A ordinary shares subject to possible redemption
On August 6, 2024 the Extraordinary General Meeting
has approved the proposed business combination with Silexion. In connection with the meeting, an additional
427,297
Class A ordinary shares subject to possible redemption have been redeemed. Consequently, $
4.8
million has been withdrawn from the trust account.
c.
Advisory and Placement Agent Agreement with Cohen & Company
On July 29, 2024 the Company has entered into
agreement with Cohen & Company, for providing capital markets advisory and placement agent services, in connection with both (i) the
completion of the proposed business combination with Silexion, and (ii) a private placement of equity, equity-linked, convertible and
/ or debt securities to be consummated with the business combination.
F-21
Report
of Independent Registered Public Accounting Firm
To
the Board of Directors and Shareholders of Moringa Acquisition Corp
Opinion
on the Financial Statements
We
have audited the accompanying balance sheets of Moringa Acquisition Corp (the "Company") as of December 31, 2023 and
2022, and the related statements of operations, changes in capital deficiency and cash flows for each of the two years in the period
ended December 31, 2023, including the related notes (collectively referred to as the "financial statements"). In our
opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December 31,
2023 and 2022, and the results of its operations and its cash flows for each of the two years in the period ended December 31,
2023 in conformity with accounting principles generally accepted in the United States of America.
Substantial
Doubt about the Company's Ability to Continue as a Going Concern
The
accompanying financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 1(e) to
the financial statements, the Company has limited cash and has incurred losses since inception. Moreover, if the Company is unable to
complete a business combination by August 19, 2024 then the Company will cease all operations except for the purpose of liquidating.
These matters raise substantial doubt about the Company's ability to continue as a going concern. Management's plans in regard
to these matters are also described in Note 1(e). The financial statements do not include any adjustments that might result from
the outcome of this uncertainty.
Basis
for Opinion
These
financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on the Company's
financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board
(United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities
laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.
We
conducted our audits of these financial statements in accordance with the standards of the PCAOB. Those standards require that we
plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether
due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial
reporting. As part of our audits we are required to obtain an understanding of internal control over financial reporting but not for the
purpose of expressing an opinion on the effectiveness of the Company's internal control over financial reporting. Accordingly, we
express no such opinion.
Our
audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or
fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding
the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant
estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide
a reasonable basis for our opinion.
/s/ Kesselman &
Kesselman
Certified
Public Accountants (Isr.)
A member firm of PricewaterhouseCoopers International Limited
Tel-Aviv,
Israel
April 1, 2024
We
have served as the Company's auditor since 2020.
F-22
MORINGA
ACQUISITION CORP
BALANCE
SHEETS
Note
December 31,
2023
December 31,
2022
U.S. Dollars
Assets
ASSETS:
Cash
        and cash equivalents
108,278
59,714
Investments
        held in Trust Account
5,697,632
116,692,038
Prepaid
        expenses
28,305
43,853
TOTAL
        ASSETS
5,834,215
116,795,605
Liabilities
        and shares subject to possible redemption
net of capital deficiency
LIABILITIES:
Accrued
        expenses
115,560
86,688
Related
        party
4
2,861,000
1,190,000
Private
        warrant liability
8,531
29,640
TOTAL
        LIABILITIES
2,985,091
1,306,328
COMMITMENTS
        AND CONTINGENCIES
5
-
-
CLASS
        A ORDINARY SHARES SUBJECT TO POSSIBLE REDEMPTION:
515,019
and
11,500,000
shares
        at redemption value $
11.06
and
        $
10.15
as
        of December 31, 2023 and 2022, respectively
5,697,632
116,692,038
CAPITAL
        DEFICIENCY:
7
Class A
        Ordinary Shares, $
0.0001
par
        value;
500,000,000
shares
        authorized,
3,354,999
and
480,000
issued
        and outstanding (excluding 515,019 and 11,500,000 shares subject to possible redemption) as of December 31, 2023 and 2022, respectively;
336
48
Class B
        Ordinary Shares, $
0.0001
par
        value;
50,000,000
shares
        authorized,
1
and
2,875,000
issued
        and outstanding as of December 31, 2023 and 2022, respectively;
*
288
Preferred
        Shares, $
0.0001
par
        value;
5,000,000
shares
        authorized,
no
shares
        issued and outstanding as of December 31, 2023 and 2022.
-
-
Additional
        paid-in capital
-
-
Accumulated
        deficit
(
2,848,844
)
(
1,203,097
)
TOTAL
        CAPITAL DEFICIENCY
(
2,848,508
)
(
1,202,761
)
TOTAL
        LIABILITIES AND SHARES SUBJECT TO POSSIBLE REDEMPTION NET OF CAPITAL DEFICIENCY
5,834,215
116,795,605
*
Less than one US dollar.
The
accompanying notes are an integral part of these financial statements
.
F-23
MORINGA
ACQUISITION CORP
STATEMENTS OF OPERATIONS
Note
Year
        ended
December 31,
2023
Year
        ended
December 31,
2022
U.S. Dollars
Except
        share data
Interest
        earned on investments held in trust account
1,364,444
1,685,666
General
        and administrative
9
(
1,122,480
)
(
1,232,342
)
Change
        in fair value of Private Warrant liability
21,109
130,701
Net
        profit for the year
263,073
584,025
Weighted
        average number of Class A Ordinary Shares subject to Possible Redemption
8
2,774,850
11,500,000
Basic
        and diluted net profit per Class A Ordinary Shares subject to Possible Redemption
$
0.51
0.07
Weighted
        average number of non-redeemable Class A and Class B Ordinary shares
3,355,000
3,355,000
Basic
        and diluted net loss per non-redeemable Class A and Class B Ordinary shares
$
(
0.34
)
(
0.07
)
The
accompanying notes are an integral part of these financial statements.
F-24
MORINGA
ACQUISITION CORP
STATEMENTS OF CHANGES IN CAPITAL DEFICIENCY
Class A
ordinary
        shares
Class B
ordinary
        shares
Additional
Number of
shares
Par
value
Number of
shares
Par
value
paid-in
capital
Accumulated
deficit
Total
U.S. Dollars
        (except share data)
BALANCE
        AT December 31, 2021
480,000
48
2,875,000
288
855,994
(
951,078
)
(
94,748
)
Subsequent
        accretion of Class A Ordinary Shares subject to possible redemption to amount as of December 31, 2022
-
-
-
-
(
855,994
)
(
836,044
)
(
1,692,038
)
Net
        profit for the year
-
-
-
-
-
584,025
584,025
BALANCE
        AT December 31, 2022
480,000
48
2,875,000
288
-
(
1,203,097
)
(
1,202,761
)
Subsequent
        accretion of Class A Ordinary Shares subject to possible redemption to amount as of December 31, 2023
-
-
-
-
-
(
1,908,820
)
(
1,908,820
)
Conversion
        of Class B ordinary shares into Class A ordinary shares
2,874,999
288
(
2,874,999
)
(
288
)
-
-
-
Net
        profit for the year
-
-
-
-
-
263,073
263,073
BALANCE
        AT December 31, 2023
3,354,999
336
1
*
-
(
2,848,844
)
(
2,848,508
)
*
Less than one US dollar.
The
accompanying notes are an integral part of these financial statements.
F-25
MORINGA
ACQUISITION CORP
STATEMENTS OF CASH FLOWS
Year
        ended
December 31,
2023
Year
        ended
December 31,
2022
U.S. Dollars
CASH FLOWS
        FROM OPERATING ACTIVITIES:
Net
        profit for the year
263,073
584,025
Adjustments
        to reconcile net profit to net cash provided by operating activities:
Changes
        in the fair value of the private warrant liability
(
21,109
)
(
130,701
)
Changes
        in operating assets and liabilities:
Decrease
        in prepaid expenses
15,548
325,000
Increase
        (decrease) in related party
20,000
(
10,000
)
Increase
        in accrued expenses
28,872
48,112
Net
        cash provided by operating activities
306,384
816,436
CASH
        FLOWS FROM FINANCING ACTIVITIES:
Partial
        redemption of Class A ordinary shares subject to possible redemption
(
112,903,226
)
-
Proceeds
        from a promissory note – related party
1,651,000
890,000
Net
        cash provided by (used in) financing activities
(
111,252,226
)
890,000
INCREASE
        (DECREASE) IN CASH, CASH EQUIVALENTS AND INVESTMENTS HELD IN A TRUST ACCOUNT
(
110,945,842
)
1,706,436
CASH,
        CASH EQUIVALENTS AND INVESTMENTS HELD IN A TRUST ACCOUNT AT BEGINNING OF YEAR
116,751,752
115,045,316
CASH,
        CASH EQUIVALENTS AND INVESTMENTS HELD IN A TRUST ACCOUNT AT END OF YEAR
5,805,910
116,751,752
RECONCILIATION
        OF CASH, CASH EQUIVALENTS AND INVESTMENTS HELD IN A TRUST ACCOUNT:
Cash
        and cash equivalents
108,278
59,714
Investments
        held in trust account
5,697,632
116,692,038
Total
        cash, cash equivalents and investments held in a trust account
5,805,910
116,751,752
SUPPLEMENTARY
        INFORMATION REGARDING NON-CASH ACTIVITIES:
Conversion
        of Class B ordinary shares into Class A ordinary shares
288
-
The
accompanying notes are an integral part of these financial statements.
F-26
MORINGA
ACQUISITION CORP
NOTES TO FINANCIAL STATEMENTS
NOTE
1 — DESCRIPTION OF ORGANIZATION AND BUSINESS OPERATIONS:
a.
Organization and General
Moringa
Acquisition Corp (hereafter — the Company) is a blank check company, incorporated on September 24, 2020 as a Cayman
Islands exempted company, formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization
or similar business combination (hereafter — the Business Combination). The Company is an emerging growth company, as
defined in Section 2(a) of the Securities Act of 1933, as amended (the "Securities Act"), as modified
by the Jumpstart Our Business Startups Act of 2012 (the "JOBS Act").
All
activity for the year ended December 31, 2023 relates to the Company's search for a target company, as well as attempts to
consummate the Proposed Holisto Merger which was terminated on August 8, 2023 as detailed in Note 1(f).
In
February 2024, the Company entered into a Business Combination Agreement with Silexion. Refer to Note 10(b) for further
information regarding the Proposed Business Combination.
The
Company has selected December 31 as its fiscal year end.
b.
Sponsor and Financing
The
Company's sponsor is Moringa Sponsor, L.P., a Cayman exempted limited partnership (which is referred to herein, together with its
wholly-owned subsidiary, Moringa Sponsor (US) LP, a Delaware limited partnership, as the "Sponsor").
The
registration statement relating to the Company's Public Offering was declared effective by the United States Securities and
Exchange Commission (the "SEC") on February 16, 2021. The initial stage of the Company's Public Offering — the
sale of
10,000,000
Units — closed
on February 19, 2021 (hereafter — the Closing of the Public Offering). Upon that closing and the concurrent closing
of the initial stage of the Private Placement (as defined below in Note 3). $
100,000,000
was
placed in a trust account (the "Trust Account") (discussed in Note 1(c) below). On March 3, 2021 upon the full
exercise by the underwriters of their over-allotment option for the Public Offering, the second stage of the Public Offering — the
sale of
1,500,000
Units — closed.
Upon that closing and the concurrent closing of the second stage of the Private Placement, an additional $
15,000,000
was
placed in the Trust Account. As part of the partial redemptions in conjunction with the First and Second Extensions, approximately $
113
million
have been withdrawn from the Investments held in Trust Account. The Company intends to finance its Initial Business Combination with the
net proceeds from the Public Offering and the Private Placement.
c.
The Trust Account
The
proceeds held in the Trust Account are invested in money market funds registered under the Investment Company Act and compliant with Rule 2a-7
thereof that maintain a stable net asset value of $
1.00
.
The
Company's complies with the provisions of ASU 2016-18, under which changes in proceeds held in the Trust Account are accounted
for as Changes in Cash, Cash Equivalents and Investments Held in a Trust Account in the Company's Statements of Cash Flows.
Refer
to Note 4(a) for information regarding proceeds loaned by the Sponsor under the Sixth and Eighth Promissory Notes, deposited
into the Trust Account.
d.
Initial Business Combination
The
Company's management has broad discretion with respect to the specific application of the net proceeds of the Public Offering, although
substantially all of the net proceeds of the Public Offering and the Private Placement are intended to be generally applied toward consummating
an Initial Business Combination. The Initial Business Combination must occur with one or more operating businesses or assets with a fair
market value equal to at least
80
%
of the net assets held in the Trust Account (excluding taxes payable on the income accrued in the Trust Account) as of the time of entry
into the related definitive agreement for the Initial Business Combination. There is no assurance that the Company will be able to successfully
consummate an Initial Business Combination.
F-27
MORINGA
ACQUISITION CORP
NOTES TO FINANCIAL STATEMENTS
NOTE
1 — DESCRIPTION OF ORGANIZATION AND BUSINESS OPERATIONS:
(cont.)
The
Company, after signing a definitive agreement for an Initial Business Combination, will provide its public shareholders the opportunity
to redeem all or a portion of their shares upon the completion of the Initial Business Combination, either (i) in connection with
a shareholder meeting called to approve the business combination or (ii) by means of a tender offer.
If
the Company holds a shareholder vote or there is a tender offer for shares in connection with an Initial Business Combination, a public
shareholder will have the right to redeem its shares for an amount in cash equal to its pro rata share of the aggregate amount then on
deposit in the Trust Account, calculated as of two days prior to the general meeting or commencement of the Company's tender
offer, including interest but less taxes payable. As a result, the Company's Class A ordinary shares subject to possible redemption
are classified as temporary equity upon the completion of the Public Offering, in accordance with the Financial Accounting Standards Board
("FASB") Accounting Standards Codification ("ASC") 480, "Distinguishing Liabilities from Equity".
Pursuant
to the Company's amended and restated memorandum and articles of association, if the Company is unable to complete the Initial Business
Combination within 24 months (as was subsequently extended, as described below) from the Closing of the Public Offering, the Company
will (i) cease all operations except for the purpose of winding up, (ii) as promptly as reasonably possible but not more than
ten business days thereafter, redeem the public shares, at a per-share price, payable in cash, equal to the aggregate amount then
on deposit in the Trust Account, including interest (which interest shall be net of taxes payable, and less up to $
100,000
of
interest to pay dissolution expenses), divided by the number of then outstanding public shares, which redemption will completely extinguish
public shareholders' rights as shareholders (including the right to receive further liquidating distributions, if any), and (iii) as
promptly as reasonably possible following such redemption, subject to the approval of the Company's remaining shareholders and the
Company's board of directors, liquidate and dissolve, subject in each case to the Company's obligations under Cayman Islands
law to provide for claims of creditors and the requirements of other applicable law.
The
Sponsor and the Company's officers and directors have entered into a letter agreement with the Company, pursuant to which they have
waived their rights to liquidating distributions from the Trust Account with respect to any Class B ordinary share, including any
Class A ordinary share issuable upon conversion of such Class B ordinary shares, and Class A ordinary share (as described
in Note 7) held by them if the Company fails to complete the Initial Business Combination within 24 months (as was subsequently
extended) of the Closing of the Public Offering or during any extended time that the Company has to consummate an Initial Business Combination
beyond 24 months as a result of a shareholder vote to amend its amended and restated memorandum and articles of association. However,
if the Sponsor or any of the Company's directors or officers acquire any Class A ordinary shares subject to possible redemption,
they will be entitled to liquidating distributions from the Trust Account with respect to such shares if the Company fails to complete
the Initial Business Combination within the prescribed time period.
In
the event of a liquidation, dissolution or winding up of the Company after an Initial Business Combination, the Company's shareholders
are entitled to share ratably in all assets remaining available for distribution to them after payment of liabilities and after provision
is made for each class of stock, if any, having preference over the ordinary shares. The Company's shareholders have no preemptive
or other subscription rights. There are no sinking fund provisions applicable to the ordinary shares, except that the Company will provide
its shareholders with the opportunity to redeem their public shares for cash equal to their pro rata share of the aggregate amount then
on deposit in the Trust Account, under the circumstances, and, subject to the limitations, described herein.
F-28
MORINGA
ACQUISITION CORP
NOTES TO FINANCIAL STATEMENTS
NOTE
1 — DESCRIPTION OF ORGANIZATION AND BUSINESS OPERATIONS:
(cont.)
On
February 9, 2023 the Company held an extraordinary general meeting in lieu of the 2022 annual general meeting of the Company (hereafter — the
First Extension Meeting). At the First Extension Meeting, the Company's shareholders approved the proposal to adopt, by way of special
resolution, an amendment to the Amended and Restated Articles to extend the date by which the Company has to consummate a business combination
from the 24 month anniversary of the Closing of the Public Offering — i.e., February 19, 2023 to August 19,
2023 (hereafter — the Extended Mandatory Liquidation Date) or such earlier date as may be determined by the Board in its
sole discretion.
On
August 18, 2023 the Company held an extraordinary general meeting in lieu of the 2023 annual general meeting of the Company (hereafter — the
Second Extension Meeting). At the Second Extension Meeting, the Company's shareholders approved, among other proposals, an amendment
to the Amended and Restated Memorandum and Articles of Association to further extend the date by which the Company has to consummate a
business combination from the Extended Mandatory Liquidation Date to August 19, 2024 (hereafter — the Second Extended
Mandatory Liquidation Date) or such earlier date as may be determined by the Board in its sole discretion.
Refer
to Note 4(a) for information regarding proceeds received by the Company from the Sponsor under the Sixth and Eighth Promissory
Notes, which were deposited into the Trust Account.
Refer
to Note 7(a) for information regarding the partial redemptions of Class A ordinary shares subject to possible redemption,
following the First and Second Extension Meetings.
Refer
to Note 5(b) for information regarding the conversion of Class B ordinary shares into Class A ordinary shares, following
the Second Extension Meeting.
e.
Substantial Doubt about the
        Company's Ability to Continue as a Going Concern
As
of December 31, 2023 the Company had approximately $
108
thousand
of cash and an accumulated deficit of approximately $
2,848
thousand.
In connection with the Company's assessment of going concern considerations in accordance with Financial Accounting Standard Board's
Accounting Standard Codification 205-40, "Going Concern", the Company will need to obtain additional funds in order to
satisfy its liquidity needs in its endeavors to consummate a business combination.
Since
its inception date and through the issuance date of these financial statements, the Company's liquidity needs were satisfied through
an initial capital injection from the Sponsor, followed by net Private Placement proceeds, as well as several withdrawals of the Sponsor
promissory notes. Management has determined that it will need to continue to rely and is significantly dependent on both outstanding and
future promissory notes, or other forms of financial support (all of which the Sponsor is not obligated to provide). Moreover, following
the Second Extension Meeting, the Company has until August 19, 2024 to consummate an Initial Business Combination. If a business
combination is not consummated by this date, there will be a mandatory liquidation and subsequent dissolution of the Company. There can
be no assurance that the Company will be able to consummate any business combination ahead of the Second Extended Mandatory Liquidation
Date, nor will it be able to raise sufficient funds to complete an Initial Business Combination. These matters raise substantial doubt
about the Company's ability to continue as a going concern, for the subsequent twelve months following the issuance date of
these financial statements. In February 2024, the Company entered into a Business Combination Agreement with Silexion Therapeutics
Ltd. (hereafter — Silexion). Refer to Note 10(b) for further information regarding the Proposed Business Combination.
No
adjustments have been made to the carrying amounts of assets or liabilities should the company fail to obtain financial support in its
pursuit to consummate an Initial Business Combination, nor if it is required to liquidate after the Second Extended Mandatory Liquidation
Date.
F-29
MORINGA
ACQUISITION CORP
NOTES TO FINANCIAL STATEMENTS
NOTE
1 — DESCRIPTION OF ORGANIZATION AND BUSINESS OPERATIONS:
(cont.)
f.
Proposed Business Combination
On
June 9, 2022 the Company entered into a Business Combination Agreement for a proposed business combination (hereafter — the
Proposed Holisto Merger) with Holisto Ltd., a company organized under the laws of the State of Israel (hereafter — Holisto)
and Holisto MergerSub, Inc., a Cayman Islands exempted company and wholly-owned subsidiary of Holisto.
On
August 7, 2023 Holisto notified the Company that it was terminating the Proposed Holisto Merger agreement. The termination became
effective as of August 8, 2023. Upon termination of the Proposed Holisto Merger, all rights and obligations of each party to the
agreement ceased, except for those obligations of the parties that are intended to survive such termination and which remain in effect
in accordance with their respective terms. Neither the Company nor Holisto has any remaining substantive obligation to one another following
the above-mentioned termination, as of date of these financial statements.
In
February 2024, the Company entered into a Business Combination Agreement with Silexion. Refer to Note 10(b) for further
information regarding the Proposed Business Combination.
g.
Impact of War in Israel
On
October 7, 2023 Hamas terrorists infiltrated Israel's southern border from the Gaza Strip and conducted a series of attacks
on civilian and military targets. Hamas also launched extensive rocket attacks on Israeli population and industrial centers located along
Israel's border with the Gaza Strip and in other areas within the State of Israel. These attacks resulted in extensive deaths, injuries
and kidnapping of civilians and soldiers. Following the attack, Israel's security cabinet declared war against Hamas and a military
campaign against these terrorist organizations commenced in parallel to their continued rocket and terror attacks.
The
intensity and duration of Israel's current war against Hamas is difficult to predict, as are such war's economic implications
on the business and operations on any target company with which the Company may combine, and on Israel's economy in general. These
events may cause wider macroeconomic deterioration in Israel, which may have a material adverse effect on the Company's ability
to effectively complete an Initial Business Combination, or on the operations of an Israel-centered target company with which the Company
may combine.
Refer
to Note 10(b) for further information regarding the Proposed Business Combination.
NOTE
2 — SIGNIFICANT ACCOUNTING POLICIES:
a.
Basis of Presentation
The
Company's financial statements have been prepared in accordance with accounting principles generally accepted in the United States
of America ("U.S. GAAP") and the rules and regulations of the SEC.
b.
Emerging Growth Company
Section 102(b)(1) of
the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until
private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a class
of securities registered under the Exchange Act) are required to comply with the new or revised financial accounting standards.
The
JOBS Act provides that a company can elect to opt out of the extended transition period and comply with the requirements that apply
to non-emerging growth companies but any such election to opt out is irrevocable. The Company has elected not to opt out of such extended
transition period which means that
when a standard is issued or revised and it has different application dates for public
or private companies, the Company, as an emerging growth company, can adopt the new or revised standard at the time private companies
adopt the new or revised standard.
F-30
MORINGA
ACQUISITION CORP
NOTES TO FINANCIAL STATEMENTS
NOTE
2 — SIGNIFICANT ACCOUNTING POLICIES:
(cont.)
This
may make comparison of the Company's financial statements with another public company which is neither an emerging growth company
nor an emerging growth company which has opted out of using the extended transition period difficult or impossible, because of the potential
differences in accounting standards used.
c.
Cash and cash equivalents
The
Company considers as cash equivalents all short-term, highly liquid investments, which include short-term bank deposits with original
maturities of three months or less from the date of purchase that are not restricted as to withdrawal or use by nature of the account
and are readily convertible to known amounts of cash.
d.
Class A Ordinary Shares
        subject to possible redemption
As
discussed in Note 1(b), all of the
11,500,000
Class A
ordinary shares sold as part of the Units in the Public Offering contained a redemption feature. In accordance with the Accounting
Standards Codification 480-10-S99-3A "Classification and Measurement of Redeemable Securities", redemption provisions
not solely within the control of the Company require the security to be classified outside of permanent equity. The Company has classified
all of the shares sold under the Public Units as subject to possible redemption.
Refer
to Note 7(a) for information regarding the partial redemptions of Class A ordinary shares subject to possible redemption,
following the First Extension Meeting and the Second Extension Meeting.
e.
Net profit (loss) per share
The
Company complies with accounting and disclosure requirements of FASB ASC Topic 260, Earnings Per Share. Net profit (loss) per share
is computed by dividing net profit (loss) by the weighted average number of shares outstanding during the period. The Company applies
the two-class method in calculating net profit (loss) per each class of shares: the non-redeemable shares, which include the Private Class A
Ordinary Shares, as defined in Note 7(a), and the Class B ordinary shares (hereafter and collectively — Non-Redeemable
class A and B ordinary shares); and the Class A ordinary shares subject to possible redemption.
In
order to determine the net profit (loss) attributable to each class, the Company first considered the total profit (loss) allocable to
both sets of shares. This is calculated using the total net profit (loss) less any interest earned on investments held in the Trust Account.
Then, any accretion is fully allocated to the Class A ordinary shares subject to redemption.
f.
Concentration of credit risk
Financial
instruments that potentially subject the Company to concentrations of credit risk consist of cash accounts in a financial institution,
which, at times, may exceed the Federal Depository Insurance Coverage of $
250,000
.
From the Company's incorporation and through December 31, 2023 the Company has not experienced any losses on these accounts.
As
of December 31, 2023 the Company held its cash and cash equivalents in an SVB bank account, and its investments Held in Trust Account
in Goldman Sachs money market funds. Money market funds are characterized as Level 1 investments within the fair value hierarchy under
ASC 820.
F-31
MORINGA
ACQUISITION CORP
NOTES TO FINANCIAL STATEMENTS
NOTE
2 — SIGNIFICANT ACCOUNTING POLICIES:
(cont.)
g.
Public Warrants
The
Company applied the provisions of ASC 815-40 and classified its public warrants, issued as part of the Public Units as detailed
in Note 3, as equity securities.
h.
Private Warrant liability
The
Company accounts for the warrants in accordance with the guidance contained in Accounting Standards Codification 815 ("ASC 815"),
"Derivatives and Hedging", under which the warrants do not meet the criteria for equity treatment and must be recorded as
derivative liabilities. Accordingly, the Company classifies the warrants as liabilities at their fair value and adjusts the warrants to
fair value at each reporting period. This liability is subject to re-measurement at each balance sheet date until the warrants are exercised
or expire, and any change in fair value is recognized in the Company's statement of operations. Refer to Note 6 for information
regarding the model used to estimate the fair value of the Private Warrants (as defined in Note 3).
i.
Financial instruments
The
fair value of the Company's assets and liabilities, which qualify as financial instruments under the FASB ASC 820, "Fair
Value Measurements and Disclosures", approximates the carrying amounts represented in the balance sheet, primarily due to their
short-term nature.
j.
Use
        of estimates in the preparation of financial statements
The
preparation of the financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect
the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements
and the reported amounts of expenses during the reporting period. Actual results may differ from those estimates and such differences
may have a material impact on the Company's financial statements.
k.
Income
        tax
The
Company accounts for income taxes in accordance with ASC 740, "Income Taxes (hereafter — ASC 740). ASC 740
prescribes the use of the liability method whereby deferred tax asset and liability account balances are determined based on differences
between the financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws that will
be in effect when the differences are expected to reverse. The Company provides a valuation allowance, if necessary, to reduce deferred
tax assets to their estimated realizable value if it is more likely than not that a portion or all of the deferred tax assets will not
be realized, based on the weight of available positive and negative evidence. Deferred tax liabilities and assets are classified as non-current
in accordance with ASU 2015-17.
l.
Recent accounting pronouncements
Management
does not believe that any recently issued, but not yet effective, accounting pronouncements, if currently adopted would have a material
effect on the Company's financial statements.
NOTE
3 — PUBLIC OFFERING AND PRIVATE PLACEMENTS:
In
the initial Public Offering, the Company issued and sold
11,500,000
units
(including
1,500,000
units
sold at a second closing pursuant to the underwriters' exercise of their over-allotment option in full) at an offering price of
$
10.00
per
unit (hereafter — the Units). The Sponsor and EarlyBirdCapital, Inc. (the representative of the underwriters) purchased,
in a private placement that occurred simultaneously with the two closings of the initial Public Offering (hereafter — the
Private Placement), an aggregate of
352,857
and
27,143
Units,
respectively, at a price of $
10.00
per
Unit.
F-32
MORINGA
ACQUISITION CORP
NOTES TO FINANCIAL STATEMENTS
NOTE
3 — PUBLIC OFFERING AND PRIVATE PLACEMENTS:
(cont.)
Each
Unit (both those sold in the initial Public Offering and in the Private Placement) consists of one Class A ordinary share, $
0.0001
par
value, and one-half of one warrant, with each whole warrant exercisable for one Class A ordinary share (hereafter — each,
a Public Warrant and a Private Warrant, and collectively, the Warrants). Each Warrant entitles the holder thereof to purchase one whole
Class A ordinary share at a price of $
11.50
per
share, subject to adjustment. No fractional shares will be issued upon exercise of the Warrants and only whole Warrants trade. Each Warrant
will become exercisable 30 days after the completion of the Company's Initial Business Combination and will expire at 5:00 p.m.,
New York City time, five years after the completion of the Initial Business Combination or earlier upon redemption (only in
the case of the Public Warrants) or liquidation.
Once
the Public Warrants become exercisable, the Company may redeem them in whole and not in part at a price of $
0.01
per
Warrant upon a minimum of 30 days' prior written notice of redemption, if and only if the last reported sale price of the Company's
Class A ordinary shares equals or exceeds $
18.00
per
share (as adjusted) for any 20 trading days within a 30-trading day period ending on the third trading day prior to the
date on which the Company sends the notice of redemption to the Public Warrant holders.
The
Private Warrants are identical to the Public Warrants except that, for so long as they are held by the Sponsor, EarlyBirdCapital, Inc.
or their respective affiliates: (1) will not be redeemable by the Company; (2) may not (including the Class A ordinary
shares issuable upon exercise thereof), subject to certain limited exceptions, be transferred, assigned or sold by the holders thereof
until 30 days after the completion of the Company's Initial Business Combination; (3) may be exercised by the holders
thereof on a cashless basis; and (4) they (including the Class A ordinary shares issuable upon exercise thereof) are entitled
to registration rights.
The
Company paid an underwriting commission of
2.0
%
of the gross proceeds of the Public Offering and the full exercise of the underwriters' over-allotment, or $
2,300,000
,
in the aggregate, to the underwriters at the two closings of the Public Offering. Refer to Note 5(a) for more information regarding
an additional fee payable to the underwriters upon the consummation of an Initial Business Combination.
NOTE
4 — RELATED PARTY TRANSACTIONS:
a.
Promissory Notes
The
Company has issued several promissory note agreements to its Sponsor throughout its life term, in order to fulfil its ongoing operational
needs or preparations towards an Initial Business Combination. All outstanding promissory notes bear no interest and are repayable in
full upon the earlier of (a) the date of the consummation of the Company's Initial Business Combination, or (b) Second
Extended Mandatory Liquidation Date (hereafter and collectively — the Maturity Date).
First
Promissory Note
The
First Promissory Note withdrawn was borrowed and repaid in full in early 2021 and has subsequently expired.
Second
to Fifth Promissory Notes
On
August 9, 2021 the Company issued its Second Promissory Note to the Sponsor, according to which the former may withdraw up to $
1
million — which
has been withdrawn in full in several installments up until June 2022.
In
December 2022 the Company issued its Third and Fourth Promissory Notes (hereafter — the Third and Fourth Promissory
Notes), according to which the Company may withdraw up to an aggregate amount of $
190
thousand — which
were withdrawn in full on the same month.
F-33
MORINGA
ACQUISITION CORP
NOTES TO FINANCIAL STATEMENTS
NOTE
4 — RELATED PARTY TRANSACTIONS:
(cont.)
On
February 8, 2023 the Company issued its Fifth Promissory Note to the Sponsor, in an amount of up to $
310
thousand,
which were withdrawn in full in several installments between February and June 2023.
According
to the terms of the outstanding Second, Third, Fourth and Fifth Promissory Notes, which comprise an aggregate principal of $
1.5
million,
the Sponsor may elect to convert any portion of the amounts outstanding into private warrants to purchase Class A ordinary shares
at a conversion price of $
1
per
private warrant on the Maturity Date. Such private warrants will have an exercise price of $
11.5
and
shall be identical to the private warrants included in the private units.
Sixth
Promissory Note
On
February 9, 2023 the Company issued its Sixth Promissory Note to the Sponsor, in an amount of $
480
thousand — under
which the funds that were loaned by the Sponsor were deposited into the Company's Trust Account, in connection with the First Extension.
The Sponsor provided six monthly injections of $
80
thousand
into the Company's Trust Account under the Sixth Promissory Note, starting February 19, 2023.
Seventh
Promissory Note
On
June 14, 2023 the Company issued its Seventh Promissory Note to the Sponsor in an amount of up to $
1
million,
of which $
210
thousand
were withdrawn at the same date; and approximately $
586
thousand
were withdrawn up until December 31, 2023.
Eighth
Promissory Note
On
August 18, 2023 the Company issued its Eighth Promissory Note to the Sponsor, in an amount of approximately $
154
thousand — under
which the funds that were loaned by the Sponsor were deposited into the Company's Trust Account, in connection with the Second Extension.
The Sponsor shall make monthly injections of approximately $
13
thousand
into the Company's Trust Account, starting August 19, 2023 and up until the earlier of the Second Extended Mandatory Liquidation
Date (or such earlier date that the Board determines to liquidate the Company) or the date on which an Initial Business Combination is
completed.
b.
Administrative Services Agreement
On
December 16, 2020 the Company signed an agreement with the Sponsor, under which the Company shall pay the Sponsor a fixed $
10
thousand
per month for office space, utilities and other administrative expenses. The monthly payments under this administrative services agreement
commenced on the effective date of the registration statement for the initial Public Offering and will continue until the earlier of (i) the
consummation of the Company's Initial Business Combination, or (ii) the Company's liquidation.
The
composition of the Related Party balance as of December 31, 2023 and 2022 is as follows:
December 31,
2023
December 31,
2022
U.S. dollars
Promissory notes
2,841,000
1,190,000
Accrual for Administrative Services Agreement
20,000
-
2,861,000
1,190,000
F-34
MORINGA
ACQUISITION CORP
NOTES TO FINANCIAL STATEMENTS
NOTE
5 — COMMITMENTS AND CONTINGENCIES:
a.
Underwriters' Deferred
        Discount
Under
the Business Combination Marketing Agreement, the Company shall pay an additional fee (hereafter — the Deferred Commission)
of
3.5
%
of the gross proceeds of the Public Offering (or $
4,025,000
)
payable upon the Company's completion of the Initial Business Combination. The Deferred Commission will become payable to the underwriters
from the amounts held in the Trust Account solely in the event the Company completes an Initial Business Combination.
b.
Nasdaq Deficiency Notices
First
Deficiency Notice
On
March 28, 2023 the Company received a notice from the Nasdaq Listing Qualifications Department indicating that it is not in compliance
with Nasdaq Listing Rule 5550(a)(3) (hereafter — the First Deficiency), according to which the Company must
satisfy the Minimum Public Holders Rule which requires listed companies to have at least 300 public holders. The Company has submitted
its compliance plan on May 11, 2023 which was accepted by Nasdaq, which has then granted an extension of up to 180 calendar days
from the date of the notice — until September 24, 2023 — to evidence compliance with the rule.
On
September 27, 2023 the Company received a notice from the Nasdaq Listing Qualifications Department indicating that it has regained
compliance with the First Deficiency.
Second
Deficiency Notice
On
June 15, 2023 the Company received another notice from Nasdaq Listing Qualifications Department indicating that it is not in compliance
with Nasdaq Listing Rule 5550(b)(2) (hereafter — the Second Deficiency), according to which the Company must
sustain a market value of listed securities of at least $
35
million,
for continued listing on the Nasdaq Capital Market. The notice was only a notification of deficiency, not of imminent delisting, and has
no current effect on the listing or trading of the Company's securities on the Nasdaq Capital Market.
NOTE
6 — FAIR VALUE MEASUREMENTS:
Following
the Second Extension Meeting, the Sponsor converted
2,874,999
of
its Class B ordinary shares on a one to one basis into Class A ordinary shares, in an effort to regain compliance with the Second
Deficiency.
On
November 24, 2023 the Company received a notice from the Nasdaq Listing Qualifications Department indicating that it has regained
compliance with the Second Deficiency.
The
fair value of a financial instrument is the amount that would be received to sell an asset or paid to transfer a liability in an orderly
transaction between market participants at the measurement date (i.e., the exit price).
The
fair value hierarchy under ASC 820 prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy gives
the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the
lowest priority to unobservable inputs (Level 3 measurements). The three levels of the fair value hierarchy are as follows:
Level
1: Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities;
F-35
MORINGA
ACQUISITION CORP
NOTES TO FINANCIAL STATEMENTS
NOTE
6 — FAIR VALUE MEASUREMENTS:
(cont.)
Level
2: Quoted prices in markets that are not active or financial instruments for which significant inputs to models are observable (including
but not limited to quoted prices for similar securities, interest rates, foreign exchange rates, volatility and credit risk), either directly
or indirectly;
Level
3: Prices or valuations that require significant unobservable inputs (including the Management's assumptions in determining fair
value measurement).
Basis
for Fair Value Measurement
The
following table presents information about the Company's assets and liabilities that are measured at fair value on a recurring basis
at December 31, 2023 by level within the fair value hierarchy:
Level
December 31,
2023
December 31,
2022
Assets:
Money market funds held in Trust Account
1
5,697,632
116,692,038
Liabilities:
Private warrant liability
3
8,531
29,640
The
estimated fair value of the Private Placement Warrants was determined using a binomial model to extract the market's implied probability
for an Initial Business Combination, using the Public Warrant's market price. Once probability was extracted, a Black-Scholes-Merton
model with Level 3 inputs was used to calculate the Private Warrants' fair value. Inherent in a Black-Scholes-Merton model are assumptions
related to expected life (term), expected stock price, volatility, risk-free interest rate and dividend yield. The Company estimates the
volatility of its warrants based on implied volatility from the Company's traded warrants and from historical volatility of selected
peer companies' Class A ordinary shares that matches the expected remaining life of the warrants. The risk-free interest rate
is based on the U.S. Treasury zero-coupon yield curve on the grant date for a maturity similar to the expected remaining life of
the warrants. The expected life of the warrants is assumed to be equivalent to their remaining contractual term. The dividend rate is
based on the historical rate, which the Company anticipates remaining at zero.
The
following table provides quantitative information regarding Level 3 fair value measurements inputs:
As of
December 31,
2023
As of
December 31,
2022
Share price
$
10.0
$
10.0
Strike price
$
11.5
$
11.5
Volatility
60
%
50
%
Risk-free interest rate
4.78
%
4.00
%
Dividend yield
0.00
%
0.00
%
U.S. dollars
Value of warrant liability measured with Level 3 inputs at December 31, 2022
29,640
Change in fair value of private warrant liability measured with Level 3 inputs
(
21,109
)
Value of warrant liability measured with Level 3 inputs at December 31, 2023
8,531
F-36
MORINGA
ACQUISITION CORP
NOTES TO FINANCIAL STATEMENTS
NOTE
7 — CAPITAL DEFICIENCY:
a.
Ordinary Shares
Class A
Ordinary Shares
On
November 20, 2020 the Company issued
100,000
Class A
ordinary shares of $
0.0001
par
value each to designees of the Representative (hereafter — the Representative Shares) for a consideration equal to the
par value of the shares. The Representative Shares are deemed to be underwriters' compensation by FINRA pursuant to Rule 5110
of the FINRA Manual.
The
Company accounted for the issuance of the Representative Shares as compensation expenses amounting to $
860
,
with a corresponding credit to Additional Paid-In Capital, for the excess value over the consideration paid. The Company estimated the
fair value of the issuance based upon the price of Class B Ordinary Shares that were issued to the Sponsor.
Pursuant
to the initial Public Offering and the concurrent Private Placement that were each effected in two closings — on February 19,
2021 and March 3, 2021 — the Company issued and sold an aggregate of
11,500,000
and
380,000
Class A
ordinary shares as part of the Units sold in those respective transactions. The Units (which also included Warrants) were sold
at a price of $
10
per
Unit, and for an aggregate consideration of $
115
million
and $
3.8
million
in the Public Offering and Private Placement, respectively. See Note 3 above for further information regarding those share issuances.
The
Company classified its
11,500,000
Class A
ordinary shares subject to possible redemption as temporary equity. The remaining
480,000
Private
Class A ordinary shares were classified as permanent equity.
In
conjunction with the First and Second Extensions,
8,910,433
and
2,074,548
Class A
Ordinary Shares subject to possible redemption were redeemed, respectively, for their redemption value, including accrued interest. As
part of the partial redemptions approximately $
113
million
has been withdrawn from the Investments held in Trust Account.
Class B
Ordinary Shares
On
November 20, 2020 the Company issued
2,875,000
Class B
ordinary shares of $
0.0001
par
value each for a total consideration of $
25
thousand
to the Sponsor's wholly-owned Delaware subsidiary. Out of the
2,875,000
Class B
ordinary shares, up to
375,000
were
subject to forfeiture if the underwriters were to not exercise their over-allotment in full or in part. Because the underwriters exercised
their over-allotment option in full on March 3, 2021 that potential forfeiture did not occur.
Class B
ordinary shares are convertible into non-redeemable Class A ordinary shares, on a one-for-one basis, automatically on the day
of the Business Combination or at the election of the holder thereof at any time prior to the Business Combination. Class B ordinary
shares also possess the sole right to vote for the election or removal of directors, until the consummation of an Initial Business Combination.
Refer
to Note 5(b) for information regarding the conversion of Class B ordinary shares into Class A ordinary shares following
the Second Extension Meeting.
b.
Preferred shares
The
Company is authorized to issue up to
5,000,000
Preferred
Shares of $
0.0001
par
value each. As of December 31, 2023 the Company has
no
preferred shares issued and outstanding.
F-37
MORINGA
ACQUISITION CORP
NOTES TO FINANCIAL STATEMENTS
NOTE
8 — NET PROFIT (LOSS) PER SHARE:
The
following table reflects the calculation of basic and diluted net profit (loss) per share (in dollars, except share amounts):
Year ended
December 31,
2023
2022
Net profit for the year
$
263,073
$
584,025
Less – interest earned on Investment
        held in Trust Account
(
1,364,444
)
(
1,685,666
)
Net loss excluding interest
$
(
1,101,371
)
$
(
1,101,641
)
Class A ordinary shares subject to possible redemption:
Numerator:
Net loss excluding interest
$
(
498,567
)
$
(
852,835
)
Accretion to Class A ordinary shares subject
        to possible redemption to redemption amount ("Accretion")
1,908,820
1,685,666
$
1,410,253
$
832,831
Denominator:
Weighted average number of shares
2,774,850
11,500,000
Basic and diluted net profit per
        Class A ordinary share subject to possible redemption
$
0.51
$
0.07
Non-redeemable Class A and B ordinary shares:
Numerator:
Net loss excluding interest
$
(
602,804
)
$
(
248,806
)
Accretion
(
544,376
)
-
(1,147,180
)
(248,806
)
Denominator:
Weighted average number of shares
3,355,000
3,355,000
Basic and diluted net loss per non-redeemable
        Class A and B ordinary share
$
(
0.34
)
$
(
0.07
)
The
potential exercise of
5,750,000
Public
Warrants and
190,000
Private
Warrants sold in the Public Offering and Private Placements as detailed in Note 3 into
5,940,000
shares
has not been included in the calculation of diluted net profit (loss) per share, since the exercise of the warrants is contingent upon
the occurrence of a future event.
Additionally,
the effect of the conversion of the Second, Third, Forth and Fifth Promissory Notes into an aggregate amount of
1,500,000
private
warrants (exercisable into
1,500,000
shares) as detailed in Note 4, has not been included in the calculation of diluted net profit (loss) per share, since the conversion
of the abovementioned promissory notes is contingent upon the occurrence of a future event.
As
a result, diluted net profit (loss) per share is the same as basic net profit (loss) per share for each of the periods presented, and
for each class.
F-38
MORINGA
ACQUISITION CORP
NOTES TO FINANCIAL STATEMENTS
NOTE
9 — GENERAL AND ADMINISTRATIVE:
The
formation and other operating expenses for the years ended December 31, 2023 and 2022 are as follows:
December 31,
2023
December 31,
2022
U.S. dollars
Legal expenses
259,000
398,903
Audit, bookkeeping and accounting
146,600
143,101
Professional services
245,538
115,651
Management fees
120,000
120,000
Insurance
281,044
325,000
Nasdaq fees
70,000
129,500
Other
298
187
1,122,480
1,232,342
NOTE
10 — SUBSEQUENT EVENTS:
a.
Nasdaq Deficiency Note
On
February 20, 2024, the Company received a notice from the staff of the Listing Qualifications Department of The Nasdaq Stock Market
LLC indicating that unless the Company timely requests a hearing before the Nasdaq Hearings Panel (hereafter — the Panel),
trading of the Company's securities on The Nasdaq Capital Market would be suspended at the opening of business on February 29,
2024, due to the Company's non-compliance with Nasdaq IM-5101-2, which requires that a special purpose acquisition company complete
one or more business combinations within 36 months of the effectiveness of its IPO registration statement.
The
Company timely requested a hearing before the Panel to request sufficient time to complete its previously disclosed proposed business
combination with Silexion. The hearing request has resulted in a stay of any suspension or delisting action pending the hearing, which
is scheduled to take place on April 23, 2024.
b.
Proposed Business Combination
On
February 21, 2024, the Company, together with its wholly-owned Israeli subsidiary (hereafter — the Merger Sub), entered
into a business combination agreement (hereafter — the BCA) with Silexion Therapeutics Ltd., an Israeli company (hereafter — Silexion).
The Business
Combination is expected to close in the third quarter of 2024, subject to the satisfaction of customary closing conditions under the BCA,
including the approval of the Business Combination by Silexion's and the Company's shareholders, and Nasdaq approval of the
initial listing of the combined company's securities.
Headquartered
in Israel, Silexion is a clinical-stage, oncology-focused biotechnology company that develops innovative treatments for unsatisfactorily
treated solid tumor cancers which have a mutated KRAS oncogene. The Business Combination values Silexion at a pre-transaction equity value
of $
62.5
million,
based on a $
10
price
per share.
The
BCA and the Business Combination have been unanimously approved by the boards of directors of the Company and Silexion.
F-39
SILEXION
THERAPEUTICS CORP
UNAUDITED
CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
SEPTEMBER
30, 2024
F-40
SILEXION
THERAPEUTICS CORP
INTERIM
FINANCIAL STATEMENTS
SEPTEMBER
30, 2024
(Unaudited)
TABLE
OF CONTENTS
Page
CONSOLIDATED
        FINANCIAL STATEMENTS:
Condensed
        Consolidated Balance Sheets (unaudited)
F-42
        - F-44
Condensed
        Consolidated Statements of Operations (unaudited)
F-45
Condensed
        Consolidated Statements of Changes in Redeemable Convertible Preferred Shares and Capital Deficiency (unaudited)
F-46
        - F-47
Condensed
        Consolidated Statements of Cash Flows (unaudited)
F-48
        - F-49
Notes
        to Condensed Consolidated Financial Statements (unaudited)
F-50
        - F-64
__________________________
______________________________________
__________________________
F-41
SILEXION
THERAPEUTICS CORP
UNAUDITED
CONDENSED CONSOLIDATED BALANCE SHEETS
September
        30,
December
        31
2024
2023
U.S.
        dollars in thousands
Assets
CURRENT
        ASSETS:
Cash
        and cash equivalents
$
1,973
$
4,595
Restricted
        cash
50
25
Prepaid
        expenses
944
335
Other
        current assets
80
24
TOTAL
        CURRENT ASSETS
3,047
4,979
NON-CURRENT
        ASSETS:
Restricted
        cash
-
25
Long-term
        deposit
5
5
Property
        and equipment, net
35
49
Operating
        lease right-of-use asset
-
198
TOTAL
        NON-CURRENT ASSETS
40
277
TOTAL
        ASSETS
$
3,087
$
5,256
The
accompanying notes are an integral part of the unaudited condensed consolidated financial statements.
F-42
SILEXION
THERAPEUTICS CORP
UNAUDITED
CONDENSED CONSOLIDATED BALANCE SHEETS
September
        30,
December
        31
2024
2023
U.S.
        dollars in thousands
Liabilities
        and redeemable convertible preferred shares, net of capital deficiency
CURRENT
        LIABILITIES:
Trade
        payables
$
799
$
319
Current
        maturities of operating lease liability
-
112
Warrants
        to preferred shares (including $
0
and $
186
due to related party, as of September 30, 2024 and December 31, 2023, respectively)
-
200
Employee
        related obligations
687
207
Accrued
        expenses and other account payable
1,858
1,358
Private warrants to purchase
        ordinary shares
10
-
Underwriters
        Promissory Note
229
-
TOTAL
        CURRENT LIABILITIES
3,583
2,196
NON-CURRENT
        LIABILITIES:
Long-term
        operating lease liability
-
59
Underwriters
        Promissory Note
977
-
Promissory
        note - related party
3,106
-
TOTAL
        NON-CURRENT LIABILITIES
$
4,083
$
59
TOTAL
        LIABILITIES
$
7,666
$
2,255
COMMITMENTS
        AND CONTINGENT LIABILITIES
REDEEMABLE
        CONVERTIBLE PREFERRED SHARES AND NON-CONTROLLING INTERESTS:
Convertible
        Series A Preferred Shares (NIS
0.09
par
        value,
0
and
56,667
shares authorized as of September 30, 2024 and December 31, 2023, respectively;
0
and
43,121
shares
        issued and outstanding as of September 30, 2024 and December 31, 2023, respectively);
Convertible
        Series A-1 Preferred Shares (NIS
0.09
par
        value per share,
0
and
13,334
shares authorized as of September 30, 2024 and December 31, 2023, respectively;
0
and
10,136
shares issued and outstanding as of September 30, 2024 and December 31, 2023, respectively);
Convertible
        Series A-2 Preferred Shares (NIS
0.09
par
        value per share,
0
and
22,223
shares authorized as of September 30, 2024 and December 31, 2023, respectively;
0
and
5,051
shares
        issued and outstanding as of September 30, 2024 and December 31, 2023, respectively);
Convertible
        Series A-3 Preferred Shares (NIS
0.09
par
        value per share,
0
and
8,889
shares authorized as of September 30, 2024 and December 31, 2023, respectively
0
and
7,037
shares
        issued and outstanding as of September 30, 2024 and December 31, 2023, respectively);
Convertible Series A-4
        Preferred Shares (NIS
0.09
par
        value per share,
0
and
90,556
shares authorized as of September 30, 2024 and December 31, 2023, respectively;
0
and
2,413
**
        shares issued and outstanding as of September 30, 2024 and December 31, 2023, respectively);
TOTAL
        REDEEMABLE CONVERTIBLE PREFERRED SHARES
-
15,057
CONTINGENTLY
        REDEEMABLE NON-CONTROLLING INTERESTS
-
3,420
TOTAL
        REDEEMABLE CONVERTIBLE PREFERRED SHARES AND CONTINGENTLY REDEEMABLE NON-CONTROLLING INTERESTS
$
-
$
18,477
F-43
SILEXION
THERAPEUTICS CORP
UNAUDITED
CONDENSED CONSOLIDATED BALANCE SHEETS
September
        30,
December
        31,
2024
2023
U.S.
        dollars in thousands
CAPITAL
        DEFICIENCY:
Ordinary
        shares ($
0.0009
par
        value per share,
22,222,222
shares
        authorized as of September 30, 2024 and December 31, 2023;
1,242,267
and
97,120
shares
        issued and outstanding as of September 30, 2024 and December 31, 2023, respectively)
1
*
Additional
        paid-in capital
37,003
11,335
Accumulated
        deficit
(
41,583
)
(
26,811
)
TOTAL
        CAPITAL DEFICIENCY
$
(
4,579
)
$
(
15,476
)
TOTAL
        REDEEMABLE CONVERTIBLE PREFERRED SHARES AND CONTINGENTLY REDEEMABLE NON-CONTROLLING INTERESTS, NET OF CAPITAL DEFICIENCY
$
(
4,579
)
$
3,001
TOTAL
        LIABILITIES, REDEEMABLE CONVERTIBLE
PREFERRED
        SHARES AND NON-CONTROLLING INTEREST NET OF CAPITAL DEFICIENCY
$
3,087
$
5,256
*
Represents an amount less than $1
**
Net of 13,458 treasury shares held by the subsidiary as of December 31, 2023
The
accompanying notes are an integral part of the unaudited condensed consolidated financial statements.
F-44
SILEXION
THERAPEUTICS CORP
UNAUDITED
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
Nine
        months ended
September
        30
Three
        months ended
September
        30,
2024
2023
2024
2023
U.S.
        dollars in
thousands
U.S.
        dollars in
thousands
U.S.
        dollars in
thousands
OPERATING
        EXPENSES:
Research
        and development (including $
1,796
and $
51
from related party for the nine months period ended September 30, 2024 and 2023, respectively, and including $
1,762
and $
17
from related party for the three months period ended September 30, 2024 and 2023, respectively)
$
4,944
$
2,451
$
3,217
$
535
General
        and administrative (including $
2,972
and $
36
from related party for the nine months period ended September 30, 2024 and 2023, respectively, and including $
2,948
and $
12
from related party for the three months period ended September 30, 2024 and 2023, respectively)
5,727
502
4,819
196
TOTAL
        OPERATING EXPENSES
10,671
2,953
8,036
731
OPERATING
        LOSS
10,671
2,953
8,036
731
Financial
        expenses (income), (including $(
47
)
        and $
40
from related party for the nine months period ended September 30, 2024 and 2023, respectively, and including $(
182
)
        and $
40
from related party for the three months period ended September 30, 2024 and 2023, respectively)
4,092
449
3,822
72
LOSS
        BEFORE INCOME TAX
$
14,763
$
3,402
$
11,858
$
803
INCOME
        TAX
9
26
2
6
NET
        LOSS
$
14,772
$
3,428
$
11,860
$
809
Attributable to:
Equity holders of the
        Company
$
14,696
$
3,214
$
11,851
$
787
Non-controlling interests
76
214
9
22
$
14,772
$
3,428
$
11,860
$
809
LOSS
        PER SHARE, BASIC AND DILUTED
$
50.43
$
28.76
$
18.30
$
7.04
WEIGHTED
        AVERAGE NUMBER OF ORDINARY SHARES OUTSTANDING USED IN COMPUTATION OF BASIC AND DILUTED LOSS PER SHARE
291,407
111,726
647,568
111,726
The
accompanying notes are an integral part of the unaudited condensed consolidated financial statements.
F-45
SILEXION
THERAPEUTICS CORP
UNAUDITED
CONDENSED CONSOLIDATED STATEMENTS
OF
CHANGES IN
REDEEMABLE CONVERTIBLE PREFERRED SHARES AND CAPITAL DEFICIENCY
(U.S.
dollars in thousands, except per share data)
Redeemable
        Convertible Preferred Shares
Ordinary
        shares
Additional
paid-in
        Capital
Accumulated
        deficit
Total
capital
deficiency
Total
        redeemable convertible preferred shares and contingently redeemable non-controlling interests, net of capital deficiency
Series
        A preferred shares
Series
        A-1 preferred shares
Series
        A-2 preferred shares
Series
        A-3 preferred shares
Series
        A-4 preferred shares
Contingently
        redeemable non-controlling
interests
Shares
Amount
Shares
Amount
Shares
Amount
Shares
Amount
Shares
Amount
Amount
Shares
Amount
BALANCE
        AT JANUARY 1, 2023
43,121
$
7,307
10,136
$
2,392
5,051
$
2,264
7,037
$
2,683
-
-
$
3,586
97,120
*
$
11,204
$
(
21,869
)
$
(
10,665
)
$
7,567
CHANGES
        DURING THE NINE MONTHS PERIOD ENDED SEPTEMBER 30, 2023
(unaudited):
Issuance
        of Preferred A-4 shares, net of issuance cost
2,413
$
411
1
1
412
Share-based
        compensation
96
96
96
Net
        loss
(
214
)
(
3,214
)
(
3,214
)
(
3,428
)
BALANCE
        AS OF SEPTEMBER 30, 2023
43,121
$
7,307
10,136
$
2,392
5,051
$
2,264
7,037
$
2,683
2,413
$
411
$
3,372
97,120
*
$
11,301
$
(
25,083
)
$
(
13,782
)
$
4,647
BALANCE
        AT JANUARY 1, 2024
43,121
$
7,307
10,136
$
2,392
5,051
$
2,264
7,037
$
2,683
2,413
$
411
$
3,420
97,120
*
$
11,335
$
(
26,811
)
$
(
15,476
)
$
3,001
CHANGES
        DURING THE NINE MONTHS PERIOD ENDED SEPTEMBER 30, 2024
(unaudited):
Exercise
        of options
13,780
**
*
*
*
Share-based
        compensation
78,650
*
5,862
5,862
5,862
Issuance
        of convertible preferred shares upon net exercise of warrants
140
925
334
-
-
-
334
Net
        loss
(
76
)
76
(
14,772
)
(
14,696
)
(
14,772
)
Conversion
        of convertible preferred shares and noncontrolling interests upon the effectiveness of the SPAC Merger (see Note 1(d))
(
43,121
)
$
(
7,307
)
(
10,276
)
$
(
2,392
)
(
5,051
)
$
(
2,264
)
(
7,037
)
$
(
2,683
)
(
3,338
)
$
(
745
)
$
(
3,344
)
478,073
1
18,734
18,735
-
Issuance
        of ordinary shares upon Transactions (see Note 1(d))
417,375
*
*
*
Issuance
        of ordinary shares for ELOC holders
157,269
*
996
996
996
BALANCE
        AS OF SEPTEMBER 30, 2024
-
-
-
-
-
-
-
-
-
-
-
1,242,267
$
1
$
37,003
$
(
41,583
)
$
(
4,579
)
$
(
4,579
)
*
Represents an amount less than $1
**
Represents fully vested pre-funded options for the Company's ordinary shares at an exercise price of $0.0226 or 0.0226 NIS per share
The
accompanying notes are an integral part of the unaudited condensed consolidated financial statements.
F-46
SILEXION
THERAPEUTICS CORP
UNAUDITED
CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN REDEEMABLE CONVERTIBLE PREFERRED SHARES AND CAPITAL DEFICIENCY
(U.S.
dollars in thousands, except per share data)
Redeemable
        Convertible Preferred Shares
Ordinary
        shares
Additional
paid-in
        Capital
Accumulated
        deficit
Total
        capital deficiency
Total
        redeemable convertible preferred shares and contingently redeemable non-controlling interests, net of capital deficiency
Series
        A preferred shares
Series
        A-1 preferred shares
Series
        A-2 preferred shares
Series
        A-3 preferred shares
Series
        A-4 preferred shares
Contingently
        redeemable non-controlling
interests
Shares
Amount
Shares
Amount
Shares
Amount
Shares
Amount
Shares
Amount
Amount
Shares
Amount
BALANCE
        AT JUNE 30, 2023
43,121
$
7,307
10,136
$
2,392
5,051
$
2,264
7,037
$
2,683
2,413
$
411
$
3,394
97,120
*
$
11,269
$
(
24,296
)
$
(
13,027
)
$
5,424
CHANGES
        DURING THE THREE MONTHS PERIOD ENDED SEPTEMBER 30, 2023
(unaudited):
Issuance
        of Preferred A-4 shares, net of issuance cost
Share-based
        compensation
32
32
32
Net
        loss
(
22
)
(
787
)
(
787
)
(
809
)
BALANCE
        AS OF SEPTEMBER 30, 2023
43,121
$
7,307
10,136
$
2,392
5,051
$
2,264
7,037
$
2,683
2,413
$
411
$
3,372
97,120
*
$
11,301
$
(
25,083
)
$
(
13,782
)
$
(
4,647
)
BALANCE
        AT JUNE 30, 2024
43,121
$
7,307
10,136
$
2,392
5,051
$
2,264
7,037
$
2,683
2,413
$
411
$
3,353
110,900
*
$
11,399
$
(
29,656
)
$
(
18,257
)
$
153
CHANGES
        DURING THE THREE MONTHS PERIOD ENDED SEPTEMBER 30, 2024
(unaudited)
:
Share-based
        compensation
78,650
*
5,798
5,798
5,798
Issuance
        of convertible preferred shares upon net exercise of warrants
140
925
334
-
-
334
Net
        loss
(
9
)
76
(
11,927
)
(
11,851
)
(
11,860
)
Conversion
        of convertible preferred shares and noncontrolling interests upon the effectiveness of the SPAC Merger (see Note 1(d))
(
43,121
)
$
(
7,307
)
(
10,276
)
$
(
2,392
)
(
5,051
)
$
(
2,264
)
(
7,037
)
$
(
2,683
)
(
3,338
)
$
(
745
)
$
(
3,344
)
478,073
1
18,734
18,735
-
Issuance
        of ordinary shares upon Transactions (see Note 1(d))
417,375
*
*
*
*
Issuance
        of ordinary shares for ELOC holders, net of issuance cost, see Note 3(d)
157,269
*
996
996
996
BALANCE
        AS OF SEPTEMBER 30, 2024
-
-
-
-
-
-
-
-
-
-
-
1,242,267
$
1
$
37,003
$
(
41,583
)
$
(
4,579
)
$
(
4,579
)
*
Represents an amount less than $1
The
accompanying notes are an integral part of the unaudited condensed consolidated financial statements.
F-47
SILEXION THERAPEUTICS CORP
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
Nine months ended
September 30,
Three months ended
September 30
2024
2023
2024
2023
U.S. dollars in thousands
U.S. dollars in thousands
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss
$
(
14,772
)
$
(
3,428
)
$
(
11,860
)
$
(
809
)
Adjustments required to reconcile loss to net cash used in operating
        activities:
Depreciation
37
39
22
10
Share-based compensation expenses
5,862
96
5,798
32
Non-cash financial expenses
3,968
365
3,749
108
Gain on disposal of property and equipment
-
(
1
)
-
(
1
)
Loss from lease termination
68
-
68
-
Changes in operating assets and liabilities:
Increase (decrease) in prepaid expenses
(
609
)
(
200
)
(
417
)
(
198
)
Increase (decrease) in other receivables
(
59
)
15
(
17
)
24
Increase (decrease) in trade payable
479
74
517
131
Net change in operating lease
(
40
)
(
7
)
(
44
)
(
2
)
Increase (decrease) in employee related obligations
480
(
75
)
436
(
13
)
Increase (decrease) in accrued expenses
(
884
)
(
150
)
(
905
)
33
Net cash used in operating activities
(
5,470
)
(
3,272
)
(
2,653
)
(
685
)
CASH FLOWS FROM INVESTING ACTIVITIES:
Proceeds from short-term deposit
-
507
-
-
Purchase of property and equipment
(
22
)
(
8
)
(
16
)
(
6
)
Proceeds from Sale of property and equipment
-
78
-
78
Net cash provided by (used in (investing activities
(
22
)
577
(
16
)
72
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from issuance of preferred shares and warrants, net of
        issuance costs
-
522
-
-
Proceeds from issuance of ordinary shares (ELOC)
620
-
620
-
Cash received from Transactions upon the effectiveness of the SPAC
        Merger
2,300
-
2,300
-
Net cash provided by financing activities
2,920
522
2,920
-
DECREASE IN CASH AND CASH EQUIVALENTS AND RESTRICTED
        CASH
(
2,572
)
(
2,173
)
251
(
613
)
EXCHANGE RATE DIFFERENCES ON CASH AND CASH EQUIVALENTS
        AND RESTRICTED CASH
(
50
)
(
324
)
25
(
66
)
BALANCE OF CASH, CASH EQUIVALENTS AND RESTRICTED
        CASH AT BEGINNING OF PERIOD
4,645
8,309
1,747
6,491
BALANCE OF CASH, CASH EQUIVALENTS AND RESTRICTED
        CASH AT END OF PERIOD
2,023
$
5,812
2,023
5,812
F-48
SILEXION
THERAPEUTICS CORP
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
Nine months ended
September 30,
Three months ended
September 30
2024
2023
2024
2023
U.S. dollars in thousands
U.S. dollars in thousands
Appendix A
–
RECONCILIATION
        OF CASH, CASH EQUIVALENTS AND RESTRICTED CASH REPORTED IN THE CONSOLIDATED BALANCE SHEETS:
Cash and cash equivalents
1,973
5,764
1,973
5,764
Restricted cash
50
48
50
48
TOTAL CASH, CASH EQUIVALENTS AND RESTRICTED CASH SHOWN IN STATEMENT OF CASH FLOWS
$
2023
$
5,812
$
2023
$
5,812
Appendix B
-
SUPPLEMENTARY INFORMATION:
SUPPLEMENTARY INFORMATION ON INVESTING AND FINANCING ACTIVITIES NOT INVOLVING CASH FLOWS:
Operating lease termination
$
(
55
)
$
-
$
(
55
)
$
-
Conversion of preferred shares
$
15,058
$
-
$
15,058
$
-
Conversion of warrants to preferred shares on a cashless basis
$
334
$
-
$
334
$
-
Conversion of non-controlling interests
$
3,344
$
-
$
3,344
$
-
SUPPLEMENTAL DISCLOSURES
OF CASH
        FLOW INFORMATION:
Interest received
$
25
$
120
$
-
$
42
The accompanying
notes are an integral part of the unaudited condensed consolidated financial statements.
F-49
SILEXION
THERAPEUTICS CORP
NOTES
TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) (continued)
(U.S.
dollars in thousands)
NOTE
1  - GENERAL:
a.
Silexion Therapeutics Corp ("New Silexion")
        (hereinafter -"the Company" or the "combined company")  is a newly formed entity that was formed for the purpose of effecting
        the Transactions (see below), and now serves as a publicly-traded holding company of its subsidiaries — including Moringa Acquisition
        Corp ("Moringa" or "the SPAC"), a Cayman Islands exempted company and Silexion Therapeutics Ltd. (formerly known
        as Silenseed Ltd.) ("Silexion"), an Israeli limited company— after the closing of the Transactions (the "Closing").
b.
Financial Information Presented:
From
its formation on April 2, 2024 until the consummation of the Transactions on August 15, 2024, the Company had no operations and had been
formed for the sole purpose of entering into the Transactions and serving as the publicly-traded company following the Transactions. Silexion,
on the other hand, as the accounting acquirer in the Transactions and the predecessor entity to the Company from an accounting perspective,
had active operations during earlier periods of time, prior to the Transactions. Consequently, these financial statements reflect
the information of Silexion (as the predecessor entity to the Company) until August 15, 2024 and the information of New Silexion (as the
combined company following the Transactions) from that date forward.
c.
Subsidiaries:
The
Company has three subsidiaries as of September 30, 2024:
1.
Silenseed
        (China) Ltd.
On April 28, 2021, Silexion (as the predecessor entity to the Company) signed an agreement with Guangzhou Sino-Israel
        Biotech Investment Fund ("GIBF") to establish a new company in China. On June 15, 2021 a company was established in China,
        named Silenseed (China) Ltd. (hereinafter - the "Subsidiary"). As of September 30, 2024, following transfer of all interests in the Subsidiary
        to the Company as part of the Transactions, the Company owns (directly or indirectly)
100
%
        of the shares of the Subsidiary. The Subsidiary has no significant operations as of September 30, 2024 (see Note c).
2.
Moringa
.
        Prior to the Transactions, Moringa's  class A ordinary shares and warrants were listed for trading on the Nasdaq Capital Market
        (Nasdaq: MACA and MACAW). As part of the Transactions, Moringa merged with a wholly-owned subsidiary of the Company and now serves as
        an inactive, wholly-owned subsidiary of the Company.
3.
Silexion.
Silexion was incorporated in Israel and began its operations on November 30, 2008. Since its incorporation, Silexion has been engaged
        in
one
operating segment - the research and development of innovative treatments for pancreatic cancer based on siRNAs, aiming to stop the production
        of a specific pancreatic cancer-causing protein known as the KRAS mutation. Silexion's long-lived assets are located in Israel.
.
4.
The Company, the Subsidiary, Moringa and Silexion
        are together referred to hereinafter as "the Group".
d.
On April 3, 2024, Silexion entered into an Amended
        and Restated Business Combination Agreement (hereinafter, "A&R BCA") with the SPAC, New Silexion, August M.S. Ltd. an
        Israeli company and wholly-owned subsidiary of New Silexion ("Merger Sub 1"), and Moringa Acquisition Merger Sub Corp, a Cayman
        Islands exempted company and wholly-owned subsidiary of New Silexion ("Merger Sub 2"). Under the A&R BCA, both Silexion
        and the SPAC were toi become wholly-owned subsidiaries of New Silexion, which was to become  a publicly-held, Nasdaq-listed entity
        (the A&R BCA and related transactions: the "Transactions").
On
August 15, 2024, the parties completed the Transactions pursuant to which Merger Sub 2 merged with and into the SPAC, with the SPAC continuing
as the surviving company of such merger and a wholly-owned subsidiary of New Silexion (the "SPAC Merger"), and Merger
Sub 1 merged with and into Silexion, with Silexion continuing as the surviving company of such merger and a wholly-owned subsidiary
of New Silexion (the "Acquisition Merger").
F-50
SILEXION
THERAPEUTICS CORP
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) (continued)
(U.S. dollars in thousands)
NOTE
1  - GENERAL
(continued):
Upon
the effectiveness of the SPAC Merger, each outstanding SPAC Class A ordinary share and the sole outstanding SPAC Class B ordinary
share was converted into an ordinary share of New Silexion on a one-for-one basis. Each outstanding warrant to purchase one SPAC
Class A ordinary share was converted into a warrant to purchase one New Silexion ordinary share, at the same exercise price. Upon
the effectiveness of the Acquisition Merger, each outstanding ordinary share and each outstanding preferred share of Silexion was converted
into
3.9829
shares of New Silexion before adjustment for reverse share split (the "Silexion Equity Exchange Ratio"). See below for post
– reverse share split figures. Each outstanding Silexion warrant and Silexion option to purchase one Silexion share, and Silexion
restricted share unit (RSU) that may be potentially settled for one Silexion share, was to become exercisable for, or became subject to
settlement for (as applicable), such number of New Silexion ordinary shares as were equal to the Silexion Equity Exchange Ratio. The exercise
price per New Silexion ordinary share of each such converted Silexion option and Silexion warrant was to be adjusted based on dividing
the existing per share exercise price by the Silexion Equity Exchange Ratio. The terms of vesting, exercise and/or settlement, as applicable,
of such converted options, warrants and RSUs were to remain the same following such conversion, except that the vesting of each Silexion
option was to accelerate immediately prior to the Acquisition Merger, such that the New Silexion option into which it was to be converted
was to be fully vested, and all Silexion warrants were to be exercised (on a cashless basis) immediately prior to the Acquisition Merger.
Immediately
prior to the Closing seven directors were elected to New Silexion's board of directors, of whom five were designated by Silexion
and two were designated by the SPAC's sponsor (the "Sponsor").
The
A&R BCA also required, as a closing condition, the transfer of the remaining outstanding shares of the Subsidiary held by GIBF to
Silexion prior to the closing of the Business Combination in exchange for the issuance to GIBF of shares of Silexion, which were to be
converted into ordinary shares of New Silexion in accordance with the Silexion Equity Exchange Ratio upon the closing.
e.
In connection with the closing of the Transactions,
        the ordinary shares and warrants of New Silexion are now listed on the Nasdaq Global Market and began trading under the symbols "SLXN"
        and "SLXNW", respectively.
f.
For more information on instruments issued as
        part of the Transactions, see Note 3.
g.
The Transactions were accounted for as a reverse
        recapitalization in accordance with US GAAP. Under this method of accounting, Silexion was treated as the accounting acquirer and
        the SPAC was treated as the "acquired" company for financial reporting purposes. Silexion was determined to be the accounting
        acquirer based on evaluation of the following facts and circumstances:
•       Silexion's
shareholders were to hold approximately
61.55
%
of the outstanding voting interests in New Silexion upon the closing of the Transactions;
•       Silexion's
senior management were to comprise the senior management of New Silexion;
•       the
directors nominated by Silexion were to constitute a majority of the board of directors of New Silexion (five out of seven of the initial
directors);
•       Silexion's
operations were to comprise the ongoing operations of New Silexion; and
•       Silexion's
name was to be the name used by New Silexion (in replacement of Biomotion Sciences).
Under
the reverse recapitalization accounting method, the Transactions were deemed to be the equivalent of a capital transaction in which Silexion
issued shares for the net assets of the SPAC. The net assets of the SPAC were stated at fair value, with no goodwill or other intangible
assets recorded. Operations prior to the Transactions are those of Silexion.
F-51
SILEXION
THERAPEUTICS CORP
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) (continued)
(U.S. dollars in thousands)
NOTE
1  - GENERAL
(continued):
In
accordance with the applicable guidance to reverse recapitalization, the equity structure has been retroactively adjusted in all comparative
periods up to the date of the Closing (the "Closing Date"), to reflect the number of New Silexion's Ordinary Shares,
$
0.0001
par
value per share issued to legacy Silexion shareholders in connection with the reverse recapitalization transaction. As such, the shares
and corresponding capital amounts and earnings per share related to legacy Silexion shareholders prior to the reverse recapitalization
have been retroactively restated as shares reflecting the exchange ratio established pursuant to the Transactions. In conjunction with
the reverse recapitalization, Silexion's Ordinary Shares underwent a
1-for-3.9829
conversion.
After adjustment for the reverse share split, the conversion rate is
0.4425
New Silexion Ordinary Shares, $
0.0009
par value, for each legacy Silexion share.
On
November 19, 2024, the Company's shareholders approved a
1-for-9
reverse share split of the Company's Ordinary Shares. On November 29, 2024, the reverse share split became effective. All references
made to Ordinary Shares, preferred shares and per share amounts (both of the Company and New Silexion) in these unaudited consolidated
financial statements, unless otherwise indicated, have been retroactively adjusted to reflect the reverse share split.
h.
In October 2023, Hamas terrorists infiltrated
        Israel's southern border from the Gaza Strip and conducted a series of attacks on civilian and military targets. Following the attack,
        Israel's security cabinet declared war against Hamas and commenced a military campaign against Hamas and other terrorist organizations.
In
parallel, there have been continued hostilities along Israel's northern border, as the Hezbollah terrorist organization based in
Lebanon has conducted rocket, drone, and, more recently, missile attacks against Israel. The hostilities with Hezbollah have escalated
recently, prompting Israel to send its ground forces into southern Lebanon to destroy terrorist positions and infrastructure used by Hezbollah
for attacks on northern and
central
Israel, which had caused the displacement of residents in northern Israel since early in the war. There have also been rocket, drone and
missile attacks against Israel by the Houthi movement in Yemen and from Iran.
The
Company's headquarters are located in the central region of Israel. As of the issuance date of these consolidated financial statements,
these conflicts have not had a material impact on the Company's results of operations or financial position, if at all. The Company
cannot currently predict the intensity or duration of Israel's war, however, as most of the Company's trials are not executed
in Israel, the Company does not believe the recent terrorist attack and the subsequent escalation will have any material impact on its
ongoing operations. The Company continues to monitor its ongoing activities and will make any needed adjustments to ensure continuity
of its business, while supporting the safety and well-being of its employees.
Any
hostilities involving Israel, or the interruption or curtailment of trade within Israel or between Israel and its trading partners could
adversely affect the Company's operations and results of operations and could make it more difficult for the Company to raise capital.
i.
Going concern:
Since
its inception, the Company (and, prior to the Transactions, its predecessor, Silexion) has devoted substantially all its efforts to research
and development, clinical trials, and capital raising activities. The Company is still in its development and clinical stage and has not
yet generated revenues.
The
Company (or, for those periods prior to the Transactions, its predecessor, Silexion) has incurred losses of $
14,772
and $
5,108
for the nine-months period ended on September 30, 2024 and for the year ended December 31, 2023, respectively. During the nine-month period
ended on September 30, 2024, the Company (including Silexion, for periods prior to the Transactions) had negative operating cash flows
of $
5,470
.
As of September 30, 2024, the Company had cash and cash equivalents of $
1,973
. On
August 15, 2024, Silexion completed a business combination with the SPAC.
F-52
SILEXION
THERAPEUTICS CORP
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) (continued)
(U.S. dollars in thousands)
NOTE
1  - GENERAL
(continued):
The
        Company expects to continue incurring losses, and negative cash flows from operations. Management is in the process of evaluating various
        financing alternatives, as the Company will need to finance future research and development activities, general and administrative expenses
        and working capital through fund raising. However, there is no assurance that the Company will be successful in obtaining such funding.
Under
        these circumstances, in accordance with the requirements of ASC 205-40, management has concluded that there is substantial doubt about
        the Company's ability to continue as a going concern for at least 12 months from the date these financial statements are issued.
        The unaudited condensed consolidated financial statements do not include any adjustments that may be necessary should the Company be unable
        to continue as a going concern (see Note 1 (d)).
NOTE
2  - SIGNIFICANT ACCOUNTING POLICIES:
a.
Unaudited Condensed Financial
        Statements
The
accompanying condensed financial statements are unaudited. These unaudited interim condensed consolidated financial statements have been
prepared in accordance with generally accepted accounting principles in the United States of America ("U.S. GAAP") for interim financial
statements and follow the requirements of the Securities and Exchange Commission ("SEC") for interim financial reporting.
Accordingly, they do not include all of the information and notes required by U.S. GAAP for annual financial statements. In the opinion
of management, these unaudited condensed consolidated financial statements reflect all adjustments, which include normal recurring adjustments,
necessary for a fair statement of the Company's consolidated financial position as of September 30, 2024, and the consolidated results
of operations, statements of changes in redeemable convertible preferred shares and capital deficiency and cash flows for the nine-month
and three-month periods ended September 30, 2024 and 2023.
The
consolidated results for the nine-months ended September 30, 2024 are not necessarily indicative of the results to be expected for the
year ending December 31, 2024.
These
unaudited interim condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements
of Silexion as of and for the year ended December 31, 2023, which are included in a current report on Form 8-K and in a registration statement
on Form S-1/A which the Company is filing with the SEC presently. The significant accounting policies adopted and used in the preparation
of the financial statements are consistent with those of the previous financial year.
b.
Use of estimates
The
preparation of the financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect
the amounts reported in the financial statements and accompanying notes. As applicable to these financial statements, the most significant
estimates and assumptions relate share-based compensation and to fair value of financial instruments. See Note 6 and Notes 4 and
7, respectively. These estimates and assumptions are based on current facts, future expectations, and various other factors believed to
be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and
liabilities and the recording of expenses that are not readily apparent from other sources. Actual results may differ materially and adversely
from these estimates.
F-53
SILEXION
THERAPEUTICS CORP
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) (continued)
(U.S. dollars in thousands)
NOTE
2  - SIGNIFICANT ACCOUNTING POLICIES
(continued):
c.
Restricted cash
As
of September 30, 2024 and December 31, 2023, the Company pledged an amount of $
25
in favor of a bank as collateral for guarantees provided to secure the lease payments.
The
Company is required to hold a minimum amount of NIS
85
in its bank account in order to maintain availability of a credit line from its credit card company.
d.
Fair value measurement
Fair
value is based on the price that would be received from the sale of an asset or that would be paid to transfer a liability in an orderly
transaction between market participants at the measurement date. In order to increase consistency and comparability in fair value measurements,
the guidance establishes a fair value hierarchy that prioritizes observable and unobservable inputs used to measure fair value into three
broad levels, which are described as follows:
Level 1:
Quoted prices (unadjusted) in active markets that
        are accessible at the measurement date for assets or liabilities. The fair value hierarchy gives the highest priority to Level 1 inputs.
Level 2:
Observable prices that are based on inputs not
        quoted on active markets, but corroborated by market data or active market data of similar or identical assets or liabilities.
Level 3
Unobservable inputs are used when little or no
        market data is available. The fair value hierarchy gives the lowest priority to Level 3 inputs.
In
determining fair value, the Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable
inputs to the extent possible and considers counterparty credit risk in its assessment of fair value.
e.
Concentration of credit
        risks
Financial
instruments that potentially subject the Company to concentration of credit risk consist principally of cash and cash equivalents, restricted
cash and short-term deposits. The Company deposits cash and cash equivalents mostly with three low risk financial institution. The Company
has not experienced any material credit losses in these accounts and does not believe it is exposed to significant credit risk on these
instruments.
f.
Loss per share
The
Company calculates loss per share using the two-class method required for participating securities. This method entails allocating
income available to ordinary shareholders for the period between ordinary shares and participating securities based on their respective
rights to receive dividends as if all income for the period had been distributed. Basic loss per share is computed by dividing net loss
by the weighted average number of ordinary shares outstanding during the year, and fully vested pre-funded options for the Company's
ordinary shares at an exercise price of $
0.027
or
0.0063
NIS per share. The Company considers these shares to be exercisable for little to no additional consideration. The Company also considers
its redeemable convertible preferred shares to be participating securities as the holders of the redeemable convertible preferred shares
would be entitled to dividends that would be distributed to the holders of ordinary shares, on a pro-rata basis assuming conversion
of all redeemable convertible preferred shares into ordinary shares. However, these participating securities do not contractually require
the holders to participate in the Company's losses. Consequently, net loss for the periods presented was not allocated to the Company's
participating securities. The Ordinary Shares issued as a result of the Redeemable Convertible Preferred Shares conversion on the
Closing Date were included in the basic net loss per share calculation on a prospective basis.
F-54
SILEXION
THERAPEUTICS CORP
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) (continued)
(U.S. dollars in thousands)
NOTE
2  - SIGNIFICANT ACCOUNTING POLICIES
(continued):
g.
Contracts over Ordinary
        Shares
When
the Company becomes party to freestanding convertible instruments, the Company first analyzes the provisions of ASC 480 in order to determine
whether the instrument should be classified as a liability, with subsequent changes in fair value recognized in the statements of operations
in each period. Warrants to purchase Ordinary Shares are not within the scope of ASC 480, and as such the Company further analyzes the
provisions of ASC 815-40 in order to determine whether the contract should be classified within equity or classified as a liability, with
subsequent changes in fair value recognized in the statements of operations in each period.
Under ASC
815-40, contracts that are not indexed to the Company's own stock are classified as liabilities recorded at fair value, As such,
the Company classifies private warrants (see Note 3(e)) as liabilities and measures them at their fair value at each reporting period.
This liability is subject to re-measurement at each balance sheet date until the private warrants are exercised or expire, or upon reassessment
of classification. Similarly the Company classifies the ELOC Agreement entered into (see Note 3(d)) as a derivative instrument measured
at fair value at each reporting period, as settlement provisions under this agreement are not indexed to the Company's own stock.
The
Company reassesses the classification of a contract over its own equity under the guidance above at each balance sheet date. If classification
changes as a result of events during the reporting period, the Company reclassifies the contract as of the date of the event that caused
the reclassification. When a contract over own equity is reclassified from a liability to equity, gains or losses recorded to account
for the contract at fair value during the period that the contract was classified as a liability are not reversed, and the contract is
marked to fair value immediately before the reclassification. The Redeemable Convertible Preferred Shares were converted into Ordinary
Shares in the framework of the recapitalization transaction as described in note 1(d).
h.
Promissory Notes
Under
the Fair Value Option Subsection of ASC Subtopic 825-10, the Company has an irrevocable option to designate certain financial liabilities
at fair value on an instrument-by-instrument basis, with changes in fair value reported in the statement of operations. The Company designated
Promissory Notes issued as part of the Transactions under the fair value option. See Note 3(a) and (b).
F-55
SILEXION
THERAPEUTICS CORP
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) (continued)
(U.S. dollars in thousands)
NOTE
2  - SIGNIFICANT ACCOUNTING POLICIES
(continued):
i.
New accounting pronouncements:
Recently
issued accounting standards not yet adopted:
1)
In November 2023, the FASB issued ASU No. 2023-07 Segment
        Reporting (Topic 280): Improvements to Reportable Segment Disclosures. The ASU improves reportable segments disclosure requirements, primarily
        through enhanced disclosures about significant segment expenses.  The ASU also require that a public entity that has a single reportable
        segment to provide all the disclosures required by the amendments and all existing segment disclosures in Topic 280. The ASU is effective
        for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024. The
        Company is currently evaluating this ASU to determine its impact on the Company's segment disclosures.
2)
In December 2023, the FASB issued ASU No. 2023-09,
        Improvements to Income Tax Disclosures, which requires disclosure of disaggregated income taxes paid, prescribes standard categories for
        the components of the effective tax rate reconciliation, and modifies other income tax-related disclosures. The ASU will be effective
        for fiscal years beginning after December 15, 2025, and allows adoption on a prospective basis, with a retrospective option. The Company
        is in the process of assessing the impacts and method of adoption.
3)
In November 2024, the FASB issued ASU No. 2024-03 Income
        Statement—Reporting Comprehensive Income—Expense Disaggregation Disclosures (Subtopic 220-40). The ASU improves the disclosures
        about a public business entity's expenses and provides more detailed information about the types of expenses in commonly presented
        expense captions. The amendments require that at each interim and annual reporting period an entity will, inter alia, disclose amounts
        of purchases of inventory, employee compensation, depreciation and amortization included in each relevant expense caption (such as cost
        of sales, SG&A and research and development). The ASU is effective for fiscal years beginning after December 15, 2026, and interim
        periods within fiscal years beginning after December 15, 2027. Early adoption is permitted. The Company is currently evaluating this
        ASU to determine its impact on the Company's disclosures.
NOTE
3 - FINANCIAL INSTRUMENTS ISSUED AND ASSUMED IN TRANSACTIONS
a.
Underwriters Promissory
        Note
Prior
        to the Closing, Moringa reached agreement with EarlyBird Capital, Inc. ("EarlyBird") on the reduction, to $
1,600
,
        in the aggregate, of the fee payable to EarlyBird under the Marketing Agreement entered into by Moringa with EarlyBird at the time of
        Moringa's initial public offering ("IPO"). At the Closing, Moringa paid $
350
of cash to EarlyBird from its Trust Account and New Silexion issued to EarlyBird a convertible promissory note, due December 31, 2025,
        in an amount of $
1,250
to be paid by New Silexion to EarlyBird in cash or via conversion of outstanding amounts into ordinary shares of New Silexion (the "EarlyBird
        Convertible Note").
The
        EarlyBird Convertible Note bears interest at a rate of
6
%
        per annum and matures on December 31, 2025. If not repaid on or prior to that maturity date or such earlier date as to which the repayment
        obligation may be accelerated under the note, or not converted in accordance with the terms thereof, the rate of interest applicable to
        the unpaid principal amount would be adjusted to (
15
%)
        per annum. New Silexion is required to make mandatory prepayments on the note in amounts equal to
10
%
        of the gross proceeds received by New Silexion from any equity financings consummated by it prior to the maturity date.
New
        Silexion is entitled to voluntarily prepay any additional part of, or all of, the principal and accrued interest, in one or more installments
        without penalty, prior to the maturity date.
F-56
SILEXION
THERAPEUTICS CORP
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) (continued)
(U.S. dollars in thousands)
NOTE
3 - FINANCIAL INSTRUMENTS ISSUED AND ASSUMED IN TRANSACTIONS
(continued):
EarlyBird, in turn, may
        elect, at its sole discretion, at any time on or prior to the maturity date, to elect to convert all or part of the then outstanding principal
        and/or accrued interest under the EarlyBird Convertible Note into New Silexion ordinary shares, at a per share conversion price equal
        to
95
%
        of the volume weighted average price of a New Silexion ordinary share for the five trading days immediately prior to the date of New Silexion's
        receipt of a conversion notice.
As of the date of this
        report, the Company repaid $
100
of the EarlyBird Convertible Note as a result of the share issuance under the ELOC Agreement; see Note 3(d).
b.
Sponsor Promissory Note
Effective
        as of the Closing, New Silexion issued to the Sponsor in replacement in their entirety of all previously existing promissory notes issued
        by Moringa to the Sponsor from its IPO until the Closing, an amended and restated promissory note (the "A&R Sponsor Promissory
        Note") in an amount of $
3,433
.
        This reflected the total amount owed by Moringa to the Sponsor through the Closing Date. The maturity date of the A&R Sponsor Promissory
        Note is the 30-month anniversary of the Closing Date (i.e., February 15, 2027). Amounts outstanding under the A&R Sponsor Promissory
        Note may be repaid (unless otherwise decided by New Silexion) only by way of conversion into New Silexion ordinary shares ("Note
        Shares"). New Silexion and the Sponsor may also convert amounts outstanding under the A&R Sponsor Promissory Note at the price
        per share at which New Silexion conducts an equity financing following the Closing, subject to a minimum conversion amount of $
100
,
        in an amount of Note Shares constituting up to thirty percent (
30
%)
        of the number of New Silexion ordinary shares issued and sold by New Silexion in such equity financing. The Sponsor may also elect to
        convert amounts of principal outstanding under the note into New Silexion ordinary shares at any time following the 24-month anniversary
        of the Closing Date, subject to a minimum conversion of $
10
,
        at a price per share equal to the volume weighted average price of the New Silexion ordinary shares on the principal market on which they
        are traded during the
20
consecutive trading days prior to the conversion date.
As
        of the date of this report, the Company has neither repaid, nor converted into New Silexion ordinary shares, any principal amounts outstanding
        under the Sponsor Promissory Note.
c.
PIPE Financing
In
        connection with, and immediately prior to the Closing of the Transactions, Moringa raised $
2,000
via a private investment in public entity financing (the "PIPE Financing"), whereby Moringa sold to Greenstar, LP, an affiliate
        of the Moringa Sponsor (the "PIPE Investor"),
22,223
newly issued Moringa ordinary shares at a price of $
90.00
per share, pursuant to a subscription agreement, dated as of August 15, 2024, by and among Moringa, New Silexion and the PIPE Investor
        (the "PIPE Agreement"). Those
22,223
shares automatically converted upon the Closing of the Transactions into an equivalent number of New Silexion ordinary shares (the "PIPE
        Shares").
d.
ELOC Financing
In
        connection with the Closing, New Silexion entered into an ordinary share purchase agreement, effective as of the Closing Date (the "ELOC
        Agreement"), for an equity line of credit (the "ELOC") with White Lion Capital, LLC (the "ELOC Investor"),
        whereby New Silexion will be able to request to sell to the ELOC Investor, and the ELOC Investor will be required to purchase, via private
        placement transactions, up to $
15,000
of New Silexion ordinary shares from time to time after the Closing, up until December 31, 2025 (unless the agreement is terminated sooner),
        subject to certain limitations and conditions as described therein. The number of New Silexion ordinary shares that New Silexion may require
        the ELOC Investor to purchase in any single sales notice will depend on a number of factors, including the type of purchase notice that
        New Silexion delivers.  Similarly, the purchase price to be paid by the ELOC Investor for any shares that New Silexion requires it
        to purchase will depend on the type of sales notice that New Silexion delivers.
F-57
SILEXION
THERAPEUTICS CORP
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) (continued)
(U.S. dollars in thousands)
NOTE
3 - FINANCIAL INSTRUMENTS ISSUED AND ASSUMED IN TRANSACTIONS
(continued):
Purchase
        price is determined with reference to either the lowest daily volume-weighted average price of the Company's Ordinary Shares during
        a period of three consecutive business days ending on the notice date times
97
%
        or lowest traded price of the Company's Ordinary Shares on the notice date.
Pursuant
        to the ELOC Agreement, New Silexion agreed, among other things, that if New Silexion's sales to the ELOC Investor under the ELOC
        exceed
19.99
%
        of New Silexion's total number of ordinary shares outstanding, New Silexion will seek the approval of its shareholders for the issuance
        of any New Silexion ordinary shares under the ELOC in excess of that amount, in accordance with the Nasdaq Listing Rules, subject to certain
        exceptions based on the price of the New Silexion ordinary shares to be sold in excess of that limit.
In
        consideration for the commitments of the ELOC Investor, New Silexion agreed to issue to the ELOC Investor an aggregate of $
337.5
of New Silexion ordinary shares (the "ELOC Commitment Shares"). On September 18, 2024 the Company issued
40,602
ordinary shares to White Lion LLC as the Commitment Shares. Issuance expenses amounted to $
52
.
During
        the three
months ended September 30, 2024, the Company sold
116,667
ordinary
        shares under the ELOC at an average price of $
6.255
per
        share, net of fees of approximately $
20
.
        The net proceeds from those sales were $
620
.
        For further information see Note 11.
e.
SPAC Warrants
On
        the Closing Date, Moringa, New Silexion and Continental Stock Transfer & Trust Company ("CST") entered into a certain
        Assignment, Assumption and Amendment Agreement (the "New Warrant Agreement"). The New Warrant Agreement amended Moringa's
        Warrant Agreement, dated as of February 19, 2021, to provide for the assignment by Moringa of all its rights, title and interest in the
        warrants of Moringa to New Silexion.
Upon
        Closing, New Silexion assumed
638,889
warrants sold by Moringa in its IPO ("Public Warrants") and
21,112
warrants sold by Moringa to the Sponsor and EarlyBird concurrently with its IPO (the "Private Warrants", and together with
        the Public Warrants, the "Warrants"). Each such Warrant entitles the holder thereof to purchase one Ordinary Share of New
        Silexion of $
103.50
per share, subject to adjustment. No fractional shares will be issued upon exercise of the Warrants.
Each
        Warrant became exercisable 30 days after the Closing and will expire after five years after the completion of the Closing or earlier upon
        redemption (only in the case of the Public Warrants) or liquidation.
Once
        the Public Warrants became exercisable, the Company may redeem them in whole and not in part at a price of $0.09 per Warrant upon a minimum
        of 30 days' prior written notice of redemption, if and only if the last reported sale price of the Company's ordinary shares
        equals or exceeds $162.00 per share (as adjusted) for any 20 trading days within a 30-trading day period ending on the third trading day
        prior to the date on which the Company sends the notice of redemption to the Public Warrant holders.
The
        Company recognized a net liability, measured at fair value through profit or loss, from the Transactions (see also Note 2). As such, transaction
        costs related to the Transactions were expensed as incurred.
The
        Private Warrants are identical to the Public Warrants except that, for so long as they are held by the Sponsor, EarlyBird or their respective
        affiliates, the Private Warrants: (1) will not be redeemable by the Company; (2) could not (subject to certain limited exceptions), be
        transferred, assigned or sold by the holders thereof until 30 days after the Closing; (3) may be exercised by the holders thereof on a
        cashless basis; and (4) are entitled to registration rights.
F-58
SILEXION
THERAPEUTICS CORP
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) (continued)
(U.S. dollars in thousands)
NOTE
4 - SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION:
Statement
of operations:
a.
Research and development
        expenses:
Nine months ended
September 30,
Three months ended
September 30,
2024
2023
2024
2023
U.S. dollars in thousands
U.S. dollars in thousands
Payroll and related expenses
$
928
$
729
$
453
$
198
Share-based compensation expenses
2,424
57
2,385
19
Subcontractors and consultants
1,425
1,444
297
236
Materials
3
16
-
-
Rent and maintenance
106
124
57
46
Travel expenses
13
27
-
-
Other
45
54
25
36
$
4,944
$
2,451
$
3,217
$
535
b.
General and administrative expenses:
Payroll and related expenses
$
856
$
190
$
575
$
71
Share-based compensation expenses
3,438
39
3,413
13
Professional services
1,053
79
605
51
Depreciation
37
39
22
10
Rent and maintenance
90
67
18
25
Patent registration
25
18
-
2
Travel expenses
72
31
56
15
Other
156
39
130
9
$
5,727
$
502
$
4,819
$
196
c.
Financial expense, net:
Change in fair value of financial liabilities measured at fair value
$
(
919
)
$
(
3
)
$
(
1,064
)
$
-
Issuance costs
52
47
52
44
Loss upon entering Transactions
4,783
-
4,783
-
Interest income
(
25
)
(
120
)
-
(
42
)
Foreign currency exchange loss, net
196
520
48
69
Other
5
5
3
1
Total financial expense, net
$
4,092
$
449
$
3,822
$
72
Note
5 - LEASES
a.
On August 15, 2024, the
        Company vacated its office spaces and facilities in Israel. On September 8, 2024, an early termination agreement for the operating lease
        was signed with the landlord, which included a termination penalty. As a result, the Company derecognized the right-of-use asset and the
        lease liability in its financial statements, recording a loss of $
68
from the lease termination and an additional $
18
from the disposal of leasehold improvements.
b.
On September 26, 2024 the Company signed a new
        lease agreement for an office in Israel starting November 1, 2024 and ending on October 31, 2026. The Company will pay a monthly payment
        of $
10
to the lessor.
F-59
SILEXION
THERAPEUTICS CORP
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) (continued)
(U.S. dollars in thousands)
NOTE
6  - WARRANTS TO PURCHASE PREFERRED SHARES:
On
May 30, 2023, Silexion issued warrants to acquire
2,413
Series A-4 Preferred Shares to various investors, with an exercise price of $
222.921
per
share and an expiration date of May 30, 2025. Issuance expenses amounted to $
3
.
On August 6, 2024, all of these warrants were exercised via a 'cashless' manner for
913
Preferred A4 shares of Silexion.
Silexion
classified the warrants for the purchase of shares of its convertible redeemable preferred shares as a liability in its consolidated balance
sheets, as these warrants were freestanding financial instruments which underlying shares were contingently redeemable and, therefore,
may have obligated the Company to transfer assets at some point in the future. The warrant liability was initially recorded at fair value
upon the date of issuance and was subsequently remeasured at fair value at each reporting date. The Company (or Silexion, as applicable)
recorded revaluation expenses amounting to $
134
and $
40
for the nine months periods ended September 30, 2024 and September 30, 2023 , respectively, and revaluation (income) expenses amounting
to $(
11
)
and $
43
for the three months periods ended September 30, 2024 and September 30, 2023 and accounted for such revaluation expenses as part of its
financial (income) expense, net, in the statements of operations (see Note 8).
For
further information in respect of warrants granted to a service provider and exercised, see Note 7.
For
cashless exercise of these warrants see Note 1(d).
NOTE
7  - SHARE-BASED COMPENSATION:
The
Company's (or Silexion's, as applicable) share-based expenses amounted to a total of $
5,862
and $
96
in the nine months periods ended September 30, 2024 and 2023, respectively. As of September 30, 2024,
63,953
shares
remain available for grant under the Company's 2013, 2023 and 2024 Equity Incentive Plans.
On
July 4, 2024, Silexion's board of directors approved granting fully vested
78,650
RSUs
to Silexion's employees and directors amounting to a total of $
5,578
.
For a description of the acceleration of the Company's options prior to the Closing of the Transactions, see Note 1(d).
The
fair value for the RSUs granted is based on the following assumptions:
Expected volatility
74.82
%
Assumptions regarding
        the price of the underlying shares:
Probability of an IPO
        scenario (including de-SPAC transaction)
67
%
Expected time to IPO
        (including de-SPAC transaction) (years)
0.137
Probability of other
        liquidation events
33
%
Expected time to liquidation
        (years)
2.25
Expected return on Equity
22
%
On
August 6, 2024, a service provider exercised the warrants in a 'cashless' manner, resulting in the issuance of
140
Series
A-1 Preferred Shares and 12 Series A-4 Preferred Shares of Silexion (see Note 11(1) to the audited financial statements of Silexion as
of December 31, 2023, which were published on May 9, 2024).
F-60
SILEXION
THERAPEUTICS CORP
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) (continued)
(U.S. dollars in thousands)
NOTE
7  - SHARE-BASED COMPENSATION
(continued):
Summary
of outstanding and exercisable options:
Below
        is a summary of the Company's (or for periods prior to the Closing of the Transactions, Silexion's) stock-based compensation activity
        and related information with respect to options granted to employees and non-employees for the nine month period ended September 30, 2024:
Number
        of options
Weighted-average
        exercise price (in U.S. dollars)
Weighted-
        average remaining contractual term
(in
        years)
Aggregate
intrinsic
value
Outstanding at January
        1, 2024
53,914
$
38.94
4.88
$
316
Granted
-
-
-
-
Exercised
(
13,780
)
$
0.03
(
0.01
)
$
490
Forfeited
(
326
)
$
60.52
(
6.02
)
-
Expired
(
13,492
)
$
41.06
-
-
Outstanding at September
        30, 2024
26,316
$
57.97
7.09
-
Exercisable at September
        30, 2024
26,316
$
57.97
7.09
-
Vested and expected to
        vest at September 30, 2024
26,316
$
57.97
7.09
-
Up to September 30, 2024
        and for the year ended December 31, 2023 no options were granted.
The
share-based compensation expense by line item in the accompanying consolidated statements of operations is summarized as follows:
Nine
        months ended
September
        30,
Three
        months ended
September
        30,
2024
2023
2024
2023
Research and development
$
2,424
$
57
$
2,385
$
19
General and administrative
3,438
39
3,413
13
$
5,862
$
96
$
5,798
$
32
NOTE
8  - FAIR VALUE MEASUREMENTS:
Financial
        instruments measured at fair value on a recurring basis
The Company's (or,
        for periods prior to the Closing of the Transactions, Silexion's) assets and liabilities that are measured at fair value as of September
        30, 2024, and December 31, 2023, are classified in the tables below in one of the three categories described in "Note 2 –
        Fair value measurement":
September
        30, 2024
Level
        3
Total
Financial
        Liabilities
Private
        Warrants to purchase ordinary shares
$
10
$
10
Promissory
        Notes
$
4,312
$
4,312
December
        31, 2023
Level
        3
Total
Financial
        Liabilities
Warrants
        to preferred shares
$
200
$
200
F-61
SILEXION
THERAPEUTICS CORP
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) (continued)
(U.S. dollars in thousands)
NOTE
8  - FAIR VALUE MEASUREMENTS
(continued)
:
The following is a roll
        forward of the fair value of liabilities classified under Level 3:
Nine
        months ended
September
        30, 2024
Three
        months ended
September
        30, 2024
Warrants
        to preferred shares
Warrants
        to Ordinary shares
Promissory
        Notes
Warrants
        to preferred shares
Warrants
        to Ordinary shares
Promissory
Notes
Fair value at the beginning
        of the period
$
200
$
-
$
-
$
345
$
-
$
-
Issuance
-
1,130
4,622
-
1,130
4,622
Change in fair value
134
(
1,120
)
(
310
)
(
11
)
(
1,120
)
(
310
)
Conversion
(
334
)
-
-
(
334
)
-
-
Fair value at the end
        of the period
$
-
$
10
$
4,312
$
-
$
10
$
4,312
Nine
        months ended September 30, 2023
Three
        months ended September 30, 2023
Warrants
        to preferred share
Warrants
        to preferred shares
Fair value at the beginning
        of the period
$
3
$
111
Issuance
111
-
Change in fair value
40
43
Fair value at the end
        of the period
$
154
$
154
ELOC
        agreement
As the ELOC agreement
        is in substance a purchased call option over the Company's own shares at a price mentioned in Note 3(d), the fair value of this
        agreement will generally be approximately zero, until the Company sells shares under the agreement. Once the Company sells share under
        the agreement, the difference between cash raised (net of transaction costs) and the closing price of the Ordinary Shares as of the date
        of their issuance is recognized as financing income or expenses.
Fair value gain and losses
        arising from ELOC agreement are measured with reference to the spot price of the Company's shares sold less consideration receivable
        from the investor.
Warrant
        to preferred shares
The fair value of Silexion's
        warrant to purchase preferred shares as of September 30, 2023 and December 31, 2023 was estimated using a hybrid model in order to reflect
        two scenarios: (1) an IPO event (including de-SPAC transaction) and (2) other liquidation events. For further details see Note 12 in the
        annual consolidated financial statements.
The valuation under the
        'other liquidation events' scenario was assessed using an option pricing model (OPM) by implementing a Monte Carlo Simulation,
        which treats the financial instruments
in
        Silexion's equity as contingent claims whose future payoff depends on Silexion's future equity value. Silexion's entire
        equity value in 2023 was calculated based, among others, on the financing round closest to the valuation date.
Promissory
        Notes
In measuring the fair
        value of the Company's Promissory Notes, a discount rate of
11.4
%-
13.1
%
        was used, based on a B- rated US dollar zero-coupon discount curve, plus a credit spread of
6.67
%.
        The expected timing of conversion or redemption of the notes was determined using the Company's forecasts.
F-62
SILEXION
THERAPEUTICS CORP
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) (continued)
(U.S. dollars in thousands)
NOTE
8  - FAIR VALUE MEASUREMENTS
(continued)
:
Warrants
        over ordinary shares
A Black-Scholes-Merton
        model with Level 3 inputs was used to calculate the warrants' fair value. Inherent in a Black-Scholes-Merton model are assumptions
        related to expected life (term), expected stock price, volatility, risk-free interest rate and dividend yield. The Company estimates the
        volatility of its warrants based on implied volatility from the Company's traded warrants and from historical volatility of selected
        peer companies' Class A ordinary shares that matches the expected remaining life of the warrants. The risk-free interest rate is
        based on the U.S. Treasury zero-coupon yield curve on the grant date for a maturity similar to the expected remaining life of the warrants.
        The expected life of the warrants is assumed to be equivalent to their remaining contractual term. The dividend rate is based on the historical
        rate, which the Company anticipates remaining at zero.
The following table provides
        quantitative information regarding Level 3 fair value measurements inputs of the warrants:
September 30,
August 15,
2024
2024
Volatility
76.86
%
80.23
%
Dividend yield
0
%
0
%
Financial
        instruments not measured at fair value
The carrying amounts
        of cash and cash equivalents, restricted cash, receivables, trade payables and other liabilities approximate their fair value due to the
        short-term maturity of such instruments.
NOTE
9  - NET LOSS PER SHARE:
The following table sets
        forth the computation of basic and diluted net loss per share attributable to ordinary shareholders for the periods presented (USD in
        thousands, except per share data):
Nine
        months ended
September
        30,
Three
        months ended
September
        30,
2024
2023
2024
2023
Numerator:
Net
        loss
$
14,772
$
3,428
$
11,860
$
809
Net
        loss attributable to ordinary shareholders, basic and diluted:
$
14,696
$
3,214
$
11,851
$
787
Denominator:
Weighted-average
        shares used in computing net loss per share attributable to ordinary shareholders, basic and diluted
291,407
111,726
647,568
111,726
Net
        loss per share attributable to ordinary shareholders, basic and diluted
$
50.43
$
28.76
$
18.30
$
7.04
Basic loss per share
        is computed on the basis of the net loss for the period divided by the weighted average number of ordinary shares outstanding during the
        period, including fully vested pre-funded options for the Company's (or Silexion's, as applicable) ordinary shares at an exercise
        price of $
0.027
or
0.0063
NIS per share, as the Company (or Silexion, as applicable) considers these shares to be exercised for little to no additional
        consideration.
As of September 30, 2024
        and September 30, 2023, the basic loss per share calculation included a weighted average number of
133
and
14,652
,
        respectively, of fully vested pre-funded options. As the inclusion of other potential ordinary shares equivalents in the calculation would
        be anti-dilutive for all periods presented, diluted net loss per share is the same as basic net loss per share.
F-63
SILEXION
THERAPEUTICS CORP
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) (continued)
(U.S. dollars in thousands)
NOTE
9  - NET LOSS PER SHARE
(continued)
:
The following instruments
        were not included in the computation of diluted earnings per share because of their anti-dilutive effect:
-
Redeemable convertible preferred shares;
-
Warrants to purchase redeemable convertible preferred
        shares;
-
Share-based compensation issuable at substantial
        consideration;
-
Private Warrants to purchase ordinary shares;
-
Promissory Notes.
NOTE
10  - TRANSACTIONS AND BALANCES WITH RELATED PARTIES
:
Transactions
with related parties which are shareholders and directors of the Company (or Silexion, for periods prior to the Closing of the Transactions):
a.
Transactions:
Nine
        months ended
September
        30,
Three
        months ended
September
        30
2024
2023
2024
2023
Share-based
        compensation included in research and development expenses
$
1,796
$
51
$
1,762
$
17
Share-based
        compensation included in general and administrative expenses
$
2,972
$
36
$
2,948
$
12
Financial expenses
$
(
47
)
$
40
$
(
182
)
$
40
b.
Balances:
September 30,
        2024
December 31,
        2023
Non-Current
        liabilities -
Warrants
        to purchase preferred shares
$
-
$
186
Private
        warrants to purchase ordinary shares
$
10
-
Promissory
        Note
$
3,106
$
-
NOTE
11  - SUBSEQUENT EVENTS:
a.
On October 1, 2024, the Company completed an equity
        raise through the ELOC, issuing
293,777
ordinary shares for a total consideration of $
1,658
.
b.
On October 22, 2024, the Company completed an
        equity raise through the ELOC, issuing
66,667
ordinary shares for a total consideration of $
200
.
c.
On October 29, 2024, the Company received a deficiency
        letter from the Listing Qualifications Department (the "Staff") of the Nasdaq Stock Market LLC ("Nasdaq") notifying
        the Company that, for the 30 consecutive business days preceding the letter, the closing bid price of the Company's Ordinary Shares
        was below the minimum $1.00 per share required for continued listing on The Nasdaq Stock Market.
The
        Company has been given 180 calendar days, or until April 28, 2025, to regain compliance. If at any time before April 28, 2025, the bid
        price of the Ordinary Shares closes at $1.00 per share or more for a minimum of 10 consecutive business days, the Staff will provide written
        confirmation that the Company has achieved compliance.
d.
d. For information regarding the reverse share
        split, see Note 1 (g)
_______________________
________________________________
_______________________
F-64
SILEXION
THERAPEUTICS CORP
CONSOLIDATED
FINANCIAL STATEMENTS
AS
OF DECEMBER 31
, 2023
F-65
SILEXION
THERAPEUTICS CORP
CONSOLIDATED
FINANCIAL STATEMENTS
AS
OF DECEMBER 31
, 2023
TABLE
OF CONTENTS
Page
Report
        of Independent Registered Public Accounting Firm
F-67
CONSOLIDATED
        FINANCIAL STATEMENTS:
Consolidated
        Balance Sheets
F-68
        - F-69
Consolidated
        Statements of Operations
F-70
Consolidated
        Statements of Changes in Redeemable Convertible Preferred Shares and Capital Deficiency
F-71
Consolidated
        Statements of Cash Flows
F-72
        - F-73
Notes
        to Consolidated Financial Statements
F-74
        - F-99
_______________________
________________________________
_______________________
F-66
REPORT
OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
To
the board of directors and shareholders of
SILEXION
THERAPEUTICS CORP
Opinion
on the Financial Statements
We
have audited the accompanying consolidated balance sheets of Silexion Therapeutics Corp (formerly known as Silexion Therapeutics Ltd.)
and its subsidiaries (the "Company") as of December 31, 2023 and 2022, and the related consolidated statements of operations,
changes in redeemable convertible preferred shares and capital deficiency and cash flows for the years then ended, including the related
notes (collectively referred to as the "consolidated financial statements"). In our opinion, the consolidated financial statements
present fairly, in all material respects, the financial position of the Company as of December 31, 2023 and 2022, and the results of its
operations and its cash flows for each of the years then ended, in conformity with accounting principles generally accepted in the United
States of America.
Substantial
Doubt about the Company's Ability to Continue as a Going Concern
The
accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern. As discussed
in Note 1e to the consolidated financial statements, the Company has suffered recurring losses from operations and has cash outflows from
operating activities that raise substantial doubt about its ability to continue as a going concern. Management's plans in regard
to these matters are also described in Note 1e. The consolidated financial statements do not include any adjustments that might result
from the outcome of this uncertainty.
Basis
for Opinion
These
consolidated financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion
on the Company's consolidated financial statements based on our audits. We are a public accounting firm registered with the Public
Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance
with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.
We
conducted our audits of these consolidated financial statements in accordance with the standards of the PCAOB. Those standards require
that we plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free of material
misstatement, whether due to error or fraud.
Our audits included performing procedures to assess the risks of material misstatement
of the consolidated financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures
included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements. Our audits
also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall
presentation of the consolidated financial statements. We believe that our audits provide a reasonable basis for our opinion.
/s/Kesselman & Kesselman
Certified Public Accountants (lsr.)
A member firm of PricewaterhouseCoopers International Limited
Tel-Aviv, Israel
May 9, 2024, except for the effects of the reverse share split
        discussed in note 1c, and except for the effects of the merger exchange ratio discussed in note 1c, as to which the date is January 13,
        2025
Kesselman & Kesselman, 146 Derech Menachem Begin, Tel-Aviv 6492103,
        Israel,
P.O Box 50005 Tel-Aviv 6150001, Telephone: +972 -3- 7954555, Fax:+972
        -3- 7954556, www.pwc.com/il
F-67
SILEXION
THERAPEUTICS CORP
CONSOLIDATED
BALANCE SHEETS
(U.S.
dollars in thousands, except share data)
December
        31
2023
2022
Assets
CURRENT
        ASSETS:
Cash
        and cash equivalents
$
4,595
$
8,259
Restricted
        cash
25
25
Short
        term deposits
-
507
Prepaid
        expenses
335
6
Other
        current assets
24
42
TOTAL
        CURRENT ASSETS
4,979
8,839
NON-CURRENT
        ASSETS:
Restricted
        cash
25
25
Long-term
        deposit
5
5
Property
        and equipment, net
49
159
Operating
        lease right-of-use asset
198
305
TOTAL
        NON-CURRENT ASSETS
277
494
TOTAL
        ASSETS
$
5,256
$
9,333
The
accompanying notes are an integral part of these consolidated financial statements.
F-68
SILEXION
THERAPEUTICS CORP
CONSOLIDATED
BALANCE SHEETS
(U.S.
dollars in thousands, except share data)
December
        31
2023
2022
Liabilities
        and redeemable convertible preferred shares, net of capital deficiency
CURRENT
        LIABILITIES:
Trade
        payables
$
319
$
240
Current
        maturities of operating lease liability
112
115
Warrants
        to preferred shares (including $
186
and $
0
due to related party, respectively)
200
3
Employee
        related obligations
207
253
Accrued
        expenses
1,358
999
TOTAL
        CURRENT LIABILITIES
2,196
1,610
NON-CURRENT
        LIABILITIES:
Long-term
        operating lease liability
59
156
TOTAL
        NON-CURRENT LIABILITIES
$
59
$
156
TOTAL
        LIABILITIES
$
2,255
$
1,766
COMMITMENTS
        AND CONTINGENT LIABILITIES
(Note 6)
REDEEMABLE
        CONVERTIBLE PREFERRED SHARES AND NON-CONTROLLING INTERESTS:
Convertible
        Series A Preferred Shares (NIS
0.09
par value,
56,667
shares authorized as of December 31, 2023 and 2022,
43,121
shares issued and outstanding as of December 31, 2023 and 2022); aggregate liquidation preference of $
8,162
as of December 31, 2023;
Convertible
        Series A-1 Preferred Shares (NIS
0.09
par value per share,
13,334
shares authorized as of December 31, 2023 and 2022,
10,136
shares issued and outstanding as of December 31, 2023 and 2022); aggregate liquidation preference of $
2,443
as of December 31, 2023;
Convertible
        Series A-2 Preferred Shares (NIS
0.09
par value per share,
22,223
shares authorized as of December 31, 2023 and 2022,
5,051
shares issued and outstanding as of December 31, 2023 and 2022); aggregate liquidation preference of $
2,763
as of December 31, 2023;
Convertible
        Series A-3 Preferred Shares (NIS
0.09
par value per share,
8,889
shares authorized as of December 31, 2023 and 2022,
7,037
shares issued and outstanding as of December 31, 2023 and 2022); aggregate liquidation preference of $
2,887
as of December 31, 2023;
Convertible
        Series A-4 Preferred Shares (NIS
0.09
par value per share,
90,556
and
0
shares authorized as of December 31, 2023 and 2022, respectively,
2,413
**
        and
0
shares issued and outstanding as of December 31, 2023 and 2022, respectively); aggregate liquidation preference of $
1,076
as of December 31, 2023;
TOTAL
        REDEEMABLE CONVERTIBLE PREFERRED SHARES
15,057
14,646
CONTINGENTLY
        REDEEMABLE NON-CONTROLLING INTERESTS
3,420
3,586
TOTAL
        REDEEMABLE CONVERTIBLE PREFERRED SHARES AND CONTINGENTLY REDEEMABLE NON-CONTROLLING INTERESTS
$
18,477
$
18,232
CAPITAL
        DEFICIENCY:
Ordinary
        shares (($
0.0009
par value per share,
22,222,222
shares authorized as of December 31, 2023 and 2022;
97,120
shares issued and outstanding as of December 31, 2023 and 2022)
*
*
Additional
        paid-in capital
11,335
11,204
Accumulated
        deficit
(
26,811
)
(
21,869
)
TOTAL
        CAPITAL DEFICIENCY
$
(
15,476
)
$
(
10,665
)
TOTAL
        REDEEMABLE CONVERTIBLE PREFERRED SHARES AND CONTINGENTLY REDEEMABLE NON-CONTROLLING INTERESTS, NET OF CAPITAL DEFICIENCY
$
3,001
$
7,567
TOTAL
        LIABILITIES, REDEEMABLE CONVERTIBLE
PREFERRED
        SHARES AND NON-CONTROLLING INTEREST NET OF CAPITAL DEFICIENCY
$
5,256
$
9,333
*
Represents an amount less than $1
**
Net of 13,458 treasury shares held by a subsidiary as of December 31, 2023 (see Note 9(b)(2))
The
accompanying notes are an integral part of these consolidated financial statements.
F-69
SILEXION THERAPEUTICS CORP
CONSOLIDATED STATEMENTS OF OPERATIONS
(U.S. dollars in thousands, except share data)
Year ended December 31
2023
2022
OPERATING EXPENSES:
Research and development,
        net (including $
69
and $
49
from related party, respectively)
$
3,708
$
3,226
General and administrative
        (including $
48
and $
37
from related party, respectively)
973
634
TOTAL OPERATING EXPENSES
4,681
3,860
OPERATING LOSS
4,681
3,860
Financial expenses (income), net (including $
83
and $
0
from related party, respectively)
395
(
396
)
LOSS BEFORE INCOME TAX
$
5,076
$
3,464
INCOME TAX
32
24
NET LOSS FOR THE YEAR
$
5,108
$
3,488
Attributable to:
Equity holders of the Company
4,942
3,215
Non-controlling interests
166
273
$
5,108
$
3,488
LOSS PER SHARE, BASIC AND DILUTED
$
44.23
$
28.79
WEIGHTED
        AVERAGE NUMBER OF ORDINARY SHARES OUTSTANDING USED IN COMPUTATION OF BASIC AND DILUTED LOSS PER SHARE
111,726
111,686
The accompanying notes are an integral part of these
consolidated financial statements.
F-70
SILEXION
THERAPEUTICS CORP
CONSOLIDATED
STATEMENTS OF CHANGES IN REDEEMABLE CONVERTIBLE PREFERRED SHARES AND CAPITAL DEFICIENCY
(U.S. dollars
in thousands, except per share data)
Re
deemable
        Convertible Preferred Shares
Ordinary
        shares
Additional
        paid-in
Capital
Accumulated
deficit
Total
capital
deficiency
Total
redeemable
convertible
preferred
shares
        and
contingently
redeemable
non-
controlling
interests,
net
        of
capital
deficiency
Series A
preferred shares
Series A-1
preferred shares
Series A-2
preferred shares
Series A-3
preferred shares
Series A-4
preferred shares
Contingently
        redeemable non- controlling interests
Shares
Amount
Shares
Amount
Shares
Amount
Shares
Amount
Shares
Amount
Amount
Shares
Amount
BALANCE
        AT JANUARY 1, 2022
43,121
$
7,307
10,136
$
2,392
-
-
-
-
-
-
$
3,859
97,074
*
$
11,007
$
(
18,654
)
$
(
7,647
)
$
5,911
CHANGES
        DURING 2022:
Issuance
        of Preferred A-2 shares, net of issuance cost, see Note 9(b)
5,051
2,264
2,264
Conversion
        of simple agreements for future equity (SAFE) to Preferred A-3 shares, see Note 7
7,037
2,683
69
69
2,752
Exercise
        of options
46
*
3
3
3
Share-based
        compensation
125
125
125
Net
        loss
(
273
)
(
3,215
)
(
3,215
)
(
3,488
)
BALANCE
        AT DECEMBER 31, 2022
43,121
$
7,307
10,136
$
2,392
5,051
$
2,264
7,037
$
2,683
-
-
$
3,586
97,120
*
$
11,204
$
(
21,869
)
$
(
10,665
)
$
7,567
CHANGES
        DURING 2023:
Issuance
        of Preferred A-4 shares, net of issuance cost, see Note 9(b)
2,413
411
1
1
412
Share-based
        compensation
130
130
130
Net
        loss
(
166
)
(
4,942
)
(
4,942
)
(
5,108
)
BALANCE
        AT DECEMBER 31, 2023
43,121
$
7,307
10,136
$
2,392
5,051
$
2,264
7,037
$
2,683
2,413
$
411
$
3,420
97,120
*
$
11,335
$
(
26,811
)
$
(
15,476
)
$
3,001
*
Represents
        an amount less than $1
The
accompanying notes are an integral part of these consolidated financial statements.
F-71
SILEXION
THERAPEUTICS CORP
CONSOLIDATED
STATEMENTS OF CASH FLOWS
(U.S.
dollars in thousands)
Year
        ended December 31
2023
2022
CASH
        FLOWS FROM OPERATING ACTIVITIES:
Net
        loss
$
(
5,108
)
$
(
3,488
)
Adjustments
        required to reconcile loss to net cash used in operating activities:
Depreciation
45
57
Share-based
        compensation expenses
130
125
Non-cash
        financial expenses
318
(
268
)
Gain
        on disposal of property and equipment
(
1
)
-
Changes
        in operating assets and liabilities:
Increase
        (decrease) in prepaid expenses
(
329
)
415
Increase
        (decrease) in other receivables
18
(
40
)
Increase
        (decrease) in trade payable
79
(
38
)
Net
        change in operating lease
6
(
34
)
Increase
        (decrease) in employee related obligations
(
46
)
(
53
)
Increase
        (decrease) in accrued expenses
359
(
11
)
Net
        cash used in operating activities
(
4,529
)
(
3,335
)
CASH
        FLOWS FROM INVESTING ACTIVITIES:
Proceeds
        from long-term deposits
-
16
Investment
        in short-term deposit
-
(
500
)
Proceeds
        from short-term deposit
507
-
Purchase
        of property and equipment
(
12
)
(
40
)
Proceeds
        from sale of property and equipment
78
-
Net
        cash provided by (used in (investing activities
573
(
524
)
CASH
        FLOWS FROM FINANCING ACTIVITIES:
Proceeds
        from issuance of preferred shares and warrants, net of issuance costs
522
2,749
Exercise
        of options
-
3
Net
        cash provided by financing activities
522
2,752
DECREASE
        IN CASH AND CASH EQUIVALENTS AND RESTRICTED CASH
(
3,434
)
(
1,107
)
EXCHANGE
        RATE DIFFERENCES ON CASH AND CASH EQUIVALENTS AND RESTRICTED CASH
(
230
)
(
667
)
BALANCE
        OF CASH, CASH EQUIVALENTS AND RESTRICTED CASH AT BEGINNING OF YEAR
8,309
10,083
BALANCE
        OF CASH, CASH EQUIVALENTS AND RESTRICTED CASH AT END OF YEAR
$
4,645
$
8,309
The
accompanying notes are an integral part of these consolidated financial statements.
F-72
SILEXION
THERAPEUTICS CORP
CONSOLIDATED
STATEMENTS OF CASH FLOWS
(U.S.
dollars in thousands)
Year
        ended December 31
2023
2022
Appendix
        A
–
RECONCILIATION OF CASH, CASH EQUIVALENTS AND RESTRICTED CASH REPORTED IN
        THE CONSOLIDATED BALANCE SHEETS:
Cash
        and cash equivalents
4,595
8,259
Restricted
        cash
50
50
TOTAL
        CASH, CASH EQUIVALENTS AND RESTRICTED CASH SHOWN IN STATEMENT OF CASH FLOWS
$
4,645
$
8,309
Appendix
        B
-
SUPPLEMENTARY INFORMATION:
SUPPLEMENTARY
        INFORMATION ON INVESTING AND FINANCING ACTIVITIES NOT INVOLVING CASH FLOWS:
Transition
        to ASC 842 - recognition of operating right of use assets and operating lease liabilities
$
-
$
391
Conversion
        of SAFEs to preferred shares and warrants
$
-
$
2,683
SUPPLEMENTAL
        DISCLOSURES
OF CASH FLOW INFORMATION:
Interest
        received
$
153
$
114
F-73
SILEXION
THERAPEUTICS CORP
NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS
(continued)
U.S.
DOLLARS IN THOUSANDS
NOTE
1  - GENERAL:
a.
Silexion
        Therapeutics Ltd. (formerly known as Silenseed Ltd.) (hereinafter -"the Company") was incorporated in Israel and began its operations
        on November 30, 2008. Since its incorporation, the Company has been engaged in
one
operating segment – the research and development of innovative treatments for pancreatic cancer based on siRNAs, aiming to stop
        the production of a specific pancreatic cancer-causing protein known as the KRAS mutation. The Company's long-lived assets are located
        in Israel.
b.
On
        April 28, 2021, the Company signed an agreement with Guangzhou Sino-Israel Biotech Investment Fund (GIBF) to establish a new company in
        China. On June 15, 2021 a company was established in China, named Silenseed (China) Ltd (hereinafter - the "Subsidiary"). The Company
        owns
51
%
        of the shares of the Subsidiary. The Subsidiary has not yet started significant operations as of December 31, 2023. The Company and
        Silenseed (China) Ltd., together - "the Group" (see Note 9d).
c.
On
        April 3, 2024, the Company entered into an Amended and Restated Business Combination Agreement (hereinafter, "A&R BCA")
        with Moringa acquisition Corp (the "SPAC"), Biomotion Sciences, August M.S. Ltd. and Moringa Acquisition Merger Sub Corp (hereinafter
        - the "Business Combination") which replaced an earlier business combination agreement, for further information see Note
        15(a) and (b). Subsequently, Biomotion Sciences changed its name to Silexion Therapeutics Corp ("New Silexion").
The
A&R BCA was accounted for as a reverse recapitalization in accordance with US GAAP. Under this method of accounting, the Company
was treated as the accounting acquirer and the SPAC was treated as the "acquired" company for financial reporting purposes.
Under
the reverse recapitalization accounting method, the A&R BCA was deemed to be the equivalent of a capital transaction in which Silexion
issued shares for the net assets of the SPAC. Operations prior to the A&R BCA are those of Silexion.
In
accordance with the applicable guidance to reverse recapitalization, the equity structure has been retroactively adjusted in all comparative
periods up to the date of the Closing (the "Closing Date"), to reflect the number of New Silexion's Ordinary Shares,
$
0.0001
par value per share (prior to reverse share split, see below) issued to legacy Silexion shareholders in connection with the reverse recapitalization
transaction. As such, the shares and corresponding capital amounts and earnings per share related to legacy Silexion shareholders prior
to the reverse recapitalization have been retroactively restated as shares reflecting the exchange ratio established pursuant to the Transactions.
In conjunction with the reverse recapitalization, Silexion's Ordinary Shares underwent a 1-for-3.9829 conversion (prior to
reverse share split, see below). Also, under ASC 250, the reporting entity changed such that financial statements covering periods prior
to the Closing Date are now deemed to be those of New Silexion.
On
November 22, 2024, New Silexion announced a prospective 1-for-9 reverse share split of all of its issued and outstanding, and authorized
but unissued, Ordinary Shares. See Note 13. The reverse share split was to result in a corresponding increase in the par value of New
Silexion's Ordinary Shares, from $
0.0001
per share to $
0.0009
per share. No fractional shares were to be issued as a result of the reverse split, as any fractional share totals to which shareholders
became entitled were to be rounded up to the nearest whole number of shares. The reverse share split became effective after market close
on November 27, 2024 and was reflected at the start of trading in New Silexion's Ordinary Shares on November 29, 2024. Unless otherwise
noted, all Ordinary Shares, preferred shares and per share amounts contained in these consolidated financial statements (both of the Company
and New Silexion) have been retroactively adjusted to reflect a 1-for-9 reverse share split.
d.
In
        October 2023, Hamas terrorists infiltrated Israel's southern border from the Gaza Strip and conducted a series of attacks on civilian
        and military targets. Following the attack, Israel's security cabinet declared war against Hamas and commenced a military campaign
        against Hamas and other terrorist organizations.
F-74
S
ILEXION
THERAPEUTICS CORP
NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS (continued)
U.S.
DOLLARS IN THOUSANDS
NOTE
1  - GENERAL
(continued):
The
Company's headquarters are located in Modiin, Israel. As of the issuance date of these consolidated financial statements, the conflict
between Israel and Hamas has not had a material impact on the Company's results of operations or financial position, if at all.
The Company cannot currently predict the intensity or duration of Israel's war against Hamas, however, as most of the Company's
trials are not executed in Israel, the Company does not believe the recent terrorist attack and the subsequent declaration of war by the
Israeli government against the Hamas terrorist organization will have any material impact on its ongoing operations. The Company continues
to monitor its ongoing activities and will make any needed adjustments to ensure continuity of its business, while supporting the safety
and well-being of its employees.
Any
hostilities involving Israel, or the interruption or curtailment of trade within Israel or between Israel and its trading partners could
adversely affect the Company's operations and results of operations and could make it more difficult for the Company to raise capital.
e.
Going
        concern
:
Since
its inception, the Company has devoted substantially all its efforts to research and development, clinical trials, and capital raising
activities. The Company is still in its development and clinical stage and has not yet generated revenues.
The
Company has incurred losses of $
5,108
and $
3,488
for the years ended on December 31, 2023  and 2022, respectively.
During the years ended on December 31, 2023 and 2022, the
Company had negative operating cash flows of $
4,529
and $
3,335
,
respectively.  As of December 31, 2023, the Company had cash and cash equivalents of $
4.6
million. The Company expects to continue incurring losses, and negative cash flows from operations. Management is in the process of evaluating
various financing alternatives, as the Company will need to finance future research and development activities, general and administrative
expenses and working capital through fund raising. However, there is no assurance that the Company will be successful in obtaining such
funding.
Under
these circumstances, in accordance with the requirements of ASC 205-40, management has concluded that there is substantial doubt about
the Company's ability to continue as a going concern for at least 12 months from the date these financial statements are issued.
The financial statements do not include any adjustments that may be necessary should the Company be unable to continue as a going concern.
NOTE
2  - SIGNIFICANT ACCOUNTING POLICIES:
a.
Basis
        of presentation
The
Company's consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the
United States ("U.S. GAAP").
b.
Use of
        estimates
The
preparation of the financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect
the amounts reported in the financial statements and accompanying notes. Actual results could differ from those estimates. As applicable
to these financial statements, the most significant estimates and assumptions relate to fair value of financial instruments and share-based
compensation see Notes 12 and 11, respectively.
c.
Functional
        currency
The
Company's operations are currently conducted in Israel and some of the Company's expenses are currently paid in new Israeli
shekels ("NIS"); however, the markets for the Company's future products are located outside of Israel. Financing activities
are conducted in U.S. dollar ("dollar" or "$"). The Company's management believes that the US dollar
is the currency of the primary economic environment in which the Company operates. Thus, the functional and reporting currency of the
Company is the dollar. The functional currency of the Subsidiary is U.S. dollar, inter alia, in light of the composition of expenses
and expected volume of intercompany transactions with the Company.
F-75
S
ILEXION
THERAPEUTICS CORP
NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS (continued)
U.S.
DOLLARS IN THOUSANDS
NOTE
2  - SIGNIFICANT ACCOUNTING POLICIES
(continued):
Transactions
and balances originally denominated in dollars are presented at their original amounts. Balances in non- U.S. dollar currencies are
translated into dollars using historical and current exchange rates for non-monetary and monetary balances, respectively. For non-dollar
transactions and other items in the statements of operations (indicated below), the following exchange rates are used: (i) for transactions — exchange
rates at transaction dates or average exchange rates; and (ii) for other items (derived from non-monetary balance sheet items such
as depreciation and amortization) — historical exchange rates. Currency transaction gains and losses are presented in financial
income or expenses, as appropriate.
d.
Principles
        of consolidation
The
accompanying consolidated financial statements include the accounts of the Company and its subsidiary. All intercompany balances and transactions
have been eliminated in consolidation.
The
financial statements of the Company and of the Subsidiary are prepared as of the same dates and periods. The consolidated financial statements
are prepared using uniform accounting policies by all companies in the Group.
e.
Cash and
        cash equivalents
The
Company considers as cash equivalents all short-term, highly liquid investments, which include short-term bank deposits with original
maturities of three months or less from the date of purchase that are not restricted as to withdrawal or use and are readily convertible
to known amounts of cash.
Bank
balances for which use by the Company is subject to third party contractual restrictions are included as part of cash unless the restrictions
result in a bank balance no longer meeting the definition of cash. If the contractual restrictions to use the cash extend beyond 12 months
after the end of the reporting period, the related amounts are classified as non-current in Balance sheets.
f.
Restricted
        cash
As
of December 31, 2023 and 2022, the Company pledged an amount of $
25
in favor of a bank as collateral for guarantees provided to secure the lease payments.
The
Company is required to hold a minimum amount of NIS
85
in its bank account in order to maintain availability of a credit line from its credit card company.
g.
Property
        and equipment:
Property
and equipment are stated at cost, net of accumulated depreciation.
Depreciation
is calculated using the straight-line method over the estimated useful lives of the assets, at the following annual rates:
%
Computers
        and software
33
Laboratory
        and electronic equipment
15
Leasehold
        improvements*
15
-
40
F-76
S
ILEXION
THERAPEUTICS CORP
NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS (continued)
U.S.
DOLLARS IN THOUSANDS
NOTE
2  - SIGNIFICANT ACCOUNTING POLICIES
(continued):
*
Leasehold improvements are amortized
        by the straight-line method over the expected lease term, which is shorter than the estimated useful life of the improvements.
h.
Employee
        rights upon retirement
The
Company is required to make severance payments upon dismissal of an employee or upon termination of employment in certain circumstances.
In
accordance with the current employment terms with all of its employees located in Israel, and pursuant to Section 14 of the Israeli
Severance Pay Law, 1963, the Company makes and has been continuously making, since the beginning of employment of each of its current
employees, regular deposits, at a rate of
8.33
%
of their monthly salary, with certain insurance companies for accounts controlled by each applicable employee in order to secure the employee's
full severance pay obligation.
Under
these circumstances, the Company is currently relieved from any severance pay liability with respect to each such employee. Neither the
liability in respect of these employees nor the credit for the amounts funded are reflected on the Company's consolidated balance
sheets, as the amounts funded are not under the control or management of the Company and the severance pay risks have been irrevocably
transferred to the applicable insurance companies.
The
amounts of severance payment expenses were $
74
and $
82
for the years ended December 31, 2023 and 2022, respectively.
i.
Fair
        value measurement
Fair
value is based on the price that would be received from the sale of an asset or that would be paid to transfer a liability in an orderly
transaction between market participants at the measurement date. In order to increase consistency and comparability in fair value measurements,
the guidance establishes a fair value hierarchy that prioritizes observable and unobservable inputs used to measure fair value into three
broad levels, which are described as follows:
Level 1:
Quoted
        prices (unadjusted) in active markets that are accessible at the measurement date for assets or liabilities. The fair value hierarchy
        gives the highest priority to Level 1 inputs.
Level 2:
Observable
        prices that are based on inputs not quoted on active markets, but corroborated by market data or active market data of similar or identical
        assets or liabilities.
Level 3:
Unobservable
        inputs are used when little or no market data is available. The fair value hierarchy gives the lowest priority to Level 3 inputs.
In
determining fair value, the Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable
inputs to the extent possible and considers counterparty credit risk in its assessment of fair value.
j.
Financial
        instruments issued
When
the Company issues preferred shares, it first considers the provisions of ASC 480, Distinguishing Liabilities from Equity ("ASC 480")
in order to determine whether the preferred share should be classified as a liability. If the instrument is not within the scope of ASC 480,
the Company further analyzes the instrument's characteristics in order to determine whether it should be classified within temporary
equity (mezzanine) or within permanent equity in accordance with the provisions of ASC 480-10-S99. The Company's redeemable
convertible preferred shares are not mandatorily or currently redeemable. However, they include clauses that could constitute as in-substance
redemption clauses that are outside of the Company's control. As such, all shares of redeemable convertible preferred shares have
been presented outside of permanent equity.
F-77
S
ILEXION
THERAPEUTICS CORP
NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS (continued)
U.S.
DOLLARS IN THOUSANDS
NOTE
2  - SIGNIFICANT ACCOUNTING POLICIES
(continued):
When
the Company issues other freestanding instruments, the Company first analyzes the provisions of ASC 480 in order to determine whether
the instrument should be classified as a liability, with subsequent changes in fair value recognized in the statements of operations in
each period. If the instrument is not within the scope of ASC 480, the Company further analyzes the provisions of ASC 815-40
in order to determine whether the instrument should be classified within equity or classified as an asset or liability, with subsequent
changes in fair value recognized in the statements of operations in each period.
The
Company's issued financial instruments convertible to preferred shares are in the scope of ASC 480. For further details see
Note 7 and Note 8.
k.
Redeemable
        Non-controlling Interest
Non-controlling
interests with embedded redemption features, whose settlement is not at the Company's discretion, are considered redeemable non-controlling
interest. Redeemable non-controlling interests are considered to be temporary equity and are therefore presented as a mezzanine section
between liabilities and equity on the Company's consolidated balance sheets. Redeemable non-controlling interests are measured at
the greater of the initial carrying amount adjusted for the non-controlling interest's share of comprehensive income or loss or
its redemption value. Subsequent adjustment of the amount presented in temporary equity is currently not required because the Company's
management estimates that it is not probable that the instrument will become redeemable. Adjustments of redeemable non-controlling interest
to its redemption value are recorded through additional paid-in capital.
l.
Research
        and development expenses
Research
and development costs are charged to the statements of operations as incurred. Research and development expenses include costs directly
attributable to the conduct of research and development programs, including the cost of payroll and subcontractors, as well as share-based
payments. Advance payments for goods or services that will be used or rendered for future research and development activities are deferred.
Such amounts are recognized as an expense as the related goods are used or the services are rendered.
Grants
received from the Israeli Innovation Authority ("IIA") for approved research and development projects are recognized at the
time the Company is entitled to such grants, on the basis of the costs incurred and included as a deduction from research and development
expenses, see Note 5(a). The Company did not receive any grants during 2022 and 2023.
m.
Share-based
        compensation
The
Company's employees and non-employees share-based payment awards are classified as equity awards. The Company accounts for these
awards using the grant-date fair value method. The fair value of share-based payment transactions is recognized as an expense over the
requisite service period using the straight-line method.
The
Company elected to recognize compensation costs for awards conditioned only on continued service that have a graded vesting schedule using
the straight-line method based on the multiple-option award approach. Forfeitures are recognized as they occur.
The
Company accounts for its non-employees' equity-classified share-based payment in a similar manner.
F-78
S
ILEXION
THERAPEUTICS CORP
NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS (continued)
U.S.
DOLLARS IN THOUSANDS
NOTE
2  - SIGNIFICANT ACCOUNTING POLICIES
(continued):
n.
Leases
The
Company adopted the ASC 842, Leases accounting guidance. The Company recognized new right-of-use assets and operating lease liabilities
of $
391
as of January 1, 2022. The Company does not have any finance leases.
The
Company recognizes operating lease payments in the consolidated statements of operations on a straight-line basis over the lease term.
Right-of-use ("ROU") assets represent the right to use an underlying asset for the lease term and lease liabilities represent
the obligation to make minimum lease payments arising from the lease. ROU assets are initially measured at amounts representing the discounted
present value of the lease payments over the lease, plus any initial direct costs incurred. The lease liability is initially measured
at lease commencement date based on the discounted present value of minimum lease payments over the lease term. The discount rate for
the lease is the rate in the lease unless that rate cannot readily determined. As the Company's leases do not provide an implicit
rate, the Company uses an estimated incremental borrowing rate ("IBR") based on the information available at commencement
date in determining the present value of lease payments. The Company's IBR is estimated to approximate the interest rate for collateralized
borrowing with similar terms and payments and in economic environments where the leased asset is located. The lease agreement included
an option to extend or terminate the lease. The Company exercised its option to extend the lease period up to July 2025.
Payments
under the Company's lease arrangements are primarily fixed, however, certain lease agreements contain variable payments, which are
expensed as incurred and not included in the operating lease right-of-use assets and liabilities. The Company elected the practical expedient
not to separate lease and non-lease components.
o.
Loss
        per share
The
Company calculates loss per share using the two-class method required for participating securities. This method entails allocating income
available to ordinary shareholders for the period between ordinary shares and participating securities based on their respective rights
to receive dividends as if all income for the period had been distributed. Basic loss per share is computed by dividing net loss by the
weighted average number of shares of Ordinary shares outstanding during the year, and fully vested pre-funded options for the Company's
Ordinary shares at an exercise price of $
0.027
or
0.0063
NIS per share. The Company considers these shares to be exercised for little to no additional consideration. The Company also considers
its redeemable convertible preferred shares to be participating securities, as the holders of the redeemable convertible preferred shares
would be entitled to dividends that would be distributed to the holders of ordinary shares, on a pro-rata basis assuming conversion of
all redeemable convertible preferred shares into ordinary shares. However, these participating securities do not contractually require
the holders to participate in the Company's losses. Consequently, net loss for the periods presented was not allocated to the Company's
participating securities.
p.
Income
        taxes:
1)
Deferred taxes
Income
taxes are computed using the asset and liability method. Under the asset and liability method, deferred income tax assets and liabilities
are determined based on the differences between the financial reporting and tax bases of assets and liabilities and are measured using
the currently enacted tax rates and laws. A valuation allowance is recognized to the extent that it is more likely than not that the deferred
taxes will not be realized in the foreseeable future. Given the Company's losses, the Company has provided a full valuation allowance
with respect to its deferred tax assets.
F-79
S
ILEXION
THERAPEUTICS CORP
NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS (continued)
U.S.
DOLLARS IN THOUSANDS
NOTE
2  - SIGNIFICANT ACCOUNTING POLICIES
(continued):
2)
Uncertainty in
        income tax
The
Company follows a two-step approach in recognizing and measuring uncertain tax positions. The first step is to evaluate the tax position
for recognition by determining if the available evidence indicates that it is more likely than not that the tax position will be sustained
upon examination, including resolution of any related appeals or litigation processes, based on the technical merits of the position.
If this threshold is met, the second step is to measure the tax position as the largest amount that has more than a 50% likelihood of
being realized upon ultimate settlement.
q.
Concentration
        of credit risks
Financial
instruments that potentially subject the Company to concentration of credit risk consist principally of cash and cash equivalents, restricted
cash and short-term deposits. The Company deposits cash and cash equivalents mostly with three low risk financial institution. The Company
has not experienced any material credit losses in these accounts and does not believe it is exposed to significant credit risk on these
instruments.
r.
Operating
        segments and geographical information:
The
Company is managed as one R&D department during its startup phase that has yet to earn revenues. The Company's Chief Executive
Office ("CEO") was identified as the chief operating decision maker ("CODM"). The CODM reviews the financial information
every quarter. Accordingly, the company had determined to operate under one reportable segment.
All
of the Company long-lived assets are located in Israel.
s.
New accounting
        pronouncements:
The
Company qualifies as an emerging growth company ("EGC") as defined under the Jumpstart Our Business Startups Act (the "JOBS
Act"). Using exemptions provided under the JOBS Act for EGCs, the Company has elected to defer compliance with new or revised ASUs
until it is required to comply with such updates, which is generally consistent with the adoption dates of private companies.
Recently
Adopted accounting pronouncements:
In
June 2016, the FASB issued ASU 2016-13, "Financial Instruments - Credit Losses (Topic 326): Measurement
of Credit Losses on Financial Instruments", which replaces the existing incurred loss model with a current expected credit loss
("CECL") model that requires consideration of a broader range of reasonable and supportable information to inform credit loss
estimates. Subsequent to the issuance of ASU 2016-13, the FASB issued several additional Accounting Standard Updates to clarify implementation
guidance, provide narrow-scope improvements and provide additional disclosure guidance. Under the ASU, the Company is required to use
a forward-looking CECL model for accounts receivables and other financial instruments. The Company adopted the ASU on January 1,
2023 and it did not have a material impact on its consolidated financial statement.
Recently
issued accounting standards not yet adopted:
1)
In
        June 2022, the FASB issued ASU 2022-03 "Fair Value Measurement of Equity Securities Subject to Contractual Sale Restrictions".
        The ASU clarifies that a contractual restriction on the sale of an equity security is not considered part of the unit of account of the
        equity security and, therefore, is not considered in measuring
F-80
S
ILEXION
THERAPEUTICS CORP
NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS (continued)
U.S.
DOLLARS IN THOUSANDS
NOTE
2  - SIGNIFICANT ACCOUNTING POLICIES
(continued):
2)
its
        fair value. The ASU also clarifies that an entity cannot, as a separate unit of account, recognize and measure a contractual sale restriction.
        The ASU also introduces new disclosure requirements for equity securities subject to contractual sale restrictions. As an Emerging Growth
        Company, the ASU is effective for fiscal years beginning after December 15, 2024, and interim periods within those fiscal years. Early
        adoption is permitted for both interim and annual financial statements that have not yet been issued or made available for issuance. The
        Company is currently evaluating the effect that ASU 2022-03 will have on its consolidated financial statements and related disclosures.
3)
In
        November 2023, the FASB issued ASU No. 2023-07 Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures. The ASU
        improves reportable segments disclosure requirements, primarily through enhanced disclosures about significant segment expenses.  The
        ASU also require that a public entity that has a single reportable segment to provide all the disclosures required by the amendments and
        all existing segment disclosures in Topic 280. The ASU is effective for fiscal years beginning after December 15, 2023, and interim periods
        within fiscal years beginning after December 15, 2024. The Company is currently evaluating this ASU to determine its impact on the Company's
        segment disclosures.
4)
In
        December, 2023, the FASB issued ASU 2023-09, Improvements to Income Tax Disclosures, which requires disclosure of disaggregated income
        taxes paid, prescribes standard categories for the components of the effective tax rate reconciliation, and modifies other income tax-related
        disclosures. The ASU will be effective for fiscal years beginning after December 15, 2025, and allows adoption on a prospective basis,
        with a retrospective option. The Company is in the process of assessing the impacts and method of adoption.
F-81
S
ILEXION
THERAPEUTICS CORP
NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS (continued)
U.S.
DOLLARS IN THOUSANDS
NOTE 3  - PROPERTY AND EQUIPMENT, NET:
Composition of property and equipment, grouped by major
classifications, is as follows:
December 31
2023
2022
Cost:
Computers
$
75
$
67
Laboratory and electronic equipment
-
274
Office furniture
2
2
Communication equipment
3
3
Leasehold improvements
56
52
$
136
$
398
Accumulated depreciation:
Computers
55
41
Laboratory and electronic equipment
-
179
Office furniture
2
1
Communication equipment
3
3
Leasehold improvements
27
15
$
87
$
239
Property and equipment, net
$
49
$
159
Depreciation expenses were $
45
and $
57
in the years ended December 31, 2023 and 2022, respectively.
NOTE
4  - LEASES:
The
Company leases offices for its facilities in Israel by way of an operating lease. The lease agreement for such offices is denominated
in NIS and linked to the Israeli consumer price index ("CPI").
The
Company provided the lessor with a bank guarantee as a rental security. The bank in turn placed a pledge over restricted cash of $
25
.
The
lease for the offices expires on July 31, 2025. The remaining lease term is up to
1.58
years
as of December 31, 2023.
Operating
lease costs for the years ended December 31, 2022 and 2023 are as follows:
Year
        Ended December 31,
2023
2022
Fixed payments and variable payments that depend on
        an index or rate:
Office
        and operational lease expenses
$
131
$
132
Variable
        lease cost (included in the operating lease costs)
$
9
$
3
Total
        operating lease costs
$
140
$
135
Operating
cash flows, for amounts included in the measurement of lease liabilities, are as follows:
Year
        Ended December 31,
2023
2022
Office
        and operational spaces lease expenses
$
101
$
119
F-82
S
ILEXION
THERAPEUTICS CORP
NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS (continued)
U.S.
DOLLARS IN THOUSANDS
NOTE
4  - LEASES
(continued):
Supplemental
information related to operating leases is as follows:
Year
        Ended December 31,
2023
2022
Operating
        lease right-of-use assets
$
198
$
305
Operating
        lease liabilities
$
171
$
271
Weighted
        average remaining lease term (years)
1.58
2.58
Weighted
        average discount rate
12.69
%
12.69
%
As
of December 31, 2023, the Company has not entered into lease agreements that include options to extend them that are not included
in the measurement of the lease liability.
The
following table outlines maturities of the Company's operating lease liabilities as of December 31, 2023:
Operating
lease liabilities
2024
$
117
2025
68
Total undiscounted lease payments
$
185
Less – imputed
        interest
$
14
Present
        value of lease liabilities
$
171
NOTE
5  - SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION:
Statement
of operations:
a.
Research
        and development expenses, net:
Year ended December 31,
2023
2022
Payroll
        and related expenses
$
973
$
1,192
Subcontractors
        and consultants
2,467
1,595
Materials
13
191
Rent and
        maintenance
160
175
Travel expenses
37
42
Other
58
31
$
3,708
$
3,226
b.
General
        and administrative expenses:
Payroll
        and related expenses
$
356
$
219
Professional
        services
386
197
Depreciation
45
57
Rent and
        maintenance
86
71
Patent registration
22
32
Travel expenses
31
-
Other
47
58
$
973
$
634
F-83
S
ILEXION
THERAPEUTICS CORP
NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS (continued)
U.S.
DOLLARS IN THOUSANDS
NOTE
5  - SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION
(continued):
c.
Financial
        expense, net:
Change
        in fair value of financial liabilities measured at fair value
$
86
$
(
1,017
)
Issuance
        costs
3
84
Interest
        income
(
153
)
(
114
)
Foreign
        currency exchange loss, net
453
650
Other
6
1
Total
        financial expense (income), net
$
395
$
(
396
)
NOTE 6  - COMMITMENTS AND CONTINGENT LIABILITIES:
During 2009 to 2020, the Company received
several approvals from the IIA for participation in research and development activities performed by the Company ("Support Grants")
in a total amount of $
5.8
million.
The Company is obligated to pay royalties
to the IIA amounting to
3
%-
5
%
of the sales of the core products and other related revenues generated from such projects, up to
100
%
of the Support Grants received, linked to the U.S. dollar and bearing interest at the rate of LIBOR. The obligation to pay these
royalties is contingent upon actual sales of the products and, in the absence of such sales, no payment is required. In October 2023,
it was published that the interest rate on the Support Grants will be replaced with the
12
-month
term Secured Overnight Financing Rate (SOFR) published on the first trading day of each calendar year.
As of December 31, 2023, the total
royalty amount that may be payable by the Company is approximately $
5.8
million
($
6.4
million
including interest).
NOTE
7  - SIMPLE AGREEMENT FOR FUTURE EQUITY
On
March 15, 2021, a Simple Agreement for Future Equity ("SAFE") was signed between the Company and a group of investors, for an aggregate
amount of up to $
4,000
,
of which $
2,887
were actually raised. The SAFE was for a period of 9 months and was convertible into preferred shares with the most senior class of rights
issued   by the Company at the time of conversion.
The
conversion rate and timing were subject to events as determined in the SAFE, the principal amount thereon was to be converted to the most
senior class of shares of the Company in accordance with the terms mentioned in the SAFE, as follows: in an event that the Company consummates
an equity investment of at least $
2,000
,
the principal amount will be converted automatically to the most senior class of equity at the lower of (i) the price per share of the
most senior shares issued in such equity investment less a
25
%
discount, or (ii) a price per share reflecting a fully diluted pre-money Company valuation of $
70,000
.
However, in no event was the price per share to be lower than a price per share reflecting a fully-diluted pre-money valuation of the
Company of $
30,000
.
Total
consideration for the SAFE agreements was $
2,887
.
On
January 14, 2022, the Company converted the SAFE in the total amount of $
3,204
(its fair value as of conversion date) into
7,037
Series A-3 Preferred Shares and
5,278
warrants exercisable into Series A-2 Preferred Shares. In accordance with ASC 480 the Company recorded financial expenses in amount of
$
317
with respect to the discount on the SAFE conversion.
F-84
S
ILEXION
THERAPEUTICS CORP
NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS (continued)
U.S.
DOLLARS IN THOUSANDS
NOTE 8  - WARRANTS TO PURCHASE PREFERRED SHARES:
a.
In
        connection with the Series A-2 Preferred Shares (see Note 9(b)), the Company issued warrants to acquire
10,329
Series A-2 Preferred Shares to various investors, including
5,278
warrants issued as part of the converted SAFE (see Note 9(b)). These warrants feature an exercise price of $
547.047
per share and expired during 2023. As of December 31, 2022, there are
10,329
outstanding warrants. As of December 31, 2023, all warrants are expired.
b.
Concerning
        the Series A-4 Preferred Shares (see Note 9(b)), the Company issued warrants to acquire
2,413
Series A-4 Preferred Shares to various investors, with an exercise price of $
222.921
per share and an expiration date of May 30, 2025. Issuance expenses amounted to $
3
.
        As of December 31, 2023, there are outstanding warrants of
2,413
.
        Regarding the warrants issued to the subsidiary see Note 9(b)(2).
The Company
classified the warrants for the purchase of shares of its convertible redeemable preferred shares as a liability in its consolidated balance
sheets, as these warrants were freestanding financial instruments which underlying shares are contingently redeemable and, therefore,
may obligate the Company to transfer assets at some point in the future. The warrant liability was initially recorded at fair value upon
the date of issuance and was subsequently remeasured at fair value at each reporting date. The Company recorded revaluation expenses (income)
amounting to $(
86
) and
$
1,017
for
the years ended 2023 and 2022, respectively, and accounted for such revaluation expenses as part of its financial income (expense),
net, in the statements of operations.
For further information in respect of
warrants issuance to service provider see Note 11(1).
NOTE
9 - REDEEMABLE CONVERTIBLE PREFERRED SHARES AND SHAREHOLDERS' EQUITY:
a.
As
        of December 31, 2023 and 2022, the share capital is composed of 0.09 NIS par value shares, as follows:
December
        31, 2023
Authorized
Issued
        and paid
Carrying
Value
Liquidation
Preference
Ordinary
        Shares
22,222,222
97,120
$
4,685
Preferred
        A Shares
56,667
43,121
$
7,307
$
8,162
Preferred
        A-1 Shares
13,334
10,136
$
2,392
$
2,443
Preferred
        A-2 Shares
22,223
5,051
$
2,264
$
2,763
Preferred
        A-3 Shares
8,889
7,037
$
2,683
$
2,887
Preferred
        A-4 Shares
90,556
2,413
$
411
$
1,076
December
        31, 2022
Authorized
Issued
        and paid
Carrying
Value
Liquidation
Preference
Ordinary
        Shares
22,222,222
97,120
$
4,685
Preferred
        A Shares
56,667
43,121
$
7,307
$
8,162
Preferred
        A-1 Shares
13,334
10,136
$
2,392
$
2,443
Preferred
        A-2 Shares
22,223
5,051
$
2,264
$
2,763
Preferred
        A-3 Shares
8,889
7,037
$
2,683
$
2,887
F-85
S
ILEXION
THERAPEUTICS CORP
NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS (continued)
U.S.
DOLLARS IN THOUSANDS
NOTE
9 - REDEEMABLE CONVERTIBLE PREFERRED SHARES AND SHAREHOLDERS' EQUITY
(continued):
b.
Issuance
        of shares:
1)
On
        January 14, 2022, the Company signed an agreement to issue shares in consideration for an investment in the amount of $
2,763
.
        In return for this investment, the Company issued
5,051
Series A-2 Preferred Shares with a par value of NIS
0.09
.
        Issuance expenses amounted to $
14
.
Following
this investment, the Company converted the SAFE in the total amount of $
3,204
into
7,037
Series A-3 Preferred Shares.
In
addition, the Company issued
10,329
warrants for Series A-2 Preferred Shares NIS
0.09
par value per share, including
5,278
warrants issued as part of the converted SAFE (see Note 8(a)), each exercisable at a price     of $
547.02
per share.
2)
On
        May 30, 2023, the Company entered into an agreement to receive an investment in a total amount of $
538
.
        In exchange for this investment, the Company issued
2,413
Series A-4 Preferred Shares with a par value of NIS
0.09
.
        Issuance expenses amounted to $
16
.
Additionally,
the Company issued
2,413
warrants for Series A-4 Preferred Shares, each with a par value of NIS
0.09
,
exercisable at a price of $
222.921
per share.
In
addition, on May 30, 2023, the Subsidiary made an investment totaling $
3
million in the Company. This investment resulted in the acquisition by the Subsidiary of
13,458
Series A-4 Preferred Shares and
13,458
warrants convertible into series A-4 Preferred Shares. Each warrant is exercisable into one series A-4 Preferred Share at an exercise
price of $
222.921
per share. As the acquisition was eliminated in consolidation, it had no impact on the consolidated financial statement.
c.
Shareholders
        rights:
1)
The
        Ordinary shares confer upon their holders the right to participate and vote in general shareholders meetings of the Company and to share
        in the distribution of dividends, if any declared by the Company.
The
Series A Preferred Shares, Series A-1 Preferred Shares, Series A-2 Preferred Shares, Series A-3 Preferred Shares and Series A-4 Preferred
Shares (collectively, the "Preferred A Shares") confer upon their holders all of the rights conferred upon the holders of Ordinary Shares
in the Company, as well as the following rights:
a)
Distribution
        Preference
First,
the holders of Series A-4 Preferred Shares shall be entitled to receive, prior and in preference to any holders of Series A-3 Preferred
Shares, Series A-2 Preferred Shares, Series A-1 Preferred Shares, Series A Preferred Shares, Ordinary Shares or any other equity securities
of the Company, for each outstanding Series A-4 Preferred Share held by them, an amount equal to (i)
200
%
of the Original Issue Price per each Series A-4 Preferred Share (in cash, cash equivalents or, if applicable, securities) plus (ii) declared
and unpaid dividend in respect of such share (the "Series A-4 Preference Amount").
In
the event that the distributable proceeds are insufficient for the distribution of the Series A-4 Preference Amount in full to all holders
of Series A-4 Preferred Shares, then the Distributable Proceeds shall be distributed pari passu among such holders of Series A-4 Preferred
Shares in proportion to the respective full Series A-4 Preference Amount such holders would otherwise be entitled to receive.
F-86
S
ILEXION
THERAPEUTICS CORP
NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS (continued)
U.S.
DOLLARS IN THOUSANDS
NOTE
9 - REDEEMABLE CONVERTIBLE PREFERRED SHARES AND SHAREHOLDERS' EQUITY
(continued):
Second,
the holders of Series A Preferred Shares, Series A-1 Preferred Shares, Series A-2 Preferred Shares and Series A-3 Preferred Shares, shall
be entitled to receive, prior and in preference to any holders of Ordinary Shares, for each outstanding Preferred A Share held by them,
an amount equal to: (a) Series A and Series A-1 Shares - the issue price paid for such share; (b) Series A-2 preferred share - US$
547.047
per each Series A-2 share, and (c) Series A-3 Preferred Shares - US$
410.283
per each Preferred A-3 share; plus any declared and unpaid dividend in respect of such share (the "Series A, A-1, A-2 and A-3 Preference
Amount", and together with the Series A-4 Preference Amount, the "Preference Amounts").
In
the event that the distributable proceeds are insufficient for the distribution of the Series A, A-1, A-2 and A-3 Preference Amount in
full to all holders of Preferred A Shares, then the Distributable Proceeds shall be distributed pari passu among such holders of Series
A Preferred Shares, Series A-1 Preferred Shares, Series A-2 Preferred Shares and Series A-3 Preferred Shares in proportion to the respective
full Series A, A-1, A-2 and A-3 Preference Amount such holders would otherwise be entitled to receive.
Third,
following the distribution of the Preference Amounts, any remaining distributable proceeds shall be distributed pro rata among all the
holders of Ordinary Shares and Preferred A Shares, based on their respective holdings of outstanding shares of the Company, on a pari
passu and as converted basis.
b)
Liquidation
        Preference:
If
the Company is liquidated, dissolved or wound up (including, without limitation, upon appointment of a receiver or liquidator to all or
substantially all of the Company's assets, whether voluntary or involuntary), then all the assets and funds of the Company available for
distribution shall first be distributed in accordance with the Preference Amounts, and thereafter among all shareholders of the Company
pro rata based on the number of Ordinary Shares and Series A Preferred Shares held by each, on an as-converted basis.
For
the purpose of this clause, a liquidation event also includes (a) a merger of the Company into another corporation(s) in which the holders
of the Company's shares do not, immediately after such merger, represent a majority of the voting power of the surviving corporation
(other than a merger with a company in which the shareholders of the Company receive stock of the surviving company which is publicly
traded at the time of such merger); (b) a sale of all or substantially all of the assets of the Company to entities not controlled by
the Company's existing shareholders; and (c) a grant of an exclusive, irrevocable licensing of all or substantially all of the Company's
intellectual property to a third party
.
c)
Dividend
        Preference:
In
the event that the Company distributes a dividend in respect of its shares, the holders of Preferred A Shares shall be entitled to receive
the Preference Amounts prior to and in preference to the distribution of dividends to all shareholders of the Company.
F-87
S
ILEXION
THERAPEUTICS CORP
NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS (continued)
U.S.
DOLLARS IN THOUSANDS
NOTE
9 - REDEEMABLE CONVERTIBLE PREFERRED SHARES AND SHAREHOLDERS' EQUITY
(continued):
d)
Conversion
        Rights:
Each
Preferred A Share is convertible into Ordinary Shares. Their number is determined by multiplying such Preferred A Share by a quotient
equal to (a) the applicable Original Issue Price for such share divided by (b) the Conversion Price (as defined below) at the time in
effect for such share. The Preferred A Shares are convertible without payment of additional consideration by the holder thereof, upon
each of the following events: (i) at the option of the holder thereof, at any time and from time to time; (ii) upon the consent of, or
conversion by, the holders of a majority of the Preferred A Shares; or (iii) immediately before the consummation of an initial public
offering of the Company's securities.
The
initial conversion price per each Preferred A Share is the applicable Original Issue Price for such share (the "Conversion Price"). The
Conversion Price per each Preferred A Share shall be adjusted in the event of a share combination or subdivision, share split, distribution
of bonus shares or any other reclassification, reorganization or recapitalization (each, a "Recapitalization Event"), so that the holder
of each Preferred A Share shall be entitled to receive, upon conversion, such number of Ordinary Shares they would have been entitled
to receive following the Recapitalization Event had each Preferred A Share been converted into Ordinary Shares prior to the Recapitalization
Event.
Additionally,
in the event that the Company issues Additional Shares (as such term is defined in the Company's articles of association), for a consideration
per share lower than the applicable Conversion Price for Series A-4 Preferred Shares in effect immediately prior to such issuance (the
"Reduced Price"), then the Conversion Price for Series A-4 Preferred Shares shall be reduced, for no additional consideration, concurrently
with such issuance, to the Reduced Price.
d.
Silenseed
        China Minority Equityholder Rights:
The
articles of association of Silenseed (China) Ltd. (the " Subsidiary's Articles") provide the minority shareholder, Guangzhou Sino-Israel
Bio-industry Investment Fund (LLP) ("GIBF") with the following minority shareholder protections:
a.
Conversion
        ("Put/Call") Option: Either GIBF or the Company may elect that the equity rights of GIBF in the Subsidiary shall be exchanged for the
        most senior shares (i.e., preferred shares) of the Company, consequently turning the Subsidiary into a wholly-owned subsidiary of the
        Company. The number of shares to be issued to GIBF upon such exchange shall be calculated by converting the total cash amount invested
        by GIBF in the Subsidiary (the "Contribution Amount"), into the most senior class of shares of the Company as of May 30, 2023, based on
        a pre-money valuation of the Company of US$
20
million on a fully diluted basis as of September 1, 2023, or later, as shall be mutually agreed between the parties.
b.
"Company
        Exit Event" means the consummation of: (i) an initial public offering of Company, in a stock exchange, directly or via a SPAC (or similar
        methods); (ii) the sale of all or substantially all of the securities or assets of the Company (or an exclusive license with respect to
        all or substantially all of the assets of Company); (iii) a merger or acquisition of the Company (following which existing shareholders
        as of immediately prior to such transaction hold less than
50
%
        of the voting power of the surviving or acquiring entity); (iv) sale of at least
50
%
        of the means of control or assets of the Company; (v) liquidation, dissolution or winding up of the Company; or (vi) at any time upon
        a party's written notice, provided, however that the exercise of such right by the Company shall be subject to GIBF's written
        consent, which shall not be unreasonably withheld.
F-88
S
ILEXION
THERAPEUTICS CORP
NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS (continued)
U.S.
DOLLARS IN THOUSANDS
NOTE
9 - REDEEMABLE CONVERTIBLE PREFERRED SHARES AND SHAREHOLDERS' EQUITY
(continued):
1)
Anti-Dilution
        Protection
: If the Subsidiary issues any additional equity rights in the Subsidiary to a third-party investor in the next two equity
        investment rounds of the Subsidiary, reflecting a purchase price per equity right lower than the purchase price per equity right paid
        by GIBF, GIBF will be issued additional equity rights of the Subsidiary for no consideration, based on a broad based weighted average
        formula.
2)
Registration
        Rights
: GIBF shall be entitled to the same rights to register its equity rights in the Subsidiary as part of an IPO of the Subsidiary,
        as granted to Company, on a pro-rata basis.
3)
Liquidation
        Preference
: In the event of an IPO in which the Subsidiary's valuation is at least $
200
million or an Exit Event (as defined in the Subsidiary's Articles), GIBF shall be entitled to be paid out of the assets legally
        available for distribution to equity holders of the Subsidiary (the "Distributable Proceeds"), prior to any payment made to any other
        equity holder, an amount in cash equal to the Contribution Amount (the "Preference Amount"). Following payment of the Preference Amount,
        any remaining Distributable Proceeds shall be distributed among all holders of equity rights excluding GIBF, on a pro-rata basis, provided
        that GIBF shall have the right to waive its right to receive the Preference Amount, in which case all Distributable Proceeds shall be
        distributed among all equity holders of the Subsidiary on a pari passu and pro rata basis.
4)
Other
        rights, such as right of first refusal for GIBF to purchase the Company's equity rights in the Subsidiary if the Company proposes
        to sell or receives an offer to sell its equity rights; a right of co-sale for GIBF to participate in a proposed sale of the Company's
        equity rights in the Subsidiary on a pro-rata basis; a preemptive right for both investors to participate in the issuance of new securities
        by the Subsidiary until the consummation of an IPO or an Exit Event (as defined in the Subsidiary's Articles).
NOTE
10  - INCOME TAXES:
a.
Corporate
        taxation in Israel
The
Company is taxed according to the regular corporate income tax in Israel.  The corporate tax rate is
23
%
in 2023 and 2022.
b.
Income
        taxes on non-Israeli subsidiary
The
Subsidiary is taxed under the tax laws of China and the corporate tax rate is
25
%.
c.
Tax
        loss carryforwards
As
of December 31, 2023, the expected tax loss carryforwards of the Company were approximately $
19,151
,
which may be carried forward and offset against taxable income in the future for an indefinite period. The Company has recognized valuation
allowance for the full amount in respect of these tax loss carryforwards since their utilization is not expected in the foreseeable future.
F-89
S
ILEXION
THERAPEUTICS CORP
NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS (continued)
U.S.
DOLLARS IN THOUSANDS
NOTE
10  - INCOME TAXES
(continued):
Israel
and foreign components of loss from continuing operations, before income taxes consisted of:
Year ended December 31
2023
2022
Israel
$
4,769
$
2,929
Subsidiary
        outside of Israel
307
535
Total
$
5,076
$
3,464
d.
Uncertainty
        in income tax
As
of December 31, 2023 and 2022, no liability for unrecognized tax benefits was recorded due to immateriality.
e.
Tax
        rate reconciliation
Income
tax expense attributable to income from continuing operations was $
32
and $
24
for the years ended December 31, 2023 and 2022, respectively, and differed from the amounts computed by applying an Israeli Statutory
income tax rate of
23
%
to pretax income from continuing operations, mainly as a result of changes in valuation allowance of $
922
and $
268
respectively, as well as nondeductible expenses.
The
reconciliation of the theoretical tax benefit (expense) by the Israeli statutory tax rate to the Company's effective benefit (expense)
taxes are as follows:
Year ended December 31
2023
2022
Loss
        before income taxes
$
(
5,076
)
$
(
3,464
)
Statutory
        tax rate
23
%
23
%
Computed
        "expected" tax income
(
1,167
)
(
797
)
Exchange
        rate differences
120
588
Non-deductible
        share-based compensation
30
29
Non-deductible
        financial instruments valuation
21
(
215
)
Effect
        of other non-deductible differences
112
162
Change
        in valuation allowance
922
268
Subsidiary
        tax rate differences
(
6
)
(
11
)
Reported
        taxes on income
$
32
$
24
F-90
S
ILEXION
THERAPEUTICS CORP
NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS (continued)
U.S.
DOLLARS IN THOUSANDS
NOTE
10  - INCOME TAXES
(continued):
f.
Deferred
        tax
Deferred
taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting
purposes and the amounts used for income tax purposes. Significant components of the Company's deferred tax assets are as follows:
December
        31
2023
2022
Deferred
        tax assets
Operating
        loss carryforwards
$
4,405
3,752
Research
        and development
780
592
Accrued
        expenses
304
219
Lease
        liability
39
62
Other
25
30
Total
        deferred tax assets
$
5,553
$
4,655
Deferred
        tax liabilities
Right
        of use asset
(
46
)
(
70
)
Total
        deferred tax liabilities
$
(
46
)
$
(
70
)
Valuation
        allowance
$
(
5,507
)
$
(
4,585
)
Deferred
        tax assets, net of valuation allowance
$
-
$
-
g.
Roll
        forward of valuation allowance:
The
following table presents a reconciliation of the beginning and ending valuation allowance:
Balance
        as of December 31, 2021
$
(
4,317
)
Additions
(
268
)
Balance
        as of December 31, 2022
$
(
4,585
)
Additions
(
922
)
Balance
        as of December 31, 2023
$
(
5,507
)
In
assessing the realization of deferred tax assets, management considers whether it is more likely than not that all or some portion of
the deferred tax assets will not be realized. The ultimate realization of the deferred tax assets is dependent upon the generation of
future taxable income during the periods in which temporary differences are deductible and net operating losses are utilized. Based on
these factors, the Company recorded a full valuation allowance on December 31, 2023 and 2022.
h.
Income
        tax assessments
The
Company has tax assessments that are considered to be final through tax year 2018.
The
subsidiary does not have final tax assessments.
F-91
S
ILEXION
THERAPEUTICS CORP
NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS (continued)
U.S.
DOLLARS IN THOUSANDS
NOTE
11  - SHARE-BASED COMPENSATION:
1)
Warrants
        to service provider
In
conjunction with the issuance of Series A-1 Preferred Shares, the Company issued warrants to acquire
427
Series A-1 Preferred Shares to a service provider who assisted in raising the funds, which warrants were classified as part of the
issue expenses. These warrants carry an exercise price of $
241.02
per share and are set to expire on January 31, 2027. As of December 31, 2023 and 2022, all
427
of such warrants remained outstanding.
In
conjunction with the issuance of Series A-2 Preferred Shares, the Company issued warrants to acquire
446
Series A-3 Preferred Shares to a service provider who assisted in raising the funds, which were recorded as part of issue expenses.
These warrants carry an exercise price of $
410.283
per share and are set to expire on January 14, 2029. As of December 31, 2023 and 2022, all
446
of such warrants remained outstanding.
The
warrants for both the Series A-1 Preferred Shares and Series A-3 Preferred Shares were recognized as issuance costs of the SAFE round
and recognized as financial expenses.
In
conjunction with the issuance of Series A-4 Preferred Shares, the Company issued warrants to acquire
12
Series A-4 Preferred Shares to a service provider who assisted in raising the funds, which were recorded as part of issue expenses.
These warrants carry an exercise price as those issued to the investors in such round, and expire on May 30, 2030. As of December 31,
2023, all
12
of such warrants remained outstanding. The warrants were recognized as issuance costs and the portion attributed to the issuance
of Series A-4 Preferred Shares was classified as part of the shareholders' equity. The portion attributed to the issuance of the
warrants was recognized as financial expenses.
2)
Employee
        Stock Option Plan
As
of December 31, 2023, the Board of Directors approved a pool of
57,925
Ordinary Shares for grant to Company employees, consultants, directors and other service providers.
Under
the Company's 2013 and 2023 Incentive Option Plans (collectively "the Plan"), options to purchase Ordinary Shares may be granted to certain
entities and individuals. Each option granted under the Plan is exercisable until
10
years
from the date of grant, or earlier upon cessation of employment or engagement of the grantee and certain other occurrences.
Grants
to employees are made in accordance with the Plan and are carried out within the provisions of Section 102 of the Israel Income Tax
Ordinance, under the capital gains track described in subsection (b)(2) of Section 102. In accordance with such track selected by the
Company and the provisions associated with it, the Company is not entitled to claim a tax deduction for the employee benefits.
The
Company's options expenses amounted to a total of $
130
and $
125
in 2023 and 2022, respectively. As of December 31, 2023,
4,019
shares remain available for grant under the Plan.
F-92
S
ILEXION
THERAPEUTICS CORP
NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS (continued)
U.S.
DOLLARS IN THOUSANDS
NOTE 11  - SHARE-BASED COMPENSATION
(continued):
Summary
of outstanding and exercisable options:
Below
is a summary of the Company's stock-based compensation activity and related information with respect to options granted to employees and
non-employees for the year ended December 31, 2023 and 2022:
Number
        of options
Weighted-average
        exercise price (in U.S. dollars)
Weighted-
        average remaining contractual term
(in
        years)
Aggregate
intrinsic
value
Outstanding
        at December 31, 2022
54,135
$
38.93
5.88
$
144
Granted
-
$
-
-
$
-
Exercised
-
$
-
-
$
-
Forfeited
-
$
-
-
$
-
Expired
(
221
)
$
(
38.41
)
-
$
-
Outstanding
        at December 31, 2023
53,914
$
38.94
4.88
$
316
Exercisable
        at December 31, 2023
39,340
$
30.95
3.62
$
316
Vested
        and expected to vest at December 31, 2023
53,914
$
38.94
4.88
$
316
Number
        of options
Weighted-average
        exercise price (in U.S. dollars)
Weighted-
        average remaining contractual term
(in
        years)
Aggregate
intrinsic
value
Outstanding
        at December 31, 2021
31,897
$
23.88
4.46
$
493
Granted
24,119
$
60.51
9.98
$
-
Exercised
(
46
)
$
60.49
(
8.22
)
$
-
Forfeited
(
1,128
)
$
60.50
(
9.18
)
$
-
Expired
(
707
)
$
(
61.01
)
-
$
-
Outstanding
        at December 31, 2022
54,135
$
38.93
5.88
$
144
Exercisable
        at December 31, 2022
30,677
$
22.46
3.29
$
144
Vested
        and expected to vest at December 31, 2022
54,135
$
38.93
5.88
$
144
F-93
S
ILEXION
THERAPEUTICS CORP
NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS (continued)
U.S.
DOLLARS IN THOUSANDS
NOTE 11  - SHARE-BASED COMPENSATION
(continued):
The
fair value for options granted in 2022 is estimated at the date of grant using a Black-Scholes option pricing model based on the following
assumptions:
Year ended
December 31, 2022
Employees
Expected
        term (in years)
6.05
-
10.00
Expected
        volatility
82.97
%
        -
88.45
%
Risk-free
        interest rate
2.31
%
        -
2.90
%
Expected
        dividend yield
0.00
%
Exercise
        price
$
60.51
Non-Employees
Expected
        term (in years)
9.78
Expected
        volatility
88.46
%
Risk-free
        interest rate
2.31
%
Expected
        dividend yield
0.00
%
Exercise
        price
$
60.51
The
option-pricing model requires a number of assumptions, of which the most significant are the expected stock price volatility and the expected
option term. Since the Company is not traded, the expected volatility was based on the average volatility rate of
8
public companies in the healthcare industry.
The
expected term of options granted represents the period during which options granted are expected to remain outstanding. The risk-free
interest rate is based on the yield from U.S. treasury bonds with an equivalent term. The Company has historically not paid dividends
and has no foreseeable plans to pay dividends. The Company uses the simplified method for nonexecutive employees, due to insufficient
historical exercise experience".
The
fair value of options granted during 2022 was $
529
.
Options
granted to employees and non-employees:
In
2023 no options were granted, neither to employees nor to non-employees.
In
the year ended December 31, 2022, the Company granted options as follows:
Year
        ended December 31, 2022
Award
        amount
Exercise
        price
Vesting
        period
Expiration
Employees
23,234
60.51
up
        to 4 years
10
years
Non-employees
886
60.51
Immediate
10
years
Total
        granted
24,120
F-94
S
ILEXION
THERAPEUTICS CORP
NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS (continued)
U.S.
DOLLARS IN THOUSANDS
NOTE 11  - SHARE-BASED COMPENSATION
(continued):
Summary
of status of the Company's nonvested employee options:
The
following table summarizes the number of options outstanding for the years ended December 31, 2023 and December 31, 2022, and related
information:
Number
        of
options
Weighted-average
        grant-date fair
value
        price
Outstanding
        at December 31, 2022
23,393
$
21.67
Granted
-
$
-
Vested
(
8,827
)
$
21.60
Forfeited
-
$
-
Outstanding
        at December 31, 2023
14,566
$
21.72
Outstanding
        at December 31, 2021
1,976
$
17.33
Granted
23,234
$
21.76
Vested
(
690
)
$
16.04
Forfeited
(
1,127
)
$
19.34
Outstanding
        at December 31, 2022
23,393
$
21.67
Summary
of status of the Company's nonvested nonemployee options:
The
following table summarizes the number of options outstanding for the years ended December 31, 2023 and December 31, 2022, and related
information:
Number
        of
options
Weighted-average
        grant-date fair
value
        price
Outstanding
        at December 31, 2022
59
$
11.21
Granted
-
$
-
Vested
(
59
)
$
11.21
Forfeited
-
$
-
Outstanding
        at December 31, 2023
-
$
-
Outstanding
        at December 31, 2021
135
$
11.09
Granted
886
$
26.96
Vested
(
962
)
$
25.69
Forfeited
-
$
-
Outstanding
        at December 31, 2022
59
$
11.21
On
December 31, 2023, there was $
284
of total unrecognized compensation cost related to unvested stock options granted under the Plan. That cost is expected to be recognized
over a weighted-average period of
2.22
years.
On
December 31, 2022, there was $
414
of total unrecognized compensation cost related to unvested stock options granted under the Plan. That cost is expected to be recognized
over a weighted-average period of
3.20
years.
F-95
S
ILEXION
THERAPEUTICS CORP
NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS (continued)
U.S.
DOLLARS IN THOUSANDS
NOTE 11  - SHARE-BASED COMPENSATION
(continued):
The share-based compensation expense by line item in the accompanying
consolidated statements of operations is summarized as follows:
Year ended December 31
2023
2022
Research and development
$
78
$
60
General and administrative
52
65
$
130
$
125
NOTE
12  - FAIR VALUE MEASUREMENTS:
Financial
instruments measured at fair value on a recurring basis
The
Company's assets and liabilities that are measured at fair value as of December 31, 2023, and December 31, 2022, are classified
in the tables below in one of the three categories described in "Note 2 – Fair value measurement" above:
December
        31, 2023
Level
        3
Total
Financial
        Liabilities
Warrants
        to preferred shares
$
200
$
200
December
        31, 2022
Level
        3
Total
Financial
        Liabilities
Warrants
        to preferred shares
$
3
$
3
The
following is a roll forward of the fair value of liabilities classified under Level 3:
2023
2022
Warrants
Warrants
SAFE
Fair value
        at the beginning of the year
$
3
$
-
$
3,204
Issuance
111
1,020
-
Change in
        fair value
86
(
1,017
)
-
Conversion
        to equity
-
-
(
3,204
)
Fair value
        at the end of the year
$
200
$
3
$
-
The
fair value of the Company's warrant liabilities as of December 31, 2023 was estimated using a hybrid model in order to reflect two
scenarios: (1) an IPO event (including de-SPAC transaction) and (2) other liquidation events.
The
IPO scenario (including de-SPAC transaction) was based on management estimation regarding the expected value of the Company's entire
equity at the IPO event (including de-SPAC transaction). Valuation under this scenario was assessed using the probability-weighted expected
return method (PWERM).
The
valuation under the 'other liquidation events' scenario was assessed using an option pricing model (OPM) by implementing a
Monte Carlo Simulation, which treats the financial instruments in the Company's equity as contingent claims whose future payoff depends
on the Company's future equity value. The Company's entire equity value in 2023 was calculated based, among others, on the financing
round closest to the valuation date.
The
fair value of the Company's warrant liabilities as of December 31, 2022 was estimated using only the 'other liquidation events'
scenario.
F-96
S
ILEXION
THERAPEUTICS CORP
NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS (continued)
U.S.
DOLLARS IN THOUSANDS
NOTE
12  - FAIR VALUE MEASUREMENTS
(continued):
Application
of these approaches and methodologies involves the use of estimates, judgments and assumptions that are highly complex and subjective,
such as those regarding discount rates, the
selection of comparable public companies, and the probability of and timing
associated with possible future events.
The
following table presents the main assumptions used in the hybrid model for the periods presented:
December
        31
2023
2022
Expected
        volatility
73.8
%
87.3
%
Assumptions
        regarding the price of the underlying shares:
Probability
        of an IPO scenario (including de-SPAC transaction)
25
%
-
Expected
        time to IPO (including de-SPAC transaction) (years)
0.414
-
Probability
        of other liquidation events
75
%
100
%
Expected
        time to liquidation (years)
2.75
3.00
Expected
        return on Equity
22
%
23
%
A
significant increase in the expected volatility, or in the probability of an IPO (including de-SPAC transaction) (in 2023), could each
increase the fair value of the related instruments. A significant decrease in the expected term of the warrants or expected time to IPO
(including de-SPAC transaction), could each decrease the fair value of related instruments. In combination, changes in these inputs could
result in a significantly higher or lower fair value measurement if the input changes were to be compounding, or could result in a minimally
higher or lower fair value measurement if the input changes were of opposite effects and consequently offset each other.
Financial
instruments not measured at fair value
The
carrying amounts of cash and cash equivalents, restricted cash, receivables, trade payables and other liabilities approximate their fair
value due to the short-term maturity of such instruments.
NOTE
13  - NET LOSS PER SHARE:
The
following table sets forth the computation of basic and diluted net loss per share attributable to ordinary shareholders for the periods
presented (USD in thousands, except per share data):
Year
        ended December 31
2023
2022
Numerator:
Net
        loss for the year
$
5,108
$
3,488
Net
        loss attributable to ordinary shareholders, basic and diluted:
$
4,942
$
3,215
Denominator:
Weighted-average
        shares used in computing net loss per share attributable to ordinary shareholders, basic and diluted
111,726
111,686
Net
        loss per share attributable to ordinary shareholders, basic and diluted
$
44.23
$
28.79
F-97
S
ILEXION
THERAPEUTICS CORP
NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS (continued)
U.S.
DOLLARS IN THOUSANDS
NOTE
13  - NET LOSS PER SHARE
(continued)
:
Basic
loss per share is computed on the basis of the net loss for the period divided by the weighted average number of ordinary shares outstanding
during the period, and fully vested Pre-Funded options for the Company's ordinary shares at an exercise price of $
0.0226
or
0.0226
NIS per share, as the Company considers these shares to be exercised for little to no additional consideration.
As
of December 31, 2023 and 2022, the basic loss per share calculation included a weighted average number of
14,652
of fully vested Pre-Funded options. As the inclusion of shares of ordinary shares equivalents in the calculation would be anti-dilutive
for all periods presented, diluted net loss per share is the same as basic net loss per share.
The
following instruments were not included in the computation of diluted earnings per share because of their anti-dilutive effect:
-
Redeemable
        convertible preferred shares (see Note 9);
-
Warrants
        to purchase redeemable convertible preferred shares (see Note 8);
-
Simple
        agreements for future equity (see Note 7);
-
Share-based
        compensation issuable at substantial consideration (see Note 11).
NOTE
14  - TRANSACTIONS AND BALANCES WITH RELATED PARTIES
:
Transactions
with related parties which are shareholders and directors of the Company:
a.
Transactions:
Year
        ended December 31
2023
2022
Share-based
        compensation included in research and development expenses
$
69
$
49
Share-based
        compensation included in general and administrative expenses
$
48
$
37
Financial
        expenses
$
83
$
-
b.
Balances:
December
        31
2023
2022
Non-Current
        liabilities —
Warrants
        to preferred shares
$
186
$
-
NOTE
15  - SUBSEQUENT EVENT:
The
Company's management has performed an evaluation of subsequent events through May 09
th
, 2024, the date the financial
statements were available to be issued.
a.
On February 21, 2024, the Company
        entered into a business combination agreement with Moringa Acquisition Corp. (the "SPAC"), an exempted company incorporated
        under the Laws of the Cayman Islands whose class A ordinary shares (as well as other instruments) are listed for trade on the Nasdaq Global
        Market (NASDAQ:MACA), and April.M.G. Ltd. (the "April Merger Sub"), a limited liability company organized under the laws
        of the State of Israel and a wholly-owned subsidiary of the SPAC (the "Original BCA"). According to the Original BCA, April
        Merger Sub would merge with and into the Company, with the Company continuing as the surviving entity and a wholly-owned subsidiary of
        the SPAC, and with the SPAC continuing as a public company following the completion of the merger and with its securities continuing to
        be traded on Nasdaq.
F-98
S
ILEXION
THERAPEUTICS CORP
NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS (continued)
U.S.
DOLLARS IN THOUSANDS
NOTE
15  - SUBSEQUENT EVENT
(continued):
b.
On April 3, 2024, the SPAC
        and the Company restructured the transactions contemplated under the Original BCA by entering into the A&R BCA by and among Biomotion
        Sciences, a Cayman Islands exempted company (the "New Pubco"), August M.S. Ltd., an Israeli company and a wholly owned
        subsidiary of New Pubco (the "Merger Sub 1"), Moringa Acquisition Merger Sub Corp, a Cayman Islands exempted company and a
        wholly owned subsidiary of New Pubco (the "Merger Sub 2"), the SPAC and the Company. The A&R BCA amends and restates,
        in its entirety, the Original BCA.
Pursuant
to the A&R BCA, Merger Sub 2 will merge with and into the SPAC, with the SPAC continuing as the surviving company of such merger and
a wholly-owned subsidiary of New Pubco (the "SPAC Merger"), and Merger Sub 1 will merge with and into the Company, with the
Company continuing as the surviving company of such merger and a wholly-owned subsidiary of New Pubco (the "Acquisition Merger").
Upon
the effectiveness of the SPAC Merger, each outstanding SPAC Class A ordinary share and the sole outstanding SPAC Class B ordinary
share will convert into an ordinary share of New Pubco on a one-for-one basis, and each outstanding warrant to purchase
one
SPAC Class A ordinary share will convert into a warrant to purchase
one
New Pubco ordinary share, at the same exercise price.
Upon
the effectiveness of the Acquisition Merger, each outstanding ordinary share and preferred share of the Company will convert into such
number of ordinary shares of New Pubco as is equal to the quotient obtained by dividing (x) the quotient obtained by dividing (1) $
62,500,000
by (2) the number of fully diluted Company equity securities, by (y) $
10.00
(the "Company Equity Exchange Ratio"). Each outstanding Company warrant and Company option to purchase one Company share,
and Company restricted share unit (RSU) that may be potentially settled for one Company share, will become exercisable for, or will be
subject to settlement for (as applicable), such number of New Pubco ordinary shares as are equal to the Company Equity Exchange Ratio.
The exercise price per New Pubco ordinary share of each such converted Company options and Company warrants will be adjusted based on
dividing the existing per share exercise price by the Company Equity Exchange Ratio. The terms of vesting, exercise and/or settlement,
as applicable, of such converted options, warrants and RSUs shall remain the same following such conversion, except that the vesting of
each Company option will accelerate immediately prior to the Acquisition Merger, such that the New Pubco option into which it has been
converted will be fully vested.
The
completion of the A&R BCA is subject to the satisfaction of certain conditions, including obtaining the consent of the shareholders
of each of the SPAC and the Company and the declaration of effectiveness of a registration statement on form S-4 by the U.S. Securities
and Exchange Commission in relation to issuance of New Pubco ordinary shares to be issued or issuable to the SPAC's and the Company's
respective security holders pursuant to the A&R BCA. To facilitate the A&R BCA, the parties further entered into certain
ancillary agreements.
The
A&R BCA further imposes various restrictions on the total liabilities which the SPAC may incur prior to closing, including the total
indebtedness toward the sponsor of the SPAC, and the terms on which such indebtedness will be repaid or converted, whereas such conversion,
if and when it occurs, will further dilute the holdings of all shareholders of New Pubco at that time, including the former shareholders
of the Company.
c.
For
        information regarding the reverse share split, see Note 1 (c)
_______________________
________________________________
_______________________
F-99
Silexion Therapeutics Corp
Up to 2,377,030 Ordinary Shares
PROSPECTUS
,
2025
PART II
INFORMATION
NOT REQUIRED IN PROSPECTUS
Item 13. Other
Expenses of Issuance and Distribution.
The following table sets forth all costs and expenses, other than underwriting discounts
and commissions, payable by us in connection with the sale of the securities being registered. All amounts shown are estimates, except
for the SEC registration fee.
Amount
SEC registration fee
$
517
Accountants' fees and expenses
$
40,000
Legal fees and expenses
$
10,000
Printing fees
$
2,500
Miscellaneous
$
1,983
Total expenses
$
55,000
Discounts, concessions, commissions and similar
selling expenses attributable to the sale of ordinary shares covered by this prospectus will be borne by the Selling Securityholders.
We will pay all expenses (other than discounts, concessions, commissions and similar selling expenses) relating to the registration of
the shares with the SEC, as estimated in the table above.
Item 14. Indemnification
of Directors and Officers.
Cayman Islands law does not limit the extent
to which a company's memorandum and articles of association may provide for indemnification of officers and directors, except to
the extent any such provision may be held by the Cayman Islands courts to be contrary to public policy, such as to provide indemnification
against willful default, willful neglect, actual fraud or the consequences of committing a crime. New Silexion's amended and restated
memorandum and articles of association provide for indemnification of its officers and directors to the maximum extent permitted by law,
including for any liability incurred in their capacities as such, except through their own actual fraud, willful default or willful neglect.
New Silexion has purchased a policy of directors' and officers' liability insurance that insures its officers and directors
against the cost of defense, settlement or payment of a judgment in some circumstances and insures it against its obligations to indemnify
its officers and directors.
We believe that
these provisions and the insurance are necessary to attract and retain talented and experienced officers and directors.
Insofar as indemnification
for liabilities arising under the Securities Act may be permitted to directors, officers or persons controlling us pursuant to the foregoing
provisions, we have been informed that in the opinion of the SEC such indemnification is against public policy as expressed in the Securities
Act and is therefore unenforceable.
New Silexion has entered into indemnity agreements
with each of its officers and directors. These agreements require New Silexion to indemnify these individuals and entity to the fullest
extent permitted under applicable Cayman Islands law and to hold harmless, exonerate and advance expenses incurred as a result of any
proceeding against them as to which they could be indemnified.
Insofar as indemnification for liabilities
arising under the Securities Act may be permitted to New Silexion's directors, officers, and controlling persons pursuant to the
foregoing provisions, or otherwise, New Silexion has been advised that, in the opinion of the SEC, such indemnification is against public
policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such
liabilities (other than the payment of expenses incurred or paid by a director, officer or controlling person in a successful defense
of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being
registered, New Silexion will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to the
court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities
Act and will be governed by the final adjudication of such issue.
II-1
Item 15. Recent
Sales of Unregistered Securities.
Since our formation
on April 2, 2024, we have sold securities in transactions not registered under the Securities Act as described below:
Initial
Issuance Upon Formation
Upon its formation
on April 2, 2024, the Company initially sold one ordinary share to its initial shareholder, Maples Corporate Services Limited, in exchange
for corporate services provided by that initial shareholder. That issuance was effected without registration under the Securities Act
in an offshore transaction pursuant to the exemption provided by Regulation S under the Securities Act.
Unregistered
Issuances Upon Closing of Business Combination
Issuance of EarlyBird
Convertible Note and Underlying Ordinary Shares
Prior to the Closing of the Business Combination,
on August 11, 2024, Moringa reached agreement with EarlyBird on the reduction, to $1.6 million, in the aggregate, of the fee payable to
EarlyBird under the Business Combination Marketing Agreement, dated as of February 19, 2021, entered into by Moringa with EarlyBird at
the time of Moringa's initial public offering. As part of that agreement, New Silexion issued to EarlyBird the EarlyBird Convertible
Note, in an amount of $1.25 million to be paid by New Silexion to EarlyBird in cash and/or via conversion of outstanding amounts into
ordinary shares of New Silexion, which convertible note bears interest at a rate of 6% per annum and is due on December 31, 2025.
EarlyBird may elect, at its sole discretion,
at any time on or prior to the maturity date of the EarlyBird Convertible Note, to convert all or part of the then outstanding principal
and/or accrued interest under the note into New Silexion ordinary shares, at a per share conversion price equal to 95% of the volume weighted
average price of a New Silexion ordinary share for the five trading days immediately prior to the date of New Silexion's receipt
of a conversion notice, provided, however, that New Silexion is not required to issue, and EarlyBird may not elect to convert the principal
and/or accrued interest into an aggregate number of New Silexion ordinary shares that would exceed the maximum number of ordinary shares
permitted by Section 5635 of the Nasdaq Listing Rules to be issued without the approval of New Silexion's shareholders, unless such
approval is obtained.
Under the EarlyBird
Convertible Note, New Silexion agreed to promptly file a registration statement with the SEC covering the resale of the ordinary shares
that may be issued upon conversion of the note and use its best efforts to have such registration statement declared effective as soon
thereafter as possible. In the event such registration statement is not declared effective by the SEC within 180 days from the date hereof,
then an event of default shall have occurred under the note, triggering all amounts under the note to become due and payable immediately
and automatically.
The issuance of
the EarlyBird Convertible Note and the potential issuance of New Silexion ordinary shares upon conversion of amounts outstanding under
the EarlyBird Convertible Note, has been, and will be (respectively), effected in reliance upon the exemption from registration provided
under Section 4(a)(2) and/or Rule 506 of Regulation D of the Securities Act in a transaction not requiring registration under the Securities
Act.
II-2
Issuance of PIPE
Financing Shares
As described under "
Certain Relationships and Related
Party Transactions—PIPE Financing
" above, in connection with, and immediately prior to the Closing of, the Business
Combination, Moringa raised $2.0 million via the PIPE Financing, whereby Moringa sold to the PIPE Investor 200,000 newly issued Moringa
Class A ordinary shares at a price of $10.00 per share, pursuant to the PIPE Agreement. Upon the Closing of the Business Combination,
the Company issued 200,000 New Silexion ordinary shares to the PIPE Investor upon conversion of those 200,000 Moringa Class A ordinary
shares.
The issuance of those 200,000 PIPE Shares by
the Company to the PIPE Investor (a Cayman Islands exempted limited partnership) was effected without registration under the Securities
Act in an offshore transaction pursuant to the exemption provided by Regulation S under the Securities Act.
Issuances of
Equity Line of Credit Financing Shares to White Lion
As described above in this registration
statement under "
White Lion Transaction
", also in connection with the Closing of the
Business Combination, New Silexion entered into the White Lion Purchase Agreement, under which it will be able to request to sell to White
Lion, and White Lion will be required to purchase, under an equity line of credit, up to $15.0 million of New Silexion ordinary shares—
the Purchase Notice Shares— from time to time after the Closing, up until December 31, 2025 (unless the agreement is terminated
sooner), subject to certain limitations and conditions as described therein. New Silexion is furthermore required to issue to White Lion
ordinary shares constituting the Commitment Shares, having a value equal to $337,500, as a commitment fee under the White Lion Purchase
Agreement The issuance of all ordinary shares to White Lion under the White Lion Purchase Agreement will be effected in reliance upon
the exemption from registration provided under Section 4(a)(2) and/or Rule 506 of Regulation D of the Securities Act in a transaction
not requiring registration under the Securities Act.
Issuance of Amended
and Restated Sponsor Promissory Note and Underlying Shares to Moringa Sponsor
As described above
in this registration statement under "
Certain Relationships and Related Party Transactions
—
Amended and Restated Sponsor Promissory Note
", upon the Closing of the Business Combination,
New Silexion issued to the Sponsor, in amendment and restatement, and replacement, in their entirety, of all existing promissory notes
issued by Moringa to the Sponsor from Moringa's initial public offering until the Closing, the A&R Sponsor Promissory Note in
an amount of $3,433,000, which matures on February 15, 2027. Amounts outstanding under the A&R Sponsor Promissory Note may be repaid
only by way of conversion by either the Company or the Sponsor into ordinary shares, under various circumstances.
The issuance by
the Company to the Sponsor (a Cayman Islands exempted limited partnership) of the A&R Sponsor Promissory Note, and the prospective
issuance by the Company to the Sponsor of underlying Note Shares, was or will be (as applicable), effected without registration under
the Securities Act in an offshore transaction pursuant to the exemption provided by Regulation S under the Securities Act.
None of the foregoing
transactions described in this "Recent Sales of Unregistered Securities" section involved any underwriters, underwriting discounts
or commissions, or any public offering. The recipients of the securities in each of these transactions represented their intentions to
acquire the securities for investment only and not with a view to or for sale in connection with the distribution thereof (absent registration
under the Securities Act), and appropriate legends were placed on the securities certificates issued in these transactions. All recipients
had adequate access, through their relationships with us, to information about us. The sales of these securities were made without any
general solicitation or advertising.
II-3
Item 16.
Exhibits and Financial Statement Schedules
Exhibit
        No.
Description
2.1.1†
Amended
        and Restated Business Combination Agreement, dated as of April 3, 2024, by and among Biomotion Sciences (now known as Silexion Therapeutics
        Corp), August M.S. Ltd., Moringa Acquisition Merger Sub Corp, Silexion Therapeutics Ltd. and Moringa Acquisition Corp (incorporated by
        reference to Exhibit 2.1 to Moringa Acquisition Corp's Current Report on Form 8-K, filed with the SEC on April 3, 2024)
2.1.2
Waiver
        letter, dated June 18, 2024, under Amended and Restated Business Combination Agreement (incorporated by reference to Exhibit 10.1 to Moringa
        Acquisition Corp's Current Report on Form 8-K filed with the SEC on June 24, 2024)
2.2
Plan
        of Merger for merger of Moringa Acquisition Corp and Moringa Acquisition Merger Sub Corp (incorporated by reference to Exhibit 2.2 to
        Silexion Therapeutics Corp's Current Report on Form 8-K filed with the SEC on August 21, 2024)
3.1
Amended
        and Restated Memorandum and Articles of Association of Silexion Therapeutics Corp (formerly Biomotion Sciences) (incorporated by reference
        to Exhibit 3.1 to Silexion Therapeutics Corp's Current Report on Form 8-K filed with the SEC on August 21, 2024)
3.2
Ordinary
        Resolution Effecting 1-for-9 Reverse Share Split to Share Capital of Silexion Therapeutics Corp (incorporated by reference to Exhibit
        3.1 to Silexion Therapeutics Corp's Current Report on Form 8-K filed with the SEC on November 29, 2024)
4.1
Warrant
        Agreement, dated February 19, 2021, by and between Moringa Acquisition Corp and Continental Stock Transfer & Trust Company,
        as warrant agent (incorporated by reference to Exhibit 4.1 to Moringa Acquisition Corp's Current Report on Form 8-K, filed
        with the SEC on February 22, 2021)
4.2
Assignment,
        Assumption and Amendment Agreement, dated as of August 15, 2024, by and among Moringa Acquisition Corp, Silexion Therapeutics Corp (formerly
        known as Biomotion Sciences) and Continental Stock Transfer & Trust Company (incorporated by reference to Exhibit 4.1 to Silexion
        Therapeutics Corp's Current Report on Form 8-K filed with the SEC on August 21, 2024)
4.3
Warrant
        Adjustment Notice, dated November 29, 2024, in respect of 1-for-9 Reverse Share Split of Silexion Therapeutics Corp (incorporated by reference
        to Exhibit 4.1 to Silexion Therapeutics Corp's Current Report on Form 8-K filed with the SEC on November 29, 2024)
5.1*
Opinion
        of Conyers Dill & Pearman LLP, Cayman legal counsel to Silexion Therapeutics Corp
10.1.1
Final
        invoice issued by EarlyBirdCapital, Inc. to Moringa Acquisition Corp under the Business Combination Marketing Agreement, dated February
        16, 2021, by and between EarlyBirdCapital, Inc. and Moringa Acquisition Corp (incorporated by reference to Exhibit 10.1.1 to Silexion
        Therapeutics Corp's Current Report on Form 8-K filed with the SEC on August 21, 2024)
10.1.2
Convertible
        Promissory Note, dated August 15, 2024, in an amount of $1,250,000, issued by Silexion Therapeutics Corp (formerly known as Biomotion
        Sciences) to EarlyBirdCapital, Inc. (incorporated by reference to Exhibit 10.1.2 to Silexion Therapeutics Corp's Current Report
        on Form 8-K filed with the SEC on August 21, 2024)
10.2
Subscription
        Agreement, dated August 15, 2024, by and among Moringa Acquisition Corp, Silexion Therapeutics Corp (formerly known as Biomotion Sciences)
        and Greenstar, L.P. (incorporated by reference to Exhibit 10.2 to Silexion Therapeutics Corp's Current Report on Form 8-K filed
        with the SEC on August 21, 2024)
10.3.1
Ordinary
        Share Purchase Agreement, dated August 13, 2024 and effective as of the closing date of the Business Combination, by and between Silexion
        Therapeutics Corp (formerly known as Biomotion Sciences) and White Lion Capital, LLC (incorporated by reference to Exhibit 10.3.1 to Silexion
        Therapeutics Corp's Current Report on Form 8-K filed with the SEC on August 21, 2024)
10.3.2*
Amendment
        No. 1, effective January 14, 2025, to Ordinary Share Purchase Agreement, dated August 13, 2024 and effective as of the closing date of
        the Business Combination, by and between Silexion Therapeutics Corp and White Lion Capital, LLC
10.3.3
Registration
        Rights Agreement, dated August 13, 2024 and effective as of the closing date of the Business Combination, by and between Silexion Therapeutics
        Corp (formerly known as Biomotion Sciences) and White Lion Capital, LLC (incorporated by reference to Exhibit 10.3.2 to Silexion Therapeutics
        Corp's Current Report on Form 8-K filed with the SEC on August 21, 2024)
10.4
Amended
        and Restated Registration Rights and Lock-Up Agreement, dated August 14, 2024 and effective as of the Closing Date, by and among Silexion
        Therapeutics Corp (formerly known as Biomotion Sciences), Moringa Acquisition Corp, Moringa Sponsor, L.P., the distributees of Sponsor
        Investment Shares that were issuable to Moringa Sponsor, L.P., EarlyBirdCapital, Inc., certain of Silexion Therapeutics Ltd.'s pre-Business
        Combination shareholders and Greenstar, L.P. (incorporated by reference to Exhibit 10.4 to Silexion Therapeutics Corp's Current
        Report on Form 8-K filed with the SEC on August 21, 2024)
10.5
Amended
        and Restated Promissory Note, dated August 15, 2024, issued by Silexion Therapeutics Corp (formerly known as Biomotion Sciences) to Moringa
        Sponsor, L.P. (incorporated by reference to Exhibit 10.5 to Silexion Therapeutics Corp's Current Report on Form 8-K filed with the
        SEC on August 21, 2024)
10.6
Form
        of Director and Officer Indemnification Agreement, dated August 15, 2024, by and between Silexion Therapeutics Corp (formerly known as
        Biomotion Sciences) and each of its executive officers and directors (incorporated by reference to Exhibit 10.6 to Silexion Therapeutics
        Corp's Current Report on Form 8-K filed with the SEC on August 21, 2024)
10.11.1#
Employment
        Agreement, dated April 1, 2022, by and between Silexion Therapeutics Ltd. and Ilan Hadar (incorporated by reference to Exhibit 10.12.1
        to Amendment No. 3 to the Company's Registration Statement on Form S-4 (File No. 333-279281), filed with the SEC on July 12, 2024)
.
10.11.2#
Amendment
        No. 1 to Employment Agreement, dated May 2024, by and between Silexion Therapeutics Ltd. and Ilan Hadar ((incorporated by reference to
        Exhibit 10.12.2 to Amendment No. 3 to the Company's Registration Statement on Form S-4 (File No. 333-279281), filed with the SEC
        on July 12, 2024)
10.12#
Silexion
        Therapeutics Corp 2024 Equity Incentive Plan (incorporated by reference to Exhibit 10.12 to Silexion Therapeutics Corp's Current
        Report on Form 8-K filed with the SEC on August 21, 2024)
10.13#
Silexion
        Therapeutics Ltd. 2023 Equity Incentive Plan
(incorporated by reference to Exhibit 10.13 to Silexion Therapeutics Corp's
        Registration Statement on Form S-1 (File No. 333-282017), filed with the SEC on September 10, 2024)
10.14#
Silexion
        Therapeutics Ltd. 2013 Share Option Plan
(incorporated by reference to Exhibit 10.14 to Silexion Therapeutics Corp's
        Registration Statement on Form S-1 (File No. 333-282017), filed with the SEC on September 10, 2024)
10.15
Securities
        Purchase Agreement, dated January 15, 2025, by and between the Company and each investor party thereto (incorporated by reference to Exhibit
        10.1 to Silexion Therapeutics Corp's Current Report on Form 8-K filed with the SEC on January 17, 2025)
10.16
Form
        of Ordinary Warrant (incorporated by reference to Exhibit 4.1 to Silexion Therapeutics Corp's Current Report on Form 8-K filed with
        the SEC on January 17, 2025)
10.17
Form
        of Pre-Funded Warrant (incorporated by reference to Exhibit 4.2 to Silexion Therapeutics Corp's Current Report on Form 8-K filed
        with the SEC on January 17, 2025)
10.18
Form
        of Placement Agent Warrant (incorporated by reference to Exhibit 4.3 to Silexion Therapeutics Corp's Current Report on Form 8-K
        filed with the SEC on January 17, 2025)
10.19
Form
        of Inducement Letter (incorporated by reference to Exhibit 10.1 to Silexion Therapeutics Corp's Current Report on Form 8-K filed
        with the SEC on January 30, 2025)
10.20
Form
        of New Warrant (incorporated by reference to Exhibit 10.2 to Silexion Therapeutics Corp's Current Report on Form 8-K filed with
        the SEC on January 30, 2025)
10.21
Form
        of Placement Agent Warrant (incorporated by reference to Exhibit 10.3 to Silexion Therapeutics Corp's Current Report on Form 8-K
        filed with the SEC on January 30, 2025)
21.1
List
        of Subsidiaries (incorporated by reference to Exhibit 21.1 to Silexion Therapeutics Corp's Current Report on Form 8-K filed with
        the SEC on August 21, 2024)
23.1*
Consent
        of Kesselman & Kesselman, a member firm of PricewaterhouseCoopers International Limited, independent registered public accounting
        firm of Moringa Acquisition Corp
23.2*
Consent
        of Kesselman & Kesselman, a member firm of PricewaterhouseCoopers International Limited, independent registered public accounting
        firm of Silexion Therapeutics Corp
23.3*
Consent
        of Conyers Dill & Pearman LLP (included in Exhibit 5.1)
24.1
Power
        of attorney (included on the signature page to this registration statement)
107*
Filing
        fee table
*
Filed
        herewith.
†
Certain
        of the exhibits and schedules to this Exhibit have been omitted in accordance with Regulation S-K Item 601(a)(5). The registrant agrees
        to furnish a copy of all omitted exhibits and schedules to the SEC upon its request.
#
Indicates
        management contract or compensatory plan, contract or arrangement.
Item 17.
Undertakings
The undersigned
Registrant hereby undertakes
:
(a) To file, during
any period in which offers or sales are being made, a post-effective amendment to this Registration Statement:
(i) To include
any prospectus required by section 10(a)(3) of the Securities Act of 1933;
II-4
(ii) To reflect
in the prospectus any facts or events arising after the effective date of this Registration Statement (or the most recent post-effective
amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in this Registration
Statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities
offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range
may be reflected in the form of prospectus filed with the Commission pursuant to Rule 424(b) if, in the aggregate, the changes in volume
and price represent no more than 20% change in the maximum aggregate offering price set forth in the "Calculation of Registration
Fee" table in the effective registration statement; and
(iii) To include
any material information with respect to the plan of distribution not previously disclosed in this Registration Statement or any material
change to such information in this Registration Statement.
(b) That, for
the purpose of determining any liability under the Securities Act of 1933, each such post-effective amendment that contains a form of
prospectus shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities
at that time shall be deemed to be the initial bona fide offering thereof.
(c) To remove
from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination
of the offering.
(d) That, for
the purpose of determining liability under the Securities Act of 1933 to any purchaser, each prospectus filed pursuant to Rule 424(b)
as part of a registration statement relating to an offering, other than registration statements relying on Rule 430B or other than prospectuses
filed in reliance on Rule 430A, shall be deemed to be part of and included in the registration statement as of the date it is first used
after effectiveness. Provided, however, that no statement made in a registration statement or prospectus that is part of the registration
statement or made in a document incorporated or deemed incorporated by reference into the registration statement or prospectus that is
part of the registration statement will, as to a purchaser with a time of contract of sale prior to such first use, supersede or modify
any statement that was made in the registration statement or prospectus that was part of the registration statement or made in any such
document immediately prior to such date of first use.
(e) That, for
the purpose of determining liability of the registrant under the Securities Act of 1933 to any purchaser in the initial distribution of
the securities, the undersigned registrant undertakes that in a primary offering of securities of the undersigned registrant pursuant
to this registration statement, regardless of the underwriting method used to sell the securities to the purchaser, if the securities
are offered or sold to such purchaser by means of any of the following communications,
(i) Any preliminary
prospectus or prospectus of the undersigned registrant relating to the offering required to be filed pursuant to Rule 424;
(ii) Any free
writing prospectus relating to the offering prepared by or on behalf of the undersigned registrant or used or referred to by the undersigned
registrant;
(iii) The portion
of any other free writing prospectus relating to the offering containing material information about the undersigned registrant or its
securities provided by or on behalf of the undersigned registrant; and
(iv) Any other
communication that is an offer in the offering made by the undersigned registrant to the purchaser.
Insofar as indemnification
for liabilities arising under the Securities Act of 1933 may be permitted to directors, officers and controlling persons of the Registrant
pursuant to the foregoing provisions, or otherwise, the Registrant has been advised that in the opinion of the SEC such indemnification
is against public policy as expressed in the Securities Act of 1933 and is, therefore, unenforceable. In the event that a claim for indemnification
against such liabilities (other than the payment by the Registrant of expenses incurred or paid by a director, officer or controlling
person of the Registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling
person in connection with the securities being registered, the Registrant will, unless in the opinion of its counsel the matter has been
settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by them is against
public policy as expressed in the Securities Act of 1933 and will be governed by the final adjudication of such issue.
II-5
SIGNATURES
Pursuant to the requirements of the Securities Act, the registrant has duly caused this
registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in Ramat Gan, Israel, on February 12,
2025.
SILEXION THERAPEUTICS CORP
By:
/s/ Ilan Hadar
Name:
Ilan Hadar
Title:
Chairman and Chief Executive Officer
POWER OF ATTORNEY
KNOW ALL BY
THESE PRESENTS, that each person whose signature appears below hereby constitutes and appoints Ilan Hadar and Mirit Horenshtein Hadar,
and each of them, as his true and lawful agents, proxies and attorneys-in-fact, with full power of substitution and resubstitution, for
him or her and in his or her name, place and stead, in any and all capacities, to (i) act on, sign and file with the Securities and Exchange
Commission any and all amendments (including post-effective amendments) to this registration statement together with all schedules and
exhibits thereto and any subsequent registration statement filed pursuant to Rule 462(b) under the Securities Act of 1933, as amended,
together with all schedules and exhibits thereto, (ii) act on, sign and file such certificates, instruments, agreements and other documents
as may be necessary or appropriate in connection therewith, (iii) act on and file any supplement to any prospectus included in this registration
statement or any such amendment or any subsequent registration statement filed pursuant to Rule 462(b) under the Securities Act of 1933,
as amended, and (iv) take any and all actions which may be necessary or appropriate to be done, as fully for all intents and purposes
as he might or could do in person, hereby approving, ratifying and confirming all that such agent, proxy and attorney-in-fact or any of
his substitutes may lawfully do or cause to be done by virtue thereof.
Pursuant to the
requirements of the Securities Act of 1933, this registration statement has been signed by the following persons in the capacities and
on the dates indicated.
Signature
Title
Date
/s/ Ilan Hadar
Chairman and Chief Executive Officer
February 12, 2025
Ilan Hadar
(Principal Executive Officer)
/s/ Mirit Horenshtein Hadar
Chief Financial Officer and Secretary
February 12, 2025
Mirit Horenshtein Hadar
(Principal Financial and Accounting Officer)
/s/ Dror J. Abramov
Director
February 12, 2025
Dror J. Abramov
/s/ Ruth Alon
Director
February 12, 2025
Ruth Alon
/s/ Ilan Levin
Director
February 12, 2025
Ilan Levin
/s/ Avner Lushi
Director
February 12, 2025
Avner Lushi
/s/ Shlomo Noy
Director
February 12, 2025
Shlomo Noy
/s/ Amnon Peled
Director
February 12, 2025
Amnon Peled
II-6
AUTHORIZED REPRESENTATIVE
Pursuant to the requirements of the Securities Act of 1933,
as amended, the undersigned, the duly authorized representative of the Registrant in the United States, has signed registration statement
in Newark, Delaware, on February 12, 2025.
PUGLISI & ASSOCIATES
By:
/s/ Donald J. Puglisi
Name:
Donald J. Puglisi
Title:
Authorized Representative
II-7